<SEC-DOCUMENT>0001144204-19-048109.txt : 20191011
<SEC-HEADER>0001144204-19-048109.hdr.sgml : 20191011
<ACCEPTANCE-DATETIME>20191011150817
ACCESSION NUMBER:		0001144204-19-048109
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		94
FILED AS OF DATE:		20191011
DATE AS OF CHANGE:		20191011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adynxx, Inc.
		CENTRAL INDEX KEY:			0001054274
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				582349413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-232169
		FILM NUMBER:		191148052

	BUSINESS ADDRESS:	
		STREET 1:		100 PINE ST., STE. 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111
		BUSINESS PHONE:		(415) 512-7740

	MAIL ADDRESS:	
		STREET 1:		100 PINE ST., STE. 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alliqua BioMedical, Inc.
		DATE OF NAME CHANGE:	20140610

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alliqua, Inc.
		DATE OF NAME CHANGE:	20101222

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEPALIFE TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20030529
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>tv528145-s1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
  <head>
    <title>tv528145-s1a - block - 22.6596825s</title>
  </head>
  <body style="width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:19pt;margin-bottom:21.71pt;margin-left:27pt;width:541pt;">

          <div style="text-align:center; width:541pt; line-height:11pt;font-weight:bold;font-size:10pt;">As filed with the U.S. Securities and Exchange Commission on October 11, 2019 </div>

        <div style="margin-top:-3pt; text-align:right; width:541pt; line-height:10pt;font-weight:bold;">Registration No. 333-232169&#8203;</div>
        <div style="margin-top:0.5pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541pt; line-height:11pt;font-weight:bold;font-size:10pt;">UNITED STATES <br >SECURITIES AND EXCHANGE COMMISSION <br >Washington, D.C. 20549 </div>
        <div style="margin-top:4.5pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="margin-top:4pt; text-align:center; width:541pt; line-height:9pt;font-weight:bold;">AMENDMENT NO. 3 TO<br >FORM S-1 <br >REGISTRATION STATEMENT <br >UNDER <br >THE SECURITIES ACT OF 1933 </div>

        <div style="margin-top:4.5pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5pt; text-align:center; width:541pt; line-height:19pt;font-weight:bold;font-size:18pt;">ADYNXX, INC. </div>
        <div style="margin-top:-2pt; text-align:center; width:541pt; line-height:10pt;">(Exact name of registrant as specified in our charter) </div>
        <div style="margin-top:1.5pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:541pt;height:25.4pt;margin-top:1.5pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174.34pt;">
              <div style="text-align:center;">Delaware </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:168.33pt;">
              <div style="text-align:center;">2834 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174.33pt;">
              <div style="text-align:center;">58-2349413 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.4pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0.733pt 0pt 0.5pt 0pt; width:174.34pt;">
              <div style="text-align:center;">(State or Other Jurisdiction of <br >Incorporation or Organization)</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.733pt 0pt 0.5pt 0pt; width:168.33pt;">
              <div style="text-align:center;">(Primary Standard Industrial <br >Classification Code Number) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.733pt 0pt 0.5pt 0pt; width:174.33pt;">
              <div style="text-align:center;">(I.R.S. Employer <br >Identification No.)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-align:center; width:541pt; line-height:8pt;font-weight:bold;">Adynxx, Inc. <br >100 Pine Street, Suite 500 <br >San Francisco, CA 94111 <br >(415) 512-7740 <br ><font style="font-weight:normal;">(Address, including zip code, and telephone number, including</font> <br ><font style="font-weight:normal;">area code, of registrant&#8217;s principal executive offices) </font></div>
        <div style="margin-top:2.89pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541pt; line-height:8pt;font-weight:bold;">Rick Orr <br >President and Chief Executive Officer <br >Adynxx, Inc. <br >100 Pine Street, Suite 500 <br >San Francisco, CA 94111 <br >(415) 512-7740 <br ><font style="font-weight:normal;">(Name, address, including zip code, and telephone number, including</font> <br ><font style="font-weight:normal;">area code, of agent for service) </font></div>
        <div style="margin-top:2.8pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541pt; line-height:9pt;font-weight:bold;">Copies to:</div>

          <table style="width:501pt;margin-left:20pt;margin-top:-3pt;border-collapse: collapse;">
            <tr style="line-height:8.3pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:244.5pt;">
                <div style="text-align:center;">Laura A. Berezin <br >John T. McKenna <br >Cooley LLP <br >3175 Hanover Street <br >Palo Alto, CA 94304 <br >(650) 843-5000</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:244.5pt;">
                <div style="text-align:center;">Rick A. Werner <br >Haynes and Boone, LLP <br >30 Rockefeller Plaza, 26th Floor <br >New York, NY 10112 <br >(212) 659-7300</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:1.5pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:1pt; text-align:center; width:541pt; line-height:8.5pt;font-weight:bold;font-size:8.5pt;">Approximate date of commencement of proposed sale to the public: <br >As soon as practicable after the effective date of this registration statement. </div>
        <div style="margin-top:1.733pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:1pt; width:541pt; line-height:8.5pt;font-size:8.3pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933 check the following box: &#9746;</div>
        <div style="text-indent:20pt; margin-top:0.5pt; width:541pt; line-height:8.5pt;font-size:8.3pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>
        <div style="text-indent:20pt; margin-top:0.5pt; width:541pt; line-height:8.5pt;font-size:8.3pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>
        <div style="text-indent:20pt; margin-top:0.5pt; width:541pt; line-height:8.5pt;font-size:8.3pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>
        <div style="text-indent:20pt; margin-top:0.5pt; width:541pt; line-height:8.5pt;font-size:8.3pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of&#8201; &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </div>
        <table style="width:501pt;height:24pt;margin-left:20pt;margin-top:1.29999999999995pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.5pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:120pt;white-space:nowrap;">Large accelerated filer<br ></div>
              <div style=" line-height:8pt; text-align:left; margin-left:120pt;">&#9744;</div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.5pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:120pt;white-space:nowrap;">Accelerated filer<br ></div>
              <div style=" line-height:8pt; text-align:left; margin-left:120pt;">&#9744;</div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; width:244.5pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:120pt;white-space:nowrap;">Non-accelerated filer<br ></div>
              <div style=" line-height:8pt; text-align:left; margin-left:120pt;">&#9746;</div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; width:244.5pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:120pt;white-space:nowrap;">Smaller reporting company<br ></div>
              <div style=" line-height:8pt; text-align:left; margin-left:120pt;">&#9746;</div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; width:244.5pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:120pt;white-space:nowrap;">Emerging growth company<br ></div>
              <div style=" line-height:8pt; text-align:left; margin-left:120pt;">&#9744;</div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.5pt;white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="width:541pt;">
          <div style="text-indent:20pt; margin-top:0.5pt; line-height:8.5pt;font-size:8.3pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9744;</div>
        </div>
        <div style="text-align:center; width:541pt; line-height:9pt;font-weight:bold;">Calculation of Registration Fee </div>

          <table style="width:541pt;height:71.79pt;margin-top:-7.00000000000006pt;border-collapse: collapse;">
            <tr style="line-height:7pt;white-space:nowrap;text-align:left;vertical-align:bottom;">
              <td style="border-bottom:3px double #000000;padding:0pt 0pt 1pt 0pt; width:0pt;" colspan="13">&#8203;</td>
              <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
              <td style="border-bottom:1px solid #000000;padding:0.067pt 0pt 0.833pt 0pt; width:380.41pt;text-align:left;">
                <div style="white-space:nowrap;">Title of Each Class of Securities to be Registered </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0.067pt 0pt 0.833pt 0pt;" colspan="4">
                <div style="text-align:center;">Proposed Maximum Aggregate <br >Offering Price<font style=" position:relative; bottom:2.75pt;font-size:5.5pt;">(1)</font></div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0.067pt 0pt 0.833pt 0pt;" colspan="4">
                <div style="text-align:center;">Amount of <br >Registration Fee<font style=" position:relative; bottom:2.75pt;font-size:5.5pt;">(1)</font></div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0.9pt 0pt 0.5pt 0pt; width:380.41pt;text-align:left;">
                <div style="white-space:nowrap;">Common stock, par value $0.001 per share</div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0.9pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:0.9pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,125,000</td>
              <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.745pt;width:0pt;">&#8203;</td>
              <td style="padding:0.9pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:0.9pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.745pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:1.15pt 0pt 0.5pt 0pt; width:380.41pt;text-align:left;">
                <div style="white-space:nowrap;">Common warrants to purchase shares of common stock and common stock issuable upon exercise thereof </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
              <td style="padding:1.15pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.15pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,125,000</td>
              <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.745pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.745pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:1.15pt 0pt 0.5pt 0pt; width:380.41pt;text-align:left;">
                <div style="white-space:nowrap;">Pre-funded warrants to purchase shares of common stock and common stock issuable upon exercise thereof </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
              <td style="padding:1.15pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.15pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,125,000<font style="position:absolute;"><font style=" position:relative; bottom:2.75pt;font-size:6pt;">(2)</font></font></td>
              <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:1.14pt 0pt 0.5pt 0pt; width:380.41pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Placement agent warrants to purchase shares of common stock and common stock issuable upon exercise thereof </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
              <td style="padding:1.14pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.14pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">759,375<font style="position:absolute;"><font style="font-weight:bold;font-size:10pt;"></font><font style=" position:relative; bottom:2.75pt;font-size:6pt;">(3)</font></font></td>
              <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.745pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.745pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:3px double #000000;padding:0pt 0pt 0.333pt 0pt; width:380.41pt;text-align:left;">
                <div style="white-space:nowrap;">Total </div>
              </td>
              <td style="padding:0pt;border-bottom:3px double #000000; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:3px double #000000; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:25.295pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
              <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">31,134,375<font style="position:absolute;"><font style="font-weight:bold;font-size:10pt;"></font><font style=" position:relative; bottom:2.75pt;font-size:6pt;">(</font><font style=" position:relative; bottom:2.75pt;font-size:6pt;">4</font><font style=" position:relative; bottom:2.75pt;font-size:6pt;">)</font></font></td>
              <td style="padding:0pt;padding-left:25.295pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:3px double #000000; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:3px double #000000; width:4pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.745pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
              <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">4,042</td>
              <td style="padding:0pt;padding-left:15.745pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style=" float:left; line-height:7.8pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">(1)<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:7.8pt; text-align:left; margin-left:20pt;font-size:7.5pt;">Estimated solely for purposes of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. The registrant previously paid $1,818 in connection with a prior filing of this Registration Statement. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; line-height:7.8pt; margin-top:2.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">(2)<br ></div>
          <div style=" margin-top:2.19pt; margin-bottom:0pt; line-height:7.8pt; text-align:left; margin-left:20pt;font-size:7.5pt;">The proposed maximum aggregate offering price of the common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the aggregate offering price of the pre-funded warrants offered and sold in the offering (plus the aggregate exercise price of the common stock issuable upon exercise of the pre-funded warrants), and as such the proposed aggregate maximum offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $10,125,000.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:7.7pt; margin-top:2.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">(3)<br ></div>
          <div style=" margin-top:2.29pt; margin-bottom:0pt; line-height:7.7pt; text-align:left; margin-left:20pt;font-size:7.5pt;">Represents warrants issuable to the placement agent or its designees to purchase a number of shares of common stock equal to 7.5% of the number of shares of common stock and pre-funded warrants being offered at an exercise price equal to 125% of the public offering price. See &quot;Plan of Distribution.&quot;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:7.7pt; margin-top:2.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">(4)<br ></div>
          <div style=" margin-top:2.18pt; margin-bottom:0pt; line-height:7.7pt; text-align:left; margin-left:20pt;font-size:7.5pt;">Pursuant to Rule 416 under the Securities Act of 1933, as amended, the securities being registered hereunder include such indeterminate number of additional securities as may be issuable to prevent dilution resulting from stock splits, dividends or similar transactions. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:1pt; width:541pt; line-height:8pt;font-weight:bold;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission acting pursuant to said Section&#160;8(a), may determine.</div>
        <div style="margin-top:0.8pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:19pt;margin-bottom:21.71pt;margin-left:63pt;width:505pt;">
        <div style="text-align:justify; width:505pt; line-height:9.5pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;font-size:7.4pt;">
          <font style="letter-spacing:-0.3pt;font-size:8pt;">The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities, and we are not soliciting offers to buy these securities, in any jurisdiction where the offer or sale is not permitted.</font>
        </div>

          <div style="margin-top:12pt; text-align:center; width:505pt; line-height:11pt;font-weight:bold;color:#FC0014;font-size:10pt;">Subject to Completion, Dated October 11, 2019</div>

        <div style="margin-top:4pt; width:505pt; line-height:8.5pt;font-weight:bold;">PRELIMINARY PROSPECTUS </div>
        <div style="position:relative;z-index:-1;margin-top:7pt; text-align:center; width:505pt;">
          <img src="lg_adynxx.jpg" alt="[MISSING IMAGE: lg_adynxx.jpg]" height="60" width="241" >
        </div>

          <div style="margin-top:9pt; text-align:center; width:505pt; line-height:11pt;font-weight:bold;font-size:10pt;">7,500,000 Shares of Common Stock</div>


          <div style="margin-top:4pt; text-align:center; width:505pt; line-height:11pt;font-weight:bold;font-size:10pt;">Pre-Funded Warrants to Purchase Shares of Common Stock</div>


          <div style="margin-top:4pt; text-align:center; width:505pt; line-height:11pt;font-weight:bold;font-size:10pt;">Common Warrants to Purchase 7,500,000 Shares of Common Stock</div>


          <div style="text-indent:20pt; margin-top:4pt; width:505pt; line-height:8.5pt;">Adynxx, Inc. is offering 7,500,000 shares of common stock and accompanying common warrants to purchase an aggregate of 7,500,000 shares of our common stock. The accompanying common warrants will be exercisable immediately and will expire five years from the date of issuance. Each common warrant has an exercise price of&#8201; $&#8199;&#8199;&#8199;&#8199; per share of common stock.</div>


          <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">We are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded warrants, in lieu of shares of common stock that would otherwise result in such purchaser&#8217;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant is exercisable for one share of our common stock and will be accompanied by a common warrant to purchase one share of common stock. The purchase price of each pre-funded warrant is equal to the price at which a share of common stock is sold to the public in this offering, minus $0.01, and the exercise price of each pre-funded warrant will be $0.01 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full.</div>


          <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">This offering also relates to the shares of common stock issuable upon exercise of the accompanying common warrants and any pre-funded warrants sold in this offering. For each pre-funded warrant that we sell, the number of shares of common stock we are offering will be reduced on a one-for-one basis. Therefore, the number of common warrants sold in this offering will not change as a result of a change in the mix of the shares of our common stock and pre-funded warrants sold. The shares of common stock and pre-funded warrants, and the accompanying common warrants, can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance.</div>


          <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">Our common stock is presently quoted on The OTCQB Market tier of the OTC Markets Group, Inc., or OTCQB, under the symbol &#8220;ADYX.&#8221; On October 9, 2019, the last reported sale price of our common stock was $1.35 per share. The prices quoted on the OTCQB may not be indicative of the market price of our common stock on a national securities exchange. There is no established public trading market for the pre-funded warrants and the accompanying common warrants, and we do not expect a market to develop. In addition, we do not intend to apply for a listing of our common stock, the pre-funded warrants or the accompanying common warrants on any national securities exchange or other nationally recognized trading system.</div>


          <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">The actual combined public offering price per share of common stock and accompanying common warrant or pre-funded warrant and accompanying common warrant, as the case may be, will be determined through negotiation between us and the investors in the offering and may be at a discount to the current market price. Therefore, the recent market price used throughout this prospectus may not be indicative of the offering price. We have retained H.C. Wainwright &amp; Co., LLC to act as our exclusive placement agent in connection with the securities offered by this prospectus. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The placement agent is not purchasing or selling any of the securities we are offering and the placement agent is not required to arrange the purchase or sale of any specific or minimum number of securities or dollar amount. We have agreed to pay to the placement agent the placement agent fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus. See &#8220;Plan of Distribution&#8221; for more information regarding these arrangements.</div>


          <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">Because there is no minimum offering amount required as a condition to the closing of this offering, the actual public offering amount, placement agent fees and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth below. We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue the business goals outlined in this prospectus. In addition, because there is no escrow account and no minimum offering amount in this offering, investors could be in a position where they have invested in us, but we are unable to fulfill our objectives due to a lack of interest in this offering.</div>

        <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8pt;font-weight:bold;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; beginning on page <a href="#tRF">8</a> of this prospectus.</div>
        <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8pt;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</div>

          <table style="width:465pt;height:50pt;margin-left:20pt;margin-top:0.5pt;border-collapse: collapse;">
            <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7.5pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.46pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">PER SHARE </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
                <div style="text-align:center;">PER<br >PRE-FUNDED<br >WARRANT</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
                <div style="text-align:center;">PER<br >COMMON<br >WARRANT</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">TOTAL<font style=" position:relative; bottom:3pt;font-size:5.5pt;">(2)</font></div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:7.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7.5pt;">
              <td style="padding:1.25pt 0pt 0.5pt 0pt; width:251.46pt;text-align:left;">
                <div style="white-space:nowrap;">Public offering price </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.5pt;width:0pt;">&#8203;</td>
              <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:12.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.895pt;width:0pt;">&#8203;</td>
              <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:15.895pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.085pt;width:0pt;">&#8203;</td>
              <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:10.085pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
              <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:7.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7.5pt;">
              <td style="padding:1.5pt 0pt 0.5pt 0pt; width:251.46pt;text-align:left;">
                <div style="white-space:nowrap;">Placement agent&#8217;s fees<font style=" position:relative; bottom:3pt;font-size:5.5pt;">(1)</font></div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.5pt;width:0pt;">&#8203;</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.895pt;width:0pt;">&#8203;</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.895pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.085pt;width:0pt;">&#8203;</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.085pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:7.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7.5pt;">
              <td style="padding:1.5pt 0pt 1pt 0pt; width:251.46pt;text-align:left;">
                <div style="white-space:nowrap;">Proceeds, before expenses, to us </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.5pt;width:0pt;">&#8203;</td>
              <td style="padding:1.5pt 0pt 1pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.5pt 0pt 1pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.895pt;width:0pt;">&#8203;</td>
              <td style="padding:1.5pt 0pt 1pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.5pt 0pt 1pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.895pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.085pt;width:0pt;">&#8203;</td>
              <td style="padding:1.5pt 0pt 1pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.5pt 0pt 1pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.085pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
              <td style="padding:1.5pt 0pt 1pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.5pt 0pt 1pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:6.4pt; width:505pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style=" float:left; margin-top:8.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
          <div style=" margin-top:8.29pt; margin-bottom:0pt; line-height:7.5pt; text-align:left; margin-left:20pt;">We have agreed to reimburse the placement agent for certain expenses in connection with this offering. See &#8220;Plan of Distribution.&#8221;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:9.5pt; margin-top:-1.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
          <div style=" margin-top:-1.2pt; margin-bottom:0pt; line-height:9.5pt; text-align:left; margin-left:20pt;">The public offering price is $&#8199;&#8199;&#8199;&#8199; per share of common stock, $&#8199;&#8199;&#8199;&#8199; per pre-funded warrant, and $&#8199;&#8199;&#8199;&#8199; per accompanying common warrant.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">Provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG, convertible notes in the aggregate principal amount of&#8201; $6.35 million held by entities affiliated with Domain Associates, and any unpaid accrued interest, will automatically convert into 4,874,744 shares of common stock, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying common warrant, the last reported sale price of our common stock by OTCQB on October 9, 2019. The issuance of these shares will not be registered under the Securities Act of 1933, as amended.</div>


          <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">Entities affiliated with Domain Associates, or Domain, and TPG Biotechnology Partners IV, L.P, or TPG, have indicated an interest in purchasing up to an aggregate of&#8201; $4.25 million of securities in this offering at the public offering price per share of common stock and accompanying common warrant or pre-funded warrant and accompanying common warrant, as the case may be. However, because indications of interest are not binding agreements or commitments to purchase, either of Domain or TPG may elect to purchase more, fewer or no securities in this offering or the placement agent may elect to sell more, fewer or no securities in this offering to either of Domain or TPG. The placement agent will receive the same fee from the sale of any of our securities to Domain or TPG as it will from any other of our securities sold to the public in this offering. Any securities purchased by Domain or TPG in this offering will not be subject to the lock-up agreements with the placement agent that are described below. </div>


          <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">Delivery of the shares of common stock, pre-funded warrants, and accompanying common warrants is expected to be made on or about &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2019.</div>


          <div style="margin-top:2pt; text-align:center; width:505pt; line-height:12pt;font-weight:bold;font-size:10pt;">H.C.Wainwright&#160;&amp; Co.</div>

        <div style="margin-top:4pt; text-align:center; width:505pt; line-height:12pt;font-size:10pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2019 </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">TABLE OF CONTENTS </div>

          <table style="width:456pt;height:424.5pt;margin-top:7pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:414pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3pt 0pt;text-align:center;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Page </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.75pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tCD">Certain Defined Terms </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:3.75pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.75pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tCD">ii</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tPS">Prospectus Summary </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tPS">1</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tRF">Risk Factors </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tRF">8</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tSNR">Special Note Regarding Forward-Looking Statements </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tSNR">40</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tIMD">Industry and Market Data </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tIMD">42</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tUOP">Use of Proceeds </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tUOP">43</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tDP">Dividend Policy </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tDP">44</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <a href="#tCAP">Capitalization</a>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tCAP">45</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <a href="#tDIL">Dilution</a>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tDIL">47</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tMOCS">Market for Our Common Stock</a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tMOCS">49</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tMDA">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tMDA">50</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tOB">Our Business </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tOB">63</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tMAN">Management </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tMAN">95</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tECOA">Executive Compensation of Adynxx</a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tECOA">100</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tECA">Executive Compensation of Alliqua</a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tECA">104</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tCR">Certain Relationships and Related Person Transactions </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tCR">108</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tPSS">Principal Stockholders </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tPSS">111</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tDCS">Description of Capital Stock </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tDCS">114</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tDSO">Description of Securities We Are Offering</a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tDSO">118</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tMAT">Material U.S. Federal Income Tax Consequences  </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tMAT">121</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tPOD">Plan of Distribution </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tPOD">128</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tLM">Legal Matters </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tLM">133</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tEXP">Experts </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tEXP">133</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tWYCF">Where You Can Find More Information </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tWYCF">133</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tPF">Adynxx Inc. Unaudited Pro Forma Financial Information</a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tPF">134</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tIF">Index to Financial Statements</a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
                <a href="#tIF">F-1</a>
              </td>
              <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="text-indent:20pt; margin-top:8.98pt; width:456pt; line-height:12pt;">Neither we nor the placement agent have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by us or on our behalf. Neither we nor the placement agent take responsibility for, and can provide no assurance as to the reliability of, any information that others may give you. We and the placement agent are not offering to sell, or seeking offers to buy, the securities offered hereby in any jurisdiction where such offer or sale is not permitted. The information contained in this prospectus or in any applicable free writing prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any sale of the securities offered hereby. Our business, financial condition, results of operations and prospects may have changed since that date. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Persons in jurisdictions outside the United States who come into possession of this prospectus and any applicable free writing prospectus must inform themselves about, and observe any restrictions relating to, this offering and the distribution of this prospectus and any applicable free writing prospectus applicable to such jurisdictions. </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">i</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCD">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CERTAIN DEFINED TERMS </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">As used in this prospectus, unless the context otherwise requires, references to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">&#8220;Adynxx&#8221; or &#8220;Private Adynxx&#8221; refer to Adynxx, Inc. prior to the consummation of the Merger; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">&#8220;Alliqua&#8221; refers to Alliqua BioMedical, Inc. and, unless otherwise stated or the context otherwise requires, its consolidated subsidiaries prior to the consummation of the Merger; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">&#8220;Merger&#8221; refers to the business combination between Adynxx, Inc. and Alliqua BioMedical, Inc., consummated on May&#160;3, 2019, pursuant to which (i)&#160;Embark Merger Sub, Inc., a then wholly-owned subsidiary of Alliqua BioMedical, Inc., merged with and into Adynxx, Inc., with Adynxx, Inc. surviving as a wholly-owned subsidiary of Alliqua BioMedical, Inc., (ii) Alliqua BioMedical, Inc. issued shares of its common stock to stockholders of Adynxx, Inc. at an exchange rate of 0.0359 shares of common stock in exchange for each share of Adynxx, Inc. common stock outstanding immediately prior to the Merger (which exchange rate reflects a 1-for-6 reverse stock split of the issued and outstanding share capital of Alliqua BioMedical, Inc. effected on May&#160;3, 2019, or the &#8220;Merger Stock Split&#8221;). Immediately after the Merger, the former Private Adynxx stockholders, warrantholders and optionholders owned approximately 86% of the fully-diluted common stock of the combined company, and the Alliqua stockholders and optionholders, whose shares of Alliqua common stock remained outstanding after the Merger, owned approximately 14% of the fully-diluted common stock of the combined company, and (iii)&#160;Alliqua BioMedical, Inc. was renamed &#8220;Adynxx, Inc.&#8221;; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and similar references refer: (i)&#160;prior to the consummation of the Merger, to Adynxx, Inc., and (ii) following the consummation of the Merger, to Adynxx, Inc. (formerly Alliqua BioMedical, Inc.) and, unless otherwise stated or the context otherwise requires, all of its subsidiaries.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">ii</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPS">&#8203;</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PROSPECTUS SUMMARY </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">The following summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our securities, you should carefully read this entire prospectus carefully, including our consolidated financial statements and the related notes included in this prospectus and the information set forth herein under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are a clinical stage biopharmaceutical company focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Transcription factor decoys are short strands of DNA that specifically bind to and block the activity of their target transcription factors. Transcription factors are proteins that specifically bind to the regulatory regions of one or more target genes and regulate the expression of those genes. Since the founding of Adynxx in 2007, we have leveraged our AYX platform of proprietary transcription factor decoys to identify and develop novel product candidates designed to modify the course of pain. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe that our transcription factor decoy technology can transform the treatment of pain, and going forward has the potential to be applied to additional disease states. We plan to continue advancing our AYX platform programs while simultaneously developing new transcription factor decoy candidates, collaborating with twoXAR, our artificial intelligence-driven drug discovery partner, and evaluating in-licensing opportunities in order to expand our pipeline and leverage our business development, clinical development and regulatory expertise. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">The AYX Platform of Transcription Factor Decoys </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The AYX platform consists of a wide range of transcription factor decoys, each of which has multiple binding sites capable of targeting one or more transcription factors, and we believe that we have the technological expertise to generate additional decoys based on desired therapeutic characteristics. The AYX platform&#8217;s current drug candidates are intended to treat postoperative pain, or post-surgical, and chronic pain. We plan to leverage our expertise in transcription factor decoy drug discovery and development to identify additional product candidates to treat inflammation-related diseases, including, but not limited to, organ scarring, heart disease and cancer. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Product Pipeline </div>
          <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following table outlines the status of our development programs: </div>
          <div style="position:relative;z-index:-1;margin-top:10.98pt; text-align:center; width:456pt;">
            <img src="tv523241_chrt-org.jpg" alt="[MISSING IMAGE: tv523241_chrt-org.jpg]" height="143" width="553" >
          </div>
          <div style="margin-top:19.39pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Brivoligide for postoperative pain </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Based on data from the Agency for Healthcare Research and Quality&#8217;s 2014 Healthcare Cost and Utilization Project, there are more than 37&#160;million surgical procedures performed in the United States annually. Postoperative pain remains a significant clinical problem, compromising rehabilitation and </div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">health-related quality of life. Severe postoperative pain can result in increased opioid use, prolonged hospital stays, poorer prognosis, and poorer health overall compared to people with less intense pain. In addition, sustained postoperative pain that continues beyond the recovery period is relatively common and not well addressed by current therapies. </div>

            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide is a transcription factor decoy specifically designed to inhibit the function of transcription factor Early Growth Response 1, or EGR1, in the dorsal root ganglia, or DRG, and spinal cord when administered at the time of surgery. EGR1 is a transcription factor expressed in the spinal cord and DRG in response to trauma such as surgery for a period of approximately 12 hours. In normal animals, EGR1 initiates a wide range of gene regulation that results in increased or exacerbated pain following trauma or injury. In contrast, in animals that are unable to express EGR1, third party studies have shown that there is a reduction of pain intensity in response to trauma or injury, which may suggest that EGR1 has a role in elevated post-surgical pain. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">By inhibiting the function of EGR1 in people undergoing surgery, we believe brivoligide can prevent the regulation of genes that lead to an increased sensitivity to pain in some patients following surgery. These patients, who are at greater risk of experiencing increased and prolonged pain after surgery, are readily identifiable prior to surgery as patients scoring high on the Pain Catastrophizing Scale, or PCS, and represent approximately one-third of the surgical population. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pain catastrophizing is an amplified, negative orientation toward pain, which may reflect a specific underlying physiology of pain associated with an enhanced response to painful stimuli as well as relative insensitivity to analgesic, or pain-relieving, therapies such as opioids. Catastrophizing is readily assessed by the PCS, a screening assessment tool for patient selection purposes. Once the PCS is completed by the patient, summation of the responses allows results to be easily available well in advance of surgery in order to determine which patients would potentially benefit from receiving brivoligide. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Patients who have high scores on the PCS may have a specific underlying physiology associated with an enhanced response to painful stimuli. Based on the clinical data we have generated to date from our clinical studies, we believe these patients have an altered pain response that results in the full manifestation of EGR1 activity in response to trauma such as surgery. In this population of patients undergoing surgery, post-hoc anlyses of data generated in the three Phase 2 studies of brivoligide conducted to date indicate that patients receiving a single administration of brivoligide at the time of surgery, in addition to standard of care, experienced reduced pain for weeks and shortened time to achieve mild pain, both as measured using the numerical rating scale, or NRS, when compared to patients receiving placebo and standard of care. These differences were either not statistically significant or could not be considered significant due to the post-hoc nature of the analyses. </div>

            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We estimate that of the 37 million surgical procedures performed in the United States annually, approximately 16 million of those result in a sufficient duration and severity of postoperative pain to be characterized as high unmet analgesic need procedures. Of those 16 million high unmet analgesic need procedures, we expect that approximately one third will be conducted on patients scoring high (&ge;16) on the PCS, representing approximately 5.3 million patients who we believe could be candidates for brivoligide treatment. See &#8220;Business&#8201;&#8212;&#8201;Our Product Candidates&#8201;&#8212;&#8201;Postoperative Pain and Pain Catastrophizing.&#8221; </div>


            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have filed with the U.S. Food and Drug Administration, or the FDA, an Investigational New Drug application, or IND, for brivoligide for the reduction of postoperative pain in patients scoring &ge;16 on the PCS. This IND allows us to conduct the activities required for us to submit a New Drug Application, or NDA, to the FDA for marketing approval and eventual commercialization of brivoligide. In particular, an IND must become effective before human clinical studies for the applicable product candidate may begin and must be updated annually or when significant changes are made. Successful completion of human clinical studies is a prerequisite to submitting an NDA to the FDA, which must be approved before we may commercialize brivoligide in the United States. </div>


            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We plan to conduct a Phase 2 randomized double-blind, placebo-controlled study to evaluate the safety and efficacy of a single intrathecal preoperative administration of brivoligide injection in patients with a PCS score &ge;16 undergoing mastectomy, with prospective enrichment of the study population (in which patients are chosen who are more likely to respond to drug treatment). We plan to commence this Phase 2 </div>

        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">

            <div style="width:456pt; line-height:12pt;">clinical trial as early as the first quarter of 2020, with top-line results expected as early as the first half of 2021, subject to receipt of additional capital to fund the trial through top-line results including receipt of additional funds from our grant award from the National Institute of Drug Abuse, or NIDA, described under &#8220;&#8212; NIH Grant.&#8221; In addition, we plan to conduct a Phase 2 randomized double-blind, placebo-controlled study to evaluate the safety and efficacy of a single intrathecal preoperative administration of brivoligide injection in patients with a PCS score &ge;16 undergoing total knee arthroplasty, or TKA to further explore the results obtained in prior Phase 2 studies in TKA in the proposed target population. We are evaluating whether to commence this Phase 2 clinical trial as early as the first quarter of 2020, with top-line results expected as early as the fourth quarter of 2020, subject to receipt of additional capital to fund the trial through top-line results.</div>


            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">&#8220;Top-line&#8221; data from our clinical studies refer to the results from the initial planned analyses of primary and certain key secondary endpoints from our clinical trials after enrollment has been completed and the data from the study database is locked. Top-line data remain subject to audit and verification procedures that may result in the final data being materially different from previously published top-line data.</div>

          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">AYX2 for chronic pain </div>
          <div style="text-indent:20pt; margin-top:5.21pt; width:456pt; line-height:12pt;">Chronic pain affects as many as 25 million patients annually in the United States and includes such types of pain as low back pain, pain associated with pinched or compressed nerves known as radiculopathy, and pain associated with inflammation of the spinal nerve root known as radiculitis. Chronic pain can be caused and maintained by changes in various components of the pain pathway, including the ongoing regulation of gene activity in the spinal cord and DRG. The transcription factors driving this regulation include a family of transcription factors known as Kruppel-like Factors, or KLF, and constitute a promising class of targets that can potentially alter the course of pain with a single or short-term treatment. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">AYX2, the second product candidate in our pipeline originating from the AYX platform, is a transcription factor decoy targeting the activity of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15. It is being developed for the treatment of chronic pain from multiple causes or origins, including pain resulting from inflammation known as inflammatory pain and pain resulting from nerve damage known as neuropathic pain. Our preclinical work showed that KLF6, KLF9 and KLF15 transcription factors are important to maintaining chronic inflammatory or neuropathic pain. AYX2 is designed to bind to KLF 6, KLF 9 and KLF 15 and block their activity in the spinal cord and DRG. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have tested AYX2 in multiple models of pre-clinical pain, including the spared-nerve injury, or SNI, and chronic constriction injury, or CCI, both of which are well recognized models to test the response to painful stimuli in rats. In these studies, AYX2 produced up to a 60% to 70% reduction in response to painful stimuli compared to control animals, or animals treated with an inactive solution, and the effect was sustained for several weeks.</div>

            <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">NIH Grants</div>


            <div style="text-indent:20pt; margin-top:5.21pt; width:456pt; line-height:12pt;">In December&#160;2018, we received a grant award from NIDA, part of the National Institutes of Health, or NIH, for up to $5.7&#160;million to be reimbursed over 2019 and 2020 to support the conduct of the Phase&#160;2 mastectomy study. If successful, we plan to follow the Phase&#160;2 studies of brivoligide with Phase&#160;3 pivotal studies in both TKA and mastectomy. The design and size of the Phase&#160;3 studies will be determined after completion of the respective Phase&#160;2 studies. Based on the funding opportunity announcement under which we received the award, and on the milestones and budget outlined in our application, following completion of milestones related to the Phase&#160;2 mastectomy study, including receipt of positive data for the Phase 2 mastectomy study and clear guidance from the FDA at an end of phase 2 meeting, we may be eligible to receive an additional award of up to $9.0&#160;million over three&#160;years to fund a Phase&#160;3 mastectomy study.</div>


            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In September 2019, we received a Notice of Award from the National Institute on Neurological Disease and Stroke, or NINDS, part of the NIH, for up to approximately $0.6&#160;million to be paid over 12&#160;months to support our planned preclinical studies of AYX2. The funds will become available after approval from the Office of Laboratory Animal Welfare, or OLAW, of the planned preclinical studies for AYX2.</div>

        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Collaboration with twoXAR to identify product candidates for the treatment of endometriosis </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Endometriosis is an often painful disorder in which tissue similar to the lining of the uterus grows in other places outside of the uterus. Approximately 4.4&#160;million women suffer from endometriosis in the United States, with up to 175,000 new diagnoses projected annually by 2022. Symptoms of endometriosis include chronic pelvic pain, painful menstruation and sexual intercourse, infertility, and painful hypersensitivity. In endometriosis patients, severity of symptoms increases with age, yet symptom severity is not always correlated with extent of disease. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2018, we entered into a collaboration with twoXAR, an artificial intelligence-driven drug discovery company, in order to identify product candidates for the treatment of endometriosis. Through this collaboration, we seek to identify product candidates with disease-modifying potential to treat or prevent the recurrence of endometriosis and associated symptoms. New disease-modifying treatments addressing the underlying pathology of endometriosis are sought to address the unmet need associated with the current standard of care. In June 2019, we received an initial set of product candidate predictions from twoXAR. We have initiated a review of the potential product candidates to determine if any are viable candidates for further research and development. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Highly experienced management team with significant operational and commercialization experience </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have a highly experienced management team whose members have, in the course of their prior employment, participated in bringing more than 10 product candidates through clinical development, regulatory approval and/or into commercialization, including such approved products as Zerbaxa, Teflaro, Doribax, Vibativ, Symproic, Embeda, Revlimid, Mulpleta, Osphena, Comtan, FocalinXR, Trileptal, Kapvay and Cuvposa. We plan to leverage our management team&#8217;s breadth and depth of experience in clinical and regulatory drug development as well as market development and commercialization to advance our existing product candidates, and to discover and develop additional product candidates in-house using the AYX platform and build our pipeline through collaboration and in-licensing activities. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Corporate Information </div>

            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Private Adynxx was a Delaware corporation that was originally formed in 2007 under the name Adynxx, Inc. On May&#160;3, 2019, Private Adynxx completed the Merger with Alliqua BioMedical, Inc., or Alliqua, and we survived as a wholly-owned subsidiary of Alliqua. Following the consummation of the Merger, Adynxx changed its name to Adynxx Sub, Inc., and Alliqua BioMedical, Inc. changed its name to Adynxx, Inc. Our common stock subsequently began trading on The Nasdaq Capital Market, or Nasdaq, under the symbol &#8220;ADYX.&#8221; In June 2019, Nasdaq delisted our common stock due to our noncompliance with Nasdaq&#8217;s minimum stockholders&#8217; equity requirement and minimum round lot shareholder requirement. Our common stock is presently quoted on The OTCQB Market tier of the OTC Markets Group, Inc., or OTCQB, under the symbol &#8220;ADYX.&#8221; We do not intend to list our common stock or any other securities offered hereby on a national securities exchange in connection with this offering.</div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Alliqua was a Delaware corporation that was originally formed in 1997 under the name Zeta Corporation in Florida. On April&#160;17, 2003, Zeta Corporation changed its name to Hepalife Technologies, Inc., and on December&#160;20, 2010, Zeta Corporation changed its name to Alliqua, Inc. On June&#160;6, 2014, pursuant to an Agreement and Plan of Merger, Alliqua merged with and into its wholly-owned Delaware subsidiary, Alliqua BioMedical, Inc. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our principal executive offices are located at 100 Pine Street, Suite 500, San Francisco, California 94111, and our telephone number is (415) 512-7740. Our corporate website address is www.adynxx.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">&#8220;Adynxx,&#8221; the Adynxx logo, &#8220;Alliqua&#8221; and other trademarks or service marks of Adynxx appearing in this prospectus are our property. This prospectus contains additional trade names, trademarks, and service marks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.</div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">THE OFFERING </div>
          <div style="width:156pt;">
            <div style="margin-top:6pt; line-height:12pt;">Common stock offered by us </div>
          </div>

            <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">7,500,000 shares.</div>


            <div style="width:156pt;">
              <div style="margin-top:6pt; line-height:12pt;">Pre-funded warrants offered by us</div>
            </div>


            <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">We are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the closing of this offering, the opportunity to purchase, if such purchasers so choose, pre-funded warrants to purchase shares of common stock, in lieu of shares of common stock that would otherwise result in any such purchaser&#8217;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant is exercisable for one share of our common stock. The purchase price of each pre-funded warrant and accompanying common warrant is equal to the price at which a share of common stock and accompanying common warrant is being sold to the public in this offering, minus $0.01, and the exercise price of each pre-funded warrant is $0.01 per share. The pre-funded warrants are exercisable immediately and may be exercised at any time until all of the pre-funded warrants are exercised in full.</div>


            <div style="margin-left:180pt; margin-top:6pt; width:276pt; line-height:12pt;">This offering also relates to the shares of common stock issuable upon exercise of any pre-funded warrants sold in this offering. For each pre-funded warrant that we sell, the number of shares of common stock that we are offering will be reduced on a one-for-one basis. Because we will issue a common warrant for each share of our common stock and for each pre-funded warrant to purchase one share of our common stock sold in this offering, the number of common warrants sold in this offering will not change as a result of a change in the mix of the shares of our common stock and pre-funded warrants sold.</div>


            <div style="width:156pt;">
              <div style="margin-top:6pt; line-height:12pt;">Common warrants offered by us</div>
            </div>


            <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">Common warrants to purchase an aggregate of 7,500,000 shares of our common stock. Each share of our common stock and each pre-funded warrant is being sold together with a common warrant to purchase one share of our common stock. Each common warrant will have an exercise price of&#8201; $&#8199;&#8199;&#8199;&#8199; per share, will be immediately exercisable and will expire on the fifth anniversary of the original issuance date. This prospectus also relates to the offering of the shares of common stock issuable upon exercise of the common warrants.</div>

          <div style="width:156pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">Common stock to be outstanding after this offering </div>
          </div>

            <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">18,182,621 shares, assuming no sale of any pre-funded warrants and assuming no exercise of any common warrants issued in this offering. </div>

          <div style="width:156pt;">
            <div style="margin-top:6pt; line-height:12pt;">Use of proceeds </div>
          </div>

            <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">We estimate that the net proceeds from this offering will be approximately $8.2 million, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying common warrant, the last reported sale price of our common stock by OTCQB on October&#160;9, 2019, after </div>

        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">

            <div style="margin-left:180pt; width:276pt; line-height:12pt;">deducting placement agent fees and estimated offering expenses payable by us, and assuming the sale of the maximum offering amounts set forth in this prospectus. </div>


            <div style="margin-left:180pt; margin-top:6pt; width:276pt; line-height:12pt;">We intend to use the net proceeds from this offering to conduct clinical trials of brivoligide for postoperative pain and to further develop AYX2 for chronic pain, to fund continued research and development, to service our outstanding indebtedness and for working capital and other general corporate purposes. See &#8220;Use of Proceeds&#8221; for additional information. </div>

          <div style="width:156pt;">
            <div style="margin-top:6pt; line-height:12pt;">Risk factors </div>
          </div>

            <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">Investing in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our securities. </div>

          <div style="width:156pt;">
            <div style="margin-top:6pt; line-height:12pt;">OTCQB symbol </div>
          </div>
          <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">&#8220;ADYX&#8221; </div>

            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June 2019, Nasdaq delisted our common stock due to our noncompliance with Nasdaq&#8217;s minimum stockholders&#8217; equity requirement and minimum round lot shareholder requirement. We do not intend to list the common stock, pre-funded warrants or common warrants on any securities exchange or nationally recognized trading system in connection with this offering. Without a trading market, the liquidity of the common stock, pre-funded warrants and common warrants will be extremely limited. </div>


            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG, convertible notes in an aggregate principal amount of&#8201; $6.35&#160;million held by entities affiliated with Domain Associates, and any unpaid accrued interest, will automatically convert into 4,874,744&#160;shares of common stock, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying common warrant, the last reported sale price of our common stock by OTCQB on October&#160;9, 2019. The issuance of these shares will not be registered under the Securities Act of 1933, as amended, or the Securities Act.</div>


            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Domain and TPG have indicated an interest in purchasing up to an aggregate of&#8201; $4.25 million of securities in this offering at the public offering price per share of common stock and accompanying common warrant or pre-funded warrant and accompanying common warrant, as the case may be. However, because indications of interest are not binding agreements or commitments to purchase, either of Domain or TPG may elect to purchase more, fewer or no securities in this offering or the placement agent may elect to sell more, fewer or no securities in this offering to either of Domain or TPG. The placement agent will receive the same fee from the sale of any of our securities to Domain or TPG as it will from any other of our securities sold to the public in this offering. Any securities purchased by Domain or TPG in this offering will not be subject to the lock-up agreements with the placement agent that are described below.</div>


            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The number of shares of common stock that will be outstanding after this offering is based on 5,807,877 shares of common stock outstanding as of June&#160;30, 2019, and excludes:</div>


            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">747,879 shares of common stock issuable upon the exercise of outstanding stock options as of June 30, 2019, with a weighted-average exercise price of&#8201; $20.52 per share, under our equity incentive plans or not granted pursuant to a written equity incentive plan;</div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">3,332 shares of common stock issuable from time to time after this offering upon the settlement of restricted stock awards, or RSAs, outstanding as of June&#160;30, 2019 under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan; </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">57,897 shares of common stock issuable upon the exercise of outstanding warrants as of June&#160;30, 2019, with a weighted-average exercise price of&#8201; $97.66 per share; </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">9,188 shares of common stock reserved for future issuance under the Alliqua, Inc. 2011 Long-Term Incentive Plan; and </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">6</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">

            <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" line-height:12pt; text-align:left; margin-left:40pt;">72,436 shares of common stock reserved for future issuance under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan. </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, unless we specifically state otherwise, all information in this prospectus reflects or assumes:</div>


            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the issuance of 4,874,744 shares of common stock at the closing of the offering upon the conversion of outstanding convertible notes in the aggregate principal amount of&#8201; $6.35&#160;million plus accrued interest based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying common warrant, the last reported sale price of our common stock by OTCQB on October&#160;9, 2019, provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG; </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">no exercise of the outstanding options or warrants described above; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">no exercise of the common warrants or placement agent warrants; and</div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">no sale of any pre-funded warrants in this offering.</div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">7</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">RISK FACTORS </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">Investing in the securities offered hereby involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this prospectus, including our consolidated financial statements and related notes included in this prospectus, before deciding whether to invest in the securities offered hereby. If any of these risks actually occur, it could harm our business, financial condition, results of operations and cash flows and our prospects. In that event, the trading price of our common stock and the value of the pre-funded warrants could decline and you could lose part or all of your investment.</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Our Financial Condition and Capital Requirements </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have incurred losses since our inception, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are a clinical development-stage biopharmaceutical company with a limited operating history. On May&#160;3, 2019, we completed the Merger with Alliqua BioMedical, Inc., and we survived as a wholly-owned subsidiary of Alliqua. Following the consummation of the Merger, Adynxx changed its name to Adynxx Sub, Inc., and Alliqua BioMedical, Inc. changed its name to Adynxx, Inc. Adynxx was deemed to be the accounting acquirer in the Merger and the historical financial statements of Private Adynxx are deemed to be the historical financial statements of the combined company. We have incurred net losses for the past several&#160;years, including net losses of&#8201; $7.1&#160;million, $6.0&#160;million and $11.6&#160;million for the six&#160;months ended June&#160;30, 2019 and the&#160;years ended December&#160;31, 2018 and 2017, respectively. As of June&#160;30, 2019, we had an accumulated deficit of&#8201; $44.4&#160;million. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, we had $12.0&#160;million in current and long-term liabilities. In addition, since June&#160;30, 2019, we issued an additional $0.6&#160;million in convertible promissory notes, or Notes. Our management concluded that there is substantial doubt about our ability to continue as a going concern. The audit report to our financial statements for the year ended December&#160;31, 2018, which is included elsewhere in this prospectus, also includes an explanatory paragraph related to our ability to continue as a going concern. The doubts concerning our ability to continue as a going concern may impact our ability to obtain financing on reasonable terms or at all. As of June&#160;30, 2019, we had cash and cash equivalents of&#8201; $24,000. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have devoted substantially all of our financial resources to identifying and developing our product candidates, including conducting clinical trials and providing general and administrative support for our operations. To date, we have financed our operations primarily through the sale of equity securities, payments associated with strategic collaborations, secured loan agreements and convertible notes. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We expect losses to increase as we continue Phase&#160;2 development of our lead program brivoligide in two models of postoperative pain and potentially advance additional product candidates through investigational new drug, or IND, enabling activities and into clinical development. While we have not yet commenced pivotal clinical trials for any product candidate and it may be several&#160;years, if ever, before we complete pivotal clinical trials and have a product candidate approved for commercialization, we expect to invest significant funds into these clinical candidates to determine the potential to advance these compounds to regulatory approval. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market acceptance, hospital formulary access, pricing, reimbursement from third-party payors, and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates, because the potential markets in which our product candidates may ultimately receive regulatory approval could be very small, we may never become profitable despite obtaining such market share and acceptance of our products.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">8</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">continue the clinical development of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">advance our programs into larger, more expensive clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">initiate additional nonclinical, clinical, or other studies for our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">identify and develop potential commercial opportunities, such as reduction in postoperative pain for patients scoring &ge;16 on the Pain Catastrophizing Scale, or PCS, for the brivoligide product candidate; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">seek regulatory and marketing approvals and reimbursement for our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">continue manufacturing our product candidates and plan for scale-up of outsourced manufacturing capabilities as we commence additional clinical trials for our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">seek to identify, assess, acquire, and/or develop other product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">make milestone, royalty or other payments under third party license agreements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">seek to maintain, protect, and expand our intellectual property portfolio; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">seek to attract and retain skilled personnel; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">experience any delays or encounter issues with the development and potential for regulatory approval of our clinical candidates such as safety issues, clinical trial accrual delays, longer follow-up for planned studies, additional major studies, or supportive studies necessary to support marketing approval. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have never generated any revenue from product sales and may never be profitable. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have no products approved for commercialization and have never generated any revenue from product sales. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of our product candidates. We do not anticipate generating revenue from product sales for the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">completing research and development of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">obtaining regulatory and marketing approvals for our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that meet regulatory requirements and our supply needs in sufficient quantities to meet market demand for our product candidates, if approved; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">marketing, launching and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">gaining market acceptance of our product candidates as treatment options; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">addressing any competing products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">9</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">protecting and enforcing our intellectual property rights, including patents, trade secrets, and know-how; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.62pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:3.62pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">obtaining reimbursement or pricing for our product candidates that supports profitability; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:3.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">attracting, hiring, and retaining qualified personnel. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. We will have to develop or acquire commercial-scale manufacturing capabilities in order to continue development and potential commercialization of our product candidates. Additionally, if we are not able to generate revenue from the sale of any approved products, we may never become profitable. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Servicing our indebtedness requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial indebtedness. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, our total current and long-term liabilities balance was $12.0&#160;million, of which $2.4&#160;million was secured indebtedness, collateral for which includes, but is not limited to, our intellectual property rights. Our ability to make scheduled payments of the principal, to pay interest on, to refinance the secured loan agreement with Oxford Finance, or the Loan Agreement, or Notes or to make cash payments in connection with any conversion of the Notes depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control and ability to raise additional capital. We may not be able to raise sufficient capital or generate cash flow from operations in the future sufficient to service our indebtedness and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives if they are available to us based on the terms of the instruments and agreements governing the indebtedness, such as restructuring indebtedness or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. If we default under the Loan Agreement, Oxford Finance will have the ability to exercise its rights as collateral agent to take possession and dispose of the collateral securing the indebtedness under the Loan Agreement, which collateral includes all of our property, including our intellectual property. Our business, financial condition and results of operations could be substantially harmed as a result of any such foreclosure. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Despite our current indebtedness levels, we may still incur substantially more indebtedness or take other actions which would intensify the risks discussed above. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Despite our current indebtedness levels, and the restrictions we are under based on the terms of the Loan Agreement from incurring additional senior indebtedness, we may be able to incur substantial additional indebtedness in the future, subject to any restrictions contained in our then-existing debt instruments, some of which may be secured indebtedness, however the terms of such indebtedness may not be commercially attractive, if available. </div>

          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We face risks related to government funded awards. If NIDA/NIH or NINDS/NIH were to eliminate, reduce or delay funding from these awards, this would have a significant negative impact on the brivoligide program. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are substantially dependent upon awards from NIDA/NIH and NINDS/NIH for the costs related to the planned brivoligide Phase&#160;2 and Phase&#160;3 mastectomy model studies and the development of AYX2, respectively. If NIDA/NIH or NINDS/NIH were to eliminate, reduce or delay the funding for either or both of these awards or disallow some of our incurred costs, we would have to obtain additional funding for continued development or regulatory registration for brivoligide and AYX2 or significantly delay, reduce or stop the development effort. In contracting with NIDA/NIH and NINDS/NIH, we are subject to various U.S. government contract requirements which may limit reimbursement or if we are found to be in violation could result in contract termination. If the U.S. government terminates our award for its convenience, or if we default by failing to perform in accordance with the award schedule and terms, significant negative impact on our cash flows and operations could result. </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">10</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">To the extent that we raise additional capital through the sale of equity, debt or other securities convertible into equity, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, would likely involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or more of our development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on potential business opportunities, which could materially affect our business, financial condition, and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to the Development of Our Product Candidates </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are heavily dependent on the success of our lead product candidate, brivoligide, which is in the early stages of clinical development, and our other product candidates, which are in pre-clinical development. We cannot give any assurance that we will generate data sufficient to receive regulatory approval, which will be required before any of our product candidates can be commercialized. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">To date, we have invested substantially all of our efforts and financial resources to identify and develop our portfolio of product candidates. Our future success is dependent on our ability to successfully further develop, obtain regulatory approval for, and commercialize one or more product candidates. We currently generate no revenue from sales of any drugs, and we may never be able to develop or commercialize a product candidate. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our product candidate brivoligide, which is currently in Phase&#160;2 of clinical development, is being developed for the reduction of postoperative pain in patients scoring &ge;16 on the PCS. We have not prospectively demonstrated a statistically significant clinical benefit in this patient population for the primary endpoint in any clinical trial and may not be able to do so. Furthermore, the U.S. Food and Drug Administration, or the FDA, has not previously granted an indication for the reduction of postoperative pain in patients scoring &ge;16 on the PCS. Additionally, in order to obtain an indication for the reduction of postoperative pain without restriction by type of surgical procedure, we intend to study brivoligide in pivotal trials in one orthopedic and one soft-tissue model of postoperative pain. We have studied brivoligide to date in TKA, an orthopedic model of postoperative pain, and intend to study brivoligide in mastectomy with immediate tissue expander or implant placement, or mastectomy, as a soft-tissue model of postoperative pain. Failure to demonstrate efficacy in both an orthopedic and soft-tissue model of postoperative pain may limit the likelihood of FDA approval for brivoligide for postoperative pain, may limit approval to a subset of surgical procedures, and may limit the addressable patient population and related commercial opportunity. Further, we may not be able to replicate or develop additional data to satisfy regulatory requirements for approval. Our other product candidate, AYX2, has not yet been evaluated in clinical trials and may fail to show the desired safety and efficacy during clinical development. There can be no assurance that the data that we develop for our product candidates in their planned indications will be sufficient to obtain regulatory approval. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our current product candidates are for the treatment of pain. The evaluation of pain therapeutics often relies upon patient-reported outcomes of pain, such as the Numerical Rating Scale, or NRS, as clinical trial endpoints. While these endpoints are well-validated and accepted by the FDA and comparable foreign authorities for evaluation of efficacy of product candidates for the treatment of pain, there may be increased variability associated with these patient-reported outcomes as compared to objective measures used in evaluation of efficacy for product candidates treating other disease states. If these patient-reported endpoints are associated with increased variability in future studies, the data generated may not be sufficient to obtain regulatory approval. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">11</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">In addition, none of our product candidates have advanced into a pivotal study for their proposed indications and it may be&#160;years before such studies are initiated and completed, if at all. We are not permitted to market or promote any of our product candidates before they receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our research and development is focused on discovering and developing novel drugs based on transcription factor decoys, and the approach we are taking to discover and develop drugs is not proven and may never lead to marketable products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The discovery and development of drugs based on transcription factor decoys is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing differentiated product candidates based on these discoveries is both preliminary and limited, and has not led to products which have obtained regulatory approval by the FDA or comparable foreign authorities. Therefore, we do not know if our approach will be successful. Failure by any transcription factor decoy, including those currently being developed by us, would adversely impact this platform technology. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, our product candidates are all based on a single platform technology. If we were required to discontinue development of brivoligide because the related trials are unsuccessful or do not demonstrate sufficiently positive results to continue development of brivoligide, development of our other product candidates may be harmed. Moreover, if we decide to leverage any success with brivoligide to develop our other product candidates reliant on our platform technology, we may not be successful in such efforts. In any such event, our business will be adversely impacted.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our research and development is focused on discovering and developing non-opioid therapies to treat pain. We are not developing our product candidates to address opioid dependence, and any potential impact these therapies may have on opioid usage is speculative and may never be supported by clinical data. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our product candidates are being developed for the treatment of pain. There can be no assurance that any of these product candidates will have any impact on potential opioid usage in patients who use our product candidates, if approved. There remains significant uncertainty regarding the assessment of opioid-sparing outcomes in clinical trials of product candidates addressing pain as well as the clinical relevance of any such results. Further, there is no clear guidance from regulators on the design or endpoints of clinical trials intended to evaluate pain and related opioid usage and what clinical data, if any, would be necessary to support potential claims of reduced opioid usage or opioid-sparing effects. As a result of this uncertainty, we cannot assess, and can provide no assurance of, the potential impact, if any, that our product candidates may have on opioid usage for pain or as analgesic therapy. In addition, we have not evaluated, and do not intend to evaluate, the potential effect of our product candidates on opioid dependence. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have yet to present the current clinical data to the relevant regulatory authorities to give an opinion on the clinical development pathway for brivoligide. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We plan to present the clinical and non-clinical data sets for brivoligide to the FDA and relevant foreign regulatory authorities after completion of the planned Phase&#160;2 studies at an End of Phase&#160;2 meeting or receipt of scientific advice from the EMA, as applicable. Until the results of these meetings are known and documented, there can no assurance as to what requirements may be imposed for filing a New Drug Application, or NDA, or Marketing Approval in the EMA for brivoligide. We are currently relying on opinions from experts and regulatory precedents to design our development program. It is possible that the official position of the applicable regulatory authorities will be substantially different from the advice we have received. Any such difference could increase both the time and cost required to obtain the necessary regulatory approvals for brivoligide, which may in turn limit or prohibit its further development, resulting in a material harm to our business, financial condition, results of operations and prospects. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">12</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Even if we successfully complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the regulatory approval may be for a more narrow indication than we seek. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many&#160;years following the commencement of clinical trials, and depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. We have not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the FDA or comparable foreign regulatory authorities may disagree with the design, size or implementation of our clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the FDA or comparable foreign regulatory authorities may disagree with the use of and definition of one orthopedic and one soft-tissue surgical model of postoperative pain as appropriate for approval for general postoperative pain; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the FDA does not currently have published guidance on the requirements for a general postoperative pain indication and may publish guidance that is not in alignment with our current clinical development plans, which may cause us to alter development plans, thereby increasing the costs and time required to complete clinical development of brivoligide; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the FDA or comparable foreign regulatory authorities may disagree with the use of the PCS as a tool for patient selection for treatment with brivoligide; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the population studied in our clinical trials may not be sufficiently broad or representative to assure safety in the full population for which we seek approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from our preclinical studies or clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United&#160;States or foreign jurisdictions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the FDA or comparable foreign regulatory authorities may find failures in our manufacturing processes, validation procedures and specifications, or facilities of the third-party manufacturers with which we contract for clinical and commercial supplies that may delay or limit our ability to obtain regulatory approval for our product candidates; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our NDA or other applicable regulatory submissions insufficient for approval. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The lengthy and uncertain regulatory approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. Even if our product candidates meet their safety and efficacy endpoints in clinical trials, the relevant regulatory authorities may not complete their review processes in a timely manner, may issue a complete response letter, or ultimately, may not approve our product candidates. In addition, we may experience delays or rejections if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">13</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of data obtained from preclinical and clinical testing could delay, limit or prevent the receipt of marketing approval for a product candidate. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Drug development involves a lengthy and expensive process with an uncertain outcome, and results of preclinical studies and earlier clinical trials may not be predictive of future results. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Clinical testing is expensive and generally takes many&#160;years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of larger, later-stage clinical trials. Product candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical trials. Our clinical trials to date have been conducted on a small number of patients in limited numbers of clinical sites. We will have to conduct larger studies in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. We have spent several years conducting clinical studies for our lead product candidate and anticipate that we will continue conducting clinical studies for a few more years. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether any Phase&#160;2, Phase&#160;3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to obtain regulatory approval to receive regulatory approval or market our product candidates. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Interim, &#8220;top-line,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as additional analyses are conducted, and as the data are subject to audit and verification procedures that could result in material changes in the final data.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">From time to time, we may publish interim, &#8220;top-line,&#8221; or preliminary data from our clinical studies. Interim data are data analyzed before completion of enrollment of a clinical trial, and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. &#8220;Top-line&#8221; or preliminary data from our clinical studies refer to the initial planned analyses of primary and certain key secondary endpoints from clinical trials after enrollment has been completed and the data from the study database is locked. These data remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, &#8220;top-line&#8221; and preliminary data should be viewed with caution until the final data are available. Significant changes between preliminary, &#8220;top-line,&#8221; or interim data and final data could harm our business.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may find it difficult to enroll patients in our clinical trials given the limited number of patients scoring &ge;16&#160;on the PCS who are undergoing the procedures we intend to use as our models of postoperative pain for testing of brivoligide. We may also find it difficult to enroll patients in surgical models that are performed under general anesthesia due to the intrathecal route of administration of brivoligide. Difficulty in enrolling patients could delay or prevent the completion of clinical trials of our product candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Identifying and qualifying patients to participate in clinical trials of our product candidates is essential to their success. The timing of our clinical trials depends in part on the rate at which we can recruit patients to participate in clinical trials of our product candidates, and we may experience delays in completion of our clinical trials if we encounter difficulties in enrollment. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In future clinical trials of brivoligide, we will be evaluating brivoligide using surgical models including but not limited to TKA and mastectomy. While we have successfully completed enrollment in three Phase&#160;2 studies of postoperative pain following TKA to date within projected timelines, we may not be able to do so successfully in the future. We have never conducted a study using the mastectomy model of postoperative pain, and may not meet projected enrollment timelines. Some competitors have ongoing clinical trials for product candidates that use the same surgical models as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in competitors&#8217; clinical trials. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The eligibility criteria of our planned clinical trials may further limit the availability of suitable clinical trial participants as we expect to require that patients have specific measurable characteristics or meet </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">14</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">certain criteria to assure that they are appropriate for inclusion in our clinical trials. In future clinical trials of brivoligide, we will be evaluating brivoligide in patients scoring &ge;16 on the PCS. Approximately one-third of individuals score &ge;16 on the PCS, however if this rate is not reflected in patient populations at the clinical trial sites, we may have fewer patients eligible for enrollment than expected. In addition, we may not be able to identify, recruit, and enroll a sufficient number of patients to complete our clinical trials in a timely fashion because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical trials, the willingness of patients to receive an intrathecal injection if undergoing a surgical procedure typically performed under general anesthesia, and the willingness of physicians to participate in our planned clinical trials. If patients are unwilling to participate in our clinical trials for any reason, the timeline for conducting studies and obtaining regulatory approval of our product candidates may be delayed. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In addition, any delays in completing our clinical trials would likely increase overall costs, impair product candidate development and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences may harm our business, financial condition, and prospects significantly. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Clinical trials are costly, time consuming and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Clinical development is expensive, time consuming and involves significant risk. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of development. Events that may prevent successful or timely completion of clinical development include but are not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">inability to generate satisfactory preclinical, toxicology, or other <font style="font-style:italic;">in vivo</font> or <font style="font-style:italic;">in vitro</font> data to support the initiation or continuation of clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">delays in reaching agreement on acceptable terms with contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">delays in obtaining required Institutional Review Board, or IRB, approval at each clinical trial site; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">refusal to permit the conduct of a clinical trial by regulatory authorities, after review of an IND, or equivalent foreign application or amendment; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">delays in recruiting qualified patients in our clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">failure by clinical sites or our CROs or other third parties to adhere to clinical trial requirements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">failure to perform in accordance with the FDA&#8217;s Good Clinical Practice requirements, or GCP, or applicable foreign regulatory guidelines; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">high patient drop-out rate in our clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">occurrence of adverse events, or AEs, associated with our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the cost of clinical trials of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">negative or inconclusive results from our clinical trials which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development programs in other ongoing or planned indications for a product candidate; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">delays in reaching agreement on acceptable terms with third party manufacturers and the time for manufacture of sufficient quantities of our product candidates for use in clinical trials. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">15</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Any inability to successfully complete clinical development and obtain regulatory approval could result in additional costs to us or impair our ability to generate revenue. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow competitors to develop and bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or terminate clinical trials, delay regulatory approval by the FDA or comparable foreign regulatory authorities or, even if approved, result in restrictive labelling of our products. We will continue to evaluate our product candidates in additional clinical trials, and there is no guarantee that severe side effects will not be identified. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide targets Early Growth Response 1, or EGR1, a transcription factor that has a role in memory consolidation within the hippocampus. There is a potential risk of transient alteration in memory function with brivoligide if sufficient material is distributed to the brain. This risk has been evaluated in preclinical studies and in the clinical trials conducted to date, but has not been observed; however, studies using the mastectomy model will involve movement of the brivoligide injection to the upper regions of the spinal canal which may involve increased risk of brain exposure and possible transient cognitive or memory dysfunction. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide is intended to prevent or reduce exacerbated pain following surgery and not to mask, numb or otherwise alter a patient&#8217;s normal response to pain. However, we have not conducted studies on or otherwise evaluated any masking effect of brivoligide on a patient&#8217;s pain response function. If patients, physicians or other healthcare providers consider brivoligide to alter patients&#8217; normal pain response in a manner that would be considered detrimental to recovery, that would be considered an undesirable side effect and would harm our ability to develop brivoligide and future market acceptance of brivoligide. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additionally, even if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, potentially significant negative consequences could result, including but not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">withdrawal of regulatory approvals of such products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">requirements by regulatory authorities to place additional warnings on the label of such products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">requirement by regulatory authorities to create a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">potential lawsuits, which may result in us being held liable for harm caused to patients; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reputational harm. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, even if approved, and could significantly harm our business, results of operations, and prospects. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may not be successful in any efforts to identify, license, discover, develop, or commercialize additional product candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although a substantial amount of our effort will focus on the continued clinical testing, potential approval, and commercialization of our existing product candidates, the success of our business is also expected to depend in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development and commercialization for a number of reasons, including but not limited to the following: </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">16</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our collaboration with twoXAR, which relies upon artificial intelligence technology to generate potential product opportunities, may not generate viable product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our product candidates may not succeed in preclinical or clinical testing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">competitors may develop alternatives that render our product candidates obsolete or less attractive; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the market for a product candidate may change during our development program so that such a product may become unreasonable to continue to develop; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, license, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may not be successful in meeting our diligence obligations under our existing collaboration with twoXAR or under future license agreements necessary to maintain and continue to use product candidate licenses in effect. In addition, if required in order to commercialize our product candidates, we may be unsuccessful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may seek to obtain rights to intellectual property, through licenses from third parties and under patents that we do not own, to develop and commercialize additional product candidates, such as our collaboration with twoXAR. Because our programs may require the collaboration with or use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to maintain in effect these collaborations and proprietary rights. For example, we have certain specified diligence obligations under our collaboration with twoXAR. We may not be able to achieve the required diligence milestones in a timely manner, which may result in a right of termination by twoXAR, and we may be unable to successfully negotiate an extension or waiver of those termination rights. Any termination of the collaboration with twoXAR or future license agreements with third parties with respect to our product candidates would be expected to negatively impact our business prospects. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if we are able to license or acquire third-party intellectual property rights that are necessary for our product candidates, there can be no assurance that they will be available on favorable terms. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">17</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We collaborate with U.S. and foreign academic institutions to identify product candidates, accelerate our research and conduct development. Typically, these institutions have provided us with an option to negotiate an exclusive license to any of the institution&#8217;s rights in the patents or other intellectual property resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue a program of interest to us. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we are unable to successfully obtain and maintain rights to required third-party intellectual property, we may have to abandon development of that product candidate or pay additional amounts to the third party, and our business and financial condition could suffer. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory requirements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If our product candidates are approved, they will be subject to ongoing regulatory requirements with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy and other post-approval information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Manufacturers and manufacturers&#8217; facilities are required to continuously comply with FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices, or cGMP, regulations and corresponding foreign regulatory manufacturing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA or marketing authorization application, or MAA. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product candidate may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase&#160;4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. We will be required to report certain adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. If our original marketing approval for a product candidate was obtained through an accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial in order to confirm the clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If a regulatory agency discovers previously unknown problems with a product, such as AEs of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, the regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">issue warning letters; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">impose civil or criminal penalties; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">suspend or withdraw regulatory approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">suspend any of our ongoing clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">refuse to approve pending applications or supplements to approved applications submitted by us; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">require a product recall. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">18</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Any government investigation of alleged violations of law would be expected to require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to develop and commercialize our products and our value and operating results would be adversely affected. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We rely on third parties to conduct our clinical trials, and perform other clinical development-related services, such as drug shipping, blinding and randomization, data collection, and biostatistical analysis. If these third parties do not successfully perform and comply with regulatory requirements, we may not be able to successfully complete clinical development, obtain regulatory approval or commercialize our product candidates and our business could be substantially harmed. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have relied upon and plan to continue to rely upon third-party CROs to conduct, monitor and manage our ongoing clinical program. We rely on these parties for execution of clinical trials and we manage and control only certain aspects of their activities. We remain responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with all applicable laws, regulations and guidelines, including those required by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. If we or any of our CROs or vendors fail to comply with applicable laws, regulations and guidelines, the results generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot guarantee that our CROs and other vendors will meet these requirements, or that upon inspection by any regulatory authority, such regulatory authority will determine that activities conducted by our third-party vendors in support of any of our clinical trials comply with applicable requirements. Failure to comply with these laws, regulations and guidelines may require us to repeat clinical trials, which would be costly and delay the regulatory approval process. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs in a timely manner or do so on commercially reasonable terms. In addition, our CROs may not prioritize our clinical trials relative to those of other customers and any turnover in personnel or delays in the allocation of CRO employees by the CRO may negatively affect our clinical trials. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, our clinical trials may be delayed or terminated and we may not be able to meet our current plans with respect to our product candidates. CRO contracts may also involve higher costs than anticipated, which could negatively affect our financial condition and operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, and if approved, we intend to rely on third parties to produce and process our product candidates. Our commercialization of any of our product candidates could be stopped, delayed or made less profitable if those third parties fail to obtain approval of government regulators, fail to provide us with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We do not currently have nor do we plan to acquire the infrastructure or capability internally to manufacture our clinical supplies for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on outside vendors to manufacture clinical supplies of our product candidates and plan to continue relying on third parties to manufacture our product candidates on a commercial scale, if approved. We plan to rely on third-party manufacturers and their responsibilities will include purchasing from third-party suppliers the materials necessary to produce our product candidates for our clinical trials and regulatory approval. There are expected to be a limited number of suppliers for the materials that we expect to use to manufacture our product candidates, and we may not be able to identify alternative suppliers to prevent a possible disruption of the manufacture our product candidates for our clinical trials, and, if approved, ultimately for commercial sale. Although we generally do not expect to begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the study, any significant delay or discontinuity in the supply of a product candidate, or the active ingredient or other material components in the manufacture of the product candidate could delay completion of our clinical trials and result in potential delay in regulatory approval of our product candidates, which would harm our business and results of operations. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">19</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="text-indent:20pt; width:456pt; line-height:12pt;">We do not have long-term supply agreements or commitments from those parties to supply our materials. Moreover, even if we had a longer-term supply arrangement, we may be precluded from entering into a back-up or alternative supplier arrangement which may increase the risk for further development, regulatory approval, or commercialization of our product candidates. We may also receive supply of drug substance or drug product that is deficient in quality or otherwise does not meet the specifications required to be used in clinical trials. In the past, we have experienced such deficiencies and have been required to seek alternative sources to meet our needs. We have not established clinical trial material supply agreements for AYX2 and may not be able to do so. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Certain components used in the manufacture of brivoligide are sourced from a single vendor. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide is an oligonucleotide, and there are currently a limited number of oligonucleotide manufacturers with commercial sale capabilities globally. We currently use Nitto-Denko Avecia, Inc., or Avecia, as a single supplier for the brivoligide drug substance and do not have a long-term supply agreement or commitment from Avecia to supply our drug substance. If Avecia is unable or unwilling to meet our current or future needs for our drug substance on acceptable terms, or at all, we may be unable to locate alternative suppliers or manufacturers. While we intend to develop secondary sources for manufacturing of our drug candidates in the future, we may not be able to do so on commercially reasonable terms or at all. Any interruption in the supply of a key material could significantly delay our research and development process or increase our expenses for development and commercialization of our product candidates. Any interruption in supply of our product candidates from Avecia could result in delay of our clinical trials or interrupt our commercial supply, which would harm our business and results of operations. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We face intense competition from other companies developing products for the reduction of postoperative pain. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide faces significant competition. If we are able to successfully develop brivoligide for the reduction of postoperative pain, it would compete with EXPAREL (bupivacaine liposome injectable suspension, marketed by Pacira Pharmaceuticals, Inc.), HTX-011 (bupivacaine and meloxicam, in development by Heron Therapeutics, NDA submitted to the FDA in 2019), Ofirmev (intravenous acetaminophen, marketed by Mallinckrodt Pharmaceuticals), branded and generic oral opioid pain therapeutics, branded and generic oral nonsteroidal anti-inflammatory drugs, or NSAIDs, and potentially other products in development for the reduction of postoperative pain that reach the market. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do, and have significantly greater experience in the discovery and development of product candidates, as well as in obtaining regulatory approvals of those product candidates in the United&#160;States and in foreign countries. Many of our current and potential future competitors also have significantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a smaller number of our competitors. Competition may reduce the number and types of patients available to us to participate in clinical trials, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Small or early-stage companies and research institutions may also prove to be significant competitors, particularly through collaborative arrangements with large and established pharmaceutical companies. We will also face competition from these parties in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, and acquiring or in-licensing technologies and products complementary to our programs or potentially advantageous to our business. If any of our competitors succeed in obtaining approval from the FDA or other regulatory authorities for their products sooner than we do or for products that are more effective or less costly than our products, our commercial opportunity could be significantly reduced. Major technological changes can happen quickly in the biotechnology and pharmaceutical industries, and the development of new mechanisms of action, technologically improved or different products or drug delivery technologies may make our product candidates or platform technologies obsolete or noncompetitive. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">20</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We currently have no marketing and sales experience or capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have no experience selling and marketing our product candidates and we currently have no marketing or sales organization. To successfully commercialize any products that may result from our development programs, we will need to invest in and develop these capabilities, either on our own or with others, which would be expensive, difficult and time consuming. Any failure or delay in the timely development of our internal commercialization capabilities could adversely impact the potential for success of our products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Further, given our lack of prior experience in marketing and selling pharmaceutical products, we may rely on future collaborators to commercialize our products. If collaborators do not commit sufficient resources to commercialize our future products and we are unable to develop the necessary marketing and sales capabilities on our own, we will be unable to generate sufficient product revenue to sustain or grow our business. We may be competing with companies that currently have extensive and well-funded marketing and sales operations, in particular in the markets our product candidates are intended to address. Without appropriate capabilities, whether directly or through third-party collaborators, we may be unable to compete successfully against these more established companies. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The commercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to extensive internal efforts, the successful commercialization of brivoligide will require many third parties, over whom we have no control, to choose to utilize brivoligide. These third parties include physicians and hospital pharmacy and therapeutics committees, or P&amp;T committees. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, there is significant uncertainty related to the insurance coverage and reimbursement for newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for products such as our and what reimbursement codes our products may receive. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to limit or reduce healthcare costs may result in restrictions on coverage and the level of reimbursement for new products and, as a result, they may not cover or provide adequate payment for our products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Physicians must prescribe brivoligide for our commercialization to be successful. Because administration of brivoligide will be intended for patients scoring &ge;16 on the PCS, and will require administration of the one-page PCS evaluation tool prior to surgery, physicians may not accept brivoligide as a viable addition to their patient treatment pathway. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">If brivoligide does not achieve broad market acceptance, the revenues that are generated from our sales will be limited. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to our Business Operations </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our future success depends in part on our ability to retain our President and Chief Executive Officer, Chief Medical Officer, and Chief Scientific Officer, and to attract, retain, and motivate other qualified personnel. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are highly dependent upon the efforts of our senior management, including Rick Orr, our President and Chief Executive Officer, Donald C. Manning, our Chief Medical Officer, and Julien Mamet, our founder and Chief Scientific Officer. The loss of the services provided by these individuals may adversely impact the achievement of our objectives. These individuals could leave our employment at any time, as they are &#8220;at will&#8221; employees. The loss of the services of these individuals and other members of our senior management could delay or prevent the achievement of research, development, marketing, or product commercialization objectives. We do not maintain any &#8220;key-man&#8221; insurance policies on any of the key </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">21</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">employees nor do we intend to obtain such insurance coverage. Recruiting and retaining other qualified employees, consultants, and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of highly qualified personnel in our industry, which is likely to continue. As a result, competition for personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, failure to succeed in development and commercialization of our product candidates may make it more challenging to recruit and retain qualified personnel. The inability to recruit and retain qualified personnel, or the loss of the services of key members of senior management could impede the progress of our research, development, and commercialization objectives. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations. </div>
        <div style="text-indent:20pt; margin-top:4.81pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, we had six full-time employees. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial, legal, and other resources. Our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.</div>
        <div style="text-indent:20pt; margin-top:4.62pt; width:456pt; line-height:12pt;">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, research data, our proprietary business information and that of our suppliers, technical information about our products, clinical trial plans and employee records. Similarly, our third-party providers possess certain of our sensitive data and confidential information. The secure maintenance of this information is critical to our operations and business strategy. Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, ransomware, cyber fraud, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, encrypted, lost or stolen. Any such access, inappropriate disclosure of confidential or proprietary information or other loss of information, including our data being breached at third-party providers, could result in legal claims or proceedings, liability or financial loss under laws that protect the privacy of personal information, disruption of our operations or our product development programs and damage to our reputation, which could adversely affect our business. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions. </div>
        <div style="text-indent:20pt; margin-top:4.61pt; width:456pt; line-height:12pt;">We may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">22</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing, and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot provide any assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on our business and prospects. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict and may have a significant adverse effect on our business and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate postapproval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Among policy makers and payors in the United States there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access and the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the Affordable Care Act, substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S.&#160;pharmaceutical industry. The Affordable Care Act, among other things: (1)&#160;introduced a new average manufacturer price definition for drugs and biologics that are inhaled, infused, instilled, implanted or injected and not generally dispensed through retail community pharmacies; (2)&#160;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and expanded rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well; (3)&#160;established a branded prescription drug fee that pharmaceutical manufacturers of branded prescription drugs must pay to the federal government; (4)&#160;expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program; (5)&#160;established a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts (which through subsequent legislative amendments, was increased to 70% from 50% starting in 2019) off negotiated prices of applicable branded drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D; (6)&#160;extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; (7)&#160;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals, including individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability; (8)&#160;created a licensure framework for follow-on biologic products; and (9)&#160;established a Center for Medicare and Medicaid Innovation at the Centers for Medicare and Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the Affordable Care Act. For example, the Tax Cuts and Jobs Act of 2017, or TCJA, was enacted, which includes a provision repealing, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the Affordable Care Act are invalid as well. While the Trump administration and CMS have both stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, if any, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">23</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">pursuant to the Budget Control Act of 2011 and subsequent laws, which began in 2013 and will remain in effect through 2027, unless additional Congressional action is taken. In January&#160;2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. New laws may result in additional reductions in Medicare and other healthcare funding, which may materially adversely affect customer demand and affordability for our products and, accordingly, the results of our financial operations. Also, there has been heightened governmental scrutiny recently over the manner in which pharmaceutical companies set prices for their marketed products, which have resulted in several Congressional inquiries and proposed federal legislation, as well as state efforts, designed to, among other things, bring more transparency to product pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part&#160;D plans to negotiate the price of certain drugs under Medicare Part&#160;B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the Trump administration released a &#8220;Blueprint,&#8221; or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. While some proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Most recently, the Trump administration released a &#8220;Blueprint,&#8221; or plan, to reduce the cost of drugs. The Trump administration&#8217;s Blueprint contains certain measures that the U.S. Department of Health and Human Services is already working to implement. At the state level, individual states in the United States are increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we obtain FDA approval for any of our product candidates and begins commercializing those products in the United States, our operations may be subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations. These laws may impact, among other things, our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">24</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, which imposes certain requirements relating to the privacy, security, and transmission of individually identifiable health information; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the federal physician sunshine requirements under the Health Care Reform Laws requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S.&#160;Department of Health and Human Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. For example, the Health Care Reform Law, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the Health Care Reform Law provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities may involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of hazardous materials. In some cases, hazardous materials and various wastes resulting from their use may be stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of hazardous materials generally comply with the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">25</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. </div>
        <div style="margin-top:9.43pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </div>
        <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;">Our corporate headquarters is located in the San Francisco Bay Area which has in the past experienced severe earthquakes and other natural disasters. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations or those of our collaborators, and have a material adverse effect on our business, results of operations, financial condition, and prospects. If a natural disaster, terrorist attack, power outage, or other event occurred that prevented us from using or damaged critical elements of our business and operations (such as the manufacturing facilities of our third-party contract manufacturers) our business may be disrupted for a substantial period of time. We have limited or no disaster recovery and business continuity plans in place currently and our business would be impaired in the event of a serious disaster or similar event. We may incur substantial expenses to develop and implement any disaster recovery and business continuity plans, which could have a material adverse effect on our business. </div>
        <div style="margin-top:9.43pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The terms of our Loan Agreement with Oxford place restrictions on our operating and financial flexibility. </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">The Loan Agreement subjects us and our subsidiaries to various affirmative and restrictive covenants, including a covenant against the occurrence of a &#8220;change in control,&#8221; financial reporting obligations, and certain limitations on the incurrence of indebtedness, liens (including a negative pledge on intellectual property and other assets), investments, distributions (including dividends), collateral, transactions with affiliates or mergers or acquisitions. Compliance with these covenants may limit our flexibility in operating our business and our ability to take actions that might be advantageous to us and our shareholders. </div>
        <div style="text-indent:20pt; margin-top:5.01pt; width:456pt; line-height:12pt;">Additionally, we may be required to repay the entire amount of outstanding indebtedness under the Loan Agreement in cash if we fail to stay in compliance with our covenants or suffer some other event of default under the Loan Agreement. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In that case, we may be required to delay, limit, reduce or terminate our clinical development efforts or grant to others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Oxford could also exercise its rights as collateral agent to take possession and dispose of the collateral securing the loan for its benefit, which collateral includes all of our property, including our intellectual property. Our business, financial condition and results of operations could be substantially harmed as a result of any of these events. </div>
        <div style="margin-top:9.43pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Substantially all of our assets are subject to a first-priority lien in favor of Oxford under the Loan Agreement. The foreclosure on such assets or exercise of other remedies available to Oxford under the Loan Agreement could substantially harm our business operations and financial condition. </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">Substantially all of our assets are subject to a first-priority lien in favor of Oxford under the Loan Agreement. There can be no assurance that we will remain in compliance with our obligations under the Loan Agreement, including making required payments and complying with affirmative and negative covenants. In the event of foreclosure or exercise of other remedies by Oxford under such agreement on the assets pledged to Oxford, our business operations and financial condition will be substantially harmed. </div>
        <div style="margin-top:9.42pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to our Intellectual Property </div>
        <div style="margin-top:8.23pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We intend to rely on exclusivity from patent rights for our product candidates and any future product candidates. If we are unable to obtain or maintain exclusivity, we may not be able to compete effectively in our markets. </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business. This process can be </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">26</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain in flux. We own the rights to issued patents and to patent applications that cover our product candidates and their application. The patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. Further, third parties may challenge the validity of our issued patents, their enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing intellectual property around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have filed several patent applications covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may not have sufficient patent term protections for our products to effectively protect our business. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20&#160;years after it is filed. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, our products may be open to competition from generic medications. In addition, upon issuance in the United States any patent term can be adjusted based on certain delays caused by the applicant(s) or the United States Patent and Trademark Office, or USPTO. For example, a patent term can be reduced based on certain delays caused by the patent applicant during patent prosecution. Further, it is possible for a third party to challenge the validity of our issued patents via litigation and/or post-grant administrative proceedings at the USPTO, which if successful, could invalidate the issued patents and lead to earlier market entry and competition by others. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Patent term extensions under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent or data, regulatory exclusivity terms associated with the products. With respect to our product candidates brivoligide and AYX2, a portion of the potential commercial opportunity will likely rely on patent term extensions, and we cannot provide any assurances that any such patent term extensions will be obtained and, if so, for how long. As a result, we may not be able to maintain exclusivity for our products for an extended period, which would negatively impact our business and results of operations. If we do not have sufficient patent terms or regulatory exclusivity to protect our products, our business and results of operations will be adversely affected. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Patent laws and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of their protection. The laws of foreign countries may not protect our patent rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. We therefore cannot be certain that we were the first to make the invention claimed in our owned and licensed patents or pending applications, or that we were the first to file for patent protection of </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">27</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">such inventions. Assuming the other requirements for patentability are met, in the United States prior to March&#160;15, 2013, the first to make the claimed invention is entitled to the patent, while outside the United&#160;States, the first to file a patent application is entitled to the patent. After March&#160;15, 2013, under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted on September&#160;16, 2011, the United&#160;States has moved to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and may also affect patent litigation. The applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. In general, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although we require all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements can be duly enforced or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. We have conducted freedom to operate analyses with respect to only certain of our product candidates, and have not requested independent formal written opinions, and therefore we do not know whether there are any third-party patents that would impair our ability to commercialize these product candidates. We also </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">28</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">cannot guarantee that any of our analyses are exhaustive, nor can we be sure that we have identified each and every patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our product candidates. Because patent applications can take many&#160;years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, third parties may obtain patents in the future and claim that the use of our technologies infringes upon their patents. If any third-party patents were held by a court of competent jurisdiction to cover aspects of our product candidate&#8217;s formulations, manufacturing process, methods of use, or of any molecules formed during their manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Such a license may not be available on commercially reasonable terms, or at all. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Intellectual property may be discovered in the future through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have received grant awards from NIDA/NIH and NINDS/NIH for the development of brivoligide in the mastectomy&#160;model of postoperative pain and the development of AYX2, respectively. Intellectual property may be generated through the use of this U.S. government funding and would therefore be subject to certain federal regulations. As a result, the U.S.&#160;government may in the future have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or the Bayh-Dole Act. These U.S.&#160;government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we fail to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our product candidates may be subject to generic competition. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application, or ANDA, seeking approval of a generic copy of an approved innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA under section 505(b)(2) that references the FDA&#8217;s finding of safety and effectiveness of a previously approved drug. A 505(b)(2) NDA product may be </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">29</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">for a new or improved version of the original innovator product. Innovative small molecule drugs may be eligible for certain periods of regulatory exclusivity (e.g., five&#160;years for new chemical entities, three&#160;years for changes to an approved drug requiring a new clinical trial, seven&#160;years for orphan drugs), which preclude FDA approval (or in some circumstances, FDA filing and review of) an ANDA or 505(b)(2) NDA relying on the FDA&#8217;s finding of safety and effectiveness for the innovative drug. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the final drug product, which would be listed with the product in the FDA publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; known as the &#8220;Orange Book.&#8221; If there are patents listed in the Orange Book, a generic applicant that seeks to market its product before expiration of the patents must include in the ANDA or 505(b)(2) what is known as a &#8220;Paragraph IV certification,&#8221; challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the innovator, too, and if within 45&#160;days of receiving notice the innovator sues to protect its patents, approval of the ANDA is stayed for 30&#160;months, or as lengthened or shortened by the court. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If there are patents listed for our product candidates in the Orange Book, ANDAs and 505(b)(2) NDAs with respect to those product candidates would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict whether any patents issuing from our pending patent applications will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or licenses. Moreover, if any patents that are granted and listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could more immediately face generic competition and our sales would likely decline materially. Should sales decline, we may have to write off a portion or all of the intangible assets associated with the affected product and our results of operations and cash flows could be materially and adversely affected. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">All of our assets are subject to a first-priority lien in favor of Oxford under a security agreement entered into in connection with the Loan Agreement with Oxford. The foreclosure on such assets or exercise of other remedies available to Oxford under the Loan Agreement could materially adversely affect our business operations and future prospects. </div>
        <div style="text-indent:20pt; margin-top:5.6pt; width:456pt; line-height:12pt;">All of the assets (including intellectual property) owned by us are subject to a first-priority lien in favor of Oxford under a security agreement entered into in connection with the Loan Agreement with Oxford. There can be no assurance that we will remain in compliance with our obligations under the Loan Agreement. In the event of foreclosure or exercise of other remedies by Oxford under such agreement on the assets (including such intellectual property) pledged to Oxford, our ability to use and develop our product candidates as well as our business operations and future prospects will be materially adversely affected. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Although we are not currently involved in any significant litigation, we may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming, and unsuccessful. </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">Competitors may infringe our patents or the patents of our potential licensors. Although we are not currently involved in any litigation, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are a commonplace. Grounds for a validity challenge of a patent could be an alleged failure to meet any of several statutory requirements for patentability, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome of such interference proceeding could require us to cease using </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">30</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we have written agreements and make every effort to ensure that our employees, consultants, and independent contractors do not use the proprietary information or intellectual property rights of others in their work for us, and we are not currently subject to any claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties, we may in the future be subject to such claims. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United&#160;States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop our own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">31</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Risks Related to our Corporate Governance </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of a fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws; any action asserting a claim against us that is governed by the internal affairs doctrine; or, to the maximum extent permitted by law, any other claim or dispute. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of, and consented to, the provisions of our bylaws described in the preceding sentence. If a court were to find the choice of forum provisions contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a significant impact on our business, financial condition and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, jurisdiction over which is exclusively vested by statute in the U.S. federal courts. As a result, this may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and such persons. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Some provisions of our charter document and Delaware law may have antitakeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by the our stockholders to replace or remove our management. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Provisions in our certificate of incorporation and bylaws as well as provisions of the DGCL, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit stockholders, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">allowing the authorized number of our directors to be changed only by resolution of the board of directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">authorizing the issuance of&#8201;&#8201; &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">eliminating the ability of stockholders to call a special meeting of stockholders; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove management by making it more difficult for stockholders to replace members of our board of directors, which will be responsible for appointing the members of our management. In addition, we will be subject to Section&#160;203 of the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three&#160;years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by the board of directors. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders.</div>

          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are not subject to compliance with rules requiring the adoption of certain corporate governance measures and as a result our stockholders may have limited protections.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Each of the New York Stock Exchange and the Nasdaq Stock Market LLC require the implementation of various measures relating to corporate governance for listed companies. These measures </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">32</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">are designed to enhance the integrity of corporate management and the securities markets and apply to securities which are listed on those stock exchanges. While we have adopted these measures, we will not be required to comply with many of the corporate governance provisions in the future for so long as our common stock is not listed on a national securities exchange. As a result, if we elect to cease compliance with any such measures, our stockholders may lose protections afforded to listed companies.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to this Offering and Ownership of the Securities Offered Hereby</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Private Adynxx has a material weakness in its internal control over financial reporting. If this material weakness persists or if we fail to establish and maintain effective internal control over financial reporting, our ability to accurately report its financial results could be adversely affected. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to the closing of the Merger, Adynxx was a private company and had limited accounting and financial reporting personnel and other resources with which to address its internal control over financial reporting. In connection with the audit of Private Adynxx&#8217;s financial statements for the year ended December&#160;31, 2018 and preparation of interim financial statements for the first quarter of 2019, Private Adynxx and its independent registered public accounting firm identified a material weakness in Private Adynxx&#8217;s internal controls over financial reporting. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity&#8217;s financial statements will not be prevented or detected and corrected on a timely basis. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The material weakness related to Private Adynxx&#8217;s inability to prepare accurate financial statements, resulting from a lack of adequate accounting personnel to timely and appropriately account for and disclose the impact of complex, non-routine transactions in accordance with GAAP, including the recording of convertible note and related disclosures. In response to the material weakness, Adynxx is currently working to remediate the material weakness by retaining third-party consultants to help enhance its internal controls over financial reporting. There can be no assurance that these efforts will remediate the material weakness or avoid future weaknesses or deficiencies. Any failure to remediate the material weakness and any future weaknesses or deficiencies or any failure to implement required new or improved controls or difficulties encountered in their implementation could cause Adynxx to fail to meet its reporting obligations or result in material misstatements in its financial statements. Following the closing of this offering, Adynxx&#8217;s management will be required to assess the effectiveness of its disclosure controls and procedures and internal control over financial reporting. If Adynxx is unable to remediate its material weakness, Adynxx&#8217;s management may not be able to conclude that its disclosure controls and procedures or internal control over financial reporting are effective, which could result in investors losing confidence in its reported financial information and may lead to a decline in the stock price. Failure to comply with Section&#160;404 of Sarbanes-Oxley could potentially subject Adynxx to sanctions or investigations by the SEC, the Financial Industry Regulatory Authority or other regulatory authorities, as well as increasing the risk of liability arising from litigation based on securities law.</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our stock price may be volatile and may decline regardless of our operating performance. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our stock price has been and is likely to continue to be volatile. The trading prices of the securities of companies in our industry have been highly volatile. As a result of this volatility, investors may not be able to sell their common stock at or above their purchase price. The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">adverse regulatory decisions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the commencement, enrollment or results of any future clinical trials we may conduct, or changes in the development status of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">adverse results from, delays in or termination of clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">33</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">unanticipated serious safety concerns related to the use of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">lower than expected market acceptance of our product candidates following approval for commercialization; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">changes in financial estimates by us or by any securities analysts who might cover our stock; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">conditions or trends in our industry; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">changes in the market valuations of similar companies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the pharmaceutical industry; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">investors&#8217; general perception of our company and our business; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">recruitment or departure of key personnel; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">overall performance of the equity markets; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">limited trading volume of our common stock; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">significant lawsuits, including patent or stockholder litigation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">proposed changes to healthcare laws in the United States or foreign jurisdictions, or speculation regarding such changes;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">failure to comply with covenants and obligations under our debt instruments and agreements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">general political and economic conditions; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">other events or factors, many of which are beyond our control. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies in our industry. Stock prices of such companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management, and harm our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Based upon our common stock outstanding as of June&#160;30, 2019, our executive officers, directors and current beneficial owners of 5% or more of our common stock, in the aggregate, beneficially own approximately 89.3% of our outstanding common stock. These stockholders, acting together, are able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and any merger or other significant corporate transactions. The interests of this group of stockholders may not coincide with the interests of other stockholders. </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">34</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We will incur costs and demands upon our management as a result of complying with the laws and regulations affecting reporting companies in the United States, which may harm our business. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As a public company in the United States quoted on the OTCQB and subject to the reporting requirements of the Exchange Act, we will incur significant additional legal, accounting and other expenses. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from regular business activities to compliance activities. If, notwithstanding our efforts, we fail to comply with new laws, regulations and standards, regulatory authorities may initiate legal proceedings against us and our business may be harmed. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Failure to comply with these rules might also make it more difficult for us to obtain certain types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management. </div>

          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The sale or availability for sale of a substantial number of shares of our common stock could negatively impact the market price of our shares. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Sales of a significant number of shares of our common stock, or the expectation that such sales may occur, including by our directors, officers and significant stockholders following the expiration of lock-up arrangements entered into in connection with the Merger, could significantly reduce the market price of our common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additionally, sales of our common stock by our officers or directors, even when done during an open trading window under our policies with respect to insider sales may adversely impact the trading price of our common stock. Although we do not expect that the relatively small volume of such sales will itself significantly impact the trading price of our common stock, the market could react negatively to the announcement of such sales, which could in turn affect the trading price of our common stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Shares of our common stock are thinly traded and may continue to be thinly traded in the future. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although a trading market for our common stock exists, the trading volume has not been significant, due in part to a substantial number of our outstanding shares being subject to contractual lock-up and other legal restrictions. There can be no assurance that an active trading market for our common stock will develop or, if developed, be sustained in the future, even following the lapse or expiration of such lock-up or other legal restrictions. As a result of the thin trading market or &#8220;float&#8221; for our stock, the market price for our common stock may fluctuate significantly more than the stock market as a whole. Without a large float, our common stock is less liquid than the stock of companies with broader public ownership and, as a result, the trading prices of our common stock may be more volatile. In the absence of an active public trading market, an investor may be unable to liquidate his or her investment in our common stock. Trading of a relatively small volume of our common stock may have a greater impact on the trading price for our stock than would be the case if our public float were larger. We cannot predict the prices at which our common stock will trade in the future. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, the price of our securities can vary due to general economic conditions and forecasts, our general business condition and the release of our financial reports. Additionally, because our securities are currently quoted on the OTC Markets, the liquidity and price of our securities may be substantially more limited than if we were quoted or listed on another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained. In the absence of an active trading market for our common stock, stockholders may not be able to sell their common stock at or above the price at which they acquired the shares or at the time that they would like to sell. We cannot predict the prices at </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">35</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">which our common stock will trade. We do not intend to apply to list the common stock on any securities exchange or nationally recognized trading system in connection with the offering. In addition, we cannot assure you that we will be able to meet the initial listing standards of any national securities exchange, or, if we do meet such initial qualitative listing standards, that we will be able to maintain any such listing.</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports about our business, or if they downgrade our common stock, the price of our common stock could decline. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We are not currently covered by any securities or industry analysts. If no analysts elect to cover us in the future, or if one or more of the analysts who may cover us in the future downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. Further, we do not have any control over these analysts. In addition, if our operating results fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Management will have broad discretion as to the use of the net proceeds from this offering, and we may not use these proceeds effectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development of our products and cause the price of our common stock to decline. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If you purchase shares of our common stock in this offering, you will suffer immediate dilution of your investment. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The assumed combined public offering price per share of our common stock and accompanying warrant is substantially higher than the pro forma as adjusted net tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock and accompanying common warrants in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted net tangible book value per share after this offering. Based on an assumed combined public offering price of $1.35 per share of common stock and accompanying common warrant, the closing price of our common stock as reported by OTCQB on October&#160;9, 2019, you will experience immediate dilution of&#8201; $1.09 per share, representing the difference between our pro forma as adjusted net tangible book value per share after this offering and the assumed combined public offering price. In addition, to the extent outstanding stock options are exercised, there will be further dilution to investors in this offering. See &#8220;Dilution&#8221; for a more detailed description of the dilution to investors in the offering. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our certificate of incorporation authorizes us to issue up to 95,000,000 shares of common stock and up to 1,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. For example, we have issued from time to time Notes to certain of our significant shareholders that will convert into shares of our common stock upon, among other things, the closing of this offering. We have also previously issued and currently have outstanding warrants to purchase shares of our common stock. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">36</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">There is no public market for the pre-funded warrants or common warrants being offered in this offering.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There is no established public trading market for the pre-funded warrants or common warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the pre-funded warrants or common warrants on any securities exchange or nationally recognized trading system. Without an active market, the liquidity of the pre-funded warrants and common warrants will be limited.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Holders of our pre-funded warrants and common warrants will have no rights as a common stockholder until they acquire our common stock.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Until you acquire shares of our common stock upon exercise of your pre-funded warrants or common warrants, you will have no rights with respect to shares of our common stock issuable upon exercise of your pre-funded warrants or common warrants. Upon exercise of your pre-funded warrants or common warrants, you will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The pre-funded warrants and common warrants are speculative in nature.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Except in limited circumstances, neither the pre-funded warrants nor the common warrants offered hereby confer any rights of common stock ownership on their holders, such as voting rights, but rather merely represent the right to acquire shares of common stock at a fixed price. Specifically, commencing on the date of issuance, holders of the pre-funded warrants may acquire the common stock issuable upon exercise of such warrants at an exercise price of&#8201; $0.01 per share of common stock and holders of the common warrants may acquire the common stock issuable upon exercise of such warrants at an exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. Moreover, following this offering, the market value of the pre-funded warrants and common warrants is uncertain and there can be no assurance that the market value of the pre-funded warrants or common warrants will equal or exceed their public offering price. There can be no assurance that the market price of the common stock will ever equal or exceed the exercise price of the pre-funded warrants or common warrants, and consequently, whether it will ever be profitable for holders of the pre-funded warrants to exercise the pre-funded warrants or the holders of the common warrants to exercise the common warrants.</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our common stock is subject to the &#8220;penny stock&#8221; rules of the SEC and the trading market in the securities is limited, which makes transactions in the stock cumbersome and may reduce the value of an investment in the stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Rule 15g-9 under the Exchange Act establishes the definition of a &#8220;penny stock,&#8221; for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person&#8217;s account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In order to approve a person&#8217;s account for transactions in penny stocks, the broker or dealer must: (a)&#160;obtain financial information and investment experience objectives of the person and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) confirms that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers may be less willing to execute transactions in securities subject to the &#8220;penny stock&#8221; rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our common stock. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">37</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker or dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.</div>
        <div style="margin-top:9.82pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we fail to remain current in our reporting requirements, we could lose certain privileges on the OTCQB which would impact the ability of broker-dealers to sell our securities and the ability of stockholders to sell their securities in the secondary market. </div>

          <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">As a company traded on the OTCQB, we must be current with our filings pursuant to Sections 13 and 15(d) of the Exchange Act in order to maintain price quotation privileges on the OTCQB. If we fail to remain current in our reporting requirements, the market liquidity of our securities could be harmed by impacting the ability of broker-dealers to trade our securities and the ability of stockholders to sell their securities in the secondary market.</div>


          <div style="margin-top:9.82pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our common stock is not listed on a national securities exchange. As a result, holders of the common warrants or pre-funded warrants may not be able to exercise their warrants without compliance with applicable state securities laws, and the value of such warrants may be significantly reduced.</div>


          <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">Our common stock is not listed on a national securities exchange, and we do not intend to list our common stock on any national securities exchange in connection with this offering. As a result, the exercise of the common warrants or the pre-funded warrants by holders may not be exempt from state securities laws. Depending on the state of residence of a holder of the common warrants or the pre-funded warrants, a holder may not be able to exercise its common warrants or pre-funded warrants unless we comply with any state securities law requirements necessary to permit such exercise or an exemption applies. Although we plan to use our reasonable efforts to assure that holders will be able to exercise their common warrants or pre-funded warrants under applicable state securities laws if no exemption exists, there is no assurance that we will be able to do so. As a result, your ability to exercise your warrants or pre-funded warrants may be limited until such time that our common stock is listed on a national securities exchange, if at all. The value of the common warrants or pre-funded warrants may be significantly reduced if holders are not able to exercise their warrants or pre-funded warrants under applicable state securities laws.</div>


          <div style="margin-top:9.83pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Because our offering will be conducted on a best efforts basis, there can be no assurance that we can raise the maximum proceeds set forth in this prospectus.</div>


          <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;">The placement agent is offering the securities on a &#8220;best efforts&#8221; basis with no minimum, and the placement agent is under no obligation to purchase any securities for their own account. The placement agent is not required to sell any specific number or dollar amount of securities in this offering but will use its best efforts to sell the securities offered in this prospectus. As a &#8220;best efforts&#8221; offering, there can be no assurance that the offering contemplated hereby will ultimately be consummated. If the offering is not consummated or we receive less than the maximum proceeds, our business could be harmed.</div>


          <div style="margin-top:9.83pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Because there is no minimum required for the offering to close, investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue the business goals outlined in this prospectus.</div>


          <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;">We have not specified a minimum offering amount nor have or will we establish an escrow account in connection with this offering. Because there is no escrow account and no minimum offering amount, investors could be in a position where they have invested in our company, but we are unable to fulfill our objectives due to a lack of interest in this offering. Further, because there is no escrow account in operation and no minimum investment amount, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. Investor funds will not be returned under any circumstances whether during or after the offering.</div>


          <div style="margin-top:9.63pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Since our securities will be listed on the OTCQB, our securities holders may face significant restrictions on the resale of our securities due to state &#8220;blue sky&#8221; laws.</div>


          <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">Each state has its own securities laws, often called &#8220;blue sky&#8221; laws, which (i) limit sales of securities to a state&#8217;s residents unless the securities are registered in that state or qualify for an exemption from </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">38</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">registration, and (ii) govern the reporting requirements for broker-dealers doing business directly or indirectly in the state. Before a security is sold in a state, there must be a registration in place to cover the transaction, or the transaction must be exempt from registration. The applicable broker must be registered in that state. We do not know whether securities will be registered or exempt from registration under the laws of any state. Since our securities will be listed on the OTCQB, a determination regarding registration will be made by those broker-dealers, if any, who agree to serve as the market-makers for our common stock. There may be significant state blue sky law restrictions on the ability of investors to sell, and on purchasers to buy, our securities. You should therefore consider the resale market for our securities to be limited, as you may be unable to resell our securities without the significant expense of state registration or qualification.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our ability to use net operating losses to offset future taxable income may be subject to limitation. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our net operating loss, or NOL, carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Our NOLs generated in tax&#160;years ending on or prior to December&#160;31, 2017 are only permitted to be carried forward for 20&#160;years under applicable U.S. tax law. Under the tax act informally known as the 2017 Tax Cuts and Jobs Act, our federal NOLs generated in tax&#160;years ending after December&#160;31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited. It is uncertain if and to what extent various states will conform to the 2017 Tax Cuts and Jobs Act. As of December&#160;31, 2018, we had federal net operating loss carry forwards of approximately $33.5&#160;million. The net operating loss of $28.7&#160;million, carried forward from tax&#160;years ended before January&#160;1, 2018, will begin to expire in 2033. Net operating losses incurred after December&#160;31, 2017, which currently amounts to $4.8&#160;million, may be carried forward indefinitely and will not expire. As of January&#160;1, 2019, we had federal and California research and development tax credit carry forwards of approximately $1.8&#160;million and $0.7&#160;million, respectively. The federal research and development tax credit carry forwards will begin to expire in 2031 and the California research and development tax credit carry forwards are available indefinitely until utilized. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or, the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating losses and net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. It is possible that we have in the past undergone, and in the future may undergo, an ownership change, which could result in additional limitations on our use of net operating loss carryforwards and certain other tax attributes. This could have a material adverse effect on cash flow and results of operations. </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">39</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNR">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This prospectus contains forward-looking statements about us and our industry within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;contemplate&#8221; or the negative of these terms or other similar expressions. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, factors and assumptions described under the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus regarding, among other things: </div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to continue as a going concern; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the progress, timing, costs and results of our clinical trials; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the timing of meetings with and feedback from regulatory authorities as well as any submission of filings for regulatory approval of brivoligide or any of our product candidates; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the potential advantages and differentiated profile of our product candidates compared to existing therapies or other product candidates in development; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to successfully commercialize any of our product candidates, if approved; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the rate and degree of market acceptance of any of our product candidates, if approved; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our expectations regarding the size of the patient populations for and opportunity for and clinical utility of brivoligide or any other product candidates, if approved for commercial use; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to identify, acquire or in-license and develop new product candidates; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to maintain intellectual property protection for our product candidates; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the uncertainty regarding the adequacy of our liquidity to pursue or complete business objectives; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to comply with Current Good Manufacturing Practices, or cGMPs; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">loss or retirement of key executives; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our plans to make significant additional outlays of working capital before we expect to generate significant revenues and the uncertainty regarding when we will begin to generate significant revenues, if we are able to do so; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">adverse economic conditions and/or intense competition; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">loss of a key supplier; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">entry of new competitors; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">adverse federal, state and local government regulation; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">technical problems with our research and products; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">risks of mergers and acquisitions including the time and cost of implementing transactions and the potential failure to achieve expected gains, revenue growth or expense savings; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">price increases for supplies; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">40</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">

          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">inability to carry out our business plans; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our planned uses of the proceeds of this offering;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to service our indebtedness and interest thereon when it becomes due; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our dependence on funding from government sources;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to maintain collaborations and enter into new collaborations; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the other factors discussed under the heading &#8220;Risk Factors&#8221; in this prospectus. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These forward-looking statements are based on information available as of the date of this prospectus, and current expectations, forecasts and assumptions, and involve a number of risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, statements that we &#8220;believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to such party as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and these statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">You should not place undue reliance on these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">You should read this prospectus with the understanding that our actual future results, levels of activity, performance and achievements may be different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.<br ></div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">41</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIMD">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">INDUSTRY AND MARKET DATA </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This prospectus contains estimates, projections and other information concerning our industry and our business, including estimated market size, projected growth rates and the incidence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market, medical and other information from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this information is derived. In that regard, when we refer to one or more sources of this type of information in any paragraph, you should assume that other information of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This industry, business, market, medical and other information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information included in this prospectus. Although we are responsible for all of the disclosure contained in this prospectus and we believe the market position, market opportunity, market size and medical information included in this prospectus is reliable, such information is inherently imprecise. In addition, projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">42</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">USE OF PROCEEDS </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We estimate that the net proceeds to us from the sale of 7,500,000 shares of common stock and accompanying warrants will be approximately $8.2 million, based on an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying common warrant (the closing price of our common stock as reported by OTCQB on October&#160;9, 2019), after deducting placement agent fees and estimated offering expenses payable by us. However, this is a best efforts offering with no minimum, and we may not sell all or any of the securities; as a result, we may receive significantly less in net proceeds, and the net proceeds received may not be sufficient to continue to operate our business. If a holder of common warrants elects to exercise the common warrants issued in this offering, we may also receive proceeds from the exercise of the common warrants. We cannot predict when or if the common warrants will be exercised. It is possible that the common warrants may expire and may never be exercised.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Each $1.00 increase or decrease in the assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying common warrant would increase or decrease, respectively, our net proceeds by $6.9 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting placement agent fees and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase or decrease of 1,000,000 in the number of shares we are offering would increase or decrease, respectively, the net proceeds from this offering, after deducting placement agent fees, by $1.2&#160;million, assuming the assumed combined public offering price stays the same. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We intend to use the net proceeds from this offering, together with our existing cash and additional funds from our grant awards from NIDA/NIH and NINDS/NIH, as follows: </div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">approximately $4.0 to $6.0 million to conduct our clinical trials of brivoligide for postoperative pain;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">approximately $0.5 to $1.0 million to further develop AYX2 for chronic pain; and</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the remaining proceeds for research and drug discovery activities related to additional product candidates and general corporate purposes, funding our working capital needs, servicing of our indebtedness, including scheduled principal and interest payments to Oxford Finance under the Loan Agreement, and any necessary capital expenditures.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We anticipate the net proceeds from this offering, together with our existing cash and additional funds from our grant awards from NIDA/NIH and NINDS/NIH, will be sufficient to fund our planned operations through at least the second quarter of 2020. However, due to the uncertainties inherent in the product development process, the amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development, the status of our results from clinical trials, as well as any collaborations that we may enter with third parties or any other product candidates we may seek to develop, and any unforeseen cash needs. As a result, management will have broad discretion over the use of the net proceeds from this offering. The amounts and timing of our expenditures will depend upon numerous factors including the results of our research and development efforts, the timing and success of preclinical studies and any ongoing clinical trials or clinical trials we may commence in the future, the timing of regulatory submissions and the amount of cash obtained through future collaborations, if any. Following this offering, we will require additional funding in order to complete clinical development and commercialize our product candidates. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pending the use of the proceeds from this offering as described above, we intend to invest the net proceeds in interest-bearing investment-grade securities or government securities.<br ></div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">43</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDP">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DIVIDEND POLICY </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Special Cash Dividend </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In April&#160;2019, Alliqua announced a one-time special cash distribution to the pre-Merger holders of shares of Alliqua as of April&#160;22, 2019 in the amount of&#8201; $1.05 per share, for an aggregate of&#8201; $5,245,000. On May&#160;29, 2019, we paid $6.30 per share to the pre-Merger holders of record of Alliqua BioMedical, Inc. as of April&#160;22, 2019. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, we are restricted from making dividend payments except under limited circumstances under our Loan Agreement. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Divestiture of AquaMed </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2019, we completed the distribution of all outstanding shares of AquaMed Technologies, Inc., previously our wholly-owned subsidiary, on a pro&#160;rata basis to the record holders of Alliqua common stock as of April&#160;22, 2019, which distribution was previously approved by the board of directors of Alliqua in November&#160;2018.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">44</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCAP">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CAPITALIZATION </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table sets forth our cash and cash equivalents and our capitalization as of June&#160;30, 2019, on: </div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">an actual basis;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">a pro forma basis to reflect the issuance of 4,874,744 shares of common stock at the closing of the offering upon the conversion of outstanding convertible promissory notes in the aggregate principal amount of&#8201; $6.35 million (which includes $0.85 million additional principal amount of convertible promissory notes issued subsequent to June 30, 2019), plus accrued but unpaid interest, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the closing price of our common stock as reported by OTCQB on October&#160;9, 2019, provided that this offering results in total proceeds to us of at least $5.0&#160;million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG; and</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">a pro forma as adjusted basis to reflect the sale of 7,500,000 shares of common stock and accompanying warrants in this offering at an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the closing price of our common stock as reported by OTCQB on October&#160;9, 2019, after deducting placement agent fees and estimated offering expenses payable by us.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">You should read this information together with the sections of this prospectus titled &#8220;Description of Capital Stock,&#8221; and &#8220;Description of Securities We are Offering&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; as well as our consolidated financial statements and related notes included elsewhere in this prospectus.</div>


          <table style="width:416pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="16">
                <div style="white-space:nowrap; text-align:center;">June&#160;30, 2019 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Actual</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">Pro <br >Forma</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">Pro Forma <br >As <br >Adjusted<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt; width:0pt;text-align:center;" colspan="16">
                <div style="text-align:center;">(unaudited)<br >(in thousands, except share data) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.25pt 0pt 2.25pt 0pt; width:266pt;text-align:left;">
                <div style="white-space:nowrap;">Cash and cash equivalents </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">24</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">24</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,188</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:1.75pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">
                <div style="white-space:nowrap;">Convertible promissory notes<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">5,497</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">
                <div style="white-space:nowrap;">Term loan, net of discount </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,390</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,390</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,390</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:8.5pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">Stockholders&#8217; equity:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:1.167pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Common stock, $0.001 par value per share, 95,000,000 shares <br >authorized, actual, pro forma and pro forma as adjusted; <br >5,807,877 shares outstanding, actual; 10,682,621 shares <br >outstanding, pro forma; and 18,182,621 shares outstanding, <br >pro forma as adjusted </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">11</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">18</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">
                <div style="white-space:nowrap;">Additional paid-in capital </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">35,160</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">41,736</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">49,893</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">
                <div style="white-space:nowrap;">Accumulated deficit </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,417<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,417<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,417<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:266pt;text-align:left;">
                <div style="white-space:nowrap;">Total stockholders&#8217; equity (deficit) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(9,251<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,670<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,494</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.25pt 0pt 2.25pt 0pt; width:266pt;text-align:left;">
                <div style="white-space:nowrap;">Total capitalization </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,364<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(280<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">7,884</td>
              <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:8.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Each $1.00 increase or decrease in the assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the closing price of our common stock as reported by OTCQB on October&#160;9, 2019, would increase or decrease, respectively, the amount of cash and cash equivalents, additional paid-in-capital, total stockholders&#8217; equity (deficit) and total capitalization by $6.9 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same after deducting placement agent fees and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase or decrease of 1,000,000 in the number of shares we are offering would increase or decrease, respectively, the amount of cash and cash equivalents, additional paid-in-capital, total stockholders&#8217; equity (deficit) </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">45</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">

          <div style="margin-left:20pt; width:436pt; line-height:12pt;">and total capitalization by $1.2 million, assuming the assumed combined public offering price per share, as set forth on the cover page of this prospectus, remains the same and after deducting placement agent fees and estimated offering expenses payable by us. The pro forma as adjusted information is illustrative only, and will be adjusted based on the actual offering price and other terms of this offering determined at pricing. </div>


          <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Figure is shown net of unamortized debt issuance costs. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:10.98pt; width:456pt; line-height:12pt;">The number of shares of common stock that will be outstanding after this offering is based on 5,807,877 shares of common stock outstanding as of June&#160;30, 2019, and excludes:</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">747,879 shares of common stock issuable upon the exercise of outstanding stock options as of June 30, 2019, with a weighted-average exercise price of&#8201; $20.52 per share, under our equity incentive plans or not granted pursuant to a written equity incentive plan;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">3,332 shares of common stock issuable from time to time after this offering upon the settlement of restricted stock awards, or RSAs, outstanding as of June&#160;30, 2019 under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">57,897 shares of common stock issuable upon the exercise of outstanding warrants as of June&#160;30, 2019, with a weighted-average exercise price of&#8201; $97.66 per share;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">9,188 shares of common stock reserved for future issuance under the Alliqua, Inc. 2011 Long-Term Incentive Plan; and</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">72,436 shares of common stock reserved for future issuance under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">46</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DILUTION </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering price per share of our common stock and accompanying warrants and the pro forma as adjusted net tangible book value (deficit) per share of our common stock immediately after the closing of this offering. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The pro forma net tangible book deficit of our common stock as of June&#160;30, 2019 was $(10.1)&#160;million, or $(1.74) per share, based on the total number of shares of our common stock outstanding as of June&#160;30, 2019, after giving effect to the issuance and sale of&#8201; $0.85 million additional principal amount of convertible promissory notes subsequent to June 30, 2019. Pro forma net tangible book value per share represents our total tangible assets less our total liabilities, divided by the number of outstanding shares of common stock. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">After giving effect to (i)&#160;the receipt of the net proceeds from our sale of 7,500,000 shares of common stock and accompanying common warrants in this offering at an assumed combined public offering price of $1.35 per share of common stock and accompanying warrant, the closing price of our common stock as reported by OTCQB on October&#160;9, 2019, after deducting placement agent fees and estimated offering expenses payable by us, and (ii)&#160;the issuance of 4,874,744 shares of common stock at the closing of the offering upon the conversion of outstanding convertible promissory notes in the aggregate principal amount of&#8201; $6.35 million, plus accrued but unpaid interest, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the closing price of our common stock as reported by OTCQB on October&#160;9, 2019, provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG, our pro forma as adjusted net tangible book value as of June&#160;30, 2019 would have been $4.6 million, or $0.26 per share. This represents an immediate increase in pro forma net tangible book value of&#8201; $2.00 per share to our existing stockholders and immediate dilution of $1.09 per share to investors purchasing common stock in this offering. </div>

        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following table illustrates this dilution on a per share basis to new investors: </div>

          <table style="width:416pt;height:131pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:290pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Assumed combined public offering price per share and accompanying common warrant </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.35</td>
              <td style="padding:0pt;padding-left:21.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
                <div style="margin-left:10pt;">Pro forma net tangible book deficit per share as of June&#160;30, 2019 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(1.74<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:290pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">Increase in pro forma as adjusted net tangible book value per share attributable to new investors purchasing shares in this offering </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">2.00</td>
              <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.645pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.645pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:290pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Pro forma as adjusted net tangible book value per share after this offering </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.26</td>
              <td style="padding:0pt;padding-left:21.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:1.917pt 0pt 2.583pt 0pt; width:290pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Dilution in pro forma net tangible book value per share to new investors in this offering </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.645pt;width:0pt;">&#8203;</td>
              <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">1.09</td>
              <td style="padding:0pt;padding-left:21.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="text-indent:20pt; margin-top:10.01pt; width:456pt; line-height:12pt;">Each $1.00 increase or decrease in the assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying comon warrant would increase or decrease, respectively, our pro forma as adjusted net tangible book value per share after this offering by $0.46 and $0.32 per share, respectively, and the dilution to new investors by $0.54 and $0.68 per share, respectively, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting placement agent fees and estimated offering expenses payable by us. An increase of 1,000,000 shares in the number of shares of common stock offered by us would increase the pro forma as adjusted net tangible book value by $0.05 per share and the dilution to new investors would decrease by $0.05 per share, assuming the assumed combined public offering price remains the same and after deducting placement agent fees. A decrease of 1,000,000 shares in the number of shares of common stock offered by us would decrease the pro forma as adjusted net tangible book value by $0.06 per share and the dilution to new investors would increase by $0.06 per share, assuming the assumed combined public offering price remains the same and after deducting placement agent fees.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The information discussed above is illustrative only and will be adjusted based on the actual combined public offering price of the common stock and accompanying common warrant or pre-funded warrant and accompanying common warrant, as the case may be, the actual number of shares that we offer in this </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">47</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">offering, and other terms of this offering determined at pricing. The discussion and table above assume (i) no sale of pre-funded warrants, which, if sold, would reduce the number of shares of common stock that we are offering on a one-for-one basis and (ii) no exercise of common warrants accompanying the shares of common stock, if any, sold in this offering.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If investors in this offering exercise in full the common warrants for 7,500,000 shares of common stock offered hereby for cash at an assumed exercise price of&#8201; $1.35 per share (the closing price of our common stock as reported by OTCQB on October&#160;9, 2019), our pro forma as adjusted net tangible book value after this offering would be $0.29 per share, representing an increase in pro forma as adjusted net tangible book value of&#8201; $2.03 per share and immediate dilution in pro forma net tangible book value of&#8201; $1.06 per share to new investors in this offering.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The number of shares of common stock that will be outstanding after this offering is based on 5,807,877 shares of common stock outstanding as of June&#160;30, 2019, and excludes:</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">747,879 shares of common stock issuable upon the exercise of outstanding stock options as of June 30, 2019, with a weighted-average exercise price of&#8201; $20.52 per share, under our equity incentive plans or not granted pursuant to a written equity incentive plan;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">3,332 shares of common stock issuable from time to time after this offering upon the settlement of restricted stock awards, or RSAs, outstanding as of June&#160;30, 2019 under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">57,897 shares of common stock issuable upon the exercise of outstanding warrants as of June&#160;30, 2019, with a weighted-average exercise price of&#8201; $97.66 per share;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">9,188 shares of common stock reserved for future issuance under the Alliqua, Inc. 2011 Long-Term Incentive Plan; and</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">72,436 shares of common stock reserved for future issuance under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, to the extent any outstanding options or warrants are exercised, new investors would experience further dilution. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">48</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMOCS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">MARKET FOR OUR COMMON STOCK </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Since July&#160;22, 2019, our common stock has been listed on the OTCQB under the symbol &#8220;ADYX,&#8221; and from June&#160;13, 2019 until July&#160;18, 2019, our common stock was listed on the OTC Pink tier of the OTC Markets under the symbol &#8220;ADYX.&#8221; Prior to June 13, 2019, our common stock was listed on the Nasdaq Capital Market under the symbol &#8220;ADYX.&#8221; Any over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions. The prices of our common stock quoted on the OTCQB may not be indicative of the market price of our common stock on a national securities exchange. As of September&#160;30, 2019, there were 258 holders of record of our common stock. We do not intend to list our common stock or any of the other securities offered hereby on a national securities exchange in connection with this offering.<br ></div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">49</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMDA">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION <br >AND RESULTS OF OPERATIONS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included in this prospectus. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere particularly in the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">On May&#160;3, 2019, Private Adynxx completed the Merger with Alliqua BioMedical, Inc., or Alliqua, and we survived as a wholly-owned subsidiary of Alliqua. Following the consummation of the Merger, Adynxx changed its name to Adynxx Sub, Inc., and Alliqua BioMedical, Inc. changed its name to Adynxx, Inc. For financial reporting purposes, Alliqua was deemed to be the acquired entity in the Merger. The following management&#8217;s discussion and analysis relates to the results of operations of Adynxx, Inc. for periods subsequent to the Merger and Adynxx, the private company, for periods prior to the Merger. Accordingly, references in this section to &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221; refer to pre-Merger Adynxx.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are a clinical stage biopharmaceutical company focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market novel, disease-modifying products for the treatment of pain and inflammation. Transcription factor decoys are short strands of DNA that specifically bind to and block the activity of their target transcription factors. Transcription factors are proteins that specifically bind to the regulatory regions of one or more target genes and regulate the expression of those genes. Since our founding in 2007, we have leveraged our AYX platform of proprietary transcription factor decoys to identify and develop novel product candidates designed to modify the course of pain. We believe that our transcription factor decoy technology can transform the treatment of pain, and going forward has the potential to be applied to additional disease states. We plan to continue advancing our AYX platform programs while simultaneously developing new transcription factor decoy candidates, collaborating with twoXAR, our artificial intelligence-driven drug discovery partner, and evaluating in-licensing opportunities in order to expand our pipeline and leverage our business development, clinical development and regulatory expertise. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have no products approved for commercial sale and have not generated any revenue from product sales. From inception to June&#160;30, 2019, we have raised net cash proceeds of approximately $62.2&#160;million, primarily through the sale of equity securities, receipts associated with a strategic collaboration, issuance of Notes, and gross proceeds from the Oxford term loans. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2018, we received a grant from the National Institute on Drug Abuse, or NIDA, part of the National Institutes of Health, or NIH, the NIH grant, to support the clinical development of our lead product candidate, brivoligide. NIH grants provide funds for certain types of expenditures in connection with research and development activities over a contractually defined period. The maximum funding to be available under this grant for qualified expenditures over the next two&#160;years is expected&#8201;to be approximately $5.7&#160;million. We started drawing from this NIH grant in February&#160;2019 and recognized $1.2 million and $0 as grant reimbursement contra-expense in our operating expenses for the six&#160;months ended June&#160;30, 2019 and 2018, respectively. In September 2019, we received a Notice of Award from the National Institute on Neurological Disease and Stroke, or NINDS, part of the NIH, for up to approximately $0.6&#160;million to be paid over 12&#160;months to support our planned preclinical studies of AYX2. The funds will become available after approval from the Office of Laboratory Animal Welfare, or OLAW, of the planned preclinical studies for AYX2, and we have not yet drawn from this NIH grant. We intend to continue to evaluate pursuing additional government grant opportunities on a case-by-case basis. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have incurred operating losses in each year since inception, with the exception of 2014, when we received a $20.0&#160;million option payment as part of a strategic collaboration, which was subsequently terminated in 2014. Our net losses were $7.1 million and $2.9 million, for the six months ended June 30, 2019 and 2018, respectively. As of June 30, 2019, we had an accumulated deficit of&#8201;&#8201;$44.4 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">50</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We expect to incur significant expenses and increasing operating losses for at least the next several&#160;years as we initiate and continue the clinical development of, and seek regulatory approval for, our product candidates and add personnel necessary to operate as a public company with an advanced clinical pipeline of products. In addition, operating as a publicly traded company involves the hiring of additional financial and other personnel, upgrading our financial information systems and incurring costs associated with operating as a public company. We expect that our operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of clinical development programs and efforts to achieve regulatory approval of any of our product candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our current capital resources are insufficient to fund our planned operations for a 12-month period, and therefore, raise substantial doubt about our ability to continue as a going concern. We will continue to require substantial additional capital to continue our clinical development and potential commercialization activities. Accordingly, we will need to raise substantial additional capital to continue to fund our operations. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Basis of Presentation </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Research and Development Expenses </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Research and development expenses represent costs incurred to conduct research and development, such as the development of our product candidates. We recognize all research and development costs as they are incurred. Research and development expenses consist primarily of the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">expenses incurred under agreements with consultants and clinical trial sites that conduct research and development activities on our behalf; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">laboratory and vendor expenses related to the execution of clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">contract manufacturing expenses, primarily for the production of clinical supplies; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">internal costs that are associated with activities performed by our research and development organization. These costs are not separately allocated by product candidate as we typically use our employee resources across various research and development activities. Unallocated internal research and development costs consist primarily of: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#9702;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">personnel costs, which include salaries, benefits and stock-based compensation expense; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#9702;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">regulatory expense related to development activities. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The largest component of our operating expenses has historically been the investment in research and development activities. However, we do not allocate internal research and development costs, such as salaries, benefits, stock-based compensation expense and indirect costs to product candidates on a program-specific basis. The following table shows our research and development expenses by program (in&#160;thousands): </div>
        <table style="width:456pt;height:140pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Years Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six Months Ended June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(unaudited) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">Direct research and development expenses by program:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-005 TKA </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">185</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">892</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-004 TKA </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,201</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">95</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">87</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">AYX Platform </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">607</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">918</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-006 Mastectomy </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">26</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">455</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-003 TKA </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">twoXAR Platform </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">75</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">51</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <table style="width:456pt;height:74.5pt;margin-top:0pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Years Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Six Months Ended <br >June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(unaudited) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">Internal research and development costs </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,913</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,706</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,125</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">884</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">Total research and development expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">8,722</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,137</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,269</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,226</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.19pt; width:456pt; line-height:12pt;">We expect research and development expenses will increase in the future as we advance our product candidates into and through clinical trials and pursue regulatory approvals, which will require a significant investment in regulatory support and contract manufacturing. In addition, we continue to evaluate opportunities to acquire or in-license other product candidates and technologies, which may result in higher research and development expenses due to license fees and/or milestone payments. While we are engaged in discussions to in-license other product candidates and technologies, we will need to raise additional capital before consummating any such transaction. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2018, we received a NIH grant to support the clinical development of our lead product candidate, brivoligide. The grant is expected to provide approximately $2.8&#160;million in funding in 2019 that will support research and development activities for the ADYX-006 Mastectomy study. We record qualified expenses reimbursable under the NIH grant as grant reimbursements, a contra operating expense. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in timely developing and achieving regulatory approval for our product candidates. The probability of success of our product candidates may be affected by numerous factors, including clinical data, competition, intellectual property rights, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">General and Administrative Expenses </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our general and administrative expenses consisted of personnel-related costs, professional fees for legal, consulting, audit and tax services, overhead expenses, such as rent, equipment depreciation, insurance and utilities, and other general operating expenses not otherwise included in research and development expenses. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We expect to incur additional expenses associated with operating as a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, and standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to increase the size of our administrative headcount to support the growth of our business and operate as a public company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Grant Reimbursements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We accounted for reimbursements of qualified grant related research and development expenses in accordance with the guidance provided by the Financial Accounting Standards Board, or FASB, in the Accounting Standards Update (ASU) 2018-08, &#8220;<font style="font-style:italic;">Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made</font>,&#8221; or ASU 2018-08, which it adopted in January&#160;2019. Based on this guidance, we determined that reimbursements of qualified expenses per the terms of the grant, met the definition of a &#8216;conditional contribution&#8217; (versus an exchange contract) because (i)&#160;we have limited discretion in the way the funds may be spent, which creates a barrier to entitlement, and (ii) the grant contains provisions that release the awarding agency from the obligation to transfer funds that are not expended at the time the award is terminated. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We recognized the grant reimbursements as a contra operating expense in the period in which the related costs are incurred and the related services are rendered, provided that the applicable performance obligations under the government grants have been met. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">52</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Interest Income (Expense), Net </div>
        <div style="text-indent:20pt; margin-top:5.01pt; width:456pt; line-height:12pt;">Interest income (expense), net, consists primarily of cash interest expense on the Oxford term loans, or Term Loans, and non-cash interest expense and amortization of debt issuance and debt discount costs related to the Term Loans and the debt discounts on the issuance of Notes, as well as the recognition of $2.1 million of a contingent beneficial conversion feature that was recognized upon the date of the Merger. Debt discount is accreted to interest expense over the debt borrowing term. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Other Income </div>
        <div style="text-indent:20pt; margin-top:5.01pt; width:456pt; line-height:12pt;">Other income consists primarily of gains and losses resulting from the revaluation of our preferred stock warrant liabilities and convertible debt derivative liabilities, both of which are revalued at the end of each reporting period and any change in fair value recorded as a component of other income or expense. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We had preferred stock warrants related to Term Loans as well as convertible debt derivatives relating to the issuance of Notes. Both the warrants and Notes derivatives were recorded as a liability, with an offsetting amount recorded as debt discount. The preferred stock warrants were converted into warrants to purchase shares of common stock upon the closing of the Merger. We recorded adjustments to the fair value of the convertible debt derivative liability, as applicable, for the duration that they were outstanding. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Income Taxes </div>
        <div style="text-indent:20pt; margin-top:4.82pt; width:456pt; line-height:12pt;">We recognize deferred income taxes for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. We periodically evaluate the positive and negative evidence bearing upon realizability of our deferred tax assets. Based upon the weight of available evidence, which includes our historical operating performance, reported cumulative net losses since inception and difficulty in accurately forecasting our future results, we maintained a full valuation allowance on the net deferred tax assets at June&#160;30, 2019 and December&#160;31, 2018. We intend to maintain a full valuation allowance on the federal and state deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Results of Operations </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Comparison of the Six Months Ended June&#160;30, 2018 and 2019 (in thousands) </div>
        <table style="width:416pt;height:182.5pt;margin-left:20pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.46pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.75pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six Months Ended June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.46pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 1.75pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 1.75pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 1.75pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Dollar Change </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:251.46pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(unaudited) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.75pt 0pt; width:251.46pt;text-align:left;">Operating expenses:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="margin-left:10pt;">Research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,269</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3,226</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,957</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="margin-left:10pt;">General and administrative </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,292</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,317</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,025</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="margin-left:10pt;">Grant reimbursements </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,198<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,198<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="margin-left:20pt;">Total operating expenses, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,561</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">4,345</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,784</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,561<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,345<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Interest expense, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(445<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,641<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,196<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Other income (expense), net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">60</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(94<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(154<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from continuing operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,946<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(7,080<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,134<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from discontinued operations </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(58<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(58<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 2.5pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,946<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(7,138<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,192<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-style:italic;">Research and Development </div>
        <div style="text-indent:20pt; margin-top:4.81pt; width:456pt; line-height:12pt;">Research and development expenses increased by $1.9 million to $3.2 million for the six months ended June&#160;30, 2019, from $1.3 million for the six months ended June&#160;30, 2018. The increase was primarily due to&#8201;$1.3 million in connection with start-up activities related to the planned Phase 2 ADYX-005 TKA and Phase 2 ADYX-006 Mastectomy clinical trials and $0.8 million related to the initiation of drug supply manufacturing with Avecia, partially offset by a $0.2 million reduction in salaries and benefits associated with the resignation of one employee. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">53</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;">General and Administrative </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">General and administrative expenses increased by $1.0 million to $2.3 million for the six months ended June&#160;30, 2019, from $1.3 million for the six months ended June&#160;30, 2018. This increase was primarily due to an increase of&#8201;$0.9 million in legal and professional service costs incurred in connection with the Merger and preparation to be a public company, and an increase of&#8201; $0.1 million in other general and administrative costs, including insurance, associated with us being a public company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Grant Reimbursements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Beginning in February 2019, we started to receive payments from a NIH grant to support the clinical development of our lead product candidate, brivoligide. In the six months ended June&#160;30, 2019, we recorded $1.2 million of grant reimbursements relating to qualified expenses incurred under the terms of the NIH grant. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Interest Expense, Net </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Interest expense, net, increased by $2.2 million to $2.6 million during the six months ended June&#160;30, 2019, from $0.4 million during the six months ended June&#160;30, 2018. The increase was primarily attributable to the recognition of&#8201; $2.1 million associated with the beneficial conversion feature recognized upon the modification and conversion of two Notes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Loss from Discontinued Operations </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Loss on discontinued operations relates to the AquaMed business that was incurred from the date of the Merger to its spin-off that occurred on June&#160;21, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Comparison of the Year Ended December&#160;31, 2017 and 2018 (in thousands) </div>
        <table style="width:416pt;height:143.5pt;margin-left:20pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:254.06pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Years Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:254.06pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Dollar Change </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:254.06pt;text-align:left;">Operating expenses:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:254.06pt;text-align:left;">
              <div style="margin-left:10pt;">Research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">8,722</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,137</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,585<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:254.06pt;text-align:left;">
              <div style="margin-left:10pt;">General and administrative </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,341</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,982</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">641</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:254.06pt;text-align:left;">
              <div style="margin-left:20pt;">Total operating expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">11,063</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">5,119</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,944<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:254.06pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,063<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,119<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">5,944</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:254.06pt;text-align:left;">
              <div style="white-space:nowrap;">Interest expense, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(515<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(992<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(477<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:254.06pt;text-align:left;">
              <div style="white-space:nowrap;">Other income </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">126</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">109</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:254.06pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,561<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,985<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">5,576</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-style:italic;">Research and Development </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Research and development expenses decreased by $6.6&#160;million to $2.1&#160;million in 2018, from $8.7&#160;million in 2017. This decrease was primarily due to a decrease of&#8201;$6.4&#160;million related to the completion of the ADYX-004 clinical trial initiated in 2017. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">General and Administrative </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">General and administrative expenses increased by $0.7&#160;million to $3.0&#160;million in 2018, from $2.3&#160;million in 2017. This increase was primarily due to an increase of&#8201;$0.7&#160;million for legal and professional fees incurred in connection with the Merger and preparation to be a public company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Interest Expense, Net </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Interest expense, net, increased by $0.5&#160;million to $1.0&#160;million in 2018, from $0.5&#160;million in 2017. The increase was primarily attributable to an increase in interest paid on the Term Loans, accretion of a final charge due at maturity for the Term Loans, accrued interest on outstanding Notes, and the amortization of debt discount related to the embedded derivatives for the Notes. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">54</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;">Other Income (Expense), Net </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">Other income (expense), net increased by $0.1&#160;million to $0.1&#160;million in 2018 due primarily to the change in valuation of the warrant liability and embedded derivatives related to the Notes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Liquidity and Capital Resources </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Since inception through June&#160;30, 2019, our operations have been financed primarily by the sale of equity securities, payments from strategic collaborators, borrowings under term loans and the issuance of convertible notes. As of June&#160;30, 2019, we had $24,000 in cash and cash equivalents and an accumulated deficit of&#8201; $44.4&#160;million. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We expect that our research and development and general and administrative expenses will increase, and, as a result, we anticipate that we will continue to incur increasing losses in the foreseeable future. As stated above, we also expect that our current capital resources will be insufficient to fund our planned operations for a 12-month period. Therefore, we will need to raise additional capital to fund our operations, which may be through the issuance of additional equity, and potentially through the incurrence of additional debt. In addition, we may be required to raise additional capital in the future to service our indebtedness, including outstanding indebtedness that will become due and payable during fiscal year 2019, and make necessary capital expenditures. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts and our ability to refinance outstanding indebtedness before the applicable maturity date. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. In addition, if we default under the loan and security agreement, or the Loan Agreement, with Oxford Finance, Oxford Finance will have the ability to exercise its rights as collateral agent to take possession and dispose of the collateral securing the indebtedness under the Loan Agreement, which collateral includes all of our property, including our intellectual property. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Beginning in February&#160;2019, we started to receive payments from a NIH grant to support the clinical development of our lead product candidate, brivoligide. While these payments will offset certain qualifying expenses incurred on this research and development program, it will not be adequate to cover other expenses expected to be incurred for research, development, general and administrative expenses. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize any of our product candidates. At the same time, we expect our expenses to increase in connection with our ongoing development and manufacturing activities, particularly as we continue the research, development, manufacture and clinical trials of, and seek regulatory approval for, our product candidates. Subject to obtaining regulatory approvals of any of our product candidates, we anticipate that we will need substantial additional funding in connection with our continuing operations. Further, we expect to continue to incur additional costs associated with operating as a public company following the Merger. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Until we can generate a sufficient amount of product revenue to finance our cash requirements, we expect to finance our future cash needs primarily through the issuance of additional equity and potentially through borrowings, and strategic alliances with partner companies. To the extent that we raise additional capital through the issuance of additional equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates to third parties that we would otherwise prefer to develop and market ourselves.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">55</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash Flows </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">The following table shows a summary of our cash flows for each of the periods shown below (in thousands): </div>
        <table style="width:456pt;height:104.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:265.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Years Ended <br >December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Six Months Ended <br >June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:265.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:265.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">(unaudited) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">(unaudited) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:265.61pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash used in operating activities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,183<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,019<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,527<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,223<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:265.61pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash used in investing activities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:265.61pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash (used) provided by financing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(59<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">3,610</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">884</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,559</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:265.61pt;text-align:left;">
              <div style="white-space:nowrap;">Net decrease in cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,245<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,414<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,643<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,664<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.82pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash Flows from Operating Activities </div>
        <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;">Cash used in operating activities for the six months ended June&#160;30, 2019 was $4.2 million, consisting of a net loss of&#8201;&#8201;$7.1 million, which was offset by non-cash charges of&#8201;&#8201;$2.9 million primarily for non-cash interest expense on Notes, stock-based compensation expense, accretion of the charge due upon maturity of debt, and amortization of right of use assets, and a net increase in cash resulting from changes in operating assets and liabilities of&#8201;$0.1 million. The change in our net operating assets and liabilities included cash generated from an increase in accounts payable of&#8201;$1.3 million and an increase of&#8201;&#8201;$0.5 million for accrued liabilities, both of which were due primarily to an increase in legal, accounting and other professional fees and expenses incurred in connection with the Merger and preparation to be a public company, which was offset by cash used due to an increase in prepaid expense of&#8201; $1.6 million primarily related to clinical trial activity and $0.1 million of lease liability payments. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">Cash used in operating activities for the six months ended June&#160;30, 2018 was $3.5 million, consisting of a net loss of&#8201;&#8201;$2.9 million, which was offset by noncash charges of&#8201;&#8201;$0.4 million primarily for stock-based compensation expense, accretion of the charge due upon maturity of debt and amortization of debt discount and debt financing costs. In addition, $0.9 million of cash was consumed resulting from changes in operating assets and liabilities. The change in our net operating assets and liabilities was due primarily to a decrease in accounts payable of&#8201;&#8201;&#8201;$0.6 million related to the completion of the ADYX-004 clinical trial initiated in 2017 and a decrease of&#8201;&#8201;&#8201;$0.3 million due to the reduction of accrued liabilities relating to the ADYX-004 clinical trial. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">Cash used in operating activities for 2018 was $6.0&#160;million, consisting of a net loss of&#8201;&#8201;$6.0&#160;million, which was offset by non-cash charges of&#8201;$0.8&#160;million primarily for stock-based compensation expense, non-cash interest expense, and accretion of final charge due upon maturity of debt, and net cash used due to changes in operating assets and liabilities of&#8201;$0.8&#160;million. The cash used in our net operating assets and liabilities was primarily due to the decrease of&#8201; $0.6&#160;million for the reduction of accrued liabilities relating to the completion of the ADYX-004 clinical trial initiated in 2017 and $0.2&#160;million for the reduction of accounts payable related to clinical trial activity and professional fees related to merger activities. </div>
        <div style="text-indent:20pt; margin-top:5.01pt; width:456pt; line-height:12pt;">Cash used in operating activities for 2017 was $10.2&#160;million, consisting of a net loss of&#8201;&#8201;$11.6&#160;million, which was offset by non-cash charges of&#8201;$0.5&#160;million primarily for stock-based compensation expense, accretion of final charge due upon maturity of debt and amortization of debt discount and debt financing costs, and a net increase in cash resulting from a changes in operating assets and liabilities of&#8201;$0.9&#160;million. The change in our net operating assets and liabilities was due primarily to an increase in accounts payable of&#8201;$0.6&#160;million related to increased clinical trial activity and a decrease of&#8201;$0.3&#160;million in prepaid expenses primarily related to research and development activities. </div>
        <div style="margin-top:10.82pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash Flows from Investing Activities </div>
        <div style="margin-left:20pt; margin-top:4.02pt; width:436pt; line-height:12pt;">Cash used in investing activities for all periods presented was nominal. </div>
        <div style="margin-top:10.82pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash Flows from Financing Activities </div>
        <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;">During the six months ended June&#160;30, 2019, net cash provided by financing activities was $2.6 million, consisting of&#8201; $4.0 million proceeds from the issuance of Notes, offset by $1.4 million used to repay principal of the Term Loans. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">56</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">During the six months ended June&#160;30, 2018, net cash used in financing activities was $0.9 million consisting of&#8201; $1.5 million proceeds from the issuance of Notes, offset by $0.6 million used to repay principal under the Term Loans. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2018, net cash provided by financing activities was $3.6&#160;million consisting primarily of proceeds from the issuance of Notes of&#8201;&#8201;$4.5&#160;million, offset by $0.9&#160;million used to repay principal of the Term Loans. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2017, net cash used in financing activities was $59,000 resulting primarily from $139,000 used to repay principal for the Term Loans, offset partially by $80,000 cash generated from the exercise of warrants to purchase our Series&#160;A preferred stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Contractual Obligations and Commitments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table summarizes our contractual obligations as of December&#160;31, 2018 (in thousands): </div>
        <table style="width:456pt;height:90.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:240pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">Payments Due by Period </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:240pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Less <br >Than <br >1 Year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">1&#8201;&#8211;&#8201;3 <br >Years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">3&#8201;&#8211;&#8201;5 <br >Years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">More <br >Than <br >5&#160;years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Term loan and interest<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,683</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,683</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible promissory notes and interest<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,712</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,712</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Operating lease commitments<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,634</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,395</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:7.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Reflects principal, interest payments and final balloon payment due to Oxford Finance under a loan and security agreement. Interest rate is floating and future interest payments are estimated based upon the December&#160;2018 interest rate. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">See &#8220;&#8212;&#8201;Convertible Notes&#8221; below.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">We lease our office space under a non-cancellable long-term operating lease. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following table summarizes our contractual obligations as of June&#160;30, 2019 (in thousands): </div>
        <table style="width:456pt;height:90.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:240pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">Payments Due by Period </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:240pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Less <br >Than <br >1 Year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">1 &#8211; 3 <br >Years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">3 &#8211; 5 <br >Years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">More <br >Than <br >5&#160;years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Term loan and interest<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,135</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,135</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible promissory notes and interest<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,941</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,941</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Operating lease commitments<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-2.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,006</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">346</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">463</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">197</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,082</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,422</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">463</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">197</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:7.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Reflects principal, interest payments and final balloon payment due to Oxford Finance under a loan security agreement. Interest rate is floating and future interest payments are estimated based upon the June&#160;2019 interest rate. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">See &#8220;&#8212;&#8201;Convertible Notes&#8221; below.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">We lease our office space under a non-cancellable long-term operating lease. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Notes </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, $5.5 million aggregate principal amount remained outstanding under outstanding Notes. In July 2019, we issued additional Notes to affiliates of a significant stockholder that totaled $0.6 million principal amount for general corporate purposes and working capital. Provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from securities sold to Domain Associates or TPG, these convertible promissory notes, plus accrued but unpaid interest, will convert into 4,874,744 shares of common stock, based upon an assumed combined</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">57</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the last reported sale price of our common stock by OTCQB on October 9, 2019, provided that this offering results in total proceeds to us of at least $5.0&#160;million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG. The issuance of these shares will not be registered under the Securities Act.</div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In November&#160;2015, we entered into the Loan Agreement with Oxford Finance pursuant to which Oxford Finance agreed to lend us up to $10.0&#160;million principal amount issuable in three tranches, or the Term Loans, of which $5.0&#160;million had been drawn as of June&#160;30, 2019. The Term Loans will mature on November&#160;1, 2019. The Loan Agreement has been amended several times. We have the option to prepay all, but not less than all, of the borrowed amounts, provided that we will be obligated to pay a prepayment fee. The Term Loans bear interest at a floating per annum rate equal to (i)&#160;7.06% plus (ii) the greater of&#8201; (a)&#160;the 30-day U.S. Dollar LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (b)&#160;0.19%. We will be required to make a final payment of 4.25% of the funded amount, payable on the earlier of&#8201;&#8201;(i) the maturity date or (ii)&#160;the prepayment of the Term Loans. Our obligations under the Loan Agreement are secured by a perfected first-priority lien on all of our assets, including our intellectual property. In connection with the Merger, Alliqua was named as an additional borrower under the Loan Agreement. As of June&#160;30, 2019, we were in compliance with all covenants under the Loan Agreement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January&#160;2019, we and Oxford Finance amended the Loan Agreement to provide for two&#160;months of interest-only payments followed by eight&#160;months of repayments. We also placed $200,000 in a segregated bank account that is subject to a blocked control agreement in favor of Oxford Finance. The funds in the segregated account will be released upon the closing of this offering. The amendment fee was $50,000. The amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In May&#160;2019, we and Oxford agreed to an additional amendment to provide consent to the Merger. This consent amended certain provisions of the term loan to protect Oxford&#8217;s rights under the original Term Loan agreement. The consent allowed Alliqua to be named as an additional borrower. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June 2019, we and Oxford agreed to amend the Loan Agreement. Oxford agreed to two months of interest-only payments and the maturity date of the Term Loans was extended two months to January&#160;1, 2020. The amendment fee amounted to $20,000. The amendment was accounted for as a debt modification. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with the Loan Agreement, we issued warrants to purchase our preferred stock to Oxford Finance. Upon the closing of the Merger, these warrants were converted into warrants to purchase 11,829 shares of our common stock at an exercise price of&#8201; $6.34 per share. The warrants are immediately exercisable and expire ten&#160;years from the issuance date. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Other Contracts </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We enter into contracts in the normal course of business with various third parties for preclinical research studies, clinical trials, testing and other general and administrative services. These contracts generally provide for termination upon notice, and therefore we believe that our non-cancelable obligations under these agreements are not material. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Off-Balance Sheet Arrangements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December 31, 2017 and 2018 and June&#160;30, 2018 and 2019, we did not have any off-balance sheet arrangements and did not have any holdings in variable interest entities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Summary of Significant Accounting Policies and Estimates </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Use of Estimates </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with Generally Accepted Accounting Principles, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">58</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Merger Transaction</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Merger was treated by Alliqua as a reverse merger and recapitalization effected by a share exchange for financial accounting and reporting purposes. The pro forma condensed combined financial information under the section titled &#8220;Adynxx, Inc. Unaudited Pro Forma Financial Information&#8221; also gives effect to the spin-off of Alliqua&#8217;s wholly owned subsidiary, AquaMed, which is engaged in the custom hydrogel manufacturing business, in the form of a pro rata distribution of the common equity of the subsidiary to Alliqua&#8217;s stockholders. Since Alliqua was deemed to have no operations upon consummation of the spin-off, Alliqua was not considered to be a business for accounting purposes. Accordingly, no goodwill or intangible assets was recorded as a result of the merger. Because Private Adynxx was treated as the acquiring company, Private Adynxx&#8217;s assets and liabilities were recorded at their pre-combination carrying amounts.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Accrued Research and Development Expenses </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We record accrued expenses for estimated costs of our research and development activities conducted by external service providers. We recognize external development costs based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations that conduct and manage clinical trials on our behalf. This process involves reviewing contracts with service providers, identifying services that have been performed on our behalf, confirming the level of service performed are aligned with the contract, expected remaining period of performance and the associated cost incurred for the service when we have not been invoiced or otherwise notified of actual cost. We estimate our accrued research and development expenses as of the date of each of our balance sheets. Expenses that are paid in advance of performance are deferred as a prepaid expense and expensed as the services are provided. Our management made significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Through June&#160;30, 2019, we have had no significant adjustments to accrued clinical trial expense. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Stock-based Compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We recognize compensation costs related to stock-based awards granted to employees, directors and non-employees based on the estimated fair value of the awards on the date of grant. We estimate the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options, the fair value of our common stock on the date of grant for restricted stock&#160;units, or RSUs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We generally recognized the grant date fair value of the stock-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. For non-employee awards, the grant date fair value is recognized on a straight-line basis over the associated service period of the award. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We use the Black-Scholes valuation model to assist us in determining the fair value of our stock options. The Black-Scholes valuation model requires the use of following assumptions: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;">Expected volatility.&nbsp;&nbsp;&nbsp;</font>Expected volatility is estimated using comparable public companies&#8217; volatility for similar terms. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;">Expected term.&nbsp;&nbsp;&nbsp;</font>The expected term represents the period that our stock-based awards are expected to be outstanding and is determined using the simplified method. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">59</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;">Risk-free interest rate.&nbsp;&nbsp;&nbsp;</font>The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:3.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;">Expected dividend.&nbsp;&nbsp;&nbsp;</font>The Black-Scholes model calls for a single expected dividend yield as an input. We have never paid dividends and have no plans to pay cash dividends. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the guidance of ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, we accounted for forfeitures as they occurred. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We did not grant any stock options to employees during the six months ended June&#160;30, 2019 or the years ended December&#160;31, 2018 and 2017. Stock-based compensation expense recorded in research and development and general and administrative expenses was $136,000 and $150,000 for the six months ended June&#160;30, 2019 and 2018, respectively, and $293,000 and $301,000 for the years ended December&#160;31, 2018 and 2017, respectively. As of June&#160;30, 2019, unrecognized stock-based compensation expense related to employees totaled approximately $395,000, which is expected to be recognized over approximately 1.5 years. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Stock-based compensation expense recorded in exchange for services related to non-employee options was $32,000 and $0 for the six months ended June&#160;30, 2019 and 2018, respectively. As of June&#160;30, 2019, unrecognized stock-based compensation expense related to unvested non-employees stock options was approximately $16,000, which is expected to be recognized over a weighted-average period of three months. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Income Taxes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We account for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We provide a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In evaluating the ability to recover our deferred income tax assets, we consider all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event we determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We recognize the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company&#8217;s tax return. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Freestanding warrants are classified as liabilities on our balance sheets. Warrants are subject to re-measurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. We will continue to adjust the carrying values of freestanding warrants classified as liabilities for changes in fair value until the earlier of the exercise or expiration of the warrants. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Derivative Instruments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We evaluate our convertible debt to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Accounting Standards Codification, or ASC 815-15, &#8220;<font style="font-style:italic;">Derivatives and Hedging: Embedded Derivatives</font>.&#8221; The result of this accounting treatment is that the fair value of the bifurcated derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the Statement of Operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">60</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12&#160;months of the balance sheet date. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Debt Modifications and Extinguishments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">When we modify debt, we do so in accordance with ASC 470-50, &#8220;<font style="font-style:italic;">Debt: Modifications and Extinguishments,</font>&#8221; which requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#8220;substantial modifications.&#8221; Based on the guidance relied upon and the analysis performed, if the debt modifications were considered to be substantial modifications, then they were treated as an extinguishment of the debt. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In accordance with ASC 470-50 we determined that the October&#160;2018 modification of the March&#160;2018 and September&#160;2018 Notes to add an additional conversion option in the event of a reverse merger, was considered to be a &#8220;substantial modification.&#8221; As a result, we treated this modification as an &#8220;extinguishment&#8221; of those debts and recognized $11,000 of net gain from this debt extinguishment in other income. All other changes to debt provisions were not considered substantial and were treated as debt modifications. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Recently Adopted Accounting Pronouncements </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Lease Accounting </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In February 2016, the FASB issued ASU No. 2016-02, <font style="font-style:italic;">Leases (Topic 842)</font>, or ASU 2016-02. ASU 2016-02 is intended to improve financial reporting of leasing transactions by requiring organizations that lease assets to recognize assets and liabilities for the rights and obligations created by leases that extend more than 12 months on the balance sheet. This accounting update also requires additional disclosures surrounding the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for financial statements issued for annual and interim periods beginning after December 15, 2018 for public business entities. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. We adopted the new standard on January 1, 2019 and used the effective date as its date of initial application. Consequently, we have not adjusted prior period amounts. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have elected the package of practical expedients permitted in ASC Topic 842. Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a) whether the contracts contain a lease under ASC Topic 842, (b) whether classification of the operating leases would be different in accordance with ASC Topic 842, or (c) whether the unamortized initial direct costs would have met the definition of initial direct costs in ASC Topic 842 at lease commencement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The most significant impact from the adoption of this standard was the recognition of right-of-use, or ROU, assets and lease obligations on the balance sheet for operating leases. This standard did not have a material impact on our cash flows from operations and operating results. As a result of the adoption of the new lease accounting guidance, we recognized on January 1, 2019 (a) a lease liability of approximately $227,000, which represents the present value of the remaining lease payments of approximately $239,000, discounted using the Company&#8217;s incremental borrowing rate of 9.41%, and (b) a ROU asset of approximately $227,000 which represents the lease liability of&#8201; $227,000. The ROU asset is being amortized over the remaining term of the lease of 12 months from January 1, 2019.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">61</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Recent Accounting Pronouncements Not Yet Effective </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In August 2018, the FASB issued No. ASU 2018-13, <font style="font-style:italic;">Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)</font>. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year, with early adoption permitted. We are currently assessing whether these amendments will have a material effect on our financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In August 2018, the FASB issued ASU 2018-15, <font style="font-style:italic;">Intangibles&#8201;&#8212;&#8201;Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font>, or ASU 2018-15. The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January 1, 2020 and early adoption is permitted. We are currently assessing whether these amendments will have a material effect on our financial statements. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">62</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tOB">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">OUR BUSINESS </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are a clinical stage biopharmaceutical company focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Transcription factor decoys are short strands of DNA that specifically bind to and block the activity of their target transcription factors. Transcription factors are proteins that specifically bind to the regulatory regions of one or more target genes and regulate the expression of those genes. Since the founding of Adynxx in 2007, we have leveraged our AYX platform of proprietary transcription factor decoys to identify and develop novel product candidates designed to modify the course of pain. Our resulting pipeline includes brivoligide, a Phase&#160;2 drug candidate intended to address postoperative, or post-surgical pain in a readily-identified group of patients with a greater risk of experiencing increased pain and elevated opioid use following surgery, and AYX2, a pre-clinical candidate intended to treat chronic pain. Both programs were discovered by us and are part of our AYX platform of transcription factor decoys. We plan to continue advancing our AYX platform programs while simultaneously developing new transcription factor decoy candidates, collaborating with twoXAR, our artificial intelligence-driven drug discovery partner, and evaluating in-licensing opportunities to expand our pipeline and leverage our business development, clinical development and regulatory expertise. We are currently collaborating with twoXAR to use their artificial intelligence-driven drug discovery platform to identify endometriosis treatments. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following table outlines the status of our development programs: </div>
        <div style="position:relative;z-index:-1;margin-top:10.98pt; text-align:center; width:456pt;">
          <img src="tv523241_chrt-org.jpg" alt="[MISSING IMAGE: tv523241_chrt-org.jpg]" height="143" width="553" >
        </div>
        <div style="text-indent:20pt; margin-top:13.98pt; width:456pt; line-height:12pt;">We believe that our transcription factor decoy technology can transform the treatment of pain, and going forward has the potential to be applied to additional disease states. The AYX platform drug candidates are currently focused on postoperative pain and pre-existing chronic pain. We plan to leverage our expertise in transcription factor decoy drug discovery and development to identify additional product candidates in inflammation related disease states including but not limited to organ scarring, heart disease and cancer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have a highly experienced management team whose members have, in the course of their prior employment, participated in bringing more than 10 product candidates through clinical development, regulatory approval and/or into commercialization, including such approved products as Zerbaxa, Teflaro, Doribax, Vibativ, Symproic, Embeda, Revlimid, Mulpleta, Osphena, Comtan, FocalinXR, Trileptal, Kapvay and Cuvposa. We plan to leverage our management team&#8217;s breadth and depth of experience in clinical and regulatory drug development as well as market development and commercialization to continue to develop existing product candidates, and to discover and develop additional product candidates in-house using the AYX platform and build our pipeline through collaboration and in-licensing activities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Strategy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our goal is to be a leader in the development and commercialization of novel therapeutics for pain and inflammation. Our focus to achieve this goal will be to utilize our experience and capabilities to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Advance our existing product candidates through late-stage clinical trials, generating meaningful clinical results; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">63</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">Work with U.S. and international regulatory authorities for expeditious, efficient development pathways toward registration of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:4.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Prepare for commercialization of each program; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:4.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Use our expertise in transcription factor decoy drug development to discover and develop&#160;additional transcription factor decoy product candidates targeting a range of inflammation-related diseases; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:4.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Collaborate with twoXAR to use AI-driven drug discovery technology to identify novel drug candidates for the treatment of endometriosis; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:4.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Use our industry and academic relationships and experience to source, evaluate and in-license well-characterized product candidates to continue pipeline development; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:4.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Identify potential commercial or distribution partners for our product candidates in relevant territories. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Transcription Factor Decoy Technology </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Transcription factor decoys are short strands of DNA that specifically bind to and block the activity of their target transcription factors by preventing their interaction with DNA (Figure 1). Transcription factors are proteins that specifically bind to the regulatory regions of one or more target genes and regulate the expression of those genes. Using a screening assay, we discover and develop transcription factor decoys that are designed with binding and size parameters suitable for clinical application. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Figure 1<br >&#8199;<br >Transcription Factor Decoy Mechanism of Action </div>
        <div style="position:relative;z-index:-1;margin-top:7pt; text-align:center; width:456pt;">
          <img src="tv523241_img.jpg" alt="[MISSING IMAGE: tv523241_img.jpg]" height="133" width="368" >
        </div>
        <div style="margin-top:11pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">Transcription Factor Decoy Mechanism of Action.</font> (A) A transcription factor, or TF, binds to the regulatory region of the target gene on the DNA to regulate gene expression. (B) A TF decoy mimics the regulatory region of the target gene normally bound by its TF target. The mechanism of action is direct; by binding its TF target, the decoy prevents it from binding to its intended target, and thus blocks gene expression. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The AYX Platform of Transcription Factor Decoys </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The AYX platform consists of a wide range of transcription factor decoys, each of which has multiple binding sites capable of targeting one or more transcription factors, and we believe that we have the technological expertise to generate additional decoys based on desired therapeutic characteristics. The current AYX drug candidates are intended to treat postoperative pain and chronic pain. We plan to leverage our expertise in transcription factor decoy drug discovery and development to identify additional product candidates to treat inflammation-related diseases, including but not limited to organ scarring, heart disease and cancer. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Product Candidates </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Brivoligide for Postoperative Pain </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide is a transcription factor decoy specifically designed to inhibit the function of the transcription factor Early Growth Response 1, or EGR1, when administered at the time of surgery. EGR1 is expressed in the spinal cord and dorsal root ganglia, or DRG, in response to trauma such as surgery for a period of </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">64</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">approximately 12 hours. In normal animals, EGR1 initiates a wide range of gene regulation that results in increased or exacerbated pain following trauma or injury. In contrast, in animals that are unable to express EGR1, third party studies have shown that there is a reduction of pain intensity in response to trauma or injury, which may suggest that EGR1 has a role in elevated post-surgical pain. By inhibiting the function of EGR1 in people undergoing surgery, we believe brivoligide can prevent the regulation of genes that lead to an increased sensitivity to pain in some patients following surgery. We have evaluated brivoligide in four clinical trials: a Phase&#160;1 dose-escalating safety study in healthy volunteers and three Phase&#160;2 studies in subjects undergoing unilateral total knee arthroplasty, or TKA. A total of 264 subjects have received a single injection of brivoligide into the spinal canal, or an intrathecal injection, in doses ranging from 1.25 mg/3 mL (1.25 milligrams of brivoligide in 3 milliliters of solution) to 1,100 mg/10 mL. Brivoligide has been observed to be well-tolerated in the trials we have completed to date. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Post-hoc analyses of data generated in the three completed Phase 2 studies indicate that patients receiving a single administration of brivoligide at the time of surgery, in addition to standard of care, experienced reduced pain for weeks and shortened time to achieve mild pain, both as measured using the numerical rating scale, or NRS, when compared to patients receiving placebo and standard of care, in each case in a population of patients at greater risk of experiencing increased and prolonged pain following surgery. These differences were either not statistically significant or could not be considered significant due to the post-hoc nature of the analyses. These patients are readily indentifiable prior to surgery as patients who score high on the Pain Catastrophizing Scale, or PCS, and represent approximately one-third of the surgical population. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Postoperative Pain and Pain Catastrophizing </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to varying across the type of surgery, the severity and duration of postoperative pain varies across individuals. A growing body of literature indicates that the psychological construct known as pain catastrophizing is also an important factor in predicting the onset, severity, and duration of postoperative pain. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pain catastrophizing is as an amplified, negative orientation toward pain. It&#160;is comprised of elements of rumination (continuous or repetitive thoughts, anxious preoccupation with pain, and the inability to inhibit pain-related thoughts and fears); magnification (magnification of the unpleasantness of pain situations and expectations for negative outcomes from pain); and a sense of helplessness (perceived inability to control painful situations and experiences). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pain catastrophizing likely reflects a specific underlying physiology of pain associated with an enhanced response to painful stimuli, both in intensity and duration, as well as a relative insensitivity to pain relieving or analgesic therapies such as opioids. This physiology is associated with an enhanced and prolonged response to painful stimuli that suggests limited ability to appropriately inhibit pain signals being conveyed to the brain. Further, there is evidence that this underlying physiology can be inherited.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We estimate that of the 37 million surgical procedures performed in the United States annually, approximately 16 million of those result in a sufficient duration and severity of postoperative pain to be characterized as high unmet analgesic, or pain relieving, need procedures. Of those 16 million high-unmet analgesic need procedures, based on publications focused on the PCS, we expect that approximately one third will be conducted on patients scoring high (&ge;16) on the PCS, representing approximately 5.3 million patients who we believe could be candidates for brivoligide treatment. See &#8220;&#8212; The Role of the PCS in Identifying Patients Who May Benefit from Brivoligide.&#8221;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">To estimate the number of surgical procedures and the number of high-unmet analgesic need procedures, we use datasets sourced from samples and databases maintained by the Healthcare Cost and Utilization Project, or HCUP. The HCUP is a family of health care databases and related software tools and products developed through a federal-state industry partnership with and sponsored by the Agency for Healthcare Research and Quality, or the AHRQ. The HCUP is based on statewide data collected by individual data organizations across the United States and provided to AHRQ through the HCUP partnership. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For inpatient procedure estimates, we used the HCUP Nationwide Inpatient Sample, or the NIS, a large publicly available all-payer inpatient care database in the United States containing data on more than </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">65</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">seven million hospital stays. We believe that the large sample size from the NIS is ideal for developing national and regional estimates and enables analyses of rare conditions, uncommon treatments, and special populations. For outpatient procedure estimates we used the HCUP State Ambulatory Surgery and Services Database, or the SASD, which includes 29 states and captures two-thirds of the United States population. The SASD also includes data for ambulatory surgery and other outpatient services from hospital-owned facilities and, for some states, from non-hospital-owned facilities. There is no dataset available after 2015 for SASD, and as a result, the 2014 data are the most recent for both NIS and SASD. However, we believe that the 2014 data remain relevant for purposes of estimating the quantity of surgical procedures due to the relative year-over-year stability of prior estimates in this dataset and the fact that 2014 is the most recently available complete year of this large dataset.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Based on consultations with pain management experts, we classified individual surgical procedures to identify those that we believe result in a sufficient duration and severity of postoperative pain to be characterized as high-unmet analgesic need procedures. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Table 1: Estimated Annual Procedures with High-Unmet Analgesic Need</div>

          <table style="width:456pt;height:269pt;margin-top:7pt;border-collapse: collapse;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Procedure classes </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">Inpatient <br >Procedures <br >HCUP NIS 2014</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">ASC/Outpatient <br >Procedures <br >HCUP SASD <br >2014</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">Total <br >Procedures</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.25pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">TKA (incl. revisions) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">755,226</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">83,255</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">838,481</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Lower extremity orthopedic surgeries </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">742,295</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">44,339</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">786,634</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:1.167pt 0pt 0.5pt 0pt; width:234pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Hip arthroplasty (incl. revisions and partial arthroplasties) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">521,080</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">21,678</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">542,758</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Spine/Back </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">844,161</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">322,679</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,166,840</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Other orthopedic procedures </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,390,091</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">927,404</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,317,495</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Chest/lung/thoracotomy </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">381,145</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">50,901</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">432,046</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Breast procedures </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">69,790</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">817,511</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">887,301</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Abdominal </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">527,410</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">660,044</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,187,454</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Cardiac </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">432,310</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">43,527</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">475,837</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Genital/urinary </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">471,050</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">524,039</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">995,089</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Hernia </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">166,885</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">856,442</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,023,327</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Lower gastrointestinal </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">612,310</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">122,088</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">734,398</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">OB/Gyn </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">821,665</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">828,702</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,650,367</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Upper gastrointestinal </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">430,035</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">92,784</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">522,819</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Vascular </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,333,795</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">338,927</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,672,723</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Other </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">829,343</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">829,343</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.25pt 0pt 2.25pt 0pt; width:234pt;text-align:left;">Total</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">9,499,248</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">6,563,663</td>
              <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">16,062,912</td>
              <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The Role of the PCS in Identifying Patients Who May Benefit from Brivoligide </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Catastrophizing is readily assessed by the PCS, a screening assessment tool that contains 13 questions covering the three components of pain catastrophizing: rumination, helplessness and magnification of pain. Each question is self-rated on a five point scale (from zero to four) and the total score ranges from zero to 52. The PCS has been extensively validated, having been established in over 100 studies. For patient selection purposes, the PCS can be segmented, with high scores predictive of more pain and lower analgesic response after surgery. Results from the literature and from the brivoligide study data suggest that a PCS of&#8201;&ge;16 may represent a clinically relevant threshold among TKA patients to predict positive response to brivoligide. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The importance of determining how a specific patient will respond to a specific treatment or procedure, or patient phenotyping, to predict the response to novel therapies has been recognized by the FDA. Once the PCS is completed by the patient, summation of the responses allows results to be easily available well in advance of surgery in order to determine which patients would potentially benefit from receiving brivoligide due to their underlying physiology. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">66</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Publications focused on the PCS suggest that approximately one-third of people presenting for surgery have PCS scores &ge; 16 and that these same patients experience postoperative pain that is higher in intensity and longer in duration than expected and display a relative resistance to standard analgesic therapies. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Current Therapy for Postoperative Pain </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Postoperative pain management is currently largely opioid-based and supported by adjunctive therapies and techniques such as local anesthetic nerve blocks and direct administration of local anesthetic into the surgical site, all of which only provide short-term relief. The proliferation of adjunctive and alternative therapies suggests that there are a considerable number of patients receiving inadequate pain relief, especially from movement-evoked pain, which is particularly insensitive to opioids. Persistent opioid use after surgery, even among those who are new to opioids, puts patients at increased risk of developing opioid use disorder. A non-opioid approach to postoperative pain relief specifically targeting the high PCS scoring population, a population that is relatively insensitive to standard postoperative analgesic therapies, is urgently needed. We believe there is no approved therapeutic agent that can provide weeks to&#160;months of reduction in postoperative pain and opioid utilization in patients who score high on the PCS with a single administration at the time of surgery. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Solution: Brivoligide for Postoperative Pain in Patients Scoring &ge;16 on the PCS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are pursuing an innovative approach to postoperative pain in people scoring &ge;16 on the PCS. Our lead compound, brivoligide, is designed to be a non-opioid, non-addictive agent given a single time prior to surgery and directed at core mechanisms of increased sensitivity to pain in the high PCS scoring population. In this population, brivoligide may reduce the intensity and duration of acute pain in the postoperative period. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pharmacology of Brivoligide </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">EGR1 is a transcription factor expressed in the spinal cord and dorsal root ganglia, or DRG, in response to trauma such as surgery for a period of approximately 12 hours. In normal animals, EGR1 initiates a wide range of gene regulation that results in increased or exacerbated pain following trauma or injury. In contrast, in animals that are unable to express EGR1, studies have shown that there is a reduction of pain intensity in response to trauma or injury. The structure of brivoligide has not been modified to protect it from breakdown through metabolic processes. In the space near the spinal cord and DRG for intrathecal injections, based on results from our animal studies, we have observed that brivoligide is present for a certain period of time and at a concentration sufficient in such studies to inhibit the function of EGR1 when administered into the intrathecal space at the time of injury. However, outside of the intrathecal space, there are higher rates of metabolic activity, which break down brivoligide in a matter of minutes, preventing concentrations from reaching levels with meaningful pharmacologic activity. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As described above, patients who have high scores on the PCS have an amplified, negative orientation toward pain which likely reflects a specific underlying physiology associated with an enhanced response to painful stimuli. Based on the data we have generated to date from clinical studies, we believe these patients have an altered pain response that results in the full manifestation of EGR1 activity in response to trauma such as surgery. By binding to EGR1 and inhibiting its activity in the spinal cord and DRG during surgery, we believe brivoligide can reduce the severity and duration of postoperative pain in patients that score high on the PCS and would otherwise experience increased or exacerbated pain following surgery.</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Brivoligide Clinical Data </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide has been evaluated in four clinical trials, all of which were sponsored and conducted by us under an Investigational New Drug application, or IND, owned by us: a Phase&#160;1 dose-escalating safety study in healthy volunteers and three Phase&#160;2 studies in subjects undergoing unilateral TKA. A total of 264&#160;subjects have received a single intrathecal administration of brivoligide injection in doses ranging from 1.25 mg/3 mL to 1,100 mg/10 mL (Table 2). Brivoligide was shown to be well tolerated by patients in clinical&#160;trials conducted to date. In the Phase&#160;1 study in healthy volunteers, the study drug (highest dose of&#160;330mg/3mL) was well tolerated by all 25 people that received it. All of the AEs that were reported are among those expected when an injection in the spinal canal is given (for example, headache, backache, and </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">67</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">nausea). In&#160;three subsequently completed Phase&#160;2 clinical trials in TKA evaluating doses of brivoligide up to 1,100mg/10mL, there was no meaningful difference between the study drug and placebo groups in the rate of the complications that are typically seen in patients undergoing knee replacement surgery with spinal anesthetic and receiving analgesic medication. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Table 2: Brivoligide Doses Administered </div>
        <table style="width:416pt;height:137.5pt;margin-left:20pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">Study Number(s) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:68.64pt;">
              <div style="white-space:nowrap; text-align:center;">Dose </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:99.53pt;">
              <div style="text-align:center;">Number of Subjects Receiving <br >Dose </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-001 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">1.25 mg/3 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">5 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-001 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">5 mg/3 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">5 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-001 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">20 mg/3 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">5 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-001 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">80 mg/3 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">5 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-002 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">110 mg/3 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">13 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-001 and ADYX-002 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">330 mg/3 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">46 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-003 and ADYX-004 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">660 mg/6 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">147 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-003 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="white-space:nowrap; text-align:center;">1,100 mg/10 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">38</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.59pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">ADYX-001:</font>&nbsp;&nbsp;&nbsp;The first-in-human study, ADYX-001, was a Phase&#160;1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ascending dose levels of a&#160;single intrathecal injection of brivoligide versus placebo in healthy adult subjects. Single doses&#160;of intrathecal brivoligide versus placebo were evaluated in five sequential ascending dose cohorts: 1.25 mg/3 mL, 5 mg/3 mL, 20 mg/3 mL, 80 mg/3 mL, and 330 mg/3 mL; six subjects were randomized 5:1&#160;to receive brivoligide injection or placebo in each cohort (total n=30). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All 30 subjects received study drug (25 subjects received brivoligide injection and five subjects received placebo) and completed the in-house and 30-day follow-up visits. Safety assessments consisted of the collection of adverse events, or AEs, and serious adverse events, or SAEs, clinical laboratory assessments, vital signs, and physical/neurological examination. AEs that occurred or worsened after administration of the study drug were classified as treatment emergent adverse events, or TEAEs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A total of 41 TEAEs were reported in 20 of the 30 study subjects. Most of the TEAEs were consistent with an intrathecal route of administration (backache, headache and associated nausea). All AEs were transient and resolved completely. There were no SAEs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to the safety evaluations, including physical/neurological exam, vital signs, ECG, clinical labs, and collection of other medications taken after surgery, or concomitant medications, a battery of cognitive assessments was performed to evaluate any potential effects of brivoligide on memory. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The cognitive assessments were performed at screening, baseline and after dosing at two hours, eight&#160;hours, 24 hours and on Day 3. No clinically significant changes in cognitive function from baseline were observed at any dose level. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">ADYX-002:</font>&nbsp;&nbsp;&nbsp;ADYX-002 was a Phase&#160;2 randomized, double-blind, placebo-controlled, adaptive study to evaluate the safety and efficacy of a single intrathecal preoperative administration of brivoligide injection at two dose levels compared to placebo in patients undergoing unilateral TKA. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ADYX-002 assessed the effect of brivoligide on acute and persistent (subacute) pain at rest and with movement as well as effects on opioid requirements in subjects undergoing unilateral TKA. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The study population consisted of healthy male and female subjects between 40 and 80&#160;years of age, inclusive, who were scheduled to undergo primary unilateral TKA for painful osteoarthritis with an American Society of Anesthesiologists Physical Status Classification System of&#8201;&#8201;&le;3, which system assesses fitness of patients before surgery on a scale of zero to six. Subjects randomized to the brivoligide treatment group received a single 3 mL intrathecal brivoligide injection (110 mg/3 mL or 330 mg/3 mL) just before administration of anesthesia using the same needle. Subjects participated in the study for 42&#160;days (&#177; 5&#160;days). </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">68</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The primary and key secondary endpoints were assessed using a standard numerical rating scale, or NRS, whereby subjects are asked to select a number between 0 and 10 that best represents their pain intensity. An NRS score of 0 represents no pain and a score of 10 represents the worst pain possible. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following assessments were used to evaluate efficacy: NRS pain assessment at rest; NRS pain assessment before removal of intravenous patient controlled analgesic therapy, and before administration of opioid medication in hospital; a defined distance walk (5 meters inpatient, 15 meters outpatient) with NRS pain assessment before and after; range of motion, or ROM, with NRS pain assessments; Brief Pain Inventory, or BPI, questionnaire daily through Day 28 and at Day 42; and the collection of analgesic medication data through Day 42. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Safety profile assessments consisted of the collection of AEs and SAEs, clinical laboratory assessments, vital signs, and physical/neurological examination. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Out of 100 subjects randomized, six withdrew and 94 completed the study post dosing. After initial dosing of 30 patients randomized 1:1:1 between 3 mL placebo, 110 mg/3 mL brivoligide and 330 mg/3 mL brivoligide, the Data Monitoring Committee reviewed the data to select the appropriate dose going forward based on prespecified criteria. Following review by the Data Monitoring Committee, all remaining subjects were enrolled in the 3 mL placebo or 330 mg/3mL brivoligide groups. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Safety </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Overall, 44 subjects treated with placebo, 13 subjects treated with brivoligide 110 mg/3 mL and 40&#160;subjects treated with brivoligide 330 mg/3 mL groups reported at least one TEAE. The overall AE profile was 96% mild or moderate with no AE clearly related to brivoligide. Four SAEs in three subjects were reported in the brivoligide group and two SAEs in two subjects were reported in the placebo group. No SAEs were considered related to brivoligide. In summary, brivoligide was shown to be well tolerated in patients. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Efficacy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For pain with walking, at rest, and with joint range of motion, as well as total use of opioid medications, either during the hospital stay or following discharge, no significant difference was observed between brivoligide 330 mg/3 mL and placebo 3 mL treated groups. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Post-hoc analysis of the study data suggested higher doses in larger volumes could provide broader distribution and clinically meaningful benefit, regardless of injection site. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">ADYX-003:</font>&nbsp;&nbsp;&nbsp;The second Phase&#160;2 study, ADYX-003, was a randomized, double-blind, placebo-controlled, two-stage study to evaluate the safety and efficacy of two dose levels of brivoligide injection administered at one of two potential spinal injection sites before surgery in patients undergoing TKA. The two potential spinal injection sites are the space between lumbar vertebrae 3 and 4, or L 3/4, and the space between lumbar vertebrae 4 and 5, or L 4/5. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The total subject population was 120 subjects distributed over two dose, and two injection sites within each dose, with a brivoligide to placebo control ratio of 2:1 in each group: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Brivoligide (660 mg in 6 mL) injected at L4/5; n= 20 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Placebo (vehicle control 6 mL) injected at L4/5; n= 10 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Brivoligide (660 mg in 6 mL) injected at L3/4; n=20 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Placebo (vehicle control 6 mL) injected at L3/4; n=10 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Brivoligide (1,100 mg in 10 mL) injected at L4/5; n=20 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Placebo (vehicle control 10 mL) injected at L4/5; n=10 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Brivoligide (1,100 mg in 10 mL) injected at L3/4; n=20 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Placebo (vehicle control 10mL) injected at L3/4; n=10 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">69</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The following assessments were used to evaluate efficacy: NRS pain assessment at rest; a defined distance walk (5 meters inpatient, 15 meters outpatient), with NRS for pain upon standing for the walk and pain during the walk; range of motion with NRS pain assessments; and collection of analgesic medication data through Day 42. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Safety assessments consisted of the collection of AEs and SAEs, clinical laboratory assessments, vital signs and physical/neurological examination. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Safety </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Overall, all subjects in the brivoligide 660 mg/6 mL and brivoligide 1,100 mg/10 mL groups, and 95% of subjects in the placebo 6 mL and placebo 10 mL groups, reported at least one TEAE. The overall AE profile was 90% mild to moderate with no AE clearly related to brivoligide. No subject withdrew in association with an AE. Ten SAEs in nine subjects were reported in the brivoligide group and three SAEs in two subjects were reported in the placebo group. No SAEs were considered related to study drug. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Efficacy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide 660 mg/6 mL significantly reduced pain with walking (15 meters) during the Day 7&#8201;to Day&#8201;28 period (LS Mean 2.0 &#177; 0.2 vs. 2.9 &#177; 0.3, p=0.026) as illustrated in Figure 2. Neither dose of brivoligide gave statistically significant reduction of pain with walking (5 meters) during the zero to 48 hour period. This early period (0-48 hours) is consistent with the time required for the effect of EGR1-driven gene regulations to show effects on pain. NRS pain scores with brivoligide 1,100 mg/10 mL did not show statistical significance compared with placebo 10 mL for pain scores with walking. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide 660 mg/6 mL also significantly reduced pain scores at rest during the outpatient period&#160;(Day 7&#8201;to Day&#8201;28) when compared to placebo 6 mL across injection groups (LS Mean 1.5 &#177; 0.2 vs. 2.4 &#177; 0.3, p=0.033) as illustrated in Figure 3. Brivoligide 660 mg/6 mL had no statistically significant effect on pain scores at rest during the 0-48 hour period. NRS pain scores with brivoligide 1,100 mg/10 mL, did not show statistical significance compared with placebo 10 mL for pain scores at rest. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A p-value is a statistical measure of the probability that the difference in two values could have occurred by chance. The smaller the p-value, the greater the statistical significance and confidence in the result. Typically, results are considered statistically significant if they have a p-value less than 0.05, meaning that there is less than a one-in-20 likelihood that the observed results occurred by chance.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">70</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;">
          <tr style="line-height:12pt;min-height:59pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">
              <div style="text-align:center;">Figure 2<br >&#8199;<br >ADYX-003 Least Squares Means Estimate <br >for NRS Pain During the 5 and 15-Meter Walk Tests <br >(Imputation Method 1, mITT Population) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">
              <div style="text-align:center;">Figure 3<br >&#8199;<br >ADYX-003 Least Squares Means Estimate <br >for NRS Pain at Rest (mITT Population) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="min-height:196pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 5pt 0pt; width:222pt;">
              <div style="position:relative;margin-left:10pt; text-align:center;">
                <img src="tv523241_chrt-line1.jpg" alt="[MISSING IMAGE: tv523241_chrt-line1.jpg]" height="251" width="261" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 5pt 0pt; width:222pt;">
              <div style="position:relative;text-align:center;">
                <img src="tv523241_chrt-line2.jpg" alt="[MISSING IMAGE: tv523241_chrt-line2.jpg]" height="247" width="265" >
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:55pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:222pt;">
              <div style="margin-left:20pt; line-height:10pt;">Imputation Method 1: If the walk test was not <br >completed due to pain or the entire distance was not <br >completed due to pain, the worst possible pain score <br >(10) was used.<br >mITT: Modified intent to treat population</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:222pt;text-align:center;">
              <div style="text-align:center;">mITT: Modified intent to treat population</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.98pt; width:456pt; line-height:12pt;">Brivoligide 660 mg/6 mL demonstrated similar differences in pain reduction between injection sites (L3/4 vs. L4/5) when compared to the combined 6 mL placebo, suggesting brivoligide 660 mg/6 mL can be administered without limitation as to injection site. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Opioid utilization was similar between brivoligide 660 mg/6 mL and 1,100 mg/10 mL and placebo groups during the zero to&#8201;48 hour inpatient and Day 7&#8201;to Day 28 outpatient periods. The use of opioids for postoperative pain management was collected to evaluate the potential impact, if any, differential opioid use may have on pain scores. The study was not designed to evaluate the potential for brivoligide to reduce opioid usage, and surgeons were allowed to prescribe opioids on a fixed scheduled basis without restriction. No clinically significant difference was noted for range of motion assessments in either time period. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pain ratings in the 1,100 mg/10 mL dose group showed a reduction relative to placebo only at the earliest time points. The 1,100 mg/10 mL dose did not display any dose related safety concerns and was not superior to 660 mg/6 mL for efficacy, so 660&#160;mg/6 mL was the dose selected for use in subsequent studies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">ADYX-004:</font>&nbsp;&nbsp;&nbsp;ADYX-004 was a multicenter, Phase&#160;2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of brivoligide injection 660 mg/6 mL compared to placebo 6 mL administered intrathecally before surgery in patients undergoing TKA. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Protocol changes relative to ADYX-003 included: allowance of NSAIDs from the perioperative period and beyond; allowance of local anesthetic mixtures injected between joints; lengthened follow-up to 90&#160;days post-surgery; use of an eDiary to collect daily pain ratings for least, average and worst pain as well as daily collection of opioid use out to 90&#160;days; and postoperative and outpatient opioid dosing was to be on an &#8220;as needed&#8221; basis and not on a fixed schedule. In addition, ADYX-004 was designed to assure a balance in the high PCS scoring subjects by using PCS scores &ge;20/&lt;20 for randomization.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following assessments were used to evaluate efficacy: NRS pain assessment at rest; a defined distance walk (5 meters inpatient, 15 meters outpatient), with NRS for pain during the walk; NRS pain assessment with rising from a seated position and worst, least and average pain over the last 24 hours (collected by subjects daily via eDiary); and collection of analgesic medication data through Day 90. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">71</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Safety assessments consisted of physical examination, vital signs, clinical laboratory assessments, and collection of AEs and SAEs. AEs were monitored from the time of randomization through Day 28 and SAEs were monitored from the time of consent through Day 28. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The primary efficacy endpoint was the mean NRS pain rating with walking during the 15-meter distance walk Day 7 to Day 28. The secondary efficacy endpoints included: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Mean NRS pain rating at rest, Day 7 to Day 28; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Total use of postoperative opioid medications 48 hours to Day 90 (analyzed for mITT and for PCS &ge;20/&lt;20);</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Total use of postoperative opioid medications 0 to 48 hours (analyzed for mITT and for PCS &ge;20/&lt;20); and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Time to achieve an NRS pain score of&#8201; &le;3 for worst pain (analyzed for mITT and for PCS&#160;&ge;20/&lt;20).</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A total of 210 subjects were dosed with either brivoligide 660 mg/6 mL (108 subjects) or placebo (102&#160;subjects) and 17 subjects prematurely discontinued from the study (five subjects prior to dosing and 12&#160;subjects after dosing): nine subjects in the brivoligide treatment group (two prior to dosing) and eight&#160;subjects in the placebo group (three prior to dosing). One subject was randomized to placebo but incorrectly received brivoligide and was incorporated into the brivoligide group only for the safety analyses. A total of 198 subjects completed the study. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Safety </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">No subject withdrew because of an AE and no tolerability signals were identified following dosing of brivoligide 660 mg/6 mL. The overall AE profile was primarily mild to moderate with no AE clearly related to brivoligide. No subjects were discontinued from the study due to TEAEs. Five SAEs in five subjects were reported in the brivoligide group and eight SAEs in six subjects were reported in the placebo group. No SAEs were considered related to study drug except for one SAE in the placebo group that was considered possibly related. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Efficacy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For the primary endpoint, no significant difference was observed between the brivoligide 660 mg/6 mL and placebo 6 mL treated groups. The results of the analyses of the secondary and additional endpoints in the total mITT population also did not show a clinically relevant effect of brivoligide 660 mg/6 mL vs. placebo 6 mL. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although results of the analyses were not clinically relevant, several prespecified secondary and additional endpoints suggested efficacy of brivoligide when compared with placebo in subjects with PCS score &ge;20. These endpoints included time to achieve an NRS pain score &le;3 for worst pain over the previous 24 hours and opioid use over the period of 48 hours to Day 90. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A Kaplan-Meier analysis of time to achieve an NRS pain score of&#8201;&#8201;&le;3 for worst pain is presented in Table 3. A Kaplan-Meier analysis is a statistical method used to measure the fraction of patients that have a particular trait or attribute over a given period of time.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">72</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Table 3 </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">ADYX-004 Time to NRS Pain Score &le;3 for Worst Pain&#8201;&#8212;&#8201;Kaplan Meier Analysis (mITT and Sub Populations) </div>
        <table style="width:456pt;height:157pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:170.4pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">PCS Score &ge;20 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">PCS Score &lt;20 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Overall </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">Endpoint Statistic </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL <br >(N=25) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Placebo <br >6 mL <br >(N=27) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL <br >(N=82) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Placebo <br >6 mL <br >(N=76) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL <br >(N=107) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Placebo <br >6 mL <br >(N=103) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">N </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">76</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">103</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">N of Censored </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">22</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:170.4pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">Days to NRS pain score &le;3 for derived <br >worst pain</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">25<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> Percentile </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.0</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">24.0</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">14.0</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">13.0</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">13.0</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">14.0</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">Median </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">15.0</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">41.0</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">31.0</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">29.0</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">27.0</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">31.0</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">75<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> Percentile </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">47.0</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">70.0</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">62.0</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">48.0</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">59.0</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">62.0</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.184</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.432</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.542</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:8.99pt; width:436pt; line-height:12pt;">Abbreviations: NRS = Numeric Rating Scale, PCS = Pain Catastrophizing Scale, NE = Not Estimable. <br >Note: An event is defined as 3 consecutive pain scores &le;3 over a 4-day period (allows for one missing eDiary entry). Time to event (days) is defined as the date of the first pain score &le;3 that starts the event&#8201;&#8212;&#8201;the end date of surgery. Subjects who reach Day 90 or withdraw from the study before an event are censored on the date of the last NRS score assessed or Day 90 if the last score is collected after Day 90. Subjects who do not have any eDiary pain scores for an assessment are censored on the day of surgery. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Derived worst pain is the higher score (of the reported worst/least scores) reported in the eDiary. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Total postoperative opioid utilization 48 hours to Day 90 is presented in Table 4. If an eDiary day was missing, the dosage for the opioid medications were imputed with the mean morphine equivalent from the previous two days with recordings. Indications of no opioid use for a day were counted as zero. The results of these analyses without imputation were similar.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">73</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:18pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Table 4 </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">ADYX-004 Total Postoperative Opioid Medication Use: 48 Hours to Day 90&#8201;&#8212;&#8201;IV Morphine Equivalents (mg) (mITT Postoperative Opioid Use Population) </div>
      </div>
      <div style="margin-top:18pt;margin-bottom:18pt;margin-left:27.5pt;width:541pt;">
        <table style="width:541pt;height:220pt;margin-top:0pt;border-collapse: collapse;">
          <tr style="line-height:7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:114.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">PCS Score &ge;20 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">PCS Score &lt;20 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Overall </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">Postoperative Duration Statistic </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL <br >(N=25) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="text-align:center;">Placebo <br >6 mL <br >(N=27) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL <br >(N=82) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="text-align:center;">Placebo <br >6 mL <br >(N=75) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL <br >(N=107) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="text-align:center;">Placebo <br >6 mL <br >(N=102) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.25pt 0pt 2pt 0pt; width:114.18pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">48 Hours to Day 90 (with imputation)<font style=" position:relative; bottom:3.5pt;font-size:6.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">N </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">75</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">102</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">Mean (SD) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">225.16 (235.911) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">371.39 (340.927) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">376.08 (463.543) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">317.20 (291.180) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">340.82 (425.338) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">331.54 (304.333) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">Median </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">172.50</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">228.75</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">189.58</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">212.92</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">176.25</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">220.21</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">(Min, Max) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(5.2, 1148.2) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(22.5, 1202.5) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(0.0, 2431.7) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(1.7, 1138.8) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(0.0, 2431.7) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(1.7, 1202.5) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">P-value</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.105</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.915</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.366</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">48 Hours to Day 90 (no imputation)</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">N </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">75</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">102</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">Mean (SD) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">213.66 (229.409) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">352.17 (329.340) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">355.79 (440.461) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">305.66 (281.431) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">322.58 (404.743) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">317.97 (293.900) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">Median </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">150.00</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">228.75</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">181.25</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">182.50</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">170.83</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">213.13</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">(Min, Max) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(5.2,1118.2) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(22.5, 1202.5) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(0.0,2375.4) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(1.7,1135.1) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(0.0,2375.4) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(1.7,1202.5) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.115</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.936</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.391</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:18pt;height:357pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:20pt; margin-top:11.48pt; width:436pt; line-height:12pt;font-size:10pt;">Abbreviation: PCS = Pain Catastrophizing Scale. </div>
        <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">(1)<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">For 48 Hours to Day 90, morphine equivalents for missing eDiary dates are imputed with the mean of the previous two days. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;font-size:10pt;">Post-hoc Analysis </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-size:10pt;">In the endpoints analyzed by PCS score &ge;20, including opioid utilization out to 90 days and time to achieve NRS pain score &le;3 for worst pain, there were numerical but not statistically significant differences between the brivoligide 660 mg/6 mL treatment group and the placebo 6 mL group that suggested a clinically meaningful effect. Further investigation was then undertaken by post-hoc analysis, including mixed effects analysis of pain with walking, pain at rest, analysis of worst pain, time to NRS pain score &le;3 for worst pain, total opioid utilization, and time to little or no opioid utilization. Post-hoc analyses also included investigation of these analyses using a PCS cut-off value of&#8201;&#8201;&ge;16. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-size:10pt;">A mixed effects analysis of NRS pain score with walking during the 15-meter distance walk from Days&#160;7 to 28 by baseline PCS score is presented in Table 5. Similar post-hoc analyses of NRS pain score at rest from Days 7 to 28 by baseline PCS score, worst pain over the last 24 hours from the patient diary by baseline PCS for the additional time period of Day 3 to 28 and Day 7 to 28, time to NRS pain score &le;3 for worst pain by baseline PCS score, and total postoperative opioid utilization by baseline PCS score consistently suggest that a PCS score &ge;16 represents an appropriate cut-off value.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">74</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Table 5 </div>
        <div style="margin-top:15.98pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">ADYX-004 Mixed Effects Analysis of NRS Pain Score with Walking During the 15-Meter Walk Test Days 7&#160;to 28 by Baseline PCS Score (mITT&#8201;&#8212;&#8201;15-Meter Walk Population) </div>
        <table style="width:456pt;height:323.5pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Visit Mixed Effects Results<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60pt;">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60pt;">
              <div style="text-align:center;">Difference <br >Brivoligide&#8201;&#8211;&#8201;Placebo </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:66pt;">
              <div style="text-align:center;">Placebo <br >6 mL </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">PCS &lt; 20 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">79 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:66pt;">
              <div style="text-align:center;">72 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">LS mean (95% CI) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
              <div style="text-align:center;">2.73 <br >(1.29, 3.16) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
              <div style="text-align:center;">2.56 <br >(2.10, 3.01) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Difference in LS means </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.17 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">95% CI for Difference </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-0.46, 0.80 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.595 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">PCS &ge; 20 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">24 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;">
              <div style="text-align:center;">26 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">LS mean (95% CI) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
              <div style="text-align:center;">2.61 <br >(1.82, 3.40) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
              <div style="text-align:center;">3.52 <br >(2.76, 4.29) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Difference in LS means </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-0.91 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">95% CI for Difference </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-2.01, 0.19 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.106 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">PCS &ge; 16 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">30 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;">
              <div style="text-align:center;">33 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">LS mean (95% CI) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
              <div style="text-align:center;">2.53 <br >(1.83, 3.23) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
              <div style="text-align:center;">3.61 <br >(2.94, 4.28) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Difference in LS means </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-1.08 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">95% CI for Difference </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-2.05, -0.11 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.029</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:20pt; margin-top:11.98pt; width:436pt; line-height:12pt;">Abbreviations: NRS = Numeric Rating Scale, LS = Least Square, CI = Confidence Interval, PCS = Pain Catastrophizing Scale. </div>
        <div style="margin-left:20pt; margin-top:11.98pt; width:436pt; line-height:12pt;">Note: The worst rating (score of 10) is imputed if missing due to pain. </div>
        <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Results are obtained from a mixed effects model with terms for treatment, actual Screening PCS and treatment by Screening PCS interaction as fixed effects. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:10.99pt; width:456pt; line-height:12pt;">A Kaplan Meier analysis of time to less than 5mg of opioid per day analyzed by PCS &ge;16 is presented in Figure 4. This analysis suggests that brivoligide has the potential to shorten the time required for patients to achieve little to no postoperative opioid utilization.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">75</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always;margin-left:-8pt;margin-top:-8pt;position:relative;width:595.31pt;height:775.71pt;overflow:hidden;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;position:absolute;z-index:1;top:8pt;left:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:54pt;left:70pt;height:660pt;width:464pt;z-index:0;">
        <div style="text-align:center; width:456pt; line-height:12pt;">Figure 4<br >&#8199;<br >ADYX-004 Kaplan-Meier Analysis of Time to<br >&lt;5mg Opioid Use for Subjects with a Baseline PCS &ge;16 </div>
        <div style="position:relative;z-index:-1;margin-top:10.78pt; text-align:center; width:456pt;">
          <img src="tv523241_chrt-line3.jpg" alt="[MISSING IMAGE: tv523241_chrt-line3.jpg]" height="283" width="378" >
        </div>
        <div style="margin-top:17pt; width:456pt; line-height:11pt;font-style:italic;">ADYX-003 and ADYX-004 Data Combination and Meta-analysis by PCS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-weight:normal;">Due to the similar study design and brivoligide dose used in studies ADYX-003 and ADYX-004, these studies were combined and analyzed for consistency of PCS score effect on brivoligide efficacy. Data for the combined studies analyzed by PCS &ge;16 suggested a consistent therapeutic effect of brivoligide in patients scoring &ge;16 on the PCS and are presented in Figure 5 and Figure 6. </div>
        <table style="width:456pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:12pt;min-height:59pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">
              <div style="text-align:center;">Figure 5 <br >&#8199;<br >Combined ADYX-003 and ADYX-004 <br >NRS during the 5 and 15-Meter Walk Test for Subjects with PCS&ge;16 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;white-space:nowrap;">
              <div style="text-align:center;">Figure 6 <br >&#8199;<br >Combined ADYX-003 and ADYX-004 <br >NRS at Rest for Subjects with PCS&ge;16 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="min-height:233.7pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 0.5pt 0pt; width:222pt;">
              <div style="position:relative;margin-left:10pt;">
                <img src="tv523241_chrt-line4.jpg" alt="[MISSING IMAGE: tv523241_chrt-line4.jpg]" height="281" width="289" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 0.5pt 0pt; width:222pt;white-space:normal;">
              <div style="position:relative;">
                <img src="tv523241_chrt-line5.jpg" alt="[MISSING IMAGE: tv523241_chrt-line5.jpg]" height="280" width="288" >
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="width:456pt; line-height:12pt;font-weight:normal;"></div>
      </div>
      <div style="position:absolute;top:730pt;left:70pt;height:12pt;width:464pt;z-index:0;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-weight:normal;">76</div>
      </div>
      <hr style="margin-top:773.71pt;" >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">

          <div style="text-indent:20pt; width:456pt; line-height:12pt;">Post-hoc mixed effect analyses of NRS pain score with walking during the 15-meter distance walk and at rest from Days 7 to 28 by baseline PCS score are presented in Table 6 and Table 7, respectively. These analyses suggest patients scoring &ge;16 on the PCS who received brivoligide at the time of surgery reported lower levels of pain than patients scoring &ge;16 on the PCS who did not receive brivoligide, and reported similar levels of pain to patients scoring &lt;16 on the PCS.</div>


          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Table 6</div>


          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Combined ADYX-003 and ADYX-004 Meta-Analysis: Mixed Effects Analysis of NRS Pain Score <br >with Walking During the 15-Meter Walk Test Days 7 to 28 by Baseline PCS Score <br >(mITT&#8201;&#8211;&#8201;15-Meter Walk Population)</div>


          <table style="width:456pt;height:323.5pt;margin-top:7pt;border-collapse: collapse;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Visit Mixed Effects Results<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60pt;">
                <div style="text-align:center;">Brivoligide <br >660 mg/6 mL</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60pt;">
                <div style="text-align:center;">Difference <br >Brivoligide&#8201;&#8211;&#8201;Placebo</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:66pt;">
                <div style="text-align:center;">Placebo <br >6 mL</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Overall  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">142 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:66pt;">
                <div style="text-align:center;">118 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">LS mean (95% CI)  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
                <div style="text-align:center;">2.51 <br >(2.20, 2.82)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
                <div style="text-align:center;">2.80 <br >(2.46, 3.14)</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Difference in LS means  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">-0.29 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">95% CI for Difference  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">-0.75, 0.17 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">P-value  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">0.213 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">PCS &ge; 16  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">38 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;">
                <div style="text-align:center;">42 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">LS mean (95% CI)  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
                <div style="text-align:center;">2.32 <br >(1.72, 2.91)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
                <div style="text-align:center;">3.55 <br >(2.98, 4.11)</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Difference in LS means  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">-1.23 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">95% CI for Difference  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">-2.05, -0.41 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">P-value  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">0.003 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">PCS &lt; 16  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">104 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;">
                <div style="text-align:center;">76 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">LS mean (95% CI)  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
                <div style="text-align:center;">2.58 <br >(2.22, 2.94)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
                <div style="text-align:center;">2.39 <br >(1.98, 2.81)</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Difference in LS means  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">0.19 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">95% CI for Difference  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">-0.36, 0.73 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">P-value  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">0.506</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:14.48pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="margin-left:20pt; margin-top:11.98pt; width:436pt; line-height:12pt;">Abbreviations: NRS = Numeric Rating Scale, LS = Least Square, CI = Confidence Interval, PCS = Pain Catastrophizing Scale.</div>


          <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Note: The worst rating (score of 10) is imputed if missing due to pain.</div>


          <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Results are obtained from a mixed effects model with terms for treatment, actual Screening PCS and treatment by Screening PCS interaction as fixed effects.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">77</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Table 7</div>


          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Combined ADYX-003 and ADYX-004 Meta-Analysis: Mixed Effects Analysis of NRS Pain Score <br >with Rest Days 7 to 28 by Baseline PCS Score (mITT) </div>


          <table style="width:456pt;height:323.5pt;margin-top:7pt;border-collapse: collapse;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Visit Mixed Effects Results<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60pt;">
                <div style="text-align:center;">Brivoligide <br >660 mg/6 mL</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60pt;">
                <div style="text-align:center;">Difference <br >Brivoligide&#8201;&#8211;&#8201;Placebo</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:66pt;">
                <div style="text-align:center;">Placebo <br >6 mL</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Overall  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">142</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:66pt;">
                <div style="text-align:center;">118</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">LS mean (95% CI)  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
                <div style="text-align:center;">1.94 <br >(1.64, 2.23)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
                <div style="text-align:center;">2.39 <br >(2.06, 2.72)</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Difference in LS means  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">-0.46 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">95% CI for Difference  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">-0.90, -0.01 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">P-value  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">0.044 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">PCS &ge; 16  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">38</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;">
                <div style="text-align:center;">42</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">LS mean (95% CI)  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
                <div style="text-align:center;">1.77 <br >(1.21, 2.34)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
                <div style="text-align:center;">3.13 <br >(2.59, 3.67)</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Difference in LS means  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">-1.35 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">95% CI for Difference  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">-2.14, -0.57 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">P-value  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">0.0008 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">PCS &lt; 16  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">104</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;">
                <div style="text-align:center;">76</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">LS mean (95% CI)  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
                <div style="text-align:center;">2.00 <br >(1.65, 2.34)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
                <div style="text-align:center;">1.99 <br >(1.59, 2.39)</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">Difference in LS means  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">0.007 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">95% CI for Difference  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">-0.52, 0.53 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
                <div style="white-space:nowrap;">P-value  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
                <div style="text-align:center;">0.980</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">Abbreviations: NRS = Numeric Rating Scale, LS = Least Square, CI = Confidence Interval, PCS = Pain Catastrophizing Scale.</div>


          <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Note: The worst rating (score of 10) is imputed if missing due to pain.</div>


          <div style=" float:left; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Results are obtained from a mixed effects model with terms for treatment, actual Screening PCS and treatment by PCS interaction as fixed effects.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In summary, we believe high scores on the preoperative PCS can be used to identify people that may benefit from brivoligide administration before surgery. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Brivoligide Development Plan and Registration Strategy </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have filed with the FDA an IND for brivoligide for the reduction of postoperative pain in patients scoring &ge;16 on the PCS. This IND allows us to conduct the activities required for us to submit an NDA to the FDA for marketing approval and eventual commercialization of brivoligide. In particular, an IND must become effective before human clinical studies for the applicable product candidate may begin and must be updated annually or when significant changes are made. Successful completion of human clinical studies is a prerequisite to submitting an NDA to the FDA, which must be approved before we may commercialize brivoligide in the United States. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We plan to conduct a Phase 2 study in subjects undergoing mastectomy with predictive enrichment of the study population with patients scoring &ge;16 on the PCS. If successful, we intend to file for Breakthrough Therapy Designation, as positive data on a clinically significant endpoint from that study could support that brivoligide may offer substantial treatment advantages over existing options for patients scoring &ge;16 on </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">78</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">the PCS and suffering from postoperative pain, a condition that we believe qualifies as serious. We have received a grant award from NIDA/NIH for up to $5.7 million to support the conduct of the Phase 2 mastectomy study. We also plan to conduct a study in subjects undergoing TKA who score high on the PCS to further explore the results obtained in the prior Phase 2 studies in TKA in the proposed target population. If successful, we plan to follow the Phase&#160;2 studies of brivoligide with Phase&#160;3 pivotal studies in both TKA and mastectomy. The design and size of the Phase&#160;3 studies will be determined after completion of the respective Phase&#160;2 studies. Based on the funding opportunity announcement under which we received the award, and on the milestones and budget outlined in our application, following completion of milestones related to the Phase&#160;2 mastectomy study, including receipt of positive data for the Phase&#160;2 mastectomy study and clear guidance from the FDA at an end of phase&#160;2 meeting, we may be eligible to receive an additional award of up to $9.0&#160;million over three years to fund a Phase&#160;3 mastectomy study. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">&#8220;Top-line&#8221; data from our clinical studies refer to the results from the initial planned analyses of primary and certain key secondary endpoints from our clinical trials after enrollment has been completed and the data from the study database is locked. Top line data remain subject to audit and verification procedures that may result in the final data being materially different from previously published top line data. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We propose to use a predictive enrichment strategy in which patients are chosen who are more likely to respond to the drug treatment than other patients with the condition being treated and only enroll subjects with PCS scores &ge;16 in the Phase&#160;3 studies of brivoligide. The rationale for this approach is as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Post-hoc analyses of Phase&#160;2 studies ADYX-003 and ADYX-004 suggest that patients with PCS scores of&#8201;&#8201;&ge;16 are more likely to respond to brivoligide treatment, while analyses of those with PCS &lt;16 do not show meaningful evidence of efficacy; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">The PCS is an easy to administer assessment and can be incorporated into clinical practice to identify patients who are more likely to respond to brivoligide treatment; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Adequate data has been generated from the 180 subjects with PCS &lt;16 (104 brivoligide vs. 76 placebo) in studies ADYX-003 and ADYX-004 to suggest that this patient population is unlikely to derive a benefit from brivoligide treatment, and continuing to enroll subjects in this patient population would be medically inappropriate; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">We believe predictive enrichment of the Phase&#160;3 studies will support an indication of reduction of postoperative pain in patients who score &ge;16 on the PCS. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">ADYX-005 Study </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ADYX-005 is a Phase&#160;2 randomized double-blind, placebo-controlled study to evaluate the safety and efficacy of a single intrathecal preoperative administration of brivoligide injection in patients with a PCS score &ge;16 undergoing TKA. We are evaluating whether to commence this Phase&#160;2 clinical trial as early as the first quarter of 2020, with top-line results expected as early as the fourth quarter of 2020, subject to receipt of additional capital to fund the trial through top-line results. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The study protocol calls for approximately 122 subjects to be enrolled in the study and randomized 1:1&#160;into two treatment groups (brivoligide injection 660 mg/6 mL and placebo 6 mL) with randomization by study center. Subjects will receive study drug just prior to administration of spinal anesthesia via the same needle. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Safety and laboratory assessments will be performed in the standard manner up to Day 28. Concomitant medications will be collected through Day 28; analgesic medications will be collected through Day 42. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pain at rest and with walking will be recorded by study staff postoperatively at follow-up visits. Daily ratings of worst pain over the previous 24 hours will be collected via electronic diary, or eDiary, by subjects every evening from Day 1 until the Day 42 visit. Analgesic medication use will be collected via eDiary by subjects daily after discharge until the Day 42 visit. Follow-up visits will occur on Days 7, 14, 21, 28 and 42 </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">79</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">The primary endpoint will be reduction in pain with walking from Day 7 to Day 28 as measured using the NRS. Secondary endpoints include pain at rest and pain with passive knee flexion to 90 degrees from Day 7 to day 28 as measured by the NRS, and total use of postoperative opioid medications (morphine equivalents) postoperatively to Day 42.</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">ADYX-006 Study </div>

          <div style="text-indent:20pt; margin-top:4.41pt; width:456pt; line-height:12pt;">ADYX-006 is a Phase&#160;2 randomized double-blind, placebo-controlled study to evaluate the safety and efficacy of a single intrathecal preoperative administration of brivoligide injection in patients with a PCS score &ge;16 undergoing mastectomy. We plan to commence this Phase&#160;2 clinical trial as early as the first quarter of 2020, with top-line results expected as early as the first half of 2021, subject to receipt of additional capital to fund the trial through top-line results, including receipt of additional funds from our grant award from the National Institute of Drug Abuse, or NIDA, described under &#8220;&#8212;&#8201;Our Solution: Brivoligide for Postoperative Pain in Patients Scoring &ge;16 on the PCS&#8201;&#8212;&#8201;Brivoligide Development Plan and Registration Strategy.&#8221; </div>

        <div style="text-indent:20pt; margin-top:5.42pt; width:456pt; line-height:12pt;">The study protocol calls for approximately 126 subjects to be enrolled in the study and randomized 1:1 into two treatment groups (brivoligide injection 660 mg/6 mL and placebo 6 mL). Safety and laboratory assessments will be performed up to Day 21. Concomitant medications will be collected through Day 21; analgesic medications will be collected through Day 21. </div>

          <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">Data for pain at rest with general movement involving the chest and upper body, and worst pain over the last 24 hours, with deep full breath and forceful cough, will be collected by subjects via eDiary every evening from Day 1 until the Day 21 visit. NRS pain assessment upon certain movements of the arm will be collected by subjects via eDiary from Day 14 to 21 as allowed by the subject&#8217;s surgeon. Analgesic medication use will be recorded after discharge until the Day 21 visit by subjects daily via eDiary. A physical well-being questionnaire will be collected at screening and at the Day 21 follow-up visit. Follow-up visits will occur on Days 7 and 21. The primary endpoint will be mean pain rating with general movement involving the chest and upper body from Day 3 to Day 14. Secondary endpoints include pain at rest and pain with deep full breath and forceful cough from Day 3 to Day 14, and total use of postoperative opioid medications (morphine equivalents) from Day 3 to Day 14.</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">AYX2 for Chronic Pain </div>
        <div style="text-indent:20pt; margin-top:4.42pt; width:456pt; line-height:12pt;">Chronic pain, which includes types of pain such as low back pain, pain associated with pinched or compressed nerves known as radiculopathy, and pain associated with inflammation of the spinal nerve root known as radiculitis, affects as many as 25&#160;million patients annually in the United States. Chronic pain can be caused by changes in various components of the pain pathway, including the ongoing regulation of gene activity in the spinal cord and DRG. The transcription factors driving this regulation include a family of transcription factors known as Kruppel-like Factors, or KLF, and constitute a promising class of targets that can potentially alter the course of pain with a single or short-term treatment. AYX2 is a differential inhibitor of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pharmacology of AYX2 </div>
        <div style="text-indent:20pt; margin-top:4.22pt; width:456pt; line-height:12pt;">Chronic pain is a dynamic state that is maintained by a number of factors, including the ongoing regulation of gene activity in the spinal cord and DRG. We identified a group of transcription factors with the potential to control these gene regulations based on their known functions. We then screened decoys designed against those factors and identified two decoys that bind to KLF6, KLF9 and KLF15 that significantly reduced chronic pain following a single administration in multiple models testing the response to painful stimuli in rats, including the spared-nerve injury, or SNI, and chronic constriction injury, or CCI, models. </div>
        <div style="text-indent:20pt; margin-top:5.21pt; width:456pt; line-height:12pt;">Results demonstrated that a single administration of decoys binding to KLF6, KLF9, and KLF15 produced a significant and weeks-long reduction in pain sensitivity compared to controls. In the SNI model, the clinical reduction in pain sensitivity from a given decoy was correlated to its capacity to bind KLF15 and KLF9 at a specific ratio. In the CCI model, the clinical reduction in pain sensitivity from a given decoy was correlated to the combined binding capacity to KLF6 and KLF9. AYX2 was optimized to achieve both binding patterns. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">80</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We conducted a non-Good Laboratory Practice toxicology study to determine potential toxicity and tolerability of single and repeated AYX2 intrathecal injections in a study that included a total of 30 rats. Standard toxicology study data were collected, including clinical observations, clinical pathology, spinal and brain histopathology. Single and repeated AYX2 injections were well tolerated. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">AYX2 Development Path </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Based on the non-clinical data generated to date, we believe AYX2 has the potential to be developed as a one-time or short-course treatment for chronic pain. We plan to conduct an IND-enabling toxicology program. Phase&#160;1 is planned to be a single ascending dose study design, using healthy subjects. An initial Phase&#160;2 proof-of-concept is planned in radiculopathy and radiculitis. The study is planned to be a randomized, placebo-controlled, safety and efficacy study of single administration AYX2 or placebo.</div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In September 2019, we received a Notice of Award from the National Institute on Neurological Disease and Stroke, or NINDS, part of the NIH, for up to approximately $0.6&#160;million to be paid over 12&#160;months to support our planned preclinical studies of AYX2. The funds will become available after approval from the Office of Laboratory Animal Welfare, or OLAW, of the planned preclinical studies for AYX2.</div>

        <div style="margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Discovery and Development of Additional Product Candidates Using the AYX Platform</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The AYX platform drug candidates are currently focused on postoperative pain and pre-existing chronic pain. We plan to leverage our expertise in transcription factor decoy drug discovery and development to identify additional product candidates in inflammation related disease states including but not limited to organ scarring, heart disease and cancer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The discovery and preclinical development of an AYX decoy may include the following steps, as appropriate and relevant depending on the target disease: (1)&#160;identifying potentially relevant transcription factor targets based on pre-established scientific knowledge in the target disease or in biological systems with similar features and/or on the direct analysis of transcription factor DNA binding motives in the promoter of relevant genes, (2)&#160;designing preliminary decoys against those potential transcription factor targets using their known, consensus DNA binding sequence and directly screening the therapeutic profile of those decoys for efficacy in non-clinical models, (3)&#160;designing AYX decoy by optimizing the sequences of the initial decoys into sequences optimal for clinical use and confirming their therapeutic profile, mechanism of action and pharmacology in non-clinical models, (4)&#160;performing IND-enabling studies to allow submitting an IND and testing the decoy in clinical trials. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">twoXAR Collaboration </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe that artificial intelligence-, or AI-based platforms, such as twoXAR&#8217;s, are helping create portfolios of drug programs more efficiently through faster, more predictive models than traditional approaches. Such technology can accelerate the entire drug development process, decrease risk and substantially reduce overall costs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Endometriosis is an often painful disorder in which tissue similar to the lining of the uterus grows in other places outside of the uterus. We are seeking to identify product candidates with the potential to address the underlying biological drivers of endometriosis instead of masking symptoms, in order to significantly differentiate from standard of care, using twoXAR&#8217;s proprietary AI-driven platform, which has demonstrated <font style="font-style:italic;">in vivo</font> success rates significantly greater than those of traditional approaches across therapeutic areas including diseases such as liver cancer, rheumatoid arthritis, and type 2 diabetes. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2018 we entered into a collaboration agreement with twoXAR. Under our agreement, twoXAR will use its proprietary AI technology to identify a set of medical treatments with the potential to treat or prevent the recurrence of endometriosis and associated symptoms. We will select product candidate(s) from this set to test for efficacy in <font style="font-style:italic;">in vivo</font> models of endometriosis based on predetermined criteria. Following identification of one or more candidate compounds based on those evaluated <font style="font-style:italic;">in vivo</font>, we intend to select one or more compounds on which to conduct preclinical characterization work, IND-enabling work and clinical development. If currently approved compounds are identified, we could potentially employ the 505(b)(2) regulatory pathway to efficiently develop this indication. Under the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">81</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">agreement, we will use commercially reasonable efforts to develop and commercialize selected compounds, and we are subject to a number of obligations including, but not limited to, the outside dates for initiation of pre-clinical and clinical development activities and regulatory filing. Both we and twoXAR will not develop drug candidates with the same product profile as the selected compounds for the term of the agreement. In June 2019, we received an initial set of product candidate predictions from twoXAR. We have initiated a review of the potential product candidates to determine if any are viable candidates for further research and development. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Approximately 4.4&#160;million women suffer from endometriosis in the United States, with up to 175,000 new diagnoses projected annually by 2022. Symptoms of endometriosis include chronic pelvic pain, painful menstruation and sexual intercourse, infertility, and/or painful hypersensitivity. Over time, endometriosis may be associated with pain-related adhesions and scarring from chronic inflammation and in some cases cancer. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Initial diagnosis of endometriosis is based on clinical presentation, with definitive diagnosis requiring laparoscopy with histologic confirmation. There is no accepted screening or preoperative diagnostic test, and because symptoms may be vague, and because diagnosis is invasive and carries a small risk of complications, diagnosis can be delayed for more than six&#160;years. We believe that existing therapies are insufficient, and new disease-modifying treatments addressing the underlying disease drivers of endometriosis are sought to address the unmet need associated with the current standard of care.</div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">twoXAR retains all intellectual property rights to its computational methods and disease models and grants us a non-exclusive license to use intellectual property rights solely for the development of our selected product candidates for the treatment of endometriosis. We own all intellectual property developed following selection of the selected product candidates, twoXAR will assign all residual right, title and interests to such intellectual property to us. Under the agreement, we control prosecution, defense and enforcement of such intellectual property rights relating to selected product candidates, and twoXAR has backup rights to prosecution, defense and enforcement with respect to such intellectual property for which we elect not to exercise such rights. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The agreement with twoXAR will remain in effect until expiration of the applicable royalty term unless terminated by us upon 60&#160;days prior written notice to twoXAR or terminated by either party upon certain events of material breach. Upon termination, all licenses granted under the agreement will terminate. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Competition </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The biopharmaceutical industry is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Given the significant unmet medical need for novel therapies to treat pain, as well as the ongoing public health crisis associated with OUD in the United States, many public and private universities and research organizations are actively engaged in the discovery, research and development of product candidates. As a result, there are and will likely continue to be extensive resources invested in the discovery and development of new products to treat these unmet medical needs. We anticipate facing intense and increasing competition as new products enter the market and advanced technologies become available. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, there are numerous multinational pharmaceutical companies and large biotechnology companies currently marketing or pursuing the development of products or product candidates targeting the same indications as our product candidates. Many of our competitors, either alone or with strategic partners, have or will have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than us in developing or marketing products and technologies that are more effective, safer or less costly. Additionally, our competitors may obtain regulatory approval for their products more rapidly and may achieve more widespread market acceptance. Accelerated mergers and acquisitions activity in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">82</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">While brivoligide has a novel therapeutic profile, competing non-opioid products and product candidates for postoperative pain include, but are not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">EXPAREL (marketed by Pacira Pharmaceuticals, Inc.); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Ofirmev (marketed by Mallinckrodt Pharmaceuticals); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">HTX-011 (in development by Heron Therapeutics, NDA submitted to FDA in 2018, Complete Response Letter received from FDA on April&#160;30, 2019); and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">CA-008 (in development by Concentric Analgesics). </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additional competitive products that comprise current analgesic standard of care include opioids and oral and topical NSAIDs. Potential competitive products or product candidates for AYX2 include opioids, oral and topical NSAIDs, oral gabapentinoids, and steroid injections. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe that the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety and tolerability profile, duration of effect, product labeling, cost-effectiveness, price, the level of generic competition, hospital formulary access, and the availability of reimbursement from the government and other third-parties. Our commercial opportunity could be reduced or eliminated for any of our products if our competitors have products that are approved earlier than our product candidates or are superior compared to our product candidates or if our product candidates do not result in an improvement in condition compared to those other products. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Manufacturing </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We currently contract with third parties for the drug substance supply and manufacturing of our product candidates for preclinical studies and clinical trials and intend to do so in the future. We do not own or operate manufacturing facilities for the production of clinical trial quantities of our product candidates and do not plan to build our own clinical or commercial scale manufacturing capabilities. Although we rely on contract manufacturers, we have extensive experience overseeing CMOs. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We contract drug substance for preclinical and clinical studies from several suppliers in the United States. For IND-enabling and for clinical trials, we contract with the largest manufacturer of GMP oligonucleotide worldwide. Alternate GMP manufacturers exist for oligonucleotide product candidates but they do not currently have the production scale of our current supplier. Drug product manufacturing is contracted by a separate CMO. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">With respect to our brivoligide product candidate, we rely on Nitto-Denko Avecia, Inc., or Avecia, for drug substance manufacturing, and Pyramid Laboratories, Inc., or Pyramid, for drug product supply. We do not have long-term supply agreements or commitments from those parties to supply our materials. We may also receive supply of drug substance or drug product that is deficient in quality or otherwise does not meet the specifications required to be used in clinical trials. In the past, we have experienced such deficiencies and have been required to seek alternative sources to meet our needs. We expect our current drug substance manufacturer to be capable of providing sufficient quantities of our product candidates to meet anticipated full-scale commercial demand. However, while preliminary feasibility assessments have been conducted with the manufacturer, we cannot be certain that full commercial scale production can be successful, cost effective, or completed on a timely basis without significant delay in the development or commercialization of our product candidates. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Brivoligide </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide drug substance for all clinical trials was manufactured by Avecia and brivoligide drug product was manufactured by Pyramid or Corden Pharma GmbH. We currently have sufficient drug substance available to conduct the currently planned ADYX-005 and ADYX-006 studies, subject to standard testing by the manufacturer to confirm the material meets manufacturing specifications; however, we will have to manufacture new drug product for these studies. We do not have long-term supply agreements or commitments from any parties to supply drug substance or drug product. </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">83</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">AYX2 </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">AYX2 drug substance for preclinical studies was manufactured by Avecia, TriLink BioTechnologies, Inc., and Invitrogen Corporation. We currently plan to use the same CMOs for drug substance and drug product for AYX2 GMP manufacturing as currently used for brivoligide. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Intellectual Property </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">We are dedicated to protecting our proprietary technologies that are core to our business. We seek and maintain, where available, patent protection for our product candidates including but not limited to composition of matter, method(s) of use and/or formulation. We plan to continue to expand our intellectual property portfolio by filing patent applications on new dosage or formulation forms, methods of treatment, and compositions of matter for our product candidates as appropriate. We file and prosecute patent applications in the United States and Europe, and when appropriate, additional countries, including Canada, Australia, Japan, Brazil, Russia, India or China. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our success will depend significantly upon our ability to: (i)&#160;obtain and maintain patents and other available exclusivity protections for commercially important technology, inventions and know-how related to our business; (ii) prosecute our patent applications to issue as patents and defend and enforce our patents; (iii) maintain any licenses to use intellectual property owned by others; (iv) preserve the confidentiality of our trade secrets, and (v)&#160;operate without infringing the valid and enforceable patents and other proprietary rights of others. In addition to maintaining our existing proprietary assets, we seek to strengthen our proprietary positions when economically reasonable to do so. Our ability to augment our proprietary position relies on our: (i)&#160;know-how; (ii) ability to access technological innovations, and (iii)&#160;ability to in-license technology when appropriate. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The patent positions of pharmaceutical/biotechnology companies like us are generally uncertain and involve complex legal, scientific, and factual issues. In addition, the scope claimed in a patent application can be significantly reduced before any patent issues. After issuance of a patent application, if the issued patent is challenged, then the courts can redefine the scope of the patent, including by invalidating it or rendering it unenforceable in its entirety. Consequently, we do not know with certainty whether patents will issue in each country where it or our licensor&#8217;s file patent applications, or if those patent applications, if ever issued, will issue with claims that cover our product candidates, or, even if they do whether the patent or our relevant claims will remain enforceable upon challenge. Accordingly, we cannot predict with certainty whether the patent applications we are currently pursuing will issue as patents in a particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from potential competitors to make any of our products commercially successful. Any of our patents, including already issued in-licensed patents or any patents that may issue to us or our licensors in the future could potentially be challenged, narrowed, circumvented, or invalidated by third parties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Because newly filed patent applications in the United States Patent and Trademark Office, or the USPTO, and certain other patent offices are maintained in secrecy for a minimum of 18&#160;months, and because publications of discoveries in the scientific or patent literature often lag far behind the actual discoveries themselves, we cannot be certain of the priority of our inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention, although patent applications filed after 2013 are given priority based on first to file in the U.S. The date of an invention is typically not publicly disclosed. Also, while we are not currently participating in any interferences or post-grant challenge proceedings, such as patent oppositions and patent litigation, that seek to invalidate the patentability of patents before or after they issue, respectively, we may have to participate in such proceedings in the future. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The term of individual patents depends upon the legal term of the patents in the countries where they are issued. In most countries, the standard patent term for inventions relating to human drugs and their formulation and use is 20&#160;years from the date of filing the first non-provisional patent or international application under the Patent Cooperation Treaty of 1970, or the PCT. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have received grant awards from NIDA/NIH and NINDS/NIH for the development of brivoligide in the mastectomy&#160;model of postoperative pain and the developmentof AYX2, respectively. Intellectual property may be generated through the use of this U.S.&#160;government funding and would therefore be subject </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">84</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">to certain federal regulations. As a result, the U.S.&#160;government may in the future have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S.&#160;government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we fail to disclose the invention to the government or fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Patent Protection of our Product Candidates </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We fully-own the patents and patent applications protecting our oligonucleotide product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Brivoligide </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The patent and patent applications protecting brivoligide encompass composition of matter, method of use, formulation, dosage and target patient populations. Composition of matter and method of use for brivoligide and closely related compounds patents have issued in the United States and additional geographies. Those patents will expire in 2028 and 2029 and could be subject to extension. The brivoligide formulation patent has also issued in the United States and is under prosecution in additional geographies. It will expire in 2033 and could be subject to extension. A dosing regimen patent application is under prosecution in the United States with an expiration date, if issued, of 2037 that could be subject to extension. An International PCT patent application pertaining to the brivoligide target patient population (&ge;16 on the PCS) was filed in February&#160;2019. We anticipate prosecuting this application at least in the United States, Europe, Canada, Japan, Australia, Brazil, Russia, India and China. If issued, this application would be valid until 2039 and could be subject to extension. The final list of countries to prosecute this application under will be decided at the time of National Stage Entry of the current PCT application, which occurs in August&#160;2020. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">AYX2 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A patent covering AYX2 composition of matter and method of use has been issued in the U.S. and will expire in 2035 and could be subject to extension. Further, patent applications covering AYX2 composition of matter and method of use are also under prosecution in the United States, Europe, Japan, Canada, Australia, Brazil, Russia, India and China. If issued, these patents will expire in 2035 and could be subject to extension. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Patent Term </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Depending upon the timing, duration and specifics of the FDA approval of our drug candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five&#160;years beyond the normal expiration of the patent, limited to the approved indication (or any additional indications approved during the period of extension), as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">85</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. Similar provisions may be available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug. In Europe, through the European Medicines Agency, there is a period of ten&#160;years of regulatory data exclusivity from the time of approval if the centralized procedure is used, however under the centralized procedure this term would run concurrently with the period of exclusivity provided by the patent. When possible, depending upon the length of clinical trials and other factors involved in the filing of NDAs for our products, we expect to apply for PTEs for patents covering our product candidates and their methods of use both in the United States and any foreign jurisdiction where available. There is no guarantee, however, that the applicable authorities will agree to grant extensions, and if granted, what the length of those extensions will be. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Other Proprietary Rights and Processes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We also rely on trade secret protection for some of our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets and disclose our technology. If these events happen, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business, scientific, development or financial affairs that are either developed or made known to the individual during the course of the individual&#8217;s relationship with us are to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or based on the employee&#8217;s use of our confidential information are our exclusive property or that we have an exclusive royalty free license to use such technology. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Government Regulations and Product Approvals </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">FDA Approval Process </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All of our current product candidates are subject to regulation in the United States by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDC Act, and its implementing regulations. The FDA subjects drugs to extensive pre and post market regulation. Failure to comply with the FDC Act and other federal and state statutes and regulations may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal penalties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">FDA approval is required before any new unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States. The process required by the FDA before a new drug may be marketed in the United States is long, expensive, and inherently uncertain. Drug development in the United States typically involves completion of preclinical laboratory and animal tests, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">86</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">submission to the FDA of an IND, which must become effective before clinical testing may commence, approval by an IRB, at each clinical site before each trial may be initiated, performance of adequate and well controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought, submission to the FDA of an NDA, satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced, and FDA review and approval of the NDA. Developing the data to satisfy FDA pre-market approval requirements typically takes many&#160;years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product, disease or indication. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Preclinical tests include laboratory evaluation of the product&#8217;s chemistry, formulation, and toxicity, as well as animal studies to characterize and assess the potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practice, or GLP, regulations. These preclinical results are submitted to the FDA as part of an IND along with other information, including information about the product&#8217;s chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term preclinical studies including reproductive toxicity and carcinogenicity may be initiated or continue after the IND is submitted. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">An IND must become effective before United States clinical trials may begin. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the IND automatically becomes effective and the clinical trial proposed in the IND may begin. If the FDA does raise any concerns or questions and places the clinical trial on a clinical hold, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, a submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations, including GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials; and (ii) with protocols that detail, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to and approved by an IRB at each study site before the study commences at that site and the IRB must monitor the clinical trial until it is completed. An IRB may also require the clinical trial at that site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or if the drug candidate has been associated with unexpected serious harm to patients, or the IRB may impose other conditions. The study sponsor or the FDA may also suspend or discontinue a clinical trial at any time on various grounds, including a determination that the subjects are being exposed to an unacceptable health risk. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Clinical trials to support an NDA for marketing approval are typically conducted in three sequential phases, although there is leeway to overlap or combine these phases.&nbsp;&nbsp;&nbsp; </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Phase&#160;1.&nbsp;&nbsp;&nbsp;</font>The drug candidate is initially introduced into healthy human subjects or patients with the target disease or condition, and is tested to assess safety, dosage tolerance, pharmacokinetics and pharmacological activity, and, when possible, to ascertain evidence of efficacy. The drug candidate may also be tested in patients with severe or life-threatening diseases to gain an early indication of its effectiveness. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Phase&#160;2.&nbsp;&nbsp;&nbsp;</font>The trials are conducted using a limited patient population for the purposes of preliminarily determining the effectiveness of the drug in that particular indication, ascertaining dosage tolerance, discerning the optimal dosage, and identifying possible adverse effects and safety&#160;risks. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">87</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Phase&#160;3.&nbsp;&nbsp;&nbsp;</font>If a compound demonstrates evidence of efficacy and has an acceptable safety profile in the Phase&#160;2 clinical trials, then Phase&#160;3 clinical trials are undertaken to obtain additional information from an expanded and diverse patient population, at multiple, geographically dispersed clinical trial sites, in randomized controlled studies often with a double-blind design to maximize the reproducibility of the study results. Typically, a minimum of two positive Phase&#160;3 clinical trials are submitted to support the product&#8217;s marketing application. These Phase&#160;3 clinical trials are intended to provide sufficient data demonstrating evidence of the efficacy and safety of the drug such that the FDA can evaluate the overall benefit-risk of the drug and provide adequate information for the labeling and package insert for the drug. Trials conducted outside of the United States under similar, GCP-compliant conditions in accordance with local applicable laws may also be acceptable to FDA in support of product approval. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Sponsors of clinical trials for investigational drugs must publicly disclose certain clinical trial information, including detailed trial design. These requirements are subject to specific timelines and apply to most Phase&#160;3 clinical trials of FDA-regulated products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In some cases, FDA may condition approval of an NDA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical trials after NDA approval. In other cases, a sponsor may voluntarily conduct additional clinical trials post approval to gain more information about the drug. Such post approval trials are typically referred to as Phase&#160;4 clinical trials. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if SAEs occur. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the study. Phase&#160;1, Phase&#160;2, Phase&#160;3 and Phase&#160;4 clinical trials may not be completed successfully within any specified period, or at all. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Concurrent with clinical trials, companies usually finalize a process for manufacturing the drug in commercial quantities in accordance with current good manufacturing practice, or cGMP, requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA requesting approval to market the drug for one or more specified indications. FDA review and approval of the NDA is required before marketing of the product may begin in the United States. The NDA must include the results of all preclinical, clinical, and other testing, including negative or ambiguous results as well as positive findings, together with other detailed information including compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. The NDA must also contain extensive manufacturing information. The FDA reviews an NDA to determine, among other things, whether a drug is safe and effective for its intended use. The cost of preparing and submitting an NDA is substantial. Under federal law, the submission of most NDAs is subject to both a substantial application user fee and annual program user fees. The sum of these fees may total several million dollars and they are typically increased annually. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA has 60&#160;days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. Once the submission is accepted for filing, the FDA begins an in-depth review. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Prescription Drug User Fee Act PDUFA, guidelines that are currently in effect, the FDA has agreed to certain performance goals in the review of NDAs. Standard NDAs are generally reviewed within ten&#160;months of filing, or twelve&#160;months from submission. Although FDA often meets its user fee performance goals, the FDA can extend these timelines if necessary, and FDA review may not occur on a </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">88</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">timely basis. The FDA usually refers applications for novel drugs, or drugs that present difficult questions of safety or efficacy, to an advisory committee&#8201;&#8212;&#8201;a panel of independent experts, typically including clinicians and other scientific experts&#8201;&#8212;&#8201;for review, evaluation, and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of the advisory committee, but it generally follows its recommendations. Before approving an NDA, the FDA will typically inspect one, or more, clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve an application unless it verifies that compliance with cGMP requirements is satisfactory and that the manufacturing processes and facilities are adequate to assure consistent production of the product within required specifications. The FDA will not approve a drug unless the application contains data showing substantial evidence that it is safe and effective in the indication studied. </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">After the FDA evaluates the NDA and conducts its inspections, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies contained in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application, including potentially significant, expensive and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. Even if such data are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data from clinical trials are not always conclusive, and the FDA may interpret data differently than we do. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the application, the FDA will typically issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six&#160;months depending on the type of additional information requested. FDA approval is never guaranteed. The FDA may refuse to approve an NDA if applicable regulatory criteria are not satisfied. </div>
        <div style="text-indent:20pt; margin-top:5.62pt; width:456pt; line-height:12pt;">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. The approval for a drug may be significantly more limited than requested in the application, including limitations on the specific diseases and dosages or the indications for use, which could restrict the commercial value of the product. The FDA may also require that certain contraindications, warnings, or precautions be included in the product&#8217;s package insert, or labeling. </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">In addition, as a condition of approval, the FDA may require a REMS, to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guidelines, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing-including dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS or use of a companion diagnostic with a drug can materially affect the potential market and profitability of the drug. Moreover, product approval may require, as a condition of approval, substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. The FDA may also condition approval on, among other things, changes to proposed labeling or development of adequate controls and specifications. </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">Once granted, product approvals may be withdrawn if compliance with regulatory standards are not maintained or problems are identified following initial marketing. In addition, after approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</div>

          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Breakthrough Therapy Designation</div>


          <div style="text-indent:20pt; margin-top:4.62pt; width:456pt; line-height:12pt;">Breakthrough Therapy Designation by the FDA provides more extensive development consultation opportunities with FDA senior staff, allows for the rolling review of the product&#8217;s application for approval and indicates that the product could be eligible for priority review if supported by clinical data at the time of application submission for products that are intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new product candidate may request that FDA designate the product candidate for a specific indication as a breakthrough therapy concurrent with, or after, the filing of the IND for the product candidate. The FDA must determine if the product candidate qualifies for Breakthrough Therapy Designation within 60 days of receipt of the sponsor&#8217;s request.</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">89</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Advertising and Promotion </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing post-approval regulatory requirements. For instance, the FDA closely regulates the post-approval marketing, labeling, advertising and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Failure to comply with these requirements can result in adverse publicity as well as significant penalties, including the issuance of warning letters directing a company to correct any deviations from the FDA&#8217;s standards. The FDA may also impose a requirement that future advertising and promotional materials be pre-cleared by the FDA, and we may face federal and/or state civil and criminal investigations and prosecutions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">AE Reporting and cGMP Compliance </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Recordkeeping, AE reporting and the submission of periodic reports are required following the FDA&#8217;s approval of an NDA. The FDA also may require post-marketing testing or Phase&#160;4 clinical trials, REMS, or surveillance to monitor the effects of an approved drug. In addition, the FDA may place conditions on an approval that could restrict the distribution or use of the product. Furthermore, manufacture, packaging, labeling, storage and distribution procedures must continue to conform to cGMPs after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies to assess compliance with ongoing regulatory requirements, including cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMPs. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that it or our present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may halt our clinical trials, require us to recall a drug from distribution or withdraw approval of the NDA for that drug. Regulatory authorities may also withdraw product approvals, request product recalls, or impose marketing restrictions through labeling changes or product removals upon discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Other Healthcare Laws and Compliance Requirements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA. These other agencies include, without limitation, the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services,&#160;the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, as well as state and local governments. Such agencies enforce a variety of laws, including without limitation, anti-kickback and false claims laws, data privacy and security laws, and physician payment transparency&#160;laws. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or arranging for or </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">90</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to or approval by the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-reimbursable, uses. In addition, the civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. HIPAA, created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, ACA broadened the reach of certain criminal healthcare fraud statutes created under HIPAA by amending the intent requirement such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, including the final Omnibus Rule published on January&#160;25, 2013, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, defined as service providers of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties and gave state attorneys general new authority to file civil actions for </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">91</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health information in certain circumstances, many of which differ from HIPAA and each other in significant ways and may not have the same effect, thus complicating compliance efforts. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. ACA imposed, among other things, new annual reporting requirements for covered manufacturers for certain payments and &#8220;transfers of value&#8221; provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties of up to an aggregate of&#8201;&#8201;$150,000 per year and up to an aggregate of&#8201;&#8201;$1&#160;million per year for &#8220;knowing failures.&#8221; Covered manufacturers were required to begin collecting data on August&#160;1, 2013 and submit reports on aggregate payment data to the government for the first reporting period (August&#160;1, 2013&#8201;&#8212;&#8201;December&#160;31, 2013) by March&#160;31, 2014, and were required to report detailed payment data for the first reporting period and submit legal attestation to the completeness and accuracy of such data by June&#160;30, 2014. Thereafter, covered manufacturers must submit reports by the 90<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> day of each subsequent calendar year. In addition, certain states require implementation of commercial compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or tracking and reporting of gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to it, we may be subject to penalties, including potentially significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">International Regulation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, commercial sales, and distribution of drugs. Whether or not we obtain FDA approval for a drug, we or our collaborators must obtain approval of the drug by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing of the drug in those countries. The approval process varies from country to country and the time to approve may be longer or shorter than that required for FDA approval. Further, to the extent that any of our products are sold in a foreign country, we may be subject to additional foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pharmaceutical Coverage, Pricing and Reimbursement </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the United States and other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of any products for which we receive regulatory approval for commercial sale will therefore depend in part on the availability of reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Generally, if we obtain FDA approval of brivoligide, before we can attempt to sell brivoligide in a hospital, brivoligide must be approved for addition to that hospital&#8217;s list of approved drugs, or formulary list, by the hospital&#8217;s P&amp;T committee. A hospital&#8217;s P&amp;T committee typically governs all matters pertaining to the use of medications within the institution, including the review of medication formulary data and recommendations for the appropriate use of drugs within the institution to the medical staff. The frequency </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">92</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">of P&amp;T committee meetings at hospitals varies considerably, and P&amp;T committees often require additional information to aid in their decision-making process. We may experience substantial delays in obtaining formulary approvals, and hospital pharmacists may be concerned that the cost of acquiring brivoligide for use in their institutions will adversely impact their overall pharmacy budgets, which could cause pharmacists to resist efforts to add brivoligide to the formulary, or to implement restrictions on the usage of brivoligide in order to control costs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The process for determining whether a third-party payor will provide coverage for a drug product typically is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payor not to cover our product candidates could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of drug products and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. By way of example, in the United&#160;States, ACA contains provisions that may reduce the profitability of drug products. The ACA, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions for individuals enrolled in Medicaid managed care plans, imposed mandatory discounts for certain Medicare Part&#160;D beneficiaries and subjected manufacturers to new annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Other legislative changes have been proposed and adopted since ACA was enacted. On August&#160;2, 2011, the President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not recommend and Congress did not enact legislation to reduce the deficit by at least $1.2 trillion for the&#160;years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and will remain in effect through 2024 unless additional Congressional action is taken. On January&#160;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">93</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Legal Proceedings </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Facilities </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, we conducted all of our operations, other than our outsourced operations, at office space located at 100 Pine Street, Suite 500, San Francisco, CA 94111. This office space is subleased from REC Americas, LLC, and the term of the lease is for 62&#160;months and expires on December&#160;31, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employees </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, we had a total of six full-time employees in the United States, three of whom were primarily engaged in research and development activities and three of whom were engaged in general management and administration. Two of our employees have either an M.D. or a Ph.D. None of our employees are represented by a labor union or subject to a collective bargaining agreement. We have never experienced any work stoppage and consider our relations with our employees to be good. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">94</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAN">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">MANAGEMENT </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Executive Officers and Board of Directors </div>

          <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following persons are our executive officers and directors as of September&#160;30, 2019. </div>


          <table style="width:456pt;height:164.5pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:162pt;">
                <div style="white-space:nowrap;">Name </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:36pt;">
                <div style="white-space:nowrap;">Age </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:234pt;">
                <div style="white-space:nowrap;">Position(s) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:162pt;">Executive Officers</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
                <div style="white-space:nowrap;">Rick Orr</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">58 </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">President, Chief Executive Officer and Director </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
                <div style="white-space:nowrap;">Julien Mamet, Ph.D.</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">43 </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Chief Scientific Officer and Director </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
                <div style="white-space:nowrap;">Donald Manning, M.D., Ph.D.</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">61</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Chief Medical Officer </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:9.5pt 0pt 1.5pt 0pt; width:162pt;">Non-Employee Directors</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
                <div style="white-space:nowrap;font-size:7.5pt;">
                  <font style="font-size:10pt;">Dennis Podlesak</font><font style=" position:relative; bottom:4.25pt;">(1)(2)(3)</font></div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">61 </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Chairperson </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
                <div style="white-space:nowrap;">Eckard Weber, M.D.<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">69</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Director </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
                <div style="white-space:nowrap;font-size:7.5pt;">
                  <font style="font-size:10pt;">Stan Abel</font><font style=" position:relative; bottom:4.25pt;">(1)(3)</font></div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">53 </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Director </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
                <div style="white-space:nowrap;">Gregory J. Flesher</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">49 </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Director </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
                <div style="white-space:nowrap;">Matthew Ruth<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">50</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Director</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:6.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:6.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Member of the Audit Committee. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Member of the Compensation Committee. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Member of the Nominating and Corporate Governance Committee. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Executive Officers </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Rick Orr</font> has served as a member of our board of directors and as President and Chief Executive Officer since May&#160;2019. From December&#160;2010 to May&#160;2019, Mr.&#160;Orr served as a member of the board of directors and as President and Chief Executive Officer of Adynxx. Prior to joining Adynxx, Mr.&#160;Orr was Chief Operating Officer at Corthera, Inc., a private, clinical-stage biopharmaceutical company focused on developing therapies for acute heart failure, from May&#160;2009 to July&#160;2010. Corthera was acquired by Novartis Pharmaceuticals Corporation in February&#160;2010. Prior to Corthera, Mr.&#160;Orr served as Sr. Vice President of Operations at Cerexa, Inc., a wholly owned subsidiary of Forest Laboratories, Inc. focused on developing novel anti-infective therapies, from October&#160;2007 to May&#160;2009. Mr.&#160;Orr was part of the management team that founded Cerexa in July&#160;2005 and served as General Counsel from the company&#8217;s inception until October&#160;2007. Forest Laboratories acquired Cerexa in January&#160;2007. Mr.&#160;Orr received a B.A. from The Ohio State University, an M.A. from the University of California, Santa Barbara, and a J.D. from the University of San Francisco School of Law. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr.&#160;Orr was selected to serve on the Adynxx board of directors because of his extensive experience in the biopharmaceutical industry and his executive leadership experience. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Julien Mamet, Ph.D.</font> has served as a member of our board of directors and our Chief Scientific Officer since May&#160;2019. Prior to joining us, Dr.&#160;Mamet founded Adynxx and served as a member of its board of directors since its inception in October&#160;2007 and as Chief Scientific Officer since December&#160;2010. Previously, Dr.&#160;Mamet served as President and Chief Executive Officer of Adynxx from its inception to December&#160;2010. Prior to founding Adynxx, Dr.&#160;Mamet completed his post-doctoral work at the Scripps Research Institute, a nonprofit biomedical research institute, from September&#160;2006 to December&#160;2006, and at the Genomics Institute of the Novartis Research Foundation, a research institute of Novartis International AG, a global pharmaceutical company, from February&#160;2004 to September&#160;2006. Dr.&#160;Mamet received a B.S. and M.S. from the University Claude Bernard in Lyon, France and a Ph.D. from the Institute of Molecular and Cellular Pharmacology in Nice-Sophia Antipolis, France. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Dr.&#160;Mamet was selected to serve on the Adynxx board of directors because of extensive experience as inventor of the AYX technology platform. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">95</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Donald C. Manning, M.D., Ph.D.</font> has served as our Chief Medical Officer since May&#160;2019. From January&#160;2012 to May&#160;2019, Dr.&#160;Manning served as Chief Medical Officer of Adynxx. Prior to joining Adynxx, Dr.&#160;Manning served as Chief Medical Officer at Shionogi Inc., the U.S. subsidiary of Shionogi &amp; Co., Ltd., a global pharmaceutical company, from July&#160;2009 to May&#160;2011 and as Executive Vice President of Clinical Development, Medical Affairs and Pharmacovigilance from March&#160;2010 to May&#160;2011. Prior to Shionogi, Dr.&#160;Manning served as Vice President of Medical Affairs at King Pharmaceuticals Inc., from January&#160;2009 to June&#160;2009, and as Vice President of Clinical Research and Development at Alpharma Inc., a global specialty pharmaceutical company, from August&#160;2008 to January&#160;2009. Alpharma was acquired by King Pharmaceuticals in January&#160;2009. Prior to Alpharma, Dr.&#160;Manning served as Vice President and Therapeutic Area Head for Neurosciences at Celgene Corporation, a biotechnology company that develops and commercializes medicines for cancer and inflammatory disorders, from October&#160;2006 to August&#160;2008 and as Executive Director from April&#160;2003 to October&#160;2006. Dr.&#160;Manning received a B.S. from McGill University and an M.D. and Ph.D. from Johns Hopkins School of Medicine. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Non-Employee Directors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Dennis Podlesak</font> has served as a member of our board of directors since May&#160;2019 and has served as a member of the board of directors of Adynxx since 2010. Since 2007, Mr.&#160;Podlesak has served as a Partner of Domain Associates LLC, a private venture capital management firm focused on life sciences. While at Domain, Mr.&#160;Podlesak has been the founder and the Chief Executive Officer of a number of companies, including Calixa Therapeutics, Inc., a privately held biopharmaceutical company which was acquired by Cubist Pharmaceuticals, Inc. in December&#160;2009. Mr.&#160;Podlesak was also the Executive Chairman of Corthera, Inc., a biopharmaceutical company, which was acquired by Novartis AG in January&#160;2010. Mr.&#160;Podlesak currently serves as the chairperson of the board of directors of Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company. Mr.&#160;Podlesak received a B.A. from Western Illinois University and an M.B.A. from Pepperdine University. He completed post-graduate studies at The Wharton School, University of Pennsylvania. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr.&#160;Podlesak was selected to serve on the Adynxx board of directors because of his experience as the Chief Executive Officer and Chairman of other successful companies in the biotechnology industry, his over 20&#160;years of strategic, operational and commercial experience in the pharmaceutical industry, and his service as a director of other publicly traded and privately held life science companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Eckard Weber, M.D.</font> has served as a member of our board of directors since May&#160;2019 and has served as a member of the board of directors of Adynxx since 2010. Dr.&#160;Weber has served as a partner with Domain Associates, LLC, a private venture capital management firm focused on life sciences, since 2001. Dr.&#160;Weber has been the founding Chief Executive Officer of multiple Domain Associates portfolio companies including Acea Pharmaceuticals, Ascenta Therapeutics, Calixa Therapeutics, Cytovia and NovaCardia, each a biopharmaceutical company. Dr.&#160;Weber received his German undergraduate degree from Kolping Kolleg in Germany and an M.D. from the University of Ulm Medical School in Germany. Dr.&#160;Weber received his postdoctoral training in neuroscience at Stanford University Medical School. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Dr.&#160;Weber was selected to serve on the Adynxx board of directors because of his extensive experience in the life sciences industry as an entrepreneur, chief executive officer and venture capitalist, as well as his training as a physician. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Stan Abel</font> has served as a member of our board of directors since May&#160;2019 and has served as a member of the board of directors of Adynxx since 2008. Since 2010, Mr.&#160;Abel has served as the President and Chief Executive Officer of SiteOne Therapeutics Inc., a pain company focused on developing a novel platform of highly selective sodium channel 1.7 inhibitors. From 2007 to 2010, Mr.&#160;Abel served as Chief Executive Officer of Corthera, Inc., a biopharmaceutical company, through the sale of the company to Novartis AG in February&#160;2010. Mr.&#160;Abel received a B.S. in Business from Indiana University and an M.B.A., with honors, from the University of Chicago. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr.&#160;Abel was selected to serve on the Adynxx board of directors because of his extensive experience in strategic biopharmaceutical transactions and leadership of clinical-stage companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Gregory&#160;J. Flesher</font> has served as a member of our board of directors since July 2019. Mr.&#160;Flesher has served as the Chief Executive Officer and a member of the board of directors of Novus Therapeutics, Inc., </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">96</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose and throat, since May&#160;2017. Prior to Novus, Mr.&#160;Flesher served as Chief Executive Officer and a member of the board of directors for Otic Pharma, Ltd. from 2015 to 2017. Mr.&#160;Flesher has more than 20&#160;years of pharmaceutical industry experience and has been closely involved with several successful drug development programs that have resulted in multiple product approvals and commercial launches in the U.S. and Europe. Prior to Otic Pharma, Mr.&#160;Flesher served as Senior Vice President of Corporate Development and Chief Business Officer, and other executive management roles at Avanir Pharmaceuticals, Inc. from 2006 to 2015. Mr.&#160;Flesher received his B.S. in Biology from Purdue University and studied Biochemistry and Molecular Biology at Indiana University School of Medicine. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr.&#160;Flesher was selected to serve on the Adynxx board of directors because of his extensive senior leadership experience at numerous biopharmaceutical companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Matthew Ruth</font> has served as a member of our board of directors since May&#160;2019. Mr.&#160;Ruth is currently Senior Vice President, US Chief Commercial Officer for Adapt Pharma, a division of Emergent Bio Solutions commercializing Narcan Nasal Spray, a product that can reverse the effects of opioid and heroin overdoses. From 2012 to 2015, Mr.&#160;Ruth was Chief Operating Officer for RightCare Solutions. Mr.&#160;Ruth earned a Bachelor of Science degree from Missouri State University. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our board of directors believes that Mr.&#160;Ruth&#8217;s experience in leading commercial roles at a number of biopharmaceutical companies qualifies him to serve as a member of our board of directors. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Family Relationships </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">There are no family relationships among any of our directors or executive officers. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Board Composition </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our board of directors consists of seven members. Our certificate of incorporation and bylaws provide that directors are to be elected at each annual meeting of stockholders to hold office until the next annual meeting and until their respective successors are elected and qualified. Vacancies on the board of directors resulting from death, resignation, retirement, disqualification or removal may be filled by the affirmative vote of a majority of the remaining directors then in office, whether or not a quorum of the board of directors is present. Newly created directorships resulting from any increase in the number of directors may, unless the board of directors determines otherwise, be filled only by the affirmative vote of the directors then in office, whether or not a quorum of the board of directors is present. Any director elected as a result of a vacancy shall hold office for a term expiring at the next annual meeting of stockholders and until such director&#8217;s successor shall have been elected and qualified.</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Committees of the Board of Directors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our board of directors has the authority to appoint committees to perform certain management and administration functions. Our board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee. The composition and responsibilities of each committee are described below. Members will serve on these committees until their resignation or until otherwise determined by the board of directors. The charters for each of these committees are available on our website at www.adynxx.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of such website address in this prospectus is an inactive textual reference only. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Audit Committee </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our audit committee consists of Mr.&#160;Abel, Mr.&#160;Podlesak and Mr.&#160;Ruth. The board of directors has determined that each committee member is independent under Rule&#160;10A-3(b)(1) of the Exchange Act. The chairperson of our audit committee is Mr.&#160;Abel. The board of directors has determined that Mr.&#160;Abel is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. In arriving at this determination, the board of directors has examined each audit committee member&#8217;s scope of experience and the nature of their employment in the life sciences industry. </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">97</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The primary purpose of the audit committee is to discharge the responsibilities of the board of directors with respect to our accounting, financial, and other reporting and internal control practices and to oversee our independent registered accounting firm. Specific responsibilities of our audit committee include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">selecting a qualified firm to serve as the independent registered public accounting firm to audit our financial statements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">helping to ensure the independence and performance of the independent registered public accounting firm; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing policies on risk assessment and risk management; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing related party transactions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">obtaining and reviewing a report by the independent registered public accounting firm at least annually, that describes our internal quality-control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">approving (or, as permitted, pre-approving) all audit and all permissible non-audit service to be performed by the independent registered public accounting firm.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Compensation Committee </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The compensation committee consists of Mr.&#160;Podlesak and Dr.&#160;Weber. Our board of directors has determined each member is a &#8220;non-employee director&#8221; as defined in Rule&#160;16b-3 promulgated under the Exchange Act. The chairperson of the compensation committee is Mr. Podlesak. The primary purpose of the compensation committee is to discharge the responsibilities of the board of directors to oversee our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate. Specific responsibilities of the compensation committee will include: </div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing and approving, or recommending that our board of directors approve, the compensation of our executive officers; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing and recommending to our board of directors the compensation of our directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing and approving, or recommending that our board of directors approve, the terms of compensatory arrangements with our executive officers; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">administering our stock and equity incentive plans; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">selecting independent compensation consultants and assessing whether there are any conflicts of interest with any of the committee&#8217;s compensation advisors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing and approving, or recommending that our board of directors approve, incentive compensation and equity plans, severance agreements, change-of-control protections and any other compensatory arrangements for our executive officers and other senior management, as appropriate; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing and establishing general policies relating to compensation and benefits of our employees; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing our overall compensation philosophy.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">98</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">Our nominating and corporate governance committee consists of Mr.&#160;Abel and Mr. Podlesak. The chairperson of our nominating and corporate governance committee is Mr.&#160;Podlesak. </div>

        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Specific responsibilities of our nominating and corporate governance committee include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">identifying, evaluating and selecting, or recommending that our board of directors approve, nominees for election to our board of directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">evaluating the performance of our board of directors and of individual directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing developments in corporate governance practices; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">evaluating the adequacy of our corporate governance practices and reporting; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing management succession plans; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">developing and making recommendations to our board of directors regarding corporate governance guidelines and matters. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">99</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tECOA">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">EXECUTIVE COMPENSATION <font style="text-transform:uppercase;">of adynxx</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Adynxx&#8217;s named executive officers, consisting of Adynxx&#8217;s principal executive officer and the next two most highly compensated executive officers, for the year ended December&#160;31, 2018, were: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Rick Orr, Adynxx&#8217;s President and Chief Executive Officer; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Julien Mamet, Ph.D., Adynxx&#8217;s Chief Scientific Officer; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Donald Manning, M.D., Ph.D., Adynxx&#8217;s Chief Medical Officer. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Following the consummation of the Merger in May&#160;2019, each of Adynxx&#8217;s executive officers, including Adynxx&#8217;s named executive officers, were appointed as our executive officers. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Summary Compensation Table </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table presents all of the compensation paid or awarded to or earned by Adynxx&#8217;s named executive officers during 2018: </div>
        <table style="width:456pt;height:92.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:265.26pt;text-align:left;">
              <div style="white-space:nowrap;">Name and Principal Position </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Salary </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">All Other <br >Compensation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0.917pt 0pt 0.5pt 0pt; width:265.26pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Rick Orr<br ><font style="font-style:italic;">President and Chief Executive Officer</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">435,663</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">37,926<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font></font></td>
            <td style="padding:0pt;padding-left:4.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">473,589</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:265.26pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Julien Mamet, Ph.D.<br ><font style="font-style:italic;">Chief Scientific Officer</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">340,540</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.19pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">37,926<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font></font></td>
            <td style="padding:0pt;padding-left:4.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">378,466</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:265.26pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Donald Manning, M.D., Ph.D.<br ><font style="font-style:italic;">Chief Medical Officer</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">360,149</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.19pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">37,926<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font></font></td>
            <td style="padding:0pt;padding-left:4.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">398,075</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Comprised of non-elective 401(k) plan safe harbor contributions, health insurance premium payments and gym membership and related fee reimbursements. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Outstanding Equity Awards as of December&#160;31, 2018 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table provides information about outstanding equity awards held by each of our named executive officers at December&#160;31, 2018. </div>

          <table style="width:456pt;height:173.5pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:242.61pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
                <div style="white-space:nowrap; text-align:center;">Option Awards </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;height:23pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:242.61pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">Number of Securities <br >Underlying Unexercised <br >Options (#) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
                <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Option <br >Exercise <br >Price </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
                <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Option <br >Expiration <br >Date </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:242.61pt;text-align:left;">
                <div style="white-space:nowrap;">Name </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Exercisable<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Unexercisable </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:242.61pt;text-align:left;">
                <div style="white-space:nowrap;">Rick Orr </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">660<font style="position:absolute;"><font style="font-weight:bold;"></font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(6)</font></font></td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.39</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/17/2022</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:242.61pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">95,416<font style="position:absolute;"><font style="font-weight:bold;"></font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(2)(5)</font></font></td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.06</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/15/2026</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.61pt;text-align:left;">
                <div style="white-space:nowrap;">Julien Mamet, Ph.D. </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">33<font style="position:absolute;"><font style="font-weight:bold;"></font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(6)</font></font></td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.39</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/17/2022</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:242.61pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">158,148<font style="position:absolute;"><font style="font-weight:bold;"></font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(3)(5)</font></font></td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.06</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/15/2026</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.61pt;text-align:left;">
                <div style="white-space:nowrap;">Donald Manning, M.D., Ph.D. </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">23,857<font style="position:absolute;"><font style="font-weight:bold;"></font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(6)</font></font></td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.11</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/7/2022</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:242.61pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">7,886<font style="position:absolute;"><font style="font-weight:bold;"></font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(6)</font></font></td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.39</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7/16/2022</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:242.61pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">3,943<font style="position:absolute;"><font style="font-weight:bold;"></font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(6)</font></font></td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.39</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/17/2022</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:242.61pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">56,406<font style="position:absolute;"><font style="font-weight:bold;"></font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(4)(5)</font></font></td>
              <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.06</td>
              <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/15/2026</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Each option held by the named executive officers is exercisable immediately following grant, also known as &#8220;early exercisable,&#8221; and unvested shares purchased upon an early exercise are subject to a repurchase right in our favor on termination of employment that lapses along the same vesting schedule as contained in the option grant. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
          <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">1/4<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> of the shares subject to the option vested one year after December&#160;16, 2016, the vesting commencement date, and 1/36<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> of the shares subject to the option vest monthly thereafter. As of December&#160;31, 2018, 47,708 shares underlying the option were vested. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">100</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
          <div style=" line-height:12pt; text-align:left; margin-left:20pt;">1/4<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> of the shares subject to the option vested one year after December&#160;16, 2016, the vesting commencement date, and 1/36<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> of the shares subject to the option vest monthly thereafter. As of December&#160;31, 2018, 79,074 shares underlying the option were vested. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:12pt; margin-top:3.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
          <div style=" margin-top:3.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">1/4<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> of the shares subject to the option vested one year after December&#160;16, 2016, the vesting commencement date, and 1/36<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> of the shares subject to the option vest monthly thereafter. As of December&#160;31, 2018, 28,203 shares underlying the option were vested. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">During the 12&#160;months following a change in control and the three months preceding a change of control, if&#8201; (a)&#160;the named executive officer is involuntarily terminated without cause or (b)&#160;the named executive officer resigns for good reason, and in either case, other than as a result of death or disability (and provided such termination constitutes a separation from service, without regard to any alternative definition thereunder), then the vesting of the option shall be accelerated such that 100% of the total unvested shares under the option shall be vested.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
        <div style=" margin-top:3.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">All shares subject to this option have vested as of December&#160;31, 2018. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employment Arrangements </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">Upon the closing of the Merger, the executive officers of Private Adynxx were appointed as our executive officers, and each of Alliqua&#8217;s then-appointed executive officers resigned. Our executive officers following the consummation of the Merger consist of Mr.&#160;Orr, our and Adynxx&#8217;s President and Chief Executive Officer, Dr.&#160;Mamet, our and Adynxx&#8217;s Chief Scientific Officer, and Dr.&#160;Manning, our and Adynxx&#8217;s Chief Medical Officer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have offer letters with each of our executive officers. The offer letters generally provide for at-will employment and set forth the executive officer&#8217;s initial base salary, eligibility for employee benefits and confirmation of the terms of previously issued equity grants, including in some cases severance benefits on a qualifying termination of employment. The key terms of employment with our and Adynxx&#8217;s named executive officers set forth in the tables above are described below. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Rick Orr </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">In October&#160;2010, Adynxx entered into an offer letter with Mr.&#160;Orr, our President and Chief Executive Officer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2018, Mr.&#160;Orr received a base salary of&#8201; $435,663. For 2019, Mr.&#160;Orr will receive an annual base salary of&#8201; $443,913 with an annual target bonus of 40% of such base salary, payable based on the achievement of certain corporate and individual performance goals to be established by our Compensation Committee. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon an involuntary termination without cause or termination due to constructive termination, Mr.&#160;Orr will be entitled to receive a lump sum cash payment equal to 12&#160;months of his annual base salary and an amount equal to 100% of his most recently paid bonus. In addition, Mr.&#160;Orr will be eligible for 12&#160;months of continued company paid health insurance benefits (assuming he timely elects continued coverage under COBRA). All such severance benefits are subject to Mr.&#160;Orr signing a general release in our favor of all known and unknown claims in substantially the form provided in his offer letter. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Julien Mamet, Ph.D. </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">In September&#160;2011, Adynxx entered into an offer letter with Dr.&#160;Mamet, our Chief Scientific Officer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2018, Dr. Mamet received a base salary of&#8201; $340,540. For 2019, Dr.&#160;Mamet will receive an annual base salary of&#8201; $348,790 with an annual target bonus of 35% of such base salary, payable based on the achievement of certain corporate and individual performance goals to be established by our Compensation Committee. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon an involuntary termination without cause or termination due to constructive termination, Dr.&#160;Mamet will be entitled to receive a lump sum cash payment equal to 12&#160;months of his annual base salary. In addition, Dr.&#160;Mamet will be eligible for 12&#160;months of continued company paid health insurance benefits (assuming he timely elects continued coverage under COBRA). All such severance benefits are subject to Dr.&#160;Mamet signing a general release in our favor of all known and unknown claims in substantially the form provided in his offer letter. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">101</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Donald Manning, M.D., Ph.D. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January&#160;2012, Adynxx entered into an offer letter with Dr.&#160;Manning, our Chief Medical Officer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2018, Dr.&#160;Manning received a base salary of&#8201; $360,149. For 2019, Dr.&#160;Manning will receive an annual base salary of&#8201; $368,399 with an annual target bonus of 35% of such base salary, payable based on the achievement of certain corporate and individual performance goals to be established by our Compensation Committee. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon an involuntary termination without cause or termination due to constructive termination, not within one month prior to or 13&#160;months following a change in control, Dr.&#160;Manning will be entitled to receive a lump sum cash payment equal to 9&#160;months of his annual base salary. In addition, Dr.&#160;Manning will be eligible for nine months of company paid continued health insurance benefits (assuming he timely elects continued coverage under COBRA). Upon an involuntary termination without cause or termination due to constructive termination, within one month prior to or 13&#160;months following a change in control, Dr.&#160;Manning will be entitled to receive a lump sum cash payment equal to 12&#160;months of his annual base salary. In addition, Dr.&#160;Manning will be eligible for 12&#160;months of continued company paid health insurance benefits (assuming he timely elects continued coverage under COBRA) and all unvested stock options held by Dr.&#160;Manning will immediately vest in full. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All such severance benefits are subject to Dr.&#160;Manning signing a general release in our favor of all known and unknown claims in substantially the form provided in his offer letter. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employee Benefit Plans </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe that our ability to grant equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders. In addition, we believe that our ability to grant options and other equity-based awards helps us to attract, retain and motivate employees, consultants and directors and encourages them to devote their best efforts to our business and financial success. The principal features of our equity incentive plans, our health benefit plan and our 401(k) plan are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans, which, other than the health benefit plan and 401(k) plan, are filed or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">2010 Equity Incentive Plan </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the closing of the Merger, we assumed the Adynxx 2010 Equity Incentive Plan, or the Adynxx Plan, and all outstanding stock options thereunder. The Adynxx Plan was adopted by the board of directors of Adynxx and approved by Adynxx&#8217;s stockholders in December 2010. The Adynxx Plan provides for the granting of stock options to employees and consultants of Adynxx. Options granted under the Adynxx Plan may be either incentive stock options, or ISOs, or nonqualified stock options, or NSOs. ISOs may be granted only to Adynxx employees (including officers and directors who are also employees). NSOs may be granted to Adynxx employees and consultants. Options under the Adynxx Plan may be granted for periods of up to 10&#160;years and at prices no less than 100% of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the Adynxx board of directors; provided, however, that the exercise price of an ISO and NSO granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. The Adynxx Plan requires that options be exercised no later than 10&#160;years after the grant. A total of 690,071 shares of common stock are reserved for issuance under the Adynxx Plan as of December&#160;31, 2018.</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">401(k) Plan </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We maintain a 401(k) plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees are able to defer compensation up to certain limits imposed by the Code. We have the ability to make matching and discretionary contributions to the 401(k) plan. Currently, we do not make matching contributions to the 401(k) plan. We make a nonelective 401(k) safe harbor contribution on behalf of each employee equal to 3% of their annual salary. The 401(k) plan is intended to be qualified under Section&#160;401(a) of the Code, with the related trust intended to be tax exempt </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">102</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">under Section&#160;501(a) of the Code. As a tax-qualified retirement plan, contributions to the 401(k) plan are deductible by us when made, and contributions and earnings on those amounts are generally not taxable to a participating employee until withdrawn or distributed from the 401(k) plan. </div>
        <div style="margin-top:16.98pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Health and Welfare Benefits </div>
        <div style="text-indent:20pt; margin-top:9.99pt; width:456pt; line-height:12pt;">We pay premiums for medical insurance, dental insurance and vision insurance for all full-time employees, including our named executive officers. These benefits are available to all full-time employees, subject to applicable laws. </div>
        <div style="margin-top:16.98pt; width:456pt; line-height:11pt;font-weight:bold;">Pension Benefits </div>
        <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">Adynxx&#8217;s named executive officers did not participate in, or otherwise receive any benefits under, any pension or defined benefit retirement plan sponsored by Adynxx during the year ended December&#160;31, 2018. </div>
        <div style="margin-top:16.98pt; width:456pt; line-height:11pt;font-weight:bold;">Nonqualified Deferred Compensation </div>
        <div style="text-indent:20pt; margin-top:9.99pt; width:456pt; line-height:12pt;">Adynxx&#8217;s named executive officers did not participate in, or earn any benefits under, a non-qualified deferred compensation plan sponsored by Adynxx during the year ended December&#160;31, 2018. </div>
        <div style="margin-top:16.98pt; width:456pt; line-height:11pt;font-weight:bold;">Director Compensation </div>
        <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">The following table sets forth information regarding compensation earned by or paid to Adynxx&#8217;s non-employee directors during 2018. Adynxx did not have any compensation arrangements or policies with respect to non-employee directors during 2018. </div>
        <table style="width:416pt;height:62.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:304.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Fees Earned or <br >Paid in Cash</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:304.61pt;text-align:left;">
              <div style="white-space:nowrap;">Dennis Podlesak<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">120,000</td>
            <td style="padding:0pt;padding-left:5.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">120,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.61pt;text-align:left;">
              <div style="white-space:nowrap;">Eckard Weber<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">120,000</td>
            <td style="padding:0pt;padding-left:5.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">120,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.61pt;text-align:left;">
              <div style="white-space:nowrap;">Stan Abel<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">72,000</td>
            <td style="padding:0pt;padding-left:5.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">72,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
          <div style=" margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">As of December&#160;31, 2018, Mr.&#160;Podlesak held options to purchase an aggregate of 56,275 shares of common stock.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">As of December&#160;31, 2018, Mr.&#160;Weber held options to purchase an aggregate of 56,275 shares of common stock.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
          <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">As of December&#160;31, 2018, Mr&#160;Abel held options to purchase an aggregate of 28,137 shares of common stock.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:10.99pt; width:456pt; line-height:12pt;">We expect that our board of directors will adopt a director compensation policy for non-employee directors following the closing of this offering. Pursuant to this policy, we expect that any director who is also an employee of ours or our subsidiary will not receive any additional compensation for his or her service as a director. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">103</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tECA">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">EXECUTIVE COMPENSATION OF ALLIQUA </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Alliqua&#8217;s named executive officers, consisting of Alliqua&#8217;s principal executive officer and the next two most highly compensated executive officers, for the year ended December&#160;31, 2018, were: </div>
        <div style=" float:left; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">David Johnson, Alliqua&#8217;s former President and Chief Executive Officer; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Bradford Barton, Alliqua&#8217;s former Chief Operating Officer; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Pellegrino Pionati, Alliqua&#8217;s former Chief Strategy and Marketing Officer; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Joseph Warusz, Alliqua&#8217;s former Chief Financial Officer, Treasurer and Secretary. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Following the consummation of the Merger in May&#160;2019, each of Alliqua&#8217;s executive officers, including Alliqua&#8217;s named executive officers, resigned and Adynxx&#8217;s executive officers were appointed as our executive officers. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Summary Compensation Table </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table presents all of the compensation paid or awarded to or earned by Alliqua&#8217;s former named executive officers during 2017 and 2018: </div>
        <table style="width:456pt;height:161.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:165.84pt;text-align:left;">
              <div style="white-space:nowrap;">Name and Principal Position </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Salary </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Bonus </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Stock <br >Awards<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">All Other <br >Compensation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7.25pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:165.84pt;white-space:normal;text-align:left;" rowspan="2">
              <div style="margin-left:10pt; text-indent:-10pt; line-height:12pt; padding-bottom:0.666666666666667pt;font-style:italic;">
                <font style="font-style:normal;">David Johnson</font><font style=" position:relative; bottom:4.25pt;font-style:normal;font-size:7.5pt;">(6)</font>
                <br >Former President and Chief Executive Officer</div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">350,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">279,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">11,400<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(3)</font></font></td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">640,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:24pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">350,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">276,500<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(2)</font></font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">274,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">11,400<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(3)</font></font></td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">911,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:13pt;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:165.84pt;text-align:left;" rowspan="2">
              <div style="margin-left:10pt; text-indent:-10pt; line-height:12pt; padding-bottom:0pt;">Bradford Barton<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(6)</font><br ><font style="font-style:italic;">Former Chief Operating Officer</font></div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">87,040</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">53,301</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">263,730<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(5)</font></font></td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">404,071</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:13pt;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">246,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">118,310<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(2)</font></font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">103,829</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">8,400<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(4)</font></font></td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">477,339</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:13pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:165.84pt;text-align:left;" rowspan="2">
              <div style="margin-left:10pt; text-indent:-10pt; line-height:12pt; padding-bottom:0pt;">Pellegrino Pionati<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(6)</font><br ><font style="font-style:italic;">Former Chief Operating Officer</font></div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">87,040</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">54,970</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">263,730<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(5)</font></font></td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">405,740</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:13pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">246,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">118,310<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(2)</font></font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">103,829</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">8,400<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(4)</font></font></td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">477,339</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:13pt;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:165.84pt;white-space:normal;text-align:left;" rowspan="2">
              <div style="margin-left:10pt; text-indent:-10pt; line-height:12pt; padding-bottom:0.666666666666667pt;font-style:italic;">
                <font style="font-style:normal;">Joseph Warusz</font><font style=" position:relative; bottom:4.25pt;font-style:normal;font-size:7.5pt;">(6)</font>
                <br >Former Chief Financial Officer, Treasurer and Secretary</div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">281,960</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">281,960</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:27pt;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">The amounts reported represent the aggregate grant date fair value of the awards, calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic&#160;718&#8201;&#8212;&#8201;Compensation&#8201;&#8212;&#8201;Stock Compensation, or ASC 718, with the exception that the amount shown assumes no forfeitures. Alliqua used the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. Assumptions used in the calculation of these amounts include, for the year ended December 31, 2017, the risk free interest rate of 1.81% to 2.43%, expected term of 5.04 to 6.50 years, expected volatility of 81.94% to 87.00% and no expected dividends. The risk-free interest rate is based on rates of treasury securities with the same expected term as the options. Alliqua used the &#8220;simplified method&#8221; to calculate the expected term of employee and director stock-based options. The expected term used for consultants is the contractual life. Alliqua utilized an expected volatility figure based on a review of Alliqua&#8217;s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that Alliqua had not historically paid dividends, and did not expect to pay dividends in the near future. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents a discretionary year-end performance bonus earned in 2017 paid in 2018. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Comprised of&#8201; (i)&#160;automobile expense allowance payments of&#8201; $9,000 and (ii) life insurance premium payments of&#8201; $2,400. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Comprised of automobile expense allowance payments. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Comprised of&#8201; (i)&#160;automobile expense allowance payments of&#8201; $2,927, (ii) vacation payout payments of $11,203 and (iii) severance payments of&#8201; $249,600. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">104</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">In May&#160;2018, Mr.&#160;Barton resigned as Alliqua&#8217;s Chief Operating Officer and Mr.&#160;Pionati resigned as Alliqua&#8217;s Chief Strategy and Marketing Officer. Mr.&#160;Warusz resigned in March&#160;2019. Mr.&#160;Johnson resigned in May&#160;2019 in connection with the consummation of the Merger. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Outstanding Equity Awards as of December&#160;31, 2018 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table provides information about outstanding equity awards held by each of Alliqua&#8217;s named executive officers at December&#160;31, 2018. </div>

          <table style="width:456pt;height:284.5pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:231.95pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
                <div style="white-space:nowrap; text-align:center;">Option Awards </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;height:14pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">Number of Securities Underlying <br >Unexercised Options (#) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
                <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Option <br >Exercise <br >Price </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
                <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Option <br >Expiration <br >Date </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:231.95pt;text-align:left;">
                <div style="white-space:nowrap;">Name </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Exercisable </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Unexercisable </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:231.95pt;text-align:left;">
                <div style="white-space:nowrap;">David Johnson </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">986</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">262.30</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/29/2022</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">986</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">393.60</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/29/2022</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">986</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">525.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/29/2022</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,653</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">196.80</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/4/2023</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,952</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">210.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/14/2023</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">12,176</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">409.20</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/20/2023</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,917</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">373.80</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/6/2025</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:231.95pt;text-align:left;">
                <div style="white-space:nowrap;">Bradford Barton </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">914</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">262.80</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/10/2023</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">914</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">328.20</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/10/2023</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">914</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">393.60</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/10/2023</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">914</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">525.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/10/2023</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">914</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">656.40</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/10/2023</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,167</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">540.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/6/2024</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,917</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">373.80</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/6/2025</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:231.95pt;text-align:left;">
                <div style="white-space:nowrap;">Pellegrino Pionati </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,667</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">315.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">6/15/2025</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:231.95pt;text-align:left;">
                <div style="white-space:nowrap;">Joseph Warusz </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employment Arrangements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the closing of the Merger, the executive officers of Private Adynxx were appointed as our executive officers, and each of Alliqua&#8217;s then-appointed executive officers resigned. The key terms of employment with the former named executive officers of Alliqua set forth in the table above are described below. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">David Johnson </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with the appointment of David Johnson as Chief Executive Officer, in February 2013, Alliqua entered into an Executive Employment Agreement with Mr. Johnson, as subsequently amended. Mr. Johnson&#8217;s service as Chief Executive Officer was terminated without cause immediately prior to consummation of the Merger. Pursuant to the terms of his employment agreement, and subject to compliance with the confidentiality, non-solicitation and non-disparagement requirements of the employment agreement and the execution of a release of claims, Alliqua paid Mr. Johnson an aggregate amount of&#8201; $1,050,000 following the closing of the Merger.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Bradford Barton </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with the appointment of Mr. Barton as Chief Operating Officer, in May 2013, Alliqua entered into an Offer Letter with Mr. Barton. In May 2018, Alliqua and Mr.&#160;Barton entered into a general release and severance agreement, or the Barton Separation Agreement, which became effective in May&#160;2018. Pursuant to the Barton Separation Agreement, Mr.&#160;Barton released Alliqua from any and all claims. In consideration of the Barton Separation Agreement and his general release of claims, Mr.&#160;Barton was </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">105</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">entitled to&#160;his 2017 performance bonus of&#8201; $118,310, severance pay equal to his base salary for 12&#160;months and the stock options and restricted stock previously granted to Mr.&#160;Barton&#160;became fully and immediately vested. The stock options shall remain exercisable until the earlier of May 2020 or the end of the applicable stock option&#8217;s term. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pellegrino Pionati </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Alliqua and Mr.&#160;Pionati entered into a general release and severance agreement, or the Pionati Separation Agreement, which became effective in May&#160;2018. Pursuant to the Pionati Separation Agreement, Mr.&#160;Pionati released Alliqua from any and all claims. In consideration of the Pionati Separation Agreement and his general release of claims, Mr.&#160;Pionati was entitled to&#160;his 2017 performance bonus of&#8201;&#8201; $118,310.40, severance pay equal to his base salary for 12&#160;months and the stock options and restricted stock previously granted to Mr.&#160;Pionati&#160;became fully and immediately vested. The stock options shall remain exercisable until the earlier of May 2020 or the end of the applicable stock option&#8217;s term. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Joseph Warusz </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr.&#160;Warusz did not have an employment agreement with Alliqua and his employment was terminable by either party at any time upon written notice. Mr.&#160;Warusz was entitled to an hourly salary of&#8201; $250 per hour. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employee Benefit Plans </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Alliqua Stock Compensation Plans </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The principal features of Alliqua&#8217;s equity incentive plans are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans, which are filed or incorporated by reference as exhibits to the registration statement of which this prospectus is a part.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">2011 Long-Term Incentive Plan </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The 2011 Long-Term Incentive Plan, or the 2011 Plan, was adopted by Alliqua&#8217;s board of directors in November&#160;2011 and approved by Alliqua&#8217;s stockholders in December&#160;2011. The 2011 Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock&#160;units, performance awards, dividend equivalent rights, and other awards which may be granted singly, in combination, or in tandem, and which may be paid in cash or shares of common stock. The 2011 Plan is administered by our board of directors. A total of 30,476 shares of common stock are reserved for award under the 2011 Plan, of which 7,854 remained available for future awards as of December&#160;31, 2018. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">2014 Long-Term Incentive Plan </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The 2014 Long-Term Incentive Plan, or the 2014 Plan, was adopted by Alliqua&#8217;s board of directors in April&#160;2014 and approved by Alliqua&#8217;s stockholders in June&#160;2014. In February&#160;2015, Alliqua&#8217;s board of directors approved an amendment to the 2014 Plan to increase the total number of shares available for issuance pursuant to awards under the 2014 Plan, which was approved by Alliqua&#8217;s stockholders in May&#160;2015. The 2014 Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock&#160;units, performance awards, dividend equivalent rights, and other awards which may be granted singly, in combination, or in tandem, and which may be paid in cash or shares of common stock. The 2014 Plan is administered by our board of directors. A total of 158,333 shares of common stock are reserved for award under the 2014 Plan, of which 70,519 remained available for future awards as of December&#160;31, 2018.</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">106</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Director Compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">The following table sets forth information regarding compensation earned by or paid to Alliqua&#8217;s non-employee directors during 2018. </div>
        <table style="width:376pt;height:77.5pt;margin-left:40pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:269.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Fees Earned or <br >Paid in Cash </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:269.61pt;text-align:left;">
              <div style="white-space:nowrap;">Joseph Leone </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">33,750</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">33,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.61pt;text-align:left;">
              <div style="white-space:nowrap;">Gary Restani </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">32,626</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">32,626</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.61pt;text-align:left;">
              <div style="white-space:nowrap;">Jeffrey Sklar </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">34,500</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">34,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.61pt;text-align:left;">
              <div style="white-space:nowrap;">Mark Wagner </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">27,750</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">27,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.99pt; width:456pt; line-height:12pt;">For the year ended December&#160;31, 2018, cash compensation for non-employee directors, including the chairperson of the board of directors, was $26,250. In addition, the audit committee chairperson was paid $10,500, the compensation committee chairperson was paid $8,750, other audit committee members were each paid $5,250, other compensation committee members were each paid $3,938, and nominating and corporate governance committee members, including the chairperson, were each paid $2,625. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">107</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCR">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">The following is a summary of transactions since January&#160;1, 2017 to which Alliqua and Private Adynxx have been a participant, in which: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the amount involved exceeded or will exceed the lesser of&#8201; $120,000 or 1% of our average total assets at year end for the last two completed fiscal&#160;years; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any of our directors, executive officers, or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest, other than compensation and other arrangements that are described in the sections titled &#8220;Executive Compensation of Adynxx&#8221; and &#8220;Executive Compensation of Alliqua&#8221;, or that were approved by our compensation committee. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe the terms obtained or consideration that Alliqua or Private Adynxx, as applicable, paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable in arm&#8217;s-length transactions. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Adynxx </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Notes </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In March&#160;2018 and September&#160;2018, Private Adynxx issued $3.0&#160;million aggregate principal amount of Notes to entities affiliated with Domain Associates LLC and TPG Biotech, which beneficially owned more than 5% of Adynxx&#8217;s capital stock at the time of such issuance. The Notes accrued simple interest on the outstanding principal amount at a rate of 8.0% per annum. The Notes converted into 367,041 shares of our common stock upon the closing of the Merger. </div>

        <table style="width:456pt;height:38.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:348.67pt;">
              <div style="white-space:nowrap;">Purchaser </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Aggregate Principal Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:348.67pt;text-align:left;">
              <div style="white-space:nowrap;">Entities affiliated with Domain Associates LLC<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:24.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,350,000</td>
            <td style="padding:0pt;padding-left:24.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:348.67pt;text-align:left;">
              <div style="white-space:nowrap;">TPG Biotechnology Partners IV, L.P. </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:24.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">650,000</td>
            <td style="padding:0pt;padding-left:24.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Mr.&#160;Podlesak and Dr.&#160;Weber, each a member of our board of directors, are Partners with Domain Associates LLC. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">From December&#160;2018 to May&#160;2019, Private Adynxx issued $5.5&#160;million aggregate principal amount of Notes, and in July 2019 and August 2019, we issued $0.85&#160;million aggregate principal amount of Notes, in each case to entities affiliated with Domain Associates LLC, which beneficially owned more than 5% of Adynxx&#8217;s capital stock at the time of such issuance. The Notes accrue simple interest on the outstanding principal amount at a rate of 8.0% per annum and mature on the first anniversary of the applicable issuance date. The Notes have conversion and repayment options as follows: </div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event that we issue and sell shares of our preferred stock or common stock to investors in a qualified financing with total proceeds to us of not less than $5.0&#160;million, excluding conversion of the Notes, then the outstanding principal amount of the Notes and any unpaid accrued interest will automatically convert in whole into equity securities sold in the qualified financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the qualified financing; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if we consummate a change of control while the Notes remain outstanding, we will repay the holders in cash in an amount equal to 200% of the outstanding principal amount of the Notes, plus any unpaid accrued interest on the original principal. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of September&#160;30, 2019, $6.35&#160;million aggregate principal amount remained outstanding under the Notes.</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">108</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The following table summarizes the issuances of Notes outstanding immediately prior to the offering held by entities Domain Associates LLC: </div>

          <table style="width:456pt;height:23.5pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:348.67pt;">
                <div style="white-space:nowrap;">Purchaser </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Aggregate Principal Amount </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 2.5pt 0pt; width:348.67pt;text-align:left;">
                <div style="white-space:nowrap;">Entities affiliated with Domain Associates LLC<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:24.96pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6,350,000</td>
              <td style="padding:0pt;padding-left:24.96pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:6.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Mr.&#160;Podlesak and Dr.&#160;Weber, each a member of our board of directors, are Partners with Domain Associates LLC.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Employment Arrangements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have entered into offer letters with our executive officers. For more information regarding these offer letters, see &#8220;Executive Compensation of Adynxx&#8201;&#8212;&#8201;Employment Arrangements.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Alliqua </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Separation Agreements </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;">Brian Posner </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with his resignation as Alliqua&#8217;s Chief Financial Officer, in March&#160;2018, Alliqua and Brian Posner entered into a general release and severance agreement, or the Separation Agreement. Pursuant to the Separation Agreement, Mr.&#160;Posner released Alliqua from any and all claims. In consideration of the Separation Agreement and his general release of claims, Mr.&#160;Posner was entitled to (i)&#160;his 2017 performance bonus in the amount of&#8201;$118,310 (less applicable taxes and other withholdings) and (ii) severance pay in an amount equal to his base salary for 12&#160;months, less applicable taxes and other withholdings. Stock options and restricted stock previously granted to Mr.&#160;Posner remain outstanding, and his stock options are fully vested and remain exercisable until the earlier of April 2020 or the end of the applicable stock option&#8217;s term. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;">David Johnson </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr. Johnson&#8217;s service as Chief Executive Officer was terminated without cause immediately prior to the consummation of the Merger. For more information regarding his separation arrangements, see &#8220;Executive Compensation of Alliqua&#8201;&#8212;&#8201;Employment Arrangements&#8201;&#8212;&#8201;David Johnson.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Private Placement </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On February&#160;27, 2017, Alliqua closed a private placement of 923,333 shares of common stock at a purchase price of&#8201;$3.00 per share, for gross proceeds of&#8201;$2,770,000. Celgene Corporation, or Celgene, which beneficially owned more than 5% of Alliqua&#8217;s common stock at the time of the closing, purchased 4,000,000 shares of common stock for a purchase price of&#8201;$2,000,000, and Dr.&#160;Zeldis, the former chairman of Alliqua&#8217;s board of directors, purchased 66,666 shares of common stock for a purchase price of&#8201;$200,000 in the private placement. Additional shares of common stock were issuable to Celgene and Dr.&#160;Zeldis pursuant to the &#8220;most favored nation&#8221; provision in the securities purchase agreement entered into in the private placement, or the Securities Purchase Agreement, which issuance was subject to stockholder approval as may be required by the applicable rules and regulations of Nasdaq. Following approval at the 2017 annual meeting of stockholders, Alliqua issued 117,287 additional shares of common stock to Celgene and 16,666 additional shares of common stock to Dr.&#160;Zeldis, in each case, pursuant to the &#8220;most favored nation&#8221; provision in the Securities Purchase Agreement. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Perceptive Credit Agreement and Warrant </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In May&#160;2015, Alliqua and each of its subsidiaries entered into a credit agreement, or the Credit Agreement, with Perceptive Credit Opportunities Fund, L.P., or Perceptive, an affiliate of Perceptive Advisors, LLC, which beneficially owned more than 5% of our common stock. The Credit Agreement provided for a $15.5&#160;million senior secured term loan. The Credit Agreement had a four year term, accrued interest at an annual rate equal to the greater of&#8201;(a) one-month LIBOR or 1% plus (b)&#160;9.75%, provided for interest-only payments for the first 24&#160;months, followed by monthly amortization payments of&#8201; $225,000, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">109</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">with the remaining unpaid balance due on the maturity date, and was secured by a first priority lien on substantially all of our assets. In May&#160;2018, Alliqua fully repaid the amounts outstanding under the Credit Agreement and terminated the Credit Agreement in connection with the sale of substantially all of its assets to Celularity, Inc. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with the entry into the Credit Agreement, a five-year warrant, or the Warrant, to purchase 12,500 shares of Alliqua common stock at an exercise price of&#8201;&#8201;$330.828 per share, was issued to Perceptive. Alliqua granted Perceptive customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon exercise of the Warrant. In June&#160;2017, Alliqua amended the Warrant to be exercisable for 35,000 shares of common stock at an exercise price of&#8201;&#8201;$28.20 per share. Perceptive will not have the right to exercise the warrant to the extent that after giving effect to such exercise, Perceptive would beneficially own in excess of 9.99% of the common stock outstanding immediately after giving effect to such exercise. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Manufacturing Supply Agreement </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mark Wagner, a former member of Alliqua&#8217;s board of directors, is a director of Minnetronix, Inc. In November&#160;2015, Alliqua entered into a manufacturing supply agreement with Minnetronix, pursuant to which Minnetronix agreed to perform manufacturing and other services in exchange for certain fees and expenses, with such amounts being variable and contingent on various factors. During 2017, Alliqua incurred costs of&#8201; $412,000 under the manufacturing supply agreement. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Related Party Transaction Policy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although Adynxx did not have a written policy for the review and approval of transactions with related persons, its board of directors historically reviewed and approved any transaction where a director or officer had a financial interest, including the transactions described above. Prior to approving such a transaction, the material facts as to a director or officer&#8217;s relationship or interest in the agreement or transaction were disclosed to the board of directors. Adynxx&#8217;s board of directors took this information into account when evaluating the transaction and in determining whether such transaction was fair to the company and in the best interest of all its stockholders. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Alliqua had adopted, and we have assumed, a formal written policy that its executive officers, directors, holders of more than 5% of any class of our voting securities, and any member of the immediate family of and any entity affiliated with any of the foregoing persons, will not be permitted to enter into a related party transaction with us without the prior consent of our audit committee, or other independent members of our board of directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. Any request for Alliqua to enter into a transaction with an executive officer, director, principal stockholder, or any of their immediate family members or affiliates, in which the amount involved exceeds the lesser of&#8201; $120,000 or 1% of its average total assets at year end for the last two completed fiscal&#160;years must first be presented to the audit committee for review, consideration and approval. In approving or rejecting any such proposal, the audit committee will consider the relevant facts and circumstances available and deemed relevant to the audit committee, including, but not limited to, whether the transaction will be on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related party&#8217;s interest in the transaction. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Indemnification Agreements </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our amended certificate of incorporation contains provisions limiting the liability of directors, and our bylaws provide that we will indemnify the directors and executive officers to the fullest extent permitted under Delaware law. Our amended certificate of incorporation and bylaws will also provide the board of directors with discretion to indemnify the other officers, employees, and agents when determined appropriate by the board of directors. In addition, we have entered into an indemnification agreement with each of our directors and executive officers, which requires us to indemnify them. For more information regarding these agreements, see &#8220;Description of Capital Stock&#8201;&#8212;&#8201;Limitation on Liability and Indemnification of Directors and Officers.&#8221;</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">110</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPSS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PRINCIPAL STOCKHOLDERS </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table sets forth information regarding the beneficial ownership of shares of our common stock as of September&#160;30, 2019: </div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">each of our current executive officers; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">each of our current directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">all of our current executive officers and directors as a group. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have determined beneficial ownership in accordance with the rules of the SEC and therefore it represents sole or shared voting or investment power with respect to our securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable. We have deemed shares of common stock subject to options that are currently exercisable or exercisable within 60&#160;days of September&#160;30, 2019, to be outstanding and to be beneficially owned by the person holding the option for the purpose of computing the&#160;percentage ownership of that person but have not treated them as outstanding for the purpose of computing the&#160;percentage ownership of any other person. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have based&#160;percentage ownership of common stock before this offering on  5,807,877 shares of common stock outstanding as of September&#160;30, 2019. Percentage ownership of common stock following this offering assumes (i)&#160;the sale of 7,500,000 shares of common stock in this offering, (ii) the issuance of 4,874,744&#160;shares of common stock at the closing of the offering upon the conversion of convertible promissory notes in the aggregate principal amount of&#8201; $6.35&#160;million, plus accrued but unpaid interest, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the last reported sale price of our common stock as reported by OTCQB on October 9, 2019, provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG, and (iii)&#160;no exercise of the common warrants or the placement agent warrants or sale of any pre-funded warrants.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Domain and TPG have indicated an interest in purchasing up to an aggregate of&#8201; $4.25&#160;million of securities in this offering at the public offering price per share of common stock and accompanying common warrant or pre-funded warrant and accompanying common warrant, as the case may be. However, because indications of interest are not binding agreements or commitments to purchase, either of Domain or TPG may elect to purchase more, fewer or no securities in this offering or the placement agent may elect to sell more, fewer or no securities in this offering to either of Domain or TPG. The placement agent will receive the same fee from the sale of any of our securities to Domain or TPG as it will from any other of our securities sold to the public in this offering. Any securities purchased by Domain or TPG in this offering will not be subject to the lock-up agreements with the placement agent that are described below.</div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o&#160;Adynxx, Inc., 100 Pine Street, Suite 500, San Francisco, California 94111. </div>

          <table style="width:456pt;height:123pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">Shares Beneficially <br >Owned Prior to this<br >Offering </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">Shares Beneficially<br >Owned Following this<br >Offering </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:213pt;text-align:left;">
                <div style="white-space:nowrap;">Name of Beneficial Owner </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Shares </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">% </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Shares </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">% </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">5% Shareholder</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">
                <div style="margin-left:10pt;">Entities Affiliated with Domain Associates<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
              </td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,058,571</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">52.7<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">7,933,315</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">43.6<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">
                <div style="margin-left:10pt;">TPG Biotechnology Partners IV, L.P.<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
              </td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,112,290</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">19.2</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,112,290</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.1</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">Executive Officers and Directors</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">
                <div style="margin-left:10pt;">Rick Orr<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3)</font></div>
              </td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">238,166</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.0</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">238,166</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.3</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">
                <div style="margin-left:10pt;">Donald Manning, M.D., Ph.D.<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(4)</font></div>
              </td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">92,092</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.6</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">92,092</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">111</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <table style="width:462pt;height:149pt;margin-top:0pt;border-collapse: collapse;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">Shares Beneficially<br >Owned Prior to this<br >Offering </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">Shares Beneficially<br >Owned Following this<br >Offering </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:213pt;text-align:left;">
                <div style="white-space:nowrap;">Name of Beneficial Owner </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Shares </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">% </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Shares </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">% </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 1pt 0pt; width:213pt;text-align:left;">
                <div style="margin-left:10pt;">Julien Mamet, Ph.D.<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(5)</font></div>
              </td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">398,635</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.7</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">398,635</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2.2</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:213pt;text-align:left;">
                <div style="margin-left:10pt;">Dennis Podlesak<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(6)</font></div>
              </td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">141,529</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.4</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">141,529</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:213pt;text-align:left;">
                <div style="margin-left:10pt;">Eckard Weber<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(7)</font></div>
              </td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">141,529</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.4</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">141,529</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:213pt;text-align:left;">
                <div style="margin-left:10pt;">Stan Abel<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(8)</font></div>
              </td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">82,254</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.4</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">82,254</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:213pt;text-align:left;">
                <div style="margin-left:10pt;">Gregory Flesher</div>
              </td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:213pt;text-align:left;">
                <div style="margin-left:10pt;">Matthew Ruth </div>
              </td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:1.667pt 0pt 1pt 0pt; width:213pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">All current executive officers and directors as a group (8&#160;persons)<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(9)</font></div>
              </td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:1.667pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.667pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,094,205</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:1.667pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.667pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">17.4</td>
              <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:1.667pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.667pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,094,205</td>
              <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:1.667pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.667pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">5.9</td>
              <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt; width:3pt;">&#8203;</td>
              <td style="padding:0pt 0.5pt 0.5pt 0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" margin-top:8.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents beneficial ownership of less than one&#160;percent. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
          <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Consists of&#8201;(i) 3,036,044 shares held of record by Domain Partners VIII, L.P. (&#8220;DP VIII) and (ii)&#160;22,527 shares held of record by DP VIII Associates, L.P. (&#8220;DP VIII A&#8221;). The sole general partner of DP VIII and DP VIII A is One Palmer Square Associates VIII, LLC, a Delaware limited liability company (&#8220;OPSA VIII&#8221;). The principal business of OPSA VIII is that of acting as the general partner of DP VIII and DP VIII A. James C. Blair, Jesse I. Treu, Brian H. Dovey, Brian K. Halak, and Nicole Vitullo are the managing members of OPSA VIII. The principal business address of each of the entities in this footnote 1 is c/o&#160;Domain Associates, LLC, 202 Carnegie Center, Suite 104, Princeton, NJ 08540. The share amounts and percentage set forth under the column &#8220;Shares Beneficially Owned Following this Offering&#8221; include 4,874,744 shares of common stock to be issued at the closing of this offering  upon the conversion of convertible promissory notes in the aggregate principal amount of $6.35&#160;million, plus accrued but unpaid interest, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the last reported sale price of our common stock as reported by OTCQB on October 9, 2019, provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">TPG Group Holdings (SBS) Advisors, Inc. (&#8220;TPG Group Advisors&#8221;) is the is the sole member of TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG Group Holdings (SBS), L.P., a Delaware limited partnership, which is the sole member of TPG Holdings I-A, LLC, a Delaware limited liability company, which is the general partner of TPG Holdings I, L.P., a Delaware limited partnership, which is the sole member of TPG Biotechnology GenPar IV Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG Biotechnology GenPar IV, L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology Partners IV, L.P., a Delaware limited partnership (&#8220;TPG Biotech IV&#8221;). Because of the relationship of TPG Group Advisors to TPG Biotech IV, TPG Group Advisors may be deemed to beneficially own the shares of common stock held by TPG Biotech IV. David Bonderman and James G. Coulter are sole shareholders of TPG Group Advisors. Because of the relationship of Messrs. Bonderman and Coulter to TPG Group Advisors, each of Messrs. Bonderman and Coulter may be deemed to beneficially own the shares of common stock held by TPG Biotech IV. Messrs. Bonderman and Coulter disclaim beneficial ownership of the shares of common stock held by TPG Biotech IV except to the extent of their pecuniary interest therein. The principal business address of each of the entities in this footnote 2 is c/o&#160;TPG Global, LLC, 301 Commerce Street, Suite 3300, Fort Worth, Texas 76102. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents (i)&#160;142,090 shares of common stock and (ii) 96,076 shares of common stock issuable pursuant to immediately exercisable options, including 70,234 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
          <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Consists of 92,092 shares of common stock issuable pursuant to immediately exercisable options, including 76,816 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">112</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">

          <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
          <div style=" line-height:12pt; text-align:left; margin-left:20pt;">Represents (i)&#160;240,454 shares of common stock and (ii) 158,181 shares of common stock issuable pursuant to immediately exercisable options, including 115,350 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents (i)&#160;85,254 shares of common stock and (ii) 56,275 shares of common stock issuable pursuant to immediately exercisable options, including 41,141 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(7)<br ></div>
          <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents of&#8201; (i)&#160;85,254 shares of common stock held of record by Eckard Weber Living Trust and (ii)&#160;  56,275 shares of common stock issuable pursuant to immediately exercisable options, including 41,141 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. Mr.&#160;Weber is the sole trustee of the Eckard Weber Living Trust and holds sole voting and dispositive power over these shares. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(8)<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents (i)&#160;54,117 shares of common stock and (ii) 28,137 shares of common stock issuable pursuant to immediately exercisable options, including 20,570 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(9)<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Includes (i)&#160;607,169 shares of common stock and (ii) 487,036 shares of common stock issuable pursuant to immediately exercisable options, including 365,252 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">113</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDCS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DESCRIPTION OF CAPITAL STOCK </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">The description below of our capital stock and provisions of our amended certificate of incorporation and bylaws are summaries and are qualified by reference to the amended certificate of incorporation and the bylaws filed as exhibits to the registration statement of which this prospectus is part, and by the applicable provisions of Delaware law. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Capital Stock </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have authorized 96,000,000 shares of capital stock, par value $0.001 per share, of which 95,000,000 are common stock and 1,000,000 are preferred stock. As of June 30, 2019, there were 5,807,877 shares of common stock issued and outstanding, held by 262 stockholders of record, and no shares of preferred stock issued and outstanding. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Common Stock </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The holders of our common stock are entitled to one vote per share. Our certificate of incorporation does not provide for cumulative voting. The holders of our common stock are entitled to take any action that may be taken at an annual or special meeting of stockholders through a consent in writing, setting forth the action taken and signed by the holders of outstanding stock of at least the minimum number of votes that would be necessary to authorize or take such action at a meeting of stockholders. The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by our board of directors out of legally available funds; however, the current policy of our board of directors is to retain earnings, if any, for operations and growth. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all assets that are legally available for distribution. The holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated solely by action of our board of directors and issued in the future. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our common stock is presently quoted on OTCQB under the symbol &#8220;ADYX.&#8221; In June 2019, Nasdaq delisted our common stock due to our noncompliance with Nasdaq&#8217;s minimum stockholders&#8217; equity requirement and minimum round lot shareholder requirement. We do not intend to list the common stock on a national securities exchange in connection with this offering.</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Preferred Stock </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our board of directors is authorized, subject to any limitations prescribed by law, without further vote or action by our stockholders, to issue from time to time shares of preferred stock in one or more series and, as to each series, to establish the number of shares to be included in each such series, and to fix the designations, preferences, voting powers, qualifications, and special or relative rights or privileges of the shares in each such series, which may include, among others, dividend rights, voting rights, liquidation preferences, conversion rights and preemptive rights. Issuance of preferred stock by our board of directors could result in such shares having dividend or liquidation preferences senior to the rights of the holders of our common stock and could dilute the voting rights of the holders of our common stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to the issuance of shares of each series of preferred stock, our board of directors is required by the DGCL and our certificate of incorporation to adopt resolutions and file a certificate of designation with the Secretary of State of the State of Delaware. The certificate of designation fixes for each class or series the designations, powers, preferences, rights, qualifications, limitations and restrictions, including, but not limited to, some or all of the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the number of shares constituting that series and the distinctive designation of that series, which number may be increased or decreased (but not below the number of shares then outstanding) from time to time by action of the board of directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the dividend rate and the manner and frequency of payment of dividends on the shares of that series, whether dividends will be cumulative, and, if so, from which date; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">114</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">whether that series will have voting rights, in addition to any voting rights provided by law, and, if so, the terms of such voting rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the terms and conditions of any conversion privilege of the series, including provision for adjustment of the conversion rate in such events as the board of directors may determine; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">whether or not the shares of that series will be redeemable, and, if so, the terms and conditions of such redemption; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">whether that series will have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of such sinking fund; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">whether or not the shares of that series will have priority over, be on a parity with or be junior to the shares of any other series or class in any respect; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the rights of the shares of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of the corporation, and the relative rights or priority, if any, of payment of shares of that series; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any other relative rights, preferences and limitations of that series. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although our board of directors has no intention at the present time of doing so, it could authorize the issuance of a series of preferred stock that could, depending on the terms of such series, impede the completion of a merger, tender offer or other takeover attempt. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Delaware Anti-Takeover Law </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are subject to Section&#160;203 of the Delaware General Corporation Law. Section&#160;203 generally prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three&#160;years after the date of the transaction in which the person became an interested stockholder, unless: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (i)&#160;shares owned by persons who are directors and also officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66<font style=" position:relative; bottom:2.66pt;font-size:7pt;">2</font>&#8725;<font style="font-size:7pt;">3</font>% of the outstanding voting stock which is not owned by the interested stockholder. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Section&#160;203 defines a business combination to include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any merger or consolidation involving the corporation and the interested stockholder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with, or controlling, or controlled by, the entity or person. The term &#8220;owner&#8221; is broadly defined to include any </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">115</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">person that, individually, with or through that person&#8217;s affiliates or associates, among other things, beneficially owns the stock, or has the right to acquire the stock, whether or not the right is immediately exercisable, under any agreement or understanding or upon the exercise of warrants or options or otherwise or has the right to vote the stock under any agreement or understanding, or has an agreement or understanding with the beneficial owner of the stock for the purpose of acquiring, holding, voting or disposing of the stock. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The restrictions in Section&#160;203 do not apply to corporations that have elected, in the manner provided in Section&#160;203, not to be subject to Section&#160;203 of the Delaware General Corporation Law or, with certain exceptions, which do not have a class of voting stock that is listed on a national securities exchange or held of record by more than 2,000 stockholders. Our certificate of incorporation and bylaws do not opt out of Section&#160;203. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Section&#160;203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Certificate of Incorporation and Bylaws </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Provisions of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which shareholders might otherwise receive a premium for their shares, or transactions that our shareholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our certificate of incorporation and bylaws: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">permit our board of directors to issue up to 1,000,000 shares of preferred stock, without further action by the shareholders, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">provide that the authorized number of directors may be changed only by resolution of the board of directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">provide that special meetings of our shareholders may be called only by our board of directors; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">set forth an advance notice procedure with regard to the nomination, other than by or at the direction of our board of directors, of candidates for election as directors and with regard to business to be brought before a meeting of shareholders. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Choice of Forum </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for: (i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action asserting a breach of fiduciary duty owed by any director, officer or other employee to us or our stockholders; (iii)&#160;any action asserting a claim against us or any director or officer or other employee arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or bylaws; (iv)&#160;any action asserting a claim against us or any director or officer or other employee that is governed by the internal affairs doctrine or (v)&#160;to the maximum extent permitted by law, any other claim or dispute. This exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">116</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, jurisdiction over which is exclusively vested by statute in the U.S. federal courts.</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Limitations on Liability and Indemnification of Officers and Directors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our certificate of incorporation contains a provision permitted under the DGCL relating to the liability of directors. This provision eliminates a director&#8217;s personal liability to the fullest extent permitted by the DGCL for monetary damages resulting from a breach of fiduciary duty; provided that such provision will not eliminate or limit a director&#8217;s liability for: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any breach of the director&#8217;s duty of loyalty; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of the law; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Section&#160;174 of the DGCL (unlawful dividends); or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any transaction from which the director derives an improper personal benefit. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The principal effect of the limitation on liability provision is that a stockholder is unable to prosecute an action for monetary damages against a director unless the stockholder can demonstrate a basis for liability for which indemnification is not available under the DGCL. This provision, however, should not limit or eliminate our rights or any stockholder&#8217;s rights to seek non-monetary relief, such as an injunction or rescission, in the event of a breach of a director&#8217;s fiduciary duty. This provision does not alter a director&#8217;s liability under federal securities laws. The inclusion of this provision in our certificate of incorporation may discourage or deter stockholders or management from bringing a lawsuit against directors for a breach of their fiduciary duties, even though such an action, if successful, might otherwise have benefited us and our stockholders. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our certificate of incorporation and bylaws provide that we are required to indemnify our directors and officers, to the fullest extent permitted by law, subject to any permissible expansion or limitation of such indemnification, as may be set forth in any stockholders&#8217; or directors&#8217; resolution or by contract. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have entered into indemnification agreements and employment agreements with our directors and certain of our executive officers, respectively, pursuant to which we have agreed to indemnify such persons against any liability, damage, cost or expense incurred in connection with the defense of any action, suit or proceeding to which such persons are a party to the extent permitted by applicable law, subject to certain exceptions. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">117</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDSO">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DESCRIPTION OF SECURITIES WE ARE OFFERING </div>

          <div style="text-indent:20pt; margin-top:4.61pt; width:456pt; line-height:12pt;">We are offering 7,500,000 shares of our common stock and/or pre-funded warrants and accompanying common warrants to purchase up to 7,500,000 shares of our common stock. The shares of common stock, pre-funded warrants, and accompanying common warrants will be issued separately. We are also registering the shares of common stock issuable from time to time upon exercise of the pre-funded warrants and common warrants offered hereby. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Common Stock </div>

          <div style="text-indent:20pt; margin-top:4.62pt; width:456pt; line-height:12pt;">The material terms and provisions of our common stock and each other class of our securities which qualifies or limits our common stock are described under the caption &#8220;Description of Capital Stock&#8221; in this prospectus.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Pre Funded Warrants</div>


          <div style="text-indent:20pt; margin-top:4.61pt; width:456pt; line-height:12pt;font-style:italic;">The following summary of certain terms and provisions of pre-funded warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the pre-funded warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of pre-funded warrant for a complete description of the terms and conditions of the pre-funded warrants.</div>


          <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Duration and Exercise Price.</font>&nbsp;&nbsp;&nbsp;Each pre-funded warrant offered hereby will have an initial exercise price per share equal to $0.01. The pre-funded warrants will be immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price.</div>


          <div style="text-indent:20pt; margin-top:5.62pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Exercisability.</font>&nbsp;&nbsp;&nbsp;The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the pre-funded warrant to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61&#160;days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s pre-funded warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such&#160;percentage ownership is determined in accordance with the terms of the pre-funded warrants. Purchasers of pre-funded warrants in this offering may also elect prior to the issuance of the pre-funded warrants to have the initial exercise limitation set at 9.99% of our outstanding common stock. No fractional shares of common stock will be issued in connection with the exercise of a pre-funded warrant. In lieu of fractional shares, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share.</div>


          <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Cashless Exercise.</font>&nbsp;&nbsp;&nbsp;If, at the time a holder exercises its pre-funded warrants, a registration statement registering the issuance of the shares of common stock underlying the pre-funded warrants under the Securities Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the pre-funded warrants.</div>


          <div style="text-indent:20pt; margin-top:5.62pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Transferability.</font>&nbsp;&nbsp;&nbsp;Subject to applicable laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrant to us together with the appropriate instruments of transfer.</div>


          <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Exchange Listing.</font>&nbsp;&nbsp;&nbsp;There is no trading market available for the pre-funded warrants on any securities exchange or nationally recognized trading system. We do not intend to list the pre-funded warrants on any securities exchange or nationally recognized trading system.</div>


          <div style="text-indent:20pt; margin-top:5.42pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Right as a Stockholder.</font>&nbsp;&nbsp;&nbsp;Except as otherwise provided in the pre-funded warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holders of the pre-funded warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their pre-funded warrants.</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">118</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="text-indent:20pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Fundamental Transaction.</font>&nbsp;&nbsp;&nbsp;In the event of a fundamental transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction.</div>


          <div style="margin-top:11.02pt; width:456pt; line-height:11pt;font-weight:bold;">Common Warrants</div>


          <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;font-style:italic;">The following summary of certain terms and provisions of common warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the common warrants, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of common warrant for a complete description of the terms and conditions of the common warrants.</div>


          <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Duration and Exercise Price.</font>&nbsp;&nbsp;&nbsp;Each common warrant offered hereby will have an initial exercise price per share equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The common warrants will be immediately exercisable and will expire on the fifth anniversary of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. The common warrants will be issued separately from the common stock, and may be transferred separately immediately thereafter. A common warrant to purchase one share of our common stock will be issued for every one share of common stock or pre-funded warrant purchased in this offering. </div>


          <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Exercisability.</font>&nbsp;&nbsp;&nbsp;The common warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s common warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants. Purchasers in this offering may also elect prior to the issuance of the common warrants to have the initial exercise limitation set at 9.99% of our outstanding common stock. No fractional shares of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share.</div>


          <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Cashless Exercise.</font>&nbsp;&nbsp;&nbsp;If, at the time a holder exercises its common warrants, a registration statement registering the issuance of the shares of common stock underlying the common warrants under the Securities Act is not then effective or available and an exemption from registration under the Securities Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the common warrants.</div>


          <div style="text-indent:20pt; margin-top:5.01pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Transferability.</font>&nbsp;&nbsp;&nbsp;Subject to applicable laws, a common warrant may be transferred at the option of the holder upon surrender of the common warrant to us together with the appropriate instruments of transfer.</div>


          <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Exchange Listing.</font>&nbsp;&nbsp;&nbsp;There is no trading market available for the common warrants on any securities exchange or nationally recognized trading system. We do not intend to list the common warrants on any securities exchange or nationally recognized trading system.</div>


          <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Right as a Stockholder.</font>&nbsp;&nbsp;&nbsp;Except as otherwise provided in the common warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holders of the common warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their common warrants.</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">119</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">

          <div style="text-indent:20pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Fundamental Transaction.</font>&nbsp;&nbsp;&nbsp;In the event of a fundamental transaction, as described in the common warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the common warrants will be entitled to receive upon exercise of the common warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the common warrants immediately prior to such fundamental transaction. Notwithstanding the foregoing, in the event of a fundamental transaction, the holders will have the option, which may be exercised within 30 days after the consummation of the fundamental transaction, to require us or our successor entity to purchase the common warrants from the holder by paying to the holder an amount of cash equal to the Black Scholes value of the remaining unexercised portion of the common warrant on the date of the consummation of the fundamental transaction. However, if the fundamental transaction is not within our control, including not approved by our board of directors, the holder will only be entitled to receive from us or our successor entity, as of the date of consummation of such fundamental transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes value of the unexercised portion of the common warrant, that is being offered and paid to the holders of common stock in connection with the fundamental transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of common stock are given the choice to receive from among alternative forms of consideration in connection with the fundamental transaction.</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">120</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAT">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following is a general discussion of the material U.S. federal income tax considerations of the purchase, ownership and disposition of shares of our common stock issued pursuant to this offering, or Shares, the purchase, exercise, disposition and lapse of warrants to purchase shares of our common stock issued pursuant to this offering, or Common Warrants, and the purchase, ownership and disposition of shares of our common stock issuable upon exercise of the Common Warrants, or Warrant Shares, and the purchase, ownership and disposition of pre-funded warrants to purchase shares of our common stock issued pursuant to this offering, or Pre-Funded Warrants. The Shares, the Common Warrants, the Warrant Shares  and the Pre-Funded Warrants are collectively referred to herein as our &#8220;securities.&#8221; The foregoing defined terms only apply to this section and not in other sections of this prospectus. All prospective holders of our securities should consult their tax advisors with respect to the U.S. federal, state, local and non-U.S. tax consequences of the purchase, ownership and disposition of our securities.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating to the purchase, ownership and disposition of our securities. This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing U.S. Treasury Regulations promulgated thereunder, published administrative pronouncements and rulings of the U.S. Internal Revenue Service, or the IRS, and judicial decisions, all as in effect as of the date of this prospectus. These authorities are subject to change and to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the tax consequences to holders described in this discussion. There can be no assurance that a court or the IRS will not challenge one or more of the tax consequences described herein, and we have not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax consequences to a holder of the purchase, ownership or disposition of our securities.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We assume in this discussion that a holder holds our securities as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular holder in light of that holder&#8217;s individual circumstances, nor does it address any alternative minimum, Medicare contribution, estate or gift tax consequences, or any aspects of U.S. state, local or non-U.S. taxes or any other U.S. federal tax laws. This discussion also does not address consequences relevant to holders subject to special tax rules, such as holders that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below), corporations that accumulate earnings to avoid U.S. federal income tax, tax-exempt organizations, governmental organizations, banks, financial institutions, investment funds, insurance companies, brokers, dealers or traders in securities, commodities or currencies, tax-qualified retirement plans, holders who hold or receive our securities pursuant to the exercise of employee stock options or otherwise as compensation, holders holding our securities as part of a hedge, straddle or other risk reduction strategy, conversion transaction or other integrated investment, holders deemed to sell our securities under the constructive sale provisions of the Code, holders subject to special tax accounting rules under Section&#160;451(b) of the Code, controlled foreign corporations, passive foreign investment companies and certain former U.S. citizens or long-term residents.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, this discussion does not address the tax treatment of partnerships (or entities or arrangements that are treated as partnerships or disregarded entities for U.S. federal income tax purposes) or persons that hold our securities through such partnerships. If a partnership, including any entity or arrangement treated as a partnership for U.S. federal income tax purposes, holds our securities, the U.S. federal income tax treatment of a partner in such partnership will generally depend upon the status of the partner and the activities of the partnership. Such partners and partnerships should consult their tax advisors regarding the tax consequences of the purchase, ownership and disposition of our securities.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Treatment of Pre-Funded Warrants</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although it is not entirely free from doubt, we believe a Pre-Funded Warrant should be treated as a Share for U.S. federal income tax purposes and a holder of Pre-Funded Warrants should generally be taxed in the same manner as a holder of Shares, as described below. Accordingly, no gain or loss should be recognized upon the exercise of a Pre-Funded Warrant and, upon exercise, the holding period of a Pre-Funded Warrant should carry over to the Share received. Similarly, the tax basis of the Pre-Funded Warrant should carry over to the Share received upon exercise, increased by the exercise price of&#8201; $0.01 per </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">121</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">share. However, our characterization is not binding on the IRS, and the IRS may treat our Pre-Funded Warrants as warrants to acquire our common stock. If so, the amount and character of your gain with respect to an investment in our Pre-Funded Warrants could change. Accordingly, each holder should consult his, her or its own tax advisor regarding the risks associated with the acquisition of Pre-Funded Warrant pursuant to this offering (including potential alternative characterizations). The balance of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax purposes.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Allocation of Purchase Price</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For U.S. federal income tax purposes, the purchase of Shares and the associated Common Warrants or Pre-Funded Warrants and the associated Common Warrant in this offering by holders should be treated for U.S. federal income tax purposes as an &#8220;investment unit&#8221; consisting of one Share and the associated Common Warrant or one Pre-Funded Warrant and the associated Common Warrant. Each holder must allocate its purchase price of such unit between each Share  or Pre-Funded Warrant, as applicable, and the Common Warrant based on their respective relative fair market values of each at the time of issuance. This allocation of the purchase price will establish the holder&#8217;s initial tax basis for U.S. federal income tax purposes for each Share, Pre-Funded Warrant and Common Warrant. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A holder&#8217;s allocation of the purchase price among the Shares, Pre-Funded Warrants and Common Warrants is not binding on the IRS or the courts, and no assurance can be given that the IRS or the courts will agree with a holder&#8217;s allocation. Each holder should consult its own tax advisor regarding the allocation of the purchase price among the Shares, Pre-Funded Warrants and Common Warrants. </div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Tax Considerations Applicable to U.S. Holders</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Definition of U.S. Holder</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In general, a &#8220;U.S. holder&#8221; means a beneficial owner of our securities (other than a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes) that is, for U.S. federal income tax purposes:</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">an individual who is a citizen or resident of the United States;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">a corporation, or an entity treated as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States or of any state thereof or the District of Columbia;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">a trust if&#8201; (a)&#160;a U.S. court can exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons have the authority to control all of the trust&#8217;s substantial decisions or (b)&#160;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Distributions on the Shares, the Warrant Shares or the Common Warrants</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As described in the section entitled &#8220;Dividend Policy,&#8221; we do not anticipate paying any future distributions on our common stock. However, if we do make distributions (including constructive distributions as described below) on the Shares, the Warrant Shares or the Common Warrants, such distributions will constitute dividends to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles, and will be includible in your income as ordinary income when received. However, with respect to dividends received by individuals, such dividends are generally taxed at the lower applicable long-term capital gains rates, provided certain holding period requirements are satisfied. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the U.S. holder&#8217;s investment, up to such U.S. holder&#8217;s adjusted tax basis in the Shares, the Warrant Shares or the Common Warrants, as applicable. Any remaining excess will be treated as capital gain from the sale or exchange of such Shares, Warrant Shares or Common Warrants, subject to the tax treatment described below in &#8220;&#8212;&#8201;Sale or Other Taxable Disposition of the Shares and Warrant Shares.&#8221;</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">122</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Sale or Other Taxable Disposition of the Shares and Warrant Shares</div>


          <div style="text-indent:20pt; margin-top:4.81pt; width:456pt; line-height:12pt;">Upon the sale, exchange or other taxable disposition of the Shares or Warrant Shares, a U.S. holder will generally recognize capital gain or loss equal to the difference between the amount of cash and the fair market value of any property received upon the sale, exchange or other taxable disposition and such U.S. holder&#8217;s adjusted tax basis in the Shares or Warrant Shares. This capital gain or loss will be long-term capital gain or loss if the U.S. holder&#8217;s holding period in such Shares or Warrant Shares is more than one year at the time of the sale, exchange or other taxable disposition. Long-term capital gains recognized by certain non-corporate U.S. holders, including individuals, generally will be subject to reduced rates of U.S. federal income tax. The deductibility of capital losses is subject to certain limitations.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Sale or Other Disposition or Exercise of Common Warrants</div>


          <div style="text-indent:20pt; margin-top:4.82pt; width:456pt; line-height:12pt;">Upon the sale or other disposition of a Common Warrant (other than by exercise), a U.S. holder will generally recognize capital gain or loss equal to the difference between the amount realized on the sale or other disposition and the U.S. holder&#8217;s tax basis in the Common Warrant. This capital gain or loss will be long-term capital gain or loss if the U.S. holder&#8217;s holding period in such Common Warrant is more than one year at the time of the sale or other disposition. The deductibility of capital losses is subject to certain limitations.</div>


          <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">A U.S. holder generally will not recognize gain or loss on the exercise of a Common Warrant and the related receipt of Warrant Shares (unless cash is received in lieu of the issuance of a fractional Warrant Share). A U.S. holder&#8217;s initial tax basis in a Warrant Share will be equal to the sum of&#8201; (a)&#160;such U.S. holder&#8217;s tax basis in the Common Warrant plus (2)&#160;the exercise price paid by such U.S. holder on the exercise of such Common Warrant. A U.S. holder&#8217;s holding period in a Warrant Share received on the exercise of a Common Warrant should begin on the day after the date that such Common Warrant is exercised by such U.S. holder. Although there is no direct legal authority as to the U.S. federal income tax treatment of an exercise of a warrant on a cashless basis, we intend to take the position that such exercise will not be taxable, either because the exercise is not a gain realization event or because it qualifies as a tax-free recapitalization. In the former case, the holding period of the Warrant Share should commence on the day after the Common Warrant is exercised. In the latter case, the holding period of the Warrant Share would include the holding period of the exercised Common Warrant. However, our position is not binding on the IRS, and the IRS may treat a cashless exercise of a Common Warrant as a taxable exchange. U.S. holders are urged to consult their tax advisors as to the consequences of an exercise of a Common Warrant on a cashless basis, including with respect to their holding period and tax basis in the Warrant Share.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Lapse of Common Warrants</div>


          <div style="text-indent:20pt; margin-top:4.61pt; width:456pt; line-height:12pt;">If a U.S. holder allows a Common Warrant to expire unexercised, such U.S. holder will recognize a capital loss in an amount equal to such holder&#8217;s tax basis in the Common Warrant. Because the term of the Common Warrants purchased in this offering is more than one year, the U.S. holder&#8217;s capital loss will be treated as a long-term capital loss. The deductibility of capital losses is subject to certain limitations.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Constructive Dividends on Common Warrants</div>


          <div style="text-indent:20pt; margin-top:4.62pt; width:456pt; line-height:12pt;">Under Section&#160;305 of the Code, an adjustment to the number of Warrant Shares that will be issued on the exercise of the Common Warrants, or an adjustment to the exercise price of the Common Warrants, may be treated as a constructive distribution to a U.S. holder of the Common Warrants if, and to the extent that, such adjustment has the effect of increasing such U.S. holder&#8217;s proportionate interest in our earnings and profits as determined under U.S. federal income tax principles or our assets, depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or other property to our shareholders).</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Backup Withholding and Information Reporting</div>


          <div style="text-indent:20pt; margin-top:4.61pt; width:456pt; line-height:12pt;">A U.S. holder may be subject to information reporting and backup withholding when such holder receives payments on our securities (including constructive dividends) or receives proceeds from the sale or other taxable disposition of our securities. Certain U.S. holders are exempt from backup withholding, including C corporations and certain tax-exempt organizations. A U.S. holder will be subject to backup withholding if such holder is not otherwise exempt and such holder:</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">123</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">fails to furnish the holder&#8217;s taxpayer identification number, which for an individual is ordinarily his or her social security number;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">furnishes an incorrect taxpayer identification number;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">is notified by the IRS that the holder previously failed to properly report payments of interest or dividends; or</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">fails to certify under penalties of perjury that the holder has furnished a correct taxpayer identification number and that the IRS has not notified the holder that the holder is subject to backup withholding.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a U.S. holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. U.S. holders should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Tax Considerations Applicable to Non-U.S. Holders</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Definition of non-U.S. Holder</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For purposes of this discussion, a &#8220;non-U.S. holder&#8221; is a beneficial owner of our securities that is neither a U.S. holder nor a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Exercise of Common Warrants</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A non-U.S. holder generally will not recognize gain or loss on the exercise of a Common Warrant and the related receipt of Warrant Shares (unless cash is received in lieu of the issuance of a fractional Warrant Share and certain other conditions are present, as discussed below under &#8220;&#8212;&#8201;Gain on Sale, Exchange or Other Taxable Disposition of Our Securities&#8221;). See &#8220;&#8212;&#8201;Tax Considerations Applicable to U.S. Holders&#8201;&#8212; Sale or Other Disposition or Exercise of Common Warrants.&#8221; However, if a cashless exercise of Common Warrants results in a taxable exchange, as described in &#8220;&#8212;&#8201;Tax Considerations Applicable to U.S. Holders&#8201;&#8212;&#8201;Sale or Other Disposition or Exercise of Common Warrants,&#8221; the rules described below under &#8220;Gain on Sale, Exchange or Other Taxable Disposition of Our Securities&#8221; would apply.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Lapse of Common Warrants</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If a non-U.S. holder allows a Common Warrant to expire unexercised, such non-U.S. holder will recognize a capital loss in an amount equal to such holder&#8217;s tax basis in the Common Warrant. See &#8220;&#8212;&#8201;Tax Considerations Applicable to U.S. Holders&#8201;&#8212;&#8201;Lapse of Common Warrants&#8221; above.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Constructive Dividends on the Common Warrants</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">See the discussion of the rules applicable to constructive distributions on a Common Warrant under the heading &#8220;&#8212;Tax Considerations Applicable to U.S. Holders&#8212;Constructive Dividends on Common Warrants&#8221; above. If an adjustment to the number of Warrant Shares that will be issued on the exercise of the Common Warrants, or an adjustment to the exercise price of the Common Warrants, results in a constructive distribution, as described in &#8220;&#8212;&#8201;Tax Considerations Applicable to U.S. Holders&#8201;&#8212; Constructive Dividends on Common Warrants,&#8221; the rules described below under &#8220;&#8201;Distributions on the Shares, the Warrant Shares or the Common Warrants&#8221; would apply.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Distributions on the Shares, the Warrant Shares or the Common Warrants</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we make distributions (including constructive distributions as described above) on the Shares, the Warrant Shares or the Common Warrants, such distributions will constitute dividends to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder&#8217;s investment, up to such non-U.S. holder&#8217;s adjusted tax</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">124</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">basis in the Shares, the Warrant Shares or the Common Warrants, as applicable. Any remaining excess will be treated as capital gain from the sale or exchange of such Shares, Warrant Shares or Common Warrants, subject to the tax treatment described below in &#8220;&#8212;&#8201;Gain on Sale, Exchange or Other Taxable Disposition of Our Securities.&#8221;</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Dividends paid to a non-U.S. holder will generally be subject to withholding of U.S. federal income tax at a 30% rate of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty between the United States and such non-U.S. holder&#8217;s country of residence for purposes of such treaty. In the case of any constructive dividend, it is possible that the U.S. federal tax on the constructive dividend would be withheld from Warrant Shares, sales proceed subsequently paid or credited, or other amounts payable or distributable to a non-U.S. holder.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Dividends that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States, are generally exempt from the 30% withholding tax if the non-U.S. holder satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code). Any U.S. effectively connected income received by a non-U.S. holder that is a corporation may also, under certain circumstances, be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such non-U.S. holder&#8217;s country of residence for purposes of such treaty.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">To claim a reduction or exemption from withholding, a non-U.S. holder generally will be required to provide (a) a properly executed IRS Form W-8BEN or IRS Form W-8BEN-E (or successor form) and satisfy applicable certification and other requirements to claim the benefit of an applicable income tax treaty between the United States and such non-U.S. holder&#8217;s country of residence, or (b)&#160;a properly executed IRS Form W-8ECI stating that dividends are not subject to withholding because they are effectively connected with such non-U.S. holder&#8217;s conduct of a trade or business within the United States. Non-U.S. holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Distributions will also be subject to the discussion below under the headings &#8220;&#8212;&#8201;Backup Withholding and Information Reporting&#8221; and &#8220;&#8212;&#8201;Foreign Accounts.&#8221;</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Gain on Sale, Exchange or Other Taxable Disposition of Our Securities</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Subject to the discussion below under the headings &#8220;&#8212;&#8201;Backup Withholding and Information Reporting&#8221; and &#8220;&#8212;&#8201;Foreign Accounts,&#8221; in general, a non-U.S. holder will not be subject to any U.S. federal income tax on any gain realized upon such non-U.S. holder&#8217;s sale, exchange or other taxable disposition of our securities unless:</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:3.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the gain is effectively connected with a U.S. trade or business of the non-U.S. holder and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed base maintained in the United States by such non-U.S. holder, in which case the non-U.S. holder generally will be taxed at the graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code) and, if the non-U.S. holder is a foreign corporation, the branch profits tax described above in &#8220;&#8212;&#8201;Distributions on the Shares, the Warrant Shares or the Common Warrants&#8221; also may apply;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the non-U.S. holder is a nonresident alien individual who is present in the United States for 183&#160;days or more in the taxable year of the disposition and certain other conditions are met, in which case the non-U.S. holder will be subject to a 30% U.S. federal income tax (or such lower rate as may be specified by an applicable income tax treaty) on the net gain derived from the disposition, which may be offset by U.S. source capital losses of the non-U.S. holder, if any (even though the individual is not considered a resident of the United States); or</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">125</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">we are, or have been, at any time during the five-year period preceding such disposition (or the non-U.S. holder&#8217;s holding period, if shorter) a &#8220;U.S. real property holding corporation&#8221; in which case such non-U.S. holder generally will be taxed on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code) and may be subject to withholding at a rate of 15%. Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. Even if we are or become a U.S. real property holding corporation, provided that our common stock is regularly traded, as defined by applicable U.S. Treasury Regulations, on an established securities market, the Shares and the Warrant Shares will be treated as a U.S. real property interest only with respect to a non-U.S. holder that holds more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the 5-year period ending on the date of the disposition or the period that the non-U.S. holder held the Shares or Warrant Shares, as applicable. There can be no assurance that our common stock will continue to qualify as regularly traded on an established securities market. Disposition by a non-U.S. holder of our Common Warrants (that are not expected to be regularly traded on an established securities market) may also be eligible for an exemption from withholding even if we are treated as a U.S. real property holding corporation, if on the date such Common Warrants were acquired by such non-U.S. holder such holdings had a fair market value no greater than the fair market value on that date of 5% of our regularly-traded common stock, provided that, if a non-U.S. holder holding our not-regularly-traded Common Warrants subsequently acquires additional Common Warrants, then such interests would be aggregated and valued as of the date of the subsequent acquisition to apply this 5% limitation.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Backup Withholding and Information Reporting</div>


          <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">We must report annually to the IRS and to each non-U.S. holder the gross amount of the dividends on our securities paid to such non-U.S. holder and the tax withheld, if any, with respect to such dividends. Non-U.S. holders will have to comply with specific certification procedures to establish that the holder is not a U.S. person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to any dividends on our securities. A non-U.S. holder generally will not be subject to U.S. backup withholding with respect to payments of dividends on our securities if it certifies its non-U.S. status by providing a valid IRS Form W-8BEN or IRS Form W-8BEN-E (or successor form) or IRS Form W-8ECI, or otherwise establishes an exemption; provided we do not have actual knowledge or reason to know such non-U.S. holder is a U.S. person, as defined in the Code. Dividends paid to non-U.S. holders subject to the U.S. withholding tax, as described above in &#8220;&#8212;&#8201;Distributions on the Shares, the Warrant Shares or the Common Warrants,&#8221; generally will be exempt from U.S. backup withholding.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Information reporting and backup withholding will generally apply to the proceeds of a disposition of our securities by a non-U.S. holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Copies of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is established under the provisions of a specific treaty or agreement.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder may be allowed as a credit against the non-U.S. holder&#8217;s U.S. federal income tax liability, if any, and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">126</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Foreign Accounts</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Code generally imposes a U.S. federal withholding tax of 30% on dividends and, subject to the discussion below regarding proposed regulations recently issued by the U.S. Treasury Department, the gross proceeds of a disposition of our securities paid to a &#8220;foreign financial institution&#8221; (as defined in the Code), unless such institution enters into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding accounts held by certain &#8220;specific United States persons&#8221; or &#8220;United States-owned foreign entities&#8221; (each as defined in the Code), or otherwise qualifies for an exemption from these rules. A U.S. federal withholding tax of 30% also applies to dividends and, subject to the discussion below regarding proposed regulations recently issued by the U.S. Treasury Department, will apply to the gross proceeds of a disposition of our securities paid to a &#8220;non-financial foreign entity&#8221; (as defined in the Code), unless such entity provides the withholding agent with either a certification that it does not have any substantial United States owners&#8221; (as defined in the Code), provides information regarding each substantial United States owners of the entity, or otherwise qualifies for an exemption from these rules. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of such taxes. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The withholding provisions described above currently apply to dividends paid on our securities. The U.S. Treasury Department recently released proposed regulations which, if finalized in their present form, would eliminate the U.S. federal withholding tax of 30% applicable to the gross proceeds of a sale or other disposition of our securities. In its preamble to such proposed regulations, the U.S. Treasury Department stated that taxpayers may generally rely on the proposed regulations until final regulations are issued.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE AND LOCAL AND NON-U.S. TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR SECURITIES, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS.</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">127</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PLAN OF DISTRIBUTION</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We engaged H.C. Wainwright &amp; Co., LLC, which we refer to as H.C. Wainwright or the placement agent, to act as our exclusive placement agent to solicit offers to purchase the securities offered by this prospectus. H.C. Wainwright is not purchasing or selling any securities, nor are they required to arrange for the purchase and sale of any specific number or dollar amount of securities, other than to use their &#8220;reasonable best efforts&#8221; to arrange for the sale of the securities by us. Therefore, we may not sell the entire amount of the securities being offered. There is no minimum amount of proceeds that is a condition to closing of this offering. We will enter into a securities purchase agreement directly with the institutional investors, at the investor&#8217;s option, which purchase our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering. H.C. Wainwright may engage one or more sub-placement agents or selected dealers to assist with the offering.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Domain and TPG have indicated an interest in purchasing up to an aggregate of&#8201; $4.25&#160;million of securities in this offering at the public offering price per share of common stock and accompanying common warrant or pre-funded warrant and accompanying common warrant, as the case may be. However, because indications of interest are not binding agreements or commitments to purchase, either of Domain or TPG may elect to purchase more, fewer or no securities in this offering or the placement agent may elect to sell more, fewer or no securities in this offering to either of Domain or TPG. As discussed in more detail below, the placement agent&#8217;s fees are partially dependent on the total amount of our securities that the placement agent sells in this offering to investors other than Domain or TPG. Any securities purchased by Domain or TPG in this offering will not be subject to the lock-up agreements with the placement agent that are described below.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Fees and Expenses</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table shows the placement agent fees we will pay in connection with the sale of the securities in this offering, assuming the purchase of all of the securities we are offering.</div>


          <table style="width:416pt;height:52pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:379pt;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">Per share of common stock and accompanying common warrant placement agent cash <br >fees  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:379pt;text-align:left;">
                <div style="margin-left:10pt;">Per pre-funded warrant and accompanying common warrant placement agent cash fees </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:379pt;text-align:left;">
                <div style="white-space:nowrap;">Total  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have agreed to pay the placement agent a total cash fee equal to a percentage of the aggregate gross proceeds raised in this offering as follows:</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are less than $2.5 million, a cash fee equal to 7% of the aggregate gross proceeds raised in this offering (inclusive of any gross proceeds raised from Domain and TPG);</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are $2.5 million or more, a cash fee equal to 7.25% of the aggregate gross proceeds raised in this offering (inclusive of any gross proceeds raised from Domain and TPG); or</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are $5.0 million or more, a cash fee equal to 7.5% of the aggregate gross proceeds raised in this offering (inclusive of any gross proceeds raised from Domain and TPG).</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have also agreed to pay the placement agent a management fee equal to a percentage of the aggregate gross proceeds raised in this offering as follows:</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are less than $2.5 million, no management fee;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are $2.5 million or more, a management fee equal to 0.5% of the aggregate gross proceeds raised in this offering (inclusive of any gross proceeds raised from Domain and TPG); or</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">128</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are $5.0 million or more, a management fee equal to 1.0% of the aggregate gross proceeds raised in this offering (inclusive of any gross proceeds raised from Domain and TPG).</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, we have agreed to reimburse the placement agent for up to $150,000 of certain of its counsel fees and expenses and other out-of-pocket and non-accountable expenses and up to $10,000 for clearing expenses. We estimate the total offering expenses of this offering that will be payable by us, excluding the placement agent fees and expenses, will be approximately $1,100,000. After deducting the placement agent fees and our estimated offering expenses, we expect the net proceeds from this offering to be approximately $8.2&#160;million, which assumes that we will sell the maximum amount of securities offered hereby. However, because there is no minimum offering amount required as a condition to closing in this offering, the actual offering amount, placement agent fees and proceeds to us, if any, in this offering may be substantially less than the maximum offering amounts set forth in this prospectus.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Placement Agent Warrants</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have agreed to issue placement agent warrants to H.C. Wainwright or its designees to purchase a number of shares of our common stock equal to a percentage of the aggregate number of shares of common stock and pre-funded warrants issued in this offering as follows:</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are less than $2.5 million, no placement agent warrants;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are $2.5 million or more, a number of placement agent warrants equal to 3.75% of the aggregate number of shares of common stock and pre-funded warrants issued in this offering (inclusive of any shares of common stock and pre-funded warrants issued to Domain and TPG); or</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are $5.0 million or more, a number of placement agent warrants equal to 7.5% of the aggregate number of shares of common stock pre-funded warrants issued in this offering (inclusive of any shares of common stock and pre-funded warrants issued to Domain and TPG).</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The placement agent warrants will have an exercise price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (125% of the public offering price of the securities offered hereby) and will terminate on the five year anniversary of the pricing date of the offering. The placement agent warrants are registered on the registration statement of which this prospectus is a part. Pursuant to FINRA Rule 5110(g), the placement agent warrants and any shares issued upon exercise of the placement agent warrants shall not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the date of effectiveness or commencement of sales of this offering, except the transfer of any security:</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">by operation of law or by reason of our reorganization;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction set forth above for the remainder of the time period;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate amount of our securities held by the placement agent or related persons do not exceed 1% of the securities being offered;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">that is beneficially owned on a pro rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund and the participating members in the aggregate do not own more than 10% of the equity in the fund; or</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the exercise or conversion of any security, if all securities remain subject to the lock-up restriction set forth above for the remainder of the time period.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">129</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:11pt;font-weight:bold;">Right of First Refusal</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have also granted the placement agent a 12-month right of first refusal to act as sole book-running manager, sole underwriter or sole placement agent for each and every future public or private equity or debt offering or debt refinancing by us or any of our successors or subsidiaries, as well as the right to serve as exclusive financial advisor in the event of any disposition, acquisition or other business combination, in each case subject to certain limitations.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Tail Financing Payments</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have also agreed to pay the placement agent a tail fee equal to the cash and warrant compensation in this offering, if any investor, who was contacted or introduced to us by the placement agent during the term of the placement agent&#8217;s engagement, provides us with capital in any public or private offering or other financing or capital raising transaction during the 12-month period following expiration or termination of our engagement of the placement agent.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Other Relationships </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The placement agent in the past has provided investment banking and other financial services to Alliqua and its affiliates for which the placement agent and its affiliates have received compensation.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In February&#160;2017, the placement agent acted as a financial advisor to Alliqua in connection with a private placement of common stock for which the placement agent received a financial advisory fee of approximately $160,000. In April&#160;2017, the placement agent acted as the sole book-running manager of a public offering by Alliqua of common stock for which the placement agent received fees of approximately $210,000. In March&#160;2018, the placement agent was engaged by Alliqua in connection with a proposed offering that was never consummated and received reimbursement of&#8201; $50,000 of legal fees.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, the placement agent acted as financial advisor to Alliqua in connection with the Merger. The placement agent was paid a fee of&#8201; $50,000 at the time of its engagement for its services in connection with the Merger and a fee of&#8201; $250,000 for rendering its fairness opinion delivered in connection with the Merger. In addition, upon consummation of the Merger, the placement agent received additional compensation of&#8201; $350,000 of cash and 21,704 shares of common stock. Alliqua also reimbursed the placement agent for $50,000 of expenses incurred in connection with the Merger. In accordance with Financial Industry Regulatory Authority, Inc. Rule&#160;5110, the placement agent&#8217;s reimbursed expenses and the compensation received by the placement agent in connection with the Merger may be deemed underwriting compensation for this offering.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Determination of Offering Price</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The public offering price of the securities we are offering and the exercise price and other terms of the pre-funded warrants and common warrants were negotiated between us and the investors, in consultation with the placement agent based on the trading of our common stock prior to the offering, among other things, and may be at a discount to the current market price. Other factors considered in determining the public offering price of the securities we are offering and the exercise price and other terms of the pre-funded warrants and common warrants include our history and prospects, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management, general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Lock-up Agreements</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We, our officers and our directors and certain significant stockholders have agreed, subject to certain specified exceptions, not to directly or indirectly, for a period of 90&#160;days after the date of the prospectus, without the prior written consent of H.C. Wainwright:</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#8220;put equivalent position&#8221; within the meaning of Rule&#160;16a-1(h) under the Exchange Act, </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">130</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="margin-left:40pt; width:416pt; line-height:12pt;">or otherwise dispose of, any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">enter into any swap, hedge or other agreement or transaction that transfers, in whole or in part, the economic consequence of ownership of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock; or</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">publicly announce an intention to do any of the foregoing.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The restrictions in the immediately preceding paragraph do not apply in certain circumstances, including:</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the issuance of shares of our common stock in this offering and shares of our common stock underlying the pre-funded warrants and common warrants;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">transfers by gift, will or operation of law;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">transfers to certain related entities;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">certain exercises of options;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the establishment of 10b5-1 trading plans, provided no sales can occur during the 90-day lock-up period;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">transfers of shares of common stock and accompanying warrants acquired in this offering or on the open market following this offering; and</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">transfers to us pursuant to contractual arrangements that provide for the repurchase of shares by us in connection with the termination of employment with us.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, we and each such person agree that, without the prior written consent of H.C. Wainwright, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">H.C. Wainwright may, in its sole discretion and at any time or from time to time before the termination of the 90-day period, release all or any portion of the securities subject to lock-up agreements.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Transfer Agent and Registrar</div>


          <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The transfer agent and registrar for our common stock is Action Stock Transfer Corporation.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Listing</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our common stock is presently quoted on OTCQB under the trading symbol &#8220;ADYX.&#8221; We do not intend to apply to list any of our securities on any securities exchange or nationally recognized trading system in connection with this offering.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">State Blue Sky Information</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have not applied to register the securities to be issued in this offering for offers and sales to retail customers under the securities laws, or &#8220;blue sky&#8221; laws, of any state. In connection with this offering, we will rely on exemptions from registration for sales of securities in this offering solely to institutional investors pursuant to an exemption provided for sales to these investors under state blue sky laws. The definition of an &#8220;institutional investor&#8221; varies from state to state but generally includes financial institutions, broker-dealers, banks, insurance companies and other qualified entities.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The National Securities Markets Improvement Act of 1996, or NSMIA, which is a federal statute, pre-empts states from regulating transactions in certain securities, which are referred to as &#8220;covered securities.&#8221; The resale of the securities issued in this offering by persons other than underwriters or dealers is exempt from state registration requirements under NSMIA because we are required to file periodic and annual reports under the Exchange Act. However, states are permitted to require notice filings and collect </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">131</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">fees with regard to these transactions and a state may suspend the offer and sale of securities within such state if any such required filing is not made or fee is not paid. Whether a notice filing or fee payment is required is a state-by-state analysis. Additionally, if any state that has not yet adopted a statute relating to NSMIA adopts such a statute in the future requiring a filing or fee or if any state amends its existing statutes with respect to its requirements, we would need to comply with those new requirements in order for our securities to continue to be eligible for resale in those jurisdictions.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Aside from the exemption from registration provided by NSMIA, the securities issued in this offering may be eligible for sale on a secondary market basis in various states based on the availability of other applicable exemptions from state registration requirements, in certain instances subject to waiting periods, notice filings or fee payments.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Indemnification</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have agreed to indemnify the placement agent against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the placement agent may be required to make with respect to any of these liabilities.</div>


          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Regulation&#160;M</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The placement agent may be deemed to be an underwriter within the meaning of Section&#160;2(a)(11) of the Securities Act and any fees received by it and any profit realized on the sale of the securities by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. The placement agent will be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule&#160;10b-5 and Regulation&#160;M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities by the placement agent. Under these rules and regulations, the placement agent may not (i)&#160;engage in any stabilization activity in connection with our securities; and (ii) bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until they have completed their participation in the distribution.</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">132</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLM">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">LEGAL MATTERS </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The validity of the securities offered hereby will be passed upon for us by Cooley LLP, Palo Alto, California. Haynes and Boone, LLP, New York, New York is acting as counsel to the placement agent in connection with this offering. </div>

        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">EXPERTS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The financial statements of Adynxx, Inc. as of December&#160;31, 2018 and 2017, and for the&#160;years then ended, included in this prospectus have been so included in reliance on the report of BDO USA, LLP, independent registered public accounting firm (the report on the financial statements contains an explanatory paragraph regarding our ability to continue as a going concern), appearing elsewhere herein, given on the authority of said firm as experts in auditing and accounting. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the securities being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further information with respect to our company and the securities offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">You can read our SEC filings, including the registration statement, over the internet at the SEC&#8217;s website at www.sec.gov. We are subject to the information reporting requirements of the Exchange Act, and file annual, quarterly and special reports, proxy statements and other information with the SEC. These reports, proxy statements and other information are available for inspection on the website of the SEC referred to above. We also maintain a website at www.adynxx.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated into, this prospectus.</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">133</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">
          <font style="text-transform:uppercase;">ADYNXX INC. Unaudited Pro Forma Financial Information</font></div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">The following unaudited pro&#160;forma condensed combined financial statements were prepared using the acquisition method of accounting under U.S. GAAP and gives effect to the merger transaction (the &#8220;Merger&#8221;) between Alliqua BioMedical, Inc. (&#8220;Alliqua&#8221;) and privately-held Adynxx (&#8220;Private Adynxx&#8221;). The merger will be treated by Alliqua as a reverse merger and recapitalization effected by a share exchange for financial accounting and reporting purposes. The notes below titled &#8220;<font style="font-style:italic;">Adynxx Transactions</font>&#8221; and &#8220;<font style="font-style:italic;">Distribution of Cash</font>&#8221; provide additional information regarding this transaction. The pro&#160;forma condensed combined financial statements give effect to the spin-off of Alliqua&#8217;s wholly owned subsidiary, AquaMed Technologies, Inc. (&#8220;AquaMed&#8221;), engaged in the custom hydrogel manufacturing business, in the form of a pro&#160;rata distribution of the common equity of the subsidiary to Alliqua&#8217;s stockholders, (the &#8220;Spin-off Transaction&#8221;). See note below titled &#8220;<font style="font-style:italic;">Aquamed Spin-Off.</font>&#8221; Since Alliqua will be deemed to have no operations upon consummation of the Spin-off, Alliqua is not considered to be a business for accounting purposes. Accordingly, no goodwill or intangible assets will be recorded as a result of the merger. Because Private Adynxx will be treated as the acquiring company, Private Adynxx&#8217;s assets and liabilities will be recorded at their pre-combination carrying amounts and the historical operations that are reflected in the unaudited pro&#160;forma condensed combined financial information will be those of Private Adynxx. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Private Adynxx was determined to be the accounting acquirer based upon the terms of the Merger Agreement and other factors including: (i)&#160;Private Adynxx equity holders owned approximately 86% of the voting interests of the combined company immediately following the closing of the transaction and Alliqua equity holders owned approximately 14%; (ii) directors appointed by Private Adynxx hold a majority of board seats in the combined company; and (iii) Private Adynxx management held all key positions in the management of the combined company.</div>

        <div style="margin-top:6pt; width:456pt; line-height:11pt;font-style:italic;">Adynxx Transactions </div>

          <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, Adynxx, Inc., formerly known as &#8220;Alliqua BioMedical, Inc.,&#8221; completed a business combination with Private Adynxx in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of October&#160;11, 2018, as amended and supplemented from time to time (the &#8220;Merger Agreement&#8221;) by and among us, Embark Merger Sub, Inc. (&#8220;Merger Sub&#8221;), and Private Adynxx, pursuant to which Merger Sub merged with and into Private Adynxx, with Private Adynxx surviving as a wholly-owned subsidiary of the re-named Adynxx, Inc. which is referred to herein as the Merger. Also, on May&#160;3, 2019, in connection with, and immediately prior to the completion of the Merger, we effected a reverse stock split at a ratio of one new share for every six shares of our common stock outstanding (the &#8220;Merger Stock Split&#8221;) and immediately following the Merger, we changed our name to &#8220;Adynxx, Inc.&#8221; Following the completion of the Merger, the business conducted by Private Adynxx became primarily the business conducted by us, which is the development of novel, disease-modifying pharmaceutical product candidates for the treatment of pain and inflammation. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the terms of the Merger Agreement, we issued shares of our common stock to Private Adynxx&#8217;s stockholders at an exchange rate of 0.0359 shares of common stock  in exchange for each share of Private Adynxx common stock outstanding immediately prior to the Merger (which exchange rate reflects the Merger Stock Split). The exchange rate was determined pursuant to the terms of the Merger Agreement. We also assumed all of the stock options outstanding under Private Adynxx&#8217;s 2010 Equity Incentive Plan (the &#8220;Private Adynxx Plan&#8221;) with such stock options representing the right to purchase a number of shares of our common stock equal to 0.0359  multiplied by the number of shares of Private Adynxx common stock previously represented by such options under the Private Adynxx Plan. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Immediately after the Merger, the former Private Adynxx stockholders, warrant holders and option holders owned approximately 86% of the fully-diluted common stock of the combined company, with our stockholders and option holders immediately prior to the Merger, whose shares of our common stock remain outstanding after the Merger, owning approximately 14% of the fully-diluted common stock of the combined company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Distribution of Cash </div>

          <div style="text-indent:20pt; margin-top:5.21pt; width:456pt; line-height:12pt;">On April&#160;11, 2019, Alliqua announced that its board of directors has (i)&#160;declared a conditional special cash dividend (the &#8220;Special Dividend&#8221;) of&#8201; $1.05 for each share of common stock outstanding as of the close of business on April&#160;22, 2019 (the &#8220;Record Date&#8221;), for an aggregate of&#8201; $5,245,000, and (ii) set the </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">134</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">Record Date as the record date for determining stockholders entitled to receive shares of AquaMed in connection with Alliqua&#8217;s spin-off of AquaMed. </div>

          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">The payment of the Special Dividend was subject to the consummation of the Merger. In May&#160;2019, we made a one-time special cash distribution to the pre-Merger holders of shares of Alliqua BioMedical, Inc. in the amount of&#8201; $6.30 per share, post-split. </div>

        <div style="margin-top:6pt; width:456pt; line-height:11pt;font-style:italic;">AquaMed Spin-Off </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">AquaMed is engaged in the custom hydrogel manufacturing business. In June 2019, we effectuated the spin-off of AquaMed into a separate, stand-alone company upon consummation of the following steps:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Pursuant to an Asset Contribution and Separation Agreement entered into by and between us and AquaMed, or the Separation Agreement, we transfered certain assets and liabilities utilized primarily in connection with Alliqua&#8217;s custom hydrogels contract manufacturing business to AquaMed;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">AquaMed issued shares of its common stock to us in consideration of the contribution of assets pursuant to the Separation Agreement; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">We distributed to the pre-Merger holders of shares of Alliqua as of April&#160;22, 2019 all of the issued and outstanding shares of common stock, par value $0.001 per share, of AquaMed by way of a pro rata dividend.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The unaudited pro&#160;forma condensed combined statements of operations for the six&#160;months ended June&#160;30, 2019 and for the year ended December&#160;31, 2018, assumes that the transactions took place as of January&#160;1, 2018, and combines the historical results of Alliqua for the period from January&#160;1, 2019 to May&#160;2, 2019 and the year ended December&#160;31, 2018 and Private Adynxx for the six months ended June&#160;30, 2019 and year ended December&#160;31, 2018, respectively. The historical financial statements of Alliqua and Private Adynxx have been adjusted to give pro&#160;forma effect to events that are (i)&#160;directly attributable to the transaction, (ii) factually supportable, and (iii) with respect to the statements of operations, expected to have a continuing impact on the combined company&#8217;s results.</div>


          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">The following information also gives effect to the Merger Stock Split as if such split occurred on the same date as the transactions. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The unaudited pro&#160;forma condensed combined financial statements are based on the assumptions and adjustments that are described in the accompanying notes. The pro&#160;forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro&#160;forma condensed combined financial statements. Differences between these preliminary estimates and the final amounts, expected to be completed after the closing of the transaction, will occur and these differences could have a material impact on the accompanying unaudited pro&#160;forma condensed combined financial statements and the combined company&#8217;s future results of operations and financial position. </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">The unaudited pro&#160;forma condensed combined financial statements do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro&#160;forma condensed combined financial statements are preliminary and have been prepared for illustrative purposes only and are not necessarily indicative of the financial position or results of operations in future periods or the results that actually would have been realized had Alliqua and Private Adynxx been a combined company during the specified periods. The actual results reported in periods following the transaction may differ significantly from those reflected in the unaudited pro&#160;forma condensed combined financial statements presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this pro&#160;forma financial statement. </div>

          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">The unaudited pro&#160;forma condensed combined financial statements, including the notes thereto, should be read in conjunction with the Private Adynxx historical financial statements. Private Adynxx&#8217;s historical unaudited financial statements for the six&#160;months ended June&#160;30, 2019, and audited financial statements for the years ended December&#160;31, 2018 and December&#160;31, 2017 are included elsewhere in this prospectus.</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">135</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:18pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Adynxx, Inc.</div>

          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Unaudited Pro Forma Condensed Combined Statement of Operations <br >For the Six Months Ended June&#160;30, 2019 <br >(In thousands, except per share data) </div>

      </div>
      <div style="margin-top:18pt;margin-bottom:18pt;margin-left:27.5pt;width:541pt;">

          <table style="width:541pt;height:354.5pt;margin-top:0pt;border-collapse: collapse;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Adynxx, Inc. <br >(Accounting <br >Acquirer) <br >Historical </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Alliqua <br >BioMedical, <br >Inc. <br >(Accounting <br >Acquiree)<br >From <br >January&#160;1, 2019 <br >to May&#160;2, 2019</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">AquaMed <br >Spin-off </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Adynxx <br >Transactions </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Total Pro <br >Forma <br >Adjustments </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:19.94pt;">
                <div style="white-space:nowrap; text-align:center;">Notes </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Pro Forma <br >Combined </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
                <div style="white-space:nowrap;">Revenue, net </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">152</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(152<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(152<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">
                <div style="text-align:center;">(n) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:182.85pt;text-align:left;">
                <div style="white-space:nowrap;">Cost of revenues </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">300</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(300<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(300<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:19.94pt;text-align:center;">
                <div style="text-align:center;">(n) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
                <div style="white-space:nowrap;">Gross loss </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(148<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">148</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">148</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:9pt 0pt 0.5pt 0pt; width:182.85pt;">Operating expenses:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
                <div style="margin-left:10pt;">Selling, general and administrative </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">2,317</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">1,070</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(762<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(762<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">
                <div style="text-align:center;">(n) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">2,625</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
                <div style="margin-left:10pt;">Research and product development </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">3,226</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">3,226</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
                <div style="margin-left:10pt;">Grant reimbursement </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(1,198<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(1,198<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:182.85pt;text-align:left;">
                <div style="margin-left:10pt;">Acquisition related expenses </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">2,401</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,401<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(2,401<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:19.94pt;text-align:center;">
                <div style="text-align:center;">(p) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:182.85pt;text-align:left;">
                <div style="white-space:nowrap;">Total operating expenses </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">4,345</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">3,471</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(762<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,401<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(3,163<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">4,653</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
                <div style="white-space:nowrap;">Loss from operations </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(4,345<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(3,619<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">910</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,401</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,311</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(4,653<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:9pt 0pt 0.5pt 0pt; width:182.85pt;">Interest and other income (expense):</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
                <div style="margin-left:10pt;">Interest income (expense) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(2,641<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">16</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">81</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">81</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">
                <div style="text-align:center;">(q) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,101</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,101</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">
                <div style="text-align:center;">(r)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(443<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:182.85pt;text-align:left;">
                <div style="margin-left:10pt;">Change in fair value of warrant liability </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">(94<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">94</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">94</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3pt 0pt 2pt 0pt; width:19.94pt;text-align:center;">
                <div style="text-align:center;">(o)</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:2.75pt 0pt 2.75pt 0pt; width:182.85pt;text-align:left;">
                <div style="white-space:nowrap;">Loss from continuing operations </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">(7,080<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(3,603<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">910</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">4,677</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,587</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.75pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">(5,096<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:8.25pt 0pt 0.5pt 0pt; width:182.85pt;">
                <div style="margin-left:10pt; text-indent:-10pt;">Net loss per share basic and diluted common share</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
                <div style="margin-left:10pt;">Loss from continuing operations </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(1.43<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(0.88<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 2.75pt 0pt; width:182.85pt;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Pro&#160;forma weighted average shares outstanding <br >used in computing basic and diluted net loss <br >per common share </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">4,966,491</td>
              <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">841,386</td>
              <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 2.75pt 0pt; width:19.94pt;text-align:center;">
                <div style="text-align:center;">(t)(u)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">5,807,877</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="height:4.5pt;line-height:4.5pt;">
              <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="41">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:18pt;margin-bottom:172.5pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-size:10pt;">&nbsp;&nbsp;&nbsp;</div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:10pt;">See accompanying notes to the unaudited pro forma condensed combined financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">136</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:18pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Adynxx, Inc.</div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Unaudited Pro Forma Condensed Combined Statement of Operations <br >For the Year Ended December&#160;31, 2018 <br >(In Thousands, Except Per Share Data) </div>
      </div>
      <div style="margin-top:18pt;margin-bottom:18pt;margin-left:27.5pt;width:541pt;">

          <table style="width:541pt;height:511.5pt;margin-top:0pt;border-collapse: collapse;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Adynxx, Inc. <br >(Accounting <br >Acquirer) <br >Historical </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Alliqua <br >BioMedical, <br >Inc. <br >(Accounting <br >Acquiree) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">AquaMed <br >Spin-Off </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Adynxx <br >Transactions </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Total Pro <br >Forma <br >Adjustments </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:19.41pt;">
                <div style="white-space:nowrap; text-align:center;">Notes </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Pro Forma <br >Combined </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
                <div style="white-space:nowrap;">Revenue, net </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,216</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,216<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(2,216<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">
                <div style="text-align:center;">(n) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
                <div style="white-space:nowrap;">Cost of revenues </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,720</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(1,720<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">(1,720<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:19.41pt;text-align:center;">
                <div style="text-align:center;">(n) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
                <div style="white-space:nowrap;">Gross profit </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">496</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(496<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(496<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:9pt 0pt 0.5pt 0pt; width:186.76pt;">Operating expenses:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
                <div style="margin-left:10pt;">Selling, general and administrative </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,982</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,778</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,502<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(2,502<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">
                <div style="text-align:center;">(n) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">5,258</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
                <div style="margin-left:10pt;">Acquisition related expenses </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,014</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(1,014<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(1,014<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">
                <div style="text-align:center;">(p) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:186.76pt;text-align:left;">
                <div style="margin-left:10pt;">Research and development </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">2,137</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">2,137</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:186.76pt;text-align:left;">
                <div style="white-space:nowrap;">Total operating expenses </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">5,119</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,792</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,502<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(1,014<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">(3,516<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">7,395</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
                <div style="white-space:nowrap;">Loss from operations </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(5,119<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(5,296<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,006</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">1,014</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">3,020</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(7,395<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:9pt 0pt 0.5pt 0pt; width:186.76pt;">Interest and other income (expenses):</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
                <div style="margin-left:10pt;">Interest income (expense) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(980<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">24</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">334</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">334</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">
                <div style="text-align:center;">(q) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(622<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
                <div style="margin-left:10pt;">Change in fair value of warrant liability </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(97<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(26<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">97</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">97</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">
                <div style="text-align:center;">(o) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(26<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
                <div style="margin-left:10pt;">Change in fair value of derivative liability </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">211</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(211<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(211<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">
                <div style="text-align:center;">(q) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:186.76pt;text-align:left;">
                <div style="margin-left:10pt;">Loss on early extinguishment of debt, net </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(1,706<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(1,706<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:2.75pt 0pt 2.75pt 0pt; width:186.76pt;text-align:left;">
                <div style="white-space:nowrap;">Net loss from continuing operations </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(5,985<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">(7,004<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">2,006</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">1,234</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">3,240</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.75pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(9,749<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:8.25pt 0pt 0.5pt 0pt; width:186.76pt;">
                <div style="margin-left:10pt; text-indent:-10pt;">Net loss per share basic and diluted common share</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
                <div style="margin-left:10pt;">Loss from continuing operations </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(8.54<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(1.68<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 2.75pt 0pt; width:186.76pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Pro&#160;forma weighted average shares outstanding used in computing basic and diluted net loss per common share </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">820,565</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">4,987,870</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 2.75pt 0pt; width:19.41pt;text-align:center;">
                <div style="text-align:center;">(t)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">5,808,435</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:9.5pt 0pt 0.5pt 0pt; width:186.76pt;">
                <div style="margin-left:10pt; text-indent:-10pt;">Reconciliation of pro&#160;forma weighted average shares outstanding:</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">Weighted average number of shares held by Adynxx shareholders pre-merger </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">136,866,375</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:186.76pt;text-align:left;">
                <div style="margin-left:10pt;">Conversion ratio </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:19.41pt;text-align:center;">
                <div style="text-align:center;">(s)</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">0.0364</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:186.76pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">Weighted average number of shares held by Adynxx shareholders post-merger </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">4,987,870</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:186.76pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">Weighted average number of shares held by Alliqua shareholders </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:19.41pt;text-align:center;">
                <div style="text-align:center;">(s)</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">820,565</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
              <td style="padding:2.75pt 0pt 2.75pt 0pt; width:186.76pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Total pro&#160;forma weighted average shares outstanding </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.75pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">5,808,435</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="height:10pt;line-height:10pt;">
              <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="41">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:18pt;margin-bottom:15.5pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-size:10pt;">&nbsp;&nbsp;&nbsp;</div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:10pt;">See accompanying notes to the unaudited pro forma condensed combined financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">137</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to the Unaudited Pro Forma Condensed Combined Financial Information </div>
        <div style=" float:left; line-height:11pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">1.<br ></div>
        <div style=" margin-top:12pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:20pt;font-weight:bold;">Description of Transaction and Basis of Presentation </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The unaudited pro&#160;forma condensed combined financial information was prepared pursuant to the rules and regulations of SEC Regulation&#160;S-X and presents the pro&#160;forma financial position and results of operations of the combined companies based upon the historical data of Alliqua and Private Adynxx. The Merger will be treated by Alliqua as a reverse merger and recapitalization effected by a share exchange for financial accounting and reporting purposes. The pro&#160;forma condensed combined financial information also gives effect to the spin-off of Alliqua&#8217;s wholly owned subsidiary, AquaMed, engaged in the custom hydrogel manufacturing business, in the form of a pro&#160;rata distribution of the common equity of the subsidiary to Alliqua&#8217;s stockholders. See note below titled &#8220;AquaMed Spin-Off.&#8221; Since Alliqua will be deemed to have no operations upon consummation of the Spin-off Transaction, Alliqua is not considered to be a business for accounting purposes. Accordingly, no goodwill or intangible assets will be recorded as a result of the merger. Because Private Adynxx will be treated as the acquiring company, Private Adynxx&#8217;s assets and liabilities will be recorded at their pre-combination carrying amounts and the historical operations that are reflected in the unaudited pro&#160;forma condensed combined financial information will be those of Private Adynxx. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Description of Transaction </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, Adynxx, Inc., formerly known as &#8220;Alliqua BioMedical, Inc.,&#8221; completed a business combination with privately-held &#8220;Adynxx, Inc.&#8221; in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of October&#160;11, 2018, as amended and supplemented from time to time, by and among us, Merger Sub, and Private Adynxx, pursuant to which Merger Sub merged with and into Private Adynxx, with Private Adynxx surviving as a wholly-owned subsidiary of the re-named Adynxx, Inc. which is referred to herein as the Merger. Also, on May&#160;3, 2019, in connection with, and immediately prior to the completion of the Merger, we effected the Merger Stock Split, and immediately following the Merger, we changed our name to &#8220;Adynxx, Inc.&#8221; Following the completion of the Merger, the business conducted by Private Adynxx became primarily the business conducted by us, which is the development of novel, disease-modifying pharmaceutical product candidates for the treatment of pain and inflammation. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the terms of the Merger Agreement, we issued shares of our common stock to Private Adynxx&#8217;s stockholders at an exchange rate of 0.0359 shares of common stock in exchange for each share of Private Adynxx common stock outstanding immediately prior to the Merger (which exchange rate reflects the Merger Stock Split). The exchange rate was determined pursuant to the terms of the Merger Agreement. We also assumed all of the stock options outstanding under the Private Adynxx Plan, with such stock options representing the right to purchase a number of shares of our common stock equal to 0.0359 multiplied by the number of shares of Private Adynxx common stock previously represented by such options under the Private Adynxx Plan. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Immediately after the Merger, the former Private Adynxx stockholders, warrant holders and option holders owned approximately 86% of the fully-diluted common stock of the combined company, with our stockholders and option holders immediately prior to the Merger, whose shares of our common stock remain outstanding after the Merger, owning approximately 14% of the fully-diluted common stock of the combined company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Distribution of Cash </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On April&#160;11, 2019, Alliqua announced that its board of directors has (i)&#160;declared the Special Dividend of&#8201; $1.05 for each share of common stock outstanding as of the Record Date, for an aggregate of $5,245,000, and (ii) set the Record Date as the record date for determining stockholders entitled to receive shares of AquaMed in connection with the Spin-off Transaction. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The payment of the Special Dividend was subject to the consummation of the Merger. In May&#160;2019, we made a one-time special cash distribution to the pre-Merger holders of shares of Alliqua BioMedical, Inc. in the amount of&#8201; $6.30 per share, post-split. </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">138</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to the Unaudited Pro Forma Condensed Combined Financial Information<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;">AquaMed Spin-Off </div>
        <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">AquaMed is engaged in the custom hydrogel manufacturing business. In June 2019, we effectuated the spin-off of AquaMed into a separate, stand-alone company upon consummation of the following steps:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Pursuant to an Asset Contribution and Separation Agreement entered into by and between us and AquaMed, or the Separation Agreement, we transfered certain assets and liabilities utilized primarily in connection with Alliqua&#8217;s custom hydrogels contract manufacturing business to AquaMed;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">AquaMed issued shares of its common stock to us in consideration of the contribution of assets pursuant to the Separation Agreement; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">We distributed to the pre-Merger holders of shares of Alliqua as of April&#160;22, 2019 all of the issued and outstanding shares of common stock, par value $0.001 per share, of AquaMed by way of a pro rata dividend.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:10.98pt; width:456pt; line-height:12pt;">The pro&#160;forma adjustments described in Note 2 were based on available information and certain assumptions made by management and may be revised as additional information becomes available. The historical financial information has been adjusted in the unaudited pro&#160;forma condensed combined financial information to give effect to events that are (1)&#160;directly attributable to the merger transaction, (2)&#160;factually supportable, and (3)&#160;with respect to the statement of operations, expected to have a continuing impact on the combined results. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">2.<br ></div>
        <div style=" margin-top:15.99pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:20pt;font-weight:bold;">Pro Forma Adjustments </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">The accompanying unaudited pro&#160;forma condensed combined statement of operations has been prepared as if the acquisition was completed on January&#160;1, 2018 in each of the periods presented. </div>
        <div style="text-indent:20pt; margin-top:10.98pt; width:456pt; line-height:12pt;">The calculation of the net loss per share in the unaudited pro&#160;forma condensed combined statement of operations assume the issuance of common shares to Alliqua stockholders in the Merger had occurred on January&#160;1, 2018.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">139</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to the Unaudited Pro Forma Condensed Combined Financial Information<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The unaudited pro&#160;forma condensed combined statements of operations reflect the following pro&#160;forma adjustments: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(n)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To reflect the impact of the Spin-off Transaction whereby Alliqua is expected to spin-off its existing contract manufacturing operations prior to the Merger. After this Spin-off Transaction, Alliqua will no longer have any operating assets and liabilities and no operating activities. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(o)<br ></div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To eliminate the changes in fair value of warrant liability. In connection with the Merger, the outstanding warrants held by Adynxx shareholders were exchanged for warrants that are exercisable into shares of common stock and qualify for equity classification. As such, mark-to-market adjustments are no longer applicable. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(p)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To eliminate the impact of acquisition costs incurred by Alliqua prior and up-to the consummation of the Merger. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(q)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To eliminate interest expense and changes in the fair value of the derivative liability as a result of the conversion of the associated 2018 Notes as described more fully in item (g)&#160;above.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(r)<br ></div>
          <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To eliminate the impact of the beneficial conversion feature of&#8201; $2.1&#160;million that was recognized as interest expense by Private Adynxx. In accordance with ASC 470-20-25-6, the contingent beneficial conversion feature is not recognized in earnings until the contingency is resolved. Upon the date of the Merger (occurrence of the contingency), the full amount of the beneficial conversion feature of&#8201; $2.1&#160;million was recognized as interest expense in the condensed consolidated statement of operations for the six months ended June&#160;30, 2019.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(s)<br ></div>
          <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To compute the impacts of the Merger on the weighted average shares outstanding, computed as the sum of&#8201; (1)&#160;the weighted average shares held by Adynxx shareholders prior to the Merger, adjusted for an estimated exchange ratio on January&#160;1, 2018 of 0.0364 and (2)&#160;the weighted average shares outstanding held by Alliqua shareholders derived from the Alliqua Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2018, adjusted for the 1-for-6 Merger Stock Split effected at the time of the Merger. The estimated exchange ratio will vary from the actual exchange ratio established on the closing date of the Merger due to difference in shares outstanding at January&#160;1, 2018 and May&#160;3, 2019. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(t)<br ></div>
          <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Because the pro&#160;forma combined statement of operations yields a net loss, pro&#160;forma weighted average shares outstanding, adjusted for the Merger Stock Split, excludes the impacts of 101,000 warrants outstanding, 3,266,269 options outstanding and 3,333 non-vested restricted stock at December&#160;31, 2018 and 50,774 warrants outstanding and 747,880 options outstanding at June&#160;30, 2019, as the effects of such dilutive securities are anti-dilutive.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(u)<br ></div>
          <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To adjust the weighted average shares outstanding as if the Merger occurred on January&#160;1, 2018.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">140</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a><a name="tIF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Years Ended December&#160;31, 2017 and 2018 <br >and Six Months Ended June&#160;30, 2018 and 2019 (Unaudited) </div>
        <table style="width:456pt;height:293.5pt;margin-top:13pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:414pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Page </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.25pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">Audited Consolidated Financial Statements for the Years Ended December 31, 2017 and 2018</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tfRIRPAF">Report of Independent Registered Public Accounting Firm </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfRIRPAF">F-2</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">Financial Statements:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfBS">Balance Sheets </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfBS">F-3</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfSO">Statements of Operations </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfSO">F-4</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfSRCPSSD">Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfSRCPSSD">F-5</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfSCF">Statements of Cash Flows </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfSCF">F-6</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfNFS">Notes to Financial Statements </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfNFS">F-7</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.167pt 0pt 1.833pt 0pt; width:414pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Unaudited Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2018 and 2019</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">Condensed Consolidated Financial Statements:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfuBS">Condensed Consolidated Balance Sheets </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfuBS">F-27</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfuSO">Condensed Consolidated Statements of Operations </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfuSO">F-28</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.167pt 0pt 1.833pt 0pt; width:414pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <a href="#tfuSRC">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.167pt 0pt 1.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.167pt 0pt 1.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfuSRC">F-29</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfuSCF">Condensed Consolidated Statements of Cash Flows </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfuSCF">F-30</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfuNFS">Notes to Condensed Consolidated Financial Statements </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfuNFS">F-31</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="width:456pt; line-height:12pt;"></div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfRIRPAF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</div>

        <div style="margin-top:6pt; width:456pt; line-height:12pt;">Stockholders and Board of Directors <br >Adynxx, Inc. <br >San Francisco, California </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Opinion on the Financial Statements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have audited the accompanying balance sheets of Adynxx, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2017 and 2018, the related statements of operations, redeemable convertible preferred stock and stockholders&#8217; deficit, and cash flows for the&#160;years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2017 and 2018, and the results of its operations and its cash flows for the&#160;years then ended, in conformity with accounting principles generally accepted in the United States of America. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Going Concern Uncertainty </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company does not have a commercial product that can generate cash and accordingly will need to raise additional capital to fund its operations. These factors, among others, raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Basis for Opinion </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</div>


          <div style="margin-top:6pt; width:456pt; line-height:12pt;">/s/ BDO USA, LLP</div>

        <div style="margin-top:6pt; width:456pt; line-height:12pt;">We have served as the Company&#8217;s auditor since 2012. </div>

          <div style="margin-top:6pt; width:456pt; line-height:12pt;">San Jose, California <br >June&#160;7, 2019</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfBS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:72pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Balance Sheets <br >(In thousands, except share and per share data) </div>

          <table style="width:456pt;height:489.5pt;margin-top:7pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:363.53pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2017 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2018 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:13.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Assets:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Current assets</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:10pt;">Cash and cash equivalents </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,301</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,887</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:10pt;">Restricted cash </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">55</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 1.75pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:10pt;">Prepaid expenses and other current assets </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">34</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:20pt;">Total current assets </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,335</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,952</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="white-space:nowrap;">Property and equipment, net </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">13</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="white-space:nowrap;">Restricted cash </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">55</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 1.75pt 0pt; width:363.53pt;text-align:left;">
                <div style="white-space:nowrap;">Other assets </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:2.75pt 0pt 2.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:20pt;">Total assets </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">4,421</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,980</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:8.25pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Current liabilities</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:10pt;">Accounts payable </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">703</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">491</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:10pt;">Accrued liabilities </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,158</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">857</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:10pt;">Operating lease liability </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:10pt;">Convertible promissory notes&#8201;&#8211;&#8201;related party </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,500</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 1.75pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:10pt;">Current portion of term loan, net of discount </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,711</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">3,812</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:20pt;">Total current Liabilities </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,572</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,660</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="white-space:nowrap;">Term loan, net of current portion and discount </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,951</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="white-space:nowrap;">Warrant liability </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">42</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">140</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Commitments and contingencies (Note 6)</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Redeemable convertible preferred stock:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:11pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:1.5pt 0pt 0.5pt 0pt; width:363.53pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">Series&#160;A redeemable convertible preferred stock, $0.001 par value; 57,002,183 shares authorized; 56,672,658 shares issued and outstanding as of December&#160;31, 2017 and 2018 (liquidation value of&#8201; $12,898,697 as of December&#160;31, 2017 and 2018) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12,814</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12,814</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:11pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:1.5pt 0pt 0.5pt 0pt; width:363.53pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">Series&#160;B redeemable convertible preferred stock, $0.001 par value; 51,069,262 shares authorized; 51,069,262 shares issued and outstanding as of December&#160;31, 2017 and 2018 (liquidation value of&#8201; $16,000,000 as of December&#160;31, 2017 and 2018) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">15,897</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">15,897</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Stockholders&#8217; deficit:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:11pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:2pt 0pt 0.5pt 0pt; width:363.53pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">Common stock, $0.001 par value; 148,000,000 shares authorized; 19,548,969 shares issued and outstanding as of December&#160;31, 2017 and 2018 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">20</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">20</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:10pt;">Additional paid-in capital </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">419</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">728</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 1.75pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:10pt;">Accumulated deficit </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(31,294<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(37,279<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:20pt;">Total stockholders&#8217; deficit </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(30,855<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(36,531<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:2.75pt 0pt 2.5pt 0pt; width:363.53pt;text-align:left;">
                <div style="margin-left:30pt;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; deficit </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">4,421</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,980</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:10pt;">The accompanying notes are an integral part of these financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">F-3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfSO">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:387.5pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Statements of Operations <br >(In thousands) </div>
        <table style="width:456pt;height:167.5pt;margin-top:13pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:344pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">Years Ended <br >December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:15.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">Operating expenses</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">8,722</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,137</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">General and administrative </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,341</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,982</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Total operating expenses, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">11,063</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">5,119</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,063<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,119<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Interest expense, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(515<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(992<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Other income (expense), net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">126</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,561<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,985<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;">The accompanying notes are an integral part of these financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfSRCPSSD">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:18pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit <br >(In thousands, except share data) </div>
      </div>
      <div style="margin-top:18pt;margin-bottom:18pt;margin-left:27.5pt;width:541pt;">

          <table style="width:541pt;height:142pt;margin-top:0pt;border-collapse: collapse;">
            <tr style="line-height:8pt;height:25.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:158.28pt;text-align:left;" rowspan="2">
                <div style="white-space:nowrap; line-height:8pt; padding-bottom:0pt;">For the periods ended: </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">Series&#160;A Redeemable <br >Convertible <br >Preferred Stock</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">Series&#160;B Redeemable <br >Convertible <br >Preferred Stock</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">Common Stock </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt;" colspan="4" rowspan="2">
                <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">Additional <br >Paid-in <br >Capital </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt;" colspan="4" rowspan="2">
                <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">Accumulated <br >Deficit </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt;" colspan="4" rowspan="2">
                <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">Total <br >Stockholders&#8217; <br >Deficit </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
            </tr>
            <tr style="line-height:7pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Shares </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Amount </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Shares </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Amount </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Shares </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Amount </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.25pt 0pt 0.5pt 0pt; width:158.28pt;text-align:left;">
                <div style="white-space:nowrap;">Balance, December&#160;31, 2016 </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">56,321,165</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">12,734</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">51,069,262</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">15,897</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">19,548,969</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">20</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">118</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(19,733<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(19,595<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:158.28pt;text-align:left;">
                <div style="white-space:nowrap;">Exercise of warrants </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">351,493</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">80</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:158.28pt;text-align:left;">
                <div style="white-space:nowrap;">Stock-based compensation expense </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">301</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">301</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:158.28pt;text-align:left;">
                <div style="white-space:nowrap;">Net loss </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(11,561<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(11,561<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.25pt 0pt 0.5pt 0pt; width:158.28pt;text-align:left;">
                <div style="white-space:nowrap;">Balance, December&#160;31, 2017 </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">56,672,658</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">12,814</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">51,069,262</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">15,897</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">19,548,969</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">20</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">419</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(31,294<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(30,855<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:158.28pt;text-align:left;">
                <div style="white-space:nowrap;">Stock-based compensation expense </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">309</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">309</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:158.28pt;text-align:left;">
                <div style="white-space:nowrap;">Net loss </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(5,985<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(5,985<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.25pt 0pt 2.75pt 0pt; width:158.28pt;text-align:left;">
                <div style="white-space:nowrap;">Balance, December&#160;31, 2018 </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">56,672,658</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">12,814</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">51,069,262</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">15,897</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">19,548,969</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:6pt; text-align:right; white-space:nowrap;">20</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9pt; text-align:right; white-space:nowrap;">728</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(37,279<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(36,531<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="height:4pt;line-height:4pt;">
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:18pt;margin-bottom:392pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-size:10pt;">&nbsp;&nbsp;&nbsp;</div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:10pt;">The accompanying notes are an integral part of these financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">F-5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfSCF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:137.5pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Statements of Cash Flows <br >(In thousands) </div>
        <table style="width:456pt;height:424pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:344pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">Years Ended <br >December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:13.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">Cash flows from operating activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,561<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,985<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;">
              <div style="margin-left:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Depreciation expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Stock-based compensation expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">301</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">309</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Changes in fair value of warrant liability </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">98</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Accretion of final charge upon maturity of Oxford Term Loan A and B </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">106</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">224</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:344pt;white-space:normal;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">Amortization of issuance cost and discounts for term loans and convertible notes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">54</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">40</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Non-cash interest expense on convertible promissory notes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">126</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Changes in operating assets and liabilities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Prepaid expenses and other current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">329</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">23</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Other assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Accounts payable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">601</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(212<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Accrued liabilities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(650<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:30pt;">Net Cash Used in Operating Activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,183<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,019<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">Cash flows from investing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Purchases of property and equipment </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Net cash used in investing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">Cash flows from financing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Payments on term loan </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(139<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Proceeds from exercise of warrants </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">80</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Proceeds from issuance of convertible promissory notes&#8201;&#8211;&#8201;related party </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">4,500</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Net cash provided (used) by financing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(59<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">3,610</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Net decrease in cash and cash equivalents and restricted cash </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,245<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,414<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Cash and cash equivalents and restricted cash at beginning of year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">14,601</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">4,356</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Cash and cash equivalents and restricted cash at end of year </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">4,356</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,942</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">Other supplemental disclosure:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Cash paid for interest </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">355</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">376</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:10pt;">The accompanying notes are an integral part of these financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">F-6</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfNFS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 1.&nbsp;&nbsp;&nbsp;Organization and Basis of Presentation </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The Company </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Adynxx, Inc. (the &#8220;Company&#8221;) was incorporated on October&#160;24, 2007, in the state of Delaware. The Company is a clinical-stage pharmaceutical entity that is developing a technology platform to address pain at its molecular roots. The Company is primarily engaged in developing initial product technology, recruiting personnel, and raising capital. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Basis of Presentation </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying financial statements have been prepared using accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Liquidity </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As of December&#160;31, 2018, the Company had $1.9 million in cash and cash equivalents, had Oxford term loans, or Term Loans, including accrued interest outstanding of&#8201;$4.2 million, and convertible promissory notes, or Notes, including accrued interest, outstanding to investors of&#8201;$4.6 million. From inception through December&#160;31, 2018 the Company had an accumulated deficit of approximately $37.2 million. The Company expects to incur substantial losses in future periods. The Company is subject to risks common to companies in the clinical stage, including, but not limited to, development of new products, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product development plans. The Company has a limited operating history and has yet to generate any revenues from customers. There is no guarantee that profitable operations, if ever achieved, could be sustained on a continuing basis. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company plans to finance its operations and capital funding needs through equity and/or debt financing. However, there can be no assurance that additional funding will be available to the Company on acceptable terms on a timely basis, if at all, or that the Company will generate sufficient cash from operations to adequately fund operating needs or ultimately achieve profitability. The conditions above, among others, raise substantial doubt about the ability of the Company to continue as a going concern within one year after the date of the issuance of the financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying financial statements do not include any adjustments that might result from the outcome of these uncertainties. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 2.&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Use of Estimates </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Actual results could differ from those estimates and such differences could be material to the Company&#8217;s financial position and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Significant estimates and assumptions include the valuation of equity instruments and equity-linked instruments, including the valuation of the Company&#8217;s common stock and the valuation of the Company&#8217;s common stock options for purposes of accounting for stock-based compensation, and accruals for clinical trials and the valuation allowances on deferred tax assets.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-7</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk and Other Risks and Uncertainties </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation insured limits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company&#8217;s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company&#8217;s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support its growth. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s postoperative pain reduction product candidate, brivoligide, is an oligonucleotide. The Company currently uses Avecia as a single supplier for the brivoligide drug substance. There are currently a limited number of oligonucleotide manufacturers with commercial scale capabilities globally. While the Company intends to develop secondary sources for manufacturing of its drug candidates in the future, there can be no assurance that it will be able to do so on commercially reasonable terms, or at all. Any interruption in the supply of this key material could significantly delay the research and development process or increase the expenses for development and commercialization of the Company&#8217;s product candidates. The quality of materials can be critical to the performance of a drug delivery technology. Therefore, the lack of a reliable source that provides a consistent supply of high quality materials would harm the Company. At December&#160;31, 2018, this vendor&#8217;s activity was not material to total accounts payable. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At December&#160;31, 2017, two vendors represented 56% and 31%, of total accounts payable. The vendor that represented 56% of the Company&#8217;s accounts payable, supported manufacturing activities and the other vendor was associated with clinical study activities. At December&#160;31, 2018, three vendors represented 52%, 26% and 15% of total accounts payable. Two of these vendors supported general and administrative activities, primarily associated with the Merger and next round of equity financing, which accounted for 67% of the total accounts payable. The remaining vendor supported clinical study activities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Clinical Trial Accruals </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s clinical trial accruals are based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical trials on the Company&#8217;s behalf. The Company accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, the Company modifies the estimates of accrued expenses accordingly. To date, the Company has had no significant adjustments to accrued clinical trial expenses. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In March&#160;2018, the Company closed its contracts with Premier Research International LLC and CRF Health, Inc. (&#8220;Contract Research Organizations or CROs&#8221;) upon completion of a Phase&#160;2 clinical trial in March&#160;2018. For the&#160;years ended December&#160;31, 2017 and 2018, the Company incurred $6.2 million and $95,000, respectively, of expenses in connection with this clinical study. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In November&#160;2018, the Company entered into agreements with PRA Health, Inc. and CRF Health, Inc. (&#8220;Contract Research Organizations or CROs&#8221;) pursuant to which the CROs agreed to assist the Company with the conduct of a Phase&#160;2 clinical trial. To support additional clinical trial activities the Company also entered into agreements with Premier Research International LLC for biostatistical services, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-8</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">ICON Central Laboratories for laboratory services and Almac Clinical Services for storage and distribution services. In connection with this clinical study, the Company incurred expenses of&#8201; $0 and $185,000 for the&#160;years ended December&#160;31, 2017 and 2018, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company considers all highly liquid investments purchased with a maturity of three&#160;months or less on the date of acquisition to be cash and cash equivalents. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Property and Equipment, Net </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line method over the estimated useful lives of the assets, generally three to five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. As of December&#160;31, 2017 and 2018, the Company had not experienced any impairment losses on its long-lived assets. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Restricted Cash </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December 31, 2017 and 2018, the Company had $55,000 restricted and held by a bank as collateral for a letter of credit provided to the Company&#8217;s facility landlord.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Stock-Based Compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company uses the Black-Scholes option-pricing model (the &#8220;Black-Scholes model&#8221;) as the method for determining the estimated fair value of stock options. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected Term&#8201;&#8212; </font>The expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected Volatility&#8201;&#8212; </font>Expected volatility is estimated using comparable public companies&#8217; volatility for similar terms. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected Dividend&#8201;&#8212; </font>The Black-Scholes model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Risk-Free Interest Rate&#8201;&#8212; </font>The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-9</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Research and Development </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, preclinical studies, clinical studies performed by Contract Research Organizations (or &#8220;CROs&#8221;), materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development costs, including clinical study costs, to expense when incurred. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Collaboration Agreement </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2018, the Company entered into a collaboration agreement with twoXAR, an artificial intelligence-driven drug discovery company, in order to identify potential product candidates for the treatment of endometriosis. Through December&#160;31, 2018, the Company was not obligated to make any payments under the terms of the collaboration agreement. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Grant Reimbursements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2018, the Company received a Notice of Award from the National Institute on Drug Abuse (&#8220;NIDA&#8221;), part of the National Institutes of Health (&#8220;NIH&#8221;), to support the clinical development of its lead product candidate, brivoligide. NIH grants provide funds for certain types of expenditures in connection with research and development activities over a contractually defined period. The maximum funding expected to be available under this grant for qualified expenditures over the two year period through December&#160;2020 is&#8201;approximately $5.7&#160;million. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">As of December&#160;31, 2018, the Company had not incurred qualified expenses. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Income Taxes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company&#8217;s tax return. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Preferred Stock Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Freestanding warrants to acquire shares of convertible preferred stock are classified as liabilities on the accompanying balance sheets. These warrants are subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. The Company will continue to adjust the carrying values of freestanding warrants classified as liabilities for changes in fair value until the earlier of the exercise or expiration of the warrants or the completion of a liquidation event, including the completion of an initial public offering. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-10</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Debt Modifications and Extinguishments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">When the Company modifies debt, it does so in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 470-50, <font style="font-style:italic;">Debt: Modifications and Extinguishments</font>, which requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#8220;substantial modifications&#8221;. A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, the Company determined that the October&#160;2018 modification of the March&#160;2018 and September&#160;2018 Notes, to add an additional conversion option in the event of a reverse merger, was considered to be a &#8220;substantial modification&#8221;. As a result, it treated this modification as an &#8216;extinguishment&#8217; of those debts and recognized $11,000 of net gain from this debt extinguishment in other income. All other changes to debt provisions were not considered substantial and were treated as debt modifications. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Derivative Instruments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASC 815-15, <font style="font-style:italic;">Derivatives and Hedging: Embedded Derivatives</font>, generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a)&#160;the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b)&#160;the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)&#160;a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirement of ASC 815. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company issued certain Notes in March&#160;2018, September&#160;2018, and December&#160;2018, which contained various embedded derivative features. In particular, these Notes contained the following features: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">A share settled redemption in a qualified preferred stock financing; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">The right to an accelerated cash repayment in the event of a change in control. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These embedded features were not considered clearly and closely related to the debt host, therefore, they were bifurcated and accounted for separately from the debt host as a derivative liability. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in the statement of operations at each period end while such instruments are outstanding. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In October&#160;2018, the Company modified the March&#160;2018 and September&#160;2018 Notes to add an additional conversion feature. The Company determined this was a <font style="font-style:italic;">&#8220;substantial modification&#8221; </font>as defined in ASC 470-50 <font style="font-style:italic;">&#8216;Debt: Modifications and Extinguishments&#8217;</font>. As a result, these Notes were accounted for as an &#8216;extinguishment&#8217; of the debt and related derivative liability. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2018, the Company determined that there was no fair value associated with the embedded derivatives that remained with the modified March&#160;2018, the modified September&#160;2018 and December&#160;2018 Notes. See <font style="font-style:italic;">&#8216;Note 5&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217; </font>for further discussion of the Notes and the bifurcated derivative liability. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASC 820-10, <font style="font-style:italic;">Fair Value Measurement</font>, provides a framework for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. The standard defines fair value as an exit price, representing the amount that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. The standard also establishes a fair value hierarchy, which prioritizes the inputs used in measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Level&#160;1&#8201;&#8212; </font>Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-11</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Level&#160;2</font>&#8201;&#8212; Inputs other than quoted prices included within Level&#160;1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Level&#160;3</font>&#8201;&#8212; Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following tables present the Company&#8217;s fair value hierarchy for all of its financial instruments measured at fair value on a recurring basis as of December&#160;31, 2017 and December&#160;31, 2018 (in thousands): </div>
        <table style="width:456pt;height:63.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:48pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;1 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:48pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;2 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:48pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;3 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:54pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:210pt;">Financial liabilities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:210pt;text-align:left;">
              <div style="margin-left:10pt;">Warrant liability </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:210pt;text-align:left;">
              <div style="margin-left:20pt;">Total financial liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:63.5pt;margin-top:13pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, 2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:48pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;1 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:48pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;2 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:48pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;3 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:54pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:210pt;">Financial liabilities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:210pt;text-align:left;">
              <div style="margin-left:10pt;">Warrant liability </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:210pt;text-align:left;">
              <div style="margin-left:20pt;">Total financial liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.39pt; width:456pt; line-height:12pt;">The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the Company&#8217;s term loan is based on the borrowing rate currently available to the Company for borrowings with similar terms and maturity and approximates its carrying value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Derivative liability instruments are considered Level&#160;3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level&#160;3 liability instruments consist of the preferred stock warrant liability and derivative liability, for both of which there is no observable market data for the determination of fair value and requires significant management judgment and estimation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The fair value of the warrant liability was determined using the Black-Scholes model (see <font style="font-style:italic;">&#8216;Note 8&#8201;&#8212; Warrants&#8217; </font>for a further discussion of the preferred stock warrants). The change in fair value of the preferred stock warrant liability is summarized below (in thousands): </div>
        <table style="width:456pt;height:98.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">Years Ended <br >December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:338.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:338.5pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value, beginning of period </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">54</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:338.5pt;text-align:left;">
              <div style="white-space:nowrap;">Preferred stock warrants &#8211; exercised </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:338.5pt;text-align:left;">
              <div style="white-space:nowrap;">Change in fair value of preferred stock warrants </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">98</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:338.5pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value at end of period </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.39pt; width:456pt; line-height:12pt;">The fair value of the embedded derivative liability related to the Company&#8217;s Notes was determined using a bond plus option model. As of December&#160;31, 2018, the Company determined that there was no fair value remaining for the embedded derivatives associated with the modified March&#160;2018, modified September&#160;2018 and December&#160;2018 Notes. See <font style="font-style:italic;">&#8216;Note 5&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217;</font> for further discussion on the derivative liability activity. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-12</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The change in fair value of the derivative liability relating to the Notes is summarized below (in thousands): </div>
        <table style="width:456pt;height:124.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">Years Ended <br >December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:337.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value, beginning of period </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Embedded derivative liability from the issuance of Notes </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">864</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Change in value of embedded derivatives </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(211<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.667pt 0pt 1.333pt 0pt; width:337.5pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Termination of the embedded derivative liability due to the extinguishment of the related Notes </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.667pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.667pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.667pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.667pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(653<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value at end of period </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-weight:bold;">Recently Adopted Accounting Pronouncements </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Restricted Cash </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In November&#160;2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows: Restricted Cash. This ASU requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the total in the statement of cash flows to the related captions in the balance sheet. This guidance is effective for fiscal periods beginning after December&#160;15, 2017 and interim periods within that fiscal year, with early adoption permitted. The amendments in this ASU should be applied retrospectively to all periods presented. The Company adopted the guidance on a retrospective basis on January&#160;1, 2018 and the beginning and ending of cash and cash equivalents for all periods presented in our statements of cash flows include restricted cash. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Non-employee Share-Based Payment Accounting </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2018, FASB issued ASU No. 2018-07, &#8220;Compensation&#8201;&#8212;&#8201;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#8221; (&#8220;ASU 2018-07&#8221;). This new guidance changes the accounting for non-employee share-based payments to align with the accounting for employee stock compensation. The Company early adopted the guidance as of January&#160;1, 2018 and the impact to its financial statements was not material. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Recent Accounting Pronouncements Not Yet Effective </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Lease Accounting</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02. This standard introduces the new leases standard that applies a right-of-use (&#8220;ROU&#8221;) model and requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset and a liability to make lease payments. For leases with a term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. At inception, lessees must classify all leases as either finance or operating based on five criteria. Balance sheet recognition of finance and operating leases is similar, but the pattern of expense recognition in the income statement, as well as the effect on the statement of cash flows, differs depending on the lease classification. This ASU is effective for public entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. The Company is currently assessing whether these amendments will have a material effect on its financial statements. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-13</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">In August&#160;2018, the FASB issued No. ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2019, including interim periods within that fiscal year, with early adoption permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 3.&nbsp;&nbsp;&nbsp;Property and Equipment, Net </div>
        <div style="margin-left:20pt; margin-top:5.41pt; width:436pt; line-height:12pt;">Property and equipment, net, consist of the following (in thousands): </div>
        <table style="width:456pt;height:132pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Furniture and fixtures </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Office equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Computer equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Laboratory equipment </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="margin-left:10pt;">Total property and equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">51</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Less accumulated depreciation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(44<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(41<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:330pt;text-align:left;">
              <div style="margin-left:10pt;">Property and equipment, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:9.41pt; width:456pt; line-height:12pt;">Depreciation expense for the&#160;years ended December&#160;31, 2017 and 2018 was $10,000 and $8,000, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 4.&nbsp;&nbsp;&nbsp;Accrued Liabilities </div>
        <div style="margin-left:20pt; margin-top:5.41pt; width:436pt; line-height:12pt;">Accrued liabilities consist of the following (in thousands): </div>
        <table style="width:456pt;height:103.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Payroll and related expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">273</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">241</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Accrued term loan final payment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">197</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">421</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Accrued clinical trial expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">654</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Professional fees and other costs </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">34</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">195</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:330pt;text-align:left;">
              <div style="margin-left:10pt;">Total accrued liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,158</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">857</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-weight:bold;">Note 5.&nbsp;&nbsp;&nbsp;Term Loans and Convertible Promissory Notes </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Term Loans </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">On November&#160;24, 2015, the Company entered into a loan and security agreement (&#8220;Loan Agreement&#8221;) with Oxford Finance, LLC (&#8220;Oxford&#8221;), pursuant to which Oxford agreed to lend the Company up to $10.0&#160;million, issuable in three tranches of&#8201; $3.0&#160;million (the &#8220;Term Loan A&#8221;), $2.0&#160;million (the &#8220;Term Loan&#160;B&#8221;) and $5.0&#160;million (the &#8220;Term Loan C&#8221;). Term Loan A, Term Loan B and Term Loan C will collectively be referred to as Term Loans. On November&#160;24, 2015, the Company received $3.0&#160;million in proceeds from Term Loan A and on January&#160;29, 2016, the Company received $2.0&#160;million in proceeds from Term Loan B. Warrants were issued in connection with Term Loan A and Term Loan B (See <font style="font-style:italic;">Note 8&#8201;&#8212; Warrants</font>). Under the terms of the Loan Agreement, the Company may, at its sole discretion, borrow $5.0&#160;million under the Term Loan C following the achievement of a defined milestone event until the earlier of 30&#160;days thereafter or March&#160;31, 2016. The Company did not draw on Term Loan C at March&#160;31, 2016 and the availability of the $5.0&#160;million under Term Loan C expired. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-14</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">All outstanding Term Loans will mature on November&#160;1, 2019 (the &#8220;Maturity Date&#8221;) and the Company will have interest only payments through November&#160;1, 2016, followed by 36&#160;months of principal and interest payments. The term loans will bear interest at a floating per annum rate equal to (a)&#160;7.06% plus (ii) the greater of&#8201; (a)&#160;the 30 day U.S. Dollar LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (b)&#160;0.19%. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has the option to prepay all, but not less than all, of the borrowed amounts, provided that the Company will be obligated to pay a prepayment fee equal to (i)&#160;3% of the outstanding principal balance of the applicable Term Loan if prepayment is made prior to the first anniversary of the applicable funding date of the Term Loan, provided, however, the prepayment fee will be reduced to 1% if the Company is acquired within six&#160;months from the Term Loan closing date, or (ii) 2% of the outstanding principal balance of the applicable Term Loan if prepayment is made prior to the second anniversary of the applicable funding date of the Term Loan, or (iii) 1% of the applicable Term Loan prepaid thereafter and prior to the Maturity Date. The Company will be required to make a final payment of 4.25% of the funded amount, payable on the earlier of&#8201; (i)&#160;the Maturity Date or (ii) the prepayment of the Term Loan. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company may use the proceeds from the Term Loans solely for working capital and to fund its general business requirements. The Company&#8217;s obligations under the Loan Agreement are secured by a perfected first priority lien in all of its assets with a negative pledge on owned intellectual property. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January&#160;2017, the Company and Oxford Finance agreed to amend the Loan Agreement. After the Company made principal payments on December&#160;1, 2016 and January&#160;1, 2017, Oxford agreed to an additional 12&#160;months of interest-only payments followed by 23&#160;months of amortization. The amendment fee amounted to $100,000. The amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In March&#160;2018, the Company and Oxford Finance agreed to amend the Loan Agreement. After the Company made principal payments on January&#160;1, 2018, February&#160;1, 2018 and March&#160;1, 2018 Oxford agreed to another 5&#160;months of interest-only payments followed by 15&#160;months of amortization. The amendment fee amounted to $200,000. This amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">In September&#160;2018, the Company and Oxford Finance agreed to amend the debt agreement. Oxford agreed to 1 month of interest-only payments upon closing a $1.5&#160;million convertible promissory note with current investors followed by 2&#160;months of interest-only payments upon entering into a merger followed by 11&#160;months of repayments. The maturity date of the Term Loans remains unchanged. The amendment fee amounted to $25,000. The amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">In December&#160;2018, the Company and Oxford Finance agreed to amend the debt agreement. Oxford agreed to 1 month of interest-only payments upon closing a $1.5&#160;million convertible promissory note with current investors by December&#160;31, 2018, followed by 10&#160;months of repayments. The maturity date of the loans remains unchanged. The amendment fee amounted to $35,000. The amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">The amendment fees are due and payable upon the earlier of: (i)&#160;the Maturity Date, (ii) the acceleration of any Term Loan, or (iii) the prepayment of a Term Loan, and are being accrued over the expected term of the Term Loan as interest expense. </div>
        <div style="text-indent:20pt; margin-top:5.82pt; width:456pt; line-height:12pt;">Upon the respective dates of the debt modifications, no gain or loss was recorded, and a new effective interest rate was established based on the carrying value of the debt and the revised cash flows. </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">The Term Loan A was recorded at its initial carrying value of&#8201; $3.0&#160;million less debt issuance costs of approximately $141,000, Term Loan B was recorded at its initial carrying value of&#8201; $2.0&#160;million, less debt issuance costs of approximately $3,000. The debt issuance costs are being amortized to interest expense over the life of the Term Loan using the effective interest method. The final payment is accrued over the life of the Term Loan through interest expense using the effective interest method. At December&#160;31, 2017, $2.8&#160;million was outstanding under Term Loan A and $1.9&#160;million was outstanding under Term Loan B. As of December&#160;31, 2018, $2.3&#160;million was outstanding under Term Loan A and $1.5&#160;million was outstanding under Term Loan B.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-15</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">Interest expense recorded for the years ended December&#160;31, 2017 and 2018 was $515,000 and $644,000, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2018, the Company was in compliance with all covenants under the Loan Agreement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Future principal payments for the Term Loans due under the Loan Agreement as of December&#160;31, 2018, were as follows (in thousands): </div>
        <table style="width:416pt;height:40.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">Year Ending, <br >December&#160;31, <br >2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.667pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Total principal payments </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.667pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.667pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,833</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.39pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Promissory Notes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The table below reflects the principal amount of the Notes issued by the Company to current investors (in thousands): </div>
        <table style="width:456pt;height:89.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on March&#160;29, 2019, interest at 8.0% p.a. </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on September&#160;27, 2019, interest at 8.0% p.a. </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on December&#160;21, 2019, interest at 8.0% p.a. </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:330pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:19.59pt; width:456pt; line-height:11pt;font-style:italic;">Conversion rights </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The December&#160;2018 Notes were issued with conversion and repayment rights, which are as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event that the Company issues and sells shares of its preferred stock to the investors with proceeds to the Company of at least $5&#160;million, on or before the maturity date, and prior to the closing of a reverse merger, then the outstanding principal amount of these Notes and any unpaid accrued interest will automatically convert in whole into equity securities sold in the preferred stock financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the such preferred stock financing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(b)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event that the Company issues and sells shares of its common stock to the investors with proceeds to the Company of at least $5&#160;million, on or before the maturity date, and after the closing of a reverse merger, then the outstanding principal amount of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities sold in the common stock financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the common stock financing, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(c)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event of a preferred stock financing after the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) has determined that the Company should not pursue the proposed reverse merger with Alliqua BioMedical, Inc. or that such reverse merger is not viable, then in connection with the preferred stock financing the conversion price shall equal eighty&#160;percent (80%) of the cash price paid per share for the preferred securities by the investors in the preferred stock financing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(d)<br ></div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the Company consummates a change of control while the Notes remain outstanding, the Company shall repay the holders in cash in an amount equal to 200% of the outstanding principal amount of the Notes; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-16</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:-1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(e)<br ></div>
        <div style=" margin-top:-1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event the Company consummates an IPO on or before the maturity date, then the outstanding principal amount of the Notes and any unpaid accrued interest will automatically convert into common stock at a conversion price equal to the per share offering price to the public for common stock in the IPO. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Modified March&#160;2018 and Modified September&#160;2018 Notes were outstanding as of December&#160;31, 2018, and had conversion and repayment rights as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event that the Company issues and sells shares of its preferred stock to the investors on or before the maturity date, in a preferred stock financing, then the outstanding principal amount of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities sold in the qualified financing at a conversion price equal to 80% of the cash price paid per share for equity securities by the investors in the qualified financing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(b)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the Company consummates a change of control while the Notes remain outstanding, the Company shall repay the holders in cash in an amount equal to 200% of the outstanding principal amount of the Notes; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(c)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event the Company consummates an IPO on or before the maturity date, then the outstanding principal amount of the Notes and any unpaid accrued interest will automatically convert into common stock at a conversion price equal to the per share offering price to the public for common stock in the IPO. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(d)<br ></div>
          <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In October&#160;2018, the Company modified the terms of the March&#160;2018 and September&#160;2018 Notes to add an additional conversion option. The additional conversion option stipulated that if the Company consummates a reverse merger on or before the Maturity Date and prior to a Qualified Financing (as such terms are defined in the Notes Agreement), then the outstanding principal amount of the Notes and any unpaid accrued interest, shall automatically convert in whole without any further action by the Holder into shares of the Company&#8217;s Series&#160;B convertible preferred stock at a conversion price equal to $0.3133 per share immediately prior to the closing of the reverse merger. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In October&#160;2018, the Company determined that the modification of the March&#160;2018 and September&#160;2018 Notes adding the additional conversion right upon a reverse merger was a &#8220;substantial modification&#8221; as outlined in ASC 470-50 <font style="font-style:italic;">&#8216;Debt: Modifications and Extinguishments&#8217; </font>and treated this modification as an extinguishment of the original Notes and recognized an $11,000 gain from debt extinguishment in its statement of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Derivative Liability </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company evaluated its Notes and determined that embedded components relating to conversion and redemption features of those contracts qualified as derivatives, which need to be separately accounted for in accordance with ASC 815. The Notes contained embedded features that are required to be bifurcated as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">On or before the maturity date of the March&#160;2018 and September&#160;2018 notes, the principal and accrued interest of the notes will automatically convert into equity securities issued and sold in the initial closing of the Company&#8217;s next qualified equity financing with gross proceeds of at least $5.0&#160;million, exclusive of the conversion of the notes. The number of shares to be issued to the note holders will be equal to dividing the outstanding principal and any unpaid accrued interest by 80% of the price paid per share of the next equity security sold to investors. The discount in share price to note holders is not considered clearly and closely related to the debt host and results in an embedded derivative that must be bifurcated and accounted for separately from the debt host. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">For all Notes, in the event of a change in control prior to repayment, the outstanding principal and unpaid accrued interest will be repaid in cash, plus a repayment premium equal to 100% of </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-17</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-left:40pt; margin-top:1pt; width:416pt; line-height:12pt;">the outstanding principal at the time of the change in control. Change in control means (i)&#160;a merger, consolidation, or other capital reorganization or business combination transaction of the Company, with or into, another corporation after which the shares of the capital stock represent a minority after the close of the transaction, or (ii) any transaction or series of related transactions to which the Company is a party in which in excess of 50% of the Company&#8217;s voting power is transferred, or (iii) the sale of all or substantially all of the Company&#8217;s assets or the exclusive license of all or substantially all of the Company&#8217;s material intellectual property. The premium to note holders is not considered clearly and closely related to the debt host and results in an embedded derivative that must be bifurcated and accounted for separately from the debt host. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">For the December&#160;2018 Notes, in the event the Company&#8217;s Board of Directors has determined the proposed reverse merger should not be pursued or is not viable, then in connection with the closing of a preferred stock financing with gross proceeds of at least $5.0&#160;million exclusive of the conversion of the notes, the conversion price shall equal 80% of the cash price paid per share for the securities in the preferred stock financing. However, if any of the holder&#8217;s shares of preferred stock of the Company are converted into common stock or any other equity security that is junior to the shares issued in the preferred stock financing, the notes shall not convert into equity securities sold in the preferred stock financing without the holder&#8217;s prior written consent and instead shall remain outstanding. The discount in share price to note holders is not considered clearly and closely related to the debt host and results in an embedded derivative that must be bifurcated and accounted for separately from the debt host. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Accordingly, upon the issuance of the March&#160;2018 Notes, the estimated fair value of the embedded derivative was determined using a bond plus option valuation model and assuming a probability of 30% that a qualified financing would occur and a probability of 15% that a change in control would occur. The Company recorded the estimated fair value of these embedded derivatives as a liability of&#8201; $496,000 with an offsetting amount recorded as debt discount, which offsets the carrying amount of the debt. The debt discount is amortized over the debt&#8217;s expected term of one year. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the issuance of the September&#160;2018 Notes, the estimated fair value of the embedded derivatives was determined using a bond plus option valuation model and assuming a probability of 40% that a qualified financing would occur and a zero probability that a change in control would occur. The Company recorded the estimated fair value of these embedded derivatives as a liability of&#8201; $368,000 with an offsetting amount recorded as debt discount, which offsets the carrying amount of the debt. The debt discount is amortized over the debt expected term of one year. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In October&#160;2018, the Company modified the March&#160;2018 and September&#160;2018 Notes by adding an additional conversion right upon a reverse merger. The Company deemed this modification to be a <font style="font-style:italic;">&#8220;substantial modification&#8221;</font> as defined in ASC 470-50 <font style="font-style:italic;">&#8216;Debt: Modifications and Extinguishments&#8217;</font> and treated it as an extinguishment of the original Notes and the termination of the related derivative liability. The extinguishment of the March&#160;2018 and September&#160;2018 Notes, resulted in a net gain of&#8201; $11,000 being recorded in other income due to the expensing of the unamortized debt discount of&#8201; $641,000 and the release of the then fair value of the derivative liabilities of&#8201; $653,000. As of December&#160;31, 2018, the Company evaluated the fair value of the derivative liability associated with the modified March&#160;2018, modified September&#160;2018 and December&#160;2018 Notes. It determined that the bifurcated derivative liability had no value because the Company assumed a zero probability that a qualified financing would occur if the then planned reverse merger was not consummated and a zero probability that a change in control would occur. As a result, the Company estimated the fair value of the derivative liability to be $0 at December&#160;31, 2018. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For the&#160;years ended December&#160;31, 2017, and 2018, the Company had recorded interest expense for debt discount on these Notes of&#8201; $0 and $223,000, respectively. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-18</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">Note 6.&nbsp;&nbsp;&nbsp;Commitments and Contingencies </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Operating Leases </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company leases office facilities under a non-cancelable operating lease agreement expiring on December&#160;31, 2019. The total undiscounted future non-cancellable lease payments under the Company&#8217;s operating lease as of December&#160;31, 2018 are as follows (in thousands): </div>
        <table style="width:416pt;height:46pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:338pt;">
              <div style="white-space:nowrap;">Year ending December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">Future <br >Commitments </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:338pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.98pt; width:456pt; line-height:12pt;">Rent expense related to the Company&#8217;s operating leases was $225,000 and $232,000 for the&#160;years ended December&#160;31, 2017 and 2018, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Indemnifications </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has agreed to indemnify its directors and officers for certain events or occurrences arising as a result of the officers or directors serving in such capacity. The Company has a directors&#8217; and officers&#8217; liability insurance policy that limits its exposure and enables the Company to recover a portion of any future amounts paid resulting from the indemnification of its officers and directors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. The Company&#8217;s management believes the estimated fair value of these indemnification agreements is minimal and has not recorded a liability for these agreements as of December&#160;31, 2018. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 7.&nbsp;&nbsp;&nbsp;Stockholders&#8217; Deficit </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Redeemable Convertible Preferred Stock </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017 and 2018, the Company had 56,672,658 shares of Series&#160;A convertible preferred stock issued and outstanding, including 3,531,889 shares issued as a result of a conversion of notes to investors and accrued interest to Series&#160;A convertible preferred stock in 2010. As of December&#160;31, 2017 and 2018, the Company had 51,069,262 shares of Series&#160;B convertible preferred stock issued and outstanding, including 6,469,356 shares issued as a result of a conversion of notes to investors and accrued interest to Series&#160;B convertible preferred stock in 2016. </div>

        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The holders of preferred stock have various rights and preferences including the following: </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Voting Rights&#8201;&#8212; </font>A holder of each share of Series&#160;A and Series&#160;B convertible preferred stock shall have the right to one vote for each share of common stock into which such preferred stock could be converted. Series&#160;A convertible preferred stock holders voting as a separate class are entitled to elect two directors to the Company&#8217;s Board of Directors as long as shares of Series&#160;A convertible preferred stock remain outstanding. Series&#160;B convertible preferred stock holders voting as a separate class are entitled to elect one director to the Company&#8217;s Board of Directors as long as at least 10,000,000 shares of Series&#160;B convertible preferred stock remain outstanding. Common stockholders voting as a separate class are entitled to elect two directors. The holders of preferred and common stock voting together as a single class on an as-if-converted basis are entitled to elect all remaining directors. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;">Dividends&#8201;&#8212; </font>Holders of Series&#160;B convertible preferred stock, in preference to the holders of Series&#160;A preferred and common stock, are entitled to receive noncumulative dividends at the annual rate of&#8201; $0.0251 per share, when, as, and if declared by the Board of Directors. Holders of Series&#160;A convertible preferred </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-19</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">stock are entitled to receive noncumulative dividends at the annual rate of&#8201; $0.0182 per share, when, as, and if declared by the Board of Directors. No dividends on preferred stock have been declared by the Board of Directors during the&#160;years ended December&#160;31, 2017 and 2018. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Liquidation Preference&#8201;&#8212; </font>In the event of any liquidation, dissolution, or winding up of the Company, including a merger, acquisition, or sale of assets, as defined, the holders of Series&#160;B convertible preferred stock are entitled to receive an amount of&#8201; $0.3133 per share (as adjusted for recapitalizations, stock combinations, stock dividends, stock splits, and the like), plus any declared but unpaid dividends prior to and in preference to any distribution to the holders of Series&#160;A preferred or common stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">After distributions have been made to all holders of Series&#160;B convertible preferred stock as described above, the remaining assets of the Company available for distribution to stockholders shall be distributed to all holders of Series&#160;A convertible preferred stock. The holders of Series&#160;A convertible preferred stock are entitled to receive an amount of&#8201; $0.2276 per share (as adjusted for recapitalizations, stock combinations, stock dividends, stock splits, and the like), plus any declared but unpaid dividends prior to and in preference to any distribution to the holders of common stock. The remaining assets of the Company available for distribution to stockholders shall be distributed ratably among the holders of the common stock and preferred stock on an as-if-converted basis. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Conversion Rights&#8201;&#8212; </font>Each share of Series&#160;A and Series&#160;B convertible preferred stock is convertible, at the option of the holder, into shares of common stock on a one for one basis (subject to adjustment for certain events). The preferred stock will also be converted automatically into shares of common stock (1)&#160; immediately prior to an initial public offering with aggregate proceeds of at least $40&#160;million and an offering price of not less than $1.00 per common share or (2)&#160;upon the date specified by written consent of holders of a majority of the outstanding preferred shares on an as-converted basis. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Series&#160;A and Series&#160;B Preferred Stock were classified as temporary equity in the accompanying balance sheets as of the December&#160;31, 2017 and 2018, as shares are subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control. As of December&#160;31, 2017 and 2018, the Series&#160;A and Series&#160;B Preferred Stock were not redeemable. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Common Stock </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s articles of incorporation, as amended, authorize the Company to issue 148,000,000 shares of&#8201; $0.001 par value common stock. As of December&#160;31, 2017 and 2018, the Company had 19,548,969 shares outstanding. Common stockholders are entitled to dividends when and if declared by the Board of Directors and after any Series&#160;B and Series&#160;A convertible preferred shares dividends are fully paid. The holder of each share of common stock is entitled to one vote. At December&#160;31, 2018, no dividends had been declared. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Shares Reserved for Future Issuance </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The Company reserved shares of common stock for future issuances as follows (in thousands): </div>

          <table style="width:456pt;height:103.5pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2017 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2018 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">
                <div style="white-space:nowrap;">Series&#160;A convertible preferred stock </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">56,673</td>
              <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">56,673</td>
              <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">
                <div style="white-space:nowrap;">Series&#160;B convertible preferred stock </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">51,069</td>
              <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">51,069</td>
              <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">
                <div style="white-space:nowrap;">Warrants for Series&#160;A convertible preferred stock </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">330</td>
              <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">330</td>
              <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:330pt;text-align:left;">
                <div style="white-space:nowrap;">Common stock options issued and outstanding </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">19,222</td>
              <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">19,222</td>
              <td style="padding:0pt;padding-left:10.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 2.75pt 0pt; width:330pt;text-align:left;">
                <div style="margin-left:10pt;">Total </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">127,294</td>
              <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">127,294</td>
              <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="height:4.5pt;line-height:4.5pt;">
              <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-20</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>

          <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">Note 8.&nbsp;&nbsp;&nbsp;Warrants </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with convertible notes agreements with investors issued between January&#160;1, 2009 and July&#160;1, 2010, the Company issued warrants to purchase such number of shares of Series&#160;A convertible preferred stock issued in the next round of equity financing equal to 20% of notes payable principal amounts divided by the price per share of such preferred stock. The warrants are exercisable after closing of each preferred stock financing for five&#160;years and expire seven&#160;years from the issuance date. At the issuance dates, the Company estimated the fair value of issued warrants as minimal due to the uncertainty of the Series&#160;A convertible preferred stock financing. The Company estimated the fair value of outstanding warrants at the date of closing of the Series&#160;A convertible preferred stock financing and used the Black-Scholes model with the following assumptions: expected lives equal to the remaining contractual life in a range of 3.92 to 7&#160;years, risk-free interest rates in a range of 1.46% to 2.66%, expected dividend yield of zero, volatility in the range of 73.6% to 81.5%, and a fair value of Series&#160;A convertible preferred stock of $0.2276 per share. As of December&#160;31, 2017, the outstanding warrants had been exercised.</div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with the Oxford Loan Agreement signed in November&#160;2015, the Company issued a warrant to purchase 197,715 shares of the Company&#8217;s preferred stock at an exercise price equal to the Series&#160;A preferred stock price of&#8201; $0.2276. The warrant is exercisable after closing and expires ten&#160;years from the issuance date. The Company estimated the fair value of the warrant at closing and used the Black-Scholes model with the following assumptions: expected life equal to the remaining contractual life of 10&#160;years, risk-free interest rate of 2.07%, expected dividend yield of zero, volatility of 68.7%, and a fair value of Series&#160;A convertible preferred stock of&#8201; $0.20 per share. The Company recorded the fair value of the warrant of&#8201; $33,000 as a debt discount to be amortized to interest expense over the life of the Term Loan&#160;A. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January&#160;2016, in connection with the Oxford Loan Agreement signed in November&#160;2015, the Company issued a warrant to purchase 131,810 shares of the Company&#8217;s preferred stock at an exercise price equal to the Series&#160;A preferred stock price of&#8201; $0.2276. The warrant is exercisable after closing and expires ten&#160;years from the issuance date. The Company estimated the fair value of the warrant at closing and used the Black-Scholes model with the following assumptions: expected life equal to the remaining contractual life of 10&#160;years, risk-free interest rate of 2.09%, expected dividend yield of zero, volatility of 68.6%, and a fair value of Series&#160;A convertible preferred stock of&#8201; $0.23 per share. The Company recorded the fair value of the warrant of&#8201; $22,000 as a debt discount to be amortized to interest expense over the life of the Term Loan B. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The change in fair value of the warrants issued in connection with Term Loan A and B at December&#160;31, 2017 and 2018 of&#8201; ($12,000) and $98,000 respectively, were recorded to other expense (income). As of December&#160;31, 2018, the warrants remained outstanding and exercisable. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The above Black-Scholes model assumptions were determined as follows: </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;font-style:italic;">Term<font style="font-style:normal;">&#8201;&#8212; The term represents the remaining contractual term of the warrants. </font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Risk-free interest rate&#8201;&#8212; </font>The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal the remaining term of the warrants. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected</font> <font style="font-style:italic;">volatility</font>&#8201;&#8212; The expected volatility is derived from historical volatilities of several unrelated publicly listed peer companies over a period approximately equal to the remaining term of the warrants because the Company has limited information on the volatility of the preferred stock since there is currently no trading history. When making the selections of the Company&#8217;s industry peer companies to be used in the volatility calculation, the Company considered the size and operational and economic similarities to the Company&#8217;s principal business operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected dividend yield</font>&#8201;&#8212; The expected dividend yield is based on the Company&#8217;s history of not paying dividends. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-21</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The warrants are classified as a liability as they are exercisable into shares that are potentially redeemable. The fair value of the warrant liability is re-measured at each balance sheet date with the change as other income recorded in the statements of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The fair value of the Series&#160;A convertible preferred stock warrants outstanding at December&#160;31, 2017 and 2018 was $42,000 and $140,000 respectively, and the details of the warrants were as follows: </div>

          <table style="width:456pt;height:69pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:237.1pt;text-align:left;">
                <div style="white-space:nowrap;">Issuance Date </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:68.9pt;">
                <div style="white-space:nowrap; text-align:center;">Expiration Date </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Exercise Price </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Number of <br >Shares <br >(in thousands) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 1pt 0pt; width:237.1pt;text-align:left;">
                <div style="white-space:nowrap;">November, 2015 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.75pt 0.5pt 1pt 0pt; width:68.9pt;">
                <div style="white-space:nowrap; text-align:right;">November, 2025&#8203;</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.2276</td>
              <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:22.5pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">198</td>
              <td style="padding:0pt;padding-left:22.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:237.1pt;text-align:left;">
                <div style="white-space:nowrap;">January, 2016 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0.5pt 2pt 0pt; width:68.9pt;">
                <div style="text-align:right;">January, 2026&#8203;</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">0.2276</td>
              <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:22.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">132</td>
              <td style="padding:0pt;padding-left:22.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 2.75pt 0pt; width:237.1pt;text-align:left;">
                <div style="margin-left:10pt;">Total </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0.5pt 0.75pt 0pt; width:68.9pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:22.5pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">330</td>
              <td style="padding:0pt;padding-left:22.5pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="text-indent:20pt; margin-top:13.99pt; width:456pt; line-height:12pt;">The fair value of the Series&#160;A convertible preferred stock warrants was determined using the following assumptions: </div>
        <table style="width:456pt;height:89pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:323.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:323.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:45.83pt;">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:62.28pt;">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:45.83pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:62.28pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:323.89pt;text-align:left;">
              <div style="white-space:nowrap;">Risk-free interest rate </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:45.83pt;">
              <div style="text-align:center;">2.28% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:62.28pt;">
              <div style="text-align:center;">2.56%&#8201;&#8211;&#8201;2.59% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:323.89pt;text-align:left;">
              <div style="white-space:nowrap;">Remaining contractual life (in&#160;years) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:45.83pt;">
              <div style="text-align:center;">7.92&#8201;&#8211;&#8201;8.08 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:62.28pt;">
              <div style="text-align:center;">6.92&#8201;&#8211;&#8201;7.08 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:323.89pt;text-align:left;">
              <div style="white-space:nowrap;">Dividend yield </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:45.83pt;">
              <div style="text-align:center;">&#8212;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:62.28pt;">
              <div style="text-align:center;">&#8212;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:323.89pt;text-align:left;">
              <div style="white-space:nowrap;">Expected volatility </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:45.83pt;">
              <div style="text-align:center;">71.00% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:62.28pt;">
              <div style="text-align:center;">76.84%</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.98pt; width:456pt; line-height:11pt;font-weight:bold;">Note 9.&nbsp;&nbsp;&nbsp;Stock Option Plans </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2010, the Company adopted the 2010 Equity Incentive Plan (the &#8220;Plan&#8221;). The Plan provides for the granting of stock options to employees and consultants of the Company. Options granted under the Plan may be either incentive stock options (&#8220;ISOs&#8221;) or non-qualified stock options (&#8220;NSOs&#8221;). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants. The Company has 19,222,032 shares of common stock reserved for issuance under the Plan as of December&#160;31, 2018. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Options under the Plan may be granted for periods of up to 10&#160;years and at prices no less than 100% of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the Board of Directors provided, however, that the exercise price of an ISO and NSO granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. The Plan requires that options be exercised no later than 10&#160;years after the grant. Options granted to employees generally vest ratably on a monthly basis over four&#160;years. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-22</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The following table summarizes stock option activity under the Company&#8217;s stock plan and related information (in thousands, except exercise prices and&#160;years): </div>

          <table style="width:456pt;height:156pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:183.48pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.21pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.21pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="16">
                <div style="white-space:nowrap; text-align:center;">Outstanding Options</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:183.48pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Shares <br >Available <br >For Grant </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Options <br >Outstanding </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Weighted- <br >Average <br >Exercise <br >Price <br >Per Share </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Weighted- <br >Average <br >Remaining <br >Contractual <br >Life <br >(in years) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Aggregate <br >Intrinsic <br >Value<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(a)</font></div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 2.75pt 0pt; width:183.48pt;text-align:left;">
                <div style="white-space:nowrap;">Balance at December&#160;31, 2016 </div>
              </td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;5</td>
              <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,222</td>
              <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.10</td>
              <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">9.4</td>
              <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 2.75pt 0pt; width:183.48pt;text-align:left;">
                <div style="white-space:nowrap;">Balance at December&#160;31, 2017 </div>
              </td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;5</td>
              <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,222</td>
              <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.10</td>
              <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">8.4</td>
              <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,639</td>
              <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 2.75pt 0pt; width:183.48pt;text-align:left;">
                <div style="white-space:nowrap;">Balance at December&#160;31, 2018 </div>
              </td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;5</td>
              <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,222</td>
              <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.10</td>
              <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.4</td>
              <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,956</td>
              <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.167pt 0pt 2.083pt 0pt; width:183.48pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Vested and expected to vest as of December&#160;31, 2018 </div>
              </td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,222</td>
              <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.167pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.10</td>
              <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.4</td>
              <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.167pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,956</td>
              <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 2.083pt 0pt; width:183.48pt;text-align:left;">
                <div style="white-space:nowrap;">Exercisable at December&#160;31, 2018 </div>
              </td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">11,146</td>
              <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.09</td>
              <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.4</td>
              <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt; width:9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,119</td>
              <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:9.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
          <div style=" margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company&#8217;s common stock of $0.46 and $0.44 per share as of December&#160;31, 2018 and 2017.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:10.98pt; width:456pt; line-height:12pt;">The Company did not grant any common stock options to employees during the&#160;years ended December&#160;31, 2017 and 2018. Stock-based compensation expense recorded in research and development and general and administrative expenses was $301,000 and $293,000 for the&#160;years ended December&#160;31, 2017 and 2018, respectively. As of December&#160;31, 2018, unrecognized stock-based compensation expense related to employees totaled approximately $531,000, which is expected to be recognized over approximately 2.0&#160;years. </div>
        <div style="margin-top:16.98pt; width:456pt; line-height:11pt;font-style:italic;">Stock Options Granted to Non-Employees </div>
        <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">Stock-based compensation expense recorded in exchange for services related to non-employee options was $0 and $16,000 for the&#160;years ended December&#160;31, 2017 and 2018, respectively. </div>
        <div style="text-indent:20pt; margin-top:10.99pt; width:456pt; line-height:12pt;">As of December&#160;31, 2018, unrecognized stock-based compensation expense related to unvested non-employees stock options was approximately $48,000, which is expected to be recognized over a weighted-average period of nine&#160;months. </div>
        <div style="margin-top:16.98pt; width:456pt; line-height:11pt;font-weight:bold;">Note 10.&nbsp;&nbsp;&nbsp;Income Taxes </div>
        <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">The Company recorded no income tax benefit or expense for the years ended December&#160;31, 2017 and 2018. No tax benefit was recorded through December&#160;31, 2018 because, given the history of operating losses, the Company believes it is more likely than not that the deferred tax asset will not be realized, and a full valuation allowance has been provided. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-23</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table presents significant components of the Company&#8217;s deferred tax assets (in thousands): </div>
        <table style="width:416pt;height:120pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Net operating loss carry forward </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">6,158</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">7,051</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Research and development credits </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,284</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,601</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Accruals and reserves </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">99</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">142</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Fixed assets </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:266pt;text-align:left;">
              <div style="margin-left:10pt;">Total deferred tax asset </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">7,541</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">8,795</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Valuation allowance </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(7,541<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(8,795<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:266pt;text-align:left;">
              <div style="margin-left:10pt;">Net deferred tax asset </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:9.41pt; width:456pt; line-height:12pt;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#8217;s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2017 and 2018. The valuation allowance decreased approximately $964,000 and increased $1.2 million during the&#160;years ended December&#160;31, 2017 and 2018, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On December&#160;22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;). The Tax Act makes broad and complex changes to the U.S. tax code that affect fiscal 2017, including, but not limited to requiring a one-time transition tax on certain un-repatriated earnings of foreign subsidiaries (the &#8220;Transition Tax&#8221;). The Tax Act also establishes new tax laws that will affect 2018 and later&#160;years, including, but not limited to, a reduction of the U.S. federal corporate tax rate from 35% to 21% and a transition of U.S. international taxation from a worldwide tax system to a territorial system. During the year ended December&#160;31, 2017, the Company did not recognize an amount for the one-time transition tax, nor did the Company make any accounting policy elections on the treatment of the other international provisions of tax reform due to the fact the Company does not currently have any foreign subsidiaries. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2017, the Company corrected the balance of Net Operating Losses and Research and Development Credits and the associated Valuation Allowances in connection with the Company&#8217;s determination of nexus in an additional state which was previously not identified correctly. The correction of such error did not have any impact on the Company&#8217;s financial position and results of operations for any period presented or any prior period results. The Company has corrected the gross amount of deferred tax assets and the valuation allowance for 2016 to correct the error. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2018, the Company had federal net operating loss, or NOL, carry forwards of $33.5&#160;million available to reduce future taxable income, if any. The NOL carry forwards prior to January&#160;1, 2018 of&#8201; $28.7&#160;million will begin to expire in 2033. The NOL carry forwards incurred post December&#160;31, 2017 of&#8201; $4.8&#160;million will carry forward indefinitely. As of December&#160;31, 2018, the Company had federal and state research and development credits of&#8201; $1.8&#160;million and $0.7&#160;million, respectively. The federal research and development credits will begin to expire in 2031. The state research and development credit will carry forward indefinitely. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Internal Revenue Code (&#8220;IRC&#8221;) Section&#160;382 and similar California rules place a limitation on the amount of taxable income that can be offset by NOL and credit carry forwards after a change in control. Generally, after a control change, a corporation cannot deduct NOL or credit carry forwards in excess of the Section&#160;382 limitations. Although the Company has not completed an analysis under Section&#160;382 of the Code since the year ended December&#160;31, 2012, it believes that it is unlikely that the utilization of the NOLs and tax credit carry forwards will be substantially limited. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-24</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The tax return&#160;years 2014 through 2018 remain open to examination by the major domestic taxing jurisdictions to which the Company is subject. Net operations losses generated on a tax return basis by the Company for calendar&#160;years 2013 and 2015 to 2018 remain open to examination by the IRS. Net operating losses generated on state returns by the Company for calendar&#160;years 2007 to 2013 and 2015 to 2018 remain open to examination by state authorities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASC 740-10 requires companies to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities. The following table summarizes the activity related to the Company&#8217;s gross unrecognized tax benefits (in thousands): </div>
        <table style="width:416pt;height:83pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">Years Ended <br >December&#160;31, <br >2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Balance at December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">331</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Changes related to prior year positions </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">330</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Increases related to current year positions </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Balance at December&#160;31, 2018 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:11.2pt; width:456pt; line-height:12pt;">The Company&#8217;s policy is to record interest related to uncertain tax positions as interest and any penalties as other expense in its statement of operations. As of the date of adoption and through December&#160;31, 2018, the Company did not have any interest and penalties associated with unrecognized tax benefits. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 11.&nbsp;&nbsp;&nbsp;Related-Party Transactions </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In March&#160;2018, September&#160;2018, and December&#160;2018, the Company issued Notes to the Company&#8217;s majority investors totaling $4.5&#160;million as of December&#160;31, 2018. These Notes accrue simple interest on the outstanding principal amount at the rate of 8% per annum. As of December&#160;31, 2018, accrued interest on the Notes was $126,000&#8201;&#8212; for further details see the section above titled <font style="font-style:italic;">&#8216;Note 5&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217;.</font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 12.&nbsp;&nbsp;&nbsp;Employee Benefit Plan </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has established a 401(k) Plan (the &#8220;401(k) Plan&#8221;) that permits participants to make contributions by salary deduction pursuant to Section&#160;401(k) of the IRC. The Company may, at its discretion, make matching contributions to the 401(k) Plan. The Company has made no contributions to the 401(k) Plan since its inception. The Company makes a nonelective 401(k) safe harbor contribution on behalf of each employee equal to 3% of their annual salary. The Company&#8217;s non-elective safe harbor contributions totaled $54,000 and $49,000 for the&#160;years ended December&#160;31, 2017 and 2018, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 13.&nbsp;&nbsp;&nbsp;Subsequent Events </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January 2019, the Company and Oxford Finance agreed to amend the debt agreement. Oxford agreed to 2 months of interest-only payments followed by 8 months of repayments upon delivery by February 1, 2019 of an executed term sheet between the Company and Domain, the Company&#8217;s majority investor and an affiliate thereof, that would result in aggregate proceeds to the Company of&#8201;$20.0 million. The Company was also required to place $200,000 in a segregated bank account that is subject to a blocked control agreement in favor of Oxford. The funds in the segregated account were to be released upon the earlier of, the consummation of a merger by March 31, 2019 or the consummation of the equity financing. The Company recorded the $200,000 as restricted cash in its balance sheet at March 31, 2019. The maturity date of the loans remained unchanged. The amendment fee amounted to $50,000. The amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Beginning in January 2019, the Company amended the 401(k) Plan to discontinue the nonelective safe harbor contribution on behalf of each employee equal to 3% of their annual salary. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-25</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">In April&#160;2019 and May&#160;2019, the Company&#8217;s primary investor agreed to provide the Company with $2.0&#160;million and $0.5&#160;million in the form of Notes to fund the Company&#8217;s operations. These notes accrue simple interest on the outstanding principal amount at the rate of 8% per annum and mature on April&#160;26, 2020 and May&#160;29, 2020. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In May&#160;2019, the Company and Oxford Finance agreed to a seventh amendment to provide consent to the Merger. This consent amended certain provisions of the term loan to protect Oxford&#8217;s rights under the original term loan agreement. The consent allowed Alliqua to be named as an additional borrower. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;3, 2019 the Company completed its Merger into Alliqua Biomedical Inc. (&#8220;Alliqua&#8221;). Immediately following the Merger, the combined company&#8217;s name was changed from &#8220;Alliqua BioMedical, Inc.&#8221; to &#8220;Adynxx, Inc.&#8221; The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. Under the Exchange Ratio formula in the Merger Agreement, as of immediately following the Merger, but excluding the effect of certain financings (as further described in the Merger Agreement), Adynxx equity holders now own approximately 86% of the aggregate number of shares of the combined company and Alliqua equity holders own approximately 14% of the combined company. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Subject to the terms and conditions of the Merger Agreement (a)&#160;each outstanding share of capital stock of Adynxx, was converted into the right to receive the number of shares of Alliqua&#8217;s common stock equal to the Exchange Ratio formula in the Merger Agreement and (b)&#160;each outstanding Adynxx stock option, whether vested or unvested, and warrant that has not previously been exercised, was assumed by the post merged company and converted into a stock option or warrant, as the case may be, to purchase shares of the post merged Adynxx Company&#8217;s common stock at the Exchange Ratio formula in the Merger Agreement. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, prior to the closing of the Merger, the $3.0&#160;million of Notes and $203,000 of cumulative accrued interest, was converted into 10,223,996 shares of Series&#160;B convertible preferred stock. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has evaluated subsequent events through June&#160;7, 2019, the date the financial statements were issued, for appropriate accounting and financial statement disclosures.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-26</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfuBS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:11pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Condensed Consolidated Balance Sheets <br >(In thousands, except share and per share data) <br >(unaudited) </div>

          <table style="width:456pt;height:539pt;margin-top:7pt;border-collapse: collapse;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">December&#160;31, <br >2018 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">June&#160;30, <br >2019 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.25pt 0pt 0.5pt 0pt; width:350.37pt;">Assets:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;">Current assets</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:10pt;">Cash and cash equivalents </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,887</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">24</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:10pt;">Restricted cash </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">55</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">254</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:10pt;">Prepaid expenses and other current assets </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,622</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.25pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:20pt;">Total current assets </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,952</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,900</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="white-space:nowrap;">Property and equipment, net </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="white-space:nowrap;">Right of use asset, net </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">779</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="white-space:nowrap;">Other assets </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.25pt 0pt 2.25pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:20pt;">Total assets </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,980</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,703</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:7.75pt 0pt 0.5pt 0pt; width:350.37pt;">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;">Current liabilities</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:10pt;">Accounts payable </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">491</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,748</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:10pt;">Accrued liabilities </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">857</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,480</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:10pt;">Current portion of operating lease liability </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">346</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:10pt;">Convertible promissory notes - related party </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,500</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">5,497</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:10pt;">Current portion of term loan, net of discount </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">3,812</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,390</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.25pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:20pt;">Total current liabilities </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,660</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">11,461</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="white-space:nowrap;">Operating lease liability, net of current portion </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">493</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="white-space:nowrap;">Warranty liability </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">140</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;">
                <div style="white-space:nowrap;">Commitments and contingencies (Note 7) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;">Redeemable convertible preferred stock</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:1.167pt 0pt 0.5pt 0pt; width:350.37pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">Series&#160;A redeemable convertible preferred stock, $0.001 par value; 2,046,378 shares authorized, 2,034,548 shares issued and outstanding at December&#160;31, 2018, 0 shares authorized, issued and outstanding at June&#160;30, 2019 (unaudited) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12,814</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:1.167pt 0pt 0.5pt 0pt; width:350.37pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">Series&#160;B redeemable convertible preferred stock, $0.001 par value; 1,833,387 shares authorized, issued and outstanding at December&#160;31, 2018, 0 shares authorized, issued and outstanding at June&#160;30, 2019 (unaudited); </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">15,897</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;">Stockholders&#8217; deficit</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:1.167pt 0pt 0.5pt 0pt; width:350.37pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">Preferred stock, $0.001 par value; 1,000,000 shares authorized no shares issued or outstanding  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:1.167pt 0pt 0.5pt 0pt; width:350.37pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">Common stock, $0.001 par value; 5,313,200 shares authorized, 701,808 shares issued and outstanding at December&#160;31, 2018, 95,000,000 shares authorized, 5,807,877 shares issued and outstanding at June&#160;30, 2019 (unaudited) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:10pt;">Additional paid-in capital </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">747</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">35,160</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:10pt;">Accumulated deficit </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(37,279<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,417<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.5pt 0pt; width:350.37pt;text-align:left;">
                <div style="margin-left:20pt;">Total stockholders&#8217; deficit </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(36,531<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(9,251<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0.917pt 0pt 1.583pt 0pt; width:350.37pt;white-space:normal;text-align:left;">
                <div style="margin-left:30pt; text-indent:-10pt;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; deficit </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,980</td>
              <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,703</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-27</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfuSO">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:281.5pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Condensed Consolidated Statements of Operations <br >(In thousands, except share and per share data) <br >(Unaudited) </div>

          <table style="width:456pt;height:268.5pt;margin-top:7pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">Six Months Ended June&#160;30, </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2018 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2019 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;">Operating expenses</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="margin-left:10pt;">Research and development </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,269</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,226</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="margin-left:10pt;">General and administrative </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,292</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,317</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="margin-left:10pt;">Grant reimbursements </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1,198<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="margin-left:20pt;">Total operating expenses, net </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,561</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">4,345</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">Loss from operations </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(2,561<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(4,345<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">Interest expense, net </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(445<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(2,641<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">Other income (expense), net </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">60</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(94<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">Loss from continuing operations </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(2,946<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(7,080<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">Loss from discontinued operations </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(58<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">Net loss </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(2,946<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(7,138<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 1.5pt 0pt; width:341.17pt;">Net loss per basic and diluted share:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="margin-left:10pt;">Loss from continuing operations </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(0.64<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(1.43<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="margin-left:10pt;">Loss from discontinued operations </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(0.01<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">Net loss per basic and diluted share </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(0.64<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1.44<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">Weighted-average number of common shares outstanding&#8201;&#8211;&#8201;basic and diluted </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">4,569,742</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">4,966,491</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-28</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfuSRC">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:18pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit<br >(In thousands, except share amounts) (Unaudited)</div>
      </div>
      <div style="margin-top:18pt;margin-bottom:309pt;margin-left:27.5pt;width:541pt;">

          <table style="width:541pt;height:260pt;margin-top:0pt;border-collapse: collapse;">
            <tr style="line-height:8pt;height:25.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">Series&#160;A Redeemable <br >Convertible <br >Preferred Stock</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">Series&#160;B Redeemable <br >Convertible <br >Preferred Stock</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">Common Stock </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt;" colspan="4" rowspan="2">
                <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">Additional <br >Paid-In <br >Capital </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt;" colspan="4" rowspan="2">
                <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">Accumulated <br >Deficit </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt;" colspan="4" rowspan="2">
                <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">Total <br >Stockholders&#8217; <br >Deficit </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
            </tr>
            <tr style="line-height:7pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Shares </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Amount </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Shares </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Amount </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Shares </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Amount </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.25pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">
                <div style="white-space:nowrap;">Balance, December&#160;31, 2018 </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">2,034,548</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">12,814</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">1,833,387</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">15,897</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">701,808</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">1</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">747</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(37,279<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(36,531<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">
                <div style="white-space:nowrap;">Stock-based compensation expense </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">84</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">84</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:159.64pt;text-align:left;">
                <div style="white-space:nowrap;">Net loss </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,462<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,462<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:159.64pt;text-align:left;">
                <div style="white-space:nowrap;">Balance, March&#160;31, 2019 </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">2,034,548</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">12,814</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">1,833,387</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">15,897</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">701.808</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:6pt; text-align:right; white-space:nowrap;">1</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">831</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(39,741<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(38,909<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:159.64pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Conversion of convertible notes into convertible preferred stock </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">367,041</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">3,203</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:159.64pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Recognition of beneficial conversion feature upon conversion of convertible notes </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,101</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:159.64pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Conversion of of convertible preferred stock into common stock </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,034,548<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(12,814<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,200,428<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(21,201<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,234,976</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">4</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">34,011</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">34,015</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">
                <div style="white-space:nowrap;">Issuance of common stock for merger </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">854,017</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">1</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">1</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">
                <div style="white-space:nowrap;">Equity issuance costs paid in stock </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">17,076</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:159.64pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Impact of change of warrants subject to fair value measure to equity warrants </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">234</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">234</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">
                <div style="white-space:nowrap;">Spin-off of AquaMed </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">
                <div style="white-space:nowrap;">Stock-based compensation expense </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">84</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">84</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:159.64pt;text-align:left;">
                <div style="white-space:nowrap;">Net loss </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(4,676<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(4,676<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:3.25pt 0pt 2.75pt 0pt; width:159.64pt;text-align:left;">
                <div style="white-space:nowrap;">Balance, June&#160;30, 2019 </div>
              </td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt; width:4.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,807,877</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:6pt; text-align:right; white-space:nowrap;">6</td>
              <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">35,160</td>
              <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(44,417<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt; width:5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(9,251<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="height:4pt;line-height:4pt;">
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="">&#8203;</td>
              <td style="" colspan="4">&#8203;</td>
              <td style="">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:338pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">F-29</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfuSCF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Condensed Consolidated Statements of Cash Flows <br >(In thousands) (Unaudited) </div>
        <table style="width:456pt;height:540pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:352.3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six&#160;Months Ended June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:352.3pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:352.3pt;">Cash flows from operating activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,946<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(7,138<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;">
              <div style="margin-left:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Depreciation expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Stock-based compensation expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">150</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">168</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Changes in fair value of warrant liability </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">95</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Changes in fair value of derivative liability </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(60<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Accretion of final charge upon maturity of Oxford Term Loan A and B </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">94</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">148</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:352.3pt;white-space:normal;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">Amortization of issuance cost and discounts for term loans and convertible notes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">130</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Non-cash interest expense on convertible promissory notes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">31</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,304</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Non-cash operating lease cost </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;">
              <div style="margin-left:10pt;">Changes in operating assets and liabilities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Prepaid expenses and other current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1,611<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Other assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Accounts payable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(607<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,255</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Accrued liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(312<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">475</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Lease liability </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(136<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:30pt;">Net cash used in operating activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,527<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(4,223<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:352.3pt;">Cash flows from investing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:30pt;">Net cash used in investing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:352.3pt;">Cash flows from financing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Payments on term loan </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(616<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1,437<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Proceeds from issuance of convertible promissory notes - related party </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">3,996</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:30pt;">Net cash provided by financing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">884</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,559</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="white-space:nowrap;">Net decrease in cash, cash equivalents and restricted cash </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,643<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1,664<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="white-space:nowrap;">Cash, cash equivalents and restricted cash at beginning of period </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">4,356</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,942</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:352.3pt;text-align:left;">
              <div style="white-space:nowrap;">Cash, cash equivalents and restricted cash at end of period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,713</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">278</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:352.3pt;">Other supplemental disclosure:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Cash paid for interest </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">190</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">173</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:352.3pt;">Non-cash investing and financing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Right-of-use assets obtained in exchange for operating lease obligations<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">227</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Reclassification of warrant liability to paid in capital </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">234</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Conversion of convertible preferred stock into common stock </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">34,015</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:9.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Amounts for the six&#160;months ended June&#160;30, 2019 pertains to the transition adjustment for the adoption of ASC 842.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-30</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfuNFS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 1.&nbsp;&nbsp;&nbsp;Organization and Basis of Presentation </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The Company </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, Adynxx, Inc. (&#8220;Adynxx&#8221; or the &#8220;Company&#8221;), formerly known as &#8220;Alliqua BioMedical, Inc.,&#8221; or Alliqua completed its reverse merger with what was then known as Adynxx, Inc., or Private Adynxx, which we refer to as the Merger. This transaction was accounted for as a reverse merger. See <font style="font-style:italic;">&#8216;Note 3&#8201;&#8212;&#8201;Reverse Merger&#8217;</font>. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company is a clinical stage biopharmaceutical company focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company is primarily engaged in developing initial product technology, recruiting personnel, and raising capital. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Basis of Presentation </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These unaudited financial statements represent the condensed consolidated financial statements of Adynxx and, for periods prior to the Merger, the condensed consolidated financial statements of Private Adynxx. The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and pursuant to the instructions of the SEC on Form 10-Q and Article&#160;10 of Regulation&#160;S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the Company&#8217;s financial position on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the periods ended June&#160;30, 2018 and 2019 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the periods ended June&#160;30, 2018 and 2019 is unaudited. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements and the notes thereto as set forth in the Company&#8217;s Form 8-K/A filed with the SEC on June&#160;10, 2019.</div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All share and per share data, for all periods presented, of the issued and outstanding common stock of Adynxx, Inc., have been retroactively restated to reflect the exchange ratio used in the Merger of 0.0359 shares of capital stock in exchange for each share of Private Adynxx, Inc. capital stock outstanding immediately prior to the Merger (which exchange ratio reflects a 1-for-6 reverse stock split of the issued and outstanding capital stock of Alliqua BioMedical, Inc. effected on May 3, 2019 immediately prior to the reverse merger).</div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amount of assets, liabilities, revenue, costs, expenses and other (expenses) income that are reported in the condensed consolidated financial statements and accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events, historical experience, actions that the Company may undertake in the future and on various other assumptions that are believed to be reasonable under the circumstances. As a result, actual results may be different from these estimates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Liquidity </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As of June&#160;30, 2019, the Company had $24,000 in cash and cash equivalents, had term loans (&#8220;Term Loans&#8221;), including accrued interest outstanding, of&#8201; $3.0&#160;million from Oxford Finance, LLC (&#8220;Oxford&#8221;), and $5.6&#160;million aggregate principal amount of convertible promissory notes (&#8220;Notes&#8221;), including accrued interest, outstanding. From inception through June&#160;30, 2019, the Company had an accumulated deficit of approximately $44.4&#160;million. The Company expects to incur substantial losses in </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-31</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">future periods. The Company is subject to risks common to companies in the clinical stage, including, but not limited to, development of new products, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product development plans. The Company has a limited operating history and has yet to generate any revenues from customers. There is no guarantee that profitable operations, if ever achieved, could be sustained on a continuing basis. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In April&#160;2019 and May&#160;2019, the Company issued Notes to current investors and received an additional $2.0&#160;million and $0.5&#160;million, respectively. The Notes accrue interest at 8% per annum and mature on the first anniversary of the applicable issuance date. For further details, see the section below titled <font style="font-style:italic;">&#8216;Note 6&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217;.</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company plans to finance its operations and capital funding needs through equity and/or debt financing. However, there can be no assurance that additional funding will be available to the Company on acceptable terms on a timely basis, if at all, or that the Company will generate sufficient cash from operations to adequately fund operating needs or ultimately achieve profitability. The conditions above, among others, raise substantial doubt about the ability of the Company to continue as a going concern within one year after the date of the issuance of the financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying financial statements do not include any adjustments that might result from the outcome of these uncertainties. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 2.&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Use of Estimates </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Actual results could differ from those estimates and such differences could be material to the Company&#8217;s financial position and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Significant estimates and assumptions include the valuation of equity instruments and equity-linked instruments, including the valuation of the Company&#8217;s common stock and the valuation of the Company&#8217;s common stock options for purposes of accounting for stock-based compensation, and accruals for clinical trials and the valuation allowances on deferred tax assets. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk and Other Risks and Uncertainties </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation insured limits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company&#8217;s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company&#8217;s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support its growth. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s postoperative pain reduction product candidate, brivoligide, is an oligonucleotide. The Company currently uses Nitto-Denko Avecia, Inc. (&#8220;Avecia&#8221;) as a single supplier for the brivoligide drug substance. There are currently a limited number of oligonucleotide manufacturers with commercial scale </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-32</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">capabilities globally. While the Company intends to develop secondary sources for manufacturing of its drug candidates in the future, there can be no assurance that it will be able to do so on commercially reasonable terms, or at all. Any interruption in the supply of this key material could significantly delay the research and development process or increase the expenses for development and commercialization of the Company&#8217;s product candidates. The quality of materials can be critical to the performance of a drug delivery technology. Therefore, the lack of a reliable source that provides a consistent supply of high quality materials would harm the Company. At June&#160;30, 2019, this vendor&#8217;s activity was not material to total accounts payable. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At December&#160;31, 2018, three vendors represented 52%, 26% and 15% of total accounts payable. Two of these vendors supported general and administrative activities, primarily associated with the Merger and next round of equity financing, which accounted for 67% of the total accounts payable. The remaining vendor supported clinical study activities. At June&#160;30, 2019, three vendors represented 26%, 22% and 17% of total accounts payable, respectively. Two of these vendors supported general and administrative activities associated with the Merger and the next round of equity financing, which accounted for 44% of the total accounts payable. The remaining supported clinical study activities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Clinical Trial Accruals </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s clinical trial accruals are based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical trials on the Company&#8217;s behalf. The Company accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, the Company modifies the estimates of accrued expenses accordingly. To date, the Company has had no significant adjustments to accrued clinical trial expenses. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company considers all highly liquid investments purchased with a maturity of three&#160;months or less on the date of acquisition to be cash and cash equivalents. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Property and Equipment, Net </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line method over the estimated useful lives of the assets, generally three to five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. As of December&#160;31, 2018 and June&#160;30, 2019, the Company had not experienced any impairment losses on its long-lived assets. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-33</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Restricted Cash </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At December 31, 2018 and June 30, 2019, the Company had $55,000 restricted and held by a bank as collateral for a letter of credit provided to the Company&#8217;s facility landlord. In addition, as of June 30, 2019, the Company had $200,000 restricted from withdrawal and held by a bank in the form of a secured money market account as collateral for Oxford in conjunction with a debt amendment that occurred in January 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Stock-Based Compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company uses the Black-Scholes option-pricing model (the &#8220;Black-Scholes model&#8221;) as the method for determining the estimated fair value of stock options. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected Term</font>&#8201;&#8212; The expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected Volatility&#8201;&#8212; </font>Expected volatility is estimated using comparable public companies&#8217; volatility for similar terms. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected Dividend&#8201;&#8212; </font>The Black-Scholes model calls for a single expected dividend yield as an input. Other than the dividend paid in connection with the Merger, the Company has never paid dividends and has no plans to pay dividends. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Risk-Free Interest Rate&#8201;&#8212; </font>The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Research and Development </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, preclinical studies, clinical studies performed by contract research organizations (&#8220;CROs&#8221;), materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development costs, including clinical study costs, to expense when incurred. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Collaboration Agreement </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2018, the Company entered into a collaboration agreement with twoXAR, an artificial intelligence-driven drug discovery company, in order to identify potential product candidates for the treatment of endometriosis. In May&#160;2019, the Company made a collaboration initiation payment of $75,000, which was charged to research and development expenses for the six&#160;months ended June&#160;30, 2019. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2019, Adynxx received an initial set of candidate predictions from twoXAR. The Company has initiated a review of the potential products to determine if any are viable candidates for further research and development. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Grant Reimbursements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2018, the Company received a Notice of Award from the National Institute on Drug Abuse (&#8220;NIDA&#8221;), part of the National Institutes of Health (&#8220;NIH&#8221;), to support the clinical development of its lead product candidate, brivoligide. NIH grants provide funds for certain types of expenditures in </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-34</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">connection with research and development activities over a contractually defined period. The maximum funding expected to be available under this grant for qualified expenditures over the two-year period through December&#160;2020 is&#8201;approximately $5.7&#160;million. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On January&#160;1, 2019, the Company adopted Accounting Standards Update (ASU) 2018-08, &#8220;Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.&#8221; Based on this guidance, the Company determined that grant payments received met the definition of a &#8216;conditional contribution&#8217; (versus an exchange contract) because (i)&#160;the Company has limited discretion in the way the funds may be spent, which creates a barrier to entitlement, and (ii) the grant contains provisions that release the awarding agency from the obligation to transfer funds that are not expended at the time the award is terminated. The Company recognizes grant reimbursements as a contra operating expense and reflects this as a component of its loss from operations in the period during which the qualifying expenses are incurred and the related services rendered, provided that the applicable performance obligations have been met. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For the six&#160;months ended June&#160;30, 2019, the Company incurred qualified expenses and recognized $1,198,000 of grant reimbursements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Income Taxes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company&#8217;s tax return. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Preferred Stock Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At December&#160;31, 2018, freestanding warrants to acquire shares of convertible preferred stock were classified as liabilities on the accompanying balance sheet. These warrants were subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. In connection with the Merger, the warrants were exchanged into warrants that no longer met the definition of a derivative and thus, $234,000 of warrant liabilities was reclassified into equity during the six&#160;months ended June&#160;30, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Debt Modifications and Extinguishments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">When the Company modifies debt, it does so in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 470-50, <font style="font-style:italic;">Debt: Modifications and Extinguishments</font>, which requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#8220;substantial modifications&#8221;. A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, the Company determined that the October&#160;2018 modification of the March&#160;2018 and September&#160;2018 Notes, to add an additional conversion option in the event of a reverse </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-35</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">merger, was considered to be a &#8220;substantial modification&#8221;. As a result, it treated this modification as an &#8216;extinguishment&#8217; of those debts and recognized $11,000 of net gain from this debt extinguishment in other income in October&#160;2018. All other changes to debt provisions were not considered substantial and were treated as debt modifications. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Derivative Instruments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASC 815-15, <font style="font-style:italic;">Derivatives and Hedging: Embedded Derivatives</font>, generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a)&#160;the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b)&#160;the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)&#160;a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirement of ASC 815. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At December 31, 2018 and June&#160;30, 2019, the Company maintained outstanding Notes which contained various embedded derivative features. In particular, these Notes contained the following features: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">A share settled redemption in a qualified preferred stock financing; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">The right to an accelerated cash repayment in the event of a change in control. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These embedded features were not considered clearly and closely related to the debt host, therefore, they were bifurcated and accounted for separately from the debt host as a derivative liability. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in the statement of operations at each period end while such instruments are outstanding. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December 31, 2018 and June&#160;30, 2019, the Company determined that there was no fair value associated with the embedded derivatives that remained with the outstanding convertible notes. See <font style="font-style:italic;">&#8216;Note&#160;6&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217; </font>for further discussion of the Notes and the bifurcated derivative liability. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASC 820-10, <font style="font-style:italic;">Fair Value Measurement</font>, provides a framework for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. The standard defines fair value as an exit price, representing the amount that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. The standard also establishes a fair value hierarchy, which prioritizes the inputs used in measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Level&#160;1</font>&#8201;&#8212; Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Level&#160;2</font>&#8201;&#8212; Inputs other than quoted prices included within Level&#160;1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Level&#160;3</font>&#8201;&#8212; Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-36</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The following table presents the Company&#8217;s fair value hierarchy for its warrant liability measured at fair value on a recurring basis at December&#160;31, 2018 (in thousands): </div>
        <table style="width:456pt;height:63.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:211.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, 2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:211.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;1 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;2 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;3 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:211.5pt;">Financial liabilities</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:211.5pt;text-align:left;">
              <div style="margin-left:10pt;">Warrant liability </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:15.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:211.5pt;text-align:left;">
              <div style="margin-left:20pt;">Total financial liabilities </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:15.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:11pt; width:456pt; line-height:12pt;">The Level&#160;3 derivative at December&#160;31, 2018 consisted of a warrant liability of Private Adynxx that, at December&#160;31, 2018, was exercisable into preferred shares that were potentially redeemable. In connection with the Merger, the warrants were exchanged into warrants that no longer met the definition of a derivative and thus, the balance was reclassified into equity during the six&#160;months ended June&#160;30, 2019. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The change in fair value of the warrant liability for the six&#160;months ended June&#160;30, 2018 and 2019 are as follows (in thousands): </div>
        <table style="width:416pt;height:77.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six&#160;Months Ended June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value, beginning of period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Change in fair value of preferred stock warrants </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">94</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Exchange of warrants upon Merger </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(234<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value at end of period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:11pt; width:456pt; line-height:12pt;">The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the Company&#8217;s term loan is based on the borrowing rate currently available to the Company for borrowings with similar terms and maturity and approximates its carrying value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Derivative liability instruments are considered Level&#160;3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level&#160;3 liability instruments consist of the preferred stock warrant liability and derivative liability, for both of which there is no observable market data for the determination of fair value and requires significant management judgment and estimation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">While the Company&#8217;s Notes contain embedded derivative liabilities, the Company determined that the fair value of these liabilities were zero at December&#160;31, 2018 and June&#160;30, 2019. See &#8216;<font style="font-style:italic;">Note 6&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217;</font> for further discussion on the derivative liability activity. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The change in fair value of the derivative liability relating to the Notes for the six&#160;months ended June&#160;30, 2018 and 2019 is summarized below (in thousands): </div>
        <table style="width:416pt;height:77.5pt;margin-left:20pt;margin-top:8.00000000000006pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six&#160;Months Ended June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value, beginning of period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Embedded derivative liability from the issuance of Notes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">496</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Change in value of embedded derivatives </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(60<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value at end of period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">436</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Discontinued Operations </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Discontinued operations represent the activities of the AquaMed business between the date of the Merger and the date of the spin-off. See &#8216;<font style="font-style:italic;">Note 3&#8201;&#8212; Reverse Merger&#8217;</font>. There are no ongoing activities or obligations associated with discontinued operations at June&#160;30, 2019. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-37</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Lease Accounting </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In February&#160;2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;). ASU 2016-02 is intended to improve financial reporting of leasing transactions by requiring organizations that lease assets to recognize assets and liabilities for the rights and obligations created by leases that extend more than twelve&#160;months on the balance sheet. This accounting update also requires additional disclosures surrounding the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for financial statements issued for annual and interim periods beginning after December&#160;15, 2018 for public business entities. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1)&#160;its effective date or (2)&#160;the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company adopted the new standard on January&#160;1, 2019 and used the effective date as its date of initial application. Consequently, the Company has not adjusted prior period amounts. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has elected the package of practical expedients permitted in ASC Topic 842. Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a)&#160;whether the contracts contain a lease under ASC Topic 842, (b)&#160;whether classification of the operating leases would be different in accordance with ASC Topic 842, or (c)&#160;whether the unamortized initial direct costs would have met the definition of initial direct costs in ASC Topic 842 at lease commencement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The most significant impact from the adoption of this standard was the recognition of right-of-use, or ROU, assets and lease obligations on the balance sheet for operating leases. This standard did not have a material impact on the Company&#8217;s cash flows from operations and operating results. As a result of the adoption of the new lease accounting guidance, the Company recognized on January&#160;1, 2019 (a)&#160;a lease liability of approximately $227,000, which represents the present value of the remaining lease payments of approximately $239,000, discounted using the Company&#8217;s incremental borrowing rate of 9.41%, and (b)&#160;a right-of-use asset of approximately $227,000 which represents the lease liability of&#8201; $227,000. The ROU asset is being amortized over the remaining term of the lease of twelve&#160;months from January&#160;1, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Effective </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In August&#160;2018, the FASB issued No. ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2019, including interim periods within that fiscal year, with early adoption permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In August&#160;2018, the FASB issued ASU 2018-15, Intangibles&#8201;&#8212;&#8201;Goodwill and Other&#8201;&#8212;&#8201;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, (&#8220;ASU 2018-15&#8221;). The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January&#160;1, 2020 and early adoption is permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-38</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">Note 3.&nbsp;&nbsp;&nbsp;Reverse Merger </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Merger </div>
        <div style="text-indent:20pt; margin-top:4.41pt; width:456pt; line-height:12pt;">On May&#160;3, 2019 the Company completed its reverse merger with Alliqua BioMedical Inc. (&#8220;Alliqua&#8221;). Immediately following the Merger, the combined company&#8217;s name was changed from &#8220;Alliqua BioMedical, Inc.&#8221; to &#8220;Adynxx, Inc.&#8221; Private Adynxx changed its name to &#8220;Adynxx Sub, Inc.&#8221; and is currently a wholly owned subsidiary of the Company. The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. </div>

          <div style="text-indent:20pt; margin-top:5.42pt; width:456pt; line-height:12pt;">Subject to the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of October&#160;11, 2018, as amended and supplemented from time to time (the &#8220;Merger Agreement&#8221;), (a)&#160;each outstanding share of capital stock of Private Adynxx, was converted into the right to receive the number of shares of Alliqua&#8217;s common stock equal to the exchange ratio formula in the Merger Agreement (&#8220;Exchange Ratio&#8221;) of 0.0359 shares of common stock (which exchange rate reflects a 1-for-6 reverse stock split of the issued and outstanding capital stock of Alliqua BioMedical, Inc. effected on May&#160;3, 2019 immediately prior to the Merger) and (b)&#160;each outstanding Private Adynxx stock option, whether vested or unvested, and warrant that has not previously been exercised, was assumed by the post-Merger company and converted into a stock option or warrant, as the case may be, to purchase shares of the post-Merger Adynxx Company&#8217;s common stock at the Exchange Ratio formula in the Merger Agreement. </div>


          <div style="text-indent:20pt; margin-top:5.22pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, prior to the closing of the Merger, $3.0&#160;million aggregate principal amount of Notes and $203,000 of cumulative accrued interest on such Notes were converted into 367,041 shares of common stock. </div>


          <div style="text-indent:20pt; margin-top:5.21pt; width:456pt; line-height:12pt;">Upon the completion of the Merger, Private Adynxx equity holders held 4,936,784 shares of common stock. Equity issuance costs in connection with the Merger were recorded as an offset to additional paid in capital. </div>

        <div style="text-indent:20pt; margin-top:5.22pt; width:456pt; line-height:12pt;">As described in &#8220;Spin-off&#8221; below, at the time of the Merger, Alliqua had in place a plan to spin-off all existing operations. Since Alliqua was deemed to have no operations upon consummation of the Spin-off, Alliqua was not considered to be a business for accounting purposes. Accordingly, no goodwill or intangible assets were recorded as a result of the Merger. Because Private Adynxx is treated as the acquiring company, Private Adynxx&#8217;s assets and liabilities are recorded at their pre-combination carrying amounts and the historical operations that are reflected in periods prior to the closing date of the Merger will be those of Private Adynxx. All share and per share amounts have been retroactively restated to give effect to the Exchange Ratio. </div>
        <div style="text-indent:20pt; margin-top:5.21pt; width:456pt; line-height:12pt;">Private Adynxx was determined to be the accounting acquirer based upon the terms of the Merger Agreement and other factors including: (i)&#160;Private Adynxx equity holders owned approximately 86% of the voting interests of the combined company immediately following the closing of the transaction and Alliqua equity holders owned approximately 14%; (ii) directors appointed by Private Adynxx hold a majority of board seats in the combined company; and (iii) Private Adynxx management hold all key positions in the management of the combined company. </div>
        <div style="text-indent:20pt; margin-top:5.22pt; width:456pt; line-height:12pt;">In connection with a previous modification of its Notes, the Company had computed a contingent beneficial conversion feature (&#8220;BCF&#8221;) that was contingent upon the occurrence of a reverse merger. In accordance with ASC 470-20-25-6, the contingent BCF is not recognized in earnings until the contingency is resolved. Upon the date of the Merger, the full amount of beneficial conversion feature of&#8201; $2.1&#160;million was recognized as interest expense in the condensed consolidated statement of operations for the six&#160;months ended June&#160;30, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Dividend </div>

          <div style="text-indent:20pt; margin-top:4.22pt; width:456pt; line-height:12pt;">In contemplation of the Merger, Alliqua declared a special cash dividend to the pre-Merger shareholders of Alliqua as of April&#160;22, 2019. The aggregate dividend of&#8201; $5,245,000, or $1.05 per share, was paid on May&#160;29, 2019. </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-39</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Spin-off </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On November&#160;27, 2018, Alliqua had entered into an agreement whereby its existing operations would be distributed to existing shareholders as of a record date. With the exception of a corporate lease, substantially all of Alliqua&#8217;s assets and liabilities were contributed to a subsidiary, AquaMed Technologies Inc. (&#8220;AquaMed&#8221;), whose shares were then distributed to the pre-Merger shareholders of Alliqua by way of a pro&#160;rata stock dividend on June&#160;21, 2019. The book value of the dividend was less than $0.01 per share. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Because the historical periods presented prior to the merger are those of Private Adynxx, the results of AquaMed are only reflected in these financial statements from the merger date to the date of the pro&#160;rata dividend of AquaMed and are presented as discontinued operations in the condensed consolidated statement of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pro Forma Financial Information </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As the only significant operations of Alliqua have been discontinued with the spin-off transaction, pro&#160;forma financial information for periods prior to the merger is not presented herein as such results are not meaningful. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 4.&nbsp;&nbsp;&nbsp;Property and Equipment, Net </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Property and equipment, net, consist of the following (in thousands): </div>
        <table style="width:416pt;height:116.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">December&#160;31, <br >2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">June&#160;30, <br >2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Furniture and fixtures </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Office equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Computer equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Laboratory equipment </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Total property and equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">51</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">51</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Less accumulated depreciation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(41<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(45<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Property and equipment, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.98pt; width:456pt; line-height:12pt;">Depreciation expense at December 31, 2018 and for the six&#160;months ended June&#160;30, 2018 and 2019 was $8,000, $4,000 and $4,000, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 5.&nbsp;&nbsp;&nbsp;Other Balance Sheet Information </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Prepaid and other current assets consist of the following (in thousands): </div>
        <table style="width:416pt;height:88pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">December&#160;31, <br >2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">June&#160;30, <br >2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Prepaid clinical trial expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">435</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Equity issuance costs </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">343</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Prepaid insurance </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">670</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Other prepaid expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">174</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Total prepaid and other current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,622</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-40</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-left:20pt; margin-top:1pt; width:436pt; line-height:12pt;">Accrued liabilities consist of the following (in thousands): </div>
        <table style="width:416pt;height:88pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">December&#160;31, <br >2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">June&#160;30, <br >2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Payroll and related expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">241</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">508</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Accrued term loan final payment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">421</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">569</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Accrued clinical trial expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Professional fees and other costs </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">195</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">395</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Total accrued liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">857</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,480</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-weight:bold;">Note 6.&nbsp;&nbsp;&nbsp;Term Loans and Convertible Promissory Notes </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Term Loans </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On November&#160;24, 2015, the Company entered into a loan and security agreement (&#8220;Loan Agreement&#8221;) with Oxford, pursuant to which the Company received $3.0&#160;million in proceeds from a Term Loan A and $2.0&#160;million in proceeds from a Term Loan B under the Loan Agreement (collectively the &#8220;Term Loans&#8221;). Warrants to purchase 11,829 shares of common stock were issued to Oxford in connection with the Term Loans (&#8216;<font style="font-style:italic;">Note 9&#8201;&#8212; Warrants&#8217;</font>). The Term Loans bear interest at a floating per annum rate equal to (a)&#160;7.06% plus (ii) the greater of&#8201; (a)&#160;the 30 day U.S. Dollar LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (b)&#160;0.19%. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Term Loan A was recorded at its initial carrying value of&#8201; $3.0&#160;million less debt issuance costs of approximately $141,000, and the Term Loan B was recorded at its initial carrying value of&#8201; $2.0&#160;million, less debt issuance costs of approximately $3,000. The debt issuance costs are being amortized to interest expense over the life of the Term Loans using the effective interest method. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2018, $2.3&#160;million was outstanding under Term Loan A and $1.5&#160;million was outstanding under Term Loan B. At June&#160;30, 2019, $1.4&#160;million was outstanding under Term Loan A and $1.0&#160;million was outstanding under Term Loan B. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following modifications have been made during the six&#160;months ended June&#160;30, 2019: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In January&#160;2019, the Company and Oxford agreed to amend the Loan Agreement. Oxford agreed to two&#160;months of interest-only payments followed by eight&#160;months of repayments upon delivery by February&#160;1, 2019 of an executed term sheet for equity financing that would result in aggregate proceeds to the Company of&#8201; $20.0&#160;million. The Company was also required to place $200,000 in a segregated bank account that is subject to a blocked control agreement in favor of Oxford. The funds in the segregated account were to be released upon the earlier of the consummation of a merger by March&#160;31, 2019 or the consummation of an equity financing by March&#160;31, 2019. The Company recorded the $200,000 as restricted cash in its balance sheet at June&#160;30, 2019. The maturity date of the Term Loans remained unchanged. The amendment fee amounted to $50,000. The amendment was accounted for as a debt modification. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In May&#160;2019, the Company and Oxford agreed to an amendment to provide consent to the Merger. This consent amended certain provisions of the Term Loans to protect Oxford&#8217;s rights under the original Loan Agreement. The consent allowed Alliqua (now Adynxx, Inc.) to be named as an additional borrower. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In June&#160;2019, the Company and Oxford agreed to amend the Loan Agreement. Oxford agreed to two&#160;months of interest-only payments and the maturity date of the Term Loans was extended two&#160;months to January&#160;1, 2020. The amendment fee amounted to $20,000. The amendment was accounted for as a debt modification. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-41</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">Upon the respective dates of the debt modifications, no gain or loss was recorded, and a new effective interest rate was established based on the carrying value of the debt and the revised cash flows. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Interest expense associated with the Term Loans was $309,000 and $336,000 for the six&#160;months ended June&#160;30, 2018 and 2019, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, the Company was in compliance with all covenants under the Loan Agreement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Principal payments for the Term Loans due under the Loan Agreement as of June&#160;30, 2019 are due monthly beginning September&#160;1, 2019 and the Term Loans mature on January&#160;1, 2020. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Promissory Notes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The table below reflects the principal amount of the Notes issued by the Company (in thousands): </div>
        <table style="width:416pt;height:116pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">December&#160;31, <br >2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">June&#160;30, <br >2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on March&#160;29, 2019 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on September&#160;27, 2019 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on December&#160;21, 2019 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on March&#160;29, 2020 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on April&#160;26, 2020 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on May&#160;29, 2020 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,500</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-style:italic;">Outstanding Notes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Notes outstanding at June&#160;30, 2019 were issued with conversion and repayment rights as described below: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" margin-top:8.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event that the Company issues and sells equity securities with proceeds to the Company of at least $5&#160;million, on or before the maturity date, then the outstanding principal amount of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities of the same class sold in the equity financing at a conversion price equal to the cash price paid per share for equity securities in the financing, and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(b)<br ></div>
        <div style=" margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the Company consummates a change of control while the Notes remain outstanding, the Company shall repay the holders in cash in an amount equal to 200% of the outstanding principal amount of the Notes. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In April&#160;2019 and May&#160;2019, affiliates of Domain Partners, LLC, a significant shareholder of the Company, purchased from the Company $2.0&#160;million and $0.5&#160;million aggregate principal amount of Notes. The proceeds from the issuances were used for general corporate purposes and working capital. These Notes accrue simple interest on the outstanding principal amount at a rate of 8% per annum and mature on April&#160;26, 2020 and May&#160;29, 2020, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Converted Notes </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In May&#160;2019, under the terms of the then-outstanding Notes, the principal and accrued unpaid interest of two Notes totaling $3.2&#160;million were automatically converted into the Company&#8217;s Series&#160;B convertible preferred stock. Upon consummation of the Merger, and subject to the terms and conditions of the Merger Agreement, each outstanding share of capital stock of Adynxx was converted into the right to receive the number of shares of the combined Company&#8217;s common stock equal to the Exchange Ratio. An aggregate of 367,041 post-Merger common shares were issued associated with the conversion of these Notes. </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-42</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">In connection with a previous modification, the Company had computed a contingent BCF that was contingent upon the occurrence of a reverse merger. In accordance with ASC 470-20-25-6, the contingent BCF is not recognized in earnings until the contingency is resolved. Upon the date of the Merger, the full amount of beneficial conversion feature of&#8201; $2.1&#160;million was recognized as interest expense in the condensed consolidated statement of operations for the six&#160;months ended June&#160;30, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Derivative Liability </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company evaluated its outstanding Notes and determined that certain embedded components relating to conversion and redemption features of those contracts qualified as derivatives, which need to be separately accounted for in accordance with ASC 815. With the consummation of the Merger, several of these clauses no longer apply. However, the redemption provision upon change of control described above is an embedded feature that is required to be bifurcated. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December 31, 2018, the Company evaluated the fair value of the derivative liability and determined that the bifurcated derivative liability had no value because the Company estimated a zero probability of the embedded feature being triggered. As a result, the Company estimated the fair value of the derivative liability to be zero at December 31, 2018. Similarly, the embedded derivatives that were in place at June&#160;30, 2019 also had a fair value of zero. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 7.&nbsp;&nbsp;&nbsp;Leases </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company leases office facilities under a non-cancelable operating lease agreement expiring on December&#160;31, 2019. The Company also leases a corporate office facility previously utilized by Alliqua through an operating lease agreement, located in Yardley, Pennsylvania that expires in 2023. Effective February&#160;1, 2019, this property has been subleased to The Pinnacle Health Group, Inc. through April&#160;20, 2023 and the Company receives monthly lease payments. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Future minimum payments under non-cancellable leases as of June&#160;30, 2019 are as follows (in thousands): </div>
        <table style="width:416pt;height:130.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:350pt;">
              <div style="white-space:nowrap;">Period ending December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">Future <br >Commitments </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">2019 (remaining 6&#160;months) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">232</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">2020 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">227</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">2021 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">232</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">2022 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">236</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">2023 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">80</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">Total future minimum lease payments </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,007</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">Less: imputed interest </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(167<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">840</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.78pt; width:456pt; line-height:12pt;">Total operating lease expenses for the six&#160;months ended June&#160;30, 2018 and 2019 was $115,000 and $165,000, respectively, and are reflected in general and administrative expenses in the condensed consolidated statements of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, the Company had no leases that were classified as a financing lease. As of June&#160;30, 2019, the Company did not have additional operating and financing leases that have not yet commenced.&nbsp;&nbsp;&nbsp; </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During the six&#160;months ended June&#160;30, 2019, the Company recognized $42,000 of sublease income on its condensed consolidated statement of operations, which is recorded as an offset against general and administrative expenses. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-43</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">Note 8.&nbsp;&nbsp;&nbsp;Redeemable Convertible Preferred Stock </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At December&#160;31, 2018, Private Adynxx had 2,034,548 shares of Series&#160;A convertible preferred stock issued and outstanding, and 1,833,387 shares of Series&#160;B convertible preferred stock issued and outstanding. During 2019, prior to the Merger, an additional 367,041 shares were issued upon conversion of convertible notes described in <font style="font-style:italic;">&#8216;Note 6&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217;.</font></div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the consummation of the Merger, all outstanding shares of Series&#160;A and Series&#160;B convertible preferred stock were cancelled and exchanged for shares of the Company&#8217;s common stock. Following the Merger, Private Adynxx survived as a wholly-owned subsidiary of new Adynxx, Inc. and adopted a new certificate of incorporation with no shares of preferred stock authorized or outstanding. The Company has 1,000,000 shares of preferred stock authorized under its certificate of incorporation, as amended. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 9.&nbsp;&nbsp;&nbsp;Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Private Adynxx had issued warrants that were previously classified as a liability as they were exercisable for preferred shares that were potentially redeemable. The fair value of the warrant liability was re-measured at each balance sheet date up through the date of the Merger with the change as other income recorded in the statements of operations. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, in connection with the closing of the Merger, each outstanding Adynxx warrant that had not previously been exercised was converted into a stock warrant to purchase shares of the Company&#8217;s common stock at the Exchange Ratio and, as a result, outstanding warrants were converted into warrants to purchase an aggregate of 11,829 shares of the Company&#8217;s common stock at an exercise price of $6.34 per share. As such warrants qualify for equity classification, the Company reclassified the balance of&#8201; $234,000 from warrant liability to additional paid in capital. These warrants are exercisable at any time and expire in 2025 and 2026. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additionally, upon the closing of the Merger on May&#160;3, 2019, the Company assumed outstanding Alliqua warrants to purchase an aggregate of 38,945 shares of common stock at exercise prices ranging from $26.40 to $28.20 per share. These warrants are exercisable at any time and expire in 2022. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 10.&nbsp;&nbsp;&nbsp;Stock Options </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, in connection with the closing of the Merger, each outstanding Private Adynxx stock option, whether vested or unvested, was converted into a stock option to purchase shares of the Company&#8217;s common stock at the Exchange Ratio and, as a result, the Company issued options to purchase an aggregate of 690,058 shares of the Company&#8217;s common stock at exercise prices ranging from $1.11 to $3.06 per share. </div>


          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additionally, at the date of the Merger, Alliqua had outstanding employee options to purchase an aggregate of 57,822 shares of the post-Merger Company&#8217;s common stock at exercise prices ranging from $21.00 to $656.40 per share to former Alliqua option holders that were assumed as part of the merger. All Alliqua employees were terminated in connection with the Merger; however, such options have provisions that extend the expiration date beyond the employees&#8217; termination date. </div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-44</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">A summary of the Company&#8217;s stock option activity during the six&#160;months ended June&#160;30, 2019 is as follows (in thousands, except exercise prices): </div>

          <table style="width:456pt;height:122pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:211.5pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Number of <br >Options </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Weighted <br >Average <br >Exercise Price </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Weighted <br >Average <br >Remaining <br >Life In Years </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Intrinsic Value </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 1pt 0pt; width:211.5pt;text-align:left;">
                <div style="white-space:nowrap;">Outstanding, December&#160;31, 2018 </div>
              </td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">690</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2.76</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:211.5pt;text-align:left;">
                <div style="margin-left:10pt;">Alliqua options assumed in Merger </div>
              </td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">58</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">289.76</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:211.5pt;text-align:left;">
                <div style="margin-left:10pt;">Exercised </div>
              </td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:211.5pt;text-align:left;">
                <div style="margin-left:10pt;">Cancelled </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:17.75pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:17.75pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 2.75pt 0pt; width:211.5pt;text-align:left;">
                <div style="white-space:nowrap;">Outstanding, June&#160;30, 2019 </div>
              </td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">748</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">24.95</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">6.2</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:17.75pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">188</td>
              <td style="padding:0pt;padding-left:17.75pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.25pt 0pt 2.75pt 0pt; width:211.5pt;text-align:left;">
                <div style="white-space:nowrap;">Exercisable, June&#160;30, 2019 </div>
              </td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">530</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">33.93</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">5.7</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:17.75pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">188</td>
              <td style="padding:0pt;padding-left:17.75pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="text-indent:20pt; margin-top:13.98pt; width:456pt; line-height:12pt;">A summary of the Company&#8217;s stock options as of June&#160;30, 2019 is as follows (in thousands, except exercise prices): </div>

          <table style="width:456pt;height:118.5pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:8pt;height:8.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:151.5pt;" rowspan="2">
                <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Range of Exercise Price </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">Options Outstanding </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="16">
                <div style="white-space:nowrap; text-align:center;">Options Exercisable </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;height:39.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="margin-left:10pt; text-indent:-10pt; text-align:center;">Weighted <br >Average <br >Exercise <br >Price </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Outstanding <br >Number of <br >Options </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Weighted <br >Average <br >Exercise Price </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Weighted <br >Average <br >Remaining <br >Life In Years </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Exercisable <br >Number of <br >Options</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; width:151.5pt;text-align:center;">
                <div style="text-align:center;">$1.11 &#8211; $1.38</div>
              </td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1.11</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">73</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1.11</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2.5</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">73</td>
              <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:151.5pt;text-align:center;">
                <div style="text-align:center;">1.39 &#8211; 3.05</div>
              </td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1.39</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">37</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1.39</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">3.2</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">37</td>
              <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:151.5pt;text-align:center;">
                <div style="text-align:center;">3.06 &#8211; 20.99</div>
              </td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3.06</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">580</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3.06</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.5</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">362</td>
              <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:151.5pt;text-align:center;">
                <div style="text-align:center;">21.00 &#8211; 656.40</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">289.81</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">58</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">289.81</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">0.7</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:20.25pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">58</td>
              <td style="padding:0pt;padding-left:20.25pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.75pt 0pt; width:151.5pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">24.95</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">748</td>
              <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">24.95</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">5.7</td>
              <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt; width:4.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">530</td>
              <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="text-indent:20pt; margin-top:13.99pt; width:456pt; line-height:12pt;">The Company did not grant any stock options to employees during the six months ended June 30, 2019. Stock-based compensation expense recorded in research and development and general and administrative expenses was $150,000 and $136,000 for the six months ended June 30, 2018 and 2019, respectively. As of June 30, 2019, unrecognized stock-based compensation expense related to employees totaled approximately $395,000, which is expected to be recognized over approximately 1.5 years. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Stock-based compensation expense recorded in exchange for services related to non-employee options was $0 and $32,000 for the six months ended June 30, 2018 and 2019, respectively. As of June 30, 2019, unrecognized stock-based compensation expense related to unvested non-employees stock options was approximately $16,000, which is expected to be recognized over a weighted-average period of three months.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 11.&nbsp;&nbsp;&nbsp;Related-Party Transactions </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="font-style:normal;">At June&#160;30, 2019, the Company had $5.5&#160;million aggregate principal amount of outstanding convertible notes issued to a significant shareholder. &#8216;</font>Note 6&#8201;&#8212;&#8201;Term Loans and Convertible Promissory Notes&#8217;<font style="font-style:normal;">. </font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with the Merger, Alliqua&#8217;s existing CEO resigned from the company and received severance pay of&#8201; $1,091,000. As such amounts were accrued by Alliqua prior to the Merger, this severance payment had no impact to our condensed consolidated statement of operations for six&#160;months ended June&#160;30, 2019.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-45</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">Note 12.&nbsp;&nbsp;&nbsp;Subsequent Events </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In July&#160;2019, affiliates of Domain Partners, LLC, a significant shareholder of the Company, purchased from the Company $600,000 aggregate principal amount of Notes. The proceeds from the issuance of the Notes will be used for general corporate purposes and working capital. These Notes accrue simple interest on the outstanding principal amount at a rate of 8% per annum and mature one year from the date of issuance.</div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On August 1, 2019 and August 2, 2019, the Company&#8217;s board of directors and a majority of the Company&#8217;s stockholders, respectively, approved a reverse stock split at a range of between 1-for-2 and 1-for-10, with the final exchange ratio to be determined by the board of directors, which as of the date of filing has not yet occurred. The share and per share information contained in the financial statements and footnotes do not reflect the impact of any such reverse stock split.</div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In August 2019, the Company and Oxford agreed to amend the Loan Agreement pursuant to a ninth amendment to the Loan Agreement. The ninth amendment provides for two additional months of interest-only payments by the Company, contingent upon the completion of certain financing events by specified dates. The ninth amendment also clarifies that the secured funds will be released by Oxford upon the receipt by the Company of net proceeds of at least $10 million from the issuance and sale of its equity securities.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-46</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:14pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:28pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:3.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;z-index:-1;margin-top:110.5pt; text-align:center; width:456pt;">
          <img src="lg_adynxx.jpg" alt="[MISSING IMAGE: lg_adynxx.jpg]" height="60" width="241" >
        </div>

          <div style="margin-top:17pt; text-align:center; width:456pt; line-height:17pt;">7,500,000 Shares of Common Stock <br >Pre-Funded Warrants to Purchase Shares of Common Stock <br >Common Warrants to Purchase 7,500,000 Shares of Common Stock<br >&#8199;<br >&#8199;<br >&#8199;<br >&#8199;</div>

        <div style="margin-top:48.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 27.302%; margin-right: 27.302%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">PRELIMINARY PROSPECTUS </div>
        <div style="margin-top:16.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 27.302%; margin-right: 27.302%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="margin-top:10pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">&#8199;<br >&#8199;<br >&#8199;<br >&#8199;<br >&#8199; <br >&#8199;<br >&#8199;</div>


          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:19pt;font-size:18pt;">H.C. Wainwright &amp; Co.</div>

        <div style="margin-top:120pt; text-align:center; width:456pt; line-height:11pt;font-weight:normal;font-size:10pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2019 </div>
        <div style="margin-top:49.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PART II<br >&#8199; <br >INFORMATION NOT REQUIRED IN PROSPECTUS </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;13. Other Expenses of Issuance and Distribution. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table sets forth all costs and expenses, other than placement agent fees, payable by us in connection with the sale of the common stock, common warrants and pre-funded warrants being registered. All amounts shown are estimates except for the SEC registration fee and the Financial Industry Regulatory Authority, or FINRA, filing fee. </div>


          <table style="width:456pt;height:144pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:390pt;">
                <div style="white-space:nowrap;">Item </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Amount </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
                <div style="white-space:nowrap;">SEC registration fee </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,894</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
                <div style="white-space:nowrap;">FINRA filing fee </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,000</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
                <div style="white-space:nowrap;">Printing and engraving expenses </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">145,000</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
                <div style="white-space:nowrap;">Legal fees and expenses </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">700,000</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
                <div style="white-space:nowrap;">Accounting fees and expenses </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">200,000</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
                <div style="white-space:nowrap;">Blue Sky fees and expenses </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">10,000</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
                <div style="white-space:nowrap;">Transfer agent and registrar fees and expenses </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">10,000</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:390pt;text-align:left;">
                <div style="white-space:nowrap;">Miscellaneous </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">26,106</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:390pt;text-align:left;">
                <div style="margin-left:10pt;">Total </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,100,000</td>
              <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="margin-top:20.98pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;14. Indemnification of Directors and Officers. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Section&#160;145 of the Delaware General Corporation Law authorizes a court to award, or a corporation&#8217;s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act of 1933, as amended, or the Securities Act. Our certificate of incorporation, as amended, allows for our indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and our bylaws provide for indemnification of our directors and executive officers to the maximum extent permitted by the Delaware General Corporation Law. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have entered into indemnification agreements with our directors and officers, whereby we have agreed to indemnify our directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee, or agent of Adynxx, Inc., provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of Adynxx, Inc. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At present, there is no pending litigation or proceeding involving a director or officer regarding which indemnification is sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the Securities Exchange Act of 1934, as amended, that might be incurred by any director or officer in his or her capacity as such.</div>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Item&#160;15. Recent Sales of Unregistered Securities. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">The following sets forth information regarding all unregistered securities sold within the last three years: </div>

        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Issuances of Capital Stock </div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
          <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In February 2017, Alliqua issued an aggregate of 92,333 shares of common stock to certain accredited investors at a purchase price per share of&#8201; $30.00.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
          <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">From April to June 2017, Alliqua issued an aggregate of 23,083 shares of common stock to certain accredited investors for no consideration pursuant to anti-dilution adjustments set forth in a securities purchase agreement entered in February 2017. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
          <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In May&#160;2019, we issued an aggregate of 4,975,548 shares of common stock to 21 stockholders in connection with the Merger. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Promissory Notes </div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
          <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">From May&#160;through August 2019, we issued and sold convertible promissory notes in the aggregate principal amount of&#8201; $1.85&#160;million to two accredited investors. The outstanding principal amount under such notes, along with any unpaid accrued interest, will automatically convert into shares of common stock at the public offering price upon the consummation of the offering to which this Registration Statement relates. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Issuances of Common Stock Warrants</div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
          <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">From January to June 2017, Alliqua amended outstanding warrants to purchase common stock to provide for the purchase of an additional aggregate of 22,500 shares of common stock to one investor at an exercise price per share of&#8201; $28.20.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
          <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In April 2017, Alliqua issued warrants to purchase up to an aggregate of 3,949 shares of common stock to a total of six investors at an exercise price per share of&#8201; $26.40.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Issuances of Restricted Stock Awards and Options to Purchase Common Stock</div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(7)<br ></div>
          <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">From March 31, 2016 through the date of this registration statement, Alliqua issued to certain employees, consultants and directors restricted stock awards for an aggregate of 45,307 shares of common stock under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(8)<br ></div>
          <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">From March 31, 2016 through the date of this registration statement, Alliqua issued to certain employees, consultants and directors options to purchase an aggregate of 48,812 shares of common stock under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan, at exercise prices ranging from $12.54 to $74.40 per share. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise specified above, we believe these transactions were exempt from registration under the Securities Act in reliance on Section&#160;4(a)(2) of the Securities Act (and Regulation&#160;D promulgated thereunder), or Rule&#160;701 promulgated under Section&#160;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule&#160;701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Item&#160;16. Exhibits and Financial Statement Schedules. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;font-size:10pt;">(a) Exhibits. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Exhibit&#160;Index </div>

          <table style="width:456pt;margin-top:7pt;border-collapse: collapse;">
            <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:45.51pt;" rowspan="2">
                <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Exhibit<br >Number </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:187.01pt;" rowspan="2">
                <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Description </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">Incorporation By Reference </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:30.48pt;">
                <div style="white-space:nowrap; text-align:center;">Form </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:45.92pt;">
                <div style="text-align:center;">SEC File <br >No. </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:36.29pt;">
                <div style="white-space:nowrap; text-align:center;">Exhibit </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:77pt;">
                <div style="white-space:nowrap; text-align:center;">Filing Date</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.583pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">1.1*</div>
              </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:2.583pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">Engagement Letter, dated as of June&#160;10, 2019, between Adynxx, Inc. and H.C. Wainwright &amp; Co., LLC</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">2.1&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">Agreement and Plan of Merger and Reorganization, dated as of October&#160;11, 2018, as amended and supplemented from time to time, by and among Alliqua BioMedical, Inc., Embark Merger Sub, Inc., and Adynxx, Inc. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">DEFM <br >14A </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">Annex A </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">January&#160;24, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">2.2&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">Amendment No. 1, dated January&#160;8, 2019, to Agreement and Plan of Merger </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">10-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">2.8 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">February&#160;22, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">2.3&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">Amendment No. 2, dated April 29, 2019, to Agreement and Plan of Merger </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">8-K</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">001-36278</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">2.3</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">April 12, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">3.1&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">Certificate of Incorporation of Alliqua BioMedical, Inc. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">3.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">June&#160;11, 2014 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">3.2&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">Certificate of Amendment to the Certificate of Incorporation dated June&#160;5, 2014 </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">3.3 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">June&#160;11, 2014 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">3.3&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">Certificate of Amendment to the Certificate of Incorporation dated May&#160;6, 2016 </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">3.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">May&#160;6, 2016 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">3.4&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">Certificate of Amendment to the Certificate of Incorporation dated October&#160;5, 2017 </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">3.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">October&#160;5, 2017 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">3.5&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">Certificate of Amendment to the Certificate of Incorporation dated May&#160;3, 2019 </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">3.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">3.6&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">Certificate of Amendment to the Certificate of Incorporation dated May&#160;3, 2019 </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">3.2 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">3.7&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">Bylaws </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">3.2 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">June&#160;11, 2014 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">4.1&#8224; </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <div style="white-space:nowrap;">Reference is made to Exhibits&#160;<a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">3.1</a> through <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">3.7</a></div>
              </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">4.2&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">Form of Common Stock Certificate </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">4.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">May&#160;9, 2019</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="tv528145_ex4-3.htm">4.3&#8201;&#8201; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-3.htm">Form of Common Warrant</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-3.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="tv528145_ex4-4.htm">4.4&#8201;&#8201;</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-4.htm">Form of Pre-Funded Warrant</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex4-4.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">4.5*</div>
              </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">Form of Placement Agent Warrant</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">5.1&#8201;&#8201;</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">Form of Opinion of Cooley LLP </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">10.1&#8224;&#8199;&#8201; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">Loan and Security Agreement, dated as of November&#160;24, 2015 and as amended from time to time, including by the ninth amendment, by and among Adynxx, Inc. and Oxford Finance LLC </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">S-1</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">333-232169</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">10.1</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">August&#160;22, 2019</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885_ex10-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">10.2+&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">Offer Letter, dated as of October&#160;15, 2010, by and between Rick Orr and Adynxx, Inc. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">10.4 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">10.3+&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">Offer Letter, dated as of January&#160;4, 2012, by and between Donald Manning, M.D., Ph.D., and Adynxx, Inc. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">10.5 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">10.4+&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">Offer Letter, dated as of September&#160;1, 2011, by and between Julien Mamet, Ph.D., and Adynxx, Inc. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">10.6 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">10.5+&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">Adynxx, Inc. 2010 Equity Incentive Plan </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">10.7 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
            </tr>
          </table>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">II-3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <table style="width:456pt;height:643.5pt;margin-top:0pt;border-collapse: collapse;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:45.51pt;" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Exhibit<br >Number </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:187.01pt;" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Description </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Incorporation By Reference </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:30.48pt;">
              <div style="white-space:nowrap; text-align:center;">Form </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:45.92pt;">
              <div style="text-align:center;">SEC File<br >No. </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:36.29pt;">
              <div style="white-space:nowrap; text-align:center;">Exhibit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:77pt;">
              <div style="white-space:nowrap; text-align:center;">Filing Date</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">10.6+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">Form of Stock Option Grant Notice and Notice of Exercise under the Adynxx, Inc. 2010 Equity Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">10.8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">May&#160;9, 2019 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">10.7+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">2011 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">000-29819 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">10.1 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="white-space:nowrap; text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">December&#160;20, 2011 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">10.8+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">First Amendment to the 2011 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">000-29819 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">10.1 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="white-space:nowrap; text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">December&#160;20, 2012 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">10.9+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">Form of Nonstatutory Stock Option Agreement under the 2011 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">10-K/A </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">000-29819 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">10.32 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">May&#160;16, 2013 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8201;10.10+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">Form of Incentive Stock Option Agreement under the 2011 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">10-K/A </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">000-29819 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">10.33 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">May&#160;16, 2013 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8201;10.11+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">Nonqualified Stock Option Agreement dated December&#160;20, 2013, by and between Alliqua, Inc. and David Johnson </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">000-29819 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">10.2 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="white-space:nowrap; text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">December&#160;27, 2013 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8201;10.12+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">Form of Restricted Stock Award Agreement under the 2011 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">10-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">10.62 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">March 24, 2014 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8201;10.13+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">Form of Restricted Stock Award Agreement for 2013 Executive Bonuses under the 2011 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">10-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">10.63 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">March 24, 2014 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8201;10.14+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">Form of Nonqualified Stock Option Agreement (outside of any incentive plan) </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">S-8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">333-193513 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">99.8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">January&#160;23, 2014 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">10.15+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">2014 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">10.1 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">June&#160;11, 2014 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">10.16+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">First Amendment to the 2014 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">10.1 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">May&#160;6, 2015 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">10.17+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">Form of Incentive Stock Option Agreement under the 2014 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">S-8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">333-206133 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">99.3 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">August&#160;6, 2015 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8201;10.18+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">Form of Nonqualified Stock Option Agreement under the 2014 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">S-8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">333-206133 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">99.4 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">August&#160;6, 2015 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8201;10.19+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">Form of Restricted Stock Award Agreement under the 2014 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">S-8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">333-206133 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">99.5 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">August&#160;6, 2015 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">10.20+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">Form of Restricted Stock Unit Agreement under the 2014 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">S-8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">333-206133 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">99.6 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">August&#160;6, 2015 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">10.21+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">Second Amendment to the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan, effective as of June&#160;23, 2017 </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">10.1 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">June&#160;23, 2017 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">10.22&#8224;&#8201; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">Form of promissory note issued to Oxford Finance LLC </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">10.2 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">May&#160;9, 2019 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">10.23&#8224;&#8201; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">Form of warrant issued to Oxford Finance LLC </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">10.3 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">May&#160;9, 2019 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">10.24&#8224;&#8201; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">Form of convertible promissory note issued to Domain Partners </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">10-Q </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">10.24 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">August&#160;14, 2019 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">10.25&#8224;&#8201; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">Warrant, dated May&#160;29, 2015, by and between Alliqua BioMedical, Inc. and Perceptive Credit Opportunities Fund, LP </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">10.3 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">June&#160;1, 2015 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">10.26&#8224;&#8201; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">Amended Warrant, dated January&#160;26, 2017, by and between Alliqua BioMedical, Inc. and Perceptive Credit Holdings, LP. </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">10.2 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">January&#160;30, 2017 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">10.27&#8224;&#8201; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">Amended Warrant, dated March&#160;7, 2017, by and between Alliqua BioMedical, Inc. and Perceptive Credit Holdings, LP. </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">10.2 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">March&#160;13, 2017 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">II-4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <table style="width:456pt;margin-top:0pt;border-collapse: collapse;">
            <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:45.51pt;" rowspan="2">
                <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Exhibit<br >Number </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:187.01pt;" rowspan="2">
                <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Description </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">Incorporation By Reference </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:30.48pt;">
                <div style="white-space:nowrap; text-align:center;">Form </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:45.92pt;">
                <div style="text-align:center;">SEC File<br >No. </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:36.29pt;">
                <div style="white-space:nowrap; text-align:center;">Exhibit </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:77pt;">
                <div style="white-space:nowrap; text-align:center;">Filing Date</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">10.28&#8224;&#8201; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">Amended Warrant, dated April&#160;6, 2017, by and between Alliqua BioMedical, Inc. and Perceptive Credit Holdings, LP. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">10.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">April&#160;12, 2017 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">10.29&#8224;&#8201; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">Form of Warrant, dated April&#160;14, 2014, by and between Alliqua, Inc. and certain accredited investors </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">10.2 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">April&#160;15, 2014 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">10.30&#8224;&#8199;&#8201; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">Form of Warrant, dated April&#160;3, 2017, by and between Alliqua BioMedical, Inc. and H.C. Wainwright &amp; Co. LLC and its designees </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">4.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">April&#160;4, 2017 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">10.31&#8224;&#8199; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">Sublease, dated as of February&#160;8, 2016, by and between the Registrant and REC Americas LLC, to the Office Lease, dated as of October&#160;27, 2014, by and between REC Americas LLC and 100 Pine Street Investment Group LLC </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">10-Q </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">10.31 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">August&#160;14, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">10.32&#8224;&#8199; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">Form of Indemnification Agreement, by and between the Registrant and each of its directors and executive officers </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">10-Q </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">10.32 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">August&#160;14, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">10.33&#8224;&#8199;</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">Asset Contribution and Separation Agreement between Alliqua BioMedical, Inc. and AquaMed Technologies, Inc.<font style=" position:relative; bottom:4pt;font-size:7pt;">#</font></a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">S-1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">333-232169 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">10.33 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">July&#160;25, 2019</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:45.51pt;">
                <div style="text-align:center;">10.34*&#8199;</div>
              </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:187.01pt;text-align:left;">Form of Securities Purchase Agreement</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:30.48pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:45.92pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:36.29pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:77pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">16.1&#8224;&#8199;&#8199;</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">Letter from Marcum LLP to the Securities and Exchange Commission, dated May&#160;29, 2019. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">16.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">May&#160;31, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">21.1&#8224;&#8199;&#8199; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">Subsidiaries of the Registrant </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">S-1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">333-232169 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">21.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">July&#160;25, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex23-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="tv528145_ex23-1.htm">23.1&#8199;&#8199;&#8199; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex23-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex23-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="tv528145_ex23-1.htm">Consent of Independent Registered Public Accounting Firm </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex23-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex23-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex23-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex23-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex23-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">23.2&#8199;&#8199;&#8199;</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">Consent of Cooley LLP (included in Exhibit&#160;5.1) </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv528145_ex5-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">24.1&#8224;&#8199;&#8199;&#8199; </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419031211/tv523241-s1.htm#tPOA">Power of Attorney (see signature page to the </a><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419031211/tv523241-s1.htm">registration statement on Form S-1 filed June&#160;17, 2019</a> and <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885-s1a.htm">August&#160;22, 2019</a>) </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">101&#8199;&#8199;&#8201; </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:0pt;white-space:normal;text-align:left;" colspan="13">The following financial information of Adynxx, Inc. formatted in Extensible Business Reporting Language (XBRL) is filed herewith: (i) Balance sheets as of June&#160;30, 2019 (unaudited), December 31, 2018 and December 31, 2017; (ii) Statements of operations for the six months ended June&#160;30, 2019 (unaudited) and June&#160;30, 2018 (unaudited), and years ended December 31, 2018 and 2017; (iii)&#160;Statements of redeemable convertible preferred stock and stockholders&#39; deficit for the six months ended June&#160;30, 2019 (unaudited) and June&#160;30, 2018 (unaudited), and the years ended December 31, 2018 and 2017; (iv) Statements of cash flows for the six months ended June&#160;30, 2019 (unaudited) and June&#160;30, 2018 (unaudited), and the years ended December 31, 2018 and 2017; and (v) Notes to financial statements</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:11pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style=" float:left; margin-top:3.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">*<br ></div>
          <div style=" margin-top:3.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">To be filed by amendment.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">+<br ></div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">Indicates management contract or compensatory plan or arrangement. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">&#8224;<br ></div>
        <div style=" margin-top:3.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">Indicates documents that have been previously filed.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">#<br ></div>
        <div style=" margin-top:3.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;font-size:10pt;">(b) Financial Statement Schedules. </div>
        <div style="text-indent:20pt; margin-top:5.01pt; width:456pt; line-height:12pt;font-size:10pt;">All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or the notes thereto. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">II-5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <div style="width:456pt; line-height:11pt;font-weight:bold;">Item&#160;17. Undertakings.</div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The undersigned registrant hereby undertakes:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(i)<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(ii)<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &quot;Calculation of Registration Fee&quot; table in the effective registration statement;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(iii)<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(i)<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424 (&#167;230.424 of this chapter);</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(ii)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(iii)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-6</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:40pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">(iv)<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:60pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-7</div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSIG">&#8203;</a>
      </div>
      <div style="margin-top:46pt;min-height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SIGNATURES </div>

          <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Francisco, California on October 11, 2019. </div>

        <div style="margin-left:240pt; margin-top:4.99pt; width:216pt; line-height:12pt;font-weight:bold;">ADYNXX, INC.</div>
        <div style=" float:left; margin-left:240pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">By:<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:260pt;">/s/ <font style="text-transform:uppercase;">R<font style="font-size:7pt;">ick</font> O<font style="font-size:7pt;">rr</font></font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:260pt; margin-top:2.5pt; width:196pt;">
          <div style="margin-left: 0pt; width: 196pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="margin-left:260pt; margin-top:2pt; width:196pt; line-height:12pt;">Name: Rick Orr <br >Title:&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</div>

        <div style="text-indent:20pt; margin-top:10.98pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </div>

          <table style="width:456pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.25pt 0pt; width:114pt;">
                <div style="white-space:nowrap; text-align:center;">Signature </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.25pt 0pt; width:235pt;">
                <div style="white-space:nowrap; text-align:center;">Title </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.25pt 0pt; width:83pt;">
                <div style="white-space:nowrap; text-align:center;">Date </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:6.667pt 0pt 1.833pt 0pt; width:114pt;">
                <div style="text-align:center;">/s/ <font style="text-transform:uppercase;">R<font style="font-size:7pt;">ick</font> O<font style="font-size:7pt;">rr</font></font></div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Rick Orr </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:6.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;font-style:italic;">
                  <font style="font-style:normal;">President and Chief Executive Officer and Director</font> <br >(Principal Executive Officer and Principal Financial&#160;Officer)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:6.667pt 0pt 1.833pt 0pt; width:83pt;white-space:nowrap;">
                <div style="text-align:center;">October 11, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">/s/<font style="text-transform:uppercase;"> D<font style="font-size:7pt;">ina</font> G<font style="font-size:7pt;">onzalez</font></font></div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Dina Gonzalez </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Controller <br ><font style="font-style:italic;">(Principal Accounting Officer)</font></div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="text-align:center;">October 11, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Dennis Podlesak </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Chairman of the Board of Directors </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="text-align:center;">October 11, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Stan Abel </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="text-align:center;">October 11, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Gregory J. Flesher </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="text-align:center;">October 11, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Julien Mamet, Ph.D. </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="text-align:center;">October 11, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Matthew Ruth </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="text-align:center;">October 11, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Eckard Weber, M.D. </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="text-align:center;">October 11, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:9.667pt 0pt 1.833pt 0pt; width:114pt;">
                <div style=" float:left; line-height:10pt; text-align:left; width:25pt;white-space:nowrap;">*By:<br ></div>
                <div style=" line-height:10pt; text-align:left; margin-left:25pt;">/s/ <font style="text-transform:uppercase;">R<font style="font-size:7pt;">ick</font> O<font style="font-size:7pt;">rr</font></font></div>
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
                <div style="margin-left:25.03pt; margin-top:2.5pt;">
                  <div style="margin-left: 0pt; width: 88.97pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-left:25.03pt; margin-top:2pt;">Rick Orr<br ><font style="font-style:italic;">Attorney-in-fact</font></div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
          </table>

      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>tv528145_ex4-3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.3</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADYNXX,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Warrant Shares: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: right"><FONT STYLE="font-size: 10pt">Initial Exercise Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Issue Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">THIS WARRANT TO PURCHASE COMMON STOCK (the
 &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after [ISSUE DATE] (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on
or prior to 5:00 p.m.&nbsp;(New York City time) on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2024<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1
</SUP></FONT>(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Adynxx,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (as subject to adjustment
hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this
Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section&nbsp;1</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section&nbsp;1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then
listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as
applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group,&nbsp;Inc. (or a similar organization or
agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or
(d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which
banking institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Common Stock Equivalents</U>&rdquo;
means any securities of the Company or any subsidiaries of the Company which would entitle the holder thereof to acquire at any
time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT>Insert the date that is the [__] year anniversary of the Initial Exercise Date; provided, however, that, if such
date is not a Trading Day, insert the immediately following Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo; means
an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Registration Statement</U>&rdquo;
means the Company&rsquo;s registration statement on Form&nbsp;S-1 (File No.&nbsp;333-232169).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question:
the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange
(or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means Action Stock Transfer Corporation, the current transfer agent of the Company, with a mailing address of 2469 E. Fort Union
Blvd, Suite 214, Salt Lake City, Utah 84121, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo; means,
for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as
applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group,&nbsp;Inc. (or a similar organization or
agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or
(d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section&nbsp;2</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Exercise of Warrants</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other
office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder
appearing on the books of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the
form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and
(ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein)
following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price to the Company for the Warrant
Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in the applicable Notice of Exercise. No&nbsp;ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice
of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">surrender
this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been
exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder
and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice. <B>The Holder
and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Without limiting the rights of a Holder to
receive Warrant Shares on a &ldquo;cashless exercise&rdquo; and without limiting the liquidated damages provision in Section&nbsp;2(d)(i)&nbsp;and
the buy-in provision in Section&nbsp;2(d)(iv), in no event will the Company be required to net cash settle a Warrant exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Exercise Price</U>. The exercise price per Warrant Share under this Warrant shall be $[&bull;], subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised,
in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.7pt">(A)&nbsp;=&nbsp;&nbsp; as applicable: (i)&nbsp;the
VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both
executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both executed and
delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule&nbsp;600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at
the option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of
Exercise or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the
time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours
after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the
VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of
Exercise is both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof after the close of &ldquo;regular trading hours&rdquo;
on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.7pt">(B)&nbsp;=&nbsp;&nbsp; the Exercise Price, as adjusted
hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt">(X)&nbsp;=&nbsp;&nbsp; the number of Warrant Shares
that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means
of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">If Warrant Shares are issued in
such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company agrees
not to take any position contrary to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 82pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with
The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is
then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the
Warrant Shares to or resale of the Warrant Shares by the Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise
and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder
or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified
by the Holder in the Notice of Exercise by the date that is the earlier of (i)&nbsp;the earlier of (A)&nbsp;two (2)&nbsp;Trading
Days after the delivery to the Company of the Notice of Exercise and (B)&nbsp;one (1)&nbsp;Trading Day after delivery of the aggregate
Exercise Price to the Company and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the
Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that
payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i)&nbsp;two
(2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following delivery of
the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of
Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth (5th) Trading Day after such liquidated
damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or
Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long
as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the
standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to
the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section&nbsp;2(d)(i)&nbsp;by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with
the provisions of Section&nbsp;2(d)(i)&nbsp;above pursuant to an exercise on or before the Warrant Share Delivery Date, and if
after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares
which the Holder anticipated receiving upon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">such exercise but did not receive (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase
price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained
by multiplying (1)&nbsp;the number of Warrant Shares that the Company was required to deliver, but failed to deliver, to the Holder
in connection with the exercise at issue times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation
was executed, and (B)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant
Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder
the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery
obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In
with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation
of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000.
The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and,
upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue
any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of
the Warrant as required pursuant to the terms hereof.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No&nbsp;Fractional Shares or Scrip</U>. No&nbsp;fractional shares or scrip representing fractional shares shall be issued upon
the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal
to such fraction multiplied by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">vi.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by
the Holder; <U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name
of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice
of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions)
required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">vii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Holder&rsquo;s Exercise Limitations</U> . The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving
effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons,
 &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and
its Affiliates and Attribution Parties shall include the number of shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">issuable upon exercise of this Warrant
with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other securities
of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp;
Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial ownership shall be calculated
in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion
of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned
by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each
case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance
with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. For purposes of this
Section&nbsp;2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A)&nbsp;the Company&rsquo;s most recent periodic or annual report filed with the Commission,
as the case may be, (B)&nbsp;a more recent public announcement by the Company or (C)&nbsp;a more recent written notice by the Company
or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of
a Holder, the Company shall within one (1)&nbsp;Trading Day confirm orally and in writing to the Holder the number of shares of
Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving
effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution
Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo; <U>Beneficial Ownership
Limitation</U>&rdquo; shall be [9.99/4.99%] of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase
or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial Ownership Limitation
in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section&nbsp;2(e)&nbsp;shall
continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice
is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph (or any portion hereof) which may be
defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a
successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section&nbsp;3</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend
or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues
by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall
become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the
Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property
pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder
could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant
(without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately
before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken,
the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in
the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend
or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock other than as set forth
in Section&nbsp;3(a), by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock
or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement
or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then, in each
such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to
the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall
be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the
Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all
or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer,
tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock
are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of 50% or more of the outstanding Common Stock, (iv)&nbsp;the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v)&nbsp;the Company,
directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group
of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any
shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other
Persons making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental
Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each
Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
at the option of the Holder (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number
of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or
any additional consideration (the &ldquo;<U>Alternate Consideration</U> &ldquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental
Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant). For purposes of any such
exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based
on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and
the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to
the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or,
if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder
by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised portion of this Warrant
on the date of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, if the Fundamental Transaction
is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, Holder shall only
be entitled to receive from the Company or any Successor Entity, as of the date of consummation of such Fundamental Transaction,
the same type or form of consideration (and in the same proportion), at the Black Scholes Value (as defined below) of the unexercised
portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental
Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common
Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction.
 &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black and Scholes Option Pricing Model obtained
from the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation
of the applicable Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Termination Date, (B)&nbsp;an expected volatility equal to the greater of 100% and the 100 day volatility obtained
from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental
Transaction, (C)&nbsp;the underlying price per share used in such calculation shall be the greater of (i)&nbsp;the sum of the price
per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental
Transaction and (ii)&nbsp;the greater of (x)&nbsp;the last VWAP immediately prior to the public announcement of such Fundamental
Transaction and (y)&nbsp;the last VWAP immediately prior to the consummation of such Fundamental Transaction and (D)&nbsp;a remaining
option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination
Date.&nbsp; The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business
Days of the Holder&rsquo;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause
any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section&nbsp;3(d)&nbsp;pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this
Warrant a security of the Successor Entity evidenced by a written</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">instrument substantially similar in form and substance to this
Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity)
equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations
on the exercise of this Warrant) prior to such Fundamental Transaction, and with an Exercise price which applies the Exercise price
hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to
such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental
Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental
Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant
with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Calculations</U>. All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3,
the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notice to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C)&nbsp;the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for
or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company
shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company
is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or
involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause
to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the
Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified,
a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification,
consolidation, liquidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as
of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, liquidation, merger, sale, transfer
or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not
affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in
this Warrant constitutes, or contains,&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">material, non-public information
regarding the Company or any subsidiaries of the Company, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing
on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set
forth herein.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term
of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for
any period of time deemed appropriate by the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section&nbsp;4</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with
a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney
and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within two (2)&nbsp;Trading
Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if
properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a
new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section&nbsp;5</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No&nbsp;Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or
other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0">certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such
Warrant or stock certificate.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Saturdays, Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any
right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on
the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">The Company covenants that during
the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares
to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing
the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized,
validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the
issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Except and to the extent as waived
or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will
at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality
of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor
upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal
courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">delivery (with evidence of delivery) to such party
at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of
this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action
or proceeding.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Nonwaiver and Expenses</U>. No&nbsp;course of dealing or any delay or failure to exercise any right hereunder on the part of
Holder shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting
any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to
cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by email, or sent by a nationally recognized
overnight courier service, addressed to the Company, at Adynxx,&nbsp;Inc., 100 Pine Street, Suite 500, San Francisco, California
94111, Attention: Principal Financial Officer, email address: rorr@adynxx.com, or such other facsimile number, email address or
address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries
to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally
recognized overnight courier service addressed to each Holder at the facsimile number,&nbsp; e-mail address or address of such
Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and
effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via facsimile at the
facsimile number or via e-mail at the e-mail address set forth in this Section&nbsp;prior to 5:30 p.m.&nbsp;(New York City time)
on any date, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or via e-mail at the email address set forth in this Section&nbsp;on a day that is not a Trading Day or
later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (iii)&nbsp;the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the party to whom such notice
is required to be given.&nbsp; To the extent that any notice provided hereunder constitutes, or contains, material, non-public
information regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Limitation of Liability</U>. No&nbsp;provision hereof, in the absence of any affirmative action by the Holder to exercise this
Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any
liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is
asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be
adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to
waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or
the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">IN WITNESS WHEREOF, the Company has caused
this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADYNXX,&nbsp;INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B>ADYNXX,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(1)&nbsp;&nbsp; The undersigned hereby elects
to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warrant Shares of the Company pursuant to the terms of the attached
Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(2)&nbsp;&nbsp; Payment shall take the form
of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT> in lawful
money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT> if permitted
the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(3)&nbsp;&nbsp; Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrant Shares shall be delivered to the following DWAC
Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Name of Investing Entity:</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name of Authorized Signatory:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title of Authorized Signatory:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt"><I>(To assign the foregoing Warrant, execute
this form and supply required information.&nbsp; Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing Warrant
and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Phone Number:</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Email Address:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dated:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Holder&rsquo;s Address:</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>3
<FILENAME>tv528145_ex4-4.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.4</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>PRE-FUNDED COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADYNXX, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Warrant Shares: </FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                               <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<FONT STYLE="font-size: 10pt">Initial Exercise Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Issue Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PRE-FUNDED WARRANT
TO PURCHASE COMMON STOCK (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after [ISSUE DATE] (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) until this Warrant is exercised in full (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Adynxx, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price
of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on
a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)in all other
cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the
Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or any subsidiaries of the Company which would entitle the holder
thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or
other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof
to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the Securities Purchase Agreement, dated as of _____, 2019, by and among the Company and the purchasers
signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-1, as amended and supplemented from time to time
(File No. 333-232169).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or
the New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Action Stock Transfer Corporation, the current transfer agent of the Company, with a mailing address of
2469 E. Fort Union Blvd, Suite 214, Salt Lake City, Utah 84121, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the
volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)in all other
cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the
Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Exercise
of Warrants</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or
agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing
on the books of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed
hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid,
the Holder shall deliver the unpaid portion of the aggregate Exercise Price to the Company for the Warrant Shares specified in
the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise
procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of
the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number
of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase
of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may
be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Without limiting the
rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; and without limiting the liquidated damages provision
in Section 2(d)(i) and the buy-in provision in Section 2(d)(iv), in no event will the Company be required to net cash settle a
Warrant exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.01 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal
exercise price of $0.01 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this
Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price
under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to
the Termination Date. The exercise price per Warrant Share under this Warrant shall be $[&#9679;], subject to adjustment hereunder.
The remaining unpaid exercise price per Warrant Share under this Warrant shall be $0.01 subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (C)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(A) =
as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed
and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as
defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option
of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z)
the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo;
on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of
Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant
to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B) = the
Exercise Price, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(C) =
the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company
agrees not to take any position contrary to this Section 2(c)</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(d) <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Transfer Agent is then a
participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares
to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise and otherwise by
physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee,
for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder
in the Notice of Exercise by the date that is the earlier of (i) the earlier of (A) two (2) Trading Days after the delivery to
the Company of the Notice of Exercise and (B) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company
and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of
Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder
shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this
Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii)
the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company
fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery
Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares
subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading
Day (increasing to $20 per Trading Day on the fifth (5<SUP>th</SUP>) Trading Day after such liquidated damages begin to accrue)
for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed
in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the
date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered
on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time
of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m.
(New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise but did not receive (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the
Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the
shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company
was required to deliver, but failed to deliver, to the Holder in connection with the exercise at issue times (2) the price at which
the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the
portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise
shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company
timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder
and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees
to the Depository Trust Company (or another</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">established clearing corporation performing similar functions) required for same-day
electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution
Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)
exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence,
for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible
for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e)
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)
and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder
may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual
report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent
written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written
or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after
giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be [9.99/4.99%] of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the
Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section
2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP>
day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which
may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">to such limitation. The limitations contained in this paragraph shall apply to a
successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such
extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase
Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock other than as set forth in Section
3(a), by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities,
property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar
transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then, in each such case, the
Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to the extent
that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any
shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon
such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard
to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and/or any additional consideration (the &ldquo;<U>Alternate
Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common
Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall
be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect
of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate
Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction,
then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the
Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company
under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction
and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced
by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number
of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such
Fundamental Transaction, and with an Exercise price which applies the Exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value
of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity
shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this
Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power
of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email
to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least
20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which
a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to
be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption,
rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, liquidation, merger, sale,
transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the
Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, liquidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required
to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public
information regarding the Company or any subsidiaries of the Company, the Company shall simultaneously file such notice with the
Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly
set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant
in full, in which case, the Holder shall surrender this Warrant to the Company within two (2) Trading Days</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">of the date on which
the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue
Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>No
Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in
Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The Company
covenants that during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law
thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New
York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of
New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper
or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be
reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Restrictions.
</U>The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder
does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any
material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by
the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h) <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation,
any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company, at Adynxx, Inc., 100 Pine Street, Suite 500, San Francisco, California 94111, Attention: Principal
Financial Officer,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">email address: rorr@adynxx.com, or such other facsimile number, email address or address as the Company may
specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by
the Company hereunder shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized
overnight courier service addressed to each Holder at the facsimile number, e-mail address or address of such Holder appearing
on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the
earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number or
via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading
Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number or via e-mail
at the email address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time)
on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight
courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice
provided hereunder constitutes, or contains, material, non-public information regarding the Company or any subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>ADYNXX, iNC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT>&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">[<I>Signature Page to<BR>
Pre-Funded Common Stock Purchase Warrant</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Adynxx, Inc.</I>]</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>ADYNXX,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The undersigned hereby elects to purchase Warrant Shares of the Company pursuant to the terms
of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with
all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth
in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to
the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Please issue said Warrant Shares in the name of the undersigned or in such other name as is
specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to
the following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">[SIGNATURE OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of
Investing Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _______________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the
foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED,
the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding: 2pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify; padding: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding: 2pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding: 2pt"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding: 2pt 2pt 2.5pt"><FONT STYLE="font-size: 10pt">Phone Number:</FONT></TD>
    <TD STYLE="text-align: justify; padding: 2pt 2pt 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt 2pt 2.5pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding: 2pt"><FONT STYLE="font-size: 10pt">Email Address:</FONT></TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt 2pt 2.5pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding: 2pt"><FONT STYLE="font-size: 10pt">Dated: _______________ __, ______</FONT></TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 13%; padding: 2pt; white-space: nowrap"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid; padding: 2pt; width: 37%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2%; padding: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 48%; padding: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding: 2pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding: 2pt; white-space: nowrap"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="text-align: justify; padding: 2pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>tv528145_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John T. McKenna</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 650 843 5059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">jmckenna@cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 11, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adynxx, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 Pine Street, Suite 500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Francisco, CA 94111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as counsel to Adynxx, Inc.,
a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the filing by the Company of a Registration
Statement on Form&nbsp;S-1 (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;) with the Securities and Exchange Commission
and a related prospectus included in the Registration Statement (the &ldquo;<B><I>Prospectus</I></B>&rdquo;), covering a public offering of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">up to 7,500,000 shares (the &ldquo;<B><I>Shares</I></B>&rdquo;) of common stock of the Company,
par value $0.001 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">pre-funded warrants to purchase up to an aggregate of  7,500,000 shares of Common Stock (the
                                                                 &ldquo;<B><I>Pre-Funded Warrants</I></B>&rdquo;), and the shares of Common Stock issuable upon exercise thereunder; and</TD></TR></TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">warrants to purchase up to  7,500,000 shares of Common Stock (the &ldquo;<B><I>Common
                                                                 Warrants</I></B>&rdquo;) and the shares of Common Stock issuable upon exercise thereunder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Registration Statement also covers the issuance of warrants to purchase up to 562,500 shares of Common Stock being issued to the placement agent (the &ldquo;<B><I>Placement Agent Warrants</I></B>&rdquo;) and the shares of Common Stock issuable upon exercise thereunder.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Pre-Funded Warrants, the Placement Agent Warrants and the Common Warrants are
collectively referred to herein as the &ldquo;<B><I>Warrants</I></B>&rdquo; and the shares of Common Stock issuable upon
exercise of the Warrants are referred to as the &ldquo;<B><I>Warrant Shares</I></B>&rdquo;. The Shares, the Warrants and the
Warrant Shares are to be issued by the Company as described in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this opinion, we have
(i) examined and relied upon (a) the Registration Statement and the Prospectus, (b) the form of Warrant, (c) the Company&rsquo;s
Certificate of Incorporation, as amended, and Amended and Restated Bylaws, each as currently in effect and (d) originals or copies
certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are
necessary or appropriate to enable us to render the opinion expressed below and (ii) assumed that the Shares and the Warrants will
be sold, and the exercise price of the Warrants will be set, at a price established by the Board of Directors of the Company or
a duly authorized committee thereof. We have assumed the genuineness and authenticity of all documents submitted to us as originals,
and the conformity to originals of all documents submitted to us as copies and the due execution and delivery of all documents
by all persons other than the Company where due execution and delivery are a prerequisite to the effectiveness thereof. As to certain
factual matters, we have relied upon a certificate of an officer of the Company and have not sought independently to verify such
matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With regard to our opinion regarding the
Warrants and the Warrant Shares, we express no opinion to the extent that, notwithstanding its current reservation of shares of
Common Stock, future issuances of securities of the Company, including the Warrant Shares, and/or antidilution adjustments to outstanding
securities of the Company, including the Warrants, cause the Warrants to be exercisable for more shares of Common Stock than the
number that then remain authorized but unissued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With regard to our opinion concerning the
Warrants constituting valid and binding obligations of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
opinion is subject to, and may be limited by, (a) applicable bankruptcy, reorganization, insolvency, moratorium, fraudulent conveyance,
debtor and creditor, and similar laws which relate to or affect creditors&rsquo; rights generally, and (b) general principles of
equity (including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing) regardless of whether
considered in a proceeding in equity or at law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
opinion is subject to the qualification that the availability of specific performance, an injunction or other equitable remedies
is subject to the discretion of the court before which the request is brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
express no opinion as to any provision of the Warrants that: (a) provides for liquidated damages, buy-in damages, monetary penalties,
prepayment or make-whole payments or other economic remedies to the extent such provisions may constitute unlawful penalties, (b)
relates to advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements,
statutes of limitations, trial by jury, or procedural rights, (c) restricts non-written modifications and waivers, (d) provides
for the payment of legal and other professional fees where such payment is contrary to law or public policy, (e) relates to exclusivity,
election or accumulation of rights or remedies, (f) authorizes or validates conclusive or discretionary determinations, or (g)
provides that provisions of the Warrants are severable to the extent an essential part of the agreed exchange is determined to
be invalid and unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
express no opinion as to whether a state court outside of the State of New York or a federal court of the United States would give
effect to the choice of New York law or jurisdiction provided for in the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our opinion is expressed only with respect
to the General Corporation Law of the State of Delaware and, as to the Warrants constituting valid and legally binding obligations
of the Company, the laws of the State of New York. We express no opinion to the extent that any other laws are applicable to the
subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law,
rule or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the basis of the foregoing, and in reliance
thereon, we are of the opinion that (i) the Shares, when sold in accordance with the Registration Statement and the Prospectus,
will be validly issued, fully paid and nonassessable, (ii) the Warrants, when duly executed and delivered by the Company against
payment therefor as provided in the Registration Statement and the Prospectus, will be valid and legally binding obligations of
the Company, and (iii) the Warrant Shares, when issued and paid for in accordance with the terms of the Warrants, will be validly
issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the reference to our firm
under the caption &ldquo;Legal Matters&rdquo; in the Prospectus included in the Registration Statement and to the filing of this
opinion as an exhibit to the Registration Statement. This opinion is expressed as of the date hereof, and we disclaim any undertaking
to advise you of any changes in the facts stated or assumed herein or any changes in applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cooley LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: <U>/s/John T. McKenna&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">John T. McKenna</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>tv528145_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="color: Black"><B>Exhibit 23.1</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in; color: fuchsia"><FONT STYLE="color: Black"><U>Consent
of Independent Registered Public Accounting Firm</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: fuchsia"><FONT STYLE="color: Black"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">Adynxx,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">San
Francisco, California</FONT></P>

<P STYLE="color: fuchsia; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="color: fuchsia; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">We
hereby consent to the use in the Prospectus constituting a part of this Registration Statement on Form S-1 (Amendment No. 3) of
our report dated June 7, 2019, relating to the financial statements of Adynxx, Inc., which is contained in that Prospectus. Our
report contains an explanatory paragraph regarding the Company&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">We
also consent to the reference to us under the caption &ldquo;Experts&rdquo; in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><U>/s/ BDO
USA, LLP&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">BDO USA, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">San
Jose, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">October
11, 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>adyx-20190630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!-- Created by Toppan Merrill -->
<xbrli:xbrl xmlns:adyx="http://www.adynxx.com/20190630" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="adyx-20190630.xsd"/>
  <xbrli:context id="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember_srt-RangeAxis_srt-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputPriceVolatilityMember_srt-RangeAxis_srt-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember_srt-RangeAxis_srt-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember_srt-RangeAxis_srt-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember_srt-RangeAxis_srt-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember_srt-RangeAxis_srt-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember_srt-RangeAxis_srt-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputPriceVolatilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputSharePriceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputPriceVolatilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputPriceVolatilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputConversionPriceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember_srt-RangeAxis_srt-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember_srt-RangeAxis_srt-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputPriceVolatilityMember_srt-RangeAxis_srt-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember_srt-RangeAxis_srt-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputPriceVolatilityMember_srt-RangeAxis_srt-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember_srt-RangeAxis_srt-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputConversionPriceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-IncomeTaxAuthorityAxis_us-gaap-DomesticCountryMember_us-gaap-IncomeTaxAuthorityNameAxis_us-gaap-InternalRevenueServiceIRSMember_us-gaap-TaxCreditCarryforwardAxis_us-gaap-ResearchMember_us-gaap-TaxPeriodAxis_us-gaap-EarliestTaxYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-IncomeTaxAuthorityAxis_us-gaap-DomesticCountryMember_us-gaap-IncomeTaxAuthorityNameAxis_us-gaap-InternalRevenueServiceIRSMember_us-gaap-TaxCreditCarryforwardAxis_us-gaap-ResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-IncomeTaxAuthorityAxis_us-gaap-StateAndLocalJurisdictionMember_us-gaap-TaxCreditCarryforwardAxis_us-gaap-ResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2016-01-01_2016-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_us-gaap-PlanNameAxis_adyx-ThePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adyx:ThePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-03-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adyx:DomainMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_adyx-LetterOfCredit1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">adyx:LetterOfCredit1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_adyx-LetterOfCredit1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">adyx:LetterOfCredit1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adyx-ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">adyx:ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adyx-ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">adyx:ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adyx-ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">adyx:ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adyx-ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">adyx:ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_srt-RangeAxis_srt-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_srt-RangeAxis_srt-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_adyx-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adyx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_adyx-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adyx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2016-03-31_2016-03-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-31</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2016-01-29_2016-01-29_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-29</xbrli:startDate>
      <xbrli:endDate>2016-01-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-11-24_2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-11-24</xbrli:startDate>
      <xbrli:endDate>2015-11-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-TaxPeriodAxis_us-gaap-EarliestTaxYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-IncomeTaxAuthorityAxis_us-gaap-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-LongtermDebtTypeAxis_us-gaap-ConvertibleDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel3Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel3Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantIssuedInConnectionWithTermLoanAAndBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantIssuedInConnectionWithTermLoanAAndBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantIssuedInConnectionWithTermLoanAAndBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantIssuedInConnectionWithTermLoanAAndBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-DividendsAxis_adyx-NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">adyx:NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-DividendsAxis_adyx-NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">adyx:NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel3Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel3Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-01_2019-05-31_us-gaap-DebtInstrumentAxis_adyx-SecondNoteToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:SecondNoteToFundTheCompanysOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:MajorityInvestorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-04-30_us-gaap-DebtInstrumentAxis_adyx-FirstNoteToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:FirstNoteToFundTheCompanysOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:MajorityInvestorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-31_us-gaap-DebtInstrumentAxis_adyx-NotesToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:NotesToFundTheCompanysOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:MajorityInvestorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:MajorityInvestorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-09-27_2018-09-27_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedSeptember272018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertiblePromissoryNoteIssuedSeptember272018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-27</xbrli:startDate>
      <xbrli:endDate>2018-09-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-03-29_2018-03-29_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedOnMarch292019Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertiblePromissoryNoteIssuedOnMarch292019Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-29</xbrli:startDate>
      <xbrli:endDate>2018-03-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-10-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember_us-gaap-StatementEquityComponentsAxis_adyx-ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2018AndModifiedSeptember2018NotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">adyx:ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-11-25_2015-11-25_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_srt-RangeAxis_srt-MinimumMember_us-gaap-VariableRateAxis_us-gaap-LondonInterbankOfferedRateLiborSwapRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLiborSwapRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-11-25</xbrli:startDate>
      <xbrli:endDate>2015-11-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-03_2019-05-03_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_us-gaap-StatementClassOfStockAxis_adyx-SeriesBConvertiblePreferredStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">adyx:ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-03</xbrli:startDate>
      <xbrli:endDate>2019-05-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2016-01-01_2016-12-31_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">adyx:ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010-01-01_2010-12-31_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">adyx:ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adyx:AccountsPayable1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">adyx:Vendor3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adyx:AccountsPayable1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">adyx:Vendor2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adyx:AccountsPayable1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">adyx:Vendor1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adyx:AccountsPayable1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">adyx:TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adyx:AccountsPayable1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">adyx:Vendor2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adyx:AccountsPayable1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">adyx:Vendor1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-OneOfTheTwoVendorsSupportingManufacturingActivitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adyx:AccountsPayable1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">adyx:OneOfTheTwoVendorsSupportingManufacturingActivitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsReserveForSeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsReserveForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsReserveForSeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsReserveForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockIssuedInJanuary2016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockIssuedInJanuary2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018September2018December2018AndMarch2019NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2018September2018December2018AndMarch2019NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018September2018December2018AndMarch2019NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2018September2018December2018AndMarch2019NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-AwardTypeAxis_adyx-NonEmployeeOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adyx:NonEmployeeOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-AwardTypeAxis_adyx-NonEmployeeOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adyx:NonEmployeeOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-PlanNameAxis_adyx-ThePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adyx:ThePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-10-01_2018-10-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2018AndModifiedSeptember2018NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-01</xbrli:startDate>
      <xbrli:endDate>2018-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018September2018December2018AndMarch2019NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2018September2018December2018AndMarch2019NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-09-27_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedSeptember272018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertiblePromissoryNoteIssuedSeptember272018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-03-29_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedOnMarch292019Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertiblePromissoryNoteIssuedOnMarch292019Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-03_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2016-11-01_2016-11-01_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-11-01</xbrli:startDate>
      <xbrli:endDate>2016-11-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2018AndModifiedSeptember2018NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_adyx-ConversionOfPreferredStockToCommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">adyx:ConversionOfPreferredStockToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2018-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2016-03-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-11-24_2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-11-24</xbrli:startDate>
      <xbrli:endDate>2015-11-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-01-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adyx:DomainMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertiblePromissoryNoteOf15MillionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-09-30_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertiblePromissoryNoteOf15MillionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-03-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-01-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-03-01_2018-03-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-01-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-01-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adyx:DomainMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-12-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertiblePromissoryNoteOf15MillionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-09-01_2018-09-30_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertiblePromissoryNoteOf15MillionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2019AndModifiedDecember2018NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2019AndModifiedDecember2018NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2019AndModifiedDecember2018NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2019AndModifiedDecember2018NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2018AndModifiedSeptember2018NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-03_2019-05-03_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">adyx:ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-03</xbrli:startDate>
      <xbrli:endDate>2019-05-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2016-01-31_2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-31</xbrli:startDate>
      <xbrli:endDate>2016-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-11-30_2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-11-30</xbrli:startDate>
      <xbrli:endDate>2015-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010-07-01_2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-07-01</xbrli:startDate>
      <xbrli:endDate>2010-07-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010-07-01_2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantsForSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-07-01</xbrli:startDate>
      <xbrli:endDate>2010-07-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-11-24_2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_srt-RangeAxis_srt-MinimumMember_us-gaap-VariableRateAxis_us-gaap-LondonInterbankOfferedRateLiborSwapRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLiborSwapRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-11-24</xbrli:startDate>
      <xbrli:endDate>2015-11-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2016-01-29_2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-29</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-06-30_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-06-30_us-gaap-AwardTypeAxis_adyx-NonEmployeeOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adyx:NonEmployeeOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-04-01_2018-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-04-01_2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-04-01_2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-04-01_2018-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-04-01_2018-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-04-01_2018-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-04-01_2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-04-01_2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-04-01_2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-10-01_2018-10-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-01</xbrli:startDate>
      <xbrli:endDate>2018-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-01-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adyx:DomainMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-01-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-AwardTypeAxis_adyx-NonEmployeeOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adyx:NonEmployeeOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">adyx:ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adyx:AccountsPayable1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">adyx:TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adyx:AccountsPayable1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">adyx:Vendor1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adyx:AccountsPayable1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">adyx:Vendor2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adyx:AccountsPayable1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">adyx:Vendor3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2019AndModifiedDecember2018NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2019AndModifiedDecember2018NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-IncomeStatementLocationAxis_us-gaap-InterestExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-IncomeStatementLocationAxis_us-gaap-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_srt-RangeAxis_srt-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_srt-RangeAxis_srt-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adyx:PriceRange1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adyx:PriceRange2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adyx:PriceRange3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange4Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adyx:PriceRange4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-04-30_us-gaap-DebtInstrumentAxis_adyx-FirstNoteToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:FirstNoteToFundTheCompanysOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:MajorityInvestorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-06-30_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-06-30_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">adyx:ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-01_2019-05-31_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">adyx:ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-01_2019-05-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">adyx:ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-01_2019-05-31_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">adyx:ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-01_2019-05-31_us-gaap-DebtInstrumentAxis_adyx-SecondNoteToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:SecondNoteToFundTheCompanysOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:MajorityInvestorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-01_2019-05-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-03_2019-05-03">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-03</xbrli:startDate>
      <xbrli:endDate>2019-05-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-03_2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-03</xbrli:startDate>
      <xbrli:endDate>2019-05-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-03_2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchaseCommonStockConvertedInMergerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchaseCommonStockConvertedInMergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-03</xbrli:startDate>
      <xbrli:endDate>2019-05-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-03_2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">adyx:ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-03</xbrli:startDate>
      <xbrli:endDate>2019-05-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-03_2019-05-03_dei-LegalEntityAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-NonmonetaryTransactionTypeAxis_adyx-ReverseStockSplitFromMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">adyx:ReverseStockSplitFromMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-03</xbrli:startDate>
      <xbrli:endDate>2019-05-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-03_2019-05-03_us-gaap-RelatedPartyTransactionAxis_adyx-SeverancePayMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_srt-ChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adyx:SeverancePayMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-03</xbrli:startDate>
      <xbrli:endDate>2019-05-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-29_2019-05-29_dei-LegalEntityAxis_adyx-AlliquaBiomedicalIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-29</xbrli:startDate>
      <xbrli:endDate>2019-05-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-05-31_2019-05-31_us-gaap-DebtInstrumentAxis_adyx-SecondNoteToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:SecondNoteToFundTheCompanysOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:MajorityInvestorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-31</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-06-01_2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-06-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-07-01_2019-07-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adyx:DomainMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-08-01_2019-08-01_us-gaap-NonmonetaryTransactionTypeAxis_adyx-ReverseStockSplitMember_srt-RangeAxis_srt-MaximumMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">adyx:ReverseStockSplitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-08-01</xbrli:startDate>
      <xbrli:endDate>2019-08-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-08-01_2019-08-01_us-gaap-NonmonetaryTransactionTypeAxis_adyx-ReverseStockSplitMember_srt-RangeAxis_srt-MinimumMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">adyx:ReverseStockSplitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-08-01</xbrli:startDate>
      <xbrli:endDate>2019-08-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-08-02_2019-08-02_us-gaap-NonmonetaryTransactionTypeAxis_adyx-ReverseStockSplitMember_srt-RangeAxis_srt-MaximumMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">adyx:ReverseStockSplitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-08-02</xbrli:startDate>
      <xbrli:endDate>2019-08-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2019-08-02_2019-08-02_us-gaap-NonmonetaryTransactionTypeAxis_adyx-ReverseStockSplitMember_srt-RangeAxis_srt-MinimumMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">adyx:ReverseStockSplitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-08-02</xbrli:startDate>
      <xbrli:endDate>2019-08-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-24_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2017-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-03-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-10-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018September2018December2018AndMarch2019NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2018September2018December2018AndMarch2019NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableFiveMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableFourMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableSixMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableSixMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel1Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel1Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel2Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel2Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2018-12-31_srt-RangeAxis_srt-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-01-01_us-gaap-AdjustmentsForNewAccountingPronouncementsAxis_us-gaap-AccountingStandardsUpdate201602Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-01-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adyx:DomainMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-03-31_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-03-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchaseCommonStockConvertedInMergerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:WarrantToPurchaseCommonStockConvertedInMergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_srt-RangeAxis_srt-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_srt-RangeAxis_srt-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-03_us-gaap-ClassOfWarrantOrRightAxis_adyx-AlliquaWarrantsAssumedInMergerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:AlliquaWarrantsAssumedInMergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-03_us-gaap-ClassOfWarrantOrRightAxis_adyx-AlliquaWarrantsAssumedInMergerMember_srt-RangeAxis_srt-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:AlliquaWarrantsAssumedInMergerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-03_us-gaap-ClassOfWarrantOrRightAxis_adyx-AlliquaWarrantsAssumedInMergerMember_srt-RangeAxis_srt-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adyx:AlliquaWarrantsAssumedInMergerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-03_dei-LegalEntityAxis_adyx-AlliquaBiomedicalIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-03_dei-LegalEntityAxis_adyx-AlliquaBiomedicalIncMember_srt-RangeAxis_srt-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-03_dei-LegalEntityAxis_adyx-AlliquaBiomedicalIncMember_srt-RangeAxis_srt-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-05-31_us-gaap-DebtInstrumentAxis_adyx-NotesToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:NotesToFundTheCompanysOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:MajorityInvestorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-20_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adyx:DomainMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-21_dei-LegalEntityAxis_adyx-AquaMedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adyx:AquaMedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">adyx:AlliquaBiomedicalIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adyx:DomainMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_srt-CounterpartyNameAxis_adyx-OxfordFinanceLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableFiveMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableFourMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableSixMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableSixMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ConvertibleNotePayableTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2018AndModifiedSeptember2018NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018September2018December2018AndMarch2019NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2018September2018December2018AndMarch2019NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2019AndModifiedDecember2018NotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adyx:ModifiedMarch2019AndModifiedDecember2018NotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:MajorityInvestorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adyx:OxfordFinanceLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adyx:TermLoanBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-LongtermDebtTypeAxis_us-gaap-ConvertibleDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-PropertyPlantAndEquipmentByTypeAxis_adyx-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adyx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_adyx-LetterOfCredit1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">adyx:LetterOfCredit1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap-MoneyMarketFundsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adyx:PriceRange1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adyx:PriceRange2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adyx:PriceRange3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange4Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adyx:PriceRange4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adyx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2019-07-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adyx:DomainMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Duration20190809_MinimumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-08-01</xbrli:startDate>
      <xbrli:endDate>2019-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2017-01-01_2017-12-31_SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2018-01-01_2018-12-31_SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I20190630_NonEmployeeOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001054274</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adyx:NonEmployeeOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-USD_xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-9d083aac-d494-4509-845a-6178e9e91be8_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember_srt-RangeAxis_srt-MinimumMember" unitRef="xbrli-pure">2.56</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-f3742fb2-bc0e-4458-a3cb-833f7fbf2f5d_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputPriceVolatilityMember_srt-RangeAxis_srt-MinimumMember" unitRef="xbrli-pure">76.84</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-1cd90374-2ad4-4b41-b22f-a3ea78dd2d75_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember_srt-RangeAxis_srt-MinimumMember" unitRef="iso4217-USD">6.92</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-6a09ef6d-d65f-4cf2-a954-29d77cdcb20f_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember_srt-RangeAxis_srt-MaximumMember" unitRef="iso4217-USD">2.59</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-78d36b6c-59e8-4726-84e2-a271ceb6aa66_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember_srt-RangeAxis_srt-MaximumMember" unitRef="iso4217-USD">7.08</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-caf1310d-3e85-4bff-8ad1-cbefe23856dc_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember_srt-RangeAxis_srt-MinimumMember" unitRef="iso4217-USD">7.92</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-96ca97b4-052d-4212-9024-cb0a1cbf6918_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember_srt-RangeAxis_srt-MaximumMember" unitRef="iso4217-USD">8.08</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-41c7d5fc-bc9f-4d27-8281-1a8d7c478f33_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember" unitRef="xbrli-pure">2.28</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-e8d1b185-c137-42cd-88b3-a0a9523f66d2_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputPriceVolatilityMember" unitRef="xbrli-pure">71.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-3fe89fbf-d9a1-4809-9235-be33e5d47815_20181231" decimals="INF" contextRef="I2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputSharePriceMember" unitRef="xbrli-pure">0.23</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-2ca9fcd3-280e-470d-b3fa-ef04da26aa6d_20181231" decimals="INF" contextRef="I2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember" unitRef="xbrli-pure">0.0209</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-601b03e1-9ded-4578-9b0a-acb1a3f10ac0_20181231" decimals="INF" contextRef="I2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputPriceVolatilityMember" unitRef="xbrli-pure">0.686</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-a53ed3ea-ec5d-48e3-8435-036e057f1eec_20181231" decimals="INF" contextRef="I2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember" unitRef="xbrli-pure">10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-b7999b0f-d3b2-4cfe-95c0-680b2435dbbc_20181231" decimals="INF" contextRef="I2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember" unitRef="xbrli-pure">0.0207</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-eb8b4f7b-bfd0-44ab-8885-d474c0a6a935_20181231" decimals="INF" contextRef="I2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputPriceVolatilityMember" unitRef="xbrli-pure">0.687</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-427bce57-0824-4724-9d57-1f7455823e86_20181231" decimals="INF" contextRef="I2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember" unitRef="xbrli-pure">10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-afb082fa-fcd0-4d7e-8a27-3c4ee64d1bf8_20181231" decimals="INF" contextRef="I2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputConversionPriceMember" unitRef="xbrli-pure">0.20</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-932a9ca7-87be-4564-9e12-ca18086cabcb_20181231" decimals="INF" contextRef="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember_srt-RangeAxis_srt-MinimumMember" unitRef="xbrli-pure">3.92</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-4c2b99a7-503c-4a55-b3bf-fabdc0bf7c42_20181231" decimals="INF" contextRef="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember_srt-RangeAxis_srt-MinimumMember" unitRef="xbrli-pure">0.0146</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-d4554fa5-da82-4554-b708-fab5949d6917_20181231" decimals="INF" contextRef="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputPriceVolatilityMember_srt-RangeAxis_srt-MinimumMember" unitRef="xbrli-pure">0.736</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-c9a129df-0ad2-4ab5-b54c-020d55531c01_20181231" decimals="INF" contextRef="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputRiskFreeInterestRateMember_srt-RangeAxis_srt-MaximumMember" unitRef="xbrli-pure">0.0266</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-9c94e309-e360-4f88-803e-fdd70309a9d7_20181231" decimals="INF" contextRef="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputPriceVolatilityMember_srt-RangeAxis_srt-MaximumMember" unitRef="xbrli-pure">0.815</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-7cc20f4a-e1f2-402c-a0b8-477a23b7d261_20181231" decimals="INF" contextRef="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputExpectedTermMember_srt-RangeAxis_srt-MaximumMember" unitRef="xbrli-pure">7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Fact-57c5e446-45e9-47b7-bc5f-b77fa9eb19b4_20181231" decimals="INF" contextRef="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember_us-gaap-MeasurementInputTypeAxis_us-gaap-MeasurementInputConversionPriceMember" unitRef="xbrli-pure">0.2276</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstanding id="Fact-31b74eec-94c6-4e83-b8f0-4fdab9c9a7d8_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember" unitRef="iso4217-USD">42000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreferencePerShare id="Fact-e4752145-401e-41c6-a74f-ac95920755fc_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBConvertiblePreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.3133</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
  <us-gaap:TemporaryEquityLiquidationPreferencePerShare id="Fact-f07bb4ff-53f5-443c-8195-b7ea1dc16458_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesAConvertiblePreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.2276</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
  <us-gaap:TemporaryEquityLiquidationPreference id="Fact-2de3bf8d-008e-42fb-b640-997c078b21a5_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">12898697000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Fact-2fdd2032-b309-49f0-8f84-70e284461635_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">12814000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesAuthorized id="c49927390_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">2046378</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="c49928186_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">2034548</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="c49928193_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">2034548</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital id="c49927388_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">0.001</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Fact-3d1e2477-8d8c-434d-b5f2-5d92246a6006_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">15897000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityLiquidationPreference id="Fact-b2291f89-4f41-40f9-a001-126f7e154978_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">16000000000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-27b37a6e-5af3-4a1f-b893-4b1863a9c5de_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">51069262</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-fa434c4e-6267-4f57-a034-18cd8a30f4ef_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">51069262</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-a65428fd-7bd4-4e75-8835-24bf6258fe62_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">51069262</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-fac9867a-80e4-4d0d-be29-0fdca7560fe5_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">51069262</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital id="Fact-f434aad0-6a65-4cf9-9fd0-6f1936f6af43_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">0.001</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Fact-aabc923f-815e-4f76-8e7a-8442cec6b25a_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">12814000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityLiquidationPreference id="Fact-b5b9cf85-10e9-41cb-b981-200344631d6e_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">12898697000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-5fc0a12d-4b7e-4409-9979-7025dc018f13_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">57002183</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-1d8492fc-6d66-4ccf-86f0-392645428074_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">56672658</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-eeeadba2-0def-4d8b-9aa3-00b41608ed33_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">56672658</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital id="Fact-1e5d959b-7a23-4857-9e44-584150baaf01_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">0.001</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
  <us-gaap:TaxCreditCarryforwardExpirationDate id="Fact-48bdb4e0-b825-4852-9709-5c4a1d19afe8_20181231" contextRef="D2018-01-01_2018-12-31_us-gaap-IncomeTaxAuthorityAxis_us-gaap-DomesticCountryMember_us-gaap-IncomeTaxAuthorityNameAxis_us-gaap-InternalRevenueServiceIRSMember_us-gaap-TaxCreditCarryforwardAxis_us-gaap-ResearchMember_us-gaap-TaxPeriodAxis_us-gaap-EarliestTaxYearMember">2031-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
  <us-gaap:TaxCreditCarryforwardAmount id="Fact-6ec5c094-0908-4cc8-aaf9-7fbd32d9d621_20181231" decimals="-5" contextRef="I2018-12-31_us-gaap-IncomeTaxAuthorityAxis_us-gaap-DomesticCountryMember_us-gaap-IncomeTaxAuthorityNameAxis_us-gaap-InternalRevenueServiceIRSMember_us-gaap-TaxCreditCarryforwardAxis_us-gaap-ResearchMember" unitRef="iso4217-USD">1800000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount id="Fact-69260812-b8f6-4565-97e6-ea6389d2ea0d_20181231" decimals="-5" contextRef="I2018-12-31_us-gaap-IncomeTaxAuthorityAxis_us-gaap-StateAndLocalJurisdictionMember_us-gaap-TaxCreditCarryforwardAxis_us-gaap-ResearchMember" unitRef="iso4217-USD">700000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:StockholdersEquity id="Fact-52dfc3ac-a1f1-42af-836c-affeb21aaa1b_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-37279000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="c49927506_20190630" decimals="-3" contextRef="I2018-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">728000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Fact-ad727f68-70b7-4bf1-ae67-d7224ff184c8_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-31294000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="c49927641_20190630" decimals="-3" contextRef="I2017-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">419000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Fact-0c1bed4d-36c8-4055-8ce7-81f36e68a47c_20181231" decimals="-3" contextRef="I2016-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-19733000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Fact-434a279a-fb28-4b6e-90b4-0518272085f3_20181231" decimals="-3" contextRef="I2016-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">118000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927502_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">1833387</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Fact-d472435a-24bb-438e-9831-43a4c1d44d6e_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">15897000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927500_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">2034548</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Fact-2c76c943-56e4-4037-86b1-dd5177fb982c_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">12814000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927504_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">701808</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="c49927505_20190630" decimals="-3" contextRef="I2018-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">20000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927637_20190630" decimals="INF" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">1833387</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Fact-ec1a36ce-1f62-4a77-85b9-d5fb2c781252_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">15897000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927635_20190630" decimals="INF" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">2034548</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Fact-e73071ff-4ea4-4130-ac7f-2c050469abb3_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">12814000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927639_20190630" decimals="INF" contextRef="I2017-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">701808</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="c49927640_20190630" decimals="-3" contextRef="I2017-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">20000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="Fact-de60c8ba-92ed-4c89-902d-3869911738e8_20181231" decimals="INF" contextRef="I2016-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">51069262</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Fact-6139c4fa-60ac-407d-a1d1-1a27258a95c1_20181231" decimals="-3" contextRef="I2016-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">15897000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="Fact-92ecbe4a-63ff-4798-9a77-e619c5ab7a7c_20181231" decimals="INF" contextRef="I2016-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">56321165</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Fact-bc1d28cd-bee2-4946-8b52-2af335d853d8_20181231" decimals="-3" contextRef="I2016-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">12734000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="Fact-6ffb83c5-0cb1-4f49-833e-c1c39857456c_20181231" decimals="0" contextRef="I2016-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">140362</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Fact-394e35cb-6eb4-4b41-9017-a31b5e140aef_20181231" decimals="-3" contextRef="I2016-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">20000</us-gaap:StockholdersEquity>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Fact-0badbed9-9c70-49f8-a99d-fd50ad4274eb_20181231" contextRef="D2016-01-01_2016-12-31">P9Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Fact-26fc3637-c7d3-4654-8986-c0dbef18791d_20181231" contextRef="D2018-01-01_2018-12-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_us-gaap-PlanNameAxis_adyx-ThePlanMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Fact-3637629d-e461-4577-a874-cec4ad7fccae_20181231" contextRef="D2018-01-01_2018-12-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_us-gaap-PlanNameAxis_adyx-ThePlanMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:RestrictedCash id="Fact-3ba1f08a-30bc-46b9-8b88-3765ca29715f_20181231" decimals="INF" contextRef="I2019-03-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="iso4217-USD">200000</us-gaap:RestrictedCash>
  <us-gaap:RestrictedCash id="Fact-50d6ef65-1572-4a10-8408-0383910ecf8e_20181231" decimals="INF" contextRef="I2019-03-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="iso4217-USD">200000</us-gaap:RestrictedCash>
  <us-gaap:RestrictedCash id="Fact-cb524484-f90a-49da-9aa1-a91b34100916_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_adyx-LetterOfCredit1Member" unitRef="iso4217-USD">55000</us-gaap:RestrictedCash>
  <us-gaap:RestrictedCash id="Fact-fff42478-50b7-4ddf-a714-20bc8fc40cc2_20181231" decimals="INF" contextRef="I2017-12-31_us-gaap-RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_adyx-LetterOfCredit1Member" unitRef="iso4217-USD">55000</us-gaap:RestrictedCash>
  <us-gaap:ResearchAndDevelopmentExpense id="Fact-80ce0bc8-daff-43fd-8d5b-8c85dc2096d2_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31_us-gaap-ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adyx-ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" unitRef="iso4217-USD">95000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Fact-32f59660-06bd-46bf-aea4-c98912984fb7_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31_us-gaap-ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adyx-ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" unitRef="iso4217-USD">185000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Fact-658f36d7-cb86-4e7c-8255-bb2a4279842e_20181231" decimals="-5" contextRef="D2017-01-01_2017-12-31_us-gaap-ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adyx-ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" unitRef="iso4217-USD">6200000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Fact-da3322d3-c7e0-4bfc-b3af-d4301489b650_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31_us-gaap-ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_adyx-ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" unitRef="iso4217-USD">0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="Fact-60301731-986d-4ae3-980c-15952db2d89a_20181231" contextRef="D2018-01-01_2018-12-31_srt-RangeAxis_srt-MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="Fact-0f9dc1cd-a22d-411a-8395-4f1e3169f828_20181231" contextRef="D2018-01-01_2018-12-31_srt-RangeAxis_srt-MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-58a8bc50-cd3b-46aa-810a-1ac8d572f8d0_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-OfficeEquipmentMember" unitRef="iso4217-USD">2000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-a3d22711-7aa3-4d9b-b765-9b7f0c46e478_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-FurnitureAndFixturesMember" unitRef="iso4217-USD">29000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-fa0fd87c-5fdf-485b-8658-be7a95a5f4e8_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-ComputerEquipmentMember" unitRef="iso4217-USD">18000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-1252d82e-5bc3-4c25-8654-4a75f3e8cfbd_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_adyx-LaboratoryEquipmentMember" unitRef="iso4217-USD">2000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-b5614e78-486f-4d78-a310-e4543acb5f24_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-OfficeEquipmentMember" unitRef="iso4217-USD">2000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-7d229a1f-be3c-4239-aeb0-8ef3fb5017e5_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-FurnitureAndFixturesMember" unitRef="iso4217-USD">29000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-73f523ec-9bfc-42d6-9e39-b7c0383f2024_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-ComputerEquipmentMember" unitRef="iso4217-USD">24000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-b64f1223-88cb-4d13-90b1-cc9c05d05b91_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_adyx-LaboratoryEquipmentMember" unitRef="iso4217-USD">2000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:ProceedsFromIssuanceOfDebt id="Fact-8e318264-faef-446a-840d-625681b587cf_20181231" decimals="-5" contextRef="D2016-03-31_2016-03-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanCMember" unitRef="iso4217-USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromIssuanceOfDebt id="Fact-61d8f637-2780-4065-92c6-6fda22e90726_20181231" decimals="-5" contextRef="D2016-01-29_2016-01-29_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember" unitRef="iso4217-USD">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromIssuanceOfDebt id="c49928091_20190630" decimals="INF" contextRef="D2015-11-24_2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember" unitRef="iso4217-USD">3000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:OperatingLossCarryforwardsExpirationDate id="Fact-217b6fc5-89e3-4c09-b76d-4125331f7aae_20181231" contextRef="D2018-01-01_2018-12-31_us-gaap-TaxPeriodAxis_us-gaap-EarliestTaxYearMember">2033-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
  <us-gaap:OpenTaxYear id="Fact-cf956269-ce48-4f6a-87d6-b641e5f6d24f_20181231" contextRef="D2018-01-01_2018-12-31_us-gaap-IncomeTaxAuthorityAxis_us-gaap-DomesticCountryMember">2014 2015 2016 2017 2018</us-gaap:OpenTaxYear>
  <us-gaap:NotesPayable id="Fact-d0de3a74-a87c-4117-a7c2-5a6ae24865ec_20181231" decimals="-5" contextRef="I2018-12-31_us-gaap-LongtermDebtTypeAxis_us-gaap-ConvertibleDebtMember" unitRef="iso4217-USD">4600000</us-gaap:NotesPayable>
  <us-gaap:NetIncomeLoss id="Fact-40c4354c-1635-474f-a0aa-431b040d24c2_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-5985000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Fact-99b13710-bd79-4dc1-a582-5a954a100c87_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-11561000</us-gaap:NetIncomeLoss>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths id="Fact-d46448d5-c95c-4531-8e2d-b4470c5b3cb2_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">3833000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
  <us-gaap:LoansPayable id="c49928098_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember" unitRef="iso4217-USD">1500000</us-gaap:LoansPayable>
  <us-gaap:LongTermDebt id="Fact-919f2614-85ff-41a4-b5d5-b8f9ae50f1ce_20181231" decimals="-5" contextRef="I2018-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember" unitRef="iso4217-USD">1500000</us-gaap:LongTermDebt>
  <us-gaap:LoansPayable id="c49928097_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember" unitRef="iso4217-USD">2300000</us-gaap:LoansPayable>
  <us-gaap:LongTermDebt id="Fact-d771ea6b-5e75-484a-9b98-d1b2477dce9d_20181231" decimals="-5" contextRef="I2018-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember" unitRef="iso4217-USD">2300000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="Fact-f20dc6bc-02f8-460b-bdf2-87ea0ae67082_20181231" decimals="-5" contextRef="I2017-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember" unitRef="iso4217-USD">1900000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="Fact-bbf202ee-8462-4852-947b-47cfc93c3a85_20181231" decimals="-5" contextRef="I2017-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember" unitRef="iso4217-USD">2800000</us-gaap:LongTermDebt>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Fact-0b800053-b08d-428f-921d-8f4fef9222e4_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel3Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember" unitRef="iso4217-USD">140000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Fact-56c5ec23-ac8b-4b5f-8b42-d260463ae704_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember" unitRef="iso4217-USD">140000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Fact-d4484712-c306-4811-991b-947f8570e69c_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel3Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember" unitRef="iso4217-USD">42000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Fact-83f3f593-b157-4031-bb4c-f8dc3cb60e83_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember" unitRef="iso4217-USD">42000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Fact-2898844d-a355-4fee-928b-84b8c4fa2830_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">140000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Fact-d6355e04-f75d-4532-a075-17e8148ebe6d_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">42000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Fact-24e682d2-0f08-449e-be0a-dfd629cd8ba5_20181231" decimals="-3" contextRef="I2016-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">54000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="Fact-f22e913b-b0fa-4c99-b2e1-45dde24d310d_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">98000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="Fact-c072a7ec-f130-4a7a-b078-d0bb1156ce93_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD">-211000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="Fact-0c8d12a9-30ef-4a2d-bf94-8362ce95b0fc_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD">864000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales id="Fact-1f3204ed-b87e-46b0-acbc-752aa774add7_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD">653000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="Fact-53b2a09c-23a0-4532-aafc-b31d8efd9011_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">-4000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements id="Fact-cce33539-236f-43dc-a481-0b5599512b89_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">-8000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock id="Fact-ec66a107-23f8-4c2a-8165-8ec68bb34045_20181231" contextRef="D2018-01-01_2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;As&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 2.28&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;2.56% &amp;#x2013; 2.59&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Remaining contractual life (in years) &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;7.92 &amp;#x2013; 8.08&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;6.92 &amp;#x2013; 7.08&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 71.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 76.84&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAdjustmentOfWarrants id="Fact-18a694c1-62a1-45b9-9260-99222a494536_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantIssuedInConnectionWithTermLoanAAndBMember" unitRef="iso4217-USD">98000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants id="Fact-a1d6c0f3-405f-4520-a84a-7949abeb1110_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantIssuedInConnectionWithTermLoanAAndBMember" unitRef="iso4217-USD">-12000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:DividendsPayableAmountPerShare id="Fact-7cd7bde4-6b61-4373-b942-62012060fb00_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-DividendsAxis_adyx-NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.0251</us-gaap:DividendsPayableAmountPerShare>
  <us-gaap:DividendsPayableAmountPerShare id="Fact-5a9b65ff-96ce-4219-9086-2ad7ea74ace4_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-DividendsAxis_adyx-NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.0182</us-gaap:DividendsPayableAmountPerShare>
  <us-gaap:DerivativeLiabilities id="Fact-ff94e4fe-e7c5-4430-98dd-66d62bf5511a_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel3Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">140000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="Fact-c91e54ed-358d-448a-87bb-36ad82c1ab19_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">140000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="Fact-001fdc46-7d44-41e1-be67-b8382a86310c_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel3Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">42000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="Fact-b181be68-52da-49de-a5d5-342842a344f2_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">42000</us-gaap:DerivativeLiabilities>
  <us-gaap:DebtInstrumentMaturityDate id="Fact-9f4e228e-c81f-4d75-bda0-e165d314b637_20181231" contextRef="D2019-05-01_2019-05-31_us-gaap-DebtInstrumentAxis_adyx-SecondNoteToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">2020-05-29</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:ProceedsFromNotesPayable id="Fact-04ac80d2-a099-4a66-9c8c-3a16c80d76ae_20181231" decimals="-5" contextRef="D2019-05-01_2019-05-31_us-gaap-DebtInstrumentAxis_adyx-SecondNoteToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="iso4217-USD">500000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:DebtInstrumentMaturityDate id="Fact-d10cac0f-734a-4268-a3b8-b6238cb8ffba_20181231" contextRef="D2019-04-01_2019-04-30_us-gaap-DebtInstrumentAxis_adyx-FirstNoteToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">2020-04-26</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:ProceedsFromNotesPayable id="Fact-6e2b8d06-ed56-465f-a583-d2fc1dea5079_20181231" decimals="-5" contextRef="D2019-04-01_2019-04-30_us-gaap-DebtInstrumentAxis_adyx-FirstNoteToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="iso4217-USD">2000000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:DebtInstrumentMaturityDate id="Fact-ab370d83-6095-4bd8-8145-bb1d5387d659_20181231" contextRef="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableTwoMember">2019-09-27</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate id="Fact-12b324de-e6c7-4ed4-b188-4275580b2501_20181231" contextRef="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableThreeMember">2019-12-21</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate id="Fact-8bfb9661-5ddb-4dc7-9a32-94590159caae_20181231" contextRef="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableOneMember">2019-03-29</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate id="Fact-d83db709-7818-4e0c-a3ac-b68583bbcf3e_20181231" contextRef="D2017-01-01_2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableTwoMember">2019-09-27</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate id="Fact-5af61bc2-921d-4526-924e-e5bb51d2ed67_20181231" contextRef="D2017-01-01_2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableThreeMember">2019-12-21</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate id="Fact-1f9b4a16-1d61-4849-93ca-4c229e8bfbf5_20181231" contextRef="D2017-01-01_2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableOneMember">2019-03-29</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Fact-6c6a0f0b-bfbb-4c6b-98db-1184ed7fbaae_20181231" decimals="2" contextRef="I2019-05-31_us-gaap-DebtInstrumentAxis_adyx-NotesToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Fact-82148f1f-47d9-40c8-910e-d97db7d80612_20181231" decimals="3" contextRef="I2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableTwoMember" unitRef="xbrli-pure">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Fact-95098600-79e9-4388-967b-44f7851e81a2_20181231" decimals="3" contextRef="I2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableThreeMember" unitRef="xbrli-pure">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Fact-377e7514-dccb-439d-a5b9-f8a22f1360b9_20181231" decimals="3" contextRef="I2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableOneMember" unitRef="xbrli-pure">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount id="Fact-2c997017-725f-44ae-bb32-6e517939c145_20181231" decimals="-5" contextRef="I2018-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember" unitRef="iso4217-USD">4500000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Fact-ce01e46f-a273-4676-9b76-e64804315aba_20181231" decimals="2" contextRef="I2018-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember" unitRef="xbrli-pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="Fact-a40825be-fbf0-43bc-b723-14adba399c66_20181231" decimals="0" contextRef="I2018-12-31_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember" unitRef="iso4217-USD">126000</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:DebtInstrumentFaceAmount id="Fact-593f2c20-b2b8-4d30-83f4-92d0dfccf470_20181231" decimals="-5" contextRef="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanCMember" unitRef="iso4217-USD">5000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DeferredFinanceCostsNet id="Fact-80a1f2d0-dc35-464b-83f1-17655e7aaa2e_20181231" decimals="INF" contextRef="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember" unitRef="iso4217-USD">3000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:DebtInstrumentFaceAmount id="c49928085_20190630" decimals="INF" contextRef="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember" unitRef="iso4217-USD">2000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DeferredFinanceCostsGross id="c49928092_20190630" decimals="INF" contextRef="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember" unitRef="iso4217-USD">141000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:DeferredFinanceCostsNet id="Fact-fd63288e-56fe-4b49-909f-4f3fc11bda1d_20181231" decimals="INF" contextRef="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember" unitRef="iso4217-USD">141000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:DebtInstrumentFaceAmount id="c49928084_20190630" decimals="INF" contextRef="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember" unitRef="iso4217-USD">3000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount id="Fact-21b5c24e-8413-430d-a26f-db4809f432cb_20181231" decimals="-5" contextRef="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember" unitRef="iso4217-USD">10000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 id="Fact-5cd7e532-d05b-4977-8ad5-299c4cfc8821_20181231" contextRef="D2018-09-27_2018-09-27_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedSeptember272018Member">P1Y</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
  <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 id="Fact-9349c4f8-1cf8-40e3-a126-84ed46a105c3_20181231" contextRef="D2018-03-29_2018-03-29_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedOnMarch292019Member">P1Y</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="Fact-6b1b258a-0fc6-46f6-aeca-5cc842087670_20181231" decimals="INF" contextRef="I2018-10-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember_us-gaap-StatementEquityComponentsAxis_adyx-ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.3133</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="Fact-cd0d0cb2-ebb7-4616-9ad6-cb79720d3330_20181231" decimals="4" contextRef="D2015-11-25_2015-11-25_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_srt-RangeAxis_srt-MinimumMember_us-gaap-VariableRateAxis_us-gaap-LondonInterbankOfferedRateLiborSwapRateMember" unitRef="xbrli-pure">0.0019</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Fact-a3a12a7c-844b-4346-81f0-aa15103e1441_20181231" decimals="INF" contextRef="D2019-05-03_2019-05-03_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_us-gaap-StatementClassOfStockAxis_adyx-SeriesBConvertiblePreferredStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-shares">10223996</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Fact-5f8aac4f-4e04-4320-ac37-f8fe48e9b0ed_20181231" decimals="INF" contextRef="D2016-01-01_2016-12-31_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" unitRef="xbrli-shares">6469356</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Fact-3a7a6597-f325-44fa-99d1-ac22f0b04d34_20181231" decimals="INF" contextRef="D2010-01-01_2010-12-31_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" unitRef="xbrli-shares">3531889</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance id="Fact-5402f3d5-e1ca-47ee-9ba0-951208edf764_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">51069000</us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance>
  <us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance id="Fact-0e49e5f0-1775-45b1-a929-b7c8633efd32_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">56673000</us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance>
  <us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance id="Fact-320130aa-56f3-4dfc-82ca-cf29d432104b_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">51069000</us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance>
  <us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance id="Fact-ca090056-278a-4172-a726-8c7fc632970f_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">56673000</us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Fact-074741b0-2ade-42c5-91ba-2858f9742ef6_20181231" decimals="3" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableTwoMember" unitRef="xbrli-pure">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:ConvertibleDebt id="Fact-000a26f8-9e0f-441e-9a80-71b1985ea090_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableTwoMember" unitRef="iso4217-USD">1500000</us-gaap:ConvertibleDebt>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Fact-c3266a3c-74b5-4d32-965b-f27d24e29cf4_20181231" decimals="3" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableThreeMember" unitRef="xbrli-pure">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:ConvertibleDebt id="Fact-6fd65db3-3f72-4cfb-88a5-f3dfa7ebc6f6_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableThreeMember" unitRef="iso4217-USD">1500000</us-gaap:ConvertibleDebt>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Fact-a352f889-40ad-49c7-8e52-d092bc5fc160_20181231" decimals="3" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableOneMember" unitRef="xbrli-pure">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:ConvertibleDebt id="Fact-57d14ef1-7ba6-4a33-8cde-ca30d7875d24_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableOneMember" unitRef="iso4217-USD">1500000</us-gaap:ConvertibleDebt>
  <us-gaap:ConcentrationRiskPercentage1 id="c49927819_20190630" decimals="4" contextRef="D2018-01-01_2018-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor3Member" unitRef="xbrli-pure">0.15</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="c49927815_20190630" decimals="4" contextRef="D2018-01-01_2018-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor2Member" unitRef="xbrli-pure">0.26</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="c49927813_20190630" decimals="4" contextRef="D2018-01-01_2018-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor1Member" unitRef="xbrli-pure">0.52</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="c49927821_20190630" decimals="4" contextRef="D2018-01-01_2018-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" unitRef="xbrli-pure">0.67</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="Fact-29c41e10-c0dd-496c-b64a-f59c7e47aac2_20181231" decimals="2" contextRef="D2017-01-01_2017-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor2Member" unitRef="xbrli-pure">0.31</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="Fact-692cd172-99b3-408a-b973-9d7448120622_20181231" decimals="2" contextRef="D2017-01-01_2017-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor1Member" unitRef="xbrli-pure">0.56</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="Fact-50f73494-c214-4e07-84ad-cc27ad18bf13_20181231" decimals="2" contextRef="D2017-01-01_2017-12-31_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" unitRef="xbrli-pure">0.56</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Fact-eb69007e-21df-4cd7-b5a2-c737055a9ad5_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember" unitRef="xbrli-shares">330</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding id="Fact-07214cca-01cc-4517-b53a-24df8c12b2d9_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember" unitRef="iso4217-USD">140000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Fact-4bf8ea9d-d023-4ca3-8d94-752c42ff7724_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsReserveForSeriesAConvertiblePreferredStockMember" unitRef="xbrli-shares">330000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Fact-4d9169ba-1f1a-4e5a-880e-b955da8d5bf1_20181231" decimals="-3" contextRef="I2017-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsReserveForSeriesAConvertiblePreferredStockMember" unitRef="xbrli-shares">330000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Fact-2739de35-aed2-40df-9740-7ac2e1946989_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" unitRef="iso4217-USD_xbrli-shares">0.2276</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Fact-6d745084-b9e3-4194-b59e-5acad655258e_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" unitRef="xbrli-shares">198</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Fact-13388ba4-ec17-44ca-9aa3-74b68aa15cd9_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockIssuedInJanuary2016Member" unitRef="iso4217-USD_xbrli-shares">0.2276</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Fact-28f83d17-62ef-4c85-8126-46119bad1635_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockIssuedInJanuary2016Member" unitRef="xbrli-shares">132</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Fact-ab551df1-29a0-4074-ae7b-a1a55b75e936_20181231" decimals="INF" contextRef="I2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" unitRef="iso4217-USD_xbrli-shares">0.2276</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Fact-6e3f0f9a-3014-415b-bda9-a9d6a5d472a1_20181231" decimals="INF" contextRef="I2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" unitRef="xbrli-shares">131810</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Fact-a32a3106-7805-4e21-ba62-df432d6816c9_20181231" decimals="INF" contextRef="I2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" unitRef="iso4217-USD">22000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Fact-ca1c13f5-ea98-4dd7-b562-5a3c7cf1ca67_20181231" decimals="INF" contextRef="I2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" unitRef="iso4217-USD_xbrli-shares">0.2276</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Fact-b08ed644-b845-41f5-837f-da42b0c0ef86_20181231" decimals="INF" contextRef="I2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" unitRef="xbrli-shares">197715</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Fact-803fb6cd-24f5-4709-9078-0633ffe220e4_20181231" decimals="INF" contextRef="I2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" unitRef="iso4217-USD">33000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="Fact-e0dcad0d-e69f-4b6a-b736-54dfc557c341_20181231" decimals="-3" contextRef="I2016-12-31" unitRef="iso4217-USD">14601000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Fact-0253f590-98bd-4b01-a630-ade09b456f8f_20181231" decimals="-3" contextRef="I2016-12-31" unitRef="xbrli-shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Fact-ab3ed345-acfc-4e0d-9e86-ac3d4d44dcaf_20181231" decimals="INF" contextRef="I2016-12-31" unitRef="xbrli-shares">19222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Fact-6a07c215-5ddb-4506-a9c7-e3d1d4855711_20181231" decimals="INF" contextRef="I2016-12-31" unitRef="iso4217-USD_xbrli-shares">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquity id="Fact-8b79b22e-06f9-46e9-be6c-7fc7453303c4_20181231" decimals="-3" contextRef="I2016-12-31" unitRef="iso4217-USD">-19595000</us-gaap:StockholdersEquity>
  <us-gaap:AmortizationOfDebtDiscountPremium id="Fact-8ccd68ba-f279-4c2b-b8a3-25a96b6023f6_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018September2018December2018AndMarch2019NotesMember" unitRef="iso4217-USD">223000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium id="Fact-ec101503-89ab-4b76-b58d-b03b2737a4cc_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018September2018December2018AndMarch2019NotesMember" unitRef="iso4217-USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Fact-76a79e83-4c1e-4102-a435-92b3d309d522_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember" unitRef="iso4217-USD">293000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Fact-29d2265c-a94c-4411-b8bd-50dd8995cc47_20181231" contextRef="D2018-01-01_2018-12-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Fact-c6210bbd-f465-47be-8528-8144b6aaae9a_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31_us-gaap-AwardTypeAxis_adyx-NonEmployeeOptionsMember" unitRef="iso4217-USD">16000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Fact-92d0e40b-d40b-406b-b811-3ebf58891fbd_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember" unitRef="iso4217-USD">301000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Fact-5c6804db-94f9-4ff2-9966-7ee6b7b6a0b2_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31_us-gaap-AwardTypeAxis_adyx-NonEmployeeOptionsMember" unitRef="iso4217-USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Fact-b7044efc-2c62-429b-966a-21830e70292a_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">309000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Fact-187e2be4-dede-493c-98a3-7974cd46d587_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">301000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="c49927746_20190630" decimals="-3" contextRef="I2018-06-30" unitRef="iso4217-USD">1713000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:StockholdersEquity id="c49927697_20190630" decimals="-3" contextRef="I2018-06-30" unitRef="iso4217-USD">-33650000</us-gaap:StockholdersEquity>
  <adyx:TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector id="Fact-e91acdae-5a88-43e9-887a-4d52e3abde3a_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">10000000</adyx:TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector>
  <us-gaap:TemporaryEquityLiquidationPreference id="Fact-41f069d8-0ec6-472e-b8f6-3f2e33660cdb_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">16000000000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Fact-e00da3e4-09b6-4056-beb1-46b3c67eecc3_20181231" decimals="-3" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">15897000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesAuthorized id="c49927400_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">1833387</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="c49928187_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">1833387</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="c49928194_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">1833387</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital id="Fact-cc9f706e-3ef7-4e16-a76a-a40582ae0581_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">0.001</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
  <adyx:StockIssuedDuringPeriodSharesWarrantExercised id="Fact-59feb4b6-5d38-485c-88a3-f084cb720a50_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">351493</adyx:StockIssuedDuringPeriodSharesWarrantExercised>
  <adyx:StockIssuedDuringPeriodValueWarrantExercised id="Fact-523d80a2-1d1e-49e0-a743-595cf897a3af_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">80000</adyx:StockIssuedDuringPeriodValueWarrantExercised>
  <adyx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares id="Fact-23e8a532-d19f-4810-99e6-526b4d8b3ea2_20181231" decimals="2" contextRef="I2018-12-31_us-gaap-PlanNameAxis_adyx-ThePlanMember" unitRef="xbrli-pure">1.00</adyx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares>
  <adyx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder id="Fact-97aa7bfe-a080-40d4-9aff-7a98d3d6fca3_20181231" decimals="2" contextRef="I2018-12-31_us-gaap-PlanNameAxis_adyx-ThePlanMember" unitRef="xbrli-pure">1.10</adyx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder>
  <adyx:ReleaseOfDerivativeLiabilities id="Fact-b1844931-97e4-4d42-af69-53bf0ff80974_20181231" decimals="INF" contextRef="D2018-10-01_2018-10-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="iso4217-USD">653000</adyx:ReleaseOfDerivativeLiabilities>
  <us-gaap:AmortizationOfDebtDiscountPremium id="Fact-7411a07f-1799-41b8-a4b6-cd70ca9f69a7_20181231" decimals="INF" contextRef="D2018-10-01_2018-10-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="iso4217-USD">641000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="Fact-48015e61-d937-4848-9f50-e3f139c314c5_20181231" decimals="INF" contextRef="D2018-10-01_2018-10-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="iso4217-USD">11000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="Fact-a95f1e2f-3d4b-4705-98a3-a32389824313_20181231" decimals="INF" contextRef="D2018-10-01_2018-10-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="iso4217-USD">11000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="Fact-ee94636c-8c5d-494b-839e-f3de64fea9c4_20181231" decimals="INF" contextRef="D2018-10-01_2018-10-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="iso4217-USD">11000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <adyx:ProbabilityOfChangeInControlOccurring id="Fact-f66de1fb-fa95-437b-95f4-db8470ccc8e8_20181231" decimals="2" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018September2018December2018AndMarch2019NotesMember" unitRef="xbrli-pure">0.00</adyx:ProbabilityOfChangeInControlOccurring>
  <adyx:ProbabilityOfQualifiedFinancingOccurring id="Fact-3e9d7b38-9b1c-4793-8d61-73dbf3e2a543_20181231" decimals="2" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018September2018December2018AndMarch2019NotesMember" unitRef="xbrli-pure">0.00</adyx:ProbabilityOfQualifiedFinancingOccurring>
  <adyx:ProbabilityOfChangeInControlOccurring id="Fact-cc4fba89-65fe-4efa-b4fe-7afe7c8f270e_20181231" decimals="2" contextRef="I2018-09-27_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedSeptember272018Member" unitRef="xbrli-pure">0.00</adyx:ProbabilityOfChangeInControlOccurring>
  <adyx:ProbabilityOfQualifiedFinancingOccurring id="Fact-c525b806-c485-4969-be99-8dee5e613b37_20181231" decimals="2" contextRef="I2018-09-27_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedSeptember272018Member" unitRef="xbrli-pure">0.40</adyx:ProbabilityOfQualifiedFinancingOccurring>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent id="Fact-bd62ff00-2fb3-4b82-8cea-9093d16c0bf1_20181231" decimals="INF" contextRef="I2018-09-27_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedSeptember272018Member" unitRef="iso4217-USD">369000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability id="Fact-19095b5e-a0fe-4d6b-b08e-154d58690e70_20181231" decimals="INF" contextRef="I2018-09-27_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedSeptember272018Member" unitRef="iso4217-USD">368000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <adyx:ProbabilityOfChangeInControlOccurring id="Fact-50b5cbd1-efe8-473c-b591-fa72c25b4c2a_20181231" decimals="2" contextRef="I2018-03-29_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedOnMarch292019Member" unitRef="xbrli-pure">0.15</adyx:ProbabilityOfChangeInControlOccurring>
  <adyx:ProbabilityOfQualifiedFinancingOccurring id="Fact-5bb6994d-62bf-4546-9c21-d2d4a4e93c6e_20181231" decimals="2" contextRef="I2018-03-29_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedOnMarch292019Member" unitRef="xbrli-pure">0.30</adyx:ProbabilityOfQualifiedFinancingOccurring>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent id="Fact-bac56ff3-380e-420e-960b-79c409e539f5_20181231" decimals="INF" contextRef="I2018-03-29_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedOnMarch292019Member" unitRef="iso4217-USD">496000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability id="Fact-3d38bfd4-5ba3-4eba-95cf-8aeedaa5baaf_20181231" decimals="INF" contextRef="I2018-03-29_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteIssuedOnMarch292019Member" unitRef="iso4217-USD">496000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <adyx:PercentageOfNotePayablePrincipal id="Fact-ca2b6b04-5a05-4ff6-9c5a-72d1275270d6_20181231" decimals="INF" contextRef="I2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" unitRef="xbrli-pure">0.2</adyx:PercentageOfNotePayablePrincipal>
  <adyx:MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree id="Fact-6a389b61-7de2-4235-8d74-03cf0fd3e12f_20181231" decimals="2" contextRef="I2019-05-03_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-pure">0.14</adyx:MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree>
  <adyx:MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer id="Fact-d85ecc72-c7c0-4c49-b28e-ea06a94aba4e_20181231" decimals="2" contextRef="I2019-05-03_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-pure">0.86</adyx:MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer>
  <adyx:LongtermDebtPrincipalAndInterestPaymentsTerm id="Fact-09cd2e94-ef11-4459-88f5-316598b6e63d_20181231" contextRef="D2016-11-01_2016-11-01_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">P3Y</adyx:LongtermDebtPrincipalAndInterestPaymentsTerm>
  <adyx:FinancingThresholdProceedsToConvertNotesToEquity id="Fact-f1558516-aa3d-4673-b69b-9d0c971f5221_20181231" decimals="-5" contextRef="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="iso4217-USD">5000000</adyx:FinancingThresholdProceedsToConvertNotesToEquity>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 id="Fact-7925f81c-5dbe-474e-8b4c-14cd9f045264_20181231" decimals="0" contextRef="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="xbrli-pure">80</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <adyx:EquityConvertibleAggregateProceedsTrigger id="Fact-e3dc94bd-cf38-47c2-af21-a8fe43235408_20181231" decimals="-6" contextRef="D2018-01-01_2018-12-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_adyx-ConversionOfPreferredStockToCommonStockMember" unitRef="iso4217-USD">40000000</adyx:EquityConvertibleAggregateProceedsTrigger>
  <adyx:EquityConvertibleStockPriceTrigger id="Fact-f11f2f02-dc3f-4ff0-ac96-bc6b4e0ddf9f_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_adyx-ConversionOfPreferredStockToCommonStockMember" unitRef="iso4217-USD_xbrli-shares">1.00</adyx:EquityConvertibleStockPriceTrigger>
  <adyx:DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary id="Fact-102647c9-c977-4abc-8fa0-c74f6f1767fc_20181231" decimals="2" contextRef="D2017-01-01_2018-12-31" unitRef="xbrli-pure">0.03</adyx:DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary>
  <adyx:DebtInstrumentUnusedBorrowingCapacityExpired id="Fact-1cee0a31-21e0-4e42-8335-55a3c491729a_20181231" decimals="-5" contextRef="I2016-03-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanCMember" unitRef="iso4217-USD">5000000</adyx:DebtInstrumentUnusedBorrowingCapacityExpired>
  <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount id="Fact-a296e6d7-a754-4869-9c0e-0b73fb9b66be_20181231" decimals="-5" contextRef="I2016-03-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanCMember" unitRef="iso4217-USD">5000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
  <adyx:DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage id="Fact-723b9b2b-cfbe-47da-98b6-37c9f8f7c0f3_20181231" decimals="2" contextRef="D2015-11-24_2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="xbrli-pure">0.01</adyx:DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage>
  <adyx:DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage id="Fact-7cbfe4c4-4840-4d21-ba2c-a9c2d8744dc3_20181231" decimals="2" contextRef="D2015-11-24_2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="xbrli-pure">0.03</adyx:DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage>
  <adyx:DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage id="Fact-38ff86b8-92b1-4e4e-af97-8354b73d72f2_20181231" decimals="2" contextRef="D2015-11-24_2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="xbrli-pure">0.02</adyx:DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage>
  <adyx:DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage id="Fact-ba50c3da-25dc-4b8e-a7bb-ef2df518d09d_20181231" decimals="2" contextRef="D2015-11-24_2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="xbrli-pure">0.01</adyx:DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage>
  <adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid id="Fact-59eaf0f6-7567-473a-a24e-82ad17c4a411_20181231" decimals="INF" contextRef="I2019-01-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="iso4217-USD">50000</adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid>
  <adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid id="Fact-07238ad1-d7bb-4281-b9dd-13a89e66b21f_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">35000</adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid>
  <adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid id="Fact-186af6ef-2c8c-46cc-b247-38b7e3b75808_20181231" decimals="INF" contextRef="I2018-09-30_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">25000</adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid>
  <adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid id="Fact-acf7b946-d971-4855-a2ea-58e23d70f541_20181231" decimals="INF" contextRef="I2018-03-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">200000</adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid>
  <adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid id="Fact-c34ead62-1ace-4808-9740-335d6bb0751e_20181231" decimals="INF" contextRef="I2017-01-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">100000</adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid>
  <adyx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage id="Fact-e7d5eb7a-6b06-45b7-9ec9-c76595af999e_20181231" decimals="4" contextRef="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="xbrli-pure">0.0425</adyx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Fact-90670fe6-4198-4dba-9335-8bbace76ca10_20181231" decimals="4" contextRef="I2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="xbrli-pure">0.0706</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <adyx:DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments id="Fact-4be0812d-2eb1-4b63-a126-d6244232a0ab_20181231" contextRef="D2018-03-01_2018-03-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">P150D</adyx:DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments>
  <adyx:DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments id="Fact-16d433ef-ccc9-4e07-80a5-00d6c11ab219_20181231" contextRef="D2018-03-01_2018-03-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">P1Y90D</adyx:DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments>
  <adyx:DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments id="Fact-f26c92d8-3fe5-4127-ac64-44f9e3a637dd_20181231" contextRef="D2017-01-01_2017-01-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">P1Y</adyx:DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments>
  <adyx:DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments id="Fact-a65d388d-2aa7-465a-bb9e-55b7437e0b44_20181231" contextRef="D2017-01-01_2017-01-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">P1Y330D</adyx:DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments>
  <adyx:DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet id="Fact-fef8a492-9d4e-416c-bbfa-063ff83f1c9a_20181231" contextRef="D2019-01-01_2019-01-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">P60D</adyx:DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet>
  <adyx:DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet id="Fact-d827d7ee-2715-4dd7-aadb-2cfd0b366be6_20181231" contextRef="D2019-01-01_2019-01-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">P240D</adyx:DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet>
  <us-gaap:ProceedsFromMinorityShareholders id="Fact-ad92e354-59da-468a-8dfe-57d46178d043_20181231" decimals="-5" contextRef="D2019-01-01_2019-01-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="iso4217-USD">20000000</us-gaap:ProceedsFromMinorityShareholders>
  <adyx:DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote id="Fact-65b9d626-a711-4890-a32a-a64f20ab3dec_20181231" contextRef="D2018-12-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">P30D</adyx:DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote>
  <adyx:DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote id="Fact-5153c03f-571e-41e7-bcb8-00de7b457dee_20181231" contextRef="D2018-12-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">P300D</adyx:DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote>
  <us-gaap:ProceedsFromConvertibleDebt id="Fact-90181728-cdc9-4c85-877b-f92bcc39ef2c_20181231" decimals="-5" contextRef="D2018-12-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">1500000</us-gaap:ProceedsFromConvertibleDebt>
  <adyx:DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote id="Fact-c9553a90-847b-4784-8346-7c06d3273bb1_20181231" contextRef="D2018-09-01_2018-09-30_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">P30D</adyx:DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote>
  <adyx:DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger id="Fact-18ccf2d4-9924-4c64-b473-57a27adcae3e_20181231" contextRef="D2018-09-01_2018-09-30_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">P330D</adyx:DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger>
  <us-gaap:ProceedsFromConvertibleDebt id="Fact-5da680ed-3b01-4fc6-8edb-5e2e9e7fc2b4_20181231" decimals="-5" contextRef="D2018-09-01_2018-09-30_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">1500000</us-gaap:ProceedsFromConvertibleDebt>
  <adyx:DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger id="Fact-111165d2-f6a3-4abe-b0cf-358763442601_20181231" contextRef="D2018-09-01_2018-09-30_us-gaap-DebtInstrumentAxis_adyx-ConvertiblePromissoryNoteOf15MillionMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">P60D</adyx:DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger>
  <adyx:DebtInstrumentConvertibleCommonStockProceedsTrigger id="Fact-086a262a-2bae-4ec6-94aa-44440f96ceb6_20181231" decimals="-6" contextRef="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2019AndModifiedDecember2018NotesMember" unitRef="iso4217-USD">5000000</adyx:DebtInstrumentConvertibleCommonStockProceedsTrigger>
  <adyx:DebtInstrumentConvertiblePreferredStockProceedsTrigger id="Fact-ae399414-6fdb-4b51-ac91-d79d4bc045c3_20181231" decimals="-6" contextRef="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2019AndModifiedDecember2018NotesMember" unitRef="iso4217-USD">5000000</adyx:DebtInstrumentConvertiblePreferredStockProceedsTrigger>
  <adyx:FinancingThresholdProceedsToConvertNotesToEquity id="Fact-524b9f70-ee5f-4599-8d38-88e0f7285d7b_20181231" decimals="-5" contextRef="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2019AndModifiedDecember2018NotesMember" unitRef="iso4217-USD">5000000</adyx:FinancingThresholdProceedsToConvertNotesToEquity>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 id="Fact-90f31f89-71af-4322-9d9e-6d279a046f53_20181231" decimals="0" contextRef="D2018-01-01_2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2019AndModifiedDecember2018NotesMember" unitRef="xbrli-pure">80</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <adyx:DebtInstrumentConversionToCashInCaseOfChangeInControl id="Fact-1399688e-8423-4346-bc18-daac2ef4edaf_20181231" decimals="2" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2019AndModifiedDecember2018NotesMember" unitRef="xbrli-pure">2.00</adyx:DebtInstrumentConversionToCashInCaseOfChangeInControl>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset id="c49927954_20190630" decimals="INF" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="iso4217-USD">0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset>
  <adyx:DebtInstrumentConversionToCashInCaseOfChangeInControl id="Fact-53976937-f688-4840-bfe0-9e02094f8c0f_20181231" decimals="2" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="xbrli-pure">2.00</adyx:DebtInstrumentConversionToCashInCaseOfChangeInControl>
  <adyx:DebtInstrumentConversionToCashInCaseOfChangeInControlPremium id="Fact-631390f0-e025-4289-9b63-2caa1cda404c_20181231" decimals="2" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="xbrli-pure">1.00</adyx:DebtInstrumentConversionToCashInCaseOfChangeInControlPremium>
  <adyx:VotingRightsTransferredToBeConsideredAChangeInControl id="Fact-fef18785-7cf9-4029-acff-e8a33f2ffbca_20181231" decimals="2" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="xbrli-pure">0.50</adyx:VotingRightsTransferredToBeConsideredAChangeInControl>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability id="Fact-89ffa975-f84c-4e5b-9963-62c4d7b1cfaa_20181231" decimals="INF" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="iso4217-USD">0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <adyx:DebtConversionOriginalDebtAmountCumulativeAccruedInterest id="Fact-1cb5b7d9-9689-4cc2-8108-d93901166c32_20181231" decimals="INF" contextRef="D2019-05-03_2019-05-03_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="iso4217-USD">203000</adyx:DebtConversionOriginalDebtAmountCumulativeAccruedInterest>
  <adyx:DebtConversionOriginalDebtAmountPrincipal id="Fact-215d0e6d-6fd4-4452-ae15-e87247f4c899_20181231" decimals="-5" contextRef="D2019-05-03_2019-05-03_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="iso4217-USD">3000000</adyx:DebtConversionOriginalDebtAmountPrincipal>
  <adyx:ClassOfWarrantsOrRightExercisableTerm id="Fact-a4037c73-8de0-454a-8595-cf556d66fa32_20181231" contextRef="D2016-01-31_2016-01-31_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">P10Y</adyx:ClassOfWarrantsOrRightExercisableTerm>
  <adyx:ClassOfWarrantsOrRightExercisableTerm id="Fact-f6c40ab8-b153-41be-82ab-933058ddadfe_20181231" contextRef="D2015-11-30_2015-11-30_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">P10Y</adyx:ClassOfWarrantsOrRightExercisableTerm>
  <adyx:ClassOfWarrantsOrRightExercisableTerm id="Fact-aab1dcbf-3c6d-4fab-851a-b9525fb3df0f_20181231" contextRef="D2010-07-01_2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">P5Y</adyx:ClassOfWarrantsOrRightExercisableTerm>
  <adyx:ClassOfWarrantsOrRightExercisableTerm id="Fact-240a1c35-7de0-473d-89c3-d066d5a97c12_20181231" contextRef="D2010-07-01_2010-07-01_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantsForSeriesAConvertiblePreferredStockMember">P7Y</adyx:ClassOfWarrantsOrRightExercisableTerm>
  <adyx:AccruedClinicalTrialExpenseCurrent id="c49928078_20190630" xsi:nil="true" contextRef="I2018-12-31" unitRef="iso4217-USD"/>
  <adyx:EquityIssuanceCostsCurrent id="c49928066_20190630" xsi:nil="true" contextRef="I2018-12-31" unitRef="iso4217-USD"/>
  <adyx:PrepaidClinicalTrialExpenseCurrent id="c49928064_20190630" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">5000</adyx:PrepaidClinicalTrialExpenseCurrent>
  <us-gaap:ConvertibleDebtCurrent id="c49927372_20190630" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">4500000</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:DerivativeLiabilities id="c49927380_20190630" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">140000</us-gaap:DerivativeLiabilities>
  <us-gaap:OtherPrepaidExpenseCurrent id="c49928070_20190630" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">5000</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="c49927411_20190630" decimals="INF" contextRef="I2018-12-31" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="c49927414_20190630" decimals="INF" contextRef="I2018-12-31" unitRef="xbrli-shares">1000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="c49927417_20190630" decimals="INF" contextRef="I2018-12-31" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="c49927420_20190630" decimals="INF" contextRef="I2018-12-31" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue id="c49927408_20190630" xsi:nil="true" contextRef="I2018-12-31" unitRef="iso4217-USD"/>
  <us-gaap:PrepaidInsurance id="c49928068_20190630" xsi:nil="true" contextRef="I2018-12-31" unitRef="iso4217-USD"/>
  <adyx:EquitySharesReservedForFutureIssuance id="Fact-06c6f1fb-950b-449e-b03a-adcfd3791b41_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="xbrli-shares">127294</adyx:EquitySharesReservedForFutureIssuance>
  <adyx:NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount id="Fact-8cb26623-e2e8-412c-8bef-8036efc524c9_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="iso4217-USD">48000</adyx:NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount>
  <adyx:NumberOfForeignSubsidiaries id="Fact-0a01ab58-383e-4954-992d-1c7efb269704_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">0</adyx:NumberOfForeignSubsidiaries>
  <adyx:OperatingLeaseCarryforwardsWithExpirationDates id="Fact-26ea9f89-3069-440e-9d52-ffe104da0a20_20181231" decimals="-5" contextRef="I2018-12-31" unitRef="iso4217-USD">28700000</adyx:OperatingLeaseCarryforwardsWithExpirationDates>
  <adyx:OperatingLossCarryforwardsExpiringIndefinitely id="Fact-9ed231a3-dc0c-410d-8704-dd557a14561e_20181231" decimals="-5" contextRef="I2018-12-31" unitRef="iso4217-USD">4800000</adyx:OperatingLossCarryforwardsExpiringIndefinitely>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Fact-785cb574-c12e-4477-8aef-31953ec10840_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="xbrli-shares">19222</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:DeferredIncomeTaxAssetsNet id="Fact-9babb699-0673-47b8-87c5-a734a391c12e_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="iso4217-USD">0</us-gaap:DeferredIncomeTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsGross id="Fact-c42a6aed-5987-4ea9-9ce2-df0cef42aade_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">8795000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="Fact-647e88a5-4e9a-4830-8f6a-40035710e31b_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">7051000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment id="Fact-53d18f12-3818-41b3-8964-ecfdd0da6440_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">1000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="Fact-18998d3f-b894-4ea1-8240-5131668d6051_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">1601000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals id="Fact-774283a4-ec0e-4d9e-9e54-492bfaedaaf3_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">142000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="Fact-0133c586-e8a2-43ae-9d4a-6905b93b3e72_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">8795000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="Fact-1d2b0032-3539-40cc-bef9-55d9f07edc14_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="iso4217-USD">531000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:GrantsReceivable id="Fact-35355b9c-8562-4847-b272-4649ebe29fd1_20181231" decimals="-5" contextRef="I2018-12-31" unitRef="iso4217-USD">5700000</us-gaap:GrantsReceivable>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear id="Fact-1d162ce4-47e6-4da4-b09c-91a55b614db7_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">239000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
  <us-gaap:LoansPayable id="Fact-23fa48d3-2514-4be5-b9cc-ac44662ac25d_20181231" decimals="-5" contextRef="I2018-12-31" unitRef="iso4217-USD">4200000</us-gaap:LoansPayable>
  <us-gaap:OperatingLeaseLiability id="Fact-d81fde6b-04c2-4742-a61f-9ab67a5d608d_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">239000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLossCarryforwards id="Fact-79bb6833-6de8-4c55-a160-037c7e61a0e9_20181231" decimals="-5" contextRef="I2018-12-31" unitRef="iso4217-USD">33500000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Fact-fa385030-2ef9-42d7-9703-de24930a1807_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="xbrli-shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="Item-0005_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">4119000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Fact-e28c9d17-ad06-4b80-bbf6-c5a5a095202f_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="xbrli-shares">19222032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Fact-2f2cf08b-444d-4eb7-b164-5a1400bdf4f3_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="iso4217-USD_xbrli-shares">0.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Item-0003_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">6956000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue id="Item-0004_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">6956000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="Fact-6cc041ab-eae9-445c-a1b7-4be0faf141ec_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="xbrli-shares">19222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="Fact-51219820-f0c3-409a-b465-7c2a582e60bf_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="iso4217-USD_xbrli-shares">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharePrice id="Fact-8e61e78d-e940-4fc0-b8df-1cf990871775_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="iso4217-USD_xbrli-shares">64.07</us-gaap:SharePrice>
  <us-gaap:UnrecognizedTaxBenefits id="Fact-9843f86e-126b-4362-bbf7-4a8ef4e849c4_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">703000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="Fact-653acde4-83fa-4e10-ab9a-c85c41daf9a5_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="iso4217-USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <adyx:AccruedPayrollAndRelatedExpensesCurrent id="Fact-a1751be9-7da7-4b7b-a5bb-dd51062b40cf_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">241000</adyx:AccruedPayrollAndRelatedExpensesCurrent>
  <adyx:AccruedTermLoanPaymentsCurrent id="Fact-55d1da06-a4d2-4aed-a170-5a95b4fc949e_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">421000</adyx:AccruedTermLoanPaymentsCurrent>
  <us-gaap:AccountsPayableCurrent id="Fact-b1aee2bd-824e-4320-8c51-e70070c4958f_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">491000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Fact-cab9a351-a8e2-4f55-8521-704caddac3a7_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">857000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="Fact-ea19c9e1-694f-4920-a8b5-99879b20e41c_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">195000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Fact-f5021ff8-ffe4-448f-ba6d-6011a42e60be_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">41000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital id="c49927435_20190630" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">747000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:Assets id="Fact-ada11af1-6fa6-4267-bb36-2ed84717b877_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">1980000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="Fact-f3b53bd1-b5bc-454e-a10b-7f712e112752_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">1952000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Fact-3ce96bd3-66a7-4dd2-91db-a63d47daa69d_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">1887000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="Fact-0fd88785-c791-43db-8e17-ea248a9c3d32_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">1942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CommitmentsAndContingencies id="Fact-4c0a29a8-e2f4-4072-9eff-a7baf05f0fc9_20181231" xsi:nil="true" contextRef="I2018-12-31" unitRef="iso4217-USD"/>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Fact-290b540a-6795-4d2c-bea9-8473ec1c975c_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued id="c49927431_20190630" decimals="INF" contextRef="I2018-12-31" unitRef="xbrli-shares">701808</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="c49927433_20190630" decimals="INF" contextRef="I2018-12-31" unitRef="xbrli-shares">701808</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue id="c49927423_20190630" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">1000</us-gaap:CommonStockValue>
  <us-gaap:ConvertibleDebt id="Fact-27f6b443-15e6-4f2f-8a20-b6207e479840_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">4500000</us-gaap:ConvertibleDebt>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Fact-c8c82746-8f3d-4bdc-8abd-90fc43093764_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">1980000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="Fact-919a9c85-1739-41f4-8a69-1a62bce55d3a_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">9660000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtCurrent id="Fact-a1f8cb6f-89a9-4cf8-a705-12595e1379f8_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">3812000</us-gaap:LongTermDebtCurrent>
  <us-gaap:OtherAssetsNoncurrent id="Fact-45bb5ffb-38c2-4be1-947f-6bf87bcb1973_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">18000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Fact-4555424b-5ea1-492f-be29-8a5e5c0964b2_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">10000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-dc49f4aa-730c-438c-a7f8-f525aff855f8_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">51000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet id="Fact-6356e58c-27cc-471d-88ef-540200c5132a_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">10000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashCurrent id="Fact-e842b7ed-88f2-4327-80fb-5bb53ca3f7ff_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">55000</us-gaap:RestrictedCashCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Fact-402c5121-b8c5-45c3-8ca2-590bbf0f09a0_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">-37279000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="c49928262_20190630" decimals="INF" contextRef="I2018-12-31" unitRef="xbrli-shares">19222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="c49928263_20190630" decimals="INF" contextRef="I2018-12-31" unitRef="iso4217-USD_xbrli-shares">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquity id="Fact-d8626ae3-f739-49ca-a478-e09dc76a61ff_20181231" decimals="-3" contextRef="I2018-12-31" unitRef="iso4217-USD">-36531000</us-gaap:StockholdersEquity>
  <adyx:AccruedClinicalTrialExpenseCurrent id="Fact-e3ba8d07-7d80-4173-94e7-0fa3492d79c4_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">654000</adyx:AccruedClinicalTrialExpenseCurrent>
  <adyx:AccruedPayrollAndRelatedExpensesCurrent id="Fact-dd56bbf5-6c15-4452-a45d-f32964a4f922_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">273000</adyx:AccruedPayrollAndRelatedExpensesCurrent>
  <adyx:AccruedTermLoanPaymentsCurrent id="Fact-1c509356-8148-434f-a661-c016a4943dca_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">197000</adyx:AccruedTermLoanPaymentsCurrent>
  <adyx:EquitySharesReservedForFutureIssuance id="Fact-bebe97c5-fa02-4749-8e3b-97e7437a91b5_20181231" decimals="INF" contextRef="I2017-12-31" unitRef="xbrli-shares">127294</adyx:EquitySharesReservedForFutureIssuance>
  <us-gaap:AccountsPayableCurrent id="Fact-e9443ef9-f2ff-41d9-8137-9c7a91dabef9_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">703000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Fact-521611b2-df9c-476a-8164-89760bc0d654_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">1158000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Fact-c5d94612-7fe4-4a5c-9bee-f23b83f81064_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">1158000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="Fact-293c4653-6717-499c-b1ca-ceb7f7250ceb_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">34000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Fact-fc1a46c9-5a6b-4885-ad2c-b23cf7a1ff7a_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">44000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital id="Fact-86ab8dbd-e4ed-4099-a206-137aa2baee0f_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">419000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:Assets id="Fact-3d584bb7-1020-4aae-944a-493dc89a1889_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">4421000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="Fact-711d208f-6f8f-4e49-92e7-099066958ebc_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">4335000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Fact-9373bf8e-a64c-4636-92fe-da1b1fc6ae6d_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">4301000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommitmentsAndContingencies id="Fact-bc924cd2-ebb6-48b6-bc4c-5fa479dba6d5_20181231" xsi:nil="true" contextRef="I2017-12-31" unitRef="iso4217-USD"/>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Fact-c16f7de7-0017-4b16-9fac-fcdfa88b0d55_20181231" decimals="INF" contextRef="I2017-12-31" unitRef="xbrli-shares">19222</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Fact-bc53baab-7058-49f5-ad12-e9d5f1c3864e_20181231" decimals="INF" contextRef="I2017-12-31" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Fact-328b1192-2d6f-433f-9277-01f4d01d180c_20181231" decimals="INF" contextRef="I2017-12-31" unitRef="xbrli-shares">148000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="Fact-77c26d0d-cb4e-4933-9b26-d8b009df6d2b_20181231" decimals="INF" contextRef="I2018-12-31" unitRef="xbrli-shares">5313200</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="Fact-aff25fd4-b286-49d3-95bc-5da8d9c656cb_20181231" decimals="INF" contextRef="I2017-12-31" unitRef="xbrli-shares">19548969</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Fact-564d930f-4b5f-47db-a501-f53fd759cfd0_20181231" decimals="INF" contextRef="I2017-12-31" unitRef="xbrli-shares">19548969</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue id="Fact-4c5f51ef-587f-4e60-b4e6-e0f9ff3af2af_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">20000</us-gaap:CommonStockValue>
  <us-gaap:DeferredTaxAssetsGross id="Fact-230d0331-74ce-4390-8836-48159919e845_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">7541000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="Fact-ccd816cd-798a-4fcb-9a3e-892b77b3ad88_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">6158000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="Fact-a21afe9a-162d-4d14-9a11-7cf9b5556ddb_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">1284000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals id="Fact-07fc58c2-a6e7-4c4d-a612-704a6df4800b_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">99000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="Fact-03685ae2-0f42-4db3-bbff-6d265a68676c_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">7541000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Fact-41e2b2a0-38c9-4d92-9f3b-6e300b5b95c5_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">4421000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="Fact-a0c06954-b96e-4ac9-bb22-608f8b8e70dc_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">3572000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtCurrent id="Fact-bb71a898-ddd1-42e6-9381-c99be3f776e6_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">1711000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtNoncurrent id="Fact-4a75d798-6f62-4c20-84f1-9f4f34477fd0_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">2951000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="Fact-b853233d-6d30-40ad-98a5-77247623a286_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">18000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Fact-6a94ea6c-e151-4046-b33b-ca7184e505a7_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">34000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-782aaea2-26f3-43c6-a0b6-04ff25819fd1_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">57000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet id="Fact-5bac3703-bbe1-488f-bd84-13369c644b50_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">13000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="Fact-6add5027-ce03-4618-8b7e-4b6daf7424e3_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">13000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashNoncurrent id="Fact-aa756b70-307b-40af-a648-66fa5dac7600_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">55000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Fact-4497e6cd-3221-4947-8dd0-25eb8182e186_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">-31294000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Fact-36814660-e93c-48c6-a84e-afed2692d991_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="xbrli-shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Item-0002_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">6639000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Fact-98721605-1c81-4fe9-8cbc-8c336c3283ff_20181231" decimals="INF" contextRef="I2017-12-31" unitRef="xbrli-shares">19222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Fact-cbc7a0d7-1d74-43fa-981c-56f4288a0d6c_20181231" decimals="INF" contextRef="I2017-12-31" unitRef="iso4217-USD_xbrli-shares">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharePrice id="Fact-9da55d0d-15e3-4ebb-937e-ca42c0a4cda6_20181231" decimals="INF" contextRef="I2017-12-31" unitRef="iso4217-USD_xbrli-shares">61.28</us-gaap:SharePrice>
  <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability id="Fact-1f58f353-c69d-49c7-a43e-f1a2051edd48_20181231" decimals="INF" contextRef="I2017-12-31" unitRef="iso4217-USD">0</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
  <us-gaap:UnrecognizedTaxBenefits id="Fact-25242bd5-ef9b-4379-9af5-865bc80de71f_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">331000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="Fact-fd62575e-5a28-4f81-8ffb-c497b81c7e76_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">4356000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:StockholdersEquity id="Fact-69aa6e12-109d-4ded-b229-d96c7f5f0cd4_20181231" decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">-30855000</us-gaap:StockholdersEquity>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="c49927951_20190630" decimals="INF" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <adyx:AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB id="Fact-5e5732a6-5804-454a-ac03-f97c6c9ad54d_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">224000</adyx:AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB>
  <adyx:ClinicalTrialAccrualsPolicyPolicyTextBlock id="Fact-2b757f1d-0229-438d-90d9-2eefc2fe4a5a_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Clinical Trial Accruals&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;The Company&amp;#x2019;s clinical trial accruals are based on patient enrollment and related costs at clinical investigator&amp;nbsp;&amp;nbsp;sites as well as for the services received and efforts expended pursuant to contracts&amp;nbsp;&amp;nbsp;with multiple research institutions and contract&amp;nbsp;&amp;nbsp;research organizations that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The Company&amp;nbsp;&amp;nbsp;accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol.&amp;nbsp;&amp;nbsp;If timelines or contracts&amp;nbsp;&amp;nbsp;are modified based upon changes in the clinical trial protocol&amp;nbsp;&amp;nbsp;or scope of work to be performed, the Company&amp;nbsp;&amp;nbsp;modifies the estimates of accrued expenses accordingly. To date, the Company&amp;nbsp;&amp;nbsp;has had no significant adjustments to accrued clinical trial expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;In March 2018, the Company&amp;nbsp;&amp;nbsp;closed its contracts&amp;nbsp;&amp;nbsp;with Premier Research International LLC and CRF Health,&amp;nbsp;&amp;nbsp;Inc. (&amp;#x201C;Contract Research Organizations or CROs&amp;#x201D;) upon completion&amp;nbsp;&amp;nbsp;of a Phase 2 clinical trial in March 2018. For the years ended December 31, 2017 and 2018, the Company&amp;nbsp;&amp;nbsp;incurred $6.2 million and $95,000, respectively, of expenses in connection&amp;nbsp;&amp;nbsp;with this clinical study.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;In November&amp;nbsp;&amp;nbsp;2018, the Company&amp;nbsp;&amp;nbsp;entered into agreements with PRA Health,&amp;nbsp;&amp;nbsp;Inc. and CRF Health, Inc. (&amp;#x201C;Contract Research Organizations or CROs&amp;#x201D;) pursuant to which the CROs agreed to assist the Company&amp;nbsp;&amp;nbsp;with the conduct of a Phase 2 clinical trial. To support&amp;nbsp;&amp;nbsp;additional clinical trial activities the Company&amp;nbsp;&amp;nbsp;also entered into agreements with Premier Research International LLC for biostatistical services, ICON Central Laboratories for laboratory services and Almac Clinical Services for storage and distribution services. In connection&amp;nbsp;&amp;nbsp;with this clinical study, the Company&amp;nbsp;&amp;nbsp;incurred expenses of $0 and $185,000 for the years ended December 31, 2017 and 2018, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</adyx:ClinicalTrialAccrualsPolicyPolicyTextBlock>
  <adyx:ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock id="Fact-81ed09e9-2c45-46cd-8a9b-e4bed32e9703_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Convertible Preferred Stock Warrants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Freestanding warrants&amp;nbsp;&amp;nbsp;to acquire shares of convertible preferred stock are classified as liabilities on the accompanying balance sheets. These warrants&amp;nbsp;&amp;nbsp;are subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. The Company&amp;nbsp;&amp;nbsp;will continue to adjust the carrying values of freestanding&amp;nbsp;&amp;nbsp;warrants&amp;nbsp;&amp;nbsp;classified as liabilities for changes in fair value until the earlier of the exercise or expiration&amp;nbsp;&amp;nbsp;of the warrants&amp;nbsp;&amp;nbsp;or the completion&amp;nbsp;&amp;nbsp;of a liquidation event, including the completion&amp;nbsp;&amp;nbsp;of an initial public offering.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</adyx:ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock>
  <adyx:DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock id="Fact-cfd67ed3-25c8-495b-aaa7-6fe0fd94fdbf_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Debt Modif ications and Extinguishments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;When the Company&amp;nbsp;&amp;nbsp;modifies debt, it does so in accordance with Accounting Standards Codification (&amp;#x201C;ASC&amp;#x201D;) 470-50, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Debt: Modifications and Extinguishments&lt;/font&gt;&lt;font style="display:inline;"&gt;, which requires modification&amp;nbsp;&amp;nbsp;to debt instruments to be evaluated to assess whether the modifications&amp;nbsp;&amp;nbsp;are considered &amp;#x201C;substantial modifications&amp;#x201D;. A substantial modification&amp;nbsp;&amp;nbsp;of terms shall be accounted&amp;nbsp;&amp;nbsp;for like an extinguishment.&amp;nbsp;&amp;nbsp;Based on the guidance relied upon and the analysis performed,&amp;nbsp;&amp;nbsp;the Company&amp;nbsp;&amp;nbsp;determined&amp;nbsp;&amp;nbsp;that the October 2018 modification&amp;nbsp;&amp;nbsp;of the March 2018 and September 2018 Notes, to add an additional conversion option in the event of a reverse merger, was considered to be a &amp;#x201C;substantial modification&amp;#x201D;. As a result, it treated this modification&amp;nbsp;&amp;nbsp;as an &amp;#x2018;extinguishment&amp;#x2019; of those debts and recognized $11,000 of net gain from this debt extinguishment&amp;nbsp;&amp;nbsp;in other income. All other changes to debt provisions were not considered substantial and were treated as debt modifications.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</adyx:DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock>
  <adyx:DefinedContributionPlanNonelectiveSafeHarborContributionAmount id="Fact-5b35a431-445d-41b4-851f-9e1af7342c29_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">49000</adyx:DefinedContributionPlanNonelectiveSafeHarborContributionAmount>
  <adyx:GrantReimbursementPolicyPolicyTextBlock id="Fact-8fed041b-37f6-4d04-9929-1170f4c004af_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Grant Reimbursements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In December 2018, the Company&amp;nbsp;&amp;nbsp;received a Notice of Award from the National Institute&amp;nbsp;&amp;nbsp;on Drug Abuse (&amp;#x201C;NIDA&amp;#x201D;), part of the National Institutes&amp;nbsp;&amp;nbsp;of Health (&amp;#x201C;NIH&amp;#x201D;), to support&amp;nbsp;&amp;nbsp;the clinical development&amp;nbsp;&amp;nbsp;of its lead product&amp;nbsp;&amp;nbsp;candidate,&amp;nbsp;&amp;nbsp;brivoligide. NIH grants provide funds for certain types of expenditures in connection&amp;nbsp;&amp;nbsp;with research and development&amp;nbsp;&amp;nbsp;activities over a contractually defined period. The maximum funding expected to be available under this grant for qualified expenditures over the two year period through December 2020 is approximately $5.7 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2018, the Company&amp;nbsp;&amp;nbsp;had not incurred qualified expenses.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</adyx:GrantReimbursementPolicyPolicyTextBlock>
  <adyx:NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition id="Fact-958cc5d9-b4cd-4c3f-b19c-3576099e7fc4_20181231" contextRef="D2018-01-01_2018-12-31">P270D</adyx:NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition>
  <adyx:WarrantsDisclosureTextBlock id="Fact-53ad85dd-dfd3-4a9d-80a0-862fdc042927_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;color:#000000;"&gt;Note 8.&amp;nbsp;&amp;nbsp;&amp;nbsp;Warrants &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;In connection with convertible notes agreements with investors issued between January&amp;nbsp;1, 2009 and July&amp;nbsp;1, 2010, the Company issued warrants to purchase such number of shares of Series&amp;nbsp;A convertible preferred stock issued in the next round of equity financing equal to 20% of notes payable principal amounts divided by the price per share of such preferred stock. The warrants are exercisable after closing of each preferred stock financing for five&amp;nbsp;years and expire seven&amp;nbsp;years from the issuance date. At the issuance dates, the Company estimated the fair value of issued warrants as minimal due to the uncertainty of the Series&amp;nbsp;A convertible preferred stock financing. The Company estimated the fair value of outstanding warrants at the date of closing of the Series&amp;nbsp;A convertible preferred stock financing and used the Black-Scholes model with the following assumptions: expected lives equal to the remaining contractual life in a range of 3.92 to 7&amp;nbsp;years, risk-free interest rates in a range of 1.46% to 2.66%, expected dividend yield of zero, volatility in the range of 73.6% to 81.5%, and a fair value of Series&amp;nbsp;A convertible preferred stock of $0.2276 per share. As of December&amp;nbsp;31, 2017, the outstanding warrants had been exercised.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;In connection with the Oxford Loan Agreement signed in November&amp;nbsp;2015, the Company issued a warrant to purchase 197,715 shares of the Company&amp;#x2019;s preferred stock at an exercise price equal to the Series&amp;nbsp;A preferred stock price of&amp;#x2009; $0.2276. The warrant is exercisable after closing and expires ten&amp;nbsp;years from the issuance date. The Company estimated the fair value of the warrant at closing and used the Black-Scholes model with the following assumptions: expected life equal to the remaining contractual life of 10&amp;nbsp;years, risk-free interest rate of 2.07%, expected dividend yield of zero, volatility of 68.7%, and a fair value of Series&amp;nbsp;A convertible preferred stock of&amp;#x2009; $0.20 per share. The Company recorded the fair value of the warrant of&amp;#x2009; $33,000 as a debt discount to be amortized to interest expense over the life of the Term Loan&amp;nbsp;A. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;In January&amp;nbsp;2016, in connection with the Oxford Loan Agreement signed in November&amp;nbsp;2015, the Company issued a warrant to purchase 131,810 shares of the Company&amp;#x2019;s preferred stock at an exercise price equal to the Series&amp;nbsp;A preferred stock price of&amp;#x2009; $0.2276. The warrant is exercisable after closing and expires ten&amp;nbsp;years from the issuance date. The Company estimated the fair value of the warrant at closing and used the Black-Scholes model with the following assumptions: expected life equal to the remaining contractual life of 10&amp;nbsp;years, risk-free interest rate of 2.09%, expected dividend yield of zero, volatility of 68.6%, and a fair value of Series&amp;nbsp;A convertible preferred stock of&amp;#x2009; $0.23 per share. The Company recorded the fair value of the warrant of&amp;#x2009; $22,000 as a debt discount to be amortized to interest expense over the life of the Term Loan B. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;The change in fair value of the warrants issued in connection with Term Loan A and B at December&amp;nbsp;31, 2017 and 2018 of&amp;#x2009; ($12,000) and $98,000 respectively, were recorded to other expense (income). As of December&amp;nbsp;31, 2018, the warrants remained outstanding and exercisable.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;The above Black-Scholes model assumptions were determined as follows: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;"&gt;Term&lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2009;&amp;#x2014; The term represents the remaining contractual term of the warrants. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;"&gt;Risk-free interest rate&amp;#x2009;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal the remaining term of the warrants. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;"&gt;Expected&lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;"&gt;volatility&lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2009;&amp;#x2014; The expected volatility is derived from historical volatilities of several unrelated publicly listed peer companies over a period approximately equal to the remaining term of the warrants because the Company has limited information on the volatility of the preferred stock since there is currently no trading history. When making the selections of the Company&amp;#x2019;s industry peer companies to be used in the volatility calculation, the Company considered the size and operational and economic similarities to the Company&amp;#x2019;s principal business operations. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;"&gt;Expected dividend yield&lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2009;&amp;#x2014; The expected dividend yield is based on the Company&amp;#x2019;s history of not paying dividends. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;The warrants are classified as a liability as they are exercisable into shares that are potentially redeemable. The fair value of the warrant liability is re-measured at each balance sheet date with the change as other income recorded in the statements of operations. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;The fair value of the Series&amp;nbsp;A convertible preferred stock warrants outstanding at December&amp;nbsp;31, 2017 and 2018 was $42,000 and $140,000 respectively, and the details of the warrants were as follows: &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Issuance Date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Expiration&amp;nbsp;Date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&amp;nbsp;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;(in&amp;nbsp;thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;November, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;November, 2025&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; 0.2276&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; 198&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;January, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;January, 2026&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; 0.2276&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; 132&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; 330&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:20pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;The fair value of the Series&amp;nbsp;A convertible preferred stock warrants was determined using the following assumptions: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:20pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;As&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; 2.28&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;2.56% &amp;#x2013; 2.59&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;Remaining contractual life (in years) &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;7.92 &amp;#x2013; 8.08&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;6.92 &amp;#x2013; 7.08&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; 71.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; 76.84&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</adyx:WarrantsDisclosureTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="Fact-01de89d6-2742-4406-907a-45cdff276387_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Note&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;"&gt;4.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Accrued Liabilities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;As of December 31,&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Payroll and related expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 273&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 241&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Accrued term loan final payment&amp;nbsp;&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 197&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 421&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Accrued clinical trial expense&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 654&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Professional fees and other costs &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 34&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 195&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Total accrued liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 1,158&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 857&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Fact-d808ba48-84ac-42d8-be47-15f4737a5ff6_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">309000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="Fact-ae88040e-834b-4a9b-875c-38b861938266_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">40000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="Fact-297ab686-787b-4654-8286-aa2245b4d511_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Cash and Cash Equivalents&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;The Company&amp;nbsp;&amp;nbsp;considers all highly liquid investments purchased&amp;nbsp;&amp;nbsp;with a maturity&amp;nbsp;&amp;nbsp;of three months or less on the date of acquisition&amp;nbsp;&amp;nbsp;to be cash and cash equivalents.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="Fact-c7d487d4-71d9-482d-81fa-f2838e4a99e8_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Restricted Cash&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2017 and 2018, the Company&amp;nbsp;&amp;nbsp;had $55,000 restricted and held by a bank as collateral for a letter of credit provided to the Company&amp;#x2019;s facility landlord.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Fact-680fcbfb-be98-4def-81ba-d7d3d4fca129_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">-2414000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CollaborativeArrangementAccountingPolicy id="Fact-6afefdf3-8620-4b2c-8aff-d9f4ca905802_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Collaboration Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June 2018, the Company&amp;nbsp;&amp;nbsp;entered into a collaboration agreement with twoXAR,&amp;nbsp;&amp;nbsp;an artificial intelligence-driven drug discovery company, in order to identify potential&amp;nbsp;&amp;nbsp;product&amp;nbsp;&amp;nbsp;candidates&amp;nbsp;&amp;nbsp;for the treatment of endometriosis.&amp;nbsp;&amp;nbsp;Through&amp;nbsp;&amp;nbsp;December 31, 2018, the Company&amp;nbsp;&amp;nbsp;was not obligated to make any payments under the terms of the collaboration agreement.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Fact-aeb1a234-684c-4459-95a9-17bcb74db612_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Note&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;"&gt;6.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Commitments and Contingencies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Operating Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;leases office facilities under a non-cancelable&amp;nbsp;&amp;nbsp;operating&amp;nbsp;&amp;nbsp;lease agreement expiring on December 31, 2019. The total undiscounted future non-cancellable&amp;nbsp;&amp;nbsp;lease payments under the Company&amp;#x2019;s operating&amp;nbsp;&amp;nbsp;lease as of December 31, 2018 are as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;Future&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;Year ending December 31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;Commitments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 239&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 239&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Rent expense related to the Company&amp;#x2019;s operating&amp;nbsp;&amp;nbsp;leases was $225,000 and $232,000 for the years ended December 31, 2017 and 2018, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Indemnif ications&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;has agreed to indemnify its directors and officers for certain events or occurrences arising as a result of the officers or directors serving in such capacity. The Company&amp;nbsp;&amp;nbsp;has a directors&amp;#x2019; and officers&amp;#x2019; liability insurance policy that limits its exposure and enables the Company&amp;nbsp;&amp;nbsp;to recover a portion&amp;nbsp;&amp;nbsp;of any future amounts&amp;nbsp;&amp;nbsp;paid resulting from the indemnification of its officers and directors.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;has not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. The Company&amp;#x2019;s management believes the estimated fair value of these indemnification agreements is minimal and has not recorded a liability for these agreements as of December 31, 2018. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockDividendsPerShareDeclared id="Fact-b3ad1450-2d9f-4c95-9a38-e5fed5219651_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD_xbrli-shares">0</us-gaap:CommonStockDividendsPerShareDeclared>
  <us-gaap:ConcentrationRiskCreditRisk id="Fact-11c06a24-674d-4be9-8a6d-1a3bb18fa914_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Financial&amp;nbsp;&amp;nbsp;instruments that potentially&amp;nbsp;&amp;nbsp;subject the Company&amp;nbsp;&amp;nbsp;to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance&amp;nbsp;&amp;nbsp;Corporation insured limits. To date, the Company&amp;nbsp;&amp;nbsp;has not experienced any losses on its deposits of cash and cash equivalents.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company&amp;#x2019;s future financial position, results of operations, or cash flows: ability to obtain&amp;nbsp;&amp;nbsp;future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory&amp;nbsp;&amp;nbsp;approval&amp;nbsp;&amp;nbsp;and market acceptance of the Company&amp;#x2019;s products;&amp;nbsp;&amp;nbsp;development&amp;nbsp;&amp;nbsp;of sales channels; certain strategic relationships;&amp;nbsp;&amp;nbsp;litigation or claims against the Company&amp;nbsp;&amp;nbsp;based on intellectual property,&amp;nbsp;&amp;nbsp;patent,&amp;nbsp;&amp;nbsp;product,&amp;nbsp;&amp;nbsp;regulatory, or other factors; and the Company&amp;#x2019;s ability to attract&amp;nbsp;&amp;nbsp;and retain employees necessary to support&amp;nbsp;&amp;nbsp;its growth.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s postoperative pain reduction&amp;nbsp;&amp;nbsp;product&amp;nbsp;&amp;nbsp;candidate,&amp;nbsp;&amp;nbsp;brivoligide, is an oligonucleotide.&amp;nbsp;&amp;nbsp;The Company&amp;nbsp;&amp;nbsp;currently uses Avecia as a single supplier for the brivoligide drug substance.&amp;nbsp;&amp;nbsp;There are currently a limited number of oligonucleotide&amp;nbsp;&amp;nbsp;manufacturers with commercial scale capabilities globally. While the Company&amp;nbsp;&amp;nbsp;intends to develop secondary sources for manufacturing of its drug candidates&amp;nbsp;&amp;nbsp;in the future, there can be no assurance that it will be able to do so on commercially reasonable&amp;nbsp;&amp;nbsp;terms, or at all. Any interruption in the supply of this key material could significantly delay the research and development process or increase the expenses for development&amp;nbsp;&amp;nbsp;and commercialization of the Company&amp;#x2019;s product candidates.&amp;nbsp;&amp;nbsp;The quality of materials can be critical to the performance of a drug delivery technology. Therefore, the lack of a reliable source that provides a consistent supply of high quality materials would harm the Company.&amp;nbsp;&amp;nbsp;At December 31, 2018, this vendor&amp;#x2019;s activity was not material to total accounts payable.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;At December 31, 2017, two vendors represented&amp;nbsp; 56% and 31%, of total accounts payable. The vendor that represented&amp;nbsp; 56% of the Company&amp;#x2019;s accounts payable, supported manufacturing activities and the other vendor was associated with clinical study activities. At December 31, 2018, three vendors represented&amp;nbsp; 52%, &amp;nbsp;26% and 15% of total accounts payable. Two of these vendors supported general and administrative activities, primarily associated with the Merger and next round of equity financing, which accounted&amp;nbsp;&amp;nbsp;for 67% of the total accounts payable. The remaining vendor supported clinical study activities.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ConvertibleDebtTableTextBlock id="Fact-ca0da7c2-d1af-4950-94c3-137b6c7097a8_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;As of December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Convertible&amp;nbsp;&amp;nbsp;note payable, due on March 29, 2019, interest at 8.0% p.a&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 1,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Convertible&amp;nbsp;&amp;nbsp;note payable, due on September 27, 2019, interest at 8.0% p.a&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 1,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Convertible&amp;nbsp;&amp;nbsp;note payable, due on December 21, 2019, interest at 8.0% p.a&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 1,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Total&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 4,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:ConvertibleDebtTableTextBlock>
  <us-gaap:DebtDisclosureTextBlock id="Fact-1d31018f-5aa8-4273-8481-6f3d031b50fa_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Note&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;"&gt;5.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Term Loans and Convertible Promissory Notes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Term Loans&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On November&amp;nbsp;&amp;nbsp;24, 2015, the Company&amp;nbsp;&amp;nbsp;entered into a loan and security agreement (&amp;#x201C;Loan&amp;nbsp;&amp;nbsp;Agreement&amp;#x201D;) with Oxford Finance, LLC (&amp;#x201C;Oxford&amp;#x201D;), pursuant to which Oxford agreed to lend the Company&amp;nbsp;&amp;nbsp;up to $10.0 million, issuable in three tranches of $3.0 million (the &amp;#x201C;Term Loan A&amp;#x201D;), $2.0 million (the &amp;#x201C;Term Loan B&amp;#x201D;) and $5.0 million (the &amp;#x201C;Term Loan C&amp;#x201D;). Term Loan A, Term Loan B and Term Loan C will collectively be referred to as Term Loans. On November&amp;nbsp;&amp;nbsp;24, 2015, the Company&amp;nbsp;&amp;nbsp;received $3.0 million in proceeds from Term Loan A and on January&amp;nbsp;&amp;nbsp;29, 2016, the Company&amp;nbsp;&amp;nbsp;received $2.0 million in proceeds from Term Loan B. Warrants were issued in connection&amp;nbsp;&amp;nbsp;with Term Loan A and Term Loan B (See &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Note 8 &amp;#x2014; Warrants&lt;/font&gt;&lt;font style="display:inline;"&gt;). Under the terms of the Loan Agreement, the Company&amp;nbsp;&amp;nbsp;may, at its sole discretion, borrow $5.0 million under the Term Loan C following the achievement of a defined milestone event until the earlier of 30 days thereafter&amp;nbsp;&amp;nbsp;or March 31, 2016. The Company&amp;nbsp;&amp;nbsp;did not draw on Term Loan C at March 31, 2016 and the availability of the $5.0 million under Term Loan C expired.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;All outstanding Term Loans will mature on November&amp;nbsp;&amp;nbsp;1, 2019 (the &amp;#x201C;Maturity Date&amp;#x201D;) and the Company will have interest only payments through&amp;nbsp;&amp;nbsp;November&amp;nbsp;&amp;nbsp;1, 2016, followed by 36 months of principal and interest payments. The term loans will bear interest at a floating per annum rate equal to (a) 7.06% plus (ii) the greater of (a) the 30 day U.S. Dollar LIBOR rate reported&amp;nbsp;&amp;nbsp;in the Wall Street Journal&amp;nbsp;&amp;nbsp;on the last business day of the month that immediately precedes the month in which the interest will accrue or (b) 0.19%.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;has the option to prepay all, but not less than all, of the borrowed&amp;nbsp;&amp;nbsp;amounts,&amp;nbsp;&amp;nbsp;provided that the Company&amp;nbsp;&amp;nbsp;will be obligated to pay a prepayment fee equal to (i) 3% of the outstanding principal balance of the applicable Term Loan if prepayment is made prior to the first anniversary&amp;nbsp;&amp;nbsp;of the applicable funding date of the Term Loan, provided, however, the prepayment fee will be reduced to 1% if the Company is acquired within six months from the Term Loan closing date, or (ii) 2% of the outstanding principal balance of the applicable Term Loan if prepayment is made prior to the second anniversary&amp;nbsp;&amp;nbsp;of the applicable funding date of the Term Loan, or (iii) 1% of the applicable Term Loan prepaid thereafter&amp;nbsp;&amp;nbsp;and prior to the Maturity Date. The Company&amp;nbsp;&amp;nbsp;will be required to make a final payment of 4.25% of the funded amount, payable on the earlier of (i) the Maturity Date or (ii) the prepayment of the Term Loan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;may use the proceeds from the Term Loans solely for working capital and to fund its general business requirements. The Company&amp;#x2019;s obligations&amp;nbsp;&amp;nbsp;under the Loan Agreement are secured by a perfected first priority lien in all of its assets with a negative pledge on owned intellectual property.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In January&amp;nbsp;&amp;nbsp;2017, the Company&amp;nbsp;&amp;nbsp;and Oxford Finance agreed to amend the Loan Agreement. After the Company&amp;nbsp;&amp;nbsp;made principal payments on December 1, 2016 and January&amp;nbsp;&amp;nbsp;1, 2017, Oxford agreed to an additional 12 months of interest-only payments followed by 23 months of amortization. The amendment fee amounted to $100,000. The amendment was accounted&amp;nbsp;&amp;nbsp;for as a debt modification.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In March 2018, the Company&amp;nbsp;&amp;nbsp;and Oxford Finance agreed to amend the Loan Agreement. After the Company&amp;nbsp;&amp;nbsp;made principal payments on January&amp;nbsp;&amp;nbsp;1, 2018, February 1, 2018 and March 1, 2018 Oxford agreed to another&amp;nbsp; 5 months of interest-only payments followed by 15 months of amortization. The amendment fee amounted to $200,000. This amendment was accounted&amp;nbsp;&amp;nbsp;for as a debt modification.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In September 2018, the Company&amp;nbsp;&amp;nbsp;and Oxford Finance agreed to amend the debt agreement. Oxford agreed to 1 month of interest-only payments upon closing a $1.5 million convertible promissory note with current investors followed by 2 months of interest-only payments upon entering into a merger followed by 11 months of repayments.&amp;nbsp;&amp;nbsp;The maturity&amp;nbsp;&amp;nbsp;date of the Term Loans remains unchanged.&amp;nbsp;&amp;nbsp;The amendment fee amounted to $25,000. The amendment was accounted&amp;nbsp;&amp;nbsp;for as a debt modification.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In December 2018, the Company&amp;nbsp;&amp;nbsp;and Oxford Finance agreed to amend the debt agreement. Oxford agreed to 1 month of interest-only payments upon closing a $1.5 million convertible promissory note with current investors by December 31, 2018, followed by 10 months of repayments.&amp;nbsp;&amp;nbsp;The maturity&amp;nbsp;&amp;nbsp;date of the loans remains unchanged.&amp;nbsp;&amp;nbsp;The amendment fee amounted to $35,000. The amendment was accounted&amp;nbsp;&amp;nbsp;for as a debt modification.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The amendment fees are due and payable upon the earlier of: (i) the Maturity Date, (ii) the acceleration of any Term Loan, or (iii) the prepayment of a Term Loan, and are being accrued over the expected term of the Term Loan as interest expense.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Upon the respective dates of the debt modifications, no gain or loss was recorded, and a new effective interest rate was established based on the carrying value of the debt and the revised cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Term Loan A was recorded at its initial carrying value of $3.0 million less debt issuance costs of approximately $141,000, Term Loan B was recorded at its initial carrying value of $2.0 million, less debt issuance costs of approximately $3,000. The debt issuance costs are being amortized&amp;nbsp;&amp;nbsp;to interest expense over the life of the Term Loan using the effective interest method.&amp;nbsp;&amp;nbsp;The final payment is accrued over the life of the Term Loan through&amp;nbsp;&amp;nbsp;interest expense using the effective interest method.&amp;nbsp;&amp;nbsp;At December 31, 2017, $2.8 million was outstanding under Term Loan A and $1.9 million was outstanding under Term Loan B. As of December 31, 2018, $2.3 million was outstanding under Term Loan A and $1.5 million was outstanding under Term Loan B.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Interest expense recorded for the years ended December 31, 2017 and 2018 was $515,000 and $644,000, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2018, the Company&amp;nbsp;&amp;nbsp;was in compliance with all covenants under the Loan Agreement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Future&amp;nbsp;&amp;nbsp;principal payments for the Term Loans due under the Loan Agreement as of December 31, 2018, were as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;Year Ending, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Total principal payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 3,833&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Convertible Promissory Notes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The table below reflects the principal amount&amp;nbsp;&amp;nbsp;of the Notes issued by the Company&amp;nbsp;&amp;nbsp;to current investors (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;As of December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Convertible&amp;nbsp;&amp;nbsp;note payable, due on March 29, 2019, interest at 8.0% p.a&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 1,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Convertible&amp;nbsp;&amp;nbsp;note payable, due on September 27, 2019, interest at 8.0% p.a&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 1,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Convertible&amp;nbsp;&amp;nbsp;note payable, due on December 21, 2019, interest at 8.0% p.a&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 1,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Total&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 4,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Conversion rights&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The December 2018 Notes were issued with conversion and repayment&amp;nbsp;&amp;nbsp;rights, which are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(a)&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"&gt;&lt;/font&gt;in the event that the Company&amp;nbsp;&amp;nbsp;issues and sells shares of its preferred stock to the investors with proceeds to the Company&amp;nbsp;&amp;nbsp;of at least $5 million, on or before the maturity&amp;nbsp;&amp;nbsp;date, and prior to the closing of a reverse merger, then the outstanding principal amount&amp;nbsp;&amp;nbsp;of these Notes and any unpaid accrued interest will automatically convert in whole into equity securities sold in the preferred stock financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the such preferred stock financing;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(b)&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"&gt;&lt;/font&gt;in the event that the Company&amp;nbsp;&amp;nbsp;issues and sells shares of its common stock to the investors with proceeds to the Company&amp;nbsp;&amp;nbsp;of at least $5 million, on or before the maturity&amp;nbsp;&amp;nbsp;date, and after the closing of a reverse merger, then the outstanding principal amount&amp;nbsp;&amp;nbsp;of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities sold in the common stock financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the common stock financing,&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(c)&amp;nbsp;&amp;nbsp;&amp;nbsp;in the event of a preferred stock financing after the Company&amp;#x2019;s Board of Directors&amp;nbsp;&amp;nbsp;(the &amp;#x201C;Board&amp;#x201D;) has determined&amp;nbsp;&amp;nbsp;that the Company&amp;nbsp;&amp;nbsp;should not pursue the proposed&amp;nbsp;&amp;nbsp;reverse merger with Alliqua BioMedical, Inc. or that such reverse merger is not viable, then in connection&amp;nbsp;&amp;nbsp;with the preferred stock financing the conversion price shall equal eighty percent (80%) of the cash price paid per share for the preferred securities by the investors in the preferred stock financing;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(d)&amp;nbsp;&amp;nbsp;&amp;nbsp;if the Company&amp;nbsp;&amp;nbsp;consummates&amp;nbsp;&amp;nbsp;a change of control while the Notes remain outstanding, the Company&amp;nbsp;&amp;nbsp;shall repay the holders in cash in an amount&amp;nbsp;&amp;nbsp;equal to 200% of the outstanding principal amount&amp;nbsp;&amp;nbsp;of the Notes; and&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(e)&amp;nbsp;&amp;nbsp;&amp;nbsp;in the event the Company&amp;nbsp;&amp;nbsp;consummates&amp;nbsp;&amp;nbsp;an IPO on or before the maturity&amp;nbsp;&amp;nbsp;date, then the outstanding principal amount&amp;nbsp;&amp;nbsp;of the Notes and any unpaid accrued interest will automatically convert into common stock at a conversion price equal to the per share offering price to the public for common stock in the IPO.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Modified March 2018 and Modified September 2018 Notes were outstanding as of December 31, 2018, and had conversion and repayment&amp;nbsp;&amp;nbsp;rights as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(a)&amp;nbsp;&amp;nbsp;&amp;nbsp;in the event that the Company&amp;nbsp;&amp;nbsp;issues and sells shares of its preferred stock to the investors on or before the maturity&amp;nbsp;&amp;nbsp;date, in a preferred stock financing, then the outstanding principal amount&amp;nbsp;&amp;nbsp;of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities sold in the qualified financing at a conversion price equal to 80% of the cash price paid per share for equity securities by the investors in the qualified financing;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(b)&amp;nbsp;&amp;nbsp;&amp;nbsp;if the Company&amp;nbsp;&amp;nbsp;consummates&amp;nbsp;&amp;nbsp;a change of control while the Notes remain outstanding, the Company&amp;nbsp;&amp;nbsp;shall repay the holders in cash in an amount&amp;nbsp;&amp;nbsp;equal to 200% of the outstanding principal amount&amp;nbsp;&amp;nbsp;of the Notes; and&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(c)&amp;nbsp;&amp;nbsp;&amp;nbsp;in the event the Company&amp;nbsp;&amp;nbsp;consummates&amp;nbsp;&amp;nbsp;an IPO on or before the maturity&amp;nbsp;&amp;nbsp;date, then the outstanding principal amount&amp;nbsp;&amp;nbsp;of the Notes and any unpaid accrued interest will automatically convert into common stock at a conversion price equal to the per share offering price to the public for common stock in the IPO.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(d)&amp;nbsp;&amp;nbsp;&amp;nbsp;In October 2018, the Company&amp;nbsp;&amp;nbsp;modified the terms of the March 2018 and September 2018 Notes to add an additional conversion option.&amp;nbsp;&amp;nbsp;The additional conversion option stipulated&amp;nbsp;&amp;nbsp;that if the Company&amp;nbsp;&amp;nbsp;consummates&amp;nbsp;&amp;nbsp;a reverse merger on or before the Maturity Date and prior to a Qualified Financing&amp;nbsp;&amp;nbsp;(as such terms are defined in the Notes Agreement), then the outstanding principal amount&amp;nbsp;&amp;nbsp;of the Notes and any unpaid accrued interest, shall automatically convert in whole without any further action by the Holder into shares of the Company&amp;#x2019;s Series B convertible preferred stock at a conversion price equal to $0.3133 per share immediately prior to the closing of the reverse merger.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In October 2018, the Company&amp;nbsp;&amp;nbsp;determined&amp;nbsp;&amp;nbsp;that the modification&amp;nbsp;&amp;nbsp;of the March 2018 and September 2018 Notes adding the additional conversion right upon a reverse merger was a &amp;#x201C;substantial modification&amp;#x201D; as outlined in ASC 470-50 &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x2018;Debt: Modifications and Extinguishments&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;"&gt; and treated this modification&amp;nbsp;&amp;nbsp;as an extinguishment&amp;nbsp;&amp;nbsp;of the original Notes and recognized an $11,000 gain from debt extinguishment&amp;nbsp;&amp;nbsp;in its statement&amp;nbsp;&amp;nbsp;of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Derivative Liability&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;evaluated its Notes and determined&amp;nbsp;&amp;nbsp;that embedded components&amp;nbsp;&amp;nbsp;relating to conversion and redemption features of those contracts&amp;nbsp;&amp;nbsp;qualified as derivatives, which need to be separately accounted for in accordance&amp;nbsp;&amp;nbsp;with ASC 815. The Notes contained&amp;nbsp;&amp;nbsp;embedded features that are required to be bifurcated as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(1)&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"&gt;&lt;/font&gt;On or before the maturity&amp;nbsp;&amp;nbsp;date of the March 2018 and September 2018 notes, the principal and accrued interest of the notes will automatically convert into equity securities issued and sold in the initial closing of the Company&amp;#x2019;s next qualified equity financing with gross proceeds of at least $5.0 million, exclusive of the conversion of the notes. The number of shares to be issued to the note holders will be equal to dividing the outstanding principal and any unpaid accrued interest by 80% of the price paid per share of the next equity security sold to investors. The discount in share price to note holders is not considered clearly and closely related to the debt host and results in an embedded derivative that must be bifurcated&amp;nbsp;&amp;nbsp;and accounted&amp;nbsp;&amp;nbsp;for separately from the debt host.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(2)&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"&gt;&lt;/font&gt;For all Notes, in the event of a change in control prior to repayment,&amp;nbsp;&amp;nbsp;the outstanding principal and unpaid accrued interest will be repaid in cash, plus a repayment&amp;nbsp;&amp;nbsp;premium equal to 100% of the outstanding principal at the time of the change in control. Change in control means (i) a merger, consolidation, or other capital reorganization or business combination transaction of the Company,&amp;nbsp;&amp;nbsp;with or into, another&amp;nbsp;&amp;nbsp;corporation after which the shares of the capital stock represent a minority after the close of the transaction, or (ii) any transaction or series of related transactions to which the Company&amp;nbsp;&amp;nbsp;is a party in which in excess of 50% of the Company&amp;#x2019;s voting power is transferred, or (iii) the sale of all or substantially&amp;nbsp;&amp;nbsp;all of the Company&amp;#x2019;s assets or the exclusive license of all or substantially&amp;nbsp;&amp;nbsp;all of the Company&amp;#x2019;s material intellectual property.&amp;nbsp;&amp;nbsp;The premium to note holders is not considered clearly and closely related to the debt host and results in an embedded derivative that must be bifurcated&amp;nbsp;&amp;nbsp;and accounted&amp;nbsp;&amp;nbsp;for separately from the debt host.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(3)&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"&gt;&lt;/font&gt;For the December 2018 Notes, in the event the Company&amp;#x2019;s Board of Directors&amp;nbsp;&amp;nbsp;has determined&amp;nbsp;&amp;nbsp;the proposed&amp;nbsp;&amp;nbsp;reverse merger should not be pursued or is not viable, then in connection&amp;nbsp;&amp;nbsp;with the closing of a preferred stock financing with gross proceeds of at least $5.0 million exclusive of the conversion of the notes, the conversion price shall equal 80% of the cash price paid per share for the securities in the preferred stock financing. However, if any of the holder&amp;#x2019;s shares of preferred stock of the Company&amp;nbsp;&amp;nbsp;are converted into common stock or any other equity security that is junior to the shares issued in the preferred stock financing, the notes shall not convert into equity securities sold in the preferred stock financing without the holder&amp;#x2019;s prior written consent and instead shall remain outstanding. The discount in share price to note holders is not considered clearly and closely related to the debt host and results in an embedded derivative that must be bifurcated&amp;nbsp;&amp;nbsp;and accounted&amp;nbsp;&amp;nbsp;for separately from the debt host.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Accordingly, upon the issuance of the March 2018 Notes, the estimated fair value of the embedded derivative was determined&amp;nbsp;&amp;nbsp;using a bond plus option valuation&amp;nbsp;&amp;nbsp;model and assuming a probability of 30% that a qualified financing would occur and a probability of 15% that a change in control would occur. The Company&amp;nbsp;&amp;nbsp;recorded the estimated fair value of these embedded derivatives as a liability of $496,000 with an offsetting amount&amp;nbsp;&amp;nbsp;recorded as debt discount,&amp;nbsp;&amp;nbsp;which offsets the carrying amount&amp;nbsp;&amp;nbsp;of the debt. The debt discount is amortized&amp;nbsp;&amp;nbsp;over the debt&amp;#x2019;s expected term of one year.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Upon the issuance of the September 2018 Notes, the estimated fair value of the embedded derivatives was determined&amp;nbsp;&amp;nbsp;using a bond plus option valuation&amp;nbsp;&amp;nbsp;model and assuming a probability of 40% that a qualified financing would occur and a zero probability that a change in control would occur. The Company recorded the estimated fair value of these embedded derivatives as a liability of $368,000 with an offsetting amount&amp;nbsp;&amp;nbsp;recorded as debt discount,&amp;nbsp;&amp;nbsp;which offsets the carrying amount&amp;nbsp;&amp;nbsp;of the debt. The debt discount is amortized&amp;nbsp;&amp;nbsp;over the debt expected term of one year.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In October 2018, the Company&amp;nbsp;&amp;nbsp;modified the March 2018 and September 2018 Notes by adding an additional conversion right upon a reverse merger. The Company&amp;nbsp;&amp;nbsp;deemed this modification&amp;nbsp;&amp;nbsp;to be a &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x201C;substantial modification&amp;#x201D;&lt;/font&gt;&lt;font style="display:inline;"&gt; as defined in ASC 470-50 &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x2018;Debt: Modifications and Extinguishments&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;"&gt; and treated it as an extinguishment&amp;nbsp;&amp;nbsp;of the original Notes and the termination of the related derivative liability. The extinguishment&amp;nbsp;&amp;nbsp;of the March 2018 and September 2018 Notes, resulted in a net gain of $11,000 being recorded in other income due to the expensing of the unamortized debt discount of $641,000 and the release of the then fair value of the derivative liabilities of $653,000. As of December 31, 2018, the Company&amp;nbsp;&amp;nbsp;evaluated the fair value of the derivative liability associated with the modified March 2018, modified September 2018 and December 2018 Notes. It determined&amp;nbsp;&amp;nbsp;that the bifurcated&amp;nbsp;&amp;nbsp;derivative liability had no value because the Company&amp;nbsp;&amp;nbsp;assumed a zero probability that a qualified financing would occur if the then planned reverse merger was not consummated and a zero probability that a change in control would occur. As a result, the Company&amp;nbsp;&amp;nbsp;estimated the fair value of the derivative liability to be $0 at December 31, 2018.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;For the years ended December 31, 2017, and 2018, the Company&amp;nbsp;&amp;nbsp;had recorded interest expense for debt discount on these Notes of $0 and $223,000, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:Depreciation id="Fact-2bef1723-e509-4508-8096-e724c79ecb37_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">8000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="Fact-cc416c05-ae96-4785-a5e9-1fcaadf2057d_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">8000</us-gaap:Depreciation>
  <us-gaap:DerivativesPolicyTextBlock id="Fact-0291dcd3-cb2d-4353-a4fc-f48a5b6ade5d_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Derivative Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;ASC 815-15, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Derivatives and Hedging: Embedded Derivatives&lt;/font&gt;&lt;font style="display:inline;"&gt;, generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding&amp;nbsp;&amp;nbsp;derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics&amp;nbsp;&amp;nbsp;and risks of the embedded derivative instrument&amp;nbsp;&amp;nbsp;are not clearly and closely related to the economic characteristics&amp;nbsp;&amp;nbsp;and risks of the host contract,&amp;nbsp;&amp;nbsp;(b) the hybrid instrument&amp;nbsp;&amp;nbsp;that embodies both the embedded derivative instrument&amp;nbsp;&amp;nbsp;and the host contract&amp;nbsp;&amp;nbsp;is not re-measured at fair value under otherwise applicable generally accepted accounting&amp;nbsp;&amp;nbsp;principles with changes in fair value reported&amp;nbsp;&amp;nbsp;in earnings as they occur and (c) a separate instrument&amp;nbsp;&amp;nbsp;with the same terms as the embedded derivative instrument&amp;nbsp;&amp;nbsp;would be considered a derivative instrument&amp;nbsp;&amp;nbsp;subject to the requirement&amp;nbsp;&amp;nbsp;of ASC 815.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;issued certain Notes in March 2018, September 2018, and December 2018, which contained&amp;nbsp;&amp;nbsp;various embedded derivative features. In particular, these Notes contained&amp;nbsp;&amp;nbsp;the following features:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(1)&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"&gt;&lt;/font&gt;A share settled redemption in a qualified preferred stock financing; and&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(2)&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"&gt;&lt;/font&gt;The right to an accelerated cash repayment&amp;nbsp;&amp;nbsp;in the event of a change in control.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;These embedded features were not considered clearly and closely related to the debt host, therefore, they were bifurcated&amp;nbsp;&amp;nbsp;and accounted&amp;nbsp;&amp;nbsp;for separately from the debt host as a derivative liability. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in the statement&amp;nbsp;&amp;nbsp;of operations at each period end while such instruments are outstanding.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In October 2018, the Company&amp;nbsp;&amp;nbsp;modified the March 2018 and September 2018 Notes to add an additional conversion feature. The Company determined this was a &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x201C;substantial modification&amp;#x201D;&lt;/font&gt;&lt;font style="display:inline;"&gt; as defined in ASC 470-50 &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x2018;Debt: Modifications and Extinguishments&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;"&gt;. As a result, these Notes were accounted&amp;nbsp;&amp;nbsp;for as an &amp;#x2018;extinguishment&amp;#x2019; of the debt and related derivative liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2018, the Company&amp;nbsp;&amp;nbsp;determined&amp;nbsp;&amp;nbsp;that there was no fair value associated with the embedded derivatives that remained with the modified March 2018, the modified September 2018 and December 2018 Notes. See &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x2018;Note 5 &amp;#x2014; Term Loans and Convertible Promissory Notes&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;"&gt; for further discussion of the Notes and the bifurcated&amp;nbsp;&amp;nbsp;derivative liability.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Fact-e7108fed-0b11-4b8b-80db-647986b9d5ff_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt;
&lt;div&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Note 9.&amp;#160;&amp;#160;&amp;#160;Stock Option Plans&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;In December&amp;#160;2010, the Company adopted the 2010 Equity Incentive Plan (the &amp;#8220;Plan&amp;#8221;). The Plan provides for the granting of stock options to employees and consultants of the Company. Options granted under the Plan may be either incentive stock options (&amp;#8220;ISOs&amp;#8221;) or non-qualified stock options (&amp;#8220;NSOs&amp;#8221;). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants. The Company has 19,222,032 shares of common stock reserved for issuance under the Plan as of December&amp;#160;31, 2018.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;Options under the Plan may be granted for periods of up to 10&amp;#160;years and at prices no less than 100% of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the Board of Directors provided, however, that the exercise price of an ISO and NSO granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. The Plan requires that options be exercised no later than 10&amp;#160;years after the grant. Options granted to employees generally vest ratably on a monthly basis over four&amp;#160;years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;The following table summarizes stock option activity under the Company&amp;#8217;s stock plan and related information (in thousands, except exercise prices and&amp;#160;years):&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%; TEXT-INDENT: 20pt;" /&gt;
&lt;div style="WIDTH: 100%;"&gt;
&lt;table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" align="center"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 35.76%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="9"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #231f20; DISPLAY: inline;"&gt;Outstanding Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Weighted-&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Weighted-&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Average&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Average&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Remaining&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Contractual&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Aggregate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Available&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Life&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Intrinsic&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;For&amp;#160;Grant&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Outstanding&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Per&amp;#160;Share&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;(in&amp;#160;years)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.3%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Value&lt;/font&gt;&lt;font style="FONT-SIZE: 4pt; POSITION: relative; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline; LINE-HEIGHT: 100%; TOP: -3.2pt;"&gt;(a)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;5&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
19,222&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;0.10&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;9.4&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;5&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap"&gt;19,222&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
0.10&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;8.4&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;6,639&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;Balance at December 31, 2018&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;5&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
19,222&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
0.10&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;7.4&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;6,956&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;Vested and expected to vest as of December 31, 2018&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #231f20; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
19,222&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
0.10&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;7.4&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;6,956&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;Exercisable at December 31, 2018&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #231f20; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
11,146&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
0.09&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;7.4&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;4,119&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;hr style="BORDER-LEFT-WIDTH: 0px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 25%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000;" align="left" /&gt;&lt;/div&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 1pt; COLOR: #000000; DISPLAY: inline;"&gt;&amp;#8203;&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 100%;"&gt;
&lt;table style="text-align:left;WIDTH: 100%;" cellspacing="0" cellpadding="0"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="WIDTH: 0pt;"&gt;
&lt;p style="FONT-SIZE: 0pt; WIDTH: 0pt;" /&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt;" valign="top" align="left"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%;"&gt;(a)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 0pt;"&gt;
&lt;p style="FONT-SIZE: 0pt; WIDTH: 0pt;" /&gt;
&lt;/td&gt;
&lt;td valign="top" align="left"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company&amp;#8217;s common stock of $0.46 and $0.44 per share as of December&amp;#160;31, 2018 and 2017.&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-SIZE: 1pt; COLOR: #000000; DISPLAY: inline;"&gt;&amp;#8203;&lt;/font&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;The Company did not grant any common stock options to employees during the&amp;#160;years ended December&amp;#160;31, 2017 and 2018. Stock-based compensation expense recorded in research and development and general and administrative expenses was $301,000 and $293,000 for the&amp;#160;years ended December&amp;#160;31, 2017 and 2018, respectively. As of December&amp;#160;31, 2018, unrecognized stock-based compensation expense related to employees totaled approximately $531,000, which is expected to be recognized over approximately 2.0&amp;#160;years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; FONT-STYLE: italic; DISPLAY: inline;"&gt;Stock Options Granted to Non-Employees&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 20pt;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;Stock-based compensation expense recorded in exchange for services related to non-employee options was $0 and $16,000 for the&amp;#160;years ended December&amp;#160;31, 2017 and 2018, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;As of December&amp;#160;31, 2018, unrecognized stock-based compensation expense related to unvested non-employees stock options was approximately $48,000, which is expected to be recognized over a weighted-average period of nine&amp;#160;months.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="Fact-9d1d826b-001f-4c0b-be52-7d41953dcb92_20181231" decimals="2" contextRef="D2018-01-01_2018-12-31" unitRef="xbrli-pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:FairValueAdjustmentOfWarrants id="Fact-9e06eece-f048-47f4-8a4a-1cf4d8b139d5_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">98000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="Fact-e9765b65-9caa-456b-9042-c4aa998931a3_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="middle" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Years Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="middle" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Fair value, beginning of period&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 54&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Preferred stock warrants &amp;#x2013; exercised &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (8)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Change in fair value of preferred stock warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (4)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 98&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Fair value at end of period&amp;nbsp;&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="middle" style="width:20.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Years Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="middle" style="width:20.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Fair value, beginning of period &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$ &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Embedded derivative liability from the issuance of Notes&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 864&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Change in value of embedded derivatives&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (211)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Termination of the embedded derivative liability due to the extinguishment&amp;nbsp;&amp;nbsp;of the related Notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; (653)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Fair value at end of period &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="Fact-f0f4964b-c731-4635-a82b-1c8822b61dba_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;ASC 820-10, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Fair Value Measurement&lt;/font&gt;&lt;font style="display:inline;"&gt;, provides a framework&amp;nbsp;&amp;nbsp;for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. The standard defines fair value as an exit price, representing the amount&amp;nbsp;&amp;nbsp;that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. The standard also establishes a fair value hierarchy, which prioritizes the inputs used in measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Level 1&lt;/font&gt;&lt;font style="display:inline;"&gt; &amp;#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the Company&amp;nbsp;&amp;nbsp;has the ability to access as of the measurement&amp;nbsp;&amp;nbsp;date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Level 2&lt;/font&gt;&lt;font style="display:inline;"&gt; &amp;#x2014; Inputs&amp;nbsp;&amp;nbsp;other than quoted prices included within Level 1 that are directly observable for the asset or liability or indirectly observable through&amp;nbsp;&amp;nbsp;corroboration with observable market data.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Level 3&lt;/font&gt;&lt;font style="display:inline;"&gt; &amp;#x2014; Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement&amp;nbsp;&amp;nbsp;date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining&amp;nbsp;&amp;nbsp;fair value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following tables present the Company&amp;#x2019;s fair value hierarchy for all of its financial instruments measured at fair value on a recurring basis as of December 31, 2017 and December 31, 2018 (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:49.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;As of December 31, 2017&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;Level 1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;Level 2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;Level 3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Financial liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Warrant liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Total financial liabilities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:49.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Financial liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Level 1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Level 2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Level 3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Warrant liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 12pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Total financial liabilities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities.&amp;nbsp;&amp;nbsp;The fair value of the Company&amp;#x2019;s term loan is based on the borrowing&amp;nbsp;&amp;nbsp;rate currently available to the Company&amp;nbsp;&amp;nbsp;for borrowings&amp;nbsp;&amp;nbsp;with similar terms and maturity&amp;nbsp;&amp;nbsp;and approximates its carrying value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Derivative liability instruments are considered Level 3 when their fair values are determined&amp;nbsp;&amp;nbsp;using pricing models, discounted&amp;nbsp;&amp;nbsp;cash flow methodologies,&amp;nbsp;&amp;nbsp;or similar techniques, and at least one significant model assumption or input is unobservable. Level 3 liability instruments consist of the preferred stock warrant liability and derivative liability, for both of which there is no observable market data for the determination of fair value and requires significant management judgment and estimation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value of the warrant liability was determined&amp;nbsp;&amp;nbsp;using the Black-Scholes model (see &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x2018;Note 8 &amp;#x2014; Warrants&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;"&gt; for a further discussion of the preferred stock warrants). The change in fair value of the preferred stock warrant liability is summarized below (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="middle" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Years Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="middle" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Fair value, beginning of period&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 54&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Preferred stock warrants &amp;#x2013; exercised &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (8)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Change in fair value of preferred stock warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (4)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 98&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Fair value at end of period&amp;nbsp;&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value of the embedded derivative liability related to the Company&amp;#x2019;s Notes was determined using a bond plus option model. As of December 31, 2018, the Company&amp;nbsp;&amp;nbsp;determined&amp;nbsp;&amp;nbsp;that there was no fair value remaining for the embedded derivatives associated with the modified March 2018, modified September 2018 and December 2018 Notes. See &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x2018;Note 5 &amp;#x2014; Term Loans and Convertible Promissory Notes&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;"&gt; for further discussion on the derivative liability activity.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The change in fair value of the derivative liability relating to the Notes is summarized below (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="middle" style="width:18.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Years Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="middle" style="width:18.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Fair value, beginning of period &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$ &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Embedded derivative liability from the issuance of Notes&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 864&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Change in value of embedded derivatives&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (211)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Termination of the embedded derivative liability due to the extinguishment&amp;nbsp;&amp;nbsp;of the related Notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; (653)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Fair value at end of period &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:GeneralAndAdministrativeExpense id="Fact-8e7ec088-8106-4b53-ae5d-4484909ea599_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">2982000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock id="Fact-f093a742-fb63-44b2-bf48-e8b9788c2e0d_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;The Company&amp;#x2019;s long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount&amp;nbsp;&amp;nbsp;of the asset may not be recoverable. Recoverability&amp;nbsp;&amp;nbsp;of an asset to be held and used is measured by a comparison of the carrying amount&amp;nbsp;&amp;nbsp;of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount&amp;nbsp;&amp;nbsp;by which the carrying amount of the asset exceeds its fair value. As of December 31, 2017 and 2018, the Company&amp;nbsp;&amp;nbsp;had not experienced any impairment losses on its long-lived assets.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="Fact-184b92c0-8895-4bd8-9810-73207de8ff57_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Note&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;"&gt;10.&amp;nbsp;&amp;nbsp;&amp;nbsp;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;recorded no income tax benefit or expense for the years ended December 31, 2017 and 2018. No tax benefit was recorded through&amp;nbsp;&amp;nbsp;December 31, 2018 because, given the history of operating losses, the Company&amp;nbsp;&amp;nbsp;believes it is more likely than not that the deferred tax asset will not be realized, and a full valuation&amp;nbsp;&amp;nbsp;allowance has been provided.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts&amp;nbsp;&amp;nbsp;of assets and liabilities for financial reporting&amp;nbsp;&amp;nbsp;purposes and the amounts&amp;nbsp;&amp;nbsp;used for income tax purposes. The following table presents significant components&amp;nbsp;&amp;nbsp;of the Company&amp;#x2019;s deferred tax assets (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;As of December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Net operating loss carry forward&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 6,158&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 7,051&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Research and development credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 1,284&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 1,601&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Accruals and reserves&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 99&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 142&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Fixed assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Total deferred tax asset&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 7,541&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 8,795&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; (7,541)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; (8,795)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Net deferred tax asset &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&amp;#x2019;s history of operating&amp;nbsp;&amp;nbsp;losses, the Company&amp;nbsp;&amp;nbsp;has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company&amp;nbsp;&amp;nbsp;has provided a full valuation&amp;nbsp;&amp;nbsp;allowance for deferred tax assets as of December 31, 2017 and 2018. The valuation&amp;nbsp;&amp;nbsp;allowance decreased approximately $964,000 and increased $1.2 million during the years ended December 31, 2017 and 2018, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On December 22, 2017, the U.S. government&amp;nbsp;&amp;nbsp;enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the &amp;#x201C;Tax Act&amp;#x201D;). The Tax Act makes broad and complex changes to the U.S. tax code that affect fiscal 2017, including, but not limited to requiring a one-time transition tax on certain un-repatriated earnings of foreign subsidiaries (the &amp;#x201C;Transition Tax&amp;#x201D;). The Tax Act also establishes new tax laws that will affect 2018 and later years, including, but not limited to, a reduction&amp;nbsp;&amp;nbsp;of the U.S. federal corporate tax rate from 35% to 21% and a transition of U.S. international taxation&amp;nbsp;&amp;nbsp;from a worldwide tax system to a territorial system. During the year ended December 31, 2017, the Company&amp;nbsp;&amp;nbsp;did not recognize an amount&amp;nbsp;&amp;nbsp;for the one-time transition tax, nor did the Company&amp;nbsp;&amp;nbsp;make any accounting&amp;nbsp;&amp;nbsp;policy elections on the treatment of the other international provisions of tax reform due to the fact the Company does not currently have any foreign subsidiaries.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During 2017, the Company&amp;nbsp;&amp;nbsp;corrected the balance of Net Operating&amp;nbsp;&amp;nbsp;Losses and Research and Development&amp;nbsp;&amp;nbsp;Credits and the associated Valuation&amp;nbsp;&amp;nbsp;Allowances in connection&amp;nbsp;&amp;nbsp;with the Company&amp;#x2019;s determination of nexus in an additional state which was previously not identified correctly. The correction of such error did not have any impact on the Company&amp;#x2019;s financial position and results of operations for any period presented or any prior period results. The Company&amp;nbsp;&amp;nbsp;has corrected the gross amount&amp;nbsp;&amp;nbsp;of deferred tax assets and the valuation&amp;nbsp;&amp;nbsp;allowance for 2016 to correct the error.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2018, the Company&amp;nbsp;&amp;nbsp;had federal net operating&amp;nbsp;&amp;nbsp;loss, or NOL, carry forwards of $33.5 million available to reduce future taxable income, if any. The NOL carry forwards prior to January 1, 2018 of $28.7 million will begin to expire in 2033. The NOL carry forwards incurred post December 31, 2017 of $4.8 million will carry forward indefinitely. As of December 31, 2018, the Company&amp;nbsp;&amp;nbsp;had federal and state research and development&amp;nbsp;&amp;nbsp;credits of $1.8 million and $0.7 million, respectively. The federal research and development&amp;nbsp;&amp;nbsp;credits will begin to expire in 2031. The state research and development credit will carry forward indefinitely.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Internal&amp;nbsp;&amp;nbsp;Revenue Code (&amp;#x201C;IRC&amp;#x201D;) Section 382 and similar California&amp;nbsp;&amp;nbsp;rules place a limitation&amp;nbsp;&amp;nbsp;on the amount&amp;nbsp;&amp;nbsp;of taxable income that can be offset by NOL and credit carry forwards after a change in control. Generally, after a control change, a corporation cannot deduct NOL or credit carry forwards in excess of the Section 382 limitations.&amp;nbsp;&amp;nbsp;Although&amp;nbsp;&amp;nbsp;the Company&amp;nbsp;&amp;nbsp;has not completed an analysis under Section 382 of the Code since the year ended December 31, 2012, it believes that it is unlikely that the utilization&amp;nbsp;&amp;nbsp;of the NOLs and tax credit carry forwards will be substantially&amp;nbsp;&amp;nbsp;limited.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The tax return years 2014 through&amp;nbsp;&amp;nbsp;2018 remain open to examination by the major domestic taxing jurisdictions to which the Company&amp;nbsp;&amp;nbsp;is subject. Net operations losses generated on a tax return basis by the Company&amp;nbsp;&amp;nbsp;for calendar years 2013 and 2015 to 2018 remain open to examination by the IRS. Net operating losses generated on state returns by the Company&amp;nbsp;&amp;nbsp;for calendar years 2007 to 2013 and 2015 to 2018 remain open to examination by state authorities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;ASC 740-10 requires companies to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities. The following table summarizes the activity related to the Company&amp;#x2019;s gross unrecognized tax benefits (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;Years&amp;nbsp;Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 331&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Changes related to prior year positions&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 330&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Increases related to current year positions&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Balance at December 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 703&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s policy is to record interest related to uncertain&amp;nbsp;&amp;nbsp;tax positions as interest and any penalties as other expense in its statement&amp;nbsp;&amp;nbsp;of operations. As of the date of adoption and through December 31, 2018, the Company&amp;nbsp;&amp;nbsp;did not have any interest and penalties associated with unrecognized tax benefits.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit id="Fact-cf1e3a6c-cf0e-4808-857c-bca95af3f184_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxPolicyTextBlock id="Fact-64ff472b-c040-4d6c-9893-45ee64b4ac93_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;The Company&amp;nbsp;&amp;nbsp;accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined&amp;nbsp;&amp;nbsp;based on differences between the financial reporting&amp;nbsp;&amp;nbsp;and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company&amp;nbsp;&amp;nbsp;provides a valuation&amp;nbsp;&amp;nbsp;allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;In evaluating the ability to recover its deferred income tax assets, the Company&amp;nbsp;&amp;nbsp;considers all available positive and negative evidence, including its operating&amp;nbsp;&amp;nbsp;results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company&amp;nbsp;&amp;nbsp;determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation&amp;nbsp;&amp;nbsp;allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined&amp;nbsp;&amp;nbsp;not to be realizable in the future, an adjustment to the valuation&amp;nbsp;&amp;nbsp;allowance would be charged to earnings in the period such determination is made.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;The Company&amp;nbsp;&amp;nbsp;recognizes the tax benefit from uncertain&amp;nbsp;&amp;nbsp;tax positions in accordance&amp;nbsp;&amp;nbsp;with GAAP, which prescribes a recognition threshold&amp;nbsp;&amp;nbsp;and measurement&amp;nbsp;&amp;nbsp;attribute for the financial statement&amp;nbsp;&amp;nbsp;recognition and measurement&amp;nbsp;&amp;nbsp;of uncertain&amp;nbsp;&amp;nbsp;tax positions taken or expected to be taken in a company&amp;#x2019;s tax return.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Fact-b9647120-b7c6-48c2-8218-a2cfe112e0ae_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">-212000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Fact-2cbbd803-6a02-469e-8828-0a9f86e25395_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">-650000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Fact-7db45cb1-8864-4b94-874b-75d8b8a17724_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">-23000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestExpense id="Fact-71c3bf9f-32d5-4bdb-a848-b020f7352909_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">644000</us-gaap:InterestExpense>
  <us-gaap:InterestIncomeExpenseNet id="Fact-442ac42f-965d-4314-8a34-0ade6f371e41_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">-992000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestPaidNet id="Fact-cd14a8f3-3e47-4c21-9618-71c79d22ac05_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">376000</us-gaap:InterestPaidNet>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="Fact-63f28f30-1180-4e11-b066-faac9dba27f9_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;Future&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;Year ending December 31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;Commitments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 239&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 239&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="Fact-b0761bc0-2ad5-4926-9f8c-857759573673_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">3610000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="Fact-177f6430-537e-42d0-86c1-5beee40b20c9_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">-5000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="Fact-65f5e926-4970-451d-b639-2829db47fc92_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">-6019000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="Fact-d89965e6-3941-406b-a290-17146f9fbd58_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">-5985000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Fact-05ca1ede-debf-4cb1-9488-d9e2ad77797e_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">-5985000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Fact-3d8f41ee-60d7-415e-9a6a-d8f17ad0f19d_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">-5985000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Fact-d109e032-4f83-41c7-affb-6ac77dd15a44_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In November&amp;nbsp;&amp;nbsp;2016, the FASB issued ASU No. 2016-18, Statement&amp;nbsp;&amp;nbsp;of Cash Flows: Restricted&amp;nbsp;&amp;nbsp;Cash. This ASU requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts&amp;nbsp;&amp;nbsp;shown on the statement&amp;nbsp;&amp;nbsp;of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation&amp;nbsp;&amp;nbsp;of the total in the statement&amp;nbsp;&amp;nbsp;of cash flows to the related captions in the balance sheet. This guidance is effective for fiscal periods beginning after December 15, 2017 and interim periods within that fiscal year, with early adoption permitted.&amp;nbsp;&amp;nbsp;The amendments in this ASU should be applied retrospectively to all periods presented. The Company&amp;nbsp;&amp;nbsp;adopted the guidance on a retrospective basis on January&amp;nbsp;&amp;nbsp;1, 2018 and the beginning and ending of cash and cash equivalents for all periods presented in our statements&amp;nbsp;&amp;nbsp;of cash flows include restricted cash.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Non-employee Share-Based Payment Accounting&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June 2018, FASB issued ASU No. 2018-07, &amp;#x201C;Compensation &amp;#x2014; Stock Compensation (Topic 718): Improvements to Nonemployee&amp;nbsp;&amp;nbsp;Share-Based Payment Accounting&amp;#x201D; (&amp;#x201C;ASU 2018-07&amp;#x201D;). This new guidance changes the accounting&amp;nbsp;&amp;nbsp;for non-employee share-based&amp;nbsp;&amp;nbsp;payments to align with the accounting&amp;nbsp;&amp;nbsp;for employee stock compensation. The Company&amp;nbsp;&amp;nbsp;early adopted&amp;nbsp;&amp;nbsp;the guidance as of January&amp;nbsp;&amp;nbsp;1, 2018 and the impact to its financial statements&amp;nbsp;&amp;nbsp;was not material.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Recent Accounting Pronouncements Not Yet Effective&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Lease Accounting&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February 2016, the Financial&amp;nbsp;&amp;nbsp;Accounting&amp;nbsp;&amp;nbsp;Standards Board (&amp;#x201C;FASB&amp;#x201D;) issued ASU No. 2016-02. This standard introduces the new leases standard that applies a right-of-use (&amp;#x201C;ROU&amp;#x201D;) model and requires a lessee to record, for all leases with a lease term of more than 12 months,&amp;nbsp;&amp;nbsp;an asset representing its right to use the underlying asset and a liability to make lease payments. For leases with a term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. At inception, lessees must classify all leases as either finance or operating&amp;nbsp;&amp;nbsp;based on five criteria. Balance sheet recognition of finance and operating&amp;nbsp;&amp;nbsp;leases is similar, but the pattern of expense recognition in the income statement, as well as the effect on the statement&amp;nbsp;&amp;nbsp;of cash flows, differs depending on the lease classification. This ASU is effective for public entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted&amp;nbsp;&amp;nbsp;for all entities. The Company&amp;nbsp;&amp;nbsp;is currently assessing whether these amendments will have a material effect on its financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In August 2018, the FASB issued No. ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements&amp;nbsp;&amp;nbsp;as part of its disclosure framework&amp;nbsp;&amp;nbsp;project. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year, with early adoption permitted.&amp;nbsp;&amp;nbsp;The Company&amp;nbsp;&amp;nbsp;is currently assessing whether these amendments will have a material effect on its financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:OperatingExpenses id="Fact-b077a813-9f58-43f4-bb30-5a7ddf5d4356_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">5119000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Fact-365ee325-c8f7-4869-ac53-8965856dd02e_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">-5119000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeaseExpense id="Fact-5457dc55-2194-41bb-a4d2-f360182a643d_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">232000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock id="Fact-12fed744-ac47-4264-b1db-0394204d1298_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; FONT-WEIGHT: bold; MARGIN: 0pt 0pt 12pt;"&gt;&lt;font style="font-family: Times New Roman,Times,serif; COLOR: #231f20; DISPLAY: inline;"&gt;Note&amp;#160;&lt;/font&gt;&lt;font style="DISPLAY: inline;"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Organization and Basis of Presentation&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt;"&gt;&lt;font style="FONT-WEIGHT: bold; FONT-STYLE: italic; DISPLAY: inline;"&gt;The Company&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;Adynxx, Inc. (the &amp;#8220;Company&amp;#8221;) was incorporated on October 24, 2007, in the state of Delaware. The Company&amp;#160;&amp;#160;is a clinical-stage pharmaceutical entity that is developing a technology platform&amp;#160;&amp;#160;to address pain at its molecular roots. The Company&amp;#160;&amp;#160;is primarily engaged in developing initial product&amp;#160;&amp;#160;technology, recruiting personnel, and raising capital.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt;"&gt;&lt;font style="FONT-WEIGHT: bold; FONT-STYLE: italic; DISPLAY: inline;"&gt;Basis of Presentation&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;The accompanying financial statements&amp;#160;&amp;#160;have been prepared&amp;#160;&amp;#160;using accounting&amp;#160;&amp;#160;principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;).&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt;"&gt;&lt;font style="FONT-WEIGHT: bold; FONT-STYLE: italic; DISPLAY: inline;"&gt;Liquidity&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;The accompanying financial statements&amp;#160;&amp;#160;have been prepared&amp;#160;&amp;#160;assuming the Company&amp;#160;&amp;#160;will continue as a going concern. As of December 31, 2018, the Company&amp;#160;&amp;#160;had $1.9 million in cash and cash equivalents, had Oxford term loans, or Term Loans, including accrued interest outstanding of $4.2 million, and convertible promissory notes, or Notes, including accrued interest, outstanding to investors of $4.6 million. From inception through&amp;#160;&amp;#160;December 31, 2018 the Company&amp;#160;&amp;#160;had an accumulated deficit of approximately $37.2 million. The Company&amp;#160;&amp;#160;expects to incur substantial losses in future periods. The Company&amp;#160;&amp;#160;is subject to risks common to companies in the clinical stage, including, but not limited to, development&amp;#160;&amp;#160;of new products, development&amp;#160;&amp;#160;of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product&amp;#160;&amp;#160;development&amp;#160;&amp;#160;plans. The Company&amp;#160;&amp;#160;has a limited operating history and has yet to generate any revenues from customers. There is no guarantee&amp;#160;&amp;#160;that profitable operations, if ever achieved, could be sustained on a continuing&amp;#160;&amp;#160;basis.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;The Company&amp;#160;&amp;#160;plans to finance its operations and capital funding needs through&amp;#160;&amp;#160;equity and/or&amp;#160;&amp;#160;debt financing. However, there can be no assurance that additional funding will be available to the Company&amp;#160;&amp;#160;on acceptable terms on a timely basis, if at all, or that the Company&amp;#160;&amp;#160;will generate sufficient cash from operations to adequately&amp;#160;&amp;#160;fund operating&amp;#160;&amp;#160;needs or ultimately achieve profitability. The conditions&amp;#160;&amp;#160;above, among others, raise substantial doubt&amp;#160;&amp;#160;about the ability of the Company&amp;#160;&amp;#160;to continue as a going concern within one year after the date of the issuance of the financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;The accompanying financial statements&amp;#160;&amp;#160;do not include any adjustments that might result from the outcome of these uncertainties.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:PaidInKindInterest id="Fact-aeb8fb80-2c29-4ebc-89e0-046d7e9153e0_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">126000</us-gaap:PaidInKindInterest>
  <us-gaap:PaymentsForProceedsFromProductiveAssets id="Fact-d4f0ee08-9ece-4512-8f96-8c43dcb86fba_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">5000</us-gaap:PaymentsForProceedsFromProductiveAssets>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="Fact-52f02c58-609e-4c5d-b3d9-f0db88fc2ca2_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;"&gt;Note 12.&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman;"&gt;Employee Benefit Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;"&gt;The Company&amp;nbsp;&amp;nbsp;has established a 401(k) Plan (the &amp;#x201C;401(k) Plan&amp;#x201D;) that permits participants to make contributions by salary deduction&amp;nbsp;&amp;nbsp;pursuant to Section 401(k) of the IRC. The Company&amp;nbsp;&amp;nbsp;may, at its discretion, make matching contributions to the 401(k) Plan. The Company&amp;nbsp;&amp;nbsp;has made no contributions to the 401(k) Plan since its inception. The Company&amp;nbsp;&amp;nbsp;makes a nonelective 401(k) safe harbor&amp;nbsp;&amp;nbsp;contribution on behalf of each employee equal to 3% of their annual salary. The Company&amp;#x2019;s non-elective safe harbor contributions totaled $54,000 and $49,000 for the years ended December 31, 2017 and 2018, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:PreferredStockDividendsPerShareDeclared id="Fact-9518cf48-5afc-430f-94a2-38815dd0bcb4_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD_xbrli-shares">0</us-gaap:PreferredStockDividendsPerShareDeclared>
  <us-gaap:ProceedsFromRelatedPartyDebt id="Fact-f2d504c5-3149-4fc1-93c4-b0ce85f67cea_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">4500000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="Fact-e3cad203-d85a-4d2e-92bb-53892eec28d4_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Note&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;"&gt;3.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Property and Equipment, Net&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property&amp;nbsp;&amp;nbsp;and equipment,&amp;nbsp;&amp;nbsp;net, consist of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;As of December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Furniture and fixtures&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 29&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 29&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Office equipment&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Computer equipment &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 24&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 18&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Total property and equipment&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 57&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 51&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Less accumulated depreciation &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (44)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (41)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Property and equipment, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 13&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 10&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Depreciation expense for the years ended December 31, 2017 and 2018 was $10,000 and $8,000, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="Fact-5cc6a7ad-3697-4817-b378-024bcc94a783_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and Equipment, Net&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property&amp;nbsp;&amp;nbsp;and equipment&amp;nbsp;&amp;nbsp;are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line&amp;nbsp;&amp;nbsp;method over the estimated useful lives of the assets, generally three to five years. Leasehold improvements&amp;nbsp;&amp;nbsp;are amortized&amp;nbsp;&amp;nbsp;over the shorter of the estimated useful life of the asset or the remaining term of the lease.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Expenditures&amp;nbsp;&amp;nbsp;for repairs and maintenance are charged to expense as incurred. Upon disposition&amp;nbsp;&amp;nbsp;of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements&amp;nbsp;&amp;nbsp;of operations.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="Fact-cbd91d12-8b96-4ba4-af8c-a896f4b8334b_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;As of December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Furniture and fixtures&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 29&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 29&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Office equipment&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Computer equipment &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 24&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 18&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Total property and equipment&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 57&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 51&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Less accumulated depreciation &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (44)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (41)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Property and equipment, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 13&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 10&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="Fact-e2ea52a7-e255-41cb-a9ce-063c705ffcc0_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Note&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;"&gt;11.&amp;nbsp;&amp;nbsp;&amp;nbsp;Related-Party Transactions&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In March 2018, September 2018, and December 2018, the Company&amp;nbsp;&amp;nbsp;issued Notes to the Company&amp;#x2019;s majority investors totaling&amp;nbsp;$4.5 million as of December 31, 2018. These Notes accrue simple interest on the outstanding principal amount&amp;nbsp;&amp;nbsp;at the rate of&amp;nbsp;8%&amp;nbsp;per annum.&amp;nbsp;&amp;nbsp;As of December 31, 2018, accrued interest on the Notes was&amp;nbsp;$126,000&amp;nbsp;&amp;#x2014; for further details see the section above titled &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x2018;Note 5 &amp;#x2014; Term Loans and Convertible Promissory Notes&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;"&gt;.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:RepaymentsOfLongTermDebt id="Fact-3fdc4e25-1468-426a-8b63-cff976a6b743_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">890000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:ResearchAndDevelopmentExpense id="Fact-f5ee2611-9f78-4d79-a173-d4a41714cbd2_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">2137000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="Fact-cd2f8391-f40c-4961-becd-cc17c4a44252_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and Development&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and development&amp;nbsp;&amp;nbsp;expenses consist of personnel costs, including salaries, benefits and stock-based&amp;nbsp;&amp;nbsp;compensation, preclinical studies, clinical studies performed&amp;nbsp;&amp;nbsp;by Contract Research Organizations (or &amp;#x201C;CROs&amp;#x201D;), materials and supplies, licenses and fees, and overhead allocations&amp;nbsp;&amp;nbsp;consisting of various administrative and facilities related costs. The Company&amp;nbsp;&amp;nbsp;charges research and development&amp;nbsp;&amp;nbsp;costs, including clinical study costs, to expense when incurred.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="Fact-d9c19f48-f38b-4dcf-99f4-7728d0745e18_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;As of December 31,&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Payroll and related expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 273&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 241&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Accrued term loan final payment&amp;nbsp;&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 197&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 421&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Accrued clinical trial expense&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 654&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Professional fees and other costs &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 34&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 195&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Total accrued liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 1,158&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 857&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfDebtInstrumentsTextBlock id="Fact-f8869d08-747e-459a-86cd-62dfa6221dbd_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;Year Ending, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Total principal payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 3,833&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="Fact-77dce1d2-cd91-4ce0-8e42-df94a50b536f_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;As of December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Net operating loss carry forward&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 6,158&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 7,051&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Research and development credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 1,284&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 1,601&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Accruals and reserves&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 99&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 142&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Fixed assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Total deferred tax asset&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 7,541&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 8,795&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; (7,541)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; (8,795)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Net deferred tax asset &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="Fact-a5956cd1-99d6-43ef-afbe-4bc48c032c50_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:49.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;As of December 31, 2017&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;Level 1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;Level 2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;Level 3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Financial liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Warrant liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Total financial liabilities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:49.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Financial liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Level 1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Level 2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Level 3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Warrant liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 12pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Total financial liabilities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="Fact-7ab83742-2b4d-4c21-9c42-8b7327127591_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;" /&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%; TEXT-INDENT: 20pt;" /&gt;
&lt;div style="WIDTH: 100%;"&gt;
&lt;table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" align="center"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 35.76%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="9"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #231f20; DISPLAY: inline;"&gt;Outstanding Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Weighted-&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Weighted-&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Average&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Average&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Remaining&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Contractual&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Aggregate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Available&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Life&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Intrinsic&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;For&amp;#160;Grant&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Outstanding&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Per&amp;#160;Share&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;(in&amp;#160;years)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.3%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Value&lt;/font&gt;&lt;font style="FONT-SIZE: 4pt; POSITION: relative; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline; LINE-HEIGHT: 100%; TOP: -3.2pt;"&gt;(a)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;5&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
19,222&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;0.10&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;9.4&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;5&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap"&gt;19,222&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
0.10&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;8.4&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;6,639&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;Balance at December 31, 2018&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;5&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
19,222&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
0.10&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;7.4&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;6,956&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;Vested and expected to vest as of December 31, 2018&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #231f20; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
19,222&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
0.10&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;7.4&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;6,956&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;Exercisable at December 31, 2018&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #231f20; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
11,146&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
0.09&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;7.4&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #231f20; DISPLAY: inline;"&gt;4,119&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;hr style="BORDER-LEFT-WIDTH: 0px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 25%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000;" align="left" /&gt;&lt;/div&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 1pt; COLOR: #000000; DISPLAY: inline;"&gt;&amp;#8203;&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 100%;"&gt;
&lt;table style="text-align:left;WIDTH: 100%; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 0pt;"&gt;
&lt;p style="FONT-SIZE: 0pt; WIDTH: 0pt;" /&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt;" valign="top" align="left"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%;"&gt;(a)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 0pt;"&gt;
&lt;p style="FONT-SIZE: 0pt; WIDTH: 0pt;" /&gt;
&lt;/td&gt;
&lt;td valign="top" align="left"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="COLOR: #000000; DISPLAY: inline;"&gt;The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company&amp;#8217;s common stock of $0.46 and $0.44 per share as of December&amp;#160;31, 2018 and 2017.&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock id="Fact-add645aa-b5ce-4466-9268-2e0e00912e7c_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0.5pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:8pt;"&gt;Issuance&amp;nbsp;Date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:8pt;"&gt;Expiration&amp;nbsp;Date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:8pt;"&gt;Exercise&amp;nbsp;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:8pt;"&gt;Number&amp;nbsp;of&amp;nbsp;Shares&amp;nbsp;(in&amp;nbsp;thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;November, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;November, 2025&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.2276
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;198
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:52.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;January, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;January, 2026&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.2276
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;132
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:52.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityTableTextBlock id="Fact-da9530aa-b889-4253-b5fc-4a286c56c02a_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;As&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Series&amp;nbsp;A convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;56,673
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;56,673
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Series&amp;nbsp;B convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;51,069
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;51,069
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Warrants for Series&amp;nbsp;A convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Common stock options issued and outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,222
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,222
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;127,294
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;127,294
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;

&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
  <us-gaap:ShareBasedCompensation id="Fact-490cb29b-e3c3-455f-9e01-b67a20390360_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">309000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="Fact-e55479cc-6556-4cfc-ad9f-ccaf164ece67_20181231" contextRef="D2018-01-01_2018-12-31">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Fact-d8dd672d-744b-4a2b-aca0-15c40f310738_20181231" decimals="INF" contextRef="D2018-01-01_2018-12-31" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Fact-2991bbb1-9bb5-438f-98e6-98fd47917a14_20181231" contextRef="D2018-01-01_2018-12-31">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="Fact-4ec54eb9-07a4-4e3e-a565-b47312d5f8c8_20181231" contextRef="D2018-01-01_2018-12-31">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="Fact-a8b2f130-1c79-491f-8166-aaa47b96b203_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line&amp;nbsp;&amp;nbsp;basis over the requisite service period, which is generally the vesting period. The Company&amp;nbsp;&amp;nbsp;recognizes forfeitures as they occur.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;uses the Black-Scholes option-pricing model (the &amp;#x201C;Black-Scholes model&amp;#x201D;) as the method for determining&amp;nbsp;&amp;nbsp;the estimated fair value of stock options.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Term &amp;#x2014;&lt;/font&gt;&lt;font style="display:inline;"&gt; The expected term represents the period that the Company&amp;#x2019;s stock-based&amp;nbsp;&amp;nbsp;awards are expected to be outstanding and is determined&amp;nbsp;&amp;nbsp;using the simplified method.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Volatility &amp;#x2014;&lt;/font&gt;&lt;font style="display:inline;"&gt; Expected volatility is estimated using comparable public companies&amp;#x2019; volatility for similar terms.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Dividend &amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;"&gt;The Black-Scholes model calls for a single expected dividend yield as an input. The Company&amp;nbsp;&amp;nbsp;has never paid dividends and has no plans to pay dividends.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Risk-Free Interest Rate &amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;"&gt;The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero-coupon&amp;nbsp;&amp;nbsp;issues in effect at the time of grant for periods corresponding with the expected term of the option.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="Fact-278a0ff0-dbaf-4914-b25f-f4caac68465a_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Note&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;"&gt;2.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Summary of Significant Accounting Policies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;The preparation of financial statements&amp;nbsp;&amp;nbsp;in conformity&amp;nbsp;&amp;nbsp;with GAAP requires management to make estimates and assumptions&amp;nbsp;&amp;nbsp;that affect the reported&amp;nbsp;&amp;nbsp;amounts&amp;nbsp;&amp;nbsp;of assets and liabilities, the disclosure of contingent&amp;nbsp;&amp;nbsp;liabilities at the date of the financial statements,&amp;nbsp;&amp;nbsp;and the reported&amp;nbsp;&amp;nbsp;amounts&amp;nbsp;&amp;nbsp;of expenses incurred during the reporting&amp;nbsp;&amp;nbsp;period. Actual results could differ from those estimates and such differences could be material to the Company&amp;#x2019;s financial position and results of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;Significant estimates and assumptions&amp;nbsp;&amp;nbsp;include the valuation&amp;nbsp;&amp;nbsp;of equity instruments and equity-linked instruments, including the valuation&amp;nbsp;&amp;nbsp;of the Company&amp;#x2019;s common stock and the valuation&amp;nbsp;&amp;nbsp;of the Company&amp;#x2019;s common stock options for purposes of accounting&amp;nbsp;&amp;nbsp;for stock-based&amp;nbsp;&amp;nbsp;compensation, and accruals for clinical trials and the valuation&amp;nbsp;&amp;nbsp;allowances on deferred tax assets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Financial&amp;nbsp;&amp;nbsp;instruments that potentially&amp;nbsp;&amp;nbsp;subject the Company&amp;nbsp;&amp;nbsp;to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance&amp;nbsp;&amp;nbsp;Corporation insured limits. To date, the Company&amp;nbsp;&amp;nbsp;has not experienced any losses on its deposits of cash and cash equivalents.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company&amp;#x2019;s future financial position, results of operations, or cash flows: ability to obtain&amp;nbsp;&amp;nbsp;future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory&amp;nbsp;&amp;nbsp;approval&amp;nbsp;&amp;nbsp;and market acceptance of the Company&amp;#x2019;s products;&amp;nbsp;&amp;nbsp;development&amp;nbsp;&amp;nbsp;of sales channels; certain strategic relationships;&amp;nbsp;&amp;nbsp;litigation or claims against the Company&amp;nbsp;&amp;nbsp;based on intellectual property,&amp;nbsp;&amp;nbsp;patent,&amp;nbsp;&amp;nbsp;product,&amp;nbsp;&amp;nbsp;regulatory, or other factors; and the Company&amp;#x2019;s ability to attract&amp;nbsp;&amp;nbsp;and retain employees necessary to support&amp;nbsp;&amp;nbsp;its growth.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s postoperative pain reduction&amp;nbsp;&amp;nbsp;product&amp;nbsp;&amp;nbsp;candidate,&amp;nbsp;&amp;nbsp;brivoligide, is an oligonucleotide.&amp;nbsp;&amp;nbsp;The Company&amp;nbsp;&amp;nbsp;currently uses Avecia as a single supplier for the brivoligide drug substance.&amp;nbsp;&amp;nbsp;There are currently a limited number of oligonucleotide&amp;nbsp;&amp;nbsp;manufacturers with commercial scale capabilities globally. While the Company&amp;nbsp;&amp;nbsp;intends to develop secondary sources for manufacturing of its drug candidates&amp;nbsp;&amp;nbsp;in the future, there can be no assurance that it will be able to do so on commercially reasonable&amp;nbsp;&amp;nbsp;terms, or at all. Any interruption in the supply of this key material could significantly delay the research and development process or increase the expenses for development&amp;nbsp;&amp;nbsp;and commercialization of the Company&amp;#x2019;s product candidates.&amp;nbsp;&amp;nbsp;The quality of materials can be critical to the performance of a drug delivery technology. Therefore, the lack of a reliable source that provides a consistent supply of high quality materials would harm the Company.&amp;nbsp;&amp;nbsp;At December 31, 2018, this vendor&amp;#x2019;s activity was not material to total accounts payable.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;At December 31, 2017, two vendors represented&amp;nbsp; 56% and 31%, of total accounts payable. The vendor that represented&amp;nbsp; 56% of the Company&amp;#x2019;s accounts payable, supported manufacturing activities and the other vendor was associated with clinical study activities. At December 31, 2018, three vendors represented&amp;nbsp; 52%, &amp;nbsp;26% and 15% of total accounts payable. Two of these vendors supported general and administrative activities, primarily associated with the Merger and next round of equity financing, which accounted&amp;nbsp;&amp;nbsp;for 67% of the total accounts payable. The remaining vendor supported clinical study activities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Clinical Trial Accruals&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;The Company&amp;#x2019;s clinical trial accruals are based on patient enrollment and related costs at clinical investigator&amp;nbsp;&amp;nbsp;sites as well as for the services received and efforts expended pursuant to contracts&amp;nbsp;&amp;nbsp;with multiple research institutions and contract&amp;nbsp;&amp;nbsp;research organizations that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The Company&amp;nbsp;&amp;nbsp;accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol.&amp;nbsp;&amp;nbsp;If timelines or contracts&amp;nbsp;&amp;nbsp;are modified based upon changes in the clinical trial protocol&amp;nbsp;&amp;nbsp;or scope of work to be performed, the Company&amp;nbsp;&amp;nbsp;modifies the estimates of accrued expenses accordingly. To date, the Company&amp;nbsp;&amp;nbsp;has had no significant adjustments to accrued clinical trial expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;In March 2018, the Company&amp;nbsp;&amp;nbsp;closed its contracts&amp;nbsp;&amp;nbsp;with Premier Research International LLC and CRF Health,&amp;nbsp;&amp;nbsp;Inc. (&amp;#x201C;Contract Research Organizations or CROs&amp;#x201D;) upon completion&amp;nbsp;&amp;nbsp;of a Phase 2 clinical trial in March 2018. For the years ended December 31, 2017 and 2018, the Company&amp;nbsp;&amp;nbsp;incurred $6.2 million and $95,000, respectively, of expenses in connection&amp;nbsp;&amp;nbsp;with this clinical study.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;In November&amp;nbsp;&amp;nbsp;2018, the Company&amp;nbsp;&amp;nbsp;entered into agreements with PRA Health,&amp;nbsp;&amp;nbsp;Inc. and CRF Health, Inc. (&amp;#x201C;Contract Research Organizations or CROs&amp;#x201D;) pursuant to which the CROs agreed to assist the Company&amp;nbsp;&amp;nbsp;with the conduct of a Phase 2 clinical trial. To support&amp;nbsp;&amp;nbsp;additional clinical trial activities the Company&amp;nbsp;&amp;nbsp;also entered into agreements with Premier Research International LLC for biostatistical services, ICON Central Laboratories for laboratory services and Almac Clinical Services for storage and distribution services. In connection&amp;nbsp;&amp;nbsp;with this clinical study, the Company&amp;nbsp;&amp;nbsp;incurred expenses of $0 and $185,000 for the years ended December 31, 2017 and 2018, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Cash and Cash Equivalents&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;The Company&amp;nbsp;&amp;nbsp;considers all highly liquid investments purchased&amp;nbsp;&amp;nbsp;with a maturity&amp;nbsp;&amp;nbsp;of three months or less on the date of acquisition&amp;nbsp;&amp;nbsp;to be cash and cash equivalents.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and Equipment, Net&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property&amp;nbsp;&amp;nbsp;and equipment&amp;nbsp;&amp;nbsp;are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line&amp;nbsp;&amp;nbsp;method over the estimated useful lives of the assets, generally three to five years. Leasehold improvements&amp;nbsp;&amp;nbsp;are amortized&amp;nbsp;&amp;nbsp;over the shorter of the estimated useful life of the asset or the remaining term of the lease.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Expenditures&amp;nbsp;&amp;nbsp;for repairs and maintenance are charged to expense as incurred. Upon disposition&amp;nbsp;&amp;nbsp;of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements&amp;nbsp;&amp;nbsp;of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;The Company&amp;#x2019;s long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount&amp;nbsp;&amp;nbsp;of the asset may not be recoverable. Recoverability&amp;nbsp;&amp;nbsp;of an asset to be held and used is measured by a comparison of the carrying amount&amp;nbsp;&amp;nbsp;of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount&amp;nbsp;&amp;nbsp;by which the carrying amount of the asset exceeds its fair value. As of December 31, 2017 and 2018, the Company&amp;nbsp;&amp;nbsp;had not experienced any impairment losses on its long-lived assets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Restricted Cash&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2017 and 2018, the Company&amp;nbsp;&amp;nbsp;had $55,000 restricted and held by a bank as collateral for a letter of credit provided to the Company&amp;#x2019;s facility landlord.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line&amp;nbsp;&amp;nbsp;basis over the requisite service period, which is generally the vesting period. The Company&amp;nbsp;&amp;nbsp;recognizes forfeitures as they occur.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;uses the Black-Scholes option-pricing model (the &amp;#x201C;Black-Scholes model&amp;#x201D;) as the method for determining&amp;nbsp;&amp;nbsp;the estimated fair value of stock options.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Term &amp;#x2014;&lt;/font&gt;&lt;font style="display:inline;"&gt; The expected term represents the period that the Company&amp;#x2019;s stock-based&amp;nbsp;&amp;nbsp;awards are expected to be outstanding and is determined&amp;nbsp;&amp;nbsp;using the simplified method.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Volatility &amp;#x2014;&lt;/font&gt;&lt;font style="display:inline;"&gt; Expected volatility is estimated using comparable public companies&amp;#x2019; volatility for similar terms.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Dividend &amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;"&gt;The Black-Scholes model calls for a single expected dividend yield as an input. The Company&amp;nbsp;&amp;nbsp;has never paid dividends and has no plans to pay dividends.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Risk-Free Interest Rate &amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;"&gt;The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero-coupon&amp;nbsp;&amp;nbsp;issues in effect at the time of grant for periods corresponding with the expected term of the option.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and Development&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and development&amp;nbsp;&amp;nbsp;expenses consist of personnel costs, including salaries, benefits and stock-based&amp;nbsp;&amp;nbsp;compensation, preclinical studies, clinical studies performed&amp;nbsp;&amp;nbsp;by Contract Research Organizations (or &amp;#x201C;CROs&amp;#x201D;), materials and supplies, licenses and fees, and overhead allocations&amp;nbsp;&amp;nbsp;consisting of various administrative and facilities related costs. The Company&amp;nbsp;&amp;nbsp;charges research and development&amp;nbsp;&amp;nbsp;costs, including clinical study costs, to expense when incurred.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Collaboration Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June 2018, the Company&amp;nbsp;&amp;nbsp;entered into a collaboration agreement with twoXAR,&amp;nbsp;&amp;nbsp;an artificial intelligence-driven drug discovery company, in order to identify potential&amp;nbsp;&amp;nbsp;product&amp;nbsp;&amp;nbsp;candidates&amp;nbsp;&amp;nbsp;for the treatment of endometriosis.&amp;nbsp;&amp;nbsp;Through&amp;nbsp;&amp;nbsp;December 31, 2018, the Company&amp;nbsp;&amp;nbsp;was not obligated to make any payments under the terms of the collaboration agreement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Grant Reimbursements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In December 2018, the Company&amp;nbsp;&amp;nbsp;received a Notice of Award from the National Institute&amp;nbsp;&amp;nbsp;on Drug Abuse (&amp;#x201C;NIDA&amp;#x201D;), part of the National Institutes&amp;nbsp;&amp;nbsp;of Health (&amp;#x201C;NIH&amp;#x201D;), to support&amp;nbsp;&amp;nbsp;the clinical development&amp;nbsp;&amp;nbsp;of its lead product&amp;nbsp;&amp;nbsp;candidate,&amp;nbsp;&amp;nbsp;brivoligide. NIH grants provide funds for certain types of expenditures in connection&amp;nbsp;&amp;nbsp;with research and development&amp;nbsp;&amp;nbsp;activities over a contractually defined period. The maximum funding expected to be available under this grant for qualified expenditures over the two year period through December 2020 is approximately $5.7 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2018, the Company&amp;nbsp;&amp;nbsp;had not incurred qualified expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;The Company&amp;nbsp;&amp;nbsp;accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined&amp;nbsp;&amp;nbsp;based on differences between the financial reporting&amp;nbsp;&amp;nbsp;and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company&amp;nbsp;&amp;nbsp;provides a valuation&amp;nbsp;&amp;nbsp;allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;In evaluating the ability to recover its deferred income tax assets, the Company&amp;nbsp;&amp;nbsp;considers all available positive and negative evidence, including its operating&amp;nbsp;&amp;nbsp;results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company&amp;nbsp;&amp;nbsp;determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation&amp;nbsp;&amp;nbsp;allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined&amp;nbsp;&amp;nbsp;not to be realizable in the future, an adjustment to the valuation&amp;nbsp;&amp;nbsp;allowance would be charged to earnings in the period such determination is made.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;The Company&amp;nbsp;&amp;nbsp;recognizes the tax benefit from uncertain&amp;nbsp;&amp;nbsp;tax positions in accordance&amp;nbsp;&amp;nbsp;with GAAP, which prescribes a recognition threshold&amp;nbsp;&amp;nbsp;and measurement&amp;nbsp;&amp;nbsp;attribute for the financial statement&amp;nbsp;&amp;nbsp;recognition and measurement&amp;nbsp;&amp;nbsp;of uncertain&amp;nbsp;&amp;nbsp;tax positions taken or expected to be taken in a company&amp;#x2019;s tax return.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Convertible Preferred Stock Warrants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Freestanding warrants&amp;nbsp;&amp;nbsp;to acquire shares of convertible preferred stock are classified as liabilities on the accompanying balance sheets. These warrants&amp;nbsp;&amp;nbsp;are subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. The Company&amp;nbsp;&amp;nbsp;will continue to adjust the carrying values of freestanding&amp;nbsp;&amp;nbsp;warrants&amp;nbsp;&amp;nbsp;classified as liabilities for changes in fair value until the earlier of the exercise or expiration&amp;nbsp;&amp;nbsp;of the warrants&amp;nbsp;&amp;nbsp;or the completion&amp;nbsp;&amp;nbsp;of a liquidation event, including the completion&amp;nbsp;&amp;nbsp;of an initial public offering.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Debt Modif ications and Extinguishments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;When the Company&amp;nbsp;&amp;nbsp;modifies debt, it does so in accordance with Accounting Standards Codification (&amp;#x201C;ASC&amp;#x201D;) 470-50, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Debt: Modifications and Extinguishments&lt;/font&gt;&lt;font style="display:inline;"&gt;, which requires modification&amp;nbsp;&amp;nbsp;to debt instruments to be evaluated to assess whether the modifications&amp;nbsp;&amp;nbsp;are considered &amp;#x201C;substantial modifications&amp;#x201D;. A substantial modification&amp;nbsp;&amp;nbsp;of terms shall be accounted&amp;nbsp;&amp;nbsp;for like an extinguishment.&amp;nbsp;&amp;nbsp;Based on the guidance relied upon and the analysis performed,&amp;nbsp;&amp;nbsp;the Company&amp;nbsp;&amp;nbsp;determined&amp;nbsp;&amp;nbsp;that the October 2018 modification&amp;nbsp;&amp;nbsp;of the March 2018 and September 2018 Notes, to add an additional conversion option in the event of a reverse merger, was considered to be a &amp;#x201C;substantial modification&amp;#x201D;. As a result, it treated this modification&amp;nbsp;&amp;nbsp;as an &amp;#x2018;extinguishment&amp;#x2019; of those debts and recognized $11,000 of net gain from this debt extinguishment&amp;nbsp;&amp;nbsp;in other income. All other changes to debt provisions were not considered substantial and were treated as debt modifications.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Derivative Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;ASC 815-15, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Derivatives and Hedging: Embedded Derivatives&lt;/font&gt;&lt;font style="display:inline;"&gt;, generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding&amp;nbsp;&amp;nbsp;derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics&amp;nbsp;&amp;nbsp;and risks of the embedded derivative instrument&amp;nbsp;&amp;nbsp;are not clearly and closely related to the economic characteristics&amp;nbsp;&amp;nbsp;and risks of the host contract,&amp;nbsp;&amp;nbsp;(b) the hybrid instrument&amp;nbsp;&amp;nbsp;that embodies both the embedded derivative instrument&amp;nbsp;&amp;nbsp;and the host contract&amp;nbsp;&amp;nbsp;is not re-measured at fair value under otherwise applicable generally accepted accounting&amp;nbsp;&amp;nbsp;principles with changes in fair value reported&amp;nbsp;&amp;nbsp;in earnings as they occur and (c) a separate instrument&amp;nbsp;&amp;nbsp;with the same terms as the embedded derivative instrument&amp;nbsp;&amp;nbsp;would be considered a derivative instrument&amp;nbsp;&amp;nbsp;subject to the requirement&amp;nbsp;&amp;nbsp;of ASC 815.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;nbsp;&amp;nbsp;issued certain Notes in March 2018, September 2018, and December 2018, which contained&amp;nbsp;&amp;nbsp;various embedded derivative features. In particular, these Notes contained&amp;nbsp;&amp;nbsp;the following features:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(1)&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"&gt;&lt;/font&gt;A share settled redemption in a qualified preferred stock financing; and&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(2)&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"&gt;&lt;/font&gt;The right to an accelerated cash repayment&amp;nbsp;&amp;nbsp;in the event of a change in control.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;These embedded features were not considered clearly and closely related to the debt host, therefore, they were bifurcated&amp;nbsp;&amp;nbsp;and accounted&amp;nbsp;&amp;nbsp;for separately from the debt host as a derivative liability. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in the statement&amp;nbsp;&amp;nbsp;of operations at each period end while such instruments are outstanding.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In October 2018, the Company&amp;nbsp;&amp;nbsp;modified the March 2018 and September 2018 Notes to add an additional conversion feature. The Company determined this was a &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x201C;substantial modification&amp;#x201D;&lt;/font&gt;&lt;font style="display:inline;"&gt; as defined in ASC 470-50 &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x2018;Debt: Modifications and Extinguishments&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;"&gt;. As a result, these Notes were accounted&amp;nbsp;&amp;nbsp;for as an &amp;#x2018;extinguishment&amp;#x2019; of the debt and related derivative liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2018, the Company&amp;nbsp;&amp;nbsp;determined&amp;nbsp;&amp;nbsp;that there was no fair value associated with the embedded derivatives that remained with the modified March 2018, the modified September 2018 and December 2018 Notes. See &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x2018;Note 5 &amp;#x2014; Term Loans and Convertible Promissory Notes&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;"&gt; for further discussion of the Notes and the bifurcated&amp;nbsp;&amp;nbsp;derivative liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;ASC 820-10, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Fair Value Measurement&lt;/font&gt;&lt;font style="display:inline;"&gt;, provides a framework&amp;nbsp;&amp;nbsp;for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. The standard defines fair value as an exit price, representing the amount&amp;nbsp;&amp;nbsp;that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. The standard also establishes a fair value hierarchy, which prioritizes the inputs used in measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Level 1&lt;/font&gt;&lt;font style="display:inline;"&gt; &amp;#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the Company&amp;nbsp;&amp;nbsp;has the ability to access as of the measurement&amp;nbsp;&amp;nbsp;date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Level 2&lt;/font&gt;&lt;font style="display:inline;"&gt; &amp;#x2014; Inputs&amp;nbsp;&amp;nbsp;other than quoted prices included within Level 1 that are directly observable for the asset or liability or indirectly observable through&amp;nbsp;&amp;nbsp;corroboration with observable market data.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Level 3&lt;/font&gt;&lt;font style="display:inline;"&gt; &amp;#x2014; Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement&amp;nbsp;&amp;nbsp;date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining&amp;nbsp;&amp;nbsp;fair value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following tables present the Company&amp;#x2019;s fair value hierarchy for all of its financial instruments measured at fair value on a recurring basis as of December 31, 2017 and December 31, 2018 (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:49.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;As of December 31, 2017&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;Level 1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;Level 2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;Level 3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Financial liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Warrant liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Total financial liabilities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:49.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Financial liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Level 1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Level 2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Level 3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Warrant liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 12pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Total financial liabilities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities.&amp;nbsp;&amp;nbsp;The fair value of the Company&amp;#x2019;s term loan is based on the borrowing&amp;nbsp;&amp;nbsp;rate currently available to the Company&amp;nbsp;&amp;nbsp;for borrowings&amp;nbsp;&amp;nbsp;with similar terms and maturity&amp;nbsp;&amp;nbsp;and approximates its carrying value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Derivative liability instruments are considered Level 3 when their fair values are determined&amp;nbsp;&amp;nbsp;using pricing models, discounted&amp;nbsp;&amp;nbsp;cash flow methodologies,&amp;nbsp;&amp;nbsp;or similar techniques, and at least one significant model assumption or input is unobservable. Level 3 liability instruments consist of the preferred stock warrant liability and derivative liability, for both of which there is no observable market data for the determination of fair value and requires significant management judgment and estimation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value of the warrant liability was determined&amp;nbsp;&amp;nbsp;using the Black-Scholes model (see &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x2018;Note 8 &amp;#x2014; Warrants&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;"&gt; for a further discussion of the preferred stock warrants). The change in fair value of the preferred stock warrant liability is summarized below (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="middle" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Years Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="middle" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Fair value, beginning of period&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 54&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Preferred stock warrants &amp;#x2013; exercised &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (8)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Change in fair value of preferred stock warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (4)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 98&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Fair value at end of period&amp;nbsp;&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value of the embedded derivative liability related to the Company&amp;#x2019;s Notes was determined using a bond plus option model. As of December 31, 2018, the Company&amp;nbsp;&amp;nbsp;determined&amp;nbsp;&amp;nbsp;that there was no fair value remaining for the embedded derivatives associated with the modified March 2018, modified September 2018 and December 2018 Notes. See &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;&amp;#x2018;Note 5 &amp;#x2014; Term Loans and Convertible Promissory Notes&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;"&gt; for further discussion on the derivative liability activity.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The change in fair value of the derivative liability relating to the Notes is summarized below (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="middle" style="width:18.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;Years Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="middle" style="width:18.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Fair value, beginning of period &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$ &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Embedded derivative liability from the issuance of Notes&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; 864&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Change in value of embedded derivatives&amp;nbsp; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt; (211)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Termination of the embedded derivative liability due to the extinguishment&amp;nbsp;&amp;nbsp;of the related Notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; (653)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#231F20;"&gt;Fair value at end of period &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In November&amp;nbsp;&amp;nbsp;2016, the FASB issued ASU No. 2016-18, Statement&amp;nbsp;&amp;nbsp;of Cash Flows: Restricted&amp;nbsp;&amp;nbsp;Cash. This ASU requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts&amp;nbsp;&amp;nbsp;shown on the statement&amp;nbsp;&amp;nbsp;of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation&amp;nbsp;&amp;nbsp;of the total in the statement&amp;nbsp;&amp;nbsp;of cash flows to the related captions in the balance sheet. This guidance is effective for fiscal periods beginning after December 15, 2017 and interim periods within that fiscal year, with early adoption permitted.&amp;nbsp;&amp;nbsp;The amendments in this ASU should be applied retrospectively to all periods presented. The Company&amp;nbsp;&amp;nbsp;adopted the guidance on a retrospective basis on January&amp;nbsp;&amp;nbsp;1, 2018 and the beginning and ending of cash and cash equivalents for all periods presented in our statements&amp;nbsp;&amp;nbsp;of cash flows include restricted cash.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Non-employee Share-Based Payment Accounting&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June 2018, FASB issued ASU No. 2018-07, &amp;#x201C;Compensation &amp;#x2014; Stock Compensation (Topic 718): Improvements to Nonemployee&amp;nbsp;&amp;nbsp;Share-Based Payment Accounting&amp;#x201D; (&amp;#x201C;ASU 2018-07&amp;#x201D;). This new guidance changes the accounting&amp;nbsp;&amp;nbsp;for non-employee share-based&amp;nbsp;&amp;nbsp;payments to align with the accounting&amp;nbsp;&amp;nbsp;for employee stock compensation. The Company&amp;nbsp;&amp;nbsp;early adopted&amp;nbsp;&amp;nbsp;the guidance as of January&amp;nbsp;&amp;nbsp;1, 2018 and the impact to its financial statements&amp;nbsp;&amp;nbsp;was not material.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Recent Accounting Pronouncements Not Yet Effective&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Lease Accounting&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February 2016, the Financial&amp;nbsp;&amp;nbsp;Accounting&amp;nbsp;&amp;nbsp;Standards Board (&amp;#x201C;FASB&amp;#x201D;) issued ASU No. 2016-02. This standard introduces the new leases standard that applies a right-of-use (&amp;#x201C;ROU&amp;#x201D;) model and requires a lessee to record, for all leases with a lease term of more than 12 months,&amp;nbsp;&amp;nbsp;an asset representing its right to use the underlying asset and a liability to make lease payments. For leases with a term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. At inception, lessees must classify all leases as either finance or operating&amp;nbsp;&amp;nbsp;based on five criteria. Balance sheet recognition of finance and operating&amp;nbsp;&amp;nbsp;leases is similar, but the pattern of expense recognition in the income statement, as well as the effect on the statement&amp;nbsp;&amp;nbsp;of cash flows, differs depending on the lease classification. This ASU is effective for public entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted&amp;nbsp;&amp;nbsp;for all entities. The Company&amp;nbsp;&amp;nbsp;is currently assessing whether these amendments will have a material effect on its financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In August 2018, the FASB issued No. ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements&amp;nbsp;&amp;nbsp;as part of its disclosure framework&amp;nbsp;&amp;nbsp;project. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year, with early adoption permitted.&amp;nbsp;&amp;nbsp;The Company&amp;nbsp;&amp;nbsp;is currently assessing whether these amendments will have a material effect on its financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Fact-5937ab64-26ef-4333-b0d1-8ab2661cabfd_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; FONT-WEIGHT: bold; MARGIN: 0pt 0pt 12pt;"&gt;&lt;font style="font-family: Times New Roman,Times,serif; COLOR: #231f20; DISPLAY: inline;"&gt;Note&amp;#160;&lt;/font&gt;&lt;font style="font-family: Times New Roman,Times,serif; DISPLAY: inline;"&gt;7&lt;/font&gt;&lt;font style="DISPLAY: inline;"&gt;.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Stockholders&amp;#8217; Deficit&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; FONT-WEIGHT: bold; FONT-STYLE: italic; MARGIN: 0pt 0pt 12pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;Redeemable Convertible Preferred Stock&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;As of December 31, 2017 and 2018, the Company&amp;#160;&amp;#160;had 56,672,658 shares of Series A convertible preferred stock issued and outstanding, including 3,531,889 shares issued as a result of a conversion of notes to investors and accrued interest to Series A convertible preferred stock in 2010. As of December 31, 2017 and 2018, the Company&amp;#160;&amp;#160;had 51,069,262 shares of Series B convertible preferred stock issued and outstanding, including 6,469,356 shares issued as a result of a conversion of notes to investors and accrued interest to Series B convertible preferred stock in 2016.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;The holders of preferred stock have various rights and preferences including the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline;"&gt;Voting Rights &amp;#8212;&lt;/font&gt; &lt;font style="DISPLAY: inline;"&gt;A holder of each share of Series A and Series B convertible preferred stock shall have the right to one vote for each share of common stock into which such preferred stock could be converted. Series A convertible preferred stock holders voting as a separate class are entitled to elect two directors to the Company&amp;#8217;s Board of Directors&amp;#160;&amp;#160;as long as shares of Series A convertible preferred stock remain outstanding. Series B convertible preferred stock holders voting as a separate class are entitled to elect one director to the Company&amp;#8217;s Board of Directors&amp;#160;&amp;#160;as long as at least 10,000,000 shares of Series B convertible preferred stock remain outstanding. Common&amp;#160;&amp;#160;stockholders voting as a separate class are entitled to elect two directors. The holders of preferred and common stock voting together as a single class on an as-if-converted basis are entitled to elect all remaining directors.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline;"&gt;Dividends &amp;#8212;&lt;/font&gt; &lt;font style="DISPLAY: inline;"&gt;Holders of Series B convertible preferred stock, in preference to the holders of Series A preferred and common stock, are entitled to receive noncumulative dividends at the annual rate of $0.0251 per share, when, as, and if declared by the Board of Directors.&amp;#160;&amp;#160;Holders of Series A convertible preferred stock are entitled to receive noncumulative dividends at the annual rate of $0.0182 per share, when, as, and if declared by the Board of Directors.&amp;#160; No dividends on preferred stock have been declared by the Board of Directors&amp;#160;&amp;#160;during the years ended December 31, 2017 and 2018.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline;"&gt;Liquidation Preference &amp;#8212;&lt;/font&gt; &lt;font style="DISPLAY: inline;"&gt;In the event of any liquidation, dissolution,&amp;#160;&amp;#160;or winding up of the Company, including a merger, acquisition,&amp;#160;&amp;#160;or sale of assets, as defined, the holders of Series B convertible preferred stock are entitled to receive an amount&amp;#160;&amp;#160;of $0.3133 per share (as adjusted for recapitalizations, stock combinations, stock dividends, stock splits, and the like), plus any declared but unpaid dividends prior to and in preference to any distribution to the holders of Series A preferred or common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;After distributions have been made to all holders of Series B convertible preferred stock as described above, the remaining assets of the Company&amp;#160;&amp;#160;available for distribution to stockholders shall be distributed to all holders of Series A convertible preferred stock. The holders of Series A convertible preferred stock are entitled to receive an amount&amp;#160;&amp;#160;of $0.2276 per share (as adjusted for recapitalizations, stock combinations, stock dividends, stock splits, and the like), plus any declared but unpaid dividends prior to and in preference to any distribution to the holders of common stock. The remaining assets of the Company available for distribution to stockholders shall be distributed ratably among the holders of the common stock and preferred stock on an as-if-converted basis.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline;"&gt;Conversion Rights &amp;#8212;&lt;/font&gt; &lt;font style="DISPLAY: inline;"&gt;Each share of Series A and Series B convertible preferred stock is convertible, at the option of the holder, into shares of common stock on a one for one basis (subject to adjustment for certain events). The preferred stock will also be converted automatically into shares of common stock (1) immediately prior to an initial public offering with aggregate proceeds of at least $40 million and an offering price of not less than $1.00 per common share or (2) upon the date specified by written consent of holders of a majority of the outstanding preferred shares on an as-converted&amp;#160;&amp;#160;basis.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;The Series A and Series B Preferred Stock were classified as temporary equity in the accompanying balance sheets as of the December 31, 2017 and 2018, as shares are subject to redemption upon the occurrence of uncertain&amp;#160;&amp;#160;events not solely within the Company&amp;#8217;s control. As of December 31, 2017 and 2018, the Series A and Series B Preferred Stock were not redeemable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; FONT-WEIGHT: bold; FONT-STYLE: italic; MARGIN: 0pt 0pt 12pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;span style="FONT-SIZE: 13px; TEXT-DECORATION: none; font-family: Times New Roman; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; text-align: left; ORPHANS: 2; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: transparent; TEXT-INDENT: 26px; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s articles of incorporation, as amended, authorize the Company to issue 148,000,000 shares of&amp;#8201; $0.001 par value common stock. As of December&amp;#160;31, 2017 and 2018, the Company had 19,548,969 shares outstanding. Common stockholders are entitled to dividends when and if declared by the Board of Directors and after any Series&amp;#160;B and Series&amp;#160;A convertible preferred shares dividends are fully paid. The holder of each share of common stock is entitled to one vote. At December&amp;#160;31, 2018, no dividends had been declared.&amp;#160;&lt;/span&gt;&amp;#160;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt;"&gt;&lt;font style="FONT-WEIGHT: bold; FONT-STYLE: italic; DISPLAY: inline;"&gt;Shares Reserved for Future Issuance&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;The Company&amp;#160;&amp;#160;reserved shares of common stock for future issuances as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 16px; TEXT-DECORATION: none; font-family: Times New Roman; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; text-align: left; ORPHANS: 2; MARGIN: 0px; LETTER-SPACING: normal; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px;" /&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;" /&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;As&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Series&amp;nbsp;A convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;56,673
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;56,673
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Series&amp;nbsp;B convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;51,069
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;51,069
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Warrants for Series&amp;nbsp;A convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Common stock options issued and outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,222
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,222
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;127,294
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;127,294
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;

&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="Fact-9fcf3974-3968-4349-ace1-50358487b6d7_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; FONT-WEIGHT: bold; MARGIN: 0pt 0pt 12pt;"&gt;&lt;font style="font-family: Times New Roman,Times,serif; COLOR: #231f20; DISPLAY: inline;"&gt;Note&amp;#160;&lt;/font&gt;&lt;font style="DISPLAY: inline;"&gt;13.&amp;#160;&amp;#160;&amp;#160;Subsequent Events&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;In January&amp;#160;&amp;#160;2019, the Company and Oxford Finance agreed to amend the debt agreement. Oxford agreed to 2 months of interest-only payments followed by 8 months of repayments&amp;#160;&amp;#160;upon delivery by February 1, 2019 of an executed term sheet between the Company&amp;#160;&amp;#160;and Domain,&amp;#160;&amp;#160;the Company&amp;#8217;s majority investor and an affiliate thereof, that would result in aggregate proceeds to the Company&amp;#160;&amp;#160;of $20.0 million. The Company&amp;#160;&amp;#160;was also required to place $200,000 in a segregated bank account that is subject to a blocked control agreement in favor of Oxford. The funds in the segregated account were to be released upon the earlier of, the consummation of a merger by March 31, 2019 or the consummation of the equity financing. The Company&amp;#160;&amp;#160;recorded the $200,000 as restricted cash in its balance sheet at March 31, 2019. The maturity date of the loans remained unchanged.&amp;#160;&amp;#160;The amendment fee amounted to $50,000. The amendment was accounted&amp;#160;&amp;#160;for as a debt modification.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;Beginning in January&amp;#160;&amp;#160;2019, the Company&amp;#160;&amp;#160;amended the 401(k) Plan to discontinue&amp;#160;&amp;#160;the nonelective safe harbor&amp;#160;&amp;#160;contribution on behalf of each employee equal to 3% of their annual salary.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;In April 2019 and May 2019, the Company&amp;#8217;s primary investor agreed to provide the Company&amp;#160;&amp;#160;with $2.0 million and $0.5 million in the form of Notes to fund the Company&amp;#8217;s operations. These notes accrue simple interest on the outstanding principal amount&amp;#160;&amp;#160;at the rate of 8% per annum and mature on April 26, 2020 and May 29, 2020.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;In May 2019, the Company and Oxford Finance agreed to a seventh amendment to provide consent to the Merger. This consent amended certain provisions of the term loan to protect Oxford&amp;#8217;s rights under the original term loan agreement. The consent allowed Alliqua to be named as an additional borrower.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;On May 3, 2019 the Company completed its Merger into Alliqua Biomedical Inc. (&amp;#8220;Alliqua&amp;#8221;). Immediately following the Merger, the combined company&amp;#8217;s name was changed from &amp;#8220;Alliqua BioMedical, Inc.&amp;#8221; to &amp;#8220;Adynxx, Inc.&amp;#8221; The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal&amp;#160;&amp;#160;Revenue Code of 1986, as amended. Under the Exchange Ratio formula in the Merger Agreement, as of immediately following the Merger, but excluding the effect of certain financings (as further described in the Merger Agreement), Adynxx equity holders now own approximately 86% of the aggregate number of shares of the combined company and Alliqua equity holders own approximately 14% of the combined company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;Subject to the terms and conditions of the Merger Agreement (a) each outstanding share of capital stock of Adynxx, was converted into the right to receive the number of shares of Alliqua&amp;#8217;s common stock equal to the Exchange Ratio formula in the Merger Agreement and (b) each outstanding Adynxx stock option,&amp;#160;&amp;#160;whether vested or unvested, and warrant that has not previously been exercised, was assumed by the post merged company and converted into a stock option or warrant, as the case may be, to purchase shares of the post merged Adynxx Company&amp;#8217;s common stock at the Exchange Ratio formula in the Merger Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;&lt;span style="FONT-SIZE: 13px; TEXT-DECORATION: none; font-family: Times New Roman; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; text-align: left; ORPHANS: 2; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: transparent; TEXT-INDENT: 26px; -webkit-text-stroke-width: 0px;"&gt;On May&amp;#160;3, 2019, prior to the closing of the Merger, the $3.0&amp;#160;million of Notes and $203,000 of cumulative accrued interest, was converted into 10,223,996 shares of Series&amp;#160;B convertible preferred stock.&lt;/span&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: justify; text-justify: inter-ideograph; MARGIN: 0pt; TEXT-INDENT: 36pt;"&gt;&lt;font style="DISPLAY: inline;"&gt;The Company has evaluated subsequent events through June 7, 2019, the date the financial statements were issued, for appropriate accounting&amp;#160;&amp;#160;and financial statement&amp;#160;&amp;#160;disclosures.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock id="Fact-dbe0ffc5-11f7-43f8-baba-d55246da7796_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;Years&amp;nbsp;Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 331&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Changes related to prior year positions&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 330&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Increases related to current year positions&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;Balance at December 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;color:#000000;"&gt; 703&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;
</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="Fact-0be2c55b-79b5-4a0d-8b40-227073764528_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">42000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions id="Fact-f6f12898-e1b4-4e4c-ad4b-202494bddbc7_20181231" decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">330000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UseOfEstimates id="Fact-560f756c-918c-452f-b58e-34af8092d295_20181231" contextRef="D2018-01-01_2018-12-31">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;The preparation of financial statements&amp;nbsp;&amp;nbsp;in conformity&amp;nbsp;&amp;nbsp;with GAAP requires management to make estimates and assumptions&amp;nbsp;&amp;nbsp;that affect the reported&amp;nbsp;&amp;nbsp;amounts&amp;nbsp;&amp;nbsp;of assets and liabilities, the disclosure of contingent&amp;nbsp;&amp;nbsp;liabilities at the date of the financial statements,&amp;nbsp;&amp;nbsp;and the reported&amp;nbsp;&amp;nbsp;amounts&amp;nbsp;&amp;nbsp;of expenses incurred during the reporting&amp;nbsp;&amp;nbsp;period. Actual results could differ from those estimates and such differences could be material to the Company&amp;#x2019;s financial position and results of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;"&gt;Significant estimates and assumptions&amp;nbsp;&amp;nbsp;include the valuation&amp;nbsp;&amp;nbsp;of equity instruments and equity-linked instruments, including the valuation&amp;nbsp;&amp;nbsp;of the Company&amp;#x2019;s common stock and the valuation&amp;nbsp;&amp;nbsp;of the Company&amp;#x2019;s common stock options for purposes of accounting&amp;nbsp;&amp;nbsp;for stock-based&amp;nbsp;&amp;nbsp;compensation, and accruals for clinical trials and the valuation&amp;nbsp;&amp;nbsp;allowances on deferred tax assets.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="Fact-361c0217-a2a5-452a-bf62-0526b3d972e2_20181231" decimals="-5" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">1200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <adyx:AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB id="Fact-1c423357-d48e-44d9-aad4-1422b073d9a6_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">106000</adyx:AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB>
  <adyx:DefinedContributionPlanNonelectiveSafeHarborContributionAmount id="Fact-04d76544-6cf1-4dbf-ada7-7e7a7597618a_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">54000</adyx:DefinedContributionPlanNonelectiveSafeHarborContributionAmount>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Fact-8eef1776-97ba-41df-ad3c-f4fc8eeb5caf_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">301000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="Fact-27c2a9e2-f2ef-4e10-9f22-0b810ab6c078_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">54000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Fact-152f34a9-7b0b-4304-9884-05f2c3772722_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-10245000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:Depreciation id="Fact-bd1afbd6-2ba5-48df-9b09-a055500da943_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">10000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="Fact-0e25e092-ffde-4957-b1df-e2f917c7b82f_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">10000</us-gaap:Depreciation>
  <us-gaap:FairValueAdjustmentOfWarrants id="Fact-8d76b4ef-03fb-4d78-83b5-d3a1b8120f65_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-12000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:GeneralAndAdministrativeExpense id="Fact-e66f42ed-9a0c-4fc2-8363-145421939e93_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">2341000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit id="Fact-fd1dc20f-5178-423e-8c6c-7e2c00c32f24_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Fact-82682bad-83e4-456d-80cb-98f7d611570c_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">601000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Fact-31e5fbc4-9554-4647-94b5-e02ae4e5da05_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-12000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="Fact-977951a6-552e-4223-87ac-325e1408d47b_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-1000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Fact-7af2c65f-82a6-4943-9073-16bbe1979a8f_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-329000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestExpense id="Fact-95500879-1322-459c-8a99-1d01a4fc82ef_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">515000</us-gaap:InterestExpense>
  <us-gaap:InterestIncomeExpenseNet id="Fact-91cf4f45-5cc2-4f2c-a841-5df1d0882b54_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-515000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestPaidNet id="Fact-f7f70c59-bad8-476b-9dce-9b4db93b3644_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">355000</us-gaap:InterestPaidNet>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="Fact-643449fd-5025-45a1-b728-7d833cafa002_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-59000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="Fact-fc66b7d8-86be-44db-996a-48d787857886_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-3000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="Fact-370eb4cd-f61f-4ef7-a38a-e1fd8a2aabc9_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-10183000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="Fact-153ee35e-40a3-4bc5-9ca2-2a9c34c799fe_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-11561000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Fact-06075d18-5ff1-45cc-9e85-5c8c30c3c5db_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-11561000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Fact-a400ccc5-f2a2-4ae0-a021-c85029f28bc1_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-11561000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses id="Fact-13c1fe63-dd11-4725-bb34-03592353400e_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">11063000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Fact-a7cc57a5-31f3-4628-8176-4097679f2a22_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-11063000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeaseExpense id="Fact-620d3b07-c278-4fc7-bc1f-03aa3e66f77c_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">225000</us-gaap:OperatingLeaseExpense>
  <us-gaap:PaymentsForProceedsFromProductiveAssets id="Fact-b4266e53-9962-4143-b5c8-1de503548f5d_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">3000</us-gaap:PaymentsForProceedsFromProductiveAssets>
  <us-gaap:PreferredStockDividendsPerShareDeclared id="Fact-cc489ace-b056-4d9e-aa99-73b33bd1d917_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD_xbrli-shares">0</us-gaap:PreferredStockDividendsPerShareDeclared>
  <us-gaap:ProceedsFromWarrantExercises id="Fact-bb2bcd4b-26d8-40fc-bf1a-0a188e6fd4a5_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">80000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:RepaymentsOfLongTermDebt id="Fact-d2f92b4a-ef6b-4687-9879-b33b4a6f7240_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">139000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:ResearchAndDevelopmentExpense id="Fact-aa334ead-c0c2-4e06-9d8a-8f9ceee5b550_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">8722000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensation id="Fact-02723e73-fda6-44ed-a12f-a144b8bfca37_20181231" decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">301000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Fact-221a39de-93a6-467d-87d3-70fc30f7a623_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Fact-d9e77bc7-b15c-4171-82d0-476b9926bed3_20181231" contextRef="D2017-01-01_2017-12-31">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="Fact-a143efb7-dbba-4a5f-ac64-9a72640ce05a_20181231" decimals="INF" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">-964000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="c49928090_20190630" decimals="4" contextRef="D2015-11-24_2015-11-24_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember_srt-RangeAxis_srt-MinimumMember_us-gaap-VariableRateAxis_us-gaap-LondonInterbankOfferedRateLiborSwapRateMember" unitRef="xbrli-pure">0.0019</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:ProceedsFromIssuanceOfDebt id="c49928093_20190630" decimals="INF" contextRef="D2016-01-29_2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember" unitRef="iso4217-USD">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927652_20190630" decimals="-3" contextRef="D2018-01-01_2018-03-31" unitRef="iso4217-USD">75000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="c49927661_20190630" decimals="-3" contextRef="D2018-01-01_2018-03-31" unitRef="iso4217-USD">-1523000</us-gaap:NetIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927645_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927654_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927647_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927656_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927650_20190630" decimals="-3" contextRef="D2018-01-01_2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">75000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="c49927659_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927649_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927658_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927651_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927660_20190630" decimals="-3" contextRef="D2018-01-01_2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-1523000</us-gaap:NetIncomeLoss>
  <adyx:AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB id="c49927711_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">94000</adyx:AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB>
  <adyx:GrantReimbursementsExpense id="c49927454_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD"/>
  <adyx:IncreaseDecreaseInLeaseLiability id="c49927728_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD"/>
  <adyx:NoncashPortionOfLeaseExpense id="c49927717_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD"/>
  <adyx:ReclassificationOfWarrantLiabilityToPaidInCapital id="c49927754_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD"/>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="c49927713_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">130000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="c49927742_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">-2643000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:ConversionOfStockAmountConverted1 id="c49927756_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD"/>
  <us-gaap:Depreciation id="c49928047_20190630" decimals="INF" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">4000</us-gaap:Depreciation>
  <us-gaap:DerivativeGainLossOnDerivativeNet id="c49927709_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">60000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax id="c49927478_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD"/>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare id="c49927491_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD_xbrli-shares"/>
  <us-gaap:EarningsPerShareBasicAndDiluted id="c49927495_20190630" decimals="INF" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD_xbrli-shares">-0.64</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:FairValueAdjustmentOfWarrants id="c49927707_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">1000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:GeneralAndAdministrativeExpense id="c49927450_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">1292000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeLossFromContinuingOperations id="c49927474_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">-2946000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="c49927487_20190630" decimals="INF" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD_xbrli-shares">-0.64</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="c49927724_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">-607000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="c49927726_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">-312000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="c49927722_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD"/>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="c49927720_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">12000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestExpense id="c49927466_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">445000</us-gaap:InterestExpense>
  <us-gaap:InterestPaidNet id="c49927749_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">190000</us-gaap:InterestPaidNet>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="c49927740_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">884000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="c49927733_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD"/>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="c49927730_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">-3527000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="c49927700_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">-2946000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense id="c49927470_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">60000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingExpenses id="c49927458_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">2561000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="c49927462_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">-2561000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaidInKindInterest id="c49927715_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">31000</us-gaap:PaidInKindInterest>
  <us-gaap:ProceedsFromRelatedPartyDebt id="c49927738_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">1500000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:RepaymentsOfLongTermDebt id="c49927736_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">616000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:ResearchAndDevelopmentExpense id="c49927446_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">1269000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="c49927752_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD"/>
  <us-gaap:ShareBasedCompensation id="c49927705_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">150000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="c49927499_20190630" decimals="INF" contextRef="D2018-01-01_2018-06-30" unitRef="xbrli-shares">4569742</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:AllocatedShareBasedCompensationExpense id="c49928228_20190630" decimals="INF" contextRef="D2018-01-01_2018-06-30_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember" unitRef="iso4217-USD">150000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="c49928238_20190630" decimals="INF" contextRef="D2018-01-01_2018-06-30_us-gaap-AwardTypeAxis_adyx-NonEmployeeOptionsMember" unitRef="iso4217-USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="c49928000_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD">-60000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="c49927996_20190630" decimals="-3" contextRef="D2018-01-01_2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD">496000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 id="c49927984_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="c49927980_20190630" xsi:nil="true" contextRef="D2018-01-01_2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD"/>
  <us-gaap:InterestExpenseDebt id="c49928115_20190630" decimals="INF" contextRef="D2018-01-01_2018-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">309000</us-gaap:InterestExpenseDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927679_20190630" decimals="-3" contextRef="D2018-04-01_2018-06-30" unitRef="iso4217-USD">75000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="c49927998_20190630" decimals="-3" contextRef="D2018-04-01_2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD">-60000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="c49927994_20190630" xsi:nil="true" contextRef="D2018-04-01_2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 id="c49927982_20190630" xsi:nil="true" contextRef="D2018-04-01_2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="c49927978_20190630" xsi:nil="true" contextRef="D2018-04-01_2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD"/>
  <us-gaap:InterestExpenseDebt id="c49928111_20190630" decimals="INF" contextRef="D2018-04-01_2018-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">171000</us-gaap:InterestExpenseDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927672_20190630" xsi:nil="true" contextRef="D2018-04-01_2018-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927681_20190630" xsi:nil="true" contextRef="D2018-04-01_2018-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927674_20190630" xsi:nil="true" contextRef="D2018-04-01_2018-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927683_20190630" xsi:nil="true" contextRef="D2018-04-01_2018-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927677_20190630" decimals="-3" contextRef="D2018-04-01_2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">75000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="c49927686_20190630" xsi:nil="true" contextRef="D2018-04-01_2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927676_20190630" xsi:nil="true" contextRef="D2018-04-01_2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927685_20190630" xsi:nil="true" contextRef="D2018-04-01_2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927678_20190630" xsi:nil="true" contextRef="D2018-04-01_2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927687_20190630" decimals="-3" contextRef="D2018-04-01_2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-1422000</us-gaap:NetIncomeLoss>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="c49927867_20190630" decimals="INF" contextRef="D2018-10-01_2018-10-31" unitRef="iso4217-USD">11000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <adyx:DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet id="c49928101_20190630" contextRef="D2019-01-01_2019-01-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">P240D</adyx:DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet>
  <us-gaap:ProceedsFromMinorityShareholders id="c49928102_20190630" decimals="INF" contextRef="D2019-01-01_2019-01-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">20000000</us-gaap:ProceedsFromMinorityShareholders>
  <adyx:GainLossDebtModification id="c49928109_20190630" decimals="INF" contextRef="D2019-01-01_2019-01-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">0</adyx:GainLossDebtModification>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927517_20190630" decimals="-3" contextRef="D2019-01-01_2019-03-31" unitRef="iso4217-USD">84000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="c49927526_20190630" decimals="-3" contextRef="D2019-01-01_2019-03-31" unitRef="iso4217-USD">-2462000</us-gaap:NetIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927510_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927519_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927512_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927521_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927515_20190630" decimals="-3" contextRef="D2019-01-01_2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">84000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="c49927524_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927514_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927523_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927516_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927525_20190630" decimals="-3" contextRef="D2019-01-01_2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-2462000</us-gaap:NetIncomeLoss>
  <adyx:AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB id="c49927710_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">148000</adyx:AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB>
  <adyx:ClinicalTrialAccrualsPolicyPolicyTextBlock id="c49927791_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Clinical Trial Accruals&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The Company&amp;#x2019;s clinical trial accruals are based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The Company accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, the Company modifies the estimates of accrued expenses accordingly. To date, the Company has had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; significant adjustments to accrued clinical trial expenses.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
</adyx:ClinicalTrialAccrualsPolicyPolicyTextBlock>
  <adyx:ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock id="c49927817_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Convertible Preferred Stock Warrants &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;At December&amp;nbsp;31, 2018, freestanding warrants to acquire shares of convertible preferred stock were classified as liabilities on the accompanying balance sheet. These warrants were subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. In connection with the Merger, the warrants were exchanged into warrants that no longer met the definition of a derivative and thus, $234,000 of warrant liabilities was reclassified into equity during the six&amp;nbsp;months ended June&amp;nbsp;30, 2019. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</adyx:ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock>
  <adyx:DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock id="c49927820_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Debt Modifications and Extinguishments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;When the Company modifies debt, it does so in accordance with Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;470&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Debt: Modifications and Extinguishments&lt;/div&gt;, which requires modification to debt instruments to be evaluated to assess whether the modifications are considered &amp;#x201c;substantial modifications&amp;#x201d;. A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, the Company determined that the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 2018 &lt;/div&gt;modification of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 2018 &lt;/div&gt;Notes, to add an additional conversion option in the event of a reverse merger, was considered to be a &amp;#x201c;substantial modification&amp;#x201d;. As a result, it treated this modification as an &amp;#x2018;extinguishment&amp;#x2019; of those debts and recognized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11,000&lt;/div&gt; of net gain from this debt extinguishment in other income in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 2018. &lt;/div&gt;All other changes to debt provisions were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; considered substantial and were treated as debt modifications.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
</adyx:DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock>
  <adyx:GrantReimbursementPolicyPolicyTextBlock id="c49927812_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Grant Reimbursements &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In December&amp;nbsp;2018, the Company received a Notice of Award from the National Institute on Drug Abuse (&amp;#x201C;NIDA&amp;#x201D;), part of the National Institutes of Health (&amp;#x201C;NIH&amp;#x201D;), to support the clinical development of its lead product candidate, brivoligide. NIH grants provide funds for certain types of expenditures in connection with research and development activities over a contractually defined period. The maximum funding expected to be available under this grant for qualified expenditures over the two-year period through December&amp;nbsp;2020 is&amp;#x2009;approximately $5.7&amp;nbsp;million. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;On January&amp;nbsp;1, 2019, the Company adopted Accounting Standards Update (ASU) 2018-08, &amp;#x201C;Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.&amp;#x201D; Based on this guidance, the Company determined that grant payments received met the definition of a &amp;#x2018;conditional contribution&amp;#x2019; (versus an exchange contract) because (i)&amp;nbsp;the Company has limited discretion in the way the funds may be spent, which creates a barrier to entitlement, and (ii) the grant contains provisions that release the awarding agency from the obligation to transfer funds that are not expended at the time the award is terminated. The Company recognizes grant reimbursements as a contra operating expense and reflects this as a component of its loss from operations in the period during which the qualifying expenses are incurred and the related services rendered, provided that the applicable performance obligations have been met. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;For the six&amp;nbsp;months ended June&amp;nbsp;30, 2019, the Company incurred qualified expenses and recognized $1,198,000 of grant reimbursements. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</adyx:GrantReimbursementPolicyPolicyTextBlock>
  <adyx:GrantReimbursements id="c49927856_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">1198000</adyx:GrantReimbursements>
  <adyx:GrantReimbursementsExpense id="c49927453_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">-1198000</adyx:GrantReimbursementsExpense>
  <adyx:IncreaseDecreaseInLeaseLiability id="c49927727_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">-136000</adyx:IncreaseDecreaseInLeaseLiability>
  <adyx:NoncashPortionOfLeaseExpense id="c49927716_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">140000</adyx:NoncashPortionOfLeaseExpense>
  <adyx:ReclassificationOfWarrantIntoEquity id="c49927950_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">234000</adyx:ReclassificationOfWarrantIntoEquity>
  <adyx:ReclassificationOfWarrantLiabilityToPaidInCapital id="c49927753_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">234000</adyx:ReclassificationOfWarrantLiabilityToPaidInCapital>
  <adyx:ReverseMergerDisclosureTextBlock id="s1285336_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;"&gt;Note 3.&amp;nbsp;&amp;nbsp;&amp;nbsp;Reverse Merger &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Merger &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;On May&amp;nbsp;3, 2019 the Company completed its reverse merger with Alliqua BioMedical Inc. (&amp;#x201C;Alliqua&amp;#x201D;). Immediately following the Merger, the combined company&amp;#x2019;s name was changed from &amp;#x201C;Alliqua BioMedical, Inc.&amp;#x201D; to &amp;#x201C;Adynxx, Inc.&amp;#x201D; Private Adynxx changed its name to &amp;#x201C;Adynxx Sub, Inc.&amp;#x201D; and is currently a wholly owned subsidiary of the Company. The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section&amp;nbsp;368(a) of the Internal Revenue Code of 1986, as amended. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Subject to the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of October&amp;nbsp;11, 2018, as amended and supplemented from time to time (the &amp;#x201C;Merger Agreement&amp;#x201D;), (a)&amp;nbsp;each outstanding share of capital stock of Private Adynxx, was converted into the right to receive the number of shares of Alliqua&amp;#x2019;s common stock equal to the exchange ratio formula in the Merger Agreement (&amp;#x201C;Exchange Ratio&amp;#x201D;) of 0.0359 shares of common stock (which exchange rate reflects a 1-for-6 reverse stock split of the issued and outstanding capital stock of Alliqua BioMedical, Inc. effected on May&amp;nbsp;3, 2019 immediately prior to the Merger) and (b)&amp;nbsp;each outstanding Private Adynxx stock option, whether vested or unvested, and warrant that has not previously been exercised, was assumed by the post-Merger company and converted into a stock option or warrant, as the case may be, to purchase shares of the post-Merger Adynxx Company&amp;#x2019;s common stock at the Exchange Ratio formula in the Merger Agreement. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;On May&amp;nbsp;3, 2019, prior to the closing of the Merger, $3.0&amp;nbsp;million aggregate principal amount of Notes and $203,000 of cumulative accrued interest on such Notes were converted into 367,041 shares of common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Upon the completion of the Merger, Private Adynxx equity holders held 4,936,784 shares of common stock. Equity issuance costs in connection with the Merger were recorded as an offset to additional paid in capital. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;As described in &amp;#x201C;Spin-off&amp;#x201D; below, at the time of the Merger, Alliqua had in place a plan to spin-off all existing operations. Since Alliqua was deemed to have no operations upon consummation of the Spin-off, Alliqua was not considered to be a business for accounting purposes. Accordingly, no goodwill or intangible assets were recorded as a result of the Merger. Because Private Adynxx is treated as the acquiring company, Private Adynxx&amp;#x2019;s assets and liabilities are recorded at their pre-combination carrying amounts and the historical operations that are reflected in periods prior to the closing date of the Merger will be those of Private Adynxx. All share and per share amounts have been retroactively restated to give effect to the Exchange Ratio. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Private Adynxx was determined to be the accounting acquirer based upon the terms of the Merger Agreement and other factors including: (i)&amp;nbsp;Private Adynxx equity holders owned approximately 86% of the voting interests of the combined company immediately following the closing of the transaction and Alliqua equity holders owned approximately 14%; (ii) directors appointed by Private Adynxx hold a majority of board seats in the combined company; and (iii) Private Adynxx management hold all key positions in the management of the combined company. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In connection with a previous modification of its Notes, the Company had computed a contingent beneficial conversion feature (&amp;#x201C;BCF&amp;#x201D;) that was contingent upon the occurrence of a reverse merger. In accordance with ASC 470-20-25-6, the contingent BCF is not recognized in earnings until the contingency is resolved. Upon the date of the Merger, the full amount of beneficial conversion feature of&amp;#x2009; $2.1&amp;nbsp;million was recognized as interest expense in the condensed consolidated statement of operations for the six&amp;nbsp;months ended June&amp;nbsp;30, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Dividend &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In contemplation of the Merger, Alliqua declared a special cash dividend to the pre-Merger shareholders of Alliqua as of April&amp;nbsp;22, 2019. The aggregate dividend of&amp;#x2009; $5,245,000, or $1.05 per share, was paid on May&amp;nbsp;29, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Spin-off &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;On November&amp;nbsp;27, 2018, Alliqua had entered into an agreement whereby its existing operations would be distributed to existing shareholders as of a record date. With the exception of a corporate lease, substantially all of Alliqua&amp;#x2019;s assets and liabilities were contributed to a subsidiary, AquaMed Technologies Inc. (&amp;#x201C;AquaMed&amp;#x201D;), whose shares were then distributed to the pre-Merger shareholders of Alliqua by way of a pro&amp;nbsp;rata stock dividend on June&amp;nbsp;21, 2019. The book value of the dividend was less than $0.01 per share. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Because the historical periods presented prior to the merger are those of Private Adynxx, the results of AquaMed are only reflected in these financial statements from the merger date to the date of the pro&amp;nbsp;rata dividend of AquaMed and are presented as discontinued operations in the condensed consolidated statement of operations. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Pro Forma Financial Information &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;As the only significant operations of Alliqua have been discontinued with the spin-off transaction, pro&amp;nbsp;forma financial information for periods prior to the merger is not presented herein as such results are not meaningful.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</adyx:ReverseMergerDisclosureTextBlock>
  <adyx:ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock id="c-5_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;December&amp;nbsp;31,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;June&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Prepaid clinical trial expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;435
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Equity issuance costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;343
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Prepaid insurance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;670
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other prepaid expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;174
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total prepaid and other current assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,622
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
</adyx:ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock>
  <adyx:WarrantsDisclosureTextBlock id="s1285347_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt;
&lt;div&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Note 9.&amp;#160;&amp;#160;&amp;#160;Warrants&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;"&gt;Private Adynxx had issued warrants that were previously classified as a liability as they were exercisable for preferred shares that were potentially redeemable. The fair value of the warrant liability was re-measured at each balance sheet date up through the date of the Merger with the change as other income recorded in the statements of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;"&gt;On May&amp;#160;3, 2019, in connection with the closing of the Merger, each outstanding Adynxx warrant that had not previously been exercised was converted into a stock warrant to purchase shares of the Company&amp;#8217;s common stock at the Exchange Ratio and, as a result, outstanding warrants were converted into warrants to purchase an aggregate of 11,829 shares of the Company&amp;#8217;s common stock at an exercise price of $6.34 per share. As such warrants qualify for equity classification, the Company reclassified the balance of&amp;#8201; $234,000 from warrant liability to additional paid in capital. These warrants are exercisable at any time and expire in 2025 and 2026.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;"&gt;Additionally, upon the closing of the Merger on May&amp;#160;3, 2019, the Company assumed outstanding Alliqua warrants to purchase an aggregate of 38,945 shares of common stock at exercise prices ranging from $26.40 to $28.20 per share. These warrants are exercisable at any time and expire in 2022.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;/div&gt;</adyx:WarrantsDisclosureTextBlock>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="c49927712_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">16000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="c49927793_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The Company considers all highly liquid investments purchased with a maturity of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months or less on the date of acquisition to be cash and cash equivalents.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="c49927800_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Restricted Cash &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;At December 31, 2018 and June 30, 2019, the Company had $55,000 restricted and held by a bank as collateral for a letter of credit provided to the Company&amp;#x2019;s facility landlord. In addition, as of June 30, 2019, the Company had $200,000 restricted from withdrawal and held by a bank in the form of a secured money market account as collateral for Oxford in conjunction with a debt amendment that occurred in January 2019. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="c49927741_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">-1664000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CollaborativeArrangementAccountingPolicy id="c49927809_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Collaboration Agreement &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In June&amp;nbsp;2018, the Company entered into a collaboration agreement with twoXAR, an artificial intelligence-driven drug discovery company, in order to identify potential product candidates for the treatment of endometriosis. In May&amp;nbsp;2019, the Company made a collaboration initiation payment of $75,000, which was charged to research and development expenses for the six&amp;nbsp;months ended June&amp;nbsp;30, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In June&amp;nbsp;2019, Adynxx received an initial set of candidate predictions from twoXAR. The Company has initiated a review of the potential products to determine if any are viable candidates for further research and development. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
  <us-gaap:ConcentrationRiskCreditRisk id="c49927789_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; font-family: times new roman; DISPLAY: inline;"&gt;
&lt;div style="FONT-SIZE: 10pt; font-family: times new roman; DISPLAY: inline;"&gt;
&lt;div style="FONT-SIZE: 10pt; font-family: times new roman; DISPLAY: inline;"&gt;
&lt;div style="FONT-SIZE: 10pt; font-family: times new roman; DISPLAY: inline;"&gt;
&lt;div style="font-family;"&gt;
&lt;div style="FONT-STYLE: italic; DISPLAY: inline;"&gt;
&lt;div style="font-weight: bold; display: inline;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="font-family;"&gt;
&lt;div style="font-weight: bold; display: inline;"&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="font-family;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;one&lt;/div&gt;
financial institution
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;may&lt;/div&gt;
be in excess of the Federal Deposit Insurance Corporation insured limits. To date, the Company has
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;not&lt;/div&gt;
experienced any losses on its deposits of cash and cash equivalents.&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company's products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company's ability to attract and retain employees necessary to support its growth.&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;The Company&amp;#8217;s postoperative pain reduction product candidate, brivoligide, is an oligonucleotide. The Company currently uses Nitto-Denko Avecia, Inc. (&amp;#8220;Avecia&amp;#8221;) as a single supplier for the brivoligide drug substance. There are currently a limited number of oligonucleotide manufacturers with commercial scale capabilities globally. While the Company intends to develop secondary sources for manufacturing of its drug candidates in the future, there can be
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;no&lt;/div&gt;
assurance that it will be able to do so on commercially reasonable terms, or at all. Any interruption in the supply of this key material could significantly delay the research and development process or increase the expenses for development and commercialization of the Company&amp;#8217;s product candidates. The quality of materials can be critical to the performance of a drug delivery technology. Therefore, the lack of a reliable source that provides a consistent supply of high quality materials would harm the Company. At
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;June 30, 2019,&lt;/div&gt;
this vendor&amp;#8217;s activity was
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;not&lt;/div&gt;
material to total accounts payable.&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;&lt;span style="FONT-SIZE: 13px; TEXT-DECORATION: none; font-family: Times New Roman; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; text-align: left; ORPHANS: 2; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: transparent; TEXT-INDENT: 26px; -webkit-text-stroke-width: 0px;"&gt;At December&amp;#160;31, 2018, three vendors represented 52%, 26% and 15% of total accounts payable. Two of these vendors supported general and administrative activities, primarily associated with the Merger and next round of equity financing, which accounted for 67% of the total accounts payable. The remaining vendor supported clinical study activities. At June&amp;#160;30, 2019, three vendors represented 26%, 22% and 17% of total accounts payable, respectively. Two of these vendors supported general and administrative activities associated with the Merger and the next round of equity financing, which accounted for 44% of the total accounts payable. The remaining supported clinical study activities.&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ConversionOfStockAmountConverted1 id="c49927755_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">34015000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConvertibleDebtTableTextBlock id="c-7_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;December&amp;nbsp;31,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;June&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible note payable, due on March&amp;nbsp;29, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible note payable, due on September&amp;nbsp;27, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible note payable, due on December&amp;nbsp;21, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible note payable, due on March&amp;nbsp;29, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible note payable, due on April&amp;nbsp;26, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible note payable, due on May&amp;nbsp;29, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;
&lt;/div&gt;
</us-gaap:ConvertibleDebtTableTextBlock>
  <us-gaap:DebtDisclosureTextBlock id="s1285342_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;"&gt;Note 6.&amp;nbsp;&amp;nbsp;&amp;nbsp;Term Loans and Convertible Promissory Notes &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Term Loans &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;On November&amp;nbsp;24, 2015, the Company entered into a loan and security agreement (&amp;#x201C;Loan Agreement&amp;#x201D;) with Oxford, pursuant to which the Company received $3.0&amp;nbsp;million in proceeds from a Term Loan A and $2.0&amp;nbsp;million in proceeds from a Term Loan B under the Loan Agreement (collectively the &amp;#x201C;Term Loans&amp;#x201D;). Warrants to purchase 11,829 shares of common stock were issued to Oxford in connection with the Term Loans (&amp;#x2018;&lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Note 9&amp;#x2009;&amp;#x2014; Warrants&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;). The Term Loans bear interest at a floating per annum rate equal to (a)&amp;nbsp;7.06% plus (ii) the greater of&amp;#x2009; (a)&amp;nbsp;the 30 day U.S. Dollar LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (b)&amp;nbsp;0.19%. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Term Loan A was recorded at its initial carrying value of&amp;#x2009; $3.0&amp;nbsp;million less debt issuance costs of approximately $141,000, and the Term Loan B was recorded at its initial carrying value of&amp;#x2009; $2.0&amp;nbsp;million, less debt issuance costs of approximately $3,000. The debt issuance costs are being amortized to interest expense over the life of the Term Loans using the effective interest method. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;As of December&amp;nbsp;31, 2018, $2.3&amp;nbsp;million was outstanding under Term Loan A and $1.5&amp;nbsp;million was outstanding under Term Loan B. At June&amp;nbsp;30, 2019, $1.4&amp;nbsp;million was outstanding under Term Loan A and $1.0&amp;nbsp;million was outstanding under Term Loan B. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The following modifications have been made during the six&amp;nbsp;months ended June&amp;nbsp;30, 2019: &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt;"&gt;
			&lt;p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt 0pt 10pt;font-family:Symbol;color:#000000;line-height:100%;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:1pt;"&gt;&lt;p style="width:1pt;width:1pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In January&amp;nbsp;2019, the Company and Oxford agreed to amend the Loan Agreement. Oxford agreed to two&amp;nbsp;months of interest-only payments followed by eight&amp;nbsp;months of repayments upon delivery by February&amp;nbsp;1, 2019 of an executed term sheet for equity financing that would result in aggregate proceeds to the Company of&amp;#x2009; $20.0&amp;nbsp;million. The Company was also required to place $200,000 in a segregated bank account that is subject to a blocked control agreement in favor of Oxford. The funds in the segregated account were to be released upon the earlier of the consummation of a merger by March&amp;nbsp;31, 2019 or the consummation of an equity financing by March&amp;nbsp;31, 2019. The Company recorded the $200,000 as restricted cash in its balance sheet at June&amp;nbsp;30, 2019. The maturity date of the Term Loans remained unchanged. The amendment fee amounted to $50,000. The amendment was accounted for as a debt modification. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:1pt;"&gt;&amp;#x200B;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt;"&gt;
			&lt;p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt 0pt 10pt;font-family:Symbol;color:#000000;line-height:100%;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:1pt;"&gt;&lt;p style="width:1pt;width:1pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In May&amp;nbsp;2019, the Company and Oxford agreed to an amendment to provide consent to the Merger. This consent amended certain provisions of the Term Loans to protect Oxford&amp;#x2019;s rights under the original Loan Agreement. The consent allowed Alliqua (now Adynxx, Inc.) to be named as an additional borrower. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt;"&gt;
			&lt;p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt 0pt 10pt;font-family:Symbol;color:#000000;line-height:100%;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:1pt;"&gt;&lt;p style="width:1pt;width:1pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In June&amp;nbsp;2019, the Company and Oxford agreed to amend the Loan Agreement. Oxford agreed to two&amp;nbsp;months of interest-only payments and the maturity date of the Term Loans was extended two&amp;nbsp;months to January&amp;nbsp;1, 2020. The amendment fee amounted to $20,000. The amendment was accounted for as a debt modification. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:1pt;"&gt;&amp;#x200B;&amp;#x200B;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;"&gt;&amp;#x2007;&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Upon the respective dates of the debt modifications, no gain or loss was recorded, and a new effective interest rate was established based on the carrying value of the debt and the revised cash flows. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Interest expense associated with the Term Loans was $309,000 and $336,000 for the six&amp;nbsp;months ended June&amp;nbsp;30, 2018 and 2019, respectively. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;As of June&amp;nbsp;30, 2019, the Company was in compliance with all covenants under the Loan Agreement. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Principal payments for the Term Loans due under the Loan Agreement as of June&amp;nbsp;30, 2019 are due monthly beginning September&amp;nbsp;1, 2019 and the Term Loans mature on January&amp;nbsp;1, 2020. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Convertible Promissory Notes &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The table below reflects the principal amount of the Notes issued by the Company (in thousands): &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;June&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Convertible note payable, due on March&amp;nbsp;29, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Convertible note payable, due on September&amp;nbsp;27, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Convertible note payable, due on December&amp;nbsp;21, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Convertible note payable, due on March&amp;nbsp;29, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Convertible note payable, due on April&amp;nbsp;26, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Convertible note payable, due on May&amp;nbsp;29, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Outstanding Notes &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Notes outstanding at June&amp;nbsp;30, 2019 were issued with conversion and repayment rights as described below: &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size:10pt;;"&gt; (a)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;in the event that the Company issues and sells equity securities with proceeds to the Company of at least $5&amp;nbsp;million, on or before the maturity date, then the outstanding principal amount of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities of the same class sold in the equity financing at a conversion price equal to the cash price paid per share for equity securities in the financing, and &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 10pt 54pt;text-indent: -18pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:1pt;"&gt;&amp;#x200B;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size:10pt;;"&gt; (b)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;if the Company consummates a change of control while the Notes remain outstanding, the Company shall repay the holders in cash in an amount equal to 200% of the outstanding principal amount of the Notes. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:1pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In April&amp;nbsp;2019 and May&amp;nbsp;2019, affiliates of Domain Partners, LLC, a significant shareholder of the Company, purchased from the Company $2.0&amp;nbsp;million and $0.5&amp;nbsp;million aggregate principal amount of Notes. The proceeds from the issuances were used for general corporate purposes and working capital. These Notes accrue simple interest on the outstanding principal amount at a rate of 8% per annum and mature on April&amp;nbsp;26, 2020 and May&amp;nbsp;29, 2020, respectively. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Converted Notes &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In May&amp;nbsp;2019, under the terms of the then-outstanding Notes, the principal and accrued unpaid interest of two Notes totaling $3.2&amp;nbsp;million were automatically converted into the Company&amp;#x2019;s Series&amp;nbsp;B convertible preferred stock. Upon consummation of the Merger, and subject to the terms and conditions of the Merger Agreement, each outstanding share of capital stock of Adynxx was converted into the right to receive the number of shares of the combined Company&amp;#x2019;s common stock equal to the Exchange Ratio. An aggregate of 367,041 post-Merger common shares were issued associated with the conversion of these Notes. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In connection with a previous modification, the Company had computed a contingent BCF that was contingent upon the occurrence of a reverse merger. In accordance with ASC 470-20-25-6, the contingent BCF is not recognized in earnings until the contingency is resolved. Upon the date of the Merger, the full amount of beneficial conversion feature of&amp;#x2009; $2.1&amp;nbsp;million was recognized as interest expense in the condensed consolidated statement of operations for the six&amp;nbsp;months ended June&amp;nbsp;30, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Derivative Liability &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Company evaluated its outstanding Notes and determined that certain embedded components relating to conversion and redemption features of those contracts qualified as derivatives, which need to be separately accounted for in accordance with ASC 815. With the consummation of the Merger, several of these clauses no longer apply. However, the redemption provision upon change of control described above is an embedded feature that is required to be bifurcated. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;As of December 31, 2018, the Company evaluated the fair value of the derivative liability and determined that the bifurcated derivative liability had no value because the Company estimated a zero probability of the embedded feature being triggered. As a result, the Company estimated the fair value of the derivative liability to be zero at December 31, 2018. Similarly, the embedded derivatives that were in place at June&amp;nbsp;30, 2019 also had a fair value of zero. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:Depreciation id="c49928046_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">4000</us-gaap:Depreciation>
  <us-gaap:DerivativeGainLossOnDerivativeNet id="c49927708_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD"/>
  <us-gaap:DerivativesPolicyTextBlock id="c49927822_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Derivative Instruments &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;ASC 815-15, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Derivatives and Hedging: Embedded Derivatives&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;, generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a)&amp;nbsp;the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b)&amp;nbsp;the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)&amp;nbsp;a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirement of ASC 815. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;At December 31, 2018 and June&amp;nbsp;30, 2019, the Company maintained outstanding Notes which contained various embedded derivative features. In particular, these Notes contained the following features: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;(1)&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A share settled redemption in a qualified preferred stock financing; and &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;(2)&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The right to an accelerated cash repayment in the event of a change in control. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:1pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;These embedded features were not considered clearly and closely related to the debt host, therefore, they were bifurcated and accounted for separately from the debt host as a derivative liability. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in the statement of operations at each period end while such instruments are outstanding. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;As of December 31, 2018 and June&amp;nbsp;30, 2019, the Company determined that there was no fair value associated with the embedded derivatives that remained with the outstanding convertible notes. See &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;&amp;#x2018;Note&amp;nbsp;6&amp;#x2009;&amp;#x2014; Term Loans and Convertible Promissory Notes&amp;#x2019; &lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;for further discussion of the Notes and the bifurcated derivative liability. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="s1285348_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt;
&lt;div&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;"&gt;Note 10.&amp;#160;&amp;#160;&amp;#160;Stock Options&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;"&gt;On May&amp;#160;3, 2019, in connection with the closing of the Merger, each outstanding Private Adynxx stock option, whether vested or unvested, was converted into a stock option to purchase shares of the Company&amp;#8217;s common stock at the Exchange Ratio and, as a result, the Company issued options to purchase an aggregate of 690,058 shares of the Company&amp;#8217;s common stock at exercise prices ranging from $1.11 to $3.06 per share.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;"&gt;Additionally, at the date of the Merger, Alliqua had outstanding employee options to purchase an aggregate of 57,822 shares of the post-Merger Company&amp;#8217;s common stock at exercise prices ranging from $21.00 to $656.40 per share to former Alliqua option holders that were assumed as part of the merger. All Alliqua employees were terminated in connection with the Merger; however, such options have provisions that extend the expiration date beyond the employees&amp;#8217; termination date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;"&gt;A summary of the Company&amp;#8217;s stock option activity during the six&amp;#160;months ended June&amp;#160;30, 2019 is as follows (in thousands, except exercise prices):&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 100%;"&gt;
&lt;table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Number&amp;#160;of&lt;br /&gt;
Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&lt;br /&gt;
Price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Weighted&amp;#160;Average&amp;#160;Remaining&lt;br /&gt;
Life&amp;#160;In&amp;#160;Years&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Intrinsic&lt;br /&gt;
Value&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;Outstanding, December&amp;#160;31, 2018&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
690&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
2.76&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;Alliqua options assumed in Merger&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;58&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
289.76&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;Outstanding, June&amp;#160;30, 2019&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
748&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
24.95&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 25%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
6.2&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
188&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;Exercisable, June&amp;#160;30, 2019&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
530&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
33.93&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 25%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
5.7&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.86%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
188&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.86%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;"&gt;A summary of the Company&amp;#8217;s stock options as of June&amp;#160;30, 2019 is as follows (in thousands, except exercise prices):&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 100%;"&gt;
&lt;div style="WIDTH: 100%;"&gt;
&lt;table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 36.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 22.5%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="3"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Options&amp;#160;Outstanding&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 35%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="5"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Options&amp;#160;Exercisable&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 36.5%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Range&amp;#160;of&amp;#160;Exercise&amp;#160;Price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Outstanding Number of Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Weighted Average Remaining Life In Years&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Exercisable Number of Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;$1.11 &amp;#8212; $1.38&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;$&lt;/div&gt;
1.11&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;73&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;$&lt;/div&gt;
1.11&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
2.5&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;73&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;1.39 &amp;#8212; 3.05&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;1.39&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;37&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;1.39&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
3.2&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;37&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;3.06 &amp;#8212; 20.99&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;3.06&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;580&lt;/font&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;3.06&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
7.5&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;362&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;21.00 &amp;#8212; 656.40&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;289.81&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;58&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;289.81&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
0.7&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;58&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="top" nowrap="nowrap"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;24.95&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;748&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;$&lt;/div&gt;
24.76&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
5.7&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;530&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;"&gt;The Company did not grant any stock options to employees during the six months ended June 30, 2019. Stock-based compensation expense recorded in research and development and general and administrative expenses was $150,000 and $136,000 for the six months ended June 30, 2018 and 2019, respectively. As of June 30, 2019, unrecognized stock-based compensation expense related to employees totaled approximately $395,000, which is expected to be recognized over approximately 1.5 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;"&gt;Stock-based compensation expense recorded in exchange for services related to non-employee options was $0 and $32,000 for the six months ended June 30, 2018 and 2019, respectively. As of June 30, 2019, unrecognized stock-based compensation expense related to unvested non-employees stock options was approximately $16,000, which is expected to be recognized over a weighted-average period of three months.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax id="c49927477_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">-58000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare id="c49927490_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD_xbrli-shares">0.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:DiscontinuedOperationsPolicyTextBlock id="c49927828_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Discontinued Operations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;Discontinued operations represent the activities of the AquaMed business&amp;nbsp;between the date of the Merger and the date of the spin-off. See &amp;#x2018;&lt;div style="display: inline; font-style: italic;"&gt;Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; &amp;#x2013; Reverse Merger&amp;#x2019;&lt;/div&gt;. There are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; ongoing activities or obligations associated with discontinued operations at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 30, 2019.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
</us-gaap:DiscontinuedOperationsPolicyTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted id="c49927494_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD_xbrli-shares">1.44</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:FairValueAdjustmentOfWarrants id="c49927706_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">95000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="c-3_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;Six&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;June&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;42
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Change in fair value of preferred stock warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;106
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Exchange of warrants upon Merger&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(234
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Fair value at end of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;42
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:20.15pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;Six&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;June&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Embedded derivative liability from the issuance of Notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;496
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Change in value of embedded derivatives&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(60
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Fair value at end of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;436
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="c49927825_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Fair Value of Financial Instruments &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;ASC 820-10, &lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt;Fair Value Measurement&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;, provides a framework for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. The standard defines fair value as an exit price, representing the amount that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. The standard also establishes a fair value hierarchy, which prioritizes the inputs used in measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt;Level&amp;nbsp;1&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#x2009;&amp;#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#x2009;&amp;#x2014; Inputs other than quoted prices included within Level&amp;nbsp;1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#x2009;&amp;#x2014; Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The following table presents the Company&amp;#x2019;s fair value hierarchy for its warrant liability measured at fair value on a recurring basis at December&amp;nbsp;31, 2018 (in thousands): &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:47.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;As&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Level&amp;nbsp;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;Financial liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;Warrant liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;Total financial liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:20.15pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The Level&amp;nbsp;3 derivative at December&amp;nbsp;31, 2018 consisted of a warrant liability of Private Adynxx that, at December&amp;nbsp;31, 2018, was exercisable into preferred shares that were potentially redeemable. In connection with the Merger, the warrants were exchanged into warrants that no longer met the definition of a derivative and thus, the balance was reclassified into equity during the six&amp;nbsp;months ended June&amp;nbsp;30, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The change in fair value of the warrant liability for the six&amp;nbsp;months ended June&amp;nbsp;30, 2018 and 2019 are as follows (in thousands): &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Six&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;June&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;42
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;Change in fair value of preferred stock warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;106
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;Exchange of warrants upon Merger&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(234
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;Fair value at end of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;42
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:20.15pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the Company&amp;#x2019;s term loan is based on the borrowing rate currently available to the Company for borrowings with similar terms and maturity and approximates its carrying value. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Derivative liability instruments are considered Level&amp;nbsp;3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level&amp;nbsp;3 liability instruments consist of the preferred stock warrant liability and derivative liability, for both of which there is no observable market data for the determination of fair value and requires significant management judgment and estimation. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;While the Company&amp;#x2019;s Notes contain embedded derivative liabilities, the Company determined that the fair value of these liabilities were zero at December&amp;nbsp;31, 2018 and June&amp;nbsp;30, 2019. See &amp;#x2018;&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt;Note 6&amp;#x2009;&amp;#x2014; Term Loans and Convertible Promissory Notes&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; for further discussion on the derivative liability activity. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The change in fair value of the derivative liability relating to the Notes for the six&amp;nbsp;months ended June&amp;nbsp;30, 2018 and 2019 is summarized below (in thousands): &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Six&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;June&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;Embedded derivative liability from the issuance of Notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;496
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;Change in value of embedded derivatives&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(60
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;Fair value at end of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;436
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:GeneralAndAdministrativeExpense id="c49927449_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">2317000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="c49927835_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock id="c49927798_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Impairment of Long-Lived Assets &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The Company&amp;#x2019;s long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. As of December&amp;nbsp;31, 2018 and June&amp;nbsp;30, 2019, the Company had not experienced any impairment losses on its long-lived assets. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
  <us-gaap:IncomeLossFromContinuingOperations id="c49927473_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">-7080000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="c49927486_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD_xbrli-shares">1.43</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeTaxPolicyTextBlock id="c49927814_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company's tax return.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="c49927723_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">1255000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="c49927725_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">475000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="c49927721_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">-57000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="c49927719_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">1611000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestExpense id="c49927465_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">2641000</us-gaap:InterestExpense>
  <us-gaap:InterestPaidNet id="c49927748_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">173000</us-gaap:InterestPaidNet>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="c-8_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 36pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; "&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 84%; border-bottom: 1px solid rgb(0, 0, 0); padding: 0px 0px 0px 2px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Period ending December 31&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); width: 0%; padding: 0px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Future Commitments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 0%; padding: 0px 0px 0px 2px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2019 (remaining 6 months)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;232&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;227&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;232&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;236&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;80&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total future minimum lease payments&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,007&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less: imputed interest&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(167&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;840&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:LesseeOperatingLeasesTextBlock id="s1285344_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;"&gt;Note 7.&amp;nbsp;&amp;nbsp;&amp;nbsp;Leases &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Company leases office facilities under a non-cancelable operating lease agreement expiring on December&amp;nbsp;31, 2019. The Company also leases a corporate office facility previously utilized by Alliqua through an operating lease agreement, located in Yardley, Pennsylvania that expires in 2023. Effective February&amp;nbsp;1, 2019, this property has been subleased to The Pinnacle Health Group, Inc. through April&amp;nbsp;20, 2023 and the Company receives monthly lease payments. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Future minimum payments under non-cancellable leases as of June&amp;nbsp;30, 2019 are as follows (in thousands): &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Period ending December 31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Future Commitments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;2019 (remaining 6 months)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt; 232&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt; 227&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt; 232&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt; 236&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt; 80&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt; 1,007&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Less: imputed interest&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt; (167)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt; 840&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Total operating lease expenses for the six&amp;nbsp;months ended June&amp;nbsp;30, 2018 and 2019 was $115,000 and $165,000, respectively, and are reflected in general and administrative expenses in the condensed consolidated statements of operations. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;As of June&amp;nbsp;30, 2019, the Company had no leases that were classified as a financing lease. As of June&amp;nbsp;30, 2019, the Company did not have additional operating and financing leases that have not yet commenced.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;During the six&amp;nbsp;months ended June&amp;nbsp;30, 2019, the Company recognized $42,000 of sublease income on its condensed consolidated statement of operations, which is recorded as an offset against general and administrative expenses. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="c49927739_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">2559000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="c49927732_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD"/>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="c49927729_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">-4223000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="c49927699_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">-7138000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="c49927831_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Recently Adopted Accounting Pronouncements &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt;Lease Accounting &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In February&amp;nbsp;2016, the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) issued ASU No. 2016-02, Leases (Topic 842) (&amp;#x201C;ASU 2016-02&amp;#x201D;). ASU 2016-02 is intended to improve financial reporting of leasing transactions by requiring organizations that lease assets to recognize assets and liabilities for the rights and obligations created by leases that extend more than twelve&amp;nbsp;months on the balance sheet. This accounting update also requires additional disclosures surrounding the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for financial statements issued for annual and interim periods beginning after December&amp;nbsp;15, 2018 for public business entities. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1)&amp;nbsp;its effective date or (2)&amp;nbsp;the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company adopted the new standard on January&amp;nbsp;1, 2019 and used the effective date as its date of initial application. Consequently, the Company has not adjusted prior period amounts. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The Company has elected the package of practical expedients permitted in ASC Topic 842. Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a)&amp;nbsp;whether the contracts contain a lease under ASC Topic 842, (b)&amp;nbsp;whether classification of the operating leases would be different in accordance with ASC Topic 842, or (c)&amp;nbsp;whether the unamortized initial direct costs would have met the definition of initial direct costs in ASC Topic 842 at lease commencement. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The most significant impact from the adoption of this standard was the recognition of right-of-use, or ROU, assets and lease obligations on the balance sheet for operating leases. This standard did not have a material impact on the Company&amp;#x2019;s cash flows from operations and operating results. As a result of the adoption of the new lease accounting guidance, the Company recognized on January&amp;nbsp;1, 2019 (a)&amp;nbsp;a lease liability of approximately $227,000, which represents the present value of the remaining lease payments of approximately $239,000, discounted using the Company&amp;#x2019;s incremental borrowing rate of 9.41%, and (b)&amp;nbsp;a right-of-use asset of approximately $227,000 which represents the lease liability of&amp;#x2009; $227,000. The ROU asset is being amortized over the remaining term of the lease of twelve&amp;nbsp;months from January&amp;nbsp;1, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Recent Accounting Pronouncements Not Yet Effective &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In August&amp;nbsp;2018, the FASB issued No. ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. This ASU is effective for fiscal&amp;nbsp;years beginning after December&amp;nbsp;15, 2019, including interim periods within that fiscal year, with early adoption permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In August&amp;nbsp;2018, the FASB issued ASU 2018-15, Intangibles&amp;#x2009;&amp;#x2014;&amp;#x2009;Goodwill and Other&amp;#x2009;&amp;#x2014;&amp;#x2009;Internal-Use Software (Subtopic 350-40): Customer&amp;#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, (&amp;#x201C;ASU 2018-15&amp;#x201D;). The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January&amp;nbsp;1, 2020 and early adoption is permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NonoperatingIncomeExpense id="c49927469_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">-94000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingExpenses id="c49927457_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">4345000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="c49927461_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">-4345000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeaseExpense id="c49928165_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">165000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock id="s1285331_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; font-family: times new roman; DISPLAY: inline;"&gt;
&lt;div style="font-family;"&gt;
&lt;div style="font-weight: bold; display: inline;"&gt;Note
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;1.&lt;/div&gt;
&amp;#160;Organization and Basis of Presentation&lt;/div&gt;
&lt;/div&gt;
&lt;div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; font-family: 'Times New Roman', Times, serif; MARGIN-TOP: 0pt;"&gt;
&lt;div style="font-weight: bold; display: inline;"&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="FONT-SIZE: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; MARGIN: 0pt 7.2pt 0pt 0pt;"&gt;
&lt;div style="FONT-STYLE: italic; DISPLAY: inline;"&gt;
&lt;div style="font-weight: bold; display: inline;"&gt;The Company&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="FONT-SIZE: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; MARGIN: 0pt 7.2pt 0pt 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;On
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;May 3, 2019,&lt;/div&gt;
Adynxx, Inc. (&amp;#8220;Adynxx&amp;#8221; or the &amp;#8220;Company&amp;#8221;), formerly known as "Alliqua BioMedical, Inc.," or Alliqua completed its reverse merger with what was then known as Adynxx, Inc., or Private Adynxx, which we refer to as the Merger. This transaction was accounted for as a reverse merger. See
&lt;div style="FONT-STYLE: italic; DISPLAY: inline;"&gt;&amp;#8216;Note
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;3&lt;/div&gt;
&amp;#8211; Reverse Merger&amp;#8217;&lt;/div&gt;
..&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;The Company is a clinical stage biopharmaceutical company focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company is primarily engaged in developing initial product technology, recruiting personnel, and raising capital.&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;
&lt;div style="font-weight: bold; display: inline;"&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="font-family;"&gt;
&lt;div style="FONT-STYLE: italic; DISPLAY: inline;"&gt;
&lt;div style="font-weight: bold; display: inline;"&gt;Basis of Presentation&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="font-family;"&gt;
&lt;div style="font-weight: bold; display: inline;"&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;These unaudited financial statements represent the condensed consolidated financial statements of Adynxx and, for periods prior to the Merger, the condensed consolidated financial statements of Private Adynxx. The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) for interim financial information and pursuant to the instructions of the SEC on Form
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;10&lt;/div&gt;
-Q and Article
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;10&lt;/div&gt;
of Regulation S-
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;X&lt;/div&gt;
of the SEC. Accordingly, they do
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;not&lt;/div&gt;
include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the Company&amp;#8217;s financial position on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the periods ended
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;June 30, 2018&lt;/div&gt;
and
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;2019&lt;/div&gt;
are
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;not&lt;/div&gt;
necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the periods ended
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;June 30, 2018&lt;/div&gt;
and
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;2019&lt;/div&gt;
is unaudited.&amp;#160;These unaudited condensed consolidated financial statements should be read in conjunction with the Company&amp;#8217;s consolidated financial statements and the notes thereto as set forth in the Company&amp;#8217;s Form
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;8&lt;/div&gt;
-K/A filed with the SEC on
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;June 10, 2019.&lt;/div&gt;
&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;&lt;span style="FONT-SIZE: 13px; TEXT-DECORATION: none; font-family: Times New Roman; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; text-align: left; ORPHANS: 2; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: transparent; TEXT-INDENT: 26px; -webkit-text-stroke-width: 0px;"&gt;All share and per share data, for all periods presented, of the issued and outstanding common stock of Adynxx, Inc., have been retroactively restated to reflect the exchange ratio used in the Merger of 0.0359 shares of capital stock in exchange for each share of Private Adynxx, Inc. capital stock outstanding immediately prior to the Merger (which exchange ratio reflects a 1-for-6 reverse stock split of the issued and outstanding capital stock of Alliqua BioMedical, Inc. effected on May 3, 2019 immediately prior to the reverse merger).&lt;/span&gt;&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;&lt;span style="FONT-SIZE: 13px; TEXT-DECORATION: none; font-family: Times New Roman; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; text-align: left; ORPHANS: 2; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: transparent; TEXT-INDENT: 26px; -webkit-text-stroke-width: 0px;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amount of assets, liabilities, revenue, costs, expenses and other (expenses) income that are reported in the condensed consolidated financial statements and accompanying disclosures. These estimates are based on management&amp;#8217;s best knowledge of current events, historical experience, actions that the Company may undertake in the future and on various other assumptions that are believed to be reasonable under the circumstances. As a result, actual results may be different from these estimates.&lt;/span&gt;&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;
&lt;div style="FONT-STYLE: italic; DISPLAY: inline;"&gt;
&lt;div style="font-weight: bold; display: inline;"&gt;Liquidity&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As of
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;June 30, 2019,&lt;/div&gt;
the Company had
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;$24,000&lt;/div&gt;
in cash and cash equivalents, had term loans&amp;#160;(&amp;#8220;Term Loans&amp;#8221;), including accrued interest outstanding, of
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;$3.0&lt;/div&gt;
million from Oxford Finance, LLC&amp;#160;(&amp;#8220;Oxford&amp;#8221;), and
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;$5.6&lt;/div&gt;
million aggregate principal amount of convertible promissory notes (&amp;#8220;Notes&amp;#8221;), including accrued interest, outstanding. From inception through
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;June 30, 2019,&lt;/div&gt;
the Company had an accumulated deficit of approximately
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;$44.4&lt;/div&gt;
million. The Company expects to incur substantial losses in future periods. The Company is subject to risks common to companies in the clinical stage, including, but
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;not&lt;/div&gt;
limited to, development of new products, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product development plans. The Company has a limited operating history and has yet to generate any revenues from customers. There is
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;no&lt;/div&gt;
guarantee that profitable operations, if ever achieved, could be sustained on a continuing basis.&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;In
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;April 2019&lt;/div&gt;
and
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;May 2019,&lt;/div&gt;
the Company issued Notes to current investors and received an additional
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;$2.0&lt;/div&gt;
million and
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;$0.5&lt;/div&gt;
million, respectively. The Notes accrue interest at
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;8%&lt;/div&gt;
per annum and mature on the
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;first&lt;/div&gt;
anniversary of the applicable issuance date. For further details, see the section below titled
&lt;div style="FONT-STYLE: italic; DISPLAY: inline;"&gt;&amp;#8216;Note
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;6&lt;/div&gt;
- Term Loans and Convertible Promissory Notes&amp;#8217;.&lt;/div&gt;
&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="FONT-SIZE: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; MARGIN: 0pt;"&gt;&lt;/div&gt;
&lt;div style="font-family;"&gt;The Company plans to finance its operations and capital funding needs through equity and/or debt financing. However, there can be
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;no&lt;/div&gt;
assurance that additional funding will be available to the Company on acceptable terms on a timely basis, if at all, or that the Company will generate sufficient cash from operations to adequately fund operating needs or ultimately achieve profitability. The conditions above, among others, raise substantial doubt about the ability of the Company to continue as a going concern within
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;one&lt;/div&gt;
year after the date of the issuance of the financial statements.&lt;/div&gt;
&lt;div style="font-family;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font-family;"&gt;The accompanying financial statements do
&lt;div style="FONT-STYLE: normal; DISPLAY: inline;"&gt;not&lt;/div&gt;
include any adjustments that might result from the outcome of these uncertainties.&lt;/div&gt;
&lt;/div&gt;
</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:PaidInKindInterest id="c49927714_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">2304000</us-gaap:PaidInKindInterest>
  <us-gaap:PaymentsOfDividends id="c49927839_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">0</us-gaap:PaymentsOfDividends>
  <us-gaap:PreferredStockTextBlock id="s1285346_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.&lt;/div&gt;&amp;nbsp;Redeemable Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;Private Adynxx had&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,034,548&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;/div&gt; shares of Series A convertible preferred stock issued and outstanding, and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,833,387&lt;/div&gt;&lt;/div&gt; shares of Series B convertible preferred stock issued and outstanding. During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019,&lt;/div&gt; prior to the Merger, an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;367,041&lt;/div&gt; shares were issued upon conversion of convertible notes described in &lt;div style="display: inline; font-style: italic;"&gt;&amp;#x2018;Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt; - Term Loans and Convertible Promissory Notes&amp;#x2019;.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Upon the consummation of the Merger, all outstanding shares of Series A and Series B convertible preferred stock were cancelled and exchanged for shares of the Company&amp;#x2019;s common stock. Following the Merger, Private Adynxx survived as a wholly-owned subsidiary of new Adynxx, Inc. and adopted a new certificate of incorporation with &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&lt;/div&gt; shares of preferred stock authorized or outstanding. The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,000,000&lt;/div&gt; shares of preferred stock authorized under its certificate of incorporation, as amended.&lt;/div&gt;&lt;/div&gt;
</us-gaap:PreferredStockTextBlock>
  <us-gaap:ProceedsFromRelatedPartyDebt id="c49927737_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">3996000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="s1285337_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;"&gt;Note 4.&amp;nbsp;&amp;nbsp;&amp;nbsp;Property and Equipment, Net &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Property and equipment, net, consist of the following (in thousands): &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;June&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;29
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;29
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Office equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Total property and equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;51
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;51
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Less accumulated depreciation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(45
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Depreciation expense at December 31, 2018 and for the six&amp;nbsp;months ended June&amp;nbsp;30, 2018 and 2019 was $8,000, $4,000 and $4,000, respectively. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="c49927796_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Property and Equipment, Net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line method over the estimated useful lives of the assets, generally &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="c-4_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;June&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;29
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;29
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Office equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Total property and equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;51
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;51
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Less accumulated depreciation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(45
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="s1285351_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;"&gt;Note 11.&amp;nbsp;&amp;nbsp;&amp;nbsp;Related-Party Transactions &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;At June&amp;nbsp;30, 2019, the Company had $5.5&amp;nbsp;million aggregate principal amount of outstanding convertible notes issued to a significant shareholder. &amp;#x2018;&lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Note 6&amp;#x2009;&amp;#x2014;&amp;#x2009;Term Loans and Convertible Promissory Notes&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In connection with the Merger, Alliqua&amp;#x2019;s existing CEO resigned from the company and received severance pay of&amp;#x2009; $1,091,000. As such amounts were accrued by Alliqua prior to the Merger, this severance payment had no impact to our condensed consolidated statement of operations for six&amp;nbsp;months ended June&amp;nbsp;30, 2019.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:RepaymentsOfLongTermDebt id="c49927735_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">1437000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:ResearchAndDevelopmentExpense id="c49927445_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">3226000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="c49927806_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Research and Development&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, preclinical studies, clinical studies performed by contract research organizations (&amp;#x201c;CROs&amp;#x201d;), materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development costs, including clinical study costs, to expense when incurred.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="c49927751_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">227000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="c-6_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;December&amp;nbsp;31,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;June&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Payroll and related expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;241
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;508
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued term loan final payment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;421
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;569
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued clinical trial expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Professional fees and other costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;195
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;395
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total accrued liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;857
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,480
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;
&lt;/div&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="c-2_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; "&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;As of December 31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Level 1 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Level 2 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Level 3 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Total &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;140&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;140&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Total financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;140&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;140&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;
</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock id="c-10_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;WIDTH: 100%;"&gt;
&lt;table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 36.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 22.5%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="3"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Options&amp;#160;Outstanding&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 35%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="5"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Options&amp;#160;Exercisable&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 36.5%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Range&amp;#160;of&amp;#160;Exercise&amp;#160;Price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Outstanding Number of Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Weighted Average Remaining Life In Years&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Exercisable Number of Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;$1.11 &amp;#8212; $1.38&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;$&lt;/div&gt;
1.11&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;73&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;$&lt;/div&gt;
1.11&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
2.5&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;73&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;1.39 &amp;#8212; 3.05&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;1.39&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;37&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;1.39&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
3.2&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;37&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;3.06 &amp;#8212; 20.99&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;3.06&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;580&lt;/font&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;3.06&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
7.5&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;362&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;21.00 &amp;#8212; 656.40&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;289.81&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;58&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;289.81&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
0.7&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;58&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="top" nowrap="nowrap"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;24.95&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;748&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;$&lt;/div&gt;
24.76&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
5.7&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;530&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="c-9_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;" /&gt;
&lt;div style="WIDTH: 100%;"&gt;
&lt;table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Number&amp;#160;of&lt;br /&gt;
Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&lt;br /&gt;
Price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Weighted&amp;#160;Average&amp;#160;Remaining&lt;br /&gt;
Life&amp;#160;In&amp;#160;Years&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;"&gt;Intrinsic&lt;br /&gt;
Value&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;Outstanding, December&amp;#160;31, 2018&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
690&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
2.76&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;Alliqua options assumed in Merger&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;58&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
289.76&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;Outstanding, June&amp;#160;30, 2019&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
748&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
24.95&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 25%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
6.2&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
188&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;Exercisable, June&amp;#160;30, 2019&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
530&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
33.93&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 25%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
5.7&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&lt;font style="FONT-SIZE: 10pt; DISPLAY: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.86%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="FLOAT: left;"&gt;&lt;/div&gt;
188&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;
&lt;td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.86%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom"&gt;
&lt;p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" /&gt;
&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensation id="c49927704_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">168000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="c49928274_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-06-30" unitRef="xbrli-shares"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="c49928271_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD_xbrli-shares"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="c49928275_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD_xbrli-shares"/>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="c49927803_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The Company uses the Black-Scholes option-pricing model (the "Black-Scholes model") as the method for determining the estimated fair value of stock options.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Expected Term&amp;#x2014;&lt;/div&gt;The expected term represents the period that the Company's stock-based awards are expected to be outstanding and is determined using the simplified method.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Expected Volatility&amp;#x2014;&lt;/div&gt;Expected volatility is estimated using comparable public companies&amp;#x2019; volatility for similar terms.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Expected Dividend&amp;#x2014;&lt;/div&gt;The Black-Scholes model calls for a single expected dividend yield as an input. Other than the dividend paid in connection with the Merger, the Company has never paid dividends and has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; plans to pay dividends.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Risk-Free Interest Rate&amp;#x2014;&lt;/div&gt;The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;zero&lt;/div&gt;-coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="c49928284_20190630" contextRef="D2019-01-01_2019-06-30">P5Y255D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="c49928280_20190630" contextRef="D2019-01-01_2019-06-30">P6Y73D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="c49928340_20190630" contextRef="D2019-01-01_2019-06-30">P5Y255D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="s1285332_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;"&gt;Note 2.&amp;nbsp;&amp;nbsp;&amp;nbsp;Summary of Significant Accounting Policies &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Use of Estimates &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Actual results could differ from those estimates and such differences could be material to the Company&amp;#x2019;s financial position and results of operations. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Significant estimates and assumptions include the valuation of equity instruments and equity-linked instruments, including the valuation of the Company&amp;#x2019;s common stock and the valuation of the Company&amp;#x2019;s common stock options for purposes of accounting for stock-based compensation, and accruals for clinical trials and the valuation allowances on deferred tax assets. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation insured limits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company&amp;#x2019;s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company&amp;#x2019;s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company&amp;#x2019;s ability to attract and retain employees necessary to support its growth. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Company&amp;#x2019;s postoperative pain reduction product candidate, brivoligide, is an oligonucleotide. The Company currently uses Nitto-Denko Avecia, Inc. (&amp;#x201C;Avecia&amp;#x201D;) as a single supplier for the brivoligide drug substance. There are currently a limited number of oligonucleotide manufacturers with commercial scale capabilities globally. While the Company intends to develop secondary sources for manufacturing of its drug candidates in the future, there can be no assurance that it will be able to do so on commercially reasonable terms, or at all. Any interruption in the supply of this key material could significantly delay the research and development process or increase the expenses for development and commercialization of the Company&amp;#x2019;s product candidates. The quality of materials can be critical to the performance of a drug delivery technology. Therefore, the lack of a reliable source that provides a consistent supply of high quality materials would harm the Company. At June&amp;nbsp;30, 2019, this vendor&amp;#x2019;s activity was not material to total accounts payable. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;At December&amp;nbsp;31, 2018, three vendors represented 52%, 26% and 15% of total accounts payable. Two of these vendors supported general and administrative activities, primarily associated with the Merger and next round of equity financing, which accounted for 67% of the total accounts payable. The remaining vendor supported clinical study activities. At June&amp;nbsp;30, 2019, three vendors represented 26%, 22% and 17% of total accounts payable, respectively. Two of these vendors supported general and administrative activities associated with the Merger and the next round of equity financing, which accounted for 44% of the total accounts payable. The remaining supported clinical study activities. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Clinical Trial Accruals &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Company&amp;#x2019;s clinical trial accruals are based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The Company accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, the Company modifies the estimates of accrued expenses accordingly. To date, the Company has had no significant adjustments to accrued clinical trial expenses. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Cash and Cash Equivalents &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Company considers all highly liquid investments purchased with a maturity of three&amp;nbsp;months or less on the date of acquisition to be cash and cash equivalents. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Property and Equipment, Net &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line method over the estimated useful lives of the assets, generally three to five&amp;nbsp;years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Impairment of Long-Lived Assets &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Company&amp;#x2019;s long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. As of December&amp;nbsp;31, 2018 and June&amp;nbsp;30, 2019, the Company had not experienced any impairment losses on its long-lived assets. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Restricted Cash &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;At December 31, 2018 and June 30, 2019, the Company had $55,000 restricted and held by a bank as collateral for a letter of credit provided to the Company&amp;#x2019;s facility landlord. In addition, as of June 30, 2019, the Company had $200,000 restricted from withdrawal and held by a bank in the form of a secured money market account as collateral for Oxford in conjunction with a debt amendment that occurred in January 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Stock-Based Compensation &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Company uses the Black-Scholes option-pricing model (the &amp;#x201C;Black-Scholes model&amp;#x201D;) as the method for determining the estimated fair value of stock options. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Expected Term&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;&amp;#x2009;&amp;#x2014; The expected term represents the period that the Company&amp;#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Expected Volatility&amp;#x2009;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Expected volatility is estimated using comparable public companies&amp;#x2019; volatility for similar terms. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Expected Dividend&amp;#x2009;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Black-Scholes model calls for a single expected dividend yield as an input. Other than the dividend paid in connection with the Merger, the Company has never paid dividends and has no plans to pay dividends. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Risk-Free Interest Rate&amp;#x2009;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Research and Development &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, preclinical studies, clinical studies performed by contract research organizations (&amp;#x201C;CROs&amp;#x201D;), materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development costs, including clinical study costs, to expense when incurred. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Collaboration Agreement &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In June&amp;nbsp;2018, the Company entered into a collaboration agreement with twoXAR, an artificial intelligence-driven drug discovery company, in order to identify potential product candidates for the treatment of endometriosis. In May&amp;nbsp;2019, the Company made a collaboration initiation payment of $75,000, which was charged to research and development expenses for the six&amp;nbsp;months ended June&amp;nbsp;30, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In June&amp;nbsp;2019, Adynxx received an initial set of candidate predictions from twoXAR. The Company has initiated a review of the potential products to determine if any are viable candidates for further research and development. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Grant Reimbursements &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In December&amp;nbsp;2018, the Company received a Notice of Award from the National Institute on Drug Abuse (&amp;#x201C;NIDA&amp;#x201D;), part of the National Institutes of Health (&amp;#x201C;NIH&amp;#x201D;), to support the clinical development of its lead product candidate, brivoligide. NIH grants provide funds for certain types of expenditures in connection with research and development activities over a contractually defined period. The maximum funding expected to be available under this grant for qualified expenditures over the two-year period through December&amp;nbsp;2020 is&amp;#x2009;approximately $5.7&amp;nbsp;million. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;On January&amp;nbsp;1, 2019, the Company adopted Accounting Standards Update (ASU) 2018-08, &amp;#x201C;Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.&amp;#x201D; Based on this guidance, the Company determined that grant payments received met the definition of a &amp;#x2018;conditional contribution&amp;#x2019; (versus an exchange contract) because (i)&amp;nbsp;the Company has limited discretion in the way the funds may be spent, which creates a barrier to entitlement, and (ii) the grant contains provisions that release the awarding agency from the obligation to transfer funds that are not expended at the time the award is terminated. The Company recognizes grant reimbursements as a contra operating expense and reflects this as a component of its loss from operations in the period during which the qualifying expenses are incurred and the related services rendered, provided that the applicable performance obligations have been met. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;For the six&amp;nbsp;months ended June&amp;nbsp;30, 2019, the Company incurred qualified expenses and recognized $1,198,000 of grant reimbursements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Income Taxes &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company&amp;#x2019;s tax return. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Convertible Preferred Stock Warrants &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;At December&amp;nbsp;31, 2018, freestanding warrants to acquire shares of convertible preferred stock were classified as liabilities on the accompanying balance sheet. These warrants were subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. In connection with the Merger, the warrants were exchanged into warrants that no longer met the definition of a derivative and thus, $234,000 of warrant liabilities was reclassified into equity during the six&amp;nbsp;months ended June&amp;nbsp;30, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Debt Modifications and Extinguishments &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;When the Company modifies debt, it does so in accordance with Accounting Standards Codification (&amp;#x201C;ASC&amp;#x201D;) 470-50, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Debt: Modifications and Extinguishments&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;, which requires modification to debt instruments to be evaluated to assess whether the modifications are considered &amp;#x201C;substantial modifications&amp;#x201D;. A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, the Company determined that the October&amp;nbsp;2018 modification of the March&amp;nbsp;2018 and September&amp;nbsp;2018 Notes, to add an additional conversion option in the event of a reverse merger, was considered to be a &amp;#x201C;substantial modification&amp;#x201D;. As a result, it treated this modification as an &amp;#x2018;extinguishment&amp;#x2019; of those debts and recognized $11,000 of net gain from this debt extinguishment in other income in October&amp;nbsp;2018. All other changes to debt provisions were not considered substantial and were treated as debt modifications. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Derivative Instruments &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;ASC 815-15, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Derivatives and Hedging: Embedded Derivatives&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;, generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a)&amp;nbsp;the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b)&amp;nbsp;the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)&amp;nbsp;a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirement of ASC 815. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;At December 31, 2018 and June&amp;nbsp;30, 2019, the Company maintained outstanding Notes which contained various embedded derivative features. In particular, these Notes contained the following features: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;(1)&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A share settled redemption in a qualified preferred stock financing; and &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;(2)&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The right to an accelerated cash repayment in the event of a change in control. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:1pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;These embedded features were not considered clearly and closely related to the debt host, therefore, they were bifurcated and accounted for separately from the debt host as a derivative liability. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in the statement of operations at each period end while such instruments are outstanding. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;As of December 31, 2018 and June&amp;nbsp;30, 2019, the Company determined that there was no fair value associated with the embedded derivatives that remained with the outstanding convertible notes. See &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;&amp;#x2018;Note&amp;nbsp;6&amp;#x2009;&amp;#x2014; Term Loans and Convertible Promissory Notes&amp;#x2019; &lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;for further discussion of the Notes and the bifurcated derivative liability. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Fair Value of Financial Instruments &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;ASC 820-10, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Fair Value Measurement&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;, provides a framework for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. The standard defines fair value as an exit price, representing the amount that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. The standard also establishes a fair value hierarchy, which prioritizes the inputs used in measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Level&amp;nbsp;1&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;&amp;#x2009;&amp;#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;&amp;#x2009;&amp;#x2014; Inputs other than quoted prices included within Level&amp;nbsp;1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;&amp;#x2009;&amp;#x2014; Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The following table presents the Company&amp;#x2019;s fair value hierarchy for its warrant liability measured at fair value on a recurring basis at December&amp;nbsp;31, 2018 (in thousands): &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:47.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;As&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;Level&amp;nbsp;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Financial liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Warrant liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Total financial liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:20.15pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Level&amp;nbsp;3 derivative at December&amp;nbsp;31, 2018 consisted of a warrant liability of Private Adynxx that, at December&amp;nbsp;31, 2018, was exercisable into preferred shares that were potentially redeemable. In connection with the Merger, the warrants were exchanged into warrants that no longer met the definition of a derivative and thus, the balance was reclassified into equity during the six&amp;nbsp;months ended June&amp;nbsp;30, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The change in fair value of the warrant liability for the six&amp;nbsp;months ended June&amp;nbsp;30, 2018 and 2019 are as follows (in thousands): &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;Six&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;June&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;42
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Change in fair value of preferred stock warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;106
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Exchange of warrants upon Merger&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(234
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Fair value at end of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;42
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:20.15pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the Company&amp;#x2019;s term loan is based on the borrowing rate currently available to the Company for borrowings with similar terms and maturity and approximates its carrying value. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Derivative liability instruments are considered Level&amp;nbsp;3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level&amp;nbsp;3 liability instruments consist of the preferred stock warrant liability and derivative liability, for both of which there is no observable market data for the determination of fair value and requires significant management judgment and estimation. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;While the Company&amp;#x2019;s Notes contain embedded derivative liabilities, the Company determined that the fair value of these liabilities were zero at December&amp;nbsp;31, 2018 and June&amp;nbsp;30, 2019. See &amp;#x2018;&lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Note 6&amp;#x2009;&amp;#x2014; Term Loans and Convertible Promissory Notes&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt; for further discussion on the derivative liability activity. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The change in fair value of the derivative liability relating to the Notes for the six&amp;nbsp;months ended June&amp;nbsp;30, 2018 and 2019 is summarized below (in thousands): &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;Six&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;June&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Embedded derivative liability from the issuance of Notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;496
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Change in value of embedded derivatives&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(60
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Fair value at end of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;436
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Discontinued Operations &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Discontinued operations represent the activities of the AquaMed business between the date of the Merger and the date of the spin-off. See &amp;#x2018;&lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Note 3&amp;#x2009;&amp;#x2014; Reverse Merger&amp;#x2019;&lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;. There are no ongoing activities or obligations associated with discontinued operations at June&amp;nbsp;30, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Recently Adopted Accounting Pronouncements &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Lease Accounting &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In February&amp;nbsp;2016, the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) issued ASU No. 2016-02, Leases (Topic 842) (&amp;#x201C;ASU 2016-02&amp;#x201D;). ASU 2016-02 is intended to improve financial reporting of leasing transactions by requiring organizations that lease assets to recognize assets and liabilities for the rights and obligations created by leases that extend more than twelve&amp;nbsp;months on the balance sheet. This accounting update also requires additional disclosures surrounding the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for financial statements issued for annual and interim periods beginning after December&amp;nbsp;15, 2018 for public business entities. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1)&amp;nbsp;its effective date or (2)&amp;nbsp;the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company adopted the new standard on January&amp;nbsp;1, 2019 and used the effective date as its date of initial application. Consequently, the Company has not adjusted prior period amounts. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The Company has elected the package of practical expedients permitted in ASC Topic 842. Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a)&amp;nbsp;whether the contracts contain a lease under ASC Topic 842, (b)&amp;nbsp;whether classification of the operating leases would be different in accordance with ASC Topic 842, or (c)&amp;nbsp;whether the unamortized initial direct costs would have met the definition of initial direct costs in ASC Topic 842 at lease commencement. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The most significant impact from the adoption of this standard was the recognition of right-of-use, or ROU, assets and lease obligations on the balance sheet for operating leases. This standard did not have a material impact on the Company&amp;#x2019;s cash flows from operations and operating results. As a result of the adoption of the new lease accounting guidance, the Company recognized on January&amp;nbsp;1, 2019 (a)&amp;nbsp;a lease liability of approximately $227,000, which represents the present value of the remaining lease payments of approximately $239,000, discounted using the Company&amp;#x2019;s incremental borrowing rate of 9.41%, and (b)&amp;nbsp;a right-of-use asset of approximately $227,000 which represents the lease liability of&amp;#x2009; $227,000. The ROU asset is being amortized over the remaining term of the lease of twelve&amp;nbsp;months from January&amp;nbsp;1, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Recent Accounting Pronouncements Not Yet Effective &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In August&amp;nbsp;2018, the FASB issued No. ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. This ASU is effective for fiscal&amp;nbsp;years beginning after December&amp;nbsp;15, 2019, including interim periods within that fiscal year, with early adoption permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In August&amp;nbsp;2018, the FASB issued ASU 2018-15, Intangibles&amp;#x2009;&amp;#x2014;&amp;#x2009;Goodwill and Other&amp;#x2009;&amp;#x2014;&amp;#x2009;Internal-Use Software (Subtopic 350-40): Customer&amp;#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, (&amp;#x201C;ASU 2018-15&amp;#x201D;). The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January&amp;nbsp;1, 2020 and early adoption is permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="c49928270_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-06-30" unitRef="xbrli-shares"/>
  <us-gaap:SubleaseIncome id="c49928176_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30" unitRef="iso4217-USD">42000</us-gaap:SubleaseIncome>
  <us-gaap:SubsequentEventsTextBlock id="s1285352_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;"&gt;Note 12.&amp;nbsp;&amp;nbsp;&amp;nbsp;Subsequent Events &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In July&amp;nbsp;2019, affiliates of Domain Partners, LLC, a significant shareholder of the Company, purchased from the Company $600,000 aggregate principal amount of Notes. The proceeds from the issuance of the Notes will be used for general corporate purposes and working capital. These Notes accrue simple interest on the outstanding principal amount at a rate of 8% per annum and mature one year from the date of issuance. &lt;/font&gt;
		&lt;/p&gt;
&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;On August&amp;nbsp;1, 2019 and August&amp;nbsp;2, 2019, the Company&amp;#x2019;s board of directors and a majority of the Company&amp;#x2019;s stockholders, respectively, approved a reverse stock split at a range of between 1-for-2 and 1-for-10, with the final exchange ratio to be determined by the board of directors, which as of the date of filing has not yet occurred. The share and per share information contained in the financial statements and footnotes do not reflect the impact of any such reverse stock split.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In August 2019, the Company and Oxford agreed to amend the Loan Agreement pursuant to a ninth amendment to the Loan Agreement. The ninth amendment provides for two additional months of interest-only payments by the Company, contingent upon the completion of certain financing events by specified dates. The ninth amendment also clarifies that the secured funds will be released by Oxford upon the receipt by the Company of net proceeds of at least $10 million from the issuance and sale of its equity securities.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock id="s1285339_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;"&gt;Note 5.&amp;nbsp;&amp;nbsp;&amp;nbsp;Other Balance Sheet Information &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Prepaid and other current assets consist of the following (in thousands): &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;June&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Prepaid clinical trial expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;435
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Equity issuance costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;343
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Prepaid insurance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;670
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Other prepaid expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;174
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Total prepaid and other current assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,622
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Accrued liabilities consist of the following (in thousands): &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;June&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Payroll and related expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;241
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;508
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Accrued term loan final payment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;421
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;569
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Accrued clinical trial expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Professional fees and other costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;195
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;395
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;Total accrued liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;857
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,480
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <us-gaap:UseOfEstimates id="c49927785_20190630" contextRef="D2019-01-01_2019-06-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Actual results could differ from those estimates and such differences could be material to the Company&amp;#x2019;s financial position and results of operations.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Significant estimates and assumptions include the valuation of equity instruments and equity-linked instruments, including the valuation of the Company&amp;#x2019;s common stock and the valuation of the Company&amp;#x2019;s common stock options for purposes of accounting for stock-based compensation, and accruals for clinical trials and the valuation allowances on deferred tax assets.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="c49927498_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30" unitRef="xbrli-shares">4966491</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:AllocatedShareBasedCompensationExpense id="c49928227_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember" unitRef="iso4217-USD">136000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="c49928232_20190630" contextRef="D2019-01-01_2019-06-30_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember">P1Y182D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="c49928243_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:AllocatedShareBasedCompensationExpense id="c49928237_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-AwardTypeAxis_adyx-NonEmployeeOptionsMember" unitRef="iso4217-USD">32000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="c49928242_20190630" contextRef="D2019-01-01_2019-06-30_us-gaap-AwardTypeAxis_adyx-NonEmployeeOptionsMember">P90D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <adyx:BeneficialConversionFeatureConversionOfConvertibleNote id="c49928142_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" unitRef="iso4217-USD">2100000</adyx:BeneficialConversionFeatureConversionOfConvertibleNote>
  <us-gaap:ConcentrationRiskPercentage1 id="c49927807_20190630" decimals="4" contextRef="D2019-01-01_2019-06-30_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" unitRef="xbrli-pure">0.44</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="c49927799_20190630" decimals="4" contextRef="D2019-01-01_2019-06-30_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor1Member" unitRef="xbrli-pure">0.26</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="c49927802_20190630" decimals="4" contextRef="D2019-01-01_2019-06-30_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor2Member" unitRef="xbrli-pure">0.22</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="c49927804_20190630" decimals="4" contextRef="D2019-01-01_2019-06-30_us-gaap-ConcentrationRiskByBenchmarkAxis_adyx-AccountsPayable1Member_us-gaap-ConcentrationRiskByTypeAxis_us-gaap-SupplierConcentrationRiskMember_us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_adyx-Vendor3Member" unitRef="xbrli-pure">0.17</us-gaap:ConcentrationRiskPercentage1>
  <adyx:DebtInstrumentConvertiblePreferredStockProceedsTrigger id="c49928118_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2019AndModifiedDecember2018NotesMember" unitRef="iso4217-USD">5000000</adyx:DebtInstrumentConvertiblePreferredStockProceedsTrigger>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="c49927999_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="c49927995_20190630" xsi:nil="true" contextRef="D2019-01-01_2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 id="c49927983_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">234000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="c49927979_20190630" decimals="-3" contextRef="D2019-01-01_2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">94000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature id="c49928039_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-IncomeStatementLocationAxis_us-gaap-InterestExpenseMember" unitRef="iso4217-USD">2100000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <adyx:CollaborationInitiationPayment id="c49927953_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-IncomeStatementLocationAxis_us-gaap-ResearchAndDevelopmentExpenseMember" unitRef="iso4217-USD">75000</adyx:CollaborationInitiationPayment>
  <us-gaap:InterestExpenseDebt id="c49928114_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">336000</us-gaap:InterestExpenseDebt>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="c49927832_20190630" contextRef="D2019-01-01_2019-06-30_srt-RangeAxis_srt-MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="c49927829_20190630" contextRef="D2019-01-01_2019-06-30_srt-RangeAxis_srt-MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="c49928307_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange1Member" unitRef="iso4217-USD_xbrli-shares">1.11</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="c49928308_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange1Member" unitRef="iso4217-USD_xbrli-shares">1.38</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="c49928312_20190630" contextRef="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange1Member">P2Y182D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="c49928314_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange2Member" unitRef="iso4217-USD_xbrli-shares">1.39</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="c49928315_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange2Member" unitRef="iso4217-USD_xbrli-shares">3.05</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="c49928319_20190630" contextRef="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange2Member">P3Y73D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="c49928321_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange3Member" unitRef="iso4217-USD_xbrli-shares">3.06</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="c49928322_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange3Member" unitRef="iso4217-USD_xbrli-shares">20.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="c49928326_20190630" contextRef="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange3Member">P7Y182D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="c49928328_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange4Member" unitRef="iso4217-USD_xbrli-shares">21.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="c49928329_20190630" decimals="INF" contextRef="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange4Member" unitRef="iso4217-USD_xbrli-shares">656.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="c49928333_20190630" contextRef="D2019-01-01_2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange4Member">P255D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ProceedsFromNotesPayable id="c49927776_20190630" decimals="INF" contextRef="D2019-04-01_2019-04-30_us-gaap-DebtInstrumentAxis_adyx-FirstNoteToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember" unitRef="iso4217-USD">2000000</us-gaap:ProceedsFromNotesPayable>
  <adyx:BeneficialConversionFeatureConversionOfConvertibleNote id="c49927553_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30" unitRef="iso4217-USD"/>
  <adyx:EquityImpactOfSpinoff id="c49927607_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30" unitRef="iso4217-USD">-1000</adyx:EquityImpactOfSpinoff>
  <adyx:EquityIssuanceCostsPaidInStock id="c49927589_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30" unitRef="iso4217-USD"/>
  <adyx:ExchangeOfWarrantsUponMerger id="c49927598_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30" unitRef="iso4217-USD">234000</adyx:ExchangeOfWarrantsUponMerger>
  <adyx:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock id="c49927562_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30" unitRef="iso4217-USD">34015000</adyx:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927616_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30" unitRef="iso4217-USD">84000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:OperatingLeaseExpense id="c49928164_20190630" decimals="INF" contextRef="D2019-04-01_2019-06-30" unitRef="iso4217-USD">98000</us-gaap:OperatingLeaseExpense>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="c49927579_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30" unitRef="iso4217-USD">2000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="c49927544_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30" unitRef="iso4217-USD"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="c49928220_20190630" decimals="INF" contextRef="D2019-04-01_2019-06-30_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature id="c49928132_20190630" decimals="INF" contextRef="D2019-04-01_2019-06-30_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" unitRef="iso4217-USD">2100000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="c49927997_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="c49927993_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 id="c49927981_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">234000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="c49927977_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD"/>
  <us-gaap:InterestExpenseDebt id="c49928110_20190630" decimals="INF" contextRef="D2019-04-01_2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">157000</us-gaap:InterestExpenseDebt>
  <adyx:BeneficialConversionFeatureConversionOfConvertibleNote id="c49927546_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <adyx:EquityImpactOfSpinoff id="c49927600_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <adyx:EquityIssuanceCostsPaidInStock id="c49927582_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <adyx:EquityIssuanceCostsPaidInStockShares id="c49927581_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares"/>
  <adyx:ExchangeOfWarrantsUponMerger id="c49927591_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <adyx:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock id="c49927554_20190630" decimals="INF" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">-2034548</adyx:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock>
  <adyx:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock id="c49927555_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">-12814000</adyx:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927609_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927618_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions id="c49927563_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares"/>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="c49927536_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares"/>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="c49927565_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="c49927537_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <adyx:BeneficialConversionFeatureConversionOfConvertibleNote id="c49927548_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">2101000</adyx:BeneficialConversionFeatureConversionOfConvertibleNote>
  <adyx:EquityImpactOfSpinoff id="c49927602_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <adyx:EquityIssuanceCostsPaidInStock id="c49927584_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <adyx:EquityIssuanceCostsPaidInStockShares id="c49927583_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares"/>
  <adyx:ExchangeOfWarrantsUponMerger id="c49927593_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <adyx:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock id="c49927556_20190630" decimals="INF" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">-2200428</adyx:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock>
  <adyx:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock id="c49927557_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">-21201000</adyx:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927611_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927620_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions id="c49927567_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares"/>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="c49927538_20190630" decimals="INF" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">367041</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="c49927569_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="c49927539_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">3203000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <adyx:BeneficialConversionFeatureConversionOfConvertibleNote id="c49927551_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD"/>
  <adyx:EquityImpactOfSpinoff id="c49927605_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">-1000</adyx:EquityImpactOfSpinoff>
  <adyx:EquityIssuanceCostsPaidInStock id="c49927587_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD"/>
  <adyx:ExchangeOfWarrantsUponMerger id="c49927596_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">234000</adyx:ExchangeOfWarrantsUponMerger>
  <adyx:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock id="c49927560_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">34011000</adyx:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927614_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">84000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="c49927623_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD"/>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="c49927575_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="c49927542_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD"/>
  <adyx:BeneficialConversionFeatureConversionOfConvertibleNote id="c49927550_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <adyx:EquityImpactOfSpinoff id="c49927604_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <adyx:EquityIssuanceCostsPaidInStock id="c49927586_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <adyx:EquityIssuanceCostsPaidInStockShares id="c49927585_20190630" decimals="INF" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">17076</adyx:EquityIssuanceCostsPaidInStockShares>
  <adyx:ExchangeOfWarrantsUponMerger id="c49927595_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <adyx:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock id="c49927558_20190630" decimals="INF" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">4234976</adyx:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock>
  <adyx:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock id="c49927559_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">4000</adyx:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927613_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927622_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions id="c49927571_20190630" decimals="INF" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">854017</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="c49927540_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares"/>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="c49927573_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="c49927541_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD"/>
  <adyx:BeneficialConversionFeatureConversionOfConvertibleNote id="c49927552_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD"/>
  <adyx:EquityImpactOfSpinoff id="c49927606_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD"/>
  <adyx:EquityIssuanceCostsPaidInStock id="c49927588_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD"/>
  <adyx:ExchangeOfWarrantsUponMerger id="c49927597_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD"/>
  <adyx:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock id="c49927561_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="c49927615_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD"/>
  <us-gaap:NetIncomeLoss id="c49927624_20190630" decimals="-3" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-4676000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="c49927577_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="c49927543_20190630" xsi:nil="true" contextRef="D2019-04-01_2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD"/>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="c49928126_20190630" decimals="INF" contextRef="D2019-05-01_2019-05-31_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" unitRef="xbrli-shares">367041</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="c49928189_20190630" decimals="INF" contextRef="D2019-05-01_2019-05-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" unitRef="xbrli-shares">367041</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionOriginalDebtAmount1 id="c49928125_20190630" decimals="INF" contextRef="D2019-05-01_2019-05-31_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" unitRef="iso4217-USD">3200000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:ProceedsFromNotesPayable id="c49928121_20190630" decimals="INF" contextRef="D2019-05-01_2019-05-31_us-gaap-DebtInstrumentAxis_adyx-SecondNoteToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember" unitRef="iso4217-USD">500000</us-gaap:ProceedsFromNotesPayable>
  <adyx:GainLossDebtModification id="c49928140_20190630" decimals="INF" contextRef="D2019-05-01_2019-05-31_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">0</adyx:GainLossDebtModification>
  <adyx:NumberOfSharesHeldByEquityHolders id="c49928019_20190630" decimals="INF" contextRef="D2019-05-03_2019-05-03" unitRef="xbrli-shares">4936784</adyx:NumberOfSharesHeldByEquityHolders>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="c49928213_20190630" decimals="INF" contextRef="D2019-05-03_2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember" unitRef="xbrli-shares">690058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <adyx:ExchangeOfWarrantsUponMerger id="c49928201_20190630" decimals="INF" contextRef="D2019-05-03_2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchaseCommonStockConvertedInMergerMember" unitRef="iso4217-USD">234000</adyx:ExchangeOfWarrantsUponMerger>
  <adyx:DebtConversionOriginalDebtAmountCumulativeAccruedInterest id="c49928017_20190630" decimals="INF" contextRef="D2019-05-03_2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" unitRef="iso4217-USD">203000</adyx:DebtConversionOriginalDebtAmountCumulativeAccruedInterest>
  <adyx:DebtConversionOriginalDebtAmountPrincipal id="c49928016_20190630" decimals="INF" contextRef="D2019-05-03_2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" unitRef="iso4217-USD">3000000</adyx:DebtConversionOriginalDebtAmountPrincipal>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="c49928018_20190630" decimals="INF" contextRef="D2019-05-03_2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-DebtConversionByUniqueDescriptionAxis_adyx-ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" unitRef="xbrli-shares">367041</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="c49927769_20190630" decimals="INF" contextRef="D2019-05-03_2019-05-03_dei-LegalEntityAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-NonmonetaryTransactionTypeAxis_adyx-ReverseStockSplitFromMember" unitRef="xbrli-pure">6</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="c49928345_20190630" decimals="INF" contextRef="D2019-05-03_2019-05-03_us-gaap-RelatedPartyTransactionAxis_adyx-SeverancePayMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_srt-ChiefExecutiveOfficerMember" unitRef="iso4217-USD">1091000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:CommonStockDividendsPerShareCashPaid id="c49928035_20190630" decimals="INF" contextRef="D2019-05-29_2019-05-29_dei-LegalEntityAxis_adyx-AlliquaBiomedicalIncMember" unitRef="iso4217-USD_xbrli-shares">1.05</us-gaap:CommonStockDividendsPerShareCashPaid>
  <us-gaap:Dividends id="c49928034_20190630" decimals="INF" contextRef="D2019-05-29_2019-05-29_dei-LegalEntityAxis_adyx-AlliquaBiomedicalIncMember" unitRef="iso4217-USD">5245000</us-gaap:Dividends>
  <us-gaap:ProceedsFromNotesPayable id="c49927777_20190630" decimals="INF" contextRef="D2019-05-31_2019-05-31_us-gaap-DebtInstrumentAxis_adyx-SecondNoteToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember" unitRef="iso4217-USD">500000</us-gaap:ProceedsFromNotesPayable>
  <adyx:DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments id="c49928106_20190630" contextRef="D2019-06-01_2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember">P60D</adyx:DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments>
  <adyx:GainLossDebtModification id="c49928141_20190630" decimals="INF" contextRef="D2019-06-01_2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">0</adyx:GainLossDebtModification>
  <us-gaap:ProceedsFromRelatedPartyDebt id="c49928350_20190630" decimals="INF" contextRef="D2019-07-01_2019-07-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="iso4217-USD">600000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="c49928358_20190630" decimals="INF" contextRef="D2019-08-01_2019-08-01_us-gaap-NonmonetaryTransactionTypeAxis_adyx-ReverseStockSplitMember_srt-RangeAxis_srt-MaximumMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-pure">10</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="c49928355_20190630" decimals="INF" contextRef="D2019-08-01_2019-08-01_us-gaap-NonmonetaryTransactionTypeAxis_adyx-ReverseStockSplitMember_srt-RangeAxis_srt-MinimumMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-pure">2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="c49928359_20190630" decimals="INF" contextRef="D2019-08-02_2019-08-02_us-gaap-NonmonetaryTransactionTypeAxis_adyx-ReverseStockSplitMember_srt-RangeAxis_srt-MaximumMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-pure">10</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="c49928356_20190630" decimals="INF" contextRef="D2019-08-02_2019-08-02_us-gaap-NonmonetaryTransactionTypeAxis_adyx-ReverseStockSplitMember_srt-RangeAxis_srt-MinimumMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-pure">2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="c49928086_20190630" decimals="INF" contextRef="I2015-11-24_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" unitRef="xbrli-shares">11829</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="c49927992_20190630" xsi:nil="true" contextRef="I2017-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD"/>
  <us-gaap:StockholdersEquity id="c49927670_20190630" decimals="-3" contextRef="I2018-03-31" unitRef="iso4217-USD">-32303000</us-gaap:StockholdersEquity>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="c49927972_20190630" decimals="-3" contextRef="I2018-03-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">42000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:SharesOutstanding id="c49927662_20190630" decimals="INF" contextRef="I2018-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">2034548</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="c49927663_20190630" decimals="-3" contextRef="I2018-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">12814000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927664_20190630" decimals="INF" contextRef="I2018-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">1833387</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="c49927665_20190630" decimals="-3" contextRef="I2018-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">15897000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="c49927668_20190630" decimals="-3" contextRef="I2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">513000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927666_20190630" decimals="INF" contextRef="I2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">701808</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="c49927667_20190630" decimals="-3" contextRef="I2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="c49927669_20190630" decimals="-3" contextRef="I2018-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-32817000</us-gaap:StockholdersEquity>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="c49928002_20190630" decimals="-3" contextRef="I2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD">436000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="c49927986_20190630" decimals="-3" contextRef="I2018-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">42000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:SharesOutstanding id="c49927689_20190630" decimals="INF" contextRef="I2018-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">2034548</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="c49927690_20190630" decimals="-3" contextRef="I2018-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">12814000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927691_20190630" decimals="INF" contextRef="I2018-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">1833387</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="c49927692_20190630" decimals="-3" contextRef="I2018-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">15897000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="c49927695_20190630" decimals="-3" contextRef="I2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">588000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927693_20190630" decimals="INF" contextRef="I2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">701808</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="c49927694_20190630" decimals="-3" contextRef="I2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="c49927696_20190630" decimals="-3" contextRef="I2018-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-34239000</us-gaap:StockholdersEquity>
  <adyx:ProbabilityOfChangeInControlOccurring id="c49928138_20190630" decimals="4" contextRef="I2018-10-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018September2018December2018AndMarch2019NotesMember" unitRef="xbrli-pure">0</adyx:ProbabilityOfChangeInControlOccurring>
  <adyx:ProbabilityOfQualifiedFinancingOccurring id="c49928136_20190630" decimals="4" contextRef="I2018-10-31_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018September2018December2018AndMarch2019NotesMember" unitRef="xbrli-pure">0</adyx:ProbabilityOfQualifiedFinancingOccurring>
  <us-gaap:ConvertibleDebt id="c49928155_20190630" xsi:nil="true" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableFiveMember" unitRef="iso4217-USD"/>
  <us-gaap:ConvertibleDebt id="c49928153_20190630" xsi:nil="true" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableFourMember" unitRef="iso4217-USD"/>
  <us-gaap:ConvertibleDebt id="c49928157_20190630" xsi:nil="true" contextRef="I2018-12-31_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableSixMember" unitRef="iso4217-USD"/>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="c49927965_20190630" xsi:nil="true" contextRef="I2018-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel1Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember" unitRef="iso4217-USD"/>
  <us-gaap:DerivativeLiabilities id="c49927961_20190630" xsi:nil="true" contextRef="I2018-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel1Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD"/>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="c49927966_20190630" xsi:nil="true" contextRef="I2018-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel2Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember" unitRef="iso4217-USD"/>
  <us-gaap:DerivativeLiabilities id="c49927962_20190630" xsi:nil="true" contextRef="I2018-12-31_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel2Member_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="c49927991_20190630" xsi:nil="true" contextRef="I2018-12-31_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD"/>
  <us-gaap:GrantsReceivable id="c49927847_20190630" decimals="INF" contextRef="I2018-12-31_srt-RangeAxis_srt-MaximumMember" unitRef="iso4217-USD">5700000</us-gaap:GrantsReceivable>
  <us-gaap:LesseeOperatingLeaseDiscountRate id="c49927934_20190630" decimals="4" contextRef="I2019-01-01_us-gaap-AdjustmentsForNewAccountingPronouncementsAxis_us-gaap-AccountingStandardsUpdate201602Member" unitRef="xbrli-pure">0.0941</us-gaap:LesseeOperatingLeaseDiscountRate>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="c49927933_20190630" decimals="INF" contextRef="I2019-01-01_us-gaap-AdjustmentsForNewAccountingPronouncementsAxis_us-gaap-AccountingStandardsUpdate201602Member" unitRef="iso4217-USD">239000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:OperatingLeaseLiability id="c49927932_20190630" decimals="INF" contextRef="I2019-01-01_us-gaap-AdjustmentsForNewAccountingPronouncementsAxis_us-gaap-AccountingStandardsUpdate201602Member" unitRef="iso4217-USD">227000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseRightOfUseAsset id="c49927935_20190630" decimals="INF" contextRef="I2019-01-01_us-gaap-AdjustmentsForNewAccountingPronouncementsAxis_us-gaap-AccountingStandardsUpdate201602Member" unitRef="iso4217-USD">227000</us-gaap:OperatingLeaseRightOfUseAsset>
  <adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid id="c49928105_20190630" decimals="INF" contextRef="I2019-01-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">50000</adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid>
  <us-gaap:StockholdersEquity id="c49927535_20190630" decimals="-3" contextRef="I2019-03-31" unitRef="iso4217-USD">-38909000</us-gaap:StockholdersEquity>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="c49927989_20190630" xsi:nil="true" contextRef="I2019-03-31_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="c49927970_20190630" decimals="-3" contextRef="I2019-03-31_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD">234000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:SharesOutstanding id="c49927527_20190630" decimals="INF" contextRef="I2019-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">2034548</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="c49927528_20190630" decimals="-3" contextRef="I2019-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">12814000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927529_20190630" decimals="INF" contextRef="I2019-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares">1833387</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="c49927530_20190630" decimals="-3" contextRef="I2019-03-31_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD">15897000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="c49927533_20190630" decimals="-3" contextRef="I2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">831000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927531_20190630" decimals="INF" contextRef="I2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">701808</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="c49927532_20190630" decimals="-3" contextRef="I2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="c49927534_20190630" decimals="-3" contextRef="I2019-03-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-39741000</us-gaap:StockholdersEquity>
  <adyx:BusinessAcquisitionExchangeRatio id="c49927767_20190630" decimals="INF" contextRef="I2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember" unitRef="xbrli-pure">0.0359</adyx:BusinessAcquisitionExchangeRatio>
  <adyx:MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree id="c49928025_20190630" decimals="INF" contextRef="I2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember" unitRef="xbrli-pure">0.14</adyx:MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree>
  <adyx:MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer id="c49928023_20190630" decimals="INF" contextRef="I2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember" unitRef="xbrli-pure">0.86</adyx:MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer>
  <us-gaap:IntangibleAssetsNetIncludingGoodwill id="c49928022_20190630" decimals="INF" contextRef="I2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember" unitRef="iso4217-USD">0</us-gaap:IntangibleAssetsNetIncludingGoodwill>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="c49928200_20190630" decimals="INF" contextRef="I2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchaseCommonStockConvertedInMergerMember" unitRef="iso4217-USD_xbrli-shares">6.34</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="c49928199_20190630" decimals="INF" contextRef="I2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_us-gaap-ClassOfWarrantOrRightAxis_adyx-WarrantToPurchaseCommonStockConvertedInMergerMember" unitRef="xbrli-shares">11829</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <adyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice id="c49928215_20190630" decimals="INF" contextRef="I2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_srt-RangeAxis_srt-MaximumMember" unitRef="iso4217-USD_xbrli-shares">3.06</adyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice>
  <adyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice id="c49928214_20190630" decimals="INF" contextRef="I2019-05-03_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember_srt-RangeAxis_srt-MinimumMember" unitRef="iso4217-USD_xbrli-shares">1.11</adyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="c49928204_20190630" decimals="INF" contextRef="I2019-05-03_us-gaap-ClassOfWarrantOrRightAxis_adyx-AlliquaWarrantsAssumedInMergerMember" unitRef="xbrli-shares">38945</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="c49928206_20190630" decimals="INF" contextRef="I2019-05-03_us-gaap-ClassOfWarrantOrRightAxis_adyx-AlliquaWarrantsAssumedInMergerMember_srt-RangeAxis_srt-MaximumMember" unitRef="iso4217-USD_xbrli-shares">28.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="c49928205_20190630" decimals="INF" contextRef="I2019-05-03_us-gaap-ClassOfWarrantOrRightAxis_adyx-AlliquaWarrantsAssumedInMergerMember_srt-RangeAxis_srt-MinimumMember" unitRef="iso4217-USD_xbrli-shares">26.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="c49928216_20190630" decimals="INF" contextRef="I2019-05-03_dei-LegalEntityAxis_adyx-AlliquaBiomedicalIncMember" unitRef="xbrli-shares">57822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <adyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice id="c49928218_20190630" decimals="INF" contextRef="I2019-05-03_dei-LegalEntityAxis_adyx-AlliquaBiomedicalIncMember_srt-RangeAxis_srt-MaximumMember" unitRef="iso4217-USD_xbrli-shares">656.40</adyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice>
  <adyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice id="c49928217_20190630" decimals="INF" contextRef="I2019-05-03_dei-LegalEntityAxis_adyx-AlliquaBiomedicalIncMember_srt-RangeAxis_srt-MinimumMember" unitRef="iso4217-USD_xbrli-shares">21.00</adyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="c49927778_20190630" decimals="INF" contextRef="I2019-05-31_us-gaap-DebtInstrumentAxis_adyx-NotesToFundTheCompanysOperationsMember_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember" unitRef="xbrli-pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid id="c49928108_20190630" decimals="INF" contextRef="I2019-06-20_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">20000</adyx:DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid>
  <adyx:CommonStockStockDividendsPerShareBookValue id="c49928036_20190630" decimals="INF" contextRef="I2019-06-21_dei-LegalEntityAxis_adyx-AquaMedMember" unitRef="iso4217-USD_xbrli-shares">0.01</adyx:CommonStockStockDividendsPerShareBookValue>
  <adyx:AccruedClinicalTrialExpenseCurrent id="c49928077_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">8000</adyx:AccruedClinicalTrialExpenseCurrent>
  <adyx:AccruedPayrollAndRelatedExpensesCurrent id="c49928073_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">508000</adyx:AccruedPayrollAndRelatedExpensesCurrent>
  <adyx:AccruedTermLoanPaymentsCurrent id="c49928075_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">569000</adyx:AccruedTermLoanPaymentsCurrent>
  <adyx:EquityIssuanceCostsCurrent id="c49928065_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">343000</adyx:EquityIssuanceCostsCurrent>
  <adyx:LesseeFinanceLeaseNotYetCommenced id="c49928172_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="xbrli-pure">0</adyx:LesseeFinanceLeaseNotYetCommenced>
  <adyx:LesseeOperatingLeaseNotYetCommenced id="c49928171_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="xbrli-pure">0</adyx:LesseeOperatingLeaseNotYetCommenced>
  <adyx:PrepaidClinicalTrialExpenseCurrent id="c49928063_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">435000</adyx:PrepaidClinicalTrialExpenseCurrent>
  <us-gaap:AccountsPayableCurrent id="c49927365_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">1748000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="c49928081_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">1480000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="c49928079_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">395000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="c49928058_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">45000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital id="c49927434_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">35160000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:Assets id="c49927361_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">2703000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="c49927353_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">1900000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="c49927770_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="iso4217-USD">24000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="c49927745_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CommitmentsAndContingencies id="c49927382_20190630" xsi:nil="true" contextRef="I2019-06-30" unitRef="iso4217-USD"/>
  <us-gaap:CommonStockParOrStatedValuePerShare id="c49927424_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="c49927427_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="xbrli-shares">95000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="c49927430_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="xbrli-shares">5807877</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="c49927432_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="xbrli-shares">5807877</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue id="c49927421_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">6000</us-gaap:CommonStockValue>
  <us-gaap:ConvertibleDebt id="c49928158_20190630" decimals="-5" contextRef="I2019-06-30" unitRef="iso4217-USD">5500000</us-gaap:ConvertibleDebt>
  <us-gaap:ConvertibleDebtCurrent id="c49927371_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">5497000</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:FinanceLeaseLiability id="c49928170_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="iso4217-USD">0</us-gaap:FinanceLeaseLiability>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="c49928182_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">1007000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive id="c49928181_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">80000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="c49928180_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">236000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="c49928179_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">232000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="c49928178_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">227000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear id="c49928177_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">232000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="c49928183_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">167000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:LiabilitiesAndStockholdersEquity id="c49927440_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">2703000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="c49927375_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">11461000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtCurrent id="c49927373_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">2390000</us-gaap:LongTermDebtCurrent>
  <us-gaap:OperatingLeaseLiability id="c49928184_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">840000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiabilityCurrent id="c49927369_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">346000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="c49927377_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">493000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseRightOfUseAsset id="c49927357_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">779000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OtherAssetsNoncurrent id="c49927359_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">18000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherPrepaidExpenseCurrent id="c49928069_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">174000</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="c49927409_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="c49928192_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="xbrli-shares">1000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="c49928191_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="c49928195_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue id="c49927406_20190630" xsi:nil="true" contextRef="I2019-06-30" unitRef="iso4217-USD"/>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="c49928071_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">1622000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidInsurance id="c49928067_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">670000</us-gaap:PrepaidInsurance>
  <us-gaap:PropertyPlantAndEquipmentGross id="c49928056_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">51000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet id="c49928060_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">6000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashCurrent id="c49927349_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">254000</us-gaap:RestrictedCashCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="c49927773_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">-44417000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="c49928282_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="xbrli-shares">530000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="c49928283_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="iso4217-USD_xbrli-shares">33.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="c49928281_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">188000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="c49928278_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="xbrli-shares">748000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="c49928279_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="iso4217-USD_xbrli-shares">24.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="c49928341_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="xbrli-shares">530000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="c49928285_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">188000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="c49928339_20190630" decimals="INF" contextRef="I2019-06-30" unitRef="iso4217-USD_xbrli-shares">24.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:StockholdersEquity id="c49927438_20190630" decimals="-3" contextRef="I2019-06-30" unitRef="iso4217-USD">-9251000</us-gaap:StockholdersEquity>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="c49928231_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember" unitRef="iso4217-USD">395000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="c49928266_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember" unitRef="xbrli-shares">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="c49928267_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-BusinessAcquisitionAxis_adyx-AlliquaBiomedicalIncMember" unitRef="iso4217-USD_xbrli-shares">1449.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:RestrictedCash id="c49928104_20190630" decimals="INF" contextRef="I2019-06-30_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoansMember" unitRef="iso4217-USD">200000</us-gaap:RestrictedCash>
  <us-gaap:LoansPayable id="c49927771_20190630" decimals="INF" contextRef="I2019-06-30_srt-CounterpartyNameAxis_adyx-OxfordFinanceLLCMember" unitRef="iso4217-USD">3000000</us-gaap:LoansPayable>
  <us-gaap:ConvertibleDebt id="c49928154_20190630" decimals="-5" contextRef="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableFiveMember" unitRef="iso4217-USD">2000000</us-gaap:ConvertibleDebt>
  <us-gaap:ConvertibleDebt id="c49928152_20190630" decimals="-5" contextRef="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableFourMember" unitRef="iso4217-USD">1500000</us-gaap:ConvertibleDebt>
  <us-gaap:ConvertibleDebt id="c49928146_20190630" xsi:nil="true" contextRef="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableOneMember" unitRef="iso4217-USD"/>
  <us-gaap:ConvertibleDebt id="c49928156_20190630" decimals="-5" contextRef="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableSixMember" unitRef="iso4217-USD">500000</us-gaap:ConvertibleDebt>
  <us-gaap:ConvertibleDebt id="c49928150_20190630" decimals="-5" contextRef="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableThreeMember" unitRef="iso4217-USD">1500000</us-gaap:ConvertibleDebt>
  <us-gaap:ConvertibleDebt id="c49928148_20190630" xsi:nil="true" contextRef="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ConvertibleNotePayableTwoMember" unitRef="iso4217-USD"/>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset id="c49927882_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="iso4217-USD">0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability id="c49927902_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018AndModifiedSeptember2018NotesMember" unitRef="iso4217-USD">0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability id="c49928137_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2018September2018December2018AndMarch2019NotesMember" unitRef="iso4217-USD">0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <adyx:DebtInstrumentConversionToCashInCaseOfChangeInControl id="c49928119_20190630" decimals="4" contextRef="I2019-06-30_us-gaap-DebtInstrumentAxis_adyx-ModifiedMarch2019AndModifiedDecember2018NotesMember" unitRef="xbrli-pure">2</adyx:DebtInstrumentConversionToCashInCaseOfChangeInControl>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="c49928001_20190630" xsi:nil="true" contextRef="I2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-DerivativeMember" unitRef="iso4217-USD"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="c49927985_20190630" xsi:nil="true" contextRef="I2019-06-30_us-gaap-FinancialInstrumentAxis_us-gaap-WarrantMember" unitRef="iso4217-USD"/>
  <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent id="c49928343_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-MajorityInvestorsMember" unitRef="iso4217-USD">5500000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:LoansPayable id="c49928095_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanAMember" unitRef="iso4217-USD">1400000</us-gaap:LoansPayable>
  <us-gaap:DeferredFinanceCostsGross id="c49928094_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember" unitRef="iso4217-USD">3000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:LoansPayable id="c49928096_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-LineOfCreditFacilityAxis_adyx-OxfordFinanceLLCMember_us-gaap-LongtermDebtTypeAxis_adyx-TermLoanBMember" unitRef="iso4217-USD">1000000</us-gaap:LoansPayable>
  <us-gaap:NotesPayable id="c49927772_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-LongtermDebtTypeAxis_us-gaap-ConvertibleDebtMember" unitRef="iso4217-USD">5600000</us-gaap:NotesPayable>
  <us-gaap:PropertyPlantAndEquipmentGross id="c49928052_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-ComputerEquipmentMember" unitRef="iso4217-USD">18000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="c49928048_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-FurnitureAndFixturesMember" unitRef="iso4217-USD">29000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="c49928054_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-PropertyPlantAndEquipmentByTypeAxis_adyx-LaboratoryEquipmentMember" unitRef="iso4217-USD">2000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="c49928050_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-OfficeEquipmentMember" unitRef="iso4217-USD">2000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:RestrictedCash id="c49927838_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_adyx-LetterOfCredit1Member" unitRef="iso4217-USD">55000</us-gaap:RestrictedCash>
  <us-gaap:RestrictedCash id="c49927836_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap-MoneyMarketFundsMember" unitRef="iso4217-USD">200000</us-gaap:RestrictedCash>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="c49928313_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange1Member" unitRef="xbrli-shares">73000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="c49928311_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange1Member" unitRef="iso4217-USD_xbrli-shares">1.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="c49928309_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange1Member" unitRef="iso4217-USD_xbrli-shares">1.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="c49928320_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange2Member" unitRef="xbrli-shares">37000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="c49928318_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange2Member" unitRef="iso4217-USD_xbrli-shares">1.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="c49928316_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange2Member" unitRef="iso4217-USD_xbrli-shares">1.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="c49928327_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange3Member" unitRef="xbrli-shares">362000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="c49928325_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange3Member" unitRef="iso4217-USD_xbrli-shares">3.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="c49928323_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange3Member" unitRef="iso4217-USD_xbrli-shares">3.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="c49928334_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange4Member" unitRef="xbrli-shares">58000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="c49928331_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange4Member" unitRef="xbrli-shares">58000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="c49928332_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange4Member" unitRef="iso4217-USD_xbrli-shares">289.81</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="c49928330_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange4Member" unitRef="iso4217-USD_xbrli-shares">289.81</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="c49927385_20190630" xsi:nil="true" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:TemporaryEquitySharesAuthorized id="c49927389_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesOutstanding id="c49927391_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital id="c49927387_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">0.001</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
  <us-gaap:SharesOutstanding id="c49927626_20190630" xsi:nil="true" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares"/>
  <us-gaap:StockholdersEquity id="c49927627_20190630" xsi:nil="true" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="c49927395_20190630" xsi:nil="true" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:TemporaryEquitySharesAuthorized id="c49927399_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesOutstanding id="c49927401_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital id="c49927397_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">0.001</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
  <us-gaap:SharesOutstanding id="c49927628_20190630" xsi:nil="true" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="xbrli-shares"/>
  <us-gaap:StockholdersEquity id="c49927629_20190630" xsi:nil="true" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesBRedeemableConvertiblePreferredStockMember_us-gaap-StatementEquityComponentsAxis_us-gaap-PreferredStockMember" unitRef="iso4217-USD"/>
  <us-gaap:StockholdersEquity id="c49927632_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">35160000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="c49927630_20190630" decimals="INF" contextRef="I2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">5807877</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="c49927631_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">6000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="c49927633_20190630" decimals="-3" contextRef="I2019-06-30_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-44417000</us-gaap:StockholdersEquity>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="c49928351_20190630" decimals="INF" contextRef="I2019-07-31_srt-CounterpartyNameAxis_adyx-DomainMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <dei:DocumentType contextRef="D2019-01-01_2019-06-30">S-1/A</dei:DocumentType>
  <dei:AmendmentFlag contextRef="D2019-01-01_2019-06-30">true</dei:AmendmentFlag>
  <dei:EntityCentralIndexKey contextRef="D2019-01-01_2019-06-30">0001054274</dei:EntityCentralIndexKey>
  <dei:EntityFilerCategory contextRef="D2019-01-01_2019-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="D2019-01-01_2019-06-30">Adynxx, Inc.</dei:EntityRegistrantName>
  <dei:DocumentPeriodEndDate contextRef="D2019-01-01_2019-06-30">2019-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityEmergingGrowthCompany contextRef="D2019-01-01_2019-06-30">false</dei:EntityEmergingGrowthCompany>
  <dei:EntitySmallBusiness contextRef="D2019-01-01_2019-06-30">true</dei:EntitySmallBusiness>
  <dei:EntityExTransitionPeriod contextRef="D2019-01-01_2019-06-30">false</dei:EntityExTransitionPeriod>
  <us-gaap:TemporaryEquitySharesIssued decimals="INF" contextRef="I2019-06-30_us-gaap-StatementClassOfStockAxis_adyx-SeriesARedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:NonoperatingIncomeExpense decimals="-3" contextRef="D2018-01-01_2018-12-31" unitRef="iso4217-USD">126000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense decimals="-3" contextRef="D2017-01-01_2017-12-31" unitRef="iso4217-USD">17000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity decimals="-6" contextRef="Duration20190809_MinimumMember_SubsequentEventMember" unitRef="iso4217-USD">1000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:DerivativeLiabilities decimals="-3" contextRef="I2017-12-31" unitRef="iso4217-USD">42000</us-gaap:DerivativeLiabilities>
  <us-gaap:OperatingLeaseExpense decimals="INF" contextRef="D2018-01-01_2018-06-30" unitRef="iso4217-USD">115000</us-gaap:OperatingLeaseExpense>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 decimals="2" contextRef="I2019-06-30" unitRef="iso4217-USD_xbrli-shares">24.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions decimals="-3" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange1Member" unitRef="xbrli-shares">73000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions decimals="-3" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange2Member" unitRef="xbrli-shares">37000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions decimals="-3" contextRef="I2019-06-30_us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adyx-PriceRange3Member" unitRef="xbrli-shares">580000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions decimals="-3" contextRef="I2019-06-30" unitRef="xbrli-shares">748000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ConversionOfStockSharesIssued1 decimals="INF" contextRef="D2018-01-01_2018-12-31_SeriesAPreferredStockMember" unitRef="xbrli-shares">11335</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockSharesIssued1 decimals="INF" contextRef="D2017-01-01_2017-12-31_SeriesAPreferredStockMember" unitRef="xbrli-shares">11335</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockSharesIssued1 decimals="INF" contextRef="D2017-01-01_2017-12-31_SeriesBPreferredStockMember" unitRef="xbrli-shares">10214</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockSharesIssued1 decimals="INF" contextRef="D2018-01-01_2018-12-31_SeriesBPreferredStockMember" unitRef="xbrli-shares">10214</us-gaap:ConversionOfStockSharesIssued1>
  <dei:AmendmentDescription contextRef="D2019-01-01_2019-06-30">AMENDMENT NO. 3</dei:AmendmentDescription>
  <adyx:NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount decimals="0" contextRef="I20190630_NonEmployeeOptionsMember" unitRef="iso4217-USD">16000</adyx:NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#Item-0005_20181231" xlink:label="Item-0005_lbl_20181231"/>
    <link:footnote xlink:type="resource" xlink:label="Footnote-01_20181231" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company's common stock of $0.46 and $0.44 per share as of December 31, 2018 and 2017.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0005_lbl_20181231" xlink:to="Footnote-01_20181231" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="#Item-0002_20181231" xlink:label="Item-0002_lbl_20181231"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0002_lbl_20181231" xlink:to="Footnote-01_20181231" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="#Item-0003_20181231" xlink:label="Item-0003_lbl_20181231"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0003_lbl_20181231" xlink:to="Footnote-01_20181231" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="#Item-0004_20181231" xlink:label="Item-0004_lbl_20181231"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0004_lbl_20181231" xlink:to="Footnote-01_20181231" order="1.0"/>
  </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>adyx-20190630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!-- Created by Toppan Merrill -->
<xsd:schema targetNamespace="http://www.adynxx.com/20190630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:adyx="http://www.adynxx.com/20190630" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="adyx-20190630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="adyx-20190630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="adyx-20190630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="adyx-20190630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:roleType roleURI="http://www.adynxx.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>52001005 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>52002005 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/StatementStatementOfCashFlows" id="StatementStatementOfCashFlows">
        <link:definition>52004005 - Statement - Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote3PropertyAndEquipmentNetPropertyAndEquipmentNetDetails" id="DisclosureNote3PropertyAndEquipmentNetPropertyAndEquipmentNetDetails">
        <link:definition>52403025 - Disclosure - Note 3 - Property and Equipment, Net -Property and equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote4AccruedLiabilitiesAccruedLiabilitiesDetails" id="DisclosureNote4AccruedLiabilitiesAccruedLiabilitiesDetails">
        <link:definition>40501 - Disclosure - Note 4 - Accrued Liabilities - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesComponentsOfDeferredTaxAssetsDetails" id="DisclosureNote10IncomeTaxesComponentsOfDeferredTaxAssetsDetails">
        <link:definition>41402 - Disclosure - Note 10 - Income Taxes - Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>52000905 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/StatementBalanceSheetsParentheticals" id="StatementBalanceSheetsParentheticals">
        <link:definition>52001055 - Statement - Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" id="StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit">
        <link:definition>52003005 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote1OrganizationAndBasisOfPresentation" id="DisclosureNote1OrganizationAndBasisOfPresentation">
        <link:definition>52101015 - Disclosure - Note 1 - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPolicies" id="DisclosureNote2SummaryOfSignificantAccountingPolicies">
        <link:definition>52102015 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote3PropertyAndEquipmentNet" id="DisclosureNote3PropertyAndEquipmentNet">
        <link:definition>52103015 - Disclosure - Note 3 - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote4AccruedLiabilities" id="DisclosureNote4AccruedLiabilities">
        <link:definition>10501 - Disclosure - Note 4 - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotes" id="DisclosureNote5TermLoansAndConvertiblePromissoryNotes">
        <link:definition>52105015 - Disclosure - Note 5 - Term Loans and Convertible Promissory Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingencies" id="DisclosureNote6CommitmentsAndContingencies">
        <link:definition>10801 - Disclosure - Note 6 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficit" id="DisclosureNote7StockholdersDeficit">
        <link:definition>11001 - Disclosure - Note 7 - Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote8Warrants" id="DisclosureNote8Warrants">
        <link:definition>52108015 - Disclosure - Note 8 - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote9StockOptionPlans" id="DisclosureNote9StockOptionPlans">
        <link:definition>52109015 - Disclosure - Note 9 - Stock Option Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote10IncomeTaxes" id="DisclosureNote10IncomeTaxes">
        <link:definition>11401 - Disclosure - Note 10 - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote11RelatedPartyTransactions" id="DisclosureNote11RelatedPartyTransactions">
        <link:definition>52111015 - Disclosure - Note 11 - Related-party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote12EmployeeBenefitPlan" id="DisclosureNote12EmployeeBenefitPlan">
        <link:definition>11601 - Disclosure - Note 12 - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote13SubsequentEvents" id="DisclosureNote13SubsequentEvents">
        <link:definition>52113015 - Disclosure - Note 13 - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesTables" id="DisclosureNote2SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>52302035 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote3PropertyAndEquipmentNetTables" id="DisclosureNote3PropertyAndEquipmentNetTables">
        <link:definition>52303035 - Disclosure - Note 3 - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote4AccruedLiabilitiesTables" id="DisclosureNote4AccruedLiabilitiesTables">
        <link:definition>30503 - Disclosure - Note 4 - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesTables" id="DisclosureNote5TermLoansAndConvertiblePromissoryNotesTables">
        <link:definition>52305035 - Disclosure - Note 5 - Term Loans and Convertible Promissory Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesTables" id="DisclosureNote6CommitmentsAndContingenciesTables">
        <link:definition>30803 - Disclosure - Note 6 - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitTables" id="DisclosureNote7StockholdersDeficitTables">
        <link:definition>31003 - Disclosure - Note 7 - Stockholders' Deficit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote8WarrantsTables" id="DisclosureNote8WarrantsTables">
        <link:definition>31203 - Disclosure - Note 8 - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote9StockOptionPlansTables" id="DisclosureNote9StockOptionPlansTables">
        <link:definition>52309035 - Disclosure - Note 9 - Stock Option Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesTables" id="DisclosureNote10IncomeTaxesTables">
        <link:definition>31403 - Disclosure - Note 10 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote1OrganizationAndBasisOfPresentationDetailsTextual" id="DisclosureNote1OrganizationAndBasisOfPresentationDetailsTextual">
        <link:definition>52401015 - Disclosure - Note 1 - Organization and Basis of Presentation (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual" id="DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual">
        <link:definition>52402015 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsRecurringBasisDetails" id="DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsRecurringBasisDetails">
        <link:definition>52402025 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesChangeInFairValueOfPreferredStockWarrantLiabilityDetails" id="DisclosureNote2SummaryOfSignificantAccountingPoliciesChangeInFairValueOfPreferredStockWarrantLiabilityDetails">
        <link:definition>52402035 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Change in Fair Value of Preferred Stock Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote3PropertyAndEquipmentNetDetailsTextual" id="DisclosureNote3PropertyAndEquipmentNetDetailsTextual">
        <link:definition>52403015 - Disclosure - Note 3 - Property and Equipment, Net (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesDetailsTextual" id="DisclosureNote5TermLoansAndConvertiblePromissoryNotesDetailsTextual">
        <link:definition>52405025 - Disclosure - Note 5 - Term Loans and Convertible Promissory Notes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesFuturePrincipalPaymentsOfTermLoansDetails" id="DisclosureNote5TermLoansAndConvertiblePromissoryNotesFuturePrincipalPaymentsOfTermLoansDetails">
        <link:definition>40702 - Disclosure - Note 6 - Term Loans and Convertible Promissory Notes - Future Principal Payments of Term Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetails" id="DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetails">
        <link:definition>5405015 - Disclosure - Note 5 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetailsParentheticals" id="DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetailsParentheticals">
        <link:definition>40703 - Disclosure - Note 6 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesDetailsTextual" id="DisclosureNote6CommitmentsAndContingenciesDetailsTextual">
        <link:definition>40801 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesFutureLeasePaymentsDetails" id="DisclosureNote6CommitmentsAndContingenciesFutureLeasePaymentsDetails">
        <link:definition>40802 - Disclosure - Note 6 - Commitments and Contingencies - Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitDetailsTextual" id="DisclosureNote7StockholdersDeficitDetailsTextual">
        <link:definition>41001 - Disclosure - Note 7 - Stockholders' Deficit (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitSharesReservedForFutureIssuanceDetails" id="DisclosureNote7StockholdersDeficitSharesReservedForFutureIssuanceDetails">
        <link:definition>41002 - Disclosure - Note 7 - Stockholders' Deficit - Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote8WarrantsDetailsTextual" id="DisclosureNote8WarrantsDetailsTextual">
        <link:definition>52408015 - Disclosure - Note 8 - Warrants (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote8WarrantsDetailsOfWarrantsDetails" id="DisclosureNote8WarrantsDetailsOfWarrantsDetails">
        <link:definition>41202 - Disclosure - Note 9 - Warrants - Details of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote8WarrantsWarrantsAssumptionsDetails" id="DisclosureNote8WarrantsWarrantsAssumptionsDetails">
        <link:definition>41203 - Disclosure - Note 9 - Warrants - Warrants Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote9StockOptionPlansDetailsTextual" id="DisclosureNote9StockOptionPlansDetailsTextual">
        <link:definition>52409015 - Disclosure - Note 9 - Stock Option Plans (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote9StockOptionPlansSummaryOfStockOptionActivityDetails" id="DisclosureNote9StockOptionPlansSummaryOfStockOptionActivityDetails">
        <link:definition>41302 - Disclosure - Note 10 - Stock Option Plans - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesDetailsTextual" id="DisclosureNote10IncomeTaxesDetailsTextual">
        <link:definition>41401 - Disclosure - Note 10 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" id="DisclosureNote10IncomeTaxesActivityRelatedToGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>41403 - Disclosure - Note 10 - Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote11RelatedPartyTransactionsDetailsTextual" id="DisclosureNote11RelatedPartyTransactionsDetailsTextual">
        <link:definition>52411015 - Disclosure - Note 11 - Related-party Transactions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote12EmployeeBenefitPlanDetailsTextual" id="DisclosureNote12EmployeeBenefitPlanDetailsTextual">
        <link:definition>41601 - Disclosure - Note 12 - Employee Benefit Plan (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/role/DisclosureNote13SubsequentEventsDetailsTextual" id="DisclosureNote13SubsequentEventsDetailsTextual">
        <link:definition>41701 - Disclosure - Note 13 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-document-and-entity-informationQuarterEnd" id="statement-document-and-entity-informationQuarterEnd">
        <link:definition>00090 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unauditedQuarterEnd" id="statement-condensed-consolidated-balance-sheets-current-period-unauditedQuarterEnd">
        <link:definition>00100 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticalsQuarterEnd" id="statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticalsQuarterEnd">
        <link:definition>00105 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-operations-unauditedQuarterEnd" id="statement-condensed-consolidated-statements-of-operations-unauditedQuarterEnd">
        <link:definition>00200 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-redeemable-convertible-preferred-stock-and-stockholders-deficit-unauditedQuarterEnd" id="statement-condensed-consolidated-statements-of-redeemable-convertible-preferred-stock-and-stockholders-deficit-unauditedQuarterEnd">
        <link:definition>00300 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-cash-flows-unauditedQuarterEnd" id="statement-condensed-consolidated-statements-of-cash-flows-unauditedQuarterEnd">
        <link:definition>00400 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentationQuarterEnd" id="statement-note-1-organization-and-basis-of-presentationQuarterEnd">
        <link:definition>10101 - Disclosure - Note 1 - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policiesQuarterEnd" id="statement-note-2-summary-of-significant-accounting-policiesQuarterEnd">
        <link:definition>10201 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-3-reverse-mergerQuarterEnd" id="statement-note-3-reverse-mergerQuarterEnd">
        <link:definition>10301 - Disclosure - Note 3 - Reverse Merger</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-netQuarterEnd" id="statement-note-4-property-and-equipment-netQuarterEnd">
        <link:definition>10401 - Disclosure - Note 4 - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-informationQuarterEnd" id="statement-note-5-other-balance-sheet-informationQuarterEnd">
        <link:definition>10601 - Disclosure - Note 5 - Other Balance Sheet Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notesQuarterEnd" id="statement-note-6-term-loans-and-convertible-promissory-notesQuarterEnd">
        <link:definition>10701 - Disclosure - Note 6 - Term Loans and Convertible Promissory Notes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leasesQuarterEnd" id="statement-note-7-leasesQuarterEnd">
        <link:definition>10901 - Disclosure - Note 7 - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stockQuarterEnd" id="statement-note-8-redeemable-convertible-preferred-stockQuarterEnd">
        <link:definition>11101 - Disclosure - Note 8 - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-9-warrants-QuarterEnd" id="statement-note-9-warrants-QuarterEnd">
        <link:definition>11201 - Disclosure - Note 9 - Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-optionsQuarterEnd" id="statement-note-10-stock-optionsQuarterEnd">
        <link:definition>11301 - Disclosure - Note 10 - Stock Options</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactionsQuarterEnd" id="statement-note-11-relatedparty-transactionsQuarterEnd">
        <link:definition>11501 - Disclosure - Note 11 - Related-party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-12-subsequent-eventsQuarterEnd" id="statement-note-12-subsequent-eventsQuarterEnd">
        <link:definition>11701 - Disclosure - Note 12 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-significant-accounting-policies-policiesQuarterEnd" id="statement-significant-accounting-policies-policiesQuarterEnd">
        <link:definition>5213025 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-tablesQuarterEnd" id="statement-note-2-summary-of-significant-accounting-policies-tablesQuarterEnd">
        <link:definition>30203 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-tablesQuarterEnd" id="statement-note-4-property-and-equipment-net-tablesQuarterEnd">
        <link:definition>30403 - Disclosure - Note 4 - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-tablesQuarterEnd" id="statement-note-5-other-balance-sheet-information-tablesQuarterEnd">
        <link:definition>30603 - Disclosure - Note 5 - Other Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-tablesQuarterEnd" id="statement-note-6-term-loans-and-convertible-promissory-notes-tablesQuarterEnd">
        <link:definition>30703 - Disclosure - Note 6 - Term Loans and Convertible Promissory Notes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leases-tablesQuarterEnd" id="statement-note-7-leases-tablesQuarterEnd">
        <link:definition>30903 - Disclosure - Note 7 - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-tablesQuarterEnd" id="statement-note-10-stock-options-tablesQuarterEnd">
        <link:definition>31303 - Disclosure - Note 10 - Stock Options (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentation-details-textualQuarterEnd" id="statement-note-1-organization-and-basis-of-presentation-details-textualQuarterEnd">
        <link:definition>40101 - Disclosure - Note 1 - Organization and Basis of Presentation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-details-textualQuarterEnd" id="statement-note-2-summary-of-significant-accounting-policies-details-textualQuarterEnd">
        <link:definition>40201 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-detailsQuarterEnd" id="statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-detailsQuarterEnd">
        <link:definition>40202 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-detailsQuarterEnd" id="statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-detailsQuarterEnd">
        <link:definition>40203 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Change in Fair Value of Preferred Stock Warrant Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-3-reverse-merger-details-textualQuarterEnd" id="statement-note-3-reverse-merger-details-textualQuarterEnd">
        <link:definition>40301 - Disclosure - Note 3 - Reverse Merger (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-details-textualQuarterEnd" id="statement-note-4-property-and-equipment-net-details-textualQuarterEnd">
        <link:definition>40401 - Disclosure - Note 4 - Property and Equipment, Net (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-property-and-equipment-net-detailsQuarterEnd" id="statement-note-4-property-and-equipment-net-property-and-equipment-net-detailsQuarterEnd">
        <link:definition>40402 - Disclosure - Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-detailsQuarterEnd" id="statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-detailsQuarterEnd">
        <link:definition>40602 - Disclosure - Note 5 - Other Balance Sheet Information - Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-accrued-liabilities-detailsQuarterEnd" id="statement-note-5-other-balance-sheet-information-accrued-liabilities-detailsQuarterEnd">
        <link:definition>40601 - Disclosure - Note 5 - Other Balance Sheet Information - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-details-textualQuarterEnd" id="statement-note-6-term-loans-and-convertible-promissory-notes-details-textualQuarterEnd">
        <link:definition>40701 - Disclosure - Note 6 - Term Loans and Convertible Promissory Notes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-detailsQuarterEnd" id="statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-detailsQuarterEnd">
        <link:definition>40704 - Disclosure - Note 6 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leases-details-textualQuarterEnd" id="statement-note-7-leases-details-textualQuarterEnd">
        <link:definition>40901 - Disclosure - Note 7 - Leases (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leases-future-minimum-lease-payments-detailsQuarterEnd" id="statement-note-7-leases-future-minimum-lease-payments-detailsQuarterEnd">
        <link:definition>40902 - Disclosure - Note 7 - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stock-details-textualQuarterEnd" id="statement-note-8-redeemable-convertible-preferred-stock-details-textualQuarterEnd">
        <link:definition>41101 - Disclosure - Note 8 - Redeemable Convertible Preferred Stock (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-9-warrants-details-textualQuarterEnd" id="statement-note-9-warrants-details-textualQuarterEnd">
        <link:definition>41201 - Disclosure - Note 9 - Warrants (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-details-textualQuarterEnd" id="statement-note-10-stock-options-details-textualQuarterEnd">
        <link:definition>41301 - Disclosure - Note 10 - Stock Options (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-summary-of-stock-option-activity-detailsQuarterEnd" id="statement-note-10-stock-options-summary-of-stock-option-activity-detailsQuarterEnd">
        <link:definition>41304 - Disclosure - Note 10 - Stock Options - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-stock-options-by-exercise-price-range-detailsQuarterEnd" id="statement-note-10-stock-options-stock-options-by-exercise-price-range-detailsQuarterEnd">
        <link:definition>41303 - Disclosure - Note 10 - Stock Options - Stock Options by Exercise Price Range (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactions-details-textualQuarterEnd" id="statement-note-11-relatedparty-transactions-details-textualQuarterEnd">
        <link:definition>41501 - Disclosure - Note 11 - Related-party Transactions (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adynxx.com/20190630/role/statement-note-12-subsequent-events-details-textualQuarterEnd" id="statement-note-12-subsequent-events-details-textualQuarterEnd">
        <link:definition>5412015 - Disclosure - Note 12 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xsd:element name="AccountsPayable1Member" id="adyx_AccountsPayable1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" id="adyx_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element name="AccruedClinicalTrialExpenseCurrent" id="adyx_AccruedClinicalTrialExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element name="AccruedPayrollAndRelatedExpensesCurrent" id="adyx_AccruedPayrollAndRelatedExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element name="AccruedTermLoanPaymentsCurrent" id="adyx_AccruedTermLoanPaymentsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element name="ClassOfWarrantsOrRightExercisableTerm" id="adyx_ClassOfWarrantsOrRightExercisableTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" id="adyx_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" id="adyx_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ClinicalTrialAccrualsPolicyPolicyTextBlock" id="adyx_ClinicalTrialAccrualsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" id="adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConversionOfPreferredStockToCommonStockMember" id="adyx_ConversionOfPreferredStockToCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" id="adyx_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" id="adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConvertibleNotePayableOneMember" id="adyx_ConvertibleNotePayableOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConvertibleNotePayableThreeMember" id="adyx_ConvertibleNotePayableThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConvertibleNotePayableTwoMember" id="adyx_ConvertibleNotePayableTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" id="adyx_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConvertiblePromissoryNoteIssuedOnMarch292019Member" id="adyx_ConvertiblePromissoryNoteIssuedOnMarch292019Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConvertiblePromissoryNoteIssuedSeptember272018Member" id="adyx_ConvertiblePromissoryNoteIssuedSeptember272018Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConvertiblePromissoryNoteOf15MillionMember" id="adyx_ConvertiblePromissoryNoteOf15MillionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtConversionOriginalDebtAmountCumulativeAccruedInterest" id="adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="DebtConversionOriginalDebtAmountPrincipal" id="adyx_DebtConversionOriginalDebtAmountPrincipal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentConversionToCashInCaseOfChangeInControl" id="adyx_DebtInstrumentConversionToCashInCaseOfChangeInControl" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" id="adyx_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="DebtInstrumentConvertibleCommonStockProceedsTrigger" id="adyx_DebtInstrumentConvertibleCommonStockProceedsTrigger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentConvertiblePreferredStockProceedsTrigger" id="adyx_DebtInstrumentConvertiblePreferredStockProceedsTrigger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" id="adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" id="adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" id="adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" id="adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" id="adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" id="adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" id="adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" id="adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" id="adyx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" id="adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element name="DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" id="adyx_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" id="adyx_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" id="adyx_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" id="adyx_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DebtInstrumentUnusedBorrowingCapacityExpired" id="adyx_DebtInstrumentUnusedBorrowingCapacityExpired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element name="DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" id="adyx_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary" id="adyx_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="DefinedContributionPlanNonelectiveSafeHarborContributionAmount" id="adyx_DefinedContributionPlanNonelectiveSafeHarborContributionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element name="DomainMember" id="adyx_DomainMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="EquityConvertibleAggregateProceedsTrigger" id="adyx_EquityConvertibleAggregateProceedsTrigger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="EquityConvertibleStockPriceTrigger" id="adyx_EquityConvertibleStockPriceTrigger" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="EquitySharesReservedForFutureIssuance" id="adyx_EquitySharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="FinancingThresholdProceedsToConvertNotesToEquity" id="adyx_FinancingThresholdProceedsToConvertNotesToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="FirstNoteToFundTheCompanysOperationsMember" id="adyx_FirstNoteToFundTheCompanysOperationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="GrantReimbursementPolicyPolicyTextBlock" id="adyx_GrantReimbursementPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="LaboratoryEquipmentMember" id="adyx_LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="LetterOfCredit1Member" id="adyx_LetterOfCredit1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="LongtermDebtPrincipalAndInterestPaymentsTerm" id="adyx_LongtermDebtPrincipalAndInterestPaymentsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="MajorityInvestorsMember" id="adyx_MajorityInvestorsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" id="adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" id="adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="ModifiedMarch2018AndModifiedSeptember2018NotesMember" id="adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" id="adyx_ModifiedMarch2018September2018December2018AndMarch2019NotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ModifiedMarch2019AndModifiedDecember2018NotesMember" id="adyx_ModifiedMarch2019AndModifiedDecember2018NotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="NonEmployeeOptionsMember" id="adyx_NonEmployeeOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" id="adyx_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element name="NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" id="adyx_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" id="adyx_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" id="adyx_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="NoteToFinancialStatementDetailsTextual" id="adyx_NoteToFinancialStatementDetailsTextual" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="NotesToFinancialStatementsAbstract" id="adyx_NotesToFinancialStatementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="NotesToFundTheCompanysOperationsMember" id="adyx_NotesToFundTheCompanysOperationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="NumberOfForeignSubsidiaries" id="adyx_NumberOfForeignSubsidiaries" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" id="adyx_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="OperatingLeaseCarryforwardsWithExpirationDates" id="adyx_OperatingLeaseCarryforwardsWithExpirationDates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element name="OperatingLossCarryforwardsExpiringIndefinitely" id="adyx_OperatingLossCarryforwardsExpiringIndefinitely" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element name="OxfordFinanceLLCMember" id="adyx_OxfordFinanceLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="PercentageOfNotePayablePrincipal" id="adyx_PercentageOfNotePayablePrincipal" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="ProbabilityOfChangeInControlOccurring" id="adyx_ProbabilityOfChangeInControlOccurring" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="ProbabilityOfQualifiedFinancingOccurring" id="adyx_ProbabilityOfQualifiedFinancingOccurring" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="ReleaseOfDerivativeLiabilities" id="adyx_ReleaseOfDerivativeLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element name="SecondNoteToFundTheCompanysOperationsMember" id="adyx_SecondNoteToFundTheCompanysOperationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="SeriesAConvertiblePreferredStockMember" id="adyx_SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="SeriesARedeemableConvertiblePreferredStockMember" id="adyx_SeriesARedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="SeriesBConvertiblePreferredStockMember" id="adyx_SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="SeriesBRedeemableConvertiblePreferredStockMember" id="adyx_SeriesBRedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" id="adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" id="adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantExercised" id="adyx_StockIssuedDuringPeriodSharesWarrantExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="StockIssuedDuringPeriodValueWarrantExercised" id="adyx_StockIssuedDuringPeriodValueWarrantExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" id="adyx_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="TermLoanAMember" id="adyx_TermLoanAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="TermLoanBMember" id="adyx_TermLoanBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="TermLoanCMember" id="adyx_TermLoanCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="TermLoansMember" id="adyx_TermLoansMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ThePlanMember" id="adyx_ThePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" id="adyx_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="Vendor1Member" id="adyx_Vendor1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="Vendor2Member" id="adyx_Vendor2Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="Vendor3Member" id="adyx_Vendor3Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="VotingRightsTransferredToBeConsideredAChangeInControl" id="adyx_VotingRightsTransferredToBeConsideredAChangeInControl" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="WarrantIssuedInConnectionWithTermLoanAAndBMember" id="adyx_WarrantIssuedInConnectionWithTermLoanAAndBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" id="adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="WarrantsDisclosureTextBlock" id="adyx_WarrantsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="WarrantsForSeriesAConvertiblePreferredStockIssuedInJanuary2016Member" id="adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInJanuary2016Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" id="adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="WarrantsForSeriesAConvertiblePreferredStockMember" id="adyx_WarrantsForSeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="WarrantsReserveForSeriesAConvertiblePreferredStockMember" id="adyx_WarrantsReserveForSeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" id="adyx_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" id="adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-10-income-taxes-tables" id="adyx_statement-statement-note-10-income-taxes-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details" id="adyx_statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details" id="adyx_statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-2-summary-of-significant-accounting-policies-tables" id="adyx_statement-statement-note-2-summary-of-significant-accounting-policies-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-3-property-and-equipment-net-property-and-equipment-net-details" id="adyx_statement-statement-note-3-property-and-equipment-net-property-and-equipment-net-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-3-property-and-equipment-net-tables" id="adyx_statement-statement-note-3-property-and-equipment-net-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" id="adyx_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-4-accrued-liabilities-tables" id="adyx_statement-statement-note-4-accrued-liabilities-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" id="adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals" id="adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details" id="adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-5-term-loans-and-convertible-promissory-notes-tables" id="adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details" id="adyx_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-6-commitments-and-contingencies-tables" id="adyx_statement-statement-note-6-commitments-and-contingencies-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details" id="adyx_statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-7-stockholders-deficit-tables" id="adyx_statement-statement-note-7-stockholders-deficit-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-8-warrants-details-of-warrants-details" id="adyx_statement-statement-note-8-warrants-details-of-warrants-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-8-warrants-tables" id="adyx_statement-statement-note-8-warrants-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-8-warrants-warrants-assumptions-details" id="adyx_statement-statement-note-8-warrants-warrants-assumptions-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" id="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-9-stock-option-plans-tables" id="adyx_statement-statement-note-9-stock-option-plans-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-significant-accounting-policies-policies" id="adyx_statement-statement-significant-accounting-policies-policies" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConvertiblePromissoryNotes" id="adyx_ConvertiblePromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element name="AlliquaBiomedicalIncMember" id="adyx_AlliquaBiomedicalIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="AlliquaWarrantsAssumedInMergerMember" id="adyx_AlliquaWarrantsAssumedInMergerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="AquaMedMember" id="adyx_AquaMedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="BeneficialConversionFeatureConversionOfConvertibleNote" id="adyx_BeneficialConversionFeatureConversionOfConvertibleNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="BusinessAcquisitionExchangeRatio" id="adyx_BusinessAcquisitionExchangeRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="CollaborationInitiationPayment" id="adyx_CollaborationInitiationPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element name="CommonStockStockDividendsPerShareBookValue" id="adyx_CommonStockStockDividendsPerShareBookValue" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="ConvertibleNotePayableFiveMember" id="adyx_ConvertibleNotePayableFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConvertibleNotePayableFourMember" id="adyx_ConvertibleNotePayableFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ConvertibleNotePayableSixMember" id="adyx_ConvertibleNotePayableSixMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="EquityImpactOfSpinoff" id="adyx_EquityImpactOfSpinoff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="EquityIssuanceCostsCurrent" id="adyx_EquityIssuanceCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element name="EquityIssuanceCostsPaidInStock" id="adyx_EquityIssuanceCostsPaidInStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="EquityIssuanceCostsPaidInStockShares" id="adyx_EquityIssuanceCostsPaidInStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ExchangeOfWarrantsUponMerger" id="adyx_ExchangeOfWarrantsUponMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="GainLossDebtModification" id="adyx_GainLossDebtModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="GrantReimbursements" id="adyx_GrantReimbursements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="GrantReimbursementsExpense" id="adyx_GrantReimbursementsExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element name="IncreaseDecreaseInLeaseLiability" id="adyx_IncreaseDecreaseInLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element name="LesseeFinanceLeaseNotYetCommenced" id="adyx_LesseeFinanceLeaseNotYetCommenced" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="LesseeOperatingLeaseNotYetCommenced" id="adyx_LesseeOperatingLeaseNotYetCommenced" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="NoncashPortionOfLeaseExpense" id="adyx_NoncashPortionOfLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element name="NumberOfSharesHeldByEquityHolders" id="adyx_NumberOfSharesHeldByEquityHolders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="PrepaidClinicalTrialExpenseCurrent" id="adyx_PrepaidClinicalTrialExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element name="PriceRange1Member" id="adyx_PriceRange1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="PriceRange2Member" id="adyx_PriceRange2Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="PriceRange3Member" id="adyx_PriceRange3Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="PriceRange4Member" id="adyx_PriceRange4Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ReclassificationOfWarrantIntoEquity" id="adyx_ReclassificationOfWarrantIntoEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="ReclassificationOfWarrantLiabilityToPaidInCapital" id="adyx_ReclassificationOfWarrantLiabilityToPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="ReverseMergerDisclosureTextBlock" id="adyx_ReverseMergerDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ReverseStockSplitFromMember" id="adyx_ReverseStockSplitFromMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ReverseStockSplitMember" id="adyx_ReverseStockSplitMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" id="adyx_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="SeverancePayMember" id="adyx_SeverancePayMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" id="adyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
  <xsd:element name="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" id="adyx_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" id="adyx_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element name="WarrantToPurchaseCommonStockConvertedInMergerMember" id="adyx_WarrantToPurchaseCommonStockConvertedInMergerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details" id="adyx_statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-10-stock-options-summary-of-stock-option-activity-details" id="adyx_statement-statement-note-10-stock-options-summary-of-stock-option-activity-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-10-stock-options-tables" id="adyx_statement-statement-note-10-stock-options-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details" id="adyx_statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-4-property-and-equipment-net-tables" id="adyx_statement-statement-note-4-property-and-equipment-net-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details" id="adyx_statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details" id="adyx_statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-5-other-balance-sheet-information-tables" id="adyx_statement-statement-note-5-other-balance-sheet-information-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" id="adyx_statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables" id="adyx_statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-7-leases-future-minimum-lease-payments-details" id="adyx_statement-statement-note-7-leases-future-minimum-lease-payments-details" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <xsd:element name="statement-statement-note-7-leases-tables" id="adyx_statement-statement-note-7-leases-tables" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>adyx-20190630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!-- Created by Toppan Merrill -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.adynxx.com/role/StatementBalanceSheets" xlink:type="simple" xlink:href="adyx-20190630.xsd#StatementBalanceSheets"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/StatementStatementsOfOperations" xlink:type="simple" xlink:href="adyx-20190630.xsd#StatementStatementsOfOperations"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/StatementStatementOfCashFlows" xlink:type="simple" xlink:href="adyx-20190630.xsd#StatementStatementOfCashFlows"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote10IncomeTaxesComponentsOfDeferredTaxAssetsDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leases-future-minimum-lease-payments-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-7-leases-future-minimum-lease-payments-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-cash-flows-unauditedQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unauditedQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-property-and-equipment-net-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-4-property-and-equipment-net-property-and-equipment-net-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-accrued-liabilities-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-5-other-balance-sheet-information-accrued-liabilities-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-operations-unauditedQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-statements-of-operations-unauditedQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unauditedQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unauditedQuarterEnd"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesComponentsOfDeferredTaxAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637021864925608024"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_637021864925608024" use="optional" order="1.0" weight="1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637021864925608024"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637021864925608024" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637021864925608024" use="optional" order="1.0" weight="1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_637021864925608024"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637021864925608024" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_637021864925608024" use="optional" order="2.0" weight="1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637021864925608024"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637021864925608024" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637021864925608024" use="optional" order="3.0" weight="1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637021864925608024"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637021864925608024" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637021864925608024" use="optional" order="4.0" weight="1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637021864925608024"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637021864925608024" use="optional" order="2.0" weight="-1"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-7-leases-future-minimum-lease-payments-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="3.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="5.0" weight="1.0"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-cash-flows-unauditedQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="2.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to FairValueAdjustmentOfWarrants" order="2.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DerivativeGainLossOnDerivativeNet" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DerivativeGainLossOnDerivativeNet" order="3.0" weight="-1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:label="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:title="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" order="4.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="5.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="Depreciation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to Depreciation" order="6.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherOperatingAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherOperatingAssets" order="7.0" weight="-1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayable" order="8.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilities" order="9.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_IncreaseDecreaseInLeaseLiability" xlink:label="IncreaseDecreaseInLeaseLiability" xlink:title="IncreaseDecreaseInLeaseLiability"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInLeaseLiability" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInLeaseLiability" order="10.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfFinancingCostsAndDiscounts" order="11.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="PaidInKindInterest" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to PaidInKindInterest" order="12.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoncashPortionOfLeaseExpense" xlink:label="NoncashPortionOfLeaseExpense" xlink:title="NoncashPortionOfLeaseExpense"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NoncashPortionOfLeaseExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NoncashPortionOfLeaseExpense" order="13.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="14.0" weight="-1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="3.0" weight="1.0"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-property-and-equipment-net-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" weight="-1.0"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PrepaidClinicalTrialExpenseCurrent" xlink:label="PrepaidClinicalTrialExpenseCurrent" xlink:title="PrepaidClinicalTrialExpenseCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="PrepaidClinicalTrialExpenseCurrent" xlink:title="calculation: PrepaidExpenseAndOtherAssetsCurrent to PrepaidClinicalTrialExpenseCurrent" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityIssuanceCostsCurrent" xlink:label="EquityIssuanceCostsCurrent" xlink:title="EquityIssuanceCostsCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="EquityIssuanceCostsCurrent" xlink:title="calculation: PrepaidExpenseAndOtherAssetsCurrent to EquityIssuanceCostsCurrent" order="2.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="PrepaidInsurance" xlink:title="PrepaidInsurance"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="PrepaidInsurance" xlink:title="calculation: PrepaidExpenseAndOtherAssetsCurrent to PrepaidInsurance" order="3.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="OtherPrepaidExpenseCurrent" xlink:title="OtherPrepaidExpenseCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="OtherPrepaidExpenseCurrent" xlink:title="calculation: PrepaidExpenseAndOtherAssetsCurrent to OtherPrepaidExpenseCurrent" order="4.0" weight="1.0"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-accrued-liabilities-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedPayrollAndRelatedExpensesCurrent" xlink:label="AccruedPayrollAndRelatedExpensesCurrent" xlink:title="AccruedPayrollAndRelatedExpensesCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedPayrollAndRelatedExpensesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedPayrollAndRelatedExpensesCurrent" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedTermLoanPaymentsCurrent" xlink:label="AccruedTermLoanPaymentsCurrent" xlink:title="AccruedTermLoanPaymentsCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedTermLoanPaymentsCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedTermLoanPaymentsCurrent" order="2.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedClinicalTrialExpenseCurrent" xlink:label="AccruedClinicalTrialExpenseCurrent" xlink:title="AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedClinicalTrialExpenseCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedClinicalTrialExpenseCurrent" order="3.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedProfessionalFeesCurrent" order="4.0" weight="1.0"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-operations-unauditedQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="IncomeLossFromContinuingOperations" xlink:title="IncomeLossFromContinuingOperations"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeLossFromContinuingOperations" xlink:title="calculation: NetIncomeLoss to IncomeLossFromContinuingOperations" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperations" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperations to NonoperatingIncomeExpense" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperations" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperations to OperatingIncomeLoss" order="2.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperations" xlink:to="InterestExpense" xlink:title="calculation: IncomeLossFromContinuingOperations to InterestExpense" order="3.0" weight="-1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:title="DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:title="calculation: NetIncomeLoss to DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" order="2.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GrantReimbursementsExpense" xlink:label="GrantReimbursementsExpense" xlink:title="GrantReimbursementsExpense"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GrantReimbursementsExpense" xlink:title="calculation: OperatingExpenses to GrantReimbursementsExpense" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="2.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="3.0" weight="1.0"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unauditedQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="RestrictedCashNoncurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="RestrictedCashNoncurrent" xlink:title="calculation: Assets to RestrictedCashNoncurrent" use="optional" order="5.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" order="4.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="RestrictedCashCurrent" xlink:title="RestrictedCashCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="RestrictedCashCurrent" xlink:title="calculation: AssetsCurrent to RestrictedCashCurrent" order="2.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="3.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="2.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="calculation: Assets to OperatingLeaseRightOfUseAsset" order="3.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="4.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="5.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to OperatingLeaseLiabilityCurrent" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="LongTermDebtCurrent" xlink:title="calculation: LiabilitiesCurrent to LongTermDebtCurrent" order="3.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="ConvertibleDebtCurrent" xlink:title="ConvertibleDebtCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="ConvertibleDebtCurrent" xlink:title="calculation: LiabilitiesCurrent to ConvertibleDebtCurrent" order="2.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="1.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="2.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="3.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="4.0" weight="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommitmentsAndContingencies" xlink:title="calculation: StockholdersEquity to CommitmentsAndContingencies" order="5.0" weight="1.0"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>adyx-20190630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!-- Created by Toppan Merrill -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.adynxx.com/role/StatementBalanceSheets" xlink:type="simple" xlink:href="adyx-20190630.xsd#StatementBalanceSheets"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/StatementBalanceSheetsParentheticals" xlink:type="simple" xlink:href="adyx-20190630.xsd#StatementBalanceSheetsParentheticals"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" xlink:type="simple" xlink:href="adyx-20190630.xsd#StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote8WarrantsTables" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote8WarrantsTables"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote1OrganizationAndBasisOfPresentationDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote1OrganizationAndBasisOfPresentationDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsRecurringBasisDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsRecurringBasisDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesChangeInFairValueOfPreferredStockWarrantLiabilityDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote2SummaryOfSignificantAccountingPoliciesChangeInFairValueOfPreferredStockWarrantLiabilityDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote3PropertyAndEquipmentNetPropertyAndEquipmentNetDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote3PropertyAndEquipmentNetPropertyAndEquipmentNetDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote5TermLoansAndConvertiblePromissoryNotesDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesFuturePrincipalPaymentsOfTermLoansDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote5TermLoansAndConvertiblePromissoryNotesFuturePrincipalPaymentsOfTermLoansDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetailsParentheticals" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetailsParentheticals"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote7StockholdersDeficitDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitSharesReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote7StockholdersDeficitSharesReservedForFutureIssuanceDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote8WarrantsDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote8WarrantsDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote8WarrantsDetailsOfWarrantsDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote8WarrantsDetailsOfWarrantsDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote8WarrantsWarrantsAssumptionsDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote8WarrantsWarrantsAssumptionsDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote9StockOptionPlansDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote9StockOptionPlansDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote10IncomeTaxesDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote11RelatedPartyTransactionsDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote11RelatedPartyTransactionsDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote13SubsequentEventsDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote13SubsequentEventsDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-informationQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-5-other-balance-sheet-informationQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-document-and-entity-informationQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-document-and-entity-informationQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentationQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-1-organization-and-basis-of-presentationQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policiesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-2-summary-of-significant-accounting-policiesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-3-reverse-mergerQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-3-reverse-mergerQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-netQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-4-property-and-equipment-netQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-6-term-loans-and-convertible-promissory-notesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leasesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-7-leasesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stockQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-8-redeemable-convertible-preferred-stockQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-9-warrants-QuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-9-warrants-QuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-optionsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-10-stock-optionsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactionsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-11-relatedparty-transactionsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-12-subsequent-eventsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-12-subsequent-eventsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-significant-accounting-policies-policiesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-significant-accounting-policies-policiesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-tablesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-2-summary-of-significant-accounting-policies-tablesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-tablesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-4-property-and-equipment-net-tablesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-tablesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-5-other-balance-sheet-information-tablesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-tablesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-6-term-loans-and-convertible-promissory-notes-tablesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leases-tablesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-7-leases-tablesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-tablesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-10-stock-options-tablesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentation-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-1-organization-and-basis-of-presentation-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-3-reverse-merger-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-3-reverse-merger-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-4-property-and-equipment-net-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-6-term-loans-and-convertible-promissory-notes-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leases-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-7-leases-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stock-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-8-redeemable-convertible-preferred-stock-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-9-warrants-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-9-warrants-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-10-stock-options-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactions-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-11-relatedparty-transactions-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-12-subsequent-events-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-12-subsequent-events-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticalsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticalsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leases-future-minimum-lease-payments-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-7-leases-future-minimum-lease-payments-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-cash-flows-unauditedQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unauditedQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-property-and-equipment-net-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-4-property-and-equipment-net-property-and-equipment-net-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-accrued-liabilities-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-5-other-balance-sheet-information-accrued-liabilities-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-operations-unauditedQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-statements-of-operations-unauditedQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unauditedQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unauditedQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-redeemable-convertible-preferred-stock-and-stockholders-deficit-unauditedQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-statements-of-redeemable-convertible-preferred-stock-and-stockholders-deficit-unauditedQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-summary-of-stock-option-activity-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-10-stock-options-summary-of-stock-option-activity-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-stock-options-by-exercise-price-range-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-10-stock-options-stock-options-by-exercise-price-range-detailsQuarterEnd"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesFuturePrincipalPaymentsOfTermLoansDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoansMember" xlink:label="adyx_TermLoansMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adyx_TermLoansMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" use="optional" priority="1" order="2.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetailsParentheticals">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableOneMember" xlink:label="adyx_ConvertibleNotePayableOneMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adyx_ConvertibleNotePayableOneMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableTwoMember" xlink:label="adyx_ConvertibleNotePayableTwoMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adyx_ConvertibleNotePayableTwoMember" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableThreeMember" xlink:label="adyx_ConvertibleNotePayableThreeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adyx_ConvertibleNotePayableThreeMember" use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" use="optional" priority="1" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" use="optional" priority="1" order="2.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitDetailsTextual">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="adyx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adyx_SeriesARedeemableConvertiblePreferredStockMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adyx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adyx_SeriesBRedeemableConvertiblePreferredStockMember" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBConvertiblePreferredStockMember" xlink:label="adyx_SeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adyx_SeriesBConvertiblePreferredStockMember" use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesAConvertiblePreferredStockMember" xlink:label="adyx_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adyx_SeriesAConvertiblePreferredStockMember" use="optional" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_637021864926388029"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_637021864926388029" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" xlink:label="adyx_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="adyx_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:label="adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DividendsAxis" use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain_637021864926388029"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain_637021864926388029" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" xlink:label="adyx_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsDomain" xlink:to="adyx_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" xlink:label="adyx_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsDomain" xlink:to="adyx_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_637021864926388029"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain_637021864926388029" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfPreferredStockToCommonStockMember" xlink:label="adyx_ConversionOfPreferredStockToCommonStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="adyx_ConversionOfPreferredStockToCommonStockMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" use="optional" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" use="optional" priority="1" order="14.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" use="optional" priority="1" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" use="optional" priority="1" order="10.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" use="optional" priority="1" order="12.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" use="optional" priority="1" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" xlink:label="adyx_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" use="optional" priority="1" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" use="optional" priority="1" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared" use="optional" priority="1" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare" use="optional" priority="1" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityConvertibleAggregateProceedsTrigger" xlink:label="adyx_EquityConvertibleAggregateProceedsTrigger"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_EquityConvertibleAggregateProceedsTrigger" use="optional" priority="1" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityConvertibleStockPriceTrigger" xlink:label="adyx_EquityConvertibleStockPriceTrigger"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_EquityConvertibleStockPriceTrigger" use="optional" priority="1" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" use="optional" priority="1" order="13.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitSharesReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsReserveForSeriesAConvertiblePreferredStockMember" xlink:label="adyx_WarrantsReserveForSeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="adyx_WarrantsReserveForSeriesAConvertiblePreferredStockMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:label="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" use="optional" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" use="optional" priority="1" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" use="optional" priority="1" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquitySharesReservedForFutureIssuance" xlink:label="adyx_EquitySharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_EquitySharesReservedForFutureIssuance" use="optional" priority="1" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ConversionOfStockSharesIssued1" xlink:title="definition: StatementLineItems to ConversionOfStockSharesIssued1" order="6.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote8WarrantsDetailsOfWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockMember" xlink:label="adyx_WarrantsForSeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="adyx_WarrantsForSeriesAConvertiblePreferredStockMember" use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" xlink:label="adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInJanuary2016Member" xlink:label="adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" use="optional" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" use="optional" priority="1" order="3.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote8WarrantsWarrantsAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockMember" xlink:label="adyx_WarrantsForSeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="adyx_WarrantsForSeriesAConvertiblePreferredStockMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" use="optional" priority="1" order="2.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_637021864926544030"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_637021864926544030" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_637021864926544030"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_637021864926544030" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637021864926544030"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637021864926544030" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" use="optional" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_637021864926544030"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_637021864926544030" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" use="optional" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" use="optional" priority="1" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" use="optional" priority="1" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" priority="1" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:label="us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" use="optional" priority="1" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NumberOfForeignSubsidiaries" xlink:label="adyx_NumberOfForeignSubsidiaries"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_NumberOfForeignSubsidiaries" use="optional" priority="1" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" use="optional" priority="1" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OperatingLeaseCarryforwardsWithExpirationDates" xlink:label="adyx_OperatingLeaseCarryforwardsWithExpirationDates"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_OperatingLeaseCarryforwardsWithExpirationDates" use="optional" priority="1" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" use="optional" priority="1" order="10.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OperatingLossCarryforwardsExpiringIndefinitely" xlink:label="adyx_OperatingLossCarryforwardsExpiringIndefinitely"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_OperatingLossCarryforwardsExpiringIndefinitely" use="optional" priority="1" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" use="optional" priority="1" order="12.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" use="optional" priority="1" order="13.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" use="optional" priority="1" order="14.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" use="optional" priority="1" order="15.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote13SubsequentEventsDetailsTextual">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoansMember" xlink:label="adyx_TermLoansMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adyx_TermLoansMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FirstNoteToFundTheCompanysOperationsMember" xlink:label="adyx_FirstNoteToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adyx_FirstNoteToFundTheCompanysOperationsMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SecondNoteToFundTheCompanysOperationsMember" xlink:label="adyx_SecondNoteToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adyx_SecondNoteToFundTheCompanysOperationsMember" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFundTheCompanysOperationsMember" xlink:label="adyx_NotesToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adyx_NotesToFundTheCompanysOperationsMember" use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBConvertiblePreferredStockMember" xlink:label="adyx_SeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adyx_SeriesBConvertiblePreferredStockMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" use="optional" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="RangeAxis" xlink:title="definition: StatementTable to RangeAxis" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OxfordFinanceLLCMember" xlink:label="adyx_OxfordFinanceLLCMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="adyx_OxfordFinanceLLCMember" use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="adyx_MajorityInvestorsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="adyx_MajorityInvestorsMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DomainMember" xlink:label="adyx_DomainMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="adyx_DomainMember" use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="definition: StatementTable to NonmonetaryTransactionTypeAxis" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain_2" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain_2" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitMember" xlink:label="ReverseStockSplitMember" xlink:title="ReverseStockSplitMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonmonetaryTransactionTypeDomain" xlink:to="ReverseStockSplitMember" xlink:title="definition: NonmonetaryTransactionTypeDomain to ReverseStockSplitMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" use="optional" priority="1" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" use="optional" priority="1" order="14.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" use="optional" priority="1" order="13.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" use="optional" priority="1" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:label="adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" use="optional" priority="1" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:label="adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" use="optional" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:label="adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" use="optional" priority="1" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="us-gaap_ProceedsFromMinorityShareholders"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromMinorityShareholders" use="optional" priority="1" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" use="optional" priority="1" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtConversionOriginalDebtAmountPrincipal" xlink:label="adyx_DebtConversionOriginalDebtAmountPrincipal"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_DebtConversionOriginalDebtAmountPrincipal" use="optional" priority="1" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:label="adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest" use="optional" priority="1" order="12.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:label="adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" use="optional" priority="1" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:label="adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" use="optional" priority="1" order="10.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="definition: StatementLineItems to ProceedsFromIssuanceOrSaleOfEquity" order="15.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-informationQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract" xlink:title="definition: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureTextBlockAbstract" xlink:to="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="definition: DisclosureTextBlockAbstract to SupplementalBalanceSheetDisclosuresTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentationQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: StatementTable to LongtermDebtTypeAxis" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain_2" xlink:title="LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain_2" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="ConvertibleDebtMember" xlink:title="ConvertibleDebtMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleDebtMember" xlink:title="definition: LongtermDebtTypeDomain to ConvertibleDebtMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: StatementTable to DebtInstrumentAxis" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FirstNoteToFundTheCompanysOperationsMember" xlink:label="FirstNoteToFundTheCompanysOperationsMember" xlink:title="FirstNoteToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="FirstNoteToFundTheCompanysOperationsMember" xlink:title="definition: DebtInstrumentNameDomain to FirstNoteToFundTheCompanysOperationsMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SecondNoteToFundTheCompanysOperationsMember" xlink:label="SecondNoteToFundTheCompanysOperationsMember" xlink:title="SecondNoteToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="SecondNoteToFundTheCompanysOperationsMember" xlink:title="definition: DebtInstrumentNameDomain to SecondNoteToFundTheCompanysOperationsMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFundTheCompanysOperationsMember" xlink:label="NotesToFundTheCompanysOperationsMember" xlink:title="NotesToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="NotesToFundTheCompanysOperationsMember" xlink:title="definition: DebtInstrumentNameDomain to NotesToFundTheCompanysOperationsMember" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="definition: StatementTable to LineOfCreditFacilityAxis" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain_2" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain_2" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="MajorityInvestorsMember" xlink:title="definition: LineOfCreditFacilityLenderDomain to MajorityInvestorsMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: StatementTable to CounterpartyNameAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OxfordFinanceLLCMember" xlink:label="OxfordFinanceLLCMember" xlink:title="OxfordFinanceLLCMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="OxfordFinanceLLCMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to OxfordFinanceLLCMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="definition: StatementTable to NonmonetaryTransactionTypeAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain_2" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain_2" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitFromMember" xlink:label="ReverseStockSplitFromMember" xlink:title="ReverseStockSplitFromMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonmonetaryTransactionTypeDomain" xlink:to="ReverseStockSplitFromMember" xlink:title="definition: NonmonetaryTransactionTypeDomain to ReverseStockSplitFromMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: EntityDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: StatementTable to BusinessAcquisitionAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="2.0" xbrldt:closed="true"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract" xlink:title="definition: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureTextBlockAbstract" xlink:to="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="definition: DisclosureTextBlockAbstract to OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policiesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: StatementTable to DebtInstrumentAxis" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:label="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="ModifiedMarch2018AndModifiedSeptember2018NotesMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="definition: DebtInstrumentNameDomain to ModifiedMarch2018AndModifiedSeptember2018NotesMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="definition: StatementTable to RangeAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="9.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: StatementTable to ConcentrationRiskByBenchmarkAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccountsPayable1Member" xlink:label="AccountsPayable1Member" xlink:title="AccountsPayable1Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="AccountsPayable1Member" xlink:title="definition: ConcentrationRiskBenchmarkDomain to AccountsPayable1Member" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: StatementTable to ConcentrationRiskByTypeAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="SupplierConcentrationRiskMember" xlink:title="SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="SupplierConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to SupplierConcentrationRiskMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:title="definition: StatementTable to ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_2" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_2" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor1Member" xlink:label="Vendor1Member" xlink:title="Vendor1Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="Vendor1Member" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain to Vendor1Member" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor2Member" xlink:label="Vendor2Member" xlink:title="Vendor2Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="Vendor2Member" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain to Vendor2Member" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor3Member" xlink:label="Vendor3Member" xlink:title="Vendor3Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="Vendor3Member" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain to Vendor3Member" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:label="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:title="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain to TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:title="definition: StatementTable to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LetterOfCredit1Member" xlink:label="LetterOfCredit1Member" xlink:title="LetterOfCredit1Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="LetterOfCredit1Member" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to LetterOfCredit1Member" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="MoneyMarketFundsMember" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to MoneyMarketFundsMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: StatementTable to IncomeStatementLocationAxis" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="definition: StatementTable to AdjustmentsForNewAccountingPronouncementsAxis" order="8.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember_2" xlink:title="TypeOfAdoptionMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember_2" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="AccountingStandardsUpdate201602Member" xlink:title="AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypeOfAdoptionMember" xlink:to="AccountingStandardsUpdate201602Member" xlink:title="definition: TypeOfAdoptionMember to AccountingStandardsUpdate201602Member" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract" xlink:title="definition: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureTextBlockAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="definition: DisclosureTextBlockAbstract to SignificantAccountingPoliciesTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-3-reverse-mergerQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtConversionByUniqueDescriptionAxis" xlink:title="definition: StatementTable to DebtConversionByUniqueDescriptionAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain_2" xlink:title="DebtConversionNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain_2" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtConversionNameDomain" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="definition: DebtConversionNameDomain to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="definition: StatementTable to NonmonetaryTransactionTypeAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain_2" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain_2" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitFromMember" xlink:label="ReverseStockSplitFromMember" xlink:title="ReverseStockSplitFromMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonmonetaryTransactionTypeDomain" xlink:to="ReverseStockSplitFromMember" xlink:title="definition: NonmonetaryTransactionTypeDomain to ReverseStockSplitFromMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: EntityDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AquaMedMember" xlink:label="AquaMedMember" xlink:title="AquaMedMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AquaMedMember" xlink:title="definition: EntityDomain to AquaMedMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: StatementTable to BusinessAcquisitionAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="2.0" xbrldt:closed="true"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: StatementTable to IncomeStatementLocationAxis" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="InterestExpenseMember" xlink:title="InterestExpenseMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="InterestExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to InterestExpenseMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract" xlink:title="definition: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseMergerDisclosureTextBlock" xlink:label="ReverseMergerDisclosureTextBlock" xlink:title="ReverseMergerDisclosureTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureTextBlockAbstract" xlink:to="ReverseMergerDisclosureTextBlock" xlink:title="definition: DisclosureTextBlockAbstract to ReverseMergerDisclosureTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-netQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract" xlink:title="definition: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureTextBlockAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="definition: DisclosureTextBlockAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: StatementTable to LongtermDebtTypeAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain_2" xlink:title="LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain_2" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="TermLoansMember" xlink:title="definition: LongtermDebtTypeDomain to TermLoansMember" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanAMember" xlink:label="TermLoanAMember" xlink:title="TermLoanAMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="TermLoanAMember" xlink:title="definition: LongtermDebtTypeDomain to TermLoanAMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanBMember" xlink:label="TermLoanBMember" xlink:title="TermLoanBMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="TermLoanBMember" xlink:title="definition: LongtermDebtTypeDomain to TermLoanBMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: StatementTable to DebtInstrumentAxis" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FirstNoteToFundTheCompanysOperationsMember" xlink:label="FirstNoteToFundTheCompanysOperationsMember" xlink:title="FirstNoteToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="FirstNoteToFundTheCompanysOperationsMember" xlink:title="definition: DebtInstrumentNameDomain to FirstNoteToFundTheCompanysOperationsMember" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SecondNoteToFundTheCompanysOperationsMember" xlink:label="SecondNoteToFundTheCompanysOperationsMember" xlink:title="SecondNoteToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="SecondNoteToFundTheCompanysOperationsMember" xlink:title="definition: DebtInstrumentNameDomain to SecondNoteToFundTheCompanysOperationsMember" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFundTheCompanysOperationsMember" xlink:label="NotesToFundTheCompanysOperationsMember" xlink:title="NotesToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="NotesToFundTheCompanysOperationsMember" xlink:title="definition: DebtInstrumentNameDomain to NotesToFundTheCompanysOperationsMember" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePromissoryNoteOf15MillionMember" xlink:label="ConvertiblePromissoryNoteOf15MillionMember" xlink:title="ConvertiblePromissoryNoteOf15MillionMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertiblePromissoryNoteOf15MillionMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertiblePromissoryNoteOf15MillionMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:label="ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:title="ModifiedMarch2019AndModifiedDecember2018NotesMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:title="definition: DebtInstrumentNameDomain to ModifiedMarch2019AndModifiedDecember2018NotesMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:label="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:title="ModifiedMarch2018September2018December2018AndMarch2019NotesMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:title="definition: DebtInstrumentNameDomain to ModifiedMarch2018September2018December2018AndMarch2019NotesMember" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtConversionByUniqueDescriptionAxis" xlink:title="definition: StatementTable to DebtConversionByUniqueDescriptionAxis" order="8.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain_2" xlink:title="DebtConversionNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain_2" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtConversionNameDomain" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="definition: DebtConversionNameDomain to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: StatementTable to ClassOfWarrantOrRightAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:label="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="definition: StatementTable to RangeAxis" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="definition: StatementTable to LineOfCreditFacilityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain_2" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain_2" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OxfordFinanceLLCMember" xlink:label="OxfordFinanceLLCMember" xlink:title="OxfordFinanceLLCMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="OxfordFinanceLLCMember" xlink:title="definition: LineOfCreditFacilityLenderDomain to OxfordFinanceLLCMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="MajorityInvestorsMember" xlink:title="definition: LineOfCreditFacilityLenderDomain to MajorityInvestorsMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: StatementTable to CounterpartyNameAxis" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DomainMember" xlink:label="DomainMember" xlink:title="DomainMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="DomainMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to DomainMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="10.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: StatementTable to BusinessAcquisitionAxis" order="9.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="VariableRateAxis" xlink:title="definition: StatementTable to VariableRateAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain_2" xlink:title="VariableRateDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain_2" xlink:title="definition: VariableRateAxis to VariableRateDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLiborSwapRateMember" xlink:label="LondonInterbankOfferedRateLiborSwapRateMember" xlink:title="LondonInterbankOfferedRateLiborSwapRateMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VariableRateDomain" xlink:to="LondonInterbankOfferedRateLiborSwapRateMember" xlink:title="definition: VariableRateDomain to LondonInterbankOfferedRateLiborSwapRateMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract" xlink:title="definition: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureTextBlockAbstract" xlink:to="DebtDisclosureTextBlock" xlink:title="definition: DisclosureTextBlockAbstract to DebtDisclosureTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-7-leasesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract" xlink:title="definition: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureTextBlockAbstract" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="definition: DisclosureTextBlockAbstract to LesseeOperatingLeasesTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stockQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesARedeemableConvertiblePreferredStockMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesBRedeemableConvertiblePreferredStockMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ConversionOfStockByUniqueDescriptionAxis" xlink:title="definition: StatementTable to ConversionOfStockByUniqueDescriptionAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfStockNameDomain" xlink:title="definition: ConversionOfStockByUniqueDescriptionAxis to ConversionOfStockNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain_2" xlink:title="ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfStockNameDomain_2" xlink:title="definition: ConversionOfStockByUniqueDescriptionAxis to ConversionOfStockNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConversionOfStockNameDomain" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="definition: ConversionOfStockNameDomain to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract" xlink:title="definition: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="PreferredStockTextBlock" xlink:title="PreferredStockTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureTextBlockAbstract" xlink:to="PreferredStockTextBlock" xlink:title="definition: DisclosureTextBlockAbstract to PreferredStockTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-9-warrants-QuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: StatementTable to ClassOfWarrantOrRightAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:label="WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:title="WarrantToPurchaseCommonStockConvertedInMergerMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantToPurchaseCommonStockConvertedInMergerMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaWarrantsAssumedInMergerMember" xlink:label="AlliquaWarrantsAssumedInMergerMember" xlink:title="AlliquaWarrantsAssumedInMergerMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="AlliquaWarrantsAssumedInMergerMember" xlink:title="definition: ClassOfWarrantOrRightDomain to AlliquaWarrantsAssumedInMergerMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="definition: StatementTable to RangeAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: StatementTable to BusinessAcquisitionAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract" xlink:title="definition: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsDisclosureTextBlock" xlink:label="WarrantsDisclosureTextBlock" xlink:title="WarrantsDisclosureTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureTextBlockAbstract" xlink:to="WarrantsDisclosureTextBlock" xlink:title="definition: DisclosureTextBlockAbstract to WarrantsDisclosureTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-10-stock-optionsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="definition: StatementTable to RangeAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: EntityDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: StatementTable to BusinessAcquisitionAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="2.0" xbrldt:closed="true"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="AwardTypeAxis" xlink:title="definition: StatementTable to AwardTypeAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NonEmployeeOptionsMember" xlink:label="NonEmployeeOptionsMember" xlink:title="NonEmployeeOptionsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="NonEmployeeOptionsMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to NonEmployeeOptionsMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract" xlink:title="definition: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureTextBlockAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="definition: DisclosureTextBlockAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactionsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="definition: StatementTable to LineOfCreditFacilityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain_2" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain_2" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="MajorityInvestorsMember" xlink:title="definition: LineOfCreditFacilityLenderDomain to MajorityInvestorsMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: StatementTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="definition: RelatedPartyDomain to ChiefExecutiveOfficerMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="definition: StatementTable to RelatedPartyTransactionAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain_2" xlink:title="RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain_2" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeverancePayMember" xlink:label="SeverancePayMember" xlink:title="SeverancePayMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionDomain" xlink:to="SeverancePayMember" xlink:title="definition: RelatedPartyTransactionDomain to SeverancePayMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract" xlink:title="definition: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureTextBlockAbstract" xlink:to="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="definition: DisclosureTextBlockAbstract to RelatedPartyTransactionsDisclosureTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-12-subsequent-eventsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="definition: StatementTable to RangeAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: StatementTable to SubsequentEventTypeAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: StatementTable to CounterpartyNameAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DomainMember" xlink:label="DomainMember" xlink:title="DomainMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="DomainMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to DomainMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="definition: StatementTable to NonmonetaryTransactionTypeAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain_2" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain_2" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitMember" xlink:label="ReverseStockSplitMember" xlink:title="ReverseStockSplitMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonmonetaryTransactionTypeDomain" xlink:to="ReverseStockSplitMember" xlink:title="definition: NonmonetaryTransactionTypeDomain to ReverseStockSplitMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract" xlink:title="definition: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureTextBlockAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="definition: DisclosureTextBlockAbstract to SubsequentEventsTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-significant-accounting-policies-policiesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="PolicyTextBlockAbstract" xlink:title="PolicyTextBlockAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PolicyTextBlockAbstract" xlink:title="definition: StatementLineItems to PolicyTextBlockAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PolicyTextBlockAbstract" xlink:to="AccountingPoliciesAbstract" xlink:title="definition: PolicyTextBlockAbstract to AccountingPoliciesAbstract" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="definition: AccountingPoliciesAbstract to UseOfEstimates" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="ConcentrationRiskCreditRisk" xlink:title="definition: AccountingPoliciesAbstract to ConcentrationRiskCreditRisk" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:label="ClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:title="ClinicalTrialAccrualsPolicyPolicyTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="ClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:title="definition: AccountingPoliciesAbstract to ClinicalTrialAccrualsPolicyPolicyTextBlock" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="definition: AccountingPoliciesAbstract to CashAndCashEquivalentsPolicyTextBlock" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="definition: AccountingPoliciesAbstract to PropertyPlantAndEquipmentPolicyTextBlock" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="definition: AccountingPoliciesAbstract to ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:title="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:title="definition: AccountingPoliciesAbstract to CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="definition: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="8.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="definition: AccountingPoliciesAbstract to ResearchAndDevelopmentExpensePolicy" order="9.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="CollaborativeArrangementAccountingPolicy" xlink:title="CollaborativeArrangementAccountingPolicy"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="CollaborativeArrangementAccountingPolicy" xlink:title="definition: AccountingPoliciesAbstract to CollaborativeArrangementAccountingPolicy" order="10.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GrantReimbursementPolicyPolicyTextBlock" xlink:label="GrantReimbursementPolicyPolicyTextBlock" xlink:title="GrantReimbursementPolicyPolicyTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="GrantReimbursementPolicyPolicyTextBlock" xlink:title="definition: AccountingPoliciesAbstract to GrantReimbursementPolicyPolicyTextBlock" order="11.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="definition: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="12.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" xlink:label="ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" xlink:title="ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" xlink:title="definition: AccountingPoliciesAbstract to ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" order="13.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" xlink:label="DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" xlink:title="DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" xlink:title="definition: AccountingPoliciesAbstract to DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" order="14.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="DerivativesPolicyTextBlock" xlink:title="DerivativesPolicyTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="DerivativesPolicyTextBlock" xlink:title="definition: AccountingPoliciesAbstract to DerivativesPolicyTextBlock" order="15.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="definition: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="16.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="DiscontinuedOperationsPolicyTextBlock" xlink:title="DiscontinuedOperationsPolicyTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="DiscontinuedOperationsPolicyTextBlock" xlink:title="definition: AccountingPoliciesAbstract to DiscontinuedOperationsPolicyTextBlock" order="17.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="definition: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="18.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-tablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="definition: StatementLineItems to TableTextBlock" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TableTextBlock" xlink:to="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="definition: TableTextBlock to ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TableTextBlock" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="definition: TableTextBlock to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-tablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="definition: StatementLineItems to TableTextBlock" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TableTextBlock" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="definition: TableTextBlock to PropertyPlantAndEquipmentTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-tablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="definition: StatementLineItems to TableTextBlock" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:label="ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:title="ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TableTextBlock" xlink:to="ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:title="definition: TableTextBlock to ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TableTextBlock" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="definition: TableTextBlock to ScheduleOfAccruedLiabilitiesTableTextBlock" order="2.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-tablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="definition: StatementLineItems to TableTextBlock" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="ConvertibleDebtTableTextBlock" xlink:title="ConvertibleDebtTableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TableTextBlock" xlink:to="ConvertibleDebtTableTextBlock" xlink:title="definition: TableTextBlock to ConvertibleDebtTableTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-7-leases-tablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="definition: StatementLineItems to TableTextBlock" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TableTextBlock" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="definition: TableTextBlock to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-tablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="2.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="definition: StatementLineItems to TableTextBlock" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TableTextBlock" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="definition: TableTextBlock to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TableTextBlock" xlink:to="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="definition: TableTextBlock to ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentation-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: StatementTable to LongtermDebtTypeAxis" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain_2" xlink:title="LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain_2" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="ConvertibleDebtMember" xlink:title="ConvertibleDebtMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleDebtMember" xlink:title="definition: LongtermDebtTypeDomain to ConvertibleDebtMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: StatementTable to DebtInstrumentAxis" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FirstNoteToFundTheCompanysOperationsMember" xlink:label="FirstNoteToFundTheCompanysOperationsMember" xlink:title="FirstNoteToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="FirstNoteToFundTheCompanysOperationsMember" xlink:title="definition: DebtInstrumentNameDomain to FirstNoteToFundTheCompanysOperationsMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SecondNoteToFundTheCompanysOperationsMember" xlink:label="SecondNoteToFundTheCompanysOperationsMember" xlink:title="SecondNoteToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="SecondNoteToFundTheCompanysOperationsMember" xlink:title="definition: DebtInstrumentNameDomain to SecondNoteToFundTheCompanysOperationsMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFundTheCompanysOperationsMember" xlink:label="NotesToFundTheCompanysOperationsMember" xlink:title="NotesToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="NotesToFundTheCompanysOperationsMember" xlink:title="definition: DebtInstrumentNameDomain to NotesToFundTheCompanysOperationsMember" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="definition: StatementTable to LineOfCreditFacilityAxis" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain_2" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain_2" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="MajorityInvestorsMember" xlink:title="definition: LineOfCreditFacilityLenderDomain to MajorityInvestorsMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: StatementTable to CounterpartyNameAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OxfordFinanceLLCMember" xlink:label="OxfordFinanceLLCMember" xlink:title="OxfordFinanceLLCMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="OxfordFinanceLLCMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to OxfordFinanceLLCMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="definition: StatementTable to NonmonetaryTransactionTypeAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain_2" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain_2" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitFromMember" xlink:label="ReverseStockSplitFromMember" xlink:title="ReverseStockSplitFromMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonmonetaryTransactionTypeDomain" xlink:to="ReverseStockSplitFromMember" xlink:title="definition: NonmonetaryTransactionTypeDomain to ReverseStockSplitFromMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: EntityDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: StatementTable to BusinessAcquisitionAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="2.0" xbrldt:closed="true"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: StatementLineItems to DebtInstrumentInterestRateStatedPercentage" order="9.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromNotesPayable" xlink:title="definition: StatementLineItems to ProceedsFromNotesPayable" order="8.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: StatementLineItems to CashAndCashEquivalentsAtCarryingValue" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayable" xlink:label="LoansPayable" xlink:title="LoansPayable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LoansPayable" xlink:title="definition: StatementLineItems to LoansPayable" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="NotesPayable" xlink:title="NotesPayable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NotesPayable" xlink:title="definition: StatementLineItems to NotesPayable" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: StatementLineItems to RetainedEarningsAccumulatedDeficit" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_BusinessAcquisitionExchangeRatio" xlink:label="BusinessAcquisitionExchangeRatio" xlink:title="BusinessAcquisitionExchangeRatio"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="BusinessAcquisitionExchangeRatio" xlink:title="definition: StatementLineItems to BusinessAcquisitionExchangeRatio" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="definition: StatementLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="3.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: StatementTable to DebtInstrumentAxis" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:label="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="ModifiedMarch2018AndModifiedSeptember2018NotesMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="definition: DebtInstrumentNameDomain to ModifiedMarch2018AndModifiedSeptember2018NotesMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="definition: StatementTable to RangeAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: StatementTable to SubsequentEventTypeAxis" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="9.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: StatementTable to ConcentrationRiskByBenchmarkAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccountsPayable1Member" xlink:label="AccountsPayable1Member" xlink:title="AccountsPayable1Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="AccountsPayable1Member" xlink:title="definition: ConcentrationRiskBenchmarkDomain to AccountsPayable1Member" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: StatementTable to ConcentrationRiskByTypeAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="SupplierConcentrationRiskMember" xlink:title="SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="SupplierConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to SupplierConcentrationRiskMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:title="definition: StatementTable to ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_2" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_2" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor1Member" xlink:label="Vendor1Member" xlink:title="Vendor1Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="Vendor1Member" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain to Vendor1Member" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor2Member" xlink:label="Vendor2Member" xlink:title="Vendor2Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="Vendor2Member" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain to Vendor2Member" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor3Member" xlink:label="Vendor3Member" xlink:title="Vendor3Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="Vendor3Member" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain to Vendor3Member" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:label="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:title="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain to TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:label="OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:title="OneOfTheTwoVendorsSupportingManufacturingActivitiesMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain to OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:title="definition: StatementTable to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LetterOfCredit1Member" xlink:label="LetterOfCredit1Member" xlink:title="LetterOfCredit1Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="LetterOfCredit1Member" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to LetterOfCredit1Member" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="MoneyMarketFundsMember" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to MoneyMarketFundsMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: StatementTable to IncomeStatementLocationAxis" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="definition: StatementTable to AdjustmentsForNewAccountingPronouncementsAxis" order="8.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember_2" xlink:title="TypeOfAdoptionMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember_2" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="AccountingStandardsUpdate201602Member" xlink:title="AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypeOfAdoptionMember" xlink:to="AccountingStandardsUpdate201602Member" xlink:title="definition: TypeOfAdoptionMember to AccountingStandardsUpdate201602Member" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="definition: StatementTable to ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:label="ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:title="ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:label="ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:title="ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="RestrictedCash" xlink:title="RestrictedCash"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RestrictedCash" xlink:title="definition: StatementLineItems to RestrictedCash" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: StatementLineItems to ConcentrationRiskPercentage1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: StatementLineItems to ResearchAndDevelopmentExpense" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: StatementLineItems to PropertyPlantAndEquipmentUsefulLife" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="GrantsReceivable" xlink:title="GrantsReceivable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GrantsReceivable" xlink:title="definition: StatementLineItems to GrantsReceivable" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="definition: StatementLineItems to GainsLossesOnExtinguishmentOfDebt" order="12.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:title="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:title="definition: StatementLineItems to EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="14.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingLeaseLiability" xlink:title="definition: StatementLineItems to OperatingLeaseLiability" order="15.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="definition: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsDue" order="16.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="definition: StatementLineItems to ImpairmentOfLongLivedAssetsHeldForUse" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="PaymentsOfDividends" xlink:title="PaymentsOfDividends"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaymentsOfDividends" xlink:title="definition: StatementLineItems to PaymentsOfDividends" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_CollaborationInitiationPayment" xlink:label="CollaborationInitiationPayment" xlink:title="CollaborationInitiationPayment"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CollaborationInitiationPayment" xlink:title="definition: StatementLineItems to CollaborationInitiationPayment" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GrantReimbursements" xlink:label="GrantReimbursements" xlink:title="GrantReimbursements"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GrantReimbursements" xlink:title="definition: StatementLineItems to GrantReimbursements" order="10.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReclassificationOfWarrantIntoEquity" xlink:label="ReclassificationOfWarrantIntoEquity" xlink:title="ReclassificationOfWarrantIntoEquity"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ReclassificationOfWarrantIntoEquity" xlink:title="definition: StatementLineItems to ReclassificationOfWarrantIntoEquity" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xlink:label="EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xlink:title="EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xlink:title="definition: StatementLineItems to EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" order="13.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseDiscountRate" xlink:title="definition: StatementLineItems to LesseeOperatingLeaseDiscountRate" order="17.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="definition: StatementLineItems to OperatingLeaseRightOfUseAsset" order="18.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-3-reverse-merger-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtConversionByUniqueDescriptionAxis" xlink:title="definition: StatementTable to DebtConversionByUniqueDescriptionAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain_2" xlink:title="DebtConversionNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain_2" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtConversionNameDomain" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="definition: DebtConversionNameDomain to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="definition: StatementTable to NonmonetaryTransactionTypeAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain_2" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain_2" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitFromMember" xlink:label="ReverseStockSplitFromMember" xlink:title="ReverseStockSplitFromMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonmonetaryTransactionTypeDomain" xlink:to="ReverseStockSplitFromMember" xlink:title="definition: NonmonetaryTransactionTypeDomain to ReverseStockSplitFromMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: EntityDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AquaMedMember" xlink:label="AquaMedMember" xlink:title="AquaMedMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AquaMedMember" xlink:title="definition: EntityDomain to AquaMedMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: StatementTable to BusinessAcquisitionAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="2.0" xbrldt:closed="true"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: StatementTable to IncomeStatementLocationAxis" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="InterestExpenseMember" xlink:title="InterestExpenseMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="InterestExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to InterestExpenseMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="definition: StatementLineItems to DebtConversionConvertedInstrumentSharesIssued1" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtConversionOriginalDebtAmountPrincipal" xlink:label="DebtConversionOriginalDebtAmountPrincipal" xlink:title="DebtConversionOriginalDebtAmountPrincipal"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtConversionOriginalDebtAmountPrincipal" xlink:title="definition: StatementLineItems to DebtConversionOriginalDebtAmountPrincipal" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:label="DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:title="DebtConversionOriginalDebtAmountCumulativeAccruedInterest"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:title="definition: StatementLineItems to DebtConversionOriginalDebtAmountCumulativeAccruedInterest" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:label="MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:title="MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:title="definition: StatementLineItems to MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" order="9.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:label="MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:title="MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:title="definition: StatementLineItems to MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" order="10.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_BusinessAcquisitionExchangeRatio" xlink:label="BusinessAcquisitionExchangeRatio" xlink:title="BusinessAcquisitionExchangeRatio"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="BusinessAcquisitionExchangeRatio" xlink:title="definition: StatementLineItems to BusinessAcquisitionExchangeRatio" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="definition: StatementLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NumberOfSharesHeldByEquityHolders" xlink:label="NumberOfSharesHeldByEquityHolders" xlink:title="NumberOfSharesHeldByEquityHolders"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NumberOfSharesHeldByEquityHolders" xlink:title="definition: StatementLineItems to NumberOfSharesHeldByEquityHolders" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="IntangibleAssetsNetIncludingGoodwill" xlink:title="IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IntangibleAssetsNetIncludingGoodwill" xlink:title="definition: StatementLineItems to IntangibleAssetsNetIncludingGoodwill" order="8.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="definition: StatementLineItems to DebtInstrumentConvertibleBeneficialConversionFeature" order="11.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends" xlink:label="Dividends" xlink:title="Dividends"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Dividends" xlink:title="definition: StatementLineItems to Dividends" order="12.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="CommonStockDividendsPerShareCashPaid" xlink:title="CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockDividendsPerShareCashPaid" xlink:title="definition: StatementLineItems to CommonStockDividendsPerShareCashPaid" order="13.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_CommonStockStockDividendsPerShareBookValue" xlink:label="CommonStockStockDividendsPerShareBookValue" xlink:title="CommonStockStockDividendsPerShareBookValue"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockStockDividendsPerShareBookValue" xlink:title="definition: StatementLineItems to CommonStockStockDividendsPerShareBookValue" order="14.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Depreciation" xlink:title="definition: StatementLineItems to Depreciation" order="2.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: StatementTable to LongtermDebtTypeAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain_2" xlink:title="LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain_2" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="TermLoansMember" xlink:title="definition: LongtermDebtTypeDomain to TermLoansMember" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanAMember" xlink:label="TermLoanAMember" xlink:title="TermLoanAMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="TermLoanAMember" xlink:title="definition: LongtermDebtTypeDomain to TermLoanAMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanBMember" xlink:label="TermLoanBMember" xlink:title="TermLoanBMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="TermLoanBMember" xlink:title="definition: LongtermDebtTypeDomain to TermLoanBMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanCMember" xlink:label="TermLoanCMember" xlink:title="TermLoanCMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="TermLoanCMember" xlink:title="definition: LongtermDebtTypeDomain to TermLoanCMember" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: StatementTable to DebtInstrumentAxis" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FirstNoteToFundTheCompanysOperationsMember" xlink:label="FirstNoteToFundTheCompanysOperationsMember" xlink:title="FirstNoteToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="FirstNoteToFundTheCompanysOperationsMember" xlink:title="definition: DebtInstrumentNameDomain to FirstNoteToFundTheCompanysOperationsMember" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SecondNoteToFundTheCompanysOperationsMember" xlink:label="SecondNoteToFundTheCompanysOperationsMember" xlink:title="SecondNoteToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="SecondNoteToFundTheCompanysOperationsMember" xlink:title="definition: DebtInstrumentNameDomain to SecondNoteToFundTheCompanysOperationsMember" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFundTheCompanysOperationsMember" xlink:label="NotesToFundTheCompanysOperationsMember" xlink:title="NotesToFundTheCompanysOperationsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="NotesToFundTheCompanysOperationsMember" xlink:title="definition: DebtInstrumentNameDomain to NotesToFundTheCompanysOperationsMember" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:label="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="ModifiedMarch2018AndModifiedSeptember2018NotesMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="definition: DebtInstrumentNameDomain to ModifiedMarch2018AndModifiedSeptember2018NotesMember" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePromissoryNoteOf15MillionMember" xlink:label="ConvertiblePromissoryNoteOf15MillionMember" xlink:title="ConvertiblePromissoryNoteOf15MillionMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertiblePromissoryNoteOf15MillionMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertiblePromissoryNoteOf15MillionMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:label="ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:title="ModifiedMarch2019AndModifiedDecember2018NotesMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:title="definition: DebtInstrumentNameDomain to ModifiedMarch2019AndModifiedDecember2018NotesMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:label="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:title="ModifiedMarch2018September2018December2018AndMarch2019NotesMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:title="definition: DebtInstrumentNameDomain to ModifiedMarch2018September2018December2018AndMarch2019NotesMember" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:label="ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:title="ConvertiblePromissoryNoteIssuedOnMarch292019Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:title="definition: DebtInstrumentNameDomain to ConvertiblePromissoryNoteIssuedOnMarch292019Member" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:label="ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:title="ConvertiblePromissoryNoteIssuedSeptember272018Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:title="definition: DebtInstrumentNameDomain to ConvertiblePromissoryNoteIssuedSeptember272018Member" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtConversionByUniqueDescriptionAxis" xlink:title="definition: StatementTable to DebtConversionByUniqueDescriptionAxis" order="8.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain_2" xlink:title="DebtConversionNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain_2" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtConversionNameDomain" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="definition: DebtConversionNameDomain to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: StatementTable to ClassOfWarrantOrRightAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:label="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="definition: StatementTable to RangeAxis" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="definition: StatementTable to LineOfCreditFacilityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain_2" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain_2" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OxfordFinanceLLCMember" xlink:label="OxfordFinanceLLCMember" xlink:title="OxfordFinanceLLCMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="OxfordFinanceLLCMember" xlink:title="definition: LineOfCreditFacilityLenderDomain to OxfordFinanceLLCMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="MajorityInvestorsMember" xlink:title="definition: LineOfCreditFacilityLenderDomain to MajorityInvestorsMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: StatementTable to CounterpartyNameAxis" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DomainMember" xlink:label="DomainMember" xlink:title="DomainMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="DomainMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to DomainMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="10.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: StatementTable to BusinessAcquisitionAxis" order="9.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="VariableRateAxis" xlink:title="definition: StatementTable to VariableRateAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain_2" xlink:title="VariableRateDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain_2" xlink:title="definition: VariableRateAxis to VariableRateDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLiborSwapRateMember" xlink:label="LondonInterbankOfferedRateLiborSwapRateMember" xlink:title="LondonInterbankOfferedRateLiborSwapRateMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VariableRateDomain" xlink:to="LondonInterbankOfferedRateLiborSwapRateMember" xlink:title="definition: VariableRateDomain to LondonInterbankOfferedRateLiborSwapRateMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:label="ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:title="ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:title="definition: EquityComponentDomain to ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: StatementLineItems to DebtInstrumentInterestRateStatedPercentage" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="definition: StatementLineItems to DebtConversionConvertedInstrumentSharesIssued1" order="45.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: StatementLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="RestrictedCash" xlink:title="RestrictedCash"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RestrictedCash" xlink:title="definition: StatementLineItems to RestrictedCash" order="23.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:label="DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:title="DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:title="definition: StatementLineItems to DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" order="27.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:label="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:title="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:title="definition: StatementLineItems to DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" order="20.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:label="DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:title="DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:title="definition: StatementLineItems to DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" order="21.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="ProceedsFromMinorityShareholders" xlink:title="ProceedsFromMinorityShareholders"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromMinorityShareholders" xlink:title="definition: StatementLineItems to ProceedsFromMinorityShareholders" order="22.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromNotesPayable" xlink:title="definition: StatementLineItems to ProceedsFromNotesPayable" order="43.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayable" xlink:label="LoansPayable" xlink:title="LoansPayable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LoansPayable" xlink:title="definition: StatementLineItems to LoansPayable" order="16.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="definition: StatementLineItems to GainsLossesOnExtinguishmentOfDebt" order="39.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:title="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:title="definition: StatementLineItems to EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="48.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="definition: StatementLineItems to DebtInstrumentConvertibleBeneficialConversionFeature" order="46.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: StatementLineItems to DebtInstrumentFaceAmount" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="ProceedsFromIssuanceOfDebt" xlink:title="ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromIssuanceOfDebt" xlink:title="definition: StatementLineItems to ProceedsFromIssuanceOfDebt" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="definition: StatementLineItems to DebtInstrumentUnusedBorrowingCapacityAmount" order="12.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentUnusedBorrowingCapacityExpired" xlink:label="DebtInstrumentUnusedBorrowingCapacityExpired" xlink:title="DebtInstrumentUnusedBorrowingCapacityExpired"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentUnusedBorrowingCapacityExpired" xlink:title="definition: StatementLineItems to DebtInstrumentUnusedBorrowingCapacityExpired" order="13.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:label="LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:title="LongtermDebtPrincipalAndInterestPaymentsTerm"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:title="definition: StatementLineItems to LongtermDebtPrincipalAndInterestPaymentsTerm" order="14.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="definition: StatementLineItems to DebtInstrumentBasisSpreadOnVariableRate1" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:label="DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:title="DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:title="definition: StatementLineItems to DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:label="DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:title="DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:title="definition: StatementLineItems to DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:label="DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:title="DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:title="definition: StatementLineItems to DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:label="DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:title="DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:title="definition: StatementLineItems to DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:label="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:title="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:title="definition: StatementLineItems to DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" order="10.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:label="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:title="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:title="definition: StatementLineItems to DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" order="30.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:label="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:title="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:title="definition: StatementLineItems to DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" order="31.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:label="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:title="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:title="definition: StatementLineItems to DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" order="28.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromConvertibleDebt" xlink:title="definition: StatementLineItems to ProceedsFromConvertibleDebt" order="29.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:label="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:title="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:title="definition: StatementLineItems to DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" order="17.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:label="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:title="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:title="definition: StatementLineItems to DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" order="18.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:label="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:title="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:title="definition: StatementLineItems to DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" order="19.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="DeferredFinanceCostsNet" xlink:title="DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DeferredFinanceCostsNet" xlink:title="definition: StatementLineItems to DeferredFinanceCostsNet" order="24.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LongTermDebt" xlink:title="definition: StatementLineItems to LongTermDebt" order="25.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="InterestExpense" xlink:title="definition: StatementLineItems to InterestExpense" order="26.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:label="DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:title="DebtInstrumentConvertiblePreferredStockProceedsTrigger"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:title="definition: StatementLineItems to DebtInstrumentConvertiblePreferredStockProceedsTrigger" order="34.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:label="DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:title="DebtInstrumentConvertibleCommonStockProceedsTrigger"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:title="definition: StatementLineItems to DebtInstrumentConvertibleCommonStockProceedsTrigger" order="35.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="DebtInstrumentConvertibleConversionRatio1" xlink:title="DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertibleConversionRatio1" xlink:title="definition: StatementLineItems to DebtInstrumentConvertibleConversionRatio1" order="36.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:label="DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:title="DebtInstrumentConversionToCashInCaseOfChangeInControl"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:title="definition: StatementLineItems to DebtInstrumentConversionToCashInCaseOfChangeInControl" order="37.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="definition: StatementLineItems to DebtInstrumentConvertibleConversionPrice1" order="38.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FinancingThresholdProceedsToConvertNotesToEquity" xlink:label="FinancingThresholdProceedsToConvertNotesToEquity" xlink:title="FinancingThresholdProceedsToConvertNotesToEquity"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FinancingThresholdProceedsToConvertNotesToEquity" xlink:title="definition: StatementLineItems to FinancingThresholdProceedsToConvertNotesToEquity" order="40.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:label="DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:title="DebtInstrumentConversionToCashInCaseOfChangeInControlPremium"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:title="definition: StatementLineItems to DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" order="41.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_VotingRightsTransferredToBeConsideredAChangeInControl" xlink:label="VotingRightsTransferredToBeConsideredAChangeInControl" xlink:title="VotingRightsTransferredToBeConsideredAChangeInControl"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="VotingRightsTransferredToBeConsideredAChangeInControl" xlink:title="definition: StatementLineItems to VotingRightsTransferredToBeConsideredAChangeInControl" order="42.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ProbabilityOfQualifiedFinancingOccurring" xlink:label="ProbabilityOfQualifiedFinancingOccurring" xlink:title="ProbabilityOfQualifiedFinancingOccurring"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProbabilityOfQualifiedFinancingOccurring" xlink:title="definition: StatementLineItems to ProbabilityOfQualifiedFinancingOccurring" order="47.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ProbabilityOfChangeInControlOccurring" xlink:label="ProbabilityOfChangeInControlOccurring" xlink:title="ProbabilityOfChangeInControlOccurring"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProbabilityOfChangeInControlOccurring" xlink:title="definition: StatementLineItems to ProbabilityOfChangeInControlOccurring" order="53.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:title="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:title="definition: StatementLineItems to DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" order="49.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="definition: StatementLineItems to AmortizationOfDebtDiscountPremium" order="50.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReleaseOfDerivativeLiabilities" xlink:label="ReleaseOfDerivativeLiabilities" xlink:title="ReleaseOfDerivativeLiabilities"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ReleaseOfDerivativeLiabilities" xlink:title="definition: StatementLineItems to ReleaseOfDerivativeLiabilities" order="51.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="DebtInstrumentUnamortizedDiscountCurrent" xlink:title="DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentUnamortizedDiscountCurrent" xlink:title="definition: StatementLineItems to DebtInstrumentUnamortizedDiscountCurrent" order="52.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_BeneficialConversionFeatureConversionOfConvertibleNote" xlink:label="BeneficialConversionFeatureConversionOfConvertibleNote" xlink:title="BeneficialConversionFeatureConversionOfConvertibleNote"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="BeneficialConversionFeatureConversionOfConvertibleNote" xlink:title="definition: StatementLineItems to BeneficialConversionFeatureConversionOfConvertibleNote" order="54.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="DeferredFinanceCostsGross" xlink:title="DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DeferredFinanceCostsGross" xlink:title="definition: StatementLineItems to DeferredFinanceCostsGross" order="15.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GainLossDebtModification" xlink:label="GainLossDebtModification" xlink:title="GainLossDebtModification"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GainLossDebtModification" xlink:title="definition: StatementLineItems to GainLossDebtModification" order="32.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="InterestExpenseDebt" xlink:title="definition: StatementLineItems to InterestExpenseDebt" order="33.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtConversionOriginalDebtAmount1" xlink:title="definition: StatementLineItems to DebtConversionOriginalDebtAmount1" order="44.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-7-leases-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingLeaseExpense" xlink:title="definition: StatementLineItems to OperatingLeaseExpense" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="LeaseAndRentalExpense" xlink:title="LeaseAndRentalExpense"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LeaseAndRentalExpense" xlink:title="definition: StatementLineItems to LeaseAndRentalExpense" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="FinanceLeaseLiability" xlink:title="FinanceLeaseLiability"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FinanceLeaseLiability" xlink:title="definition: StatementLineItems to FinanceLeaseLiability" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LesseeOperatingLeaseNotYetCommenced" xlink:label="LesseeOperatingLeaseNotYetCommenced" xlink:title="LesseeOperatingLeaseNotYetCommenced"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseNotYetCommenced" xlink:title="definition: StatementLineItems to LesseeOperatingLeaseNotYetCommenced" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LesseeFinanceLeaseNotYetCommenced" xlink:label="LesseeFinanceLeaseNotYetCommenced" xlink:title="LesseeFinanceLeaseNotYetCommenced"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LesseeFinanceLeaseNotYetCommenced" xlink:title="definition: StatementLineItems to LesseeFinanceLeaseNotYetCommenced" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SubleaseIncome" xlink:title="definition: StatementLineItems to SubleaseIncome" order="7.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stock-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesARedeemableConvertiblePreferredStockMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesBRedeemableConvertiblePreferredStockMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ConversionOfStockByUniqueDescriptionAxis" xlink:title="definition: StatementTable to ConversionOfStockByUniqueDescriptionAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfStockNameDomain" xlink:title="definition: ConversionOfStockByUniqueDescriptionAxis to ConversionOfStockNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain_2" xlink:title="ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfStockNameDomain_2" xlink:title="definition: ConversionOfStockByUniqueDescriptionAxis to ConversionOfStockNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConversionOfStockNameDomain" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="definition: ConversionOfStockNameDomain to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TemporaryEquitySharesIssued" xlink:title="definition: StatementLineItems to TemporaryEquitySharesIssued" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TemporaryEquitySharesOutstanding" xlink:title="definition: StatementLineItems to TemporaryEquitySharesOutstanding" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="definition: StatementLineItems to DebtConversionConvertedInstrumentSharesIssued1" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesIssued" xlink:title="definition: StatementLineItems to PreferredStockSharesIssued" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="definition: StatementLineItems to PreferredStockSharesAuthorized" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesOutstanding" xlink:title="definition: StatementLineItems to PreferredStockSharesOutstanding" order="7.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-9-warrants-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: StatementTable to ClassOfWarrantOrRightAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockMember" xlink:label="WarrantsForSeriesAConvertiblePreferredStockMember" xlink:title="WarrantsForSeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantsForSeriesAConvertiblePreferredStockMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantsForSeriesAConvertiblePreferredStockMember" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:label="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:label="WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:title="WarrantToPurchaseCommonStockConvertedInMergerMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantToPurchaseCommonStockConvertedInMergerMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaWarrantsAssumedInMergerMember" xlink:label="AlliquaWarrantsAssumedInMergerMember" xlink:title="AlliquaWarrantsAssumedInMergerMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="AlliquaWarrantsAssumedInMergerMember" xlink:title="definition: ClassOfWarrantOrRightDomain to AlliquaWarrantsAssumedInMergerMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:label="WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:title="WarrantIssuedInConnectionWithTermLoanAAndBMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantIssuedInConnectionWithTermLoanAAndBMember" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="definition: StatementTable to RangeAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="MeasurementInputTypeAxis" xlink:title="definition: StatementTable to MeasurementInputTypeAxis" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain_2" xlink:title="MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain_2" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="MeasurementInputSharePriceMember" xlink:title="MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputSharePriceMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputSharePriceMember" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="MeasurementInputConversionPriceMember" xlink:title="MeasurementInputConversionPriceMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputConversionPriceMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputConversionPriceMember" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: StatementTable to BusinessAcquisitionAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: StatementLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: StatementLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: StatementLineItems to ClassOfWarrantOrRightOutstanding" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="definition: StatementLineItems to WarrantsAndRightsOutstandingMeasurementInput" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ExchangeOfWarrantsUponMerger" xlink:label="ExchangeOfWarrantsUponMerger" xlink:title="ExchangeOfWarrantsUponMerger"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ExchangeOfWarrantsUponMerger" xlink:title="definition: StatementLineItems to ExchangeOfWarrantsUponMerger" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="WarrantsNotSettleableInCashFairValueDisclosure" xlink:title="WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WarrantsNotSettleableInCashFairValueDisclosure" xlink:title="definition: StatementLineItems to WarrantsNotSettleableInCashFairValueDisclosure" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="definition: StatementLineItems to FairValueAdjustmentOfWarrants" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WarrantsAndRightsOutstanding" xlink:title="definition: StatementLineItems to WarrantsAndRightsOutstanding" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PercentageOfNotePayablePrincipal" xlink:label="PercentageOfNotePayablePrincipal" xlink:title="PercentageOfNotePayablePrincipal"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PercentageOfNotePayablePrincipal" xlink:title="definition: StatementLineItems to PercentageOfNotePayablePrincipal" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ClassOfWarrantsOrRightExercisableTerm" xlink:label="ClassOfWarrantsOrRightExercisableTerm" xlink:title="ClassOfWarrantsOrRightExercisableTerm"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ClassOfWarrantsOrRightExercisableTerm" xlink:title="definition: StatementLineItems to ClassOfWarrantsOrRightExercisableTerm" order="10.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="definition: StatementTable to RangeAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: EntityDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: StatementTable to BusinessAcquisitionAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="2.0" xbrldt:closed="true"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="AwardTypeAxis" xlink:title="definition: StatementTable to AwardTypeAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NonEmployeeOptionsMember" xlink:label="NonEmployeeOptionsMember" xlink:title="NonEmployeeOptionsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="NonEmployeeOptionsMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to NonEmployeeOptionsMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="PlanNameAxis" xlink:title="definition: StatementTable to PlanNameAxis" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ThePlanMember" xlink:label="ThePlanMember" xlink:title="ThePlanMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="ThePlanMember" xlink:title="definition: PlanNameDomain to ThePlanMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: StatementLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="definition: StatementLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="12.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" order="13.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" order="14.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="15.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharePrice" xlink:title="definition: StatementLineItems to SharePrice" order="16.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: StatementLineItems to AllocatedShareBasedCompensationExpense" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="definition: StatementLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: StatementLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:label="NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:title="NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:title="definition: StatementLineItems to NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:label="NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:title="NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:title="definition: StatementLineItems to NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" order="10.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:title="definition: StatementLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="definition: StatementLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="7.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactions-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBConvertiblePreferredStockMember" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:title="SeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesBConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesBConvertiblePreferredStockMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtConversionByUniqueDescriptionAxis" xlink:title="definition: StatementTable to DebtConversionByUniqueDescriptionAxis" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain_2" xlink:title="DebtConversionNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain_2" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtConversionNameDomain" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="definition: DebtConversionNameDomain to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: StatementTable to SubsequentEventTypeAxis" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="definition: StatementTable to LineOfCreditFacilityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain_2" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain_2" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="MajorityInvestorsMember" xlink:title="definition: LineOfCreditFacilityLenderDomain to MajorityInvestorsMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: StatementTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="definition: RelatedPartyDomain to ChiefExecutiveOfficerMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="definition: StatementTable to RelatedPartyTransactionAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain_2" xlink:title="RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain_2" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeverancePayMember" xlink:label="SeverancePayMember" xlink:title="SeverancePayMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionDomain" xlink:to="SeverancePayMember" xlink:title="definition: RelatedPartyTransactionDomain to SeverancePayMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: StatementLineItems to DebtInstrumentInterestRateStatedPercentage" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromNotesPayable" xlink:title="definition: StatementLineItems to ProceedsFromNotesPayable" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: StatementLineItems to DebtInstrumentFaceAmount" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="InterestPayableCurrentAndNoncurrent" xlink:title="definition: StatementLineItems to InterestPayableCurrentAndNoncurrent" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:title="NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:title="definition: StatementLineItems to NotesPayableRelatedPartiesCurrentAndNoncurrent" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="RelatedPartyTransactionAmountsOfTransaction" xlink:title="RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RelatedPartyTransactionAmountsOfTransaction" xlink:title="definition: StatementLineItems to RelatedPartyTransactionAmountsOfTransaction" order="3.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-12-subsequent-events-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="definition: StatementTable to RangeAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: StatementTable to SubsequentEventTypeAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: StatementTable to CounterpartyNameAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DomainMember" xlink:label="DomainMember" xlink:title="DomainMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="DomainMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to DomainMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="definition: StatementTable to NonmonetaryTransactionTypeAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain_2" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain_2" xlink:title="definition: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitMember" xlink:label="ReverseStockSplitMember" xlink:title="ReverseStockSplitMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonmonetaryTransactionTypeDomain" xlink:to="ReverseStockSplitMember" xlink:title="definition: NonmonetaryTransactionTypeDomain to ReverseStockSplitMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: StatementLineItems to DebtInstrumentInterestRateStatedPercentage" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="definition: StatementLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="ProceedsFromRelatedPartyDebt" xlink:title="ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromRelatedPartyDebt" xlink:title="definition: StatementLineItems to ProceedsFromRelatedPartyDebt" order="2.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticalsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesARedeemableConvertiblePreferredStockMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesBRedeemableConvertiblePreferredStockMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TemporaryEquitySharesIssued" xlink:title="definition: StatementLineItems to TemporaryEquitySharesIssued" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TemporaryEquitySharesOutstanding" xlink:title="definition: StatementLineItems to TemporaryEquitySharesOutstanding" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="definition: StatementLineItems to CommonStockParOrStatedValuePerShare" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: StatementLineItems to CommonStockSharesAuthorized" order="12.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: StatementLineItems to CommonStockSharesOutstanding" order="14.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesIssued" xlink:title="definition: StatementLineItems to PreferredStockSharesIssued" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="definition: StatementLineItems to PreferredStockSharesAuthorized" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesOutstanding" xlink:title="definition: StatementLineItems to PreferredStockSharesOutstanding" order="10.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:title="TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:title="definition: StatementLineItems to TemporaryEquityValueExcludingAdditionalPaidInCapital" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TemporaryEquitySharesAuthorized" xlink:title="definition: StatementLineItems to TemporaryEquitySharesAuthorized" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="TemporaryEquityLiquidationPreference" xlink:title="TemporaryEquityLiquidationPreference"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TemporaryEquityLiquidationPreference" xlink:title="definition: StatementLineItems to TemporaryEquityLiquidationPreference" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesIssued" xlink:title="definition: StatementLineItems to CommonStockSharesIssued" order="13.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="definition: StatementLineItems to PreferredStockParOrStatedValuePerShare" order="7.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-7-leases-future-minimum-lease-payments-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingLeaseLiability" xlink:title="definition: StatementLineItems to OperatingLeaseLiability" order="9.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="definition: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsDue" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="definition: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="definition: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="definition: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="definition: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="definition: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="definition: StatementLineItems to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-cash-flows-unauditedQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="definition: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="definition: StatementLineItems to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="Depreciation" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to Depreciation" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to FairValueAdjustmentOfWarrants" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DerivativeGainLossOnDerivativeNet" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DerivativeGainLossOnDerivativeNet" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:label="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:title="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfFinancingCostsAndDiscounts" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PaidInKindInterest" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to PaidInKindInterest" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoncashPortionOfLeaseExpense" xlink:label="NoncashPortionOfLeaseExpense" xlink:title="NoncashPortionOfLeaseExpense"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NoncashPortionOfLeaseExpense" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to NoncashPortionOfLeaseExpense" order="8.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="definition: StatementLineItems to IncreaseDecreaseInOperatingCapitalAbstract" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingAssets" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingAssets" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayable" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilities" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_IncreaseDecreaseInLeaseLiability" xlink:label="IncreaseDecreaseInLeaseLiability" xlink:title="IncreaseDecreaseInLeaseLiability"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInLeaseLiability" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInLeaseLiability" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to NetCashProvidedByUsedInOperatingActivities" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfLongTermDebt" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfLongTermDebt" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="ProceedsFromRelatedPartyDebt" xlink:title="ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromRelatedPartyDebt" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromRelatedPartyDebt" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="definition: StatementLineItems to SupplementalCashFlowInformationAbstract" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaidNet" xlink:title="definition: SupplementalCashFlowInformationAbstract to InterestPaidNet" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NoncashInvestingAndFinancingItemsAbstract" xlink:title="definition: StatementLineItems to NoncashInvestingAndFinancingItemsAbstract" order="8.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="definition: NoncashInvestingAndFinancingItemsAbstract to RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReclassificationOfWarrantLiabilityToPaidInCapital" xlink:label="ReclassificationOfWarrantLiabilityToPaidInCapital" xlink:title="ReclassificationOfWarrantLiabilityToPaidInCapital"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="ReclassificationOfWarrantLiabilityToPaidInCapital" xlink:title="definition: NoncashInvestingAndFinancingItemsAbstract to ReclassificationOfWarrantLiabilityToPaidInCapital" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="ConversionOfStockAmountConverted1" xlink:title="definition: NoncashInvestingAndFinancingItemsAbstract to ConversionOfStockAmountConverted1" order="3.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: StatementTable to FinancialInstrumentAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeMember" xlink:label="DerivativeMember" xlink:title="DerivativeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="DerivativeMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to DerivativeMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="definition: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:title="definition: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="definition: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="definition: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="definition: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:title="definition: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="5.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-property-and-equipment-net-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: StatementTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ComputerEquipmentMember" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LaboratoryEquipmentMember" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="definition: StatementLineItems to PropertyPlantAndEquipmentGross" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="definition: StatementLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: StatementLineItems to PropertyPlantAndEquipmentNet" order="4.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PrepaidClinicalTrialExpenseCurrent" xlink:label="PrepaidClinicalTrialExpenseCurrent" xlink:title="PrepaidClinicalTrialExpenseCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PrepaidClinicalTrialExpenseCurrent" xlink:title="definition: StatementLineItems to PrepaidClinicalTrialExpenseCurrent" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityIssuanceCostsCurrent" xlink:label="EquityIssuanceCostsCurrent" xlink:title="EquityIssuanceCostsCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EquityIssuanceCostsCurrent" xlink:title="definition: StatementLineItems to EquityIssuanceCostsCurrent" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="PrepaidInsurance" xlink:title="PrepaidInsurance"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PrepaidInsurance" xlink:title="definition: StatementLineItems to PrepaidInsurance" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="OtherPrepaidExpenseCurrent" xlink:title="OtherPrepaidExpenseCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherPrepaidExpenseCurrent" xlink:title="definition: StatementLineItems to OtherPrepaidExpenseCurrent" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="definition: StatementLineItems to PrepaidExpenseAndOtherAssetsCurrent" order="6.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-accrued-liabilities-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedPayrollAndRelatedExpensesCurrent" xlink:label="AccruedPayrollAndRelatedExpensesCurrent" xlink:title="AccruedPayrollAndRelatedExpensesCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccruedPayrollAndRelatedExpensesCurrent" xlink:title="definition: StatementLineItems to AccruedPayrollAndRelatedExpensesCurrent" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedTermLoanPaymentsCurrent" xlink:label="AccruedTermLoanPaymentsCurrent" xlink:title="AccruedTermLoanPaymentsCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccruedTermLoanPaymentsCurrent" xlink:title="definition: StatementLineItems to AccruedTermLoanPaymentsCurrent" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedClinicalTrialExpenseCurrent" xlink:label="AccruedClinicalTrialExpenseCurrent" xlink:title="AccruedClinicalTrialExpenseCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccruedClinicalTrialExpenseCurrent" xlink:title="definition: StatementLineItems to AccruedClinicalTrialExpenseCurrent" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="definition: StatementLineItems to AccruedProfessionalFeesCurrent" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccruedLiabilitiesCurrent" xlink:title="definition: StatementLineItems to AccruedLiabilitiesCurrent" order="6.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: StatementTable to DebtInstrumentAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableOneMember" xlink:label="ConvertibleNotePayableOneMember" xlink:title="ConvertibleNotePayableOneMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleNotePayableOneMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleNotePayableOneMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableTwoMember" xlink:label="ConvertibleNotePayableTwoMember" xlink:title="ConvertibleNotePayableTwoMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleNotePayableTwoMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleNotePayableTwoMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableThreeMember" xlink:label="ConvertibleNotePayableThreeMember" xlink:title="ConvertibleNotePayableThreeMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleNotePayableThreeMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleNotePayableThreeMember" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableFourMember" xlink:label="ConvertibleNotePayableFourMember" xlink:title="ConvertibleNotePayableFourMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleNotePayableFourMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleNotePayableFourMember" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableFiveMember" xlink:label="ConvertibleNotePayableFiveMember" xlink:title="ConvertibleNotePayableFiveMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleNotePayableFiveMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleNotePayableFiveMember" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableSixMember" xlink:label="ConvertibleNotePayableSixMember" xlink:title="ConvertibleNotePayableSixMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleNotePayableSixMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleNotePayableSixMember" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="ConvertibleDebt" xlink:title="ConvertibleDebt"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ConvertibleDebt" xlink:title="definition: StatementLineItems to ConvertibleDebt" order="2.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-operations-unauditedQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingExpensesAbstract" xlink:title="definition: StatementLineItems to OperatingExpensesAbstract" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="definition: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GrantReimbursementsExpense" xlink:label="GrantReimbursementsExpense" xlink:title="GrantReimbursementsExpense"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingExpensesAbstract" xlink:to="GrantReimbursementsExpense" xlink:title="definition: OperatingExpensesAbstract to GrantReimbursementsExpense" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="definition: OperatingExpensesAbstract to OperatingExpenses" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingIncomeLoss" xlink:title="definition: OperatingExpensesAbstract to OperatingIncomeLoss" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingExpensesAbstract" xlink:to="InterestExpense" xlink:title="definition: OperatingExpensesAbstract to InterestExpense" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingExpensesAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="definition: OperatingExpensesAbstract to NonoperatingIncomeExpense" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="IncomeLossFromContinuingOperations" xlink:title="IncomeLossFromContinuingOperations"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingExpensesAbstract" xlink:to="IncomeLossFromContinuingOperations" xlink:title="definition: OperatingExpensesAbstract to IncomeLossFromContinuingOperations" order="8.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:title="DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingExpensesAbstract" xlink:to="DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:title="definition: OperatingExpensesAbstract to DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" order="9.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingExpensesAbstract" xlink:to="NetIncomeLoss" xlink:title="definition: OperatingExpensesAbstract to NetIncomeLoss" order="10.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="EarningsPerShareBasicAndDilutedAbstract" xlink:title="EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasicAndDilutedAbstract" xlink:title="definition: StatementLineItems to EarningsPerShareBasicAndDilutedAbstract" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:title="IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:title="definition: EarningsPerShareBasicAndDilutedAbstract to IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:label="DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:title="DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:title="definition: EarningsPerShareBasicAndDilutedAbstract to DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="definition: EarningsPerShareBasicAndDilutedAbstract to EarningsPerShareBasicAndDiluted" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="definition: EarningsPerShareBasicAndDilutedAbstract to WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="4.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: StatementTable to FinancialInstrumentAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="WarrantMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to WarrantMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: StatementTable to FairValueByMeasurementFrequencyAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: StatementTable to FairValueByFairValueHierarchyLevelAxis" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="DerivativeLiabilities" xlink:title="DerivativeLiabilities"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DerivativeLiabilities" xlink:title="definition: StatementLineItems to DerivativeLiabilities" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FinancialLiabilitiesFairValueDisclosure" xlink:title="definition: StatementLineItems to FinancialLiabilitiesFairValueDisclosure" order="3.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unauditedQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesARedeemableConvertiblePreferredStockMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesBRedeemableConvertiblePreferredStockMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsCurrentAbstract" xlink:title="definition: StatementLineItems to AssetsCurrentAbstract" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="definition: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="RestrictedCashCurrent" xlink:title="RestrictedCashCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="RestrictedCashCurrent" xlink:title="definition: AssetsCurrentAbstract to RestrictedCashCurrent" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="definition: AssetsCurrentAbstract to AssetsCurrent" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: AssetsCurrentAbstract to PropertyPlantAndEquipmentNet" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="RestrictedCashNoncurrent" xlink:title="RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="RestrictedCashNoncurrent" xlink:title="definition: AssetsCurrentAbstract to RestrictedCashNoncurrent" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="definition: AssetsCurrentAbstract to OtherAssetsNoncurrent" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="Assets" xlink:title="definition: AssetsCurrentAbstract to Assets" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="definition: AssetsCurrentAbstract to OperatingLeaseRightOfUseAsset" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesCurrentAbstract" xlink:title="definition: StatementLineItems to LiabilitiesCurrentAbstract" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityCurrent" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LongTermDebtCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to LongTermDebtCurrent" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LongTermDebtNoncurrent" xlink:title="definition: LiabilitiesCurrentAbstract to LongTermDebtNoncurrent" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DerivativeLiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to DerivativeLiabilitiesCurrent" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="definition: LiabilitiesCurrentAbstract to CommitmentsAndContingencies" order="12.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="ConvertibleDebtCurrent" xlink:title="ConvertibleDebtCurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ConvertibleDebtCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to ConvertibleDebtCurrent" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="definition: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityNoncurrent" order="10.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="DerivativeLiabilities" xlink:title="DerivativeLiabilities"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DerivativeLiabilities" xlink:title="definition: LiabilitiesCurrentAbstract to DerivativeLiabilities" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:label="RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:title="RedeemableNoncontrollingInterestEquityCarryingAmountAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:title="definition: StatementLineItems to RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:to="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="definition: RedeemableNoncontrollingInterestEquityCarryingAmountAbstract to TemporaryEquityCarryingAmountAttributableToParent" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityAbstract" xlink:title="definition: StatementLineItems to StockholdersEquityAbstract" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="definition: StockholdersEquityAbstract to CommonStockValue" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="definition: StockholdersEquityAbstract to AdditionalPaidInCapital" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="definition: StockholdersEquityAbstract to StockholdersEquity" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="definition: StockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="definition: StockholdersEquityAbstract to PreferredStockValue" order="1.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-redeemable-convertible-preferred-stock-and-stockholders-deficit-unauditedQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesARedeemableConvertiblePreferredStockMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesBRedeemableConvertiblePreferredStockMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="PreferredStockMember" xlink:title="definition: EquityComponentDomain to PreferredStockMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_BeneficialConversionFeatureConversionOfConvertibleNote" xlink:label="BeneficialConversionFeatureConversionOfConvertibleNote" xlink:title="BeneficialConversionFeatureConversionOfConvertibleNote"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="BeneficialConversionFeatureConversionOfConvertibleNote" xlink:title="definition: StatementLineItems to BeneficialConversionFeatureConversionOfConvertibleNote" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ExchangeOfWarrantsUponMerger" xlink:label="ExchangeOfWarrantsUponMerger" xlink:title="ExchangeOfWarrantsUponMerger"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ExchangeOfWarrantsUponMerger" xlink:title="definition: StatementLineItems to ExchangeOfWarrantsUponMerger" order="16.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_StockIssuedDuringPeriodSharesWarrantExercised" xlink:label="StockIssuedDuringPeriodSharesWarrantExercised" xlink:title="StockIssuedDuringPeriodSharesWarrantExercised"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesWarrantExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesWarrantExercised" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" order="10.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesAcquisitions" order="12.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueAcquisitions" order="13.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityIssuanceCostsPaidInStockShares" xlink:label="EquityIssuanceCostsPaidInStockShares" xlink:title="EquityIssuanceCostsPaidInStockShares"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EquityIssuanceCostsPaidInStockShares" xlink:title="definition: StatementLineItems to EquityIssuanceCostsPaidInStockShares" order="14.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityIssuanceCostsPaidInStock" xlink:label="EquityIssuanceCostsPaidInStock" xlink:title="EquityIssuanceCostsPaidInStock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EquityIssuanceCostsPaidInStock" xlink:title="definition: StatementLineItems to EquityIssuanceCostsPaidInStock" order="15.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityImpactOfSpinoff" xlink:label="EquityImpactOfSpinoff" xlink:title="EquityImpactOfSpinoff"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EquityImpactOfSpinoff" xlink:title="definition: StatementLineItems to EquityImpactOfSpinoff" order="17.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_StockIssuedDuringPeriodValueWarrantExercised" xlink:label="StockIssuedDuringPeriodValueWarrantExercised" xlink:title="StockIssuedDuringPeriodValueWarrantExercised"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueWarrantExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueWarrantExercised" order="18.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-summary-of-stock-option-activity-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: StatementTable to BusinessAcquisitionAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="AlliquaBiomedicalIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to AlliquaBiomedicalIncMember" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="23.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="definition: StatementLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="13.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="14.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="15.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="definition: StatementLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="17.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="18.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="19.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="definition: StatementLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="20.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="definition: StatementLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="21.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="22.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="definition: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="24.0"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-stock-options-by-exercise-price-range-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="definition: StatementTable to LegalEntityAxis" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="definition: StatementTable to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PriceRange1Member" xlink:label="PriceRange1Member" xlink:title="PriceRange1Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="PriceRange1Member" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to PriceRange1Member" order="1.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PriceRange2Member" xlink:label="PriceRange2Member" xlink:title="PriceRange2Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="PriceRange2Member" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to PriceRange2Member" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PriceRange3Member" xlink:label="PriceRange3Member" xlink:title="PriceRange3Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="PriceRange3Member" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to PriceRange3Member" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PriceRange4Member" xlink:label="PriceRange4Member" xlink:title="PriceRange4Member"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="PriceRange4Member" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to PriceRange4Member" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="definition: StatementLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="2.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="definition: StatementLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="3.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="definition: StatementLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="4.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="definition: StatementLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="5.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="definition: StatementLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="definition: StatementLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="7.0" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="definition: StatementLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="8.0" xbrldt:closed="true"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote8WarrantsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: StatementTable to ClassOfWarrantOrRightAxis" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" priority="1" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockMember" xlink:label="WarrantsForSeriesAConvertiblePreferredStockMember" xlink:title="WarrantsForSeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantsForSeriesAConvertiblePreferredStockMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantsForSeriesAConvertiblePreferredStockMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="definition: StatementLineItems to ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="definition: StatementLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="3.0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>adyx-20190630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!-- Created by Toppan Merrill -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccountsPayable1Member" xlink:label="AccountsPayable1Member" xlink:title="AccountsPayable1Member"/>
    <link:label xlink:type="resource" xlink:label="label_AccountsPayable1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayable1Member" xml:lang="en-US" id="label_AccountsPayable1Member">Accounts Payable 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayable1Member" xlink:to="label_AccountsPayable1Member" xlink:title="label_AccountsPayable1Member"/>
    <link:label xlink:type="resource" xlink:label="label_AccountsPayable1Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsPayable1Member_1" xml:lang="en-US" id="label_AccountsPayable1Member_1">Accounts Payable 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayable1Member" xlink:to="label_AccountsPayable1Member_1" xlink:title="label_AccountsPayable1Member_1"/>
    <link:label xlink:type="resource" xlink:label="label_AccountsPayable1Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AccountsPayable1Member_2" xml:lang="en-US" id="label_AccountsPayable1Member_2">Represents obligations incurred and payable to vendors for goods and services received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayable1Member" xlink:to="label_AccountsPayable1Member_2" xlink:title="label_AccountsPayable1Member_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:label="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:title="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB"/>
    <link:label xlink:type="resource" xlink:label="label_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xml:lang="en-US" id="label_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB">Accretion of final charge upon maturity of Oxford Term Loan A and B</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:to="label_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:title="label_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB"/>
    <link:label xlink:type="resource" xlink:label="label_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB_1" xml:lang="en-US" id="label_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB_1">Represents accretion of final charge upon maturity of Oxford term loan A and B.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:to="label_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB_1" xlink:title="label_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedClinicalTrialExpenseCurrent" xlink:label="AccruedClinicalTrialExpenseCurrent" xlink:title="AccruedClinicalTrialExpenseCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedClinicalTrialExpenseCurrent" xml:lang="en-US" id="label_AccruedClinicalTrialExpenseCurrent">Accrued clinical trial expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedClinicalTrialExpenseCurrent" xlink:to="label_AccruedClinicalTrialExpenseCurrent" xlink:title="label_AccruedClinicalTrialExpenseCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_AccruedClinicalTrialExpenseCurrent_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AccruedClinicalTrialExpenseCurrent_1" xml:lang="en-US" id="label_AccruedClinicalTrialExpenseCurrent_1">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trail expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedClinicalTrialExpenseCurrent" xlink:to="label_AccruedClinicalTrialExpenseCurrent_1" xlink:title="label_AccruedClinicalTrialExpenseCurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedPayrollAndRelatedExpensesCurrent" xlink:label="AccruedPayrollAndRelatedExpensesCurrent" xlink:title="AccruedPayrollAndRelatedExpensesCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_AccruedPayrollAndRelatedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedPayrollAndRelatedExpensesCurrent" xml:lang="en-US" id="label_AccruedPayrollAndRelatedExpensesCurrent">Payroll and related expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedPayrollAndRelatedExpensesCurrent" xlink:to="label_AccruedPayrollAndRelatedExpensesCurrent" xlink:title="label_AccruedPayrollAndRelatedExpensesCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_AccruedPayrollAndRelatedExpensesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AccruedPayrollAndRelatedExpensesCurrent_1" xml:lang="en-US" id="label_AccruedPayrollAndRelatedExpensesCurrent_1">Carrying value as of the balance sheet date of obligations incurred through that date and payable for payroll and related expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedPayrollAndRelatedExpensesCurrent" xlink:to="label_AccruedPayrollAndRelatedExpensesCurrent_1" xlink:title="label_AccruedPayrollAndRelatedExpensesCurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedTermLoanPaymentsCurrent" xlink:label="AccruedTermLoanPaymentsCurrent" xlink:title="AccruedTermLoanPaymentsCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_AccruedTermLoanPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedTermLoanPaymentsCurrent" xml:lang="en-US" id="label_AccruedTermLoanPaymentsCurrent">Accrued term loan final payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedTermLoanPaymentsCurrent" xlink:to="label_AccruedTermLoanPaymentsCurrent" xlink:title="label_AccruedTermLoanPaymentsCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_AccruedTermLoanPaymentsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AccruedTermLoanPaymentsCurrent_1" xml:lang="en-US" id="label_AccruedTermLoanPaymentsCurrent_1">Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued term loan payments. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedTermLoanPaymentsCurrent" xlink:to="label_AccruedTermLoanPaymentsCurrent_1" xlink:title="label_AccruedTermLoanPaymentsCurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:label xlink:type="resource" xlink:label="label_AlliquaBiomedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AlliquaBiomedicalIncMember" xml:lang="en-US" id="label_AlliquaBiomedicalIncMember">Alliqua Biomedical, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AlliquaBiomedicalIncMember" xlink:to="label_AlliquaBiomedicalIncMember" xlink:title="label_AlliquaBiomedicalIncMember"/>
    <link:label xlink:type="resource" xlink:label="label_AlliquaBiomedicalIncMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AlliquaBiomedicalIncMember_1" xml:lang="en-US" id="label_AlliquaBiomedicalIncMember_1">Information pertaining to Alliqua Biomedical, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AlliquaBiomedicalIncMember" xlink:to="label_AlliquaBiomedicalIncMember_1" xlink:title="label_AlliquaBiomedicalIncMember_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaWarrantsAssumedInMergerMember" xlink:label="AlliquaWarrantsAssumedInMergerMember" xlink:title="AlliquaWarrantsAssumedInMergerMember"/>
    <link:label xlink:type="resource" xlink:label="label_AlliquaWarrantsAssumedInMergerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AlliquaWarrantsAssumedInMergerMember" xml:lang="en-US" id="label_AlliquaWarrantsAssumedInMergerMember">Alliqua Warrants Assumed in Merger [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AlliquaWarrantsAssumedInMergerMember" xlink:to="label_AlliquaWarrantsAssumedInMergerMember" xlink:title="label_AlliquaWarrantsAssumedInMergerMember"/>
    <link:label xlink:type="resource" xlink:label="label_AlliquaWarrantsAssumedInMergerMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AlliquaWarrantsAssumedInMergerMember_1" xml:lang="en-US" id="label_AlliquaWarrantsAssumedInMergerMember_1">Represents Alliqua warrants which were assumed in the merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AlliquaWarrantsAssumedInMergerMember" xlink:to="label_AlliquaWarrantsAssumedInMergerMember_1" xlink:title="label_AlliquaWarrantsAssumedInMergerMember_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AquaMedMember" xlink:label="AquaMedMember" xlink:title="AquaMedMember"/>
    <link:label xlink:type="resource" xlink:label="label_AquaMedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AquaMedMember" xml:lang="en-US" id="label_AquaMedMember">AquaMed [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AquaMedMember" xlink:to="label_AquaMedMember" xlink:title="label_AquaMedMember"/>
    <link:label xlink:type="resource" xlink:label="label_AquaMedMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AquaMedMember_1" xml:lang="en-US" id="label_AquaMedMember_1">Information pertaining to AquaMed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AquaMedMember" xlink:to="label_AquaMedMember_1" xlink:title="label_AquaMedMember_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_BeneficialConversionFeatureConversionOfConvertibleNote" xlink:label="BeneficialConversionFeatureConversionOfConvertibleNote" xlink:title="BeneficialConversionFeatureConversionOfConvertibleNote"/>
    <link:label xlink:type="resource" xlink:label="label_BeneficialConversionFeatureConversionOfConvertibleNote" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BeneficialConversionFeatureConversionOfConvertibleNote" xml:lang="en-US" id="label_BeneficialConversionFeatureConversionOfConvertibleNote">Beneficial Conversion Feature, Conversion of Convertible Note</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialConversionFeatureConversionOfConvertibleNote" xlink:to="label_BeneficialConversionFeatureConversionOfConvertibleNote" xlink:title="label_BeneficialConversionFeatureConversionOfConvertibleNote"/>
    <link:label xlink:type="resource" xlink:label="label_BeneficialConversionFeatureConversionOfConvertibleNote_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BeneficialConversionFeatureConversionOfConvertibleNote_1" xml:lang="en-US" id="label_BeneficialConversionFeatureConversionOfConvertibleNote_1">Recognition of beneficial conversion feature upon conversion of convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialConversionFeatureConversionOfConvertibleNote" xlink:to="label_BeneficialConversionFeatureConversionOfConvertibleNote_1" xlink:title="label_BeneficialConversionFeatureConversionOfConvertibleNote_1"/>
    <link:label xlink:type="resource" xlink:label="label_BeneficialConversionFeatureConversionOfConvertibleNote_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BeneficialConversionFeatureConversionOfConvertibleNote_2" xml:lang="en-US" id="label_BeneficialConversionFeatureConversionOfConvertibleNote_2">The amount of favorable spread between the value of notes being converted and the value of the securities issued upon the conversion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialConversionFeatureConversionOfConvertibleNote" xlink:to="label_BeneficialConversionFeatureConversionOfConvertibleNote_2" xlink:title="label_BeneficialConversionFeatureConversionOfConvertibleNote_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_BusinessAcquisitionExchangeRatio" xlink:label="BusinessAcquisitionExchangeRatio" xlink:title="BusinessAcquisitionExchangeRatio"/>
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessAcquisitionExchangeRatio" xml:lang="en-US" id="label_BusinessAcquisitionExchangeRatio">Business Acquisition, Exchange Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionExchangeRatio" xlink:to="label_BusinessAcquisitionExchangeRatio" xlink:title="label_BusinessAcquisitionExchangeRatio"/>
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionExchangeRatio_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionExchangeRatio_1" xml:lang="en-US" id="label_BusinessAcquisitionExchangeRatio_1">adyx_BusinessAcquisitionExchangeRatio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionExchangeRatio" xlink:to="label_BusinessAcquisitionExchangeRatio_1" xlink:title="label_BusinessAcquisitionExchangeRatio_1"/>
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionExchangeRatio_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BusinessAcquisitionExchangeRatio_2" xml:lang="en-US" id="label_BusinessAcquisitionExchangeRatio_2">The number of new shares that will be given to existing shareholders of a company that has been acquired or that has merged with another.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionExchangeRatio" xlink:to="label_BusinessAcquisitionExchangeRatio_2" xlink:title="label_BusinessAcquisitionExchangeRatio_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ClassOfWarrantsOrRightExercisableTerm" xlink:label="ClassOfWarrantsOrRightExercisableTerm" xlink:title="ClassOfWarrantsOrRightExercisableTerm"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantsOrRightExercisableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantsOrRightExercisableTerm" xml:lang="en-US" id="label_ClassOfWarrantsOrRightExercisableTerm">Class of Warrants or Right, Exercisable, Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightExercisableTerm" xlink:to="label_ClassOfWarrantsOrRightExercisableTerm" xlink:title="label_ClassOfWarrantsOrRightExercisableTerm"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantsOrRightExercisableTerm_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantsOrRightExercisableTerm_1" xml:lang="en-US" id="label_ClassOfWarrantsOrRightExercisableTerm_1">adyx_ClassOfWarrantsOrRightExercisableTerm</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightExercisableTerm" xlink:to="label_ClassOfWarrantsOrRightExercisableTerm_1" xlink:title="label_ClassOfWarrantsOrRightExercisableTerm_1"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantsOrRightExercisableTerm_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ClassOfWarrantsOrRightExercisableTerm_2" xml:lang="en-US" id="label_ClassOfWarrantsOrRightExercisableTerm_2">Represents the term of warrant exercisable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantsOrRightExercisableTerm" xlink:to="label_ClassOfWarrantsOrRightExercisableTerm_2" xlink:title="label_ClassOfWarrantsOrRightExercisableTerm_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:label="ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:title="ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember"/>
    <link:label xlink:type="resource" xlink:label="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xml:lang="en-US" id="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember">Clinical Study, PRA Health, CRF Health, Inc., Premier Research International LLC, ICON Central Laboratories, and Almac Clinical Services [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:to="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:title="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember"/>
    <link:label xlink:type="resource" xlink:label="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember_1" xml:lang="en-US" id="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember_1">Clinical Study P R A Health C R F Health Inc Premier Research International L L C I C O N Central Laboratories And Almac Clinical Services [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:to="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember_1" xlink:title="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember_2" xml:lang="en-US" id="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember_2">Represents the clinical study undertaken with PRA Health, CRF Health, Inc., Premier Research International LLC, ICON Central Laboratories, and Almac Clinical Services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:to="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember_2" xlink:title="label_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:label="ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:title="ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember"/>
    <link:label xlink:type="resource" xlink:label="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xml:lang="en-US" id="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember">Clinical Study, Premier Research International LLC and CRF Health, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:to="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:title="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember"/>
    <link:label xlink:type="resource" xlink:label="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember_1" xml:lang="en-US" id="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember_1">Clinical Study Premier Research International L L C And C R F Health Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:to="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember_1" xlink:title="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember_2" xml:lang="en-US" id="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember_2">Represents a clinical study undertaken with Premier Research International LLC, and CRF Health, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:to="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember_2" xlink:title="label_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:label="ClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:title="ClinicalTrialAccrualsPolicyPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClinicalTrialAccrualsPolicyPolicyTextBlock" xml:lang="en-US" id="label_ClinicalTrialAccrualsPolicyPolicyTextBlock">Clinical Trial Accruals, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:to="label_ClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:title="label_ClinicalTrialAccrualsPolicyPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ClinicalTrialAccrualsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ClinicalTrialAccrualsPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_ClinicalTrialAccrualsPolicyPolicyTextBlock_1">Disclosure of accounting policy for clinical trial accounts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:to="label_ClinicalTrialAccrualsPolicyPolicyTextBlock_1" xlink:title="label_ClinicalTrialAccrualsPolicyPolicyTextBlock_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_CollaborationInitiationPayment" xlink:label="CollaborationInitiationPayment" xlink:title="CollaborationInitiationPayment"/>
    <link:label xlink:type="resource" xlink:label="label_CollaborationInitiationPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CollaborationInitiationPayment" xml:lang="en-US" id="label_CollaborationInitiationPayment">Collaboration Initiation Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationInitiationPayment" xlink:to="label_CollaborationInitiationPayment" xlink:title="label_CollaborationInitiationPayment"/>
    <link:label xlink:type="resource" xlink:label="label_CollaborationInitiationPayment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CollaborationInitiationPayment_1" xml:lang="en-US" id="label_CollaborationInitiationPayment_1">adyx_CollaborationInitiationPayment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationInitiationPayment" xlink:to="label_CollaborationInitiationPayment_1" xlink:title="label_CollaborationInitiationPayment_1"/>
    <link:label xlink:type="resource" xlink:label="label_CollaborationInitiationPayment_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CollaborationInitiationPayment_2" xml:lang="en-US" id="label_CollaborationInitiationPayment_2">Payment to start a collaborative project.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationInitiationPayment" xlink:to="label_CollaborationInitiationPayment_2" xlink:title="label_CollaborationInitiationPayment_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_CommonStockStockDividendsPerShareBookValue" xlink:label="CommonStockStockDividendsPerShareBookValue" xlink:title="CommonStockStockDividendsPerShareBookValue"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockStockDividendsPerShareBookValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockStockDividendsPerShareBookValue" xml:lang="en-US" id="label_CommonStockStockDividendsPerShareBookValue">Common Stock, Stock Dividends, Per Share, Book Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockStockDividendsPerShareBookValue" xlink:to="label_CommonStockStockDividendsPerShareBookValue" xlink:title="label_CommonStockStockDividendsPerShareBookValue"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockStockDividendsPerShareBookValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockStockDividendsPerShareBookValue_1" xml:lang="en-US" id="label_CommonStockStockDividendsPerShareBookValue_1">adyx_CommonStockStockDividendsPerShareBookValue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockStockDividendsPerShareBookValue" xlink:to="label_CommonStockStockDividendsPerShareBookValue_1" xlink:title="label_CommonStockStockDividendsPerShareBookValue_1"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockStockDividendsPerShareBookValue_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CommonStockStockDividendsPerShareBookValue_2" xml:lang="en-US" id="label_CommonStockStockDividendsPerShareBookValue_2">The book value amount of stock dividends of common stock, per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockStockDividendsPerShareBookValue" xlink:to="label_CommonStockStockDividendsPerShareBookValue_2" xlink:title="label_CommonStockStockDividendsPerShareBookValue_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xml:lang="en-US" id="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember">Conversion of Notes into Series B Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:to="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_1">Conversion of Notes into Series B Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:to="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_1" xlink:title="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_2">Represents information pertaining to the conversion of Notes into Series B convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:to="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_2" xlink:title="label_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfPreferredStockToCommonStockMember" xlink:label="ConversionOfPreferredStockToCommonStockMember" xlink:title="ConversionOfPreferredStockToCommonStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConversionOfPreferredStockToCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfPreferredStockToCommonStockMember" xml:lang="en-US" id="label_ConversionOfPreferredStockToCommonStockMember">Conversion of Preferred Stock to Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfPreferredStockToCommonStockMember" xlink:to="label_ConversionOfPreferredStockToCommonStockMember" xlink:title="label_ConversionOfPreferredStockToCommonStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConversionOfPreferredStockToCommonStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfPreferredStockToCommonStockMember_1" xml:lang="en-US" id="label_ConversionOfPreferredStockToCommonStockMember_1">Conversion Of Preferred Stock To Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfPreferredStockToCommonStockMember" xlink:to="label_ConversionOfPreferredStockToCommonStockMember_1" xlink:title="label_ConversionOfPreferredStockToCommonStockMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ConversionOfPreferredStockToCommonStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConversionOfPreferredStockToCommonStockMember_2" xml:lang="en-US" id="label_ConversionOfPreferredStockToCommonStockMember_2">Represents conversion of preferred stock to common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfPreferredStockToCommonStockMember" xlink:to="label_ConversionOfPreferredStockToCommonStockMember_2" xlink:title="label_ConversionOfPreferredStockToCommonStockMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableFiveMember" xlink:label="ConvertibleNotePayableFiveMember" xlink:title="ConvertibleNotePayableFiveMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleNotePayableFiveMember" xml:lang="en-US" id="label_ConvertibleNotePayableFiveMember">Convertible Note Payable Five [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableFiveMember" xlink:to="label_ConvertibleNotePayableFiveMember" xlink:title="label_ConvertibleNotePayableFiveMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableFiveMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleNotePayableFiveMember_1" xml:lang="en-US" id="label_ConvertibleNotePayableFiveMember_1">Represents the information pertaining to one of the convertible note payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableFiveMember" xlink:to="label_ConvertibleNotePayableFiveMember_1" xlink:title="label_ConvertibleNotePayableFiveMember_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableFourMember" xlink:label="ConvertibleNotePayableFourMember" xlink:title="ConvertibleNotePayableFourMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleNotePayableFourMember" xml:lang="en-US" id="label_ConvertibleNotePayableFourMember">Convertible Note Payable, Four [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableFourMember" xlink:to="label_ConvertibleNotePayableFourMember" xlink:title="label_ConvertibleNotePayableFourMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableFourMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleNotePayableFourMember_1" xml:lang="en-US" id="label_ConvertibleNotePayableFourMember_1">Represents the information pertaining to one of the convertible note payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableFourMember" xlink:to="label_ConvertibleNotePayableFourMember_1" xlink:title="label_ConvertibleNotePayableFourMember_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableOneMember" xlink:label="ConvertibleNotePayableOneMember" xlink:title="ConvertibleNotePayableOneMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleNotePayableOneMember" xml:lang="en-US" id="label_ConvertibleNotePayableOneMember">Convertible Note Payable, One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableOneMember" xlink:to="label_ConvertibleNotePayableOneMember" xlink:title="label_ConvertibleNotePayableOneMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableOneMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleNotePayableOneMember_1" xml:lang="en-US" id="label_ConvertibleNotePayableOneMember_1">Convertible Note Payable, One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableOneMember" xlink:to="label_ConvertibleNotePayableOneMember_1" xlink:title="label_ConvertibleNotePayableOneMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableOneMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleNotePayableOneMember_2" xml:lang="en-US" id="label_ConvertibleNotePayableOneMember_2">Represents the information pertaining to one of the convertible note payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableOneMember" xlink:to="label_ConvertibleNotePayableOneMember_2" xlink:title="label_ConvertibleNotePayableOneMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableSixMember" xlink:label="ConvertibleNotePayableSixMember" xlink:title="ConvertibleNotePayableSixMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleNotePayableSixMember" xml:lang="en-US" id="label_ConvertibleNotePayableSixMember">Convertible Note Payable Six [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableSixMember" xlink:to="label_ConvertibleNotePayableSixMember" xlink:title="label_ConvertibleNotePayableSixMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableSixMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleNotePayableSixMember_1" xml:lang="en-US" id="label_ConvertibleNotePayableSixMember_1">Represents the information pertaining to one of the convertible note payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableSixMember" xlink:to="label_ConvertibleNotePayableSixMember_1" xlink:title="label_ConvertibleNotePayableSixMember_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableThreeMember" xlink:label="ConvertibleNotePayableThreeMember" xlink:title="ConvertibleNotePayableThreeMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleNotePayableThreeMember" xml:lang="en-US" id="label_ConvertibleNotePayableThreeMember">Convertible Note Payable, Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableThreeMember" xlink:to="label_ConvertibleNotePayableThreeMember" xlink:title="label_ConvertibleNotePayableThreeMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableThreeMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleNotePayableThreeMember_1" xml:lang="en-US" id="label_ConvertibleNotePayableThreeMember_1">Convertible Note Payable, Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableThreeMember" xlink:to="label_ConvertibleNotePayableThreeMember_1" xlink:title="label_ConvertibleNotePayableThreeMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableThreeMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleNotePayableThreeMember_2" xml:lang="en-US" id="label_ConvertibleNotePayableThreeMember_2">Represents the information pertaining to one of the convertible note payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableThreeMember" xlink:to="label_ConvertibleNotePayableThreeMember_2" xlink:title="label_ConvertibleNotePayableThreeMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableTwoMember" xlink:label="ConvertibleNotePayableTwoMember" xlink:title="ConvertibleNotePayableTwoMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleNotePayableTwoMember" xml:lang="en-US" id="label_ConvertibleNotePayableTwoMember">Convertible Note Payable Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableTwoMember" xlink:to="label_ConvertibleNotePayableTwoMember" xlink:title="label_ConvertibleNotePayableTwoMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleNotePayableTwoMember_1" xml:lang="en-US" id="label_ConvertibleNotePayableTwoMember_1">Convertible Note Payable Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableTwoMember" xlink:to="label_ConvertibleNotePayableTwoMember_1" xlink:title="label_ConvertibleNotePayableTwoMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotePayableTwoMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleNotePayableTwoMember_2" xml:lang="en-US" id="label_ConvertibleNotePayableTwoMember_2">Represents the information pertaining to one of the convertible note payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotePayableTwoMember" xlink:to="label_ConvertibleNotePayableTwoMember_2" xlink:title="label_ConvertibleNotePayableTwoMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" xlink:label="ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" xlink:title="ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" xml:lang="en-US" id="label_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock">Convertible Preferred Stock Warrants, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" xlink:to="label_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" xlink:title="label_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock_1">Disclosure of accounting policy for convertible preferred stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" xlink:to="label_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock_1" xlink:title="label_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:label="ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:title="ConvertiblePromissoryNoteIssuedOnMarch292019Member"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member" xml:lang="en-US" id="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member">Convertible Promissory Note Issued on March 29, 2019 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:to="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:title="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member_1" xml:lang="en-US" id="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member_1">Convertible Promissory Note Issued On March292019 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:to="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member_1" xlink:title="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member_1"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member_2" xml:lang="en-US" id="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member_2">Represents convertible promissory note issued on March 29, 2019.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:to="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member_2" xlink:title="label_ConvertiblePromissoryNoteIssuedOnMarch292019Member_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:label="ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:title="ConvertiblePromissoryNoteIssuedSeptember272018Member"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertiblePromissoryNoteIssuedSeptember272018Member" xml:lang="en-US" id="label_ConvertiblePromissoryNoteIssuedSeptember272018Member">Convertible Promissory Note Issued September 27, 2018 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:to="label_ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:title="label_ConvertiblePromissoryNoteIssuedSeptember272018Member"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNoteIssuedSeptember272018Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePromissoryNoteIssuedSeptember272018Member_1" xml:lang="en-US" id="label_ConvertiblePromissoryNoteIssuedSeptember272018Member_1">Convertible Promissory Note Issued September272018 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:to="label_ConvertiblePromissoryNoteIssuedSeptember272018Member_1" xlink:title="label_ConvertiblePromissoryNoteIssuedSeptember272018Member_1"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNoteIssuedSeptember272018Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertiblePromissoryNoteIssuedSeptember272018Member_2" xml:lang="en-US" id="label_ConvertiblePromissoryNoteIssuedSeptember272018Member_2">Represents information related to convertible promissory note issued September 27, 2018.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:to="label_ConvertiblePromissoryNoteIssuedSeptember272018Member_2" xlink:title="label_ConvertiblePromissoryNoteIssuedSeptember272018Member_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePromissoryNoteOf15MillionMember" xlink:label="ConvertiblePromissoryNoteOf15MillionMember" xlink:title="ConvertiblePromissoryNoteOf15MillionMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNoteOf15MillionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePromissoryNoteOf15MillionMember" xml:lang="en-US" id="label_ConvertiblePromissoryNoteOf15MillionMember">Convertible Promissory Note of 1.5 Million [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNoteOf15MillionMember" xlink:to="label_ConvertiblePromissoryNoteOf15MillionMember" xlink:title="label_ConvertiblePromissoryNoteOf15MillionMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNoteOf15MillionMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertiblePromissoryNoteOf15MillionMember_1" xml:lang="en-US" id="label_ConvertiblePromissoryNoteOf15MillionMember_1">Convertible Promissory Note of 1.5 Million [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNoteOf15MillionMember" xlink:to="label_ConvertiblePromissoryNoteOf15MillionMember_1" xlink:title="label_ConvertiblePromissoryNoteOf15MillionMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNoteOf15MillionMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertiblePromissoryNoteOf15MillionMember_2" xml:lang="en-US" id="label_ConvertiblePromissoryNoteOf15MillionMember_2">Information pertaining to a convertible promissory note of $1.5 million.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNoteOf15MillionMember" xlink:to="label_ConvertiblePromissoryNoteOf15MillionMember_2" xlink:title="label_ConvertiblePromissoryNoteOf15MillionMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePromissoryNotes" xlink:label="ConvertiblePromissoryNotes" xlink:title="ConvertiblePromissoryNotes"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertiblePromissoryNotes" xml:lang="en-US" id="label_ConvertiblePromissoryNotes">Convertible promissory notes - related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotes" xlink:to="label_ConvertiblePromissoryNotes" xlink:title="label_ConvertiblePromissoryNotes"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotes_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePromissoryNotes_1" xml:lang="en-US" id="label_ConvertiblePromissoryNotes_1">Convertible Promissory Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotes" xlink:to="label_ConvertiblePromissoryNotes_1" xlink:title="label_ConvertiblePromissoryNotes_1"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotes_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertiblePromissoryNotes_2" xml:lang="en-US" id="label_ConvertiblePromissoryNotes_2">Amoount of convertible promissory notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotes" xlink:to="label_ConvertiblePromissoryNotes_2" xlink:title="label_ConvertiblePromissoryNotes_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" xlink:label="ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" xlink:title="ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" xml:lang="en-US" id="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember">Convert Notes and Accrued Interest to Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" xlink:to="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" xlink:title="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember_1" xml:lang="en-US" id="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember_1">Convert Notes And Accrued Interest To Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" xlink:to="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember_1" xlink:title="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember_2" xml:lang="en-US" id="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember_2">Represents convert notes and accrued interest to series A preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" xlink:to="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember_2" xlink:title="label_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:label="ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:title="ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xml:lang="en-US" id="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember">Convert Notes and Accrued Interest to Series B Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:to="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:title="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember_1" xml:lang="en-US" id="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember_1">Convert Notes And Accrued Interest To Series B Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:to="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember_1" xlink:title="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember_2" xml:lang="en-US" id="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember_2">Represents convert notes and accrued interest to series B preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:to="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember_2" xlink:title="label_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:label="DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:title="DebtConversionOriginalDebtAmountCumulativeAccruedInterest"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest">Debt Conversion, Original Debt, Amount, Cumulative Accrued Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:to="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:title="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest_1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest_1">adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:to="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest_1" xlink:title="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest_2" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest_2">The cumulative accrued interest portion of the amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:to="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest_2" xlink:title="label_DebtConversionOriginalDebtAmountCumulativeAccruedInterest_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtConversionOriginalDebtAmountPrincipal" xlink:label="DebtConversionOriginalDebtAmountPrincipal" xlink:title="DebtConversionOriginalDebtAmountPrincipal"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmountPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionOriginalDebtAmountPrincipal" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmountPrincipal">Debt Conversion, Original Debt, Amount, Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmountPrincipal" xlink:to="label_DebtConversionOriginalDebtAmountPrincipal" xlink:title="label_DebtConversionOriginalDebtAmountPrincipal"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmountPrincipal_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionOriginalDebtAmountPrincipal_1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmountPrincipal_1">adyx_DebtConversionOriginalDebtAmountPrincipal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmountPrincipal" xlink:to="label_DebtConversionOriginalDebtAmountPrincipal_1" xlink:title="label_DebtConversionOriginalDebtAmountPrincipal_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmountPrincipal_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtConversionOriginalDebtAmountPrincipal_2" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmountPrincipal_2">The principal portion of the amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmountPrincipal" xlink:to="label_DebtConversionOriginalDebtAmountPrincipal_2" xlink:title="label_DebtConversionOriginalDebtAmountPrincipal_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:label="DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:title="DebtInstrumentConversionToCashInCaseOfChangeInControl"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConversionToCashInCaseOfChangeInControl" xml:lang="en-US" id="label_DebtInstrumentConversionToCashInCaseOfChangeInControl">Debt Instrument, Conversion to Cash in Case of Change in Control</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:to="label_DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:title="label_DebtInstrumentConversionToCashInCaseOfChangeInControl"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionToCashInCaseOfChangeInControl_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConversionToCashInCaseOfChangeInControl_1" xml:lang="en-US" id="label_DebtInstrumentConversionToCashInCaseOfChangeInControl_1">adyx_DebtInstrumentConversionToCashInCaseOfChangeInControl</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:to="label_DebtInstrumentConversionToCashInCaseOfChangeInControl_1" xlink:title="label_DebtInstrumentConversionToCashInCaseOfChangeInControl_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionToCashInCaseOfChangeInControl_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentConversionToCashInCaseOfChangeInControl_2" xml:lang="en-US" id="label_DebtInstrumentConversionToCashInCaseOfChangeInControl_2">The conversion rate of the outstanding principal amount to cash owed to the holders of a note in the event that the company consummates a change of control.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:to="label_DebtInstrumentConversionToCashInCaseOfChangeInControl_2" xlink:title="label_DebtInstrumentConversionToCashInCaseOfChangeInControl_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:label="DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:title="DebtInstrumentConversionToCashInCaseOfChangeInControlPremium"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xml:lang="en-US" id="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium">Debt Instrument, Conversion to Cash in Case of Change in Control, Premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:to="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:title="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium_1" xml:lang="en-US" id="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium_1">adyx_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:to="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium_1" xlink:title="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium_2" xml:lang="en-US" id="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium_2">The premium, equal to a percentage of outstanding principal, of cash owed to the holders of a note in the event that the company consummates a change of control.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:to="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium_2" xlink:title="label_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:label="DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:title="DebtInstrumentConvertibleCommonStockProceedsTrigger"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConvertibleCommonStockProceedsTrigger" xml:lang="en-US" id="label_DebtInstrumentConvertibleCommonStockProceedsTrigger">Debt Instrument, Convertible, Common Stock Proceeds Trigger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:to="label_DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:title="label_DebtInstrumentConvertibleCommonStockProceedsTrigger"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleCommonStockProceedsTrigger_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConvertibleCommonStockProceedsTrigger_1" xml:lang="en-US" id="label_DebtInstrumentConvertibleCommonStockProceedsTrigger_1">adyx_DebtInstrumentConvertibleCommonStockProceedsTrigger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:to="label_DebtInstrumentConvertibleCommonStockProceedsTrigger_1" xlink:title="label_DebtInstrumentConvertibleCommonStockProceedsTrigger_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleCommonStockProceedsTrigger_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentConvertibleCommonStockProceedsTrigger_2" xml:lang="en-US" id="label_DebtInstrumentConvertibleCommonStockProceedsTrigger_2">In the event that the Company issues and sells shares of its common stock to the investors with proceeds to the Company of at least this amount, on or before the maturity date, and after the closing of a reverse merger, then the outstanding principal amount of the debt instrument and any unpaid accrued interest will automatically convert in whole into equity securities sold in the common stock financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the common stock financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:to="label_DebtInstrumentConvertibleCommonStockProceedsTrigger_2" xlink:title="label_DebtInstrumentConvertibleCommonStockProceedsTrigger_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:label="DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:title="DebtInstrumentConvertiblePreferredStockProceedsTrigger"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger" xml:lang="en-US" id="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger">Debt Instrument, Convertible, Preferred Stock Proceeds Trigger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:to="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:title="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger_1" xml:lang="en-US" id="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger_1">adyx_DebtInstrumentConvertiblePreferredStockProceedsTrigger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:to="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger_1" xlink:title="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger_2" xml:lang="en-US" id="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger_2">If the company issues and sells shares of its preferred stock to the investors with proceeds of this amount or higher, on or before the maturity date, and prior to the closing of a reverse merger, then the outstanding principal amount of the debt instrument and any unpaid accrued interest will automatically convert in whole into equity securities sold in the preferred stock financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the such preferred stock financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:to="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger_2" xlink:title="label_DebtInstrumentConvertiblePreferredStockProceedsTrigger_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:label="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:title="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote">Debt Instrument, Increase of Interest-Only Periodic Payments Upon Closing of Convertible Note</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:to="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote_1" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote_1">adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:to="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote_1" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote_2" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote_2">The increase of interest-only periodic payments upon closing of a convertible note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:to="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote_2" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:label="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:title="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet">Debt Instrument, Increase of Interest-Only Periodic Payments Upon Delivery of Executed Term Sheet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:to="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet_1" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet_1">adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:to="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet_1" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet_2" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet_2">The increase of interest-only periodic payments upon the delivery of an executed term sheet.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:to="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet_2" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:label="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:title="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger">Debt Instrument, Increase of Interest-Only Periodic Payments Upon Entering Into a Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:to="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger_1" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger_1">adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:to="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger_1" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger_2" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger_2">The increase of interest-only periodic payments upon entering into a merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:to="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger_2" xlink:title="label_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:label="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:title="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger">Debt Instrument, Increase of Periodic Payments Following Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:to="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger_1" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger_1">adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:to="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger_1" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger_2" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger_2">The increase of periodic repayments of debt following a merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:to="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger_2" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:label="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:title="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote">Debt Instrument, Increase of Periodic Payments Following the Closing of a Convertible Note</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:to="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote_1" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote_1">adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:to="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote_1" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote_2" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote_2">The increase of periodic repayments of debt following the closing of a convertible note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:to="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote_2" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:label="DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:title="DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet">Debt Instrument, Increase of Periodic Payments Upon Delivery of Executed Term Sheet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:to="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet_1" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet_1">adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:to="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet_1" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet_2" xml:lang="en-US" id="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet_2">The increase of period repayments of debt upon the delivery of an executed term sheet.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:to="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet_2" xlink:title="label_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:label="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:title="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments">Debt Instrument, Periodic Payment, Increase (Decrease) of Interest-Only Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:to="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:title="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments_1" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments_1">adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:to="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments_1" xlink:title="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments_2" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments_2">The increase (decrease) of interest-only payments to be made over the course of the applicable loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:to="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments_2" xlink:title="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:label="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:title="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments">Debt Instrument, Periodic Payment, Increase (Decrease) of Periodic Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:to="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:title="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments_1" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments_1">adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:to="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments_1" xlink:title="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments_2" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments_2">The increase (decrease) of periodic payments to be made over the course of the applicable loan which includes both interest and principal payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:to="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments_2" xlink:title="label_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:label="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:title="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:to="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:title="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_1" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_1">adyx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:to="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_1" xlink:title="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_2" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_2">The amount of payment which is greater than the preceding installment payments, as a percentage of the funded amount, to be paid at final maturity date of debt or prepayment date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:to="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_2" xlink:title="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:label="DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:title="DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid">Debt Instrument, Periodic Payment Terms, Increase (Decrease) in Balloon Payment to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:to="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:title="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid_1" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid_1">adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:to="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid_1" xlink:title="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid_2" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid_2">The increase (decrease) in the amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:to="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid_2" xlink:title="label_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:label="DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:title="DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xml:lang="en-US" id="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage">Debt Instrument, Prepayment Fee After Second Anniversary, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:to="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:title="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage_1" xml:lang="en-US" id="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage_1">adyx_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:to="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage_1" xlink:title="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage_2" xml:lang="en-US" id="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage_2">The percentage of outstanding principal balance due as a fee in the case of an early payment of the borrowed amount if the payment is made after the second anniversary and prior to the maturity date of the applicable loan funding date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:to="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage_2" xlink:title="label_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:label="DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:title="DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xml:lang="en-US" id="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage">Debt Instrument, Prepayment Fee Before First Anniversary,Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:to="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:title="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage_1" xml:lang="en-US" id="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage_1">adyx_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:to="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage_1" xlink:title="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage_2" xml:lang="en-US" id="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage_2">The percentage of outstanding principal balance due as a fee in the case of an early payment of the borrowed amount if the payment is made prior to the first anniversary of the applicable loan funding date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:to="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage_2" xlink:title="label_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:label="DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:title="DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xml:lang="en-US" id="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage">Debt Instrument, Prepayment Fee Between First and Second Anniversary, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:to="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:title="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage_1" xml:lang="en-US" id="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage_1">adyx_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:to="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage_1" xlink:title="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage_2" xml:lang="en-US" id="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage_2">The percentage of outstanding principal balance due as a fee in the case of an early payment of the borrowed amount if the payment is made after the first anniversary, but prior to the second anniversary, of the applicable loan funding date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:to="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage_2" xlink:title="label_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:label="DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:title="DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xml:lang="en-US" id="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage">Debt Instrument, Prepayment Fee if Company is Acquired Within Six Months of Closing, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:to="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:title="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage_1" xml:lang="en-US" id="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage_1">adyx_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:to="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage_1" xlink:title="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage_2" xml:lang="en-US" id="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage_2">The percentage of outstanding principal balance due as a fee in the case of an early payment of the borrowed amount if the company is acquired within six months from the loan closing date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:to="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage_2" xlink:title="label_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentUnusedBorrowingCapacityExpired" xlink:label="DebtInstrumentUnusedBorrowingCapacityExpired" xlink:title="DebtInstrumentUnusedBorrowingCapacityExpired"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentUnusedBorrowingCapacityExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentUnusedBorrowingCapacityExpired" xml:lang="en-US" id="label_DebtInstrumentUnusedBorrowingCapacityExpired">Debt Instrument, Unused Borrowing Capacity, Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnusedBorrowingCapacityExpired" xlink:to="label_DebtInstrumentUnusedBorrowingCapacityExpired" xlink:title="label_DebtInstrumentUnusedBorrowingCapacityExpired"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentUnusedBorrowingCapacityExpired_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentUnusedBorrowingCapacityExpired_1" xml:lang="en-US" id="label_DebtInstrumentUnusedBorrowingCapacityExpired_1">adyx_DebtInstrumentUnusedBorrowingCapacityExpired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnusedBorrowingCapacityExpired" xlink:to="label_DebtInstrumentUnusedBorrowingCapacityExpired_1" xlink:title="label_DebtInstrumentUnusedBorrowingCapacityExpired_1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentUnusedBorrowingCapacityExpired_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentUnusedBorrowingCapacityExpired_2" xml:lang="en-US" id="label_DebtInstrumentUnusedBorrowingCapacityExpired_2">The amount of unused borrowing capacity under the long-term financing arrangement which is no longer available to the entity as of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnusedBorrowingCapacityExpired" xlink:to="label_DebtInstrumentUnusedBorrowingCapacityExpired_2" xlink:title="label_DebtInstrumentUnusedBorrowingCapacityExpired_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" xlink:label="DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" xlink:title="DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" xml:lang="en-US" id="label_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock">Debt Modifications and Extinguishments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" xlink:to="label_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" xlink:title="label_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock_1">Disclosure of accounting policy for debt modifications and extinguishments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" xlink:to="label_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock_1" xlink:title="label_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DefinedContributionPlanNonelectiveSafeHarborContributionAmount" xlink:label="DefinedContributionPlanNonelectiveSafeHarborContributionAmount" xlink:title="DefinedContributionPlanNonelectiveSafeHarborContributionAmount"/>
    <link:label xlink:type="resource" xlink:label="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount" xml:lang="en-US" id="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount">Defined Contribution Plan, Non-elective Safe Harbor Contribution, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanNonelectiveSafeHarborContributionAmount" xlink:to="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount" xlink:title="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount"/>
    <link:label xlink:type="resource" xlink:label="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount_1" xml:lang="en-US" id="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount_1">adyx_DefinedContributionPlanNonelectiveSafeHarborContributionAmount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanNonelectiveSafeHarborContributionAmount" xlink:to="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount_1" xlink:title="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount_1"/>
    <link:label xlink:type="resource" xlink:label="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount_2" xml:lang="en-US" id="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount_2">Represents the amount paid during the period for non-elective safe harbor contributions under a defined contribution plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanNonelectiveSafeHarborContributionAmount" xlink:to="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount_2" xlink:title="label_DefinedContributionPlanNonelectiveSafeHarborContributionAmount_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary" xlink:label="DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary" xlink:title="DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary"/>
    <link:label xlink:type="resource" xlink:label="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary" xml:lang="en-US" id="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary">Defined Contribution Plan, Non-elective Safe Harbor Contribution, Percentage of Annual Salary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary" xlink:to="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary" xlink:title="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary"/>
    <link:label xlink:type="resource" xlink:label="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary_1" xml:lang="en-US" id="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary_1">adyx_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary" xlink:to="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary_1" xlink:title="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary_1"/>
    <link:label xlink:type="resource" xlink:label="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary_2" xml:lang="en-US" id="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary_2">Represents the company's nonelective safe harbor contribution made by the company on behalf of each employee, expressed as a percentage of each employee's annual salary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary" xlink:to="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary_2" xlink:title="label_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DomainMember" xlink:label="DomainMember" xlink:title="DomainMember"/>
    <link:label xlink:type="resource" xlink:label="label_DomainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DomainMember" xml:lang="en-US" id="label_DomainMember">Domain [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DomainMember" xlink:to="label_DomainMember" xlink:title="label_DomainMember"/>
    <link:label xlink:type="resource" xlink:label="label_DomainMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DomainMember_1" xml:lang="en-US" id="label_DomainMember_1">Domain [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DomainMember" xlink:to="label_DomainMember_1" xlink:title="label_DomainMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_DomainMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DomainMember_2" xml:lang="en-US" id="label_DomainMember_2">Information pertaining to Domain, the company's majority investor and an affiliate thereof.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DomainMember" xlink:to="label_DomainMember_2" xlink:title="label_DomainMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityConvertibleAggregateProceedsTrigger" xlink:label="EquityConvertibleAggregateProceedsTrigger" xlink:title="EquityConvertibleAggregateProceedsTrigger"/>
    <link:label xlink:type="resource" xlink:label="label_EquityConvertibleAggregateProceedsTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EquityConvertibleAggregateProceedsTrigger" xml:lang="en-US" id="label_EquityConvertibleAggregateProceedsTrigger">Equity, Convertible, Aggregate Proceeds Trigger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityConvertibleAggregateProceedsTrigger" xlink:to="label_EquityConvertibleAggregateProceedsTrigger" xlink:title="label_EquityConvertibleAggregateProceedsTrigger"/>
    <link:label xlink:type="resource" xlink:label="label_EquityConvertibleAggregateProceedsTrigger_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityConvertibleAggregateProceedsTrigger_1" xml:lang="en-US" id="label_EquityConvertibleAggregateProceedsTrigger_1">adyx_EquityConvertibleAggregateProceedsTrigger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityConvertibleAggregateProceedsTrigger" xlink:to="label_EquityConvertibleAggregateProceedsTrigger_1" xlink:title="label_EquityConvertibleAggregateProceedsTrigger_1"/>
    <link:label xlink:type="resource" xlink:label="label_EquityConvertibleAggregateProceedsTrigger_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EquityConvertibleAggregateProceedsTrigger_2" xml:lang="en-US" id="label_EquityConvertibleAggregateProceedsTrigger_2">Aggregate proceeds of the entity's common stock which would be required to be attained for the conversion feature embedded in equity to become effective.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityConvertibleAggregateProceedsTrigger" xlink:to="label_EquityConvertibleAggregateProceedsTrigger_2" xlink:title="label_EquityConvertibleAggregateProceedsTrigger_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityConvertibleStockPriceTrigger" xlink:label="EquityConvertibleStockPriceTrigger" xlink:title="EquityConvertibleStockPriceTrigger"/>
    <link:label xlink:type="resource" xlink:label="label_EquityConvertibleStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EquityConvertibleStockPriceTrigger" xml:lang="en-US" id="label_EquityConvertibleStockPriceTrigger">Equity, Convertible, Stock Price Trigger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityConvertibleStockPriceTrigger" xlink:to="label_EquityConvertibleStockPriceTrigger" xlink:title="label_EquityConvertibleStockPriceTrigger"/>
    <link:label xlink:type="resource" xlink:label="label_EquityConvertibleStockPriceTrigger_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityConvertibleStockPriceTrigger_1" xml:lang="en-US" id="label_EquityConvertibleStockPriceTrigger_1">adyx_EquityConvertibleStockPriceTrigger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityConvertibleStockPriceTrigger" xlink:to="label_EquityConvertibleStockPriceTrigger_1" xlink:title="label_EquityConvertibleStockPriceTrigger_1"/>
    <link:label xlink:type="resource" xlink:label="label_EquityConvertibleStockPriceTrigger_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EquityConvertibleStockPriceTrigger_2" xml:lang="en-US" id="label_EquityConvertibleStockPriceTrigger_2">Price of the entity's common stock which would be required to be attained for the conversion feature embedded in equity to become effective.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityConvertibleStockPriceTrigger" xlink:to="label_EquityConvertibleStockPriceTrigger_2" xlink:title="label_EquityConvertibleStockPriceTrigger_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityImpactOfSpinoff" xlink:label="EquityImpactOfSpinoff" xlink:title="EquityImpactOfSpinoff"/>
    <link:label xlink:type="resource" xlink:label="label_EquityImpactOfSpinoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityImpactOfSpinoff" xml:lang="en-US" id="label_EquityImpactOfSpinoff">Spin-off of AquaMed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityImpactOfSpinoff" xlink:to="label_EquityImpactOfSpinoff" xlink:title="label_EquityImpactOfSpinoff"/>
    <link:label xlink:type="resource" xlink:label="label_EquityImpactOfSpinoff_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EquityImpactOfSpinoff_1" xml:lang="en-US" id="label_EquityImpactOfSpinoff_1">The equity impact after a spin-off in which a portion of the parent company's assets are used to form a new entity, and shares of the new entity are distributed back to the parent company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityImpactOfSpinoff" xlink:to="label_EquityImpactOfSpinoff_1" xlink:title="label_EquityImpactOfSpinoff_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityIssuanceCostsCurrent" xlink:label="EquityIssuanceCostsCurrent" xlink:title="EquityIssuanceCostsCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_EquityIssuanceCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityIssuanceCostsCurrent" xml:lang="en-US" id="label_EquityIssuanceCostsCurrent">Equity issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuanceCostsCurrent" xlink:to="label_EquityIssuanceCostsCurrent" xlink:title="label_EquityIssuanceCostsCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_EquityIssuanceCostsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EquityIssuanceCostsCurrent_1" xml:lang="en-US" id="label_EquityIssuanceCostsCurrent_1">Amount of equity issuance costs classified as current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuanceCostsCurrent" xlink:to="label_EquityIssuanceCostsCurrent_1" xlink:title="label_EquityIssuanceCostsCurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityIssuanceCostsPaidInStock" xlink:label="EquityIssuanceCostsPaidInStock" xlink:title="EquityIssuanceCostsPaidInStock"/>
    <link:label xlink:type="resource" xlink:label="label_EquityIssuanceCostsPaidInStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityIssuanceCostsPaidInStock" xml:lang="en-US" id="label_EquityIssuanceCostsPaidInStock">Equity issuance costs paid in stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuanceCostsPaidInStock" xlink:to="label_EquityIssuanceCostsPaidInStock" xlink:title="label_EquityIssuanceCostsPaidInStock"/>
    <link:label xlink:type="resource" xlink:label="label_EquityIssuanceCostsPaidInStock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EquityIssuanceCostsPaidInStock_1" xml:lang="en-US" id="label_EquityIssuanceCostsPaidInStock_1">The value of stock issued as payment for the issuance of equity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuanceCostsPaidInStock" xlink:to="label_EquityIssuanceCostsPaidInStock_1" xlink:title="label_EquityIssuanceCostsPaidInStock_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityIssuanceCostsPaidInStockShares" xlink:label="EquityIssuanceCostsPaidInStockShares" xlink:title="EquityIssuanceCostsPaidInStockShares"/>
    <link:label xlink:type="resource" xlink:label="label_EquityIssuanceCostsPaidInStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityIssuanceCostsPaidInStockShares" xml:lang="en-US" id="label_EquityIssuanceCostsPaidInStockShares">Equity issuance costs paid in stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuanceCostsPaidInStockShares" xlink:to="label_EquityIssuanceCostsPaidInStockShares" xlink:title="label_EquityIssuanceCostsPaidInStockShares"/>
    <link:label xlink:type="resource" xlink:label="label_EquityIssuanceCostsPaidInStockShares_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EquityIssuanceCostsPaidInStockShares_1" xml:lang="en-US" id="label_EquityIssuanceCostsPaidInStockShares_1">The amount of shares issued for the payment of equity issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuanceCostsPaidInStockShares" xlink:to="label_EquityIssuanceCostsPaidInStockShares_1" xlink:title="label_EquityIssuanceCostsPaidInStockShares_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquitySharesReservedForFutureIssuance" xlink:label="EquitySharesReservedForFutureIssuance" xlink:title="EquitySharesReservedForFutureIssuance"/>
    <link:label xlink:type="resource" xlink:label="label_EquitySharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquitySharesReservedForFutureIssuance" xml:lang="en-US" id="label_EquitySharesReservedForFutureIssuance">Total (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySharesReservedForFutureIssuance" xlink:to="label_EquitySharesReservedForFutureIssuance" xlink:title="label_EquitySharesReservedForFutureIssuance"/>
    <link:label xlink:type="resource" xlink:label="label_EquitySharesReservedForFutureIssuance_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EquitySharesReservedForFutureIssuance_1" xml:lang="en-US" id="label_EquitySharesReservedForFutureIssuance_1">Aggregate number of equity shares reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySharesReservedForFutureIssuance" xlink:to="label_EquitySharesReservedForFutureIssuance_1" xlink:title="label_EquitySharesReservedForFutureIssuance_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ExchangeOfWarrantsUponMerger" xlink:label="ExchangeOfWarrantsUponMerger" xlink:title="ExchangeOfWarrantsUponMerger"/>
    <link:label xlink:type="resource" xlink:label="label_ExchangeOfWarrantsUponMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ExchangeOfWarrantsUponMerger" xml:lang="en-US" id="label_ExchangeOfWarrantsUponMerger">Exchange of Warrants Upon Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeOfWarrantsUponMerger" xlink:to="label_ExchangeOfWarrantsUponMerger" xlink:title="label_ExchangeOfWarrantsUponMerger"/>
    <link:label xlink:type="resource" xlink:label="label_ExchangeOfWarrantsUponMerger_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ExchangeOfWarrantsUponMerger_1" xml:lang="en-US" id="label_ExchangeOfWarrantsUponMerger_1">Impact of change of warrants subject to fair value measure to equity warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeOfWarrantsUponMerger" xlink:to="label_ExchangeOfWarrantsUponMerger_1" xlink:title="label_ExchangeOfWarrantsUponMerger_1"/>
    <link:label xlink:type="resource" xlink:label="label_ExchangeOfWarrantsUponMerger_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ExchangeOfWarrantsUponMerger_2" xml:lang="en-US" id="label_ExchangeOfWarrantsUponMerger_2">The value of warrants upon their reclassification from liabilities to equity as a result of a merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeOfWarrantsUponMerger" xlink:to="label_ExchangeOfWarrantsUponMerger_2" xlink:title="label_ExchangeOfWarrantsUponMerger_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FinancingThresholdProceedsToConvertNotesToEquity" xlink:label="FinancingThresholdProceedsToConvertNotesToEquity" xlink:title="FinancingThresholdProceedsToConvertNotesToEquity"/>
    <link:label xlink:type="resource" xlink:label="label_FinancingThresholdProceedsToConvertNotesToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FinancingThresholdProceedsToConvertNotesToEquity" xml:lang="en-US" id="label_FinancingThresholdProceedsToConvertNotesToEquity">Financing Threshold, Proceeds to Convert Notes to Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancingThresholdProceedsToConvertNotesToEquity" xlink:to="label_FinancingThresholdProceedsToConvertNotesToEquity" xlink:title="label_FinancingThresholdProceedsToConvertNotesToEquity"/>
    <link:label xlink:type="resource" xlink:label="label_FinancingThresholdProceedsToConvertNotesToEquity_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FinancingThresholdProceedsToConvertNotesToEquity_1" xml:lang="en-US" id="label_FinancingThresholdProceedsToConvertNotesToEquity_1">adyx_FinancingThresholdProceedsToConvertNotesToEquity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancingThresholdProceedsToConvertNotesToEquity" xlink:to="label_FinancingThresholdProceedsToConvertNotesToEquity_1" xlink:title="label_FinancingThresholdProceedsToConvertNotesToEquity_1"/>
    <link:label xlink:type="resource" xlink:label="label_FinancingThresholdProceedsToConvertNotesToEquity_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_FinancingThresholdProceedsToConvertNotesToEquity_2" xml:lang="en-US" id="label_FinancingThresholdProceedsToConvertNotesToEquity_2">Minimum gross proceeds required of qualified equity financing to trigger a conversion of earlier notes and accrued interest into equity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancingThresholdProceedsToConvertNotesToEquity" xlink:to="label_FinancingThresholdProceedsToConvertNotesToEquity_2" xlink:title="label_FinancingThresholdProceedsToConvertNotesToEquity_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FirstNoteToFundTheCompanysOperationsMember" xlink:label="FirstNoteToFundTheCompanysOperationsMember" xlink:title="FirstNoteToFundTheCompanysOperationsMember"/>
    <link:label xlink:type="resource" xlink:label="label_FirstNoteToFundTheCompanysOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FirstNoteToFundTheCompanysOperationsMember" xml:lang="en-US" id="label_FirstNoteToFundTheCompanysOperationsMember">First Note to Fund the Company's Operations [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstNoteToFundTheCompanysOperationsMember" xlink:to="label_FirstNoteToFundTheCompanysOperationsMember" xlink:title="label_FirstNoteToFundTheCompanysOperationsMember"/>
    <link:label xlink:type="resource" xlink:label="label_FirstNoteToFundTheCompanysOperationsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FirstNoteToFundTheCompanysOperationsMember_1" xml:lang="en-US" id="label_FirstNoteToFundTheCompanysOperationsMember_1">First Note to Fund the Company's Operations [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstNoteToFundTheCompanysOperationsMember" xlink:to="label_FirstNoteToFundTheCompanysOperationsMember_1" xlink:title="label_FirstNoteToFundTheCompanysOperationsMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_FirstNoteToFundTheCompanysOperationsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_FirstNoteToFundTheCompanysOperationsMember_2" xml:lang="en-US" id="label_FirstNoteToFundTheCompanysOperationsMember_2">Represents information pertaining to a first note to fund the company's operations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstNoteToFundTheCompanysOperationsMember" xlink:to="label_FirstNoteToFundTheCompanysOperationsMember_2" xlink:title="label_FirstNoteToFundTheCompanysOperationsMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GainLossDebtModification" xlink:label="GainLossDebtModification" xlink:title="GainLossDebtModification"/>
    <link:label xlink:type="resource" xlink:label="label_GainLossDebtModification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GainLossDebtModification" xml:lang="en-US" id="label_GainLossDebtModification">Gain (Loss) Debt Modification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossDebtModification" xlink:to="label_GainLossDebtModification" xlink:title="label_GainLossDebtModification"/>
    <link:label xlink:type="resource" xlink:label="label_GainLossDebtModification_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GainLossDebtModification_1" xml:lang="en-US" id="label_GainLossDebtModification_1">adyx_GainLossDebtModification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossDebtModification" xlink:to="label_GainLossDebtModification_1" xlink:title="label_GainLossDebtModification_1"/>
    <link:label xlink:type="resource" xlink:label="label_GainLossDebtModification_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_GainLossDebtModification_2" xml:lang="en-US" id="label_GainLossDebtModification_2">The amount of unrealized and realized gain (loss) on debt following a modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossDebtModification" xlink:to="label_GainLossDebtModification_2" xlink:title="label_GainLossDebtModification_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GrantReimbursementPolicyPolicyTextBlock" xlink:label="GrantReimbursementPolicyPolicyTextBlock" xlink:title="GrantReimbursementPolicyPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_GrantReimbursementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GrantReimbursementPolicyPolicyTextBlock" xml:lang="en-US" id="label_GrantReimbursementPolicyPolicyTextBlock">Grant Reimbursement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantReimbursementPolicyPolicyTextBlock" xlink:to="label_GrantReimbursementPolicyPolicyTextBlock" xlink:title="label_GrantReimbursementPolicyPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_GrantReimbursementPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_GrantReimbursementPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_GrantReimbursementPolicyPolicyTextBlock_1">Disclosure of accounting policy for grant reimbursement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantReimbursementPolicyPolicyTextBlock" xlink:to="label_GrantReimbursementPolicyPolicyTextBlock_1" xlink:title="label_GrantReimbursementPolicyPolicyTextBlock_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GrantReimbursements" xlink:label="GrantReimbursements" xlink:title="GrantReimbursements"/>
    <link:label xlink:type="resource" xlink:label="label_GrantReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GrantReimbursements" xml:lang="en-US" id="label_GrantReimbursements">Grant Reimbursements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantReimbursements" xlink:to="label_GrantReimbursements" xlink:title="label_GrantReimbursements"/>
    <link:label xlink:type="resource" xlink:label="label_GrantReimbursements_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GrantReimbursements_1" xml:lang="en-US" id="label_GrantReimbursements_1">adyx_GrantReimbursements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantReimbursements" xlink:to="label_GrantReimbursements_1" xlink:title="label_GrantReimbursements_1"/>
    <link:label xlink:type="resource" xlink:label="label_GrantReimbursements_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_GrantReimbursements_2" xml:lang="en-US" id="label_GrantReimbursements_2">Represents the amount of expense in the current period that reflects the allocation of grants receivable over the life of the project for which the grants were provided.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantReimbursements" xlink:to="label_GrantReimbursements_2" xlink:title="label_GrantReimbursements_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GrantReimbursementsExpense" xlink:label="GrantReimbursementsExpense" xlink:title="GrantReimbursementsExpense"/>
    <link:label xlink:type="resource" xlink:label="label_GrantReimbursementsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GrantReimbursementsExpense" xml:lang="en-US" id="label_GrantReimbursementsExpense">Grant reimbursements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantReimbursementsExpense" xlink:to="label_GrantReimbursementsExpense" xlink:title="label_GrantReimbursementsExpense"/>
    <link:label xlink:type="resource" xlink:label="label_GrantReimbursementsExpense_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_GrantReimbursementsExpense_1" xml:lang="en-US" id="label_GrantReimbursementsExpense_1">The aggregate total of expenses of grant reimbursements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantReimbursementsExpense" xlink:to="label_GrantReimbursementsExpense_1" xlink:title="label_GrantReimbursementsExpense_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_IncreaseDecreaseInLeaseLiability" xlink:label="IncreaseDecreaseInLeaseLiability" xlink:title="IncreaseDecreaseInLeaseLiability"/>
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInLeaseLiability" xml:lang="en-US" id="label_IncreaseDecreaseInLeaseLiability">Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInLeaseLiability" xlink:to="label_IncreaseDecreaseInLeaseLiability" xlink:title="label_IncreaseDecreaseInLeaseLiability"/>
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInLeaseLiability_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_IncreaseDecreaseInLeaseLiability_1" xml:lang="en-US" id="label_IncreaseDecreaseInLeaseLiability_1">The increase (decrease) during the reporting period in the amount of lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInLeaseLiability" xlink:to="label_IncreaseDecreaseInLeaseLiability_1" xlink:title="label_IncreaseDecreaseInLeaseLiability_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember"/>
    <link:label xlink:type="resource" xlink:label="label_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LaboratoryEquipmentMember" xml:lang="en-US" id="label_LaboratoryEquipmentMember">Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryEquipmentMember" xlink:to="label_LaboratoryEquipmentMember" xlink:title="label_LaboratoryEquipmentMember"/>
    <link:label xlink:type="resource" xlink:label="label_LaboratoryEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LaboratoryEquipmentMember_1" xml:lang="en-US" id="label_LaboratoryEquipmentMember_1">Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryEquipmentMember" xlink:to="label_LaboratoryEquipmentMember_1" xlink:title="label_LaboratoryEquipmentMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_LaboratoryEquipmentMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LaboratoryEquipmentMember_2" xml:lang="en-US" id="label_LaboratoryEquipmentMember_2">Long lived, depreciable assets that are used in laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryEquipmentMember" xlink:to="label_LaboratoryEquipmentMember_2" xlink:title="label_LaboratoryEquipmentMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LesseeFinanceLeaseNotYetCommenced" xlink:label="LesseeFinanceLeaseNotYetCommenced" xlink:title="LesseeFinanceLeaseNotYetCommenced"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeFinanceLeaseNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LesseeFinanceLeaseNotYetCommenced" xml:lang="en-US" id="label_LesseeFinanceLeaseNotYetCommenced">Lessee, Finance Lease, Not yet Commenced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseNotYetCommenced" xlink:to="label_LesseeFinanceLeaseNotYetCommenced" xlink:title="label_LesseeFinanceLeaseNotYetCommenced"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeFinanceLeaseNotYetCommenced_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeFinanceLeaseNotYetCommenced_1" xml:lang="en-US" id="label_LesseeFinanceLeaseNotYetCommenced_1">adyx_LesseeFinanceLeaseNotYetCommenced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseNotYetCommenced" xlink:to="label_LesseeFinanceLeaseNotYetCommenced_1" xlink:title="label_LesseeFinanceLeaseNotYetCommenced_1"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeFinanceLeaseNotYetCommenced_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LesseeFinanceLeaseNotYetCommenced_2" xml:lang="en-US" id="label_LesseeFinanceLeaseNotYetCommenced_2">Represents the amount of finance leases the company has that have not yet commenced.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseNotYetCommenced" xlink:to="label_LesseeFinanceLeaseNotYetCommenced_2" xlink:title="label_LesseeFinanceLeaseNotYetCommenced_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LesseeOperatingLeaseNotYetCommenced" xlink:label="LesseeOperatingLeaseNotYetCommenced" xlink:title="LesseeOperatingLeaseNotYetCommenced"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LesseeOperatingLeaseNotYetCommenced" xml:lang="en-US" id="label_LesseeOperatingLeaseNotYetCommenced">Lessee, Operating Lease, Not yet Commenced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseNotYetCommenced" xlink:to="label_LesseeOperatingLeaseNotYetCommenced" xlink:title="label_LesseeOperatingLeaseNotYetCommenced"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseNotYetCommenced_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeOperatingLeaseNotYetCommenced_1" xml:lang="en-US" id="label_LesseeOperatingLeaseNotYetCommenced_1">adyx_LesseeOperatingLeaseNotYetCommenced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseNotYetCommenced" xlink:to="label_LesseeOperatingLeaseNotYetCommenced_1" xlink:title="label_LesseeOperatingLeaseNotYetCommenced_1"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseNotYetCommenced_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LesseeOperatingLeaseNotYetCommenced_2" xml:lang="en-US" id="label_LesseeOperatingLeaseNotYetCommenced_2">Represents the amount of operating leases the company has that have not yet commenced.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseNotYetCommenced" xlink:to="label_LesseeOperatingLeaseNotYetCommenced_2" xlink:title="label_LesseeOperatingLeaseNotYetCommenced_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LetterOfCredit1Member" xlink:label="LetterOfCredit1Member" xlink:title="LetterOfCredit1Member"/>
    <link:label xlink:type="resource" xlink:label="label_LetterOfCredit1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LetterOfCredit1Member" xml:lang="en-US" id="label_LetterOfCredit1Member">Letter of Credit 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LetterOfCredit1Member" xlink:to="label_LetterOfCredit1Member" xlink:title="label_LetterOfCredit1Member"/>
    <link:label xlink:type="resource" xlink:label="label_LetterOfCredit1Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LetterOfCredit1Member_1" xml:lang="en-US" id="label_LetterOfCredit1Member_1">Letter of Credit 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LetterOfCredit1Member" xlink:to="label_LetterOfCredit1Member_1" xlink:title="label_LetterOfCredit1Member_1"/>
    <link:label xlink:type="resource" xlink:label="label_LetterOfCredit1Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LetterOfCredit1Member_2" xml:lang="en-US" id="label_LetterOfCredit1Member_2">Represents a document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LetterOfCredit1Member" xlink:to="label_LetterOfCredit1Member_2" xlink:title="label_LetterOfCredit1Member_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:label="LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:title="LongtermDebtPrincipalAndInterestPaymentsTerm"/>
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongtermDebtPrincipalAndInterestPaymentsTerm" xml:lang="en-US" id="label_LongtermDebtPrincipalAndInterestPaymentsTerm">Long-term Debt, Principal and Interest Payments, Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:to="label_LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:title="label_LongtermDebtPrincipalAndInterestPaymentsTerm"/>
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtPrincipalAndInterestPaymentsTerm_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongtermDebtPrincipalAndInterestPaymentsTerm_1" xml:lang="en-US" id="label_LongtermDebtPrincipalAndInterestPaymentsTerm_1">adyx_LongtermDebtPrincipalAndInterestPaymentsTerm</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:to="label_LongtermDebtPrincipalAndInterestPaymentsTerm_1" xlink:title="label_LongtermDebtPrincipalAndInterestPaymentsTerm_1"/>
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtPrincipalAndInterestPaymentsTerm_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LongtermDebtPrincipalAndInterestPaymentsTerm_2" xml:lang="en-US" id="label_LongtermDebtPrincipalAndInterestPaymentsTerm_2">The period between the interest-only payment term, and the maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:to="label_LongtermDebtPrincipalAndInterestPaymentsTerm_2" xlink:title="label_LongtermDebtPrincipalAndInterestPaymentsTerm_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:label xlink:type="resource" xlink:label="label_MajorityInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MajorityInvestorsMember" xml:lang="en-US" id="label_MajorityInvestorsMember">Majority Investors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorityInvestorsMember" xlink:to="label_MajorityInvestorsMember" xlink:title="label_MajorityInvestorsMember"/>
    <link:label xlink:type="resource" xlink:label="label_MajorityInvestorsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MajorityInvestorsMember_1" xml:lang="en-US" id="label_MajorityInvestorsMember_1">Majority Investors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorityInvestorsMember" xlink:to="label_MajorityInvestorsMember_1" xlink:title="label_MajorityInvestorsMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_MajorityInvestorsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_MajorityInvestorsMember_2" xml:lang="en-US" id="label_MajorityInvestorsMember_2">Represents information pertaining to the company's majority investors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorityInvestorsMember" xlink:to="label_MajorityInvestorsMember_2" xlink:title="label_MajorityInvestorsMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:label="MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:title="MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree"/>
    <link:label xlink:type="resource" xlink:label="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xml:lang="en-US" id="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree">Merger Agreement, Percentage Ownership in Combined Company, Acquiree</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:to="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:title="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree"/>
    <link:label xlink:type="resource" xlink:label="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree_1" xml:lang="en-US" id="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree_1">adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:to="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree_1" xlink:title="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree_1"/>
    <link:label xlink:type="resource" xlink:label="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree_2" xml:lang="en-US" id="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree_2">Represents the acquiree's percentage ownership in the combined company immediately following a merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:to="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree_2" xlink:title="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:label="MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:title="MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer"/>
    <link:label xlink:type="resource" xlink:label="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xml:lang="en-US" id="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer">Merger Agreement, Percentage Ownership in Combined Company, Acquirer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:to="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:title="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer"/>
    <link:label xlink:type="resource" xlink:label="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer_1" xml:lang="en-US" id="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer_1">adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:to="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer_1" xlink:title="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer_1"/>
    <link:label xlink:type="resource" xlink:label="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer_2" xml:lang="en-US" id="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer_2">Represents the acquirer's percentage ownership in the combined company immediately following a merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:to="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer_2" xlink:title="label_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:label="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="ModifiedMarch2018AndModifiedSeptember2018NotesMember"/>
    <link:label xlink:type="resource" xlink:label="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember" xml:lang="en-US" id="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember">Modified March 2018 and Modified September 2018 Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:to="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember"/>
    <link:label xlink:type="resource" xlink:label="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember_1" xml:lang="en-US" id="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember_1">Modified March 2018 and Modified September 2018 Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:to="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember_1" xlink:title="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember_2" xml:lang="en-US" id="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember_2">Represents the Modified March 2018 and Modified September 2018 Notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:to="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember_2" xlink:title="label_ModifiedMarch2018AndModifiedSeptember2018NotesMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:label="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:title="ModifiedMarch2018September2018December2018AndMarch2019NotesMember"/>
    <link:label xlink:type="resource" xlink:label="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xml:lang="en-US" id="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember">Modified March 2018, September 2018, December 2018, and March 2019 Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:to="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:title="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember"/>
    <link:label xlink:type="resource" xlink:label="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember_1" xml:lang="en-US" id="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember_1">Modified March 2018, September 2018, December 2018, and March 2019 Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:to="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember_1" xlink:title="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember_2" xml:lang="en-US" id="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember_2">The Modified March 2018, September 2018, December 2018, and March 2019 notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:to="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember_2" xlink:title="label_ModifiedMarch2018September2018December2018AndMarch2019NotesMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:label="ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:title="ModifiedMarch2019AndModifiedDecember2018NotesMember"/>
    <link:label xlink:type="resource" xlink:label="label_ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ModifiedMarch2019AndModifiedDecember2018NotesMember" xml:lang="en-US" id="label_ModifiedMarch2019AndModifiedDecember2018NotesMember">Modified March 2019 and Modified December 2018 Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:to="label_ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:title="label_ModifiedMarch2019AndModifiedDecember2018NotesMember"/>
    <link:label xlink:type="resource" xlink:label="label_ModifiedMarch2019AndModifiedDecember2018NotesMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ModifiedMarch2019AndModifiedDecember2018NotesMember_1" xml:lang="en-US" id="label_ModifiedMarch2019AndModifiedDecember2018NotesMember_1">Modified March 2019 and Modified December 2018 Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:to="label_ModifiedMarch2019AndModifiedDecember2018NotesMember_1" xlink:title="label_ModifiedMarch2019AndModifiedDecember2018NotesMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ModifiedMarch2019AndModifiedDecember2018NotesMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ModifiedMarch2019AndModifiedDecember2018NotesMember_2" xml:lang="en-US" id="label_ModifiedMarch2019AndModifiedDecember2018NotesMember_2">The modified March 2019 and modified December 2018 notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:to="label_ModifiedMarch2019AndModifiedDecember2018NotesMember_2" xlink:title="label_ModifiedMarch2019AndModifiedDecember2018NotesMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoncashPortionOfLeaseExpense" xlink:label="NoncashPortionOfLeaseExpense" xlink:title="NoncashPortionOfLeaseExpense"/>
    <link:label xlink:type="resource" xlink:label="label_NoncashPortionOfLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashPortionOfLeaseExpense" xml:lang="en-US" id="label_NoncashPortionOfLeaseExpense">Non-cash operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashPortionOfLeaseExpense" xlink:to="label_NoncashPortionOfLeaseExpense" xlink:title="label_NoncashPortionOfLeaseExpense"/>
    <link:label xlink:type="resource" xlink:label="label_NoncashPortionOfLeaseExpense_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NoncashPortionOfLeaseExpense_1" xml:lang="en-US" id="label_NoncashPortionOfLeaseExpense_1">Represents the noncash portion of the operating lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashPortionOfLeaseExpense" xlink:to="label_NoncashPortionOfLeaseExpense_1" xlink:title="label_NoncashPortionOfLeaseExpense_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" xlink:label="NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" xlink:title="NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" xml:lang="en-US" id="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember">Noncumulative Dividends for Holders of Series A Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" xlink:to="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" xlink:title="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember_1">Noncumulative Dividends For Holders Of Series A Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" xlink:to="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember_1" xlink:title="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember_2">Represents noncumulative dividends for holders of series A convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" xlink:to="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember_2" xlink:title="label_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" xlink:label="NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" xlink:title="NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" xml:lang="en-US" id="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember">Noncumulative Dividends for Holders of Series B Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" xlink:to="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" xlink:title="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember_1">Noncumulative Dividends For Holders Of Series B Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" xlink:to="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember_1" xlink:title="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember_2">Represents noncumulative dividends for holders of series B convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" xlink:to="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember_2" xlink:title="label_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NonEmployeeOptionsMember" xlink:label="NonEmployeeOptionsMember" xlink:title="NonEmployeeOptionsMember"/>
    <link:label xlink:type="resource" xlink:label="label_NonEmployeeOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonEmployeeOptionsMember" xml:lang="en-US" id="label_NonEmployeeOptionsMember">Non-employee Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonEmployeeOptionsMember" xlink:to="label_NonEmployeeOptionsMember" xlink:title="label_NonEmployeeOptionsMember"/>
    <link:label xlink:type="resource" xlink:label="label_NonEmployeeOptionsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonEmployeeOptionsMember_1" xml:lang="en-US" id="label_NonEmployeeOptionsMember_1">Non-employee Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonEmployeeOptionsMember" xlink:to="label_NonEmployeeOptionsMember_1" xlink:title="label_NonEmployeeOptionsMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_NonEmployeeOptionsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NonEmployeeOptionsMember_2" xml:lang="en-US" id="label_NonEmployeeOptionsMember_2">Represents information pertaining to non-employee options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonEmployeeOptionsMember" xlink:to="label_NonEmployeeOptionsMember_2" xlink:title="label_NonEmployeeOptionsMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:label="NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:title="NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount"/>
    <link:label xlink:type="resource" xlink:label="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xml:lang="en-US" id="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount">Non-employee Stock Options, Comensation Expense, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:to="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:title="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount"/>
    <link:label xlink:type="resource" xlink:label="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount_1" xml:lang="en-US" id="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount_1">adyx_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:to="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount_1" xlink:title="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount_1"/>
    <link:label xlink:type="resource" xlink:label="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount_2" xml:lang="en-US" id="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount_2">Represents the amount of unrecognized stock-based compensation expense related to unvested non-employees stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:to="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount_2" xlink:title="label_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:label="NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:title="NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition"/>
    <link:label xlink:type="resource" xlink:label="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xml:lang="en-US" id="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition">Non-employee Stock Options, Comensation Expense, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:to="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:title="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition"/>
    <link:label xlink:type="resource" xlink:label="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition_1" xml:lang="en-US" id="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition_1">adyx_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:to="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition_1" xlink:title="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition_1"/>
    <link:label xlink:type="resource" xlink:label="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition_2" xml:lang="en-US" id="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition_2">Represents the period over which unrecognized stock-based compensation expense related to unvested non-employee stock options is expected to be recognized.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:to="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition_2" xlink:title="label_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_NotesToFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NotesToFinancialStatementsAbstract" xml:lang="en-US" id="label_NotesToFinancialStatementsAbstract">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="label_NotesToFinancialStatementsAbstract" xlink:title="label_NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFundTheCompanysOperationsMember" xlink:label="NotesToFundTheCompanysOperationsMember" xlink:title="NotesToFundTheCompanysOperationsMember"/>
    <link:label xlink:type="resource" xlink:label="label_NotesToFundTheCompanysOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NotesToFundTheCompanysOperationsMember" xml:lang="en-US" id="label_NotesToFundTheCompanysOperationsMember">Notes to Fund the Company's Operations [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesToFundTheCompanysOperationsMember" xlink:to="label_NotesToFundTheCompanysOperationsMember" xlink:title="label_NotesToFundTheCompanysOperationsMember"/>
    <link:label xlink:type="resource" xlink:label="label_NotesToFundTheCompanysOperationsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NotesToFundTheCompanysOperationsMember_1" xml:lang="en-US" id="label_NotesToFundTheCompanysOperationsMember_1">Notes to Fund the Company's Operations [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesToFundTheCompanysOperationsMember" xlink:to="label_NotesToFundTheCompanysOperationsMember_1" xlink:title="label_NotesToFundTheCompanysOperationsMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_NotesToFundTheCompanysOperationsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NotesToFundTheCompanysOperationsMember_2" xml:lang="en-US" id="label_NotesToFundTheCompanysOperationsMember_2">Represents information pertaining to notes to fund the company's operations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesToFundTheCompanysOperationsMember" xlink:to="label_NotesToFundTheCompanysOperationsMember_2" xlink:title="label_NotesToFundTheCompanysOperationsMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="NoteToFinancialStatementDetailsTextual" xlink:title="NoteToFinancialStatementDetailsTextual"/>
    <link:label xlink:type="resource" xlink:label="label_NoteToFinancialStatementDetailsTextual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoteToFinancialStatementDetailsTextual" xml:lang="en-US" id="label_NoteToFinancialStatementDetailsTextual">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoteToFinancialStatementDetailsTextual" xlink:to="label_NoteToFinancialStatementDetailsTextual" xlink:title="label_NoteToFinancialStatementDetailsTextual"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NumberOfForeignSubsidiaries" xlink:label="NumberOfForeignSubsidiaries" xlink:title="NumberOfForeignSubsidiaries"/>
    <link:label xlink:type="resource" xlink:label="label_NumberOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfForeignSubsidiaries" xml:lang="en-US" id="label_NumberOfForeignSubsidiaries">Number of Foreign Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfForeignSubsidiaries" xlink:to="label_NumberOfForeignSubsidiaries" xlink:title="label_NumberOfForeignSubsidiaries"/>
    <link:label xlink:type="resource" xlink:label="label_NumberOfForeignSubsidiaries_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfForeignSubsidiaries_1" xml:lang="en-US" id="label_NumberOfForeignSubsidiaries_1">adyx_NumberOfForeignSubsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfForeignSubsidiaries" xlink:to="label_NumberOfForeignSubsidiaries_1" xlink:title="label_NumberOfForeignSubsidiaries_1"/>
    <link:label xlink:type="resource" xlink:label="label_NumberOfForeignSubsidiaries_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfForeignSubsidiaries_2" xml:lang="en-US" id="label_NumberOfForeignSubsidiaries_2">Represents the number of foreign subsidiaries of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfForeignSubsidiaries" xlink:to="label_NumberOfForeignSubsidiaries_2" xlink:title="label_NumberOfForeignSubsidiaries_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NumberOfSharesHeldByEquityHolders" xlink:label="NumberOfSharesHeldByEquityHolders" xlink:title="NumberOfSharesHeldByEquityHolders"/>
    <link:label xlink:type="resource" xlink:label="label_NumberOfSharesHeldByEquityHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfSharesHeldByEquityHolders" xml:lang="en-US" id="label_NumberOfSharesHeldByEquityHolders">Number of Shares Held by Equity Holders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesHeldByEquityHolders" xlink:to="label_NumberOfSharesHeldByEquityHolders" xlink:title="label_NumberOfSharesHeldByEquityHolders"/>
    <link:label xlink:type="resource" xlink:label="label_NumberOfSharesHeldByEquityHolders_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfSharesHeldByEquityHolders_1" xml:lang="en-US" id="label_NumberOfSharesHeldByEquityHolders_1">adyx_NumberOfSharesHeldByEquityHolders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesHeldByEquityHolders" xlink:to="label_NumberOfSharesHeldByEquityHolders_1" xlink:title="label_NumberOfSharesHeldByEquityHolders_1"/>
    <link:label xlink:type="resource" xlink:label="label_NumberOfSharesHeldByEquityHolders_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfSharesHeldByEquityHolders_2" xml:lang="en-US" id="label_NumberOfSharesHeldByEquityHolders_2">Represents the number of shares held by equity holders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesHeldByEquityHolders" xlink:to="label_NumberOfSharesHeldByEquityHolders_2" xlink:title="label_NumberOfSharesHeldByEquityHolders_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:label="OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:title="OneOfTheTwoVendorsSupportingManufacturingActivitiesMember"/>
    <link:label xlink:type="resource" xlink:label="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xml:lang="en-US" id="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember">One of the Two Vendors Supporting Manufacturing Activities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:to="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:title="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember"/>
    <link:label xlink:type="resource" xlink:label="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember_1" xml:lang="en-US" id="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember_1">One Of The Two Vendors Supporting Manufacturing Activities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:to="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember_1" xlink:title="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember_2" xml:lang="en-US" id="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember_2">Represents one of the two major vendors which supports the manufacturing activities portion of accounts payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:to="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember_2" xlink:title="label_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OperatingLeaseCarryforwardsWithExpirationDates" xlink:label="OperatingLeaseCarryforwardsWithExpirationDates" xlink:title="OperatingLeaseCarryforwardsWithExpirationDates"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseCarryforwardsWithExpirationDates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeaseCarryforwardsWithExpirationDates" xml:lang="en-US" id="label_OperatingLeaseCarryforwardsWithExpirationDates">Operating Lease Carryforwards with Expiration Dates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCarryforwardsWithExpirationDates" xlink:to="label_OperatingLeaseCarryforwardsWithExpirationDates" xlink:title="label_OperatingLeaseCarryforwardsWithExpirationDates"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseCarryforwardsWithExpirationDates_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeaseCarryforwardsWithExpirationDates_1" xml:lang="en-US" id="label_OperatingLeaseCarryforwardsWithExpirationDates_1">adyx_OperatingLeaseCarryforwardsWithExpirationDates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCarryforwardsWithExpirationDates" xlink:to="label_OperatingLeaseCarryforwardsWithExpirationDates_1" xlink:title="label_OperatingLeaseCarryforwardsWithExpirationDates_1"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseCarryforwardsWithExpirationDates_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_OperatingLeaseCarryforwardsWithExpirationDates_2" xml:lang="en-US" id="label_OperatingLeaseCarryforwardsWithExpirationDates_2">Represents the amount of operating lease carryforwards that have specific expiration dates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCarryforwardsWithExpirationDates" xlink:to="label_OperatingLeaseCarryforwardsWithExpirationDates_2" xlink:title="label_OperatingLeaseCarryforwardsWithExpirationDates_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OperatingLossCarryforwardsExpiringIndefinitely" xlink:label="OperatingLossCarryforwardsExpiringIndefinitely" xlink:title="OperatingLossCarryforwardsExpiringIndefinitely"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwardsExpiringIndefinitely" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLossCarryforwardsExpiringIndefinitely" xml:lang="en-US" id="label_OperatingLossCarryforwardsExpiringIndefinitely">Operating Loss Carryforwards Expiring Indefinitely</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsExpiringIndefinitely" xlink:to="label_OperatingLossCarryforwardsExpiringIndefinitely" xlink:title="label_OperatingLossCarryforwardsExpiringIndefinitely"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwardsExpiringIndefinitely_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLossCarryforwardsExpiringIndefinitely_1" xml:lang="en-US" id="label_OperatingLossCarryforwardsExpiringIndefinitely_1">adyx_OperatingLossCarryforwardsExpiringIndefinitely</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsExpiringIndefinitely" xlink:to="label_OperatingLossCarryforwardsExpiringIndefinitely_1" xlink:title="label_OperatingLossCarryforwardsExpiringIndefinitely_1"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwardsExpiringIndefinitely_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_OperatingLossCarryforwardsExpiringIndefinitely_2" xml:lang="en-US" id="label_OperatingLossCarryforwardsExpiringIndefinitely_2">Represents the amount of operating loss carryforwards that expire indefinitely.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsExpiringIndefinitely" xlink:to="label_OperatingLossCarryforwardsExpiringIndefinitely_2" xlink:title="label_OperatingLossCarryforwardsExpiringIndefinitely_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OxfordFinanceLLCMember" xlink:label="OxfordFinanceLLCMember" xlink:title="OxfordFinanceLLCMember"/>
    <link:label xlink:type="resource" xlink:label="label_OxfordFinanceLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OxfordFinanceLLCMember" xml:lang="en-US" id="label_OxfordFinanceLLCMember">Oxford Finance, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OxfordFinanceLLCMember" xlink:to="label_OxfordFinanceLLCMember" xlink:title="label_OxfordFinanceLLCMember"/>
    <link:label xlink:type="resource" xlink:label="label_OxfordFinanceLLCMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OxfordFinanceLLCMember_1" xml:lang="en-US" id="label_OxfordFinanceLLCMember_1">Oxford Finance, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OxfordFinanceLLCMember" xlink:to="label_OxfordFinanceLLCMember_1" xlink:title="label_OxfordFinanceLLCMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_OxfordFinanceLLCMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_OxfordFinanceLLCMember_2" xml:lang="en-US" id="label_OxfordFinanceLLCMember_2">The lender Oxford Finance, LLC ("Oxford").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OxfordFinanceLLCMember" xlink:to="label_OxfordFinanceLLCMember_2" xlink:title="label_OxfordFinanceLLCMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PercentageOfNotePayablePrincipal" xlink:label="PercentageOfNotePayablePrincipal" xlink:title="PercentageOfNotePayablePrincipal"/>
    <link:label xlink:type="resource" xlink:label="label_PercentageOfNotePayablePrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PercentageOfNotePayablePrincipal" xml:lang="en-US" id="label_PercentageOfNotePayablePrincipal">Percentage of Note Payable Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfNotePayablePrincipal" xlink:to="label_PercentageOfNotePayablePrincipal" xlink:title="label_PercentageOfNotePayablePrincipal"/>
    <link:label xlink:type="resource" xlink:label="label_PercentageOfNotePayablePrincipal_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PercentageOfNotePayablePrincipal_1" xml:lang="en-US" id="label_PercentageOfNotePayablePrincipal_1">adyx_PercentageOfNotePayablePrincipal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfNotePayablePrincipal" xlink:to="label_PercentageOfNotePayablePrincipal_1" xlink:title="label_PercentageOfNotePayablePrincipal_1"/>
    <link:label xlink:type="resource" xlink:label="label_PercentageOfNotePayablePrincipal_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PercentageOfNotePayablePrincipal_2" xml:lang="en-US" id="label_PercentageOfNotePayablePrincipal_2">Represents the percentage of notes payable principal.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfNotePayablePrincipal" xlink:to="label_PercentageOfNotePayablePrincipal_2" xlink:title="label_PercentageOfNotePayablePrincipal_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PrepaidClinicalTrialExpenseCurrent" xlink:label="PrepaidClinicalTrialExpenseCurrent" xlink:title="PrepaidClinicalTrialExpenseCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_PrepaidClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidClinicalTrialExpenseCurrent" xml:lang="en-US" id="label_PrepaidClinicalTrialExpenseCurrent">Prepaid clinical trial expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidClinicalTrialExpenseCurrent" xlink:to="label_PrepaidClinicalTrialExpenseCurrent" xlink:title="label_PrepaidClinicalTrialExpenseCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_PrepaidClinicalTrialExpenseCurrent_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PrepaidClinicalTrialExpenseCurrent_1" xml:lang="en-US" id="label_PrepaidClinicalTrialExpenseCurrent_1">Amount of assets related to consideration paid in advance for clinical trials that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidClinicalTrialExpenseCurrent" xlink:to="label_PrepaidClinicalTrialExpenseCurrent_1" xlink:title="label_PrepaidClinicalTrialExpenseCurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PriceRange1Member" xlink:label="PriceRange1Member" xlink:title="PriceRange1Member"/>
    <link:label xlink:type="resource" xlink:label="label_PriceRange1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PriceRange1Member" xml:lang="en-US" id="label_PriceRange1Member">Price Range 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriceRange1Member" xlink:to="label_PriceRange1Member" xlink:title="label_PriceRange1Member"/>
    <link:label xlink:type="resource" xlink:label="label_PriceRange1Member_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PriceRange1Member_1" xml:lang="en-US" id="label_PriceRange1Member_1">Represents a range of exercise prices for outstanding options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriceRange1Member" xlink:to="label_PriceRange1Member_1" xlink:title="label_PriceRange1Member_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PriceRange2Member" xlink:label="PriceRange2Member" xlink:title="PriceRange2Member"/>
    <link:label xlink:type="resource" xlink:label="label_PriceRange2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PriceRange2Member" xml:lang="en-US" id="label_PriceRange2Member">Price Range 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriceRange2Member" xlink:to="label_PriceRange2Member" xlink:title="label_PriceRange2Member"/>
    <link:label xlink:type="resource" xlink:label="label_PriceRange2Member_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PriceRange2Member_1" xml:lang="en-US" id="label_PriceRange2Member_1">Represents a range of exercise prices for outstanding options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriceRange2Member" xlink:to="label_PriceRange2Member_1" xlink:title="label_PriceRange2Member_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PriceRange3Member" xlink:label="PriceRange3Member" xlink:title="PriceRange3Member"/>
    <link:label xlink:type="resource" xlink:label="label_PriceRange3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PriceRange3Member" xml:lang="en-US" id="label_PriceRange3Member">Price Range 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriceRange3Member" xlink:to="label_PriceRange3Member" xlink:title="label_PriceRange3Member"/>
    <link:label xlink:type="resource" xlink:label="label_PriceRange3Member_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PriceRange3Member_1" xml:lang="en-US" id="label_PriceRange3Member_1">Represents a range of exercise prices for outstanding options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriceRange3Member" xlink:to="label_PriceRange3Member_1" xlink:title="label_PriceRange3Member_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PriceRange4Member" xlink:label="PriceRange4Member" xlink:title="PriceRange4Member"/>
    <link:label xlink:type="resource" xlink:label="label_PriceRange4Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PriceRange4Member" xml:lang="en-US" id="label_PriceRange4Member">Price Range 4 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriceRange4Member" xlink:to="label_PriceRange4Member" xlink:title="label_PriceRange4Member"/>
    <link:label xlink:type="resource" xlink:label="label_PriceRange4Member_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PriceRange4Member_1" xml:lang="en-US" id="label_PriceRange4Member_1">Represents a range of exercise prices for outstanding options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriceRange4Member" xlink:to="label_PriceRange4Member_1" xlink:title="label_PriceRange4Member_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ProbabilityOfChangeInControlOccurring" xlink:label="ProbabilityOfChangeInControlOccurring" xlink:title="ProbabilityOfChangeInControlOccurring"/>
    <link:label xlink:type="resource" xlink:label="label_ProbabilityOfChangeInControlOccurring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProbabilityOfChangeInControlOccurring" xml:lang="en-US" id="label_ProbabilityOfChangeInControlOccurring">Probability of Change in Control Occurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProbabilityOfChangeInControlOccurring" xlink:to="label_ProbabilityOfChangeInControlOccurring" xlink:title="label_ProbabilityOfChangeInControlOccurring"/>
    <link:label xlink:type="resource" xlink:label="label_ProbabilityOfChangeInControlOccurring_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProbabilityOfChangeInControlOccurring_1" xml:lang="en-US" id="label_ProbabilityOfChangeInControlOccurring_1">adyx_ProbabilityOfChangeInControlOccurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProbabilityOfChangeInControlOccurring" xlink:to="label_ProbabilityOfChangeInControlOccurring_1" xlink:title="label_ProbabilityOfChangeInControlOccurring_1"/>
    <link:label xlink:type="resource" xlink:label="label_ProbabilityOfChangeInControlOccurring_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ProbabilityOfChangeInControlOccurring_2" xml:lang="en-US" id="label_ProbabilityOfChangeInControlOccurring_2">The probability of a change in control occurring.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProbabilityOfChangeInControlOccurring" xlink:to="label_ProbabilityOfChangeInControlOccurring_2" xlink:title="label_ProbabilityOfChangeInControlOccurring_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ProbabilityOfQualifiedFinancingOccurring" xlink:label="ProbabilityOfQualifiedFinancingOccurring" xlink:title="ProbabilityOfQualifiedFinancingOccurring"/>
    <link:label xlink:type="resource" xlink:label="label_ProbabilityOfQualifiedFinancingOccurring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProbabilityOfQualifiedFinancingOccurring" xml:lang="en-US" id="label_ProbabilityOfQualifiedFinancingOccurring">Probability of Qualified Financing Occurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProbabilityOfQualifiedFinancingOccurring" xlink:to="label_ProbabilityOfQualifiedFinancingOccurring" xlink:title="label_ProbabilityOfQualifiedFinancingOccurring"/>
    <link:label xlink:type="resource" xlink:label="label_ProbabilityOfQualifiedFinancingOccurring_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProbabilityOfQualifiedFinancingOccurring_1" xml:lang="en-US" id="label_ProbabilityOfQualifiedFinancingOccurring_1">adyx_ProbabilityOfQualifiedFinancingOccurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProbabilityOfQualifiedFinancingOccurring" xlink:to="label_ProbabilityOfQualifiedFinancingOccurring_1" xlink:title="label_ProbabilityOfQualifiedFinancingOccurring_1"/>
    <link:label xlink:type="resource" xlink:label="label_ProbabilityOfQualifiedFinancingOccurring_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ProbabilityOfQualifiedFinancingOccurring_2" xml:lang="en-US" id="label_ProbabilityOfQualifiedFinancingOccurring_2">The probability that a qualified financing would occur.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProbabilityOfQualifiedFinancingOccurring" xlink:to="label_ProbabilityOfQualifiedFinancingOccurring_2" xlink:title="label_ProbabilityOfQualifiedFinancingOccurring_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReclassificationOfWarrantIntoEquity" xlink:label="ReclassificationOfWarrantIntoEquity" xlink:title="ReclassificationOfWarrantIntoEquity"/>
    <link:label xlink:type="resource" xlink:label="label_ReclassificationOfWarrantIntoEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ReclassificationOfWarrantIntoEquity" xml:lang="en-US" id="label_ReclassificationOfWarrantIntoEquity">Reclassification of Warrant into Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationOfWarrantIntoEquity" xlink:to="label_ReclassificationOfWarrantIntoEquity" xlink:title="label_ReclassificationOfWarrantIntoEquity"/>
    <link:label xlink:type="resource" xlink:label="label_ReclassificationOfWarrantIntoEquity_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ReclassificationOfWarrantIntoEquity_1" xml:lang="en-US" id="label_ReclassificationOfWarrantIntoEquity_1">adyx_ReclassificationOfWarrantIntoEquity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationOfWarrantIntoEquity" xlink:to="label_ReclassificationOfWarrantIntoEquity_1" xlink:title="label_ReclassificationOfWarrantIntoEquity_1"/>
    <link:label xlink:type="resource" xlink:label="label_ReclassificationOfWarrantIntoEquity_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ReclassificationOfWarrantIntoEquity_2" xml:lang="en-US" id="label_ReclassificationOfWarrantIntoEquity_2">Represents the amount of reclassification of warrant into equity during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationOfWarrantIntoEquity" xlink:to="label_ReclassificationOfWarrantIntoEquity_2" xlink:title="label_ReclassificationOfWarrantIntoEquity_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReclassificationOfWarrantLiabilityToPaidInCapital" xlink:label="ReclassificationOfWarrantLiabilityToPaidInCapital" xlink:title="ReclassificationOfWarrantLiabilityToPaidInCapital"/>
    <link:label xlink:type="resource" xlink:label="label_ReclassificationOfWarrantLiabilityToPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ReclassificationOfWarrantLiabilityToPaidInCapital" xml:lang="en-US" id="label_ReclassificationOfWarrantLiabilityToPaidInCapital">Reclassification of warrant liability to paid in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationOfWarrantLiabilityToPaidInCapital" xlink:to="label_ReclassificationOfWarrantLiabilityToPaidInCapital" xlink:title="label_ReclassificationOfWarrantLiabilityToPaidInCapital"/>
    <link:label xlink:type="resource" xlink:label="label_ReclassificationOfWarrantLiabilityToPaidInCapital_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ReclassificationOfWarrantLiabilityToPaidInCapital_1" xml:lang="en-US" id="label_ReclassificationOfWarrantLiabilityToPaidInCapital_1">The reclassification of warrant liabilities to paid in capital as a result of a merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationOfWarrantLiabilityToPaidInCapital" xlink:to="label_ReclassificationOfWarrantLiabilityToPaidInCapital_1" xlink:title="label_ReclassificationOfWarrantLiabilityToPaidInCapital_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReleaseOfDerivativeLiabilities" xlink:label="ReleaseOfDerivativeLiabilities" xlink:title="ReleaseOfDerivativeLiabilities"/>
    <link:label xlink:type="resource" xlink:label="label_ReleaseOfDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ReleaseOfDerivativeLiabilities" xml:lang="en-US" id="label_ReleaseOfDerivativeLiabilities">Release of Derivative Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReleaseOfDerivativeLiabilities" xlink:to="label_ReleaseOfDerivativeLiabilities" xlink:title="label_ReleaseOfDerivativeLiabilities"/>
    <link:label xlink:type="resource" xlink:label="label_ReleaseOfDerivativeLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ReleaseOfDerivativeLiabilities_1" xml:lang="en-US" id="label_ReleaseOfDerivativeLiabilities_1">adyx_ReleaseOfDerivativeLiabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReleaseOfDerivativeLiabilities" xlink:to="label_ReleaseOfDerivativeLiabilities_1" xlink:title="label_ReleaseOfDerivativeLiabilities_1"/>
    <link:label xlink:type="resource" xlink:label="label_ReleaseOfDerivativeLiabilities_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ReleaseOfDerivativeLiabilities_2" xml:lang="en-US" id="label_ReleaseOfDerivativeLiabilities_2">The release of an embedded derivative liability as a result of the associated debt instrument being extinguished.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReleaseOfDerivativeLiabilities" xlink:to="label_ReleaseOfDerivativeLiabilities_2" xlink:title="label_ReleaseOfDerivativeLiabilities_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseMergerDisclosureTextBlock" xlink:label="ReverseMergerDisclosureTextBlock" xlink:title="ReverseMergerDisclosureTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ReverseMergerDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ReverseMergerDisclosureTextBlock" xml:lang="en-US" id="label_ReverseMergerDisclosureTextBlock">Reverse Merger Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseMergerDisclosureTextBlock" xlink:to="label_ReverseMergerDisclosureTextBlock" xlink:title="label_ReverseMergerDisclosureTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ReverseMergerDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ReverseMergerDisclosureTextBlock_1" xml:lang="en-US" id="label_ReverseMergerDisclosureTextBlock_1">The disclosure for the reverse merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseMergerDisclosureTextBlock" xlink:to="label_ReverseMergerDisclosureTextBlock_1" xlink:title="label_ReverseMergerDisclosureTextBlock_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitFromMember" xlink:label="ReverseStockSplitFromMember" xlink:title="ReverseStockSplitFromMember"/>
    <link:label xlink:type="resource" xlink:label="label_ReverseStockSplitFromMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ReverseStockSplitFromMember" xml:lang="en-US" id="label_ReverseStockSplitFromMember">Reverse Stock Split From [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitFromMember" xlink:to="label_ReverseStockSplitFromMember" xlink:title="label_ReverseStockSplitFromMember"/>
    <link:label xlink:type="resource" xlink:label="label_ReverseStockSplitFromMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ReverseStockSplitFromMember_1" xml:lang="en-US" id="label_ReverseStockSplitFromMember_1">The ratio of shares representing a stock transaction before a reverse stock split where there is a reduction in the shares outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitFromMember" xlink:to="label_ReverseStockSplitFromMember_1" xlink:title="label_ReverseStockSplitFromMember_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitMember" xlink:label="ReverseStockSplitMember" xlink:title="ReverseStockSplitMember"/>
    <link:label xlink:type="resource" xlink:label="label_ReverseStockSplitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ReverseStockSplitMember" xml:lang="en-US" id="label_ReverseStockSplitMember">Reverse Stock Split [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitMember" xlink:to="label_ReverseStockSplitMember" xlink:title="label_ReverseStockSplitMember"/>
    <link:label xlink:type="resource" xlink:label="label_ReverseStockSplitMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ReverseStockSplitMember_1" xml:lang="en-US" id="label_ReverseStockSplitMember_1">The conversion of a reverse stock split where there is a reduction in the shares outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitMember" xlink:to="label_ReverseStockSplitMember_1" xlink:title="label_ReverseStockSplitMember_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:label="ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:title="ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xml:lang="en-US" id="label_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock">Schedule of Prepaid and Other Current Assets [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:to="label_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:title="label_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_1">Tabular disclosure of the carrying amounts of prepaid and other current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:to="label_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_1" xlink:title="label_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SecondNoteToFundTheCompanysOperationsMember" xlink:label="SecondNoteToFundTheCompanysOperationsMember" xlink:title="SecondNoteToFundTheCompanysOperationsMember"/>
    <link:label xlink:type="resource" xlink:label="label_SecondNoteToFundTheCompanysOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SecondNoteToFundTheCompanysOperationsMember" xml:lang="en-US" id="label_SecondNoteToFundTheCompanysOperationsMember">Second Note to Fund the Company's Operations [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondNoteToFundTheCompanysOperationsMember" xlink:to="label_SecondNoteToFundTheCompanysOperationsMember" xlink:title="label_SecondNoteToFundTheCompanysOperationsMember"/>
    <link:label xlink:type="resource" xlink:label="label_SecondNoteToFundTheCompanysOperationsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SecondNoteToFundTheCompanysOperationsMember_1" xml:lang="en-US" id="label_SecondNoteToFundTheCompanysOperationsMember_1">Second Note to Fund the Company's Operations [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondNoteToFundTheCompanysOperationsMember" xlink:to="label_SecondNoteToFundTheCompanysOperationsMember_1" xlink:title="label_SecondNoteToFundTheCompanysOperationsMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_SecondNoteToFundTheCompanysOperationsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SecondNoteToFundTheCompanysOperationsMember_2" xml:lang="en-US" id="label_SecondNoteToFundTheCompanysOperationsMember_2">Represents information pertaining to a second note to fund the company's operations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondNoteToFundTheCompanysOperationsMember" xlink:to="label_SecondNoteToFundTheCompanysOperationsMember_2" xlink:title="label_SecondNoteToFundTheCompanysOperationsMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesAConvertiblePreferredStockMember" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:title="SeriesAConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesAConvertiblePreferredStockMember" xml:lang="en-US" id="label_SeriesAConvertiblePreferredStockMember">Series A Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAConvertiblePreferredStockMember" xlink:to="label_SeriesAConvertiblePreferredStockMember" xlink:title="label_SeriesAConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesAConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesAConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_SeriesAConvertiblePreferredStockMember_1">Series A Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAConvertiblePreferredStockMember" xlink:to="label_SeriesAConvertiblePreferredStockMember_1" xlink:title="label_SeriesAConvertiblePreferredStockMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesAConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesAConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_SeriesAConvertiblePreferredStockMember_2">Series A preferred stock that may be exchanged into common shares or other types of securities at the owner's option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAConvertiblePreferredStockMember" xlink:to="label_SeriesAConvertiblePreferredStockMember_2" xlink:title="label_SeriesAConvertiblePreferredStockMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesARedeemableConvertiblePreferredStockMember" xml:lang="en-US" id="label_SeriesARedeemableConvertiblePreferredStockMember">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesARedeemableConvertiblePreferredStockMember" xlink:to="label_SeriesARedeemableConvertiblePreferredStockMember" xlink:title="label_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesARedeemableConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesARedeemableConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_SeriesARedeemableConvertiblePreferredStockMember_1">Series A Redeemable Convertible Preferred Stock Without Giving Effect To The Reverse Stock Split [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesARedeemableConvertiblePreferredStockMember" xlink:to="label_SeriesARedeemableConvertiblePreferredStockMember_1" xlink:title="label_SeriesARedeemableConvertiblePreferredStockMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesARedeemableConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesARedeemableConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_SeriesARedeemableConvertiblePreferredStockMember_2">Represents information pertaining to Series A redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesARedeemableConvertiblePreferredStockMember" xlink:to="label_SeriesARedeemableConvertiblePreferredStockMember_2" xlink:title="label_SeriesARedeemableConvertiblePreferredStockMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBConvertiblePreferredStockMember" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:title="SeriesBConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesBConvertiblePreferredStockMember" xml:lang="en-US" id="label_SeriesBConvertiblePreferredStockMember">Series B Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBConvertiblePreferredStockMember" xlink:to="label_SeriesBConvertiblePreferredStockMember" xlink:title="label_SeriesBConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesBConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesBConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_SeriesBConvertiblePreferredStockMember_1">Series B Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBConvertiblePreferredStockMember" xlink:to="label_SeriesBConvertiblePreferredStockMember_1" xlink:title="label_SeriesBConvertiblePreferredStockMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesBConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesBConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_SeriesBConvertiblePreferredStockMember_2">Represents information pertaining to Series B preferred stock that may be exchanged into common shares or other types of securities at the owner's option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBConvertiblePreferredStockMember" xlink:to="label_SeriesBConvertiblePreferredStockMember_2" xlink:title="label_SeriesBConvertiblePreferredStockMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesBRedeemableConvertiblePreferredStockMember" xml:lang="en-US" id="label_SeriesBRedeemableConvertiblePreferredStockMember">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="label_SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="label_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesBRedeemableConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesBRedeemableConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_SeriesBRedeemableConvertiblePreferredStockMember_1">Series B Redeemable Convertible Preferred Stock Without Giving Effect To The Reverse Stock Split [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="label_SeriesBRedeemableConvertiblePreferredStockMember_1" xlink:title="label_SeriesBRedeemableConvertiblePreferredStockMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesBRedeemableConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesBRedeemableConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_SeriesBRedeemableConvertiblePreferredStockMember_2">Represents information pertaining to Series B redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="label_SeriesBRedeemableConvertiblePreferredStockMember_2" xlink:title="label_SeriesBRedeemableConvertiblePreferredStockMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeverancePayMember" xlink:label="SeverancePayMember" xlink:title="SeverancePayMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeverancePayMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeverancePayMember" xml:lang="en-US" id="label_SeverancePayMember">Severance Pay [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeverancePayMember" xlink:to="label_SeverancePayMember" xlink:title="label_SeverancePayMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeverancePayMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeverancePayMember_1" xml:lang="en-US" id="label_SeverancePayMember_1">Information pertaining to severance pay.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeverancePayMember" xlink:to="label_SeverancePayMember_1" xlink:title="label_SeverancePayMember_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice"/>
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice"/>
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice_1">adyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice_1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice_1"/>
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice_2" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice_2">The exercise price price at which grantees can acquire the shares reserved for issuance under the stock option plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice_2" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares">Share-based Compensation Arrangement by Share-based Payment Award, Options, Minimum Price as Percentage of Estimated Fair Value of Underlying Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares_1">adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares_1"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares_2">Represents the minimum price of options as a percentage of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the board of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder">Share-based Compensation Arrangement by Share-based Payment Award, Options, Minimum Price as Percentage of Estimated Fair Value of Underlying Shares, 10% Shareholder</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder_1">adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder_1"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder_2">Represents the minimum price, for ten percent shareholders, of options as a percentage of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the board of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" xlink:label="statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" xlink:title="statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" xml:lang="en-US" id="label_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details">Note 10 - Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" xlink:to="label_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" xlink:title="label_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:label="statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:title="statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xml:lang="en-US" id="label_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details">Note 10 - Income Taxes - Components of Deferred Tax Assets (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:to="label_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:title="label_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-10-income-taxes-tables" xlink:label="statement-statement-note-10-income-taxes-tables" xlink:title="statement-statement-note-10-income-taxes-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-10-income-taxes-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-10-income-taxes-tables" xml:lang="en-US" id="label_statement-statement-note-10-income-taxes-tables">Note 10 - Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-10-income-taxes-tables" xlink:to="label_statement-statement-note-10-income-taxes-tables" xlink:title="label_statement-statement-note-10-income-taxes-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details" xlink:label="statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details" xlink:title="statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details" xml:lang="en-US" id="label_statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details">Note 10 - Stock Options - Stock Options by Exercise Price Range (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details" xlink:to="label_statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details" xlink:title="label_statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-10-stock-options-summary-of-stock-option-activity-details" xlink:label="statement-statement-note-10-stock-options-summary-of-stock-option-activity-details" xlink:title="statement-statement-note-10-stock-options-summary-of-stock-option-activity-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-10-stock-options-summary-of-stock-option-activity-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-10-stock-options-summary-of-stock-option-activity-details" xml:lang="en-US" id="label_statement-statement-note-10-stock-options-summary-of-stock-option-activity-details">Note 10 - Stock Options - Summary of Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-10-stock-options-summary-of-stock-option-activity-details" xlink:to="label_statement-statement-note-10-stock-options-summary-of-stock-option-activity-details" xlink:title="label_statement-statement-note-10-stock-options-summary-of-stock-option-activity-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-10-stock-options-tables" xlink:label="statement-statement-note-10-stock-options-tables" xlink:title="statement-statement-note-10-stock-options-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-10-stock-options-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-10-stock-options-tables" xml:lang="en-US" id="label_statement-statement-note-10-stock-options-tables">Note 10 - Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-10-stock-options-tables" xlink:to="label_statement-statement-note-10-stock-options-tables" xlink:title="label_statement-statement-note-10-stock-options-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details" xlink:label="statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details" xlink:title="statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details" xml:lang="en-US" id="label_statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details">Note 2 - Summary of Significant Accounting Policies - Change in Fair Value of Preferred Stock Warrant Liability (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details" xlink:to="label_statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details" xlink:title="label_statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details" xlink:label="statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details" xlink:title="statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details" xml:lang="en-US" id="label_statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details">Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Recurring Basis (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details" xlink:to="label_statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details" xlink:title="label_statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:title="statement-statement-note-2-summary-of-significant-accounting-policies-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xml:lang="en-US" id="label_statement-statement-note-2-summary-of-significant-accounting-policies-tables">Note 2 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="label_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:title="label_statement-statement-note-2-summary-of-significant-accounting-policies-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-3-property-and-equipment-net-property-and-equipment-net-details" xlink:label="statement-statement-note-3-property-and-equipment-net-property-and-equipment-net-details" xlink:title="statement-statement-note-3-property-and-equipment-net-property-and-equipment-net-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-3-property-and-equipment-net-property-and-equipment-net-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-3-property-and-equipment-net-property-and-equipment-net-details" xml:lang="en-US" id="label_statement-statement-note-3-property-and-equipment-net-property-and-equipment-net-details">Note 3 - Property and Equipment, Net -Property and equipment, Net (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-3-property-and-equipment-net-property-and-equipment-net-details" xlink:to="label_statement-statement-note-3-property-and-equipment-net-property-and-equipment-net-details" xlink:title="label_statement-statement-note-3-property-and-equipment-net-property-and-equipment-net-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-3-property-and-equipment-net-tables" xlink:label="statement-statement-note-3-property-and-equipment-net-tables" xlink:title="statement-statement-note-3-property-and-equipment-net-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-3-property-and-equipment-net-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-3-property-and-equipment-net-tables" xml:lang="en-US" id="label_statement-statement-note-3-property-and-equipment-net-tables">Note 3 - Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-3-property-and-equipment-net-tables" xlink:to="label_statement-statement-note-3-property-and-equipment-net-tables" xlink:title="label_statement-statement-note-3-property-and-equipment-net-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" xlink:label="statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" xlink:title="statement-statement-note-4-accrued-liabilities-accrued-liabilities-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" xml:lang="en-US" id="label_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details">Note 4 - Accrued Liabilities - Accrued Liabilities (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" xlink:to="label_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" xlink:title="label_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-4-accrued-liabilities-tables" xlink:label="statement-statement-note-4-accrued-liabilities-tables" xlink:title="statement-statement-note-4-accrued-liabilities-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-4-accrued-liabilities-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-4-accrued-liabilities-tables" xml:lang="en-US" id="label_statement-statement-note-4-accrued-liabilities-tables">Note 4 - Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-4-accrued-liabilities-tables" xlink:to="label_statement-statement-note-4-accrued-liabilities-tables" xlink:title="label_statement-statement-note-4-accrued-liabilities-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details" xlink:label="statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details" xlink:title="statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details" xml:lang="en-US" id="label_statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details">Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details" xlink:to="label_statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details" xlink:title="label_statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-4-property-and-equipment-net-tables" xlink:label="statement-statement-note-4-property-and-equipment-net-tables" xlink:title="statement-statement-note-4-property-and-equipment-net-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-4-property-and-equipment-net-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-4-property-and-equipment-net-tables" xml:lang="en-US" id="label_statement-statement-note-4-property-and-equipment-net-tables">Note 4 - Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-4-property-and-equipment-net-tables" xlink:to="label_statement-statement-note-4-property-and-equipment-net-tables" xlink:title="label_statement-statement-note-4-property-and-equipment-net-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details" xlink:label="statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details" xlink:title="statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details" xml:lang="en-US" id="label_statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details">Note 5 - Other Balance Sheet Information - Accrued Liabilities (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details" xlink:to="label_statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details" xlink:title="label_statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details" xlink:label="statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details" xlink:title="statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details" xml:lang="en-US" id="label_statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details">Note 5 - Other Balance Sheet Information - Prepaid and Other Current Assets (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details" xlink:to="label_statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details" xlink:title="label_statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-5-other-balance-sheet-information-tables" xlink:label="statement-statement-note-5-other-balance-sheet-information-tables" xlink:title="statement-statement-note-5-other-balance-sheet-information-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-5-other-balance-sheet-information-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-5-other-balance-sheet-information-tables" xml:lang="en-US" id="label_statement-statement-note-5-other-balance-sheet-information-tables">Note 5 - Other Balance Sheet Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-5-other-balance-sheet-information-tables" xlink:to="label_statement-statement-note-5-other-balance-sheet-information-tables" xlink:title="label_statement-statement-note-5-other-balance-sheet-information-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:label="statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:title="statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xml:lang="en-US" id="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details">Note 5 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:to="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:title="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals" xlink:label="statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals" xlink:title="statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals" xml:lang="en-US" id="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals">Note 5 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details) (Parentheticals)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals" xlink:to="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals" xlink:title="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details" xlink:label="statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details" xlink:title="statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details" xml:lang="en-US" id="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details">Note 5 - Term Loans and Convertible Promissory Notes - Future Principal Payments of Term Loans (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details" xlink:to="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details" xlink:title="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-tables" xlink:label="statement-statement-note-5-term-loans-and-convertible-promissory-notes-tables" xlink:title="statement-statement-note-5-term-loans-and-convertible-promissory-notes-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-tables" xml:lang="en-US" id="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-tables">Note 5 - Term Loans and Convertible Promissory Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-5-term-loans-and-convertible-promissory-notes-tables" xlink:to="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-tables" xlink:title="label_statement-statement-note-5-term-loans-and-convertible-promissory-notes-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details" xlink:label="statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details" xlink:title="statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details" xml:lang="en-US" id="label_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details">Note 6 - Commitments and Contingencies - Future Lease Payments (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details" xlink:to="label_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details" xlink:title="label_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-6-commitments-and-contingencies-tables" xlink:label="statement-statement-note-6-commitments-and-contingencies-tables" xlink:title="statement-statement-note-6-commitments-and-contingencies-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-6-commitments-and-contingencies-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-6-commitments-and-contingencies-tables" xml:lang="en-US" id="label_statement-statement-note-6-commitments-and-contingencies-tables">Note 6 - Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-6-commitments-and-contingencies-tables" xlink:to="label_statement-statement-note-6-commitments-and-contingencies-tables" xlink:title="label_statement-statement-note-6-commitments-and-contingencies-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:label="statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:title="statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xml:lang="en-US" id="label_statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details">Note 6 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:to="label_statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:title="label_statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables" xlink:label="statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables" xlink:title="statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables" xml:lang="en-US" id="label_statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables">Note 6 - Term Loans and Convertible Promissory Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables" xlink:to="label_statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables" xlink:title="label_statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-7-leases-future-minimum-lease-payments-details" xlink:label="statement-statement-note-7-leases-future-minimum-lease-payments-details" xlink:title="statement-statement-note-7-leases-future-minimum-lease-payments-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-7-leases-future-minimum-lease-payments-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-7-leases-future-minimum-lease-payments-details" xml:lang="en-US" id="label_statement-statement-note-7-leases-future-minimum-lease-payments-details">Note 7 - Leases - Future Minimum Lease Payments (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-7-leases-future-minimum-lease-payments-details" xlink:to="label_statement-statement-note-7-leases-future-minimum-lease-payments-details" xlink:title="label_statement-statement-note-7-leases-future-minimum-lease-payments-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-7-leases-tables" xlink:label="statement-statement-note-7-leases-tables" xlink:title="statement-statement-note-7-leases-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-7-leases-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-7-leases-tables" xml:lang="en-US" id="label_statement-statement-note-7-leases-tables">Note 7 - Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-7-leases-tables" xlink:to="label_statement-statement-note-7-leases-tables" xlink:title="label_statement-statement-note-7-leases-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details" xlink:label="statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details" xlink:title="statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details" xml:lang="en-US" id="label_statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details">Note 7 - Stockholders' Deficit - Shares Reserved for Future Issuance (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details" xlink:to="label_statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details" xlink:title="label_statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-7-stockholders-deficit-tables" xlink:label="statement-statement-note-7-stockholders-deficit-tables" xlink:title="statement-statement-note-7-stockholders-deficit-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-7-stockholders-deficit-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-7-stockholders-deficit-tables" xml:lang="en-US" id="label_statement-statement-note-7-stockholders-deficit-tables">Note 7 - Stockholders' Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-7-stockholders-deficit-tables" xlink:to="label_statement-statement-note-7-stockholders-deficit-tables" xlink:title="label_statement-statement-note-7-stockholders-deficit-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-8-warrants-details-of-warrants-details" xlink:label="statement-statement-note-8-warrants-details-of-warrants-details" xlink:title="statement-statement-note-8-warrants-details-of-warrants-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-8-warrants-details-of-warrants-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-8-warrants-details-of-warrants-details" xml:lang="en-US" id="label_statement-statement-note-8-warrants-details-of-warrants-details">Note 8 - Warrants - Details of Warrants (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-8-warrants-details-of-warrants-details" xlink:to="label_statement-statement-note-8-warrants-details-of-warrants-details" xlink:title="label_statement-statement-note-8-warrants-details-of-warrants-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-8-warrants-tables" xlink:label="statement-statement-note-8-warrants-tables" xlink:title="statement-statement-note-8-warrants-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-8-warrants-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-8-warrants-tables" xml:lang="en-US" id="label_statement-statement-note-8-warrants-tables">Note 8 - Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-8-warrants-tables" xlink:to="label_statement-statement-note-8-warrants-tables" xlink:title="label_statement-statement-note-8-warrants-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-8-warrants-warrants-assumptions-details" xlink:label="statement-statement-note-8-warrants-warrants-assumptions-details" xlink:title="statement-statement-note-8-warrants-warrants-assumptions-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-8-warrants-warrants-assumptions-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-8-warrants-warrants-assumptions-details" xml:lang="en-US" id="label_statement-statement-note-8-warrants-warrants-assumptions-details">Note 8 - Warrants - Warrants Assumptions (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-8-warrants-warrants-assumptions-details" xlink:to="label_statement-statement-note-8-warrants-warrants-assumptions-details" xlink:title="label_statement-statement-note-8-warrants-warrants-assumptions-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:label="statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:title="statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xml:lang="en-US" id="label_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details">Note 9 - Stock Option Plans - Summary of Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="label_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:title="label_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-9-stock-option-plans-tables" xlink:label="statement-statement-note-9-stock-option-plans-tables" xlink:title="statement-statement-note-9-stock-option-plans-tables"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-note-9-stock-option-plans-tables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-note-9-stock-option-plans-tables" xml:lang="en-US" id="label_statement-statement-note-9-stock-option-plans-tables">Note 9 - Stock Option Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-note-9-stock-option-plans-tables" xlink:to="label_statement-statement-note-9-stock-option-plans-tables" xlink:title="label_statement-statement-note-9-stock-option-plans-tables"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-significant-accounting-policies-policies" xlink:label="statement-statement-significant-accounting-policies-policies" xlink:title="statement-statement-significant-accounting-policies-policies"/>
    <link:label xlink:type="resource" xlink:label="label_statement-statement-significant-accounting-policies-policies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_statement-statement-significant-accounting-policies-policies" xml:lang="en-US" id="label_statement-statement-significant-accounting-policies-policies">Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="statement-statement-significant-accounting-policies-policies" xlink:to="label_statement-statement-significant-accounting-policies-policies" xlink:title="label_statement-statement-significant-accounting-policies-policies"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock">Conversion of of convertible preferred stock into common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:to="label_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_1">The number of common stock shares issued during the period as a result of the conversion of convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:to="label_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_1" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_StockIssuedDuringPeriodSharesWarrantExercised" xlink:label="StockIssuedDuringPeriodSharesWarrantExercised" xlink:title="StockIssuedDuringPeriodSharesWarrantExercised"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesWarrantExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesWarrantExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesWarrantExercised">Exercise of warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantExercised" xlink:to="label_StockIssuedDuringPeriodSharesWarrantExercised" xlink:title="label_StockIssuedDuringPeriodSharesWarrantExercised"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesWarrantExercised_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesWarrantExercised_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesWarrantExercised_1">Number of shares issued during the period for exercise warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantExercised" xlink:to="label_StockIssuedDuringPeriodSharesWarrantExercised_1" xlink:title="label_StockIssuedDuringPeriodSharesWarrantExercised_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock">Conversion of of convertible preferred stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:to="label_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:title="label_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock_1">The value of common stock issued during the period upon the conversion of convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:to="label_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock_1" xlink:title="label_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_StockIssuedDuringPeriodValueWarrantExercised" xlink:label="StockIssuedDuringPeriodValueWarrantExercised" xlink:title="StockIssuedDuringPeriodValueWarrantExercised"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueWarrantExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueWarrantExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueWarrantExercised">Exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantExercised" xlink:to="label_StockIssuedDuringPeriodValueWarrantExercised" xlink:title="label_StockIssuedDuringPeriodValueWarrantExercised"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueWarrantExercised_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueWarrantExercised_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueWarrantExercised_1">Value of shares of stock issued during the period as warrant exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantExercised" xlink:to="label_StockIssuedDuringPeriodValueWarrantExercised_1" xlink:title="label_StockIssuedDuringPeriodValueWarrantExercised_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" xlink:label="TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" xlink:title="TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" xml:lang="en-US" id="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector">Temporary Equity, Remaining Shares Outstanding Requirements To Elect One Director</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" xlink:to="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" xlink:title="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector_1" xml:lang="en-US" id="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector_1">adyx_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" xlink:to="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector_1" xlink:title="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector_1"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector_2" xml:lang="en-US" id="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector_2">The number of securities classified as temporary equity remaining outstanding that are requirements to elect one director.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" xlink:to="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector_2" xlink:title="label_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanAMember" xlink:label="TermLoanAMember" xlink:title="TermLoanAMember"/>
    <link:label xlink:type="resource" xlink:label="label_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TermLoanAMember" xml:lang="en-US" id="label_TermLoanAMember">Term Loan A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanAMember" xlink:to="label_TermLoanAMember" xlink:title="label_TermLoanAMember"/>
    <link:label xlink:type="resource" xlink:label="label_TermLoanAMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TermLoanAMember_1" xml:lang="en-US" id="label_TermLoanAMember_1">Term Loan A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanAMember" xlink:to="label_TermLoanAMember_1" xlink:title="label_TermLoanAMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_TermLoanAMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TermLoanAMember_2" xml:lang="en-US" id="label_TermLoanAMember_2">Information pertaining to Term Loan A.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanAMember" xlink:to="label_TermLoanAMember_2" xlink:title="label_TermLoanAMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanBMember" xlink:label="TermLoanBMember" xlink:title="TermLoanBMember"/>
    <link:label xlink:type="resource" xlink:label="label_TermLoanBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TermLoanBMember" xml:lang="en-US" id="label_TermLoanBMember">Term Loan B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanBMember" xlink:to="label_TermLoanBMember" xlink:title="label_TermLoanBMember"/>
    <link:label xlink:type="resource" xlink:label="label_TermLoanBMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TermLoanBMember_1" xml:lang="en-US" id="label_TermLoanBMember_1">Term Loan B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanBMember" xlink:to="label_TermLoanBMember_1" xlink:title="label_TermLoanBMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_TermLoanBMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TermLoanBMember_2" xml:lang="en-US" id="label_TermLoanBMember_2">Information pertaining to Term Loan B.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanBMember" xlink:to="label_TermLoanBMember_2" xlink:title="label_TermLoanBMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanCMember" xlink:label="TermLoanCMember" xlink:title="TermLoanCMember"/>
    <link:label xlink:type="resource" xlink:label="label_TermLoanCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TermLoanCMember" xml:lang="en-US" id="label_TermLoanCMember">Term Loan C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanCMember" xlink:to="label_TermLoanCMember" xlink:title="label_TermLoanCMember"/>
    <link:label xlink:type="resource" xlink:label="label_TermLoanCMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TermLoanCMember_1" xml:lang="en-US" id="label_TermLoanCMember_1">Term Loan C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanCMember" xlink:to="label_TermLoanCMember_1" xlink:title="label_TermLoanCMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_TermLoanCMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TermLoanCMember_2" xml:lang="en-US" id="label_TermLoanCMember_2">Information pertaining to Term Loan C.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanCMember" xlink:to="label_TermLoanCMember_2" xlink:title="label_TermLoanCMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember"/>
    <link:label xlink:type="resource" xlink:label="label_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TermLoansMember" xml:lang="en-US" id="label_TermLoansMember">Term Loans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoansMember" xlink:to="label_TermLoansMember" xlink:title="label_TermLoansMember"/>
    <link:label xlink:type="resource" xlink:label="label_TermLoansMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TermLoansMember_1" xml:lang="en-US" id="label_TermLoansMember_1">Term Loans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoansMember" xlink:to="label_TermLoansMember_1" xlink:title="label_TermLoansMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_TermLoansMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TermLoansMember_2" xml:lang="en-US" id="label_TermLoansMember_2">Term loans A, B, and C, collectively referred to as "Term Loans."</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoansMember" xlink:to="label_TermLoansMember_2" xlink:title="label_TermLoansMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ThePlanMember" xlink:label="ThePlanMember" xlink:title="ThePlanMember"/>
    <link:label xlink:type="resource" xlink:label="label_ThePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ThePlanMember" xml:lang="en-US" id="label_ThePlanMember">The Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThePlanMember" xlink:to="label_ThePlanMember" xlink:title="label_ThePlanMember"/>
    <link:label xlink:type="resource" xlink:label="label_ThePlanMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ThePlanMember_1" xml:lang="en-US" id="label_ThePlanMember_1">The Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThePlanMember" xlink:to="label_ThePlanMember_1" xlink:title="label_ThePlanMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_ThePlanMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ThePlanMember_2" xml:lang="en-US" id="label_ThePlanMember_2">Represents information pertaining to the 2010 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThePlanMember" xlink:to="label_ThePlanMember_2" xlink:title="label_ThePlanMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:label="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:title="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember"/>
    <link:label xlink:type="resource" xlink:label="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xml:lang="en-US" id="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember">Two of the Three Vendors Supporting Clinical Study Activities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:to="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:title="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember"/>
    <link:label xlink:type="resource" xlink:label="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember_1" xml:lang="en-US" id="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember_1">Two of the Three Vendors Supporting Clinical Study Activities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:to="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember_1" xlink:title="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember_2" xml:lang="en-US" id="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember_2">Represents two of the three major vendors, both of which support the clinical studies activities portion of accounts payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:to="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember_2" xlink:title="label_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor1Member" xlink:label="Vendor1Member" xlink:title="Vendor1Member"/>
    <link:label xlink:type="resource" xlink:label="label_Vendor1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Vendor1Member" xml:lang="en-US" id="label_Vendor1Member">Vendor 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Vendor1Member" xlink:to="label_Vendor1Member" xlink:title="label_Vendor1Member"/>
    <link:label xlink:type="resource" xlink:label="label_Vendor1Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_Vendor1Member_1" xml:lang="en-US" id="label_Vendor1Member_1">Vendor 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Vendor1Member" xlink:to="label_Vendor1Member_1" xlink:title="label_Vendor1Member_1"/>
    <link:label xlink:type="resource" xlink:label="label_Vendor1Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_Vendor1Member_2" xml:lang="en-US" id="label_Vendor1Member_2">Represents vendor 1.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Vendor1Member" xlink:to="label_Vendor1Member_2" xlink:title="label_Vendor1Member_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor2Member" xlink:label="Vendor2Member" xlink:title="Vendor2Member"/>
    <link:label xlink:type="resource" xlink:label="label_Vendor2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Vendor2Member" xml:lang="en-US" id="label_Vendor2Member">Vendor 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Vendor2Member" xlink:to="label_Vendor2Member" xlink:title="label_Vendor2Member"/>
    <link:label xlink:type="resource" xlink:label="label_Vendor2Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_Vendor2Member_1" xml:lang="en-US" id="label_Vendor2Member_1">Vendor 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Vendor2Member" xlink:to="label_Vendor2Member_1" xlink:title="label_Vendor2Member_1"/>
    <link:label xlink:type="resource" xlink:label="label_Vendor2Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_Vendor2Member_2" xml:lang="en-US" id="label_Vendor2Member_2">Represents vendor 2.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Vendor2Member" xlink:to="label_Vendor2Member_2" xlink:title="label_Vendor2Member_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor3Member" xlink:label="Vendor3Member" xlink:title="Vendor3Member"/>
    <link:label xlink:type="resource" xlink:label="label_Vendor3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Vendor3Member" xml:lang="en-US" id="label_Vendor3Member">Vendor 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Vendor3Member" xlink:to="label_Vendor3Member" xlink:title="label_Vendor3Member"/>
    <link:label xlink:type="resource" xlink:label="label_Vendor3Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_Vendor3Member_1" xml:lang="en-US" id="label_Vendor3Member_1">Vendor 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Vendor3Member" xlink:to="label_Vendor3Member_1" xlink:title="label_Vendor3Member_1"/>
    <link:label xlink:type="resource" xlink:label="label_Vendor3Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_Vendor3Member_2" xml:lang="en-US" id="label_Vendor3Member_2">Represents vendor 3.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Vendor3Member" xlink:to="label_Vendor3Member_2" xlink:title="label_Vendor3Member_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_VotingRightsTransferredToBeConsideredAChangeInControl" xlink:label="VotingRightsTransferredToBeConsideredAChangeInControl" xlink:title="VotingRightsTransferredToBeConsideredAChangeInControl"/>
    <link:label xlink:type="resource" xlink:label="label_VotingRightsTransferredToBeConsideredAChangeInControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_VotingRightsTransferredToBeConsideredAChangeInControl" xml:lang="en-US" id="label_VotingRightsTransferredToBeConsideredAChangeInControl">Voting Rights Transferred to be Considered a Change in Control</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VotingRightsTransferredToBeConsideredAChangeInControl" xlink:to="label_VotingRightsTransferredToBeConsideredAChangeInControl" xlink:title="label_VotingRightsTransferredToBeConsideredAChangeInControl"/>
    <link:label xlink:type="resource" xlink:label="label_VotingRightsTransferredToBeConsideredAChangeInControl_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VotingRightsTransferredToBeConsideredAChangeInControl_1" xml:lang="en-US" id="label_VotingRightsTransferredToBeConsideredAChangeInControl_1">adyx_VotingRightsTransferredToBeConsideredAChangeInControl</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VotingRightsTransferredToBeConsideredAChangeInControl" xlink:to="label_VotingRightsTransferredToBeConsideredAChangeInControl_1" xlink:title="label_VotingRightsTransferredToBeConsideredAChangeInControl_1"/>
    <link:label xlink:type="resource" xlink:label="label_VotingRightsTransferredToBeConsideredAChangeInControl_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_VotingRightsTransferredToBeConsideredAChangeInControl_2" xml:lang="en-US" id="label_VotingRightsTransferredToBeConsideredAChangeInControl_2">The percent of voting rights which must be transferred in order to be considered a change in control.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VotingRightsTransferredToBeConsideredAChangeInControl" xlink:to="label_VotingRightsTransferredToBeConsideredAChangeInControl_2" xlink:title="label_VotingRightsTransferredToBeConsideredAChangeInControl_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:label="WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:title="WarrantIssuedInConnectionWithTermLoanAAndBMember"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantIssuedInConnectionWithTermLoanAAndBMember" xml:lang="en-US" id="label_WarrantIssuedInConnectionWithTermLoanAAndBMember">Warrant Issued In Connection With Term Loan A and B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:to="label_WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:title="label_WarrantIssuedInConnectionWithTermLoanAAndBMember"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantIssuedInConnectionWithTermLoanAAndBMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantIssuedInConnectionWithTermLoanAAndBMember_1" xml:lang="en-US" id="label_WarrantIssuedInConnectionWithTermLoanAAndBMember_1">Warrant Issued In Connection With Term Loan A And B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:to="label_WarrantIssuedInConnectionWithTermLoanAAndBMember_1" xlink:title="label_WarrantIssuedInConnectionWithTermLoanAAndBMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantIssuedInConnectionWithTermLoanAAndBMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WarrantIssuedInConnectionWithTermLoanAAndBMember_2" xml:lang="en-US" id="label_WarrantIssuedInConnectionWithTermLoanAAndBMember_2">Represents warrant issued in connection with term loan A and B.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:to="label_WarrantIssuedInConnectionWithTermLoanAAndBMember_2" xlink:title="label_WarrantIssuedInConnectionWithTermLoanAAndBMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsDisclosureTextBlock" xlink:label="WarrantsDisclosureTextBlock" xlink:title="WarrantsDisclosureTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsDisclosureTextBlock" xml:lang="en-US" id="label_WarrantsDisclosureTextBlock">Warrants Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsDisclosureTextBlock" xlink:to="label_WarrantsDisclosureTextBlock" xlink:title="label_WarrantsDisclosureTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WarrantsDisclosureTextBlock_1" xml:lang="en-US" id="label_WarrantsDisclosureTextBlock_1">The entire disclosure for warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsDisclosureTextBlock" xlink:to="label_WarrantsDisclosureTextBlock_1" xlink:title="label_WarrantsDisclosureTextBlock_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInJanuary2016Member" xlink:label="WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member" xlink:title="WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member" xml:lang="en-US" id="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member">Warrants for Series A Convertible Preferred Stock Issued in January, 2016 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member" xlink:to="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member_1" xml:lang="en-US" id="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member_1">Warrants For Series A Convertible Preferred Stock Issued In January 2016 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member" xlink:to="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member_1" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member_1"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member_2" xml:lang="en-US" id="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member_2">Represents warrants issued for series A convertible preferred stock issued in January, 2016.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member" xlink:to="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member_2" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" xlink:label="WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" xlink:title="WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" xml:lang="en-US" id="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member">Warrants for Series A Convertible Preferred Stock Issued in November, 2015 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" xlink:to="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member_1" xml:lang="en-US" id="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member_1">Warrants For Series A Convertible Preferred Stock Issued In November2015 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" xlink:to="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member_1" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member_1"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member_2" xml:lang="en-US" id="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member_2">Represents warrants issued for series A convertible preferred stock issued in November 2015.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" xlink:to="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member_2" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockMember" xlink:label="WarrantsForSeriesAConvertiblePreferredStockMember" xlink:title="WarrantsForSeriesAConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsForSeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockMember" xml:lang="en-US" id="label_WarrantsForSeriesAConvertiblePreferredStockMember">Warrants for Series A Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsForSeriesAConvertiblePreferredStockMember" xlink:to="label_WarrantsForSeriesAConvertiblePreferredStockMember" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsForSeriesAConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_WarrantsForSeriesAConvertiblePreferredStockMember_1">Warrants For Series A Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsForSeriesAConvertiblePreferredStockMember" xlink:to="label_WarrantsForSeriesAConvertiblePreferredStockMember_1" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsForSeriesAConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_WarrantsForSeriesAConvertiblePreferredStockMember_2">Represents warrants issued for series A convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsForSeriesAConvertiblePreferredStockMember" xlink:to="label_WarrantsForSeriesAConvertiblePreferredStockMember_2" xlink:title="label_WarrantsForSeriesAConvertiblePreferredStockMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsReserveForSeriesAConvertiblePreferredStockMember" xlink:label="WarrantsReserveForSeriesAConvertiblePreferredStockMember" xlink:title="WarrantsReserveForSeriesAConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember" xml:lang="en-US" id="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember">Warrants Reserve for Series A Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsReserveForSeriesAConvertiblePreferredStockMember" xlink:to="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember" xlink:title="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember_1">Warrants Reserve For Series A Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsReserveForSeriesAConvertiblePreferredStockMember" xlink:to="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember_1" xlink:title="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember_2">Represents warrants reserve for series A convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsReserveForSeriesAConvertiblePreferredStockMember" xlink:to="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember_2" xlink:title="label_WarrantsReserveForSeriesAConvertiblePreferredStockMember_2"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:label="WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:title="WarrantToPurchaseCommonStockConvertedInMergerMember"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantToPurchaseCommonStockConvertedInMergerMember" xml:lang="en-US" id="label_WarrantToPurchaseCommonStockConvertedInMergerMember">Warrant to Purchase Common Stock Converted in Merger [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:to="label_WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:title="label_WarrantToPurchaseCommonStockConvertedInMergerMember"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantToPurchaseCommonStockConvertedInMergerMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WarrantToPurchaseCommonStockConvertedInMergerMember_1" xml:lang="en-US" id="label_WarrantToPurchaseCommonStockConvertedInMergerMember_1">Represents warrants that had not previously been exercised which were converted in a merger to warrants to purchase shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:to="label_WarrantToPurchaseCommonStockConvertedInMergerMember_1" xlink:title="label_WarrantToPurchaseCommonStockConvertedInMergerMember_1"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:label="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xml:lang="en-US" id="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:to="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_1" xml:lang="en-US" id="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_1">Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:to="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_1" xlink:title="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_1"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_2" xml:lang="en-US" id="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_2">Represents warrants to purchase preferred stock under oxford loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:to="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_2" xlink:title="label_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember_2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember"/>
    <link:label xlink:type="resource" xlink:label="label_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ChiefExecutiveOfficerMember" xml:lang="en-US" id="label_ChiefExecutiveOfficerMember">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefExecutiveOfficerMember" xlink:to="label_ChiefExecutiveOfficerMember" xlink:title="label_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis"/>
    <link:label xlink:type="resource" xlink:label="label_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CounterpartyNameAxis" xml:lang="en-US" id="label_CounterpartyNameAxis">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CounterpartyNameAxis" xlink:to="label_CounterpartyNameAxis" xlink:title="label_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:label xlink:type="resource" xlink:label="label_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MaximumMember" xml:lang="en-US" id="label_MaximumMember">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="label_MaximumMember" xlink:title="label_MaximumMember"/>
    <link:label xlink:type="resource" xlink:label="label_MaximumMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MaximumMember_1" xml:lang="en-US" id="label_MaximumMember_1">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="label_MaximumMember_1" xlink:title="label_MaximumMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:label xlink:type="resource" xlink:label="label_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MinimumMember" xml:lang="en-US" id="label_MinimumMember">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="label_MinimumMember" xlink:title="label_MinimumMember"/>
    <link:label xlink:type="resource" xlink:label="label_MinimumMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MinimumMember_1" xml:lang="en-US" id="label_MinimumMember_1">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="label_MinimumMember_1" xlink:title="label_MinimumMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:label xlink:type="resource" xlink:label="label_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RangeAxis" xml:lang="en-US" id="label_RangeAxis">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="label_RangeAxis" xlink:title="label_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:label xlink:type="resource" xlink:label="label_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RangeMember" xml:lang="en-US" id="label_RangeMember">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="label_RangeMember" xlink:title="label_RangeMember"/>
    <link:label xlink:type="resource" xlink:label="label_RangeMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RangeMember_1" xml:lang="en-US" id="label_RangeMember_1">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="label_RangeMember_1" xlink:title="label_RangeMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US" id="label_RepurchaseAgreementCounterpartyNameDomain">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="label_RepurchaseAgreementCounterpartyNameDomain" xlink:title="label_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_RepurchaseAgreementCounterpartyNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RepurchaseAgreementCounterpartyNameDomain_1" xml:lang="en-US" id="label_RepurchaseAgreementCounterpartyNameDomain_1">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="label_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="label_RepurchaseAgreementCounterpartyNameDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountingPoliciesAbstract" xml:lang="en-US" id="label_AccountingPoliciesAbstract">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="label_AccountingPoliciesAbstract" xlink:title="label_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="AccountingStandardsUpdate201602Member" xlink:title="AccountingStandardsUpdate201602Member"/>
    <link:label xlink:type="resource" xlink:label="label_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountingStandardsUpdate201602Member" xml:lang="en-US" id="label_AccountingStandardsUpdate201602Member">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingStandardsUpdate201602Member" xlink:to="label_AccountingStandardsUpdate201602Member" xlink:title="label_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableCurrent" xml:lang="en-US" id="label_AccountsPayableCurrent">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="label_AccountsPayableCurrent" xlink:title="label_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedLiabilitiesCurrent" xml:lang="en-US" id="label_AccruedLiabilitiesCurrent">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="label_AccruedLiabilitiesCurrent" xlink:title="label_AccruedLiabilitiesCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_AccruedLiabilitiesCurrent_1" xml:lang="en-US" id="label_AccruedLiabilitiesCurrent_1">Total accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="label_AccruedLiabilitiesCurrent_1" xlink:title="label_AccruedLiabilitiesCurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedProfessionalFeesCurrent" xml:lang="en-US" id="label_AccruedProfessionalFeesCurrent">Professional fees and other costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="label_AccruedProfessionalFeesCurrent" xlink:title="label_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:label xlink:type="resource" xlink:label="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US" id="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:label xlink:type="resource" xlink:label="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1">Less accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital"/>
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdditionalPaidInCapital" xml:lang="en-US" id="label_AdditionalPaidInCapital">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="label_AdditionalPaidInCapital" xlink:title="label_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember"/>
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdditionalPaidInCapitalMember" xml:lang="en-US" id="label_AdditionalPaidInCapitalMember">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="label_AdditionalPaidInCapitalMember" xlink:title="label_AdditionalPaidInCapitalMember"/>
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapitalMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdditionalPaidInCapitalMember_1" xml:lang="en-US" id="label_AdditionalPaidInCapitalMember_1">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="label_AdditionalPaidInCapitalMember_1" xlink:title="label_AdditionalPaidInCapitalMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US" id="label_AdjustmentsForNewAccountingPronouncementsAxis">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="label_AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="label_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense"/>
    <link:label xlink:type="resource" xlink:label="label_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="label_AllocatedShareBasedCompensationExpense">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="label_AllocatedShareBasedCompensationExpense" xlink:title="label_AllocatedShareBasedCompensationExpense"/>
    <link:label xlink:type="resource" xlink:label="label_AllocatedShareBasedCompensationExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US" id="label_AllocatedShareBasedCompensationExpense_1">Share-based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="label_AllocatedShareBasedCompensationExpense_1" xlink:title="label_AllocatedShareBasedCompensationExpense_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium"/>
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfDebtDiscountPremium" xml:lang="en-US" id="label_AmortizationOfDebtDiscountPremium">us-gaap_AmortizationOfDebtDiscountPremium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="label_AmortizationOfDebtDiscountPremium" xlink:title="label_AmortizationOfDebtDiscountPremium"/>
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfDebtDiscountPremium_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AmortizationOfDebtDiscountPremium_1" xml:lang="en-US" id="label_AmortizationOfDebtDiscountPremium_1">Amortization of Debt Discount (Premium)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="label_AmortizationOfDebtDiscountPremium_1" xlink:title="label_AmortizationOfDebtDiscountPremium_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts"/>
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US" id="label_AmortizationOfFinancingCostsAndDiscounts">Amortization of issuance cost and discounts for term loans and convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="label_AmortizationOfFinancingCostsAndDiscounts" xlink:title="label_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets"/>
    <link:label xlink:type="resource" xlink:label="label_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Assets" xml:lang="en-US" id="label_Assets">us-gaap_Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets" xlink:title="label_Assets"/>
    <link:label xlink:type="resource" xlink:label="label_Assets_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Assets_1" xml:lang="en-US" id="label_Assets_1">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets_1" xlink:title="label_Assets_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrent" xml:lang="en-US" id="label_AssetsCurrent">us-gaap_AssetsCurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent" xlink:title="label_AssetsCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_AssetsCurrent_1" xml:lang="en-US" id="label_AssetsCurrent_1">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent_1" xlink:title="label_AssetsCurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrentAbstract" xml:lang="en-US" id="label_AssetsCurrentAbstract">Current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract" xlink:title="label_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis"/>
    <link:label xlink:type="resource" xlink:label="label_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AwardTypeAxis" xml:lang="en-US" id="label_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="label_AwardTypeAxis" xlink:title="label_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionAcquireeDomain" xml:lang="en-US" id="label_BusinessAcquisitionAcquireeDomain">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="label_BusinessAcquisitionAcquireeDomain" xlink:title="label_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionAxis" xml:lang="en-US" id="label_BusinessAcquisitionAxis">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAxis" xlink:to="label_BusinessAcquisitionAxis" xlink:title="label_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue"/>
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue" xlink:title="label_CashAndCashEquivalentsAtCarryingValue"/>
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_1">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US" id="label_CashAndCashEquivalentsPolicyTextBlock">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="label_CashAndCashEquivalentsPolicyTextBlock" xlink:title="label_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:title="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US" id="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:title="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:label xlink:type="resource" xlink:label="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US" id="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:label xlink:type="resource" xlink:label="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US" id="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <link:label xlink:type="resource" xlink:label="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US" id="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:label xlink:type="resource" xlink:label="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US" id="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:label xlink:type="resource" xlink:label="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1" xml:lang="en-US" id="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfStockDomain" xml:lang="en-US" id="label_ClassOfStockDomain">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="label_ClassOfStockDomain" xlink:title="label_ClassOfStockDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfStockDomain_1" xml:lang="en-US" id="label_ClassOfStockDomain_1">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="label_ClassOfStockDomain_1" xlink:title="label_ClassOfStockDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightAxis" xml:lang="en-US" id="label_ClassOfWarrantOrRightAxis">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="label_ClassOfWarrantOrRightAxis" xlink:title="label_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightDomain" xml:lang="en-US" id="label_ClassOfWarrantOrRightDomain">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="label_ClassOfWarrantOrRightDomain" xlink:title="label_ClassOfWarrantOrRightDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightDomain_1" xml:lang="en-US" id="label_ClassOfWarrantOrRightDomain_1">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="label_ClassOfWarrantOrRightDomain_1" xlink:title="label_ClassOfWarrantOrRightDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US" id="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US" id="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xml:lang="en-US" id="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightOutstanding" xml:lang="en-US" id="label_ClassOfWarrantOrRightOutstanding">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="label_ClassOfWarrantOrRightOutstanding" xlink:title="label_ClassOfWarrantOrRightOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightOutstanding_1" xml:lang="en-US" id="label_ClassOfWarrantOrRightOutstanding_1">Class of Warrant or Right, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="label_ClassOfWarrantOrRightOutstanding_1" xlink:title="label_ClassOfWarrantOrRightOutstanding_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="CollaborativeArrangementAccountingPolicy" xlink:title="CollaborativeArrangementAccountingPolicy"/>
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CollaborativeArrangementAccountingPolicy" xml:lang="en-US" id="label_CollaborativeArrangementAccountingPolicy">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAccountingPolicy" xlink:to="label_CollaborativeArrangementAccountingPolicy" xlink:title="label_CollaborativeArrangementAccountingPolicy"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies"/>
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingencies" xml:lang="en-US" id="label_CommitmentsAndContingencies">Commitments and contingencies (Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies" xlink:title="label_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureTextBlock">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="label_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="label_CommonStockCapitalSharesReservedForFutureIssuance">Common stock options issued and outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="label_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockCapitalSharesReservedForFutureIssuance_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuance_1" xml:lang="en-US" id="label_CommonStockCapitalSharesReservedForFutureIssuance_1">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="label_CommonStockCapitalSharesReservedForFutureIssuance_1" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuance_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="CommonStockDividendsPerShareCashPaid" xlink:title="CommonStockDividendsPerShareCashPaid"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockDividendsPerShareCashPaid" xml:lang="en-US" id="label_CommonStockDividendsPerShareCashPaid">us-gaap_CommonStockDividendsPerShareCashPaid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockDividendsPerShareCashPaid" xlink:to="label_CommonStockDividendsPerShareCashPaid" xlink:title="label_CommonStockDividendsPerShareCashPaid"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockDividendsPerShareCashPaid_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockDividendsPerShareCashPaid_1" xml:lang="en-US" id="label_CommonStockDividendsPerShareCashPaid_1">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockDividendsPerShareCashPaid" xlink:to="label_CommonStockDividendsPerShareCashPaid_1" xlink:title="label_CommonStockDividendsPerShareCashPaid_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="CommonStockDividendsPerShareDeclared" xlink:title="CommonStockDividendsPerShareDeclared"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockDividendsPerShareDeclared" xml:lang="en-US" id="label_CommonStockDividendsPerShareDeclared">us-gaap_CommonStockDividendsPerShareDeclared</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockDividendsPerShareDeclared" xlink:to="label_CommonStockDividendsPerShareDeclared" xlink:title="label_CommonStockDividendsPerShareDeclared"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockDividendsPerShareDeclared_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockDividendsPerShareDeclared_1" xml:lang="en-US" id="label_CommonStockDividendsPerShareDeclared_1">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockDividendsPerShareDeclared" xlink:to="label_CommonStockDividendsPerShareDeclared_1" xlink:title="label_CommonStockDividendsPerShareDeclared_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockMember" xml:lang="en-US" id="label_CommonStockMember">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember" xlink:title="label_CommonStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockMember_1" xml:lang="en-US" id="label_CommonStockMember_1">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember_1" xlink:title="label_CommonStockMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare" xlink:title="label_CommonStockParOrStatedValuePerShare"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare_1">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare_1" xlink:title="label_CommonStockParOrStatedValuePerShare_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesAuthorized" xml:lang="en-US" id="label_CommonStockSharesAuthorized">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized" xlink:title="label_CommonStockSharesAuthorized"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesAuthorized_1" xml:lang="en-US" id="label_CommonStockSharesAuthorized_1">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized_1" xlink:title="label_CommonStockSharesAuthorized_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued" xlink:title="label_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesOutstanding" xml:lang="en-US" id="label_CommonStockSharesOutstanding">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding" xlink:title="label_CommonStockSharesOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesOutstanding_1" xml:lang="en-US" id="label_CommonStockSharesOutstanding_1">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding_1" xlink:title="label_CommonStockSharesOutstanding_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockValue" xml:lang="en-US" id="label_CommonStockValue">Common stock, $0.001 par value; 95,000,000 shares authorized, 5,807,877 shares issued and outstanding at June 30, 2019 (unaudited) 148,000,000 shares authorized, 701,808 shares issued and outstanding at December 31, 2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue" xlink:title="label_CommonStockValue"/>
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockValue_1" xml:lang="en-US" id="label_CommonStockValue_1">Common stock, $0.001 par value; 148,000,000 shares authorized; 19,548,969 shares issued and outstanding as of December 31, 2017 and 2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue_1" xlink:title="label_CommonStockValue_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember"/>
    <link:label xlink:type="resource" xlink:label="label_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComputerEquipmentMember" xml:lang="en-US" id="label_ComputerEquipmentMember">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentMember" xlink:to="label_ComputerEquipmentMember" xlink:title="label_ComputerEquipmentMember"/>
    <link:label xlink:type="resource" xlink:label="label_ComputerEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ComputerEquipmentMember_1" xml:lang="en-US" id="label_ComputerEquipmentMember_1">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentMember" xlink:to="label_ComputerEquipmentMember_1" xlink:title="label_ComputerEquipmentMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskBenchmarkDomain" xml:lang="en-US" id="label_ConcentrationRiskBenchmarkDomain">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="label_ConcentrationRiskBenchmarkDomain" xlink:title="label_ConcentrationRiskBenchmarkDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskBenchmarkDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConcentrationRiskBenchmarkDomain_1" xml:lang="en-US" id="label_ConcentrationRiskBenchmarkDomain_1">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="label_ConcentrationRiskBenchmarkDomain_1" xlink:title="label_ConcentrationRiskBenchmarkDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis"/>
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US" id="label_ConcentrationRiskByBenchmarkAxis">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="label_ConcentrationRiskByBenchmarkAxis" xlink:title="label_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis"/>
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskByTypeAxis" xml:lang="en-US" id="label_ConcentrationRiskByTypeAxis">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="label_ConcentrationRiskByTypeAxis" xlink:title="label_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk"/>
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskCreditRisk" xml:lang="en-US" id="label_ConcentrationRiskCreditRisk">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="label_ConcentrationRiskCreditRisk" xlink:title="label_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1"/>
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskPercentage1" xml:lang="en-US" id="label_ConcentrationRiskPercentage1">us-gaap_ConcentrationRiskPercentage1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="label_ConcentrationRiskPercentage1" xlink:title="label_ConcentrationRiskPercentage1"/>
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskPercentage1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConcentrationRiskPercentage1_1" xml:lang="en-US" id="label_ConcentrationRiskPercentage1_1">Concentration Risk, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="label_ConcentrationRiskPercentage1_1" xlink:title="label_ConcentrationRiskPercentage1_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskTypeDomain" xml:lang="en-US" id="label_ConcentrationRiskTypeDomain">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskTypeDomain" xlink:to="label_ConcentrationRiskTypeDomain" xlink:title="label_ConcentrationRiskTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskTypeDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConcentrationRiskTypeDomain_1" xml:lang="en-US" id="label_ConcentrationRiskTypeDomain_1">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskTypeDomain" xlink:to="label_ConcentrationRiskTypeDomain_1" xlink:title="label_ConcentrationRiskTypeDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1"/>
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockAmountConverted1" xml:lang="en-US" id="label_ConversionOfStockAmountConverted1">Conversion of convertible preferred stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockAmountConverted1" xlink:to="label_ConversionOfStockAmountConverted1" xlink:title="label_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis"/>
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockByUniqueDescriptionAxis" xml:lang="en-US" id="label_ConversionOfStockByUniqueDescriptionAxis">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="label_ConversionOfStockByUniqueDescriptionAxis" xlink:title="label_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockNameDomain" xml:lang="en-US" id="label_ConversionOfStockNameDomain">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockNameDomain" xlink:to="label_ConversionOfStockNameDomain" xlink:title="label_ConversionOfStockNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfStockNameDomain_1" xml:lang="en-US" id="label_ConversionOfStockNameDomain_1">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockNameDomain" xlink:to="label_ConversionOfStockNameDomain_1" xlink:title="label_ConversionOfStockNameDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="ConvertibleDebt" xlink:title="ConvertibleDebt"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleDebt" xml:lang="en-US" id="label_ConvertibleDebt">Convertible note payable, due on March 29, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebt" xlink:to="label_ConvertibleDebt" xlink:title="label_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="ConvertibleDebtCurrent" xlink:title="ConvertibleDebtCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleDebtCurrent" xml:lang="en-US" id="label_ConvertibleDebtCurrent">Convertible promissory notes - related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebtCurrent" xlink:to="label_ConvertibleDebtCurrent" xlink:title="label_ConvertibleDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="ConvertibleDebtMember" xlink:title="ConvertibleDebtMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleDebtMember" xml:lang="en-US" id="label_ConvertibleDebtMember">Convertible Debt [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebtMember" xlink:to="label_ConvertibleDebtMember" xlink:title="label_ConvertibleDebtMember"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleDebtMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleDebtMember_1" xml:lang="en-US" id="label_ConvertibleDebtMember_1">Convertible Debt [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebtMember" xlink:to="label_ConvertibleDebtMember_1" xlink:title="label_ConvertibleDebtMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="ConvertibleDebtTableTextBlock" xlink:title="ConvertibleDebtTableTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleDebtTableTextBlock" xml:lang="en-US" id="label_ConvertibleDebtTableTextBlock">Convertible Debt [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebtTableTextBlock" xlink:to="label_ConvertibleDebtTableTextBlock" xlink:title="label_ConvertibleDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:label="ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:title="ConvertiblePreferredStockSharesReservedForFutureIssuance"/>
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePreferredStockSharesReservedForFutureIssuance" xml:lang="en-US" id="label_ConvertiblePreferredStockSharesReservedForFutureIssuance">Series A convertible preferred stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:to="label_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:title="label_ConvertiblePreferredStockSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionByUniqueDescriptionAxis" xml:lang="en-US" id="label_DebtConversionByUniqueDescriptionAxis">Debt Conversion Description [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="label_DebtConversionByUniqueDescriptionAxis" xlink:title="label_DebtConversionByUniqueDescriptionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US" id="label_DebtConversionConvertedInstrumentSharesIssued1">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentSharesIssued1" xlink:to="label_DebtConversionConvertedInstrumentSharesIssued1" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionConvertedInstrumentSharesIssued1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1_1" xml:lang="en-US" id="label_DebtConversionConvertedInstrumentSharesIssued1_1">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentSharesIssued1" xlink:to="label_DebtConversionConvertedInstrumentSharesIssued1_1" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionNameDomain" xml:lang="en-US" id="label_DebtConversionNameDomain">Debt Conversion, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionNameDomain" xlink:to="label_DebtConversionNameDomain" xlink:title="label_DebtConversionNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionNameDomain_1" xml:lang="en-US" id="label_DebtConversionNameDomain_1">Debt Conversion, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionNameDomain" xlink:to="label_DebtConversionNameDomain_1" xlink:title="label_DebtConversionNameDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionOriginalDebtAmount1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmount1">us-gaap_DebtConversionOriginalDebtAmount1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmount1" xlink:to="label_DebtConversionOriginalDebtAmount1" xlink:title="label_DebtConversionOriginalDebtAmount1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmount1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionOriginalDebtAmount1_1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmount1_1">Debt Conversion, Original Debt, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmount1" xlink:to="label_DebtConversionOriginalDebtAmount1_1" xlink:title="label_DebtConversionOriginalDebtAmount1_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtDisclosureTextBlock" xml:lang="en-US" id="label_DebtDisclosureTextBlock">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="label_DebtDisclosureTextBlock" xlink:title="label_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentAxis" xml:lang="en-US" id="label_DebtInstrumentAxis">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="label_DebtInstrumentAxis" xlink:title="label_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US" id="label_DebtInstrumentBasisSpreadOnVariableRate1">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="label_DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="label_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentBasisSpreadOnVariableRate1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentBasisSpreadOnVariableRate1_1" xml:lang="en-US" id="label_DebtInstrumentBasisSpreadOnVariableRate1_1">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="label_DebtInstrumentBasisSpreadOnVariableRate1_1" xlink:title="label_DebtInstrumentBasisSpreadOnVariableRate1_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US" id="label_DebtInstrumentConvertibleBeneficialConversionFeature">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="label_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="label_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleBeneficialConversionFeature_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConvertibleBeneficialConversionFeature_1" xml:lang="en-US" id="label_DebtInstrumentConvertibleBeneficialConversionFeature_1">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="label_DebtInstrumentConvertibleBeneficialConversionFeature_1" xlink:title="label_DebtInstrumentConvertibleBeneficialConversionFeature_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US" id="label_DebtInstrumentConvertibleConversionPrice1">us-gaap_DebtInstrumentConvertibleConversionPrice1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionPrice1" xlink:to="label_DebtInstrumentConvertibleConversionPrice1" xlink:title="label_DebtInstrumentConvertibleConversionPrice1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleConversionPrice1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConvertibleConversionPrice1_1" xml:lang="en-US" id="label_DebtInstrumentConvertibleConversionPrice1_1">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionPrice1" xlink:to="label_DebtInstrumentConvertibleConversionPrice1_1" xlink:title="label_DebtInstrumentConvertibleConversionPrice1_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="DebtInstrumentConvertibleConversionRatio1" xlink:title="DebtInstrumentConvertibleConversionRatio1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConvertibleConversionRatio1" xml:lang="en-US" id="label_DebtInstrumentConvertibleConversionRatio1">us-gaap_DebtInstrumentConvertibleConversionRatio1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionRatio1" xlink:to="label_DebtInstrumentConvertibleConversionRatio1" xlink:title="label_DebtInstrumentConvertibleConversionRatio1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleConversionRatio1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConvertibleConversionRatio1_1" xml:lang="en-US" id="label_DebtInstrumentConvertibleConversionRatio1_1">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionRatio1" xlink:to="label_DebtInstrumentConvertibleConversionRatio1_1" xlink:title="label_DebtInstrumentConvertibleConversionRatio1_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:title="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xml:lang="en-US" id="label_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="label_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:title="label_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1" xml:lang="en-US" id="label_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="label_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1" xlink:title="label_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentFaceAmount" xml:lang="en-US" id="label_DebtInstrumentFaceAmount">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="label_DebtInstrumentFaceAmount" xlink:title="label_DebtInstrumentFaceAmount"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentFaceAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentFaceAmount_1" xml:lang="en-US" id="label_DebtInstrumentFaceAmount_1">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="label_DebtInstrumentFaceAmount_1" xlink:title="label_DebtInstrumentFaceAmount_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="label_DebtInstrumentInterestRateStatedPercentage">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="label_DebtInstrumentInterestRateStatedPercentage" xlink:title="label_DebtInstrumentInterestRateStatedPercentage"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentInterestRateStatedPercentage_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentInterestRateStatedPercentage_1" xml:lang="en-US" id="label_DebtInstrumentInterestRateStatedPercentage_1">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="label_DebtInstrumentInterestRateStatedPercentage_1" xlink:title="label_DebtInstrumentInterestRateStatedPercentage_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentMaturityDate" xml:lang="en-US" id="label_DebtInstrumentMaturityDate">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="label_DebtInstrumentMaturityDate" xlink:title="label_DebtInstrumentMaturityDate"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentMaturityDate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentMaturityDate_1" xml:lang="en-US" id="label_DebtInstrumentMaturityDate_1">Debt Instrument, Maturity Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="label_DebtInstrumentMaturityDate_1" xlink:title="label_DebtInstrumentMaturityDate_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentNameDomain" xml:lang="en-US" id="label_DebtInstrumentNameDomain">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="label_DebtInstrumentNameDomain" xlink:title="label_DebtInstrumentNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentNameDomain_1" xml:lang="en-US" id="label_DebtInstrumentNameDomain_1">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="label_DebtInstrumentNameDomain_1" xlink:title="label_DebtInstrumentNameDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="DebtInstrumentUnamortizedDiscountCurrent" xlink:title="DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentUnamortizedDiscountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentUnamortizedDiscountCurrent" xml:lang="en-US" id="label_DebtInstrumentUnamortizedDiscountCurrent">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscountCurrent" xlink:to="label_DebtInstrumentUnamortizedDiscountCurrent" xlink:title="label_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentUnamortizedDiscountCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentUnamortizedDiscountCurrent_1" xml:lang="en-US" id="label_DebtInstrumentUnamortizedDiscountCurrent_1">Debt Instrument, Unamortized Discount, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscountCurrent" xlink:to="label_DebtInstrumentUnamortizedDiscountCurrent_1" xlink:title="label_DebtInstrumentUnamortizedDiscountCurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentUnusedBorrowingCapacityAmount" xml:lang="en-US" id="label_DebtInstrumentUnusedBorrowingCapacityAmount">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="label_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="label_DebtInstrumentUnusedBorrowingCapacityAmount"/>
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentUnusedBorrowingCapacityAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentUnusedBorrowingCapacityAmount_1" xml:lang="en-US" id="label_DebtInstrumentUnusedBorrowingCapacityAmount_1">Debt Instrument, Unused Borrowing Capacity, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="label_DebtInstrumentUnusedBorrowingCapacityAmount_1" xlink:title="label_DebtInstrumentUnusedBorrowingCapacityAmount_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="DeferredFinanceCostsGross" xlink:title="DeferredFinanceCostsGross"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredFinanceCostsGross" xml:lang="en-US" id="label_DeferredFinanceCostsGross">us-gaap_DeferredFinanceCostsGross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsGross" xlink:to="label_DeferredFinanceCostsGross" xlink:title="label_DeferredFinanceCostsGross"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredFinanceCostsGross_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredFinanceCostsGross_1" xml:lang="en-US" id="label_DeferredFinanceCostsGross_1">Debt Issuance Costs, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsGross" xlink:to="label_DeferredFinanceCostsGross_1" xlink:title="label_DeferredFinanceCostsGross_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="DeferredFinanceCostsNet" xlink:title="DeferredFinanceCostsNet"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredFinanceCostsNet" xml:lang="en-US" id="label_DeferredFinanceCostsNet">us-gaap_DeferredFinanceCostsNet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsNet" xlink:to="label_DeferredFinanceCostsNet" xlink:title="label_DeferredFinanceCostsNet"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredFinanceCostsNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredFinanceCostsNet_1" xml:lang="en-US" id="label_DeferredFinanceCostsNet_1">Debt Issuance Costs, Net, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsNet" xlink:to="label_DeferredFinanceCostsNet_1" xlink:title="label_DeferredFinanceCostsNet_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="DeferredIncomeTaxAssetsNet" xlink:title="DeferredIncomeTaxAssetsNet"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredIncomeTaxAssetsNet" xml:lang="en-US" id="label_DeferredIncomeTaxAssetsNet">us-gaap_DeferredIncomeTaxAssetsNet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxAssetsNet" xlink:to="label_DeferredIncomeTaxAssetsNet" xlink:title="label_DeferredIncomeTaxAssetsNet"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredIncomeTaxAssetsNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredIncomeTaxAssetsNet_1" xml:lang="en-US" id="label_DeferredIncomeTaxAssetsNet_1">Deferred Income Tax Assets, Net, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxAssetsNet" xlink:to="label_DeferredIncomeTaxAssetsNet_1" xlink:title="label_DeferredIncomeTaxAssetsNet_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsGross" xml:lang="en-US" id="label_DeferredTaxAssetsGross">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="label_DeferredTaxAssetsGross" xlink:title="label_DeferredTaxAssetsGross"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsGross_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_DeferredTaxAssetsGross_1" xml:lang="en-US" id="label_DeferredTaxAssetsGross_1">Total deferred tax asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="label_DeferredTaxAssetsGross_1" xlink:title="label_DeferredTaxAssetsGross_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsNet" xml:lang="en-US" id="label_DeferredTaxAssetsNet">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="label_DeferredTaxAssetsNet" xlink:title="label_DeferredTaxAssetsNet"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsNet_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_DeferredTaxAssetsNet_1" xml:lang="en-US" id="label_DeferredTaxAssetsNet_1">Net deferred tax asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="label_DeferredTaxAssetsNet_1" xlink:title="label_DeferredTaxAssetsNet_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US" id="label_DeferredTaxAssetsOperatingLossCarryforwards">Net operating loss carry forward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="label_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="label_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US" id="label_DeferredTaxAssetsPropertyPlantAndEquipment">Fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="label_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="label_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US" id="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch">Research and development credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xml:lang="en-US" id="label_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">Accruals and reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="label_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:title="label_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="label_DeferredTaxAssetsValuationAllowance">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="label_DeferredTaxAssetsValuationAllowance" xlink:title="label_DeferredTaxAssetsValuationAllowance"/>
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsValuationAllowance_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US" id="label_DeferredTaxAssetsValuationAllowance_1">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="label_DeferredTaxAssetsValuationAllowance_1" xlink:title="label_DeferredTaxAssetsValuationAllowance_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation"/>
    <link:label xlink:type="resource" xlink:label="label_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Depreciation" xml:lang="en-US" id="label_Depreciation">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="label_Depreciation" xlink:title="label_Depreciation"/>
    <link:label xlink:type="resource" xlink:label="label_Depreciation_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_Depreciation_1" xml:lang="en-US" id="label_Depreciation_1">Depreciation, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="label_Depreciation_1" xlink:title="label_Depreciation_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet"/>
    <link:label xlink:type="resource" xlink:label="label_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeGainLossOnDerivativeNet" xml:lang="en-US" id="label_DerivativeGainLossOnDerivativeNet">us-gaap_DerivativeGainLossOnDerivativeNet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeGainLossOnDerivativeNet" xlink:to="label_DerivativeGainLossOnDerivativeNet" xlink:title="label_DerivativeGainLossOnDerivativeNet"/>
    <link:label xlink:type="resource" xlink:label="label_DerivativeGainLossOnDerivativeNet_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_DerivativeGainLossOnDerivativeNet_1" xml:lang="en-US" id="label_DerivativeGainLossOnDerivativeNet_1">Changes in fair value of derivative liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeGainLossOnDerivativeNet" xlink:to="label_DerivativeGainLossOnDerivativeNet_1" xlink:title="label_DerivativeGainLossOnDerivativeNet_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="DerivativeLiabilities" xlink:title="DerivativeLiabilities"/>
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeLiabilities" xml:lang="en-US" id="label_DerivativeLiabilities">Warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilities" xlink:to="label_DerivativeLiabilities" xlink:title="label_DerivativeLiabilities"/>
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DerivativeLiabilities_1" xml:lang="en-US" id="label_DerivativeLiabilities_1">Warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilities" xlink:to="label_DerivativeLiabilities_1" xlink:title="label_DerivativeLiabilities_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeLiabilitiesCurrent" xml:lang="en-US" id="label_DerivativeLiabilitiesCurrent">Derivative Liability, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesCurrent" xlink:to="label_DerivativeLiabilitiesCurrent" xlink:title="label_DerivativeLiabilitiesCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DerivativeLiabilitiesCurrent" xml:lang="en-US" id="label_DerivativeLiabilitiesCurrent_2">Warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesCurrent" xlink:to="label_DerivativeLiabilitiesCurrent_2" xlink:title="label: DerivativeLiabilitiesCurrent to label_DerivativeLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeMember" xlink:label="DerivativeMember" xlink:title="DerivativeMember"/>
    <link:label xlink:type="resource" xlink:label="label_DerivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeMember" xml:lang="en-US" id="label_DerivativeMember">Derivative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeMember" xlink:to="label_DerivativeMember" xlink:title="label_DerivativeMember"/>
    <link:label xlink:type="resource" xlink:label="label_DerivativeMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DerivativeMember_1" xml:lang="en-US" id="label_DerivativeMember_1">Derivative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeMember" xlink:to="label_DerivativeMember_1" xlink:title="label_DerivativeMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="DerivativesPolicyTextBlock" xlink:title="DerivativesPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativesPolicyTextBlock" xml:lang="en-US" id="label_DerivativesPolicyTextBlock">Derivatives, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativesPolicyTextBlock" xlink:to="label_DerivativesPolicyTextBlock" xlink:title="label_DerivativesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">Share-based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract" xlink:title="DisclosureTextBlockAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_DisclosureTextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureTextBlockAbstract" xml:lang="en-US" id="label_DisclosureTextBlockAbstract">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureTextBlockAbstract" xlink:to="label_DisclosureTextBlockAbstract" xlink:title="label_DisclosureTextBlockAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_DisclosureTextBlockAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DisclosureTextBlockAbstract_1" xml:lang="en-US" id="label_DisclosureTextBlockAbstract_1">Notes to Financial Statements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureTextBlockAbstract" xlink:to="label_DisclosureTextBlockAbstract_1" xlink:title="label_DisclosureTextBlockAbstract_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:title="DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:label xlink:type="resource" xlink:label="label_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xml:lang="en-US" id="label_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax">Loss from discontinued operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:to="label_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:title="label_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:label="DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:title="DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare"/>
    <link:label xlink:type="resource" xlink:label="label_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US" id="label_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare">Loss from discontinued operations (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:to="label_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:title="label_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="DiscontinuedOperationsPolicyTextBlock" xlink:title="DiscontinuedOperationsPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DiscontinuedOperationsPolicyTextBlock" xml:lang="en-US" id="label_DiscontinuedOperationsPolicyTextBlock">Discontinued Operations, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DiscontinuedOperationsPolicyTextBlock" xlink:to="label_DiscontinuedOperationsPolicyTextBlock" xlink:title="label_DiscontinuedOperationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends" xlink:label="Dividends" xlink:title="Dividends"/>
    <link:label xlink:type="resource" xlink:label="label_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Dividends" xml:lang="en-US" id="label_Dividends">us-gaap_Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Dividends" xlink:to="label_Dividends" xlink:title="label_Dividends"/>
    <link:label xlink:type="resource" xlink:label="label_Dividends_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_Dividends_1" xml:lang="en-US" id="label_Dividends_1">Dividends, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Dividends" xlink:to="label_Dividends_1" xlink:title="label_Dividends_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsAxis" xlink:label="DividendsAxis" xlink:title="DividendsAxis"/>
    <link:label xlink:type="resource" xlink:label="label_DividendsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DividendsAxis" xml:lang="en-US" id="label_DividendsAxis">Dividends [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsAxis" xlink:to="label_DividendsAxis" xlink:title="label_DividendsAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsDomain" xlink:label="DividendsDomain" xlink:title="DividendsDomain"/>
    <link:label xlink:type="resource" xlink:label="label_DividendsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DividendsDomain" xml:lang="en-US" id="label_DividendsDomain">Dividends [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsDomain" xlink:to="label_DividendsDomain" xlink:title="label_DividendsDomain"/>
    <link:label xlink:type="resource" xlink:label="label_DividendsDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DividendsDomain_1" xml:lang="en-US" id="label_DividendsDomain_1">Dividends [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsDomain" xlink:to="label_DividendsDomain_1" xlink:title="label_DividendsDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="DividendsPayableAmountPerShare" xlink:title="DividendsPayableAmountPerShare"/>
    <link:label xlink:type="resource" xlink:label="label_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DividendsPayableAmountPerShare" xml:lang="en-US" id="label_DividendsPayableAmountPerShare">us-gaap_DividendsPayableAmountPerShare</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPayableAmountPerShare" xlink:to="label_DividendsPayableAmountPerShare" xlink:title="label_DividendsPayableAmountPerShare"/>
    <link:label xlink:type="resource" xlink:label="label_DividendsPayableAmountPerShare_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DividendsPayableAmountPerShare_1" xml:lang="en-US" id="label_DividendsPayableAmountPerShare_1">Dividends Payable, Amount Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPayableAmountPerShare" xlink:to="label_DividendsPayableAmountPerShare_1" xlink:title="label_DividendsPayableAmountPerShare_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember"/>
    <link:label xlink:type="resource" xlink:label="label_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DomesticCountryMember" xml:lang="en-US" id="label_DomesticCountryMember">Domestic Country [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DomesticCountryMember" xlink:to="label_DomesticCountryMember" xlink:title="label_DomesticCountryMember"/>
    <link:label xlink:type="resource" xlink:label="label_DomesticCountryMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DomesticCountryMember_1" xml:lang="en-US" id="label_DomesticCountryMember_1">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DomesticCountryMember" xlink:to="label_DomesticCountryMember_1" xlink:title="label_DomesticCountryMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="EarliestTaxYearMember" xlink:title="EarliestTaxYearMember"/>
    <link:label xlink:type="resource" xlink:label="label_EarliestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarliestTaxYearMember" xml:lang="en-US" id="label_EarliestTaxYearMember">Earliest Tax Year [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarliestTaxYearMember" xlink:to="label_EarliestTaxYearMember" xlink:title="label_EarliestTaxYearMember"/>
    <link:label xlink:type="resource" xlink:label="label_EarliestTaxYearMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarliestTaxYearMember_1" xml:lang="en-US" id="label_EarliestTaxYearMember_1">Earliest Tax Year [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarliestTaxYearMember" xlink:to="label_EarliestTaxYearMember_1" xlink:title="label_EarliestTaxYearMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted"/>
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted">Net loss per basic and diluted share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted" xlink:title="label_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="EarningsPerShareBasicAndDilutedAbstract" xlink:title="EarningsPerShareBasicAndDilutedAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US" id="label_EarningsPerShareBasicAndDilutedAbstract">Net loss per basic and diluted share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="label_EarningsPerShareBasicAndDilutedAbstract" xlink:title="label_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xlink:title="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xlink:label="EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xlink:title="EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset"/>
    <link:label xlink:type="resource" xlink:label="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xml:lang="en-US" id="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xlink:to="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xlink:title="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset"/>
    <link:label xlink:type="resource" xlink:label="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset_1" xml:lang="en-US" id="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset_1">Embedded Derivative, Fair Value of Embedded Derivative Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xlink:to="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset_1" xlink:title="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:title="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:label xlink:type="resource" xlink:label="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xml:lang="en-US" id="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:title="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:label xlink:type="resource" xlink:label="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_1" xml:lang="en-US" id="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_1">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_1" xlink:title="label_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember"/>
    <link:label xlink:type="resource" xlink:label="label_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeStockOptionMember" xml:lang="en-US" id="label_EmployeeStockOptionMember">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="label_EmployeeStockOptionMember" xlink:title="label_EmployeeStockOptionMember"/>
    <link:label xlink:type="resource" xlink:label="label_EmployeeStockOptionMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeStockOptionMember_1" xml:lang="en-US" id="label_EmployeeStockOptionMember_1">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="label_EmployeeStockOptionMember_1" xlink:title="label_EmployeeStockOptionMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain"/>
    <link:label xlink:type="resource" xlink:label="label_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityComponentDomain" xml:lang="en-US" id="label_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="label_EquityComponentDomain" xlink:title="label_EquityComponentDomain"/>
    <link:label xlink:type="resource" xlink:label="label_EquityComponentDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EquityComponentDomain_1" xml:lang="en-US" id="label_EquityComponentDomain_1">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="label_EquityComponentDomain_1" xlink:title="label_EquityComponentDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAdjustmentOfWarrants" xml:lang="en-US" id="label_FairValueAdjustmentOfWarrants">Changes in fair value of warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="label_FairValueAdjustmentOfWarrants" xlink:title="label_FairValueAdjustmentOfWarrants"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueAdjustmentOfWarrants_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAdjustmentOfWarrants_1" xml:lang="en-US" id="label_FairValueAdjustmentOfWarrants_1">Fair Value Adjustment of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="label_FairValueAdjustmentOfWarrants_1" xlink:title="label_FairValueAdjustmentOfWarrants_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US" id="label_FairValueByFairValueHierarchyLevelAxis">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="label_FairValueByFairValueHierarchyLevelAxis" xlink:title="label_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByMeasurementFrequencyAxis" xml:lang="en-US" id="label_FairValueByMeasurementFrequencyAxis">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="label_FairValueByMeasurementFrequencyAxis" xlink:title="label_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel1Member" xml:lang="en-US" id="label_FairValueInputsLevel1Member">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="label_FairValueInputsLevel1Member" xlink:title="label_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel2Member" xml:lang="en-US" id="label_FairValueInputsLevel2Member">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="label_FairValueInputsLevel2Member" xlink:title="label_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel3Member" xml:lang="en-US" id="label_FairValueInputsLevel3Member">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="label_FairValueInputsLevel3Member" xlink:title="label_FairValueInputsLevel3Member"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel3Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel3Member_1" xml:lang="en-US" id="label_FairValueInputsLevel3Member_1">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="label_FairValueInputsLevel3Member_1" xlink:title="label_FairValueInputsLevel3Member_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementFrequencyDomain" xml:lang="en-US" id="label_FairValueMeasurementFrequencyDomain">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="label_FairValueMeasurementFrequencyDomain" xlink:title="label_FairValueMeasurementFrequencyDomain"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementFrequencyDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementFrequencyDomain_1" xml:lang="en-US" id="label_FairValueMeasurementFrequencyDomain_1">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="label_FairValueMeasurementFrequencyDomain_1" xlink:title="label_FairValueMeasurementFrequencyDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US" id="label_FairValueMeasurementsFairValueHierarchyDomain">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="label_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain_1" xml:lang="en-US" id="label_FairValueMeasurementsFairValueHierarchyDomain_1">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="label_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="label_FairValueMeasurementsRecurringMember">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="label_FairValueMeasurementsRecurringMember" xlink:title="label_FairValueMeasurementsRecurringMember"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsRecurringMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementsRecurringMember_1" xml:lang="en-US" id="label_FairValueMeasurementsRecurringMember_1">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="label_FairValueMeasurementsRecurringMember_1" xlink:title="label_FairValueMeasurementsRecurringMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_1" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_1">Exchange of warrants upon Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_1" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">Change in value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">Embedded derivative liability from the issuance of Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1">Termination of the embedded derivative liability due to the extinguishment of the related Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">Preferred stock warrants - exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1">Fair value, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2">Fair value at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy"/>
    <link:label xlink:type="resource" xlink:label="label_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="label_FairValueOfFinancialInstrumentsPolicy">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="label_FairValueOfFinancialInstrumentsPolicy" xlink:title="label_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="FinanceLeaseLiability" xlink:title="FinanceLeaseLiability"/>
    <link:label xlink:type="resource" xlink:label="label_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FinanceLeaseLiability" xml:lang="en-US" id="label_FinanceLeaseLiability">us-gaap_FinanceLeaseLiability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiability" xlink:to="label_FinanceLeaseLiability" xlink:title="label_FinanceLeaseLiability"/>
    <link:label xlink:type="resource" xlink:label="label_FinanceLeaseLiability_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FinanceLeaseLiability_1" xml:lang="en-US" id="label_FinanceLeaseLiability_1">Finance Lease, Liability, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiability" xlink:to="label_FinanceLeaseLiability_1" xlink:title="label_FinanceLeaseLiability_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis"/>
    <link:label xlink:type="resource" xlink:label="label_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FinancialInstrumentAxis" xml:lang="en-US" id="label_FinancialInstrumentAxis">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialInstrumentAxis" xlink:to="label_FinancialInstrumentAxis" xlink:title="label_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure"/>
    <link:label xlink:type="resource" xlink:label="label_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US" id="label_FinancialLiabilitiesFairValueDisclosure">Total financial liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilitiesFairValueDisclosure" xlink:to="label_FinancialLiabilitiesFairValueDisclosure" xlink:title="label_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember"/>
    <link:label xlink:type="resource" xlink:label="label_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FurnitureAndFixturesMember" xml:lang="en-US" id="label_FurnitureAndFixturesMember">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="label_FurnitureAndFixturesMember" xlink:title="label_FurnitureAndFixturesMember"/>
    <link:label xlink:type="resource" xlink:label="label_FurnitureAndFixturesMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FurnitureAndFixturesMember_1" xml:lang="en-US" id="label_FurnitureAndFixturesMember_1">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="label_FurnitureAndFixturesMember_1" xlink:title="label_FurnitureAndFixturesMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt"/>
    <link:label xlink:type="resource" xlink:label="label_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US" id="label_GainsLossesOnExtinguishmentOfDebt">us-gaap_GainsLossesOnExtinguishmentOfDebt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="label_GainsLossesOnExtinguishmentOfDebt" xlink:title="label_GainsLossesOnExtinguishmentOfDebt"/>
    <link:label xlink:type="resource" xlink:label="label_GainsLossesOnExtinguishmentOfDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GainsLossesOnExtinguishmentOfDebt_1" xml:lang="en-US" id="label_GainsLossesOnExtinguishmentOfDebt_1">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="label_GainsLossesOnExtinguishmentOfDebt_1" xlink:title="label_GainsLossesOnExtinguishmentOfDebt_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense"/>
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense" xlink:title="label_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="GrantsReceivable" xlink:title="GrantsReceivable"/>
    <link:label xlink:type="resource" xlink:label="label_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GrantsReceivable" xml:lang="en-US" id="label_GrantsReceivable">us-gaap_GrantsReceivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsReceivable" xlink:to="label_GrantsReceivable" xlink:title="label_GrantsReceivable"/>
    <link:label xlink:type="resource" xlink:label="label_GrantsReceivable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GrantsReceivable_1" xml:lang="en-US" id="label_GrantsReceivable_1">Grants Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsReceivable" xlink:to="label_GrantsReceivable_1" xlink:title="label_GrantsReceivable_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:label xlink:type="resource" xlink:label="label_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US" id="label_ImpairmentOfLongLivedAssetsHeldForUse">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="label_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="label_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:label xlink:type="resource" xlink:label="label_ImpairmentOfLongLivedAssetsHeldForUse_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ImpairmentOfLongLivedAssetsHeldForUse_1" xml:lang="en-US" id="label_ImpairmentOfLongLivedAssetsHeldForUse_1">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="label_ImpairmentOfLongLivedAssetsHeldForUse_1" xlink:title="label_ImpairmentOfLongLivedAssetsHeldForUse_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xml:lang="en-US" id="label_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="label_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="label_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="IncomeLossFromContinuingOperations" xlink:title="IncomeLossFromContinuingOperations"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeLossFromContinuingOperations" xml:lang="en-US" id="label_IncomeLossFromContinuingOperations">us-gaap_IncomeLossFromContinuingOperations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperations" xlink:to="label_IncomeLossFromContinuingOperations" xlink:title="label_IncomeLossFromContinuingOperations"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_IncomeLossFromContinuingOperations_1" xml:lang="en-US" id="label_IncomeLossFromContinuingOperations_1">Loss from continuing operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperations" xlink:to="label_IncomeLossFromContinuingOperations_1" xlink:title="label_IncomeLossFromContinuingOperations_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:title="IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US" id="label_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">Loss from continuing operations (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="label_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:title="label_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementAbstract" xml:lang="en-US" id="label_IncomeStatementAbstract">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="label_IncomeStatementAbstract" xlink:title="label_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementLocationAxis" xml:lang="en-US" id="label_IncomeStatementLocationAxis">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="label_IncomeStatementLocationAxis" xlink:title="label_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementLocationDomain" xml:lang="en-US" id="label_IncomeStatementLocationDomain">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="label_IncomeStatementLocationDomain" xlink:title="label_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxAuthorityAxis" xml:lang="en-US" id="label_IncomeTaxAuthorityAxis">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityAxis" xlink:to="label_IncomeTaxAuthorityAxis" xlink:title="label_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxAuthorityDomain" xml:lang="en-US" id="label_IncomeTaxAuthorityDomain">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityDomain" xlink:to="label_IncomeTaxAuthorityDomain" xlink:title="label_IncomeTaxAuthorityDomain"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxAuthorityDomain_1" xml:lang="en-US" id="label_IncomeTaxAuthorityDomain_1">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityDomain" xlink:to="label_IncomeTaxAuthorityDomain_1" xlink:title="label_IncomeTaxAuthorityDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="IncomeTaxAuthorityNameAxis" xlink:title="IncomeTaxAuthorityNameAxis"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxAuthorityNameAxis" xml:lang="en-US" id="label_IncomeTaxAuthorityNameAxis">Income Tax Authority, Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityNameAxis" xlink:to="label_IncomeTaxAuthorityNameAxis" xlink:title="label_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="IncomeTaxAuthorityNameDomain" xlink:title="IncomeTaxAuthorityNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxAuthorityNameDomain" xml:lang="en-US" id="label_IncomeTaxAuthorityNameDomain">Income Tax Authority Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityNameDomain" xlink:to="label_IncomeTaxAuthorityNameDomain" xlink:title="label_IncomeTaxAuthorityNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxAuthorityNameDomain_1" xml:lang="en-US" id="label_IncomeTaxAuthorityNameDomain_1">Income Tax Authority, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityNameDomain" xlink:to="label_IncomeTaxAuthorityNameDomain_1" xlink:title="label_IncomeTaxAuthorityNameDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock" xlink:title="label_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit" xlink:title="label_IncomeTaxExpenseBenefit"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxExpenseBenefit_1" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit_1">Income Tax Expense (Benefit), Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit_1" xlink:title="label_IncomeTaxExpenseBenefit_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="label_IncomeTaxPolicyTextBlock">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="label_IncomeTaxPolicyTextBlock" xlink:title="label_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable"/>
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccountsPayable" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayable">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="label_IncreaseDecreaseInAccountsPayable" xlink:title="label_IncreaseDecreaseInAccountsPayable"/>
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInAccountsPayable_1" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayable_1">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="label_IncreaseDecreaseInAccountsPayable_1" xlink:title="label_IncreaseDecreaseInAccountsPayable_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities"/>
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInAccruedLiabilities">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccruedLiabilities" xlink:title="label_IncreaseDecreaseInAccruedLiabilities"/>
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccruedLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInAccruedLiabilities_1" xml:lang="en-US" id="label_IncreaseDecreaseInAccruedLiabilities_1">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccruedLiabilities_1" xlink:title="label_IncreaseDecreaseInAccruedLiabilities_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets"/>
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US" id="label_IncreaseDecreaseInOtherOperatingAssets">us-gaap_IncreaseDecreaseInOtherOperatingAssets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingAssets" xlink:to="label_IncreaseDecreaseInOtherOperatingAssets" xlink:title="label_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOtherOperatingAssets_1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="label_IncreaseDecreaseInOtherOperatingAssets_1" xml:lang="en-US" id="label_IncreaseDecreaseInOtherOperatingAssets_1">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingAssets" xlink:to="label_IncreaseDecreaseInOtherOperatingAssets_1" xlink:title="label_IncreaseDecreaseInOtherOperatingAssets_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="IntangibleAssetsNetIncludingGoodwill" xlink:title="IntangibleAssetsNetIncludingGoodwill"/>
    <link:label xlink:type="resource" xlink:label="label_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IntangibleAssetsNetIncludingGoodwill" xml:lang="en-US" id="label_IntangibleAssetsNetIncludingGoodwill">us-gaap_IntangibleAssetsNetIncludingGoodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetIncludingGoodwill" xlink:to="label_IntangibleAssetsNetIncludingGoodwill" xlink:title="label_IntangibleAssetsNetIncludingGoodwill"/>
    <link:label xlink:type="resource" xlink:label="label_IntangibleAssetsNetIncludingGoodwill_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IntangibleAssetsNetIncludingGoodwill_1" xml:lang="en-US" id="label_IntangibleAssetsNetIncludingGoodwill_1">Intangible Assets, Net (Including Goodwill), Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetIncludingGoodwill" xlink:to="label_IntangibleAssetsNetIncludingGoodwill_1" xlink:title="label_IntangibleAssetsNetIncludingGoodwill_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense"/>
    <link:label xlink:type="resource" xlink:label="label_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestExpense" xml:lang="en-US" id="label_InterestExpense">us-gaap_InterestExpense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="label_InterestExpense" xlink:title="label_InterestExpense"/>
    <link:label xlink:type="resource" xlink:label="label_InterestExpense_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_InterestExpense_1" xml:lang="en-US" id="label_InterestExpense_1">Interest expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="label_InterestExpense_1" xlink:title="label_InterestExpense_1"/>
    <link:label xlink:type="resource" xlink:label="label_InterestExpense_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestExpense_2" xml:lang="en-US" id="label_InterestExpense_2">Interest Expense, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="label_InterestExpense_2" xlink:title="label_InterestExpense_2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt"/>
    <link:label xlink:type="resource" xlink:label="label_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestExpenseDebt" xml:lang="en-US" id="label_InterestExpenseDebt">us-gaap_InterestExpenseDebt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="label_InterestExpenseDebt" xlink:title="label_InterestExpenseDebt"/>
    <link:label xlink:type="resource" xlink:label="label_InterestExpenseDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestExpenseDebt_1" xml:lang="en-US" id="label_InterestExpenseDebt_1">Interest Expense, Debt, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="label_InterestExpenseDebt_1" xlink:title="label_InterestExpenseDebt_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="InterestExpenseMember" xlink:title="InterestExpenseMember"/>
    <link:label xlink:type="resource" xlink:label="label_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestExpenseMember" xml:lang="en-US" id="label_InterestExpenseMember">Interest Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseMember" xlink:to="label_InterestExpenseMember" xlink:title="label_InterestExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="InterestIncomeExpenseNet" xlink:title="InterestIncomeExpenseNet"/>
    <link:label xlink:type="resource" xlink:label="label_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestIncomeExpenseNet" xml:lang="en-US" id="label_InterestIncomeExpenseNet">Interest expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNet" xlink:to="label_InterestIncomeExpenseNet" xlink:title="label_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet"/>
    <link:label xlink:type="resource" xlink:label="label_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestPaidNet" xml:lang="en-US" id="label_InterestPaidNet">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="label_InterestPaidNet" xlink:title="label_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent"/>
    <link:label xlink:type="resource" xlink:label="label_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestPayableCurrentAndNoncurrent" xml:lang="en-US" id="label_InterestPayableCurrentAndNoncurrent">us-gaap_InterestPayableCurrentAndNoncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrentAndNoncurrent" xlink:to="label_InterestPayableCurrentAndNoncurrent" xlink:title="label_InterestPayableCurrentAndNoncurrent"/>
    <link:label xlink:type="resource" xlink:label="label_InterestPayableCurrentAndNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestPayableCurrentAndNoncurrent_1" xml:lang="en-US" id="label_InterestPayableCurrentAndNoncurrent_1">Interest Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrentAndNoncurrent" xlink:to="label_InterestPayableCurrentAndNoncurrent_1" xlink:title="label_InterestPayableCurrentAndNoncurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember"/>
    <link:label xlink:type="resource" xlink:label="label_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InternalRevenueServiceIRSMember" xml:lang="en-US" id="label_InternalRevenueServiceIRSMember">Internal Revenue Service I R S [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InternalRevenueServiceIRSMember" xlink:to="label_InternalRevenueServiceIRSMember" xlink:title="label_InternalRevenueServiceIRSMember"/>
    <link:label xlink:type="resource" xlink:label="label_InternalRevenueServiceIRSMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InternalRevenueServiceIRSMember_1" xml:lang="en-US" id="label_InternalRevenueServiceIRSMember_1">Internal Revenue Service (IRS) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InternalRevenueServiceIRSMember" xlink:to="label_InternalRevenueServiceIRSMember_1" xlink:title="label_InternalRevenueServiceIRSMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="LeaseAndRentalExpense" xlink:title="LeaseAndRentalExpense"/>
    <link:label xlink:type="resource" xlink:label="label_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LeaseAndRentalExpense" xml:lang="en-US" id="label_LeaseAndRentalExpense">us-gaap_LeaseAndRentalExpense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseAndRentalExpense" xlink:to="label_LeaseAndRentalExpense" xlink:title="label_LeaseAndRentalExpense"/>
    <link:label xlink:type="resource" xlink:label="label_LeaseAndRentalExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LeaseAndRentalExpense_1" xml:lang="en-US" id="label_LeaseAndRentalExpense_1">Operating Leases, Rent Expense, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseAndRentalExpense" xlink:to="label_LeaseAndRentalExpense_1" xlink:title="label_LeaseAndRentalExpense_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeOperatingLeaseDiscountRate" xml:lang="en-US" id="label_LesseeOperatingLeaseDiscountRate">us-gaap_LesseeOperatingLeaseDiscountRate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDiscountRate" xlink:to="label_LesseeOperatingLeaseDiscountRate" xlink:title="label_LesseeOperatingLeaseDiscountRate"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseDiscountRate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LesseeOperatingLeaseDiscountRate_1" xml:lang="en-US" id="label_LesseeOperatingLeaseDiscountRate_1">Lessee, Operating Lease, Discount Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDiscountRate" xlink:to="label_LesseeOperatingLeaseDiscountRate_1" xlink:title="label_LesseeOperatingLeaseDiscountRate_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US" id="label_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="label_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="label_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US" id="label_LesseeOperatingLeaseLiabilityPaymentsDue">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="label_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US" id="label_LesseeOperatingLeaseLiabilityPaymentsDue_1">Lessee, Operating Lease, Liability, Payments, Due, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="label_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseLiabilityPaymentsDue_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDue_2" xml:lang="en-US" id="label_LesseeOperatingLeaseLiabilityPaymentsDue_2">Total future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="label_LesseeOperatingLeaseLiabilityPaymentsDue_2" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDue_2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US" id="label_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="label_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US" id="label_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="label_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US" id="label_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="label_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US" id="label_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="label_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US" id="label_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">2019 (remaining 6 months)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="label_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="label_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US" id="label_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="label_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="label_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1" xml:lang="en-US" id="label_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1">Less: imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="label_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1" xlink:title="label_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeOperatingLeasesTextBlock" xml:lang="en-US" id="label_LesseeOperatingLeasesTextBlock">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="label_LesseeOperatingLeasesTextBlock" xlink:title="label_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity"/>
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity">Total liabilities, redeemable convertible preferred stock and stockholders' deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity" xlink:title="label_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrent" xml:lang="en-US" id="label_LiabilitiesCurrent">us-gaap_LiabilitiesCurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent" xlink:title="label_LiabilitiesCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesCurrent_1" xml:lang="en-US" id="label_LiabilitiesCurrent_1">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent_1" xlink:title="label_LiabilitiesCurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract">Current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract" xlink:title="label_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:label xlink:type="resource" xlink:label="label_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LineOfCreditFacilityAxis" xml:lang="en-US" id="label_LineOfCreditFacilityAxis">Lender Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityAxis" xlink:to="label_LineOfCreditFacilityAxis" xlink:title="label_LineOfCreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:label xlink:type="resource" xlink:label="label_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LineOfCreditFacilityLenderDomain" xml:lang="en-US" id="label_LineOfCreditFacilityLenderDomain">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="label_LineOfCreditFacilityLenderDomain" xlink:title="label_LineOfCreditFacilityLenderDomain"/>
    <link:label xlink:type="resource" xlink:label="label_LineOfCreditFacilityLenderDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LineOfCreditFacilityLenderDomain_1" xml:lang="en-US" id="label_LineOfCreditFacilityLenderDomain_1">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="label_LineOfCreditFacilityLenderDomain_1" xlink:title="label_LineOfCreditFacilityLenderDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayable" xlink:label="LoansPayable" xlink:title="LoansPayable"/>
    <link:label xlink:type="resource" xlink:label="label_LoansPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LoansPayable" xml:lang="en-US" id="label_LoansPayable">us-gaap_LoansPayable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansPayable" xlink:to="label_LoansPayable" xlink:title="label_LoansPayable"/>
    <link:label xlink:type="resource" xlink:label="label_LoansPayable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LoansPayable_1" xml:lang="en-US" id="label_LoansPayable_1">Loans Payable, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansPayable" xlink:to="label_LoansPayable_1" xlink:title="label_LoansPayable_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLiborSwapRateMember" xlink:label="LondonInterbankOfferedRateLiborSwapRateMember" xlink:title="LondonInterbankOfferedRateLiborSwapRateMember"/>
    <link:label xlink:type="resource" xlink:label="label_LondonInterbankOfferedRateLiborSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LondonInterbankOfferedRateLiborSwapRateMember" xml:lang="en-US" id="label_LondonInterbankOfferedRateLiborSwapRateMember">London Interbank Offered Rate (LIBOR) Swap Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LondonInterbankOfferedRateLiborSwapRateMember" xlink:to="label_LondonInterbankOfferedRateLiborSwapRateMember" xlink:title="label_LondonInterbankOfferedRateLiborSwapRateMember"/>
    <link:label xlink:type="resource" xlink:label="label_LondonInterbankOfferedRateLiborSwapRateMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LondonInterbankOfferedRateLiborSwapRateMember_1" xml:lang="en-US" id="label_LondonInterbankOfferedRateLiborSwapRateMember_1">London Interbank Offered Rate (LIBOR) Swap Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LondonInterbankOfferedRateLiborSwapRateMember" xlink:to="label_LondonInterbankOfferedRateLiborSwapRateMember_1" xlink:title="label_LondonInterbankOfferedRateLiborSwapRateMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt"/>
    <link:label xlink:type="resource" xlink:label="label_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebt" xml:lang="en-US" id="label_LongTermDebt">us-gaap_LongTermDebt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="label_LongTermDebt" xlink:title="label_LongTermDebt"/>
    <link:label xlink:type="resource" xlink:label="label_LongTermDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebt_1" xml:lang="en-US" id="label_LongTermDebt_1">Long-term Debt, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="label_LongTermDebt_1" xlink:title="label_LongTermDebt_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtCurrent" xml:lang="en-US" id="label_LongTermDebtCurrent">Current portion of term loan, net of discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtCurrent" xlink:to="label_LongTermDebtCurrent" xlink:title="label_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">Total principal payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent"/>
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtNoncurrent" xml:lang="en-US" id="label_LongTermDebtNoncurrent">Term loan, net of current portion and discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtNoncurrent" xlink:to="label_LongTermDebtNoncurrent" xlink:title="label_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis"/>
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongtermDebtTypeAxis" xml:lang="en-US" id="label_LongtermDebtTypeAxis">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeAxis" xlink:to="label_LongtermDebtTypeAxis" xlink:title="label_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongtermDebtTypeDomain" xml:lang="en-US" id="label_LongtermDebtTypeDomain">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeDomain" xlink:to="label_LongtermDebtTypeDomain" xlink:title="label_LongtermDebtTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtTypeDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongtermDebtTypeDomain_1" xml:lang="en-US" id="label_LongtermDebtTypeDomain_1">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeDomain" xlink:to="label_LongtermDebtTypeDomain_1" xlink:title="label_LongtermDebtTypeDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="MeasurementInputConversionPriceMember" xlink:title="MeasurementInputConversionPriceMember"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MeasurementInputConversionPriceMember" xml:lang="en-US" id="label_MeasurementInputConversionPriceMember">Measurement Input Conversion Price [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputConversionPriceMember" xlink:to="label_MeasurementInputConversionPriceMember" xlink:title="label_MeasurementInputConversionPriceMember"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputConversionPriceMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MeasurementInputConversionPriceMember_1" xml:lang="en-US" id="label_MeasurementInputConversionPriceMember_1">Measurement Input, Conversion Price [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputConversionPriceMember" xlink:to="label_MeasurementInputConversionPriceMember_1" xlink:title="label_MeasurementInputConversionPriceMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MeasurementInputExpectedTermMember" xml:lang="en-US" id="label_MeasurementInputExpectedTermMember">Measurement Input Expected Term [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedTermMember" xlink:to="label_MeasurementInputExpectedTermMember" xlink:title="label_MeasurementInputExpectedTermMember"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputExpectedTermMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MeasurementInputExpectedTermMember_1" xml:lang="en-US" id="label_MeasurementInputExpectedTermMember_1">Measurement Input, Expected Term [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedTermMember" xlink:to="label_MeasurementInputExpectedTermMember_1" xlink:title="label_MeasurementInputExpectedTermMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MeasurementInputPriceVolatilityMember" xml:lang="en-US" id="label_MeasurementInputPriceVolatilityMember">Measurement Input Price Volatility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputPriceVolatilityMember" xlink:to="label_MeasurementInputPriceVolatilityMember" xlink:title="label_MeasurementInputPriceVolatilityMember"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputPriceVolatilityMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MeasurementInputPriceVolatilityMember_1" xml:lang="en-US" id="label_MeasurementInputPriceVolatilityMember_1">Measurement Input, Price Volatility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputPriceVolatilityMember" xlink:to="label_MeasurementInputPriceVolatilityMember_1" xlink:title="label_MeasurementInputPriceVolatilityMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US" id="label_MeasurementInputRiskFreeInterestRateMember">Measurement Input Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputRiskFreeInterestRateMember" xlink:to="label_MeasurementInputRiskFreeInterestRateMember" xlink:title="label_MeasurementInputRiskFreeInterestRateMember"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputRiskFreeInterestRateMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MeasurementInputRiskFreeInterestRateMember_1" xml:lang="en-US" id="label_MeasurementInputRiskFreeInterestRateMember_1">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputRiskFreeInterestRateMember" xlink:to="label_MeasurementInputRiskFreeInterestRateMember_1" xlink:title="label_MeasurementInputRiskFreeInterestRateMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="MeasurementInputSharePriceMember" xlink:title="MeasurementInputSharePriceMember"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MeasurementInputSharePriceMember" xml:lang="en-US" id="label_MeasurementInputSharePriceMember">Measurement Input Share Price [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputSharePriceMember" xlink:to="label_MeasurementInputSharePriceMember" xlink:title="label_MeasurementInputSharePriceMember"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputSharePriceMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MeasurementInputSharePriceMember_1" xml:lang="en-US" id="label_MeasurementInputSharePriceMember_1">Measurement Input, Share Price [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputSharePriceMember" xlink:to="label_MeasurementInputSharePriceMember_1" xlink:title="label_MeasurementInputSharePriceMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MeasurementInputTypeAxis" xml:lang="en-US" id="label_MeasurementInputTypeAxis">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeAxis" xlink:to="label_MeasurementInputTypeAxis" xlink:title="label_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MeasurementInputTypeDomain" xml:lang="en-US" id="label_MeasurementInputTypeDomain">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeDomain" xlink:to="label_MeasurementInputTypeDomain" xlink:title="label_MeasurementInputTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_MeasurementInputTypeDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MeasurementInputTypeDomain_1" xml:lang="en-US" id="label_MeasurementInputTypeDomain_1">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeDomain" xlink:to="label_MeasurementInputTypeDomain_1" xlink:title="label_MeasurementInputTypeDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember"/>
    <link:label xlink:type="resource" xlink:label="label_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MoneyMarketFundsMember" xml:lang="en-US" id="label_MoneyMarketFundsMember">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MoneyMarketFundsMember" xlink:to="label_MoneyMarketFundsMember" xlink:title="label_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities"/>
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivities">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="label_NetCashProvidedByUsedInFinancingActivities" xlink:title="label_NetCashProvidedByUsedInFinancingActivities"/>
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivities_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivities_1">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="label_NetCashProvidedByUsedInFinancingActivities_1" xlink:title="label_NetCashProvidedByUsedInFinancingActivities_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesAbstract">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities"/>
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivities">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="label_NetCashProvidedByUsedInInvestingActivities" xlink:title="label_NetCashProvidedByUsedInInvestingActivities"/>
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivities_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivities_1">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="label_NetCashProvidedByUsedInInvestingActivities_1" xlink:title="label_NetCashProvidedByUsedInInvestingActivities_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesAbstract">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities"/>
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivities">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="label_NetCashProvidedByUsedInOperatingActivities" xlink:title="label_NetCashProvidedByUsedInOperatingActivities"/>
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivities_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivities_1">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="label_NetCashProvidedByUsedInOperatingActivities_1" xlink:title="label_NetCashProvidedByUsedInOperatingActivities_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesAbstract">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss"/>
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLoss" xml:lang="en-US" id="label_NetIncomeLoss">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss" xlink:title="label_NetIncomeLoss"/>
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLoss_1" xml:lang="en-US" id="label_NetIncomeLoss_1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss_1" xlink:title="label_NetIncomeLoss_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="label_NewAccountingPronouncementsPolicyPolicyTextBlock">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US" id="label_NoncashInvestingAndFinancingItemsAbstract">Non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="label_NoncashInvestingAndFinancingItemsAbstract" xlink:title="label_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:label xlink:type="resource" xlink:label="label_NonmonetaryTransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonmonetaryTransactionTypeAxis" xml:lang="en-US" id="label_NonmonetaryTransactionTypeAxis">Nonmonetary Transaction Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="label_NonmonetaryTransactionTypeAxis" xlink:title="label_NonmonetaryTransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_NonmonetaryTransactionTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonmonetaryTransactionTypeDomain" xml:lang="en-US" id="label_NonmonetaryTransactionTypeDomain">Nonmonetary Transaction Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonmonetaryTransactionTypeDomain" xlink:to="label_NonmonetaryTransactionTypeDomain" xlink:title="label_NonmonetaryTransactionTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense"/>
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonoperatingIncomeExpense" xml:lang="en-US" id="label_NonoperatingIncomeExpense">Other income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="label_NonoperatingIncomeExpense" xlink:title="label_NonoperatingIncomeExpense"/>
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonoperatingIncomeExpense" xml:lang="en-US" id="label_NonoperatingIncomeExpense_2">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="label_NonoperatingIncomeExpense_2" xlink:title="label: NonoperatingIncomeExpense to label_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="NotesPayable" xlink:title="NotesPayable"/>
    <link:label xlink:type="resource" xlink:label="label_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NotesPayable" xml:lang="en-US" id="label_NotesPayable">us-gaap_NotesPayable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayable" xlink:to="label_NotesPayable" xlink:title="label_NotesPayable"/>
    <link:label xlink:type="resource" xlink:label="label_NotesPayable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NotesPayable_1" xml:lang="en-US" id="label_NotesPayable_1">Notes Payable, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayable" xlink:to="label_NotesPayable_1" xlink:title="label_NotesPayable_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:title="NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:label xlink:type="resource" xlink:label="label_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NotesPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US" id="label_NotesPayableRelatedPartiesCurrentAndNoncurrent">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="label_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:title="label_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:label xlink:type="resource" xlink:label="label_NotesPayableRelatedPartiesCurrentAndNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NotesPayableRelatedPartiesCurrentAndNoncurrent_1" xml:lang="en-US" id="label_NotesPayableRelatedPartiesCurrentAndNoncurrent_1">Notes Payable, Related Parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="label_NotesPayableRelatedPartiesCurrentAndNoncurrent_1" xlink:title="label_NotesPayableRelatedPartiesCurrentAndNoncurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember"/>
    <link:label xlink:type="resource" xlink:label="label_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OfficeEquipmentMember" xml:lang="en-US" id="label_OfficeEquipmentMember">Office Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeEquipmentMember" xlink:to="label_OfficeEquipmentMember" xlink:title="label_OfficeEquipmentMember"/>
    <link:label xlink:type="resource" xlink:label="label_OfficeEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OfficeEquipmentMember_1" xml:lang="en-US" id="label_OfficeEquipmentMember_1">Office Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeEquipmentMember" xlink:to="label_OfficeEquipmentMember_1" xlink:title="label_OfficeEquipmentMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="OpenTaxYear" xlink:title="OpenTaxYear"/>
    <link:label xlink:type="resource" xlink:label="label_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OpenTaxYear" xml:lang="en-US" id="label_OpenTaxYear">us-gaap_OpenTaxYear</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OpenTaxYear" xlink:to="label_OpenTaxYear" xlink:title="label_OpenTaxYear"/>
    <link:label xlink:type="resource" xlink:label="label_OpenTaxYear_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OpenTaxYear_1" xml:lang="en-US" id="label_OpenTaxYear_1">Open Tax Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OpenTaxYear" xlink:to="label_OpenTaxYear_1" xlink:title="label_OpenTaxYear_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingExpenses" xml:lang="en-US" id="label_OperatingExpenses">us-gaap_OperatingExpenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="label_OperatingExpenses" xlink:title="label_OperatingExpenses"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingExpenses_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_OperatingExpenses_1" xml:lang="en-US" id="label_OperatingExpenses_1">Total operating expenses, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="label_OperatingExpenses_1" xlink:title="label_OperatingExpenses_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingExpensesAbstract" xml:lang="en-US" id="label_OperatingExpensesAbstract">Operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="label_OperatingExpensesAbstract" xlink:title="label_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingIncomeLoss" xml:lang="en-US" id="label_OperatingIncomeLoss">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss" xlink:title="label_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeaseExpense" xml:lang="en-US" id="label_OperatingLeaseExpense">us-gaap_OperatingLeaseExpense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseExpense" xlink:to="label_OperatingLeaseExpense" xlink:title="label_OperatingLeaseExpense"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeaseExpense_1" xml:lang="en-US" id="label_OperatingLeaseExpense_1">Operating Lease, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseExpense" xlink:to="label_OperatingLeaseExpense_1" xlink:title="label_OperatingLeaseExpense_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeaseLiability" xml:lang="en-US" id="label_OperatingLeaseLiability">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="label_OperatingLeaseLiability" xlink:title="label_OperatingLeaseLiability"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseLiability_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeaseLiability_1" xml:lang="en-US" id="label_OperatingLeaseLiability_1">Operating Lease, Liability, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="label_OperatingLeaseLiability_1" xlink:title="label_OperatingLeaseLiability_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeaseLiabilityCurrent" xml:lang="en-US" id="label_OperatingLeaseLiabilityCurrent">Current portion of operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="label_OperatingLeaseLiabilityCurrent" xlink:title="label_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US" id="label_OperatingLeaseLiabilityNoncurrent">Operating lease liability, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="label_OperatingLeaseLiabilityNoncurrent" xlink:title="label_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeaseRightOfUseAsset" xml:lang="en-US" id="label_OperatingLeaseRightOfUseAsset">Right of use asset, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="label_OperatingLeaseRightOfUseAsset" xlink:title="label_OperatingLeaseRightOfUseAsset"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseRightOfUseAsset_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeaseRightOfUseAsset_1" xml:lang="en-US" id="label_OperatingLeaseRightOfUseAsset_1">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="label_OperatingLeaseRightOfUseAsset_1" xlink:title="label_OperatingLeaseRightOfUseAsset_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLossCarryforwards" xml:lang="en-US" id="label_OperatingLossCarryforwards">us-gaap_OperatingLossCarryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="label_OperatingLossCarryforwards" xlink:title="label_OperatingLossCarryforwards"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwards_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLossCarryforwards_1" xml:lang="en-US" id="label_OperatingLossCarryforwards_1">Operating Loss Carryforwards, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="label_OperatingLossCarryforwards_1" xlink:title="label_OperatingLossCarryforwards_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="OperatingLossCarryforwardsExpirationDate" xlink:title="OperatingLossCarryforwardsExpirationDate"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US" id="label_OperatingLossCarryforwardsExpirationDate">us-gaap_OperatingLossCarryforwardsExpirationDate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsExpirationDate" xlink:to="label_OperatingLossCarryforwardsExpirationDate" xlink:title="label_OperatingLossCarryforwardsExpirationDate"/>
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwardsExpirationDate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLossCarryforwardsExpirationDate_1" xml:lang="en-US" id="label_OperatingLossCarryforwardsExpirationDate_1">Operating Loss Carryforwards, Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsExpirationDate" xlink:to="label_OperatingLossCarryforwardsExpirationDate_1" xlink:title="label_OperatingLossCarryforwardsExpirationDate_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US" id="label_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="label_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="label_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent"/>
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAssetsNoncurrent" xml:lang="en-US" id="label_OtherAssetsNoncurrent">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="label_OtherAssetsNoncurrent" xlink:title="label_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense"/>
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherNonoperatingIncomeExpense" xml:lang="en-US" id="label_OtherNonoperatingIncomeExpense">Other income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="label_OtherNonoperatingIncomeExpense" xlink:title="label_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="OtherPrepaidExpenseCurrent" xlink:title="OtherPrepaidExpenseCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherPrepaidExpenseCurrent" xml:lang="en-US" id="label_OtherPrepaidExpenseCurrent">Other prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherPrepaidExpenseCurrent" xlink:to="label_OtherPrepaidExpenseCurrent" xlink:title="label_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest"/>
    <link:label xlink:type="resource" xlink:label="label_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaidInKindInterest" xml:lang="en-US" id="label_PaidInKindInterest">Non-cash interest expense on convertible promissory notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaidInKindInterest" xlink:to="label_PaidInKindInterest" xlink:title="label_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="PaymentsForProceedsFromProductiveAssets" xlink:title="PaymentsForProceedsFromProductiveAssets"/>
    <link:label xlink:type="resource" xlink:label="label_PaymentsForProceedsFromProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsForProceedsFromProductiveAssets" xml:lang="en-US" id="label_PaymentsForProceedsFromProductiveAssets">us-gaap_PaymentsForProceedsFromProductiveAssets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForProceedsFromProductiveAssets" xlink:to="label_PaymentsForProceedsFromProductiveAssets" xlink:title="label_PaymentsForProceedsFromProductiveAssets"/>
    <link:label xlink:type="resource" xlink:label="label_PaymentsForProceedsFromProductiveAssets_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsForProceedsFromProductiveAssets_1" xml:lang="en-US" id="label_PaymentsForProceedsFromProductiveAssets_1">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForProceedsFromProductiveAssets" xlink:to="label_PaymentsForProceedsFromProductiveAssets_1" xlink:title="label_PaymentsForProceedsFromProductiveAssets_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="PaymentsOfDividends" xlink:title="PaymentsOfDividends"/>
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsOfDividends" xml:lang="en-US" id="label_PaymentsOfDividends">us-gaap_PaymentsOfDividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDividends" xlink:to="label_PaymentsOfDividends" xlink:title="label_PaymentsOfDividends"/>
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfDividends_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PaymentsOfDividends_1" xml:lang="en-US" id="label_PaymentsOfDividends_1">Payments of Dividends, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDividends" xlink:to="label_PaymentsOfDividends_1" xlink:title="label_PaymentsOfDividends_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis"/>
    <link:label xlink:type="resource" xlink:label="label_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PlanNameAxis" xml:lang="en-US" id="label_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="label_PlanNameAxis" xlink:title="label_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PlanNameDomain" xml:lang="en-US" id="label_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="label_PlanNameDomain" xlink:title="label_PlanNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_PlanNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PlanNameDomain_1" xml:lang="en-US" id="label_PlanNameDomain_1">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="label_PlanNameDomain_1" xlink:title="label_PlanNameDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="PolicyTextBlockAbstract" xlink:title="PolicyTextBlockAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_PolicyTextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PolicyTextBlockAbstract" xml:lang="en-US" id="label_PolicyTextBlockAbstract">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PolicyTextBlockAbstract" xlink:to="label_PolicyTextBlockAbstract" xlink:title="label_PolicyTextBlockAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_PolicyTextBlockAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PolicyTextBlockAbstract_1" xml:lang="en-US" id="label_PolicyTextBlockAbstract_1">Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PolicyTextBlockAbstract" xlink:to="label_PolicyTextBlockAbstract_1" xlink:title="label_PolicyTextBlockAbstract_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="PreferredStockDividendsPerShareDeclared" xlink:title="PreferredStockDividendsPerShareDeclared"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockDividendsPerShareDeclared" xml:lang="en-US" id="label_PreferredStockDividendsPerShareDeclared">us-gaap_PreferredStockDividendsPerShareDeclared</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsPerShareDeclared" xlink:to="label_PreferredStockDividendsPerShareDeclared" xlink:title="label_PreferredStockDividendsPerShareDeclared"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockDividendsPerShareDeclared_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockDividendsPerShareDeclared_1" xml:lang="en-US" id="label_PreferredStockDividendsPerShareDeclared_1">Preferred Stock, Dividends Per Share, Declared</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsPerShareDeclared" xlink:to="label_PreferredStockDividendsPerShareDeclared_1" xlink:title="label_PreferredStockDividendsPerShareDeclared_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockMember" xml:lang="en-US" id="label_PreferredStockMember">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="label_PreferredStockMember" xlink:title="label_PreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockMember_1" xml:lang="en-US" id="label_PreferredStockMember_1">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="label_PreferredStockMember_1" xlink:title="label_PreferredStockMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockParOrStatedValuePerShare" xml:lang="en-US" id="label_PreferredStockParOrStatedValuePerShare">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="label_PreferredStockParOrStatedValuePerShare" xlink:title="label_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesAuthorized" xml:lang="en-US" id="label_PreferredStockSharesAuthorized">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized" xlink:title="label_PreferredStockSharesAuthorized"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesAuthorized_1" xml:lang="en-US" id="label_PreferredStockSharesAuthorized_1">Preferred Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized_1" xlink:title="label_PreferredStockSharesAuthorized_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesIssued" xml:lang="en-US" id="label_PreferredStockSharesIssued">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="label_PreferredStockSharesIssued" xlink:title="label_PreferredStockSharesIssued"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesIssued_1" xml:lang="en-US" id="label_PreferredStockSharesIssued_1">Preferred Stock, Shares Issued, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="label_PreferredStockSharesIssued_1" xlink:title="label_PreferredStockSharesIssued_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesOutstanding" xml:lang="en-US" id="label_PreferredStockSharesOutstanding">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="label_PreferredStockSharesOutstanding" xlink:title="label_PreferredStockSharesOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesOutstanding_1" xml:lang="en-US" id="label_PreferredStockSharesOutstanding_1">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="label_PreferredStockSharesOutstanding_1" xlink:title="label_PreferredStockSharesOutstanding_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="PreferredStockTextBlock" xlink:title="PreferredStockTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockTextBlock" xml:lang="en-US" id="label_PreferredStockTextBlock">Preferred Stock [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockTextBlock" xlink:to="label_PreferredStockTextBlock" xlink:title="label_PreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue"/>
    <link:label xlink:type="resource" xlink:label="label_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockValue" xml:lang="en-US" id="label_PreferredStockValue">Preferred stock, $0.001 par value; 1,000,000 shares authorized no shares issued or outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="label_PreferredStockValue" xlink:title="label_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent_1">Total prepaid and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="PrepaidInsurance" xlink:title="PrepaidInsurance"/>
    <link:label xlink:type="resource" xlink:label="label_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidInsurance" xml:lang="en-US" id="label_PrepaidInsurance">Prepaid insurance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidInsurance" xlink:to="label_PrepaidInsurance" xlink:title="label_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromConvertibleDebt" xml:lang="en-US" id="label_ProceedsFromConvertibleDebt">us-gaap_ProceedsFromConvertibleDebt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConvertibleDebt" xlink:to="label_ProceedsFromConvertibleDebt" xlink:title="label_ProceedsFromConvertibleDebt"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromConvertibleDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromConvertibleDebt_1" xml:lang="en-US" id="label_ProceedsFromConvertibleDebt_1">Proceeds from Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConvertibleDebt" xlink:to="label_ProceedsFromConvertibleDebt_1" xlink:title="label_ProceedsFromConvertibleDebt_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="ProceedsFromIssuanceOfDebt" xlink:title="ProceedsFromIssuanceOfDebt"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfDebt" xml:lang="en-US" id="label_ProceedsFromIssuanceOfDebt">us-gaap_ProceedsFromIssuanceOfDebt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfDebt" xlink:to="label_ProceedsFromIssuanceOfDebt" xlink:title="label_ProceedsFromIssuanceOfDebt"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfDebt_1" xml:lang="en-US" id="label_ProceedsFromIssuanceOfDebt_1">Proceeds from Issuance of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfDebt" xlink:to="label_ProceedsFromIssuanceOfDebt_1" xlink:title="label_ProceedsFromIssuanceOfDebt_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="ProceedsFromMinorityShareholders" xlink:title="ProceedsFromMinorityShareholders"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromMinorityShareholders" xml:lang="en-US" id="label_ProceedsFromMinorityShareholders">us-gaap_ProceedsFromMinorityShareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromMinorityShareholders" xlink:to="label_ProceedsFromMinorityShareholders" xlink:title="label_ProceedsFromMinorityShareholders"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromMinorityShareholders_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromMinorityShareholders_1" xml:lang="en-US" id="label_ProceedsFromMinorityShareholders_1">Proceeds from Noncontrolling Interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromMinorityShareholders" xlink:to="label_ProceedsFromMinorityShareholders_1" xlink:title="label_ProceedsFromMinorityShareholders_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromNotesPayable" xml:lang="en-US" id="label_ProceedsFromNotesPayable">us-gaap_ProceedsFromNotesPayable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNotesPayable" xlink:to="label_ProceedsFromNotesPayable" xlink:title="label_ProceedsFromNotesPayable"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromNotesPayable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromNotesPayable_1" xml:lang="en-US" id="label_ProceedsFromNotesPayable_1">Proceeds from Notes Payable, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNotesPayable" xlink:to="label_ProceedsFromNotesPayable_1" xlink:title="label_ProceedsFromNotesPayable_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="ProceedsFromRelatedPartyDebt" xlink:title="ProceedsFromRelatedPartyDebt"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromRelatedPartyDebt" xml:lang="en-US" id="label_ProceedsFromRelatedPartyDebt">Proceeds from issuance of convertible promissory notes - related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromRelatedPartyDebt" xlink:to="label_ProceedsFromRelatedPartyDebt" xlink:title="label_ProceedsFromRelatedPartyDebt"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromRelatedPartyDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromRelatedPartyDebt_1" xml:lang="en-US" id="label_ProceedsFromRelatedPartyDebt_1">Proceeds from Related Party Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromRelatedPartyDebt" xlink:to="label_ProceedsFromRelatedPartyDebt_1" xlink:title="label_ProceedsFromRelatedPartyDebt_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromWarrantExercises" xml:lang="en-US" id="label_ProceedsFromWarrantExercises">Proceeds from exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromWarrantExercises" xlink:to="label_ProceedsFromWarrantExercises" xlink:title="label_ProceedsFromWarrantExercises"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis"/>
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US" id="label_PropertyPlantAndEquipmentByTypeAxis">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="label_PropertyPlantAndEquipmentByTypeAxis" xlink:title="label_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentDisclosureTextBlock">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross"/>
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentGross" xml:lang="en-US" id="label_PropertyPlantAndEquipmentGross">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="label_PropertyPlantAndEquipmentGross" xlink:title="label_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet"/>
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet" xlink:title="label_PropertyPlantAndEquipmentNet"/>
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_PropertyPlantAndEquipmentNet_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet_1">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet_1" xlink:title="label_PropertyPlantAndEquipmentNet_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentPolicyTextBlock">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="label_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="label_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentTextBlock">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="label_PropertyPlantAndEquipmentTextBlock" xlink:title="label_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US" id="label_PropertyPlantAndEquipmentTypeDomain">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="label_PropertyPlantAndEquipmentTypeDomain" xlink:title="label_PropertyPlantAndEquipmentTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentTypeDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentTypeDomain_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentTypeDomain_1">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="label_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="label_PropertyPlantAndEquipmentTypeDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife"/>
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US" id="label_PropertyPlantAndEquipmentUsefulLife">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="label_PropertyPlantAndEquipmentUsefulLife" xlink:title="label_PropertyPlantAndEquipmentUsefulLife"/>
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentUsefulLife_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentUsefulLife_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentUsefulLife_1">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="label_PropertyPlantAndEquipmentUsefulLife_1" xlink:title="label_PropertyPlantAndEquipmentUsefulLife_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:label="RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:title="RedeemableNoncontrollingInterestEquityCarryingAmountAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xml:lang="en-US" id="label_RedeemableNoncontrollingInterestEquityCarryingAmountAbstract">Redeemable convertible preferred stock:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:to="label_RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:title="label_RedeemableNoncontrollingInterestEquityCarryingAmountAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain"/>
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyDomain" xml:lang="en-US" id="label_RelatedPartyDomain">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="label_RelatedPartyDomain" xlink:title="label_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="RelatedPartyTransactionAmountsOfTransaction" xlink:title="RelatedPartyTransactionAmountsOfTransaction"/>
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US" id="label_RelatedPartyTransactionAmountsOfTransaction">us-gaap_RelatedPartyTransactionAmountsOfTransaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAmountsOfTransaction" xlink:to="label_RelatedPartyTransactionAmountsOfTransaction" xlink:title="label_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionAmountsOfTransaction_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RelatedPartyTransactionAmountsOfTransaction_1" xml:lang="en-US" id="label_RelatedPartyTransactionAmountsOfTransaction_1">Related Party Transaction, Amounts of Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAmountsOfTransaction" xlink:to="label_RelatedPartyTransactionAmountsOfTransaction_1" xlink:title="label_RelatedPartyTransactionAmountsOfTransaction_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis"/>
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionAxis" xml:lang="en-US" id="label_RelatedPartyTransactionAxis">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAxis" xlink:to="label_RelatedPartyTransactionAxis" xlink:title="label_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain"/>
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionDomain" xml:lang="en-US" id="label_RelatedPartyTransactionDomain">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDomain" xlink:to="label_RelatedPartyTransactionDomain" xlink:title="label_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US" id="label_RelatedPartyTransactionsByRelatedPartyAxis">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="label_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="label_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US" id="label_RelatedPartyTransactionsDisclosureTextBlock">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="label_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="label_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt"/>
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RepaymentsOfLongTermDebt" xml:lang="en-US" id="label_RepaymentsOfLongTermDebt">us-gaap_RepaymentsOfLongTermDebt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermDebt" xlink:to="label_RepaymentsOfLongTermDebt" xlink:title="label_RepaymentsOfLongTermDebt"/>
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfLongTermDebt_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RepaymentsOfLongTermDebt_1" xml:lang="en-US" id="label_RepaymentsOfLongTermDebt_1">Payments on term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermDebt" xlink:to="label_RepaymentsOfLongTermDebt_1" xlink:title="label_RepaymentsOfLongTermDebt_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US" id="label_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="label_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="label_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US" id="label_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="label_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="label_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xml:lang="en-US" id="label_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="label_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="label_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense"/>
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense" xlink:title="label_ResearchAndDevelopmentExpense"/>
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpense_1" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense_1">Research and Development Expense, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense_1" xlink:title="label_ResearchAndDevelopmentExpense_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember"/>
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="label_ResearchAndDevelopmentExpenseMember">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="label_ResearchAndDevelopmentExpenseMember" xlink:title="label_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy"/>
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US" id="label_ResearchAndDevelopmentExpensePolicy">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="label_ResearchAndDevelopmentExpensePolicy" xlink:title="label_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember"/>
    <link:label xlink:type="resource" xlink:label="label_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchMember" xml:lang="en-US" id="label_ResearchMember">Research [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchMember" xlink:to="label_ResearchMember" xlink:title="label_ResearchMember"/>
    <link:label xlink:type="resource" xlink:label="label_ResearchMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchMember_1" xml:lang="en-US" id="label_ResearchMember_1">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchMember" xlink:to="label_ResearchMember_1" xlink:title="label_ResearchMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="RestrictedCash" xlink:title="RestrictedCash"/>
    <link:label xlink:type="resource" xlink:label="label_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestrictedCash" xml:lang="en-US" id="label_RestrictedCash">us-gaap_RestrictedCash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCash" xlink:to="label_RestrictedCash" xlink:title="label_RestrictedCash"/>
    <link:label xlink:type="resource" xlink:label="label_RestrictedCash_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RestrictedCash_1" xml:lang="en-US" id="label_RestrictedCash_1">Restricted Cash, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCash" xlink:to="label_RestrictedCash_1" xlink:title="label_RestrictedCash_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:label xlink:type="resource" xlink:label="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xml:lang="en-US" id="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:title="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:label xlink:type="resource" xlink:label="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US" id="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:label xlink:type="resource" xlink:label="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xml:lang="en-US" id="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="RestrictedCashCurrent" xlink:title="RestrictedCashCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestrictedCashCurrent" xml:lang="en-US" id="label_RestrictedCashCurrent">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashCurrent" xlink:to="label_RestrictedCashCurrent" xlink:title="label_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="RestrictedCashNoncurrent" xlink:title="RestrictedCashNoncurrent"/>
    <link:label xlink:type="resource" xlink:label="label_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestrictedCashNoncurrent" xml:lang="en-US" id="label_RestrictedCashNoncurrent">us-gaap_RestrictedCashNoncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashNoncurrent" xlink:to="label_RestrictedCashNoncurrent" xlink:title="label_RestrictedCashNoncurrent"/>
    <link:label xlink:type="resource" xlink:label="label_RestrictedCashNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RestrictedCashNoncurrent_1" xml:lang="en-US" id="label_RestrictedCashNoncurrent_1">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashNoncurrent" xlink:to="label_RestrictedCashNoncurrent_1" xlink:title="label_RestrictedCashNoncurrent_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit"/>
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit" xlink:title="label_RetainedEarningsAccumulatedDeficit"/>
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit_1">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit_1" xlink:title="label_RetainedEarningsAccumulatedDeficit_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember"/>
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsMember" xml:lang="en-US" id="label_RetainedEarningsMember">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="label_RetainedEarningsMember" xlink:title="label_RetainedEarningsMember"/>
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsMember_1" xml:lang="en-US" id="label_RetainedEarningsMember_1">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="label_RetainedEarningsMember_1" xlink:title="label_RetainedEarningsMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:label xlink:type="resource" xlink:label="label_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US" id="label_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">Right-of-use assets obtained in exchange for operating lease obligations(1)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="label_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="label_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US" id="label_ScheduleOfAccruedLiabilitiesTableTextBlock">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="label_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="label_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="ScheduleOfDebtInstrumentsTextBlock" xlink:title="ScheduleOfDebtInstrumentsTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US" id="label_ScheduleOfDebtInstrumentsTextBlock">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDebtInstrumentsTextBlock" xlink:to="label_ScheduleOfDebtInstrumentsTextBlock" xlink:title="label_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US" id="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US" id="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US" id="label_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="label_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="label_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US" id="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US" id="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="ScheduleOfStockholdersEquityTableTextBlock" xlink:title="ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfStockholdersEquityTableTextBlock" xml:lang="en-US" id="label_ScheduleOfStockholdersEquityTableTextBlock">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockholdersEquityTableTextBlock" xlink:to="label_ScheduleOfStockholdersEquityTableTextBlock" xlink:title="label_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesAPreferredStockMember" xml:lang="en-US" id="label_SeriesAPreferredStockMember">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="label_SeriesAPreferredStockMember" xlink:title="label_SeriesAPreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesAPreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesAPreferredStockMember_1" xml:lang="en-US" id="label_SeriesAPreferredStockMember_1">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="label_SeriesAPreferredStockMember_1" xlink:title="label_SeriesAPreferredStockMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesBPreferredStockMember" xml:lang="en-US" id="label_SeriesBPreferredStockMember">Series B Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockMember" xlink:to="label_SeriesBPreferredStockMember" xlink:title="label_SeriesBPreferredStockMember"/>
    <link:label xlink:type="resource" xlink:label="label_SeriesBPreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesBPreferredStockMember_1" xml:lang="en-US" id="label_SeriesBPreferredStockMember_1">Series B Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockMember" xlink:to="label_SeriesBPreferredStockMember_1" xlink:title="label_SeriesBPreferredStockMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensation" xml:lang="en-US" id="label_ShareBasedCompensation">us-gaap_ShareBasedCompensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation" xlink:title="label_ShareBasedCompensation"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensation_1" xml:lang="en-US" id="label_ShareBasedCompensation_1">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation_1" xlink:title="label_ShareBasedCompensation_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">Shares Available For Grant, Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">Intrinsic Value, exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">Number of Options, exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">Weighted Average Exercise Price, exercisable (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">Weighted Average Remaining Life in Years, exercisable (Year)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">Number of Options, cancelled (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">Intrinsic Value, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">Number of Options, Alliqua options assumed in merger (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2">Number of Options, outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3">Number of Options, outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">Weighted Average Exercise Price, Alliqua options assumed in merger (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1">Weighted Average Exercise Price, outstanding (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2">Weighted Average Exercise Price, outstanding (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">Weighted Average Remaining Life in Years, outstanding (Year)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">Options Outstanding, Vested and expected to vest (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">Weighted Average Exercise Price Per Share, Vested and expected to vest (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">Weighted-average Remaining Contractual Life, Vested and expected to vest (Year)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">Weighted Average Exercise Price, exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">Weighted Average Exercise Price, cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="label_ShareBasedCompensationOptionAndIncentivePlansPolicy">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US" id="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US" id="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain">Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xml:lang="en-US" id="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">Options Exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">Options Exercisable, weighted average remaining life in years (Year)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US" id="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">Range of Exercise Price, lower (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US" id="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">Options exercisable, number of options exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US" id="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">Options Outstanding, number of options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xml:lang="en-US" id="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">Options Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="label_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US" id="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">Range of Exercise Price, upper (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="label_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xml:lang="en-US" id="label_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">Supplier [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="label_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:title="label_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xml:lang="en-US" id="label_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain">Supplier [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="label_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="label_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:label xlink:type="resource" xlink:label="label_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_1" xml:lang="en-US" id="label_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_1">Supplier [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="label_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_1" xlink:title="label_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice"/>
    <link:label xlink:type="resource" xlink:label="label_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharePrice" xml:lang="en-US" id="label_SharePrice">us-gaap_SharePrice</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="label_SharePrice" xlink:title="label_SharePrice"/>
    <link:label xlink:type="resource" xlink:label="label_SharePrice_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharePrice_1" xml:lang="en-US" id="label_SharePrice_1">Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="label_SharePrice_1" xlink:title="label_SharePrice_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharesOutstanding" xml:lang="en-US" id="label_SharesOutstanding">us-gaap_SharesOutstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="label_SharesOutstanding" xlink:title="label_SharesOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_SharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_SharesOutstanding_1" xml:lang="en-US" id="label_SharesOutstanding_1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="label_SharesOutstanding_1" xlink:title="label_SharesOutstanding_1"/>
    <link:label xlink:type="resource" xlink:label="label_SharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_SharesOutstanding_2" xml:lang="en-US" id="label_SharesOutstanding_2">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="label_SharesOutstanding_2" xlink:title="label_SharesOutstanding_2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_SignificantAccountingPoliciesTextBlock">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="label_SignificantAccountingPoliciesTextBlock" xlink:title="label_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember"/>
    <link:label xlink:type="resource" xlink:label="label_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StateAndLocalJurisdictionMember" xml:lang="en-US" id="label_StateAndLocalJurisdictionMember">State And Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="label_StateAndLocalJurisdictionMember" xlink:title="label_StateAndLocalJurisdictionMember"/>
    <link:label xlink:type="resource" xlink:label="label_StateAndLocalJurisdictionMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StateAndLocalJurisdictionMember_1" xml:lang="en-US" id="label_StateAndLocalJurisdictionMember_1">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="label_StateAndLocalJurisdictionMember_1" xlink:title="label_StateAndLocalJurisdictionMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:label xlink:type="resource" xlink:label="label_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementClassOfStockAxis" xml:lang="en-US" id="label_StatementClassOfStockAxis">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="label_StatementClassOfStockAxis" xlink:title="label_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis"/>
    <link:label xlink:type="resource" xlink:label="label_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementEquityComponentsAxis" xml:lang="en-US" id="label_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="label_StatementEquityComponentsAxis" xlink:title="label_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:label xlink:type="resource" xlink:label="label_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementLineItems" xml:lang="en-US" id="label_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="label_StatementLineItems" xlink:title="label_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_StatementOfCashFlowsAbstract">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="label_StatementOfCashFlowsAbstract" xlink:title="label_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_StatementOfFinancialPositionAbstract">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="label_StatementOfFinancialPositionAbstract" xlink:title="label_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="label_StatementOfStockholdersEquityAbstract">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="label_StatementOfStockholdersEquityAbstract" xlink:title="label_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:label xlink:type="resource" xlink:label="label_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementTable" xml:lang="en-US" id="label_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="label_StatementTable" xlink:title="label_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity"/>
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity">us-gaap_StockholdersEquity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity" xlink:title="label_StockholdersEquity"/>
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_StockholdersEquity_1" xml:lang="en-US" id="label_StockholdersEquity_1">Total stockholders' deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_1" xlink:title="label_StockholdersEquity_1"/>
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_StockholdersEquity_2" xml:lang="en-US" id="label_StockholdersEquity_2">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_2" xlink:title="label_StockholdersEquity_2"/>
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_StockholdersEquity_3" xml:lang="en-US" id="label_StockholdersEquity_3">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_3" xlink:title="label_StockholdersEquity_3"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityAbstract" xml:lang="en-US" id="label_StockholdersEquityAbstract">Stockholders' deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract" xlink:title="label_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_StockholdersEquityNoteDisclosureTextBlock">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_StockholdersEquityNoteDisclosureTextBlock" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US" id="label_StockholdersEquityNoteStockSplitConversionRatio1">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="label_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteStockSplitConversionRatio1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1_1" xml:lang="en-US" id="label_StockholdersEquityNoteStockSplitConversionRatio1_1">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="label_StockholdersEquityNoteStockSplitConversionRatio1_1" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesAcquisitions">Issuance of common stock for merger (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions" xlink:to="label_StockIssuedDuringPeriodSharesAcquisitions" xlink:title="label_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1">Conversion of convertible notes into convertible preferred stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesStockOptionsExercised">Number of Options, exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueAcquisitions">Issuance of common stock for merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="label_StockIssuedDuringPeriodValueAcquisitions" xlink:title="label_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">Conversion of convertible notes into convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome"/>
    <link:label xlink:type="resource" xlink:label="label_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubleaseIncome" xml:lang="en-US" id="label_SubleaseIncome">us-gaap_SubleaseIncome</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseIncome" xlink:to="label_SubleaseIncome" xlink:title="label_SubleaseIncome"/>
    <link:label xlink:type="resource" xlink:label="label_SubleaseIncome_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubleaseIncome_1" xml:lang="en-US" id="label_SubleaseIncome_1">Sublease Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseIncome" xlink:to="label_SubleaseIncome_1" xlink:title="label_SubleaseIncome_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember"/>
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventMember" xml:lang="en-US" id="label_SubsequentEventMember">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="label_SubsequentEventMember" xlink:title="label_SubsequentEventMember"/>
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventMember_1" xml:lang="en-US" id="label_SubsequentEventMember_1">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="label_SubsequentEventMember_1" xlink:title="label_SubsequentEventMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsTextBlock" xml:lang="en-US" id="label_SubsequentEventsTextBlock">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock" xlink:title="label_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis"/>
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTypeAxis" xml:lang="en-US" id="label_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="label_SubsequentEventTypeAxis" xlink:title="label_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTypeDomain" xml:lang="en-US" id="label_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="label_SubsequentEventTypeDomain" xlink:title="label_SubsequentEventTypeDomain"/>
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTypeDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventTypeDomain_1" xml:lang="en-US" id="label_SubsequentEventTypeDomain_1">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="label_SubsequentEventTypeDomain_1" xlink:title="label_SubsequentEventTypeDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="SummaryOfIncomeTaxContingenciesTextBlock" xlink:title="SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SummaryOfIncomeTaxContingenciesTextBlock" xml:lang="en-US" id="label_SummaryOfIncomeTaxContingenciesTextBlock">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="label_SummaryOfIncomeTaxContingenciesTextBlock" xlink:title="label_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US" id="label_SupplementalBalanceSheetDisclosuresTextBlock">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="label_SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="label_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract"/>
    <link:label xlink:type="resource" xlink:label="label_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_SupplementalCashFlowInformationAbstract">Other supplemental disclosure:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="label_SupplementalCashFlowInformationAbstract" xlink:title="label_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="SupplierConcentrationRiskMember" xlink:title="SupplierConcentrationRiskMember"/>
    <link:label xlink:type="resource" xlink:label="label_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SupplierConcentrationRiskMember" xml:lang="en-US" id="label_SupplierConcentrationRiskMember">Supplier Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplierConcentrationRiskMember" xlink:to="label_SupplierConcentrationRiskMember" xlink:title="label_SupplierConcentrationRiskMember"/>
    <link:label xlink:type="resource" xlink:label="label_SupplierConcentrationRiskMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SupplierConcentrationRiskMember_1" xml:lang="en-US" id="label_SupplierConcentrationRiskMember_1">Supplier Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplierConcentrationRiskMember" xlink:to="label_SupplierConcentrationRiskMember_1" xlink:title="label_SupplierConcentrationRiskMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TableTextBlock" xml:lang="en-US" id="label_TableTextBlock">us-gaap_TableTextBlock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TableTextBlock" xlink:to="label_TableTextBlock" xlink:title="label_TableTextBlock"/>
    <link:label xlink:type="resource" xlink:label="label_TableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TableTextBlock_1" xml:lang="en-US" id="label_TableTextBlock_1">Notes Tables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TableTextBlock" xlink:to="label_TableTextBlock_1" xlink:title="label_TableTextBlock_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount"/>
    <link:label xlink:type="resource" xlink:label="label_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TaxCreditCarryforwardAmount" xml:lang="en-US" id="label_TaxCreditCarryforwardAmount">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmount" xlink:to="label_TaxCreditCarryforwardAmount" xlink:title="label_TaxCreditCarryforwardAmount"/>
    <link:label xlink:type="resource" xlink:label="label_TaxCreditCarryforwardAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TaxCreditCarryforwardAmount_1" xml:lang="en-US" id="label_TaxCreditCarryforwardAmount_1">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmount" xlink:to="label_TaxCreditCarryforwardAmount_1" xlink:title="label_TaxCreditCarryforwardAmount_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis"/>
    <link:label xlink:type="resource" xlink:label="label_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TaxCreditCarryforwardAxis" xml:lang="en-US" id="label_TaxCreditCarryforwardAxis">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAxis" xlink:to="label_TaxCreditCarryforwardAxis" xlink:title="label_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="TaxCreditCarryforwardExpirationDate" xlink:title="TaxCreditCarryforwardExpirationDate"/>
    <link:label xlink:type="resource" xlink:label="label_TaxCreditCarryforwardExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TaxCreditCarryforwardExpirationDate" xml:lang="en-US" id="label_TaxCreditCarryforwardExpirationDate">us-gaap_TaxCreditCarryforwardExpirationDate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardExpirationDate" xlink:to="label_TaxCreditCarryforwardExpirationDate" xlink:title="label_TaxCreditCarryforwardExpirationDate"/>
    <link:label xlink:type="resource" xlink:label="label_TaxCreditCarryforwardExpirationDate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TaxCreditCarryforwardExpirationDate_1" xml:lang="en-US" id="label_TaxCreditCarryforwardExpirationDate_1">Tax Credit Carryforward, Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardExpirationDate" xlink:to="label_TaxCreditCarryforwardExpirationDate_1" xlink:title="label_TaxCreditCarryforwardExpirationDate_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TaxCreditCarryforwardNameDomain" xml:lang="en-US" id="label_TaxCreditCarryforwardNameDomain">Tax Credit Carryforward Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="label_TaxCreditCarryforwardNameDomain" xlink:title="label_TaxCreditCarryforwardNameDomain"/>
    <link:label xlink:type="resource" xlink:label="label_TaxCreditCarryforwardNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TaxCreditCarryforwardNameDomain_1" xml:lang="en-US" id="label_TaxCreditCarryforwardNameDomain_1">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="label_TaxCreditCarryforwardNameDomain_1" xlink:title="label_TaxCreditCarryforwardNameDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:label="TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:title="TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:label xlink:type="resource" xlink:label="label_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xml:lang="en-US" id="label_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:to="label_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:title="label_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:label xlink:type="resource" xlink:label="label_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_1" xml:lang="en-US" id="label_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_1">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:to="label_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_1" xlink:title="label_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis"/>
    <link:label xlink:type="resource" xlink:label="label_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TaxPeriodAxis" xml:lang="en-US" id="label_TaxPeriodAxis">Tax Period [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPeriodAxis" xlink:to="label_TaxPeriodAxis" xlink:title="label_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain"/>
    <link:label xlink:type="resource" xlink:label="label_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TaxPeriodDomain" xml:lang="en-US" id="label_TaxPeriodDomain">Tax Period [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPeriodDomain" xlink:to="label_TaxPeriodDomain" xlink:title="label_TaxPeriodDomain"/>
    <link:label xlink:type="resource" xlink:label="label_TaxPeriodDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TaxPeriodDomain_1" xml:lang="en-US" id="label_TaxPeriodDomain_1">Tax Period [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPeriodDomain" xlink:to="label_TaxPeriodDomain_1" xlink:title="label_TaxPeriodDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US" id="label_TemporaryEquityCarryingAmountAttributableToParent">Redeemable convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="label_TemporaryEquityCarryingAmountAttributableToParent" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="TemporaryEquityLiquidationPreference" xlink:title="TemporaryEquityLiquidationPreference"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityLiquidationPreference" xml:lang="en-US" id="label_TemporaryEquityLiquidationPreference">Redeemable convertible preferred stock, liquidation value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationPreference" xlink:to="label_TemporaryEquityLiquidationPreference" xlink:title="label_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="TemporaryEquityLiquidationPreferencePerShare" xlink:title="TemporaryEquityLiquidationPreferencePerShare"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationPreferencePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityLiquidationPreferencePerShare" xml:lang="en-US" id="label_TemporaryEquityLiquidationPreferencePerShare">us-gaap_TemporaryEquityLiquidationPreferencePerShare</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationPreferencePerShare" xlink:to="label_TemporaryEquityLiquidationPreferencePerShare" xlink:title="label_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationPreferencePerShare_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityLiquidationPreferencePerShare_1" xml:lang="en-US" id="label_TemporaryEquityLiquidationPreferencePerShare_1">Temporary Equity, Liquidation Preference Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationPreferencePerShare" xlink:to="label_TemporaryEquityLiquidationPreferencePerShare_1" xlink:title="label_TemporaryEquityLiquidationPreferencePerShare_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquitySharesAuthorized" xml:lang="en-US" id="label_TemporaryEquitySharesAuthorized">Redeemable convertible preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesAuthorized" xlink:to="label_TemporaryEquitySharesAuthorized" xlink:title="label_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquitySharesIssued" xml:lang="en-US" id="label_TemporaryEquitySharesIssued">us-gaap_TemporaryEquitySharesIssued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="label_TemporaryEquitySharesIssued" xlink:title="label_TemporaryEquitySharesIssued"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquitySharesIssued_1" xml:lang="en-US" id="label_TemporaryEquitySharesIssued_1">Redeemable convertible preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="label_TemporaryEquitySharesIssued_1" xlink:title="label_TemporaryEquitySharesIssued_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquitySharesOutstanding" xml:lang="en-US" id="label_TemporaryEquitySharesOutstanding">Redeemable convertible preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="label_TemporaryEquitySharesOutstanding" xlink:title="label_TemporaryEquitySharesOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquitySharesOutstanding_1" xml:lang="en-US" id="label_TemporaryEquitySharesOutstanding_1">Redeemable convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="label_TemporaryEquitySharesOutstanding_1" xlink:title="label_TemporaryEquitySharesOutstanding_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:title="TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityValueExcludingAdditionalPaidInCapital" xml:lang="en-US" id="label_TemporaryEquityValueExcludingAdditionalPaidInCapital">Redeemable convertible preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="label_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:title="label_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:label xlink:type="resource" xlink:label="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US" id="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:label xlink:type="resource" xlink:label="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xml:lang="en-US" id="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember"/>
    <link:label xlink:type="resource" xlink:label="label_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TypeOfAdoptionMember" xml:lang="en-US" id="label_TypeOfAdoptionMember">Type of Adoption [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfAdoptionMember" xlink:to="label_TypeOfAdoptionMember" xlink:title="label_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits"/>
    <link:label xlink:type="resource" xlink:label="label_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UnrecognizedTaxBenefits" xml:lang="en-US" id="label_UnrecognizedTaxBenefits">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="label_UnrecognizedTaxBenefits" xlink:title="label_UnrecognizedTaxBenefits"/>
    <link:label xlink:type="resource" xlink:label="label_UnrecognizedTaxBenefits_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_UnrecognizedTaxBenefits_1" xml:lang="en-US" id="label_UnrecognizedTaxBenefits_1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="label_UnrecognizedTaxBenefits_1" xlink:title="label_UnrecognizedTaxBenefits_1"/>
    <link:label xlink:type="resource" xlink:label="label_UnrecognizedTaxBenefits_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_UnrecognizedTaxBenefits_2" xml:lang="en-US" id="label_UnrecognizedTaxBenefits_2">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="label_UnrecognizedTaxBenefits_2" xlink:title="label_UnrecognizedTaxBenefits_2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:label xlink:type="resource" xlink:label="label_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US" id="label_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="label_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="label_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:label xlink:type="resource" xlink:label="label_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1" xml:lang="en-US" id="label_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="label_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1" xlink:title="label_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:title="UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:label xlink:type="resource" xlink:label="label_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US" id="label_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">Increases related to current year positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="label_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:title="label_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:title="UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:label xlink:type="resource" xlink:label="label_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US" id="label_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">Changes related to prior year positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="label_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:title="label_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates"/>
    <link:label xlink:type="resource" xlink:label="label_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UseOfEstimates" xml:lang="en-US" id="label_UseOfEstimates">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="label_UseOfEstimates" xlink:title="label_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:label xlink:type="resource" xlink:label="label_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US" id="label_ValuationAllowanceDeferredTaxAssetChangeInAmount">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="label_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="label_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:label xlink:type="resource" xlink:label="label_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xml:lang="en-US" id="label_ValuationAllowanceDeferredTaxAssetChangeInAmount_1">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="label_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xlink:title="label_ValuationAllowanceDeferredTaxAssetChangeInAmount_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis"/>
    <link:label xlink:type="resource" xlink:label="label_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VariableRateAxis" xml:lang="en-US" id="label_VariableRateAxis">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateAxis" xlink:to="label_VariableRateAxis" xlink:title="label_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain"/>
    <link:label xlink:type="resource" xlink:label="label_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VariableRateDomain" xml:lang="en-US" id="label_VariableRateDomain">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateDomain" xlink:to="label_VariableRateDomain" xlink:title="label_VariableRateDomain"/>
    <link:label xlink:type="resource" xlink:label="label_VariableRateDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_VariableRateDomain_1" xml:lang="en-US" id="label_VariableRateDomain_1">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateDomain" xlink:to="label_VariableRateDomain_1" xlink:title="label_VariableRateDomain_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantMember" xml:lang="en-US" id="label_WarrantMember">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember" xlink:title="label_WarrantMember"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantMember_1" xml:lang="en-US" id="label_WarrantMember_1">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember_1" xlink:title="label_WarrantMember_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsAndRightsOutstanding" xml:lang="en-US" id="label_WarrantsAndRightsOutstanding">us-gaap_WarrantsAndRightsOutstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="label_WarrantsAndRightsOutstanding" xlink:title="label_WarrantsAndRightsOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsAndRightsOutstanding_1" xml:lang="en-US" id="label_WarrantsAndRightsOutstanding_1">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="label_WarrantsAndRightsOutstanding_1" xlink:title="label_WarrantsAndRightsOutstanding_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsAndRightsOutstandingMeasurementInput" xml:lang="en-US" id="label_WarrantsAndRightsOutstandingMeasurementInput">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingMeasurementInput" xlink:to="label_WarrantsAndRightsOutstandingMeasurementInput" xlink:title="label_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstandingMeasurementInput_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsAndRightsOutstandingMeasurementInput_1" xml:lang="en-US" id="label_WarrantsAndRightsOutstandingMeasurementInput_1">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingMeasurementInput" xlink:to="label_WarrantsAndRightsOutstandingMeasurementInput_1" xlink:title="label_WarrantsAndRightsOutstandingMeasurementInput_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="WarrantsNotSettleableInCashFairValueDisclosure" xlink:title="WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsNotSettleableInCashFairValueDisclosure" xml:lang="en-US" id="label_WarrantsNotSettleableInCashFairValueDisclosure">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="label_WarrantsNotSettleableInCashFairValueDisclosure" xlink:title="label_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:label xlink:type="resource" xlink:label="label_WarrantsNotSettleableInCashFairValueDisclosure_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsNotSettleableInCashFairValueDisclosure_1" xml:lang="en-US" id="label_WarrantsNotSettleableInCashFairValueDisclosure_1">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="label_WarrantsNotSettleableInCashFairValueDisclosure_1" xlink:title="label_WarrantsNotSettleableInCashFairValueDisclosure_1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US" id="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">Weighted-average number of common shares outstanding - basic and diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag"/>
    <link:label xlink:type="resource" xlink:label="label_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentFlag" xml:lang="en-US" id="label_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="label_AmendmentFlag" xlink:title="label_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate"/>
    <link:label xlink:type="resource" xlink:label="label_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="label_CurrentFiscalYearEndDate" xlink:title="label_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus"/>
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="label_DocumentFiscalPeriodFocus" xlink:title="label_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus"/>
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalYearFocus" xml:lang="en-US" id="label_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="label_DocumentFiscalYearFocus" xlink:title="label_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="DocumentInformationLineItems" xlink:title="DocumentInformationLineItems"/>
    <link:label xlink:type="resource" xlink:label="label_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentInformationLineItems" xml:lang="en-US" id="label_DocumentInformationLineItems">Document Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentInformationLineItems" xlink:to="label_DocumentInformationLineItems" xlink:title="label_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="DocumentInformationTable" xlink:title="DocumentInformationTable"/>
    <link:label xlink:type="resource" xlink:label="label_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentInformationTable" xml:lang="en-US" id="label_DocumentInformationTable">Document Information [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentInformationTable" xlink:to="label_DocumentInformationTable" xlink:title="label_DocumentInformationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate"/>
    <link:label xlink:type="resource" xlink:label="label_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentPeriodEndDate" xml:lang="en-US" id="label_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="label_DocumentPeriodEndDate" xlink:title="label_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType"/>
    <link:label xlink:type="resource" xlink:label="label_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentType" xml:lang="en-US" id="label_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="label_DocumentType" xlink:title="label_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey"/>
    <link:label xlink:type="resource" xlink:label="label_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCentralIndexKey" xml:lang="en-US" id="label_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="label_EntityCentralIndexKey" xlink:title="label_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding"/>
    <link:label xlink:type="resource" xlink:label="label_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="label_EntityCommonStockSharesOutstanding" xlink:title="label_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus"/>
    <link:label xlink:type="resource" xlink:label="label_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCurrentReportingStatus" xml:lang="en-US" id="label_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="label_EntityCurrentReportingStatus" xlink:title="label_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:label xlink:type="resource" xlink:label="label_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityDomain" xml:lang="en-US" id="label_EntityDomain">Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityDomain" xlink:to="label_EntityDomain" xlink:title="label_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany"/>
    <link:label xlink:type="resource" xlink:label="label_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityEmergingGrowthCompany" xml:lang="en-US" id="label_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="label_EntityEmergingGrowthCompany" xlink:title="label_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory"/>
    <link:label xlink:type="resource" xlink:label="label_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityFilerCategory" xml:lang="en-US" id="label_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="label_EntityFilerCategory" xlink:title="label_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent"/>
    <link:label xlink:type="resource" xlink:label="label_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityInteractiveDataCurrent" xml:lang="en-US" id="label_EntityInteractiveDataCurrent">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="label_EntityInteractiveDataCurrent" xlink:title="label_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat"/>
    <link:label xlink:type="resource" xlink:label="label_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityPublicFloat" xml:lang="en-US" id="label_EntityPublicFloat">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="label_EntityPublicFloat" xlink:title="label_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName"/>
    <link:label xlink:type="resource" xlink:label="label_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityRegistrantName" xml:lang="en-US" id="label_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="label_EntityRegistrantName" xlink:title="label_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany"/>
    <link:label xlink:type="resource" xlink:label="label_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityShellCompany" xml:lang="en-US" id="label_EntityShellCompany">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="label_EntityShellCompany" xlink:title="label_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness"/>
    <link:label xlink:type="resource" xlink:label="label_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntitySmallBusiness" xml:lang="en-US" id="label_EntitySmallBusiness">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="label_EntitySmallBusiness" xlink:title="label_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers"/>
    <link:label xlink:type="resource" xlink:label="label_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityVoluntaryFilers" xml:lang="en-US" id="label_EntityVoluntaryFilers">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="label_EntityVoluntaryFilers" xlink:title="label_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer"/>
    <link:label xlink:type="resource" xlink:label="label_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityWellKnownSeasonedIssuer" xml:lang="en-US" id="label_EntityWellKnownSeasonedIssuer">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="label_EntityWellKnownSeasonedIssuer" xlink:title="label_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:label xlink:type="resource" xlink:label="label_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LegalEntityAxis" xml:lang="en-US" id="label_LegalEntityAxis">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalEntityAxis" xlink:to="label_LegalEntityAxis" xlink:title="label_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle"/>
    <link:label xlink:type="resource" xlink:label="label_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Security12bTitle" xml:lang="en-US" id="label_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="label_Security12bTitle" xlink:title="label_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol"/>
    <link:label xlink:type="resource" xlink:label="label_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TradingSymbol" xml:lang="en-US" id="label_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="label_TradingSymbol" xlink:title="label_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod"/>
    <link:label xlink:type="resource" xlink:label="label_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityExTransitionPeriod" xml:lang="en-US" id="label_EntityExTransitionPeriod">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityExTransitionPeriod" xlink:to="label_EntityExTransitionPeriod" xlink:title="label: EntityExTransitionPeriod to label_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US" id="label_ProceedsFromIssuanceOrSaleOfEquity">Proceeds From Issuance Or Sale Of Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquity" xlink:to="label_ProceedsFromIssuanceOrSaleOfEquity" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquity to label_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOrSaleOfEquity_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US" id="label_ProceedsFromIssuanceOrSaleOfEquity_2">Proceeds From Issuance Or Sale Of Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquity" xlink:to="label_ProceedsFromIssuanceOrSaleOfEquity_2" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquity to label_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1"/>
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockSharesIssued1" xml:lang="en-US" id="label_ConversionOfStockSharesIssued1">Conversion Of Stock Shares Issued1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesIssued1" xlink:to="label_ConversionOfStockSharesIssued1" xlink:title="label: ConversionOfStockSharesIssued1 to label_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="AmendmentDescription" xlink:title="AmendmentDescription"/>
    <link:label xlink:type="resource" xlink:label="label_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentDescription" xml:lang="en-US" id="label_AmendmentDescription">Amendment Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentDescription" xlink:to="label_AmendmentDescription" xlink:title="label: AmendmentDescription to label_AmendmentDescription"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>adyx-20190630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!-- Created by Toppan Merrill -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.adynxx.com/role/DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="adyx-20190630.xsd#DocumentDocumentAndEntityInformation"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/StatementBalanceSheets" xlink:type="simple" xlink:href="adyx-20190630.xsd#StatementBalanceSheets"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/StatementBalanceSheetsParentheticals" xlink:type="simple" xlink:href="adyx-20190630.xsd#StatementBalanceSheetsParentheticals"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/StatementStatementsOfOperations" xlink:type="simple" xlink:href="adyx-20190630.xsd#StatementStatementsOfOperations"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" xlink:type="simple" xlink:href="adyx-20190630.xsd#StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/StatementStatementOfCashFlows" xlink:type="simple" xlink:href="adyx-20190630.xsd#StatementStatementOfCashFlows"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote1OrganizationAndBasisOfPresentation" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote1OrganizationAndBasisOfPresentation"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote2SummaryOfSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote3PropertyAndEquipmentNet" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote3PropertyAndEquipmentNet"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote4AccruedLiabilities" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote4AccruedLiabilities"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotes" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote5TermLoansAndConvertiblePromissoryNotes"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingencies" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote6CommitmentsAndContingencies"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficit" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote7StockholdersDeficit"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote8Warrants" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote8Warrants"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote9StockOptionPlans" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote9StockOptionPlans"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote10IncomeTaxes" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote10IncomeTaxes"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote11RelatedPartyTransactions" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote11RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote12EmployeeBenefitPlan" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote12EmployeeBenefitPlan"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote13SubsequentEvents" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote13SubsequentEvents"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote2SummaryOfSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote3PropertyAndEquipmentNetTables" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote3PropertyAndEquipmentNetTables"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote4AccruedLiabilitiesTables" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote4AccruedLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesTables" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote5TermLoansAndConvertiblePromissoryNotesTables"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote6CommitmentsAndContingenciesTables"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitTables" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote7StockholdersDeficitTables"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote8WarrantsTables" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote8WarrantsTables"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote9StockOptionPlansTables" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote9StockOptionPlansTables"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesTables" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote10IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote1OrganizationAndBasisOfPresentationDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote1OrganizationAndBasisOfPresentationDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsRecurringBasisDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsRecurringBasisDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesChangeInFairValueOfPreferredStockWarrantLiabilityDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote2SummaryOfSignificantAccountingPoliciesChangeInFairValueOfPreferredStockWarrantLiabilityDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote3PropertyAndEquipmentNetDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote3PropertyAndEquipmentNetDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote3PropertyAndEquipmentNetPropertyAndEquipmentNetDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote3PropertyAndEquipmentNetPropertyAndEquipmentNetDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote4AccruedLiabilitiesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote4AccruedLiabilitiesAccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote5TermLoansAndConvertiblePromissoryNotesDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesFuturePrincipalPaymentsOfTermLoansDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote5TermLoansAndConvertiblePromissoryNotesFuturePrincipalPaymentsOfTermLoansDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetailsParentheticals" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetailsParentheticals"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote6CommitmentsAndContingenciesDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote6CommitmentsAndContingenciesFutureLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote7StockholdersDeficitDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitSharesReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote7StockholdersDeficitSharesReservedForFutureIssuanceDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote8WarrantsDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote8WarrantsDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote8WarrantsDetailsOfWarrantsDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote8WarrantsDetailsOfWarrantsDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote8WarrantsWarrantsAssumptionsDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote8WarrantsWarrantsAssumptionsDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote9StockOptionPlansDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote9StockOptionPlansDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote9StockOptionPlansSummaryOfStockOptionActivityDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote9StockOptionPlansSummaryOfStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote10IncomeTaxesDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote10IncomeTaxesComponentsOfDeferredTaxAssetsDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote10IncomeTaxesActivityRelatedToGrossUnrecognizedTaxBenefitsDetails"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote11RelatedPartyTransactionsDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote11RelatedPartyTransactionsDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote12EmployeeBenefitPlanDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote12EmployeeBenefitPlanDetailsTextual"/>
  <link:roleRef roleURI="http://www.adynxx.com/role/DisclosureNote13SubsequentEventsDetailsTextual" xlink:type="simple" xlink:href="adyx-20190630.xsd#DisclosureNote13SubsequentEventsDetailsTextual"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-informationQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-5-other-balance-sheet-informationQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-document-and-entity-informationQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-document-and-entity-informationQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentationQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-1-organization-and-basis-of-presentationQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policiesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-2-summary-of-significant-accounting-policiesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-3-reverse-mergerQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-3-reverse-mergerQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-netQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-4-property-and-equipment-netQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-6-term-loans-and-convertible-promissory-notesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leasesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-7-leasesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stockQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-8-redeemable-convertible-preferred-stockQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-9-warrants-QuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-9-warrants-QuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-optionsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-10-stock-optionsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactionsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-11-relatedparty-transactionsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-12-subsequent-eventsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-12-subsequent-eventsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-significant-accounting-policies-policiesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-significant-accounting-policies-policiesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-tablesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-2-summary-of-significant-accounting-policies-tablesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-tablesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-4-property-and-equipment-net-tablesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-tablesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-5-other-balance-sheet-information-tablesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-tablesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-6-term-loans-and-convertible-promissory-notes-tablesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leases-tablesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-7-leases-tablesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-tablesQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-10-stock-options-tablesQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentation-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-1-organization-and-basis-of-presentation-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-3-reverse-merger-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-3-reverse-merger-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-4-property-and-equipment-net-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-6-term-loans-and-convertible-promissory-notes-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leases-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-7-leases-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stock-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-8-redeemable-convertible-preferred-stock-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-9-warrants-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-9-warrants-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-10-stock-options-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactions-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-11-relatedparty-transactions-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-12-subsequent-events-details-textualQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-12-subsequent-events-details-textualQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticalsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticalsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-7-leases-future-minimum-lease-payments-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-7-leases-future-minimum-lease-payments-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-cash-flows-unauditedQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unauditedQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-property-and-equipment-net-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-4-property-and-equipment-net-property-and-equipment-net-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-accrued-liabilities-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-5-other-balance-sheet-information-accrued-liabilities-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-operations-unauditedQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-statements-of-operations-unauditedQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unauditedQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unauditedQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-redeemable-convertible-preferred-stock-and-stockholders-deficit-unauditedQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-condensed-consolidated-statements-of-redeemable-convertible-preferred-stock-and-stockholders-deficit-unauditedQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-summary-of-stock-option-activity-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-10-stock-options-summary-of-stock-option-activity-detailsQuarterEnd"/>
  <link:roleRef roleURI="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-stock-options-by-exercise-price-range-detailsQuarterEnd" xlink:type="simple" xlink:href="adyx-20190630.xsd#statement-note-10-stock-options-stock-options-by-exercise-price-range-detailsQuarterEnd"/>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote4AccruedLiabilities">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="adyx_NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract_637021864927012033" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="adyx_NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract_637021864927012033" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficit">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="adyx_NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract_637021864927012033" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote10IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="adyx_NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract_637021864927012033" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote12EmployeeBenefitPlan">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="adyx_NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract_637021864927012033" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote4AccruedLiabilitiesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock_637021864927012033"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock_637021864927012033" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-4-accrued-liabilities-tables" xlink:label="adyx_statement-statement-note-4-accrued-liabilities-tables"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-4-accrued-liabilities-tables" xlink:to="us-gaap_TableTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock_637021864927012033"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock_637021864927012033" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-6-commitments-and-contingencies-tables" xlink:label="adyx_statement-statement-note-6-commitments-and-contingencies-tables"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-6-commitments-and-contingencies-tables" xlink:to="us-gaap_TableTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock_637021864927012033"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock_637021864927012033" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-7-stockholders-deficit-tables" xlink:label="adyx_statement-statement-note-7-stockholders-deficit-tables"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-7-stockholders-deficit-tables" xlink:to="us-gaap_TableTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock_637021864927012033"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock_637021864927012033" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock_637021864927012033" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-10-income-taxes-tables" xlink:label="adyx_statement-statement-note-10-income-taxes-tables"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-10-income-taxes-tables" xlink:to="us-gaap_TableTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-significant-accounting-policies-policies" xlink:label="adyx_statement-statement-significant-accounting-policies-policies"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_PolicyTextBlockAbstract_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract_637021864927012033" xlink:to="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_UseOfEstimates_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637021864927012033" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:label="adyx_ClinicalTrialAccrualsPolicyPolicyTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="adyx_ClinicalTrialAccrualsPolicyPolicyTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637021864927012033" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637021864927012033" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637021864927012033" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_637021864927012033" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GrantReimbursementPolicyPolicyTextBlock" xlink:label="adyx_GrantReimbursementPolicyPolicyTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="adyx_GrantReimbursementPolicyPolicyTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock" xlink:label="adyx_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="adyx_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock" xlink:label="adyx_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="adyx_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_DerivativesPolicyTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637021864927012033" xlink:title="presentation:  to " use="optional" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637021864927012033" xlink:title="presentation:  to " use="optional" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="DiscontinuedOperationsPolicyTextBlock" xlink:title="DiscontinuedOperationsPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637021864927012033" xlink:to="DiscontinuedOperationsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to DiscontinuedOperationsPolicyTextBlock" order="16.1" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote4AccruedLiabilitiesAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" xlink:label="adyx_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedPayrollAndRelatedExpensesCurrent" xlink:label="adyx_AccruedPayrollAndRelatedExpensesCurrent_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" xlink:to="adyx_AccruedPayrollAndRelatedExpensesCurrent_637021864927012033" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedTermLoanPaymentsCurrent" xlink:label="adyx_AccruedTermLoanPaymentsCurrent_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" xlink:to="adyx_AccruedTermLoanPaymentsCurrent_637021864927012033" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedClinicalTrialExpenseCurrent" xlink:label="adyx_AccruedClinicalTrialExpenseCurrent_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" xlink:to="adyx_AccruedClinicalTrialExpenseCurrent_637021864927012033" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637021864927012033" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637021864927012033"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637021864927012033" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesDetailsTextual">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="adyx_NoteToFinancialStatementDetailsTextual"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_OperatingLeaseExpense_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote12EmployeeBenefitPlanDetailsTextual">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="adyx_NoteToFinancialStatementDetailsTextual"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary" xlink:label="adyx_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_NoteToFinancialStatementDetailsTextual" xlink:to="adyx_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DefinedContributionPlanNonelectiveSafeHarborContributionAmount" xlink:label="adyx_DefinedContributionPlanNonelectiveSafeHarborContributionAmount_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_NoteToFinancialStatementDetailsTextual" xlink:to="adyx_DefinedContributionPlanNonelectiveSafeHarborContributionAmount_637021864927324035" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesFutureLeasePaymentsDetails">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details" xlink:label="adyx_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details" xlink:to="us-gaap_OperatingLeaseLiability_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote9StockOptionPlansSummaryOfStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:label="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637021864927324035" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637021864927324035" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637021864927324035" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637021864927324035" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637021864927324035" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637021864927324035" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637021864927324035" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637021864927324035" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637021864927324035" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637021864927324035" xlink:title="presentation:  to " use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637021864927324035" xlink:title="presentation:  to " use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637021864927324035" xlink:title="presentation:  to " use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesActivityRelatedToGrossUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" xlink:label="adyx_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" xlink:to="us-gaap_UnrecognizedTaxBenefits_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6370218649273240351"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" xlink:to="us-gaap_UnrecognizedTaxBenefits_6370218649273240351" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_637021864927324035" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637021864927324035" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-document-and-entity-informationQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="DocumentInformationLineItems" xlink:title="DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="DocumentType" xlink:title="presentation: DocumentInformationLineItems to DocumentType" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="AmendmentFlag" xlink:title="presentation: DocumentInformationLineItems to AmendmentFlag" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: DocumentInformationLineItems to DocumentPeriodEndDate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityRegistrantName" xlink:title="presentation: DocumentInformationLineItems to EntityRegistrantName" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityCentralIndexKey" xlink:title="presentation: DocumentInformationLineItems to EntityCentralIndexKey" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityFilerCategory" xlink:title="presentation: DocumentInformationLineItems to EntityFilerCategory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: DocumentInformationLineItems to EntityEmergingGrowthCompany" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntitySmallBusiness" xlink:title="presentation: DocumentInformationLineItems to EntitySmallBusiness" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityExTransitionPeriod" xlink:title="presentation: DocumentInformationLineItems to EntityExTransitionPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="AmendmentDescription" xlink:title="AmendmentDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="AmendmentDescription" xlink:title="presentation: DocumentInformationLineItems to AmendmentDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote8WarrantsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: StatementTable to ClassOfWarrantOrRightAxis" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockMember" xlink:label="WarrantsForSeriesAConvertiblePreferredStockMember" xlink:title="WarrantsForSeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantsForSeriesAConvertiblePreferredStockMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to WarrantsForSeriesAConvertiblePreferredStockMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="presentation: StatementLineItems to TableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TableTextBlock" xlink:to="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="presentation: TableTextBlock to ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TableTextBlock" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:title="presentation: TableTextBlock to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-8-warrants-tables" xlink:label="statement-statement-note-8-warrants-tables" xlink:title="statement-statement-note-8-warrants-tables"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-8-warrants-tables" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-8-warrants-tables to StatementTable" order="1.0"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-8-warrants-tables" xlink:to="StatementLineItems" xlink:title="presentation: statement-statement-note-8-warrants-tables to StatementLineItems" order="2.0"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesComponentsOfDeferredTaxAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:label="adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637021864927324035" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_637021864927324035" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637021864927324035" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:to="us-gaap_DeferredTaxAssetsGross_637021864927324035" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637021864927324035" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details" xlink:to="us-gaap_DeferredTaxAssetsNet_637021864927324035" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesFuturePrincipalPaymentsOfTermLoansDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637021864927168034"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_StatementLineItems_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_LongtermDebtTypeAxis_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_637021864927168034" xlink:to="us-gaap_LongtermDebtTypeDomain_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoansMember" xlink:label="adyx_TermLoansMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_637021864927168034" xlink:to="adyx_TermLoansMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details" xlink:label="adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-future-principal-payments-of-term-loans-details" xlink:to="us-gaap_StatementTable_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetailsParentheticals">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637021864927168034"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_StatementLineItems_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_DebtInstrumentMaturityDate_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_DebtInstrumentAxis_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637021864927168034" xlink:to="us-gaap_DebtInstrumentNameDomain_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableOneMember" xlink:label="adyx_ConvertibleNotePayableOneMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637021864927168034" xlink:to="adyx_ConvertibleNotePayableOneMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableTwoMember" xlink:label="adyx_ConvertibleNotePayableTwoMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637021864927168034" xlink:to="adyx_ConvertibleNotePayableTwoMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableThreeMember" xlink:label="adyx_ConvertibleNotePayableThreeMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637021864927168034" xlink:to="adyx_ConvertibleNotePayableThreeMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals" xlink:label="adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-5-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details-parentheticals" xlink:to="us-gaap_StatementTable_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitDetailsTextual">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637021864927168034"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_StatementLineItems_637021864927168034" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_TemporaryEquitySharesIssued_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637021864927168034" xlink:title="presentation:  to " use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637021864927168034" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_CommonStockSharesAuthorized_637021864927168034" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_CommonStockSharesOutstanding_637021864927168034" xlink:title="presentation:  to " use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector" xlink:label="adyx_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="adyx_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector_637021864927168034" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_DividendsPayableAmountPerShare_637021864927168034" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_637021864927168034" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare_637021864927168034" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityConvertibleAggregateProceedsTrigger" xlink:label="adyx_EquityConvertibleAggregateProceedsTrigger_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="adyx_EquityConvertibleAggregateProceedsTrigger_637021864927168034" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityConvertibleStockPriceTrigger" xlink:label="adyx_EquityConvertibleStockPriceTrigger_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="adyx_EquityConvertibleStockPriceTrigger_637021864927168034" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_637021864927168034" xlink:title="presentation:  to " use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_StatementClassOfStockAxis_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637021864927168034" xlink:to="us-gaap_ClassOfStockDomain_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="adyx_SeriesARedeemableConvertiblePreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637021864927168034" xlink:to="adyx_SeriesARedeemableConvertiblePreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adyx_SeriesBRedeemableConvertiblePreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637021864927168034" xlink:to="adyx_SeriesBRedeemableConvertiblePreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBConvertiblePreferredStockMember" xlink:label="adyx_SeriesBConvertiblePreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637021864927168034" xlink:to="adyx_SeriesBConvertiblePreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesAConvertiblePreferredStockMember" xlink:label="adyx_SeriesAConvertiblePreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637021864927168034" xlink:to="adyx_SeriesAConvertiblePreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis_637021864927168034" xlink:to="us-gaap_DebtConversionNameDomain_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember" xlink:label="adyx_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain_637021864927168034" xlink:to="adyx_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:label="adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain_637021864927168034" xlink:to="adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_DividendsAxis_637021864927168034" xlink:title="presentation:  to " use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsAxis_637021864927168034" xlink:to="us-gaap_DividendsDomain_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember" xlink:label="adyx_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsDomain_637021864927168034" xlink:to="adyx_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember" xlink:label="adyx_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsDomain_637021864927168034" xlink:to="adyx_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_637021864927168034" xlink:title="presentation:  to " use="optional" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_637021864927168034" xlink:to="us-gaap_ConversionOfStockNameDomain_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfPreferredStockToCommonStockMember" xlink:label="adyx_ConversionOfPreferredStockToCommonStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain_637021864927168034" xlink:to="adyx_ConversionOfPreferredStockToCommonStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="adyx_NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitSharesReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637021864927168034"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637021864927168034" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsReserveForSeriesAConvertiblePreferredStockMember" xlink:label="adyx_WarrantsReserveForSeriesAConvertiblePreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637021864927168034" xlink:to="adyx_WarrantsReserveForSeriesAConvertiblePreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_StatementLineItems_637021864927168034" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:label="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637021864927168034" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquitySharesReservedForFutureIssuance" xlink:label="adyx_EquitySharesReservedForFutureIssuance_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="adyx_EquitySharesReservedForFutureIssuance_637021864927168034" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="ConversionOfStockSharesIssued1" xlink:title="presentation: StatementLineItems to ConversionOfStockSharesIssued1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_StatementClassOfStockAxis_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637021864927168034" xlink:to="us-gaap_ClassOfStockDomain_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637021864927168034" xlink:to="us-gaap_SeriesAPreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637021864927168034" xlink:to="us-gaap_SeriesBPreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details" xlink:label="adyx_statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-7-stockholders-deficit-shares-reserved-for-future-issuance-details" xlink:to="us-gaap_StatementTable_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote8WarrantsDetailsOfWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637021864927168034"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637021864927168034" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockMember" xlink:label="adyx_WarrantsForSeriesAConvertiblePreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637021864927168034" xlink:to="adyx_WarrantsForSeriesAConvertiblePreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member" xlink:label="adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637021864927168034" xlink:to="adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInJanuary2016Member" xlink:label="adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637021864927168034" xlink:to="adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInJune2016Member_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_StatementLineItems_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927168034" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-8-warrants-details-of-warrants-details" xlink:label="adyx_statement-statement-note-8-warrants-details-of-warrants-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-8-warrants-details-of-warrants-details" xlink:to="us-gaap_StatementTable_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote8WarrantsWarrantsAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637021864927168034"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637021864927168034" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockMember" xlink:label="adyx_WarrantsForSeriesAConvertiblePreferredStockMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637021864927168034" xlink:to="adyx_WarrantsForSeriesAConvertiblePreferredStockMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_StatementLineItems_637021864927324035" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="srt_RangeAxis_637021864927168034" xlink:title="presentation:  to " use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637021864927168034" xlink:to="srt_RangeMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637021864927168034" xlink:to="srt_MinimumMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637021864927168034" xlink:to="srt_MaximumMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927168034" xlink:to="us-gaap_MeasurementInputTypeAxis_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637021864927168034" xlink:to="us-gaap_MeasurementInputTypeDomain_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637021864927168034" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637021864927168034" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637021864927168034"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637021864927168034" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637021864927168034" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-8-warrants-warrants-assumptions-details" xlink:label="adyx_statement-statement-note-8-warrants-warrants-assumptions-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_statement-statement-note-8-warrants-warrants-assumptions-details" xlink:to="us-gaap_StatementTable_637021864927168034" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote10IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637021864927324035"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="us-gaap_StatementLineItems_637021864927324035" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_637021864927324035" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637021864927324035" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637021864927324035" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:label="us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_637021864927324035" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NumberOfForeignSubsidiaries" xlink:label="adyx_NumberOfForeignSubsidiaries_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="adyx_NumberOfForeignSubsidiaries_637021864927324035" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_OperatingLossCarryforwards_637021864927324035" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OperatingLeaseCarryforwardsWithExpirationDates" xlink:label="adyx_OperatingLeaseCarryforwardsWithExpirationDates_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="adyx_OperatingLeaseCarryforwardsWithExpirationDates_637021864927324035" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_637021864927324035" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OperatingLossCarryforwardsExpiringIndefinitely" xlink:label="adyx_OperatingLossCarryforwardsExpiringIndefinitely_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="adyx_OperatingLossCarryforwardsExpiringIndefinitely_637021864927324035" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_TaxCreditCarryforwardAmount_637021864927324035" xlink:title="presentation:  to " use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_637021864927324035" xlink:title="presentation:  to " use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_OpenTaxYear_637021864927324035" xlink:title="presentation:  to " use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637021864927324035" xlink:title="presentation:  to " use="optional" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="us-gaap_TaxPeriodAxis_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis_637021864927324035" xlink:to="us-gaap_TaxPeriodDomain_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain_637021864927324035" xlink:to="us-gaap_EarliestTaxYearMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="us-gaap_TaxCreditCarryforwardAxis_637021864927324035" xlink:title="presentation:  to " use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_637021864927324035" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_637021864927324035" xlink:to="us-gaap_ResearchMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637021864927324035" xlink:title="presentation:  to " use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637021864927324035" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637021864927324035" xlink:to="us-gaap_DomesticCountryMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637021864927324035" xlink:to="us-gaap_StateAndLocalJurisdictionMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_637021864927324035" xlink:title="presentation:  to " use="optional" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_637021864927324035" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain_637021864927324035" xlink:to="us-gaap_InternalRevenueServiceIRSMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="adyx_NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/role/DisclosureNote13SubsequentEventsDetailsTextual">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637021864927324035"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="us-gaap_StatementLineItems_637021864927324035" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637021864927324035" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_DebtInstrumentMaturityDate_637021864927324035" xlink:title="presentation:  to " use="optional" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637021864927324035" xlink:title="presentation:  to " use="optional" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_RestrictedCash_637021864927324035" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:label="adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid_637021864927324035" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:label="adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:label="adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet_637021864927324035" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="us-gaap_ProceedsFromMinorityShareholders_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_ProceedsFromMinorityShareholders_637021864927324035" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="us-gaap_ProceedsFromNotesPayable_637021864927324035" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtConversionOriginalDebtAmountPrincipal" xlink:label="adyx_DebtConversionOriginalDebtAmountPrincipal_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="adyx_DebtConversionOriginalDebtAmountPrincipal_637021864927324035" xlink:title="presentation:  to " use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:label="adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest_637021864927324035" xlink:title="presentation:  to " use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:label="adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer_637021864927324035" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:label="adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree_637021864927324035" xlink:title="presentation:  to " use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: StatementLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="ProceedsFromRelatedPartyDebt" xlink:title="ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="ProceedsFromRelatedPartyDebt" xlink:title="presentation: StatementLineItems to ProceedsFromRelatedPartyDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637021864927324035" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="presentation: StatementLineItems to ProceedsFromIssuanceOrSaleOfEquity" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="us-gaap_LongtermDebtTypeAxis_637021864927324035" xlink:title="presentation:  to " use="optional" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_637021864927324035" xlink:to="us-gaap_LongtermDebtTypeDomain_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoansMember" xlink:label="adyx_TermLoansMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_637021864927324035" xlink:to="adyx_TermLoansMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="us-gaap_DebtInstrumentAxis_637021864927324035" xlink:title="presentation:  to " use="optional" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637021864927324035" xlink:to="us-gaap_DebtInstrumentNameDomain_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FirstNoteToFundTheCompanysOperationsMember" xlink:label="adyx_FirstNoteToFundTheCompanysOperationsMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637021864927324035" xlink:to="adyx_FirstNoteToFundTheCompanysOperationsMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SecondNoteToFundTheCompanysOperationsMember" xlink:label="adyx_SecondNoteToFundTheCompanysOperationsMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637021864927324035" xlink:to="adyx_SecondNoteToFundTheCompanysOperationsMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFundTheCompanysOperationsMember" xlink:label="adyx_NotesToFundTheCompanysOperationsMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637021864927324035" xlink:to="adyx_NotesToFundTheCompanysOperationsMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="us-gaap_StatementClassOfStockAxis_637021864927324035" xlink:title="presentation:  to " use="optional" order="8.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637021864927324035" xlink:to="us-gaap_ClassOfStockDomain_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBConvertiblePreferredStockMember" xlink:label="adyx_SeriesBConvertiblePreferredStockMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637021864927324035" xlink:to="adyx_SeriesBConvertiblePreferredStockMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_637021864927324035" xlink:title="presentation:  to " use="optional" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis_637021864927324035" xlink:to="us-gaap_DebtConversionNameDomain_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain_637021864927324035" xlink:to="adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="RangeAxis" xlink:title="presentation: StatementTable to RangeAxis" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="us-gaap_SubsequentEventTypeAxis_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637021864927324035" xlink:to="us-gaap_SubsequentEventTypeDomain_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637021864927324035" xlink:to="us-gaap_SubsequentEventMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="us-gaap_LineOfCreditFacilityAxis_637021864927324035" xlink:title="presentation:  to " use="optional" order="2.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis_637021864927324035" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OxfordFinanceLLCMember" xlink:label="adyx_OxfordFinanceLLCMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain_637021864927324035" xlink:to="adyx_OxfordFinanceLLCMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="adyx_MajorityInvestorsMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain_637021864927324035" xlink:to="adyx_MajorityInvestorsMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="srt_CounterpartyNameAxis_637021864927324035" xlink:title="presentation:  to " use="optional" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637021864927324035" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DomainMember" xlink:label="adyx_DomainMember_637021864927324035"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637021864927324035" xlink:to="adyx_DomainMember_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637021864927324035" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="presentation: StatementTable to NonmonetaryTransactionTypeAxis" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="presentation: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitMember" xlink:label="ReverseStockSplitMember" xlink:title="ReverseStockSplitMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonmonetaryTransactionTypeDomain" xlink:to="ReverseStockSplitMember" xlink:title="presentation: NonmonetaryTransactionTypeDomain to ReverseStockSplitMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="adyx_NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adyx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable_637021864927324035" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-informationQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract_2" xlink:title="DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockAbstract_2" xlink:to="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="presentation: DisclosureTextBlockAbstract to SupplementalBalanceSheetDisclosuresTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="StatementTable" xlink:title="presentation: NotesToFinancialStatementsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract_2" xlink:title="presentation: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentationQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract_2" xlink:title="DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockAbstract_2" xlink:to="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="presentation: DisclosureTextBlockAbstract to OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="StatementTable" xlink:title="presentation: NotesToFinancialStatementsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract_2" xlink:title="presentation: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: StatementTable to LongtermDebtTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="ConvertibleDebtMember" xlink:title="ConvertibleDebtMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="ConvertibleDebtMember" xlink:title="presentation: LongtermDebtTypeAxis to ConvertibleDebtMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: StatementTable to DebtInstrumentAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FirstNoteToFundTheCompanysOperationsMember" xlink:label="FirstNoteToFundTheCompanysOperationsMember" xlink:title="FirstNoteToFundTheCompanysOperationsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="FirstNoteToFundTheCompanysOperationsMember" xlink:title="presentation: DebtInstrumentAxis to FirstNoteToFundTheCompanysOperationsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SecondNoteToFundTheCompanysOperationsMember" xlink:label="SecondNoteToFundTheCompanysOperationsMember" xlink:title="SecondNoteToFundTheCompanysOperationsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="SecondNoteToFundTheCompanysOperationsMember" xlink:title="presentation: DebtInstrumentAxis to SecondNoteToFundTheCompanysOperationsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFundTheCompanysOperationsMember" xlink:label="NotesToFundTheCompanysOperationsMember" xlink:title="NotesToFundTheCompanysOperationsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="NotesToFundTheCompanysOperationsMember" xlink:title="presentation: DebtInstrumentAxis to NotesToFundTheCompanysOperationsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="presentation: StatementTable to LineOfCreditFacilityAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="presentation: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="MajorityInvestorsMember" xlink:title="presentation: LineOfCreditFacilityAxis to MajorityInvestorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: StatementTable to CounterpartyNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OxfordFinanceLLCMember" xlink:label="OxfordFinanceLLCMember" xlink:title="OxfordFinanceLLCMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="OxfordFinanceLLCMember" xlink:title="presentation: CounterpartyNameAxis to OxfordFinanceLLCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="presentation: StatementTable to NonmonetaryTransactionTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="presentation: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitFromMember" xlink:label="ReverseStockSplitFromMember" xlink:title="ReverseStockSplitFromMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="ReverseStockSplitFromMember" xlink:title="presentation: NonmonetaryTransactionTypeAxis to ReverseStockSplitFromMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: LegalEntityAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: StatementTable to BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: BusinessAcquisitionAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policiesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract_2" xlink:title="DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockAbstract_2" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: DisclosureTextBlockAbstract to SignificantAccountingPoliciesTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="StatementTable" xlink:title="presentation: NotesToFinancialStatementsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract_2" xlink:title="presentation: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: StatementTable to DebtInstrumentAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:label="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="ModifiedMarch2018AndModifiedSeptember2018NotesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="presentation: DebtInstrumentAxis to ModifiedMarch2018AndModifiedSeptember2018NotesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="presentation: StatementTable to RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MinimumMember" xlink:title="presentation: RangeAxis to MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MaximumMember" xlink:title="presentation: RangeAxis to MaximumMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: StatementTable to ConcentrationRiskByBenchmarkAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccountsPayable1Member" xlink:label="AccountsPayable1Member" xlink:title="AccountsPayable1Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="AccountsPayable1Member" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to AccountsPayable1Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: StatementTable to ConcentrationRiskByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="SupplierConcentrationRiskMember" xlink:title="SupplierConcentrationRiskMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="SupplierConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskByTypeAxis to SupplierConcentrationRiskMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:title="presentation: StatementTable to ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="presentation: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor1Member" xlink:label="Vendor1Member" xlink:title="Vendor1Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="Vendor1Member" xlink:title="presentation: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to Vendor1Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor2Member" xlink:label="Vendor2Member" xlink:title="Vendor2Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="Vendor2Member" xlink:title="presentation: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to Vendor2Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor3Member" xlink:label="Vendor3Member" xlink:title="Vendor3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="Vendor3Member" xlink:title="presentation: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to Vendor3Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:label="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:title="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:title="presentation: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:title="presentation: StatementTable to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="presentation: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="MoneyMarketFundsMember" xlink:title="presentation: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis to MoneyMarketFundsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LetterOfCredit1Member" xlink:label="LetterOfCredit1Member" xlink:title="LetterOfCredit1Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="LetterOfCredit1Member" xlink:title="presentation: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis to LetterOfCredit1Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: StatementTable to IncomeStatementLocationAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationAxis to ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="presentation: StatementTable to AdjustmentsForNewAccountingPronouncementsAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="presentation: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="AccountingStandardsUpdate201602Member" xlink:title="AccountingStandardsUpdate201602Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="AccountingStandardsUpdate201602Member" xlink:title="presentation: AdjustmentsForNewAccountingPronouncementsAxis to AccountingStandardsUpdate201602Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-3-reverse-mergerQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract_2" xlink:title="DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseMergerDisclosureTextBlock" xlink:label="ReverseMergerDisclosureTextBlock" xlink:title="ReverseMergerDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockAbstract_2" xlink:to="ReverseMergerDisclosureTextBlock" xlink:title="presentation: DisclosureTextBlockAbstract to ReverseMergerDisclosureTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="StatementTable" xlink:title="presentation: NotesToFinancialStatementsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract_2" xlink:title="presentation: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtConversionByUniqueDescriptionAxis" xlink:title="presentation: StatementTable to DebtConversionByUniqueDescriptionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="presentation: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="presentation: DebtConversionByUniqueDescriptionAxis to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="presentation: StatementTable to NonmonetaryTransactionTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="presentation: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitFromMember" xlink:label="ReverseStockSplitFromMember" xlink:title="ReverseStockSplitFromMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="ReverseStockSplitFromMember" xlink:title="presentation: NonmonetaryTransactionTypeAxis to ReverseStockSplitFromMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: LegalEntityAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AquaMedMember" xlink:label="AquaMedMember" xlink:title="AquaMedMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="AquaMedMember" xlink:title="presentation: LegalEntityAxis to AquaMedMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: StatementTable to BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: BusinessAcquisitionAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: StatementTable to IncomeStatementLocationAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="InterestExpenseMember" xlink:title="InterestExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="InterestExpenseMember" xlink:title="presentation: IncomeStatementLocationAxis to InterestExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-netQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract_2" xlink:title="DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockAbstract_2" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: DisclosureTextBlockAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="StatementTable" xlink:title="presentation: NotesToFinancialStatementsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract_2" xlink:title="presentation: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract_2" xlink:title="DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockAbstract_2" xlink:to="DebtDisclosureTextBlock" xlink:title="presentation: DisclosureTextBlockAbstract to DebtDisclosureTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="StatementTable" xlink:title="presentation: NotesToFinancialStatementsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: StatementTable to ClassOfWarrantOrRightAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:label="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="presentation: ClassOfWarrantOrRightAxis to WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract_2" xlink:title="presentation: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: StatementTable to LongtermDebtTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanAMember" xlink:label="TermLoanAMember" xlink:title="TermLoanAMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="TermLoanAMember" xlink:title="presentation: LongtermDebtTypeAxis to TermLoanAMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanBMember" xlink:label="TermLoanBMember" xlink:title="TermLoanBMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="TermLoanBMember" xlink:title="presentation: LongtermDebtTypeAxis to TermLoanBMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="TermLoansMember" xlink:title="presentation: LongtermDebtTypeAxis to TermLoansMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: StatementTable to DebtInstrumentAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FirstNoteToFundTheCompanysOperationsMember" xlink:label="FirstNoteToFundTheCompanysOperationsMember" xlink:title="FirstNoteToFundTheCompanysOperationsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="FirstNoteToFundTheCompanysOperationsMember" xlink:title="presentation: DebtInstrumentAxis to FirstNoteToFundTheCompanysOperationsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SecondNoteToFundTheCompanysOperationsMember" xlink:label="SecondNoteToFundTheCompanysOperationsMember" xlink:title="SecondNoteToFundTheCompanysOperationsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="SecondNoteToFundTheCompanysOperationsMember" xlink:title="presentation: DebtInstrumentAxis to SecondNoteToFundTheCompanysOperationsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFundTheCompanysOperationsMember" xlink:label="NotesToFundTheCompanysOperationsMember" xlink:title="NotesToFundTheCompanysOperationsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="NotesToFundTheCompanysOperationsMember" xlink:title="presentation: DebtInstrumentAxis to NotesToFundTheCompanysOperationsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePromissoryNoteOf15MillionMember" xlink:label="ConvertiblePromissoryNoteOf15MillionMember" xlink:title="ConvertiblePromissoryNoteOf15MillionMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ConvertiblePromissoryNoteOf15MillionMember" xlink:title="presentation: DebtInstrumentAxis to ConvertiblePromissoryNoteOf15MillionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:label="ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:title="ModifiedMarch2019AndModifiedDecember2018NotesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:title="presentation: DebtInstrumentAxis to ModifiedMarch2019AndModifiedDecember2018NotesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:label="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:title="ModifiedMarch2018September2018December2018AndMarch2019NotesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:title="presentation: DebtInstrumentAxis to ModifiedMarch2018September2018December2018AndMarch2019NotesMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtConversionByUniqueDescriptionAxis" xlink:title="presentation: StatementTable to DebtConversionByUniqueDescriptionAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="presentation: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="presentation: DebtConversionByUniqueDescriptionAxis to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="presentation: StatementTable to RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MinimumMember" xlink:title="presentation: RangeAxis to MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="presentation: StatementTable to LineOfCreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="presentation: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="MajorityInvestorsMember" xlink:title="presentation: LineOfCreditFacilityAxis to MajorityInvestorsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OxfordFinanceLLCMember" xlink:label="OxfordFinanceLLCMember" xlink:title="OxfordFinanceLLCMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="OxfordFinanceLLCMember" xlink:title="presentation: LineOfCreditFacilityAxis to OxfordFinanceLLCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: StatementTable to CounterpartyNameAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DomainMember" xlink:label="DomainMember" xlink:title="DomainMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="DomainMember" xlink:title="presentation: CounterpartyNameAxis to DomainMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: StatementTable to BusinessAcquisitionAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: BusinessAcquisitionAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="VariableRateAxis" xlink:title="presentation: StatementTable to VariableRateAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="presentation: VariableRateAxis to VariableRateDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLiborSwapRateMember" xlink:label="LondonInterbankOfferedRateLiborSwapRateMember" xlink:title="LondonInterbankOfferedRateLiborSwapRateMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateAxis" xlink:to="LondonInterbankOfferedRateLiborSwapRateMember" xlink:title="presentation: VariableRateAxis to LondonInterbankOfferedRateLiborSwapRateMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-7-leasesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract_2" xlink:title="DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockAbstract_2" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="presentation: DisclosureTextBlockAbstract to LesseeOperatingLeasesTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="StatementTable" xlink:title="presentation: NotesToFinancialStatementsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract_2" xlink:title="presentation: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stockQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract_2" xlink:title="DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="PreferredStockTextBlock" xlink:title="PreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockAbstract_2" xlink:to="PreferredStockTextBlock" xlink:title="presentation: DisclosureTextBlockAbstract to PreferredStockTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="StatementTable" xlink:title="presentation: NotesToFinancialStatementsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract_2" xlink:title="presentation: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="presentation: StatementClassOfStockAxis to SeriesARedeemableConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="presentation: StatementClassOfStockAxis to SeriesBRedeemableConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ConversionOfStockByUniqueDescriptionAxis" xlink:title="presentation: StatementTable to ConversionOfStockByUniqueDescriptionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfStockNameDomain" xlink:title="presentation: ConversionOfStockByUniqueDescriptionAxis to ConversionOfStockNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="presentation: ConversionOfStockByUniqueDescriptionAxis to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-9-warrants-QuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract_2" xlink:title="DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsDisclosureTextBlock" xlink:label="WarrantsDisclosureTextBlock" xlink:title="WarrantsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockAbstract_2" xlink:to="WarrantsDisclosureTextBlock" xlink:title="presentation: DisclosureTextBlockAbstract to WarrantsDisclosureTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="StatementTable" xlink:title="presentation: NotesToFinancialStatementsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: StatementTable to ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:label="WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:title="WarrantToPurchaseCommonStockConvertedInMergerMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:title="presentation: ClassOfWarrantOrRightAxis to WarrantToPurchaseCommonStockConvertedInMergerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaWarrantsAssumedInMergerMember" xlink:label="AlliquaWarrantsAssumedInMergerMember" xlink:title="AlliquaWarrantsAssumedInMergerMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="AlliquaWarrantsAssumedInMergerMember" xlink:title="presentation: ClassOfWarrantOrRightAxis to AlliquaWarrantsAssumedInMergerMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract_2" xlink:title="presentation: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="presentation: StatementTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MinimumMember" xlink:title="presentation: RangeAxis to MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MaximumMember" xlink:title="presentation: RangeAxis to MaximumMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: StatementTable to BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: BusinessAcquisitionAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-10-stock-optionsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract_2" xlink:title="DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockAbstract_2" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureTextBlockAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="StatementTable" xlink:title="presentation: NotesToFinancialStatementsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract_2" xlink:title="presentation: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="presentation: StatementTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MinimumMember" xlink:title="presentation: RangeAxis to MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MaximumMember" xlink:title="presentation: RangeAxis to MaximumMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: LegalEntityAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: StatementTable to BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: BusinessAcquisitionAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="AwardTypeAxis" xlink:title="presentation: StatementTable to AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AwardTypeAxis to EmployeeStockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NonEmployeeOptionsMember" xlink:label="NonEmployeeOptionsMember" xlink:title="NonEmployeeOptionsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="NonEmployeeOptionsMember" xlink:title="presentation: AwardTypeAxis to NonEmployeeOptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactionsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract_2" xlink:title="DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockAbstract_2" xlink:to="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="presentation: DisclosureTextBlockAbstract to RelatedPartyTransactionsDisclosureTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="StatementTable" xlink:title="presentation: NotesToFinancialStatementsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract_2" xlink:title="presentation: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="presentation: StatementTable to LineOfCreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="presentation: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="MajorityInvestorsMember" xlink:title="presentation: LineOfCreditFacilityAxis to MajorityInvestorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: StatementTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChiefExecutiveOfficerMember" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to ChiefExecutiveOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="presentation: StatementTable to RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="presentation: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeverancePayMember" xlink:label="SeverancePayMember" xlink:title="SeverancePayMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAxis" xlink:to="SeverancePayMember" xlink:title="presentation: RelatedPartyTransactionAxis to SeverancePayMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-12-subsequent-eventsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="DisclosureTextBlockAbstract_2" xlink:title="DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockAbstract_2" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: DisclosureTextBlockAbstract to SubsequentEventsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFinancialStatementsAbstract" xlink:label="NotesToFinancialStatementsAbstract" xlink:title="NotesToFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesToFinancialStatementsAbstract" xlink:to="StatementTable" xlink:title="presentation: NotesToFinancialStatementsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DisclosureTextBlockAbstract_2" xlink:title="presentation: StatementLineItems to DisclosureTextBlockAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="presentation: StatementTable to RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MinimumMember" xlink:title="presentation: RangeAxis to MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MaximumMember" xlink:title="presentation: RangeAxis to MaximumMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: StatementTable to SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: StatementTable to CounterpartyNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DomainMember" xlink:label="DomainMember" xlink:title="DomainMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="DomainMember" xlink:title="presentation: CounterpartyNameAxis to DomainMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="presentation: StatementTable to NonmonetaryTransactionTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="presentation: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitMember" xlink:label="ReverseStockSplitMember" xlink:title="ReverseStockSplitMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="ReverseStockSplitMember" xlink:title="presentation: NonmonetaryTransactionTypeAxis to ReverseStockSplitMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-tablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="presentation: StatementLineItems to TableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TableTextBlock" xlink:to="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="presentation: TableTextBlock to ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TableTextBlock" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="presentation: TableTextBlock to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:title="statement-statement-note-2-summary-of-significant-accounting-policies-tables"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-2-summary-of-significant-accounting-policies-tables to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-tablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="presentation: StatementLineItems to TableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TableTextBlock" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: TableTextBlock to PropertyPlantAndEquipmentTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-4-property-and-equipment-net-tables" xlink:label="statement-statement-note-4-property-and-equipment-net-tables" xlink:title="statement-statement-note-4-property-and-equipment-net-tables"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-4-property-and-equipment-net-tables" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-4-property-and-equipment-net-tables to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-tablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="presentation: StatementLineItems to TableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TableTextBlock" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: TableTextBlock to ScheduleOfAccruedLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:label="ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:title="ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TableTextBlock" xlink:to="ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:title="presentation: TableTextBlock to ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-5-other-balance-sheet-information-tables" xlink:label="statement-statement-note-5-other-balance-sheet-information-tables" xlink:title="statement-statement-note-5-other-balance-sheet-information-tables"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-5-other-balance-sheet-information-tables" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-5-other-balance-sheet-information-tables to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-tablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="presentation: StatementLineItems to TableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="ScheduleOfDebtInstrumentsTextBlock" xlink:title="ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TableTextBlock" xlink:to="ScheduleOfDebtInstrumentsTextBlock" xlink:title="presentation: TableTextBlock to ScheduleOfDebtInstrumentsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="ConvertibleDebtTableTextBlock" xlink:title="ConvertibleDebtTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TableTextBlock" xlink:to="ConvertibleDebtTableTextBlock" xlink:title="presentation: TableTextBlock to ConvertibleDebtTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables" xlink:label="statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables" xlink:title="statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-6-term-loans-and-convertible-promissory-notes-tables to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-7-leases-tablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="presentation: StatementLineItems to TableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TableTextBlock" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: TableTextBlock to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-7-leases-tables" xlink:label="statement-statement-note-7-leases-tables" xlink:title="statement-statement-note-7-leases-tables"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-7-leases-tables" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-7-leases-tables to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-tablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="TableTextBlock" xlink:title="TableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TableTextBlock" xlink:title="presentation: StatementLineItems to TableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TableTextBlock" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: TableTextBlock to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TableTextBlock" xlink:to="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="presentation: TableTextBlock to ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-10-stock-options-tables" xlink:label="statement-statement-note-10-stock-options-tables" xlink:title="statement-statement-note-10-stock-options-tables"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-10-stock-options-tables" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-10-stock-options-tables to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentation-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: StatementLineItems to DebtInstrumentInterestRateStatedPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ProceedsFromNotesPayable" xlink:title="presentation: StatementLineItems to ProceedsFromNotesPayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: StatementLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: StatementLineItems to CashAndCashEquivalentsAtCarryingValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayable" xlink:label="LoansPayable" xlink:title="LoansPayable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LoansPayable" xlink:title="presentation: StatementLineItems to LoansPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="NotesPayable" xlink:title="NotesPayable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NotesPayable" xlink:title="presentation: StatementLineItems to NotesPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StatementLineItems to RetainedEarningsAccumulatedDeficit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_BusinessAcquisitionExchangeRatio" xlink:label="BusinessAcquisitionExchangeRatio" xlink:title="BusinessAcquisitionExchangeRatio"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="BusinessAcquisitionExchangeRatio" xlink:title="presentation: StatementLineItems to BusinessAcquisitionExchangeRatio" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: StatementTable to LongtermDebtTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="ConvertibleDebtMember" xlink:title="ConvertibleDebtMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="ConvertibleDebtMember" xlink:title="presentation: LongtermDebtTypeAxis to ConvertibleDebtMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: StatementTable to DebtInstrumentAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FirstNoteToFundTheCompanysOperationsMember" xlink:label="FirstNoteToFundTheCompanysOperationsMember" xlink:title="FirstNoteToFundTheCompanysOperationsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="FirstNoteToFundTheCompanysOperationsMember" xlink:title="presentation: DebtInstrumentAxis to FirstNoteToFundTheCompanysOperationsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SecondNoteToFundTheCompanysOperationsMember" xlink:label="SecondNoteToFundTheCompanysOperationsMember" xlink:title="SecondNoteToFundTheCompanysOperationsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="SecondNoteToFundTheCompanysOperationsMember" xlink:title="presentation: DebtInstrumentAxis to SecondNoteToFundTheCompanysOperationsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFundTheCompanysOperationsMember" xlink:label="NotesToFundTheCompanysOperationsMember" xlink:title="NotesToFundTheCompanysOperationsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="NotesToFundTheCompanysOperationsMember" xlink:title="presentation: DebtInstrumentAxis to NotesToFundTheCompanysOperationsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="presentation: StatementTable to LineOfCreditFacilityAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="presentation: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="MajorityInvestorsMember" xlink:title="presentation: LineOfCreditFacilityAxis to MajorityInvestorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: StatementTable to CounterpartyNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OxfordFinanceLLCMember" xlink:label="OxfordFinanceLLCMember" xlink:title="OxfordFinanceLLCMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="OxfordFinanceLLCMember" xlink:title="presentation: CounterpartyNameAxis to OxfordFinanceLLCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="presentation: StatementTable to NonmonetaryTransactionTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="presentation: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitFromMember" xlink:label="ReverseStockSplitFromMember" xlink:title="ReverseStockSplitFromMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="ReverseStockSplitFromMember" xlink:title="presentation: NonmonetaryTransactionTypeAxis to ReverseStockSplitFromMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: LegalEntityAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: StatementTable to BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: BusinessAcquisitionAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="NoteToFinancialStatementDetailsTextual" xlink:title="NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteToFinancialStatementDetailsTextual" xlink:to="StatementTable" xlink:title="presentation: NoteToFinancialStatementDetailsTextual to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="RestrictedCash" xlink:title="RestrictedCash"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="RestrictedCash" xlink:title="presentation: StatementLineItems to RestrictedCash" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: StatementLineItems to ConcentrationRiskPercentage1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: StatementLineItems to ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: StatementLineItems to PropertyPlantAndEquipmentUsefulLife" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="GrantsReceivable" xlink:title="GrantsReceivable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="GrantsReceivable" xlink:title="presentation: StatementLineItems to GrantsReceivable" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: StatementLineItems to GainsLossesOnExtinguishmentOfDebt" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:title="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:title="presentation: StatementLineItems to EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OperatingLeaseLiability" xlink:title="presentation: StatementLineItems to OperatingLeaseLiability" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="presentation: StatementLineItems to ImpairmentOfLongLivedAssetsHeldForUse" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="PaymentsOfDividends" xlink:title="PaymentsOfDividends"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PaymentsOfDividends" xlink:title="presentation: StatementLineItems to PaymentsOfDividends" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_CollaborationInitiationPayment" xlink:label="CollaborationInitiationPayment" xlink:title="CollaborationInitiationPayment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CollaborationInitiationPayment" xlink:title="presentation: StatementLineItems to CollaborationInitiationPayment" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GrantReimbursements" xlink:label="GrantReimbursements" xlink:title="GrantReimbursements"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="GrantReimbursements" xlink:title="presentation: StatementLineItems to GrantReimbursements" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReclassificationOfWarrantIntoEquity" xlink:label="ReclassificationOfWarrantIntoEquity" xlink:title="ReclassificationOfWarrantIntoEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ReclassificationOfWarrantIntoEquity" xlink:title="presentation: StatementLineItems to ReclassificationOfWarrantIntoEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xlink:label="EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xlink:title="EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" xlink:title="presentation: StatementLineItems to EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsDue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseDiscountRate" xlink:title="presentation: StatementLineItems to LesseeOperatingLeaseDiscountRate" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: StatementLineItems to OperatingLeaseRightOfUseAsset" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: StatementTable to DebtInstrumentAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:label="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="ModifiedMarch2018AndModifiedSeptember2018NotesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="presentation: DebtInstrumentAxis to ModifiedMarch2018AndModifiedSeptember2018NotesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="presentation: StatementTable to RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MinimumMember" xlink:title="presentation: RangeAxis to MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MaximumMember" xlink:title="presentation: RangeAxis to MaximumMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: StatementTable to SubsequentEventTypeAxis" order="10.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: StatementTable to ConcentrationRiskByBenchmarkAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccountsPayable1Member" xlink:label="AccountsPayable1Member" xlink:title="AccountsPayable1Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="AccountsPayable1Member" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to AccountsPayable1Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: StatementTable to ConcentrationRiskByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="SupplierConcentrationRiskMember" xlink:title="SupplierConcentrationRiskMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="SupplierConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskByTypeAxis to SupplierConcentrationRiskMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:title="presentation: StatementTable to ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="presentation: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor1Member" xlink:label="Vendor1Member" xlink:title="Vendor1Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="Vendor1Member" xlink:title="presentation: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to Vendor1Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor2Member" xlink:label="Vendor2Member" xlink:title="Vendor2Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="Vendor2Member" xlink:title="presentation: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to Vendor2Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_Vendor3Member" xlink:label="Vendor3Member" xlink:title="Vendor3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="Vendor3Member" xlink:title="presentation: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to Vendor3Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:label="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:title="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" xlink:title="presentation: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:label="OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:title="OneOfTheTwoVendorsSupportingManufacturingActivitiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" xlink:title="presentation: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to OneOfTheTwoVendorsSupportingManufacturingActivitiesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:title="presentation: StatementTable to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="presentation: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="MoneyMarketFundsMember" xlink:title="presentation: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis to MoneyMarketFundsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LetterOfCredit1Member" xlink:label="LetterOfCredit1Member" xlink:title="LetterOfCredit1Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="LetterOfCredit1Member" xlink:title="presentation: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis to LetterOfCredit1Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: StatementTable to IncomeStatementLocationAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationAxis to ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="presentation: StatementTable to AdjustmentsForNewAccountingPronouncementsAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="presentation: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="AccountingStandardsUpdate201602Member" xlink:title="AccountingStandardsUpdate201602Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="AccountingStandardsUpdate201602Member" xlink:title="presentation: AdjustmentsForNewAccountingPronouncementsAxis to AccountingStandardsUpdate201602Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="presentation: StatementTable to ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="presentation: ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:label="ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:title="ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" xlink:title="presentation: ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:label="ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:title="ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" xlink:title="presentation: ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="NoteToFinancialStatementDetailsTextual" xlink:title="NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteToFinancialStatementDetailsTextual" xlink:to="StatementTable" xlink:title="presentation: NoteToFinancialStatementDetailsTextual to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-3-reverse-merger-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="presentation: StatementLineItems to DebtConversionConvertedInstrumentSharesIssued1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtConversionOriginalDebtAmountPrincipal" xlink:label="DebtConversionOriginalDebtAmountPrincipal" xlink:title="DebtConversionOriginalDebtAmountPrincipal"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtConversionOriginalDebtAmountPrincipal" xlink:title="presentation: StatementLineItems to DebtConversionOriginalDebtAmountPrincipal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:label="DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:title="DebtConversionOriginalDebtAmountCumulativeAccruedInterest"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtConversionOriginalDebtAmountCumulativeAccruedInterest" xlink:title="presentation: StatementLineItems to DebtConversionOriginalDebtAmountCumulativeAccruedInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:label="MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:title="MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" xlink:title="presentation: StatementLineItems to MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:label="MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:title="MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" xlink:title="presentation: StatementLineItems to MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: StatementLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_BusinessAcquisitionExchangeRatio" xlink:label="BusinessAcquisitionExchangeRatio" xlink:title="BusinessAcquisitionExchangeRatio"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="BusinessAcquisitionExchangeRatio" xlink:title="presentation: StatementLineItems to BusinessAcquisitionExchangeRatio" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NumberOfSharesHeldByEquityHolders" xlink:label="NumberOfSharesHeldByEquityHolders" xlink:title="NumberOfSharesHeldByEquityHolders"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NumberOfSharesHeldByEquityHolders" xlink:title="presentation: StatementLineItems to NumberOfSharesHeldByEquityHolders" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="IntangibleAssetsNetIncludingGoodwill" xlink:title="IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IntangibleAssetsNetIncludingGoodwill" xlink:title="presentation: StatementLineItems to IntangibleAssetsNetIncludingGoodwill" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="presentation: StatementLineItems to DebtInstrumentConvertibleBeneficialConversionFeature" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends" xlink:label="Dividends" xlink:title="Dividends"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="Dividends" xlink:title="presentation: StatementLineItems to Dividends" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="CommonStockDividendsPerShareCashPaid" xlink:title="CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CommonStockDividendsPerShareCashPaid" xlink:title="presentation: StatementLineItems to CommonStockDividendsPerShareCashPaid" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_CommonStockStockDividendsPerShareBookValue" xlink:label="CommonStockStockDividendsPerShareBookValue" xlink:title="CommonStockStockDividendsPerShareBookValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CommonStockStockDividendsPerShareBookValue" xlink:title="presentation: StatementLineItems to CommonStockStockDividendsPerShareBookValue" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtConversionByUniqueDescriptionAxis" xlink:title="presentation: StatementTable to DebtConversionByUniqueDescriptionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="presentation: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="presentation: DebtConversionByUniqueDescriptionAxis to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="NonmonetaryTransactionTypeAxis" xlink:title="NonmonetaryTransactionTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="NonmonetaryTransactionTypeAxis" xlink:title="presentation: StatementTable to NonmonetaryTransactionTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="NonmonetaryTransactionTypeDomain" xlink:title="NonmonetaryTransactionTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="NonmonetaryTransactionTypeDomain" xlink:title="presentation: NonmonetaryTransactionTypeAxis to NonmonetaryTransactionTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReverseStockSplitFromMember" xlink:label="ReverseStockSplitFromMember" xlink:title="ReverseStockSplitFromMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonmonetaryTransactionTypeAxis" xlink:to="ReverseStockSplitFromMember" xlink:title="presentation: NonmonetaryTransactionTypeAxis to ReverseStockSplitFromMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: LegalEntityAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AquaMedMember" xlink:label="AquaMedMember" xlink:title="AquaMedMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="AquaMedMember" xlink:title="presentation: LegalEntityAxis to AquaMedMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: StatementTable to BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: BusinessAcquisitionAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: StatementTable to IncomeStatementLocationAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="InterestExpenseMember" xlink:title="InterestExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="InterestExpenseMember" xlink:title="presentation: IncomeStatementLocationAxis to InterestExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="NoteToFinancialStatementDetailsTextual" xlink:title="NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteToFinancialStatementDetailsTextual" xlink:to="StatementTable" xlink:title="presentation: NoteToFinancialStatementDetailsTextual to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="Depreciation" xlink:title="presentation: StatementLineItems to Depreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="NoteToFinancialStatementDetailsTextual" xlink:title="NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteToFinancialStatementDetailsTextual" xlink:to="StatementTable" xlink:title="presentation: NoteToFinancialStatementDetailsTextual to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: StatementTable to ClassOfWarrantOrRightAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:label="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="presentation: ClassOfWarrantOrRightAxis to WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: StatementLineItems to DebtInstrumentInterestRateStatedPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="presentation: StatementLineItems to DebtConversionConvertedInstrumentSharesIssued1" order="44.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: StatementLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="RestrictedCash" xlink:title="RestrictedCash"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="RestrictedCash" xlink:title="presentation: StatementLineItems to RestrictedCash" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:label="DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:title="DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" xlink:title="presentation: StatementLineItems to DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:label="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:title="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:title="presentation: StatementLineItems to DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:label="DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:title="DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" xlink:title="presentation: StatementLineItems to DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="ProceedsFromMinorityShareholders" xlink:title="ProceedsFromMinorityShareholders"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ProceedsFromMinorityShareholders" xlink:title="presentation: StatementLineItems to ProceedsFromMinorityShareholders" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ProceedsFromNotesPayable" xlink:title="presentation: StatementLineItems to ProceedsFromNotesPayable" order="42.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayable" xlink:label="LoansPayable" xlink:title="LoansPayable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LoansPayable" xlink:title="presentation: StatementLineItems to LoansPayable" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: StatementLineItems to GainsLossesOnExtinguishmentOfDebt" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:title="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:title="presentation: StatementLineItems to EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="47.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertibleBeneficialConversionFeature" xlink:title="presentation: StatementLineItems to DebtInstrumentConvertibleBeneficialConversionFeature" order="45.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: StatementLineItems to DebtInstrumentFaceAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="ProceedsFromIssuanceOfDebt" xlink:title="ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ProceedsFromIssuanceOfDebt" xlink:title="presentation: StatementLineItems to ProceedsFromIssuanceOfDebt" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="presentation: StatementLineItems to DebtInstrumentUnusedBorrowingCapacityAmount" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentUnusedBorrowingCapacityExpired" xlink:label="DebtInstrumentUnusedBorrowingCapacityExpired" xlink:title="DebtInstrumentUnusedBorrowingCapacityExpired"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentUnusedBorrowingCapacityExpired" xlink:title="presentation: StatementLineItems to DebtInstrumentUnusedBorrowingCapacityExpired" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:label="LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:title="LongtermDebtPrincipalAndInterestPaymentsTerm"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LongtermDebtPrincipalAndInterestPaymentsTerm" xlink:title="presentation: StatementLineItems to LongtermDebtPrincipalAndInterestPaymentsTerm" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="presentation: StatementLineItems to DebtInstrumentBasisSpreadOnVariableRate1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:label="DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:title="DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" xlink:title="presentation: StatementLineItems to DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:label="DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:title="DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" xlink:title="presentation: StatementLineItems to DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:label="DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:title="DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" xlink:title="presentation: StatementLineItems to DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:label="DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:title="DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" xlink:title="presentation: StatementLineItems to DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:label="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:title="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:title="presentation: StatementLineItems to DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:label="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:title="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" xlink:title="presentation: StatementLineItems to DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:label="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:title="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" xlink:title="presentation: StatementLineItems to DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:label="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:title="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" xlink:title="presentation: StatementLineItems to DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ProceedsFromConvertibleDebt" xlink:title="presentation: StatementLineItems to ProceedsFromConvertibleDebt" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:label="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:title="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" xlink:title="presentation: StatementLineItems to DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:label="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:title="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" xlink:title="presentation: StatementLineItems to DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:label="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:title="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" xlink:title="presentation: StatementLineItems to DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="DeferredFinanceCostsNet" xlink:title="DeferredFinanceCostsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DeferredFinanceCostsNet" xlink:title="presentation: StatementLineItems to DeferredFinanceCostsNet" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LongTermDebt" xlink:title="presentation: StatementLineItems to LongTermDebt" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="InterestExpense" xlink:title="presentation: StatementLineItems to InterestExpense" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:label="DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:title="DebtInstrumentConvertiblePreferredStockProceedsTrigger"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertiblePreferredStockProceedsTrigger" xlink:title="presentation: StatementLineItems to DebtInstrumentConvertiblePreferredStockProceedsTrigger" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:label="DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:title="DebtInstrumentConvertibleCommonStockProceedsTrigger"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertibleCommonStockProceedsTrigger" xlink:title="presentation: StatementLineItems to DebtInstrumentConvertibleCommonStockProceedsTrigger" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="DebtInstrumentConvertibleConversionRatio1" xlink:title="DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertibleConversionRatio1" xlink:title="presentation: StatementLineItems to DebtInstrumentConvertibleConversionRatio1" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:label="DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:title="DebtInstrumentConversionToCashInCaseOfChangeInControl"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConversionToCashInCaseOfChangeInControl" xlink:title="presentation: StatementLineItems to DebtInstrumentConversionToCashInCaseOfChangeInControl" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="presentation: StatementLineItems to DebtInstrumentConvertibleConversionPrice1" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FinancingThresholdProceedsToConvertNotesToEquity" xlink:label="FinancingThresholdProceedsToConvertNotesToEquity" xlink:title="FinancingThresholdProceedsToConvertNotesToEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="FinancingThresholdProceedsToConvertNotesToEquity" xlink:title="presentation: StatementLineItems to FinancingThresholdProceedsToConvertNotesToEquity" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:label="DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:title="DebtInstrumentConversionToCashInCaseOfChangeInControlPremium"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" xlink:title="presentation: StatementLineItems to DebtInstrumentConversionToCashInCaseOfChangeInControlPremium" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_VotingRightsTransferredToBeConsideredAChangeInControl" xlink:label="VotingRightsTransferredToBeConsideredAChangeInControl" xlink:title="VotingRightsTransferredToBeConsideredAChangeInControl"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="VotingRightsTransferredToBeConsideredAChangeInControl" xlink:title="presentation: StatementLineItems to VotingRightsTransferredToBeConsideredAChangeInControl" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ProbabilityOfQualifiedFinancingOccurring" xlink:label="ProbabilityOfQualifiedFinancingOccurring" xlink:title="ProbabilityOfQualifiedFinancingOccurring"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ProbabilityOfQualifiedFinancingOccurring" xlink:title="presentation: StatementLineItems to ProbabilityOfQualifiedFinancingOccurring" order="46.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ProbabilityOfChangeInControlOccurring" xlink:label="ProbabilityOfChangeInControlOccurring" xlink:title="ProbabilityOfChangeInControlOccurring"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ProbabilityOfChangeInControlOccurring" xlink:title="presentation: StatementLineItems to ProbabilityOfChangeInControlOccurring" order="52.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:title="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:title="presentation: StatementLineItems to DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" order="48.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: StatementLineItems to AmortizationOfDebtDiscountPremium" order="49.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReleaseOfDerivativeLiabilities" xlink:label="ReleaseOfDerivativeLiabilities" xlink:title="ReleaseOfDerivativeLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ReleaseOfDerivativeLiabilities" xlink:title="presentation: StatementLineItems to ReleaseOfDerivativeLiabilities" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="DebtInstrumentUnamortizedDiscountCurrent" xlink:title="DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentUnamortizedDiscountCurrent" xlink:title="presentation: StatementLineItems to DebtInstrumentUnamortizedDiscountCurrent" order="51.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="DeferredFinanceCostsGross" xlink:title="DeferredFinanceCostsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DeferredFinanceCostsGross" xlink:title="presentation: StatementLineItems to DeferredFinanceCostsGross" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GainLossDebtModification" xlink:label="GainLossDebtModification" xlink:title="GainLossDebtModification"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="GainLossDebtModification" xlink:title="presentation: StatementLineItems to GainLossDebtModification" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="InterestExpenseDebt" xlink:title="presentation: StatementLineItems to InterestExpenseDebt" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtConversionOriginalDebtAmount1" xlink:title="presentation: StatementLineItems to DebtConversionOriginalDebtAmount1" order="43.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_BeneficialConversionFeatureConversionOfConvertibleNote" xlink:label="BeneficialConversionFeatureConversionOfConvertibleNote" xlink:title="BeneficialConversionFeatureConversionOfConvertibleNote"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="BeneficialConversionFeatureConversionOfConvertibleNote" xlink:title="presentation: StatementLineItems to BeneficialConversionFeatureConversionOfConvertibleNote" order="53.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: StatementTable to LongtermDebtTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanAMember" xlink:label="TermLoanAMember" xlink:title="TermLoanAMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="TermLoanAMember" xlink:title="presentation: LongtermDebtTypeAxis to TermLoanAMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanBMember" xlink:label="TermLoanBMember" xlink:title="TermLoanBMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="TermLoanBMember" xlink:title="presentation: LongtermDebtTypeAxis to TermLoanBMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="TermLoansMember" xlink:title="presentation: LongtermDebtTypeAxis to TermLoansMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_TermLoanCMember" xlink:label="TermLoanCMember" xlink:title="TermLoanCMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="TermLoanCMember" xlink:title="presentation: LongtermDebtTypeAxis to TermLoanCMember" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: StatementTable to DebtInstrumentAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_FirstNoteToFundTheCompanysOperationsMember" xlink:label="FirstNoteToFundTheCompanysOperationsMember" xlink:title="FirstNoteToFundTheCompanysOperationsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="FirstNoteToFundTheCompanysOperationsMember" xlink:title="presentation: DebtInstrumentAxis to FirstNoteToFundTheCompanysOperationsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SecondNoteToFundTheCompanysOperationsMember" xlink:label="SecondNoteToFundTheCompanysOperationsMember" xlink:title="SecondNoteToFundTheCompanysOperationsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="SecondNoteToFundTheCompanysOperationsMember" xlink:title="presentation: DebtInstrumentAxis to SecondNoteToFundTheCompanysOperationsMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NotesToFundTheCompanysOperationsMember" xlink:label="NotesToFundTheCompanysOperationsMember" xlink:title="NotesToFundTheCompanysOperationsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="NotesToFundTheCompanysOperationsMember" xlink:title="presentation: DebtInstrumentAxis to NotesToFundTheCompanysOperationsMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:label="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="ModifiedMarch2018AndModifiedSeptember2018NotesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ModifiedMarch2018AndModifiedSeptember2018NotesMember" xlink:title="presentation: DebtInstrumentAxis to ModifiedMarch2018AndModifiedSeptember2018NotesMember" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePromissoryNoteOf15MillionMember" xlink:label="ConvertiblePromissoryNoteOf15MillionMember" xlink:title="ConvertiblePromissoryNoteOf15MillionMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ConvertiblePromissoryNoteOf15MillionMember" xlink:title="presentation: DebtInstrumentAxis to ConvertiblePromissoryNoteOf15MillionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:label="ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:title="ModifiedMarch2019AndModifiedDecember2018NotesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ModifiedMarch2019AndModifiedDecember2018NotesMember" xlink:title="presentation: DebtInstrumentAxis to ModifiedMarch2019AndModifiedDecember2018NotesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:label="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:title="ModifiedMarch2018September2018December2018AndMarch2019NotesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ModifiedMarch2018September2018December2018AndMarch2019NotesMember" xlink:title="presentation: DebtInstrumentAxis to ModifiedMarch2018September2018December2018AndMarch2019NotesMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:label="ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:title="ConvertiblePromissoryNoteIssuedOnMarch292019Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ConvertiblePromissoryNoteIssuedOnMarch292019Member" xlink:title="presentation: DebtInstrumentAxis to ConvertiblePromissoryNoteIssuedOnMarch292019Member" order="5.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:label="ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:title="ConvertiblePromissoryNoteIssuedSeptember272018Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ConvertiblePromissoryNoteIssuedSeptember272018Member" xlink:title="presentation: DebtInstrumentAxis to ConvertiblePromissoryNoteIssuedSeptember272018Member" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtConversionByUniqueDescriptionAxis" xlink:title="presentation: StatementTable to DebtConversionByUniqueDescriptionAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="presentation: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="presentation: DebtConversionByUniqueDescriptionAxis to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="presentation: StatementTable to RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MinimumMember" xlink:title="presentation: RangeAxis to MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="presentation: StatementTable to LineOfCreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="presentation: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="MajorityInvestorsMember" xlink:title="presentation: LineOfCreditFacilityAxis to MajorityInvestorsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_OxfordFinanceLLCMember" xlink:label="OxfordFinanceLLCMember" xlink:title="OxfordFinanceLLCMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="OxfordFinanceLLCMember" xlink:title="presentation: LineOfCreditFacilityAxis to OxfordFinanceLLCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: StatementTable to CounterpartyNameAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_DomainMember" xlink:label="DomainMember" xlink:title="DomainMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="DomainMember" xlink:title="presentation: CounterpartyNameAxis to DomainMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: StatementTable to BusinessAcquisitionAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: BusinessAcquisitionAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="VariableRateAxis" xlink:title="presentation: StatementTable to VariableRateAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="presentation: VariableRateAxis to VariableRateDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLiborSwapRateMember" xlink:label="LondonInterbankOfferedRateLiborSwapRateMember" xlink:title="LondonInterbankOfferedRateLiborSwapRateMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateAxis" xlink:to="LondonInterbankOfferedRateLiborSwapRateMember" xlink:title="presentation: VariableRateAxis to LondonInterbankOfferedRateLiborSwapRateMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="11.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:label="ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:title="ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" xlink:title="presentation: EquityComponentDomain to ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="NoteToFinancialStatementDetailsTextual" xlink:title="NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteToFinancialStatementDetailsTextual" xlink:to="StatementTable" xlink:title="presentation: NoteToFinancialStatementDetailsTextual to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-7-leases-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OperatingLeaseExpense" xlink:title="presentation: StatementLineItems to OperatingLeaseExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="LeaseAndRentalExpense" xlink:title="LeaseAndRentalExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LeaseAndRentalExpense" xlink:title="presentation: StatementLineItems to LeaseAndRentalExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="FinanceLeaseLiability" xlink:title="FinanceLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="FinanceLeaseLiability" xlink:title="presentation: StatementLineItems to FinanceLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LesseeOperatingLeaseNotYetCommenced" xlink:label="LesseeOperatingLeaseNotYetCommenced" xlink:title="LesseeOperatingLeaseNotYetCommenced"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseNotYetCommenced" xlink:title="presentation: StatementLineItems to LesseeOperatingLeaseNotYetCommenced" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LesseeFinanceLeaseNotYetCommenced" xlink:label="LesseeFinanceLeaseNotYetCommenced" xlink:title="LesseeFinanceLeaseNotYetCommenced"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LesseeFinanceLeaseNotYetCommenced" xlink:title="presentation: StatementLineItems to LesseeFinanceLeaseNotYetCommenced" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SubleaseIncome" xlink:title="presentation: StatementLineItems to SubleaseIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="NoteToFinancialStatementDetailsTextual" xlink:title="NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteToFinancialStatementDetailsTextual" xlink:to="StatementTable" xlink:title="presentation: NoteToFinancialStatementDetailsTextual to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stock-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TemporaryEquitySharesIssued" xlink:title="presentation: StatementLineItems to TemporaryEquitySharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TemporaryEquitySharesOutstanding" xlink:title="presentation: StatementLineItems to TemporaryEquitySharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="presentation: StatementLineItems to DebtConversionConvertedInstrumentSharesIssued1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StatementLineItems to PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StatementLineItems to PreferredStockSharesAuthorized" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StatementLineItems to PreferredStockSharesOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="presentation: StatementClassOfStockAxis to SeriesARedeemableConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="presentation: StatementClassOfStockAxis to SeriesBRedeemableConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ConversionOfStockByUniqueDescriptionAxis" xlink:title="presentation: StatementTable to ConversionOfStockByUniqueDescriptionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfStockNameDomain" xlink:title="presentation: ConversionOfStockByUniqueDescriptionAxis to ConversionOfStockNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="presentation: ConversionOfStockByUniqueDescriptionAxis to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="NoteToFinancialStatementDetailsTextual" xlink:title="NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteToFinancialStatementDetailsTextual" xlink:to="StatementTable" xlink:title="presentation: NoteToFinancialStatementDetailsTextual to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-9-warrants-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: StatementTable to ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:label="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" xlink:title="presentation: ClassOfWarrantOrRightAxis to WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:label="WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:title="WarrantToPurchaseCommonStockConvertedInMergerMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="WarrantToPurchaseCommonStockConvertedInMergerMember" xlink:title="presentation: ClassOfWarrantOrRightAxis to WarrantToPurchaseCommonStockConvertedInMergerMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaWarrantsAssumedInMergerMember" xlink:label="AlliquaWarrantsAssumedInMergerMember" xlink:title="AlliquaWarrantsAssumedInMergerMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="AlliquaWarrantsAssumedInMergerMember" xlink:title="presentation: ClassOfWarrantOrRightAxis to AlliquaWarrantsAssumedInMergerMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantsForSeriesAConvertiblePreferredStockMember" xlink:label="WarrantsForSeriesAConvertiblePreferredStockMember" xlink:title="WarrantsForSeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="WarrantsForSeriesAConvertiblePreferredStockMember" xlink:title="presentation: ClassOfWarrantOrRightAxis to WarrantsForSeriesAConvertiblePreferredStockMember" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:label="WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:title="WarrantIssuedInConnectionWithTermLoanAAndBMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="WarrantIssuedInConnectionWithTermLoanAAndBMember" xlink:title="presentation: ClassOfWarrantOrRightAxis to WarrantIssuedInConnectionWithTermLoanAAndBMember" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: StatementLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: StatementLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: StatementLineItems to ClassOfWarrantOrRightOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="presentation: StatementLineItems to WarrantsAndRightsOutstandingMeasurementInput" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PercentageOfNotePayablePrincipal" xlink:label="PercentageOfNotePayablePrincipal" xlink:title="PercentageOfNotePayablePrincipal"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PercentageOfNotePayablePrincipal" xlink:title="presentation: StatementLineItems to PercentageOfNotePayablePrincipal" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ClassOfWarrantsOrRightExercisableTerm" xlink:label="ClassOfWarrantsOrRightExercisableTerm" xlink:title="ClassOfWarrantsOrRightExercisableTerm"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ClassOfWarrantsOrRightExercisableTerm" xlink:title="presentation: StatementLineItems to ClassOfWarrantsOrRightExercisableTerm" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="WarrantsNotSettleableInCashFairValueDisclosure" xlink:title="WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="WarrantsNotSettleableInCashFairValueDisclosure" xlink:title="presentation: StatementLineItems to WarrantsNotSettleableInCashFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="presentation: StatementLineItems to FairValueAdjustmentOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="WarrantsAndRightsOutstanding" xlink:title="presentation: StatementLineItems to WarrantsAndRightsOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ExchangeOfWarrantsUponMerger" xlink:label="ExchangeOfWarrantsUponMerger" xlink:title="ExchangeOfWarrantsUponMerger"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ExchangeOfWarrantsUponMerger" xlink:title="presentation: StatementLineItems to ExchangeOfWarrantsUponMerger" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="presentation: StatementTable to RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="MeasurementInputTypeAxis" xlink:title="presentation: StatementTable to MeasurementInputTypeAxis" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="presentation: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="MeasurementInputConversionPriceMember" xlink:title="MeasurementInputConversionPriceMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputConversionPriceMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputConversionPriceMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="MeasurementInputSharePriceMember" xlink:title="MeasurementInputSharePriceMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputSharePriceMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputSharePriceMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: StatementTable to BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: BusinessAcquisitionAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="NoteToFinancialStatementDetailsTextual" xlink:title="NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteToFinancialStatementDetailsTextual" xlink:to="StatementTable" xlink:title="presentation: NoteToFinancialStatementDetailsTextual to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: StatementLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="presentation: StatementLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharePrice" xlink:title="presentation: StatementLineItems to SharePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: StatementLineItems to AllocatedShareBasedCompensationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: StatementLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: StatementLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:label="NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:title="NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" xlink:title="presentation: StatementLineItems to NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:label="NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:title="NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" xlink:title="presentation: StatementLineItems to NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" xlink:title="presentation: StatementLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="presentation: StatementLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RangeAxis" xlink:title="presentation: StatementTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MinimumMember" xlink:title="presentation: RangeAxis to MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="MaximumMember" xlink:title="presentation: RangeAxis to MaximumMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: LegalEntityAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: StatementTable to BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: BusinessAcquisitionAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="AwardTypeAxis" xlink:title="presentation: StatementTable to AwardTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AwardTypeAxis to EmployeeStockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NonEmployeeOptionsMember" xlink:label="NonEmployeeOptionsMember" xlink:title="NonEmployeeOptionsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="NonEmployeeOptionsMember" xlink:title="presentation: AwardTypeAxis to NonEmployeeOptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="PlanNameAxis" xlink:title="presentation: StatementTable to PlanNameAxis" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ThePlanMember" xlink:label="ThePlanMember" xlink:title="ThePlanMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="ThePlanMember" xlink:title="presentation: PlanNameDomain to ThePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="NoteToFinancialStatementDetailsTextual" xlink:title="NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteToFinancialStatementDetailsTextual" xlink:to="StatementTable" xlink:title="presentation: NoteToFinancialStatementDetailsTextual to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactions-details-textualQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: StatementLineItems to DebtInstrumentInterestRateStatedPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ProceedsFromNotesPayable" xlink:title="presentation: StatementLineItems to ProceedsFromNotesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: StatementLineItems to DebtInstrumentFaceAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="InterestPayableCurrentAndNoncurrent" xlink:title="presentation: StatementLineItems to InterestPayableCurrentAndNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:title="NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:title="presentation: StatementLineItems to NotesPayableRelatedPartiesCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="RelatedPartyTransactionAmountsOfTransaction" xlink:title="RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="RelatedPartyTransactionAmountsOfTransaction" xlink:title="presentation: StatementLineItems to RelatedPartyTransactionAmountsOfTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="7.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBConvertiblePreferredStockMember" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:title="SeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesBConvertiblePreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesBConvertiblePreferredStockMember" order="1.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtConversionByUniqueDescriptionAxis" xlink:title="presentation: StatementTable to DebtConversionByUniqueDescriptionAxis" order="6.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="presentation: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:label="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionNameDomain" xlink:to="ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" xlink:title="presentation: DebtConversionNameDomain to ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: StatementTable to SubsequentEventTypeAxis" order="4.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="presentation: StatementTable to LineOfCreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="presentation: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_MajorityInvestorsMember" xlink:label="MajorityInvestorsMember" xlink:title="MajorityInvestorsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="MajorityInvestorsMember" xlink:title="presentation: LineOfCreditFacilityAxis to MajorityInvestorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: StatementTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChiefExecutiveOfficerMember" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to ChiefExecutiveOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="presentation: StatementTable to RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="presentation: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeverancePayMember" xlink:label="SeverancePayMember" xlink:title="SeverancePayMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAxis" xlink:to="SeverancePayMember" xlink:title="presentation: RelatedPartyTransactionAxis to SeverancePayMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoteToFinancialStatementDetailsTextual" xlink:label="NoteToFinancialStatementDetailsTextual" xlink:title="NoteToFinancialStatementDetailsTextual"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteToFinancialStatementDetailsTextual" xlink:to="StatementTable" xlink:title="presentation: NoteToFinancialStatementDetailsTextual to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticalsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TemporaryEquitySharesIssued" xlink:title="presentation: StatementLineItems to TemporaryEquitySharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TemporaryEquitySharesOutstanding" xlink:title="presentation: StatementLineItems to TemporaryEquitySharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StatementLineItems to CommonStockParOrStatedValuePerShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StatementLineItems to CommonStockSharesAuthorized" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StatementLineItems to CommonStockSharesOutstanding" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StatementLineItems to PreferredStockSharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StatementLineItems to PreferredStockSharesAuthorized" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StatementLineItems to PreferredStockSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:title="TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:title="presentation: StatementLineItems to TemporaryEquityValueExcludingAdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TemporaryEquitySharesAuthorized" xlink:title="presentation: StatementLineItems to TemporaryEquitySharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="TemporaryEquityLiquidationPreference" xlink:title="TemporaryEquityLiquidationPreference"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="TemporaryEquityLiquidationPreference" xlink:title="presentation: StatementLineItems to TemporaryEquityLiquidationPreference" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StatementLineItems to CommonStockSharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StatementLineItems to PreferredStockParOrStatedValuePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="presentation: StatementClassOfStockAxis to SeriesARedeemableConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="presentation: StatementClassOfStockAxis to SeriesBRedeemableConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfFinancialPositionAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-7-leases-future-minimum-lease-payments-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OperatingLeaseLiability" xlink:title="presentation: StatementLineItems to OperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="presentation: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="presentation: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="presentation: StatementLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: StatementLineItems to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-7-leases-future-minimum-lease-payments-details" xlink:label="statement-statement-note-7-leases-future-minimum-lease-payments-details" xlink:title="statement-statement-note-7-leases-future-minimum-lease-payments-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-7-leases-future-minimum-lease-payments-details" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-7-leases-future-minimum-lease-payments-details to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-cash-flows-unauditedQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementLineItems to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="Depreciation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to Depreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to FairValueAdjustmentOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:label="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:title="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfFinancingCostsAndDiscounts" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PaidInKindInterest" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to PaidInKindInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DerivativeGainLossOnDerivativeNet" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DerivativeGainLossOnDerivativeNet" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_NoncashPortionOfLeaseExpense" xlink:label="NoncashPortionOfLeaseExpense" xlink:title="NoncashPortionOfLeaseExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NoncashPortionOfLeaseExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to NoncashPortionOfLeaseExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInOperatingCapitalAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to NetCashProvidedByUsedInOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_IncreaseDecreaseInLeaseLiability" xlink:label="IncreaseDecreaseInLeaseLiability" xlink:title="IncreaseDecreaseInLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInLeaseLiability" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="PaymentsForProceedsFromProductiveAssets" xlink:title="PaymentsForProceedsFromProductiveAssets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsForProceedsFromProductiveAssets" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsForProceedsFromProductiveAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfLongTermDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfLongTermDebt" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromWarrantExercises" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromWarrantExercises" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="ProceedsFromRelatedPartyDebt" xlink:title="ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromRelatedPartyDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromRelatedPartyDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementLineItems to SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NoncashInvestingAndFinancingItemsAbstract" xlink:title="presentation: StatementLineItems to NoncashInvestingAndFinancingItemsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ReclassificationOfWarrantLiabilityToPaidInCapital" xlink:label="ReclassificationOfWarrantLiabilityToPaidInCapital" xlink:title="ReclassificationOfWarrantLiabilityToPaidInCapital"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="ReclassificationOfWarrantLiabilityToPaidInCapital" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to ReclassificationOfWarrantLiabilityToPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="ConversionOfStockAmountConverted1" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to ConversionOfStockAmountConverted1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfCashFlowsAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="presentation: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="presentation: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:title="presentation: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="presentation: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="presentation: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="presentation: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:title="presentation: StatementLineItems to FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: StatementTable to FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeMember" xlink:label="DerivativeMember" xlink:title="DerivativeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="DerivativeMember" xlink:title="presentation: FinancialInstrumentAxis to DerivativeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="WarrantMember" xlink:title="presentation: FinancialInstrumentAxis to WarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details" xlink:label="statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details" xlink:title="statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-details to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-property-and-equipment-net-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: StatementLineItems to PropertyPlantAndEquipmentGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: StatementLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: StatementLineItems to PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: StatementTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="OfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to OfficeEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="ComputerEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to ComputerEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to LaboratoryEquipmentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details" xlink:label="statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details" xlink:title="statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-4-property-and-equipment-net-property-and-equipment-net-details to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PrepaidClinicalTrialExpenseCurrent" xlink:label="PrepaidClinicalTrialExpenseCurrent" xlink:title="PrepaidClinicalTrialExpenseCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PrepaidClinicalTrialExpenseCurrent" xlink:title="presentation: StatementLineItems to PrepaidClinicalTrialExpenseCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityIssuanceCostsCurrent" xlink:label="EquityIssuanceCostsCurrent" xlink:title="EquityIssuanceCostsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EquityIssuanceCostsCurrent" xlink:title="presentation: StatementLineItems to EquityIssuanceCostsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="PrepaidInsurance" xlink:title="PrepaidInsurance"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PrepaidInsurance" xlink:title="presentation: StatementLineItems to PrepaidInsurance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="OtherPrepaidExpenseCurrent" xlink:title="OtherPrepaidExpenseCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OtherPrepaidExpenseCurrent" xlink:title="presentation: StatementLineItems to OtherPrepaidExpenseCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: StatementLineItems to PrepaidExpenseAndOtherAssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details" xlink:label="statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details" xlink:title="statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-details to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-accrued-liabilities-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedPayrollAndRelatedExpensesCurrent" xlink:label="AccruedPayrollAndRelatedExpensesCurrent" xlink:title="AccruedPayrollAndRelatedExpensesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AccruedPayrollAndRelatedExpensesCurrent" xlink:title="presentation: StatementLineItems to AccruedPayrollAndRelatedExpensesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedTermLoanPaymentsCurrent" xlink:label="AccruedTermLoanPaymentsCurrent" xlink:title="AccruedTermLoanPaymentsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AccruedTermLoanPaymentsCurrent" xlink:title="presentation: StatementLineItems to AccruedTermLoanPaymentsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AccruedClinicalTrialExpenseCurrent" xlink:label="AccruedClinicalTrialExpenseCurrent" xlink:title="AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AccruedClinicalTrialExpenseCurrent" xlink:title="presentation: StatementLineItems to AccruedClinicalTrialExpenseCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: StatementLineItems to AccruedProfessionalFeesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: StatementLineItems to AccruedLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details" xlink:label="statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details" xlink:title="statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-5-other-balance-sheet-information-accrued-liabilities-details to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="ConvertibleDebt" xlink:title="ConvertibleDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ConvertibleDebt" xlink:title="presentation: StatementLineItems to ConvertibleDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: StatementTable to DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableOneMember" xlink:label="ConvertibleNotePayableOneMember" xlink:title="ConvertibleNotePayableOneMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ConvertibleNotePayableOneMember" xlink:title="presentation: DebtInstrumentAxis to ConvertibleNotePayableOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableTwoMember" xlink:label="ConvertibleNotePayableTwoMember" xlink:title="ConvertibleNotePayableTwoMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ConvertibleNotePayableTwoMember" xlink:title="presentation: DebtInstrumentAxis to ConvertibleNotePayableTwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableThreeMember" xlink:label="ConvertibleNotePayableThreeMember" xlink:title="ConvertibleNotePayableThreeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ConvertibleNotePayableThreeMember" xlink:title="presentation: DebtInstrumentAxis to ConvertibleNotePayableThreeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableFourMember" xlink:label="ConvertibleNotePayableFourMember" xlink:title="ConvertibleNotePayableFourMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ConvertibleNotePayableFourMember" xlink:title="presentation: DebtInstrumentAxis to ConvertibleNotePayableFourMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableFiveMember" xlink:label="ConvertibleNotePayableFiveMember" xlink:title="ConvertibleNotePayableFiveMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ConvertibleNotePayableFiveMember" xlink:title="presentation: DebtInstrumentAxis to ConvertibleNotePayableFiveMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ConvertibleNotePayableSixMember" xlink:label="ConvertibleNotePayableSixMember" xlink:title="ConvertibleNotePayableSixMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="ConvertibleNotePayableSixMember" xlink:title="presentation: DebtInstrumentAxis to ConvertibleNotePayableSixMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:label="statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:title="statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-details to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-operations-unauditedQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: StatementLineItems to OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: OperatingExpensesAbstract to OperatingIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="InterestIncomeExpenseNet" xlink:title="InterestIncomeExpenseNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="InterestIncomeExpenseNet" xlink:title="presentation: OperatingExpensesAbstract to InterestIncomeExpenseNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: OperatingExpensesAbstract to NetIncomeLoss" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_GrantReimbursementsExpense" xlink:label="GrantReimbursementsExpense" xlink:title="GrantReimbursementsExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GrantReimbursementsExpense" xlink:title="presentation: OperatingExpensesAbstract to GrantReimbursementsExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="InterestExpense" xlink:title="presentation: OperatingExpensesAbstract to InterestExpense" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: OperatingExpensesAbstract to NonoperatingIncomeExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="IncomeLossFromContinuingOperations" xlink:title="IncomeLossFromContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="IncomeLossFromContinuingOperations" xlink:title="presentation: OperatingExpensesAbstract to IncomeLossFromContinuingOperations" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:title="DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:title="presentation: OperatingExpensesAbstract to DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="EarningsPerShareBasicAndDilutedAbstract" xlink:title="EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasicAndDilutedAbstract" xlink:title="presentation: StatementLineItems to EarningsPerShareBasicAndDilutedAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:title="IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:title="presentation: EarningsPerShareBasicAndDilutedAbstract to IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:label="DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:title="DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:title="presentation: EarningsPerShareBasicAndDilutedAbstract to DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="presentation: EarningsPerShareBasicAndDilutedAbstract to EarningsPerShareBasicAndDiluted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="presentation: EarningsPerShareBasicAndDilutedAbstract to WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="StatementTable" xlink:title="presentation: IncomeStatementAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="DerivativeLiabilities" xlink:title="DerivativeLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DerivativeLiabilities" xlink:title="presentation: StatementLineItems to DerivativeLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="FinancialLiabilitiesFairValueDisclosure" xlink:title="presentation: StatementLineItems to FinancialLiabilitiesFairValueDisclosure" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: StatementTable to FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="WarrantMember" xlink:title="presentation: FinancialInstrumentAxis to WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: StatementTable to FairValueByMeasurementFrequencyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementsRecurringMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: StatementTable to FairValueByFairValueHierarchyLevelAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueInputsLevel1Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueInputsLevel2Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueInputsLevel3Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details" xlink:label="statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details" xlink:title="statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-details to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unauditedQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: StatementLineItems to AssetsCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="RestrictedCashCurrent" xlink:title="RestrictedCashCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="RestrictedCashCurrent" xlink:title="presentation: AssetsCurrentAbstract to RestrictedCashCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsCurrentAbstract to PropertyPlantAndEquipmentNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="RestrictedCashNoncurrent" xlink:title="RestrictedCashNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="RestrictedCashNoncurrent" xlink:title="presentation: AssetsCurrentAbstract to RestrictedCashNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsCurrentAbstract to OtherAssetsNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="Assets" xlink:title="presentation: AssetsCurrentAbstract to Assets" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: AssetsCurrentAbstract to OperatingLeaseRightOfUseAsset" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: StatementLineItems to LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LongTermDebtCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LongTermDebtCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LongTermDebtNoncurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LongTermDebtNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DerivativeLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to DerivativeLiabilitiesCurrent" order="9.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesCurrentAbstract to CommitmentsAndContingencies" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="ConvertibleDebtCurrent" xlink:title="ConvertibleDebtCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ConvertibleDebtCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to ConvertibleDebtCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="DerivativeLiabilities" xlink:title="DerivativeLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DerivativeLiabilities" xlink:title="presentation: LiabilitiesCurrentAbstract to DerivativeLiabilities" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:label="RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:title="RedeemableNoncontrollingInterestEquityCarryingAmountAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:title="presentation: StatementLineItems to RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" order="3.0"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableNoncontrollingInterestEquityCarryingAmountAbstract" xlink:to="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="presentation: RedeemableNoncontrollingInterestEquityCarryingAmountAbstract to TemporaryEquityCarryingAmountAttributableToParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: StatementLineItems to StockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="presentation: StatementClassOfStockAxis to SeriesARedeemableConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="presentation: StatementClassOfStockAxis to SeriesBRedeemableConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfFinancialPositionAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-redeemable-convertible-preferred-stock-and-stockholders-deficit-unauditedQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_BeneficialConversionFeatureConversionOfConvertibleNote" xlink:label="BeneficialConversionFeatureConversionOfConvertibleNote" xlink:title="BeneficialConversionFeatureConversionOfConvertibleNote"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="BeneficialConversionFeatureConversionOfConvertibleNote" xlink:title="presentation: StatementLineItems to BeneficialConversionFeatureConversionOfConvertibleNote" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_ExchangeOfWarrantsUponMerger" xlink:label="ExchangeOfWarrantsUponMerger" xlink:title="ExchangeOfWarrantsUponMerger"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ExchangeOfWarrantsUponMerger" xlink:title="presentation: StatementLineItems to ExchangeOfWarrantsUponMerger" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="presentation: StatementLineItems to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharesOutstanding_2" xlink:title="presentation: StatementLineItems to SharesOutstanding" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="presentation: StatementLineItems to StockholdersEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockholdersEquity_2" xlink:title="presentation: StatementLineItems to StockholdersEquity" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_StockIssuedDuringPeriodSharesWarrantExercised" xlink:label="StockIssuedDuringPeriodSharesWarrantExercised" xlink:title="StockIssuedDuringPeriodSharesWarrantExercised"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesWarrantExercised" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesWarrantExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="presentation: StatementLineItems to NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesAcquisitions" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueAcquisitions" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityIssuanceCostsPaidInStockShares" xlink:label="EquityIssuanceCostsPaidInStockShares" xlink:title="EquityIssuanceCostsPaidInStockShares"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EquityIssuanceCostsPaidInStockShares" xlink:title="presentation: StatementLineItems to EquityIssuanceCostsPaidInStockShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityIssuanceCostsPaidInStock" xlink:label="EquityIssuanceCostsPaidInStock" xlink:title="EquityIssuanceCostsPaidInStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EquityIssuanceCostsPaidInStock" xlink:title="presentation: StatementLineItems to EquityIssuanceCostsPaidInStock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_EquityImpactOfSpinoff" xlink:label="EquityImpactOfSpinoff" xlink:title="EquityImpactOfSpinoff"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EquityImpactOfSpinoff" xlink:title="presentation: StatementLineItems to EquityImpactOfSpinoff" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_StockIssuedDuringPeriodValueWarrantExercised" xlink:label="StockIssuedDuringPeriodValueWarrantExercised" xlink:title="StockIssuedDuringPeriodValueWarrantExercised"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueWarrantExercised" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodValueWarrantExercised" order="3.1" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="SeriesARedeemableConvertiblePreferredStockMember" xlink:title="presentation: StatementClassOfStockAxis to SeriesARedeemableConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="SeriesBRedeemableConvertiblePreferredStockMember" xlink:title="presentation: StatementClassOfStockAxis to SeriesBRedeemableConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="PreferredStockMember" xlink:title="presentation: StatementEquityComponentsAxis to PreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-summary-of-stock-option-activity-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: StatementLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: StatementLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="presentation: StatementLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="presentation: StatementLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="presentation: StatementLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: StatementTable to BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_AlliquaBiomedicalIncMember" xlink:label="AlliquaBiomedicalIncMember" xlink:title="AlliquaBiomedicalIncMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="AlliquaBiomedicalIncMember" xlink:title="presentation: BusinessAcquisitionAxis to AlliquaBiomedicalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-10-stock-options-summary-of-stock-option-activity-details" xlink:label="statement-statement-note-10-stock-options-summary-of-stock-option-activity-details" xlink:title="statement-statement-note-10-stock-options-summary-of-stock-option-activity-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-10-stock-options-summary-of-stock-option-activity-details" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-10-stock-options-summary-of-stock-option-activity-details to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adynxx.com/20190630/role/statement-note-10-stock-options-stock-options-by-exercise-price-range-detailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="presentation: StatementLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="presentation: StatementLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="presentation: StatementLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="presentation: StatementLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="presentation: StatementLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="presentation: StatementLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="presentation: StatementLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="LegalEntityAxis" xlink:title="presentation: StatementTable to LegalEntityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="presentation: StatementTable to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PriceRange1Member" xlink:label="PriceRange1Member" xlink:title="PriceRange1Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="PriceRange1Member" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to PriceRange1Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PriceRange2Member" xlink:label="PriceRange2Member" xlink:title="PriceRange2Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="PriceRange2Member" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to PriceRange2Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PriceRange3Member" xlink:label="PriceRange3Member" xlink:title="PriceRange3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="PriceRange3Member" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to PriceRange3Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_PriceRange4Member" xlink:label="PriceRange4Member" xlink:title="PriceRange4Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="PriceRange4Member" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to PriceRange4Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:href="adyx-20190630.xsd#adyx_statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details" xlink:label="statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details" xlink:title="statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details" xlink:to="StatementTable" xlink:title="presentation: statement-statement-note-10-stock-options-stock-options-by-exercise-price-range-details to StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  L (@# 2(  A$! Q$!_\0
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M?$T<MQM2I3J4Z-',*6&AB*M.K0H8BIB:53"1_FD_:>_Y6!_ /_98_P!E[_U
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M7GBN*:UN8O$UUX:T:X\0Q7%C'%%97$>M2V3ZDDUG%##%:RK<B2WCBB2%D6-
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..JKBK^M4445]8?R4?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>lg_adynxx.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_adynxx.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __
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M " Y@=,]_P!MNWO*HNTOSK/\Q"2CK'W?'K4>GI_F:O\ XJ)-X8]S?G7,>6L
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M?>=>?D/K4Z_(D.N/R'W5G=;KSSJEN..*/B2223YZ9<2"0A("4 2    '8 ,
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M"==-/"-Q97M$Y?5PES_@^7R9#C&/3I3N,Y6A*REI=)=H^F5(?2"$N)KI9;D
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M7N):H6&RM:U<$I'$_N#B3PCV6ZWU]XN=/9K2TJHNM6Z&VFT\5K5P'< )DDX
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M+K-9/H'M=TJ2A"B!/P6"4"1["O,?-CPB5O= )3VGWNP*C^^6##8>?C>- G^
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MC2^-1!<=7UK106+:IE7'!W)#<5;;R$@^20!Y#2-=1.G6+3K%NZTJ0EFX,9U
M?ZU)RK/E,TD]\6=](VKZK4&W"[+7+*ZFTU)9229GP5#,T/(G%([A"TN^+MI[
MZ<7Y\Y.Y'X:XZA<C<)6\]O)*^JJC2FWKW)D1EZ\8351WHUY)Z+!+JP4!PJZ_
M ?#4I;8[DZ#>TM0V;4%9[-?FD>$2L+RD),D'/(I'HR&,I2B'-Z=H=U*?6UQU
M'HRWIK=+OJ#V1M;8=2M21XH#9*5*](%0RS))( BE?&?<!59M*=H;6MFX?EL1
M:V)5):%20N4P2W)98=>;8<2\VM)!:=0A8\O'8ZF>JM8:2'FE)=IU"84G$2/
MX3!![087>TZJ%8ZJDJ$+IZ]M12I"P0H*&!209$$<P0(L,UD4\1VX:ILI4-MP
MNHAKD/*BMNJ&RG41E.%I#A3X%0 .VL0J@8*R[D3XI$BJ0F1V$RG*-N;O%2E
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M<",Z/2$^U)!BIBE+<6MUUQQYUU:G'7GG%O/.N+.ZW'775+<<<6?$E1))U)8
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M "2=@!N2?( >9/W:.. XQP2 )G@(T5>U]QDG#NWP9K*CANTY/NIE\%K04O\
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M>4I[YPD#3?17U';<!PR=R+G6'X%7#>7EV15=&CP)Z6IDE"9+AZ?$);C!9)^
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M<(E'6O1M<>#MML3MOH@C+[W\\JGE+N4S(1'BY0X$6<&I5(=+C$A56@.7$QL
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H:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tv523241_chrt-line1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_chrt-line1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#7 .$ P$1  (1 0,1 ?_$ 1   0 !! ,! 0$
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MH9>!:/$PI I[ZU$=RN5./?M0N1^@-H(U^%133=4G31O7@4T?"GB1B7'%X/\
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M<:B8G,SE+0TYX0R6TXHC["-)PJLLVJX:/=OX=J?)_>;"VI&)(*@
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MT"A5#QB%*DQ)%;B5.VIK,IQ!-I?1X)SE)2E$(WEW%Q1L/D9*+4N)&!!4
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M?(\$VDB2CPTJ(\YR<.S703Q*[5L/@3C3':$<B+ LI*/UB;9HI(T^@5/T[G>
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MIF?ZNH :%]3L\SZ  :%VZ%^C_D %#3Q_W=.[JG4_JZD .6A=X
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M58Y*)2M#T,]3/@(IQ);V$OR2(DD1=A%H7T"X:?I"2'R.0         &A=X
M         4,NW@1\-./89>:>A\ !@OB+8'AG">['-N[JQ7:Q3+[SS A1+UH;
M2V6[<4]$-A:YL6,RA'*[)=CDM6I?9F9]I@MCJ6;JJ453.C3CKJ?T.X!4J
M      "FA=NA:]\ 4-!&6FIEQ,]2X&1GKJ9'W.T 1P8GZ8NW[%6\2^MZ\5ZY
M+FR_>M-=IJ9%S24SXE!3(4KQEZE+<0IWPBD*-*-3_>TJ/3B(2H2Y)K<L7,DA
M$D                                                     !0_TP
M!4                             %..O<T_3 %0
M                       _1]  "[/K]H
M             !EKP,             _['_9_2                    UT
M_P"34 <==>PR\S@?F'KVEPT, 4\_QXI_8*]$ .1'J1'KKYO81^:7F "H
M
M
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M4VLU]32W'%H759\9QY1&HSU7VB"6ZNIZB!!37Z( J
M
M
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M?O-JWXPA\ K+FA[3=XOQJXS]YM6_&$/@%9<T/:;O%^-7&?O-JWXQ!\'V_P"
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M]J33BLOLQCU+C,]J++QI,S[IQFU'IVZ$,D?].7L(>]-F<XQD@
M         !0
M
M                                     #S[*NGP=W?S&>GK++[.!_8<
M.X?=%H?,1+<1^ZGY.?-J>GK[W^YX/MU&>O\ F%*;*$H8XQD     *:$? R(R
M[V@ J    #!/<-JK==L821:J3=F6'U:=QE.+:TRH^!]A.R&_,U,O,&6'R2[O
MQ*2WQ[_P9G8,1<
M
M
M  +"RBDEX^NY*BU(Z)-_BC$QWD/<1\Z%Y.7\_?\ R>GZ@S4^/V%.PE#& R
M          8*[B=4;KMC)EVJO'+#*C[=6U8KKSIIX]]QA)Z]O 9H?))]A26R
M45V_@S.H82X
M
M                                                           6
M'D[^S^[?Y$F_Q1B8[RKW$?/^7+^?OW S_K]A7C[24(<<R            8*[
MB_\ %=L8_KME?^Z>Y!FM_P"G/N,<_FCW_@S.H83(
M
M
M                            %AY._L_NW^1)W\68M'>5>XCY_P N7\_?
MN!F_7["O'VDH0XYD            P5W%_P"*[8Q_7;*_]T]R#-;_ -.?<8Y_
M/'O_  9G4,)D
M
M
M"P\G?V?W;_(D[^+,6CO*O<1\_P"7+^?OW S?K]A7C[24(<<R
M8*[B_P#%=L8_KME?^Z>Y!FM_Z<^XQS^>/?\ @S.H83(
M
M
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MF0C=O)34MD6FT2A@2
M
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M\KG4Z9FLU\3/4.!?$^#,^ *@
M
M
M   %AY._L_NW^1)W\68M'>5>XCY_RY?S]^X&;]?L*\?:2A#CF0
M #!7<7_BNV,?UVRO_=/<@S6_].?<8Y_/'O\ P9G4,)D   #4^^=:?X7L0>9E
M^S"^K56M0#W>U?>;/V(O[*,8?_>\LK_[6Z: /0P
M
M
M                   !8>3O[/[M_D2=_%F+1WE7N(^?\N7\_?N!F_7["O'V
MDH0XYD        "A:]TM/I@"H P4W%'_ .];L7[YWKE<_P#]$]QC-;^2?<8Y
M_-'O_!F=8PF0   -3[YUI_A>Q#_]^"S/_P"JM 'N]J^\V?L1?V3XP_\ O>65
M_P#:W30!Z&
M
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MQ+_\WEE?_:W3?K #T,
M
M                                                           6
M%E R+'UVF?X$F_Q1BT?F*RW$?'^7/7_\?=G_ (/ZXR_KKV%:DH@P&0   *']
M'3Z/_*0 _GZ[SNH)M3O_ .<>4Z\-X]:J]0VP;'L(5.VK!L&D6?7\C%>N:&*A
M4$-E!L:CP)SU6JLF;>\AQ;BVB0ABE)YEI00E\UN^WXA;\+WK\57[ON,K-Q.X
M_I-=83,^UFRK0NV\-F^Y'"64XMY8DD9.Q-<&%6\DT5]Z#'DT6G5V?2Z/&=>9
MJ$6,XTRM1D7,OE,]#(H[J$7%N3;4N'Y=S]YND4"/(AT.CPY<LZA*ATJG19-1
M-7/X_(8B--/S"7J?,4EU)KUUX\P!;BT\B9,M[&5-BU2X8EQS(\R1XNTW;=MU
M>Y)1++DU4Y&I$62XVV7,7%6FO<[!*50W3G["/#+>X#&]<W-[5;F0W>+5+MIG
M)<A]F79%RPZ@4BL4.-3(9QJ>_3DRII<YGS>"2LDEVC+"/P2HU6J^\K*5&FTS
M+IO=;C-TU%'HV49*4J6DW(^*[U=;,T*Y5:*123_WACP2X[O83B[&5<W58X;(
ME.T'*S:==.=S%-[-H(S+_>4JE)2)5IR=%2I#N84Y.N%;=QC1D_JR[,L/W2=F
M9 O2YK>N),%B>[3I]BW,S(8C2R5XLMULX!+03J4F:=>TAT;7/4'ICIW4[FD:
MG<O?SK5,:A;Q*+<5))MM;:-/97?O/2GI;])'KWZS](PZX]/-'MYSINY>G;A<
MGF;%IRE!TE2,YJ5$]FU(UQ^OANCV^]0?$6&+/V_9'3.JUE9#I=S5TJK0ZS2/
M!T^++BON(0J;"2EXR2R?V)]T<"UZM=#2C\5W,*=7OM.E/8WM.Z9K^GS]7EN5
M;/3-N<*+=G,K6OMNK83HV-UF-@EO658UN2LJ5150H]J6W19W)9MQ^!;F4ZD0
MX,DB?53^0T$\PKSW!)D0PR]7.B<;_P S,X:[/\I[NWXON.:OZ>WU8QL>;/IV
MU51K)?S,LW5+;1*;;?);S.F#O$Q#4X\*7 AY'FL5&+'FPUQ<;7=))^+);0\R
M\V;-.62VG&UD9&6I:&-D96<<YE;>=R[4LO<A&<7NK&2JGMYIGC7/Y6_IFHYC
M2LY%PSV6NSMW(\8SA)QE'V--<CLG=UV-(Z>9^AY4CH[>9[%5ZM)\T]5TI)%H
M,JMRW_D<5S6[;X'!G=IC"2>D:D90D'QX,8OO)[L+4_\ HZ8KL(,#IV#$NT^G
MRI\>>YS+7R37O_1(*'<,7?X#RI\>>YS+7R37O_1(G ^PC'V/P'E3X\]SF6OD
MFO?^B0P/L&/L?@/*GQY[G,M?)->_]$A@?8,?8_ >5/CSW.9:^2:]_P"B0P/L
M&/L?@/*GQY[G,M?)->_]$A@?8,?8_ >5/CSW.9:^2:]_Z)# ^P8^Q^ \J?'G
MN<RU\DU[_P!$A@?8,?8_ >5/CSW.9:^2:]_Z)# ^P8^Q^ \J?'GN<RU\DU[_
M -$A@?8,?8_ >5/CSW.9:^2:]_Z)# ^P8^Q^ \J?'GN<RU\DU[_T2&!]@Q]C
M\!Y4^//<YEKY)KW_ *)# ^P8^Q^ \J?'GN<RU\DU[_T2&!]@Q]C\!Y4^//<Y
MEKY)KW_HD,#[!C['X#RI\>>YS+7R37O_ $2&!]@Q]C\!Y4^//<YEKY)KW_HD
M,#[!C['X#RI\>>YS+7R37O\ T2&!]@Q]C\!Y4^//<YEKY)KW_HD,#[!C['X#
MRI\>>YS+7R37O_1(8'V#'V/P'E3X\]SF6ODFO?\ HD,#[!C['X#RI\>>YS+7
MR37O_1(8'V#'V/P'E3X\]SF6ODFO?^B0P/L&/L?@/*GQY[G,M?)->_\ 1(8'
MV#'V/P'E3X\]SF6ODFO?^B0P/L&/L?@/*GQY[G,M?)->_P#1(8'V#'V/P'E3
MX\]SF6ODFO?^B0P/L&/L?@/*GQY[G,M?)->_]$A@?8,?8_ >5/CSW.9:^2:]
M_P"B0P/L&/L?@/*GQY[G,M?)->_]$A@?8,?8_ >5/CSW.9:^2:]_Z)# ^P8^
MQ^ \J?'GN<RU\DU[_P!$A@?8,?8_ >5/CSW.9:^2:]_Z)# ^P8^Q^ \J?'GN
M<RU\DU[_ -$A@?8,?8_ >5/CSW.9:^2:]_Z)# ^P8^Q^ \J?'GN<RU\DU[_T
M2&!]@Q]C\!Y4^//<YEKY)KW_ *)# ^P8^Q^ \J?'GN<RU\DU[_T2&!]@Q]C\
M!Y4^//<YEKY)KW_HD,#[!C['X#RI\>>YS+7R37O_ $2&!]@Q]C\!Y4^//<YE
MKY)KW_HD,#[!C['X#RI\>>YS+7R37O\ T2&!]@Q]C\!Y4^//<YEKY)KW_HD,
M#[!C['X#RI\>>YS+7R37O_1(8'V#'V/P'E3X\]SF6ODFO?\ HD,#[!C['X#R
MI\>>YS+7R37O_1(8'V#'V/P'E3X\]SF6ODFO?^B0P/L&/L?@/*GQY[G,M?)-
M>_\ 1(8'V#'V/P'E3X\]SF6ODFO?^B0P/L&/L?@/*GQY[G,M?)->_P#1(8'V
M#'V/P'E3X\]SF6ODFO?^B0P/L&/L?@/*GQY[G,M?)->_]$A@?8,?8_ >5/CS
MW.9:^2:]_P"B0P/L&/L?@/*GQY[G,M?)->_]$A@?8,?8_ >5/CSW.9:^2:]_
MZ)# ^P8^Q^ \J?'GN<RU\DU[_P!$A@?8,?8_ >5/CSW.9:^2:]_Z)# ^P8^Q
M^ \J?'GN<RU\DU[_ -$A@?8,?8_ >5/CSW.9:^2:]_Z)# ^P8^Q^ \J?'GN<
MRU\DU[_T2&!]@Q]C\!Y4^//<YEKY)KW_ *)# ^P8^Q^ \J?'GN<RU\DU[_T2
M&!]@Q]C\!Y4^//<YEKY)KW_HD,#[!C['X#RI\>>YS+7R37O_ $2&!]@Q]C\!
MY4^//<YEKY)KW_HD,#[!C['X#RI\>>YS+7R37O\ T2&!]@Q]C\!Y4^//<YEK
MY)KW_HD,#[!C['X#RI\>>YS+7R37O_1(8'V#'V/P'E3X\]SF6ODFO?\ HD,#
M[!C['X#RI\>>YS+7R37O_1(8'V#'V/P'E3X\]SF6ODFO?^B0P/L&/L?@/*GQ
MY[G,M?)->_\ 1(8'V#'V/P'E3X\]SF6ODFO?^B0P/L&/L?@/*GQY[G,M?)->
M_P#1(8'V#'V/P'E3X\]SF6ODFO?^B0P/L&/L?@/*GQY[G,M?)->_]$A@?8,?
M8_ >5/CSW.9:^2:]_P"B0P/L&/L?@/*GQY[G,M?)->_]$A@?8,?8_ >5/CSW
M.9:^2:]_Z)# ^P8^Q^ \J?'GN<RU\DU[_P!$A@?8,?8_ >5/CSW.9:^2:]_Z
M)# ^P8^Q^ \J?'GN<RU\DU[_ -$A@?8,?8_ >5/CSW.9:^2:]_Z)# ^P8^Q^
M \J?'GN<RU\DU[_T2&!]@Q]C\!Y4^//<YEKY)KW_ *)# ^P8^Q^ \J?'GN<R
MU\DU[_T2&!]@Q]C\!Y4^//<YEKY)KW_HD,#[!C['X#RI\>>YS+7R37O_ $2&
M!]@Q]C\!Y4^//<YEKY)KW_HD,#[!C['X#RI\>>YS+7R37O\ T2&!]@Q]C\!Y
M4^//<YEKY)KW_HD,#[!C['X#RI\>>YS+7R37O_1(8'V#'V/P'E3X\]SF6ODF
MO?\ HD,#[!C['X#RI\>>YS+7R3WO_1(JX/L)Q=C+!R=NFQF_8MRPUTK),9Z9
M3GHC"9^.+MIS9OO)/D);\NF-M(26G$]1,4\6W<&]FQ;=YC]ZZQ_)@]>/ R/$
M_7CQCP7B[GC7@_ :_P#S?E\-SZ=S349MF*O K79VDJ8XYD   "AZ]S]'F?3(
M :#>.\'8TZ>?SGW(.3MYWK19F$\V8]R#?. \Q900F'C?V]W.W36(=)B7%/:=
MH+->813:FRVT\M#K*EH49))9&<[%NX%6ZR<I-*+?W)<?8_8>G?.E<G;>-T-H
M;"<=;0[\QWFC> 6Z&$]8=*PK4J9==X4^T)EN2TSI$Q5JJEN1Z0=TII2T^%<3
MHM/.DM"69..T-U@U%UE3A]MG>;G> *7=U$P7AJBW_P _MZI&++ IEXDZHENE
M<\&U:7%KA.K)2R4X52:=YC(S(SUXF(V\=Y;96JW'K9D1]I$?>U(C_5#;P!@S
MG9WQ#=SLQ>2AGP=4EY=H:B-EI6JU60NJ)(B,CT,FZ>X:3_W3+AQTUR17^7+F
M5>QI?;<9R)0E/ DI(N\24D7Z1$,98*21Z%RD9:]TB,OTQ&W@#2:Z\C"(V_ E
M$TUI)Q18\A:>5'[X?AJY%U41$6NA1_HCR-ZIQIUMFVMCE&T__P!'%?@?T3?T
MS)NY],V"K^#6\W%=FRS+_P"D0P:HU+]Z;[>.B2_2^@.@4/T$:E2F)GZ(-'CD
M'SC9(\*A1D24Z*/PO,1*(^"M.Z*J+2;WLB2EY%S:ZX>?939R/Z5F#R2YAK$K
MQH;YU8WLDS,D(3KK;=-+];KW->WB8]R=/[=!R/+^'9__ !<3^0GU&A@]0=<B
MO_WOG/\ ]8N'JAH2HM%((_HI2?T>^/KG3'M"6T)^Q0DOH)27ZA$ .6A=XOJ$
M &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=
MXOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$
M &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=
MXOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$
M &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=
MXOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$
M &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=
MXOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$
M &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=
MXOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$
M &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=
MXOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$ &A=XOJ$
M &A=XOJ$ &A=XOJ$ &A=XOJ$ //\HMD>/[M,FVEJ]9IIEX1IIQ)?O1D9Z+29
M<VG8?:1BT?F(>[:1_P#A#\G3GU+F]?\ 33E+EU\'IIRZ:::?2&7"L=.PI79V
MDH(P&0   *&6I&79KW>]YI>:0 PTWO;"=LW4-Q O"&Z.P6[VLQ%5A5ZG2(DZ
M31;BHE8@>$2S-HE>IQLU&FN*;>4ESP2TDM)Z&1@./88D[#>AET\NG-?]9RIM
MUQ5559#J].:I35U9$NJK7]5*##;=\*KVMOW"N8=%?>,B);C'(M2>&O$PJR:\
ME1$P""T+34S,N!FKCKIWC/CIQ @Y #!?<"DY.[+9''1Q7"N#+=6<[>$=O',^
MF:ZGKS<SM23P\SMX<<D/DD^PI)?$N_\  SH&,N4,^SZ.GZ1@-Z9I0=>[0]]T
M(]2_L@L@CXEP_P#&5S::]XS'DCU4_P#[US*_]W:_["/Z(OZ9&SZ:9U__ ']F
M_P#L9<A7,N[J1Z:%PX]A:=I<.TAKX_0JFV@;U\<A)U[7FBXGPU->B=>[H&RC
M)E_\O<?]U_<?TLL&EIA7$J#/BG&]DH/NZ*3;M.(R^J/<'3^S0,BO_P"3L_\
MXN)_(1ZD.OJ'KDN#U?-O_P#3W#U8?8.D@
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MMZ:,D+EJY_IR3\?R)JT+0ZA+C:B6A:24A:3U2I*BU)1&7:1D(+;SF
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MHIOP/YL]?U>[K^N9S7+T5"[G,S=O2BMT7<FYM+L3="Y1RCY
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M >'_ -@%&[Q'_ ^:%$,3[/ K^:?Z;OY&& ?D_HWVD*(8GR7@/S3_ $W?R+\
M^\"C?:0HAB?)> _-/=-W\C# /O HWVD*(8GR7@/S3W3=_(PP#[P*-]I"B&)\
MEX#\T]TW?R,, ^\"C?:0HAB?)> _-/=-W\C# /O HWVD*(8GR7@/S3W3=_(P
MP#[P*-]I"B&)\EX#\T]TW?R,, ^\"C?:0HAB?)> _-/=-W\C# /O HWVD*(8
MGR7@/S3W3=_(PP#[P*-]I"B&)\EX'%?2=Z;AI,CV7X",M#X%8-&(^SN'X$M
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MN7N7W1W_ /)7?/=[T:!_J&]%3ZK] LWJ]N*E_M;\Y\UMHVC>7'KH_F\
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M],>W;Q(O_$LTM?HMGY@F/S%7N(^O\N?F>O\ V^9X/M&?]?L*DH8XYD
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M>:*TX_B7Q*F_W&&&PBE=;/,'5F9VZ2.H]<6XO"NT>^[+N?/F4:#==<JN'Z]
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MZ'6K8=-#UQ46!1WZ;$H\MZDQ9!FA#*6E%X+SJC(CUK]Q>LG'>\7<OMX4)O\
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M2([,:?)?;Q-VQ/9_W2O_ (1B2#D             X*0DRXI(]---?TBU,^Z
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MG_D2:?'B7_1&7Z@M'>0]Q'U_ES_G_P#^3T_4&;]?L*5VDH0XYD
M  P5W%_XKMC']=LK_P!T]R#-;_TY]QCG\\>_\&9U#"9"W+INNW[,I+M=N>K0
MZ-28ZDI>FS7D,LI4YP0GG6I)<RNX,&9S.6REOSLW<A:LI_-)T7B?4T?1=5Z@
MST=-T:Q<S&=FFU"";;2W[$:MO5@PE93EUW5N2QA>=HU>D790I+-QV_3)\?QY
M%1<B--NU);*%\NCSC!F>A:F9CM'J!ZY=.YCZ>\YZ=YB_"[J4Y1C::FI?"I-I
M;'7C0V'])_TK]?9/ZW>G_5*62O973+%V,;RG;E%-N5MXMU-F'WH@2P)H5P5I
M232<CUC?**P:T(>D/*7YU+1K,D\#TU[VH\S?2_<TNQZU:/F-:S-G*:?;NN4K
MEQT@L*KM?;P/VF_JXV>I<S]'NM93I3(9K4=8N5C"UE_G<G;DH\'O>Q'+<!$6
MW<5+F+;)MZ92V_&D(42THD-J\\@UI[3+F[1P?J0R6B93U?U:[T]F+>:TK,7Y
M7HW(---S;;V]Y]K^ECU!U5K'TIZ/IO6F3NZ?K^GVK=F=FY\T,-J,6MRJJQY&
M[9TD,B4Z^MD>(8,=\W9]H45BWIZ5&2E(\40DV#,]3/3E,T^8:1W[TJS,LST?
M9A<?^9:G./LQ57N9^5/US]*9GIKZC->S%R.'+9_,ROPIN^*M?MVDF@V0>/@
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MIT%ETVW54Z-)G)0_4I2'$Z./):9;,R(DI/3F/&F]^YG(PVZ*,EB7V_X&9/\
MI2=C!Z_^?N4^T^R3'[AZ?K3#%<_<R/+R_P"SWO\ ,?Z4?8P?_K]E3[ZC%^JD
M3BGS'EY?]GO97_2C[&/=]E/[ZB^A#%/F/+R_[/>Q_I1]C'N^RG]]1?0ABGS'
MEY?]GO8_TH^QCW?93^^HOH0Q3YCR\O\ L]['^E'V,>[[*?WU%]"&*?,>7E_V
M>]C_ $H^QCW?93^^HOH0Q3YCR\O^SWL?Z4?8Q[OLI_?47T(8I\QY>7_9[V<V
M?FINQ9EYLU7[E16BB/E*7'3S$7<YR3P#%/F/+L<(*O>R,'HV;6L<[-^N_GO#
MV+9]6J5MTFE7O2VI5:5K,6U"=D:&?GE)YC6I1GIVF8KMV>TM'9B7"B]AOH%I
MW.^?U=>/Z8D@             /S6?%*>^>NNFNG+H?Z8,E5X&B[=%CHZJ_SG
M^HW 2?7S;WL'HMKV/4X=6,WXBKSM:F2ZK6HE.C->$9U?O"KO&ZXHR+2*C[(R
MX6PNFW@44OCPT::2[NS^WN-Y\FT$GD2C1!-I:2A.B22V1<J2+O$1=G>(5KM+
M/<:IF[/YI]M(W7;DLO[D;CS9E:VZSE^Z)5W5>A4MN&[ I]3G-,)EE%>=63IQ
MUK9YB29:)U"GB-B6U;$9%/6UMY^;7=-J_8-DU:YLB2I%5J=5M.%6'(S-4N"\
MJC$*-#29+6IEB-%,O".::\QZB$GPWEFXTK+9!$'VRGHBU3J!W;;>_CJR[LK2
MJ[^1JI!R1:F"H>0:4;U,H,Z857@4*Y7ZC4(L:&RXPM#3D=IHS)M)%J%4EOV#
M"VZM5=/M_P #=FPV>U_$]N6_B7"E>Q#;%!@DB'0;.LZY;52;CJB2V1,4^GSU
MO2I+Q((OL5*4?8)JB&I/YJ[#0"K\"D8(^=!VY>>_5I;&.ZYD2IO8CK-9)YZ@
M0ZU/6EJR9SRY?+&CQH\^1^^+/0B29%Q,A&U+VB5,;P\4O"GX?B;?/6CRCM\J
M72JWK1+ROJP[BH=5PG7(=,IE+N*@5&;.K,MV U;;=)B1I[[[\M%86RXDVT\R
M4),^PC,2^2WA5BL4E2-'X4-,';=:.4K;^:K;VY60&*G%H-=S!9\BP8U54\;B
M:=&J\,YRHJ'3/P<=27F33IV$6G<T*K]]47M4V./R-;/%&QU\UHO['EL=+VQH
MMPY LJA5 ZW--=/K%S42E3FD*::-*UL3YK#I)4:3(N&G 6V);=Y22DY8E\JK
M]Y)UU)NJ_M(V ;?[AR%D/)-!N&N7!3*S0K%M&RJW2:_7*U<3U+D>)I6W FOJ
MB0F7G$*6XHC,B^Q(^)DWAMQ^*2V&O;\UBP'FC)F8MTO48S):[]NTW+CC](QJ
M]4F7&JG4Z;6*XNKR5FAU)<B(S,="5*(SYC679Q(G!)\"*)-R6^6\W:'/L3^E
M]3F+_8 -!'YR-EFU\,=;3I\Y"O=GFMFAXOHK$Z3R\ZH3;F1*@[X=*#U+0G)!
M$?81<^IF1$8AJJ\"T7A:?;_8;%?5?ZA&U?$W3)RQ=]2RG:]25FO#M1MK&]%H
M]4I]2K-=JEQT-F$PA5.C2ER(S,(WB)\UD1I<+D(C/70VMQ*4HMO@B('H/TZ=
ML:Z"61<LYSP96\U4*^LUW9?,3#M(CL/SK@MFI0K5H].GDF=$E,MH?D4QPU'X
M%7+X(BXZB:T*IJ='&I;47K+[-S82I'0]R>ELS5REZWVVHOLC(]#.T.Z?'Z8.
M+W[/$JKO]V?MC_:?+4^LMLV\"A#O0[R:Z:W4-I)4&VR)!FHM'%&FT261(U[A
M@D^SQ)=W9NGN_;_:8\?.7\/U>_<6;%.J1:&-ZW:EFVG$Q_3JSCF1 ,J[9%,;
M<BU2F4F<45A$.-&BM,$VA7*VC2/V)+L+?4F5:8%O7]AMS86W^[;[BV/6YNOD
MY,M:'9EH8)CY O.-)K]*;J]$1;UF-5.MTZ53U3"D)G(>BK::2:?WUPTD6IB$
M^8:V5C\E-_"G,U*OFN&W?)6>-^V[OJG'35TO!][W1EFU;.DU?F;J]8J]V7 =
M76AIC['DI]+ELDZ:342%ZIU[-9:*Q=55[_M7\N\W-+3WN;9[XSU5=LUK9)I5
M5S'18\R14+486VIYEN RY(EZ*\-JM3332C41)X:'YHEIA-/8FL5*TXKAN-2O
MKY6!5]HO6FZ9_5*NV.X[@&G7QC6Q+VJD%O65;];MFJ51MSUPYS)EJ%+H562X
M3JC(BY%%Q,A%%0G<]G=]O?X&S]O)ZA6W?:]LYR5NMJN2+:JMM4*P'*Q;3%OU
MZCU*L5RK7!#0W;D&EP&);KKL]R3,0HVS+5)(5S<2T$IT>S>@U6.W9%^'_%[C
M2XZ!=[4#9OB+J"]=W<1&J%-Q===0N6S+;MR(RZ=?N6M75D.E5*FTJFN/I:B.
ME)K<EJ,I].I:K(R2>A$;X7L7V^U/>1'&DVU\-%LWO9O][]R9Z-MVVJ9X^<17
M^QO.ZCF=:)AO8_3[BJTW &"6[XH].K=RO-SV8ZI2X4B?%BTNEL4ECP+CRB6\
M]X3E2DB):CK5%J2K7@^'VW_;<;EFUO%>QW9Y8%+Q5MUGX6L&WR1"C.1:'==H
MHJ5?EQT*::DU!YFH^,5&<XIQ1ZGJ>JCX":I[$T'&7)T-4'YR50(&W#JE=.KJ
M 9!I2I&#:!1V;,O"=!IZYZCJ=#N6H5 VY7*VJ,A#E,KZ30:U:J+7373@[V0]
MR27VX?;L-LJW=]NTRH;;8.Y1G+MDP<4KL=%T)\:N"CMU&/3H].\,JE%1O'?&
MEU(DEX,F$HU,S(^!<2-[:A1=*?\  UFOFX],J>?NH#U,-_>/8$NG;:\P7]-M
MK'ZWVO%6:E5*:Y1W)K[$=HBCFEM#6AF7>+3M$<2^).+Y[/<;FZ2T21=TB(NW
M7L+3M^D)*'(           45V']#]0 :JGSDW;_86XBY>GUC*_9E2@4#(F>)
M%N5B73$&N7%B1*%.F,O1T$I',X3[G$M2U('NV!)-[?MO/KIWS5'8I+I=-?;O
M_*:TNPHZR<)]AOPG,TD^;P2B4IKM^Q,ST#%+@R/+L<8;>]GU_P"E'V,>[[*?
MWU%]")Q3YCR\O^SWLK_I1]C'N^RG]]1?0ABGS'EY?]GO8_TH^QCW?93^^HOH
M0Q3YCR\O^SWL?Z4?8Q[OLI_?47T(8I\QY>7_ &>]C_2C[&/=]E/[ZB^A#%/F
M/+R_[/>RG^E(V+^[[*GWS&]"&.?,>5E_V>]G#_2E[%B_]?LJ_?#!_N!&*Y^[
MW$^5E_V>]_F?+5/FGFPJKT:I42??F5SBU*.Y'-;,YAMUIQQ!)9>29)X*9<42
MNY^D)Q3>]D*W8BZQ@J][-$OJO]';<ATI\K*M_(4%N[,.W7/J4C%F5+?8F/T.
MMT5F2?@8%4<<:+UKN*G1EM%,C.JYD*6E23<;4EQ4QE^E[RMRTOGA\OVWD1QF
M6FO<%Z<SC=I-5T;NC#G7JIYDHTB)!=L[;595P0)&5,GU5B4S&>@1W4R9%N6F
MDFT)JU>GM(Y-$K2AA*^99EJG6DGP1FMPI\3/ZY&#L2VU@?$N/\.V>N6Y;6.;
M7I%J4=V<[X:8["I$1N(RY(<_WG%H;(S^B(;;,M*;>+/5A!(   6'D[^S^[?Y
M$F_Q9B8[RKW$?/\ ER_G[]P,_P"OV%>/M)0AQS(           !@KN+_ ,5V
MQC^NV5_[I[D&:W_IS[C'/YX]_P"#,ZAA,A$/UN)[U.V+7;(CS)4)]RY:!%:<
MB/N1W%F^<HS:4MLR5X-26SU+7N$--^MLI1Z7R^&3BWGK:V<523:?@>[/Z=66
MMYOZDLC:O6X7;2R=Z34DI+9AVT?'::/RZS6Y#"6I-=K#["VR2IA^H276EHTU
M\&;:W#1R<>&I&/-#A"3;HFZG]&T<CI]JYCM9;+PNIUK&$4Z\ZI;SYDN.QR2]
M$=?CO-EYUUAPVEDGND1H,C"-5*N*C[-GO,EZQEL[!Y?/6[5[+2WQG%2B^]--
M'KE?@$[B*C5F2_(F37Z@CGDR%&Z[HM;J4M>$5JHFTF6A=\AV#,:6X=/6-9GB
M<KN8G;VOA&/#\CSATGUA%?4;JOI]D;-C+:=E--C<4+244V\+QN*HL3K5FS7\
MWOO_ -<<7Y*LB6_H[3:O&E4YGFYC-DDF3Y\IF9IU4X7#LT&W_13/YBZ\]D+E
M/(A@E'O>QGYG_P!4[I=93K32.H[$?@O6)1N.E-OZ>_<;'8WX?DP
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M';,^*O!LH)""/N:F1<1.TJ?0                *&1'VD1_1+4 5
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M-?&8^FFNOAF]-.Z>O-IH1 0<4S82RU1+BK+OID-*+ZI+, <O&XOW3'].;]$
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M(CT$.KV.E"5AQ8JR4J<*?B66]T*-\+:"*+U4LLN:$9<CM-6VDN/ B4EY7;]
M1AV;D6Q;?FE[OR/T:Z$N]M*$\W53RXVKB9I:I1\A'YFKZ3/@&%?:H3_O2]WY
M'Z_F)][7_%7S![$GZH##V+WDXE^Z7N_(?F)][7_%7S![$GZH##V+WC$OW2]W
MY#\Q/O:_XJ^8/8D_5 8>Q>\8E^Z7N_(?F)][7_%7S![$GZH##V+WC$OW2]WY
M'%70DWL*TYNJKEY7*>I:TC70^S4M7^' *=B]Y&)?NE[OR.7YB?>T79U5\O\
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M P]B]XQ+]TO=^0_,3[VO^*OF#V)/U0&'L7O&)?NE[OR'YB?>U_Q5\P>Q)^J
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M%[QB7"4O=^0/H3;V3(R/JKY@,CTX'2CTX'P_^D=P,/VV_F1B_O2]WY'?8RZ
M&23W"83S+N5WS9)S[0<(UV1<ENV;58)0T*JBXLEAA7C:G'20TER09J+E,S+4
MBT$T1$GBWMMKN_ V8(<5F#$C0XY&EB*RVPTDSYC)MI)(21GW3(B$E3Z0
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MP/5("CY,>VNV/=)0?96!ZI 4?)CVUVQ[I*#[*P/5("CY,>VNV/=)0?96!ZI
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MV$\^K5C57%)\#^@(=6]_$R14(K=\5-YLKEKJ9_2^IK]#O@0<@
M
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M!;UWE9_)+_"_N9E-T]/\%&VSNZ8KMCO?<:5%^J!9T?@9ED1$6A "H
M
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M>5E\DO\ "_N9E-T\O\%&VW_[UEL__42!!=[S,T"
M
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MB"5O7>5G\DO\+^YF4?3M4:MDFVOF(R,L6V\GCW22RI*?VI$(+O>9H 0
M
M
M !8>3O[/[M_D2=_%F+1WE7N(^?\ +E_/W[@9OU^PKQ]I*$..9
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MMEQ+NHBD@].^6J0^\M7%M,S2/7N&7T2T FA4"
M
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M]7G3X<F+":)EELXJ(SB=&R,R2>D@;QZ1UN[K^CQS]ZGF>9*+IL6RFWWGY/\
MU,>D^F>BWJOG.A-(N3NY#+VX2C*;JWB<EO\ ^B9ECLYH
M
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M\UGU_4__ #B<XN/\&Q_VKI*T-F'B<
M
M                                  L/)W]G]V_R)._BS%H[RKW$?/\
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MG&=N<7&<6MZ<7M1V@N<0
M
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M]1]#ZY?Z<ZJR=[):UEY.,[5Q4:[4]TD^#3:+Z'..N
M
M                                           6'D[^S^[?Y$G?Q9BT
M=Y5[B/G_ "Y?S]^X&;]?L*\?:2A#CF0   !@-G'< !QYT&HT<Q<Q<3+ZGUP!
M4M>[](!L*@#!3<6>NZW8OYMZY7/_ /1/<@S6_DGW%)_-'O\ P9G6,)<
M #@K[-LR+4CYTF?ZWAKKYG%.@ T;++)^=\YZJ;C;#ND>\74K(D*X(CQU&XXK
M730DI29F?>%5N_Z1D;_S'_@-XUQAN0T_&D--NQWTNM/-.IYT.LND:5H6DR-*
MD+2HR,C[@R1G.W)3@VIIU3Y-&&48SBX358M49KT=2WIQJB1ZSGK"5%;5$B)>
MJ=]6Q"Y6WD1R42GJA3XQ%H\A!JYEI+BDN/8/6?HUZO\ F3M]+]27'YLJ1LW9
M;F^4GP/+/K!Z28K=SJ3IZTOA3E>MQWM<7%<6C!CI[[S*EMHRG&IEWU.>G%-:
M)ZFW!35^%=73I3I)\#-;BF9<CD20DN)=S4CX&-H>K/IW8ZST.5W(0A_OMNDK
M<MBQ+BJ]J-8^DGJ'F.C]9_AZC<E_L%UX7%UK">S:UPH_M0VU[&ONTLD6U3[M
MLFN0:]0:HTE^+.ANDM)DLN8VWD'^^,O(,]#2HB,AX*U32M0T7.3T_4[4K6;@
MZ-/\.:/=.G:CDM5RL<[D+D;F6FJIHO ?/.:                     !;=W
M6G;]\V[5K4NFF1:S0*W#=A5&FS64/QY++I:&2T+2I)F7:1Z<#'&S>4R^>R\L
MKFHJ=B:HT]S/JZ'KFJ]-ZK8UO1;T\OJ>7FIV[D&U*,ENHT:@W4^Z1%SX6GU#
M,NW6W9=QXOD.RYETV]!63M1M)2_W],J/"(O"/TXSYDJY/L> \R]?^GE_0)/4
M]*C.YI,G\26V5M]O%QY/AQ/WB^C7Z[M&]0LM:]/_ %8S<,IUE!1CEK\]EO,T
MV893W*>YJN_:8Y=,3J35?9=?$ZW,B/5FN89N1MJ'4J2CPLF5;%1:D%RU6!%<
M4DT$VA:R=01$9I[@^%T1UMF.E-0QWE*[IEU4N03W<5.'#$MS_<G3D;8^LCZ1
M,C]0W3=K5^DHY?+>H.4DYV[KI&.8MN.VU.2K6M%A?,W1L(9XQ;N(L>!D+$EU
MPKJMN;R$IZ/S(DPGUH2X<6=%<)+L9]*#[%%H?<,^(]4:-KFF=09-9_2KJN9=
M['P<7RDN#]Q_/;ZB^F?6GI3U%<Z5ZZR5S):O;W*5'&4:TQ0DMDHUY>T]D'V#
MH0
M
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MD/"F?T[.Z5FI9+4+4K6:@Z.,E1H]NY+/934LM'-Y*Y&[EYJJE%U3+E'#.6
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M">7M7W/^/?5)6<Q"#HY0FME=S<722KQ6TREU'9JFF"H
M
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M3L'BL?\ @&/24?6#;S'<5\6C_P  QZ2CZP;14>+1_P" 8])1]8-HJ/%H_P#
M,>DH^L&T5'BT?^ 8])1]8-HJ4\5C_P  QZ2W]8*LCQ*^+1_X!CTE'U@VDU'B
MT?\ @&/24?6#:*CQ:/\ P#'I*/K!M%>\IXK'_@&/26_K!M('BK'\"QZ2W]8
M/%6#[6(_I*/K=X "C,EIHRP7'N-(+AYG#MU ;]CW$2O4TZ7EL[WJ-3KTLNH4
MVR<XVI ?A4NN2(Q^M%TTLW/&$4:XD1N1U2VGN;P$CBIOPAD?#0:YZXZ!RG4]
MK^9EL-O5HQHI;E-+<I=JX/V/92GN?Z/?K+UGZ<=0N]/Z_:NZCZ<9VXIW+,9?
MYN6N4PN[E\54JJF.&Q2PJFTU%:3<&Y#IW[A)U/8?E6/DBS)\9-6IRT$_3:Y
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MDH^L&T5'BT?^ 8])1]8-HJ/%H_\  ,>DH^L&T5'BT?\ @&/24?6#:*CQ:/\
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M/24?6#:*CQ:/_ ,>DH^L&T5'BT?^ 8])1]8-HJ/%H_\  ,>DH^L&T5'BT?\
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M>!R;FRW <TX&;;N-*I.,C/NI)V D_IF,L-L)%)-UCW_@S.H8BX
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ME>E<BK<9._E;<G7#=BD\2AM6*/!)T)K-2T[_ -#O'V?I#:Q^>9R
M
M                                            6'D[^S^[?Y$F_P 4
M8M'YB'N(^?\ +E_/W[@9O^\]A0E"'',@           &"NXS_%=L8_KME?\
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MD2D*0I.I*2M)ZD9<#(;Z1^3$HRA)PFFIIT:>]4V.O<S] *@
M
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M8
M                                                  L/)W]G]V_R
M)._BS%H[RKW$?/\ ER_G[]P,WZ_85X^TE"'',@           &"NXO\ Q7;&
M/Z[97_NGN09K?^G/N,<_GCW_ (,SJ&$R                      >(9YV^
M8MW(V0]8&5:"=8HRGTRH4J+(7!J])F)(DE,I52:2;T1Y:3Y5Z:I6G@HCX:=D
MZ6ZLUOHW4UJVAW?+S"5))K%"<>4H[FN*Y'7.INE=%ZOTZ6EZW:\S+O:FG247
MSC);5^)JK;X=EMR;,LFTNKV34Z_5;&EJBU>S;OE$93Z5/:<YW:7-EQ4I24R
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MTXSBU6CI55WI\ST4<]5.J@2
M
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MGW-;4;,]3_1_KGT@U'+:5UOE5ELWFLO"_;2>).$XJ2=>YHR!'9C5X
M                                                    !8>3O[/[
MM_D2=_%F+1WE7N(^?\N7\_?N!F_7["O'VDH0XYD            P5W%_XKMC
M']=LK_W3W(,UO_3GW&.?SQ[_ ,&9U#"9                        H?Z/
MT?1 'CV:,%XVSY:,FS<E6]&K=->;<**^HN2=3GW$\I2(<E/GVUI/0S+L/0=A
MZ;ZHUCI3/QU'1KKMW52J_3)+@UQ/@]0=.:3U-D99#5[4;EF2:7-5XHT]-VFW
MJZMIF<:O0(#U3I]-I=3*J6/7XJW6'DTMU:9%.D-2B(N=:$GRJXGHI)D/T&Z$
MZMR/7G3-O.34)7IPPWH.C6+=)-?;8T>!^O.DL]T'U+*SEW..6C/%8G%M-*M5
M\7-;O<3_ '3,W[1=PUI0\2Y*J*$9FLVFIC*J,LVF?;S28JEMQJHPG5)+J345
M*2D)+BLR->FIF/*?K1Z6RZ3S\M?T:'_Y.YB=<*V^3)TK%_W6ZM<JT/4/HYZG
MPZLT^.AZQ-?\PY:-&WL\V*JE-+FU2O;4ENU+_9^CZ T(;U*@
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MUS1_.5]0WTV==?3SU)_MG4EOS='OMO+YF";MW(\$WN4Z;T9NE^C4=O/.F\J
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MA&1]G'4M2/N&7?(^\.SFL"H
M                 +#R=_9_=O\ (D[^+,6CO*O<1\_Y<OY^_<#-^OV%>/M)
M0AQS(           !@KN+_Q7;&/Z[97_ +I[D&:W_IS[C'/YX]_X,SJ&$R
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M\#V5Z4>IF5ZVTU9+..,.H<O"*N1K\]$O\Q=^]KF28Z]SN\-2[PTQ4W <A(
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M:5V5J-V-V,5LBYPDL>ZLJLGH(]1NH_,LJ
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MF+>;O].Y.TKTX24HPE"U&U&#DFTWABFU78VT]IL3E]'7@7<T^B-]'Y2%0
M                                                 %AY._L_NW^1
M)W\68M'>5>XCY_RY?S]^X&;]?L*\?:2A#CF0           #!7<5_BMV+Z^[
M7*WU?@GN33],98?Z<N[\44G\T>_\&9U#$7
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MY<G=S,VW*<Y.4I-[6VW5M]I]PN8
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M8FZJQ*HKQ")2,FT>F3G[3N>+&9;EOU%J.MR%3:FZE*5R(<F0VE&JS,T$K4N
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MT@!4 - (H@!(        -2[X
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MXAUM:2-#C:TN-K29:D:5I,TJ(R[I#7<DXR<9)J2X/8=\C)26*+31SU(Q'"O
MGC0J                       ^:3&8EQWHLIAJ1&D-K:?CNI);3K3A:+0M
M)ERJ2HCT/41**E%QDDXM4==S,EJ[<L78WK$I1O1DG%K8TUMJGV,UB.K)TC[E
MN>X/A^VJ6=!E$Y3Y;V2["IKS<6;(EL+-]%Q4**9$B2XN,I:9#2?/'RI46O$>
M>?4+TVNVLS+6.G;-<I*+E=MQ_3);7*,?VR6UI?*TWQ/V.^A[ZZ-'T;2__3#U
MMS]V#5V*T_.W$Y0C%K"[%Z6^*4J.$GL56B&_9#OIS#L-R8Y$8]<%61(JQ,7_
M (]J3;S9>$;<2U+DQXB^4XU0;)'<+56A']'6O2W5&J=):A_)RC;R\FO-M/Y9
MK\));I;^#V'O[ZCOIKZ"^IKI!9BX[2ZDA8Q9+/6VGL:K&,I+YH/OV&[CM6W;
M8>W?8YB9$Q-7VYS1+7#K=!E&4>MT&ILDDY$.?"69.D@C41MN$7(M)D9&/6/3
MO4NE]2Y%9S3I_P"*#V2B^*:_'<S^='UJ]#.OO0CJVYTIUQE7:N4QVKT?BLWK
M<OEE":V5YQWID,'SH-U">F/=+CJB;2BZ8)K,^Q)$TZ6O?XCLENW<E6BK3?V&
ME<S?LVHKS)44FDNW:B5GIFF2NGGLG6GB1[8L.&7'M)5CT0R_2&.CC\+WG(QQ
MG\47\+,Y0                                   !C?O#X[3]S)?_F&R
MN9_]K[1JYK^H8?D/S-=SYI'_ ($<X?\ ^3]Z_P#R8F6]]Y6W_HP[C:S$%@
M                                            +#R?_9_=O\B3?XHQ
M:.\K+<1\_P"7+^?OW(S?]Y[""4(<<N      !33_ ).X *@  ,%=Q?\ BMV+
M_P!=<K?W3W(,UO\ TY=Q2?SQ[W]S,ZAA+@
M        '0W+;=&O"WZQ:]Q0&*E0Z]3Y-,JD&0A*VI,.4V;;C:DJ)1:D1ZI/
MM)1$9=@Y&3S>9T_-V\]DYN&:M34HR6]-<OQ./F\I8SV5N9/-14\O=BXRB]S3
M1K;]2CI^XDVI;9=P>ZVSY$]F)C.DTFXHUKI6I:)!U2ZZ%;LEO4BT(F2K/.GS
M$CT1IOU%:[E\G&QJ%F-[,)4Q/W?VF@=3^G[I_,9^>;R,Y6,NVY.$7L;I5]G
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M]RU<LS=J[%QN)T::HU[&;(A<A=@IVVI0>YK:CZ10N
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MHWK,-M?AA.44O90]M'VS7@    !34N^ 2KN&I=\@%&5
M       !C1O*E,0]I>YM^0X3;18&RFT:CUX+?LJN,M%P_7..D0 UX/FD#B%[
M$,WFA1*(]S]ZZ:'YC9_J"9?,^\K;_P!&'<;6VH@M4
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M=9O*R=(W;;?^)?F<)Y#/+?8O?]27Y'[>N$'[NA_?#/VP9?-M_NCXHI_%S/\
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MZ[97_NGN09K?^G/N,<_GCW_@S.H83(
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MTW4-(S4LEJ5F=G-0='&2:?\ :NXW-D-0R6IY>.:R%V%VQ)53BT_^!=0X)S
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MZCH.M:1?GEM4RF8L7K<FI*=N4:-=K5"X]3[OTN!_IGV#E'R2H
M                         L/)W]G]V_R)._BS%H[RKW$?/^7+^?OW S?K
M]A7C[24(<<R            8*[B_\5VQC^NV5_[I[D&:W_IS[C'/YX]_X,SJ
M&$R                                     4)*2["(OH$0 :%W@!4
M         4,B/4C(C(RT,CXD9=XR[P;B*)['N,1L[[)< ;@42Y%Y6A#BUZ2V
M:4W%2F&8M2;<Y.5+RC0E*9"D\#\]VF7:._=+^I?572CC;T^_*66C_P!W)MQI
M^!TGJ3T]Z9ZI3GJ-B/\ )?ZTEB1!MG#HMY6L]JJW!BN]*9?%,C+?E,T=Z&Y
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M9C3+]N]::_2TVO8>B#Y)],
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M/<@S6_\ 3GW&.?SQ[_P9G4,)D
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M?Q+V;SV<AUX^^5
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MNV5_[I[D&:W_ *<^XQS^>/?^#,ZAA,@
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M5QJK@W22[T9&=S]'_8'4#M)4
M                          !^+\=B2@VI#+;[2OLFW4)<0KZ*5$9",*::
MEM3YE[=VY:FIVI.,UQ3HSPO*.V/!69J1*HF1,;VY7H,U!HD<\)N/(6@^7@4A
MA+;B#X=PR'P-0Z6T'4[4K6:RUOXEME%89>QK:C9/1GK%ZE>G^?AJ72NKYO+9
MFTZQ^-R2?^%MID:&4>A'LKOWPKEM,WKC*2LU.(5;-7;DQ4NGH>KD:H,N>$:+
MN():?HCH.<]&^G+EJ4<A<OV)OBWYE.Y.GWGL#HS^I;]0O3&&&L2T[6+*V?\
MQ%IQE3LE!JC[:,C;S#\WDOJF&^_A;*4.X([9+6B'=S3<*4XE/$D(<CFIM2C[
MFNAZCH^K^C>LY6UBTB]#,SXJ5+;IV;T>N.@?ZJO3F<<;?J'HMS*W73XLJW.*
M?-J6U(BIR/T^MZ6!YU2<D8WNDJ?3732=?ME3KT1_E5IX1OP&CIEKWR[@U[J_
M2>N:9)6<]EKLNZ+E%?\ 26RA[8Z3^J;Z>O4W+VHV]7R7\J]'_1S%%*/8\6SW
MG1XRWQ[Q]L]1DPK4R)<5N3#046;3Z]%<F(4TTYS$RN-.\XA1.(^R(M=!BR6N
MZ]HGP9#,W\O6GPQEL:6W:G4^CUC]-_H!ZOY6&9UO2LKF[">*%RS)0HVJ54H;
M7LX;B0C%W7_W46HAJ%?MHV'D&(2D$[.D-S:54DI+0EK)R&HV5DHNX:/-'=\E
MZO=5Y=PMYC^/>M+>YQ:D_;%_@>6>L_Z7?HKK;EF>E\]J>EW]M()PN6Z\%2>U
M/VDG&&>OO@"[6XU.RC9U<LVO//(;)ZD+]<J-R&E!+6XZ^3+[2TN'V:&1E] Q
MWG3O6C3KUY6-2REVTGOG!J4%XTD>-_4#^F#ZHZ#*>;Z-S^6U#381;I=7EW:[
M:)*-8M4X["5?%.]+;5F6-&79.4[:E3'_  :3I,F<U%J3;CA$:6E,.F6JM>'
MS&Q=)ZSZ:UJYY.G9JW.\J?"]CV]C_ \4=;?3YZO= 79QZBT7.0R\:_YL8.5M
MI<5)<.\RE0XAQ"7&U)<0M)*0M"DJ2I)\24E1'H9'J.T;]VXTQ)2@\,TU);TS
MEK]+Z.G^PS @J    #"#J4DD^G[O+-9$I"=MV8'%\VAIY$6/6EF9Z\-$D6OF
M"KW%H_,OMP,+_F]B5(Z5.V]*]265*DDK7MU\7IY?2[!=TQ/O,5O_ $H_X437
MZB"X      %AY._L_NW^1)W\68M'>5>XCY_RY?S]^X&;]?L*\?:2A#CF0
M        #!7<7_BNV,?UVRO_ '3W(,UO_3GW&.?S1[_P9G4,)D
M                                                    IIV<!%-H
MW[SR++N"\7YRMJ5:V2;4I]>ITI.B7EM-MU"*X1^=>AS4H\*P\7?+4=@T#JC7
M.F,['/:-?G:NQX5K%]C7$^+K?3NC]0Y262U:Q"[8ES6U=J>]$,.X+HJ6L5&J
M5;V_7=7(E89-+T6T[B>9E0Y&JSYVX]22AMUI>AZZJ3Q(M!Z+Z3^H[-_R(9?J
MS+VY6'L=VVFFN^/Y,\[]5_3MDI9>=[I3,7;687RVYM./']5*KWD-%W8[W(;.
M[I9DUQBY;(K*7EN1*Q39,IB-(*,M*M6)S7*VIM6I:I,_/$/1&2U;H[U R;MY
M9V<SEVML))-JM=\?M0T#G=(ZT].;_FYEWK%Y/9.,GA>%K<^WM[B1' /69S#:
M[4"D9<MVDY HR"8C%5F>>D7"RRGE2I]Z0WX6+4%DV7^\A)\.T:CZK^G?I_.R
MG?T&[/*9G:\+^.VWRIOC['[#:_2?U"ZS8MPM:Y9CF;%5'$OAGWUW,GBV][N<
M,;D*,[4+$N*.S4H:F&ZA;]6>9AU6.Z^CG3X)EUQ)RVC,C(E-Z\2[!Y<ZLZ!Z
MBZ/S"M:I9;LR^6Y!.473FUN]IZ;Z9ZUT'JNP[NF7EYL:8H2=)*O8]YD_J7^S
M_E'3#MQ4
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MC[Q&]4$%J,L/].7<4E\RYI_@_P S.D8BX
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MI^!VHP&<
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M^>\OZAM)5^FI9F/3'I"V].OUYP]T:'X'?U2&WZQZ>F__ .G1^^A/T-Q'Y@@
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MYLS<;3SJ6O+S;J/X%HK3C.&_KW^8N7Z8R1^27VXE7\R?VW&<PQE@
M            ( $@
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MF$^[%%.GLJ7QKYGZ.(^8<\:_H/@%05     _1J
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M#>.MI*I&6:0T^9>?0S2J6MHCXZ<IJ22CX%W>Z%8<"<+K\S.1X_WA=S+=-/\
MFFCD(K#D2XOFSL(^,]V[J"4]G&BQ%\/WI=NQ7CXEK]FRTI/ P^#D0XOA)T/W
M^"[=E\?=!][#?V@*PY#"^;]P^"[=E\?=!][#?V@*PY#"^;]P^"[=E\?=!][#
M?V@*PY#"^;]P^"[=E\?=!][#?V@*PY##+F_</@NW9?'W0O>NU]I"L.0POFRO
MP7;LOC\H7O7;^T!6'(89<W[BGP7;LOC[H/O8;^T!6'(87S?N'P7;LOC[H/O8
M;^T!6'(87S?N'P7;LOC[H/O8;^T!6'(87S?N'P7;LOC[H/O8;^T!6'(87S?N
M'P7;LOC[H/O8;^T!6'(87S?N'P7;LOC[H/O8;^T!6'(89<W[BOP7;LOC\H/O
M7;^T!6'(89<W[BGP7;LOC[H/O8;^T!6'(87S?N'P7;LOC[H/O8;^T!6'(87S
M?N'P7;LOC[H/O8;^T!6'(87S?N'P7;LOC[H/O8;^T!6'(87S?N'P7;LOC[H/
MO8;^T!6'(87S?N'P7;LOC[H/O8;^T!6'(87S?N'P7;LOC[H/O8;^T!6'(87S
M?N'P7;LOC[H/O8;^T!6'(87S?N'P7;LOC[H/O8;^T!6'(87S?N'P7;LOC[H/
MO8;^T!6'(87S?N'P7;LOC[H/O8;^T!6'(87S?N'P7;LOC[H/O8;^T!6'(87S
M?N'P7;LOC[H/O8;^T!6'(87S?N'P7;LOC[H/O8;^T!6'(87S?N'P7;LOC[H/
MO8;^T!6'(87S?N'P7;LOC[H/O8;^T!\')C"^;]P^"[=E\?=!][#?V@*PY#"^
M;]P^"[=E\?=!][#?V@*PY,87S?N'P7;LOC[H/O8;X?\ \/Q"L.0POF_<<DXM
MW5:>?SO2E.?KT4!M#9<3_P"]>+<?JA6'(87OJSC\%V[+X^Z%].V&_M A^6^8
MPRYOW%#Q=NR/0OA[H>FI<VELM),R[I)5XOJDS[XFMM;D&I<&>59OV=Y:W%8[
MJ.+LJ9<AU:U*JM+DV.S3U,O/+0E9)5SML-FGDYSTT/AJ/B=2:)ENI=*>E7YR
MM0<JN4-]5N\#8OI/ZF]4>CG6]KKKI2<5JEF-(J:32W5>WG0CO/YOEB;F(TWY
M+)/=)29*C/M[NI#5L?1/1</QYO,8NRGY'LV7]3/ZBL7P7,DH_P#V,2J?F^6)
M2(];\F&9]TDROKZ@_1+1>&;S'N_(NOZFGU#KYIY%_P#W449M[;NG]D#:;:]0
MM##&6XM'H]4DJF2FY5/<E*7*49J-Y7AF7"YS,S[!L#I'I+)=)9>Y8R]R=YW*
M5<N%-U.!Y6]</7GK?U]U^SU#UK*W_,L0P1\N*2PI4IL1D5\%N[#4^;/5$-!_
M[J;<;0O3330G/%SX]W70=L3AVFE*/FSDK%VZW7]YSO1FT]YVWD/&?TSCEH)K
M#D1A:XOW''X+MV7Q]T'WL-_: K#D,+YOW#X+MV7Q]T'WL-_: K#D,+YOW%G9
M#QCNA:L6YG*AFREU%EN ZZ_%8H[4$WHR$FI]'A38+0E)X::ZF"<:T2VDM;-K
M9Y%XO6/);\2\=1Z[^NW@_'=$_P#3> ^S[-.T9:/%VT*;.VA*N..90   H?>[
M_P!8P!_-0W^;TL[Y5ZN-[WOO V69\W4[,L&2Z_:V*]M)VU=/P92KF@-LPJ7?
MTFG041Z;57S)R2OG=4\KG4C4N4C(*QKR)<)QW)RH]GY[:5_(SZL7YRE>.";6
MAV=A3HXW]AVT&9$.*U1;4QE(M:B-1FE&Q'4_&I%-B-RI+#"]"4OF5V\>(GX/
MW%6[M*X'LKQ7VK]JFZS@/)YYIPGBK+:Z+-MM[(EAVQ=LNWZDRN//HD^M4J-+
MG4F4TX1+0[3YSCC1D?$^3417P+-4;7%'KH$&#F:]%;Q]HB5?[M,RXXG7]?ZP
MPB^F?*,D/].7VXE7\R]OW&<8QE@
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ML07UEVNQ%8OK<M3"C[J#DQ&E_10,MM?!+N*2?Q1[_P &9U#$7
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MI0PY#7M%U23CIV:L7I+>HS3]R/3!\8^L
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M -T]R#-;_P!.?<8Y_/'O_!F=0PF0
M   U3JUFJ)@#K:9CR!,L6Y[_ $%8;M.]:+/@N5&N1_'*&PA4MB(@C\(A)'HK
M730O-'MS*].7.J?IRR&EPS-G*O\ EJ6*[+#!TDZ)L\;W]=M=/?4KF\[/+7LS
M715&EJ#E./Q[71<'LV\TD2+7OU<J;3+.KT^C;9-P3%6;ITI$"14+/E,TR))6
MVIMB7.?:;4MJ-&<5SJ,DGP2-3:;Z#WKNH6K>9UG2G8QK$HW4Y-5JU%5WO<C;
MVH>L=C+Y*[=M:3J[G&#I_P##SI7<F]FY;V><])/'=!NF],I[G+HR'1;MRS>\
MR='708SS+=9MJD3'6GGF9\)2BE)0V6B",RTYC,ST'UO735LSDM-R71V2RERQ
MH>747C=7"Y)+>GNV[^X^;Z0Z=:SF?SG5N>S5N_K>:DTXI*,K=NOPVVOF^'C7
M]3;V5H>'[E<Q;IJ/U.JSBS EX7'-K-S6+-;H-M2)LB7;5'\+%8.74CI#JE0D
M+A-*4M*S3J@RU'9.CM!Z*O\ HY;UOJ?+68Y>SF8X[B25R6UTCB6W;2E*T9\#
MJK6^L+/JRM"Z<S$W=OY&Y*-N3K;CAG"./#W2]QCWNQPWO=VAX0IU]Y8W47C=
M-RY"R]0DM1Z)<%4BHHC3Q+?E4])HD>#\5<)TT^#0?(6F@[7T-U!Z<]>=1W--
MT+1,O8R>5T^?SPB\;6Z6[?LWLZ;UIHOJ-T+TS#4-;Z@S&9SN:U7+[8_Y:MQG
M<A&5I*LO@:;5*[$Z<*F<'48G9AHFV/:5N0LG(5[T1&-';<J60H-!JM39]M-,
MJ%(A2#<K"8CJ?'$J?A+YS=)1>?\ -U&N/26&@9CK+7>D=1RF6N?S%.-ASC'_
M "Y*37PU6S8U2E-QLGU4EKV3Z6TCJK3,[F+%O3[L+N9C"K=ZRHMRA)+?6E=S
M?#C52S80W VWE7;S;6<E2X\*DS;8]<ZLX\^VAN+,AL)3-2ZX9DEM2WRU(CX^
M?(:,ZCZ5SFB]67NFHQ<KZOX846]-[*>S[C<6BZ]EM4Z>M:WB2LRM8FV^Q?;V
MD;.PS)%^YLS9NEW/WC>-T-XEL:H3+6LVW'ZI+<MJ1'@QIDZH5.)#<<*(91HZ
M=.8BX*-'?&W?4W2-,Z>Z=T7HS3LO9_WS,Q5R[-17F)MJ*BWOVO\ $UEZ?ZGJ
M.NZ[K'5&=O7O]GR]SR;,,7P2C&.*4TN>)N/_ $4>'UBD;U^IU>-T7CB#.]3V
MY;>;2JS]K4!- >FQ:O<U3IZEE/GNR(;B''6R6LB/0S).FG>'9,MF/3GT:TZS
MI_4&EPU?JK,05V?F4<;<94PQ2:9UC4M/]0O5?/7,[T]K4]%Z9L3\N'E0Q7+T
MHN2E*4G)88I[$DG5JKV4K\]FY'WA],O*%K8RW!Y+E;@\(7S*;F0+\K#<IZK4
M5Z6[XI(IYU*8XN0@X[K//R*-1:++0B(^-M2TCH'UBT6]K/2F3CI74>66&5F#
M6&:2JI84DMJ=*EM%S77/I7J=K1^K-1EK&AYB58YF<,,[;;2P2^*556K3KQI3
M<=SUB*M#K]3VR5ZF/%(IE9DTRIP'R,M'8DV4B4PLC(]//M/)/Z8P>@>7NY3+
MZQE+RI>MJ49+DXJC^X^IZP3MW[VDYBW+_+G?@UW-U.WZJM\Y LG;#MO?L.][
MDLN5,I]J-RY-N5672WI#9TZCI\&ZN*XV;J32LRT/OCC>B>G:7J'66KK4LM9S
M-N,[K2N14J;9\ZT(]9L[JF1Z.R<]*S5W*9ESLK';E38Y037;557M,L]V6]2H
M;5=O&*&*%'1<>7,@V3:D"VO7-:GVRJ<FA4YERK3$FKPDI[QIPU$1GYY7$]>[
MT?H;T\M=;=69ZYFF[.@Y7,W97,.SX5.34%R5%^1W'K+K:72/3V6\F/G:OF+=
MN%M/C.44J]NUU,$:)L>ZDUD4"K;A:CO3N"LW"5M52]:MCB1(J3E-\5737JW*
MI$%I;RX3$AIHE-M$E)&1D22XC9N8]2?2'4<U#I2UT[:MY;SHV89A8<55+ I2
MV5:;VO;VFLLCZ<>K&GN?4F9ZIOWYRMSN2RKM4MK$L6&$L;<<.Z.RM-CJSV'H
MS9:R;EC$N7;BR)>-S7)5V*K541TUZI2I[E,4V[)+P;!R%K\"39MD1::$.O?4
M%H6C:)KV0RNE9>U:L.,*X(J*E5+?3?O.P>A&MZUK_2U[4=:O7+F<=V\FINKA
MAN3BE[$J'EW20RS?U3R'NVN+)^2;KNBW;)?K=6*/<%7FU*-2J?3Y9NNI@LRG
M5H:)IE"M"27'L'V_771-,M:3H62T;)V+&;S"A&L(*+G*2_4TMI\CT6U;5[VJ
M=19C6,Y>S.4L9RY@4W56[<5%X8]BVOV[RUYUY;S>JMD6\86",PO[=,"8\JS]
M+:JE$<E(JU?DLNK:0_*DPW6GY*U/-ZFA*B(B[FA<>=9T_P!/?1'2K%SJ;3UJ
MW4^;MJ3C.F&":3V)II;.-/?N^;G;W7_K)J%]=)ZN]%Z:REZ4%<MPQW+TH-Q=
M7BC2*E5;'5M<$MOB>Y2S=U.#[^VK8:W!Y"=RU0HF1:7+M:_)!.*?EDAJ43K;
M[S^KYR"-DDK):C5V=S0=CZ2U'HGJ72];U_I7*+(9B65DKEE4HMJI1+93;LH<
M+6\CUGTUJ6@Z)U)G/]QL+-QBLQ*.&4J6[DJR57M>&CVO:R>O=WNGI>T7;FUE
M&53/7RLR$6_;5IT0UFVW4KBJ\5*82'U$:5>+,DV:ED6AF1$1&0\P="=$WNN^
MK7HL9^7EH^9<NS6^-N+^*G:]R-^]:=76.CNFGK,XX[KP0MP_=<G11C[6TO:0
MZP=MF_W='&<S1?6_BDX5E73&35;)L&UKB*G4RB,25&]$A3X424GG6EKD2HEZ
M&1\1Z N]8>F'1<ET]IO2T]1MV'AO7KEO%*;6]Q;7.KV&B[O1'J?U=)ZYGNKI
M:7*\JV\OEU%0MJM4IU:<G1T?R[=W;F3T]]Q&?Z-F"_-F&ZV\+<O[(-E6W&NJ
MP\D4-^.ZW>E!*24>5%>6RHT/SH4=YIPS^RY==3[VO/57I3I7,=/Y7U#Z'L7L
MKI68O.W?R\TZV9TJGMW)M-'>?3/J3JC+:UFN@^MK]G-:GEK:N6,S;=%F+3;3
MK'A.&S%1M;4T]M%,B6NG'M&@#>)4  !B[O$VN6]O'P%>6 +IO.^K!HUXE$4_
M<^.Z[+MVYX*X4CP[28E2A/,/H:<5P<22BYB <*?;^PUUJA\TMVN7%!*D7KNH
MW77O0B6XZ5$N;)U>J=+\(X9GSG E3WHAJ,NW5O4].)F+?#VU*M2^W_ NVR?F
ML^!,?W;9MR6]N]W;QX5EU.FS:9;OPJW(FDL1:6ZA<6FQF4U+DCPFD()*6TI)
M!)X::"&HA8U2O#M_L-I6'&3"B18:%NNHB1F(R'7UFZ^XEAI+25O.*\\XZLD:
MJ4?$SXB"Q](                      !I^CL_4 #33O_5,_P!4 <3YM2T(
MM.[WP!;57LJSK@;<:KUI6S7&G2T=;J]!I52;=+MT<1,B/)7J9=TAS+&I:EE)
M*64S%ZU)<8SG'WIHX=_(9#,IQS-BS<3WXH1E7OJF>.W)M,VU77'D,U?!V,R5
M)9<87(IUH46DRDH7VJ1(ID.*M+G>5Q,AV')]>=9Y"2GEM3SOPNM)79R7M4F]
MG8?"SW1/2.H1<<SIV3=52L;4(OQC%>)BA??22V<WF2'8UFU&V*BW_P!',HU2
M>)I)'VDN&O1I9Z<.TAWO3/7SU#T]X9YB%ZSQ4HK[]YT/4_0?TZU&-5E/*O)U
M4HM_=N(Y-V/2*B8DQ==F4,-U^L7+4+20U5%VBN$M^?.H_C*&IWBO@C<-QR"R
M[X8TE_N(4-O]"^OKU[6LOHG4-FW8MWWA5W%2,9TV5[)/97FT:CZX]!?]DT?,
M:YT]=N7KV7CC\FFV<4]J7:EM2["%)IU+R2YM4/),DO,*U)QMSL4E2#T-)D9<
M1Z-:P.J^7@S049>8ECV7*;5R.:R2C[(RT+[+7N$8F+KLXD26%8GN/2<?Y:SG
MA63[:,65N\;1CR'$J6_3W*A'HE26P?G#F,I2<*6M!'H1J29D1Z#XVK:%TSU%
M;_A:Y:R^8DN$E%SC7D_F7L/IZ?K?5'3\_P";HD\Q8M2Y.2MRI^ZFQ]Y(QA'K
M29^LQ2XN<;;H&0Z"A;9L52D1%TBY4(3YUQM_D4W E*5P,E<B3(_HC4/4WTY=
M*ZDE/IF]=RF:>^,GBM[=S6]KNJ;1Z<^HKJW3,4>J;%C,9)4I.%5=V;TUL3KS
MW\R1_&W6=VO7HRA=Q0+NQ^YS<CQUV&PZP@^!*4AV,XOG01GP/3L&H-7^G3K;
M3I4RD\OFMGZ&Z^\W%HWU"]#:K;4[WGY5-_\ >QPI;:>!G%8.\?;/DN,B7:F8
M+,D$X?*EF;5XE-D<W:9&U,<:5W=!K35/3OK31IX,]I^85.*BY+Q539>F==](
MZQ%2R&?R\D_[\4_>9"TNNT2MLID4:KTRJL++5+U.G1IK:B[Y+CN.),AU*_E<
MUEI8<Q;G;ERE%K[T=HM9G+YA5L3A-?W6G]QVPP&8
M                  +#R=_9_=O\B3OXLQ:.\J]Q'S_ER_G[]P,WZ_85X^TE
M"'',@           &"NXO_%=L8_KME?^Z>Y!FM_Z<^XQS^>/?^#,ZAA,@
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M<^XQS^>/?^#,ZAA,@                                 4,N[W=-!%
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MTL5V;;<KDN<I.K;?:]FY;$C,\:^.[@
M              &-F\'D<VI;F$$XSS? 5E,CYW$$23.R*X2"7S*(D&I79WS/
M0%4?F:\GS2QHXNQ'-RGS::)S<Y>II-3B"+@AM1&>I\.;7AWQ+^9]Y6"_R85Y
M?B;5I*)1$9&1D9:D9&1D9>89'Q$%BO: *:?J"* :'WP!YQ>N(,99%B2(5Z61
M;E>:DH4AUR736"E'S$9<Q2VDHD$LM=2/F'V=-Z@UO2+BN:=FKMJ2Y2=/![/<
M?+S^BZ3JEMVL_E[=R#YI?>MI''E/I$;>[O.?-LEZIV54YKBG2:4XFHTQI2^*
MO!M*0EYM"3["U5]$;?T3U^ZMT_!:U)0S-B*2_;+9SX-FJ=:]#>D]14I9)/+W
M9-OFO8N!&]DKHQYKH+<ARP*K1;Q:)3AH:.?&ISRBYCY>5F8IK35/<&X=&^HG
MIK-R4=5A<R\MFW"Y)>U5-0ZQ]/6N96#_ -FN0O+@FTOO,&KNV"[L\9HD3*CB
M6[VB:\*LYM'A)GH)"-=7428'A2T07$CU&S-/]4^@]::M6<_EW6GPSEA]E)4-
M8Y[THZ[T23NO)7W-5>*VDZ5W.JY<RV+.SKN:P!+;];+HOFBRHCJ5I@5J3,>:
M2IL]>54>2:DDG4NP<[4>F.C.JH5O6,K<A)?-!)/;VHXFG]3=;])SP^?FU<C3
MX;C;W;:?;N)!,3]9O,]LOP4Y0MV#>$-*B0^B$1P)CB%<%+YM#0:DD>OTAJC7
M?IUZ<SL9/1;TK%QK97;%?;<;4T+ZB-=RLH+7\O&Y"NZ'S/Q\223'/6(VN71X
MHQ><ZJ6!/DJ2A3=1@RI<9M:B(CYI$=I:202CTU,:>U?Z>NM<E6>FQAF[<5^F
M23?L;-MZ3Z_=$9UJ&HW)92X^$TZ>-#-ZQMVNW#(RFFK2R_951EO)YFX"ZQ&B
M3EIT(]4Q92VG3^R[PUKJ?0/6.CU>?T_,P@M\E%N/BJFR-,ZWZ4U>BR&>R\Y-
M52Q)/P9D#%G0YS2'X4J/+861*0]&>;>;41]ADMM2B/4=2N6[MJ6"[&49)[FJ
M?>=GA<MW(X[<E*/8ZGU"A<                         L/)W]G]V_R)._
MBS%H[RKW$?/^7+^?OW S?K]A7C[24(<<R            8*[B_\ %=L8_KME
M?^Z>Y!FM_P"G/N,<_GCW_@S.H83(
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M_P!'<'',Q7M %-! *B=P
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M_KME?^Z>Y!FM_P"G/N,<_GCW_@S.H83(
M
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M
M
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MEM_)+N_(I/YX_P"+\&9U#$7
M
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M7+N*37QQ[_P9G6,19 "0
M
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MU/\ N&']ZL>@ 40];J?]PP_O5CT "B'K=3_N&']ZL>@ 40];J?\ <,/[U8]
M HAZW4_[AA_>K'H %$/6ZG_<,/[U8]  HAZW4_[AA_>K'H %$/6ZG_<,/[U8
M]  HAZW4_P"X8?WJQZ !1#UNI_W##^]6/0 *(>MU/^X8?WJQZ !1#UNI_P!P
MP_O5CT "B'K=3_N&']ZL>@ 40];J?]PP_O5CT "B'K=3_N&']ZL>@ 40];J?
M]PP_O5CT "B'K=3_ +AA_>K'H %$/6ZG_<,/[U8]  HAZW4_[AA_>K'H %$/
M6ZG_ '##^]6/0 *(>MU/^X8?WJQZ !1#UNI_W##^]6/0 *(>MU/^X8?WJQZ
M!1#UNI_W##^]6/0 *(>MU/\ N&']ZL>@ 40];J?]PP_O5CT "B'K=3_N&']Z
ML>@ 40];J?\ <,/[U8]  HAZW4_[AA_>K'H %$/6ZG_<,/[U8]  HAZW4_[A
MA_>K'H %$/6ZG_<,/[U8]  HAZW4_P"X8?WJQZ !1#UNI_W##^]6/0 *(>MU
M/^X8?WJQZ !1#UNI_P!PP_O5CT "B'K=3_N&']ZL>@ 40];J?]PP_O5CT "B
M'K=3_N&']ZL>@ 40];J?]PP_O5CT "B'K=3_ +AA_>K'H %$/6ZG_<,/[U8]
M  HAZW4_[AA_>K'H %$/6ZG_ '##^]6/0 *(>MU/^X8?WJQZ !1%/6VG=OB$
M+7_]E8] !)P=I-,>8?C.T^$MB2VME]HXK/(ZTXDT.(6DD:*2I)GKJ%6114H1
MMR.D!T_Y54GUA[ UO+G5*I2ZK,<-MDTN3)SZY,E?(<?E)*W5F>G$13;4M5GY
MET>^GV4IB86!+>2_'?:D-*0AIM*765DX@^5,<DZ$HNP*(G$^PD/MJRK7M"@4
MNU[>HM/IU"HT9N)3H#49GP,=AHN5"$I-!EP+N]HLVRE-E#O"IM.+L@0OO5CT
M BK%$5];J?\ <,/[U8]  HAZW4_[AA_>K'H %$/6ZG_<,/[U8]  HBP,I4ZF
MGCR[B7!A\IT:4HR*.TG52$&:#\Z@CYB/L%H[^PB6[88#<K?DY:>#+D]?M.73
MAIX+3L[--!F_7["O#L)1!QS(     ==5J7!K=-J-'J3*9-/JU/F4R?&7]C(@
MSV%Q9;*O^:ZPXI)_1 E-K=O,(MFW3>VH;"ZGEJK[:[$?LZ?FNMQ*_?KS]03.
M\?G07:@]%*.118_B\=IVJ/J)'GN*^T.P-U[#.XN!$7> @ #!3<47_O6[%_ZZ
MY6+_ /1/<8RV_DEW%)_-'_%^#,ZQB+@
M
M
M                  !8.4D$YCV[DGV>LLP^'?)LS+],A:.\A[B/K3_W<=.Y
MZ_:?2Y!F_7["A*&..9     !YO=      &"NXK_%;L7_ *ZY6_NGN09;?R2[
MOQ12?S1_Q?@S.H8BX
M
M
M     6'D[^S^[?Y$G?Q9BT=Y5[B/G_+E_/W[@9OU^PKQ]I*$..9
M   ,%=Q?^*[8Q_7;*_\ =/<@S6_].7<8Y_-'O_!F=0PF0
M
M
M                                 +#R=_9_=O\ (D[^+,6CO*O<1\_Y
M<OY^_<#-^OV%>/M)0AQS(           !@KN+_Q7;&/Z[97_ +I[D&:W_IS[
MC'/YX]_X,SJ&$R
M
M
M  !8>3O[/[M_D2=_%F+1WE7N(^?\N7\_?N!F_7["O'VDH0XYD
M P5W%_XKMC']=LK_ -T]R#-;_P!.?<8Y_/'O_!F=0PF0
M
M
M                                +#R=_9_=O\B3OXLQ:.\J]Q'S_ER_
MG[]P,WZ_85X^TE"'',@           &"NXO_ !7;&/Z[97_NGN09K?\ IS[C
M'/YX]_X,SJ&$R
M
M
M !8>3O[/[M_D2=_%F+1WE7N(^?\ +E_/W[@9OU^PKQ]I*$..9
M ,%=Q?\ BNV,?UVRO_=/<@S6_P#3GW&.?SQ[_P &9U#"9
M
M
M                                  L/)W]G]V_R)._BS%H[RKW$?/\
MER_G[]P,WZ_85X^TE"'',@           &"NXO\ Q7;&/Z[97_NGN09K?^G/
MN,<_GCW_ (,SJ&$R
M
M
M    !8>3O[/[M_D2=_%F+1WE7N(^?\N7\_?N!F_7["O'VDH0XYD
M   P5W%_XK=C']=LK_W3W(,UO_3GW&.?SQ[_ ,&9U#"9
M
M
M                                 L/)W]G]V_R)._BS%H[RKW$?/^7+
M^?OW S?K]A7C[24(<<R     '45FO4:W:?(JM>JM-HE,BI2J14JO.C4VG,DK
ML-V=,<:C-E]%1'P#[@=1;%^67>K4AZSKNM>[&HBDHEN6U7J;7$Q5+(^5+YTU
M^231JTX<QIU EJA=P$  8*;BB_\ >MV+^9>N5_[I[C&6W\DNXI/YH]_X,SK&
M(N
M
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MF(2W)\">I$GPJ$D1^8%=E. .Z
M   ?)-A1*C%>A36&Y,20CD?8=+F0X@C(]#+S%$1A6FT'[M-MM-H;92E#2$DA
M"4EHE*4EH1%YA$#;;JR$E'8MQ^@$@
M   'Q3X$*IQ78-0C-2XCZ>5UAY/,VX7;H:>[V"4VG5;R&DUMW'[QH[,1AF+&
M;2RQ';0RRT@M$MMMI)*$)+N$E)<!#=74G=L/V
M             '!Q"'$+;<22VW$FA:5%JE25%HHE%WC(^($->!U]+HU+HS+C
M%*A1X+#SRY#C<=!)0MUSBI9E^N48EMO?P"26X[,02
M                ?A)CL2V'HLEI#T>0VME]EPM4.M.)-*T++NI4D]#!56U;
MP<(<.+3XS4.$PW&C,))#3+2>5M"2X$22[A!5O?O(22W'U 2
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M$U>LTUB$A]B.\2TMJ6E2R(]-3+0148=E2:0CU+_L&79P[#$D%0
M                      'AFX[<7BC:EAB_,_9MN/VIXQQO2'JS=->*'*J#
MD2(UH6D>#":>E2Y#CBB2A"4F:E'H WEI;.MWV#]]>WVR-S6W6X:A<V)[_776
M+?JE6HE2MVJ>-VS7:E;=:ASZ-5H\:;"D0JK2G4&2TZ*(M2,R,C EJAD\>A<=
M=.^>G#Z?T-?TPJ01\;1.I_L^WQ9-S1B;;ID&H7C>.![CK-LWZQ)MJL4FF-3J
M%5UT2H/46K38;<&M043F^5#K*U)<29*+AQ$%FJ>PD)$E0
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M(DJY^'GM0K7?O)P85LIA6Y=FVAMI%V%]#N]H$%0
M           %K7M95JY&M*OV-?%#I]RVE=%-?I-?H-481)I]4ITDB)Z+*8<(
MT.-KT(]#[I:@.\@FZD^UKIV;&ME&<<\4;:!ANHWU1[950,:43UCA,U:NW]=\
MN+;5 AT9;IN-G/8DU7QDB)"CT9,NZ)Q2:I5E5"W%UPQ\%^7$\5^;]]'2@[,+
M?K>\7)=/I;F?]P5(.L4^ELTU<=6-+4N0TSGJ*RZ^3:RGU%DTDZ2$)0VVI1%K
MSJ!NKJ]_VVDQAY<<"?VKN]GVW&S61:%Q[?,+3_:8@DJ
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M%>J*9.J+INF;A+ERXBEF2C,^/'LU#M+?I:7-?<T;ZI&1]GZ.X!4J
M                     #@K0S(N\>OF<>PNWCQ &JIM\Z,&9LA]7K<?U >H
M?+LS+N.I-(N>CX*LRHJJDVAVK EU*GQ[;2W'J:8\5J!;MMMR4-(0?*3SZEJU
MU"NT-*KK[/#;W?VLP(WIT?%>'>OML"/I2TVW:!DBH46O4C>#3,0O-.69/L,[
MLMLO$KR9IC\F$3JX:73?29%JZTR:N*#,/B^W>2O+V*7S/[J;_NV\Z$R'71P5
MU+LP;?,T.;8\_P"*\28,MW%ERW!?%%G%7V;\NJDT:C/SZW1FIL6B2(,=$V/&
M<2C62E!\"41D9I"NS<3%5EL=']O#P(\/F7BR=V%;C75ZKE*W&O>-O+U4X^^=
MI0%FZXX9FI:E<_:?$SU#B'2FSG^"-R0"H
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M)="G&ZTO1*'FD%3B/5.OV9:]I:J/>QC4ULW5IX5V^W\#;J @
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M<Y4I4>A$DNZ0.OL(PPKB2^+_ (+\$3)D6FOFGK^D1?3[ )*@
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MY>!$DDD1<$D1:::%W-"(B^@0 Y@
M                           "FA:Z_H_1Q %0
M               !0R(^TM0!4  !30B^F *@
M        &FO;Q                                       !30N]]4
M5 %-"_5_3/7]4 -"UUT+7OZ<0!4
M
M                                   U+O@
M
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M(R_5(@!4
M
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MWM;F]E-X87OZ=>."*JW0;<JE <8EM7S62I5.J#\<HZT$Y"9-53;)"R)>I&7
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M(<H13;4TEV&QUM+W889WJX-L[<'@>YFKFL&\X9/QGM"1,ITQHDE,I528)2_
M38BST47V*B/4NT.TEJFPR6 @
M
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MBMT)N,LUMZ&HE%HH^)D>IB:23I^ Q)JM/>77T&-NF\'".]G<A7<TU>A4:B9
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M#MFZWB-<A9KK,Z;*4S+Y5&TK5)<I:::$1G5(M+GPJ36B2H
M
M                                                 #\SM &KK\Z
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M[>Q(F0 D
M
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M;H!8K]?Z_P#M @H7Z.W33S-0'$Y
4                       #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tv523241_chrt-line2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_chrt-line2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#20.$ P$1  (1 0,1 ?_$ 0P  0 !! ,! 0$
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MSQ$E#M2ZA9$M"T*;,B-+B5)4A6./(HCPZ@ YXEUR]T@!3$L2[8N0]F)>Q^\
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M3CW\4BHZ6+4RJT1919F6[E?GCG[#H%#N*_+BFHI<.P;%K"&J/-G_ "F\E$:
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MC%SJ:PS6ZW 9:3":ES'(RV$&EP\4+/M=I*E;]Q2?#3AE1M[%TORWEP,Q]4E
MX?W#"T0Y)\1O3Q4\W<NLQ+<=CW17BI/TI=MI,^IOR8*3_+(73:C!IE00O%1I
M,D*(CQ($\>HO*J6WH2?J]AA=J$M7U>?3?D+=6<&4591F?F)G+;CB,I<J:-19
M-6J]N5ZHQT--IJ4-AF,U1N]Y;IF9NO&>)8$2L#,-N"J43A%<58T\_L)\/5R=
M+%QZ<]!-'NBZZ0FWZGGK6YV94.@J42I=+H%0GU'Y%9EMI+!EU<5W>).)F23+
M$@ITEJ^XHOK?KQ(5,HLH7LY_6I<_\WK<?>D4?+JXX#-16RHR0A=!MVB4^:MQ
M.PC0J3$218\A8]<5<?74E3=6J8*/M-ZI18I5NEM,\=O7+ L?:P(6*FG5ZQUI
M_JV1N>>F3B>VPA%.M;**]+9C9K38"DHJ'-T>H+K$-\HS1ID3%R8D!Q':XGO(
M(CY2#V?:*-M270\?,6XX&F7".()KQSEXF559<J5B4VKD]9K]92MF>U6J@F6N
MFMLP9!*>1WBB/BL\>T-)=4R(5QV;=Y;W4W)=."Z:4VE[N(_K-X7^>^M%W0[Q
M"M/=<RKJC[DBCV?J8KEN,G3&I;#;KM.>?KD9UQQBERW&DDA:V7=TS(CP(6]&
M.\AM)J#:HU6CZ^LAFULZ4-!V@JT8>HGA]<1>OU//RDW?;ZK"RILZ7592KA?D
M5&.A,$G:4@FX\8D+,UK<0E*BQ('582]A2D(+BM54O/6O53K-P');B,VWIWX=
MF16J'B5WK3,C9-W,6];\JO5:%5JJ]5JK5V'/D>1*IMOTZJ3V9518B+<<,VNU
M).\O U%C&Q&I2OP^DE RHS9R\SRR[MO-3*FZ(-Y6!>%-*IV[<=/;DLQ:E"7B
M2'4,S8\66SM(\4N-H476!.N/00TU@]IJO^N1(4_PSLN5(Y&\_;7DJQV$;:*5
M.)1%CU?RA; >U,O;=$S(;A!\8+A_TGAT9,T.[L]*18=<R9RVB4N[*->$"H4F
MH/OQ"ERW'*"RIAPJPA:#W4DV>\:S(L-I&"6S>5E)-MX=9A!P<GV-:7&$UT\1
M_)_OU>FZ):LRP:?6K@A.T>?5ZO4&;@*,<6"[OFZPN.M3QJ)6ZE"-IXJ(A&*K
M7:6XHRC6.*P2>\M/P$+M=H6N+CA7M:B8];NJW8DBNVW2HCS3\F=*CS:M(8)E
MLC4:B5)BI1UL=G7".$4^BA,VG*G37[S$'1;2=).O[,W43G=Q2-6<ZP<P;<S,
MJE)@9.71*F-N(MZE*WH\R&@V)B28<;(T(::0:]O)CL.T:[L*&G+NVVZ^]6E*
MTIZ#'[3G>6A?*WUCC*JJ:5[N32-.=,@6C2(-SW= D6M%J=R/4QB-6%P"J[41
M^=#<J*^;;D$V25I1L(MTR**8>DLG%--=*?K_ -B)!LMLQ\M>&AZQCJQOW5'5
MJC8]EZD[_NN][!O,H#]0M=ZBY@-IJM F2ZI'2IAAEUF>DUGBI2%;VP]T\%&W
MZR'<C%-2PP23^PETU[>L09,Y1YD9<9":+7*9J8SFN^LTQFLQZ# GSK9H=,J1
MQ^]B<J^,1AV:X4@C4E.)-X;IGO8D2K2\Q"X:I/&NQ+::RF:6E+3[I-XME^7[
MQ1+4N&EY0ZA:Q5;V:KM.I4BX:51JI=YNU)!<Y"2I<:)&GRDMNFG?4@D;"/D,
ME1452+DDY)SIPO9NKUDF&I')OU;33SEQ4+BBWC!S4NVZ*3)*Q+'L6'/N2H5N
ML5&*LZ+ FL(@1(D./*EO(;=.0\@T)49[IF6!S3'I(;C%5]U>71UF)_&'R]L3
M)_A%:2*W:N4\?(RB5[,ZGW3]$7EQ(E2G4FGO4J04LX#<AQ9ODVY@A.Q2L2(A
M5I<2H:D7)P:V[*&SAILXS?#O@Z(;)OZNY_4&W#L/*6FT^O6?6HTJ)=ZZC1;?
MCL/1*=1#:-<]V2\P:6#2K=7O8*,MN%BK:IQ57!OJ:?\ P_.']FYKTJ7%=U%V
M!2)K>4.;V7&8+67DR:;M)JMPU64J;4J33F8SB-Y#\IME1;I&9$6!X[2$)8I=
M*-17%).4=DL$_7CYB:3U=+B<:6\@]/==T(Z@[L7D-F_DS<%5,V<Q8C]+I5=@
M-E'AOJ@5A2'(STEA4<E$E1))2#/#:6 ;'U;32XN);4IK!G@>+7J8R*XQNL72
M'H+T?UV?FI7\M<U(&8U\9BT.%,A6/1(M(;>>EQFJ_+0P<M;+:4FLDH)!GC@9
MEM.=OF%4FE55VOJ2-T++VV3LJQ+/M%;QR%6S;5%HBY!J4X;RJ; 8B*=WU;5&
MM36.($MU=343XG5I1,H>/KH?U"W3)=B6Y<]%1;\9YQ1I:6]$GT-I\FB5NDKF
MS;21[N.&.T5V8]!;BP4=]5Z2=3C-URFP.%QJ_KDB6RU3_,_4G4277":9-$]R
M'&CJ4XHL$DOOM)EC@)>PB&#(=/4Y7D.\,N]$I?;>YK/NY4J2A9+-E7R-2<6U
MD6U"BPY#!$SQ[3"'AT5Z?2?66.)W5+3@1[KK\>)7%4N@,U"-&>JLAJ@MXQ6W
MWW&F4.;YI(\5%AB6)D'2EYRV+C*O5]A)G>?%&XD="O*ZJ+'X3-TUAFF5F7$8
MJS?T:<14&6W3),CGG)REO<X1?=&9XB<*X[?2:=)]"P\Z/(3.*UQ)<8C:^$1=
M"&W)T9N0MV/:SJ&6UK22W30<L]J$[2/#8)JEM^TBDZX)_P Y&RYDM=5QWUE)
MEY=]WV?(R^N>XK8H]5K=ERE1U2+;GR6VUOTITXJEQR-@]F"3,B(\.4C$$M49
MH$\9VH0&O6.]-+;M1A$MI=EI=0J4T2V%.L1%MM.I-6+:U);49$>TR(S%9?"_
M+I-2/X5U_>;U&KK-:JY(Z9,U<UZ78YYDQK(L:K7!7;3:0B4NJ6S ICS]>;1"
M4HOE%)T]*]YHL=Y!GL,B%MIII/9TFG=EY:/JY6KZT.F%7*W R#K=OJF7)F%E
M%5*4JDU6;.I).39%/IM$YJ4_,1,4US;:$.;RE+PP(]HE[/U?+857!+:UQ+KI
MZ\<3QO >TQTS43Q-;LUPY+9<S+"TQ9=S+@:L8ZM%^27Y;,N#4*?2D,4]U2WN
M<<;FH49;Q[J2Q/ A6E$D]I:+KQ7$_<I3S]9(#ZS_ $B!F]</#WR'I3[J[MK6
MH:C5AIAD\%)9*LVZF.WO8F9N.KC*Q+#8G#;B#55Z!&7#AO=/O[#:JRPHSUN9
M;9?6[(WN?H%D6I17MXNVYVET&GP7#7R]L:V#Q"C6##:;JMC/<B2
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MG:6M^Y\J(LW4G94*+ H5_-U:J,+89@K6N&I^G-24PI3T93JB0I:-A&>P13'
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ME5K2LNCTJ>@\2,E-RF6#>;46&PTFDR$40<I/:S*LBP/_ '/9Q$D%0
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M<:6AQM9$I"VU)6A1'M(TJ29I41EU@!S
M
M
M                                %#]T :Z6O7@ T_7#J.N/4$_K,STR
MO7<3+*/H;;$E7R+3.;:2US<#<J,3!CM.U2:<2ZX+#:JD24GLE));FON9K6ZV
M^$C#RWU>:?.'SI<UQZ@;[U*7M/@WI?+U5JTYJ!9]BQTS)"YDV/!JYI<DI)E#
MI$MY33>SG$JVH!T>Q8DI37XI>E]'HIT^LW_]+>3E7R"R&RVRFK]Y52_ZU9MM
MTZDU.ZZP9]^U:9&CH;?D+(W'32E;B3,L5&>WE$+8'BS($2
M
M
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M&'R]4\"(;BS\$BK59(DU8_YEG#DYEO\ Y*<!MV6.X
M
M
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M<P^WVJC:=;-)\F!B"<>G ]P
M
M
M           L-J40E>4=QX_Q2CJ+VR<P+]\7M_$5>S LSMZ,_P#._M?(O8%O
MWA'X3-\:1<        .MUM+S3C*\30ZVMM>!FD]U:32K!1;4G@?+U !J#\6;
MA":+\J;)S S2M*A7S3KMJ%BW9=*I*[SFR&V*Q"4Z^AR&A;:.994MW:@S5L+8
M>(U[48JS-[BL_?N1K3$PD]7^X1>D#7)I0S#S S^BYE7+=5O9KS+<I\^+?4R
M35**DQ9:&EH./(-QQ+SBNV,RP+8-#8RRQ@GOJ;KVFK3CEII1RAMK)'*2'4X5
MC6J<Y=+8K%2<JT\G*A).5)4_-=0VIPU.JV=J1$0)4);;VE^0(
M
M
M                                    L1J1_9'<GX$?]*0O#XBKV(LO
M_5H_G?\ 0@M^\*_A,WQI&H          0:<;M9ED)=Y)V&64MW8G[#DA*,/L
MDDR&XM_V$_,57]I$PL]4Z_\ 8@SC_P#7I*_V#$&A+XGZ"T?[*/I]IM/"
M
M
M                                             %B-2/[([D_ C_I2
M%X?$5>Q%E_ZM'\[_ *$%OWA7\)F^-(U          "##C=X>8>\^OYH[GQ+V
M"E+P_?,;FW_83*_O(F&'JG7_ +#^<?\ Z])?^P8@VTOB9:/]E'T^TVG@
M
M
M                                             6(U(_LCN3\"/^E(
M7A\15[$67_JT?SO^A!;]X5_"9OC2-0        *'L(S]@ 08<;G]A%YF?(>4
M-S=7#DEN=D;FV_ZB:Z65H^\CU-F&/JG6'0@SBPVD>>DOD,C_ /H&+MQZHVS^
M)DQ3[N->OVFT\!(
M
M
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M[)N]Q4I1J7"UYMA(T,BGD\
M
M
M        "Q&I']D=R?@1_P!*0O#XBKV(LO\ U:/YW_0@M^\*_A,WQI&H
M    $9/%T,N@_F9CRF4?[<2?B,8^+M?_  J]3_UK?_$>P_H45?J-T;_>_P"*
M!H4Q<#9P,L>W4>!<N&"<.3K#RHO.?IMO?VE>H_6?*W@@]BL=A>UUL2^R*M[<
M50VZIBJFVMZNLRIK(S.]9J,R?S&II$6.))[WHR4'LP+#>YSJ<N SUX'/^LU3
MSV/9-_:?#7\UR:GXD\N*F,=)N?TKM>RAL5CT"?*$
M
M
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M^!TEWVJ0_%_4/LN+[$?#G\UZTH^(G+5V/PRTJ[CYKN'VFQF/01\G
M
M
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MV\3^??$_-6-3Y\S][/YO+V^[MRN2XG&%:T6$>DEN'+G20
M
M
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M5 !5     BJ "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J
M"J "J "J "J "J "J "J $@    BJ "J "J "J "J "J "J "J "J "J "J
M"J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J
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ML_('])5[,W/#Z_;ORE*W;S]Z,*]$.-TIU$Z \O'JD"     2"F'LF7N?PD%
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M/.EVJMG(9]06AM(>XLKOKZ-._P Z>_W[CO?_ &+ANX8_9%_Q]1%%2AG -(L
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MS\/<OX:<L6^5[,E.=J4G*?S-MMOUU,QACXR"
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MA'A@>"L#(2U3SE$]J?0_:;=J3Q+'V5%]@E&1?:("2H
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MI"$[VX[BE1I3O$6. G:13IZ#,0CQVD!!3$BY3( ,2ZY>Z0 K^[]WN@!R[2
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M6M&_'DPG'$%5:+48JDID4^IQB,EM/-[Q&2L-U23(R JT9<D)
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M"?,>[_#;OL/Z,\'_ $*)_P#)8_Z) ]MVO[./\E>P_)OF?_<7/Y<O:S]0U#1
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MZ2I)%&[9@E8I21'CO=3EJMN(=%"D/AJ;JQ88%R'L(MGL"Q0J
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M(U-LM-J47\8T()./V<!ZQ@N&*B]J2/SHW9JY=E-;')OUNIWBQI@
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M6)X<@]"^"5SBR>>M_+=AVQ9\(/S5;:CXL:)/I>D>RY(V%!G,^6
M                      %#^U[0 M3G!DAE+GY:)V#G3EW:N9]E*JM)KAVS
M=](BUBDE5Z'.9J5)J!19*%)[XAS&$J29&1'M2HC29D8BA<.C46DV[2J=0J!3
M*?1:+28C$"F4BE0X\"FTZ#&;)J/$A0XS;3$:.R@B)*$)))%U )/J
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M?&1]<DI_A2?7 =)4DF7*HS]LB+J?\$B  T[<<?M%M]WJ@"AI/J+/W$G]C[D
M<L.3J^SL]O\ ? %0              <5_<+_  3_ 'C CJ-4'A4_^_<XF'_J
MND?_ )1+)$OR]87Q2\Z]AM@""0             _++AQYL:1$EL,RHDJ.[&E
M19#+;T>3'>0IMYA]EQ*FW6GD*-*DF6!D>!@#'C*+2!I<R%NNYK[R8R RGRQO
M2\WG7[INNSK*H=%N"M+>5O/%,JD6&B6IIY6U:$K)"CVF0!88=!D>22+DZV
MY      "Q&I']D=R?@1_TI"\/B*O8BR_]6C^=_T(+?O"OX3-\:1J
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MAXJZ)FFY.U/2J8[(M7);//M-APAGD^594
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M]Z3I7THVMQZ)/B4
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M40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40
M40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40
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M9W(.[>]"J'2@L[Q=O+P#,[D'=O>A5#I06=XNWEX!F=R#NWO0JATH+.\7;R\
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M3V (HAS+7YIO\1/8 DIS+/YIKX-/8 BBW#F6?S37P:>P HMQ7F6?S3?XB>P
MHAS+7YIO\1/8 D<RS^:;_$3V (HGM',L_FF_Q$]@":4V#F6?S3?XB>P!%$4Y
MEG\TU\&GL *+<.99_--?!I[ "BW#F6?S37P:>P HMPYEG\TU\&GL *+<.99_
M--?!I[ "BW#F6?S37P:>P HMPYEG\TU\&GL *+<.99_--?!I[ "BW#F6?S37
MP:>P HMPYEG\TU\&GL *+<.99_--?!I[ "BW#F6?S37P:>P HMPYEG\TU\&G
ML *+<.99_--?!I[ "BW#F6?S37P:>P HMPYEG\TU\&GL *+<5YEK\TW^(GL
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MYC,
M
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MS.H9 /-@
M
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M3[6SR+^9#I-K2OJ:SW<JD<QI^4NOK<[>/:B8<9./!(
M
M
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M@
M
M                                              6(U(_LCN3\"/\
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M=DN'^3CLU*(Z\YAU$-)<WU<G4(PH]S'%%]*/LE[)8""Q4
M
M
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M:
M
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ME^U$HW"2(RX:6BHCQQ\PEF'MV'MC.GR>R*K8:C^Q>PD3$D
M
M
M                            6(U(_LCN3\"/^E(7A\15[$67_JT?SO\
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M>;DTJ$J3&ILXR66\TN7&:2HR/EQQ+ C$JE,-AIR;<JRVT1*8)*@
M
M
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ME88GD+9I'AR;([J2Y?8(;N.PXF5:X[E["1(25
M
M
M                   L-J462<I+CQ_C%'(O;YTA>&VI619G'_JS_P [P_\
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MM%6.P_,-9Q=7EYA[[8YV#3C4QY-/BV="]B)%,2/DVX<HN5IO*@0
M
M
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MC@/5?A4T^7E1UHUVH_.C^8ME[UCQZS;O*BG62QZ'BNQ]1,H,GG@(
M                 ^-<->H]JT*LW-<-1C4B@6_2Y]:K=5EJYN+3J53(KDR=
M-D.8'N,18K*EJ/J)( L71;3"RC\3#0O7I;L*E:DLMY,AI2FUH56V8Q$I!&I6
M!RRCI/M2Q$56TFC.R5Q*M#<.J0:,_J1RW^4ZC,8I\2*S6F9:W9DI:6F&2.+S
MR2-;BBVG@6T3AO%'N]AFY3I\.JP8=2ITEN9 GQF)D*6RHE,R8LEM+S#[2B(B
M4VZVLC(^J1@1U'[
M
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M@B(A**;3]XD
M
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MS+VY5ZW%5[3\AO/FB9CESG;5M"S47#,974,Q;<6J-<-V:6'F1<D<F=2
M                      AH]8(_]T+K&_\ )JP?_P KMA MOI(E\+_DOV%W
MN#=_[MK2S_ZOV?\ OR2*Q^$U+GQ>A>PDY%B@
M
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M%8[#4N?'ZO82="Q0
M
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MG&-?DVT1]#?S4>0;MZQH_/\ ;C_56X.Q*26%:[&_3@;40]&GQ7
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MMZ/V"YH
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MF^E"L-BB(R,SPQQPVD1EMY1[//R[M4DUN9S)6/4/EZNS[($'(
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MO3]-32=W,Y+,6;:;V5G<MQCCT5>)>4CQ_P!_$<R8_*@
M
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MW;=I4*FTNHOLJ[9116X%(CNM/I)6SMN4N4^IO77J.$22\QL3$9'R""2H
M                 XF?M<NTSV%@ (8?6"Y+3'"'U@)>62%/T"PV64D1F:W"
MS7L>5ND1;=[F&%J/V"%HPE-^ZME'VI&G>NV[4'*;I%IK^BV7DX-IX\-G2P:3
M(R/+]D]I&1[9DG]XQ7AE#W9;34[R%Q\<'6))V0 J
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MV4W-$IQ;2+]W[^T9-/%I4
M                                     6(U(_LCN3\"/^E(7A\15[$6
M7_JT?SO^A!;]X5_"9OC2-0          C#ULG_Z?=,I?_OT_'PE#P^SRC<V?
M@97\2)-HW^CL_P"1:_1I&V+'< *&1'RD1@"(/C3W]1K%TCPDU9:T+N3,2VZ'
M )"#7O25M3):B/9@1$U'/E,=BY1SD<CS1D;TJJ+S$4_6<)S-E)YWES/684<O
MX>>W>00Z";S*Q]6&4]<D2%QJ4XMAB:E.SG"F.FV9J+ C,MU9#WUXEY*.K^'V
M;MV<;DH<4?-PU1X-\,L[/2_$3+?Q-8V8P<6NGB[S'[$6IXR61LS*?5Q=EQK0
MR5.S,FS;LIZF3Q)UJH/N2DJ61)3NN;KNZHNH:1\)/$;2+>B\U9C+P_?2=Y>:
MY)MKT2J?M>_+^\2\MSWX$Y#2X2D\SI%J&7G7HX(J.'5A7S,Q4U>9IN9GY@\$
MXYDU<JKVG7Z=;4GG3Q=;12[XI<>.9F9<BVF\2+K#/OA9J_\ B_*,8R5)Y:4[
M7HBZ*G5N/C5]=G),.2_J)U666MJ&GY[-]_&FRMQ\3]5<3^BG&+>CQU'@:E,L
MJ4KJF?-IVX^V,A'D-T]!^D                      !&UQ3M0.8.FC2O4\
MS<MI*8UQP[HM^ EY2^;+O6<^MI[:1&HTDD\<"(]A#&_B;S%J/+FB6<WITN&_
M<S,8-]3C)]K5#UQ]%GA9RMXP>-5GD[FZ#EI%S)WYT2K[T(U75V])J>YZ\3+.
M_4IE/<V2^;T"-<5AW>W#*LTU3YN%(7!E,3HKB26RCMFY,=*BQ/J#"3\4N;U!
MJ&8CQO?'#VGUSU/\N7P,S>7G9LJ5NY)44N&CCCU-^8^IE3Q3]0^1V5]#RIRT
M*-0K1M:FN4VAQ3=/"G,GB:=Q"&\5$A:L<",L=NT@_P TN;7%1E?7'U+V.IJ:
M=^77X%Y56H9F,[LH-5P7O)>G"NS8;17">U-9AZH=/*KTS*?;E7!"J\BFNR6S
M,TR"84I//=MBI!+(L=TS/#' 9O\ #7F34.9-&NYC4<;UJ\X<6]43J_70^3OU
MN^#O*G@QXJKEWD^+CI5RQ&XHOHXNC#!TWDI(R,>,@
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M?#CCBGZ";(AF58(^=P$@
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MMQYAN92Z]![B$%?46[:E1)1XE@MGK)[B&;SYE%0                  ^0
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M=6VZML_2+&D
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MC5QP8K]TL9)1LS8=\)S0N1NL1H-1H%O425'9CQW]W_.F"<4M]XF2Q5@>TS+
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MCO\ &49)2BTTT>5;MF[8N.U?C*%V+HU)--/K3Q1WXBQI@
M
M                                              6(U)?LCN3\&/\
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MM96M>[@HU\RH?'_7=26L:SFM54>#^(OSN<.[CDY4]%3THW1Q(
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MDFL<:&46\7V.OCV?8_?'8MAADY
M
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M_$"Q:JHW[USN\?Q<*=.Q?H-TY"MY"%??)2KW2(Q\XVJ-KK/H<G55.0C9L)
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MQ>S[A]@ 5QQ_WC+]\
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M*7L+'R]S=IV,W=L/;"Y)>IT/IIEKBO9>W=6R4$_6JGUQH&N
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MB6\27F'&]TB<W%8EO&18[OLB&\<-A;A:BG*BGN3J2L@0
M
M          !8C4C^R.Y/P(_Z4A>'Q%7L19?^K1_._P"A!;]X5_"9OC2-0
M       C%UM?MZTQ_P"L*G_M&G#<V?@D1^)$F<7_ $:-_D&?T:1MG\06P[P)
M   #K6DEDM"N1:#2?7W3(R,OM_;!-IU1#2:H]AHWZRZ4W9VIS/*ET]*HWR/F
M5=C4)1(-LD&U6IG-*;/K<FZ?6'TS\/,P]0Y,TR_=:DKF3M.2\\%4^;7B5EO\
M.YPU/+VEPW(9FXXO9CQ.E#<ITY7$FZ<BLIZSO&MR18-J$^M1[QJD(HD)#RC/
MJFI9&8^>'.&3>0YHSV6>Q9J[3S.;H?0CE?-QSW+^3S$>G+V_^!%ZQULYX
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MC\4_,C<001%B9$1'O*VD1%R*/K 2<P
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M7I/C]XI^!7BEX,YY9+Q TG,9.,V^"[PN5F='MC<BN''H3:=.@R8'8#$0
M!IWZ=O\ _I[U-?\ R:H__D[IX/H](CMGYD;AY?PG^^8 J
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M[].F?C=Y?NZ=&3?<3::KL^XG%'F8](
M                       !0R_=[GV.H(!:O-+)#*+.R@2+9S9RVLW,"BR$
MX'$N>WZ=55,K29FA^'(EL.28;[1F9I6TM"B,^7:8X[4-'TK5H=UJ67LWH?KQ
M3:\SI5>=-'=.3/$;GSP[U..L<CZOJ&EZC#\67OW+55TJ48R49Q?2I)I[C7OU
M>\ FVJC"F7/I-K<BBUE<F3,D6-=U1.11UMK(W41:/4$L<_#0VK%+:%DLDD9%
MM+ AA?F3P>C[V9Y=N2<FV^ZFTDOY,J+U2Q_6/J9X#_F>ZUD\Q;T?QQR\<SIZ
MA&*SF5M\-U/8Y7(5I-O!MJC=*X-MO7HS3T[ZI-(UPM2K^LC,7*R8S,6Q2[MB
M-5:G4J8]'=WD+I=RT\VXSAKW26A!N)<-.W=(8:U'1=;T&_PYVS>LS3HI.,HI
MOIX94HZ;TZ'U4Y*\5O!?QUTN5KEG4=)UNQ*VI7,K)VKEV"DJ-7,O<K)4Q3:B
MXU_$9\Z1.-1J;T\LQK5S'J$K/6P^_&',;XJ=0GWG2(:&B:<BTFXY$EV4_&P(
MC)$KG<%8X*(CP';^7?$[F#1:6,U/^*RE<5<;E)=49UJEU.JP5$L3S#X[_EY^
M#WBK=GK?*-J'+7,O=M4R=N$,I=FW52N6%%1C+:F[?#5;4WB;-^EOB>Z4=4E,
M0=#O^D6+=R'&F)-E7[4X%O5AQ]QE"S52U3GV(]4CDXHT$IM6\9E]R,[\O^('
M+FOVTHWHY?.?^G=E&,L?E;?#+S)\6](^.GC1]&_C=X+YU_XEI=_4M":;CF\E
M;G?M))M4N<"E*W*F+4E1+I)#V7VI#3;\=UM]AU)+:>9<0XVXA18I6VM!FA:%
M%M(R,R,AWA--56*/*]RW.U-V[J<;B=&FFFGN:>*9S,]J=A\O+UMA\N'4$E#3
MLTX2&'_6>M3I-.(6MMJJM.-I6A2T&UE]!;4:DI,U$6\C;UNJ-25F[&*G*,E"
ME:T=*/8Z[F:%O,Y:=V=N%R#N)I4XE6JVJE:UP>'4;B23V'RGVROL=L8TS7.8
M                                  .*NI^$0 T]O6."_P"O+PN<"+>^
ME%?ZV)E])[8W<?8WB/#[(?A?H(_>PWX^PV^*,1E2:7B7_P!&0"]G$HR,2/VL
M0)/I@                                 #I,8]8>:N;.2>FK-C-+([*
M^?G'FI9]LR*K9V6U.CRI<ZZ*FTXVE,%F+#/ON0OFE*,DH/>5@(V;24J^HU-K
M_P#6/^)YD=8C.8F?G"9SCRTLY<R/3G;LKMB753;?[^F.ICPHB9%1E1S)^5(/
M=22L#/'80L^'HK7S?I**-_I4?7^@NCEIQZN+)F=6<MIE%X1.=",N+YJM'05]
MO6)=RZ(JA3Y2$2*O$J45R1#.,B,:E$X9FG$A%8TKC7S?I%+W$DU'AZ7Q8KT-
M&WE:57F7!:]N5VH4V319]8H5*J<^CS&UM2J5.G0F)$NFR&UDE:7H,AQ32L2Q
MQ2"+-4=#T0      L!J80I64E?W<>U5'4?+R$Y['7%X?$0RT']6C^=_T*+?O
M/+<5Z*]%3-X:1<          C%UM?MZTQ_ZPJ?\ M&G#<V?@D1^)$F<7_1HW
M^09_1I&V?Q!;#O D     BCXOUJ/5_3"BH0V.<E42Z(<A2B;-2BC.L/I<Q4E
M)X)Q20SI]/V>65YU=FXZ0NV6O354,)^/.16:Y)E>C&MZW<BT^DC-X+]ZLVUG
M3>=M+D&@KMBN+YA2R)*W&WT*(TI_C*(L.09H^HO3WGN7,OG*8Y=TKZ##OT[9
M^.GZWF].3K_$S=QKSM&T</$9[.                           IC^[ P!
M4                           !3#J@#X]=MZAW/2IU#N.CTVO4:I,.Q9]
M+JL*/.@RX[R%-NM/Q92'674+0K R,AI7K-K,6W9OQC.U+!QDDTUUIU3-_INJ
M:CHV=MZEI-^]EM0LR4H7+<Y0G&2Q3C*+33370R%W5#P/]-.;A2:[E%36<H+H
M6B4X]$I??+MNU&2ZHW$+[Q7(44!>^9_\V6X1<B2Y!B;F7PETO4I/-:++^%S3
MQ<765N7H;K'T.G4?0?P9_,;\8.1'#3.>[TM>T9.*4KG"K\(K!KCX??5/FQZS
M6[U0\,'5#IEJ:EU2RY]U6T]S[\"X;5BRZM"*.TH\$RY$1A;4:022(S0LTJP,
MC(8-U[D_F#ERY_U]B:L/9<A6<'YVJ\+ZI>P^M_@U]97@SXP9)1R>HVLEK$:*
M=C,RC;GQ-?A4FG*/6DUO9TZ9.)3JQTD=ZVC0[PJ]1LBGS7'I5B74T<YF,IT\
M7VH:ZHV]+IN\HON4&DMF U-%YVYDT&,;62S$OX:/[N5)0]3V5Z:-;S4\8_I"
M\#O'7CUW4<AE[7,EVVHQSN6:@Y4V.2MM1N8=+3V^<R#O7C@:W*]<DRJ6I<U,
MM:WW4-MPJ$B@4>7S&Z@B<6N4]$6^XMQ>)E@>PC'+WO%#FJ]==U9AP3_#!1X5
MYDXLQ7R[^7'].FEZ1;R6MY2_GM5BVY7G?NQKCA2*E2B1@O;VK+,VT]25Q:N;
M=8IE,U W8[)>N.]VH3:GJF[+BIB/K=BK+O?!V.DD&G=-)D7(-./B?SHUP7-0
MNO+]"I&M.B+PV+H5-AN+?Y<?TQVL_//1TN5)XTXVL:4;KMXFJ^]6N-28?A_<
M4363GKJCL?+K,*^8M9M6M2TIG4QB@TB$HDG*CLF2GXL1MXR43YGR]0<YROX@
M\S9[F'*9._?G<L7;T8.+4:-/;LBL?281^J/Z,O 'PT\&-2YKY4TV>7UK+Q;A
M<E>NSQX9/9*370;<?[N0>G3X8  !%4 )
M 4/D^R7[Y #3U]8W273FX7*^K]**Z@S]A-T6THB^P;A^Z'0_00O[6'G?L-ON
MD_\ S53/]7PO^]FP)/H                                   H9=4MA
MX<OV\#]@ 0%^LDKW.&)?.\M3:EYCY8)023P,W#N>(KML#/ B2D_LB'T5WEE\
M,O,2,\-YUU[0MIA<=<4XL\K:.DUK,U*-+<B8V@L3/'!+:2(L>0B(0MA-SXV9
MMX"Q0J      +$:D?V1W)^#'_2D+P^(J]B++_P!6C^=_T(+?O"OX3-\:1J
M        $8NMK]O6F/\ UA4_]HT\;BS\$BK^)$F<7_1HW^09_1I&W?Q$K8=X
M$@    &-.KZTBO/3GFG2BC%*D-6S-J$1K=)2C=@ESRS26![4L)4?V!W+P^U#
M_#><,C?;X8.\HM]4L/:=6YUR$=1Y9S=AKB?=-I=:1J@\.^ZW[4UJ95$I_O6F
MU&K'3IG.&2$&N9.9C$VHSV8EC[>(]V>+61AGO#C/-1XK\855.J+9X5\(,]=R
MGBCE+<GPY>5N:==_'%)&ZGU3]DR/J=;#K^P/G!7H/HF5$@
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M+'K8I,RQ&O5'%SMW+;I<BXOK5#LQ$E!B *_NZG9 %,=N  J
MH?)]DOWR &GKZQN:>G/PO2)6+GTEK1J1B7:H^E5O[CF'_#5O%_Q0Z"*KO8?[
MWL-OFCX%2J618[*=!]SO9O _L@2?2
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M?3   1BZVOV]:8_]85/_ &C3QN;/P21#^)$F<8L(T<CZC+1?]@D;9[23O
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MSF!>9O-D3IMM/[A;I&6*C-MPBPV];$<A#PQY"R:XY93+<+ZOT''2\4>?,_\
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MM/$95T;ZDLG;E75<M?7\CA?M9BO6OIRGFX\.GYBU%5_%7$P^O'A"ZMK/0OY
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MD&2DF77)2<2'$M23HU1G)*49*L6FCE[GN_[@51)4
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M^;'UL6?[D_\ 4P_R?UOYLM_/E^R/]5GDC_L6?_H?MC_#OYL?6Q9_N3_U,/\
M)_6_FRW\^7[(_P!5GDC_ +%G_P"A^V/\._FQ];%G^Y/_ %,/\G];^;+?SY?L
MC_59Y(_[%G_Z'[8_P[^;'UL6?[D_]3#_ "?UOYLM_/E^R/\ 59Y(_P"Q9_\
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M7#BP(=5%K\3/8<W,Z+O,[Y=]=\;F_P#\+Y#^ZY/OQ%??K4FCWF=@TB0 *'R
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M@6.SEP$;_,)?"OY:-OF-_H['^1:_Y"1+VD+8=P$@
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M,_\ A]XDZ?SOEW!Q5G4H+WH5K7>UTD@(Q29,
M
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MF$$D                      4P+''J@!@7L^Z?9 # O9]T^R *@
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M/DP,ATH[=YBN/[L# %<2,
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MQTV\?L<@5P"C%.J25>HD1$$@
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M>7X9Q<7ZI),R-E<]DL];[W)7;=VWOA)27K39]_']W^^-J;H8@"H
M
M       L1J1_9'<GX$?]*0O#XBKV(LO_ %:/YW_0@M^\*_A,WQI&H
M   1BZVOV]:8_P#6%3_VC3AN;/P2(_$B3.+_ *-&_P @S^C2-L_B"V'>!(
M                     4,\"QPQ+[?N #CO'B7:[.OB6SVR##T@KO;<,#ZF
MWV_8Y0> 56<@  %,=I%@%05      %#/#'_> %-X^M^^?[Q!@!B>&)EAR=7'
M]V  Y   *&9ER%C_  !7> 1XECAA[  J ..\>.&'V<<"QZPBJ](]AR$@
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M\<,,#Y#QQ' =72<Y7IZ#D
M                                  L1J1_9'<GX$?\ 2D+P^(J]B++_
M -6C^=_T(+?O"OX3-\:1J          $8NMK]O6F/_6%3_VC3AN;/P2(_$B3
M.+_HT;_(,_HTC;/X@MAW@2                       $;W%0S1S R?TK5"
M]LM;SK=BW-"O&A1VJY0'TL3>]I$*LDY%6I2%I7'=<0A2DF6!F@AEWP4T72]?
MYVAIVL9>UFLG++S?!-555*&/GI55ZV8T\6=8U'0N3;VI:7?GELW":I.-&TJ/
MH:::Z:-=!&]DCD1Q;<Z\L;6S0HNO6=2*3=M/54*=!J%,HC\AJ.;SC+?/*.@R
M%&>\V>.*L3P&7N9.:? ?EW6+VC9CE:%S,6)*,G&=Q)NE73WTNPPUHO)GC[K6
MFV]3L\ZW+=J]'BBGD\JZ)[%C;;=-F+/'7GG1Q..'9F':==U'YPP<^<F[CJK,
M*I5.33Z>E$9I]UI!ML*CPHKL1]HUF1_<GM(RQ+8.0T_E_P &?%K2LQE>4=/E
MI?,%F%8QC*3K15QJW5;O5M-IF-9\9?"?5+&:YSU6UK?*]V=+MV5J%F5GB:4:
M*VE%QK52KBJIIT31LAV#>=+S!LFU;YHQG\E790J;78&/;&4>I16Y"$G@18FC
M?W?9P'D/5-/O:5J5_3,Q_;6+LH/SQ=.T]89'-V\_DK6=M?V5VVI+S-5/6[^T
MBP/;R[#[ V#-VJ$6-P90ZYYFO>F9B4S.&L1-+L4X//V U(:32GF$[BIK3L;=
M[<W2Q2>.W$L2/$9LRFO^&D/"^>D7LA;?.CXJ7VO>KT8^?&IB;,Z%X@R\2[>L
MV=2DN2584993AC1SXFW/CIQ?"TN'9A7I9*>1^U]OV.39MY1A,RSYBIG@6)@!
MC]CV_P"'K"*@XDLC/VN7#$_MX$)'33I/R5!2B@S5-.*:6F'*4AU&&\VLF5&A
MQ.)'VR%;2]DA>RD[L5))QXEAOQ*W*J$J8.C(-^%'GQG9FKJ UB6OF?F7<U]4
M&S;DBHM2!7YG?;-$:7.>:4S!(T)-ELVSPP(\,"+K#TGXY<L\N:)RMH&<T7)6
M<MFLQ9?>2@N%S=-K, >#G,?,6M<S<RY/6LY<S.4RF?4+,9<-+<';A+A5$JXM
MNKJ^OH,M-+&5VLZSM2&>ES9\9L5"]<G:]%0WEE;$A]IV'0GT5+G.=BMI22FS
M5",R/DP+9M'1N=M:\/-0Y/TS)<L9&&7YAM2;S%Q53FG&E'Z3NG*>C<\9'FS5
M,_S!J$LSR_?5O^%L.,4K#C7CI-8SXZI^]\-*+ DA,\-HQ$9-*&?\/4,1Y@87
MZZ[#U'9C9'2:%I>OZ?ESF4BN4^>S7J<^4>4NG1T2$R8)*41I4T^IU)J(^J@N
ML,B>&>J<H:1S+'-<ZY6&;T=VY)PEBJNE'OPQ]9T+Q&T[FW5.6KF4Y*SCR.N.
M<7&\HJ3BDZM<,L'58=6TO!IPH>:EM9+V-1LZ;A<NG,N#2B;NBNOFE3TZ;SKA
MDMU;9$E;B6C(C/#:. YNS&B9OF',YCEVTK.D2G_5P6Q*BV>D[%R[8U3*Z-8L
MZU==[4HP2G-JCD]]"]^.WDY"Y3(^OLY2'6SFR"BZ\_<[6^+HQE!!S.N6%E4F
MG6VERQ&))'0W7'Z!2GI2UQE-FDS>?<6I7_"49CTOD>5^79^ [UVYDK,M;XY_
MU[7O_')+'J5*>8P+F]>U^WXUPT:.<NQT*643[BGN<58^]6E=^%:8D[)F1;.J
M/-!GHICUBZO6/K^T .0              *&>  ^94*Q2Z;S?RA5*;3M\SYOY
M0FQXG.'M2>YS[K9JW3ZW5"C'M-/W37)ITGUEW5#<2*_054J,U6"<E+K5,2WO
M)LF!"YAI:I"2<<0_VFZG%6)>P8AUP$:<4_,C<&@5&!46U/4^H0J@P:E?E84E
MF4V6)G@1N,.+1U.N)!]     %#+[>./M&(>&(+?WQE3EMF52WZ+?MC6S=E,D
M?\[%K-)ARBQ+D4AU39/LK+'[I"DG[(Y;3-=UK1;ZS.E9J_8OQV.$VNS8_2CC
M-1T;2=7L/+:GEK-^Q+:IQ3,%LT.$]HVS&A$S3K#G9<5!"E+:J5B5N? 7SBDF
MDC?AS7JA$D((]N[NI&3M$\=_$31[E;V:CG+?3&_",OZ45%KSF,]=\#?#W6[?
M##*/*7%L=B<H4]"='YF17YZ\%/-ZWGG)V2=\TB]:(TXI?R=7(Z*5<S4<DXDA
MHG77J=,<[7 S)Q*CZB-NS.7+'U(<NYN"M\R96>5S3_%!\5MOKV27J]._!O,W
MTX<RY>X[G+F>A>R2?P7(I7%'<FVXMNFU^K'"-&^,DM2>G&K(5>5J7K9CJ=Y<
M"IP55"+$?)I1ESS#\(B;WT'MPV8#,>F<R\G\WV7_ (;?R^83^*,N%M8;&I?I
M,2:CRYSIR9=4M5L9C+T^&=MRX73I]W8UYDL2YV5G$4UAY8+<9I6;]T5VGL\V
MF#0[S3!N*FQC;3@;2$U6,[);:,N4N<+KCAM=\(_#[6TGF-/L6KSVSL\5N3Z_
M=:78<KH'B]XAZ1<DK.>OW\MAPV[RA**?2E5<5-_%)DH.0W&Y9BTR/2]25AR%
M5CGEH3<.7R(;B'V5'^17)HTJ9'90X18[QM/8'][CRX4YI^FJ5R^[_)N;2R],
M;>8K@^FDTF_YR,S\L?4E&W:5GG3*<&9;=)6&I570W&J7J9+!D[KDTSYVQ8BK
M4S+H<"KRC-*;9N67&HMPH5C@G&"^^I#A*ZAH6HC&".8?#+G3ENY)9[)79Y>*
MKWEM.=OUI='6C._+_B/R?S':4LCG+4;S?]G<:A<_FMF6;+[4AMMYAQMYEU!.
M-.M+);;B3P-*D+3BE23(]AD9XCH<XRMR<+B:DG2CP9W>,HSBI0:<7TK8=H@L
M5
M       %B-2/[([D_ C_ *4A>'Q%7L19?^K1_._Z$%OWA7\)F^-(U
M   ",76U^WK3'_K"I_[1IPW-GX)$?B1)G%_T:-_D&?T:1MG\06P[P)
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M35=-ST(W,I?MW(25522=3V^)CC3?E0)
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ML.P@)
M+$:D?V1W)^!'_2D+P^(J]B++_P!6C^=_T(+?O"OX3-\:1J          $8NM
MK]O6F/\ UA4_]HTX;FS\$B/Q(DSB_P"C1O\ (,_HTC;/X@MAW@2
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M(\NZ?'(9**4(K%]+\Y?8=9.<
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M=N7VL#5'DA4(T:@9B7K&@QS-,FF5N9-G132G#\B;-04Z323-/\3=P$:MX?\
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MI_V<G3B6^.]=!(Z1D9$988&6);<<2ZY'U2&'_/M,L8=&PJ
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MW3+]X 5   4(L.J8 J
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MUR4VI1&./G;N6W2Y%Q?6FC>0N6[BK"2DNIIGZ!0N
M                    6(U(_LCN3\"/^E(7A\15[$67_JT?SO\ H06_>%?P
MF;XTC4          (Q=;7[>M,?\ K"I_[1IPW-GX)$/XD29QMD:/[##7Z-(V
MSVDK8=X                                               "F!=8O
M< %0
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M^UA@SY39;,SZYFA.)F-N6.X
M
M                 %#+$C+K@"V69^3.5V=%)AT+-.R*#?%)I\I4V%"KT)$Q
MF+*6WS2GV4K^Y6ILL#ZX LBC03H[;3N)T^9<$D\=GR&UAMY?XP$U;>)ZBR='
MNF;+BYHEXV-DU9-L7- P[SK%*I+4>9'P,S(VW2Q41D:L2#KZ2*O?[#)0
M          #[/V-@       "F ; ?E=@07R-+\.,\1\I.,-+Q]O%!\HU(W;L
M?AE)/SE';MO!Q5/,6YN7)3*B\=_Z36%;=8-Q)I6<NGM*49>VDDF1EB.8R?,N
MO:>DLGFKUM+=(XK-Z!HV>=<WEK4V]\48[W7P^=+5SF^X66%!I3SY&2UT^/S/
M;&6&\6"NU/J]7EZ@[;D/%CG?(M)YR[<BMG$ZG6=0\-.3\_!QED[,&_EBE]AA
MS>W!9R!N:8].I=:K%#=4LUM,M*4XPUCR$1;#W2ZPR'IOU'\TY*VK5ZW;NQIB
MWM9CK4OIUY+U";NQC*%VM51NB?ET&(%X\$/,IIV45D7W:4EDG%]Y_*LBH0%F
MC'\GSI,Q)6!X<NT9 T[ZE=$=/\3RN8C+IX5&7JJT= U+Z;-2:DM+S5E8X<3D
MJ;JT3?;ZC'6K\(+67;KCCK3%F5CF]Y;:Z-<JS6XE!&:204QB-VZBY-[JCMMC
MQ_\ #S-I+BS%NNWCM[_,V=2GX <^Y-OCEEKM-CA.2]'O(QES=TSZA\B(<&9F
MY9U2H=(GN*:A3ESHDZ.M18&23.+(?)&P^KARD.Z:#SIRGS-<E;T',0NWX*K2
M33[4CJ^M\D<W<N65?UVQ*&5DZ)\:DNK8V6)(B-.)8;>0RY#+J&>P=F;Q.M)<
M*/RS3)$*1C@>+2R).)%O'AL(O9,:ENO>Q\YHYAI96<FO=X7Y>DVU>%9 J\/2
MY;;E2CNQV9)I<AD\9[RT$DR4M*#VI1R#P=XY7LO=YVNJS).:5'0]T>#-N_;Y
M+R_>QI%P5/426C#)EH    @%B-218Y1W(>)D:4QU%ALV\ZDO<VC4MX2*RQ19
M?^K3CCM[\WL?9^1/<PP%OWA%72O69OC2+@   Y0!QW4[3P+$^4RV&?MGRF .
M0  ",76U^WK3'_K"I_[1IXW-GX)$?B1)G%VQH_\ D&OT:1MGM)6P[P
M
M
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M +1IPW-GX)$?B1)G%_T:-_D&?T:1MG\06P[P)
M
M
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MB3.+_HT;_(,_HTC;/X@MAW@2
M
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M0
M
M                                                 L1J1_9'<GX$
M?]*0O#XBKV(LO_5H_G?]""W[PK^$S?&D:@         !&+K:_;UIC_UA4_\
M:-.&YL_!(C\2),XO^C1O\@S^C2-L_B"V'>!(
M
M
M                        6(U(_LCN3\"/^E(7A\15[$67_JT?SO\ H06_
M>%?PF;XTC4          (Q=;7[>M,?\ K"I_[1IPW-GX)$?B1)G%_P!&C?Y!
MG]&D;9_$%L.\"0
M
M
M  L1J1_9'<GX$?\ 2D+P^(J]B++_ -6C^=_T(+?O"OX3-\:1J          $
M8NMK]O6F/_6%3_VC3AN;/P2(_$B3.+_HT;_(,_HTC;/X@MAW@2
M
M
M                                      %B-2/[([D_ C_I2%X?$5>Q
M%E_ZM'\[_H06_>%?PF;XTC4          (Q=;7[>M,?^L*G_ +1IPW-GX)$?
MB1)G%_T:-_D&?T:1MG\06P[P)
M
M
M             "Q&I']D=R?@1_TI"\/B*O8BR_\ 5H_G?]""W[PK^$S?&D:@
M   4,\.H9^T6( )/>+'!1;>118& *@  (Q=;6'G[TQ_ZPJ9F7L?*-/P]W ;F
MQ\$BK^)$F<;9&CEUF6B_[!(VW26.\
M
M
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M9@L&62/J--E[B"&A+:_.2MB.T02
M
M
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MII#>/)CN))./V<!3:ZDG;^[]VP
M  >(S%LYF_;/K%JO/=[HJC;*>>(L=Q3,AI\C^SS>'V1,725>@AJJH?4M.@HM
M>WJ50&W.=33(C<9+F&!K)!8;Q^R8.C=42MAZ+;^X\! *@1B4_=R@25
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MH18%@ *@#I4Z1$1D2U8_>H4K875V%M2(Z2<%M.Q*M[ \#+VR^R)(Z3D
M                             "AF1%B9X$ ./.%O;N"\2ZNXLT\A']T2
M<.J !K(NHL^OVB_M;.7$ <B42BQ+'[)&1^X8 J
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MRVC<90AMQ:'M[$R+#$]@JMF)=[<-AD6)(
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M;3Y1";H:LTE)I;#*W89\FTNKA^\8DH5
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M2'4D7/.,QTDG>/$S(BQ,$3);'TT)9!)4
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M"YJOQ<,O5TFYXGD+\$MG6_=@!5[3D
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M)NQ9L9F2Y+B/QU&:5$ZA&)ELV MA-Q/B;1(()*
M        '@,S\M+-S@L:X<N<P*)$N*S[IA'3ZW2)S3;T67&4I*MUUIS%"R)2
M2/:6PR(1[!CT;372U?\ %&T(\$-JDZ7=*^2%0SSU"7].?<1DCD_4*<B1;TI!
M<Q"J%^5=$6>5+:*=.)*8I,K>)*E&HV\,1.&T8I*M<?+RP^UGB>#!P^=4E7U4
M9S\5+6M3Z?8.:&>;3+%D97PU/RI] M66S4'C*KOJ9A1VNTJ>XA!,I,R+ RP(
MA%">*6-<-RW>D^+ZT5I.TVTSAE9N9N6]DAEI1,THUYV]659@TNU*3 NIPWW9
M#=02]6XL9N=(;DNDTK<4LVR41J(B-2C,]Y>#<O=>RAG1ZMPM;G!YTHK<5O+5
M2;HWE&9F9F5RU$L3,^K@0DK/;Z"=0"H
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M$VRHQ%NKBT=R,CF(SZ><=W9,?#<<+>,MXCVB%V%I)IX[2_@DJ
M     !:;//**V,^\H\PLGKQ;-RW,PK8JUL50R03JFF:G$=C]\(0H\#6P:R67
M)B18 ,:^7J-1/319/$7]7GB9A:<,M-+US\0+3]F1>$O,'+.Y,MVKC@U"PY<P
ME1)5NU:'&HU9-!/H)E9IQP_)F:5'M,.C$E1>-,57>EY;Z]9F=PS]">J;.S7#
MF=Q5M<MO-9975>U!IMIY69"S&JC(K5D46G+F26951DSX\0XQLHGDTA&YO&:#
MWB+JD_41).M<$]BICYZOKVFSL1$6'L%A]@ 5
M          !#[QU;1U YF\,[4'D]IDL^N7AFGF[&M6Q(S="2ZN52+;JEY4%Z
M[*HXW':>?>9*@1GV%-DDB-+RC,R(ML,8NJHJTZ70NCPC=,%2TF:$\D,I[HHC
M-&OFF6TTN\&TQ"B2'*H\HUJ3*2:$.*=9;,DF:MHGH):2]U;$28@0
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M6U%=NZWZJ4EEFG3G4&;D4V'Y+A\XT:CQ,TD>)B,>G::E%!N*;:?63F 0
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M;/?KT=LB>?0RI:U-MK<QP(SV$%*8(K)\3J9% 0                  #8
M                                     "F!=8O< # N7 L0!4
M                            #EY=H IAR<GN?O=8 5P+]WL@!@76 %-T
ML<=O\  J                                  !@0 I@1?[O4+K>P0 ;
M#V[/;_W0!4                               4,B/E(C]L ,"ZQ !ALP
M+#DV;-GN;-@ 8%L/J]D ,/:PPPY/W; !4
M                                                      4Q+KEU
MN7J]8 5
M
M
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MY1":9:4)1Q9D")*@ 4Q+KD !F1?NQ_> %0    4Q( 5 %",CY  Q+K\O\/(
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M 8EUR+V]F.S'9U]@ 8D?(>/M;0!4
M
M                                  8F:\R0>BG5>2R(TGI[S9V*Y/\
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M!.J+C*IK9F2%DX1;^&PB/$2DV4JFVDFI+>;/Z>3'89'@98;2PW2Y#ZI #D
M
M
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MII18'B8%<5@]I^X
M
M                  ]WE &/FJW+FYLW=-.?65MF/QX]U9B94WM9U =F$GO5
MJIW!0)M*CK=-1;I))4@N781\HA["8NDE4B\]7_T+9Y</70G!T_Y]KIIW;#S
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MAX[=I](
M
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MMM,LI2V@L$F9X$6)GB(PZ-A%6WCM/5B0
M
M
M
A                                        '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tv523241_chrt-line3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_chrt-line3.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1" 'L I # 1$
M A$! Q$!_\0 ^  !  (" P$! 0            4(!PD!! 8* @,! 0$!  ,!
M 0             ! @,$!@4'$   !00  @$)#Q $!@P*"P$ ! 4&!P$" P@1
M"1(A$Q2T%767UQDQLW0UE;755W<X6"DY::E!42(S<S06-E;&%T>'N%F987$8
M"H&1H3(CUO"QP=,D)54G-[<HF-%4U"9&IK;':'CA\;)$E*1%I99G2$D1 0 !
M P(#!0,'!@@+!@<    !$0(#,00A$@5!46$R!J$B$W&!D;'!T112<I+3%0="
MTB-3DY15%V+",S14=+34-746HD-SLR1%@K*#1#8G-__:  P# 0 "$0,1 #\
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MHU?23C76>]6P>QJ3?<:/FR9<.)12CV+_ $9DK?EPWVTNIU.-M1")K%7OP4
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M853$;8#US%S!K$WE>\^GDRV8Y>7*Y+N);)GQ<+:_9!0K%:,Z KCC2OF5I_C
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M^CC9!B;9ON3574]QQLP=B9$SQ]/DOW(\<QK),JN1H-EI7%KL'9:CUM1P&S&
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MYHV4NN-74OQ76VV4MA2*4[%GI8BF/IRC-]0[*S;+/"-9+;"NS'RU3AE0)%'
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M&K-_E<<I3Y-O3SW'$?MY2"=2SRPV)B-
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MV*XK4CCD*&VV;AWH6]@9[4W(4-K*=U@M=@QWX,.>I%*U[7WO#+D
M                                     !KMYKOO"YI[\PC^\!%@L:LW
M^5QRE/DV]//<<1^WE()U+/+#8F(T
M             -;FS7+ZOV*WSY>^[5):M:%FB638.^^,ZL6Y?NE'].S%3&72
MEKQH\46C*JUJIW9/I6K=F]/K?^@X=.MKPHS,5F)[EN=BM?8LVJ@^3==YK;M'
M3%LMM8\TGBBT,YR)@PG'*X\N$T04"UUIE.54L^7PFR9C'7IES6#'DIU;1*K1
MHB:7(2FA56H%CS9CFF3YLII1K"^V8]X;U35XJ9#"4*4C3)96/&[)<WMM?,.R
M1T)NE<&,K6S,1*Y+BUM;2]Y2M:5MM83EGO96V&Y4>[F':B<MF>7GS.'!IT7V
M@N:QN<(I>,#LW89GW.-LH=J!8\(\O?JKDM9YTZ6ID,9BF MCK<<,YK[35F&N
M+!A5.6:\)>U@WD%Z*L+6K7376<FVL[1D8 <C]DJY0D)<<R"TW],<HJB0L/:0
MG3&#;<N%KJV+(91\>!,2E2Y5))Y&MV.[LC+?DSWJG*V42=IMJ?-$3H$#RIKG
M#3ZA5JK":X&S%+@CYMFV @+:.GJ24E*B.U>Y]B,G'4]-6#6#%?BPVULQF,EM
M.I=42JTB=7C( Y>FC6JCU.R/K9J?!$'OU2;AYH'W?&<=-UI. XUU-02E500#
M"FDDBYG*E'%)#)Y\F&MU;+LI;'=6G&R@5(MB-&#89Y;#?CF?N9K+KSD:DC,_
MF4&F)A=$:V-#.U;X_;;5BM6BM<0*.W"[UK*[;G0F*^3-0S812+B?'H4LRUX9
M*6J1'&?%KQU#Y#<M:_39JR;E[?IR;"ZCZ$.Y]O?377!2A1G,E<92^]2*X4(&
MG_*Z"K7KSVHS+EV_*5QY,-,&?/BLK9C)E>F2O52+>/'1](XC8
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M1UX+G-XX .)W,EO\MHZ\%SF\< '$[F2W^6T=>"YS>. #B=S);_+:.O!<YO'
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MCKP7.;QP <3N9+?Y;1UX+G-XX .)W,EO\MHZ\%SF\< '$[F2W^6T=>"YS>.
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M@\RG$#B_MW,EO\MHZ\%SF\< '$[F2W^6T=>"YS>. #B=S);_ "VCKP7.;QP
M<3N9+?Y;1UX+G-XX .)W,EO\MHZ\%SF\< '$[F2W^6T=>"YS>. #B=S);_+:
M.O!<YO' !Q.YDM_EM'7@N<WC@ XG<R6_RVCKP7.;QP <77;ZF]"SU,MAT*K8
M62U[7QKQ,R@MA5;>;!GHK7I^;":M47BZ\9O%?CK;=96RF"ME:5X]*E:=$*=<
MUWWA<T]^81_> BP6-4O\KCE*?)MZ>>XXC]O*03J6>6&Q,1H   !5S=;7U3VK
MU7FK7A&<A%H*<K-&K9*.52(9U0BCY:J:<?[+,IY4P5,&L=+2-;>C;DMKQNX\
M>H B=H=<EO:&))/U]<3G2&W&$A1<314Y<2$E0-2(U971G&6<+9>I3,:5+6V>
M0&V?1TXYB(9"E,V8X7NMR9NLW]"E1YS677F:&A)\I;"[.2)'$C3E(K,C:)">
M6(6*X(]CUK1/%"B^7(WDHFCNEX/=>47(MO63EY343N<]T*69RQ7#CMQE:7Y4
MR1':H;S@-,-/FSRY]V)*;6J6MC>D5/B%U.8@_D2"XO2GJ1<F4\4-Y7 4=)%K
M8%PNMY36:_)<:LSTSW9+KKJW5K6M0J:1-&Q.[2K3U[&U9VO+5C7=UNEP+J\I
MKKC<4,QXLKJTI&%D]<84%5546\9/*!TQ?U;\N7)??=7S:C-UEDSQMB9\8B7K
M=IZ\]:;';V;39=5ZAAVF..6RRS/EMMMB-(B(NB(CY'ZMT"T8MNI=33C5WC3S
M.,"1==_]IKUIQ_P#M]-WV]Z/NOQW2,V7:[V(F/B8;KL=])UCFLFV:3VQ6DNO
MU7UCZKZYLIZ;UGJ.]W73[IB9QY<U^2R9C29MOF8K'R*CM#2K3O/O'/33SZJZ
MY&&ND:VZTKZ6W,\*1QF0TU;7I"V7)+:N02LK<N($U)7)()'$:SX\=N3/C)X;
M;ZW4Q6='M[;U9ZJVG5L^\VO4M_CW>XLMG+?;N,MMV28F8B;[HOK=-.$5F7HN
MLY<F\_=;TC;[R9RX,/4=U9CBZEUMEOP\,\ML3I$3,S2.'%GWEW(" TH2D-L-
M9%2FXVF]MIN8BH#?0D\HDHJ*CI>STI$4U)24PAA+DD].3R>"S#@PXK+,>+%9
M;;;2EM*4'IOWC;C<;OKFVW.ZNOR;K)TCIUUU]\S=====LL,W7773,S,S,S,S
M,UF>,OS#:4^%=R\O+SWZ:12Z8I\R^@\([(             @4WTY<7W=-];L
M(K,:RGA&@                ! &/QE2^]"OVREB]C,^:$^(T
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MYMMCR9)BO'C?=,M@@Z[PP             @4WTY<7W=-];L(K,:RGA&@
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MMGZBW^WWFQB^,6+I^UV\\T4GXFVP68<E/#GLGE[XHO4/GO+
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MZ>V97M&'AP            ! IOIRXONZ;ZW8168UE/"-
M " ,?C*E]Z%?ME+%[&9\T)\1H                 0ZU]H)]^$?UQ+@D_:F
M 4                 1JSZ3JO>T]VKE%C5)T=@C]Y$_0I?SFP0C1V@4
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MK=A%9C64\(T                 ( Q^,J7WH5^V4L7L9GS0GQ&@
M        !#K7V@GWX1_7$N"3]J8!0                !&K/I.J][3W:N46
M-4G1V"/WD3]"E_.;!"-':!0          8Y_6W^SG\Y@%,^:[[PN:>_,(_O
M18+&K-_E<<I3Y-O3SW'$?MY2"=2SRPV)B-        -9'.<^2QWD]P9S>?D
M2=&QAL^E-OH]8]=SPLZD)\17YO\ \VO^S_<J HGR_LV3)&,STR7=+H;I[LV6
M<:<*TMNV<DO+6G&E*<>.7)=7C7ZM1V-UU#>]1OMR[Z^<F3'CLQ6S,1%,>*V,
M>.WAKRV6VVQ,\:1Q>T]==-V'2^J;;#T_'&+%DZ7LLMT1/FR9=MCOR7>'-?=-
MU.^5[AUWBP            ! IOIRXONZ;ZW8168UE/"-
M " ,?C*E]Z%?ME+%[&9\T)\1H                 0ZU]H)]^$?UQ+@D_:F
M 4                 1JSZ3JO>T]VKE%C5)T=@C]Y$_0I?SFP0C1V@4
M      &.?UM_LY_.8!3/FN^\+FGOS"/[P$6"QJS?Y7'*4^3;T\]QQ'[>4@G4
ML\L-B8C0       #61SG/DL=Y/<&<WGY $G1L8;/I3;Z/6/7<\+.I"?$5Q=Y
ME>KP_I$D:,H"V&8NL\?[JOQU[*L ZJM2=-\'8W=8'4[8P:*IB<"%.DIN!'L(
MF;[;9$SFGWC(8NLV9[36/HGJ78,5_P#HZ#U_7_1/6.F?#WW3-MO-QTO)TW;[
MB;K<-\XXORX+,V3^4MMF*6773;KPIQH_0,W7-IZ^ZETKHV7:X=GU";]ML[MQ
M9=??=?CLBS;V73CF[EB8MMYIB(B9GM;KFFM_A*UFTX^LV%N[[?1EOL?'EZ_C
MP=U4XL?ZS9GZ&/KUF+K_ $:7]&WI4IQX4X\!X^V9FV)GA,P\5O\ ;1LM]GV<
M3S1AS7V5I2O)=-M:=E:5H] -.H            @4WTY<7W=-];L(K,:RGA&@
M                ! &/QE2^]"OVREB]C,^:$^(T                 (=:
M^T$^_"/ZXEP2?M3 *                 (U9])U7O:>[5RBQJDZ.P1^\B?H
M4OYS8(1H[0*          #'/ZV_V<_G, IGS7?>%S3WYA']X"+!8U9O\KCE*
M?)MZ>>XXC]O*03J6>6&Q,1H   !U31TD1QTRG394GBKDQXJ9#1C$7QURYKNA
MBQTORWV6UR9;Z\+:>;=7J4 =GC3AQXTX?7XTX?XP'6)GB2AA[(('"IXOT[\?
M7R9C$9P]<Q75LRX^NX;[[.GCOI6EU./&E:<*@-:7.<^2QWD]P9S>?D 2=&QA
ML^E-OH]8]=SPLZD)\12M./4J ISO,V&[_8UV]/U0D>IZFM$]FJ&ZIA+LJIG]
M&#JR]D=?ZSUWK],GV73X]+I=7CQ&_C[N_'."W)EF)MF(MBZ[MX1$4GAW0]-Z
M*Y+/6/2KYI%.H[?C/"D?&LJS_#O_ $1Q9[G+(\W^ALIE!QQ;-L1;,3$Q%'SN
MNS$]<WLQI.[S?^9<R.*^4            @4WTY<7W=-];L(K,:RGA&@
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M #';?^=8S##O_1'%GN<,C_V93!;?+'R/F]>_X[O?];S?^9<R.*^2
M    @4WTY<7W=-];L(K,:RGA&@                ! &/QE2^]"OVREB]C,
M^:$^(T                 (=:^T$^_"/ZXEP2?M3 *
M(U9])U7O:>[5RBQJDZ.P1^\B?H4OYS8(1H[0*          #'/ZV_P!G/YS
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MZ;ZW8168UE/"-                 " ,?C*E]Z%?ME+%[&9\T)\1H
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MRR;;HNI37@L\.P\F      "!3?3EQ?=TWUNPBLQK*>$:
M $ 8_&5+[T*_;*6+V,SYH3XC0                 AUK[03[\(_KB7!)^U,
M H                 C5GTG5>]I[M7*+&J3H[!'[R)^A2_G-@A&CM H
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M?ME+%[&9\T)\1H                 0ZU]H)]^$?UQ+@D_:F 4
M        1JSZ3JO>T]VKE%C5)T=@C]Y$_0I?SFP0C1V@4          &.?UM
M_LY_.8!3/FN^\+FGOS"/[P$6"QJS?Y7'*4^3;T\]QQ'[>4@G4L\L+MR2]&7'
MC%<[UD4WA3V.W$G.I.8Z93#RS@+I>*MMN?)E2DTDI'S]E*WTI7'BP9;Z\?\
M-J(U+Y.=DYY9>OSHYBNG9)W:;O9+VBEF755:E.<&QLY:^8)NE!K);>.L=RQJ
MQM6)#:LTI,28"_8[2N3GFAX,1' 4Q7];KBOK=IC1]1.KJ8BHNL^NR,VWRL2>
MW4B"XD2T"2W$4/D%^1$4@P&^52GTN$57'A5"2N[2.+&?,XC-EIC'F,76Y*4O
MI6@RU#.H*    UD<YSY+'>3W!G-Y^0!)T;&&SZ4V^CUCUW/"SJ0GQ%
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M]LI8O8S/FA/B-                 "'6OM!/OPC^N)<$G[4P"@
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M3,W5F:=E5[Z4X#NOS=R   "!3?3EQ?=TWUNPBLQK*>$:
M $ 8_&5+[T*_;*6+V,SYH3XC0                 AUK[03[\(_KB7!)^U,
M H                 C5GTG5>]I[M7*+&J3H[!'[R)^A2_G-@A&CM H
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M64\(T                 ( Q^,J7WH5^V4L7L9GS0GQ&@
M  !#K7V@GWX1_7$N"3]J8!0                !&K/I.J][3W:N46-4G1V"
M/WD3]"E_.;!"-':!0          8Y_6W^SG\Y@%,^:[[PN:>_,(_O 18+&K-
M_E<<I3Y-O3SW'$?MY2"=2SRPM%LK.S9UC@:5)[>!)35D*+V>IN;*@H>"IE><
MZEAML+(+30"_"[KZ\[%\T532-G#A<:-8Z5ZE1%E\W&PG+VG1Z),O;G;"\L_3
M&3\C[3+Y3G?6-C[:;:V3\X4=)3<1U12"S_Q94:!'U(;90B?$NC8V^GI!DR6[
M$)G_ +/%FNU6$F.UO,Y?L(Z>QW!K7EK2]HFVQ%NRS)CJ7$\P<=K[=&9;05YK
MXEMHFLV)\NETYT4T71W!6W,7+Y,5+,E:VY*7764X25CO7L$5279O;Y=A.0H^
MA.)8&>6RTYR R9"E?#'+.=++9&-O1+%IUJ)#L>2^ZWTI$$4H:.N1\I24B)U.
M.=6/F;Z4NPX"YC/BJ5>D4=SX?2=-2N\:C5R%H@-1 AS#C2[4G"8?EQ-QI1 X
MDL>QNESN7#?(9E:4\*+1-H9K_P <7]CUR4K3I!1*\'&K^R#_ )TR/9)DS75X
MP$Y6?<@'"^,^\63*C(<Z,Y,*EUBQ$DN-E!3:=[S;:@C&2B^@7Y+3R3?4MF_T
MQ0\4,Y5%JK]SFZ_%8[R4_P#Z&<WGY 0F8HV,MGTIM]'K'KN>%G4A/B*
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MV2V^S?8+LL1&MD6Y;\5+O&MDS\DLO#E?$ $"F^G+B^[IOK=A%9C64\(T
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M<ZC]?S5X)^9/O(6V4I93%2VVE*0F&_!M\*I5O#S.SU?_ "*QT6=5C1/"*
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MI8O8S/FA/B-                 "'6OM!/OPC^N)<$G[4P"@
M     "-6?2=5[VGNU<HL:I.CL$?O(GZ%+^<V"$:.T"@          QS^MO\
M9S^<P"F?-=]X7-/?F$?W@(L%C5F_RN.4I\FWIY[CB/V\I!.I9Y8;$Q&GRR3G
MM;M7=Y2I^9.;PTM,'#K?+\QM>#]4Y"@[5)QK^5IQPW$U68JH8N>S8)2H^T6>
M,^:N9M92&$P8QE3N"RW(IY[+[+JQ7Q;$.43M3LAL(W9P9.R*_BD%SPR;@G+A
MDNK%1H[7;EF98+:4LO>%9#;C6MP,^R4=>W.X,B MYDPLGX\E]<-,I(MGMRVW
M%AN+$: ''"GUJ .0&LCG.?)8[R>X,YO/R ).C8PV?2FWT>L>NYX6=2$^(H
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MMI/"*WVW74MX<:ZK^CSKXH @4WTY<7W=-];L(K,:RGA&@
M ! &/QE2^]"OVREB]C,^:$^(T                 (=:^T$^_"/ZXEP2?M3
M *                 (U9])U7O:>[5RBQJDZ.P1^\B?H4OYS8(1H[0*
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MNPBLQK*>$:                 $ 8_&5+[T*_;*6+V,SYH3XC0
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MYH3XC0                 AUK[03[\(_KB7!)^U, H
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M*-ER6FP4Q]:*-R3%9FHI]^();%UW-ULNCNHP;+V6].[A;CI3C7S1EJ-&7P4
M  !K(YSGR6.\GN#.;S\@"3HV,-GTIM]'K'KN>%G4A/B*             /XY
M\=N3'?9?QI2^RZRM:=2O"ZVM*_Y*B3%>/<U9=-E\71K$PUZQU/.B,',ALPWD
MG&+SF6,$@JQLIEP9$RY=R9VU9W*,=U[L"7CQ54+<Y:ZF7HVTMZ=*CCMZG&VL
MMP_B+HBV(CS3&G#LE^C]5]'^OO5/4,OJ*_I6:9WMTY8FRWW9YOR:SHQU2:X
MEO>[53!"SW9+NSHT7;.WKN-I=CUO)8CI.*;4^ISK)<O7AGO+YJ8^/'JVW>8/
M:](ZEAW?HCK&'XOQ+YW.RF(K,S2)SUU^6'ENL^C?5'0,=F\ZQLLVVVD\UL77
MQ$1-TTI'?5LV2_3=P_=TWUNPCQUOEAY[ME/BJ                 ( Q^,J
M7WH5^V4L7L9GS0GQ&@                !#K7V@GWX1_7$N"3]J8!0
M           !&K/I.J][3W:N46-4G1V"/WD3]"E_.;!"-':!0          8
MY_6W^SG\Y@%,^:[[PN:>_,(_O 18+&K-_E<<I3Y-O3SW'$?MY2"=2SRPV)B-
M-"K:EF;#.^+":1I]R#F9!KFW;*1X=0<RPM7M[/%J'RG%J16XTS!._+4E>SDR
M4\5BN4+5IV+C6;:9K*4S=45CM\*_8WU4ZG4$;     &LCG.?)8[R>X,YO/R
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MWH5^V4L7L9GS0GQ&@                !#K7V@GWX1_7$N"3]J8!0
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M[/;[7=V7QC_#XL>&R[X=U+KIQXXB(FMT17MA=.EU.'UOJ?T#A>6E^@
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M$3S3%:3I"U6.ZMV.RZOFW6VW5_PTXCL:O&W1RW3;'9+]@@
M( Q^,J7WH5^V4L7L9GS0GQ&@                !#K7V@GWX1_7$N"3]J8!
M0                !&K/I.J][3W:N46-4G1V"/WD3]"E_.;!"-':!0
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M"OVREB]C,^:$^(T                 (=:^T$^_"/ZXEP2?M3 *
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M<N2ZXJC?.<^2QWD]P9S>?D 2=&QAL^E-OH]8]=SPLZD)\10
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M?7_K_P 'UA:?2E8^9^@5 &/QE2^]"OVREB]C,^:$^(T
M(=:^T$^_"/ZXEP2?M3 *                 (U9])U7O:>[5RBQJDZ.P1^\
MB?H4OYS8(1H[0*          #'/ZV_V<_G, IGS7?>%S3WYA']X"+!8U9O\
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M.X3Z?SD0NR*W%[>AG[&Z]CIQI9=;2Z[CO%ML.&[FQQ-?&ZZ?KF7S^M^LNO\
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MBS)N.DV9<DQ_"O\ Q&XLYOGMLMCYEK!VGCD 8_&5+[T*_;*6+V,SYH3XC0
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MH=[L?F,^=Z &@                !#K7V@GWX1_7$N"3]J8!0
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M&SZ4V^CUCUW/"SJ0GQ%                 $"F^G+B^[IOK=A%9C64\(T
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M*    UD<YSY+'>3W!G-Y^0!)T;&&SZ4V^CUCUW/"SJ0GQ%
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M"1C7/8LQG)VY\MI7.8P/."K,&?*7I?3%DS8;,U]++JTK=;2^[A7JU'4ONO\
MQEED>7DN_P 5[K8XL,_NZZAGNMMG/'5-I$74XQ$XMQ6(GNF8BJYX[;PH
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M?B[LUM>:.:+[+L=G";*TF)F>:G"BX=OF4ZM*TX4\SZ_"@[?!X=^@
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M^(H                 @4WTY<7W=-];L(K,:RGA&@        !Q7S/\-O\
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M .-/K@''CYG5       !&K/I.J][3W:N46-4G1V"/WD3]"E_.;!"-':!0
M       8Y_6W^SG\Y@%,^:[[PN:>_,(_O 18+&K-_E<<I3Y-O3SW'$?MY2"=
M2SRPV)B-        -9'.<^2QWD]P9S>?D 2=&QAL^E-OH]8]=SPLZD)\10
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MI2M:U$G!GB*S9?$1_@S]Q27\3'XRI7>A7[92QQ]C,^:$^(T
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MENBVV-:6Q$\(K+CNPX;IK=;$R\YY/C2#X*4#>#AN?^0CM?W@>N?[5WW]-?\
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M<MLVY(LC)28R66?P9UBJQ2SZ3JO>T]VKE'8C5XV='8(_>1/T*7\YL$(T=H%
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MIM]'K'KN>%G4A/B*                 (%-].7%]W3?6["*S&LIX1H
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M9VV*LS.LS/;+."GP8B.^?K7I'BG*          "'6OM!/OPC^N)<$G[4P"@
M               "-6?2=5[VGNU<HL:I.CL$?O(GZ%+^<V"$:.Q=3I4X<> *
MQY'\7-6,\SYS-?$<Q7R&_5N2')V8<R'.O.=P%DTHHYBG7/O0I?A2L/1PV_8V
MUI6OU1BRR+*T[;IGZ7T^I=6WG5?@?C)B?P^WLPV4BE++*\L3WSQGBR*-OF
M      ,<_K;_ &<_G, IGS7?>%S3WYA']X"+!8U9O\KCE*?)MZ>>XXC]O*03
MJ6>6&Q,1H       !K(YSGR6.\GN#.;S\@"3HV,-GTIM]'K'KN>%G4A/B*
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M7XZX^/'I6UH%)2;HTKQ;YFUU$JWT>K_Y5<]4)U6-$\(H
M @4WTY<7W=-];L(K,:RGA&@                ! &/QE2^]*OVREB]C,^:$
M^(T    IIS"DE47=+MATA$3%!95C[!,82*6E$S*@H'<W=).NZR5)$\68R9R]
M"VM>C99==PI7J#V/[O<N#;>M>FY\]UMF*W<5FZZ8B(]V[C,SPAP;JL[>^(UH
MN/CK2MEE?J]"WC3ZW4IU!X[MGY7/V4?T          $.M?:"7?=']<2X)*8!
M0                !&K/I.J][3W:N46-4G1V"/WD3]"E_.;!%C1V@
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MF!?S)][?'^!2#R9$'^W9S OYD^]OC_ I#BO+&@ZO4K-G,!KQ\WCS)][*\?\
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M@_V[.8%_,GWM\?X%(/)D0?[=G,"_F3[V^/\  I# &V/+[C:.-6=EI#9$Z\P
MF]&' $R/-H&[^8OO$K6%70UXZ<:X@&+TI0G<X04[<*J1Q75+Y\67%FI3H7V7
M6UK2M28BC++*Y:\-*C-:2FH3?S ;SZBV4$^=OIS(MZ<%+S9Q+*F#-U,&&?,>
M+#2[-DNKT;;;;;?,I2E!%I#TWDR(/]NSF!?S)][?'^!2#R9$'^W9S OYD^]O
MC_ I!Y,B#_;LY@7\R?>WQ_@4@\F1!_MV<P+^9/O;X_P*0>3(@_V[.8%_,GWM
M\?X%(/)D0?[=G,"_F3[V^/\  I!Y,B#_ &[.8%_,GWM\?X%(/)D0?[=G,"_F
M3[V^/\"D'DR(/]NSF!?S)][?'^!2&>X$U0CK754<JRS7?/[Q4G403$P^:G/9
M2>-A,A BE&3QLN7;GZ:9!?%&OCSF#]]QGN?0MV56W'UWI];Q]$M&!^:[[PN:
M>_,(_O 18+&K-_E<<I3Y-O3SW'$?MY2"=2SRPV)B-        /%2/(K&B%A/
M"49-=".R8]8#=5G:\W<X#>,BBMUN(9/*?5591-9*\,98H5PW75I2EU]U>%MM
MMUU:4J&)M==L8*VH376>A=SKJF:8:LGHKV:[UCN28B?[2.K*;8M(%[BCB76D
MQWZD)SE1LM#B8<SIUA11+<<A;)EMMNK0E5C@4               !7G8/:>$
M]7TQJ'Y?<3@)'7XN&FVQ&BQ8ZDB89)?"TGI1M>5B;-BV(&D^I&=%$-!(9SZA
ME(I>?"GDL5V<Q?CQTZ0),T8>>O,BTU84;QC+2I*BFN,V8D!==K#R1Y%DP2HY
MSC0:?8U'P[UY@QJPG6_&0U(],F\19R**XFIQ-O'<EA51R%C-U,5;0K"Z2"NH
MKH0T=RMM53UUO.%+3UQ"6TDWA/I:PCJI3$>3%1-/%K\A<X0/DL]F7#EQW769
M,=]+K:UI6@BI4               '%UU+:<:_P"Y3ZG'ZM:4^H IN;W^U'+0
MXN3\5ELLX8N0Y;78'QKC,:;Z?*HZ9@;KO-L-1CZ.6>SFRN/*47%F=9'.5*8F
MXGJE%"F&_,6KEP679*$K#.4*3?&&P\>I4HQ$Y+G.SE8VL)=#!I%7VNMI"ZW%
M4X@N5KNMH.U+0G<S7<V%U/SDE-(5B))23S>&_"8PX\EM;:%97
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MK<<79\A636O'4KK;13HJDQTQN9P9<:\F-Y:4SR1?@S4-8L76<O0M"L+A"*
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M_%[5>"5<8L-W(J^E-1-P**#4UBOR83%4+/2I/IV75QW=8XVUK;P$6(I"X@*
M             "HV[\?["ROKZXXUUM-L$B[WNJ(3>=YA_O\ >L78,T2GC]EL
MG([5D!@,*27(SWLYFK3,F)RKA2LUZ7><N.8ZTSX,5*V$EI7@YC3QK^RHM?4K
M:OI[$B+6GFKSR]#<;ZRI<N3:<1(LD&--AX83GJUXT*0,P'8M1A&[PDA#,)AU
M#25/.:;],REV*4H6KC!.QL_Y;3?<]K=VOE98:CM8S5V*W3F6:8I;#Z:S@8KJ
MMC111V,R49U*['=B<BNEH99%4V,=<&$BIDB:A854\60SAQYLM]M$K$-D0B@
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MGN.(_;RD$ZEGEAL3$:
M
M   &NWFN^\+FGOS"/[P$6"QJS?Y7'*4^3;T\]QQ'[>4@G4L\L-B8C0
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MY 7D5<HGF;B9^J.J$5.A$W9QZ94Y4EGST+&;>%>-E_1NIP\P"L2F@4
M                                     !KMYKOO"YI[\PC^\!%@L:LW
M^5QRE/DV]//<<1^WE()U+/+#8F(T
M                     -5G.N;+I=W+1V*1&8U'4]G#DSP\H%6RR&TMO!T*
M)9%G2-%I4JDMIMD%1<5LI)*(9S%^,L7RY*8L5UW1X4J+"3HKALG*QOF%2IHY
M&NM\/;!YF[".W4;[33#,DGP%+L"LMB-6%$1UJ!%HHRS-+.8AISOB25U5+IF
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MO"YI[\PC^\!%@L:LW^5QRE/DV]//<<1^WE()U+/+#8F(T
M                                       #BM*5\VE*_P!= '%;:74K
M2OU?Z:T^IP 8*@36J&M9D-TH,/-8T@XGT\5*0'NKK3G=3X=CR>2J5(IYIP.E
MY/A:<3J7CV-+2RI/!4R<R6EB9;%AQ4LQV6VT%&=J4I3S '(
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M$#Q*I+KUR/3"8M,IN/&LI>1*IDS&+,-^+!7-4XKA3GS8<D$;2M'7I8C:(3Z
MKR_KY"YY35-JFNF;"*2A/BLPV\GR S-9F[';T,*$>-=9?N"P]G<#G:RIGL)F
MLQ4AGP4+Y3"A5[Y'YC[Y/H<K[#F]:>LZ%17FVC+*VQ2=,*<?E/"7U(S26C20
M\5?7<XQ4?$1CQ:><2K*2A&B3O4UHW?<2,&$HH6,WWEU"L_,H(Y>=>XIOUSV7
MQ1:@1VPIF;VM.;8:'#L*[!MG8-3*HI!]Q^UU%H2J7-QHR4&+)=+7/Y/QW)EN
M1QHN;KQFI95S]AY+@HE9[-5Y5/F32RQG ]H.E355);VWN$SK_GAZ%VE/9=XQ
M_*;=V4<TGM5AK"G-*A%31N89IJGX2=F9UEKVXI43BJ7CO3\JM4WAM"BU6LU6
MV?<TYJLXQE*T7$8:GS7!Z-MGRNQ6X_KY68]^%],=$DAANN/Y)RLR.E%TMMQM
M5>LMO[.;Z,?)J)4T7R%NACQ9\Y6K#1O<:9Y;?>J4HR],6QS82=LG%,)5$9SW
M@R'R^J3[,$$Q[N!I1#"SB;BR0G6.'E&Z U+L]%]U83R<]+4Q1J5IEM,%,I<D
M2MYN7S%9*UJDF6X]C/5_!-V" ]4*;ERRY5:;$^*2:9$J8N2 EN5':Y++'CZ-
MN61L1&/S!E*(9>P$Y0NNOQF% AUNR_.A9E5'8WF5[#9HEE="LBJ[6&36\?Y=
M4P1HY$*34&7##HU]VJW,9$2FR+R(&X];R8P9'S-E/5DY:1RE[A(%*'ND163-
M;+<U'!)FCZ!OZQ&E)])?2S9__P"=C97_ -KL )&B[ *              #7;
MS7?>%S3WYA']X"+!8U9O\KCE*?)MZ>>XXC]O*03J6>6&Q,1H
M  &L[F</AG1JUM/WY(+H0&2R6KOOKJK.5VNE6)(3=0$S#C>N/*H+"PI9BY!.
M)8[\MM+LN6^VRE;J<:]46&;NSY5<]MIFY<.R:[%<JL3FEPMK3LE!=SJQ1-.\
M7SK!ZNH)Z ^L:-8^(]?S$>IU<94GQB[LK<33)Q'4B]*V'4TL9*F"V?%T[H31
M4949.@4LIVPKAVKYU<2;"S=/.L+TU )2/:^]:(K:$2PB^G B.Y?2H^B5CJ&)
M'S.%4=;=)'#:HL'U0WFH6QX<=<&*EUM]JG!8K8B0>7I+3QBF88<YND3:I;"1
M5&BM"F"8HLE_6EUF7E#C@.(BNKQ^]V3*Q)ZLU:)%W(W2RHEFZ%<1U)/]=OP9
M>AGS67RJ\&#<D>\KQF)VOF37#G%-[6Q]0>SY9C]?E-G[!ZQO5[S4V)_?I&5)
MM4))OE%O/%!O?[WDLI>NX5T@2*YDI0,7U+8;<-N'#BM3AWJD)C(U.B?8;5-A
MZW<W-GP;%NOVG&Q4?D-EFK/.L3K<1ITRKLX@2;2.'PTI1-/9'>-AYL+:GD+'
MC*;ES%CB:7/=DVFK.AE)P[VXF ME.7'K8UX;CB-.9K ET71>SGJCNEL.R;H+
M<S@F9_/5>3G2HS)(D@&C.%U5D RYLBTHGJIV4D04CJ^8R9R]:8BUN&+P6I\I
MKRZOAS:G^'N,_P#60%K!Y37EU?#FU/\ #W&?^L8G'YBL/SY3+ET?#EU/_P $
M]QG3_:<@D6TCM*P>4RY=/PYM4/#W&?\ K(+1>:''E,N73\.;5#P]QG_K&%).
M:#RF7+I^'-JAX>XS_P!8PI)S0>4RY=/PYM4/#W&?^L84DYH/*9<NGX<VJ'A[
MC/\ UC"AS0>4RY=7U-YM3_-ZO_/W&5?\'XQA1*PK6QM@N4.R7Q/LBY]S-4WV
M[-D'R0>TA*<BSE"SHOP8D=D-^/T!DMRF0P5[F,% ;[>IV*GY*F*VF#AO+?EO
MNSW<+5.#&",]^4@DP-JYKOFYC45+S*U$E2*I7BA6<&T$)*#PS*,++9]7CQK.
MM8M*8"BPST0H<L3:8<14J>O3BF"RIOKMM^:]4X,F+VPO*9>>PF;8V0=Z=;Y&
M<I2*#T.LQCO?82&UJ*8U:SD,F\TC*#'9-<^#$6=LKE,I<@X54_G4#9I*(X"&
M&XN3KGP9U3@QK5[\HJNHB[I)7F'Q%=!RB>N_!TIFV>A8TYH\:9:0",AMR-V2
MN&\!BW"Q&4>3\2:CEU+ I&R:+CL*=DWVXL-V.U.%&<-FMLN5IM; DIZZ21OI
MKFF,676J;:#G/L_8F(TQSE4LYEP9LN5%/JQY=32IVV\O;T;\Q,Q92G'C97ZD
M6L2P_)TI<I.2&UL6B*^_,&5Q;(31!NP+WQ)FR\*D,Y=]:[DH"+,-+:YHYB4,
M22VU2FN"#13QFL9[/EJ9.UQ9L%,N&A>UXIP4S@VS0E8BUN.:7N93#NM>RV&6
M-NW_ /A1JQN7#6=0;C!VNF]3EA=AI<7'NVEYER(C%*%D?+4X8;F,R15"-3"9
MF*7W7Y,JJ<&>G@2Y0CBM;=&SS2,43Y24--C7V15&-=[V44<$^1 SE9Q+C=:\
MT.IW*#Q=2VJ)BH]5V_"X4HZC.?#C73V'&HV8,W6K53@["<5Y-J;*QZ2\?,3B
M\VCFY[+[)%X>5=G8$5HG2I.RP$Y-;W0;($5!',/?*C/R.G!C[KDC2Z9Q7GTX
MKE+=C65-8C,JO!X3+'')F5F<\F ].9ZE24T%;7V7=7XL1)"W*A=Q%=:H=FUJ
M9&.]T6#.DDE[\*U5HTP)I)7=574J%$\KB*6&.Q:Y<&54X=Z[:'M/RL$"?;MC
M2>^NNM[ZN@-L:YU(9]B8AN;'X"M-Z+CZ33_8&,YC4OPFR+#@SV9C'9G8UQ>V
MRVTO9=2M]RI6*JW2!FY.DB2PY9&4>8Q'R&SI#DED3)+^NC8V]BU+UXF:5H[S
M-XRU7U(;*R9#:]G4,9MGI&91))BPF)"_E2RURL3/5LNZ=J<'Y1<G)T09<3)&
M*<QB/,K#0)><&P;9UA-[<Q/GUI;4ZNBU9R+<GI+(IT'/W1SJSA/JN%(,+IAL
MDUHWD4"R9A.5IFHJG!-:_N3E$:YR0AOYI\R"/7.CQ\WWNU(*B.0-N(F<<2:Z
M-N1ED@MO!)A]O%Z)2R5L/W)N(D5,+BDN'$='Z28FYB:=?>5K*K6&1Y;F_E,3
M.8V0,NK?N!2F3:* 6GKC(E$/9"&BEJ<Q&:<E8ZE'VG0[<HU3G-ES3"J]?,&J
MG2U]N(MT2]G6\E<I:PK?NA*'+WD<M+DPPMN_K<J[!/T]K.=)8_[:<8P^<:U^
MM;G>BHV7)#TC$4)\58,C6ITCJ]N;*M)3C05DK6J8=(V$S9F\6)3@\)R[G9HU
M!:X\YYV)YA6N[GG!\RY+,I)R,X]QHGEW,TLDJ,2%8]4E!SOW WXV3W1(54:'
M+K<.9$14%!12"\<2B)*I2S#?:DBG>S9#V?D[0M*+#D) YC; <39AA5?2_KS!
M+UV]BM>@W7=>DA,6T!U*\4-;'>0<!8Q5LN=424S&L*RP60$I4-E$K$2P9[[*
MJG!DJ9)7Y1\XNC81VO#?Z#"BGLKJ:F:;/[$@;)0N3)I\6)*]+SB+*S5Q'K5/
M,GOB\]-2M;>;-9#I*N+"5I0I2N/+=FAP8YG4_P H.>L;SR+7,AC-EK+QB[4Z
M*OPD86S.OA19;2;IG,D@SK#KE;=KI0':CV.NY\R0=JJY#Q0\1.%,!?'C*X+K
M,N3,J<%BX$W'T6A8@X23JYOC.V1RKAPB;)J<]S_J7D46OC)X#&',0;OZ&H\A
MLA0DHW9J9,_9V ]EZ>.WK=^.WI6W#@S[?S,N73=YN\VJ'FTK_P!/D:4\SS/,
M<81,Q*UB2G,QY='#J[R:G5_;W&?^XXQ.,+S0>4QY<_5_[<FIU./#CPGJ,_J>
M9_Z1_P! M92L'E,>7/\ #DU.\/<9_P"L@+S>)Y3'ET<.']N34_A]7_G[C/J_
M^L81,QHE8G74IS,N732E>&\NIW]'_/U&?4_]8Z@O,4YF7+JI7C_;FU/^IU?T
M]1GQKP^O7\(P2K"FR6W/*WVD@F4=>I#WSUQ361+C3/LYS'VEL1$:<Y2J6H78
MKL^9&/*IY<3BIZVN*G1OS%#%E/JV5 F8F*._-&Y7*^G6"Y+U]>.^.MA)E2K&
MKFBQQGV]L-$Q-R%6XZV\;;2D91SQ]25$\LKXB!RZ[#DS%,^*W+2E;L5UOV-2
M5C115WL[D\.R4'I)!?FC)#.2Y!G6,]F79%+,V^@A+C)8G**5*/U5M/E0P'&^
MIO=3PY3D9I-YE$-KAAMW9,/7<2?AS4LR66IP>X+Y.3I8[W8</\QB.UJ%7>N3
M&ZSVHZGMM$E=8"KMV"3'>FS*O%V40M(.T[B?660W >S)"@OGF\34UHR<))Y8
MQUK)BE3@\@2;_*1NBZ38>=O-I49(9$AQ(5@M&(OK>.(U#/%$7$EA*62R+'&9
M)3$2S*X+,R$1PU<KCL<3JN+E;++E.O&^MZIP>ALLY11YLR*6>/-"0)$E6056
M*5,OLJ\=P87NV#CS'!*RKN&&$B,W@VTQN(#81X\6W.M&<.&Y(,W*UZ\IT5[E
M&T\8MOM3A\ZQ&MFR'*VUH(/_ #(W,1A24)!EQWX'W+DR3!LO#KDD^27(GMQ&
M9J#F<!]O7M%L)R2UV>W2*8F)B0DIB82+%^.,O3-F,9<LJ<&"XJ.<GN))69\C
MH_,>8+C;$5.5^/2"H%>FWT6KT$P*[I)QK99UKT8-7KA1QX<]R>YE,HF%UA85
MR+?)J)C DX".*_H45.#)LNR_RDIH=4_N]U[^P445-CM3SVG+ZQ(6R,,%"2?%
MB@9D WG56QB/=TLI![VY9(/]$V9R'"=+<>"E2E>A?7(J32>'8Q).5.3S/"2[
M4Y=YC\:M$Z[(AUGAO\(&-LUKX56F\B:GS+DG6*G"W_PF0'2D6.S\.+Z=TLIP
MH<(FB=EN.PKANXY*VIP68@/<;1>%23E*.OF_,_9+*OFDTP34)[G[4F\ZU,:?
MB.8LQ-M_H:CJ&RE"JK<:MO,]GX3^3IX<?6K\5.G2^$2S'R[GPS9*C_8%^1ZZ
M4![LET[D;)*K:=K55B2ZW%],RO''CQ*".L)N8P042>2_'=2F3%?=96MM>KU
M6-&P$%              !KMYKOO"YI[\PC^\!%@L:LW^5QRE/DV]//<<1^WE
M()U+/+#8F(T
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1*_X9UCI]#ZH<$GF[=/F?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tv523241_chrt-line4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_chrt-line4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#:@.$ P$1  (1 0,1 ?_$ 1X  0 " @(# 0$
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M.?_:  P# 0 "$0,1 #\ W^
M
M
M
M
M
M
M
M
M                                               < !J ..=_H[/*
M7)]3LZ:\I #G7ZG\M/JZ>B &O\W)KR@!KR<A:@#@S[')RF>G*>GU?2U[  \@
M
M
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MHU*S?9D--2)1'T;M2CSC;)+9(222\0BW08E
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MOVM6?*I%X2Z%CVB2;I4Q#A5*"E<ZK-/N*6<=LBK^Y?8#'%N\+'%F,^.EF/A
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M*'DK),5AI!E-5/LB33YE->1ZYMLY7/</G.,I1F\(_MZ_N,?']O0V61@9
M                            -"   -" #0
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MHLVJK3$I[)DDV*7#C-F7.2HS-U9$J$]Q"@
M
M
M
M
M
M
M                     !CNZLO8GL6JL4*]\GX\LZMR8::A&H]TWI;=OU5^
M MQUE$YFGU:I1);L-;L=Q).I0:#4A1:ZI/05)O@?DI&;L,7!4(M)H.7<85NJ
MSE]'"IE(OZU*E4)CA::HBPH=6>DR%EJ7(A)F!>F2\&9/ Q
M
M
M                                                & *_=T?"WV'[
MT,@4S*>YG;W;>5+^I%N1;1I]Q56LW=39,>W8<R94(].Z&@5^EQ'4-2ISJB4M
MLW/7:<[0B(I3&I:O!.AK0;*-B>UV^/I!F>6-N&$HV.MN^P:TZ%1IDB@URZI=
M$KF:EPJ>F;"=F5"LU*+-<AUB3TJF26>B8JT&1*)8G%X&>"75^:E/;C^[VF[
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ME[!U#ML7D^+OQ5^[ HAU/DO8.H=MB\GQ=^*OW8%$.I\E[!U#ML7D^+OQ5^[
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M*]!JJV\X9>F1S5-%I]93A",J\?0E9A#\2^(OR8V%]ZU*%7 2_$_4R@!
M
M
M                                             "+.]@M=K.8_[N0_
MN_2!'P*N/T/[#VZ?^)C^S5K_ #_)GK_K#P+^8E"*8@       ! GB6?HCW__
M &VWONLP(QS]"4V$/Q+XB_)C87WK4H5<"R_$_4R@!
M
M
M                               "+.]C]%G,G]W(?W?HXC*N)[?U,?V:
M?\,@\"_F)0BF(        0)XEGZ(]_\ ]MM[[K,",O@_0E-A#\2^(OR8V%]Z
MM*!<"R_$_4R@*8@
M
M
M    $6=['Z+.9/[N0_N_1Q&5<3V_J8_LT_X9!X%_,2A%,0        @3Q+/T
M1[__ +;;WW68$9?!^A*;"'XE\1?DQL+[U:4"X%E^)^IE 4Q
M
M
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M:=O56MO&>O3R:18]"MJV89I+D),:&TGTQ3!TK@=V
M
M
M                        !%G>Q^BSF3^[D/[OT<1E7$]OZF/[-/\ AD'@
M7\Q*$4Q        "!/$L_1'O_P#MMO?=9@1E\'Z$IL(?B7Q%^3&POO5I0+@6
M7XGZF4!3$ "@;<&E/\0SP]5:$2CVB[J"-6G*9)I+!I(S]$B-1^J(C/\ +[?^
MB7\BF
M
M                                                  !%G>Q^BSF3
M^[D/[OT<1E7$]OZF/[-/^&0>!?S$H13$        ($\2S]$>_P#^VV]]UF!&
M7P?H2FPA^)?$7Y,;"^]6E N!9?B?J90%,3C7TM3^M_+T !0-N#6@_I#/#U22
MDFI.T;=0I2"41K2E=)9)"E)[)$HT'H?HZ'IV#$X<3/\ )7U_Z)?SK]<*F (]
M10<@
M
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MJ=B.GSL2GZ3>;NI/C^5_7A>XG_3R%];3T-?1&[#YHGD
M
M
M                          BSO8_19S)_=R']WZ.(RKB>W]3']FG_  R#
MP+^8E"*8@       ! GB6?HCW_\ VVWONLP(R^#]"4V$/Q+XB_)C87WJTH%P
M++\3]3* IB:0?'?+_P"Z!U_\E&-/_P!BGCJ#W4_]N,[ZV?\ ]WM']&O\L_\
M_P 6\K_^-ZA_SX%-@UV?0 L?X22#7O\ L"^NTYM>6OT>4B2DC3]374<AVCCN
M[2/_ ,1M?>=2?GGE3Y7MS8<<M3[3?O(=X3^8 Y
M
M
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M:7\NFOZ%J.=R]G6,WE^FS9E*ERZ\<(*F+-\(O1['9]#ZO*.[9_,\<@
M
M
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M\I?=@#'DQXYVC\++:[^4ONP!CR8\<[1^%EM=_*7W8 QY,>.=H_"RVN_E+[L
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M(AQ"DSI+,1@Y51F,4^GQB>?6VV<B=/E-,,HUYSKSB4)(U*(C<> /U@
M         "F3Z0S_ +EWB _D<I__ $A66*N/T/[",PY]%Q_W%&QG]IG_ -,/
M<$(4O^
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MYRBDL(P<$;$NV/\ 1LV]_D/Q/]X5 &SEP.HDN+]3.($
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M];AIL-AADDWEE"T:=DN]9$HXQJ:?J,JZ[LF.2'24KI7E*5J9&0/B$40;_P"
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M1<F7;B%     (L[V/T6<R?W<A_=^CB,JXGM_4Q_9I_PR#P+^8E"*8@
M ! GB6?HCW__ &VWONLP(R^#]"4V$/Q+XB_)C87WJTH%P++\3]3* IB<:^EV
M?^70 :S?$2MI5Z\9[:[:JH3KY2^'SO&G(3S%+2ZHJ%*7")"2+URNWZ/H6A\J
M^33T^2;,SST[=VFYU.CAF[=7Y2ETOZF>BW7DEJ.U<_DI*L9Y6YAYI)K[#$/#
MYO2=9.Z6PXSBU16*U5F+>J2#T1SVYVL=27"5V>8Z1?SCNAW;TVWJ>QLU-+JG
M:MNY'UCC]AT[[1:E=T[>UG+R]V-V2A+PK6O[D6]<8ZX*_;&PW*%4MNM52WZD
M53MN.4^CS7Z?,[6D3G$2(QOQU(7T$A'K5IUT47(8^6'>BY<M[,2MR<8SSMB,
MJ-KJC)R3BZ<4_%<&?;'Y ]*TO6/F9T;)ZOEK&:RGP;\NB[!3CU1BG&5)558O
M%/BF:&4N+'GLR(\UEJ7'E(<;E,R4)?:D-O)YKR'T.DI+J72,R41D9&1CJY:N
MSLS5RTW&<6FFG1IKA1KD?TMYS(Y/4<E<TW4+-J_IUZVX7+5R*E;G"2HX2@\'
M%K!IHRJ6<,T,-,(9RSD1I$1IEB*VW=U;0W'8CH0AAEE"9A);:80R@D)(M$DD
MB+D(8_WD^N;;DWQJ_P!YQ*SVR[;VHJS;T#1XVJ4HLI92IZ='F_:?T)=F%5J5
M:VF[=JM6)TRJ56H8BLB5.J,]]R5-FR7:)%4[(E27C4Z^^ZKE4I1F9GRF.YG;
MN[<O;'TNY=DYW'E(5;=6\.9_+'\P>2RFG]\-UY'(6K=G)6M=S<80A%1A"*NR
MI&,5@DO!+!$G!S0TZ                     !0MQQ>!WA_BT8?77*&W1<=
M;P,<T64G$.7E129C5Z,R3LI&,\EN16E2:G9E4DJ/M:3S7)-&DN&^P2FU/L/U
M/P? '\E/<!M_S!M<S!?6!L\V+6L<Y4QS6I%"NJU:['-F3%DLGSF)D-]/.C5.
MCU.,I$B%-CK<C2XSB'6EJ0HC,U0%OG! X(&8^+3F-%4JB*SCK:)CFLQ"S%F(
MHAM/59YLVI2\;8V7*:5%JU\5:*HNF>T<C4>,X4B02EJ88?)>+X _J!6!PC>&
M;C2RK9L*V-D&V[WBM2CPZ-3G:UBJT[@K4IF(T2%3JU7JS3)E6K=8GN\YZ5+D
MNN/R9#BW'%&I1F+U/P)1'</W8W#K\R':Y\R=@^ PZI<Q1#]V-PZ_,AVN?,G8
M/@,.J7,40_=C<.OS(=KGS)V#X##JES%$/W8W#K\R':Y\R=@^ PZI<Q1#]V-P
MZ_,AVN?,G8/@,.J7,40_=C<.OS(=KGS)V#X##JES%$/W8W#K\R':Y\R=@^ P
MZI<Q1#]V-PZ_,AVN?,G8/@,.J7,414EQW=@NR+%O"-WR9 QOM-V^6+?%KXG@
MS[<NVU,4V;0[AH<Y5]VA%.72JM3J3'FP9!QY"T<]M:3YJS+L&8*3>#Y"B1E;
MZ+C_ +BC8S^TS_Z8>X(8E+_@               !I9<+FGGQ,_I%_$2XA]RL
M2ZWBC8VR[MMV[+J,&.JFTZXS56\64^K4-YQQSF=);5JW=5EH;2;J';I;<6IK
M5*%Y/#Z,/W_MYF)NFC$R-1BX>(Y]*:B7!7(E X,V!)]"BUBIQZ+.DWM&[8FT
MEB:^W3I;_,W/LHZ:3#2A:M$)+G*/0B[ KXX< ;"NPC*VZ_*VTVP,E[\,+6OM
MIW'U%Z^UY'Q7;E3:F6W:5-HE[7)3K4G-5)5VWHT3=8L>! J+ZE5-XFW)"]>C
M(NC1 :]&^KBQ9SXFV7J[PM."1-7=%3K3<NW=UN_""U4H^,\%V)(J4J@7/%L2
MYVVF&Y=0G,1I##-9B+6Y4"-2*)TIZU!C-*GK]G^4Q>/H7L\,GAL8&X7>VBA;
M?<*PUU.J2GFKDRUE"K1VD7;EO(K\1IBJ7;<#R3<4S&02.@IT%*U,T^&E+2#4
MHW'',6Z\.!:>TUL<FVTKC*_21<X[']T]>K]1V4\/?#",@T#;C'N*I4.V,HWM
M&CX<BR*Y=]-I4B"]66IMU9>[:?=6I1+IM)APS/H7W25EPP\B<2TW?[P$.&U>
MFU;+U5PCMPQAM5S;C;'=Y9"Q!F[!5#CXONJR[]LZA/W);]1J52MA5-.L49<Z
MC(8EMRC<-$5YY3*FGC2ZG&/&G,KYD$=H.\C,&]SZ*7O"R5G:MS+LR78FTC>G
MA6LWQ5),F;7+Y@X[Q1<#- N:XITMUZ14;CD4&IQH\Z6M1N3),=;[AFXXLQ?/
MR'[R8_T43_<C[:O[];B?^G>_A'P7I]["XOU^XV,I,F/#CORY;[,6)%9=DRI4
MEU#$>-'80IUY]]YU26V666TFI2E&24I(S,]!"FD?]&4JM4W+\4SC;[ZZ.T50
MQ5D7+5<MZQ[KC(3'I=6@WOFB^;XMV!!;)$=R2[3K"M^E.O.+:)SFRFE+/GNJ
MUR?!^OV?LB8_4;NPQ*:@GTLFD6O<#7",H%[L0I-EUSB VY2+OC5$VDT^1:]2
M3;$*OL3U/J2RF$[27GDNFLR22#/4]!G#S_B7WF,ON9M[M--1VFF&&FV6&6T-
M,LM(2VTTTVDD-M--H(D-MMH21)21$1$6A# R--KA;1Y]+^E5<:6FV-&Z'%$C
M"OOI>/O<Q&324Y6EW1MHG0SEK:(EHJLFI52\7-"_[8YVPISUY$,I5^C#["+Z
M\?M)%;A>(!]);LS/N<;/P1PC\'9)P?:F8,EVUAK(M6O!F-5;^Q30KTK5+QW>
MM3C'N/H9QZA=-H18<YY!PH?,<?,N@:TZ-.)3#_[R7Z5C_P"I;V_?'9C_ ..C
M 'X>,G<F^O<W]&QS_D/>WMTM_;KN/M?)^-[FO'$5DSBK-+IU@6YN LNBTFXH
MSS%WW\:R>H=8*?+UJ*NA99<6:6TIT&2HEYM?>3&OT_<;#G"UONGY,X:FP.^:
M:3:&*_LYVX//QVEJ<;A52)B2TZ=6J:EQ9$ISWLK$-^/SCY5&UJ(^.)37?XK$
MBFY(^DZ<$7%=!>54+HQ]9M;RA<\*(E3RJ5045O)=T0'IAI23;'/BXQG.K2:^
M<EGF*-)$M'/R7#V_88O]QN(C R-=GZ5/95<O'@F[GI%"AO3EV7=&";UJD>.A
M;KY4.FYJLBF528EM"%J4S3&*QVT^KD)N.RXX9\U)BK@_0C\"S7A:WW3\F<-3
M8'?--)M#%?V<[<'GX[2U.-PJI$Q):=.K5-2XLB4Y[V5B&_'YQ\JC:U!\<2FN
M_P 5B13<D?2=."+BN@O*J%T8^LVMY0N>%$2IY5*H**WDNZ(#TPTI)MCGQ<8S
MG5I-?.2SS%&DB6CGY+A[?L,7^X].PEZ9BKZ6[Q6\?71"5#<S'M@HE]V;4'>E
M2BK1VX&UFY([-/U;0W)973JE44NN%J3<BEN-ZF9*TCQX<*+]Q5A[39MWU7M;
MV-MD^[V_[KFM4ZV[.VR9UN*LS'5&DFH%*QC<\MY*"2AQ;C[Q-\QI"$J6XXI*
M4I4HR(Y'\2?F'P*(/HIIT+#? _L?)&2+@HEAV76<MY]R#4+LO.KTZV+9I-O0
M;T.S':Q4J[6I4.F4ZE(EVDZ1OON--D9'RZ:&9\%Z?O"\?4V%*M;.V[=UCZTJ
MU5:9A_<ABPJXJ\+(K!^*>4[!?N"E1K@M)=PV[4HZZU;\RH4YBJ5.GF^PM:F3
M=?:,R5SR!-K%%I7B:=/''VZXWX0&[WAX\1#A_P!)ZNUXY/W*1L19QQ)BY*:#
MCC+EMU5RCUFL'*L."@J(S+N6D,3J?5.AC<V6[*BR.:F4PAU62QQ?/[3%\C>+
M&!D               :#&'\.8HSI],3WQV%F?'%EY3LE_&%6JCMJ7[;M,NBW
MW*E3<#;?ET^>NE5>/*AJEPU.*-IPT&I'./0RU&?"K\:+[C'EZ_O-P#]V-PZ_
M,AVN?,G8/@,3JES+1#]V-PZ_,AVN?,G8/@,.J7,40_=C<.OS(=KGS)V#X##J
MES%$/W8W#K\R':Y\R=@^ PZI<Q1#]V-PZ_,AVN?,G8/@,.J7,40_=C<.OS(=
MKGS)V#X##JES%$/W8W#K\R':Y\R=@^ PZI<Q1#]V-PZ_,AVN?,G8/@,.J7,4
M1JX?2"/HS%D9;LNK;M^&YBVW[$R]95&=EY,VX6#1X="MG+=OTUE;S]PX]H-/
M;8@4K)U/CI4IV&RA#5=;3R$4TB.1./J.!_.'G09M,FS*;4H<JGU&GRI$&? G
M1W8DV#-B.K8E0YD5]#;\:5&?;4AQM:4K0M)D9$9"%+6>$=PCMP/%FW Q<;8V
MBRK1Q!:,JG3\XYQGT]U^W,>6X^[SNT('/Z-BNWY76&UHIE,0LE+41O/&W';6
MLJE[ ?UY]EFRS;]L#V_69MNVW69%M&P;1BI5)DJ2T_<=Y7&^TT58O2]*P33;
M]=NBNOM](^^YHE"22TTEMEMMM)L$KA      19WL?HLYD_NY#^[]'$95Q/;^
MIC^S3_AD'@7\Q*$4Q        "!/$L_1'O\ _MMO?=9@1E\'Z$IL(?B7Q%^3
M&POO5I0+@67XGZF4!3$C?NEVY1=T6+SQC,RAE'$;)W'2+B.[,17"U;5VFJD-
M36TTHZB_#GMG2IG;O.>:Z/URFT'J6@C53*,NEU*H:IP L)5O+5MYSK>[3>E5
M\I6E;%9LRA77.RM37IT.U[B0;5<HB3.VR(X-394I#J.0E)4?ICR6;DK%Z%^'
MXX34EZIU1C<Z;MN5J:]V46GZ/B5HTFFR,';E8%$CRI4A./<L1:.S4*DLG*A.
MIE+K34=J947$DVER;*9;YSBR(B-1GR$/H5'HUW8:<O>=_3?^4[>)T'2NZ!W#
MHJ15K5/9!SP+MN-"^B5P]\DR6N5J14K1?;/TT.3%.(/TN5*A\EN]\7;VA&W+
MC'4;"^GJDC[J?R[Y*7S0:+-<'E\P_P#D(T5NQV1U9/Z63Q66J3+3DY/K>CKK
M]8N491P=?$+"7G^W^0V'MHO'BK.'K!L'$^5\10;AMNR*#2+5I]PVG.53*J=+
MI,=$&(],BR2>AK>1'0GI%$DN<9&?9U&T-L=U=:VUD+.DWLM9S6F9>"A"C=NZ
MH+@JXQDZ<UCXGRG[[?RS=/W[N?5-\;(UVYE-6U',W<S.QF8?$M_$NOKDHRC2
M5&V^E-X52X&Q[MQWN[<]T=OTVK8QR#1WJM,CL+E6C5I;%.N2GS'/6NP%PGW$
M]NO-++LL&YJDR49%KH6]]L]P]L[GC&WE;ZM:@TJV+M(7%)^"KA/'@XUJL:+@
M?)3NU\NG=GLQJE[([QTK,1R-N;Z<S;B[EB<%PFIQ3Z$U_'3&JJ^)+3G'J1&7
M\_I]GL#G)HT\@                    !2YQ9>!SM,XM,?'-<RJ54QOEO'5
M>H+<;,%A1*<U=U<QLW6&)-TXWKZI;*X]6IM0IJI!TQ]]+CM(GK)YK5I;[+UK
MX/@"SO;SMYPYM4PY8N \!V+1L=8KQS1F*);%L41@FV666RYTFH5"2KG2JM7*
MM*4N1-FR%N29<EQ;KBU*49@W4&:!              %,GTAG_<N\0'\CE/\
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MVVZ2MW82MSB_Z4)I27TI'U"/74?H/QG(
M      *9/I#/^Y=X@/Y'*?\ ](5EBKC]#^PC,.?1<?\ <4;&?VF?_3#W!"%+
M_@                                     % _'5X:VX[B*]0GJ]R,;1
M^K9NHI.9\A_*)=54MCIK4I_O'SF+=][+9N/WRJB^T'?ZMSM=)>M]<>IZ91:7
M'FB-?87\#$H                                         &C#M)_\
M;0-[OY(;C_Z ]O8SY_U5]QCR]?WF\\,#(                         BS
MO8_19S)_=R']WZ.(RKB>W]3']FG_  R#P+^8E"*8@       ! GB6?HCW_\
MVVWONLP(R^#]"4V$/Q+XB_)C87WJTH%P++\3]3* IB   % ?%_Q^4:[K!R R
ME3:*C2Y%&DFE/K793*S2VLU^BIM#J>0=K_EZU9ST_-Z3)UE"XIKR3_?0ZO\
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M .D*RQ5Q^A_81F'/HN/^XHV,_M,_^F'N"$*7_
M
M-&':3_[:!O=_)#<?_0'M[&?/^JON,>7K^\WGA@9
M    $6=['Z+.9/[N0_N_1Q&5<3V_J8_LT_X9!X%_,2A%,0        @3Q+/T
M1[__ +;;WW68$9?!^A*;"'XE\1?DQL+[U:4"X%E^)^IE 4Q   "L[BG6"=U[
M=CN)M"5.6/5O?52M#YZ6)266G#29>@1LEV>0;I[%ZJLAN_\ 2.M,U;Z?I6/W
MFH>].E/4-GSOKCEY=?T?LC ?!TO<WK2R5CA2S)-#J5.KS2%'V'*E&1'D)079
M+3H$J/\ ^2'*_F(TSIS^3UE<;L)6_P#5=5]IQ7Y?=14M(S6C8UL7%+_72JOJ
MJ76$.M:.Q!R    !H0 XT+TB]/\ G &)<OX*Q-GBVY%J97L:AWE2)#*V"34X
MB#FQ4.&2EG J39(G0%J-/*IIQ!Z:^F/0:]MC0MS9?]-K67A>@N$N$X_U9JDH
M\/!G.-B=RM\]L]7AK>Q]2S.GY^$NK^SE[DFL%UVW6$UC^9,HUW,?1_<-WA%<
MJNVRZY>+*[VPITZ'<3LZO6R\T9*_YNT:G>VXA\\R,E^N/D&F]>[)RB_C;8S3
M7.UF&YK_ $;B]Y<O>JCZ1=G_ .:-O[0;L<EW=R4-:TWII\:PH6<PGA[SPZ9>
MF"*9\K</W?SP_:I&RG0'9[D6D/MM^.F)JE5I2&D*4I:&ZC ;90_VHZE)\Y*N
M<6O)H9C4VN;7W)M.ZLQJEB=BDO=OV9.44Z8?VD5%Q;\U3P9]!-D?-)\L/S1Y
M.>R]3C:C>OQ;_2:G;M1;?!N$VVNI/@U1^:1)_;;Q\<_8\JK-$W#4"%E&VX;1
M17W:=%CT"\H;C:4H)<E2FDHD.(2DM4N(2HS/4QR?0.ZVZM*E']7<CJ&02ITS
MZ8S\J78IUI_23J::[N?RQ.V&Z\C+4>U6:N:-K%R74E<D[V4DN44G6*>.,6UA
M@7J;;.+WM"W(UB#:U.N*K8_NRH);3'I%]1H]/CNR%I/_ )M'JK4ER,ZLEES2
M-1((S/ET&VM$[Q[9U3,QR>>C>R.8FZ)W:.VWR^(L%7PJE4^:_=WY#^^_:/(7
M=9S>5L:IHEJO5=R<I3DHK\SMN*DE3'!M^I:#%E1IL=J5"E,2XKZ"6S*BNMR&
M'D'V%M/-*6TXD_3(S(;7M7K5Z"NV91G:?!Q=4_I7$Z9W[%[+796,Q"=N_%T<
M9)QDGR::33]4?I'D/$      !QH6NNG+Z?\ I %/NV\B+C'<2,BU(E84VC+4
M6IZ&OQ.DH)1EKISB2DBU$\3-_@7+_.7!:%IIH*N!@<@              JYX
MU.#\L;D^%KO)P9@RRJCD7+.2,9T^A6395)ETF#4:_5$WO:E0=C1I5=J-)I3*
MF8$)YY1O2&R-#9DG51I2=7$C-0'9)5/I7NP7;#C+:7@O8+1ODLQ/XY^*WC73
M\-5RO_\ P]Y!NS)=;[?JBLL,'*_^&.\IG1>L+F,\Q'+S=0JN0Q)6==?Z8OY@
MMB_%K#/YW0JN0H^8ZZ_TQ?S!;%^+6&?SNA5<A1\QUU_IB_F"V+\6L,_G="JY
M"CYCKK_3%_,%L7XM89_.Z%5R%'S'77^F+^8+8OQ:PS^=T*KD*/F.NO\ 3%_,
M%L7XM89_.Z%5R%'S'77^F+^8+8OQ:PS^=T*KD*/F.NO],7\P6Q?BUAG\[H57
M(4?,==?Z8OY@MB_%K#/YW0JN0H^8ZZ_TQ?S!;%^+6&?SNA5<A1\QUU_IB_F"
MV+\6L,_G="JY"CYCKK_3%_,%L7XM89_.Z%5R%'S'77^F+^8+8OQ:PS^=T*KD
M*/F.NO\ 3%_,%L7XM89_.Z%5R%'S'77^F+^8+8OQ:PS^=T*KD*/F.NO],7\P
M6Q?BUAG\[H57(4?,==?Z8OY@MB_%K#/YW0JN0H^8ZZ_TQ?S!;%^+6&?SNA5<
MA1\QUU_IB_F"V+\6L,_G="JY"CYCKK_3%_,%L7XM89_.Z%5R%'S'77^F+^8+
M8OQ:PS^=T*KD*/F.NO\ 3%_,%L7XM89_.Z%5R%'S'77^F+^8+8OQ:PS^=T*K
MD*/F.NO],7\P6Q?BUAG\[H57(4?,==?Z8OY@MB_%K#/YW0JN0H^8ZZ_TQ?S!
M;%^+6&?SNA5<A1\QUU_IB_F"V+\6L,_G="JY"CYCKK_3%_,%L7XM89_.Z%5R
M%'S'77^F+^8+8OQ:PS^=T*KD*/F.NO\ 3%_,%L7XM89_.Z%5R%'S'77^F+^8
M+8OQ:PS^=T*KD*/F.NO],7\P6Q?BUAG\[H57(4?,==?Z8OY@MB_%K#/YW0JN
M0H^8ZZ_TQ?S!;%^+6&?SNA5<A1\QUU_IB_F"V+\6L,_G="JY"CYCKK_3%_,%
ML7XM89_.Z%5R%'S'77^F+^8+8OQ:PS^=T*KD*/F.NO\ 3%_,%L7XM89_.Z%5
MR%'S'77^F+^8+8OQ:PS^=T*KD*/F.NO],7\P6Q?BUAG\[H57(4?,==?Z8OY@
MMB_%K#/YW0JN0H^8ZZ_TQ?S!;%^+6&?SNA5<A1\QUU_IB_F"V+\6L,_G="JY
M"CYCKK_3%_,%L7XM89_.Z%5R%'S'77^F+^8+8OQ:PS^=T*KD*/F.NO\ 3%_,
M%L7XM89_.Z%5R%'S'77^F+^8+8OQ:PS^=T*KD*/F.NO],7\P6Q?BUAG\[H57
M(4?,==?Z8OY@MB_%K#/YW0JN0H^8ZZ_TQ?S!;%^+6&?SNA5<A1\S\7!KV9<7
M6=QRK]XBW$*VI53$#66,-WW1[QO"#-QS&M)JZ$VACZSK9@PZ%;-[5^I1E5&E
M6<CG&EI:3>)2UJ+G:BUX^G[A3AZF]*,2@                        $6=
M['Z+.9/[N0_N_1Q&5<3V_J8_LT_X9!X%_,2A%,0        @/Q+C46TB^N:6
MI'4;>)9\GK4>^*3(^4C_ /<A)+DT/E#P*ON)481_$QB/\F-A_>M2@#XOU,H
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M]V<1     *?=N'^^/XD7Y$MHWWH2Q/$S?X%ZEP0I@
M
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MU#'T#W-8CK.Q,U&*ZG<T^4XKF^BJ^O$Z'[:O3T3N#EUP4=15N7E'J:K['0W
M2DQC(C*0P9*(E$9.MF1I/L*(^=H9'Z?8'SS2?#Q.^X[9C?\ =#'MK?VPM&2J
M';,;_NACVUO[8*,M4.V8W_=#'MK?VP@.>V8__=#/MJ/M@)5'';,;_NACVUO[
M8*,51SVS']G9]M1]L JAVS']G9]M1]L JAVS']G9]M1]L JAVS']G9]M1]L
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MWA,!U,'M%Q'H>CU_I/0R)19$NPS29ER&1*J1I,R^J1D'$=3/2G:'BE!?^_\
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MBQWV8T^\JU5*>:UU"-$4;\6?(?0\DTRO1/UJB(RY-2..G%E4FTX^%"1/._\
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M,C+E)1&6I&1EKJ1EZ([6)IJJQ1_/4ZIT?$\A0
M
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MH9:?Z?3'M#C1Y
M
M                  BSO8_19S)_=R']WZ.(RKB>W]3']FG_  R#P+^8E"*8
M@       ! GB6?HCW_\ VVWONLP(R^#]"4V$/Q+XB_)C87WJTH%P++\3]3*
MIB     1'WTV@=Z;6<LT]+*7G*7;[ERH)1$:FRMY15-YU&I'HI$9A>I_];J.
M?]KM1_PW?6GW6Z*Y=^&__P!)[J7M:.$=Q]/6H[+S]FE7&PYK_075]Q4#PA[_
M $43.E[X[4X:"ONT#KB&M3)*WK5Z!+/US0Q+?T](N=]4=A/F#TEYG:^5U=?_
M #7,=%?*[Q^M1^HZ_=@-7AE]R9S1J^_FK"NT\*6DHK[7]9L;%_Q_ZQT\.W
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M<68MXNU-\*U<9/%/P5F!'KZ&GJ_\/9&S6=/SR
M
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MJGX'92,S[/\ R_SC]YZ@Y
M
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MZH'(H
M
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M:=*KR?%';73L_E]3R-K4,J^K+7K:G%^353MH_"?M
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MHO%2BTTTSZ@_0?C
M
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M(
M                 19WL?HLYD_NY#^[]'$95Q/;^IC^S3_AD'@7\Q*$4Q
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MU#1\]<TS5;-S+ZC9ETSMSBXSC)<4TSZVI'Z(_4?A.0          !P?8/ZP
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M NP7_+_PC9IU?.0
M                           $6=['Z+.9/[N0_N_1Q&5<3V_J8_LT_P"&
M0>!?S$H13$        ($\2S]$>__ .VV]]UF!&7P?H2FPA^)?$7Y,;"^]6E
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MY[3KL;N6GP:=?H?)KQ.YZZCUQ^\Y
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M3A/\?Z7J]WI3]Z,4G&E%1_07YCLB?,0
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M%8=?)Q5LW+&0KH4U"DS$&;*DI(E$S*8,C[)'Z0W=K.W]F=UM%CF;%R$Y]/\
M9W[=/B6WQ<9KCZQDN1IG1]P;S[5ZN\KG+<XV')==F?\ =W%PZK<N'I)<G4OK
MVP;YL0[F6WJ72W9%FWS";:7*LVY'XK<N6A:?ZR30IB%I9J\5ETC2KFDEQ.I:
MI]$NJN]^U^X=E25^^EF=+EPO6TZ+RFN,73U7F=H-F=R- WG%VLJW8U&'XK-R
MBD_.#X2C7"JQ\B:>O9[/(-;FP3D
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MNC*Y.S^6SE[?Y816&-6_%DG2',#3H
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MN6<S'C&::?UG8;)YW*9^PLSDKL+N7EPE%II_2CL@_&?J
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MU5:5W&TJ_D7.35J[3JL7J4=;5V-8RP:PPDO%$DR/7T-!RHU&<@
M
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M+X/T)380_$OB+\F-A?>M2@7 2_$_4R@!       .-"_Y/0+ZI?5 #0N7ZO\
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MSF'DK9<-_HW$F1DK0]0JJDZ73'P)RE_+_@_T"D
M
M      "+6]C]%G,G]W(?W?HXC*N)[/U,?V:?\,@\"_F)0BF(        0)XE
MGZ(]_P#]MM[[K,",O@_0E-A#\2^(OR8V%]ZM*!<"R_$_4R@*8@
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MC;6775K<<<VY80<<<69J6XM>,[84M:U'RJ4M1ZF?HBB7XGZDC@(
M
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M0:*E&4).$TU-.C3P:?)I\/0W5&4914HM.+X-<*>#/>(4
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M\QM[=.3OY/5<O=E"<+D)1JXNC<6TE*+I@U@T=\'MCC14OQT?]T]O8_(Y6O\
MWK'$Y&4?'T?V$V-G'Z(>U;_S;\'?]&-KBDE^)^I) "
M
M          !%G>Q^BSF3^[D/[OT<1E7$]OZF/[-/^&0>!?S$H13$
M($\2S]$>_P#^VV]]UF!&7P?H2FPA^)?$7Y,;"^]6E N!9?B?J90%,0
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MB_%/F=N-&UK3M?R$-2TNY&YE;BJFN*?)KP?D9('ISVH
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M+X/T)380_$OB+\F-A?>K2@7 LOQ/U,H"F(
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M8RMC)]^=T6,K:5G*QU2YTQ4>B*73'\,:*BKC@2WU(; -%U.=2 '&I>F .=0
M 5                           @[O/G\0NGT^R7MA5O[9KAJI3YIW_"W&
MU>]Z1!73B0S[WHH$BS67GD.J<Y_2&X78/D] "JGB5<4?=QQW;ASUD;;-2L \
M,CY0\:XYL[(=9K;N6,^)HTJEWO(FT^E-PJ>5'5-1-BRJ<ZMY+IDT2#;T4?/(
MQ*^!ETX=3>!<-M*E[P)N,E/;UJ/A*B9;55Y2D0\#5&YZG9C=%5H<1LY-UM-5
M)<UI6I*/3FJ+0^R+ZF+Z? E&!
M            (L[V/T6<R?W<A_=^CB,JXGM_4Q_9I_PR#P+^8E"*8@
M ! GB6?HCW__ &VWONLP(R^#]"4V$/Q+XB_)C87WJTH%P++\3]3* IB
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MS/HNPY2I5-<XR6*^E>!, NP0U]Q.>
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MJ22DF2DGRD:3)1&7ID9'H9#V:::JN!Z)IIT>#.=2Y?J=D4@U_E_Q !J .=0
M                 P!4YB'3]\9O![&O5.V__7_^?=1_XA/$\K_NEZ_O+8Q3
MQ                                                !%G>Q^BSF3^
M[D/[OT<1E7$]OZF/[-/^&0>!?S$H13$        ($\2S]$>__P"VV]]UF!&7
MP?H2FPA^)?$7Y,;"^]6E N!9?B?J90%,0
M      ];B$K2I"TH<;6E25MK22D*2HM%)6DR,E),M=2/LZBIM--530:JJ&J[
MQ%+3I5G[K;Y@T6CPZ)3JC!H%89B0FDL1W7IU,;7+EH:3HA*I,Q#AJYI$7.'>
MGM!GK^H[#RMS,W)7;T)7(-R=72,L%7R31TH[NY*QD=\7XV+<;=JY;A/!43;5
M&Z<VTR#_ "EIZ?\ J&S/L-:4KCXDZM@FYR@[9\H7%4;U=FIL6]+:12:HF&GI
M#BUJ)48DBCU9;)GHZB)'.2PK3E),DU>AH-7]U]DYO>NAV;.FJ+U3+7NN-?&#
MBU.-?-]+]8I&SNU>\LGL[6;US4Y..E9FRHR\:34DXR^A=2P_BJ;*F.,N8ZRU
M245C']U4JXHO1-N/-PI+:I<4G"/FIE1=2=95R>B6FHZ9:SM_6- O_I]6L7+,
MZM)M.CIR?!G<#2M:TO6K"S&F7H7;=$_=:;5>:,CD>H]+6I[0Y%
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MK_+ZP Y         !4WB#_?&;P?_ #3MO_\ HKE2$\3R/^[7[<RV04\8
M                                            19WL?HLYD_NY#^[]
M'$95Q/;^IC^S3_AD'@7\Q*$4Q        "!/$L_1'O\ _MMO?=9@1E\'Z$IL
M(?B7Q%^3&POO5I0+@67XGZF4!3$
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MW+2?_>VVDO5JIUHW1\C7S);6Z_BZ!>S;AQ_3-7:^E*5)A6CN)P5?O0G9V6[
MN'M@DFP5.N:F.*=)?-YG1I4^A2C7SRT(N4]1S'([SVGJ4E'(ZAE+DWP2N13^
MNAH77>U/<K;/5_C^A:IE5"O5UY>XJ4XUP?"C]AEYJ2R^@EL/,/I4DEH4RZAQ
M*TF1&2DJ09D9&D^0^P.1PN6[BK;E&2\FG]AP.=JY:ETW(RC).F*:^T]W./TN
MQKK_ *_](RQK0\95YN+XMVUK:_F"Y<*Y-5>35TVQ$I,F:]2*(4^"X=8I;54B
MM-K)]"TJ)J0V2C46A<XS[!&-4Z]W;T;0-:OZ+?RN;NW<NXJ4X1BXN4H*=%5I
MX*25?,[F]I_D8[T=Y=A93N'LY9"6BYR=R,%=N]$U\*X[<FU1KC&5$N5.+*J+
M$XL>UFV-_P!GW<W,D7:[862L'XPQQ;[#5)2JK)K5EU2?*GOS(RG22S$DLO(Z
M,^<9I/77LEIZI]\MO*RIK(ZA\9MX4AP7C2N%</K-C1_ED_,B[G1+_"O@=*?]
M\ZIX55:4=,>"QP+C]GW$IP-O7OB[;#Q+$NEFJ6?:S=VU&378+,2&[37*O%HW
M1L+;><7VRB1,;4:3+0DJ[(Y'L[N5IV\=2N:9ELKF<O>A8E=K<Z:2C&4(.G2W
MXW(FE>_?RB=S/EWVYD=S;YGDI9//YUY:W&S-RDKBM2NUDFDNGIC))I\46&$>
MO+Z'U2T&R3JL<@                                             "
M+.]C]%G,G]W(?W?HXC*N)[?U,?V:?\,@\"_F)0BF(        0)XEGZ(]_\
M]MM[[K,",O@_0E-A#\2^(OR8V%]ZM*!<"R_$_4R@*8@
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M0_$OB+\F-A?>K2A5P$OQ/U,H 0
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M<8M,[D/7'[0
M  .#+7^7I@ 1$78 #FE_+^7H@#CFEV.7_B '@XRT\GFNMH=3Z3B$.%ZBTF7*
M,)VK=S"Y&,EYI/[3.%R=MUA)Q?DVOL,=7AAS%%_MFW>N.K.N=.B2UK%OTV8Y
MHC3FD3KD?I2TT+_:] O2'H]0VMMS5?\ [1R.6NO^E;C7VI)G*]!W_O?:T^O;
MNK:ADW_X5^Y%>Q2I]1HN\6FP+1QQOMS!:^/K1AVG:D*-93L*BT&FNQZ5%?DV
M=179[D9II!M(.5-4MQ9%R<]9Z#J%O3*:?IF[=0T[(1A8R5J_%0@G113LVFZ)
MXT<G)^K=#^DSY&=T:[NWY:-!UK=&>GG=:N3S:E=O7%*Y*,<U=4%)MU?3"D5Y
M(K@-B4E)*5"GI29&:5J@RDI46G)H9M$2BY2Y2],<8Z[7\</]9?O.VZNV6Z*Y
M:;Y=<</K)$;<]J><-U==NRWL'6VY7[DLFUTWA4:8J;[SS'Z4=5AT@DT]^0J.
ME<DY4U.B><7.)*M.4A[#3=*SVMWY9/2K#S=^-N5QPATR:A%PBW1\7U3BJ+''
MR-4]V.]O;CLGIN1U3N1FUE=(U'._I;=SH^+&-Q6IW??45+W>F#QI@VO E-;U
MZ<3[8?4V3<;S-:%&HZCY]#N1,^X;,<U7R)6;ZI*5$2N4N8X1<T^QRC]4,]K^
MU[W]G/.:=?4^$E*,6U_1E6#7I1&E=5V_\FOS,9.2C+;^>U',+"]E^BQFUAX4
MZ?##%<?$L<P7](AN^D-PZ;N%P^FXE)7T4NOV'(CTQY#1%R/N4BH:+7(U_I(1
MR>D-E:/WEW#DUTZK:LYVSAC"EN;\WQ@=2^Y/\J;0<_*YG.U>OO*)JL;.=C*X
MF_X5=A@ER;Y%I>(.-OL3RI(C4^HWO6\8U62ZF.B'D.AOTEA;YI)7-9GL*DQW
M6CY2)?K4ZD-A:?WFVMF9=&?CF,HZ5;G'J@O)RA7[#I?OS^73\RNRK4\UE-.R
MVLY*$>IRR-Y76EPQ@^F2?EBRR2P<V8DRE&;EX[R-:%XL.D1H.AUJ%+</7T.A
M2[TQ*+T2-.HY]I>Z-O:W_P#96<R]Z7*,EU?3%T?U'43<_;O?6R[SL;KTG/Y"
MXO\ OK,X+VM4^LRAKR%H>OU=.S_P<H]^<-1Y
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M6BFEU0?I)8>TW5H>[-O[BMJYI.:MW9-?AK22]8O&IG8<7.1
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M[)'J6J::2NSR%V#T^J%/-BJY(]7R#WZ9\]6?,@+4?*:C5$U,S[*N1LB+4_J
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M&=M\'%IKZCZ8\!Y0
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M2M34A:&RYO(1\A#G^@]W-S9"4(:A.WJ&13HZI0NTX_WD?=<EA2L4J'4WN?\
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M>R=V%VU)53BTU]1V4?B/U
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M)9^B/?\ _;;>^ZS C+X/T)380_$OB+\F-A?>K2@7 LOQ/U,H"F(
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M>\
M            /4ZRV^VMIYM#K2RYJVW4)<;4GT24A9&E1?4/D&,HQG%PFDXM
M8IXI_090E*W)3@VIIX-.C7HS"&1=M&!LKP)M/OS$]C5U,^.[&>F/6Y2FZBA+
MR#0IUF<W%3(0\DE<BM3'%]4V3M;682CGLCEW.2IU1@H37FI12=38^T^[_<[9
M&:MYK;6N:EEG:FI**OW'!T=4G!RZ6O+ ISSCP -OM[.R9V)+OK6,)KJENMQ7
MT*J],2M9ZFVM!J)U37I:$1D-4:IV-BI.>@Y^=N'\%Z/6O125&O8SOUVX_FA]
MT]NPAEM]9#+ZSEXI)R3^%<]4^"?VE/F;N")O-PNI=5Q['A94A)-TWI=C5"32
M*NS'1JMMPXRW(TA\S)/*E!ZDHR&MM8[<[NTEN6;R<<S86/797Q/^2UU+UIAP
M.^W;G^8Q\OW<*F1W5*YHN8=*1SD(W;3EP:ZDI17'!OPJ1;M#<EOUV>UTH"KE
MS%:/O0I4#Q>O-JORZ&T<=23-M@J@V\SJ7-+11+41I/ZHXME=2U/2+M<AF<SD
MK\'PZI1H^3A-]/T)&Y]>[1_+)W[TQYE930,_\==?Q\H[$;SZO%]#3^BB=2U;
M 7TA>]+=@QJ1GS%_CHMKG=/<-K2X\"H&1J2:25!=0VVL^;KV4D-EZ)WAW1IT
M%;U2W:U"S7\55;N4\W^!G2?N?_*LV]JV9EGNV.L_X?&7X;&9C*</]=-M*OFR
MX[;YQ=]F>?*;%<5?J<8U^1(7&.V<A&S2Y:5$9$A29K2W8+A.F?)Z\C]/LC9V
MC=X]I:@U9U&5S(9NM.FZJQ?FKD:Q?TT9T"[I_(C\P/;#-SA_ACUG3(1ZOU&1
MK<BUX^XTIJGHT62T&Z;9NB&W/MJX:)<$)U*5-RJ-5(5384E:>>G^MAOO)(^:
M?8,]1L[*ZAD,]!7,E>M78-5]R<9<<?!G4?4M%UC1;SRNL97,97,1='&[;G;>
M&'":1^ZI5:E4:-VY6*G3Z5$YY-=M5*9'@1ND42C2WT\IQIKGJ))F1:ZF1&/-
M>S&7RT/B9B<+=NM*R:BJ^KH?FRF1SNH7?T^0LW;]^E>FW"4Y4YTBFZ%*/T@"
M\;6KG!VWT4.WZ];MRUJLXRMRETZCTFJTVL5*0[/RC8414J%384QR7)=I:'SE
M?U:5*1T/.(CTT'YHZKI4YJ$<UENI\/[6'_6/:3VMNF$'<>EZBTEX9:\WCY*'
M[8EM]MY)QV= H""OZRC5[R4H^:5U4/715/84D^:<[G:*3RE]08?XQI'4X_J\
MLVN5V'_6,EM/=;BI_P"%ZBHOGEKR]ON<5X\F9(C2HTUAJ5#D,2XSZ"<8DQG6
MWV'FU<J7&GFE+;<0HNP9&9&/WV[EN[!7+4E*#54TTTUY-8'H[UF]E[LK&8A*
MW>BZ.,DXR3Y-.C3]3WC,\8    !%'>\9EM>ROIKH=%C$K3TO?2$9:_4YQ$(^
M!5Q/W?J8Z_\ DT_X9!X%_,2@%,0        @3Q+/T1[_ /[;;WW68$9?!^A*
M;"'XE\1?DQL+[U:4"X%E^)^IE 4Q                       "L[B 6F[?
MMZ;5[)9K]2M1VYLL*I;=R45Y3%7HRG*/.7V[ >2:3:?1S-"/4N0QNGM/J$=*
MTW7=3E:A?C8R'4[<U6,Z3CA)<C4W<S(/5,]HNG1NW+#O:AT_$MNDX?V5QUB^
M>%/0P7G38M=6*+?<W"43-][Y/K^$6W,AQK/R8^=9H%99ME2*J_#:8>>>CQ9C
MC$97,<-.NNG*.4;7[HY'7LY_NEF=,RV1RFIM9=W<LNBY#XGNIMI)M)M553B^
MYNVV<T7+?[VY;4LWG<WI<7F(V,Q)2M7/A>]TT>"DTFE+P=.!(3=A?L#+FPY[
M($6*J- O:D6O5%P'#YQ,*ES4-3(G2=E2&GTN)(_]I)<O*.([!TJ[M_NG_A,Y
M=5W+7+L>I>-(X/UI1^IRO?&H6M<[:RU*$4K.8M6Y4_K-55>7%>A.O'5OT:V;
M&M&C4*FPJ73:?;]*:C184=N.RWK!9-Q24-I27.>6HU*/LJ,]3&KM8S>9SNJ9
MC,9J<IWIWI-MNK_$Z+Z#9&F9>SE,A9R^7C&%F-N*2BJ)8+@5_P"QS0\X[S",
MN0\JODK70R,NV)FI'KV2Y1MGNA_[,;<_]!7V(UCVZI_O!N#G_B#^PZ+M3OU.
M"L\[X,(7.\ZS1K)J%0SK;*9#ILP8MIU5EVH/PJ>VLR:;)YJ2TOF([!D?(/:;
M\TI[IVKMC<V22>8S48Y&Y1>\[L6HIRIBZ--59ZG8NJ_[O[LW-M;.N7PLM<_7
M6Z\%9NIMJ/@J23=%S\SQI,^>7#^S%G2$IRDW1GER[LG5)^,1MRHT.XKGF-0(
MI/IT4:$4GD29&9=&[H7(&8MVGW9T[:]RES):4K66BGP;MVUU.G];ZT>;*9F<
M^U^=W/9ZK69U.-W--K\25R3<%7RC3Z'0E=L/I%%A;2L.MTR-$-BH6W(F3U(9
M:,IDZ55:@<QZ4HD_\X=<7R&:M3,BT' NZ>8S-W?VHN\Y=<+R4<7A%1CTI<D<
MR[;6<O:V-IT;"71++INE,7)MR;YMOCXF&]OL6/2,][\*#1B.+0(U;@SH].BH
M-FF0ZG4+18D5$HT=LDQV'5R'%&HD)+4<DW9.>8VKM7-9GWLT[;BY/&3C&ZU&
MKXM42I4]'MB,;.Y-RY>Q[N75^,E%81C*5B+E1<$VW5T\:LZ]P_/T3<P_E S#
MR?\ P'A>J0_9W;_]O=-_]$RG_/9^+M=_[%Y[_P!,SABG:TU2'^&WD5BN7"Q:
M\!RKWRE56D&KHTOIF0W8T3FH/GJ549"28(B]%SEY",>]WS+,P[S9.>5LN_=5
MNS[JY=+3?^BL?H/2[$C8?:2_',78V;3G?K)\/QX+Z>'TF)J)N6NJY]K;6UZA
M[8\F%?MST<[6HL]FVGV+/G1YE0YZ;G.JJC)CL$RUHL^>HM221Z^@/?YK960R
M&^'OC,ZWDGI5BY\6<7<3O1:C_=]%:NO##V'H\OO3/ZAM#_<RQHF?CJ]ZU\*#
M^$U8:D_[WXE.E)+WL27F8\85C#G#*R'CVX)[=1J]OXO-J<^R2NC3(>K%-D.,
M)YYFI9QS<-)GV#T&OMN:WEMQ=[<GJ^3BX9>[GO=3Y*$E7Z>)S7<^CW] [+Y[
M2<S/XE^SILDY<W@=*N)Q]'"HLUEA)K8FV9C^#42YW-3[V3+YIC,\G3U+^I4P
MLR478T,]1[+)J/\ QWS,Y83CF;\H_P!:-B3C3SKP/RYA-]E<M;6-N64R\9<N
MF5R"E]%&ZDXYUJ6Q&VO5"W8=&I*;?+$,LVZ<W%C.4]256PY(Z8T=&;*E\\^D
MY_\ 2)7*1ZEJ-86\_G9[YAF[MVY^K_Q!>]5]7][2G&OE3@;)GD\HMIRRD+</
MTOZ)KIHNFGP^7 K'VV5"90.'?GV3126VZRQ<$-E4<U:M19;BX4HT&V?.YB(C
MZR/TDC=F\[5O-]WM)AF<4Y6WCS2JOK7M-/[.G+*=J-1EE,.F%U)KE5K#Z,/0
MS?@C#F\>%B:Q/$+/^*Z-:3]&BSJ126[%=FH9C2#Z0V7I3*$H><YVI.&6OKM2
M] <9W3N/MU=U_-+5=)SUS/JXXSD[RC5K"J3>"Y'(=MZ#OVSHN5CI^IY&.2^&
MG&*L55'C2J^LD7LSVVWGMJM"^;?O2]Z/>TZ\+]K%[-R*'2Y-'@0#K#JGWXC4
M&0M26C):NRC1)D1#AW<C>>F;TU#*YO3<M<RUK+Y6%FER2G)]"HFY+C])R7M[
MM'4MH:;F<GJ>:MYN_F,Y=O\ 5"'1&/Q).72HU:5*TPXTJ3,&NCGX
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MN/Z#,PAFVE6U-J,T_P"''!M>1+G4:_.<C4/L U+^7U] !R
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M[IN=BXYJS-QDOO\ 1K%';/3\]E]2R=O/922EE[L%*+7)G;!^$_8
M
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M/7;DI0?BL3]>H\9F<@
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M#]"4V$/Q+XB_)C87WJTH%P++\3]3* IB
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M'TW$U+DS8$91FJP::/?KJ(4
M                            XT[/U?3#B#D0 4        !%G>Q^BSF3
M^[D/[OT<1E7$]OZF/[-/^&0>!?S$H13$        ($\2S]$>_P#^VV]]UF!&
M7P?H2FPA^)?$7Y,;"^]6E N!9?B?J90%,0
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M#4E23+L&1C@,HR@W&::?FCG$91DJQ::/:(4
M                                                (L[V/T6<R?W<
MA_=^CB,JXGM_4Q_9I_PR#P+^8E"*8@       ! GB6?HCW__ &VWONLP(R^#
M]"4V$/Q+XB_)C87WJTH%P++\3]3* IB
M                                               !4OQT?]T]O8_(
MY6O_ 'K'$Y&4?'T?V$V-F_Z(>U;_ ,V_!W_1C:XI)?B?J20 @    !QH7I$
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M4
M         (L[V/T6<R?W<A_=^CB,JXGM_4Q_9I_PR#P+^8E"*8@   _GT_E_
MQ     @3Q+/T1[__ +;;WW68$9?!^A*;"'XE\1?DQL+[U:4"X%E^)^IE 4Q
M
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M<:6EQM9>FE:#-*B^L8X9*,H2Z9IJ7)G+$U)5BZH]@A0
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MP*ON)2822I&&<2(6DTJ3C*PTJ29:&1E:U*(R,O0,C!<"R_$_4R>*8@
M
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M:<@
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M1V_CVSIAQ*7D)IJ&T<R@0):F6&95$F&TRTX^HD))1DE.A=@BT>9:M.BYG?\
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M 40ZF.K#&\NFXOYQ('X,!1#J8ZL,;RZ;B_G$@?@P%$.ICJPQO+IN+^<2!^#
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MM*$7 LOQ/U,H"F(
M
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M^OZ/K^7_ %.D9BW?M>/2\57FN*^DRB/1GN
M                     (L[V/T6<Q_W<A_=^CB,JXGM_4Q_9I_PR#P+^8E"
M*8@       ! GB6?HCW_ /VVWONLP(R^#]"4V$/Q+XB_)C87WJTH%P++\3]3
M* IB
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M582BUY-'[]?1+E+Z@\1F-?Y?Z !R
M      BSO8_19S)_=R']WZ.(RKB>W]3']FG_  R#P+^8E"*8@       ! GB
M6?HCW_\ VVWONLP(R^#]"4V$/Q+XB_)C87WJTH%P++\3]3* IB
M
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MT)380_$OB+\F-A?>K2@7 LOQ/U,H"F(
M
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M",O@_0E-A#\2^(OR8V%]ZM*!<"R_$_4R@*8@
M
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M6E N!9?B?J90%,0
M
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ME^)^IE 4Q
M
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MO&8S%_-WYYK,R<[]R3E*3Q;;Q;9OZS9M9>U&Q8BH6()**6"27!)'U!X3R@
M  $6=['Z+.9/[N0_N_1Q&5<3V_J8_LT_X9!X%_,2A%,0        @3Q+/T1[
M_P#[;;WW68$9?!^A*;"'XE\1?DQL+[U:4"X%E^)^IE 4Q
M
M
M                       "FOZ0;+1#X,V_]:VS>*1AJ)3DIYNJ6W*O?EG4
MMF2X9DHFV8CLPG5K/0D(0:C,B3J3B588^3^PMYMO_P 'Z#R\A4:EEZ'+_P Q
M8Y/YO]0!\3[8$       BSO8_19S)_=R']WZ.(RKB>W]3']FG_#(/ OYB4(I
MB        $">)9^B/?\ _;;>^ZS C+X/T)380_$OB+\F-A?>K2@7 LOQ/U,H
M"F(
M
M                                         4\<?]M"^#5Q!R6E#A%@
M>:X1+2E9$XU<]MNMN$E9*(EM.I)25=E*B(RY2(P*N/T/["VNV_\ P?H/8Y:-
M3#_^86=-/J?Z"^KV0(?<        19WL?HLYD_NY#^[]'$95Q/;^IC^S3_AD
M'@7\Q*$4Q   #@CUT^KZ  Y   0(XEAD6T>_2/\ VIUO)+ZI^^C2]/L4F?\
M,(^!>?H2GPA^)?$7Y,;"^]:E"K@)?B?J90 @
M
M
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M^*$GV?\ L#5]4"^#]"5&$?Q,8C]#_P")E8?WK4H!+BS* &(
M
M
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M/?\ _;;>^ZS C'/T)380_$OB+\F-A?>M2A467XGZF4 (
M
M
M                                  19WL?HLYC_ +N0_O@HXCX%7$]O
MZF/[-/\ AD'@7\Q*$4Q        "!/$L_1'O_P#MMO?=9@1E\'Z$IL(?B7Q%
M^3&POO5I0+@67XGZF4!3$
M
M
M           BSO8_19S)_=R']WZ.(RKB>W]3']FG_#(/ OYB4(IB
M$">)9^B/?_\ ;;>^ZS C+X/T)380_$OB+\F-A?>K2@7 LOQ/U,H"F(
M
M
M                                           !%G>Q^BSF3^[D/[OT
M<1E7$]OZF/[-/^&0>!?S$H13$        ($\2S]$>_\ ^VV]]UF!&7P?H2FP
MA^)?$7Y,;"^]6E N!9?B?J90%,0
M
M
M                "+.]C]%G,G]W(?W?HXC*N)[?U,?V:?\ #(/ OYB4(IB
M       $">)9^B/?_P#;;>^ZS C+X/T)380_$OB+\F-A?>K2@7 LOQ/U,H"F
M(
M
M                                                  !%G>Q^BSF3
M^[D/[OT<1E7$]OZF/[-/^&0>!?S$H13$        ($\2S]$>_P#^VV]]UF!&
M7P?H2FPA^)?$7Y,;"^]6E N!9?B?J90%,0
M
M
M                       "+.]C]%G,G]W(?W?HXC*N)[?U,?V:?\,@\"_F
M)0BF(        0)XEGZ(]_\ ]MM[[K,",O@_0E-A#\2^(OR8V%]ZM*!<"R_$
M_4R@*8@
M
M                                                        $6=[
M'Z+.9/[N0_N_1Q&5<3V_J8_LT_X9!X%_,2A%,0        @3Q+/T1[__ +;;
MWW68$9?!^A*;"'XE\1?DQL+[U:4"X%E^)^IE 4Q
M
M
M                             (L[V/T6<R?W<A_=^CB,JXGM_4Q_9I_P
MR#P+^8E"*8@       ! GB6?HCW_ /VVWONLP(R^#]"4V$/Q+XB_)C87WJTH
M%P++\3]3* IB
M
M
M  19WL?HLYD_NY#^[]'$95Q/;^IC^S3_ (9!X%_,2A%,0        @3Q+/T1
M[_\ [;;WW68$9?!^A*;"'XE\1?DQL+[U:4"X%E^)^IE 4Q
M
M
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M ,[B7[55?< H*KD.ISN_\[B7[55?< H*KD.ISN_\[B7[55?< H*KD.ISN_\
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M"@JN0ZG.[_SN)?M55]P"@JN0ZG.[_P [B7[55?< H*KD.ISN_P#.XE^U57W
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M3[6L^V[=FR8A.%%?ET:CPZ=(=C=*E#G:ZW8YFCG)29ITU(NP!&=W
M                              88MC'-8H>:<HY(DS:>[1[XH=DTNFPF
M>G.HQ7[:A2(TMV9SV4L$T^IXNCYJU'H7*1 *\^",S%ZG\OYP!R
M                          ,,;A,=5G+.&L@XZM^73H-7NV@R*3!EU8WR
MIS#SYM&3DDXS$A\FTDD^5"%*(]- \2KZ3(-E463;=FVE;LUUE^90+9H-%EO1
M^?VN])I=+BP7W6.D2ESH7'6#-/.(CYIEJ!*UQ9V8
M                <'_+L_\   ,14;'U6IV:+TR2]-@KH]R6?;5O0X#?;'OB
MQ+HLF4[)>D<YHHQ1W4NES.:LU&?9(@+7"AEX"
M              8)W,XPKF:<$9,Q7;DZGTRLWM;QT6#4*L;Y4^*MR=#>==D*
MBM/R4F4=A?,-"><2^;H:>R3$84QK^R,VQ6U,QX[*S)2F6&FU*21I0I3;:4*-
M*3Y229ER:AY@_2
M
M
M                                           "OK>KQ,-LNQ*J61:N
M7JA==>R%D5B7.M'&F.*"FZKWJ=(@N]KR:TJE*FT]J+2DRB4TEQQU/2.(4E!*
M-*M(W0R46QLGXEFV[??-OF@8D?NZW+XQSV@]=6/,DT-FUKT@TZI])VA6$4E$
M^H)DTJ3T?(\AQ1)-1$K0S"J#BUCQ+!==?Y=D4Q
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M'31*BBLT=+*Y)%#1,G).,XU(0IM7/U4D^4B -4Q\";9'J6H$.0
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MZ1,J,9LDM'482#027].<71D9F?*#P=2K&&/G]QL<C(\8
M                  !P?9+ET[/IZ=CU !J:<:NX+YWS\0G:=P?\?%%^2RM1
M*-G[=D_!H4%ZL)MUJHU--$HYUU^++D4V/*I,%3[B6R3TW2I-?.YB.;'QH9Q3
MI^W[<3:8QQC^UL46#9N,[(IK='M"P[;I%J6W3&M.9#H]$A,P(3.J222EDRR1
MJ/0N<HS/T13%NKJSN@$                                &6O(8 AGN
M^V*X5WPP\>T#/4_(E1L.P:_*N&3C:U[RE6K9>09,A,-+4'(T.G1??2OTJ'VI
MJTPS+B:&ZO4SUY#5<"IT*H_HT%"HEK;*=S%LVW3(M%MRWN)'O)H=!HT(EE%I
M5%I-RVU I=.C=(I3G:\*$PAI)J49\U):F)S?A_D+)4=%^V+/G;Z)]V\2#B.6
MAPM&Z5496SK%=DTW,V\>Z+;(FISEVO0I]2QOCN3<!)DLT^/46W6DR(W-YQKE
M$IPCZ-)%'BZ&2]V->9[_ *-G:M LC;#N@M2TJ(Q;]JV[O,RG0[>I,9DV8\&G
M4RE6RS'CD9)22UH;4DUGIJ:C,S[(J>'TB:472/ V,2['_5_X>744\9R
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M%''=J-P6]4B34)\UY:N9TZ.?H\GG/*2HT$HN-627X?V\/O-O@9&
M          :^NY%G<WL'XG=Y[V<7;4<S;RMNV\'#EA8YS1;>W:C4VZ,SX?R)
MAF*NFVM7:;9]6J]O4VNVA<]N*90XXY-94U*0Z1J3HV2YP=?V_;]O7*M8T_;]
ML3ZFTK'>XC>SQ!5\1S/^W/(>T7&&%,7U##>W3#F9HE-I^:[LJUS*-Z\[\OJ@
MTV95(EMT:"G^KI[:7UJ?6X1I4M+2U*>-? -TC3Q_;]Q?L*8@
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MTFTV*8                  !QH7\O1^OZ@ <TOJ_7UY0!R
M                       .-"UU #0O4['U/^$ <]@
M                   <<TO].O\ HT_U !I_+0OK>EZ0 :%Z/+_+ZF@ XYI?
MZ_\ 3_I+D 'D                                 XTU_E_J]( -"_F]
M+^7* &G\_P!< <<TN734M3UY# ')$1=@ <@
M       .-"]7U/4[  <TB['( &A?5]4P T(M/J?R^L .0
M
M
M
M
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M!;DB?;;UO-UZJ6[I4ZZR]T=/GN5*CO$EI39^LYJC,B40C>)DHMKS)OBF(
M
M
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MR,W(<I]19U/HIL-;AMNIU/1:3%(?6
M
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M24TXDRTYR#T,RT,[Q,6NET,K 0
M
M                                     "H/B[<*.@\5:Q\!V=7,G5+&
M7R&9<9RC$ET^ 50*LK*/$B2*:\V;B":-<>,9)7H9I-9F6AD1B/' L6EQYELM
M!I?O)0J-12>.05(I5/I92%ZDMY,"(S$)U1:\BG":U/E[)BD(K[V]DN$=_&"K
MAP)G6A^^=M5E*GZ?4HR6O?6W:J2?ZJJ4MUTC)#R%)+G%J7.(M-2T$=? R3H\
M<4S6MM'Z)I0&KCH]M91WSYLR1MLHM8.H,85E*<A1GX3;QNQ*:[-5*D(Z!A&C
M1Z\_G([.NN@N%:BN%,:<O#]Y=AO%X1>W_=+LWL#:!;]1K^%:+AB=3JYAB[K&
MDKBUBS*_3*?-II37>@7%]\$U&+/=*1J9*-1I47]'FG&N15-XU\?VP(&;(OH]
M<?;UN1L/<;N-W57[NJJN)&93F,K7O",I%#HE8=@O4Z'6);<AYSMJ738\A:FC
MYNO2&6IZ:@E[ YU7%U)K<6OA&8VXIN.K4I-6OROX@RKCF:4_'N4;92:ZG1'#
MD)DN,JZ)V/*0@U<[F.-N$I'2*Y#UY%'7 B:I1DF.'GL\JVQS;=;6!ZUEFY\T
M5.B27IDR^;L?D/U2HR'V6&5ZG)>?=2VDHZ="YW\Q"T1&ZDUJK2X-:IE1HU3C
M-S*95X$REU&(ZDE-2H,^.Y$EQW4]A3;\=U2#+TC$(:@^0_HHM.I=_P!V5K:E
MOFS%MSQY=TZ;.DXXHR7Y%*IYSWG'7F81LS4M$VE+RD$9(0:DD6NAZ@957%57
MHS8.X>W#MP/PX\+QL488I\B1.J*(<Z^[UJYH=KEZ7(TP:9E9J#Q)Z1LIDIUQ
MXT&I9FM9J4I1Z:$1NN'@:5/"/X,N/N)#M8RQFBQL\7WMTS[:>Z3*%#5?=@..
M$BK4./<,N73XU699EQ7E&2'%DDS)Q*D\FGI2G#]O SP2;\6WP]3;OX5G"?Q)
MPQ<;7)3J#7ZIE'-V3IZZSF7-US%TEP7S5>W94J/H;RER(5/82\@C:Z0^D<02
ME=A))R,&ZX8T(1[^/H^EO[GMS]5W<;=-R5[[3\K7I#A1\EHM*&B;0;QETYKH
M(U6>B$MOM:>MDB2Z9)_K#+4S+301KD6,J8NM?(EAPT>$E2=@U<NS)5W9TO[<
M#F2\H;E+J%VW;)?;I\&EJ-HDQX4!R0^MQQ2&4D:S-!)+4B29GJ"5"RFVJ>!V
MSA;<+N@\-!O=*U0LD5+(:-RV;7<PR_?&"4,[=<5#EQ4TEH^E=.01G-4HU?4(
MBY-"*XF,FGPKQJ1XXE7!%I&]K/%M;H\,9[NW:YGMJW7+(O\ O&T&G'47_9K$
M>"W1Z=5&67&E%(I+D%/,6>O.0>G)IZZ-5,HRHN3\C'>Q_P"CZ6)LXW>8OWH/
M;AK_ ,J99LVTKNMFYW[I84;%RE<])F4LG&G#FNKCM1"F*<(E)U-1Z=@BU)4P
M\R2DGC3WJ4,W\7C@MV'Q26\977$RK<^!<SXHE.>+63K1Z;WP*DOD\3M.<*-)
MC/M*2<ASF.H7JDE&G33E($UP=?H/7=/!KB7CAKAS8SN3/MW7!7.'YN3L7<-2
M;NK3#LV;D"9:-3BU%ZAU1;\IUZ*U*.+S6U:KYG/5V 2*Y)NKYHM=W!X7MS<1
MA'*N#KM-3=OY3L.Z;'J,E#:7G835RT6;2??!EM1I2I^"J7TJ"/352"!K Q3H
MZE8_!SX/&/N$IC.^;.M^]Y&3KIONL(EU.]9].;ITTJ3'<<=B4A+*"YI--.*2
MH]-",TIY/6D%*NI6U3ICP.B<4'@3X)XBE[4G.5$OJZ-OVY.B(A18V6K',TRJ
MA @LMQH[%5C,NQ7'W&664))?.42D)YJDGR&5(J>/^4Q7L?X!C.W//=B;CL^[
MM,J[E+]Q=*3/L&F5AQ5'MJDU./ZV%4ID5#ZSJ$B.CT#;1KRI-1HU(\>GEP,W
M.J\:^9L5D,CQFM[Q*/H]EK[VMSK^[G#FY&_-KF8;@HM+HM]U"S&EKB74BDQS
MAQ9KW02&5-2CB)02^<A?.4G74B/0I3V&75PXIKD>.UWZ.QB[;!N'VT[F*+F^
M\;MR9AB'6Y.0*Y<C"I,[*5T5:JP*FFJRWSDJ5$BL=HDV32C5HGL<BC22A>M<
ML:';>(+P%[?W6[DY&[;;YN$O7:GFJ[J)XMY:JEHI==IN0J2VB&B,N6S&>9<9
MF(*&1KYQ.$I9FHC+4R$H%*G.OD?*V'_1\<=;'-Z%B;UJ1GJ^<D9#HE@7K:%X
MLW9'Z0KGFWG0U4=^H(DJF2%,-PUJZ5)&1&?8T(5*F'@').KQZF8Q^E%4+%&6
M]IF#]M%4JT3Y?LY;CL5VC@^VX[L?WZJ,NJW13X%8DDVO5V/ Z-26B69<U:C5
MIKS%Z,5B$JQ:?# N?Q_LLQ?3MB]+V47!0^U<>UG"J<97E3J2]VD^;E;MY$&X
MI,23',B:F-5!U:VEIY"4VDSU+4@IA0.7O=2_9&O?2_HN%737:39US[^\RW3M
MDA72S5Y^')Z7S54Z%&EH?8H#TUV6^T<<F4=&>IFGFJ/4C[!SI*Y+SH;8]GVE
M;UA6K;UE6E2XU%MFUJ1!H="I,1!(C4^F4YA$:)&92780VTV1?5&1XVZXOB=D
M
M
M                             !P?*6GJ_6]'_0 .BV!B_&V*:9,HF,<?
M63CJC5"HR:O.I-BVM1+3ILRJS%FY*J4J#0H,"-(GR5J,W'EI-Q9GRF8%;;XG
M>P(                         /Y?R[( QY=6),6WU<-KW;>V-[#N^Z;(F
MLU*S+CN>TJ#7JY:E1C.G(C3[<JM4@2IU$F1Y!](AV,MM:%^N(R/E M6E1&0B
M+0NR9_7/4"'(
M
M
M
5                        #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tv523241_chrt-line5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_chrt-line5.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#:@.$ P$1  (1 0,1 ?_$ 0L  0 !! (# 0
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M)!87HK+2D[.T&<)S@S14)355-QA$=)1E=39&_]H # ,!  (1 Q$ /P#?X
M
M
M
M
M
M
M
M
M
M                     !;WSM8L\L?-V>2L?^< TK6FQ?+*W/+)2&C(G%E;
M'RE\MFEO4N(^PT+4A"=27%I5:P.Y56JTRATRHUJM5&!2*/2(,JIU6JU29'I]
M-IE-@L+E3JA4)TMQF+"A0XK2W'775I;;;2:E&1$9E)&W#>=<I>1;!KMFHR)1
M+WL^L8_=A2:DU?-,N:C3K.<IT)QYF9/1<T68[13A1'X[B'7>WX&U(42C(TF0
M/#:%B6XB[J-L<Z2U"@[C,#S)C[I,L1(N8,>R)+SIF1);989N%;KCAF>G"1:Z
MA5$],N#+Z,R&9#+<B.XV^P\VAUAYEQ#K3S:TDI#C;K9K;6VM)ZDHC,C+I C[
M2W=YYFQ#CB;&IV0LJ8WL2H34)7#@WG?5K6O,EH</A0N+%KE5@OR$+5T$:4GJ
M?4!-)/8COE/J=/JT*)4J5.AU.FSV&Y4&HT^4Q-@3(SR26S(BRXSCK$AAY!ZI
M6A1I41:D8$'O
M
M
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M9:993P*0DB05I*F/-E8O#U(R#S78W.'Y %U;<-Q]Y\SK(7,HVBY$W#X]PSN
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M\$VWNAV[7#G"EJX:GANAYLQK5LJTY7#!7PS\>0+FD7=#5P5.,>CD-/1(:/\
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M%58R77&%2*;5Z5(E4^<PE]I:#6TXI)+29:ZD84IM!9[-.Z_:UMM726MQ.Y3
M. W*\2E4-O-.8\=XL76DH[7B.DHOFXZ$JHDGL%Z]CQZ<"O8,*;]P+TT.NT2Y
MJ3 K]MUBE7!0JK'1+I=:H=0B5:DU*(YJ2)4"I0'I$.9'7H>BVUJ2>G6%*8,%
MA\F;Q-HV%;UH^-<R;IMN6)<C7"Y!9H%@9,S?C.P[UKCU3=BL4UJCVK=-STJN
MU-RH/364,)986;JGD$G4U)UFC!>JMU%J1:-7JU)G-OL/6Y/J--J5/DI=:>:<
MICLF'.@S(RU(<;<0I+C3K:C(R,E)/J,%M(>PUMOL\6^BGM\G#%.?-^^\* Q5
MJSF+-5NOYGW<Y_BQY]4*G7W(@46ANY#S%=C;\WO&.I#,:,<M79H-*$)(C(A+
M6"]'WL+:S9-M:Z[6OBWZ7=EE7)0+PM6N1^_*+<MK5BG7!;]8B=HMGOJEUFDR
M9=.J$?M6E)XVG%IXDF6NI&*[-I):O-.Y_;3MNB4N?N)W#X,P)!KDA,.BS<TY
M:L'%L2L2UM2WD1:7)OFX*$S4)"V:>^LD-&M1I8</31"M'/<"Y=EWQ9>2+9I%
MZX\N^U[]LVX(;-0H%VV7<%)NFV:Y D(2XQ.I%>H<N=2JE#?;42D.LNK0I)D9
M&9!2FT': !"%S'\_Y-RUNYVC\J';;D:Y<:7SG8Y>XG=QE#'-T5.T\CXDV88G
MK,956IMG7;:]<H]VV'>>>;VCLVS K$%:9,*(<I3:D*=0ZBR2I5_3Z?Q(?!$M
M5;S3A6R\AV/A2Z,OXTMK+F0J36JICG%=S9$MFFY.OZC6G3)U5N6K6A9M8K+5
MW7?!MZD4F5*J$J)'DIC,1G77UI2A:BJ2=(QON_VEYDOJMXOQ#NBVZY5R7;,B
MH1;DQWC?-F-+XOJWY5(?E1JK&K=I6Q<U4K])D4R3!?;D(?CMJ96RM*R2:%$4
MT8,BA    #2E^T/<V?<=%OZB[:]B-Y9)QWCO;CN'P7:F]'<IC"ZI]GD64<E5
M"9,L?;%;EY6Z_'K"JA$HM&FU*ZXT26PLN!J%)2;:9#3MTL/I]/IS(WFTAS!M
MP>5-K6SC.^<L&84OS<1F:S;2::Q9A[&]EW3D"Y[MOJY:S2[5MQ7DM9E,J]Q3
M[?MZH5M%4JYL,ZM4F%(7Q(TXBJJ;]A)K-6WR@?M!&X>R+;W59/YXF8<"[CKF
MI-#R/3=KUI4/(=NX:LZJ3N]+OIF/;U@6CE&SK%BO4:;47:;5H2[&K40T1BC/
M*FL="9>WZ?1D;B3?D;;Y,^<Q;9UN#Q1O$7*H.Z';!E[)6SW.F0L:5)%E5&Z:
MQ1J05.+(=LU6S#IK%G7W%5,DL.2Z,45AJI0$SX2(R7FV&35,>?V!8EV>47ND
MR=<KNYKE][HKQE7KNRY=^2HV,Z[?M=EU"5<^=\ 71 37MOV?*[*JS;,NJW1=
M=GK3%K\A!+2NIQN^%JUF)U26];/I]/:$^),^*D@
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MDFQSE'F"[6.6/R?-EV%N6YGREY&JFZ%FZ,,;#\P[G[DI.,*-3*=,R'5T9)W
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M+BQS)M+T=33G"X;;[K93^7Z<?]HWFR\*D@
M !"!MSY8N6\.<US=!OVKF0+'J>.LX1GF[>M&FKK9W72EOMOMFW5VY5,8I:$M
M(=_A-2'=3(NC0115QWEW)=/3C7 ^9SUN3A1^;G@&S+<M6Y;:QMN#Q)<$JK8M
MR1<<28]2&Z17DQ6KLM"XW:1&E5A5&K*8,=YI32'3CR&.(D&3B]95=Q1T>#/D
M;>^55F?%W(T1RO+DR#C]>8%XXO\ LYR_*0]<$JP&JA=.4J[?D%YIV1285?5
M;@U)MAQ1PR<2KBT09%TU=>DNG'JKC1&5'*0V.7ML%V&8XVG9:K]H7Y<=I/W0
MFM5.V"GS+8JD&O2B7WJEJN4^!)>97%,TNMNL<)I4:>DA+*[*+%T7K(\MJ/)
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MKM+)KA2\;Y-VV+Z?381O-ED5)
M                            #5QWB\F_F3V/O;SOOSY/>^RR=NE^;HH]
MK.YPQ%FZUV*Y858N.W(;M+7<-/K$^P,Q4E^(_$DN2HT&3:ZWX-0=DK:G$W)2
MW&M6J(H=OV+<F?>G+WF8VYBG-^WG4;=MN.P=;%9H6!<<8QHB+=PQBJJ5YFLT
MBIW1';B6EC>DU><[1:GVC3,6UZ.2:@I,B0Y+<BQ5-JX<Q0V7Q4D
M              (^>:%R_P"T.9KLRRAM*NR\ZKCAZ\%42OV=D*D02J[]EWY:
M51;J]KUR70E3J65PT9$MLV)\ I41<J$\ZAM]ATT/(E.A#->]_E=?:@KLMJ;M
MEO/G 8%I^UJI6[-L&=?=O6,V[GQZR7Z6["X.^8F![6O9-4E(<.*XXG(R9*8Q
MZE*7H38FOO5^X4PH;(G+XV-XFY<FTO%6TC#3]6J=J8W@U)^HW1<*VEW#>MX7
M+59=PW?=]:[W2F.Q)K5=J#JVHS1=C"B)9C-_Q;*1#=?0$C-(02
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M4U%J-UVC9%87,8BO$E]*X"$(<+1*UETB6ZI>C[R%O)@A!(
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M@
M
M
M
M
M
M                                               4,]"U]C[W^DR(
M 6JK^=L*6K6I]N7-EO&UO7!2U,)J=#K5ZV[3*M3E2H[4N,B=3IE19EQ%OQ7T
M.H)Q"34VHE%T'J&PLH2>Q'VK3REC2_'I$:Q\@67>$J(TEZ5%MFYZ+7),9E:C
M0AV0Q3ILAUEI2R,B4HB(S#:0TUM.]D9'TE]W=_=(""H
M
M
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MHJ[/I4GV$G& !Z#]*IDF2Q,DT^#(F1=3BRWXD=Z3&,S-1FP^XVIUD]3U]R9
M#WB+0M/N_< %0  $:_,<;UI^V][4M&MP-E(-.FIF;U5IRD*^\78&*LLG1>M$
ME L5
M
M                                                        =8 @
M4T_]$7_&[P_L=[BE=YR;_7]Y/6+G&        $;O,9_F;;K[>XBP2_8^4V!#
MV?3F3O7I7W$D0D@
M
M
M        ($M3^J'KW?KNZ_\ P;44_+ZB^_\ F^\GM%R@        1N<QG^9M
MNG]XFP?Z38$/83^9>E?:B2,20
M
M
M                  $"7]D/_&Y_)A3\OJ+;_P";[R>T7*@       !&YS&?
MYFVZ?WB;!_I-@0]A/YEZ5]J)(Q)
M
M
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M"I<N[;I=BOW%<3\-E+3E7K3T*-"B.5&:I/&X;;3:34?00L5;JZG:P(
M
M
M                                       ($O[(?^-S^3"GY?46W_S?
M>3VBY4        (W.8S_ #-MT_O$V#_2; A["?S+TK[421B2    BNV<EIS$
MN;5[=Y;/#/VS^KVYU]'L"%M99_A7K)41)4
M
M
M                    "!+^R'_C<_DPI^7U%M_\WWD]HN5        "-SF,
M_P S;=/[Q-@_TFP(>PG\R]*^U$D8D@ #CQ%UA]H(K]G2T_I$N;5H9'_YX[/"
M/0R/0_J]+,R/3J,B,1O9=KW5ZR5 E$?5W?N_<(*[BAR!.H D
M
M
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MVSI/<67UV>K+4\]/+=$LNK/P^FU*[UU5R=:T2I1;W4F#&VSP8
M
M
M                                  0)?V0_\;G\F%/R^HMO_F^\GM%R
MH        1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20 !^=[S&M2WW;LS[AYT
MOPC+H_\ XLZ>O3J/#7<N/<VIK?\ U/-_^\W3^K+Y3%7Y:.QUO_[M9+_V2,+-
M2/7HTZ#/HT^]W"(RZQTVP]#TIM-BC[.41^?[<,?%U8@HI:'KTFJ\X!D?WBT/
M]L;=\+?_ .VWO_\ &W?_ &V6/R@_NS-?^&':JIMUZ]_[I,V[1ZA/PE
M
M
M                                       ($O[(?^-S^3"GY?46W_S?
M>3VBY4 #U9<R- COS)LF/$AQFEO294IY$:-':;(S6Z](>4AEII!=:E&1$ /D
MT6Z[7N0WBMZY*!7E1N$Y":+6*=551R6?\6;Q0),CLB61='%IJ!-&MIV "  (
MW.8U_,^W0O\ \H:PU?LE4XWX1#V%ECCPH21B2H &A?OWVR[A;OWI[H;BMG#-
M_5R@U?-5\3Z75J=1C=A3X;U5=4U*BNJ=3VC#B3(TJTT,ND>'NY[&8AW/J=;5
MZO\ 4<T\+<VJ2S%R2=5%IIIIJCV,_II^6+S'XLT'Y>>S-*UCN#2\MJ5CMW)P
MN6IW:3A)6U6,E3"2WKU$>E]8QR#BZHQ*3D>SJ_9%2J,0YL*#<$+O21*A$X;2
MI+*>-1*:2XGA/IZ_V!T4E)3=N<91N))M2C*+QK1TDDZ.CQY'JGMKO3M;O3*7
M,]VEG\KJ63M7.B<[$^J,9TJHO#;3$V"OLZ=L7%%S#GFZ9%%J+-MS<64>EQ:V
MXPI-.DU$KOA/G$8?/H6\3+2U:$7\%)^P-N^%*S[KS$X5<(:?<4G3!.5ZPXIO
M95J,G3DS\L_[K^M:5F.P>V=&M9BS+5K>M7;DK*E6Y&V\K./4UN56E7BS;1'J
M$_#D
M
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M/3IT(3M*N,EBU@9-B2
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MIC:W^Q;;;-PSX4DG0BL\*K@_XD+&CY&^D*$@
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M\<>UC_GOVR)_+Z_X$;S>9$$@
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M?8E,,R8SS4B-(:;?CR&'$.L/L.H)QIYEULU-NM.MJ)25),R41ZD*DGE
M    !TS(N0['Q)8=X90R9=%'LG'U@6Y5[MO.[K@EH@T6W;<H4)ZH5:K5&4OH
M;CPXC"E&1$I:C(DI)2C(C U1;A^UDV?==V5^5M+Y:&\O=;@2T)2XEUYYM*C5
MBD4FF]XU"IIJ\]N@T3'M_P -JEL6_ 148RZE5J8^\AQ2'F8W9J6<T(KQ)O\
MEF\U[:9S6,7W%D/;57:_$K=A3X%)R;BR_:=$HF1+ GU1,TZ1)JM-@U&JP)M
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M;1CQ_DF[,=.N.W#$HENL3BJCUJJE)(H;79)>)L^(T\:H!G^
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MG?\ ^@-8".WU/[ ]GK7VF#?V5G_H.=HO_C_<C_SFLO P;#H@D
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M&^>GI_>VDYS3[\)4;N0]S;3\<:PQW8U:W%X>+V2T_;_![ R,P$Y@
M           XJ2E:5(6E*T+2:5H41*2I*BT4E23U)25$>AD?6 -/K?M]DJV\
M[I]]5B;BL0WI&P-@R_;GG7%NOQ!;E-[!VHSVR74W*QAA3+9TVU)E_5 CCU9A
MU'>L)QY4Z*@UFMA5JIXO:12FS8;6.#\'XHVW8HL?"&$+(H>.L78ZH<2WK1M&
MWHB8E/IE.B)T-2M-7ID^8\:GI4IY3DB5(<6ZZM;BU*.I)=8
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M_P#6&>03_P <>UC_ )[]LB?R^O\ @1O-YD02
M              &IA5,09<5]KHMS,J<4Y,5AYO9>_;KF64V#=BL9-UX\65UH
MJ.Y?Q4@[414C?6EKL3EDOME$WIVADD7W>K[R-_K^XVSQ0D
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M-]H/_P#6&>03_P <>UC_ )[]LB?R^O\ @1O-YD02
M
M   &C#]E _Z0KGD?\;UN?\MVY47EME_J_B5CL7H-YX4+
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MSQ/GI9/O'3,Q8M*4DKJ@Y6I)-JO4EA5*N.XR0T5IUGKT_L^Q]X9F:E.8
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M@       !&US&U**E[<D\/N#W!6.I2O84FJP"07LEJ2U?=U0R5]=22420
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M
M
M           ($O[(?^-S^3"GY?46W_S?>3VBY4XJUTZ/O]SN?? &MMFRC;E]
MT?.=S-M<MS>]N6VZ8<Q_M0Q)D:BVGA"Y*/;U.*Z*Y4:U'JU0J'?<)^9)=J*"
M1Q=FHS(T(U+A(Q&\Y%TJ%=K)B=HNV&^=LM#O&DWSNHSWNCFW56(%2@5G.UP1
M:].M2+ B.QU4JWCB1HR(T.<Z]VK^I&:EI3^*&PHVG^%8&8*3U+4]->[H)(*@
M"-WF,_S5MS21:FK<+8BB+HUT34HI*Z_^R(0R=Q)$)(     ,9]X%D1;^V\9)
MHLF.F0<>AR:Q&29:\$JF,NO-N$7LI0:OV#&:>/=3GI7=^2S,'2MU0?HD8KWM
MIUO5.U\WE;BJOA-I<TL"!7E8U]VB;LJ12R<[&-<UK7K3I*3,D]JY"8C28S!Z
M]TY,-"B+_K1ZH\YY2.:[!N7J5E9O69+DI-IOV.AY:\'YIY3OI979"]E[R?I@
MX8?55>@V@"+3]_\ ;,S'B)<SV><A(             #UY,9B4VIF3'9D,N)4
MEQIYM+K:DJ_A)4A:5$HC]@4N6[=V+A=BI1:I1I-?6<EJ[=L35RS*4)IUJFTU
M39L,%LT<M393GF=4:Q?V![3<N2I-*:?NFA,O6_7TFK3^/:GTQ;"B?0?22C(S
MU& ZGXQ[-U25R[+*_ OW,7*S*5MUXTBTJ\<#TCX^^;WYB?&>6M:?VOW+GEI-
MF2:RUYJ_8:X.%Q/#E5$$N[?D$WM:\RH7;M"N55PT;C;=8QW=U3<8K<!I+6KR
M*=<JTNN33)TC-!/$I6A\)&766G>Y_$.MZ?=E>T.F=TU[(.BO1PY^[-+U/9B?
MI=X+_N?=NZUE[6A>>,G^TU"C4L]EK:=F;K@YY=44<,&XT556A&#3-SO,,V'U
MXL=U&^,E8K<B/I?3:%VME/HE19A.=AVE.9J29,*7!41&7&R?4?3H9C7>2U37
M^W+LLII]_-Y&\G[UKJE!)XXNV_=>.%55/94]E9SPW\JWS,:9_P![,KIND:U&
M<&OW66?1>MN:ZJ7';Z9QGLPDMO%(E_VB<_Y4A]FU]W%M---+1JSD6RX*&5(6
M:R23=1M]OA9<3V1:DIHT*-6IGJ6A#:';GF35<C-6.Y[?[O*MT^+:BHW8[/Q0
MPA-;=E'QJ>#/.W]KSX-N6L^"LY)S3QR.;FW54Q=N^ZM>]A2552B6]FPWA;<5
MA7<%0XUPXAR+;5Z0WXB)CL6F5!@ZO!;439**HTE:DSH9M..DA1J1P<?02C&]
M-![LT#N6VKFD9F%RY2K@_=N1_P!4'22IL;Q7,_*CR#XH\A^+=2GI??FDYO3[
M\9]"E<@_A3:K3HN4Z)52;5'6F+2+WC(S7AQ5U='W_P!KI+3]D 0,[%ID>=SJ
MN<H_&7VC2&-J,-:]"+233\%6# EM:DI1?Q<N,XCIZ?<])$>HKO+_ )/7_$GH
M%B@
M
M            !11Z$9]PB,SZNHB]O0@! KH?U1==#_\ QNZ:ZEU]["N\OC7G
M7[R>L6*'%7\$]2,_:+K, 1P[@N5QLXW1YNJ6?\CV]>*<NOVE0L?UJY;$R;==
ME3'K=H1S9=&IE28MJI0^)3+58<,C61*6TX6O1H(V^DLI/=L,$.710YVUWF1;
MP=D6+,H9"RWMQHV/[&R^RSDFZIU]5;#F1:[)J-(J5@4RYZ@Z_/*FN4Z$TX<>
M0XMWC3Q'TZALP+-5AU/;7Z?8;!I=/3_I_P!'<!.IQ[#HV0;-G7Q1$4:#>%RV
M2XB8S+.K6L_'C5-:6D/(.(;LEE]OO9WM-5$2=3-)=(DE-)XJI%+OAQ#7+19P
M')J&7LBW>F?FRT*:PU<,FG.HIBWJI3B.=$./$:/OM)]*35J1&GJ$%G)/=157
M_(2.KPS77'''%9ER:7:+6KA3/IJ222C,^$M(/41'H%!UX;$<?,K6?3+D[QC3
M_ 1-7Q*UY(>96L^F3)WC&G^ ACQ%>2*'A6MZ>YS-DY)^S\H4X].GIZ#@Z=0$
M]7)'RJS@6KU6B56DRLPY)DQJI3ID*5'>ETU34AJ3'6V;2T=Y%H@S5TE['0.?
M*7Y97.6<U%TE:NQDOY6F<&9MQOY:Y8DDU.#C[4T:Q^'%3<=[HK/@+JU2MUR'
MD)^@3JM 4VW4X5/J$B1$D/,K=2;27#]QKJ6G2/?'=>7AK_C[-0AC\3(J4?\
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M^(KR0\RM9],N3O&-/\!"KXBO)#S*UGTRY.\8T_P$*OB*\D/,K6?3+D[QC3_
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M<Y%I^V9_N]8DJ5 $;G,9T^1]NAZ?VA[#+7[]38Z-/;$/83OIS7W$D8D@
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M;^[H'J<_GRVLYD>HD@
M
M                          ($O[(>NG3]=W77V^]]=13\OJ+;_P"8GM%R
MH        1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20     4/7N:=?3K[  U
M]^<58CT.]K"R#'0342M6I)M]Y:4Z&Y5X,N<Z2S5U<28<ADOV!ZS^7?5(W--S
M>DS=;EN^KE/\DE%?:F>6OF$TR<;^5U:&$)696W_KQ:]=&21\N6]F;RVDXS82
MZ;TRRH\RQ:FM2N(U3*&\3S/6>I&=+GQ^@^G4QIGS%IDM.[_SLVJ6\RU?BN4U
M1_\ E1D;>\3:A'4.PLA%/JGE[?P)/_-;P^QHSF&LC8X
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MG2G(
M
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MY&[:[EO0R67N3LZG*-?@W%26"Q498QE3'8ZM8T/PW\T?*GYH\%*>>[VTQ_\
M=Y7OAPSMB2NY>=6U%U7O0<N$HJCPJS.(ED9Z?=W/:&>GG Y
M
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M&SL].U:Q>RV?MMJ5NY"4)1:=,8R29]@M>[I^Q^[^Z/J/@*@
M
M                                               "!+^R'_C<_DPI
M^7U%M_\ -]Y/:+E0        C<YC/\S;=/[Q-@_TFP(>PG\R]*^U$D8D@
M   #I61[81>E@WC::R2HKAMRKTHDK(C0:YD)YIHE$?<[11#L='SKTW5<OGU7
M]*]"7LDCX=3RL<]I]_)R55<M2C[4S4XV45I^V=V.!9;J7(SKV4$6N^ES5"FF
MJ_,G4E:7"49&E*D.$1Z^R0][>2\M'.]A:M;C1Q61=Q>FW&,\/9]1X3\9YJ61
M[[TNY<3C)YV=IIX-*;N+'Z;T;?:==.D?GP>^BH
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M <Q(
M
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M*,;D?P]3HEU+=5O:31%U%TZ^W[/ME[0\WINN)Z *BP
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M+=RS<E:NQ<;L9------8--.C33P:9YQ<H
M
M                             ! E_9#_ ,;G\F%/R^HMO_F^\GM%RH
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M,]S3[7[XR=S+9JK=N;3Z+T%*G7"6QKCP,@4:Z=/2?L^S][VAE)K Y
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M/EKF4U:W&+E;FO>2DNJ+]:Q.]CMC'
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M.&8U7*6,_/+X2BWTYG*SDD_=DO>2?LJC8<Y;O-VH&Z25)QMFHZ+9&3(4!B3
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MT 5
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MG&2::=*/<;B3355BF>34NK4M1))4
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M#[R'XW[R\6]Q7NV.]<E=R>IV9N/O)],TG^*$MDHOD7CXB]DAD-3!"H
M     U[-ZU+R=5^9_A*#B&YZ/:-Z.VDP4.L5V [4J>VA10B3QQVEH69I7[!]
MT>5/(5O4KWENQ9T>Y&UJLHV%:G+&,94>+6]4/U,^7G-]FY'Y-NX\SWYD\QGN
MWHYZ75:LS5N;QGLDTUBC*F7R\LG9ORI8F4MW6;X^0"QA4TU>S;)L^A*H]M,5
M)J23[50F-S''777DD1)]K349I'Q7W%KNK0U3O;4XYB-JG3"U"B:4E*F.Q-I5
MHJNF)I;+_-7V?XY[*U/LSP5VY/2WK%EVLUF\U>5W,2MN-'"+BDDMKYU+#;WR
M3^E]Y:>G<H=U$1=!$6DBY="TZBT+J]L<?>__ .JNC);/AY7_ -YO&S?ER;__
M &'>7][_ '.6_P#-RYE7E'<G6Z5N@OO#V!]MD?)N4Z!;=K3[_P @5>>S3J!3
MFZE0HE6H-&E.H87*<D)I$QE22):2+M"'V=P=V9G*]Z9K1.U]&MYS7X6K?QKT
MW@D[<9P3PV*,DMN+KP-(]F>(M-SOAG3._O)G=\]'[+S.;S$,ED;4'.]<=N]*
MU>NQ74HI.[":>#V&.FWR=DZ?S/KIJN4\;V]B^XZI@:FD]1K6G*FPJG'ARZZ;
M%0EK,BUD*->I*,O=&9F,6[0O:Q?\P.YK65MY'4)Y2;E:M_@IT+IGS<J5?H3W
MFV/*F6[-R?R:Y+(]EZOF]:TBQW-<Z;N8@HSMN4;-807#"E-U*'RN7NJ)D/F
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M$KT82>+C&Y@Z;/62X)(BUT/7J_"7[XWRG5'A?GO.8
M                                                       ($O[(
M?^-S^3"GY?46W_S?>3VBY4 "AF1%J?4 *ZZ@    C=YC/\S;=/[Q%A'^Q\IL
M'^\(>RA.]/FB2(20        $?\ S(__ +#\._W_ /EC_P#_ $,VT -A(
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M=QY-9[2+T;ME[:;8OA);4R[1*(^H=#6AW)R$[0
M           'JRHC$UAV-*99DQGT&T_'?;2ZR\VHC2I#C:R4E:%$?21BERW;
MNP=N[%2MR5&FJIKFCDM7KUBY&]9E*%V+JI1=&GQ36*9!KO\ >2]CG<-3ZE?6
MWY-$QEF-R:S+>CSDO,V=<<93CBJA%ELPDFY G.<1*9>(C0DTZ*+0QH[NWP]E
MK[EJ':;5G..596).EJ>VO2Z/X<JTXQ:JJ;S](OE?_N$=W>*LW9[;\I?N-8[
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M4Y
M                 @2T/ZH>FG]M[A[G7WJ*T?27W_S?>3VBQ0 # 3F*[[+(
MV';?*[DBIH*XLF7"ERUL)8UB(7)K&0\E51LX]O46)#9_CE0TS'$N2%]!$TDR
MUU$-I%HQZO08$<ACF%;K]^V/]UGUPK4M>SLG8)SM3["CT2V(B(:*=1ZY9T"Y
MF:74D-*4ARH4QU]3:U]!F>I&1:: G4236U49/D)*E->OV@!&[S&3,Z3MST(S
M+ZPMB&>A'W*G$+_?_NB&66.&^J)(M2/]K77N:"2I4       !'SS)I++6$L+
M-N+)"Y/,#Y9+3"3ZW'$<P;;=(4@NYJ3$9:OO) AXHD$XD^SU_?\ :_"!)R
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MI)D:3+5*DF1I,M-=4F6NI:#5&S V<FGL.1&1]0 J
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M354RY1*(]-.Z.X,2.76                'W?=^V
M
M       *&9%UB&"!;I^J+IH>OUW^+33IT[VT_;"I??Z__E$]0DH<5_P3_;/[
MQ'J?[@;0:I^<<R[=<I<[NYK\W.W]5;8P]R_;(M2S\9V-7+2N*HV[?F;;BH\B
MZJ_>,!N-3I,.8FTV[L88;?(E)-V":2/0^B-^)S14NFJ6/T^X]?[/#N"Q'<FX
M3FMT*CW<B;7<G;S?+FSX"J74(JZI;?D3':5-2I48H\127C,C:<4A22TT($5D
MFZ\GC[$;7)*)6NG<Z/V>[^T).,M?EFC9'K=M(B8PN&';5Q)J49Y50G,D^RJ
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M JN"^L>1VYKTCT#Q8W[P!5<%]8\CMS7I'H'BQOW@"JX+ZQY';FO2/0/%C?O
M%5P7UCR.W->D>@>+&_> *K@OK'D=N:](] \6-^\ 57!?6/([<UZ1Z!XL;]X
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M9:?L]&G3['WAKRN-#.3R$>I:_?\ WQ(*@
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M0<@
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M?CWM=D-J2Y7RB?*;CZ8\9">-3AJT272"5,2')T46\*+["=G337VQ)4J
M
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MJ:G_ ,H%Y?A C^"^PEU @
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M@TXT6PEX$$@
M                                        $"7]D/\ QN?R84_+ZBV_
M^;[R>T7*@       !&YS&?YFVZ?WB;!_I-@0]A/YEZ5]J)(Q)
M                  !%$#K=T6K;MXT:90;FI,*LTF<VMF3"FM(>:4APN%7#
MQI/@49%UEH8^O)9[.:=F(YO(W)6\Q!U3BZ'SYK*9?.V)9?-0C.S)4::K4A/W
M4\J]MMFHWMMT7)<D&\_,JEA5*2EPEM\)*2FWI*B(TN$Z1_Q:O]4^CJ'I3L3S
MJVX:9WBHJ*24;\53?_SBX4WGG;OGPA;O*>H]IMJ])MRLR>#V/W'N=5LV&$&
M]Z&>-IMP*LFL,2:A;5(G&S<-@W2V^W,BH0LRD%29#QD_ DD2#-)EJA6A=&AC
M9_=7C?M7O[*?U++-0SMR'Z=^U2C;V=26$E7UFM.V?)'=/8>:_I6H1<\G:E2=
MF[5226UP;V;#88VZ[K,5;DZ"FI655TQ*W'0W\KVI5'6F*U =6E*E<#"E$<N.
M2C,B<01]721#R+WAV)K_ &;F_@ZE;ZLJZ]%V.,)>O<^3/5_:G>FA=WY3]QI=
MW]5?BMRPG%^C>N9DT7W:Z:_N#"UL,M*B0
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M+@E3_<)1#<8(E:]9.)$U(E%*C6)G,+%
M                    @2_LA_XW/Y,*?E]1;?\ S?>3VBY4        (W.8
MS_,VW3^\38/])L"'L)_,O2OM1)&)(
M H?4>GL'U>R(?,&$VZC9!B[<U3'I\MANT<C,)-=*OFFPVUOFZAHTMLUJ*1MI
MJ<0RT(]3)9%U&-E=B>3M=[*O*U!O,:._Q6)-TIQ@_P K^KD:][X\<:'WIE^J
M^E9U6/X+\4NI/_,OS*FU,@.RQMUW [*[XIESQIE0)%,J*)-#O>VTR6Z;,.(\
MF0T<Q">AMMU*-'&G?]4S(>K- [O[2\DZ9/(RC"LX4N6;E')536#^QKD>7]<[
M/[N\;ZC#4LO.4K=N?NW;::B\4_>7##&NZI(SB[F]T&31N]\JX[G1*[#@(),^
MVYK;L.KR$)T6OO>0@EPUOJ3J:=3(C/H&G=<^7O-V\QUZ%FXRRTI_AN*C@O2M
MM*FW-#\^:??R[AK>6G;S,8[8.L9ODGBO]IZK7./I!5 RE86J::1QJ(GF;@87
M.)GBZ%*95')KC,NG34<DOEUO_"]S4H?N,,';?37TU../S!9%7:7-/O*QQ4TW
M3T4)9,+9@M+.>.;?R19TGM*36XYF[$6M"Y=+GL*-N93)R4?\')BNI-)ZZ$I.
MA]T:$[D[=S_:^LW=&U&-+UMX/=*+_#)<FC>/;^NY'N/2;6KZ?*N7NK9OBUMB
M^#3+L#HSN0                                 P\W^PZ?,V;;BRGQ(T
MM#&,+A?CIDL-ODS-;92<5YHG$J[-QN1PF2BT,8!Y1MV;G86I.]%2Z<O555:2
MZHT:X4>]&^?E@S&:R_G_ +4>5N3MN>LV(R<6U6+;ZDZ;5TUP>!^=<1:H+34S
MZ/V-2U_=(>06\3^K[!3Y#31!DK4NGK]C70OVCZA"QE@&_>36)+=@[F\[T]M5
MC6U9\&ET.X+-ID!$:W6KSH]0[#Y,1PI:1$E1^SU9+N&2NLS]D9-V[WWW%VY9
M60TO.Q>2MUZ;5R,9QC7%J-6G2O#8>%/(_P B/R\^7NY<YKN8OYG*Z_=N]5]Y
M2[;ZOB/%]495QXU6ST&9EI?:,<L06NSOC;U:-;6;:4<="N&HT7^-+759%,;D
M)X%),M"TUZ!F^3\S]U6G_P!ILY*_"G^>#^JJ^H\_Z[_:<[&S,NKMSNG/9:-=
MEZQ"[AP]UQQV^TOU9WVC:P92U%?>WBZJ,V2NARW[C@U<S+0B+5#T=E6I*(_:
MT,O;';V/.&?C)+-:;;E#_J[M/JG$UCKW]ICNBS%/MKNO)9B36R_8G:^R3W4,
MJ\?\][9Q>3T=JLM7=8Y/Z$ZNNQV'"CZZD9.)C])F1>P.XR_G/1I34,[D<W9C
MODNF:7LVFDNZ/[:/G[M^W.>GRR.I..SX,I+J]'49LV'S$=G^1UH:M?,UN2'7
M#2GLI;Z(;B5*(M"6EY1&1ZJ&4Y/RUV/G6HQS?PYM[+D7#[3SMW+\J7GGM*+G
MK7;^;C;CC6*<UAZ#*2EY&L&NDVNCWI;512ZDG&^]*S >-25$1$KA0^:NLQF.
M6U_0\WCE<W8G55PG'^)I?.]I]T::W'4-/SEEQ='U69K'V'=D+0XE*VU)6A:2
M4A:%$I*DF6I*2HC,E),NHR';J2DNJ+3B]Z.@DG&3C)-26U/:<M2]D204U+V2
M^[_= %0 U(                     0W9/>>3SQ]L[277$M+V/9'XVB49-J
M_P#/B[U>Z1KHHS4TD_OI+V!7><B_X;^G F1%CC
M                            ($O[(?\ C<_DPI^7U%M_\WWD]HN5
M    "-SF,_S-MT_O$V#_ $FP(>PG\R]*^U$D8D@
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M^FUYBOYCD7_#?TX$R@L<8
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MG1]V>%O*G8NC?]X.[M"U#3]%5V-KXUZWTP^)/J<(UKMETRIZ#( 98:P
M                                           "!+^R'_C<_DPI^7U%
MM_\ -]Y/:+E0        C<YC/\S;=/[Q-@_TFP(>PG\R]*^U$D8D@
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MK0]?8,NO[PZ"IW)77N=/=_<T_")!4
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MI?>_8'KW?R/YS.1R(]?N^^)!4
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M7H,W*G"/73_K2:_=%7]/K)6."XDDPL0
M       !X''4H29K4E!=1J4M*$ZF?#UJ,NZ(] V,@0V"4]Z)SE><S,;6;T%=
M1VT$<IY]I9%)G8>M>:<9)I<-7 P;+R$EI[A#9$>FF@A)59R-UAZ_N)\DKXNK
M0^O7A,CUT(M=--2ZST%CC/(    #B:=?N[O</]@"3YU5HM)KL)ZFUNFP*O3Y
M"%(?A5*)'FQ74J(R,ELR&W&SU(_8'+E\QF,I<5[*SG;NIU3BVFO6L3AO6;.8
MMNU?A&=M[5))I^IF$^8N7MMWRC E' M&!9%<<;5V%5MQ@HC2'E&6BW8:#)I7
M5W"+K&RNW_+?>&AW8_&S$\UED\8W'5TX)[3 ->\7]IZY9E']M;L9AK"5M=-'
MQHL"%'-&PK<%@&?*N&TBJE5HT1Y?>E?M67)8G-14J-3;CQQ%H>8(D%[HNHAZ
M4[;\J]I]UV5D\_T0S$EC"ZDXM[]N#/.G<'BGNGM:[+.Z/.Y.Q%X2MMJ22K38
M=;P]OVW$81J2:34;HK%U4YAWBD4"[G79;R2;42%ML/RB-]I)F@RZ3[H^[N'Q
M5VAW-9_<6;%NQ>>RY:22QQQ2P9\&@>5^[.VK_P"SSURYF()U<+M>KA@WN)L-
MNG,1Q'F=ANF7'-C6/=A=DA<&I.\$.4XX1?\ M60H]/X71TCS3WAXB[@[;F[^
M3B\UI[K[T5BES1Z.[1\J=O\ <T/A79K+YZ-$XR=%7DV2 Q)T:>PB5"D1I<9U
M*5-/QGD/-+)1<1&E;:E),C2>HU-<A<M2<+L7&:W-49LZ,X7(]5MIQXK%'MD>
MI?M_OBJ+%0
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MIKVH\TYS(YW3K[RVH6KEG,1>,9Q<6O4TMY]#C]KKT_T_@_='/B?*>02
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MZ5MR6?6G<+8J2/N>[JL0]#^^:"$/83157I1)'PE^[KK[8D@Y
M                       H9:@!PE^_^[U_O@!H7L=8 IPEKK[>H <)?=]W
M< '+J      4*<)?=^S^$ "21?L?=^X *&DCZ_O!M&P<):ZET?>Z"[G1][H
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M)&7<Z2ZM>@R&-8U.^W'(2            *:%KKW0 X2/H^[JT %0
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M+5ZU>@KEF49P>^+37U&D[UB_E[CM9B$[=Q;5).+7I3HSW"/4<IQ%0
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M:-APG&Y'J@TXO>G5'LBI8
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M34DULP]>PVQE,[E,]95_)W(7+4E5.+3^FT[/J7LD/C/I*@
M                                                  :%['W%U
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M-^VU5=,D_JVEU=2]DOVQTAW ,R+K/015 :E[)"05ZP
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MI1:JFM_HXGM$>HJ2
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M=(G^5Z#%>M7KE?M1/X-\'Y@       0)?V0_\;G\F%/R^HMO_F^\GM%RH
M     1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20
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M_<?M:?M  9&?X2_<_<#F 1'J?3T=S[ND/0/25($"HD
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M]UI_8=@U^_\ M&0^2I]!4
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M)[1<J        $;G,9_F;;I_>)L'^DV!#V$_F7I7VHDC$D
M
M   4/H(S$,&M1ONV5Y#QQD6_\MVE245C%EQU>?=3KD!/ JU5325/JT6>R7_
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M,M7K5^"N691E![TZKZCZ'$7=U+[Y:%U:G^T.&IR'(2
M                                               "AEKI[!=SV?8_
M: #00"HD'$B/4]=/V-2_TB <A(       @2_LA_XW/Y,*?E]1;?_ #?>3VBY
M4        (W.8S_,VW3^\38/])L"'L)_,O2OM1)&)(
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M![Y'K[/W:#B3J<A42
M                                "!+^R'_C<_DPI^7U%M_\WWD]HN5
M       "-SF,_P S;=/[Q-@_TFP(>PG\R]*^U$D8D@
M
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MC6=RU>LR<+T7&:=*-4^TV'"=NY%2MR3B^&)[XH6
M                                                   @2_LA_P"-
MS^3"GY?46W_S?>3VBY4        (W.8S_,VW3^\38/\ 2; A["?S+TK[421B
M2
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M/H3A<BIP:E%[*8GN"A8
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M5]J)(Q)4
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M"=N3C<3C).E&FC.8RC-*4&G%[T>P*E@
M                              #QNI-;3B"5PFM"TDKV#4DR(_V#,0R5
MM(&/[(NG=^NYUZ='_ <.NOLB*+90M_'[R>L6*%#TTZ?O?M]S]D 8D;Q-[NV_
M8OBVHY5W$Y#I%GTIB-(^0:$;O?=UWE5$(_V>BVI;T8G:E6)\EXTI(FFS2C75
M1D1"*XDI-^@BSY$N+\_5(M\>^?<+8-6Q?6M^^X"DY1QS8UQ-=ZW'2\1VQ;+U
M)M"I5:FJT=I3]P?*STE##A$XEKA,_P"$"XDRV_3E_ V RZOV"/N"2I;3*E8R
M?1+;1,Q/9U&O>Y2GQT.4:MU]FW(ITY2'CD/MU!\C;[=M:4$23ZR4?L!]H7,B
M>WG77N7JL7!3>2L3V):T-&;+,D41RF7TQ69$NM-5.&4>#)2TA"6(DA9D:W>G
M@(R$<B^&U;,"0Y=\;HD+62<'VF\@EJX'&\CTI!+3Q'P'PN$1D?#H1^V!&&]C
MR[W1>@FU_I)HX8DTM\6/+O=%Z";7^DFCAB*6^+'EWNB]!-K_ $DT<,12WQ8\
MN]T7H)M?Z2:.&(I;XL>7>Z+T$VO])-'#$4M\6/+O=%Z";7^DFCAB*6^+'EWN
MB]!-K_231PQ%+?%CR[W1>@FU_I)HX8BEOBQY=[HO03:_TDT<,12WQ8\N]T7H
M)M?Z2:.&(I;XL>7>Z+T$VO\ 231PQ%+?%CR[W1>@FU_I)HX8BEOBQY=[HO03
M:_TDT<,12WQ8\N]T7H)M?Z2:.&(I;XL>7>Z+T$VO])-'#$4M\6/+O=%Z";7^
MDFCAB*6^+'EWNB]!-K_231PQ%+?%CR[W1>@FU_I)HX8BEOBQY=[HO03:_P!)
M-'#$4M\6/+O=%Z";7^DFCAB*6^+'EWNB]!-K_231PQ%+?%CR[W1>@FU_I)HX
M8BEOBQY=[HO03:_TDT<,12WQ8\N]T7H)M?Z2:.&(I;XL>7>Z+T$VO])-'#$4
MM\6/+O=%Z";7^DFCAB*6^+'EWNB]!-K_ $DT<,12WQ8\N]T7H)M?Z2:.&(I;
MXL>7>Z+T$VO])-'#$4M\6/+O=%Z";7^DFCAB*6^+'EWNB]!-K_231PQ%+?%C
MR[W1>@FU_I)HX8BEOBQY=[HO03:_TDT<,12WQ8\N]T7H)M?Z2:.&(I;XL>7>
MZ+T$VO\ 231PQ%+?%CR[W1>@FU_I)HX8BEOBQY=[HO03:_TDT<,12WQ8\N]T
M7H)M?Z2:.&(I;XL>7>Z+T$VO])-'#$4M\6/+O=%Z";7^DFCAB*6^+'EWNB]!
M-K_231PQ%+?%CR[W1>@FU_I)HX8BEOBQY=[HO03:_P!)-'#$4M\6/+O=%Z";
M7^DFCAB*6^+'EWNB]!-K_231PQ%+?%CR[W1>@FU_I)HX8BEOBQY=[HO03:_T
MDT<,12WQ8\N]T7H)M?Z2:.&(I;XL>7>Z+T$VO])-'#$4M\6/+O=%Z";7^DFC
MAB*6^+'EWNB]!-K_ $DT<,12WQ8\N]T7H)M?Z2:.&(I;XL>7>Z+T$VO])-'#
M$4M\6/+O=%Z";7^DFCAB*6^+'EWNB]!-K_231PQ%+?%CR[W1>@FU_I)HX8BE
MOBQY=[HO03:_TDT<,12WQ8\N]T7H)M?Z2:.&(I;XL>7>Z+T$VO\ 231PQ%+?
M%CR[W1>@FU_I)HX8BEOBQY=;HO01:_TDT<,12WQ9Q.]=T[NI-82LV(?X\K(E
M/=0?4?\ !C)6OHT,OOF7MAB12'%G5[C9W 7?%5!NK;YB*XHB_P"$Q6+JA3FS
M,RT41D]&,SU(S[O4/MR>HZCI\_BY&_=LW.,)./V'R9O(9#.Q^%F[5N[;>Z44
MU[&C S,7+MK^1N^JG9^&;-QE<<UQQ^5)IE_%*HQJ41?Q,.D]D2(C?$6NA&9:
MF-K=M^<.\=&:L:ITY[(1HDG13IQ<GM9JWN7PMV?K?5?TY2R6?E5N4:N/H45@
MD8/7CRU-V]E,E.IMF4^[$<:C0FT:_&DU%LT:)2LXYNM.=/66A&8WWHGFKLC5
M[,8ZC>EE,RUC&Y%N&.[J2:-%ZOX9[UTBY*>EVX9NPG@X3Z9^GI;1;ZU,S;Q]
ML%84XFJ7U;_9.%$>HE]4^I5.@J:CK/MH[3,Q*6TN:>Y(T+(D]8[_ %#MSQUW
MMEZ.&5O555.Q*,9U>QMQW;\4=)DNX/)/95_&69MP3IT7XRG"BVI56W<L<-IG
MC9_.%N5+$.G7?BR [.0GLIE:B58XT1Q9F9D^N(I*EL(01Z*+IZM>Z-,=R_+Y
MFK=F69[6S,;MYO"W=]VBX=6]\#<';OGW(7K\<MW+E;EBVL)7+?O*M/\ #M1E
MW86_.5DEQAFT'L+5.HR#0@J#*RC HM62ZO7A:)%53':4X?#IPDH^DQIS5?'7
M?.AJ5S4M.OJPJ^_%=<<-_NUP-O:5W_V3K;4-+U&Q<O/\C?3*KW4=,3(J-D7<
MS+:2]%PE:$MI1:I=C90H;[2B/J-*VU*29'J,/G;NVWTSBXO@TTS+8RLSQC*J
MY4/9\N]T7H)M?Z2:.*8EJ0XL>7>Z+T$VO])-'#$4M\6/+O=%Z";7^DFCAB*6
M^+'EWNB]!-K_ $DT<,12WQ8\N]T7H)M?Z2:.&(I;XL>7>Z+T$VO])-'#$4M\
M6/+O=%Z";7^DFCAB*6^+'EWNB]!-K_231PQ%+?%CR[W1>@FU_I)HX8BEOBQY
M=[HO03:_TDT<,12WQ8\N]T7H)M?Z2:.&(I;XL>7>Z+T$VO\ 231PQ%+?%CR[
MW1>@FU_I)HX8BEOBQY=[HO03:_TDT<,12WQ8\N]T7H)M?Z2:.&(I;XL>7>Z+
MT$VO])-'#$4M\6/+O=%Z";7^DFCAB*6^+'EWNB]!-K_231PQ%+?%CR[W1>@F
MU_I)HX8BEOBQY=[HO03:_P!)-'#$4M\6/+O=%Z";7^DFCAB*6^+'EWNB]!-K
M_231PQ%+?%CR[W1>@FU_I)HX8BEOBQY=[HO03:_TDT<,12WQ8\N]T7H)M?Z2
M:.&(I;XL>7>Z+T$VO])-'#$4M\6/+O=%Z";7^DFCAB*6^+'EWNB]!-K_ $DT
M<,12WQ8\N]T7H)M?Z2:.&(I;XL>7>Z+T$VO])-'#$4M\6/+O=%Z";7^DFCAB
M*6^+'EWNB]!-K_231PQ%+?%CR[W1>@FU_I)HX8BEOBQY=[HO03:_TDT<,1^G
MQ9P7>FZ1Y*M,+69"2EMPU*E9#@.DOW!F2$][I5PDH]",STTZ0QVCW-E70BO[
M2;]3?MN]HWRC]=3M>\>W+O;OSO7B[W[YU_X+C]SQ=6@C#;]-@QK3Z?B)\A8H
M<5::=/M'U:]1D9?L:@#5JYB7+:W_ .X/FF6?O'L_'>&,Z8'PA8%F47!^*,H9
M 8H5)I]Z0V)-6N6Z:W0GD&S)6Y<M37PDHS-UF.V1]!$*NKQ6TY$U5=6XF/V6
MW%S$*O4;MB[U<589Q[0HD>$5BKQ9=\:XENF7&B1&FQH_1&99;2@F^A)$747<
M$JN\K+I_+4D'3U?=]W00DJ5 $;G,9(ODC;H9]9;AK$(C]HZK%,_VS20A["RV
MKTK[B2,25
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MNV;MB71>C*$^$DT_8SZ+=RW=CU6I*4>*::^H]T<9<
M                           #BM/&E23_ -8C+]L@! MJ7U0_:^NYI^QW
MOJ*?E]1;?_-]Y/6+E0        C<YC/\S;=/[Q-@_P!)L"'L)_,O2OM1)&)(
M
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MOO)[1<J        $;G,9_F;;I_>)L'^DV!#V$_F7I7VHDC$D
M
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MR>T7*@       !&YS&?YFVZ?WB;!_I-@0]A/YEZ5]J)(Q)
M
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M)L'^DV!#V$_F7I7VHDC$D
M
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M4        (W.8S_,VW3^\38/])L"'L)_,O2OM1)&)(
M
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M!_I-@0]A/YEZ5]J)(Q)
M
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MD8D@
M
M  *&1'[/[9EU_>^\ *@                                       XF
M1=PNGV=3]@RZ^G01@"%7[/HU$:Y8..68*DKI[6X/?,B :"T:5"3O<W!=ZJ:2
M1F1-*9T,B]L1%)+#Z8?P+3;<L>?V_P 2:HDI+J(6*G(       ! E_9#_P ;
MG\F%/R^HMO\ YOO)[1<J        $;G,9_F;;I_>)L'^DV!#V$_F7I7VHDC$
MD
M
M                                         '$R,^K7]@P!"O\ 9]83
M=,Y8F.J8RM3C-+W [XZ8RI1&2C8IV]G<!"9XR-2]5J:8(S,U&9F?29GTFI1%
MI?B?I?VLFJ J        $"7]D/\ QN?R84_+ZBV_^;[R>T7*@       !&[S
M&?YFVZ?WB+!_I-@0]A*_$O2ON)(A)
M
M
M         !:C)&<\,8@D4:)E7*V/\<2K@[X50HUZ791+:>K!1"(Y/R<W5ID5
M<M+!&7&;9*X=>D,-A*3>Q$&/(:W8[:[;Y<.,*'=V><06Q=5:SQO-K3=L5K(-
MM4ZMMLW3O)SI<-(2JF3:@Q,0J=2:M'D,D;9&XP^VLBT41B*JE=Q+3;;7%_:;
M#\>0Q+89E176Y$:2TU(CR&5I<9D,/(2XT\RX@S0XTXVHC2HC,C(R,A)4\P
M     "!+^R%_C<_DHI^7U%M_\WWD]HN5'5TGU$ ([N8AS.=J_+6Q/4<C[@;R
M9*M*@.2;2Q?0'6)^0;WD]H4=B/1:&EPGTQ%R5DER4Z2([1:FI6A&'VDI;]Q=
M78EO"L7?KM;Q?NJQO0KAMJS\I4^H3J71;I8:CUN$JEU6;1I;<Q#"W&5'WW 7
MPJ2HR4G0RZQ"=0U1\C+P20 !&SS&B,Z7MQ61EP%N"L=*B]E2JK 4@_\ V)-J
M_;_;AIDK%8<423"2
M
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M:+0^X6HC=4E;EQ:)(R+3_=/\/M"2*(J
M
M
M                      ."T$M"D'J1*(R,TF:3T,C(]#+I(^D* @7XC^J'
MKJ?%]=W^%_WMK[/LBFZI??3=7[R>L7* RU+0 <>'JT,]"[G1IT=7<Z !737K
M_9[@ KI]WW??   1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20
M
M
M                                         $"7]D/_ !N?R84_+ZBV
M_P#F^\GM%RH        1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20
M
M
M                                             $"7]D/_ !N?R84_
M+ZBV_P#F^\GM%RH        1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20
M
M
M                                                 $"7]D/_ !N?
MR84_+ZBV_P#F^\GM%RH        1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20
M
M
M                                                     $"7]D/_
M !N?R84_+ZBV_P#F^\GM%RH        1N<QG^9MNG]XFP?Z38$/83^9>E?:B
M2,20
M
M                                                         $"7
M]D/_ !N?R84_+ZBV_P#F^\GM%RH        1N<QG^9MNG]XFP?Z38$/83^9>
ME?:B2,20
M
M
M $"7]D/_ !N?R84_+ZBV_P#F^\GM%RH        1N<QG^9MNG]XFP?Z38$/8
M3^9>E?:B2,20
M
M
M     $"7]D/_ !N?R84_+ZBV_P#F^\GM%RH        1N<QG^9MNG]XFP?Z3
M8$/83^9>E?:B2,20
M
M
M         $"7]D/_ !N?R84_+ZBV_P#F^\GM%RH        1N<QG^9MNG]XF
MP?Z38$/83^9>E?:B2,20
M
M
M             $"7]D/_ !N_R84_+ZBV_P#F^\GM%RI0ST+7H_9/3_08 CQW
MF\TK9IL+KML6GN(R6JAWC=\ ZM1;/H%(J%SW,Y1RD/Q2J\BD4EEZ3%IZGXRT
M$XLB2:D'IKH9B*K>646^!W?9/S!ML',%LV\;VVS7PY=M-L"Z$VA>$&HTR90J
MW0:R]3H]4BMSZ146VIK,>;#D:M.FG@6IM:2/B0HB5(:IS,UR,SZRT_9U_P!!
M'J)(*@"-WF,_S/MT+_\ *'L$_;_G./KT?LB'L)6U/FB2(20
M
M
M                                      !P=-26W%(+59(4:"/70U$1
M\)'H1GIJ (%?[(?^-[AUZ>OO;V--=-!3\I>CKZZ_63VBY0H?5]W^GN@""C9/
M8-A9OYJ7-MSQD6R+:N/(N&,CX$VRXRKU9ALUF5:>,J7@.V[SJ=,H[,Y#T:E_
M+US7;+E2%-H)Q:WG$\7"LT@GO19[*/Z;_JJ=+<C4C ?V@RVK-Q90J3:%K;E-
MDL6\LKT&WH+%*I5P7K;E\Y1IU/N^53H32(9ULH- C-.ODA*W$I4:C-2E&=:8
M^HM6MMU-@E!$1&1=SVB+]PNH6.,MQE3*-#Q);2+HN"GUVI07*C'IJ8]O4_Y3
MG]O);?=0LXW:LZ,I)@R-6O09D!*52)[>UN/M[)ENXFE6I9F0G2LG+%JW?545
M&W2@)=B4Z?%6B-'=.6Z1RI*]4(+3K47<$;51%J->IKTE^W.8N\AU:/JS9K-*
M7%H)1TZ&E1\*C(C-/$9$HR+J(S_9$D=. _2,/>K-FH__ "?"]^&(Z2GZ1A[U
M9LU?$(7OQ&/!CI'Z1A[U9LU?$(7OPQX,=(_2,/>K-FKXA"]^&/!CI'Z1A[U9
MLU?$(7OPQX,=(_2,/>K-FKXA"]^&/!CI'Z1A[U9LU?$(7OPQX,=(_2,/>K-F
MKXA"]^&/!CI'Z1A[U9LU?$(7OPQX,=(_2,/>K-FKXA"]^&/!CI'Z1A[U9LU?
M$(7OPQX,=(_2,/>K-FKXA"]^&/!CI'Z1A[U9LU?$(7OPQX,=(_2,/>K-FKXA
M"]^&/!CI'Z1A[U9LU?$(7OPQX,=(_2,/>K-FKXA"]^&/!CI'Z1A[U9LU?$(7
MOPQX,=(_2,/>K-FKXA"]^&/!CI'Z1A[U9LU?$(7OPQX,=(_2,/>K-FKXA"]^
M&/!CI'Z1A[U9LU?$(7OPQX,=(_2,/>K/FKXA"]^&/ =(/F,NE_9GS5XOA>_$
MXCI/F1.9G3)]1J=(A;>LO2JK15-(J]/9BP%RJ<MYLG6DRFR7JV;C9D9"!TNI
M]/\ 2,NZ$?U9\U%J1?\ N"%^_P ?3TB<1TC](R[ZL^:OB$+WXC'@*+B/TC+O
MJSYJ^(0O?ACP8HN(_2,N^K/FKXA"]^&/!BBXC](R[ZL^:OB$+WX8\&*+B/TC
M+OJSYJ^(0O?ACP8HN(_2,N^K/FKXA"]^&/!BBXC](R[ZL^:OV*?"/]PE](5Y
M#IYC](R]ZLV:OB$+WXG'@QTC](P]ZLV:OB$+WXC'@QTC](P]ZLV:OB$+WX8\
M&.D?I&'O5FS5\0A>_#'@QTC](P]ZLV:OB$+WX8\&.D?I&'O5FS5\0A>_#'@Q
MTC](P]ZLV:OB$+WX8\&.D?I&'O5FS5\0A>_#'@QTC](P]ZLV:OB$+WX8\&.D
M?I&'O5FS5\0A>_#'@QTC](P]ZLV:OB$+WX8\&.D?I&'O5FS5\0A>_#'@QTC]
M(P]ZLV:OB$+WX8\&.D?I&'O5FS5\0A>_#'@QTC](P]ZLV:?B$/WPFHZ3Q/\
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MD+4C@07NE$6O#J721F0CB3'\2,EM.KK_ &S_  ZB2"H@
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MNVU)2I*CZSU(C/740MA,MIE()( @
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M2,B,CZ#(^DCT %$(0VDDH2E"2Z"2@B2DM>GH26A%T@#D
M                      IPEJ2M"XB(R)6G21&9&9:]>AF0;J;@5
M                               4,B/K#:#BA"&RX4(2A.JCX4D24ZJ/
MB49)+0M5*/4_9, <P                    !Q4M"-.-:4:]7$HDZ_>U,@!
M4C(R(RZ2/]G][H %0                                   !12DI+52
MB27LJ,B+]L^@ >/MV?\ NS7Y1'X0!Y",C(C(R,CZ2,NDC+V2, 5
M                           %"4D]2(R,TGH9$9'H?L'IU& *@"B5)46J
M5)47LI,C+]P 5                                  !P-QM)\*G$)5^
M*:DD?[1GJ .8 H:DD9)-1$H^HC,M3^\768 J
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MA4^169U0D1XG?C?2A*^$S21@G43325=IM#"2@
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MDGI*7)3;B"/4B4";KB6DETX4I_M1MWB3B
M      ##[>?MTR%N?QQ2,8V3G.[<$4J9<<23?5>L9V1"NBMVNUPG)H=,J<1Z
M/(@+D&1\1DXE"B/W>J2X3AITP+1:3JZU^E37LW18TO7E%;XN5E4-NN?,^Y(M
MS=YN F;<<VXVR[?]1O\ AW':ZV[;J'E#08$I+3%.G4QZHNK<=)*G&B-LDK(C
M5K#23PJ73<ZI_3Z4,N.=%EVN^?[E_;3KUS'=.VG;!N0R;<,;+^<+6KDFTIRZ
MU;5"J4ZR\>NW@T_$B6[!N*M,QTO.OO(93VR%K2I*.$&JD1PQ6TP6?;JFR'G
M;%<%;+MT&7=PN/,\R7XVXS'UV93D9<I]DVB3U5;>N&IS8;S]+I+S<&-V[;;S
M3+Z"2EQ)FE:3!46PM+JDO>^GT9N"%U%]X6.$J                *'[76 -
M4[[+E=5,H=@;[-OEP28-)RQB?=?>;UVV:^F)%KM/IU4K=Q(A5*3%0AN2_#=6
MQH3Q\2"-:=#]UTPE3:6EBL-M7]IT[DU47SS\XKF;[I+0.15<4PJW5K)HUW0F
MS<M^L5[Y;C4]<"+/3QL2'FXL"0Z:4J,R[/4R+I(17$M*JC]-QMQBQQ@
M                             '%75][VB/\ ?Z !J+[$[7J_-<YQVZ??
M7ERC/5O;ULJOBO;?]JE$JK[LJW6JW950DV[5[LHD)PDM)E5"L4Y^HO+U6GOA
MY7"9)X"*-]5L+[(T>W9_'^!MTETD1GW?N[I$8DH5
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MI%Q)UAK%,E4Z7].!.:1D?49'][I$E2H
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MZ<A3OD*_DRO5N/;$EQ<IP^WCMI?0I1FA:3Z0IC7>*U7,DM$D
M
M
M
M
M                !0ST^[[W27L]?< %"41]P_O]&FFFNNI&9: #D      '
MW?=^V                   "AF1=/<]GN%]\ 4XBU,NZ77[1>SIUZ=  KK_
M */W0!4       !Q-1$>G=[G46OWM3+70 <@
M
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MZD8$<MY]$
M
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M?1T=!%LY%76N.#+TB2
M
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M4GN"R*2V^HE- @
M
M                         "FA>P0 J *:%[!?M%]W< %="]@ 4T+V"_:
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M2C/N@5JFZH[?H6FFA:>QIT= 40*@
M
M                                                           ?
M4?\ IZOV0!Q_UO\ 5_WP Y                            *>QU?<9=0!
M%"[G\']C[W<^[J#>#D
3                      #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tv523241_chrt-org.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_chrt-org.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ YP.$ P$1  (1 0,1 ?_$ .,  0 " @(# 0$
M       &!P4(! D" PH+ 0$!  (# 0$! 0            0% P8'" (!"1
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MU+S=%S5,(M\^>7_OG$+_ / WC-_L-ZSG'TX_8SG_ .H[_P#/!=L^M7[?%/\
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MI0[\N9N.C/P]C<*I"M[@3W14D4M.QR)A7$:L"4VJ_3J:2N.JJTBDF>(P]R6
M#8FUJ);DFXL-&XEN!NCS!'GZ!T[+6CGY3/G;=_(VZ)4+LE>#PIY(8ZX0Q1FT
M\D8R"$V\B<R_4,0.#.+;1UTT'(34OI_4XECL1@Z&5#*XR"[:_45(K,UV6U)(
M!4X93ADD@>)F$(_TNDC&0$;&7[=BU_#8G X=5BF41.A./R:R;.LY=I@O*O'C
MDC=MD1=IGH8>T5NV1IWI)R154@BRQI5LAKF)UCSHYK]F+-#3: $(:K)Y"[D;
MUT:<^2R9U*<#;ZDXT:D$A0^*4Y2!:%[!2,0RM'X<T8!H&AK9>/X3$XG'8A\K
M2PF!AR65M$T5^K)E<C:C&UX,=)HIJ+M3CB9GKE-XT,DAZ3,\;N[/ZK7@T8K2
M#_NPP*%M@&6)Q6_>/+3'F<LT\\EJ:B+#M7:1N3FJ3#E TR(H>BR^T&,>BPZT
M(0M].]_>%R-S+9#A>2OGXEV;'72,NQG(O!KZD^FC:O[7T;VJ/RC"XWCV'^I^
M&Q$;0XV#)XAHXV]@"]F<MHZ_XHN3L+?@VC?@NI#.V+RFF$6R$%_RO<AOYD\=
MO^AW;FJ9+^U^*_HMW_LJZ;QW^Z_DW],Q/\ZZM;\VM<R3")A%V34VAKUP_;QN
M4BRY1,HE'M<JZH,*=(-!&2Q'D;F&M9[I,D,87^QJO0EH32!&B&HTY#,+&  =
M$#T/8B^49Z3)Q?5"@6)A@FM?P>Q[LLQPCM\>+5]X06'U9]-!V:/J_O-IH_HW
MB46&F_\ V^9<,]8M5J'J2O[]>O'9DW?IVT;PY+-4=K]NI>+JW9H+Z]EO<3+E
MKE7='!CCG4H9H]Q:#\B'FRGR=6+'F2)2%]E,O:T+.%N:8G'YC/D$>C[4ULX=
M;UMV5&*U ^U%HKHZNZ+FN RL>!Y%RG-?IX[EC&! $,!G( 1QFY;BD.*$C,B+
M_P!&+"W9V^U;9]+.9\?GY-P[Z>\7:Y+CZ66L6I;%J..&22:6"46&.&*>P,<8
MB[ZL\I.1:/V=NM*&JV2[J#YB.3G6]<L+E24AJQ_J=3!8!&(U)FA/,K9' 7:,
M/DK8FE%++'0+6AY +1D@5NBSSM. T)NA;%K>P %CC_(\%%%;M20Y"&P%EIII
M)(R>*MXPR!&9/' [$.FD(QCM=V=EJ5TZ?,N(<QGGQN/BN8B]2*D5:M%%./ZB
MZ58XI)H@&:TQ@^O^L%*;R>^SZ[6;<1HJ*K54WM.B9JU\:8^=$* GQA- 0:NW
M.;6Y!9G"J:5R R;2[E0KJ:$+EDI22EN\Y4HDS^ZMG75Z2>:BT7V@=%GSF8#'
M4^18\\M*,^2AUN33C%6FCELL'A1X]K$HM&\;[1,H8S]W?O[=%UBAQ+B]GD&2
MX9F(>/0'6PDNF,K52L6ZYQU6/]5-F#IUY'L-)VN S2!I(+.+NV]ZGHV-5"]1
MCC?7C:R4XQ3F7QDK<^IKDG43E%I-R/6RZ3R9,P/]1<H#ZUGJ^#(7UM,1-\?,
M;%3*FTXIND>U/2=K+KD-O.U[F5R<TE^7'0S?N;5&R,D=%HHP<PLT&GA:5P?<
M4S2#(6PNS;[JU3AU#AUO&<>PE:#$P9RQ4UL4,M1*&7*%8,PCEJY<ZM@H1/46
MJ?IW!B-MK[O>88\RU?":.XZ5=-!R'CC [%LFT+L:9>NY,U?++P/0M52RMLB:
M.M6-KC5%73"6%82/M5KLX +;G12%<GTD4=AH>@2Y\OD.1<HN4&CREG&5:=4H
MQH6(ZC.5F)Y'G,I+=64V]@Q@^^,=I;QW::UD?'<+PC@>.R6N"IYR]E+X3GEZ
MDN0<0HV? &H#08^]!&[LSE/(/A2'N9X3<>T-.>8D5KF(W_+F^JB#V^&.+?$9
M*C93(I/H:E87"41)E?GIJ9&6SF9@F@8L6[+SC6@Y6D*V<UFIQ ZX.@8MZX+<
MRM[C4$F9=BO@4D;GXD,KF,<A )&<!'%XFUF:1A)])&+71^Q<E^KV,X]B^=VH
MN, <6)E"&5HBKV:W@G+$)R $=L(YO"WNYQ.X"/AF+"VUF=;$<<+'L*0<.N<L
M%?IY,WN$1&G*S-B<-=Y0^.45C!JJ\HD)49'H\M7'-#*-2(X>S-IB2MCV/?3T
M].\U;E>*QE7G/'<C6K01Y">_/XDHQ@,DFE633>;,Q'I^&YWT70_IOG<WD/I1
MS3%W[EJ?&5,55:"&260XH6>R^K11D3A'KHVNQFU76SG6%YP3")A%9-2_]]2?
M]VI]_@&39"O_ /JS_P#/#^>*M<)_[Q'_ #<O^B-5MDU5281,(NP?]LP"(SDJ
MXEN2A4D;AT7R" X*D*,IP6ID0JFDX52A&WJ%S80N5$D;$(LD:E. T>M!V:7K
M>QZYA]7'D;B8/$S/+_$:>C.^C._Z@-&=V8G9G?VNPOI[=']B]!?_ +:FC?ZB
M2M*[M%_!KVKLVKLWA=KLSN+.[-[&<FU]FK>U1B#VSQ]H>"WNDJ][M^SIW=%3
M.=,)#;!J^&5?$XA&Y0\-#A*7TPN/W1;;A)7X:1E*);R^S0%)#!"-$,WIT$,W
M(X7DW(\CC9,O'1J8ZA=&T_@V);$DIQB31@V^K6:,-2=S?4W)M&9FTU>BP/*N
M#<*PF<AP,N5R.:R^+.B#V*L%2"&*8A>:0O#OW"EDT$?#;:#"[/J[L79OV^.S
M'->8'$'C])JZK)]@=F\>N,L;GRI^@,8D$U>"'RGFXDE8RSYZ;%LR@*EC3Z)\
MS#'UK85LXK9IX3Q#'T\RJPV,?P;-\FJ6K<>2J9.\<+!-($0N-E]6*$":*9C=
MWW>,,CZ/H+BS,O0.5M4LO]6^+\'R>/QMC"WL#2&P4M6&6P;'4/;LLR 4T'A[
M&>-JYQ-N<B/>Y=FM%5Q"/5Q2T"D<D%QTK(F;639_F$XN2N#^15@W-&X>K01Q
M-$815XZ?FK#7S(TR-M4)%#L-W9UJU8MWLM2261K0]MS%^WE<[9KU/XI;*O3K
MZPU9VI053E%Y'EEL?J8CF,@)B&/PI1$1[1)W[.=\=PF*X]QFA-D6P-"&WEK8
MC9NU?XK;OQUY/!:"&G^BE"M$QCX9RM/$;F6X2#5F*SY57E"4_>?-=B$UL51I
M&*VHO$J@M:Q*(6\@J*@!:@E\?Y-7KJQN<6G[2URB5(@DB:CU+6YFD(T)X20I
MPZ&?JIIY3DF;X]@+#')>.2E))9KPW&IVYM'$(YA,9(2*.-]?$83!G(FW.3Z"
MK[*<>X)Q?EW+Z<D46*B#(5HJ5VQC'R6/K.0---7\,X9XHY9=S;',"V1MI&T;
M"[OEV_CW F^?7G:\NC?'F,ZAO%RK;:@"A(JE]A<9I!(IU(VJ!K;M;87$:Z=)
M..%G+4#@J!%E,=4(VQT4:(4D;1$Z,!@EY/DY,;CL+2FR<OCYBQ6F9VCAO@$(
M/,U0I9)QC\5F(!>PTS%)&.X28RVO,AX)@*^9S'*\I3P4,E/C=.Y P/-9P\DM
MDS@*^$$-8I7K_NB-JKUS".0GW,0L,K:E\GV6MG2DZ>LAG=JXD-FK9A.X9,);
M1U,V/4U03"/M""/.<<4$I9#35-0 $^CIZ]2G<B&- $9B50E-4ZV/H'O=N(6,
MM#R"]BIPM18@8(I8H[=J"S:B,G,39W"U:F\$V82!Y3T8A-A[.Q<F^HU/CEKA
M&)Y%4*E)R1[,U>>?'T+5*A8B%M\9-XM&E6_4Q/J$@P Q.Q,YL["VW^4+5,NN
M2DCA6[<<<I3AS4MA.;\OD3XTMBMY>+)DC*T$O,?KAE:V\$LL&<K(VV)-[2F*
M1I4"76C=!UTB -R3,T<#R!FP="7(<ZNUA!@ B8!@ BV'.1%X<,3&Y>\PL1OJ
MSO[';ZX/QK+\NX6_JS+08CZ28N\4I2&$;R26C!O$CK"(>-/.\6C,Q$0@SML
MW9Q58\P;FA-VVVD>*U:'IJKN#5] *E@YLG,3&RI[C-;1Y-'&R0R82378 >'<
MI/V@P:$/99?4#L6]ZWT6_!L!D./80H,J<9Y2Q9FLRM'KX823FYD$>O;M'737
MLU?5UK7U<YCA^:<J"WQ^.6/!4J,%* I7UEECK"XC+)_(1ZOV.[EM87+0G<6U
M8S<ER],(F$6Q?*O_ (S+?Y=T7_R+K?-5X7_9\/Z3;_VN==+^KW]O;/\ 1,?_
M /#JJUTS:ES1,(K'IW_BY5G\QH1_B9LRJSO_ +CN?T2;_1DMHX/_ &UP_P#O
M2I_IXUV97%.N-M&_N"VO=B^5W?+9]7?(&;S$FN$E3PB-P]=,FN2."I&TFV?N
M]7I\W&4[KH/:*=18*A4G!L.TY.Q[ZO),%CN5<B^F5+C\4./AQMK&Q1O.]B4Y
M6B(&9R:#]((>(X^P?U#B+]NXM%Z%Y3G> \+^NN1Y?=L9BSF*63EE:J%.O'"\
MS,["+VGR!2/$SOJ[_I&(F[-K*+S*Z76.<)>/LW2PZM7B42[D=R=>QJ)M7\4L
M1C:$ZX=?N+TTMD/GK3)(H$IV4KR=><F)!K4I:4(4QQ7:&[%*Q^ AM?4')XXY
M[<=2#%4 _=320&3BTH@12PD$GNLS^ZQ,!.6I"6C+'GN9V:OT9PF>&GCILA=S
MV3E?]16BM11L<WB2 $-@)(VWN[#O<?$ &=@(7)W5E2^D8365M<LIBR1VBJV@
M,<6T$CCMC74T.-APBK7JXH0R6!*(K!Z*(K&VT]C/KJ2['Z;M+4):./MZ,0M&
M!V,(RJRCR'(9?"X6A/+D;63E&XYP52&"6P-:4X8Y);CSUG@ 7%M^TW*8R]CZ
M:/<9CAF&XWR?E>7JU,+0X_!+CHXK=Z,[4%([D$-BP%;&M5N#9D+Q?W3&$<=<
M&T$F!R8>),X!0$<O^A9JZPQ)*X/,N'+S;LR?J\I5S%7B.: 7VC%F:[GZCFHA
MN):*V9U;,UN#DV%IT;=L)>A#3  :82+ZH9+DUKC62Q\%@H<C!G0K1!-:'QWB
MT@D*H%LG?=.3%( 'J1^UF)W9G3+8/@.-YYALS:I1V<'9XF5V:2MCS>H,S/.
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M(]629A$1*4))08CU8CAC-@;0IF>-M'V7Y!BB<DX2<:Y15;>_PJLHW;-PPE1
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MDB(K+;Y/WCD+ 3Z[M0U$6;]VXLVFK=O:HX?4#ET=S$Y +>ES!Q#'1+PH?W
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M_>;M7U]D9Y)75#TD!0QR9^KDM7QFQX=!BOR[$U?J..6V)W%83=UUS$J,<_S
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M3NQ/8IMJ%3I3J8*&$,14"$S1PV+*(6!$2W@@:BOC6<=?GU^4B3EE@81M>V<
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M6(F?TV#R-MVSH\9$I2_LA,95/X96ZL4.@%>5NV2*5 (4)@2B6I:YBD5+E\D
M2K-"%>Z:5J]=J/H,Z1"Z?K&<5P>(M-=IQ2/;&+PQ.6:><@CU9_#C>>23P@U9
MO<CVCV-V=B^,Y]0^6\BQYXG)V(FQLMC]1)'!6JU1FGTT\:9JL,/C2=O[<N\M
M>W77M4-KJSYS5#VI?X(]Z:%K@U*V%W3*VMFD+#(&%P$4-<PR:+R5N>(S)V)8
M-.6(U$X)%*4P181"!O80[U.RN'QV:KM6R4>^,38Q=B,# V]AQR1D,D9MJ^A
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MF_N/'JGC'4:'S$7QIZ YWT3+_)V/RT^7+D)W$7+X7S?W'CU3QCJ-#YB+XT]
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ME7Q&8OIFVYD3&JC1"3A $@H8^GH +HOL+QK+\@"Q+C0A>"J E,<L\%<(Q,F
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M,;ZFK<-_15/24N'"8K+PQO,[%2\<[OZS9XPM'/J.SQ/ 9A\)X]7623(7_P"
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MV2NY*>:Q</\ :DE,I#+_ (2-W)_^-U/J4Z=" :M&*.&J/L",1 6_X!%F9O\
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M7^5QZ)XATVGY0]R?<KG_ %C(^>?>GQSN+O,F?MY?Y7'HGB'3:?E#W)]RN?\
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M[AU'MT9]6=F^KV,O8UH"NAL:S ,T?:+[HC<F$O==]-7$FT+0FT[6;5E",L%
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MM;) \1YK]5&KP/:KU@W1=>9VY*8Q.5V'5,, (981_$F6Q\65BPLDFF3FA.4
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MA1R;2=XRBC;MA?<1"HO)*V%*CFJS4Y!>C*(QN-&K5:L7B,(B\[6BFLC*/_E
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M "KR<;HN)W1A;G:V++=&\$=C\0"A<9W*%J,,3B3Y^9XK%PIE+J:3J.QF2_\
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MO3[:\_Z/D?(/N3X&7%W9S/V"O\ECUMQ#J5/S1[T^VO/^CY'R#[EV!\:^-9$
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M *NN3WCY:WZLQ]O^!]$Q'R=?\M/6?,.K9+YJ?XT^=SF?]77)[Q\M;]68^W_
M^B8CY.O^6GK/F'5LE\U/\:?.YS/^KKD]X^6M^K,?;_@?1,1\G7_+3UGS#JV2
M^:G^-/G<YG_5UR>\?+6_5F/M_P #Z)B/DZ_Y:>L^8=6R7S4_QI\[G,_ZNN3W
MCY:WZLQ]O^!]$Q'R=?\ +3UGS#JV2^:G^-/G<YG_ %=<GO'RUOU9C[?\#Z)B
M/DZ_Y:>L^8=6R7S4_P :?.YS/^KKD]X^6M^K,?;_ ('T3$?)U_RT]9\PZMDO
MFI_C3YW.9_U=<GO'RUOU9C[?\#Z)B/DZ_P"6GK/F'5LE\U/\:?.YS/\ JZY/
M>/EK?JS'V_X'T3$?)U_RT]9\PZMDOFI_C3YW.9_U=<GO'RUOU9C[?\#Z)B/D
MZ_Y:>L^8=6R7S4_QI\[G,_ZNN3WCY:WZLQ]O^!]$Q'R=?\M/6?,.K9+YJ?XT
M^=SF?]77)[Q\M;]68^W_  /HF(^3K_EIZSYAU;)?-3_&GSN<S_JZY/>/EK?J
MS'V_X'T3$?)U_P M/6?,.K9+YJ?XT^=SF?\ 5UR>\?+6_5F/M_P/HF(^3K_E
MIZSYAU;)?-3_ !KZS+ILZR6JP5J)KL*<-J,$<@!X4B"6/R-,$Y;7T76K#@D)
MUY96C5:Q08::+HZ3#1B$+I$+>]^<>"\;X[<XQ!8MT*4L[RV&<C@B(G8;,PBS
MN0N[Z"S"W;V,S,W8RLOJOR_EN.YY<IX_*9&"H,=5Q".S, ,Y5("+01-A;<3N
M3Z-VD[N_:[JJOB_;/>A8G]]I+[SS;O27%>F8_P"7A^!<Z]>\YZUEOG+'YB?%
M^V>]"Q/[[27WGCTEQ7IF/^7A^!/7O.>M9;YRQ^8GQ?MGO0L3^^TE]YX])<5Z
M9C_EX?@3U[SGK66^<L?F)\7[9[T+$_OM)?>>/27%>F8_Y>'X$]>\YZUEOG+'
MYB?%^V>]"Q/[[27WGCTEQ7IF/^7A^!/7O.>M9;YRQ^8GQ?MGO0L3^^TE]YX]
M)<5Z9C_EX?@3U[SGK66^<L?F)\7[9[T+$_OM)?>>/27%>F8_Y>'X$]>\YZUE
MOG+'YB?%^V>]"Q/[[27WGCTEQ7IF/^7A^!/7O.>M9;YRQ^8GQ?MGO0L3^^TE
M]YX])<5Z9C_EX?@3U[SGK66^<L?F)\7[9[T+$_OM)?>>/27%>F8_Y>'X$]>\
MYZUEOG+'YB?%^V>]"Q/[[27WGCTEQ7IF/^7A^!/7O.>M9;YRQ^8GQ?MGO0L3
M^^TE]YX])<5Z9C_EX?@3U[SGK66^<L?F)\7[9[T+$_OM)?>>/27%>F8_Y>'X
M$]>\YZUEOG+'YB?%^V>]"Q/[[27WGCTEQ7IF/^7A^!/7O.>M9;YRQ^8GQ?MG
MO0L3^^TE]YX])<5Z9C_EX?@3U[SGK66^<L?F)\7[9[T+$_OM)?>>/27%>F8_
MY>'X$]>\YZUEOG+'YB?%^V>]"Q/[[27WGCTEQ7IF/^7A^!/7O.>M9;YRQ^8G
MQ?MGO0L3^^TE]YX])<5Z9C_EX?@3U[SGK66^<L?F)\7[9[T+$_OM)?>>/27%
M>F8_Y>'X$]>\YZUEOG+'YB?%^V>]"Q/[[27WGCTEQ7IF/^7A^!/7O.>M9;YR
MQ^8GQ?MGO0L3^^TE]YX])<5Z9C_EX?@3U[SGK66^<L?F)\7[9[T+$_OM)?>>
M/27%>F8_Y>'X$]>\YZUEOG+'YB?%^V>]"Q/[[27WGCTEQ7IF/^7A^!/7O.>M
M9;YRQ^8GQ?MGO0L3^^TE]YX])<5Z9C_EX?@3U[SGK66^<L?F*V:>Y.3B"28)
M\O?I%-8NX]BF=T3T\+WA<A*",74<60US5'>;JT_:;V,K0@EJ0?PBZ!: 8#5>
M7?37"YS&O'B8*]/)QZO&4<8QB3_^1(P"VHOIV%H[@_:VK;A+>N _67DG&<RT
MN>M6\CA9M!E":4Y3!M>R2%Y"?:0ZOJ.K#(W8^CL)#VWL3ZTR9G;G]B7$N+0[
M)2UB!:1L79GD&ZZ=;ZH]!,+, +6PC /01ECUL(M:%K>M>4;U*UC;<E"\#QVX
MB<2%_:SM_P#4[?BSMJSMH[.[.O=F,R5',8^'*8R09J$X,8&/L(7_ .'M9V]C
ML[,XNSL[,[.RRV15.3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3"+\]']PK_/)RO_ )[V-_B);G]-OIE_=[AO]W0?S&7@?GW]M<I_3I?Y[J&<
M9^*]G<K9)+8Q69\81KH=$#I:O4RYU5L[>O,,=VJ/,$29ST;6ZF+IE,I"])T+
M2BV  5*@>]",+"$0M3^6<QQ/#:L-O+-,4<\[1LT8L3M[I&<A,Y#I%$ D<A:O
MM%NQG?L6'B_$<KRZQ-7Q;Q"\,6\BD)Q'M)A$&<1)W,W?0&TT?1]791!SI"6M
M]*,-])EK"]0ISG#Q7#^D9U+F;(J\F+<C Z-;3/6U8THD[5J8,W;*V@Y.H6$*
MRTBD AEGIS20SH>04I<_)QPADCOA7&<')A8)HB?:10DQ.Y>$6@RL["XN0OHX
MDQ/$FX]>AP0<@9XSI%.4)L+EOAD'M89A<68=[=H.SDSMV.[%V*Y2>$-HGO8H
M.5*:X%;0:/)O?5,;<Y9JRAL1S9^9M0D#?N&>H?BF"#" _P"V+;CI1ZK'KH%M
M5H28-$7U Q U_P"(/#:_@O\ $'J?JML?@;V+P_%U\7?^G\7]SXNS3Q&]FS0U
M>#P#+%/^@::K_&/T7ZK]-ND\;:[;O#T\+9XVW0O"WZ[7U4!9.+UH2*$U'+FH
M#$>YWS8I]<T_7>UZL%A3M2D5I&E7+&MJ$W>ITL%32-9IKVXK%Z;0UY9P0%B+
M(.,!8V.7XBK?NTIGD:''56GLSZ-X,+.SDT9%NW/,X-XFP0+0'%W=G(6>NK\0
MR]FA4NQ^'XE^QX5>%W?QI='9GD$=NUHA)]',B'1V=]--'?FV!QB?H9!)'8T>
MLJJ;<C,$EK/!;*-K%SF:A974JD 'G;(AD*.;P:#F.;4ZJ(\M3IGAE];,9ZA/
ML!:P6Q%]?XQO+JU_(Q8NS4N4K=F$IH/'&)FGC#;O<'BEEVD+&+E%+X<K"^KQ
MMH^GUD>)VJ-"?(P6:ENO5G:&?P2DW0F3NP[VEBBU$B%Q&2/>!$VC$ZA44I5_
ME-165=8W^+1V&5H]Q"*J=/QS^)WE4OFZ>0KV.+15$P1Y]*$XB:HJN5''N1K8
MWE%$]7:G9HRRQ3[F?K4\W4X^T<TM^W')(VQ@VQQ1.#')(YF'N[I %FC:0W=_
MV-&=V@T\!:N86UGGDABH53 'WN>XY#9W$(V #[=&U=S< ;5O>]NE.9>JC3"*
MW[.IIZJ=BJQVD<BBJQRM:"(K(;HFS&2)1((Q$7L>ORNX2H]=&VZ, -E2<!IZ
M0AM<G(XDHD7G84HAE!,H\1G8,S8N0U8IABIV'@*0MC!)('^4&-F,I-(WT8G,
M 9W=MCFS$[766P=C#05);4D)27*PSB [W((S_8<W<!#4^W1@,W;:^[;J.M09
M>*E3"*T*SJ:1VJ58YL>6LB,-85?);9?]/*E<G$LCD65LZ)P1,^D+:XZ4/9QK
MV5LDL[:<@00CZQP-ZUH51ELS5P[U1M#(3V[<=<-K,^AR,3BY:D.@-L?5VW/[
M-!?\+;$X:UF&M/6*,?TE22P>YW;4(W%B8=!+4GW-HSZ-[=295?ENJE,(F$3"
M)A$PB813>/5S,I7$[!G# S>?Q>K&V/N\\=/6#4E]1-\HDK=#V)1YDM7)G%S\
M^D;LG3]1&2H&5VG:&! 4$0]5]K*4:=VMC[,FVY<,QA':3[RCC*4VU9G$= $B
MU)Q9]-&U?1E/K8R];I6<A7#=3J,#REJ+;&D-@#L=V(M3=F]UGT]KZ-VK(VU5
M[_34\=*\DZQG7O30W1=S4JF%0M5-8R)9%&28-P"#G!O:U8CB6Q^) ?H1 0A/
M",(=C!H(Q8L+EZV=QP9.H)C 92"S&S,6L<AQ%JPD3:.0.[=OLTUT?L;-F\/9
MP.2DQ5PHRL1L#NX.[C[X#(VCD(O^R;,_8W;KIJW:N#/H-^0G!A;_ ,X06:>O
MH5#IIY[ 9!^8V]F_.#"C??RF_*?-$?JZ:Q;SSS-X0=4?F*\HPGKCZO6WDQN0
M_B44DO@6*_AV)8M)@V$7A&X>(#:ONBDTW1'V;P=BT;718LEC_P"'21Q^/7G\
M2 )-83WL.]M?#-]&VR![#'MVOV:NH+EBJ],(F$4ZGT&_(3@PM_YP@LT]?0J'
M33SV R#\QM[-^<&%&^_E-^4^:(_5TUBWGGF;P@ZH_,5Y1A/7'U>MNNQN0_B4
M4DO@6*_AV)8M)@V$7A&X>(#:ONBDTW1'V;P=BT;716&2Q_\ #I(X_'KS^) $
MFL)[V'>VOAF^C;9 ]ACV[7[-74%RQ5>F$3")A$PB81,(F$3"+[,KX_XE+_\
M=>M_^6L1SR[]//[)U_\ /6O]JG5I]9/[Q;W^:J?[%75/YNJYBF$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(MEN/'(!RJ1Y T/!RA=
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M!103W%7K9Z@9IN]CWN/TGQ]*IP+%VJ\8C:GH0/(>GOF[![NXG]XF!G<09WT
M?=%F;L6B?5&_<M<SO59Y"*K!.31AK[@;F%RVC[&<W[3=FU)^TG=;^2RP+9FD
M<:$\3FTYEG)M%^WYQ@>^/I!TD?7Z?I%TGEC$.]7>EREJU4O(N.0Q=I0[,4-.
MM/ZML3*]IQ#,+UT<WIXW"T+1E=KUX>)ER6^%QV  A=HXS_2#:T9F>L$A'HTG
M[D9"#<S,ZZ-<O96Y1%J,TTO*/3=$ZWOD4O[R3_7#@U=W\<XQ#4@_?$P^X[DS
M+#H4[B>%K$\:5F_N8D\,Y$:C3N)2D=Q;ML%^D[BBA7I0+;R9RD3<9?.!IM&
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MPB,A=QJ0 6CLVC[2$A?^1V=E5OP,N+NSF?L%?Y+-L];<0ZE3\T>]<]^VO/\
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M69_?F]Q+3*R]=8HS9>@&!_$.]ZRTQW$^59>LUW$XS(6J;N[-)#7FD!W;VMN
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MWV'8EJ-DCB%F6I!YFTSBVUAR^RG)HG,.FK%,6ENF:D_>US8F7%-1H %@\VT
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M8W*'!(WEU_#'%_=8O&4,?(6 CK8C9ULG7"*&F2%'[ =HL0Q%EE !339K*6:
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M2P]NZ,^A] @B"+6Q')>D0R=?Q!V('3L/D_GWT^M<4F_6T]TN"D+L+_&B=W[
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MJCG)8W+20%Z$GWK=.W-^--GKG'9K,,5ZC7":5SDB$& MSEVO)N9XA%BEW"+
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MGO0O]&^G)]'.X3)V9:>-N5;%R#_*1Q2QR''VZ>^(DY#V]GO,W;V*ONX7,XZ
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MB81,(F$3")A%]M?+S_CK)O\ LZ-_[!09Y)^DW]B*W^<F_P!*2VGZ\_WF7/\
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MN _B[ QLY.S>P=6U?1G=F[6[3:8CM616,B9*P>(^_IT8B-/CPT.S4].#@X#
M8("A[6MAINM'#UL?9%[ZH"P=(2PZ#TYYBYCD.3Y3)?K>30V()#9_#CDC.,1'
MLU:,39NQNS<_:[OVD[NO:WT\Q/"L)AWQO#+%6U%&[>-+%+%,9F[/H4QQN_:_
M;M%]&%NP69E<&:BM^3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
>$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tv523241_img.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_img.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M Q$!_\0 W@ !   & P$!              $&!P@)"@,$!0(+ 0$  00# 0$
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MQ-.)Y,_B!478@
M            UAO>SV9NC>W;GI%T)ZQZPJ=\9AAV5,]R=VZRNLJ3AV.3L.UY
M(>@Z\JLLOUQ9;,&OL\C<?DI2MLS6Y&;X#P%*^YE ^M6U.UW5?WO8N5]MNOF)
M]9,+]SS7;6(Q:;%-CL["Q.9N[358R=?9R+UN%71ZZYO*(T1VXRVR6[R1D:C
M?$V]"^!<_(@!$
M  '&\?#:OTI,OYC 'Y_77+3GM#YIH[W 7>]60)Q;?;?:SLS+I:R+F6<4V?/Q
M(]T_)PN?C>$U,A,2TGE8-I5&_P!6<]97!'R0</IH4\.IMTK5_M9M+^QKDO87
M*_;4Z^6G99K)2SEN!D%;CDW-8#M5F=OK"MO9D/7%KE5<^TR]$N9>,M,^=*D)
M4:$H,R\0*W]IER @
M              )!CZNUY$V#8[8C87C+&S+:@AXI99VW41$Y3.QJOD+E0J.3
M<DU]:Y61I#BEH9-?D)1\\ #@S;4NMMDS\0M<^P;%\NL\ R!K*L)G9!40[*7B
MV1L-J9:NJ.1(;6Y76"&EFGU&S(^ "X%0E*)!<GP22(S,S/@B(B^)F?V$0+BZ
M+F'P57R,>79'W)="Z#D3,>AS7-B9Q$4MI['<8?:=C0'T^!HM+;[\6.I"BX4A
M'G67VD0OEL/L'O/>D(9UZ"P=(EQ5RZFG)?S(<W[FZ(Q0[P^L'M7VHN7-*MWG
MJVY[=4\;&:DH/V7+GW8T\5QE[C%CEGO+;WL93B\/P/",<@FL_018E+N9'DY^
M[ZKGJ1D>8R^21D;IOI3V7CVTM4S,R_=IQ<:07T+B80:[_B)]R\R^Y;>TC3<3
M%KP5USNR?Q:Z4?.)^\QOBMEM'F&"83DD,U%ZR*TI5-()/)<^FX3LE'FX^:3(
M3J?I3V7D0:TO,S,>Y3@YTFJ^]47[1H7^(GW,Q+R>X='TW+Q_%6G.U*GC1OKX
MT]J,I'6[W+-![[E0\=GSG-<YS+4AEK'\G>::B3Y*^")NKM^$1)"UK/A*%>19
M_(QCIOSL!O39EN>H8\%GZ-&K=RTFY17MG#FO>U5&;79_UB]J>ZMZWI%Z\](W
M1<HECY+45.3\+5W[DZODJJ3]AD62HEI2I)D9*(E$9&1D9&7)&1EX&1BQ;33H
M^9EFFFJKD?0@D                                        @9<D *(
M2NM/7R=DR\SF:1U3*RUR?^*N9-(P+&7KQ=GY_/\ 7KLG*Y4M4OSESZAJ\W/C
MR(Z56OB5=<J4KP*VMMH:0EMM"6T(224(0DD(2E)<$E*4D1)(B+P(A)2?8
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MMUW3V+W5T=:ULC4+.9C*G7%.ERTW^&Y;=)0?Q5'X%:B\2Y'E"X0
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M@
M  %-=N[2Q/3&OLCV1FLY,"@QJ Y,D+Y+UI+Y\(B0(J#,O4ES9"DMMI^U1_(=
M_MC;>I[MUS'V_I$'/-R)]*]B7XI2]D8JK;/([[WMH/;O:F9O#<MU6=(PK3G)
M^,GRC"*\93E2,5XMFH#VC[4;%[1YU-R3*I\B)C$:4^C$L.8>7^%T=:2S)DU,
MD9(D6#S9$IUU1&9G\."(AM#[=]N=![<Z-#3]-@I:C**\Z^U\]R?CQ\(KP2-
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M]3U'1-0Q];TJX[6JXE^%ZU-/C&Y;DI1?UKC[C=<ZU;69W;H_6VS6_+ZV3XQ
MDV*4?NMVS#91+5HB^PD3V'"&I3?^VI;0WCJ&WG]S'R)*/O@_F@_^2T?I [/[
MZM=RNVFC;VMT4L["MSFEX74NFZOHFI(KJ/'%R@
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MW:^7;R,F,/\ -5V3_:V9+Q8 S#
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MF9.P^QNW] SHN.H?HU>NIJC4[[=UQ:\''K4?H+PA:TOX
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M(Y!!4
M     6B]T.L\'M!I6ZP=*XT3*Z]7XYA-L^GPA7T-"C:8=<+A:(EDWRR[P?@2
MB/[!<[M-W!O=NMW6=8EU3TRY^7D07XK<N;2Y5@_F7PIXEB?43V;Q>]G;?*VM
M6%O6[?YV'=:^Y?AQBF^:A<583IX.O@:?&88ED6!9-=89F%3*H\GQZ>_76U9,
M:6T\S(86:#61+X]1AXB\[:TF:5I,C(S(;1],U/ UC3[.K:7=C>TZ_!2A.+33
M37V-<FGQ3/S\;AT+5]K:UD[<W#8GBZYAW96[MJ2HXRB^?'G&2HXR7"2=4R6A
M]QU*Y<0!( '(PT])?8B18[TN7+?:C1(D9M;TF5)?633#$=ELC<>==<41)2DC
M,S,4SE"W!W;DE"U%-RD^"BEQ;;?))<V(0NWKL<?'A*YD3DHPA%-SG*3I&,8K
MBY-\$ES-JSVT.H$OKCK"9E^;Q&V=J;-1"L+F*M!&]C- R1N56-FYXG]07J>O
M*XX+U5$C^AR>N#U =T;6_-PPTK1Y.6W-.<HPEX7KKX3NT]G#IA[DWXF\;T;=
M@,CL_LJ[K^YK:COG6U"Y>B^>-8C5VL:O\2KUW?Y[Z>/0F9-ACZ9F
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MOAS;YMOBWQ;)P'6'>@
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MI"DJ(C(TJ3R2DF1\D9>!@FGR*6FG1\SD$D
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MF_IH9I2+P(6)+N$0
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MQK,+%O\ JX125>+HN!\^=FWM1S;N?D4\^]<E.5$DJR;;HER57P)C',?*
M                             &BA_P"9)/\ ^NO#TF7A_ _&#Y_25UD)
M<#83Z6E_Y>7GX_WA<_HP,'?4F_\ OOBKP_0K^G(H+["W_B3ZH_ZLYU_S%('H
M_41_NLS?]K:_IHZ3L!_O%L_]GN_L1^A2-:9GZ
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MG5*<1D3;=VW>K9LG*8[3>R'6/1GH:D172-2C02>301<0I)4H%&5>+=*OV?\
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M"O3MQ<+<[BBNN4(MMQBY5:3;HN!,(^,[$
M      -%'_S)"?\ ZZL0/_\ I#&"X^?_ ,9R'Q_80V$^EM_^7MY?_D+G]&!@
M]ZDU_P!]<5^'Z%?TY%!?86_\2?5'_5G._P#F*0/1^HG_ '6YO^UM?TT='V _
MWBV?]A=_8C]"@:TS/T
M                     (<%\B $0!#@OD0 CP7R #@OD   AP7R( 1 #@OD
M '!?(                                    :)O_F1D&GO9BBS6:B<T
MGBQDD_@G_P"+7R."_E29_P HV%>EMU[>7E[,^Y_1@8/>I/\ _M<5_P#45_3D
M4(]A;_Q)]3_]6<Z_YBDCT7J(_P!UF;_M;7]-'1]@:_\ B+9K_P#+W?V(_0I&
MM,S]
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M/NN<90;7M49).C\'3B5N'0';
M
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M;MI1MQ5$EP27N/1'&5@
M
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MV=C/GY<TY1]TH?>B_BBK)>)$?S'FCVP
M
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M$<BVN'GV4WRK3KC^%M>#,E)>)$?S%@S,
M
M                   "2-D9M5:XP7*\[NUDBKQ.ALKR9R9)-:($9;R64F?]
M-]Q)(+]*AVV@Z/DZ_K.+HN&JY&3>C;C[NITK]"XGG]U;BP=I;;SMS:DZ8.#C
M7+T_A"+E3XMJGTFD]N':.1;GV7E^S,IDKDVN36\N;Y%.*6W#@^JI$"!&)7/I
MQXD4DH2DO B(;;=K[=P-J:#B[?TV*CC8UI1_SI4^:3]KDZML_-]W"WQJW<C>
MFH;TUN;GFYN1.:3=?+MU:MVXUY1C&BHN!3%Q24FI2N"(N.3/[/L^0] DWP7,
M\;*48\9<CB-YI*?,:TDGP\?@7C\/U<BI0DW2CJ<;OVE'JZETD/J&2\?43P7Q
M/GP+^7C@3Y=SE1U(>187.4:?$Y2,E$1D?)'XD8H::X,Y5)255R*CZEV9D.FM
MCXAL[%Y"V+;%+B)8$A"U(3.A)=2FPK9'E,O4C38GF0I)\EXCHMR[?PMUZ%E;
M>U&*>-DVG'E]V5/EDO?&5&CUFQ-ZZKVYWCI^]]$FXY^!D1N-5:\RW5>;:E3G
M&<*IKZ? W9-8Y[4;/U_B&?T2R<J\MQ^MO(AD9*-M,Z,V\MA?')$XPXHT*+YI
M,:DMQ:+E;=US*T/,5,G%OSMOW]+HG]*XGZ0MF[GT_>FU=/W7I4NK U#$MWX>
MY7(J5'[TW1^]$^#ICTH             455V+T@G,W]>_P 3<25FD66_ DXX
MBS;79,38K:GI$5UI!*)M]EI)FI)F1EP)H^1%5XM?639%VAK^=78];0\QQZ16
MY9/<J\:F-6<9QB\L6E.I=@UJDK_UJ2T;"R6E/)I\I\\!1BJ7-DMXOO\ TQFN
M12\3Q79F&WV2052D2:6NNXCT]*X)J*83;!+)3YQ?35ZGD\WDX/D11BJY>)]8
M;O[3.PKN;CF%;*P_);V 4A4JJJKJ+(FH3$4I$E2627YGDQU(,EFCS$G@^> H
MQ5>U5.IC?8S1^7Y!*Q;&-GX?=WT%N>[,KJ^V9?<C-UA+.P<=<+AA"(?IJ]0S
M5PG@^1-!5>T]"DWQIS(ZK([VDV7AME38BHTY)9QKV"J%2^*DDJ?(-TFV4+4D
MR2KGRK,N",S$48JO:CNT>Y]5Y)3U.046?8M:TU[<HQVHL85M&=CS[UTC-NHC
MJ)?*IZR3R37@HR\>. H37A5'2O=\:;QC*F,(R'9>&4^62'&F44,^_@1[%+K_
M !Z#3[*W2^G=>Y+R)<-*E<^!&'$BI-2=@X2O+OR"G*:,\T_"BO?RP5C'.Z.F
M4?E*R*"2_6.(:OZ9%QQXA^P57TGIX[E&/9;!7:8U<0+NN1+EP%3:V2W*CE,@
M/*CS(QNMF:2>C/I-*R^PR#B2>\
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M??-=9<HRC8\?JFB:IPZ"FV5],XG-)Z8KB>8L&\>0[^&&K@B,C\HJ=/+HOO\
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MZU(C)FY/*>5'<0Z25DIEPS2?)?8*;JI*GN*\>2E:37!.O[3(V.,Y@
M
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M/.J-2C(N5*/D_$ >L
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MFNPC"*IXGQ8MZ_?N2=Q=,8^'M]_$V-B^!?J'SGWD0
M
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M !2YMF[+LMV3V?V0VK';NU[?5DSI+)R9I>=D7:4<YOV?PP7RQ7!(N8'@"\(
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M&(5? A,HCQ8<2.VEJ/&CL-DEMIEII))(B(B(B'SG<'H@
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MLA:N+*XF5$ER'.E)A.1V(\0Y#1I<0P1NFHR(RY/]0J@D?'F3G&*4'2K,2_\
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MXF9F?@1$0 X(\R++2:HTEB0E/@I3+S;J2/Y&IM2B(P!V.2^9?M( .2^9?M(
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M]QRBG2*KX<#V\AUMJ.D1-QR1DU+'R"/28O,JY;5CE$F]M+>U=BJGP)M<=45
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MZJN\XGY,=P7'TB#:R$U0OHU>/G^"B^P4S5JGR=5?><EK]17\WHI[J_RE[1?
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M.55^U/2E)87C<U2'5$TUP:VR5]I^-2Z>J2J^93^>XI-1I3@E5</?]AD2[:;
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M9#B>?@9&9']@Y>?Q.K\F\N#AQ./_ '<=_P#/_<[G9_I.DD?Z)@4.Q??X2/\
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MCRI2V2N.?'@A#:1S8]BZKJ<E2*-C%/P+]1?X!PG;D0
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04I);IMD7W?,9\?8!'[3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795475952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Other Balance Sheet Information - Prepaid and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_PrepaidClinicalTrialExpenseCurrent', window );">Prepaid clinical trial expenses</a></td>
<td class="nump">$ 435<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_EquityIssuanceCostsCurrent', window );">Equity issuance costs</a></td>
<td class="nump">343<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">670<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid and other current assets</a></td>
<td class="nump">$ 1,622<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_EquityIssuanceCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity issuance costs classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_EquityIssuanceCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_PrepaidClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets related to consideration paid in advance for clinical trials that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_PrepaidClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6809031760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment, Net (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation, Total</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6978225056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible note payable, due on March 29, 2019</a></td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableOneMember', window );">Convertible Note Payable, One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible note payable, due on March 29, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableTwoMember', window );">Convertible Note Payable Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible note payable, due on March 29, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableThreeMember', window );">Convertible Note Payable, Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible note payable, due on March 29, 2019</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableFourMember', window );">Convertible Note Payable, Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible note payable, due on March 29, 2019</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableFiveMember', window );">Convertible Note Payable Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible note payable, due on March 29, 2019</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableSixMember', window );">Convertible Note Payable Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible note payable, due on March 29, 2019</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6820515920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; font-family: times new roman; DISPLAY: inline;">
<div style="font-family;">
<div style="font-weight: bold; display: inline;">Note
<div style="FONT-STYLE: normal; DISPLAY: inline;">1.</div>
&#160;Organization and Basis of Presentation</div>
</div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; font-family: 'Times New Roman', Times, serif; MARGIN-TOP: 0pt;">
<div style="font-weight: bold; display: inline;">&#160;</div>
</div>
<div style="FONT-SIZE: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; MARGIN: 0pt 7.2pt 0pt 0pt;">
<div style="FONT-STYLE: italic; DISPLAY: inline;">
<div style="font-weight: bold; display: inline;">The Company</div>
</div>
</div>
<div style="FONT-SIZE: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; MARGIN: 0pt 7.2pt 0pt 0pt;">&#160;</div>
<div style="font-family;">On
<div style="FONT-STYLE: normal; DISPLAY: inline;">May 3, 2019,</div>
Adynxx, Inc. (&#8220;Adynxx&#8221; or the &#8220;Company&#8221;), formerly known as "Alliqua BioMedical, Inc.," or Alliqua completed its reverse merger with what was then known as Adynxx, Inc., or Private Adynxx, which we refer to as the Merger. This transaction was accounted for as a reverse merger. See
<div style="FONT-STYLE: italic; DISPLAY: inline;">&#8216;Note
<div style="FONT-STYLE: normal; DISPLAY: inline;">3</div>
&#8211; Reverse Merger&#8217;</div>
..</div>
<div style="font-family;">&#160;</div>
<div style="font-family;">The Company is a clinical stage biopharmaceutical company focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company is primarily engaged in developing initial product technology, recruiting personnel, and raising capital.</div>
<div style="font-family;">&#160;</div>
<div style="font-family;">
<div style="font-weight: bold; display: inline;">&#160;</div>
</div>
<div style="font-family;">
<div style="FONT-STYLE: italic; DISPLAY: inline;">
<div style="font-weight: bold; display: inline;">Basis of Presentation</div>
</div>
</div>
<div style="font-family;">
<div style="font-weight: bold; display: inline;">&#160;</div>
</div>
<div style="font-family;">&#160;</div>
<div style="font-family;">These unaudited financial statements represent the condensed consolidated financial statements of Adynxx and, for periods prior to the Merger, the condensed consolidated financial statements of Private Adynxx. The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and pursuant to the instructions of the SEC on Form
<div style="FONT-STYLE: normal; DISPLAY: inline;">10</div>
-Q and Article
<div style="FONT-STYLE: normal; DISPLAY: inline;">10</div>
of Regulation S-
<div style="FONT-STYLE: normal; DISPLAY: inline;">X</div>
of the SEC. Accordingly, they do
<div style="FONT-STYLE: normal; DISPLAY: inline;">not</div>
include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the Company&#8217;s financial position on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the periods ended
<div style="FONT-STYLE: normal; DISPLAY: inline;">June 30, 2018</div>
and
<div style="FONT-STYLE: normal; DISPLAY: inline;">2019</div>
are
<div style="FONT-STYLE: normal; DISPLAY: inline;">not</div>
necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the periods ended
<div style="FONT-STYLE: normal; DISPLAY: inline;">June 30, 2018</div>
and
<div style="FONT-STYLE: normal; DISPLAY: inline;">2019</div>
is unaudited.&#160;These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements and the notes thereto as set forth in the Company&#8217;s Form
<div style="FONT-STYLE: normal; DISPLAY: inline;">8</div>
-K/A filed with the SEC on
<div style="FONT-STYLE: normal; DISPLAY: inline;">June 10, 2019.</div>
</div>
<div style="font-family;">&#160;</div>
<div style="font-family;"><span style="FONT-SIZE: 13px; TEXT-DECORATION: none; font-family: Times New Roman; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; text-align: left; ORPHANS: 2; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: transparent; TEXT-INDENT: 26px; -webkit-text-stroke-width: 0px;">All share and per share data, for all periods presented, of the issued and outstanding common stock of Adynxx, Inc., have been retroactively restated to reflect the exchange ratio used in the Merger of 0.0359 shares of capital stock in exchange for each share of Private Adynxx, Inc. capital stock outstanding immediately prior to the Merger (which exchange ratio reflects a 1-for-6 reverse stock split of the issued and outstanding capital stock of Alliqua BioMedical, Inc. effected on May 3, 2019 immediately prior to the reverse merger).</span></div>
<div style="font-family;">&#160;</div>
<div style="font-family;"><span style="FONT-SIZE: 13px; TEXT-DECORATION: none; font-family: Times New Roman; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; text-align: left; ORPHANS: 2; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: transparent; TEXT-INDENT: 26px; -webkit-text-stroke-width: 0px;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amount of assets, liabilities, revenue, costs, expenses and other (expenses) income that are reported in the condensed consolidated financial statements and accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events, historical experience, actions that the Company may undertake in the future and on various other assumptions that are believed to be reasonable under the circumstances. As a result, actual results may be different from these estimates.</span></div>
<div style="font-family;">&#160;</div>
<div style="font-family;">
<div style="FONT-STYLE: italic; DISPLAY: inline;">
<div style="font-weight: bold; display: inline;">Liquidity</div>
</div>
</div>
<div style="font-family;">&#160;</div>
<div style="font-family;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As of
<div style="FONT-STYLE: normal; DISPLAY: inline;">June 30, 2019,</div>
the Company had
<div style="FONT-STYLE: normal; DISPLAY: inline;">$24,000</div>
in cash and cash equivalents, had term loans&#160;(&#8220;Term Loans&#8221;), including accrued interest outstanding, of
<div style="FONT-STYLE: normal; DISPLAY: inline;">$3.0</div>
million from Oxford Finance, LLC&#160;(&#8220;Oxford&#8221;), and
<div style="FONT-STYLE: normal; DISPLAY: inline;">$5.6</div>
million aggregate principal amount of convertible promissory notes (&#8220;Notes&#8221;), including accrued interest, outstanding. From inception through
<div style="FONT-STYLE: normal; DISPLAY: inline;">June 30, 2019,</div>
the Company had an accumulated deficit of approximately
<div style="FONT-STYLE: normal; DISPLAY: inline;">$44.4</div>
million. The Company expects to incur substantial losses in future periods. The Company is subject to risks common to companies in the clinical stage, including, but
<div style="FONT-STYLE: normal; DISPLAY: inline;">not</div>
limited to, development of new products, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product development plans. The Company has a limited operating history and has yet to generate any revenues from customers. There is
<div style="FONT-STYLE: normal; DISPLAY: inline;">no</div>
guarantee that profitable operations, if ever achieved, could be sustained on a continuing basis.</div>
<div style="font-family;">&#160;</div>
<div style="font-family;">In
<div style="FONT-STYLE: normal; DISPLAY: inline;">April 2019</div>
and
<div style="FONT-STYLE: normal; DISPLAY: inline;">May 2019,</div>
the Company issued Notes to current investors and received an additional
<div style="FONT-STYLE: normal; DISPLAY: inline;">$2.0</div>
million and
<div style="FONT-STYLE: normal; DISPLAY: inline;">$0.5</div>
million, respectively. The Notes accrue interest at
<div style="FONT-STYLE: normal; DISPLAY: inline;">8%</div>
per annum and mature on the
<div style="FONT-STYLE: normal; DISPLAY: inline;">first</div>
anniversary of the applicable issuance date. For further details, see the section below titled
<div style="FONT-STYLE: italic; DISPLAY: inline;">&#8216;Note
<div style="FONT-STYLE: normal; DISPLAY: inline;">6</div>
- Term Loans and Convertible Promissory Notes&#8217;.</div>
</div>
<div style="font-family;">&#160;</div>
<div style="FONT-SIZE: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; MARGIN: 0pt;"></div>
<div style="font-family;">The Company plans to finance its operations and capital funding needs through equity and/or debt financing. However, there can be
<div style="FONT-STYLE: normal; DISPLAY: inline;">no</div>
assurance that additional funding will be available to the Company on acceptable terms on a timely basis, if at all, or that the Company will generate sufficient cash from operations to adequately fund operating needs or ultimately achieve profitability. The conditions above, among others, raise substantial doubt about the ability of the Company to continue as a going concern within
<div style="FONT-STYLE: normal; DISPLAY: inline;">one</div>
year after the date of the issuance of the financial statements.</div>
<div style="font-family;">&#160;</div>
<div style="font-family;">The accompanying financial statements do
<div style="FONT-STYLE: normal; DISPLAY: inline;">not</div>
include any adjustments that might result from the outcome of these uncertainties.</div>
</div>
<span></span>
</td>
<td class="text"><div>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; FONT-WEIGHT: bold; MARGIN: 0pt 0pt 12pt;"><font style="font-family: Times New Roman,Times,serif; COLOR: #231f20; DISPLAY: inline;">Note&#160;</font><font style="DISPLAY: inline;">1.&#160;&#160;&#160;&#160;&#160;Organization and Basis of Presentation</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt;"><font style="FONT-WEIGHT: bold; FONT-STYLE: italic; DISPLAY: inline;">The Company</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">Adynxx, Inc. (the &#8220;Company&#8221;) was incorporated on October 24, 2007, in the state of Delaware. The Company&#160;&#160;is a clinical-stage pharmaceutical entity that is developing a technology platform&#160;&#160;to address pain at its molecular roots. The Company&#160;&#160;is primarily engaged in developing initial product&#160;&#160;technology, recruiting personnel, and raising capital.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt;"><font style="FONT-WEIGHT: bold; FONT-STYLE: italic; DISPLAY: inline;">Basis of Presentation</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">The accompanying financial statements&#160;&#160;have been prepared&#160;&#160;using accounting&#160;&#160;principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt;"><font style="FONT-WEIGHT: bold; FONT-STYLE: italic; DISPLAY: inline;">Liquidity</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">The accompanying financial statements&#160;&#160;have been prepared&#160;&#160;assuming the Company&#160;&#160;will continue as a going concern. As of December 31, 2018, the Company&#160;&#160;had $1.9 million in cash and cash equivalents, had Oxford term loans, or Term Loans, including accrued interest outstanding of $4.2 million, and convertible promissory notes, or Notes, including accrued interest, outstanding to investors of $4.6 million. From inception through&#160;&#160;December 31, 2018 the Company&#160;&#160;had an accumulated deficit of approximately $37.2 million. The Company&#160;&#160;expects to incur substantial losses in future periods. The Company&#160;&#160;is subject to risks common to companies in the clinical stage, including, but not limited to, development&#160;&#160;of new products, development&#160;&#160;of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product&#160;&#160;development&#160;&#160;plans. The Company&#160;&#160;has a limited operating history and has yet to generate any revenues from customers. There is no guarantee&#160;&#160;that profitable operations, if ever achieved, could be sustained on a continuing&#160;&#160;basis.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">The Company&#160;&#160;plans to finance its operations and capital funding needs through&#160;&#160;equity and/or&#160;&#160;debt financing. However, there can be no assurance that additional funding will be available to the Company&#160;&#160;on acceptable terms on a timely basis, if at all, or that the Company&#160;&#160;will generate sufficient cash from operations to adequately&#160;&#160;fund operating&#160;&#160;needs or ultimately achieve profitability. The conditions&#160;&#160;above, among others, raise substantial doubt&#160;&#160;about the ability of the Company&#160;&#160;to continue as a going concern within one year after the date of the issuance of the financial statements.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">The accompanying financial statements&#160;&#160;do not include any adjustments that might result from the outcome of these uncertainties.</font></p>
</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6830817312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock Options - Stock Options by Exercise Price Range (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 24.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, number of options (in shares) | shares</a></td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 24.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, weighted average remaining life in years (Year)</a></td>
<td class="text">5 years 255 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options exercisable (in shares) | shares</a></td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adyx_PriceRange1Member', window );">Price Range 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, lower (in dollars per share)</a></td>
<td class="nump">$ 1.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, upper (in dollars per share)</a></td>
<td class="nump">1.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, number of options (in shares) | shares</a></td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, weighted average remaining life in years (Year)</a></td>
<td class="text">2 years 182 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options exercisable (in shares) | shares</a></td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adyx_PriceRange2Member', window );">Price Range 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, lower (in dollars per share)</a></td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, upper (in dollars per share)</a></td>
<td class="nump">3.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, number of options (in shares) | shares</a></td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, weighted average remaining life in years (Year)</a></td>
<td class="text">3 years 73 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options exercisable (in shares) | shares</a></td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adyx_PriceRange3Member', window );">Price Range 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, lower (in dollars per share)</a></td>
<td class="nump">$ 3.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, upper (in dollars per share)</a></td>
<td class="nump">20.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, number of options (in shares) | shares</a></td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, weighted average remaining life in years (Year)</a></td>
<td class="text">7 years 182 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options exercisable (in shares) | shares</a></td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adyx_PriceRange4Member', window );">Price Range 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, lower (in dollars per share)</a></td>
<td class="nump">$ 21.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, upper (in dollars per share)</a></td>
<td class="nump">656.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 289.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, number of options (in shares) | shares</a></td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 289.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, weighted average remaining life in years (Year)</a></td>
<td class="text">255 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options exercisable (in shares) | shares</a></td>
<td class="nump">58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adyx_PriceRange1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adyx_PriceRange1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adyx_PriceRange2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adyx_PriceRange2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adyx_PriceRange3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adyx_PriceRange3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adyx_PriceRange4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adyx_PriceRange4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799999504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details', window );"><strong>Note 10 - Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Details)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Changes related to prior year positions</a></td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year positions</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 703<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_statement-statement-note-10-income-taxes-activity-related-to-gross-unrecognized-tax-benefits-details</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6818648816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">95,000,000<span></span>
</td>
<td class="nump">5,313,200<span></span>
</td>
<td class="nump">148,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">5,807,877<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="nump">19,548,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">5,807,877<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="nump">19,548,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Redeemable convertible preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,046,378<span></span>
</td>
<td class="nump">57,002,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">56,672,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">56,672,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable convertible preferred stock, liquidation value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,898,697,000<span></span>
</td>
<td class="nump">$ 12,898,697,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Redeemable convertible preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">51,069,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">51,069,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">51,069,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable convertible preferred stock, liquidation value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000,000<span></span>
</td>
<td class="nump">$ 16,000,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adyx_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adyx_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6802645360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Other Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid and Other Current Assets [Table Text Block]</a></td>
<td class="text"><div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">June&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Prepaid clinical trial expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>435
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Equity issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>343
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Prepaid insurance</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>670
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Other prepaid expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>174
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Total prepaid and other current assets</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,622
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="font-size:10pt;font-family:Times New Roman;">
<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">June&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Payroll and related expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>241
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>508
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Accrued term loan final payment</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>421
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>569
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Accrued clinical trial expense</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Professional fees and other costs</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>195
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>395
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Total accrued liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>857
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,480
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table>
</div>
<span></span>
</td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">As of December 31,</font><font style="display:inline;font-family:Times New Roman;color:#231F20;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Payroll and related expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 273</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 241</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Accrued term loan final payment&nbsp;&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 197</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 421</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Accrued clinical trial expense&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 654</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Professional fees and other costs </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 34</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 195</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Total accrued liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 1,158</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 857</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of prepaid and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6591701664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#231F20;">Note&nbsp;</font><font style="display:inline;">10.&nbsp;&nbsp;&nbsp;Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;recorded no income tax benefit or expense for the years ended December 31, 2017 and 2018. No tax benefit was recorded through&nbsp;&nbsp;December 31, 2018 because, given the history of operating losses, the Company&nbsp;&nbsp;believes it is more likely than not that the deferred tax asset will not be realized, and a full valuation&nbsp;&nbsp;allowance has been provided.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts&nbsp;&nbsp;of assets and liabilities for financial reporting&nbsp;&nbsp;purposes and the amounts&nbsp;&nbsp;used for income tax purposes. The following table presents significant components&nbsp;&nbsp;of the Company&#x2019;s deferred tax assets (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">As of December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Net operating loss carry forward</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 6,158</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 7,051</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Research and development credits</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 1,284</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 1,601</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Accruals and reserves</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 99</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 142</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Fixed assets</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Total deferred tax asset</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 7,541</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 8,795</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> (7,541)</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> (8,795)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Net deferred tax asset </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#x2019;s history of operating&nbsp;&nbsp;losses, the Company&nbsp;&nbsp;has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company&nbsp;&nbsp;has provided a full valuation&nbsp;&nbsp;allowance for deferred tax assets as of December 31, 2017 and 2018. The valuation&nbsp;&nbsp;allowance decreased approximately $964,000 and increased $1.2 million during the years ended December 31, 2017 and 2018, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">On December 22, 2017, the U.S. government&nbsp;&nbsp;enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the &#x201C;Tax Act&#x201D;). The Tax Act makes broad and complex changes to the U.S. tax code that affect fiscal 2017, including, but not limited to requiring a one-time transition tax on certain un-repatriated earnings of foreign subsidiaries (the &#x201C;Transition Tax&#x201D;). The Tax Act also establishes new tax laws that will affect 2018 and later years, including, but not limited to, a reduction&nbsp;&nbsp;of the U.S. federal corporate tax rate from 35% to 21% and a transition of U.S. international taxation&nbsp;&nbsp;from a worldwide tax system to a territorial system. During the year ended December 31, 2017, the Company&nbsp;&nbsp;did not recognize an amount&nbsp;&nbsp;for the one-time transition tax, nor did the Company&nbsp;&nbsp;make any accounting&nbsp;&nbsp;policy elections on the treatment of the other international provisions of tax reform due to the fact the Company does not currently have any foreign subsidiaries.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">During 2017, the Company&nbsp;&nbsp;corrected the balance of Net Operating&nbsp;&nbsp;Losses and Research and Development&nbsp;&nbsp;Credits and the associated Valuation&nbsp;&nbsp;Allowances in connection&nbsp;&nbsp;with the Company&#x2019;s determination of nexus in an additional state which was previously not identified correctly. The correction of such error did not have any impact on the Company&#x2019;s financial position and results of operations for any period presented or any prior period results. The Company&nbsp;&nbsp;has corrected the gross amount&nbsp;&nbsp;of deferred tax assets and the valuation&nbsp;&nbsp;allowance for 2016 to correct the error.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2018, the Company&nbsp;&nbsp;had federal net operating&nbsp;&nbsp;loss, or NOL, carry forwards of $33.5 million available to reduce future taxable income, if any. The NOL carry forwards prior to January 1, 2018 of $28.7 million will begin to expire in 2033. The NOL carry forwards incurred post December 31, 2017 of $4.8 million will carry forward indefinitely. As of December 31, 2018, the Company&nbsp;&nbsp;had federal and state research and development&nbsp;&nbsp;credits of $1.8 million and $0.7 million, respectively. The federal research and development&nbsp;&nbsp;credits will begin to expire in 2031. The state research and development credit will carry forward indefinitely.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Internal&nbsp;&nbsp;Revenue Code (&#x201C;IRC&#x201D;) Section 382 and similar California&nbsp;&nbsp;rules place a limitation&nbsp;&nbsp;on the amount&nbsp;&nbsp;of taxable income that can be offset by NOL and credit carry forwards after a change in control. Generally, after a control change, a corporation cannot deduct NOL or credit carry forwards in excess of the Section 382 limitations.&nbsp;&nbsp;Although&nbsp;&nbsp;the Company&nbsp;&nbsp;has not completed an analysis under Section 382 of the Code since the year ended December 31, 2012, it believes that it is unlikely that the utilization&nbsp;&nbsp;of the NOLs and tax credit carry forwards will be substantially&nbsp;&nbsp;limited.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The tax return years 2014 through&nbsp;&nbsp;2018 remain open to examination by the major domestic taxing jurisdictions to which the Company&nbsp;&nbsp;is subject. Net operations losses generated on a tax return basis by the Company&nbsp;&nbsp;for calendar years 2013 and 2015 to 2018 remain open to examination by the IRS. Net operating losses generated on state returns by the Company&nbsp;&nbsp;for calendar years 2007 to 2013 and 2015 to 2018 remain open to examination by state authorities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">ASC 740-10 requires companies to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities. The following table summarizes the activity related to the Company&#x2019;s gross unrecognized tax benefits (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">Years&nbsp;Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">December&nbsp;31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Balance at December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 331</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Changes related to prior year positions</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 330</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Increases related to current year positions</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Balance at December 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 703</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s policy is to record interest related to uncertain&nbsp;&nbsp;tax positions as interest and any penalties as other expense in its statement&nbsp;&nbsp;of operations. As of the date of adoption and through December 31, 2018, the Company&nbsp;&nbsp;did not have any interest and penalties associated with unrecognized tax benefits.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6818589952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Actual results could differ from those estimates and such differences could be material to the Company&#x2019;s financial position and results of operations.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Significant estimates and assumptions include the valuation of equity instruments and equity-linked instruments, including the valuation of the Company&#x2019;s common stock and the valuation of the Company&#x2019;s common stock options for purposes of accounting for stock-based compensation, and accruals for clinical trials and the valuation allowances on deferred tax assets.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Use of Estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">The preparation of financial statements&nbsp;&nbsp;in conformity&nbsp;&nbsp;with GAAP requires management to make estimates and assumptions&nbsp;&nbsp;that affect the reported&nbsp;&nbsp;amounts&nbsp;&nbsp;of assets and liabilities, the disclosure of contingent&nbsp;&nbsp;liabilities at the date of the financial statements,&nbsp;&nbsp;and the reported&nbsp;&nbsp;amounts&nbsp;&nbsp;of expenses incurred during the reporting&nbsp;&nbsp;period. Actual results could differ from those estimates and such differences could be material to the Company&#x2019;s financial position and results of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">Significant estimates and assumptions&nbsp;&nbsp;include the valuation&nbsp;&nbsp;of equity instruments and equity-linked instruments, including the valuation&nbsp;&nbsp;of the Company&#x2019;s common stock and the valuation&nbsp;&nbsp;of the Company&#x2019;s common stock options for purposes of accounting&nbsp;&nbsp;for stock-based&nbsp;&nbsp;compensation, and accruals for clinical trials and the valuation&nbsp;&nbsp;allowances on deferred tax assets.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; font-family: times new roman; DISPLAY: inline;">
<div style="FONT-SIZE: 10pt; font-family: times new roman; DISPLAY: inline;">
<div style="FONT-SIZE: 10pt; font-family: times new roman; DISPLAY: inline;">
<div style="FONT-SIZE: 10pt; font-family: times new roman; DISPLAY: inline;">
<div style="font-family;">
<div style="FONT-STYLE: italic; DISPLAY: inline;">
<div style="font-weight: bold; display: inline;">Concentration of Credit Risk and Other Risks and Uncertainties</div>
</div>
</div>
<div style="font-family;">
<div style="font-weight: bold; display: inline;">&#160;</div>
</div>
<div style="font-family;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any
<div style="FONT-STYLE: normal; DISPLAY: inline;">one</div>
financial institution
<div style="FONT-STYLE: normal; DISPLAY: inline;">may</div>
be in excess of the Federal Deposit Insurance Corporation insured limits. To date, the Company has
<div style="FONT-STYLE: normal; DISPLAY: inline;">not</div>
experienced any losses on its deposits of cash and cash equivalents.</div>
<div style="font-family;">&#160;</div>
<div style="font-family;">The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company's products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company's ability to attract and retain employees necessary to support its growth.</div>
<div style="font-family;">&#160;</div>
<div style="font-family;">The Company&#8217;s postoperative pain reduction product candidate, brivoligide, is an oligonucleotide. The Company currently uses Nitto-Denko Avecia, Inc. (&#8220;Avecia&#8221;) as a single supplier for the brivoligide drug substance. There are currently a limited number of oligonucleotide manufacturers with commercial scale capabilities globally. While the Company intends to develop secondary sources for manufacturing of its drug candidates in the future, there can be
<div style="FONT-STYLE: normal; DISPLAY: inline;">no</div>
assurance that it will be able to do so on commercially reasonable terms, or at all. Any interruption in the supply of this key material could significantly delay the research and development process or increase the expenses for development and commercialization of the Company&#8217;s product candidates. The quality of materials can be critical to the performance of a drug delivery technology. Therefore, the lack of a reliable source that provides a consistent supply of high quality materials would harm the Company. At
<div style="FONT-STYLE: normal; DISPLAY: inline;">June 30, 2019,</div>
this vendor&#8217;s activity was
<div style="FONT-STYLE: normal; DISPLAY: inline;">not</div>
material to total accounts payable.</div>
<div style="font-family;">&#160;</div>
<div style="font-family;"><span style="FONT-SIZE: 13px; TEXT-DECORATION: none; font-family: Times New Roman; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; text-align: left; ORPHANS: 2; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: transparent; TEXT-INDENT: 26px; -webkit-text-stroke-width: 0px;">At December&#160;31, 2018, three vendors represented 52%, 26% and 15% of total accounts payable. Two of these vendors supported general and administrative activities, primarily associated with the Merger and next round of equity financing, which accounted for 67% of the total accounts payable. The remaining vendor supported clinical study activities. At June&#160;30, 2019, three vendors represented 26%, 22% and 17% of total accounts payable, respectively. Two of these vendors supported general and administrative activities associated with the Merger and the next round of equity financing, which accounted for 44% of the total accounts payable. The remaining supported clinical study activities.</span></div>
</div>
</div>
</div>
</div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Concentration of Credit Risk and Other Risks and Uncertainties</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Financial&nbsp;&nbsp;instruments that potentially&nbsp;&nbsp;subject the Company&nbsp;&nbsp;to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance&nbsp;&nbsp;Corporation insured limits. To date, the Company&nbsp;&nbsp;has not experienced any losses on its deposits of cash and cash equivalents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company&#x2019;s future financial position, results of operations, or cash flows: ability to obtain&nbsp;&nbsp;future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory&nbsp;&nbsp;approval&nbsp;&nbsp;and market acceptance of the Company&#x2019;s products;&nbsp;&nbsp;development&nbsp;&nbsp;of sales channels; certain strategic relationships;&nbsp;&nbsp;litigation or claims against the Company&nbsp;&nbsp;based on intellectual property,&nbsp;&nbsp;patent,&nbsp;&nbsp;product,&nbsp;&nbsp;regulatory, or other factors; and the Company&#x2019;s ability to attract&nbsp;&nbsp;and retain employees necessary to support&nbsp;&nbsp;its growth.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s postoperative pain reduction&nbsp;&nbsp;product&nbsp;&nbsp;candidate,&nbsp;&nbsp;brivoligide, is an oligonucleotide.&nbsp;&nbsp;The Company&nbsp;&nbsp;currently uses Avecia as a single supplier for the brivoligide drug substance.&nbsp;&nbsp;There are currently a limited number of oligonucleotide&nbsp;&nbsp;manufacturers with commercial scale capabilities globally. While the Company&nbsp;&nbsp;intends to develop secondary sources for manufacturing of its drug candidates&nbsp;&nbsp;in the future, there can be no assurance that it will be able to do so on commercially reasonable&nbsp;&nbsp;terms, or at all. Any interruption in the supply of this key material could significantly delay the research and development process or increase the expenses for development&nbsp;&nbsp;and commercialization of the Company&#x2019;s product candidates.&nbsp;&nbsp;The quality of materials can be critical to the performance of a drug delivery technology. Therefore, the lack of a reliable source that provides a consistent supply of high quality materials would harm the Company.&nbsp;&nbsp;At December 31, 2018, this vendor&#x2019;s activity was not material to total accounts payable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">At December 31, 2017, two vendors represented&nbsp; 56% and 31%, of total accounts payable. The vendor that represented&nbsp; 56% of the Company&#x2019;s accounts payable, supported manufacturing activities and the other vendor was associated with clinical study activities. At December 31, 2018, three vendors represented&nbsp; 52%, &nbsp;26% and 15% of total accounts payable. Two of these vendors supported general and administrative activities, primarily associated with the Merger and next round of equity financing, which accounted&nbsp;&nbsp;for 67% of the total accounts payable. The remaining vendor supported clinical study activities.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ClinicalTrialAccrualsPolicyPolicyTextBlock', window );">Clinical Trial Accruals, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Clinical Trial Accruals</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Company&#x2019;s clinical trial accruals are based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical trials on the Company&#x2019;s behalf. The Company accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, the Company modifies the estimates of accrued expenses accordingly. To date, the Company has had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> significant adjustments to accrued clinical trial expenses.</div></div></div></div></div></div></div></div></div></div></div>
<span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Clinical Trial Accruals</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">The Company&#x2019;s clinical trial accruals are based on patient enrollment and related costs at clinical investigator&nbsp;&nbsp;sites as well as for the services received and efforts expended pursuant to contracts&nbsp;&nbsp;with multiple research institutions and contract&nbsp;&nbsp;research organizations that conduct and manage clinical trials on the Company&#x2019;s behalf. The Company&nbsp;&nbsp;accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol.&nbsp;&nbsp;If timelines or contracts&nbsp;&nbsp;are modified based upon changes in the clinical trial protocol&nbsp;&nbsp;or scope of work to be performed, the Company&nbsp;&nbsp;modifies the estimates of accrued expenses accordingly. To date, the Company&nbsp;&nbsp;has had no significant adjustments to accrued clinical trial expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">In March 2018, the Company&nbsp;&nbsp;closed its contracts&nbsp;&nbsp;with Premier Research International LLC and CRF Health,&nbsp;&nbsp;Inc. (&#x201C;Contract Research Organizations or CROs&#x201D;) upon completion&nbsp;&nbsp;of a Phase 2 clinical trial in March 2018. For the years ended December 31, 2017 and 2018, the Company&nbsp;&nbsp;incurred $6.2 million and $95,000, respectively, of expenses in connection&nbsp;&nbsp;with this clinical study.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">In November&nbsp;&nbsp;2018, the Company&nbsp;&nbsp;entered into agreements with PRA Health,&nbsp;&nbsp;Inc. and CRF Health, Inc. (&#x201C;Contract Research Organizations or CROs&#x201D;) pursuant to which the CROs agreed to assist the Company&nbsp;&nbsp;with the conduct of a Phase 2 clinical trial. To support&nbsp;&nbsp;additional clinical trial activities the Company&nbsp;&nbsp;also entered into agreements with Premier Research International LLC for biostatistical services, ICON Central Laboratories for laboratory services and Almac Clinical Services for storage and distribution services. In connection&nbsp;&nbsp;with this clinical study, the Company&nbsp;&nbsp;incurred expenses of $0 and $185,000 for the years ended December 31, 2017 and 2018, respectively.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Cash and Cash Equivalents</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Company considers all highly liquid investments purchased with a maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less on the date of acquisition to be cash and cash equivalents.</div></div></div></div></div></div></div></div></div></div></div>
<span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">The Company&nbsp;&nbsp;considers all highly liquid investments purchased&nbsp;&nbsp;with a maturity&nbsp;&nbsp;of three months or less on the date of acquisition&nbsp;&nbsp;to be cash and cash equivalents.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Property and Equipment, Net</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line method over the estimated useful lives of the assets, generally <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations.</div></div></div></div></div></div></div></div></div></div></div>
<span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Property and Equipment, Net</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Property&nbsp;&nbsp;and equipment&nbsp;&nbsp;are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line&nbsp;&nbsp;method over the estimated useful lives of the assets, generally three to five years. Leasehold improvements&nbsp;&nbsp;are amortized&nbsp;&nbsp;over the shorter of the estimated useful life of the asset or the remaining term of the lease.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Expenditures&nbsp;&nbsp;for repairs and maintenance are charged to expense as incurred. Upon disposition&nbsp;&nbsp;of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements&nbsp;&nbsp;of operations.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Impairment of Long-Lived Assets </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The Company&#x2019;s long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. As of December&nbsp;31, 2018 and June&nbsp;30, 2019, the Company had not experienced any impairment losses on its long-lived assets. </font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Impairment of Long-Lived Assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">The Company&#x2019;s long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount&nbsp;&nbsp;of the asset may not be recoverable. Recoverability&nbsp;&nbsp;of an asset to be held and used is measured by a comparison of the carrying amount&nbsp;&nbsp;of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount&nbsp;&nbsp;by which the carrying amount of the asset exceeds its fair value. As of December 31, 2017 and 2018, the Company&nbsp;&nbsp;had not experienced any impairment losses on its long-lived assets.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Restricted Cash </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">At December 31, 2018 and June 30, 2019, the Company had $55,000 restricted and held by a bank as collateral for a letter of credit provided to the Company&#x2019;s facility landlord. In addition, as of June 30, 2019, the Company had $200,000 restricted from withdrawal and held by a bank in the form of a secured money market account as collateral for Oxford in conjunction with a debt amendment that occurred in January 2019. </font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Restricted Cash</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2017 and 2018, the Company&nbsp;&nbsp;had $55,000 restricted and held by a bank as collateral for a letter of credit provided to the Company&#x2019;s facility landlord.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Stock-Based Compensation</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Company uses the Black-Scholes option-pricing model (the "Black-Scholes model") as the method for determining the estimated fair value of stock options.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;">Expected Term&#x2014;</div>The expected term represents the period that the Company's stock-based awards are expected to be outstanding and is determined using the simplified method.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;">Expected Volatility&#x2014;</div>Expected volatility is estimated using comparable public companies&#x2019; volatility for similar terms.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;">Expected Dividend&#x2014;</div>The Black-Scholes model calls for a single expected dividend yield as an input. Other than the dividend paid in connection with the Merger, the Company has never paid dividends and has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> plans to pay dividends.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;">Risk-Free Interest Rate&#x2014;</div>The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">zero</div>-coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line&nbsp;&nbsp;basis over the requisite service period, which is generally the vesting period. The Company&nbsp;&nbsp;recognizes forfeitures as they occur.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;uses the Black-Scholes option-pricing model (the &#x201C;Black-Scholes model&#x201D;) as the method for determining&nbsp;&nbsp;the estimated fair value of stock options.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Term &#x2014;</font><font style="display:inline;"> The expected term represents the period that the Company&#x2019;s stock-based&nbsp;&nbsp;awards are expected to be outstanding and is determined&nbsp;&nbsp;using the simplified method.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Volatility &#x2014;</font><font style="display:inline;"> Expected volatility is estimated using comparable public companies&#x2019; volatility for similar terms.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Dividend &#x2014; </font><font style="display:inline;">The Black-Scholes model calls for a single expected dividend yield as an input. The Company&nbsp;&nbsp;has never paid dividends and has no plans to pay dividends.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Risk-Free Interest Rate &#x2014; </font><font style="display:inline;">The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero-coupon&nbsp;&nbsp;issues in effect at the time of grant for periods corresponding with the expected term of the option.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Research and Development</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, preclinical studies, clinical studies performed by contract research organizations (&#x201c;CROs&#x201d;), materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development costs, including clinical study costs, to expense when incurred.</div></div></div></div></div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Research and development&nbsp;&nbsp;expenses consist of personnel costs, including salaries, benefits and stock-based&nbsp;&nbsp;compensation, preclinical studies, clinical studies performed&nbsp;&nbsp;by Contract Research Organizations (or &#x201C;CROs&#x201D;), materials and supplies, licenses and fees, and overhead allocations&nbsp;&nbsp;consisting of various administrative and facilities related costs. The Company&nbsp;&nbsp;charges research and development&nbsp;&nbsp;costs, including clinical study costs, to expense when incurred.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangement, Accounting Policy [Policy Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Collaboration Agreement </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In June&nbsp;2018, the Company entered into a collaboration agreement with twoXAR, an artificial intelligence-driven drug discovery company, in order to identify potential product candidates for the treatment of endometriosis. In May&nbsp;2019, the Company made a collaboration initiation payment of $75,000, which was charged to research and development expenses for the six&nbsp;months ended June&nbsp;30, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In June&nbsp;2019, Adynxx received an initial set of candidate predictions from twoXAR. The Company has initiated a review of the potential products to determine if any are viable candidates for further research and development. </font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Collaboration Agreement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In June 2018, the Company&nbsp;&nbsp;entered into a collaboration agreement with twoXAR,&nbsp;&nbsp;an artificial intelligence-driven drug discovery company, in order to identify potential&nbsp;&nbsp;product&nbsp;&nbsp;candidates&nbsp;&nbsp;for the treatment of endometriosis.&nbsp;&nbsp;Through&nbsp;&nbsp;December 31, 2018, the Company&nbsp;&nbsp;was not obligated to make any payments under the terms of the collaboration agreement.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_GrantReimbursementPolicyPolicyTextBlock', window );">Grant Reimbursement, Policy [Policy Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Grant Reimbursements </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In December&nbsp;2018, the Company received a Notice of Award from the National Institute on Drug Abuse (&#x201C;NIDA&#x201D;), part of the National Institutes of Health (&#x201C;NIH&#x201D;), to support the clinical development of its lead product candidate, brivoligide. NIH grants provide funds for certain types of expenditures in connection with research and development activities over a contractually defined period. The maximum funding expected to be available under this grant for qualified expenditures over the two-year period through December&nbsp;2020 is&#x2009;approximately $5.7&nbsp;million. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">On January&nbsp;1, 2019, the Company adopted Accounting Standards Update (ASU) 2018-08, &#x201C;Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.&#x201D; Based on this guidance, the Company determined that grant payments received met the definition of a &#x2018;conditional contribution&#x2019; (versus an exchange contract) because (i)&nbsp;the Company has limited discretion in the way the funds may be spent, which creates a barrier to entitlement, and (ii) the grant contains provisions that release the awarding agency from the obligation to transfer funds that are not expended at the time the award is terminated. The Company recognizes grant reimbursements as a contra operating expense and reflects this as a component of its loss from operations in the period during which the qualifying expenses are incurred and the related services rendered, provided that the applicable performance obligations have been met. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">For the six&nbsp;months ended June&nbsp;30, 2019, the Company incurred qualified expenses and recognized $1,198,000 of grant reimbursements. </font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Grant Reimbursements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In December 2018, the Company&nbsp;&nbsp;received a Notice of Award from the National Institute&nbsp;&nbsp;on Drug Abuse (&#x201C;NIDA&#x201D;), part of the National Institutes&nbsp;&nbsp;of Health (&#x201C;NIH&#x201D;), to support&nbsp;&nbsp;the clinical development&nbsp;&nbsp;of its lead product&nbsp;&nbsp;candidate,&nbsp;&nbsp;brivoligide. NIH grants provide funds for certain types of expenditures in connection&nbsp;&nbsp;with research and development&nbsp;&nbsp;activities over a contractually defined period. The maximum funding expected to be available under this grant for qualified expenditures over the two year period through December 2020 is approximately $5.7 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2018, the Company&nbsp;&nbsp;had not incurred qualified expenses.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Income Taxes</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company's tax return.</div></div></div></div></div></div></div></div></div></div></div>
<span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">The Company&nbsp;&nbsp;accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined&nbsp;&nbsp;based on differences between the financial reporting&nbsp;&nbsp;and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company&nbsp;&nbsp;provides a valuation&nbsp;&nbsp;allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">In evaluating the ability to recover its deferred income tax assets, the Company&nbsp;&nbsp;considers all available positive and negative evidence, including its operating&nbsp;&nbsp;results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company&nbsp;&nbsp;determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation&nbsp;&nbsp;allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined&nbsp;&nbsp;not to be realizable in the future, an adjustment to the valuation&nbsp;&nbsp;allowance would be charged to earnings in the period such determination is made.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">The Company&nbsp;&nbsp;recognizes the tax benefit from uncertain&nbsp;&nbsp;tax positions in accordance&nbsp;&nbsp;with GAAP, which prescribes a recognition threshold&nbsp;&nbsp;and measurement&nbsp;&nbsp;attribute for the financial statement&nbsp;&nbsp;recognition and measurement&nbsp;&nbsp;of uncertain&nbsp;&nbsp;tax positions taken or expected to be taken in a company&#x2019;s tax return.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock', window );">Convertible Preferred Stock Warrants, Policy [Policy Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Convertible Preferred Stock Warrants </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">At December&nbsp;31, 2018, freestanding warrants to acquire shares of convertible preferred stock were classified as liabilities on the accompanying balance sheet. These warrants were subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. In connection with the Merger, the warrants were exchanged into warrants that no longer met the definition of a derivative and thus, $234,000 of warrant liabilities was reclassified into equity during the six&nbsp;months ended June&nbsp;30, 2019. </font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Convertible Preferred Stock Warrants</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Freestanding warrants&nbsp;&nbsp;to acquire shares of convertible preferred stock are classified as liabilities on the accompanying balance sheets. These warrants&nbsp;&nbsp;are subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. The Company&nbsp;&nbsp;will continue to adjust the carrying values of freestanding&nbsp;&nbsp;warrants&nbsp;&nbsp;classified as liabilities for changes in fair value until the earlier of the exercise or expiration&nbsp;&nbsp;of the warrants&nbsp;&nbsp;or the completion&nbsp;&nbsp;of a liquidation event, including the completion&nbsp;&nbsp;of an initial public offering.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock', window );">Debt Modifications and Extinguishments, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Debt Modifications and Extinguishments</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">When the Company modifies debt, it does so in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">470</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,</div> <div style="display: inline; font-style: italic;">Debt: Modifications and Extinguishments</div>, which requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#x201c;substantial modifications&#x201d;. A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, the Company determined that the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2018 </div>modification of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2018 </div>Notes, to add an additional conversion option in the event of a reverse merger, was considered to be a &#x201c;substantial modification&#x201d;. As a result, it treated this modification as an &#x2018;extinguishment&#x2019; of those debts and recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11,000</div> of net gain from this debt extinguishment in other income in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2018. </div>All other changes to debt provisions were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> considered substantial and were treated as debt modifications.</div></div></div></div></div></div></div></div></div></div></div>
<span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Debt Modif ications and Extinguishments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">When the Company&nbsp;&nbsp;modifies debt, it does so in accordance with Accounting Standards Codification (&#x201C;ASC&#x201D;) 470-50, </font><font style="display:inline;font-style:italic;">Debt: Modifications and Extinguishments</font><font style="display:inline;">, which requires modification&nbsp;&nbsp;to debt instruments to be evaluated to assess whether the modifications&nbsp;&nbsp;are considered &#x201C;substantial modifications&#x201D;. A substantial modification&nbsp;&nbsp;of terms shall be accounted&nbsp;&nbsp;for like an extinguishment.&nbsp;&nbsp;Based on the guidance relied upon and the analysis performed,&nbsp;&nbsp;the Company&nbsp;&nbsp;determined&nbsp;&nbsp;that the October 2018 modification&nbsp;&nbsp;of the March 2018 and September 2018 Notes, to add an additional conversion option in the event of a reverse merger, was considered to be a &#x201C;substantial modification&#x201D;. As a result, it treated this modification&nbsp;&nbsp;as an &#x2018;extinguishment&#x2019; of those debts and recognized $11,000 of net gain from this debt extinguishment&nbsp;&nbsp;in other income. All other changes to debt provisions were not considered substantial and were treated as debt modifications.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives, Policy [Policy Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Derivative Instruments </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">ASC 815-15, </font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Derivatives and Hedging: Embedded Derivatives</font><font style="display:inline;color:#000000;font-size:10pt;">, generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a)&nbsp;the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b)&nbsp;the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)&nbsp;a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirement of ASC 815. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">At December 31, 2018 and June&nbsp;30, 2019, the Company maintained outstanding Notes which contained various embedded derivative features. In particular, these Notes contained the following features: </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A share settled redemption in a qualified preferred stock financing; and </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The right to an accelerated cash repayment in the event of a change in control. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:1pt;">&#x200B;</font><font style="display:inline;color:#000000;font-size:10pt;">These embedded features were not considered clearly and closely related to the debt host, therefore, they were bifurcated and accounted for separately from the debt host as a derivative liability. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in the statement of operations at each period end while such instruments are outstanding. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">As of December 31, 2018 and June&nbsp;30, 2019, the Company determined that there was no fair value associated with the embedded derivatives that remained with the outstanding convertible notes. See </font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">&#x2018;Note&nbsp;6&#x2009;&#x2014; Term Loans and Convertible Promissory Notes&#x2019; </font><font style="display:inline;color:#000000;font-size:10pt;">for further discussion of the Notes and the bifurcated derivative liability. </font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Derivative Instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">ASC 815-15, </font><font style="display:inline;font-style:italic;">Derivatives and Hedging: Embedded Derivatives</font><font style="display:inline;">, generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding&nbsp;&nbsp;derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics&nbsp;&nbsp;and risks of the embedded derivative instrument&nbsp;&nbsp;are not clearly and closely related to the economic characteristics&nbsp;&nbsp;and risks of the host contract,&nbsp;&nbsp;(b) the hybrid instrument&nbsp;&nbsp;that embodies both the embedded derivative instrument&nbsp;&nbsp;and the host contract&nbsp;&nbsp;is not re-measured at fair value under otherwise applicable generally accepted accounting&nbsp;&nbsp;principles with changes in fair value reported&nbsp;&nbsp;in earnings as they occur and (c) a separate instrument&nbsp;&nbsp;with the same terms as the embedded derivative instrument&nbsp;&nbsp;would be considered a derivative instrument&nbsp;&nbsp;subject to the requirement&nbsp;&nbsp;of ASC 815.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;issued certain Notes in March 2018, September 2018, and December 2018, which contained&nbsp;&nbsp;various embedded derivative features. In particular, these Notes contained&nbsp;&nbsp;the following features:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(1)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"></font>A share settled redemption in a qualified preferred stock financing; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(2)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"></font>The right to an accelerated cash repayment&nbsp;&nbsp;in the event of a change in control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">These embedded features were not considered clearly and closely related to the debt host, therefore, they were bifurcated&nbsp;&nbsp;and accounted&nbsp;&nbsp;for separately from the debt host as a derivative liability. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in the statement&nbsp;&nbsp;of operations at each period end while such instruments are outstanding.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In October 2018, the Company&nbsp;&nbsp;modified the March 2018 and September 2018 Notes to add an additional conversion feature. The Company determined this was a </font><font style="display:inline;font-style:italic;">&#x201C;substantial modification&#x201D;</font><font style="display:inline;"> as defined in ASC 470-50 </font><font style="display:inline;font-style:italic;">&#x2018;Debt: Modifications and Extinguishments&#x2019;</font><font style="display:inline;">. As a result, these Notes were accounted&nbsp;&nbsp;for as an &#x2018;extinguishment&#x2019; of the debt and related derivative liability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2018, the Company&nbsp;&nbsp;determined&nbsp;&nbsp;that there was no fair value associated with the embedded derivatives that remained with the modified March 2018, the modified September 2018 and December 2018 Notes. See </font><font style="display:inline;font-style:italic;">&#x2018;Note 5 &#x2014; Term Loans and Convertible Promissory Notes&#x2019;</font><font style="display:inline;"> for further discussion of the Notes and the bifurcated&nbsp;&nbsp;derivative liability.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Fair Value of Financial Instruments </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">ASC 820-10, </font><font style="display:inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;">Fair Value Measurement</font><font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">, provides a framework for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. The standard defines fair value as an exit price, representing the amount that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. The standard also establishes a fair value hierarchy, which prioritizes the inputs used in measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;">Level&nbsp;1</font><font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#x2009;&#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;">Level&nbsp;2</font><font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#x2009;&#x2014; Inputs other than quoted prices included within Level&nbsp;1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;">Level&nbsp;3</font><font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#x2009;&#x2014; Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The following table presents the Company&#x2019;s fair value hierarchy for its warrant liability measured at fair value on a recurring basis at December&nbsp;31, 2018 (in thousands): </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:47.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Level&nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">Financial liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">Warrant liability</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">Total financial liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-indent:20.15pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The Level&nbsp;3 derivative at December&nbsp;31, 2018 consisted of a warrant liability of Private Adynxx that, at December&nbsp;31, 2018, was exercisable into preferred shares that were potentially redeemable. In connection with the Merger, the warrants were exchanged into warrants that no longer met the definition of a derivative and thus, the balance was reclassified into equity during the six&nbsp;months ended June&nbsp;30, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The change in fair value of the warrant liability for the six&nbsp;months ended June&nbsp;30, 2018 and 2019 are as follows (in thousands): </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">Fair value, beginning of period</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">Change in fair value of preferred stock warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">Exchange of warrants upon Merger</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(234
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">Fair value at end of period</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-indent:20.15pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the Company&#x2019;s term loan is based on the borrowing rate currently available to the Company for borrowings with similar terms and maturity and approximates its carrying value. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Derivative liability instruments are considered Level&nbsp;3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level&nbsp;3 liability instruments consist of the preferred stock warrant liability and derivative liability, for both of which there is no observable market data for the determination of fair value and requires significant management judgment and estimation. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">While the Company&#x2019;s Notes contain embedded derivative liabilities, the Company determined that the fair value of these liabilities were zero at December&nbsp;31, 2018 and June&nbsp;30, 2019. See &#x2018;</font><font style="display:inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;">Note 6&#x2009;&#x2014; Term Loans and Convertible Promissory Notes&#x2019;</font><font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> for further discussion on the derivative liability activity. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The change in fair value of the derivative liability relating to the Notes for the six&nbsp;months ended June&nbsp;30, 2018 and 2019 is summarized below (in thousands): </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">Fair value, beginning of period</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">Embedded derivative liability from the issuance of Notes</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>496
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">Change in value of embedded derivatives</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(60
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">Fair value at end of period</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>436
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Fair Value of Financial Instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">ASC 820-10, </font><font style="display:inline;font-style:italic;">Fair Value Measurement</font><font style="display:inline;">, provides a framework&nbsp;&nbsp;for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. The standard defines fair value as an exit price, representing the amount&nbsp;&nbsp;that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. The standard also establishes a fair value hierarchy, which prioritizes the inputs used in measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Level 1</font><font style="display:inline;"> &#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the Company&nbsp;&nbsp;has the ability to access as of the measurement&nbsp;&nbsp;date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Level 2</font><font style="display:inline;"> &#x2014; Inputs&nbsp;&nbsp;other than quoted prices included within Level 1 that are directly observable for the asset or liability or indirectly observable through&nbsp;&nbsp;corroboration with observable market data.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Level 3</font><font style="display:inline;"> &#x2014; Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement&nbsp;&nbsp;date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining&nbsp;&nbsp;fair value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The following tables present the Company&#x2019;s fair value hierarchy for all of its financial instruments measured at fair value on a recurring basis as of December 31, 2017 and December 31, 2018 (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:49.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">As of December 31, 2017&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Level 1</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Level 2</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Level 3</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Financial liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Warrant liability </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Total financial liabilities </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:49.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">As of December 31, 2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Financial liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Level 1</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Level 2</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Level 3</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Warrant liability </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Total financial liabilities </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities.&nbsp;&nbsp;The fair value of the Company&#x2019;s term loan is based on the borrowing&nbsp;&nbsp;rate currently available to the Company&nbsp;&nbsp;for borrowings&nbsp;&nbsp;with similar terms and maturity&nbsp;&nbsp;and approximates its carrying value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Derivative liability instruments are considered Level 3 when their fair values are determined&nbsp;&nbsp;using pricing models, discounted&nbsp;&nbsp;cash flow methodologies,&nbsp;&nbsp;or similar techniques, and at least one significant model assumption or input is unobservable. Level 3 liability instruments consist of the preferred stock warrant liability and derivative liability, for both of which there is no observable market data for the determination of fair value and requires significant management judgment and estimation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The fair value of the warrant liability was determined&nbsp;&nbsp;using the Black-Scholes model (see </font><font style="display:inline;font-style:italic;">&#x2018;Note 8 &#x2014; Warrants&#x2019;</font><font style="display:inline;"> for a further discussion of the preferred stock warrants). The change in fair value of the preferred stock warrant liability is summarized below (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="middle" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Years Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="middle" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Fair value, beginning of period&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 54</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Preferred stock warrants &#x2013; exercised </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (8)</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Change in fair value of preferred stock warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (4)</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 98</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Fair value at end of period&nbsp;&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 42</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The fair value of the embedded derivative liability related to the Company&#x2019;s Notes was determined using a bond plus option model. As of December 31, 2018, the Company&nbsp;&nbsp;determined&nbsp;&nbsp;that there was no fair value remaining for the embedded derivatives associated with the modified March 2018, modified September 2018 and December 2018 Notes. See </font><font style="display:inline;font-style:italic;">&#x2018;Note 5 &#x2014; Term Loans and Convertible Promissory Notes&#x2019;</font><font style="display:inline;"> for further discussion on the derivative liability activity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The change in fair value of the derivative liability relating to the Notes is summarized below (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="middle" style="width:18.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Years Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="middle" style="width:18.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Fair value, beginning of period </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$ &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Embedded derivative liability from the issuance of Notes&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 864</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Change in value of embedded derivatives&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (211)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Termination of the embedded derivative liability due to the extinguishment&nbsp;&nbsp;of the related Notes</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> (653)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Fair value at end of period </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued Operations, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Discontinued Operations</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Discontinued operations represent the activities of the AquaMed business&nbsp;between the date of the Merger and the date of the spin-off. See &#x2018;<div style="display: inline; font-style: italic;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> &#x2013; Reverse Merger&#x2019;</div>. There are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> ongoing activities or obligations associated with discontinued operations at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019.</div></div></div></div></div></div></div></div></div></div></div></div>
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Recently Adopted Accounting Pronouncements </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;">Lease Accounting </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In February&nbsp;2016, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued ASU No. 2016-02, Leases (Topic 842) (&#x201C;ASU 2016-02&#x201D;). ASU 2016-02 is intended to improve financial reporting of leasing transactions by requiring organizations that lease assets to recognize assets and liabilities for the rights and obligations created by leases that extend more than twelve&nbsp;months on the balance sheet. This accounting update also requires additional disclosures surrounding the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for financial statements issued for annual and interim periods beginning after December&nbsp;15, 2018 for public business entities. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1)&nbsp;its effective date or (2)&nbsp;the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company adopted the new standard on January&nbsp;1, 2019 and used the effective date as its date of initial application. Consequently, the Company has not adjusted prior period amounts. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The Company has elected the package of practical expedients permitted in ASC Topic 842. Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a)&nbsp;whether the contracts contain a lease under ASC Topic 842, (b)&nbsp;whether classification of the operating leases would be different in accordance with ASC Topic 842, or (c)&nbsp;whether the unamortized initial direct costs would have met the definition of initial direct costs in ASC Topic 842 at lease commencement. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The most significant impact from the adoption of this standard was the recognition of right-of-use, or ROU, assets and lease obligations on the balance sheet for operating leases. This standard did not have a material impact on the Company&#x2019;s cash flows from operations and operating results. As a result of the adoption of the new lease accounting guidance, the Company recognized on January&nbsp;1, 2019 (a)&nbsp;a lease liability of approximately $227,000, which represents the present value of the remaining lease payments of approximately $239,000, discounted using the Company&#x2019;s incremental borrowing rate of 9.41%, and (b)&nbsp;a right-of-use asset of approximately $227,000 which represents the lease liability of&#x2009; $227,000. The ROU asset is being amortized over the remaining term of the lease of twelve&nbsp;months from January&nbsp;1, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Recent Accounting Pronouncements Not Yet Effective </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In August&nbsp;2018, the FASB issued No. ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. This ASU is effective for fiscal&nbsp;years beginning after December&nbsp;15, 2019, including interim periods within that fiscal year, with early adoption permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-indent:36pt;color:#000000;font-family:times new roman;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In August&nbsp;2018, the FASB issued ASU 2018-15, Intangibles&#x2009;&#x2014;&#x2009;Goodwill and Other&#x2009;&#x2014;&#x2009;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, (&#x201C;ASU 2018-15&#x201D;). The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January&nbsp;1, 2020 and early adoption is permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements.</font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Recently Adopted Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Restricted Cash</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In November&nbsp;&nbsp;2016, the FASB issued ASU No. 2016-18, Statement&nbsp;&nbsp;of Cash Flows: Restricted&nbsp;&nbsp;Cash. This ASU requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts&nbsp;&nbsp;shown on the statement&nbsp;&nbsp;of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation&nbsp;&nbsp;of the total in the statement&nbsp;&nbsp;of cash flows to the related captions in the balance sheet. This guidance is effective for fiscal periods beginning after December 15, 2017 and interim periods within that fiscal year, with early adoption permitted.&nbsp;&nbsp;The amendments in this ASU should be applied retrospectively to all periods presented. The Company&nbsp;&nbsp;adopted the guidance on a retrospective basis on January&nbsp;&nbsp;1, 2018 and the beginning and ending of cash and cash equivalents for all periods presented in our statements&nbsp;&nbsp;of cash flows include restricted cash.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Non-employee Share-Based Payment Accounting</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In June 2018, FASB issued ASU No. 2018-07, &#x201C;Compensation &#x2014; Stock Compensation (Topic 718): Improvements to Nonemployee&nbsp;&nbsp;Share-Based Payment Accounting&#x201D; (&#x201C;ASU 2018-07&#x201D;). This new guidance changes the accounting&nbsp;&nbsp;for non-employee share-based&nbsp;&nbsp;payments to align with the accounting&nbsp;&nbsp;for employee stock compensation. The Company&nbsp;&nbsp;early adopted&nbsp;&nbsp;the guidance as of January&nbsp;&nbsp;1, 2018 and the impact to its financial statements&nbsp;&nbsp;was not material.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Recent Accounting Pronouncements Not Yet Effective</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Lease Accounting</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In February 2016, the Financial&nbsp;&nbsp;Accounting&nbsp;&nbsp;Standards Board (&#x201C;FASB&#x201D;) issued ASU No. 2016-02. This standard introduces the new leases standard that applies a right-of-use (&#x201C;ROU&#x201D;) model and requires a lessee to record, for all leases with a lease term of more than 12 months,&nbsp;&nbsp;an asset representing its right to use the underlying asset and a liability to make lease payments. For leases with a term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. At inception, lessees must classify all leases as either finance or operating&nbsp;&nbsp;based on five criteria. Balance sheet recognition of finance and operating&nbsp;&nbsp;leases is similar, but the pattern of expense recognition in the income statement, as well as the effect on the statement&nbsp;&nbsp;of cash flows, differs depending on the lease classification. This ASU is effective for public entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted&nbsp;&nbsp;for all entities. The Company&nbsp;&nbsp;is currently assessing whether these amendments will have a material effect on its financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In August 2018, the FASB issued No. ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements&nbsp;&nbsp;as part of its disclosure framework&nbsp;&nbsp;project. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year, with early adoption permitted.&nbsp;&nbsp;The Company&nbsp;&nbsp;is currently assessing whether these amendments will have a material effect on its financial statements.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ClinicalTrialAccrualsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for clinical trial accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ClinicalTrialAccrualsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for convertible preferred stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ConvertiblePreferredStockWarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for debt modifications and extinguishments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtModificationsAndExtinguishmentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_GrantReimbursementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for grant reimbursement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_GrantReimbursementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6802899968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Other Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Disclosures [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Note 5.&nbsp;&nbsp;&nbsp;Other Balance Sheet Information </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Prepaid and other current assets consist of the following (in thousands): </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">June&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Prepaid clinical trial expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>435
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Equity issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>343
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Prepaid insurance</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>670
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Other prepaid expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>174
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Total prepaid and other current assets</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,622
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Accrued liabilities consist of the following (in thousands): </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">June&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Payroll and related expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>241
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>508
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Accrued term loan final payment</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>421
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>569
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Accrued clinical trial expense</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Professional fees and other costs</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>195
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>395
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Total accrued liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>857
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,480
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799632368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; FONT-WEIGHT: bold; MARGIN: 0pt 0pt 12pt;"><font style="font-family: Times New Roman,Times,serif; COLOR: #231f20; DISPLAY: inline;">Note&#160;</font><font style="font-family: Times New Roman,Times,serif; DISPLAY: inline;">7</font><font style="DISPLAY: inline;">.&#160;&#160;&#160;&#160;&#160;Stockholders&#8217; Deficit</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; FONT-WEIGHT: bold; FONT-STYLE: italic; MARGIN: 0pt 0pt 12pt;"><font style="DISPLAY: inline;">Redeemable Convertible Preferred Stock</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">As of December 31, 2017 and 2018, the Company&#160;&#160;had 56,672,658 shares of Series A convertible preferred stock issued and outstanding, including 3,531,889 shares issued as a result of a conversion of notes to investors and accrued interest to Series A convertible preferred stock in 2010. As of December 31, 2017 and 2018, the Company&#160;&#160;had 51,069,262 shares of Series B convertible preferred stock issued and outstanding, including 6,469,356 shares issued as a result of a conversion of notes to investors and accrued interest to Series B convertible preferred stock in 2016.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">The holders of preferred stock have various rights and preferences including the following:</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="FONT-STYLE: italic; DISPLAY: inline;">Voting Rights &#8212;</font> <font style="DISPLAY: inline;">A holder of each share of Series A and Series B convertible preferred stock shall have the right to one vote for each share of common stock into which such preferred stock could be converted. Series A convertible preferred stock holders voting as a separate class are entitled to elect two directors to the Company&#8217;s Board of Directors&#160;&#160;as long as shares of Series A convertible preferred stock remain outstanding. Series B convertible preferred stock holders voting as a separate class are entitled to elect one director to the Company&#8217;s Board of Directors&#160;&#160;as long as at least 10,000,000 shares of Series B convertible preferred stock remain outstanding. Common&#160;&#160;stockholders voting as a separate class are entitled to elect two directors. The holders of preferred and common stock voting together as a single class on an as-if-converted basis are entitled to elect all remaining directors.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="FONT-STYLE: italic; DISPLAY: inline;">Dividends &#8212;</font> <font style="DISPLAY: inline;">Holders of Series B convertible preferred stock, in preference to the holders of Series A preferred and common stock, are entitled to receive noncumulative dividends at the annual rate of $0.0251 per share, when, as, and if declared by the Board of Directors.&#160;&#160;Holders of Series A convertible preferred stock are entitled to receive noncumulative dividends at the annual rate of $0.0182 per share, when, as, and if declared by the Board of Directors.&#160; No dividends on preferred stock have been declared by the Board of Directors&#160;&#160;during the years ended December 31, 2017 and 2018.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="FONT-STYLE: italic; DISPLAY: inline;">Liquidation Preference &#8212;</font> <font style="DISPLAY: inline;">In the event of any liquidation, dissolution,&#160;&#160;or winding up of the Company, including a merger, acquisition,&#160;&#160;or sale of assets, as defined, the holders of Series B convertible preferred stock are entitled to receive an amount&#160;&#160;of $0.3133 per share (as adjusted for recapitalizations, stock combinations, stock dividends, stock splits, and the like), plus any declared but unpaid dividends prior to and in preference to any distribution to the holders of Series A preferred or common stock.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">After distributions have been made to all holders of Series B convertible preferred stock as described above, the remaining assets of the Company&#160;&#160;available for distribution to stockholders shall be distributed to all holders of Series A convertible preferred stock. The holders of Series A convertible preferred stock are entitled to receive an amount&#160;&#160;of $0.2276 per share (as adjusted for recapitalizations, stock combinations, stock dividends, stock splits, and the like), plus any declared but unpaid dividends prior to and in preference to any distribution to the holders of common stock. The remaining assets of the Company available for distribution to stockholders shall be distributed ratably among the holders of the common stock and preferred stock on an as-if-converted basis.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="FONT-STYLE: italic; DISPLAY: inline;">Conversion Rights &#8212;</font> <font style="DISPLAY: inline;">Each share of Series A and Series B convertible preferred stock is convertible, at the option of the holder, into shares of common stock on a one for one basis (subject to adjustment for certain events). The preferred stock will also be converted automatically into shares of common stock (1) immediately prior to an initial public offering with aggregate proceeds of at least $40 million and an offering price of not less than $1.00 per common share or (2) upon the date specified by written consent of holders of a majority of the outstanding preferred shares on an as-converted&#160;&#160;basis.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">The Series A and Series B Preferred Stock were classified as temporary equity in the accompanying balance sheets as of the December 31, 2017 and 2018, as shares are subject to redemption upon the occurrence of uncertain&#160;&#160;events not solely within the Company&#8217;s control. As of December 31, 2017 and 2018, the Series A and Series B Preferred Stock were not redeemable.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; FONT-WEIGHT: bold; FONT-STYLE: italic; MARGIN: 0pt 0pt 12pt;"><font style="DISPLAY: inline;">Common Stock</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><span style="FONT-SIZE: 13px; TEXT-DECORATION: none; font-family: Times New Roman; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; text-align: left; ORPHANS: 2; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: transparent; TEXT-INDENT: 26px; -webkit-text-stroke-width: 0px;">The Company&#8217;s articles of incorporation, as amended, authorize the Company to issue 148,000,000 shares of&#8201; $0.001 par value common stock. As of December&#160;31, 2017 and 2018, the Company had 19,548,969 shares outstanding. Common stockholders are entitled to dividends when and if declared by the Board of Directors and after any Series&#160;B and Series&#160;A convertible preferred shares dividends are fully paid. The holder of each share of common stock is entitled to one vote. At December&#160;31, 2018, no dividends had been declared.&#160;</span>&#160;</p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt;"><font style="FONT-WEIGHT: bold; FONT-STYLE: italic; DISPLAY: inline;">Shares Reserved for Future Issuance</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">The Company&#160;&#160;reserved shares of common stock for future issuances as follows (in thousands):</font></p>
<p style="FONT-SIZE: 16px; TEXT-DECORATION: none; font-family: Times New Roman; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; text-align: left; ORPHANS: 2; MARGIN: 0px; LETTER-SPACING: normal; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px;" />
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;" />
<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:70.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56,673
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56,673
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Series&nbsp;B convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51,069
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51,069
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Warrants for Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Common stock options issued and outstanding</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,222
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,222
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,294
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,294
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table>

</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6808957760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">As of December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Net operating loss carry forward</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 6,158</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 7,051</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Research and development credits</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 1,284</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 1,601</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Accruals and reserves</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 99</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 142</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Fixed assets</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Total deferred tax asset</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 7,541</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 8,795</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> (7,541)</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> (8,795)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Net deferred tax asset </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Income Tax Contingencies [Table Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">Years&nbsp;Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">December&nbsp;31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Balance at December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 331</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Changes related to prior year positions</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 330</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Increases related to current year positions</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Balance at December 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 703</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>368</ContextCount>
  <ElementCount>433</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>102</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-document-and-entity-informationQuarterEnd</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unauditedQuarterEnd</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticalsQuarterEnd</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-operations-unauditedQuarterEnd</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-redeemable-convertible-preferred-stock-and-stockholders-deficit-unauditedQuarterEnd</Role>
      <ShortName>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-condensed-consolidated-statements-of-cash-flows-unauditedQuarterEnd</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Note 1 - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentationQuarterEnd</Role>
      <ShortName>Note 1 - Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Note 2 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policiesQuarterEnd</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Note 3 - Reverse Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-3-reverse-mergerQuarterEnd</Role>
      <ShortName>Note 3 - Reverse Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Note 4 - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-netQuarterEnd</Role>
      <ShortName>Note 4 - Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Note 4 - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote4AccruedLiabilities</Role>
      <ShortName>Note 4 - Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Note 5 - Other Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-informationQuarterEnd</Role>
      <ShortName>Note 5 - Other Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Note 6 - Term Loans and Convertible Promissory Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notesQuarterEnd</Role>
      <ShortName>Note 6 - Term Loans and Convertible Promissory Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Note 6 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingencies</Role>
      <ShortName>Note 6 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Note 7 - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-7-leasesQuarterEnd</Role>
      <ShortName>Note 7 - Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Note 7 - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote7StockholdersDeficit</Role>
      <ShortName>Note 7 - Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Note 8 - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stockQuarterEnd</Role>
      <ShortName>Note 8 - Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Note 9 - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-9-warrants-QuarterEnd</Role>
      <ShortName>Note 9 - Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Note 10 - Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-10-stock-optionsQuarterEnd</Role>
      <ShortName>Note 10 - Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Note 10 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote10IncomeTaxes</Role>
      <ShortName>Note 10 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Note 11 - Related-party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactionsQuarterEnd</Role>
      <ShortName>Note 11 - Related-party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Note 12 - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote12EmployeeBenefitPlan</Role>
      <ShortName>Note 12 - Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Note 12 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-12-subsequent-eventsQuarterEnd</Role>
      <ShortName>Note 12 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policiesQuarterEnd</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-tablesQuarterEnd</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policiesQuarterEnd</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Note 4 - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-tablesQuarterEnd</Role>
      <ShortName>Note 4 - Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-netQuarterEnd</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Note 4 - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote4AccruedLiabilitiesTables</Role>
      <ShortName>Note 4 - Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adynxx.com/role/DisclosureNote4AccruedLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Note 5 - Other Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-tablesQuarterEnd</Role>
      <ShortName>Note 5 - Other Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-informationQuarterEnd</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Note 6 - Term Loans and Convertible Promissory Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-tablesQuarterEnd</Role>
      <ShortName>Note 6 - Term Loans and Convertible Promissory Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notesQuarterEnd</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Note 6 - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesTables</Role>
      <ShortName>Note 6 - Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Note 7 - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-7-leases-tablesQuarterEnd</Role>
      <ShortName>Note 7 - Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-7-leasesQuarterEnd</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Note 7 - Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitTables</Role>
      <ShortName>Note 7 - Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adynxx.com/role/DisclosureNote7StockholdersDeficit</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Note 8 - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote8WarrantsTables</Role>
      <ShortName>Note 8 - Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Note 10 - Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-10-stock-options-tablesQuarterEnd</Role>
      <ShortName>Note 10 - Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-10-stock-optionsQuarterEnd</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Note 10 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote10IncomeTaxesTables</Role>
      <ShortName>Note 10 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adynxx.com/role/DisclosureNote10IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Note 1 - Organization and Basis of Presentation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentation-details-textualQuarterEnd</Role>
      <ShortName>Note 1 - Organization and Basis of Presentation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-1-organization-and-basis-of-presentationQuarterEnd</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-details-textualQuarterEnd</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-tablesQuarterEnd</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-recurring-basis-detailsQuarterEnd</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Change in Fair Value of Preferred Stock Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-change-in-fair-value-of-preferred-stock-warrant-liability-detailsQuarterEnd</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Change in Fair Value of Preferred Stock Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Note 3 - Reverse Merger (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-3-reverse-merger-details-textualQuarterEnd</Role>
      <ShortName>Note 3 - Reverse Merger (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-3-reverse-mergerQuarterEnd</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Note 4 - Property and Equipment, Net (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-details-textualQuarterEnd</Role>
      <ShortName>Note 4 - Property and Equipment, Net (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-tablesQuarterEnd</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-4-property-and-equipment-net-property-and-equipment-net-detailsQuarterEnd</Role>
      <ShortName>Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Note 4 - Accrued Liabilities - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote4AccruedLiabilitiesAccruedLiabilitiesDetails</Role>
      <ShortName>Note 4 - Accrued Liabilities - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Note 5 - Other Balance Sheet Information - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-accrued-liabilities-detailsQuarterEnd</Role>
      <ShortName>Note 5 - Other Balance Sheet Information - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Note 5 - Other Balance Sheet Information - Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-5-other-balance-sheet-information-prepaid-and-other-current-assets-detailsQuarterEnd</Role>
      <ShortName>Note 5 - Other Balance Sheet Information - Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Note 6 - Term Loans and Convertible Promissory Notes (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-details-textualQuarterEnd</Role>
      <ShortName>Note 6 - Term Loans and Convertible Promissory Notes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-tablesQuarterEnd</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Note 6 - Term Loans and Convertible Promissory Notes - Future Principal Payments of Term Loans (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesFuturePrincipalPaymentsOfTermLoansDetails</Role>
      <ShortName>Note 6 - Term Loans and Convertible Promissory Notes - Future Principal Payments of Term Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Note 6 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote5TermLoansAndConvertiblePromissoryNotesConvertiblePromissoryNotesDetailsParentheticals</Role>
      <ShortName>Note 6 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Note 6 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-6-term-loans-and-convertible-promissory-notes-convertible-promissory-notes-detailsQuarterEnd</Role>
      <ShortName>Note 6 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Note 6 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Note 6 - Commitments and Contingencies - Future Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote6CommitmentsAndContingenciesFutureLeasePaymentsDetails</Role>
      <ShortName>Note 6 - Commitments and Contingencies - Future Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Note 7 - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-7-leases-details-textualQuarterEnd</Role>
      <ShortName>Note 7 - Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-7-leases-tablesQuarterEnd</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Note 7 - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-7-leases-future-minimum-lease-payments-detailsQuarterEnd</Role>
      <ShortName>Note 7 - Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Note 7 - Stockholders' Deficit (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitDetailsTextual</Role>
      <ShortName>Note 7 - Stockholders' Deficit (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Note 7 - Stockholders' Deficit - Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote7StockholdersDeficitSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Note 7 - Stockholders' Deficit - Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Note 8 - Redeemable Convertible Preferred Stock (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stock-details-textualQuarterEnd</Role>
      <ShortName>Note 8 - Redeemable Convertible Preferred Stock (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-8-redeemable-convertible-preferred-stockQuarterEnd</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Note 9 - Warrants (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-9-warrants-details-textualQuarterEnd</Role>
      <ShortName>Note 9 - Warrants (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-9-warrants-QuarterEnd</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Note 9 - Warrants - Details of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote8WarrantsDetailsOfWarrantsDetails</Role>
      <ShortName>Note 9 - Warrants - Details of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Note 9 - Warrants - Warrants Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote8WarrantsWarrantsAssumptionsDetails</Role>
      <ShortName>Note 9 - Warrants - Warrants Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Note 10 - Stock Options (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-10-stock-options-details-textualQuarterEnd</Role>
      <ShortName>Note 10 - Stock Options (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-10-stock-options-tablesQuarterEnd</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Note 10 - Stock Option Plans - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote9StockOptionPlansSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Note 10 - Stock Option Plans - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Note 10 - Stock Options - Stock Options by Exercise Price Range (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-10-stock-options-stock-options-by-exercise-price-range-detailsQuarterEnd</Role>
      <ShortName>Note 10 - Stock Options - Stock Options by Exercise Price Range (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41304 - Disclosure - Note 10 - Stock Options - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-10-stock-options-summary-of-stock-option-activity-detailsQuarterEnd</Role>
      <ShortName>Note 10 - Stock Options - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Note 10 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote10IncomeTaxesDetailsTextual</Role>
      <ShortName>Note 10 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/role/DisclosureNote10IncomeTaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Note 10 - Income Taxes - Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote10IncomeTaxesComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Note 10 - Income Taxes - Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41403 - Disclosure - Note 10 - Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote10IncomeTaxesActivityRelatedToGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Note 10 - Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Note 11 - Related-party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactions-details-textualQuarterEnd</Role>
      <ShortName>Note 11 - Related-party Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/20190630/role/statement-note-11-relatedparty-transactionsQuarterEnd</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Note 12 - Employee Benefit Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote12EmployeeBenefitPlanDetailsTextual</Role>
      <ShortName>Note 12 - Employee Benefit Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adynxx.com/role/DisclosureNote12EmployeeBenefitPlan</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="adyx-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Note 13 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adynxx.com/role/DisclosureNote13SubsequentEventsDetailsTextual</Role>
      <ShortName>Note 13 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>adyx-20190630.xml</File>
    <File>adyx-20190630.xsd</File>
    <File>adyx-20190630_cal.xml</File>
    <File>adyx-20190630_def.xml</File>
    <File>adyx-20190630_lab.xml</File>
    <File>adyx-20190630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>35
<FILENAME>0001144204-19-048109-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-19-048109-xbrl.zip
M4$L#!!0    ( ,5X2T_V[_0:FST" "@Q(  1    861Y>"TR,#$Y,#8S,"YX
M;6SLO>N6VTB2)OA[YBFTZM-S=L]95_H5<%=UY9[0K4J]DB)64F9-_<KC5P4K
M&60T2$J*?OHU!V\@ R1!!B\ B9II)8,$0?AGGYF;N9N;_<?_\_.N^^R[SP:=
M?N^OS\D+_/R9[]F^Z_2^_?7Y;U_0U9?7[]\__W]^_9__\7\@].QOON<S/?3N
MF7EX]F[TK\YP,'KVOC>$[P_U-__L?_]#]]RS5YA(]0RAR9=>9W[ZE:_]^WO=
M>_;19UFGVQU?\M-DW<[+^.\S>);>X*5V#S__^OQV.+Q_^<LO/W[\> %O]'[^
M?&'[=[]03!1.&#SE^-I.[[L?#&=7Q[N\&'C[XEO_^R_CS^)7&,($,3+]DO.=
M\F_ !_DO+%X^&J!O6M_/OA+TP+SH9]]^F7Q0\I5>O]<;W2T,(O^A^"TWS'X9
M/MS[7^ B!%?YK&.GW[.C+ /X'\H?;_II_,%T\0?]3WM;_J7X2?R"7/S"\';4
M<SYS_3N_\)B?W_SM7:<+TA]$O&?/U1_UAMFJQQI_6/)4HV%6C@'%6/T"GTXO
M'&3#Q_#"FR70PK/]N?*F[)?XL=$#/Y.$[MA!^7/G'\5?((N_\//13_Q@^0\0
MI=0O^:<S^@WZG))TS?-,KI@-M&/+'P8^*'L4N,0MD75RZ^27\8>S.P_OLQ6W
MAD]6W+NS[LE[H-,].T/RYZ!3!@I<2W[YWQ\_?+&W_DZCV;=^_9_/GOU'Q.KE
M(/_DLP_/<NQ>1O+_]?F@<W??C3?/W[O-?/CK\ZCY:*KB+WX.W/-?\MN,383M
M@Z'Y.7S6<7]]_CYG-*$PGC\F:HA>=_5@<!W^H;-,]X;7V>?.M]OAU<_.X(_\
MOI/W!^_ZV1?0.3^X>MT'"Y$-.Z;K;^#WP2AY]V78MW]^]'?&9[,;?_1Z,,K\
MG>\-W_?N1\.O,(#\OJLN^-P9_/DN\SZWC&"#/H/]F]P32(T^Z]ZW\0WB7Q\[
MO<[=Z&[\>0[;;,1PO\[P8?S6[,V.BV^'CL^>Y<@NZN]4Z*_?_[_/?\4@&RPX
M3?E__++\Y:6[#ORW^/C3=R?O.WB&G_?=CNT,Q\_WS'7@LO%D 0__<C:4Y[_&
M/Q?&\A^_E-YBFY^8 /QRI6B?_QIE^W)KV>[QV5:QX_FOJZY838\-CS65XH*P
MIF\6R3(1ZCU@T7?+_,DU=/CK7(-FY)A\LG#;^3VF[TSTL)&:>0.3K?^]W]5#
MF.2&#ZU2MDJYCAFM/AY8']_^O/<6@H.O/KMKE;%5QI6T:#6Q5CZK_GD^&ED<
M2ZN1K<]:-\VL-D>V&GEA&GFV<V3:<$ULO=56$X^KB6FKB>V<V&IBJXFUBAN;
MI''GJ0ZU"=HN3RU*EY-;C3BU1M1AE?]0RI",]_>W5(:O_9M19F_UH""L#7+\
M+6:.7/\,_<Q]Z.O>U3<P,1&9I^K,EUN=^5Q"9Z\N>T?]I%JU++@C*]2$^*U"
MM;[9V:E6;5RX5LE:3^\,]:L.#F&K6I57^5J]:HA>G7PE[E!*)1"!^^+F*E7K
M%#9>N6KC%$Z4H56RUBD\)_VJ@U/8JE;K%)Z;7IW<*6R5:L4%XQ^,\FW7WYNG
M5Z72.Q/5P@C'4\7-5:TV:?"XJ4KGI=HGGS(G^E<3O:[?29A6<2\LA:0VBR^7
MIYGMZ>U6*>N[8G-Y^MB>&6V5LITIZZB9E6?*5BDO3"G;F;(]K]8J8TV4L5W=
M.;HF7MI.1T,TH0Y;&(=2AD.?4FO9>WRN'.H0UW(9FB]#")KB$T\ RT<\Y\H8
MFU=G2)"5 Y\0I-K(C\R*8Q4GJL2*<S0;U5A1,UM1+U9\]L[[.PW07"X_*F-P
M)DQ9]D"JS2HM4[; X$S\CYV8TMJ4&MN40S#ES;2A!(3X)1/1^Y[MW_FO^N?5
M:'C;S^")%T+R-_#A8-BQK\>-(Y8B^L=?_J3O%F/Z?$.AI[N?_7??&WD0P'>(
M&=]__K)T*[C):\"^,WP-T<1#Z&<_=.86[O39#[S.[.WC+][DD"Q<_%8##O#D
M\.D_X5O-972Y?.;!>:F ]K@\L%K$\V?8(.,]/LU*ELP?9I$F^_WM.='FOU?*
MM&/8#; -V? -V+M?YQH^N_'LL\7O^)Z;?V/!UDP_V;NGVU0#TQJ+UE@T,X+8
M4@-SG^FJYS[TK>[^YRCK#%S'#@')5H$>*= &K%KR'FZAY.U_C> 97_?O[OL]
M^'.PQ+RA[O2\@\FX%QNB-9>!:\=;E'W9@"^: U<.M 6PU-T;W7'O>Z_U?6>H
MNV=/A;7C/A-&K%SJ:*U"[:S"T9>[6JM0<ZMPN"J:K55HBE5(:L6!UBJ<WBH<
MBA&[I654WA+8DFF7M;.RMSVX W"_!OL[#<TN:"E_C,W$EO*'7R. M^_ZO7/A
MY7KA/QKKF4C^P DRK;%KY_>Z!;H'SO1I*=_.[XVA?#N_UV1^/_JJ7CN_M_/[
M:8W=T1<QV_F]G=\OC/+M_%Z3^?T0DG\S[?8P3D:?_,2QA;@M* N9MLG6F;9+
M0.XETW9#5O]5S!9[=+[^[=U]M__@?<ZIZ_N2'+^;KN[-,FSSN>;KK8]O-E?;
M%J HI&VOPF*/5KZ(YF3.68#S& I=TRQQA3"+A(VU5/)L9)_=P\,\+)+O3?].
M=Y8Y^J'3\]=AG!SY3MN\-,[\*^/2L.\Z/=VS_L.'U\M?[O>^P6_=O?%F7G]B
M3'1X-U:4'2S[3",S\/\UBN;Z._SS2*F6/F^>HL02,&4BF#"V*(,]ZL8J*4Y^
MM5R,^_S]$B),=721"?MT^\JY5,@O+B/3D>?]B6H>?,?FLQ\,LTXLJ?-:#VZO
M>OE_HDOT77>C-U3^[EQA/_@A"'#*(=(\Q2OD<>\(Q(2PI4B<Z6Y/RYIS8LT)
M#KQ.3TT -F_\=]_MW\>17,42-M_&JP5PKTS;6)S>9S +W;WK9]?#6Y\-7CTL
MN@RONYU>Q^KNE^'(/4"L?@<"GMY^<LQIG&P%$U@4Q>=W?_>Z.X3/;*-Y]W3\
M)A1\,H 7ZD&?BN*?K\;X%P6Q06SO7U]_>NWCSW4_:-//]+"?K[KUW%7W3MO9
M_<?' !N<C'LXO3@6ZA>L3.E<F4H<CG:^J*5>-&&^2+>F>'I&%&_GBW:^.$ME
M*G&^VM8FE^ H5!/\A18'/U?!EZU>WF1]N,WP(>[F#,%.QC66W((79L3IM=<A
M@-6<7=$\7LSS$38.>KZ673KJ,UF5? H;WHVR7F<XRF(=D7>=G_%5@]V8K2BQ
M>N@M+V)NR_T(W+)+LQ,KQGW!C!AO5$S]\(=+(<1X5V+5L,^$#\NQ=^M'-,&/
M.-8IA]:/:)8?44=>M'Y$:RE:/Z(N?L2A,AR220)EX>61$B1?-Y<^#4@ZK/:C
M^U]I2Q:S_BJEM2]\8V]+K'F"/55_%%X>B=FO6F8?D-FO3L?L2*+MF%W\QMZ8
M+1"!^_(_"B^/Q.RKEMD'9/;5B9@](=$6S%[ZQC&2T<Z\/T?;%>*I!-FE0403
MF7*(Y@SG2IFRE?/266Z^Z#$[NAT_;RY+RJ>;^1I'R3#/8&5\@XEH"_O6K+!O
M#4W&AAS'ED)UIE ],OLJSSIE!X:;2)*]'8)MPAQ3*MUV0:FY8?<1%Y3.CYKM
MBM"9K B=(&>EM9H-IN9IK.:QML5;J]E@:I[&:AZ*FLL3^CO=R7[7W9%_]3![
M^7<0<3R/]? A'@%;3.^:7O.^=S\:#O(+V!)A"[?\Z/5@E.41W[LL+R%C'\KO
M5[AR\-G;499!X-=<7E>#M9 [MAK7/;*]@F1*'FF-:,[$E5BC%"V#6ZZLG=M;
M ]H:T,8HQ;$<WI;!+5<J3[:Y=]_1W??P"]DH/OL"/_ZA8_6!!F^>KAC@7/@+
M(SS7:;*5\@FE?*RN&*V43RGE0]5&7Y,#T0K\Z *O:9;#$TCR!G[NNQYVOOLS
MYLGR("^8*FL28EI[<EI[4H^4EPWV9-(Y9X+4=?:Y\^UV.-\6F;P_>-?/)LUT
M-K30:2*/5F(PV;W8&H0+MD=/IMK[P6#D8^/Z?J_G;:Q?]X_.\':V@735<PW>
M/:[(M,H87##1UDQ\+=&:3[1Z3)YE:VQO.M^CQ%RAY<"G?L^.[D;=W"6=?0[3
MQ=_[7>>SV)ENW'SQ#"?/!3@F[-H7'F>R?K='!IVC^_44!M7!$SOMIGI=-THO
M* QMMU>W?;;:!>YGD!ASD0K74KL.U&Y@'L]%:DL[/35?AYN:=G21"M=2^]34
MCDN%"F$Q62K,7Q9#<6^&2SS,X_$O'F[B/O6'_FO_W:CGOM[Z>,!:]QX&U_ (
M>5^5Y3["ZT^F?-3_RDN"O(=X=3#L9Q?7A7B^>;L,^23FWP+S/6K$AE,S*\2V
MQP>H;\O@A079B1)ML2 [T;6]K_S#??E<G3EB>*,ZO^MD@V&KS<?4YNJ0M\I\
M"F7F6RMSU+1C[A>O4N;"DF_DUXU^T/#RZX_^&6K1AK%>\/[O_HASF_D&)\MM
M2YWY:%OR/)T\U[W+H<YLK!=,G#59)^UT5;_IJAY9)/LE3CM=M>1IIZLZ3U?U
M(,[[+98[(VR#=FWD6(2M!G>[+G+D_8>E!<N#;:VUGF(M/,43;*JVKEYM7+W:
M2[_UU9HK^>U*O:Z8?ILH]X,X&DU)@SMRRZ>V3=_N_G"MVO05J+G4OJFIU&SP
MR;D&4/,T!7[/A)IM@=]#4O,T!7[K3,V6:,V1^61K6"&:_E%XN47\=I/U[SJ#
M03][B-'-^'CU%W\_S*&@:;QI<VE1):BK#, I-I&C-+?:1%[XQCZS#]BD__'T
MY1,I=MW[&(]S4!57,2^/8"7#/P6]V'9-B)>^L<^"!;C*LM/'OHOR<V/LX'M7
M/3=];ZZR\'Z^7;&\B;.VVUJ1L_FWX=97UF9YL0EP(6+?U/ZD!L#9'&-?1=Y=
M<-[GULOZ/G%%_=I%5,=?N\&'.",R=B?$'X671PI(IIHUR(;HL^Y]&U\2__K8
MZ77N1G=+=_Q=9YVX9OH9Q+JP;PH_Y?J]7&A&]_Z\#B K[^)E'SJFGWWYH>_C
M'\W3,,#BY0R9Y[_&/Q>@.=Y&:1U"K/U;B&5&S7=EMZ+4T:?<B:)N,>4N?6.?
M1U($S.9_%%X69]^Q>8V@OWKXK=?YKY%_XP<VZ]S'W?[E"3->=AUR4PS ]ZM5
MRGD\+T\J0.77%,^U;7>W2TK5V"BEA<ER)S$=8EI?%O3L--VQ'ZBV*1XEY]C8
M%D9CZ1M[,QK)/*MON?;WUD;CHKSL[12UME[M BV3K7,&DP,EF^(Y+?&A:7G5
MTG(K:(Y.2[PU+?&1RC"N=G1F5YR7Y5LSX<\NJ5.8?I3$FJHL.!M#4YD%)[,?
M)Z@WU=J".MN"8Z57MK:@SK;@6*F6;7)]W9+KCU96N4VNKV%R?3VEWR;7-U/R
MFUJ,]'L6GG1\C.YS9_#GJX=7OF=O[W166 2'B+L_Z@T'$WS(TJ)WR4U*%K[O
M 4*?/;IV>0']5F?^E1YX][=^W\5P_U._Y^_NN_T'[V%R_MZQ?O UT[V!SMLO
MO'J8WGG^N+]##-W/6'/YNDDJ$_:6BV6/*]1K!%M<I5XKV7TNF#^)&Q/0%LAQ
MBJ27FA3FN$RC0%NCT!J%54:!MD;A(HT":8U":Q16&85J6+5&X7R,PM<?_>OP
M]7:\!# FP2!>U8= L??M=;?3ZUC=_3(<N8<KN,GWSK#C&WP"N34AAS,A3Z#2
M!1N<=9TJS]'@M*%):T)J&IK4HS+;Y1J%-C1IC4+M0I/6*)S**%S'PS;1G_S1
M?^1-?M2]48"OCF(?I#8P:0W(.@.R,Y$NU-B4;:"O;!D_UM7)^[$'\_FVHEZ)
MP81G6X-P!EON3^#*9S\ !?8M97; XDR8\\B/:9ES9LPY5F+G_N:G<=&0][U/
M_>\Y,O%@\/G3Z$G G(DU.CRG_A.\39T]Q/-Y+:76X7(FC,K/;6[-J*_]FU%F
M;R'JF:.U <C?>LYGX_H3>:&];YG/<__/GF5[Q^K(S)LP9._,RVM9%'J?MLQK
MF;?(O E##F#S<EMZ;,D_20>/GHI>N>K:0@FP-][.7L<R89.+5*$T6!,5KGIM
MM&W1:/,*MND*UI*OV>2KQ^KQ!LMW]4-G[M&^TMOIDGZ<)J_SFAC-I=3"$.>[
M)BO'>,%6JC)1)HWH>E,0Q_@UV.XLD632^:U\?!=,D#736&M)3F])ZC/E5"9*
M:TDNDR!KIIKUY:IG-'*N$Z'4W1O=<>][K_5]9ZB[S27.AMK/,WZM&W<[-959
MG)90S2%4/2S4>/\))XCA!JV<39[XX#MQU>H6?_;.^[N8%W>&^0 5*_I6QN ,
M=MBJ&N%UI+FJ#-B6QOVR>%<=Q@V\.\!T4XM2J76:91;5Y*:K>Y_T7;'WQ*V/
M;S:7L\4A30\G%L=T)K8O[W8RBV@.UM6GB0PX9KN=0\0XN6"WBW'P,8Q%NW5T
M-EM'1TFH:ULD-KI%XF*H5VQWN$^.M#T.F]KC<)$?Q7Z%>^,'3(31=VX3V;8G
MTX4DLDT8LG?F+??JNIAV5_7MU520^E+?I;T%54E,BYSU72)%TW.<5H]-9,S9
M-$;<?RPW(=$6L=S2-XZQ =HN%S1[N: N6Z+KJ^?-^B+F/D3E9I>+KL?7_NO^
MW5V_U_!E]:IPE'25W(C'!1,P?43 NN^F/G&7X!! 3DZNL:+Z'MCW>=U<36Z
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MU6RW"7;6!U:3Q=2D/<^S7Y9=^#9!4IOTM'3.[#1:^MQKC4T[?'8?O:E/^JY
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M$_9;BVO!-"8O%#V9N!*-E0^)0RX1 7$;*-)*@/242U/KK*$XG(.XMC.+"ZU
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M3W2"<?D&3YE]7O9.]UUQ<)5]%G+]#/<T^[S!33"4*A(D3&Z!$_!8@X)P&!.
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M DT=Y9XJ&\KGS?UC<:3M]I6\2()+A#,,L0"6A=M@D)1:@!_G@DZ]L<D*!3D
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MM2\VSW%\3[,L39>9ACV-5<V7'8\%LJ/H%@M\4S/\;M]T=VD&"LRI]>P!=M$
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M+2R&]!V<F\I<;%OJP[] FONZYN@KJB<.$4\=3@6.B!)XODT4"D"@M@%*/B
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MN*2(W;%(2H)5^(6;PSM4@?!^D%V80"[N7*":69J <DJB2=?BWP52#G2+Q S
M2-?C"\EN6DS(++8RG^%F^'10L#?B=>_O>B*\,?.3&<-]?D_2;[@%CTDSE@)-
M31F]6L+.P@.*Y63\.J3J*1^$ (\C1?.:"BT5G*)[P&DB4;ARX_-O@?QO"97B
M1,K W(1W^4C9A/Y[GHD*)5QR^:Z%G9>OGHS"KA9V[V*)3UR54+=MA+\?)4AF
M:+1O%B5\RB]+I2HGS'L!Q434)DKOW[_BG//J\UOI[XQ$^>U5)TO$_D1Z5HN"
M5R]>%6^N'_RQ)6R BE]]_IC5M[Q^\7/!&; S4?792?U I=(GG+@G:8NT$S;!
M-)'>%B+X'MX/HH;+V7(*NJ2K5WB9S7>W%5A#$>JDTE-KHDF T0B6R&]_ZII7
M8#9=H3C&1E\@YJ/[*V2HBI%"+KYB_+%[7QP9^6W84&!9/J?W(Q^T^>!#<L<1
MV 7#K=#(>*\K8(\8A5 Y?1$4-^>&S]<;R7R!':0#T7[3 OA^&_JW8B-PG5@E
M5W(DR\(LW[3%@I98I<S7, T7Z]E\-@-[I%-_577*RY855Z:E(EFG[:,LD=;#
M?;,40H/*"\$P@R]!9W$&*6PKP,&KCQ^D5PS!#E<3+TG14,.EX6U1^<5];8XA
M%J^C*?&ERMC^4OZ&]V1P.1H_>!W0,FS9X]95]80)K'%/GMY>U%3R S#X5!'"
M1G6XM*DLS&W%6U,XK9$JA9LD_5)^^*7I0)4?_ES-X]S6SVOXAJO&?993/3?X
MB8[*J.(R< Q]PY0-S!TYQ/5D9GB,ZAK#CMH7XB?6D)0J4$H<EE()S /K#_X%
MK/PF?AZQH/B,AET8X-J :^60LN0F);/;S;#9=^-O07Q4-:#?RYUV<!(W-/\S
M#\$*%Y%BY"2_ ;99!;:,@PWM=1^'S J+'4S9J#'ILW!]T"SFS(NO]TC$"ZVR
M6\;RC+L^(&?7+0K?D<V]?P,WHE 'V<=(-D^9\%-R*2!A*MWQG!9\8@3D8>LE
MA1G./9KXOG ET,1HW!ARC[,(E>(V"#>LDAC? 3!(L,H![L%ND*B0"DFST7/[
M#G8/9ZDPAK<@>+E9+]1-<3I!+(&#.F@@JO-Q:\"T&@TH^AH.5&/;X!6&D7!L
M2!JA2H%%\(]%'J/8:S%/;86%B3>L6UDA>;>P5*,0B(_R=TD,Y[9?(<RCN? ]
MMWI&+.$T-.X5SCT0&; CH%BX_W!"?"^!7 MTK&#ZG3N5OK!P>,M;+%>=A]DM
M5_,;1+H?4,MF?#*'CV<?3$\FA-BR%3 EH*X14&_='.\!B73>"8D#4RJAR1E]
M 9Z#E.K_NF7+H:55P0L*@ )F F&8P"<P,$$0B' %%Y3<]BH.Z"*O?4$AQ$N\
M7S4HM6VW7W]YU;;)#>SS"GY="]K;>#HM>JCP^EQJ<<E&O&X#LZO"64@9UW)9
M$6SR5XHW$-F4=]N*P:B=5^$8#T3D':_)K3P-EH%U?LNXHD"L-)^\4J\!:V9
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MZK9G^;;BVN2PW0+/O$$$SC 9_&GXZE2V=&X](;3!GY_?!3<'+BC2!]\9Y53
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M^:]46('P32,_"T''APMW.:V5==RVP_GL&NZB"W."\#D@X)7P878HI3C-(CD
MG7!/!]5Q,16&9!DKQ^ 1*68WQ:"@B-$;3F+)]UB$!);'1PV38MZM=S/%@(WU
M5,4'2K8"'(T !9F6$8HV'B?2-0J>S5Z5D)V%_*TLTF8E<M/16+.7:E[(4A %
M]3VE?$X<O$/5&@9J:4W);8.X:=!J>N-ZD%II7@S%$<3/ 5 I,R'5Q&N?JHJ"
M0\87K^-3/S9-L1##G9F7P\MI-0)WL#1:=,8I!IKTD1PW4AZL_"WS4KRH(%F'
MDZS86OE-!W'RD3"-LAIS-_I4S7WI4ZOI$^VKD4#7$&CC>/,!B93#C]1$ND0=
M:N$"KB:%^2RIK5T"0F=B5A$7OY$LF=7)$G[P0PP;$D/BX-EW&&Y*%R3?9D+D
M;^>1=C'#GH?:IV*F3XM(U<:S*JMM]:"P:6'S=8:GNJSCK!CH TN*Q3!2NO+A
MZUC"'"7V=@Q1'Q0:-#\ [7;,W&J1MG(<THX.1]7Z2-7;>E<M*!8CN.>,*_+2
M4^44UO95GW<[JU>UJXH#>B-6SPG'H$:7:[_LUI+F=7S6&JS)8V*^'$;_J(2S
M%ZI!C]Q5XC'511F)R*S"A\5,R&%B\H\21;#5F<@'\J!*E?Q9HNCL"L2 A&.(
M$1<X/ISS1\I\K$&B!>3YQ&<QISILAM-YZ!BO;\Y>KZ85XPM]DJ;W?-H<B>:L
MM8PR7)^RNQ#OJ.=5#Q,Y7ULT>=V"<YEA"V-PUW 0ZA+86EE6'M#E0.3Y;E0K
M?I*)0=M\<O:/<"K"ZD]50T4AV,XA[_AJK9EAW^'=>BU^NVYH,+0PW[O%,4CR
M1>ZM.3\*@V6C2)IG9::Q@VBG++]-5NN3=A2/!V 7I$WW.]<DDY:6O^_ZN@>%
M GZ<BC00M<T@[V+V4>2OP3QPM[[E)7B12P,9"HL WJWO_FYSAW</4A:\6Z2(
MBAO+ =CWH&5!KO*8\1+..1RY7XWP>VJJW- 1T+4,0S!\K0.B@0;Y5E+EIJ04
M-PAPW/,L"KE $I%37DASQV)>)+(J4CM,4+[ET\*[TWU+8:&21AM>*!J+JV/;
MJ_#$"W%(Z7UC_AKE:#+/@)*SGY]OA/293V-U](D^^.ES[7=4X]+.;33K\,<$
M[HVH0Q^ &?PHT5Y 6@7+;83TR4<UGEP'C+/&^B_^QY%#&Q"^_J_=R6'[D4/&
M1.E;=YJ1-%[\-];2ON$AA:M=^C6,\GR4YV>)H]Z-WAT%YUD*SI/-W!WEYB@W
M1YX=[>!Q].;#1V^Z%R^Y!]F@D_>AZRC3O00QWQ>$#BK6W6,X'Y1Q#M\$ZM2Q
M\\ONJJI?.;J^MXX3GW9L#M4 3)&;/U&B?H4Y-]RV/T?N?-2_4@S>&X!7+G@L
M2KYC+Q<\LY<5-;)59P%>Z;SF@"V'4-GFQ+O?5!23)QUEX!=6D''RYLF/D1.M
MLJ#2N=5@G+;1:-]P<V!3]+1#"H<,W)./*!PR<$>Q<$;MB$?@'K&3\*4 ]^$1
MRY.;>6.NJ?]RO;>YIL/EZ,T-21W-ZN%HNWX@X:0IGN5S+X^:\!G%YR@^1\X]
MWU2].G%[-XWO4E/U]LCX(^,_%N,?@31&QM^3\9V+-]D&66JPS^SYH@F@.PZ>
M'R!!'-'$/W7.YE)0V/L!F&/YT#@8\W+9\Z@2=B"%L.?(I[T?W3FB<R>QJSYH
MI.=9>CW#$K3[^#:-_M'V1?DWPT+]@+V8@\2>#BIV!U5[=@F:[4(<BE&DG8G;
M,'R1=DX:XRQ%V@4:ZY<2+]G'C*^G7J@79<5?"DV<EWW_X*3S@W%X+GKRT*;_
MB2!_EBKT0KR"443VT5\81>2I7(E11(Y>QC%\<\GJJ6#D;8EJMMREW>IY:+B3
MZ[$^G_36X'>:S+&OP[8R[^3P['^:^I!V^_$Q=):ZYT+,\Y,S6Y_/HX_"J^\U
M-J/PZA1>QH,,9_%I[(#6APYHJQJ>93@=D5/@<+N<M69I%_W*^$BXHFF9F$U=
M@P/G&U8S@KMR%P)>5]+WV]"_Y?-%Z^%RFYN7K0.C9!H+L)1DU>D--)^1GS=<
MMO3\=6MI[A.O%0 1$AL_-T2LY)9:KCKJUH1S6(R,OL.^<ODMR3>UH>.HSSBJ
M,^P+)V6W@$=^X!VGU,Y2%K T!>+(\L3_AF.^\8%UQSI.,[,T\1FC6?GSFO?A
MU-I<BAC)<NFI68^Y3?A 9(\%"5!1OL7\<C$J>9:&.!Q1O+8<Q\ZG6:<,R1B>
MP](;EO(9E0(VS?&GV[?WR\H&?WQ <WPOS>,9"6DUK;9*SWV''4EXR@XV$/HD
MBN[+>? X _/[;1+QV;.)Q/XSQP'>&?-QGR$\.DLB?% YG+L%^("/L^?#>W/8
M78-+80\^PZ?!+DI X&AG\3U?Y QXGN.5CY)<?G'1K;#&:K&(;.[?KE[)P_1!
MWSG<NQ .]Y/I%*BHG^Q-@KP8<7I$W@ZSDD-YT]-9W?24Y^8?B>%;>#@)MW>O
MX&K07.[_O/Y\>(O;..VM$<P5L389A <ZW!>9]#(A*>6-9,*4^0CXKA<^P_OK
M&U^]X+?57[Q^\;-T2W B/+QL"AOIGN&^A5S(;I,YD!_0N#2;IR C"KV3S)*L
M^ZEMMA.RX1H8'(A1>ADFOS.*]'\EO8O]B<1G%L,JN Y9N!,X#E][%XJB%\Z^
M?$!T'.,$[23N>CM_W7K5**AX@5> %8!!!<?P0^/WR"%X>EUZYB@__5R.EE_/
M1@LOWLQ-%ZHVZ2:&"C;1)2 PFT]!F+).!@%I>$OB&X9H@TOS-(G0_XA8HPES
MRJ8$T-#0!AMGE LJX=X.OQ3$-F4"FYPP0G2'UFB22B)KBO)325+[F9IB$R]0
M\0R:5-@NLO>!1!-+[SY]W,<*>:#;< BG 3N%-U7S%B9!+;N2 *10L6:XJOQ]
M[D6ASP5;Z]$%R %6D\%&07Y/:!B$ /VB#P3&0A _U?>-,U0+<9(F#9"EIG#\
M<F&WWA*Z1R#EDJ(GNW#^\:,8>P@&5 BKE?PP?!(4*8(GMG9(G%K['<HOZ5C%
ML&TH;[2A1AOJ"/[K:$.=DPW5=]+;Y.F]BZ6/?IZ4=M1&Z3$M[2^\#H,;62D"
M%@RU3OL,D$(HY?*%TA!C"(#)!H*3&7XWZ7HQ&H7K;@(HA+-Y!*2\.M9R )&\
M$"-9XK/?"SZ37I/" JB2'T3Z/Y6.?%OJR,[H$EB8/" CX(O$35F 4:22; 4T
MKV]2QM!8_?F1N/>J"--LL%DP!@3+X$\*YBD\/H5'<205UL/?N<X1'%\;@2N#
M<E^ L>&2EPO65MNJVR LGBH37=7UAL (IU-&0T 3[&%5A@H_ME$^3)=K5S&P
M96!32 N?K(H6[B Z1.J%7]XM!KAW)LUGZ,DMLNEWX"C2"MAF<P_9) _A(4NK
M+&*XW'N<YU')>==?7DF&K<BFLES.NWM%0_TFY\5KYH'B^+VQ#L&+;W[DL.EY
MF-V*F:8-KMAE!:(\!A^8IPPEI/!=-F$'@19+K+6&-5A,  ,A(J66)2GSDYL8
M:)++_*>J>H6U2C=HL@;@+(%8\_(M7@"7HX,(",O9FD4DP-L">(=@TI,7P6PQ
M!O U",8[V/(=D]Z'Q LCM/"&*)^^KA='[(Y$<T[82"<U_6TAIE#04,HP$C0%
MV5&QV5)6!4P++H"2Y9@195-A@P0,U7^IS9*,"<<-E%_G0VN?F>>*2EQ6M3HQ
M0U9-P+X #WQ&4J&K0"NC,D=/.TFYNP9?I!3LB<ZCRR(!!*++4<V)]+72];@R
ML@HT%52J'7%@H=I,,2:05@OS0E#Q/H?]I03&U)X6'7S<U>G;SG3'6%9VM3AH
M,^YP[HK'Q2(6N\'36PXM%05N/#[8B&^%<<C5]()9UFDIQ@#,1BBJ>$<=%^/,
M<),F65;72[2K(29*70_!?OC1/$/I6@;+&EY'8Z^"K>(YAQG\4)BT@D&*716V
M)0\,EB$7#B*O8:32\"ZLS)P5EOP&!QLL[$9TKS.P5RX=8=7&PKT /*RDBN^)
MO0&!<Z&#.!$/J;SLUHZ*G#&Z4<")*"5\ &R*4BNF'(,HP;@PK6'"K0"0EGDA
M3K-YE&=%'*H21+5X%*)H.L?--N5/=SB$UO*RZP(4H0W9RJV2UIJ&'1[0>BK*
MW@):T-/\(&3/<H%'$1H5]0@\-%JY<%4.YZI;Z:_CK+5A*X_Q9X>TC)5>23.0
M#]S=6),V D=U&LZG-9>KFP.GPGW* ;Z5Z%G<\$1ZM02#*2,QSB?^&=94EETA
M+^+I6VX97Z&&2+A'[I,9FI*P]B2](6"D\PNX!@&9%[.,5YUY(#KY]V#%Q%GA
MQ;<E<">8N:!-A(N/V3;^SNZ(2SI+A-E>U.8(VX=7-K9" ^6"A;L/((??D!Y@
MJV&<<.G5KD2K8-=8.P? LQ A!$*TM2D4!#S. '=5$JJ^@,OS>FUK\UR8="(I
M+(C'1/"6$!TI'X$*3S=K_'=JL;N$FYJSY+LHP^&K$,&.<OVP 0XA$O%=(J_@
M!FJO-NI<&K]NS9M)EC&0O44I3:W_P.-@<7;05V&0+46]CDP6X3!O9 ^L; (3
MX7YE#+#DIE'SG+?FT7NL>?+N8Q@+>NB!-83;U ?N5.G7*!7T6%$M2+D,?E A
M7ZNF=W55WRZ6]=:&]=7F8L&M4]E<7#:<C0T%@!/I[R!^[U"#A@%7%L5;A,!I
M8[Q65(O/ZY" BX(B+7>8"XMC(0F&EA"^G2OM17-=I#4RZ=_SN!' +I93>!Z;
M=GK5<-H$9 M!NLY7V^X41)D)6 4W8;-]AV?FC!.D4.@Q/CK+&:%2F:U>3'./
M;LD0PWS7/)(%Z(WNKT0HGP< @(XQNM41KOA02PDPT\,IQU] PA0/Y,ZK.[K0
M]7VC_)USN4<D+\$T'EKZ1:I11!M7",YI0EGAIL.ZI^(1(!*](CZ+:])!:(F
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M'?C+9*ZL!CXA-- 4TZ8G771EZG]*P#"XKQ!2;T'17)7Z5)=]3Z.RH9NZ3(S
MEP/#(:9G$<K,YA:V6/-O!=54=+*Q'U9M0&_DR?75;0]BVT95W+LXR].YL(F&
MZ! 4=5VR:EX=PM1\W70I0<[\G=$;3)M(;TJGLW'%SH;EE73#8I;R4B!0;7<
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M:PEBW@7K#G54S6JM$V2.IMHORGMF7$(UG*<P!AZ<BLJ%9SQ:DLPSN"#CG0K
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M[L/K-Q\PS&'-\D<2X7L16H%BH" JQ4DNW:0$GH+?M!'-:2C# RQL.HN2>P:
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M+E2M8S#AL3%U-!/@B,)C'M^)@XE-G&0+8AY1LR!3#&='D2)]9^B],BH3^$R
M.L T"!.*.XMAI_6N0,WDM^ME3$N[EQ_^^LL\DV\(F3U_'69^E&3SE'T,7C4
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M[5':<YCV/$R34]K3$.TQU2:V.NVY#F+J=7Y[^J@[?=4SN(2?^5VE0D[^JS.
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M$LW#8^P=QWG[3(L^Z.^^VBOX1(!1[-2&ICY=/W9H)0)*B D(?@# SFD1T^\
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ME4U9Y5R)':#T 4&L!#3>CT'[%_16S+5,Z-L)KE*Z#I(@4))0]H)'8T\];N^
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M5N;P?5[<#A^ I<@L&HD*+Z7%=,3U_&(5 &U^KQ5?"[WKDRNA#UA@)-[KAJ3
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MQ+%FQEG2LV%3?<B:2R:_N6:1,/L!^S9FR[*GL]EXQ,;:<&;JFCD8SS5JS ;
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M5 (XTB^C%;^(OO:(M.*#3_Y-_82&I6/)RCBR;@XKDE2H _Z9<K14OY OI>M
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MGGJXQ#N&A:Z$!L@B:D?O*WNRW!I6A%JEOKL81#!!DA<$(;7;<K?R8*>U2N8
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M.O"E(R:^#P8D$C(3 _, %;EP<%D3?2LX_/,)'&(N,VV($@=A%R/DXJP'%:)
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MTB"4&XN$P#O8ZN!_4Y=0)B3R=$<&VB8"0K![!NF568\VO+E*PBBAXKS(DIG
MI7X2U\4EIE:NO()SL1DPR@8IWR_)7P7A#?6EUY#&!L"G0_] ;%?Q&.M!1'?7
MGG_.%M1S]B:-<*ZP*/=U4LKC\C<>ES$M71+24!P1$<H=<#OU0CSTEA!/MO W
ML]V(,J$(WXM?;D@->!UQ8 5>J<-PY?!0' HS]]YV\@O%;AG8(OM,+ 43*XHQ
MF!W/+]W: _I9L*_"==X%X3>9'R<],&;O#</)Z8BDO?Q,19P-A%B.+F-+1B?<
M*!P3YEM0&]WV@E,,5@==%!G7#;)G;:P\?;0Z!"N W95/?N4*FSH1NS>N7L#S
M?_C9YCXH^0RF%;>P7U),X#E*/H<$8,>'#V^YYKS]\I[\BU$O7I3NP*]\JT]>
MYE#P]G5ZG2$?^-,:V( 4O_WRJ9 -B F_0C-@91[;<?Y%R><%;I:,3=EQBV3J
MD_<2@N_A^0 U'&<?>*Q\=0>1-3MO_F'<-PAPU$M/<7^8C7J#P8"'-3&E"6#>
MN^>^;>&P&GGALZW!#^ECN=&&0Z/T8%T//@:W&UTS"Y[R(6SDC;OX"0V"T VX
MXP*2A#9\N=@KYAOJ0$XD^T4/0#C/?"'P/3%+;N3 *7?W1UXS?STUYCN4AL/Z
MCN@E7A:66/# L\KV2WOF U8\(+OIOA^%T*&:NP'FEP )A()(WPIX\/;31_*6
MG^W!M^D<3ZH"+)[-?^:E;]SG[AAR\<);4HMDSO;7]#-Y"([7LT34!O=*[ER<
MIJ4C]&&.C]3IPZ$FPP_@X \# 3;ZE*--YF$>"F]%<&KRWB@]$N1_O,N/!!50
M;M\=/4CA\",7[[5CT#,]//1<H*4M=SI"-P&3K,6V/!!Q\HSAKR3<DAK'=_88
M\%C"-!<<^#P>\O37,LBH):YO;5$CX=^>ZRBX2EG^+ _#^+I0E'F@MP<SB%L9
M,DS7NRV4S5(2;-M)\>Q"?FL1M^@]XK-8[EN292)VD#;&U#!PA6GDF-N0O<*C
M(70ND_R>R@%7#>7ML^RN8?&J"W,2CV"(.\NI$-E*O;7KAJ@ (,,.QMHX6/?)
M!XSV8VT)XBXQPKT]_117#;O=,,:+DJ4ZEDXL6F! +$QG4C)/AZU-DP3I[<DT
MN%9,Q/=PBNV,7+_C41=QB7-;8!*3A=TPDG$0?OS%#S?X:=T"UBH<LO3:*LWS
M4?OD-]S&X(.#[:"&4NL+/O2DKQ:M!Z&V"36? O LP&"2S%=E>=PTS[#%+ ;D
M*A[7<^CEA2(PUN)XXN)%>KBU,P'ZE+FI58+MU1(YRF-!L*0/@7^C?> !N0NN
ML\I].""XZB'5/!'&S#/+Q3%)^@:7SEN7W3%Q9]?-Z7ZW8.*J&/P+916#9WD<
MS')#D'AQ7HYOV. QQRR_3VK1,+SGJ,VC?UL=CA3>,.\-#^CFC-\UQWH+_$#A
M2_J"IW[L44X975OP:W&^+:]6%6[0S^_YT23>=W2C_/#UL,D6GY(??Y/$Q]Q\
M<7)2R(C:O!(KC$PL)I&M&S8FCD@2%$-SJR?\O>R7@B=IK+# (?%QX6K^6K$
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M[E:')(_/W"\GBD!1A!L$. "H97[]R\RJ @H@N(H4-\R,QR*))2OWS,K*C!N
MQ(6K,UNFB;IFE8V*SP;1KIQ(=KFB1Z[J%.?+A@+HQ0>@8P9TBB2I *>AGN*<
M'C;UP4N8+!"5-=UR"J7(@3AC-KU(T; [GDQ+I$C6.W3 U055_)*4HSD^S@-3
MQ7#4("&,3]OG$6D*JZJ>362K:9 'F2KY+$*3'&1+S\6C>()*VE-?F8O9#^&<
M(5]?:+9);74KD;)-?WBBEH>.I?@1Y4<<N0% 9Y.X9 ]Y4H%.>>*Q+5GI2AO/
M21B6V],FP^%#U390&[5I46TPB]/R"\H%L1;J=>;H$&AKOI*VUR0JN?&IK'P
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M!:H9* T/$GTD$1@CY!(<;,_M_: 6N1,O$K#C=&6M[;/11_7';=5\-N$-?-:
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M12@4X7*KH@Y=C.2*NJS*W@/83DEHL#DRL9P[J[DF*4\BY63\4\'84_!<2E#
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M=K9@%N9+QMI@KW$617G56Z%?J]I^B\,F:@VM;:RA_H:G2=1"S*T;NU><_%!
M;D=CO<6Y#BG8K6WP2Z.Q^KD-_:"#B@JVX>'5NM5<V#9PD$&!O0VFZ'0:V2S-
M&QQ4D"NJU[<NBRL>*%" ;0/5Y7K3;"^#[-7/"R@';2M@3SD*<VKJ?<]/ETSG
MJ(;V-J#,!%@S 5FBCEYYC9TM@&EFB_S7*Y-72G8[Z8V9,,Z@NLB4_;?CV4KI
MI?)2^<'/ZX"LIR&<AF!FK=&MZ&K_G0712[K:",1^&R2G4WJSJG^RT"Q?X*Q
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M \JT#1Q "CSJ*_QPSZVA!QA^P-MR-LK$99E$^Q.%/C+](<X/X%F_#&:65!2
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M+^K9[]MRX-S3T*&<;XA;'<&#,'4X:(6!XTT6Q^:/W/7'=*<ZY+N+08S'RZQ
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M(WW90+AH;;Y*)^-3/$;$?L3<2Y#"+$ZU?92%IAMS:6*&0M13SX'8&1VS%RJ
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MU=,$ 'KR*:]3HQ9R"5C#?'-^O%*7'47(D"T?'7\2IEJ.IOVJ(;.ILR+-!:'
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MZ;@(Q<G^*VU(I7-J^:R=LG![OGP]7R>'QF\#)9O.3(B,+5YGT%F^?1+ZMZ+
M&ANR^1NPDWCN'Q'4'^"C^X%4+DOLN19B</)BH'<]/WR1^).JH[B=$H0>GF)\
MX*GOKN0.3.K+[[@;4\C+;N4E-XS?'WDY(AF)2:H$)/[BEHKIP.=,B<<79Z!=
M<^TE?_^+LZ P-(6A.1U#<^U%@>.%CI62D']BX>K:<E [<2DXWNC7^-2[^._?
M;F_^^'995K4KEL7Y8+"P!F#]J#C^1PXG65B HZ:8+"<I^66/>C?"U&1R420C
M:\7WR50L19L]3EJL"(%N+'1I%@,+5D%&WFR#;,'2YR\WO7M54!036]5$M[K5
M@N)KIZGD!L&1HV8M-31S3,C&Q4CN'>Q:DLQ*NU6(TOH9W\-&3 [W'51V_$BX
M:+?J>&OQU=8Y:N-QSV'RT_&&/\<5XZ1/CX3Q81''DV<[]BFZV6-^WU((LY1W
MU>P4Q-@-,?0ANZ]W>SO='3F^!T'*K7FWA0M[R/RP>3^U<$8/DC..U^,\F82[
MJF.P]\GI/,SX:\_B^9VIS;7X,#Y4;4[WOBHX\; Y<2^,><&5>\>51=:\X*)"
MMQU-H'*8_'2\,<QQ!2H7V#C==?<K4-ECOMY%UJ9P[O82JP?-4WMA8 O^.I8(
M87]TUKZ$ 8?$#Z>B;_;#H=]CSBB\=L3X3E7SSC713E9_O.>K]A#9!:L=)ZLM
M;V,+MCLDMCOHH]<%JQT2JQ4:[@@BAB)@*$J5UCP;G-\\?Y_R;(>Y'784YX+;
MC9V4YQ\ZQ8MSP<6YX.P!B4:EVRQDZ:VT)P50NZ9YJV(6%"^T9Z$]7RU)M<YB
M/Z0HPRKBLQ/<Z]D<EQ:9J]=DK@Z<#@6#OMG@B()%WYX2,R9+%*0HM,6^\.A^
M[?D=.!T*!BW,V1%3HC!G![&+>Y!H.=X$PG'MXLJ&$SAR_!!V<?<X9;;+_F>K
MY4&;]9WT:?[_V7NSY<:-9 'T>?P5=7O:,=T1),U%N\:.4$O=MLZ16[J2VCYS
M7R9 H$AB&@1H%"")\_4W,ZL %$!0E"@N(%DQ'ELDL51E9N6^; 3NEA@V,+&!
M5\4&ED#XG4[CN&-(?Q4QTF6PK<:AP9UA6Y5A6P>K(ORUQ"TK3/;&MEBWC;M^
M-KMQSI9GG%YM,/F<( 83;&6NEDV MJ&UI;A8#;6MV)%J &Z.]ZI"?(;6#*T9
M4;+!\%9VI0%X%2)OU=U[8@*K#QB^R7Y+_ ;+--;5A-RWO"*)94K:GHR$M::\
M.Q\#ZQR,HAF J\P"9_FTBB\LGU?$1#P<6N&8!3T6#3@[#X8CRQ^G_<T.3P6\
M(;"_:R.-\-KRZ!YSZ?=>X'G!HV ?7!\>&L3"\AU18_S)YK!3KMK2LU'HVEQ\
M/'G.SZ;YM5*NEA#WRRX@>DXNB?A35*=C>$+^,?V6A)4!X*[.;NX D#;LPQH)
MGG?-2<<:PXZ58F39KM__^5U3?E9N(_R<G:BU>)7>(#8Z!XTRI;",M:]?7%S_
M\?GVR]7UGR=LX#H.]]4QE =AL:QI\;JW@?-*X-QJ&C ;<MX:.!MR-N2\17 V
MY&S(>8O@;,C9D/,6P=F0\VK ;*#\/)2KDJ:CG".[DAU5P:C7"[:O>^ML[D<\
MK%IHIETNOZK8Y+*S1GS,\G'3%W^J^[J!YTQK+RA]UQE^M7Z#K\_R-$=AH>[F
M33D(^]MX$+22K;D/PKI#I>L^!FO7318?[*G.^5LVZK4 [#+J)%]Z,&\MOZ\%
M5(/>Q!'5?KW!P*F16^O.KMGI<[-\6?4GQQH8[K"S!QY:?<Z2@\ ,_1OZKRX&
M%J:K938*^QH/NSS$Q)M$@S/4;ZB_BA@PW-_0OZ'_)=#_+1]:KH_"X,KM<7;I
MLW]Q*S2"P!R$:F)@40=!\U M4 TR/JOMC:>M;FK2T@Y'>4.*5J/58MKH<0;?
M=(ZJ) $VLT']VQMXK&<@@>Q0DG;V .HP.)\[LDU(W%S K)85'78,US%<QW"=
M7<%Y#N6 38-Q(V<J+F<JW#IYE?2WS8;>1EMS8+H=YXRY3J.Y7R6MJL)$O20Q
M^B)9B7@SZ%BUC-MT0=8YW.VC/;-XPASD2AWDU:/C=39(9SV#;#<"=X8)+YX)
M;T"\R)@,.QP; N/A(&=-M)N-XTI-6]E,\[FB#CM$MT%BA43C%OO@]H^:>3Z2
M@;PJ):2;3I:&MQ@DKC.B<V@B.D::K$A1/6A7QPC;3 +<9OMLHXVP=JO1;.:L
ML(/]@\9><VZ"WU4/UNJ]C^VCX\;16A)9-@(AQJ4XU3@RA]L<;H.09<9ZFF96
MIV',*V3,)M:S>[;$.@_O^GG76G:_JT67AM0,J1E2,Z1F2,V0FB&U30&V(35#
M:F8"I;%"MS'CL"J<<#/#L>O, $&Z*7.POB]-TEK(7^V]QK')%JF2JW:+LT4.
M]RH57]MT$MRL%+5\HPG@.X<F+W'KD9[#^?YZ(G^;CG$C:>:(%W;F3],R>8G&
MBMO),./BZ-1XM=[BU3+4::ASPZFSNG@P!&H(M-)X, 1J"+32># $:@BTTGBH
MOAV_!C->?:#1H.EOB6=NF0X'K5?8O*](@"T/Q.3 Q]:4=^='/78.1M$,P%5F
M@;.<7L47ECK![@><G0?#D>6/F>,ZS \BU@\M>"Q^(Z+ _LX".7F#10'CPY$7
MC#GLS(E#G$P3P?W"?6)#6,E ,.X[W&'_$_N<=9HUUFZVCAOL#I]2[UH"?K+A
M7=P7%CZ1\2?\F[.0VT&(-[H^_"VX%=H#>+_#'/[ O6 TY+0>A_6YST/+H[\M
M9^CZKHA">-8#3YXEV*,EV/O6?K.&?!$O?-_J'-"'7A#.7N\1W8,+K^%:1MS&
MQWOC!CL3.(8DM[<:BWU<?-]W_\L=":[G-^I9..$G!\DHB"P/OK1&HS!X<H=P
MA3=F[SO'^[CJ&GL<N  .5]!3;'5[5T)-O3AXX&'A_E9CGXUQ7%#C.2?G=A'S
MJPB-/]D#',%*9"%X^.#:L$<-0W[@UQ,LI6> J$O15:==/;**_0<N\&]]]:)P
MD'$3!6IK';R2V-BC&E=5M]2XJA$/W<#!S42#$$ F8?$L^>6$2^F'?_X4BWK?
MLD8G%ZZPO4#$(;_NG6M0N)6;/P]$).X&5L@_(:!NK#%R#7'/GZ)/'FS^EQ\8
M^Z?^+%B1Z\?<N89UTX,N?0 NOPJ$^!(&P])++HCIW0S@#==Q=$,;_LJCZ]Z]
M]<1<Y^=W]M[Q<?MP[_#PWXC'YD&G^0Z8F U@]L3/[^H='"[N1["F6][[^=T%
M7E1OMN"??\L_#^IX1^R[\@)7!'OMUF']V]W%NU_J^T> HCQ %KV)A4 I>1@\
M&G#AVF>^<^%Z,2")\*,#ZKA9"JC+KU_FA]2_G[JAY]8%ODN\^Z79:+;>#K09
M>YH--W$#ZKD]3NE1@\)1^TB#P@NV_4LAI.JX8N19XY09,CQN]9XU=#WX,B+F
M[0/S#B7SIE\%G&7)7%,&;)YHGK@S3\P_@;3]O^( %.*\JI/]4)-:4 UU!;<W
M\8Y3-K3"ONLK(P>/<)W,O6*JP\Q=T8_P'6B%KOV*^Z1 5I/UZ#:=$;&,$^GR
M==K?; ?!18OWNV(T%2J5@U .PT&*85#71FA(@4*-FJF%RJ8;N5Q([8RSL[]B
MZW>XI1L+@(@0V=:[/'KDW*>K'%"LDCM^YV$?]3[08HL_B9'KUX->#RP]4/ND
MX?R$.N_<"/P:P-/GN#F/6=<? &2C_)5^$(*.H3I3Y?&9+KQSRF[!\@Q%LNWL
MI^,<#308V,^@T:!6L_SE^D%NO8'?#] $U[$;LJ +-**HP!(BL%TR#1[=:  &
M?CFU6-$*5E_P"KSDB*WR[Q]FZ(A%_2VG\7VV0IS3*T [3$P0747,:;Q[2]=X
M6XV]O6PW,]:6V\<7RPW_L+R8GSG_B46$%M1U[T\K1(>0T'9QV#Q8@H%SO)^S
M;YY=3/FRKURKZWIT%G[G%MJ*SC48B'8<HLF#.Q??_*"+UCXZ.2_]40SK@!7;
M<!>AN:"?USOS:>:Z@"#J^MO?"B?LT76BP4D^AXT\K\SFGJ=2J'Y^AZ^%SV)D
MV<EG]8 N>C+"NAUXGC42_"3YXU0^&?TMC?3I\/Z_R22MY-/?E#^\F,&96]ZA
M?$2:T)6X:^@!?\LYD)2PPDN08]0'DB_0!G7)6!"'-2D#I0@L2D#M77\K>H@2
M#J485'9K=F=!GI?X()(')\[PE\*EV6[LOQXNF@A7V8T+@52["*G\MF?N% @'
MR NVNC^9SYO;=?N =JT(+PI&)QAV\@-@ZW^_.,;_L>1'U%"F_RJ??I(&K=(P
M5G)!*"$R<7\U #X/:2HQ2<IF&:W>N4\9WGXGSUGV^3.Z$[./*$BS3R!1%T[>
MK7F.?<7(6P]L&>YGN-\L[M>>P?U:;:(&P_V6P/W06#14:JBT\E0Z=;Z*$;4O
M%;54P%PF9[N6_;T?!K'OH%$3A"?L[^?GGS]_^?)*Z&A!Z$8K 98+*I0?G;"Z
M^K(J4AI-5P1-S&NLRV$':*NC8TU&4Y?$%!<%ZFHPQUD'K-6NVHX70#CO%TT:
M<#".CIX#U!P[;1685=(PMJ1,M. >Z7F!%9V@B)JH$=UK&_(WY+^SY-_::[Y5
MVZ@6-:Q7Z]ABW>)<YK>Y/NNE6@:I%B'O\3!,,LO8H_*I5\,"JP1/?:V]-;_^
M+GE"54@F"W3N5<1MM)'D4!E9T3Q8L66Z!1)A)^W0STDV-,B'1!ZP>!3X20:$
M,427X*5;U.YW69X8$JJVO?*AW=E;GL&R02;KQU<<@&I)LL6 <&X(KBRB:>#U
M!D:TOHB309LA<T/F.X6VS?-RK@=>QD?ZXO@K9L%SWUEZ['43K9*7A)A,("D7
M2*J*^?7V:*DAV.TGV ,3PM@)G[C\E#3XT?G$#S-0K01X&\3W/GPG-:JD'<?B
M<3\OXB<5I&37(^U#A>MPICMS%FEYE/X^S?!($ O+ %BOBOCS;\6F(R#E'D\&
MK@.$J!' _"QC=0:W0=W+4+>,S"<#^]7#/DFF,K!? ]T;GF-XS@["WO"<M=*]
M45$7#_M7>6]-">O275L5*[N:B&&9 GY3P+^C586&^^T\]ZM^!+\: %\&]S,%
M_(9*-X)*30'_\M)$=K)PPA3PFPKFZL3QGZU@-A%^<[[,^3+GJP(9--6B-M.!
M8%E5I<,N=W 4#M@;[H,<U.2I'KUCU@N#(340=X6(+=^FXE-L_6TZ$63[VM32
M\[WC-Y2>[PZZC,S8@:Q+8U"_@I*RKC5IPQH^*4:6)2*V0S&9V^M8_6KR@S=T
MOYJ%X@VR;C[.0?^F/86Q=+9"GFUR1>;F"J/UPFN# F@&;8;,#9GO%-HV3Q-8
M#[R,Q]3T(S#EW3O=CZ"SDWYA0[&OIECC9-@!U[C\],J&!(M?_PRT/J?P))L8
MZ7SPI^)NF/ZA9,;I B>7EH]&O>Y]<7T++K>\2U]$88SS5-506VVRZU%[?Z$3
M3Z?I8T=E:,PWE="1&A%2LPGO4X_H2\YG.:%,2R'%YYRHD<<E"RS3W_Y( A<I
MR)D&<S:=?.8!FJ[.=@Y&Q=8<JX;B;!"=W9VSHW83-.\:F^"';\'=_*A21P[1
MLZ@5S7Y_C8W"X,%UX#:+]4)KR!^#\#OK!2$;TGHPD52;W "&(P_9KV=G-S2%
M/>1_Q6X(-_.GD>53=,P5MA?@1G  ?-\*G<(3AMDV!8TNAWW!K7 A<W@/=B3T
MJRU8EP]/=R-8J&OS6C95'I]+@^6'8,[BC'FP51Z#V'-8E\-5-G<?8#W4/IP&
MQ%L>'0=XG"4$CW!.^<AR'18%+ HM7_1PLKR6&>+Z>"VY'[RQO 2GG,/CDO'T
M<#*^PX-&5ABYMCNR)G=D>2)@7*!L<<5  CG;W,#EH17:@W&-/0Y<>X!;#$+@
MO_^%*RDG!3FL8+' \=U^*48F0"CLT.W2_2'GS.,/W!.X;_4L M/0&B.0Z+FP
M?842[:DGV\T?YCFI5PC)3/RV5G=&4]VM>9S3X]@WWZ*IY(#%O^( _T-G1!#I
MVI3H)$E4T(%V$?RN#8* #H# $^!E(E^2!I+=>3 $8AZS@27),#D10"J6#<\7
M>"R!I/ W[3@SQXJ '@WE/$\Y[0I0SJ5D!@%@,$2\^Q,$9'LQLO-'-QH -16)
M7]**!3S# ?9O1\ @,[V0B(WH)N&S&5-%,O3+[@%V%<3] 6A[81AT@Y#427J]
M?I7BN$!HEB&T6836J0"AZ?9"(H*>(P\?J(+$TN. D]P.,3,3KH@B#X2_B_(;
MQ*6B V)RE,4Y_9&*I^T8GYJ-LOL!P#750#)-#H$%&$#^7G[P)&JL!\OUZ"?4
M U&)<'UW"*_0'Q"78)_N=GC$0[RCH,OL/$Z0>7I>\$C*+8%-:;M"E\S9$3L^
M%:4:I13X"&XY1T<[$.HD.'@R])EL@%-4FZ6QS[IH[>,E%Z!)#[L\U/A*J\:P
MUI9]</&(!K$ $A ?7Z S5KCE8:EG:^]XX9ZM%Q/:&_Q\%:K7+S^3N:+3N:$S
M;QYBJS4CK+UWN&$M2I8)Y87[L@J.&*U#2=#+_BYE.YH2O8Q:_\7XL5=/X:\*
M:!M&MS.,;F;ZSA*:^AH^5\[G9KJ/#-4:JJTZU4ZZK@S5&JJM.M5.^L$,U1JJ
MK1S5W@>1Y1F;9AZ;9C))5QDTRRI>?=;5F.;SKHO2BCD&:0*(%NU;$D]<37YY
MI7CCTG8\D4RX*A 81!M$&T0;1!M$;QFB5UD#5EVE<(=4OS^+T=^*FL)5.1Z+
MKH!9(^H77A'3/)JG(F:)K'&Q\%IJA8PY)>:4F%-B3HDY);E3\IJ%++H&N+7W
MYB9>AE(-I5:=4A=?F[LMAMW\NUP*"6],8M.V0VD)XU-7&_+<=@0=+7[&JD&0
MX3.&SQ@$&3ZS20@R?,;PF2U D.$S%4>0X3.&SVP!@@R?J3B"5NNKJQZ4%N,%
M-#F_?95,SGHF\W<C)U1N80!E$W+M%@O)%83**TB-YLR9,V?.G#ESYLR]9GI=
MI5,(#-T;NG^>[@^VDNY-M40U]E\]1\5F\<U-A=_:'<H&=6_4A0SJ-@]UAFL9
MKK6CJ#-<:V-19[B6X5H[BCK#M386=89K&:ZUHZA37D.#NLU#757\HM6#7][C
M*C^]=:RHGF74;C9:^Z.5S3%Y6<OU9*>[-::EV&.6 :]Q'RP:NO;\U!0[\(5+
M0]MP&F')@!;X^H:>Q=F9,_:?GFC:5NWYQ];@03B&D8>V*]2\G2C Z3$]'N*T
M%S&PY'@?').(8Y5&083SX"S/P^D_#N=#O*W!+GU<HL_M; (7CI[YG8=]'M;H
M;[5F(1_$G^R!Y?=I1B&\,OV17N4'S O@1YPG*2<QT91'EQY. - !AZ.$!K&0
M;^E:GN7;G#86<MNSA'![;O(:G%<$P'+D0$2:\.@^97 9 MX& H?7PPW_$_M<
M UF30'9LQ@T!T"3J<&*@/@NHIZ-9(\UDSM8K07U$F$68T\PX2Z@I1V+[1P@=
M-LUDC>WKF[T_H\%@^\!,$%J47C:K;_:=SHM^)UZ4??Z,3"G[.,&=EJ0<5PCZ
M*YLA9#C=-G*ZF:U4VV9"P*HXW5*&GAE*-92Z#$H]-J)U'M$ZF8=WN-AFU1M=
MUO8EM5%KK,MA1S1!&,S5$0_=P-G: (U)?:YBZC.<C>JF_.^U#=D;LM\YLC<9
M_V_6-'9(GSB?XOW6PB918']/8QH5M;ZJ:FN9,E-#$@626*ML:!ZLV_K<# E@
M;$UXZF<5UD9YD,:TXU'@JU"X,387Y9$S;0H,&2V3C-8I<SZT.WO+,T@VV"S]
M^ K"KY94VZ:,Q<UB*=6%WP9%H0P:S3$PQ\"@<6E*R>["S_A?YX[G8G8[]YVE
MQW(WQ?HQ,]O>'*#:[.BK(=3=(-0#$R;9&7^\_&0J K>SDLH*PS&FHUE#T(HC
MK%D;!6%$]6I4-&79=C $ZX@N2HK;Q(#S2%!AE6V) 15*T1]8WP8G $ @:G0K
M/7-DC:G""2^#+\,8'J_U=F?6:!0&3^X0BP?AG:!=:8%M!_X?!>I[,8#%,;@P
M#NG6!L--3!:!G<LU9V?Y^%2PB(=#!M+/9ZZ K0@L9I2;!*LK#!YQAR&NP8[#
M$+;@C9GU8+D>K5TN(7DP;3V]2\B"0^$"(JR0WB-HLVJA8[GS;)>"N0"6%/:T
M])TO[+O(2BJSVCW7%U$8#Y&@J J/ZE#!0@;<312S/@ZX/T$_\C:'(U)@C0Z+
M!8)\%+I86,>&@<,]H%78"1$K5X0,6M(C%G\. @<6W@=2JS% >89B>^"[?\7X
M->$V8AZW1,306A<@ -R>:V,5(CV?64+$PY&L'@UA3Z,X0AJ,_: K>/@@2U@G
M]E,.!56)FU#ZE*0/[69<GU,"VYHB8J!<#!8.7)MJ9@%:L#0_8-G:@([#[SQB
MCA59:35E E(K*8K53B&^,D1>@,6[.7!8OM7GN!'VG]CITQ]X,1<1'@QXTLX?
M@S\'KL>G,[&O ;(/((+( @Z-==4.5K"6()AH5N=9VB&@*N>HC'6*W -DK?1_
M>1C,J ]')$XK6+[CG&6;.)K4JMZDO>%M)VX$:I?] N@B^-A!NIKF<4[?8_<H
M(JY 1$C^?1[X#SR,7#P#-T 4KA!!.)8XT-&RJ!W-7C\=OUX<XD$EIA4+0>?/
M5X>RA(=:-GP!?^S\T9I5.EX*O9![\!56ZTL-0![ M]>4 Y,%H0!PAC4ZK,M1
MX)C"\O6;UJ;<TA26;W 1FRDL7[P'Q' ZP^DV)4)<(2 OF=.9PG)#J1M#J::P
M?+'I!B;9OV\*RY<9_:W@+C<@+FSF-YHS9\Z<.7.;?>:JDBNZ7A5KAQ2IS\^$
MT<:L!^LA9[\K1$SY#Z!BR1A0-<W/JAJ;:\UM/'Y#&?5VH\7(B!W)Y#/&]D*Z
MKJ0QXY+LBV6)A,U51N;V3%:S,OI@B3/)-]BR^3@'W9N6"Q608)O+6*HEV[:I
M(G"S!%-UX;=!P3B#1G,,S#$P:-QX;:)Z\#/>V+G#VJ:^_O5!-!,JJVY]?6=G
M?-"&4M]&J:; WKCE%ZL2;)-*546.N:E06O X^C;\[@0QUIVM*A%XRS&4Y/@8
M#%450X;3&$ZS#1A2BJ?!4&4QM&+]MGI0RFO.\M-;6U-5MPU5XEKXJ;@]IG_X
MYT^QJ/<M:W2"GK,_T'%VW?OB^I9ONY9WF?6.N0D\UQ[_\@-C_TSN^)7[/+2\
M,]\Y<X:N[\*UE,?R^6G$?<&9Z_S\SMX[/FX?[NT=_QL+F9H'G>8[YG#;'5J>
M^/E=O?..VI& M7G+>S^_N\"+ZLT6_/-O^>=!'>^(?5=>X(I@K]TZK'^[NWCW
M2[O3.@2H9UN8L:#<XB^'(]@P;NVZ=Q7X_2NXSCD3@D?B-^XY7X+P6VX+1YW]
MTBU<?OWRECUHJW_1BJ;M(;P J@F$Y4W<>^G;7HPG_M*/++^/_4CD#Q*C\M_W
ML/I/'O8 RG9\>'RD[?@%6_Q%D5Q*9#//T_3^(.MM!T*_35;FX7->WBXFPP[Z
MH!$K=4(+D^ W#56F="GR$%(>0<J2D,*^)P%UK4F^"#D+^8/+'^$B;*?B9K#&
M3E[\ :Z%?V'/*^PS1^EW O/O;#>TXZ&(,!4;OW!<6W:.4SV-"CWMDNXN]%XV
MM,:@<D2LBV^W WB)[+YUFWR0.=]PC^6K6Z( KQ[ ^:5=Q-@XSA5LR"T18^.M
M[IA9C+KDA< 7_.1])<O0'TG=E^((G@!LI:S]F& <>)Z-W\D5](DU1O*-Z8X:
M[++'1&P/U*-=H3=)DW=*T')']H/2 "U_1D#T?>I#H^_+$O(M<OGPSK1'V/,@
MYD\VYX[L<9<UV6G F<'KYFHBE6]D-; <PB'")W0YD %B9JQOS M@*0+;(N$J
M)LCQN59(KQ6Z2^#@>0GA VWQ*]C0%SCKY[!DUX_A2=<CI 87<*U+Z</.$J1T
M_;!YU,R)Z=F+>N4>;GCXR1*N#8+_PO5BH/*[ ;((;6M'!XN7WO]^ZH:>6Q?X
M+O'NEU9CK_.:34Y9=<G>[ZVGZ6+ZJ+4WGY@N<G6FV#K3^3HK"@M6D!9E82SS
M1//$[7YB_@DD<_Z* U!J\FI0]D.-T4\U)D#J]";><<J4CL?H@Q9^8_^)1>3V
MQJ<OWYC44YE25%]^GU)X&6F\4H4E]L. _ZCB!"7 IOW-J@*FO'U<L=5IFF_6
MYYBT6 GN",&M>LUFFA$J.%E=H6POB\INR+O8GE,U<H5[2Z]7[TFZ,$]TMDU;
M&CMN#Q[%Z9HNCQZY[(O+>HE/0'5Y)@7.ER^$FUW2SS1]/=>C&;O<POM2[3#;
M&_<MJ:7"8T+J;DPW6X]"ZN2/KN>1%NHS#@NSH[13;VZE^'1=XPW1 A!<MGA.
M8#T*@P=0;>%JTBIE\UG+ W4905)C;@^X #Q-6.&X)I_BQ#8O :[(NDJK[K,<
MF]8"LO]+71.ETEI%VJOVR;@$+"O4)+2OZ)>P0586*>4I2K(CHS"3U_83:T8@
MGK6.W*!HNU2IB]3F\[XLV^5('I(4$I6;WA9(G0U;?',1>_@2T- #6B.\&%@I
M=4^1[9SA('.PPR(Z$,I(@ZOHM6JU2':P<;#XP/Q$*JQWQW7]LSQ18)U)2B=+
MMKP=KSHF+IR+(/:P%RA+6HY+>N0SX)7T:E<KQ7/VA&= F65 X3XP$X1]B-5J
MTF:K92\<6M\YV:8.8C(Q#/&)I6=,FH'R5G6\9"=J.)K4C+;(!QNJD:[@WKB6
M+#8!".P<\0JW@/V<6I*XX+(S6V!Y<\C2O)QT?>"^;I2_T@]","TD.8.=F3ME
MB<6<\HD<[&LO!F.&:QLLAKYD>=P*?>HGKQXJDQZE=9_OMXUVNN48_O0VR9TZ
M/J2G@^0@]WD/3@85_<> J) :;1./((9#]K9/PCAT)":Q^?^O9V<WR=$8 8NQ
M0[=+8DJ]@[ 6#>"70: <24J4RB;H400W@ &9=A;.A+6(0#;15?JSBD^ @S-M
MN1&<;^H\7W HR>]Q,TP->?B'D%*< S'[C9>HB\O^^X>B.3YI2!>M;3B<@E]P
M^=]+_TRI9S=J"H7F'6\OPUG2:N_O%WTESR]I]@9P9,:5IHWI>RB/:;QM#WN'
M+]A"85$S=G&-SM_K1 HK_[F^C]8R'%?[AS/V4;:L&3NY >W9<IT+)9Y49.K,
M=^A9DSMK+2-PUCIHM69L[27K+&P51 PHPR7!OX-E4%G[8*^XA]P"2A=W UOZ
MBG[N#,![1\L \&&G=&WJ_;FU78&RQ7E*15<(_^1DC']70V#N\:@7O'_U.<-S
M"_:*R#[Q,C4C;1'_@I;Q4N*J9 ZV_V,B@V5Z"*,8UJ2<?JO@S]6N-$=/\%9X
MY2E[EZH949BLD,8WV):7J (RJ^)4N]1)$_<7K8^HOOE'>P"7?&(,:XV>5&5:
MV.]^:-88_O/QE"6)';BM]/]MV.*[5:I0E/K#]"^2=6?9"_,YHVZD0LM]LLN2
M4!#KM)[U1JG\CR7CJTQWS;]8+V0L%((DB]+53M50=6E8DH>,OBF05S0 I:Z,
MOA1)-G_,D]H+R.L?A>7^H[#*0GA8R[>9;#'[%@J:\[8OTC0&Q7_HDFGV<E_H
M:J@OP8?.(F:1I$J$>AG+8Y.UF4@;[>9>C;4[1_"O_?V/*V6,12JL-,.CF2T?
MP-8"\PIYUP&3TUX^OI!>DB$J/RZ>'\QF7,M?PR1/TFJCGEU,Y\>\L2YKE5:U
MP.4[D-J=]@1[R0-DBBA9/;:6S&GV]XG)K)+3;!![:3<-)YEK#5O/0-J'AH&L
M2U79) ;2,@S$,!"C@1@-9%X&TC8,Q#"04@9R8!B(T4!F,Y".82!E[M@IWO[-
MX3.OVM#2V=%1LWK<J,Q[:W2<JK&H^P (+DF3P^K283QD'D9K80_CB;# [G*P
MS6%-*^(YK5JS:=PP1@F:Q6$P$^0$"Q&Q%@S(2N:,K)^IS!->-+K2YNM*'UH'
MF\"VII/G1Z,DK4-)6C_'J@1SFGFZ.X!$U>)H\GA7.?K]JHVLP*;;VP"CKO-6
MHVY*KZ(LR72.1-*9B:@BGW,J6NVC_<[>G 7G.J^BM3_?YH3@F.\C\FPSJ@*N
MWM;61&_^,KN7"0YT9(<-#9$E?TF SM_V)6LK/;W-RTH ]*K>+M)$QG*RGFMS
MUK/LI X!Y"IV=,$F;G4;BV%D:5Y6;">-:ZL?<EFEPI]&;DA3ROWIG4".\S6?
MEB>"9 E8J1*. BPS+2P':T/Y@QO$PANS.'(]ZF?2';,SSW/_BBTLO@GB_@ K
MM*:NK\;@G%A2=6?_LD+'X^,:N^&^+\;>@^6[EJQ8HVW(;C3H]FRPSU38B@6(
M7W@WC*UPG.VJE?4P<066R<';(^QB@M6YW&<"N2[5[D8!;?S&]7W+!CC^QBT/
M:XM@X:,:N_3M1KJ+LU'H>MD[VM0HI=V1];SY$B>.<^EDNIHW+K@[GFN$LCVT
M_"7O\4DVK\@W(UY)O0FI4?UD>3\:JD.TL.+;HTX]'ZA@#V@/P"\^GLP&JB9-
MD]Z+ )U"0OZL+'S5*5!FU:8240EV@(IGC00_2?XX3?+19??H''2G=Y\N;4,(
MCV@OLI7GZP>US#,.H]'<7QB!'N7?NS!YE#[W^4SYA+1R=#5_\]J]!>.R]/>=
M1>7S*D5!<WP=9E\^6NFPT5XTEE=U8B<+"#8$\5.*#EZ&8LUVJ!"7?M7)7NS<
MX$6>^=?.N)BM8CQ?'[!-_'J3L)KGK6_NO7RPZ.ET6POXMQZGQ0_5V6\<;,>Q
MZ:388X7R.ND\K"I*69*'NC/R;_YC61VLI84IVR3"JL<OMTI0;3=XURY)=D9>
MJ,*GG9$7RU#PJH//M$)IFR3))NGD6R5C=A7P:Y<^QHXQ=LQF2I_78&TSI,]V
ML[JURYCM!N_:)<GNR(N#W9(76V_'=+9.DNRJ.KT,&?.ZN/BN0GX9XF=-D-]8
MR73T&M?^%@BFZIVHMZ+PI16MVR2KJH?%JDLD UYC]:Q:MF05TSLC7C9)E7LK
M?I\I=-XF6;-)**VZ%#)VT8[91>4YW!676U@Q_YJDW2V06]4[4 LQB[9.&%4/
M3U46.6WX756T;TI5V0[F42\?2QMK024]$>:10_)3:;>!J9!:3;5N6;N$9(?)
MPK>L_%@ZZ8I%YUP..9-CH[%D6[A/&5QD]1#6?X)Y55J$?$2UWE1W]&@)]K[5
MVJ_A\<%OW[<.Z$,-I]V.9&4ZSEY-ICB'O.?)29"NS_K<AY5Y\D<'G8@B"M4T
MW62-:B"I'2"LL50=I_*B5DG%\NF$2BJ95AN%"W:CNOSLF4+Q_"CC@85]3)("
M<SD<&^QF9GN6$&[/Q>&\V.- S?Y,2*7!7OX*Q\571/ JG(P,C!(1D:,^&G"<
M?X%:"]V#-X]YA!-!ASA(V9G1$F,G4'P1A\DTZU>>T@)ZTHFS<$;WVG1> ;%)
M!PAMN#1.?)YUVO*'+9D^ZPIMU+.@=A>]'DV3[UNN+Z*7G/?G#B[^A>T+?BI*
M%J9_>+ZGC2AO7_.51^>6&-S((>_.I_$WV/RE_R6AUC-D9!,34#O+F*_9WM\_
M;NKS'U^^MI=LZ=)_P*GS4[?4UK;T)-P3W_5^?A>%,7_#GGYZR<*R4:BE"VLO
M ];UO7:[\Q)@ERRNN"<Y)/@J$/JR#XZ7LNS#5N>HN.SL_865/:JAO[!ZV)8?
MX+!F$IERFG%AIK&V^*-.:R6]FH[*-, 2UJB8;T3,-QLN.B_SG<G0]9)[^1)J
M'Z;ZC,WFW;<<NP9X8W;F!"/DGQDB6!X3\XNRJL+NE: BWJS#9[$ F2'K5PVA
MV?"X]$O:.<%).Y!"_4LZHET#V5T$<M4*'<$^!? ?]H'N_/L3W'9^^N7L[E/V
M^>+T(TAK$2--WGUC7X,&:@P']6:[QE2GL0_WP<BUP11L?\P_"6]0%^<>V&#:
M+Z@+8&B&U),HP' -<%1]MGS(1T%(ZP9= G404G-"RQ>6+8?'=U%I^2M67;O"
MO@7:BZ7FRJ/2J#IHR:G7\(Y4PTF^0S7#TV:7)^8.6=_RYZ +]KAZ*$ZOCF3G
M+ETW!=+A./$^ '49O@!SY)%[#WQ"%0NDH=*U/.SHQ,2 \PC;B0$DK Q)\0A5
M*=E93.X.&SYEVC)0D>T%(L:OX=_D#$\40&N(3ZGA=&7X2MI4R$+""-2K:(R
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M_DMPET?" 89EXU$74?)&<H ,N>)(O$>7RG66WE5$(4OE8>(]0:Y@S@M <P@
M8\(%S0"QCP@%T@9 DEPDL8J<,"4*D"DI*T3O)BD,4K-(+B+]H1[TZL *"?NW
MU]]J.:6#,*'K%F7* 1VI(@4JC2%=0MZK!E((Y2Y0@]J$>JXZKID^=GPJ=%V
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MZQMMVM.\0,PV/O^67K=\?;88NO3=WCC9$^V''3;:22;SM-WI:$ZF>[V<^%X
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M:Z#\PY+AU>9Y?EYT9+X+.JB4_9-N+GMRZ</(@*<9?;#=D96X?0IQ:,TO EN
MAX (%$F6M4?1>S[2$D>^^?3N.WR/! C((F"8.=G]Z]G9C2Z49>1?N7^SQ0)#
M0L&2ZL^C.!0QAE<5&#'A.XQ5*I>*(MU]/D=6_ 5NG%^CSXUK_:'^_]+;SW (
ML_<&.R'_5%CO+>_'GMS>77WNY_Y?\;$*#),I%V/F!'._Q@]RD]Y_2/UKGI?
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M?HODE?>W9U_OOES?_IZ\\<O5]=E]^@%?\.?GRU]_@Z_VFLU3=GY]=7U[HL;
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MF=*90CZT7)]&9N'4-76)AR]O5)&$RP];55;W&555A[HJ"E)+0SZRW%#.L4-
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MZ,H&1Q@27</XU_+)$@85AEM4A4:K%?/;<#P8 C7B;(LQ8<391D1Q-Q(LV^M
MV*XHKFHX@2/'-R&*6V&7V3K[G[W.#[K?64N?YHW W1+#!B8V\*K8P!((O]-I
M''<,Z:\B1KH,MM4X-+@S;*LR;.M@582_EKAEA<G>V!;KMG'7SV8WSMGRC-.K
M#2:?$\1@@JW,U;()T#:TMA07JZ&V%3M2#<#-\5Y5B,_0FJ$U(THV&-[*KC0
MKT+DK;I[3TQ@]0'#-]EOB=]@F<:ZFI#[EE<DL4Q)VY.1L-:4=^=C8)V#430+
M< H@__PI%O6^98U.[NP!=V*/7_?N!E;(/UF".^?!<,1]8>$4H+LHL+]?RX%
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M+96Y9":0QTU$Y)%.'^;ZE-3;1]6>H<.!4G8?P2; _R9JF\H/IE1C#N=)^B+
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M_USEFJ,R':YH3>6@4DDHEABI%"R*&F7*9['G#I49%-+^T 820C6[HPB8ED"
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MW0&! !G!]EJM=S/0?DA;5106!2-T'C,?1V;__>(8_\>2'SW>BZ;_*I].OXO
M X-,'?[T@E""8>+^"D%Y+@],T1.9X2KH97^7LI9\YL_"J;@USXFN !7+CZ%A
M9H:9Y9A9>P8O:TDI:'C9@GC93#>*H4Q#F56@S$GOCJ%,0YE5H,Q)+Y*A3$.9
M:Z',>YSB;6R,>6P,(+YR Z-KV=____:^;+EM)%GT?;X"X3/GGNX(22; W=WM
M"*T].M>V="UY.N;) 0%%"6T08&.1Q/[ZFUD%$%4@ &(E00H1TV.*Q));965F
MY?)(!ZL?LXB7]%_GYY>75U<%*2)% ;P3.1;"DXZ#+W?IGEPEI4<UI-OJ(NH>
MZ;BZ,.86%E5JNR-!Q^B.T1VC.T9WC#XP1LOUHKVGAM^!F7=_Q$].V^&VMG8)
MR,I>'2[\LW9V3DXFDRIN7]TJKN2!2Y"$TTE[)^V=M'?2WDE[).TY<9 31?V=
M9-DOCKKX[1W[=Y7VQ&5%S4Q;]3Y@Z';UZWOX&3_+@UXGC9TT'H(TEHJ/OPFG
MJ#R6I<6TK<DV!TD)IKOVY_CN()G M&?'A$XGM((2G4YH 1,ZG= ")G0ZH=,)
M+6)"IQ-:P(1.)W0ZH45,Z'1""YBPW?C1;BA13_3IS>1BTD3>Y(9U#6U)^YOM
M46B[:1^6[0G [T.>4W%J;>%8M(52U:V=;NUT:Z=;._N]=O;V2+B3[4ZV3R:C
M@Y3M+CN\'?BW.:31%OW79AKM/ #:L:?5H=&./9V&Z33, ;.GTS"M9D^G83H-
ML^?LZ31,J]G3:9A.P^PY>X(H5\>>=K*G+;&Z-B2=L+^P)WL\'/J/#<=Q06:(
MTCN1AXL=#KO(U4XXQ/0 9PG$&R_R<]^R6_O3295T:@^=%+H^10"^OJ7/(M*I
MOK1>7X/)X9F//:+C \DK<33##28_>#8_$!9'R 93?NB,RX7MX4"@8-2D3L@<
M;Z-S?0%$BVC1Y!:<C_"9.(^$S?D-80[&;Y)7-FY29Z]<_4A?9=F2:<./.!G,
M"T9ESNB,2S9+3YB5R<;I^2Y[RX-JXJAQBIA#-%-U73;EEKX&)V< L70VVHK.
MZC)>([K,@6]/+DZN)&DS&=_.X(MH&BT_E6+&\Y*3OW!V2T%ZLO&72%@Z4 B'
MS]-Y&^[A#[,8][K^[X?7,7:XH267,NIF6101P4T=8^]X??.9ZIOH[TM4/-&?
M:QJH(7.U113>VC2+3IL=HC;;V&!0Z?I?UZG-&AFQTTEC)XUEI7':;9%EMLCU
MK*MQO:U86U\ =+7R&8^D!P)0TP&2X#XNP'.W]8,]BN@25G>5L I"W]YD[('2
MB78GV@<IVETN=F6KX,#V_O.4R#%WKN#9VH]5T+\='L_>^#==0=Z;9/M.=7QO
MM&6/;T\U^9OQ[RZ#\UO4ZZO#6W]A6\&9;^?@U17-Z@JS.U&I*BJ[W#M^4OJ#
MYAR$EKN"/Q<0[G;M0/N6*[=?JF&W--JC$Y6WSJI.G#MQ/B!6[4<T<#<TZF*)
MF>>(F,I,++WQ,\1]\0ZZJ3RY#DWV^]2O$\;#$<91%[H_J!@Q^ZNKQ]KC$A?5
M<9:8EZ3.P=STL&)H83L>K1:BU2RJIMES<"WH16%ID?M$B.?2BA=-=9]H!0O]
M@-5%(.: MWM$;Z7/7*A+6GJ"E\&7C@^/Y]HA2^IBX=BOQAQ+M^"=8.YPIZ8Z
M_.?9P??N$P GP86^0V\]D1")]>J<<P9SM&"GO[B21YRY!%N5)1DNH.)B*1E#
M$EP6QWY!#!V$0?,=!U PEY+ZK!HFA9V!$#Z8HKZZRV7E7JX!#%0=^AZ7(AL
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M%M%K"99_ ?=I>H0ZRO2I3QAWPM!LH2X"V GL/1(^GAEBU,581KO RE(4W0(
MF.OMO3+;.&L'-1R01&=D>3' LXIO:0QEW"N05$GN2CE%<FC+(EH2P-UKV'6L
M1VS-Z_Z?E&@O__WOMJU3XJ.$WR!S\MQUC2)CJ>;Q-V#CG3WS7C"@^].=_^#1
MY=0?]HX'O9\_2.< OCT7(\HNKP!1F*_G"Y-MEU2DSJG5>FU1 :(>B"J=F[:O
M4^GRZ6VGV)8[:'U]CX)ZC9;*'7&>#0VED#D!1XDA)Z13+.1T_R1((Y5^["@>
M1EG 6 SVPM@RU]0%U?Y_TX4DXA%:WSP>3W80-.#@IPL-PSN2&\ ?.C%LQ55]
M,2A''9NAVPL67*>ZRP@YB*:&N^(@2D$"C$$,B^D,;$B><C]L@P1<\Y"B(IOI
M 4B (6'P4O.F*%&,P,6GVH$%VKPL_C%@A. $E?@'/O80J<YDHT7IL<[JHO8S
MW%TKP+W5?V6/9</,YO?Q4V>)_^/7][Y[_*BJBP]WD:,7J9U;&R05MO)[(,29
M:6L_/OY#DGY=W8*M_Z^I;KWP,6Q\2W?&NR<0<9?^>$/9[UZ^$D<S,)!EZ+^]
MTP;3J3)1QKWOJ.9ZHW[OG?3J&A\LP_SMG>?XY!V587CE5S+[[=T%7G7<D^%_
MW]G'T3'>XH-?22]X?7!,X]BE;WWW7H00\S/   <E"=J5>[L\'G%OUXD&;H/I
M_O;N^LM5P;<;KCU0Y/'QM[N+=Q\'H/5['$V%U\<A"T)SE\\HH"L*4R!=69D,
M^T.%@S$'4!\#GJ^XO#'/H%VN0L[365DYX19 PJ>(MA(C[EOQ#O[7-\7S*[!?
M0?V#BTM'O, F<F&CDRK=@FEM$0>L]D^?SH]P\^#"/'0E/0%#0/^*TVN.I(7O
M:$]T4,TJ"A1J\G^.P/E'AUM]?'3((QH$"U *FK' L#2-**]Z!;$] .QWC1#=
M36XJ%/78#W<A&@K''?*1 /#P5,UV%C8-%P!<"YL&3&'S0>< -Y%@[Z<O<\.'
ML7$_.%(%; &V/1-W%0^R?8]N?L&P%A%ZV&G5571B\M^XI=%#FGDT6H?042SH
M!D1(K4+T 7*9QOB!"./-NDW.'VJLV>NAMY4:*GJ@9ZQ 11:RM1W&:C0"_K2=
M(-Z5>C<=4L-$&F0>&!X<<V%HGH:-GHE.(W@LNX/-M &4C173+78*$.:RR,<@
MA\<*A8%]EGM'D1F*)@@>% 1#)FCT$.W+!V$F4&"0K:,61NC455)-*$.XED$T
MP^.;)4:^-&:_LC5%%R\%"Z63_658 . \M'EIM'_3Z9:%"\WV++ID=)N^S"$S
M/!IA"S6(HH)9"DO?]6F$;8UXY:RNEHCPRJU<%TWF!+X"54%J0-DQYX%:J?0R
MG  CG>(/U$8'Y80KWZ,726 \@Y2L3-HP)B/>$]CBL4M14 T]/%I_L?F3[/!8
M?+;2:<>V!3;U*F(;2-M*E;/TH$=\KK\(U!\>AYHD#%N'\9M 1$#NR'/X*%Q!
M[-P81=--AI<>NVNFZK!XT&HRD$M 9%&7^Y8>J7>'4&.)KHN N"O 8&$0 U2@
MB 0":1$OVDA0'L.96/^4>Q*(C(G(K&\PR$%7-4D88$*_$90(A8R=C==H6J?9
M>C&+<!%ZI^89.^ZXP]..*%B7:"3VIYV1F& D#C?8B#2$(P5TEBBAI6M.3[X%
MB_'6(0O5T-FA%CO19:YX>"07&_HVLTV3'=$<_'RB43?1HV(E3PNZUH?8Y>\I
M,MYU3Y$6$;G4.5\LA3QIJ)\8I>^$M1/6=@CK^H L(9+2CDJH%@BJ6-U4N&Y^
M],9:K(9&E@97T/1!CQU9O"[P!*AKK5JII+9]6!87D/K;DPPWS#/(B5TC;72&
MG61WDGV0DCWH5Y#MMG3+VZU1<&!;_R6+*:YBCC3?I!T.S]ZX-UV3K3?)]ETJ
M\OZ@OV6O;D_5]9OSX0S+]1U4Y9W75E?TJAN-T(E*55'9Y68Q&E>8G=)9_0=H
M];.3Y46P930<YVN[A.RC_5<Y1-4QI7ZFR.-!9Y37KTWWK;5>&Y?A;BEQN.?%
M>\J03C0[T6PI0]JT2^Z&$EW@JY O<V]C:X[%ACS1+L11<KUU)[U[>=(K-S@N
MMQ/M3K1W*=I'(T7I IKM, _VS;C:+PW89AKM?F)(QY\<*KSC3SOYT^F83L?L
M.W\Z'=-N_K3&UFU#((W]57#&4:O;9Z7#O6]5WJ>TX8TXFN%-%':G^V=UGC,D
M_IZF44-I #" /4UJ"/%-V*08&UI_>#)T$%=.3LI'2+9GQG7L2F=7$V&[CM[;
MH7?=)EY'[TZ?M(K>G3[I],D!TSMT 3MZ5Z9WH8.7KF-3UP1G7S/'6MX$I^O8
MU GKW@AKU[%I'[,:6I_T>*LN'3N8].(0DPZI[=HUU>$(M@_+XM+QMO+!E('<
MR78GVP<IV\/>9/]/?W=K$QS8SA\>E=(!GB8VY&>#'((>^NWP?/;&S]GEVAXH
ME?>MCBT-J-S1=,ONUYXJUC?C;(4J-[D];N=NU15SZOHL=:*RSWV6.E.],]7%
MEGSV#&?%TME7,Q),_@NJD[L^JWME%<K3KN52"]G2K\*6MV2L'W:F?QN7X6XI
M<;@'OGO*D$XT.]%L*4/:M$ONAA)=0*Q$RR5UO6BK"W"47&+=\>Q>'L].AN-.
MMCO9KB+;H[;*MGPTF'1]XUMB$NR;0;5?&K#--.I:H+2:/UT+E';SI],QG8[9
M=_Z$9F+'GW;RIS6V;AN"9^RO0VJS%+I,[^,(2?P?O[[WW>-'55U\N/,7"Y-@
M,JYJGJDFSN*[>R+$NS!<S;1=WR'N/?AJ9Z:M_?CX#TGZ-;SQFTMN9I>N9\Q5
M#S V]-_>:8/I5!F/)\/O6"W6&_6Q,Q$ "?=_);/?WEW@U\<]&?[WG7T<'<,U
M'V-N7D@)*2"%Q--7\BB!+2"P0PDLQ2B<Y#AV3^R>>-A/%)] %<5?ONW]$E-'
MT0]'$OWI2'*)8\S6WO&+%"@\B?[!A6ND/WU8]+/E+_D1HS_"=Z!B#*W ?4&Y
MJD3K5>EMH'2PQ=I*[? Z+>VSM$^D6D<YIO1;C.#]$V&3+1S5,VP+&875'I:&
M^<>N!_S";0:V"@MWA9GMS'&8]XOA/4F_GY[>2@[YRS=@OX'76>HCO5CR;/CK
M!Y'(:J/!K#35=?WY E_B2MZ3ZDGJ;$8TC[;> P!L!RM,U3E8-_ Z (--U:"W
M<N<_1_1Z?;71X96X78'Q@Z_FV_NI[-DZ0+!J\9> VA%]11H48<DK$(".^] E
MW7>P1V!T _ZU ";8^HETJGD^/!T(XIL>=ACT3;C# $P=:0:: =L*NG'*N+[V
M%%Q$8"L/;WL@$EY#,\&!I/C"<WN^4*UEE/$[_<7ED%K8KD&YR(IV&0R A W@
M4?:Z)VV4P>35TA;H[N K8V9H*HA7ND2#>)B^3BB7P)3W5ZL)UP>L&,-R/<=G
M:PGO95\?@Q;Y073^UZ/@4:&,"0]+E0'-GL_A$M<#BV\ESR5NM0-T8*%+"]\!
M@2)L,6H:+@D$"G^B%Q\_J"[6+,!#88G0%[&U1(]M59,]12QI<!. 4['MIDH%
M'_[2"2P#7&>>^AKH@),\.T;3GR/K6S2B!?OZ#[H3$/WT&1;<(_GB8Q>1F]G=
MD^J0&]\#I6,A8\]4U]!.+?W",'W4-Y$=/IA..#M<)QJ\Q'1_>W?]Y2J762[Y
MEL$N>'UP3./8Q3>[[SX.IJ/18"I'2)2#5$#V%/BF85\ >M,9"L,Y)PN73'-&
MR$T495P%N>_!BX]/7U1'OU\NR.FKX:Z^O9PO3'M)R!W*Y@V5X\^TBPM'%,.U
M!XH\/OYV=_'NH]P?]7J]B"3Y\!%(L'HG<9X-=,*2;OQB6\^@.(#6"+=+4QOX
MW\]MU_MB>_\A *-F@[+YF^BW=#^YLIW@*[Q.YDG95PKY:Z5I]_%6_H\\42XB
M,FT79X'<R>\Z=1S58J;'V3*ZY):5JU( &$KN[W"AYUY;[$V_.[;K\C0=]'<L
MGN*:Y42S <0K+N5^$TM9U9>OQR Z(:T"Z+.7<5_9WU4\J&459Y/MX^VTM]OE
MB_!].",6 2O*P ?!PQTL6KDBJ@<V?/3%S8Q]]HP'D\ +>)&3!6*5%[DSWP77
MS75/-3#!F+T<41&DQ_C+5\\,>TYT-%NN+8W1<77_!7GP(HC/EM\LN(-<$%=S
MC(7X-!XQQ 96H&<#X<$[.>,0O74"FX?JAFQI5V0:3O_U?06B"L(/OV%')N8?
M?#7<'\!'_ *, DY4QY->\H(?%*+]VLO.EH""]@26^ ^."<S8=$&18917CC$@
MX2%KVI9&2 WBK%T;>U8D_K_;MNZ"I0.B3\0EXMZ#]G15S:/L#I\<@7O_8M_,
MP(^^?W((^3>Q=-MQ\2KF&IX']N^=Y^M+< ^-9^J=INA^L+D):/Z3P2!:L5D<
M*L/*\73:L3*9E8Q[\@;F**/FF#/I)6NYCCD!<Y1-S%&:9,Z@8TX6<_H;F"./
M"S"'[G"XVUZOHB.IF^:M8VN$@*7B&(^/Q.'-!KF21RUL^Q$@$>*?;=V8&43_
MK#K:$]X'Y N_"_N(8L-0NO]G[^W#'K^WE\-<$.LKU7#^K9H^^4Q4#);B@_XP
MO*=OEOW@ E]1L*ZM!;C[:+-9FF$:C!L$8YV!^^]^"F*JR]]5P_H$KL,UBW7I
MU]:EZEAP&7^2.!5VEU?7^& 9YF_O  U2B-Y7850S1O2('X[Q#- ^DTRBOF^2
M(->NZQ,1^>'A(;]"EZH $#WWQO=N9I_(,S'[//*39/_YN%\K[G^HZ/9Z&\SD
M_D#P"AO!??=K;9QLR>V"XM-Z"%Z8' (34G5FAJ/$[16]?C(]B^X5 "7XCW?A
M$=,G#$B$CF%TC4<<\+&#@$1.KZ\*HM&F>HXCI1YLMO5>HZM./P6!(U[ AO6$
MQ/(0Y"MQ">ZA&&W&Y64O\-)<Y!D/HVTS&S=!6F(L0)H*AD.RL5<4]T^&1< %
MA_W:\*Y4C8IS9#[<O,YL1V<KD'SZ=!XSS3[9UB/VX4/8Q'C//7S[R58W1L=B
M0>X$G 6:@#FQ %%:WIJPXH$5EW_Y!F7$-Y?,?/.3,2.\05PT#.TZWO%7#%I2
M1/"OS^JK,??GJV#5\#\1L#F J0*\,JT,//CV//#]"L G1^+HM^ZI[SW9#D;9
MOEDZ<;@8,C[=O7P%T]EPP3($2YU"^,E^(0[[9,P-7JS[*8&<HF)= =RSY3K
MD6!'WZW[X9QH?Q>#Y?*)+&^*E]=#R^:8]FVQ2&5:/4Y,ZYC6GS3$M!@MUYGV
M4-.+@F_0G@GB[K&CU:]D#L8+1@)M]'9I@@@J;X7GKUSR(&"+#/UXJ\1. EM"
MQYUHT9J,@RWP;SU@EKD@IP>L1>7A(3*M?](;=EJ4\K>@0;<#AJ*-..YW2I3R
M2Y'W93VN![8SU^/H@)6H4L\Q?,N8IO1.IDUM?7NF1951:[5H?Z5%QYTM&C%L
M;YS#09$5B36/AZQ'ZXDUMXQKH^'H9- 4V_9,D?;[K56D@\BI'PY;KD;#$^XK
MQY[34_0@)8)/:1J/"BVF043Y09Y#_BO#H0F/Y-Z^\BW]_HD$I13NS:JT)AZY
MSPS[?U;_!%)ZRVN:9VD[&Z+X2B]V_I-&D_KR+<=#X>QG\UGV0)3FS"-I"N$E
M+8&Y!CIJWLWL;F%8]FS& 3!*B52GG&[F>__'8SDZ*TJ$8 U U_7Q< 9S7H',
MAGYM4='G234IEO-0G%2OVA.NJ)M9<!;K?EM@_K@CY+J,ARG5(]4H%IZE;X0D
M@I<2B&9'Z!>T7(XE!],#X13I$[-:[NUS6I:T1NE1LO=1#4- 4.:.$.N%7DRT
MU[&VC!9ZW=NGND[3CU63B=6YNL!RVV0=_)6P=.4P(8O!Q.5:4_#XY2,GZ\1J
MI)J(Q_Q-XR,0+]"UUN,G D];+TJ01\6"LCE1GDX$E!.A$$V1#/GALL[Y3(YA
ML4R.O"M7 #PO6+EQ25D+=YC"P4IP.00'@\94Y);*@Y1>%>G:Y_*@BFDU<K]8
MR"B-<@=2N5$YAV>WZ9WC*NNXG1F.^=,[*YG$[40^?WIG<K0^WQ;5I7>62>_<
MSEK+0_+WA3+GZMDI=YLY)P_'N3+G:O*V!Z-:>+W*L3PW5=<%IQ8WI@AWMH6=
M?B4Z(7.4V0V;V?ISF5.,=H9MH=DO2%*!_;!0(*#WUFF3)P:A=$1*)!*+7@JD
MD@^?5(*S4":4] 9HE").*3XODZ-JX:MAI0C%?E!5=%./E5Y_,!Q,LF-K96F[
MC9#C,#EKK*#=VVJ6Q2+DV&SAX,*AO4HQ^OWCHVBQ?R$>*\+Y)$2UQB.A//;-
MD253':7%:D?U1 %:3;($\R$7S0K%A/MOP.<I3LC,<X)1L0+CO219X>5:_#2B
M7T]D9<_(6%>HHLHI<S':G;6 =ABYEVOIN90SVK%%1[X-]"T7[:ATG'C 1$J(
M=FS17-D5J2I'.]X C780[2B=E;<_5(U'.Y1>;Z#L<[2C2M+=?K!,C'8HLL)O
M[P<2[9"W&+YM Q]S1CN4+9XDM8\LY:(=6W256J'$&XMV%"O3V7]"?NR/QKV!
MO#$#,2<MJ\=.MA@!WIO%7R)V4B55=?^HB W&^[D3:?-)<5T5&C5O\IDD2S%8
MZDORJ/>8K79<&JH<J7EW;92%>9WI*H4'V^!DNRI:DI/EVD,MK(XY0 <I.1.C
M/63?9:5-NO]4<YRL(755Q4H<MWT?DMM4U5/S6463VU<-]E;-T8-,;#DE69^-
M5?.I24,(Y+&;:DX=V"XF"8<TQ5J3-8=/K"'<N#<>B39O)DHEC,6:$QKJ9F23
MQR,U!X1JXOD S./IBNO[>(11;X"B%HGZ>'@)E?(V;<%B*W>S';M-NZ4<[*6"
M]>-B'?6VI5(F0_ AQSD#P46MUA*A^$%;#+F:LP/'A29P;$GSM<I?V6;$M(2U
M48./LDW-]I5XJF$1/2Q>K<]1V:9Y7Q&+/-Y*S4GVS:"3UV+?9LBZ+#(-QFNW
MJ4)*H+\34W";3EP%FJ3;@UN,!A>"_^/Q8#061[@(2%0W&5J^FNLW ;;IME1
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MZ41Q086NKF%>%KU CMD]W",Y-^W*H<>?VC+Y>=R5D;-6J.XT]-$YN@E$RED
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MKD)1H,IC9/N.@%&A_.5,JR#6H*XH5*51NG\2T_OD^OPDI:^4QHF"51ZI%UM
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M:WT^1L+9?NO.\-M0<)+G#/\M\J8-2>8=;\HEE@YC4_'>/',JMIENEE)1#Y7
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MM\FV&"81]B?A+^+W=DM-B=,B&L*MUF!-5_:X6K+T86;G+JR?_X@FL\F*3]=
M@&T8%(4,>)Q6\=@P<NC,V; :D-$@,YE=HVAQ$]"O2ER*10RHG&M0X:!P1H[@
M-("2@_*!1%Y HX3A+S3&9W>R+UR/0__CGPE9<=M]P;'B\0<<(Q*DV'7"20OQ
M^<G9R2F'>%,5_,%K<\[@1\;:X6NOG/E_.\#><4LO<?GE3VGM_S7XA<(OSL>>
MQQ+L?R)H2@+"Q\KJ$XTW-*+7^,#YR<7)J-8!SN%'RM(I\%0\'1 W(3XZN0WA
M%7Y$SSBZILL5#>4H^0'/,*Q9?7@QCB*8>VA@;\Y$A_WH_.2T%OO1"?R2-3FB
M*OAS4QOO^K/Z^&M'UCCX0)T/4"_A_6+V/^^EPYC$ZUM87+*ED#X%VJ:D8< ^
MN10#=L:B^'/,NW#!SRDP') R+#+N$(-'"QP34$*[Y-@J:5R 7.@7(,Y/989#
MHS*L2.ZQC_$230-\3<,GOOR$GW<L[:<>8NK] 6U _+^@@8\9=)$SXI%8LX!I
MS], _YEIO;.IV2E4[>1U.Z)2,?<J5O^?3BK X"VJ87C"YB@D_Q9" WA7*"*
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M<DHH$K'<\ZE#]6ATS;N>+3HV$E:/2->\ZZWTU:/2->]Z*_VY1OKSGDI_C[T
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M$$W.*R3;5B(T<=UP*:R#7O;1#__M1T]_Q>M-,DM1T_>#M"UV]\B_';'6(_1
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M#[%;?C>I 64FN:LH+0VXN7&&*5\IK-$7ZY/KXJ\[OC#]\,O_ 5!+ P04
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M$ J>'WV7[T"_$X>!*XG*$' QT3C;)^,I !M*IU9QG7D6E29A.IVI82^Y8FU
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M6=%K4K+7"2;#7CD%EN1-@3J3S0&GDPXX=0V"U;HZ(.Y0Q&1D8X0FM#4<I ]
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M@!GQ,8>0BABF'6$EH=JBT+&"&@TH;[=P83 EUZ)B;&/"4/5*D&BM"74E:MA
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MJ.;/GC)IKK)]&!NP?"$3 [8'A_(,KP,'R/#LWR/FJ.Q45P'&7Z"!D0TFQ+3
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MSD$3XH-[4$D,47-6\IFX"-7L*O'DSO29[5_O4+A]3 G-(U-%VWPQ176GWZ"
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MQ+([0L6!>0D+IT>;USA^2A#9\J;<DC#VPYT7+>-#,%GI4^7>TY;KPK[H\;Z
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M>D%-7U>O%\<[1]"*8R1-<=:#H7'$K);A!%#7OY]<1,CJJZPFG3P-")M1NXT
MR&++;8-".XXF,#3D.#D<=NJIGD TK;,,11@3B<T QWXHE''KAL 6MU> /DT/
M.4=>N[X2==W.D!S?#"CV16R#=#S.YD%V2ABZ8]_S3H"4/7R@.N_#X6X#R!M0
MGGR/&4E3/:ZM-%!S]BVA%!Q^-RDA0LM<,KOC[Q:O4N$#;B#,<7G!OS-@,CJ\
MO$'DJ9W*WSWGGC.6B#-$1 W7<\/-4\*ZR]W&2>[A-5MUB=EFB!_X6J'3D(OE
M;:0FERFASJY'W-TV:M53HFE #YU!:QXVZ+ F+[L9;KUX=T6>DO>KP*-%[PV
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M"4];88"!-K$"!Q7BJ6!!*E\W/%39N8\H'0X3<J/$D%J!"N@FB9V$W7 A,DC
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MR)4D^G8(\'X!JR1%LU5*JA>#&D,VW[T>\N[U%-0]7\@^S87LUX6#^99V9S!
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MV_)30F'/SNF./?N*H;I)SS&3F-!,B.RMR3S5;?XSVXR\:VY+3>G+K:>6?D*
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M1L"B;:#I9Q.TNUCOHS"JJJ%<P$:X?(34<(B%#F4.+'X-PM)#U*@4X>2#;OC
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M0/@">;X#<+X#<+ [ -'=4S%?#=?CU7#G<!$@%EFCOO%QO@-P,I>XS7< SG<
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M3%38S?CUXG1!"CSZ=14JJUQZAQ43Y\HJ5)6U@WC:2KL)*:"1ZX[>L8H9PZV
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M[J3^#^KDZ9 )%XBKG""FA+C6S %D#1SBWJFNW3,-]. 2N95'".3U$KRIRE<
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M\-27+R8V@ N6;B/,Z_JPL[?9 U;4*'KQ@[)$(>X?9OJV0'"]THLN@!3*B_[
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MVF)3H_]5(]JR8-1;FP/5$Q6")LV 1[>@P.M*N@)W11W]F2\>7W5\'7=--QG
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M"59@B#WYH$=>4HQ$GR!\3*L'D6)@"(6N%\0>O:!$*X2:;YZ+@E!X-2P#1(K
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M8W,.,+$G2)$_'0XJ#V(]YG1H@S1I5-O#U=W.Q* -6OZ9^@=%K[C$>\:O*0X
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M0^4C >PSNY)&.S08VS;N/#ZG?.S=)\W?0RG(+@3/IV/SYKU(\]N[?$6*#7?
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M@%7//,Y?<HX?/)$^-<E#F!P_PC0BN-+'$  ]"3P X,@@??3EY%AZ339)ED>
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M5P#4Z;-$+S5PE2</.ML4(-"/F/<_LBV4''C_4,^<]QN]P*%XV+K@O-^Y\XK
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MF4CO24LI[0EPDY9X$YG&B1+K2EV^;SO?K9VM +AE5^MM;.OK]9J &%<*F&*
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M^-25'V_VPEKM+0@[9>RHYJD0QWB%]X86_!6(U7F^?IMM=Q5=WSZDDX58SG'
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M7-4;R,<I[9+:&F!O-< O@ ?/ _THT3Q@J ;\LY/$!GCX'[@$E\;#^_#*%6T
MT[$TRDQ1J*!I Y(TRC, &"!S[./_<)Q\BF;Q%:2V4_B;D0!P" []]FVD-S2G
MFTS^*$UI-0;\R H%Z_+,2#"?! <@?.23&'HT#F0KZC<%M;;0>EL/Y?8SP$MR
M6-=]-*RW!\D/[>$?8WC[U[7ZIL%\8AU<S RKT@UF8SE#71]NR(TD:%8KM55.
M/6#'NV#:5,LIN$%+EV&U7Q3:!=_0[RUM_GN5GZ]6;,>W(4U?)&_O@NT/8#?8
M.Z(>UAIG^!O3:'E@\$[ U0C-"6#MF76!+/O;*VBP9P6 ; [HX3.%[B?R=*(P
M44\5C'Y1*6NQH^O>AGD0<56XZ/1U[(+.%D6;/*CL-),E5<8!]%H[LHZ/1RHT
MZ*FDQY"%HV\D^9=>64(W2+4"S'^-9DM0?]BQ4>*I:SQBW*Y"S^\OTJ>LOI)6
M+_:V=%0*L](1EU2F]F&+M":?#:^489*+ASH&+4F6=V]BY/<D;;8!X/L^]3CW
MU\A(9\2*AGI G%F[1T3!ZH$6^W8V;^>:Z:=Q4E-/YH1,.TV[T"DGSV5%-UD(
MS=Q(9A\;V73(T!'-C"@K5_^XFO6U]SO;R9(RLRO.^(1)_-ZJ^ GC"#Q;4CC'
M(]8W!7U*L_7;]JO/[;WY\WPM6@X4;YL@2C$'!<$EH4V[L<4>F-N&E*"0FL$
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M)0MPR0'LT+Q\8PF511FROW_67 #RG:_R<@Q*H]V!$PH[1S+HLR.\8:3+H>6
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M\!+7 -]^APLT<(]LM0-R9XNO&:-6^!A #RELJ=UY#@F[/AA$R+IQ60ULDJ,
MXN$-"PN,"_U,,T&AU?'6)H9=DS%18J6E!Y\H-?)7^OB9%C9*.?2 Z&7KX8TI
MPQ9YU,Y]HIED:?V-A"&?&LL8IS-R%,"((X4.W"]* C4[4-@0:.@!(5#KX8U
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M2@#OT45A?K/[O,U6EUN6RK$M.3X =/^X.XHEV3"@.PQKPFO?N@-I\QL1/T8
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MV&!+5J;I/EOJ8K8XEED>T*NN>+\3WM?_2OY;]TO]/Y_3DB;_[?\#4$L#!!0
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M4HEI/"8=^XIF?Z#)'_P@5)[BZ0^6MJ+4U\,SM0S)WS\5/=.HQ^3DP-5-=&/
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MH4 1E7U#-DP>U= MY.)J?!Y/(/;7!/'W &!Z"4#J]&-!104( 69DPM;1(ZA
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MD=74R*U1  Q 6:A;1FG?0A NEVJE)^7DZM,# J&X9Q4@6CE(1CYI@(!!C!G
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MT@&1>/X4W'5D28M@GCMFA,>*#=1IG Q*ED=M&B6M#] R5X-6,)96-=;X,J?
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M42F08.]7KM,N6JGG=8OM+P0 B]F)0T.I(=B#LR[QYN9Q.T_.BY!DL4SL,1H
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M :5>LJNDJA1<=H01[R-_I<3VS9Y:TJFF316ST\,+=]Z$DBLQ,_(\"L2&%$6
MB51>C1Q7ULVD]WG8]^$4\8JJ4I 11TFYOUPJIK0?&W Y=6$AY3S.6#.]@GV$
M5["/G)1O>@3;^4>P18_-1A%=%GMG(5ZC@%U@$]V<5A.6:5G$A!::%"R6TL R
M3M:D79W3%MZB@&]AWK?2J+5O-MI1TGBUZ>J%74U\RHG2X4RH"BIQ[).E$RQ,
M'M5$*^3B:A8NGD!%<"EW6@;32P!2IQ\+*BI "# C$[:.'D$%(A@U&/<**+O4
M:CB92O1IUZ0ZY:=V,3_U$=^$FO)33_FIK0%1?@]/EI%:2G,(3.706 \6M6":
M(.$RM&9?-R5VF1*['"NQRX^S38(W*$EW,R\.9H@NVC;Y5Y1.25Z&$^!F2O(B
M6PI*DKPXMT6X0+2U=(AALK8BDMJ?]E%(E4^C6[AM1RQM/2SPOEI\I#MGTR'7
MD0ZYCKSFG@ZY3O60:UH=3ZOC8ZV.?Z9+WV0]B[ 7DVQ][!]""-G">1T2@I-=
M1DRFY7+O IQ''B&+Y1\>RQ&;+I+[</6<<J9<)=T^J;"(SKYI&"J3:D*6\''U
M;)0K$G?J!E#*H#'RQ*Z&@ @G@!E?R%P(&NN6 D7S'O'=-O&?/5()Z\XBON?"
MB.\O='I(%J]+*LH-'=SW:7VXGM6AJRG,,U@U5L/W2,K5P/YP+7+5@S%YK3I[
MK4SN_8[MMJKF12C/3.Z]-#]8"0X9T%I.+=V"W-P5TH*C@T?@$#.47#]/A9SY
M2"EDIZ38EH#0QJ38/QX[=^R >XU]FBSD;Y,PI8N"<R^*4'"V*^A(00C:J.IS
MD^U9-+C9">!^=01*OM"UQI$2*?;V)F&:A#[MPBQ;20.P_(^'5P*K'^V$DU0"
M"#J:#$IC6Y+)I;XNH*N $ >A?^?MLJ4I2M;D.O831/<Q%RC_\SH^HTC&."Z)
M\!GB) ?JGS%WG=>)L9V0&TQS^NO$;I674#]VLD<0U$LQ%LMR,8SC:-<0F'S9
MX/@"12%=I.P6R\M7.IK3GLST\/",$.^5@H%J$&QR^JC!A5XPA"Y-MDV]M*+<
MU!\[H;=FOQBF+PR#_]/&_'@X-\7V!S<S6]XEV$<H(-G5^3#&=.6^R_:CS]Q<
MT5#RPA!*<CM1J2DE!&YJEB6.W$RF694ORR-$^P_G$%U%QL%-C<Q^O$BDTL5)
MG57I%G)ST\S.=P28X'TJ@_^JG^RTO:3U$'O7BY?KI&,_B->/C7_SPIC<8$(0
M6<27KVD8K[8A>68R+Y9LOFT8'DQ?Z%--;R=$=.6$X ; LSS4./8C3_V Z7+]
MA(( !1=T/?:2O;%VY85)EM&5+L-:'V]"[RF,Z*3:C$7MR*:,6S5E8R<B>](*
M!*CF5943WO2\P?2\@2//&_SHYL1=E_G*\U'^OJ44CVTR+N8J9"[@2BB5/G:J
MK$:\K=/OWHZ=4GNQC[@+.C4A9W_7(+03)&#)=/=X36:.OY-2ZP!?XBU!P1E.
M$OR-KD_/O8WGL_LRZK$%5)([W,A+V@DN<]GU!R4%][%>= $YZ@5MOWS=A F2
MG\;"BNH@JBSJ,*3XTO>&J3U[RYYRN<'QBEU38D+LGY&?Q_O'NTO//_/QMUQ5
M^D7WKBR-HG:"JH/T,%>8#GOW'W4Y=* SCX3D@0KA!8OX=R\)F3>01:KRHC5U
MBG$'-$DQ.W%G*+7^0"9C;?[6RQ&"F!*TR3O'%:+[U"5.T%68D'0>Q^S<DG@)
MK0 4?6[$B1^FI,7)!>!UT8U!())>;>;IWHX,S^ME\=K[-2F20P9_A.ES&#^$
MK[<X3I_)8GD>84(7$L ;$_VQ5P/9C+USZ.Y#BQTA;]B$D5Y;-AFFTV\(Q46?
M#AZ0C^.@TKE-P*_/$S)T@WDZ!W-C?74>SN'UCO3&LSZ@YTM:82\PAG)2@U?)
MR3G(:NJF(U#5M17P//89LW%L/S]R&XK2#@S!L?Q*ADY@MKNF^HG=5U=:(-C*
MT.2&1,V+"(VH[,(_H@-A/8X0# ,Y.@AB(UUU1C&TUC)\U$T<-Z.NNV%8Q,T,
MORUN)X%=A8X&P&V[QC)"[=B'G3U?ERJVH70_>H@68;&[4A#WQ[[C12DA>Q=@
MWKL6A[PB)6Y".7B[&>I6C6>HB*8($!%0<B)$FI1V A,NFVZ,2(M;"1<K=UWP
M_G#)OM,.P9Z<GM^B9-7*)#8 YXZC)8^SG7@<3G=#CI'<VLNS7BN]NN*K@U>8
M[CU91(06MH%<-*^'-KFXA5D]G?1Y_;-54XE%*QVR #D>G]%^'3(W6[!VXFV*
M6RGO$T&SAOX&P;B\_A+Y;MXGNBC:FZ?H1N>8I.0SYPZ_E&H/7CZ5K3"$R 0#
ME(!3N2!U,QB+!9X]%H%GG("_YJ=*0-_^DYV6E[0>&I!W*%[:V,VT=(TWS!IF
M%GSEOP)GJ;'E,D#LW>)0FMS*J")A5N%RZ_R8A"O5LEN7B>I:G9R)G<#I12.=
MKM8I*BK=Q,>>771A>([7:QQWP:":@PJ $@Z.H0^LBT[0D]52XL[-&4\B<GE]
M]9[I3!YC#BBGAF2CG'- E,K=$7Y-WB7H+)YS67,?,4ON>1V?9SO*\V<O7J%K
MEMPXI4T!( K,0X(N-0]WD*:K#U/4 >HI$7AL;^O1AKV[)/055VL Y>##7E'.
M'3!"Y.YIV"MYEZ"SQ*U:/.3&7&)43I:C;;\ZP(4<67:N1WSY==O..F-:O-"M
M=G$[H=51"Q"$Z5=1 LW*."G@&$WW2^MPV[R<V@>K+K-MR<I.,/:HG<'FWGUU
MY65#2P*C?L<LOUB>O/\Q\6*2MX=%T]*6DY V%@5S^2*P$X]"\68\[,1C'_J
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M="MP^B2B'LXBF0#5A(6*)81V @HL&00\,F8C'5$,!Y3Y-GW&2?AO$%C:Q!+
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M.P:^8U,!FP:RN*S+5[8O;9Z]0DCWS]!)2$\5DQKZ.0X<Y0UR]?XE54K"!+E
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MHU;GS+V_DU5UGA9B_1%EKS_BY 6C](W*?!^?<KK[4F:>*I.DTW_F:4IL^";
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MMW8["267BS=+LL#EXHUS%V],KJ'/..4$9B14K?5OG\I6Q\M:K7:OA,-MQG=
MBELS5RN<'X]!^DXO?.!H'T>[* SHVRAAF.1T#;!?G9)#%-*D@;L@2E=OP2%'
MJR,*<)Y6=T521%]4H:0O9$Y;4N4M=T4<NBOBW?FI+RB-WHJSQ(VTTMU@CHCF
MG$.+16.]\YEA<H@\D* XAX_^B.W #OE=% =Q& 6'ADAW9"3^.QV(::CFD-"A
MN(,0Q5*5CJ&EW$21GLP07($Y>W+1?EG#J:_A7%^7+VNX>:[ASF./,*6JA*H[
MOCN?7!4FC\R6N5Q\!<-S&L28M!:OX^T32M_(PBS>;W8,.?$S:0MF?V(.$F.P
MKKK)*&M;6)4A,AE5A6VD<]I"(6^V#;[:R1]!2@_8,_.&,;_5>R.M;PY#320$
M&"L=)K[NX)X]\9OWWR]QJ;L4_<Q1'+(\7(42]<P)*.'@+*HLIW1&A7#T'D@L
MT9B3ID*)+I $):R-.PIP272$[XQ,\NI:D!-5X^M$Q1(./]8!=>;\I5)$ +I>
M$8]1)Q'?&.SZ]7@_U-V\GW_^;X12FASE_1M-C2*>-@&%^C.GJ)#3DR=<6H7Y
M4\C4UV-.3*OI2PJ>3*5E12,<MZP#0QT$4KS1#J@3[K GJ)L[\O'K]'[JO8]/
M>88+%7P2S[A\RBX,&90>@DXJ[V"(L6KP?DYM"'4%!M05&%!7LP 46UZ3@+KJ
M ,K?R;0AU#484-=@0%W/ E!L>4T"ZKH#*/OOJG#3(8]YL*N#/:MMD"7G'K4-
MSJ7IGD3CAA)VC]G6&1_;Y*3N;CW_C%=4*Y3Z5%PY7_)W+V<R73J3Z9TCML:8
M6-5M:52<4_1"FDIG;!KKG=_OX@0F#^3L'(>/KU&#VP#3[-'T?U]_YA&9D^A$
MM,YN@S1])Q-1X3-VH*%4IGZO"E3&%G3$X$CT1&ZCB5E%\8(5C+6O 'M$1-0H
M)),UE;"2OP,H(<TE^3N#QEG 0$0" H3#RM>PTD.*3D&TK?(2$>1OLE>4MJ3O
MP$.A1*592 EGH:,N+A!((,:S\&E$OHS(AW$7% :ZG]W1?B9S?TAI^LCL_8$L
M$S."9#IS%F]?]#-X0TC/PX: U%EH* @('BA$''V]B=:>1[\G<0AP1OID3'^D
M0>8L3H"":7DE36[Z[^\Z<#VM,25R$2*DJ5^*8-(XBPV(2$!@<%AII()V8M0H
M)6$Z%$Q/PMT^9C9:R7<8E)S9OM-PSHGZ#048/=*T-IO=#^()4^&Z-@ZA[;X*
MPZ1U%@\J(D)M7\S2U[=B&M=DQ4%3.6%]ZY1/Z&;X%"P9)(8J8N9K6&-=;O/A
MZ@5ZSD)42%3/(VPB:[=9Y3V? "7K7''E,BYF' Y#7^.@1)XT)RWM"=V'B)CN
M@A(.G?-  <FGB!4>3U^'D_9,6DOVSL8,C)CIK?2(W4:/DJ0J$)(Q]C4L^BV)
M]\\H/7Y!+QD;/ **VEEA4+@-$[E,*MA@<M./<KCFRTI]6*GOZCH:3,XU@DE&
M8UWCP*JXB6YNR$M,Q!@G' AZJ0\5P- 7?+280P",F82,/71 2$7IW/P83A2D
M5,&-F&TC\&;MJ%!R/$99<5"5GE<I4NKO41SV\_D!*.MC00)*MU$ EU$%!$*N
M UY4M7S(+(G?4)I%9!W/]T/%1&>\,(E<API ,C64L!GZNC/+67SQ-^"@].(E
MKS<^BJJ\!A:^#,]%Y\E$!UT7B,\"<58<QXQZ#EH-]\3C1_\>T1:A(PTM4ZB3
MB9:TZ5"\1EN]8?PSI_&?ZA#N^DB#T9Q='Q.LSJ=*!K!R<^?(H'8@>TO#JFN$
M^:SE1$3'4Y(&Z3NSI5F61B]Y1N5[3AX"QN2H7;[.;JA<WA;NC" K&:ZQ-BR'
MM*K(>*C>&E_WQ)ZR)/SG:W(@K<>EM)P15DYXOHO&)71S= 1+!AG[1,SLI'TV
M$W5(XD(RYETDSN=&?*'UV1X*I/V<2*7I8H#'LHXDM%GYNA6ZWFXC*G%P> BB
M[7U\&YRB+#AT]\W%5/6N.8?*;5C 9%-!!Y>CK_N<C_2F?(RV]<-VZS#,C_F!
M7B;_@G91&/6==FB!LVLN+> VBI0E5@$4A+FO4U!?<JE[(G5+',>*5"(5;+"8
MZ8<J7=@RO41 :%IR&3R@Y/W]=3:YV]!1E%8%2'+6OI[*>*C;RG5T!1272Z\]
M"K>A(I=)!1U,;OXNC:L%WNTAP'BS*V1BY+"5TG63M/3HK*^+^;E:)#*!4[;T
M^?@*BZ8DS*2S?()Z1=PGL(X ;C\G ($X*.CR+-;$#%[3(X&3^^X)I71>NX0/
M&[N\[:&-F3)1MW@]/J@6=QHT Y6A "GUFJ8/PP@!=S,,<.K%6X!3*.X!X+25
MH0PXE9KLA'261QPG>,31]8<YORZ/.,[R$<<S0AO/K3TDN @I<[?PX$6Z:Q91
M$>NF#I%'+<<LA/7'2PE[)L TPVYZGO\H53T!KLYB$W(R!:Z"N/I510U6VS(8
MO:2075+(?M 4LIS5P V*"],(#J5#B8D0=RC(\A1=_K#9-;S-[TG61>LP)I4:
M-9E8!TP?%HDAC4#.?NA6-/VU) X O_X*7X-XCS:[ZAU/_..4Q+^C=-];>D)(
M:U]21.HF9!2D@P!#S*[V&;R[,_#T2M2+-WE&_()X&\7[[IS#^UY/.;WO;J)!
M)@?H7%B?A[ZO6.;@)Q6EF=U=6&4$_.-J+ACH23(0!1HWETL8$+?9,@CF=39#
M[:BH#@CXF^8:P21WQ@)U&/1' W^!H#<>\*'P2<,='#P@\+8I:#/O,<[1]DM.
MW\9Y*$%7C&:52_/U%TK#"%_B#LU>5RW;A .XK,-(T90?#"$X?U\/EZZW_Y?C
M\E;V<\(Y.EO(_!(0.6^3(TVP7BCN$1'#PE&&GE#Z%H6HU,\C"I-]7'!A'?69
MJKKSF>B1JW/3-B;6,L2<QF^2KT=POZ/L/@Z3(_J6X&YTD?FMTGK[FYM %+4?
M@II.>5^3  CG$DX(ZXF^E\>ZU6V&&<03D#-S$W5&-3385P!4J'&T]V\EKF.T
MISM(#JQ0^N(7X[(A=*OQ$H,;R,LK;&OI9P"TH?5-GQ9;9ZG%$:1]YN@Y:=P[
M-# F [@/&*1%W+U"MB$=CC6,"UN@_Z3 -.@76?%@\ ]DKC^&SP;Z9C0XTB@/
M ;Y_:96$0\ Z+%>B1!5*3CFK'&1H;Y7S"KE2N0</QVW>WJ9J$AF>.MRXQ0"#
MJ;]@DTD]= !D0\W^)8=R8X,VFKXG?YM@^J($#:<5PI1FTCU=HE"D/F4"*>(F
M7C2D!9TZ ;&M<6+_^)NXO4H(4<*&EZ@PCH<+$B:,3(N1<#P%8;;9/9VB.-GM
MV !@T[3[O4/C='<+Y5'HY2Z?NG,GO):OL<;3VTL6%@6X%'[O)$.D'^I:"/:1
M/_GFR"Z7^L>_U.]=@K/E4O](E_KMNY7+I?X/=:G?E2P2RZ7^#W*IW[NY[JR&
M*KMQ<CPE,3WP)'*#1+1=5XA):QUF?'<((!O8)6+S\O62>4<:=A8!$4UK(=ZE
ML0X)8<<G,-$XR&"QOBS/>RQ]/3$&F,\ P[2;\Y(,'?KS#P\<KC@VQM.&,X'!
M_=Y/'.X+)&0B*>*!P<Y7IX-SE)H)#!"M.)NX+X!1$541/!+6OEX$Z6:Y9B)(
M3,3))NX+9D#"*8*%Q]/7RPJ-_#W].W;R]$CR,OW\2((RUB$%DD@[0Q*?]XQ3
M),5)AE:?_EHE.4I.Q;&+%<Z/QR!]I^F1FA]61!?1&U',:DL-[8"7E$=+RB/%
M* 5/"C]2'AG,-W'3O7FWIIN3^T+&F_<+R4/P3O^T_C-(MYO2/AN9%[[GK-BK
M:?[L?!=&); .V3XPDRDT"<ZW818O^J;C3J8&[ZSH>K&BD31IUXHT;IRXDO3&
MG$[^0-'^-4/;]1M*@SVJ#]D\I%'8\\NFK=6\M0EKG;T-*NA\8KL4MVP.V8GF
M;*]CSH^+Q8*U[J+-ZEQM<V6*%=VK*CY6.M%*/25D +GUQF;@J$4,U<3@>W"<
M2GS=]Y::,9;8<:T#?!^7:C(YJXQ2.71J,5NYH_9DLP>,3#.&&^CKHX]#I^.[
M)-VAB&;X/BO*L LHJ,&0L\>JP5.S&ZS+*5PX9BNF3T#CR$3(T,:44Z%F]:8F
M0]7J/;7+<7MAD@E1N8G3O^I@T*)[V2W[P]N+\@KU$='#KN3OMTE<' _(@\,S
M2H]7+*.VTX*F74_< H=-VVI?@*U[ZE;ZF\S%7 SJGB@EBG$4LI(HCUZ/^6AG
MIQZ';7("O4X<S^RVQ4(&&S?LJW(DZ &>4?;7N?P-V5.?_SSM2*;'*>R'T88!
M+\K,QFXFW*-3K-6\C<UQP3B*SB>V1]C^W(=;'_(UQ/.U/QE>'PYH@:'UH4X+
M'+9DJWTQQ?I0JY6UA4^85MDY"V_[]",:,J<B\_;:K6CV9BG6[,36UVM,?33-
MOPS.NHY&Z>9O=N6YBO5;$!VH9NZ2]#>:H\V4=PNL9J@[*ZO&8?,:7ZNC.JS2
MIM2F]>'BFW]'F$[P\?;KKQ,*R<_GA/YI[&L/JM4:6DF"JYV9*0[3^A1K27C3
M+"1Q]L54)XP$F6G,9&;] >-&1GO(C2$ %F7R+X'#P#6#LN*F"CZ9;YBA-:[!
MACD\>+BAH.G7T"8;7P\J\SNU/W@T7N_W:?'4Y:@'(P:W8S(?@]<.AT<(!_K%
M#<^"VU8+;TE0KK@> # *_WV?O/UEBZ+2]LF/KLF3/_WC&VG]X6N<T81$_=2V
MG*]5%W2_6@=L+S&,N/VRK#"]TG82"RKW:=ED=B):QJ<Z_VSSDZVNY'58(FQZ
MNR,[/(J,LJVROB8+O<DQ&=UP\[T\ALU*J"J5\:C<LV&8/#);YG*9$QCHSQ0A
MIN6#Z04 :=/;@HH,$!S,B(1MHX=3 0]&'<;.O+&P/ARBGWEP$R5'M(W"X' ?
MA^Q<LE+".I$LG]!A,(#% Z- Q'%Z'X'3_9<TC*82,G9@,UX%57^,4($MF(ZH
M*[64I.8;\O'RE[;^]?*^0E4\>76B >55L;I<DI@N24R7)*:&HY#5,8P\>TW2
MZ%]H^X,8>-K(FO)P""Y9&8K=G4=JB]^2/U%:_HJ.$>STC]FJA+%$0U591[1"
MN' 4[>I'!$TUQ]>UI%&M_#B=IK(V3E5C6%NWJ@]@;6+M3FYMO>;X^LP+>YM2
M4RN-O8AJTT)TV.$&[:.8;EC>! ?ZP#ELX]YNTX1;]Y::YK#UNZ(B4]OWMIJ_
M>,Y$B_7YY[XVQYS6Y;6.,<,+:G78W"?7^>3SOJAEWCZ]9'*H:US] 0QUHT[Y
MFDT98XI7;8K#-NY&[TP^A2LWU^M$N9-I;5B&,6NMLC)&S",3F>T^<V_DD&<L
MFTF6WH$^5U^14_C]_%K']/L9M3ILY)/KW)K?SVJ9G4S R^':Y7#M<KAVIH=K
M!XQ=-^_]T8MA[R/6,'Q>Y-;@WK@SOAZE)RW&:,$'-)R^*ICCZH@UC.%06A[E
MQS0/T]XG8,(901SCKJIS1[\O3?O$//'-_5YU0?_[3-$L4\0D6&0TPIE3Y)>V
M74F0="5!TM5'01);$1,CZ:J#I GWL:5(NI8@Z5J"I.N/@B2V(B9&TG4'21-N
MMDJ1]%F"I,\2)'W^*$AB*V)B)'WN(&G"C;KA=Z14+GWH7Y32J47]MI12+1Y<
MF=+2VFCWIE1:,_WEJ>H#_0_=;ON??_M_4$L! A0#%     @ Q7A+3_;O]!J;
M/0( *#$@ !$              ( !     &%D>7@M,C Q.3 V,S N>&UL4$L!
M A0#%     @ Q7A+3V5&@Z&C'@  E(@! !$              ( !RCT" &%D
M>7@M,C Q.3 V,S N>'-D4$L! A0#%     @ Q7A+3\X5-3@(#0  LZ<  !4
M             ( !G%P" &%D>7@M,C Q.3 V,S!?8V%L+GAM;%!+ 0(4 Q0
M   ( ,5X2T]@ S:=:HT  -XS"@ 5              "  ==I @!A9'EX+3(P
M,3DP-C,P7V1E9BYX;6Q02P$"% ,4    " #%>$M/-%PAK[W'  !]NPP %0
M            @ %T]P( 861Y>"TR,#$Y,#8S,%]L86(N>&UL4$L! A0#%
M  @ Q7A+3\Q^(]"DD0  ; $+ !4              ( !9+\# &%D>7@M,C Q
C.3 V,S!?<')E+GAM;%!+!08     !@ & (H!   [400    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799587520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; "> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%; border-bottom: 1px solid rgb(0, 0, 0); padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Period ending December 31</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); width: 0%; padding: 0px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Future Commitments</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 0%; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019 (remaining 6 months)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">232</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">227</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">232</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">236</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total future minimum lease payments</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,007</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(167</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div>
<span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Future</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Year ending December 31</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Commitments</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 239</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 239</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6819584672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Change in Fair Value of Preferred Stock Warrant Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in value</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (60)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Embedded derivative liability from the issuance of Notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="nump">864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Termination of the embedded derivative liability due to the extinguishment of the related Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(653)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at end of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Preferred stock warrants - exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Exchange of warrants upon Merger</a></td>
<td class="num">(234)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at end of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799503408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Warrants - Details of Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member', window );">Warrants for Series A Convertible Preferred Stock Issued in November, 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | $ / shares</a></td>
<td class="nump">$ 0.2276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">us-gaap_ClassOfWarrantOrRightOutstanding</a></td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInJanuary2016Member', window );">Warrants for Series A Convertible Preferred Stock Issued in January, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | $ / shares</a></td>
<td class="nump">$ 0.2276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">us-gaap_ClassOfWarrantOrRightOutstanding</a></td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Warrants for Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">us-gaap_ClassOfWarrantOrRightOutstanding</a></td>
<td class="nump">330<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInNovember2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInJanuary2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockIssuedInJanuary2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6699158544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_NoteToFinancialStatementDetailsTextual', window );"><strong>Note To Financial Statement Details Textual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="nump">$ 232,000<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_NoteToFinancialStatementDetailsTextual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_NoteToFinancialStatementDetailsTextual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6819005840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Deficit (Details Textual) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Preferred Stock, Dividends Per Share, Declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">5,313,200<span></span>
</td>
<td class="nump">148,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance</a></td>
<td class="nump">701,808<span></span>
</td>
<td class="nump">19,548,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,807,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common Stock, Dividends, Per Share, Declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=adyx_ConversionOfPreferredStockToCommonStockMember', window );">Conversion of Preferred Stock to Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_EquityConvertibleAggregateProceedsTrigger', window );">Equity, Convertible, Aggregate Proceeds Trigger</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_EquityConvertibleStockPriceTrigger', window );">Equity, Convertible, Stock Price Trigger</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsAxis=adyx_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember', window );">Noncumulative Dividends for Holders of Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends Payable, Amount Per Share</a></td>
<td class="nump">0.0251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsAxis=adyx_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember', window );">Noncumulative Dividends for Holders of Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends Payable, Amount Per Share</a></td>
<td class="nump">$ 0.0182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember', window );">Convert Notes and Accrued Interest to Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,531,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember', window );">Convert Notes and Accrued Interest to Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,469,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock Without Giving Effect To The Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">56,672,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">56,672,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock Without Giving Effect To The Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">51,069,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector', window );">Temporary Equity, Remaining Shares Outstanding Requirements To Elect One Director</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">51,069,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Temporary Equity, Liquidation Preference Per Share</a></td>
<td class="nump">$ 0.3133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Temporary Equity, Liquidation Preference Per Share</a></td>
<td class="nump">$ 0.2276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_EquityConvertibleAggregateProceedsTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds of the entity's common stock which would be required to be attained for the conversion feature embedded in equity to become effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_EquityConvertibleAggregateProceedsTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_EquityConvertibleStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of the entity's common stock which would be required to be attained for the conversion feature embedded in equity to become effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_EquityConvertibleStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity remaining outstanding that are requirements to elect one director.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_TemporaryEquityRemainingSharesOutstandingRequirementsToElectOneDirector</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=adyx_ConversionOfPreferredStockToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=adyx_ConversionOfPreferredStockToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=adyx_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=adyx_NoncumulativeDividendsForHoldersOfSeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=adyx_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=adyx_NoncumulativeDividendsForHoldersOfSeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConvertNotesAndAccruedInterestToSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adyx_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adyx_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adyx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adyx_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W%?:==3OWCXTO@G4%O^ZB_@)02P,$%     @ Q7A+3YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    " #%>$M/2H0:-"T"  !.!P  &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'55VXZ;,!#]%<0'K+')700IV6K52JT4;=7VV2&3@-;&K.V$
M[=_7-BQ%V+S@VSES9CQX)FN%?%,E@(X^.*O5/BZU;G8(J:($3M63:* V)U<A
M.=5F*6](-1+HQ9$X0R1)5HC3JH[SS.V=9)Z)NV95#2<9J3OG5/X] A/M/L;Q
MY\9K=2NUW4!YUM ;_ 3]JSE)LT*#E4O%H5:5J",)UWU\P+LC3BW!(7Y7T*K1
M/+*AG(5XLXMOEWV<6(^ 0:&M"6J&!SP#8]:2\>.]-QH/FI8XGG]:?W'!FV#.
M5,&S8'^JBR[W\2:.+G"E=Z9?1?L5^H"6<=1'_QT>P S<>F(T"L&4^T;%76G!
M>RO&%4X_NK&JW=AV)^FBIX4)I">0@4"(BZ43<IY_H9KFF11M)+O+;ZC-,=X1
M<S>%W717X<Z,\\KL/O(D0P]KID<<.P09(?" 0,;V($!" D?BT4F8G@;]2QT]
M'='3,'T1I"\<?3&B+R;A^8AE6& 9%%AZ]-5$P$>LPP*KH,#*HV\F CYB&Q98
M!P76'AU/?X$ 9.8?V 0E-CZ?3"0"D)E$;X,26Y\_S70 ,I-JG(3?2N);F&8[
MA)G)-YYYD=BW,$UY"#-S73CX+ ^8^!:V4Q4?0Y(9E?#KQ:EO 4]5?(SW=Z%1
M.>,@;ZZ0JZ@0]]IUD='NT"P.73G\#^\ZS0\J;U6MHK/0IJBZTG<50H-Q)7DR
M;[4TS6U8,+AJ.UV;N>PJ?+?0HNF[%QI::/X/4$L#!!0    ( ,5X2T](0]2G
M400  'P6   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULE9A?;^I&$,6_
M"O+[O?;,[OI/!$@-J&JE5HINU?;9@26@:V-J.^'VV]<V#L([9TGZ$FQS9O?,
M>/G-9N?GJO[>[*UM9S_*XM@L@GW;GA["L-GL;9DW7ZN3/7;?[*JZS-ONMGX)
MFU-M\^T05!8A1U$<EOGA&"SGP[.G>CFO7MOB<+1/]:QY+<N\_O?1%M5Y$5#P
M_N#;X67?]@_"Y?R4O]@_;/OGZ:GN[L+K*-M#:8_-H3K.:KM;!#_1PUJ9/F!0
M_'6PY^;F>M:G\EQ5W_N;7[>+(.H=V<)NVGZ(O/MXLRM;%/U(G8]_QD&#ZYQ]
MX.WU^^@_#\EWR3SGC5U5Q=^';;M?!&DPV]I=_EJTWZKS+W9,R 2S,?O?[)LM
M.GGOI)MC4Q7-\'>V>6W:JAQ'Z:R4^8_+Y^$X?)['\=_#< "/ 7P-('TW0(T!
MZK,!>@S03D!X266HS3IO\^6\KLZS^O)Z3WF_BNA!=]7?] ^'8@_?=>5INJ=O
M2^9Y^-:/,TH>+Q*^E4P5*Z!04\D:2/15$G86KSX9^N0A7MW&&QRO8+P:XO5M
M?.SD>9&807(<+491Y.0J592FB="MI4ZKB&YU$]<:NM;2=>*XODCB6]<&V)8R
M8[QF##1CI)G4,6/$+!0S2S= %\D22I727L\Q]!Q+SYGC.99>LDBZ62&=D;FM
MI4XKY:]U GTGPK=RYGE,Q#RQ-"U%J-! I;R&4V@X_7"EKM/_LP0S.$LFRT).
M63(Q2Y)DWFDHPE2,Y$0"BY&L6BK?P.=DZP]E4]L>F).TK5S;)(&11 H8ET+*
M4K!Z@%!K]J..,.%)(EYY6@1AQI.$O#)N^DIFE6CTWJ109P2RESJGG%/K&/0D
M2:_<_D22X:3!"UD!86I BT(#DKFSZG!?(-D8E-NE"+$\]L^$:4X2Y\IM023Y
M:W0FLU\!H393\$\]85(30+7;8D@"EE6&WIP4JI1 DP%"2NC.;PY3FR2VM=MG
M2'*;2,?RI[ "RBR.$3&D4)F$_>YQ-R#9#C2Y4\E^P)GQ%XIQ0V#9$+3;$%@B
M7&=^$C!F.$N&:X?A*P9HUJ#.0*?]56;/SINE(>VF#C3&-?VQ9GU?,W6+>P K
MT45T[!D!HY@EBK6+,Z01^=[53)U@L+($JW9QQQ*L8!L(5*"5 17[><B8T2P9
MK5T>LD2O,@1(L0+*1(-6!G2:_-L^QBQGR7+CXI E>;]HK0ET&"15"4^WHZ-_
M)"7._/_O,"8Z2Z(;=XO,$K]?,C: Z$BI8J/0XD'2*+VSQ6=,=994-P*U@.IP
M$PN$>!,+A'<WL0KW"27[A%&>$3#_%0F &<\V6&%@*PE1XVZ#@48 ;-1,:L<I
MR<.%]6>44^>>0QJY@3<>>"L,;Z4_7ST,726A*ZL'P"RJ9^1!D4G!1G3]&>7%
M>7ASJM>?R_Z>UR^'8S-[KMJV*H=CO%U5M;8;-?K:C;>W^?9Z4]A=VU\FW75]
M.0^]W+35:3SK#:\'SLO_ %!+ P04    " #%>$M/QB#K4%8#  "R#P  &
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MO9&)O:IO WU?MJ?(MJ'DJ3LA._=C^NH?4$L#!!0    ( ,5X2T]0;<;\EP,
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MROE5UG#',<QQX D Z@N/,@%YE DX&&7N1(:=T<@TWD&C4288BS)B^ 2#G.%
M&B<03>.4\Z=QXWG,PVQ-+O $@F4L@,D"F-R@QX'.!M13#-?3[QKN@@9=$!9X
MPF#/C#-9 ),',"M#W$Y;^8"P&,7Z_<,-T! #5/+1E DU0 )Z5H@?,T###= 0
M U0P[L,,D&%LA1@W0(/2EAHE8\S,;I%8^0B,<NG"M[TTW  -,T#( Z$'5P3T
M1/G'#JX,=S3##JX@#X0=7#&,11DQS /D*1_F 78BQ?( XP;R )<Z@U('!Z&&
M/'I+E/&$Q'(!LT3 E#PB(Q LJP%,9IE714F:))XV<Q>RQ(7DQFQ)(&QSP#.Q
MCKD>0$*N<TM.C9R*Q3!;$6QFK86M(N,6VGD&D.7*98ER03:PH8_%",C7"0(.
MK1.66Y E%@39P(8]%F,862<8)L-,% :R 8%H-J"</QM8SY=>V/D8=%2 % 4P
M60"36S09T,6 >HKA>OI=PW7(H@Z!+A(&>V:<R0*8/(!96?(0S<:)Y]&6Y2IE
MF4K!G2.$=\Z$)4XB.9:SX<KZ;>968XG5*'D 2"!L<P+3V&CYU"0+J"D/8%8!
M3#',]#N'6Y,EUJ3D 0^!L'.("\%RD074E <PJP"F&&;ZG<-%R9+3+YE1EY:8
MDB?1,5)'D94^F!'2:F,7OMGJN'\YYE_2YQT>6<U8KF.<5AI"3#A15>Y0U8R-
M9!)>D>9#D#U5>>+LN/,YYGQRZT @F 0!3.;0P%+7-MFCJ8XKF",*)O<>2P)A
MD\>9S)%C,1E2(G$RG.-7*D@UGH,*Q^W.$;O34EH(A/T2<,;ER /+)/).4JY9
MCFB6EILD F&+ S0K@,D#F%4 4PPS_:[Q?!^:G#K)+_HM"81=$^!9 4SNR F7
M_!+\*J"B8J2B?N=P%7-$Q;14,0)AYXPS60"3.Z)TL :,UU,,U]/O&FY\CAD?
M3*D XPM@,H>G5X/G#HZ+F&,B!F,]0,0"F,RAK,ES!X*P<P>"T7,'QI%SA_G5
MKX^./VG[K=P_KW>'R9>Z:>KMZ>=&3W7=5&V5T8>VLI>J?+R\V51/S?%ETK[>
MGW]*=G[3U*_=S^3FE]_JW?T'4$L#!!0    ( ,5X2T_!WJI@+P4  -L;   8
M    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULC9G;;N,V$(9?Q?!]5N*0U"%P
M#,2RBA9H@6"+MM>*S<3&2I8K*?'V[4L=XEB<7T)N8DOY.)P9'GZ.N;J4U8_Z
M8$RS^%GDI_IA>6B:\[WGU;N#*;+Z6WDV)_N?E[(JLL8^5J]>?:Y,MN\:%;E'
MOA]X178\+=>K[MU3M5Z5;TU^/)FG:E&_%456_;<Q>7EY6(KEQXOOQ]=#T[[P
MUJMS]FK^-,U?YZ?*/GE7*_MC84[UL3PM*O/RL'P4]ZD,VP8=\??17.J;[XLV
ME.>R_-$^_+9_6/JM1R8WNZ8UD=F/=Y.8/&\M63_^'8PNKWVV#6^_?UC_I0O>
M!O.<U28I\W^.^^;PL(R6B[UYR=[RYGMY^=4, >GE8HC^=_-N<HNWGM@^=F5>
M=W\7N[>Z*8O!BG6ER'[VG\=3]WD9['\TPPUH:$#7!K;ON09R:" _&ZC9!FIH
MH#X;!+,-]-! .SUX?>Q=,K=9DZU757E95/U\.&?MM!/WV@[7KGW9C4[W/YO/
MVKY]7PO2*^^]-30PFYZA6V9,;#D1TA7QK -7+PAYL2'6GL8]))P(I>,$,.(@
M*4 4]E/";,FNO1QE*\ &%#2@.@/JQD"DG&SWB.Z04X?<A4)&ON\[*0$@Q2I@
MX!: .HXT U, "J$#<4N.@M0P2 VR%&(# 300L"P)BIPT]4QPXZOB*?H*M.40
M3W;*H38K$VD)850AC\IW%M(FY-T$8.@!IGT>&<>D'_/8$#8]YA$,+@)#%CO!
M1:R?F$_"A%."1P9,@4'CU)V@R<!B&%C, Y-./QO.*&</36+N2C ]@82/-VL?
M..-.H0$:)5"!.02X&*P.@!%Q+D7=^L%TA!-R)$"$Y$8HP"H! 0),@E4".,6Q
M%&!:3<<'A>Y1$(A/NO$13[GTP?8&0 D6"\"L;$V[CK5/2."Z*UX#-)Y\/)D)
M,':S9,;N8"45BJN,G#*!=4IHY@23F8$9[R&!X%E.($E@-#A'$DPWCDF*IP<-
M*ZG@4LJ7$]<V'8+XN"EWETN!J6DA$5@F!==)R4ZD0 !) S$!H-UW>71;!!(8
MOA2 P8Q:"BR7@NNE#-P@N7RI$,4(9$["F0?  )P;4@3."*? RBF0=+(@@3!:
M"D0Y*[+C&@.K)R'U#!U_B,O8G2*P0!-$2DU@;B'2SAEP$D.D/21&<C+WA'64
M!-@=HPD36*H(257LAL:EY0X4%@B;B0D+$ $!4NY1#$#L+/8%9DM<R&!@ )L)
M#$L9 2E38L($EC+B4B:4N]$34B@EP5Z/R "<L;8(C&*PI<"^Y;2>$=8S J6A
M8E4^KNBF>L(R1*!<4^YQAT#I%,=@]P)@7[&QA')0.>#8>ZPO!.HQ=XYOB&_S
M5D3YMI0 ,(I K0 X&0@T&X# Z)G)@ 6&@, H5V ("4P0@-,T(BE0?.O?0E()
M4!7!WGU2>C)6B<5+ O%2KGA)4(/%BI\$$@ JJ<'Z_BJ8HJ[5W,%(8N&2H !4
M[J%<\E*,0E#B DZ$ @PH E'B4@"Z^1A'B;55$MCQXPD3$S]% C74KAI*4(Z%
MX"R#.+"+;P?N]A="&:+9 #@],^>Q+DJ@BWI"%R7610ET4;NZ*$%%!LYQ"3 V
M=0256+XDD"_MEO^2RQ=)L%\!8Y/N8(V30..TJW$#-!I+Y0M0B !SS"'OYF*B
M,-5K=TM4+W;EVZEIA_KF[?4FZI':BPWG_4;<)P*\WXK[M+]G^C3?7WO]D56O
MQU.]>"Z;IBRZ2X^7LFR,==W_9L,[F&Q_?<C-2]-^#>WWJK]NZA^:\CQ<I7G7
M^[SU_U!+ P04    " #%>$M/W+33",P!  !M!   &    'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;(U4W6Z;,!A]%<L/4">0-%T$2$VFJ9-6*>JT[=J!#[#J
M'VJ;T+[];$,8H5SL)K8_SCD^Q_:7I%/ZU=0 %KT++DV*:VN;/2$FKT%0<Z<:
MD.Y+J;2@UBUU14RC@1:!)#B)5JM[(BB3.$M"[:2S1+66,PDGC4PK!-4?!^"J
M2_$:7PLOK*JM+Y L:6@%/\'^:D[:K<BH4C !TC ED88RQ8_K_7'C\0'PFT%G
M)G/DDYR5>O6+[T6*5]X0<,BM5Z!NN, 1./="SL;;H(G'+3UQ.K^J?PO9798S
M-7!4_ \K;)WB!XP**&G+[8OJGF#(L\5H"/\#+L =W#MQ>^2*F_"+\M98)085
M9T70]WYD,HS=H'^E+1.B@1#]+R$>"/&,0'IG(>I7:FF6:-4AW5]60_V;6.]C
M=YBY+X:S"]]<6N.JEVR]W2;DXH4&S*''1%/,+>+X&;&+1@AQ!D87T9*+0_2)
M'\UV6$#$RSO$BSGCP(]O<MXO"VP6!39!8',CL)L=U!+F819D"?-E9H1,;D^
MKL)#-RA7K0Q--JF.O?08A=O_!^\;\9GJBDF#SLJZ-Q1NNE3*@K.RNG.ONW:]
M/RXXE-9/=VZN^P[H%U8U0W.3\1\F^PM02P,$%     @ Q7A+3X_&"R[. 0
M;00  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6Q]5-%NI" 4_17"!Q1'
M9Z;-1$TZL]GL)KO)I,UNGQF]*BF("SAV_[Z U%IK^B+<RSF'>X!K.DCUK!L
M@UX$;W6&&V.Z R&Z:$!0?2,[:.U*)96@QH:J)KI30$M/$IS$4;0G@K(6YZG/
MG56>RMYPUL)9(=T+0=7_(W Y9'B#WQ(/K&Z,2Y \[6@-CV#^=&=E(S*IE$Q
MJYELD8(JP_>;PVGK\![PE\&@9W/DG%RD?';!SS+#D2L(.!3&*5 [7.$$G#LA
M6\:_H(FG+1UQ/G]3_^Z]6R\7JN$D^1,K39/A.XQ*J&C/S8,<?D#PL\,HF/\%
M5^ 6[BJQ>Q22:_]%1:^-%$'%EB+HRSBRUH_#N+*+ VV=$ ="/!'NHB\)22 D
M"P(9*_-6OU%#\U3) :GQLCKJWL3FD-C#+%S2GYU?LVZUS5[SS3Y*R=4)!<QQ
MQ,1SS$?$Z3/B-IX@Q!8P51&O57&,/_'CQ0XKB&1]AV359^+YR=S#;K\NL%T5
MV'J![8>#6AS#<0VS-+*&63HAL]L3H&K_T#4J9-_Z)IMEIUZZ]^^+O,/'1OQ-
M5<U:C2[2V#?D;[J2TH M);JQK[NQO3\%'"KCIK=VKL8.& ,CN]#<9/K#Y*]0
M2P,$%     @ Q7A+3[."K2*V 0  T@,  !@   !X;"]W;W)K<VAE971S+W-H
M965T.2YX;6QM4^UNVR 4?17$ Y3$<;(NLBTUG:9-6J6HT];?Q+ZV48'K 8[;
MMQ]@UW,[_P'NY9QS/[AD YIGVP(X\J*DMCEMG>N.C-FR!<7M#7:@_4V-1G'G
M3=,PVQG@520IR9+-YL 4%YH66?2=39%A[Z30<#;$]DIQ\WH"B4-.M_3-\2B:
MU@4'*[*.-_ 3W*_N;+S%9I5**-!6H"8&ZIS>;8^G-. CX+> P2[.)%1R07P.
MQO<JIYN0$$@H75#@?KO"/4@9A'P:?R9-.H<,Q.7Y3?UKK-W7<N$6[E$^B<JU
M.;VEI(*:]](]XO -IGKVE$S%_X K2 \/F?@8)4H;5U+VUJ&:5'PJBK^,N]!Q
M'\:;W>>)MDY()D(R$VYC'#8&BIE_X8X7F<&!F+'W'0]/O#TFOC=E<,96Q#N?
MO/7>:[$]I!F[!J$)<QHQR1(S(YA7GT,D:R%.R7_T9)V^6\UP%^F[9?3]85T@
M715(HT#ZKL3]AQ+7,!^#L$5/%9@F3I,E)?8Z3O+".P_L71+?Y!]\G/8';AJA
M+;F@\R\;^U\C.O"I;&[\"+7^@\V&A-J%XR=_-N.8C8;#;OI!;/[&Q5]02P,$
M%     @ Q7A+3Q@1E9W2 0  ;00  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL?53;;IPP$/T5RQ\0L\!>N@*D[%95*C72*E7;9R\,%\7&Q#9+\O>U
M#:&$6'W!GO$YQV=L#\D@Y+.J 31ZY:Q5*:ZU[HZ$J+P&3M6=Z* U*Z60G&H3
MRHJH3@(M'(DS$@;!CG#:M#A+7.XBLT3TFC4M7"12/>=4OIV B2'%&_R>>&JJ
M6ML$R9*.5O 3]*_N(DU$9I6BX="J1K1(0IGB^\WQ'%N\ _QN8%"+.;*57(5X
MML'W(L6!-00,<FT5J!EN< ;&K)"Q\3)IXGE+2US.W]6_N=I-+5>JX"S8GZ;0
M=8H/&!50TI[I)S$\P%3/%J.I^!]P V;@UHG9(Q=,N2_*>Z4%GU2,%4Y?Q[%I
MW3B,*]MXHOD)X40(9\(A^"\AF@C1BD!&9Z[4KU33+)%B0'*\K([:-[$Y1N8P
M<YMT9^?63+7*9&_99K=/R,T*39C3B F7F(^(\V?$/IPAQ!B8780^%Z?P$S]<
M[>!!1/X=(F^=D>-'RQJV.[] [!6(G4#\X: .JX/R8;ZL"O%@]L'*"%G<'@=9
MN8>N4"[ZUC79(COWTGWH;O\??&S$1RJKIE7H*K1Y0^ZF2R$T&"O!G7G=M>G]
M.6!0:CO=F[D<.V ,M.BFYB;S'R;["U!+ P04    " #%>$M/"6=5-+@!  #4
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6QM4^UNG# 0?!7+#Q ?
MOJ_H!$BY1%$KM=(I5=O?/EC BHVI;8[T[;LVA-*4/]B[S,S.VNMT,/;5-0">
MO&G5NHPVWG<GQES1@!;NSG30XI_*6"T\AK9FKK,@RDC2BO'-YL"TD"W-TYB[
MV#PUO5>RA8LEKM=:V-]G4&;(:$+?$R^R;GQ(L#SM1 W?P'_O+A8C-JN44D/K
MI&F)A2JC#\GIO OX"/@A87"+/0F=7(UY#<'G,J.;8 @4%#XH"%QN\ A*!2&T
M\6O2I'/)0%SNW]6?8^_8RU4X>#3JIRQ]D]%[2DJH1*_\BQD^P=3/GI*I^2]P
M X7PX 1K%$:Y^"5%[[S1DPI:T>)M7&4;UV'\<]A/M'4"GPA\)MS'.FPL%)T_
M"2_RU)J!V/'L.Q&N.#EQ/)LB).-1Q']HWF'VEB?')&6W(#1ASB.&+S!'/D,8
MRL\U^%J-,_^/S[?K_.VJQVWD;Y<>]X=U@=VJP"X*[/YIDG]H<@WST25;G*H&
M6\=Y<J0P?1MG>9&=1_:!QUOY"Q_G_:NPM6P=N1J/=QMOH#+& UK9W.$0-?C$
MYD!!Y</VB'L[#MH8>---;XC-#SG_ U!+ P04    " #%>$M/S_1HC+8!  #2
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6QM4]MNW" 0_17$!X1=
MUIM$*]M2-E'42HVT2M3VF;7'%P48%_ Z^?L =EPW]0LPPSEG+@SI@.;5-@".
MO"FI;48;Y[H#8[9H0 E[A1UH?U.A4<)YT]3,=@9$&4E*,K[97#,E6DWS-/I.
M)D^Q=[+5<#+$]DH)\WX$B4-&M_33\=S6C0L.EJ>=J.$%W,_N9+S%9I6R5:!M
MBYH8J#)ZMST<DX"/@%\M#'9Q)J&2,^)K,+Z7&=V$A$!"X8*"\-L%[D'*(.33
M^#-ITCED("[/G^J/L79?RUE8N$?YNRU=D]%;2DJH1"_=,P[?8*IG3\E4_ ^X
M@/3PD(F/4:"T<25%;QVJ2<6GHL3;N+<Z[L-XL^<3;9W )P*?";<Q#AL#Q<P?
MA!-Y:G @9NQ])\(3;P_<]Z8(SMB*>.>3M]Y[R;<W2<HN06C"'$<,7V)F!//J
M<PB^%N+(_Z/S=?IN-<-=I.^6T??7ZP+)JD 2!9)_2MQ_*7$-\S4(6_14@:GC
M-%E28*_C)"^\\\#>Q4=D?^'CM#\)4[?:DC,Z_[*Q_Q6B Y_*YLJ/4.,_V&Q(
MJ%PXWOBS&<=L-!QVTP]B\S?./P!02P,$%     @ Q7A+3R?WWS32 0  ;00
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M?PXX5,9-[^Q<31TP!4;VH;G)_(?)_P)02P,$%     @ Q7A+3WY431W2 0
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MMO?G@$-IW'1GYVKL@#$PLIN:F\Q_F.PO4$L#!!0    ( ,5X2T]TW,% T $
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MQZF4TH"U$MU9+[5]8.: 0VG<=&_G:KQF8V!D-[T@9'[&LM]02P,$%     @
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M:&5E=#,S+GAM;(U476_;(!3]*X@?4!R<Q%%D6VHZ39VT25&GK<_$OOY0P;B
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MS;64!FPJNP>;2VO[>%UPJ(V;IG:NYM<\+XP<ED8EZ]^B^ -02P,$%     @
MQ7A+3^>W.!+] @  90P  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
MC5=;;]HP&/TK4=[;Q)=<J !IT!8F;5+5:=NS"P:B)G&6&.C^_>S$9$G\A?)"
M+IQSON/+^3#3LRC?JP/GTOG(TKR:N0<IBP?/JS8'GK'J7A0\5]_L1)DQJ1[+
MO5<5)6?;FI2E'O;]T,M8DKOS:?WNI9Q/Q5&F2<Y?2J<Z9ADK_RYX*LXS%[F7
M%Z_)_B#U"V\^+=B>_^#R9_%2JB>O5=DF&<^K1.1.R7<S]PMZ6&-?$VK$KX2?
MJ\Z]HX?R)L2[?OBZG;F^=L13OI%:@JG+B2]YFFHEY>./$77;FIK8O;^H/]>#
M5X-Y8Q5?BO1WLI6'F1N[SI;OV#&5K^*\YF9 @>N8T7_C)YXJN':B:FQ$6M6?
MSN9829$9%64E8Q_--<GKZ]GH7V@P 1L";@GX.H$8 FD)B%PE4$.@MU8(#"'X
M3T!7":$AA+<2(D.(;B7$AA /"%ZS'/7Z/C+)YM-2G)VRV:(%TTE #[':01O]
MLMXP]7=JB2OU]C0GV)]Z)RUD,(L&@WL8U,<L(0SN8QYOT'F",*2/>88PM(]9
M09B@CUE#F+#%>&K>VLG#X.3A6H#V!**!V083U)B\QF#J^X,I7MDH%,>1A5O;
M.$I\U,7U;!/0-@%LQP-##2;L%E(-<;00!0M1H-!D,#_4*G1'*47VV%?4&OL=
MB7 TL6<)0B(\H:/V ]!^8-LG(P(A*! " H,-OX(P&"X2@44B0(#  C$H$ ,"
M@S@]Q?8N]J]LAPE8: (4"F !Y,/=RO_<Z\* NF:#OE?3CC[%]2V--% $6!KI
M(@AN(PCH(\-]L@!!5H>]#NJ;@9L# KH#B48DX-@C(/<D'C9Q._A!""S3"MEI
MIN&U=8+#C* T3T8DX#@C(*O#QOEL0%V[Y%I4$)QJ!,2:CDG N49 L*GUNQU;
MRS"V>>%0(R#5=&3+83C5&$@U'?SH+PU(A[9UZM_[)!BNH=<Y^N@#^'=6[I.\
M<MZ$5*>H^JRS$T)R)>K?JV4ZJ#-_^Y#RG=2WD;HOFX-O\R!%80[U7OO/8OX/
M4$L#!!0    ( ,5X2T_/ .N_@@0   <8   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;)68ZVZC.!B&;P5Q 0,^8$.41&K3IKO2KE3-:'=_T\0Y: !G
M@32S=[^<F@;[-9/YTP!]OY/M[\%X?M'E]^J@5.W]R+.B6OB'NC[-@J#:'%2>
M5E_T217-?W:ZS-.ZN2WW074J5;KMC/(LH&$H@CP]%OYRWCU[+9=S?:ZS8Z%>
M2Z\ZYWE:_O>H,GU9^,3_>/#UN#_4[8-@.3^E>_5-U7^=7LOF+KAZV1YS551'
M77BEVBW\!S)[X:(UZ!1_']6ENKGVVE+>M/[>WOR^7?AAFY'*U*9N7:3-S[M:
MJ2QK/35Y_#LX]:\Q6\/;ZP_OZZ[XIIBWM%(KG?USW-:'A1_[WE;MTG-6?]67
MW]104.1[0_5_J'>5-?(VDR;&1F=5]]?;G*M:YX.7)I4\_='_'HON]S+X_S##
M!G0PH%>#)O:4 1L,V+T&?##@GP9\TB :#*)/ S%I( 8#<6\$.1A(PR#H1[>;
MKJ>T3I?S4E^\LE]QI[1=V&0FFP6Q:1]V\]_]KYFQJGGZOF2<SX/WUM&@>>PU
M=*2)QIJ5K2%CQ;.MD/0J"9HDKYE2E.DC!5D((PM;0\>*)ULAF9$H<&)(UD!B
M#-H+2E?B>AF<&=8YX",'L5%OKXDZ3=%K*!5A&!I5VSI"16+IGFT=)4Q:NK6M
MBR6EM[I1@1P6R$&!B5%@KQ$W@<R4IQ2C)"*81&0G$1DA5M&](00,(4 (LSF$
M%2)JA]TUH!(&DB"0L?Y7T@I$2!([ \4P4 P"&2VRBJU E'%GG 3&24 <$TZ)
MO;2),PP),01#$,@B7&A5%//0[B&@HRQQI^3@,@$IF;@;1*/9#$/IC@7)^D H
MB"7-6-2*)>5$61AJ!% MBATN,#8(X(8Y62^#:$0R.C$P& X$T4&8H2([U-1\
M8T@01(G$# 5$PA4',X(@2$@SCORUT<.4(  3@CA<8 "0>PA ?@D!%".  @0(
M$Y[4;FVS^R<EXT1PXU/0^,*$*[4;WTID2C).!%.! BH([G"!NYV";A<F5P?1
M""R1>_HP%"B @A .%[C9*6AV85*0VGL!.O&>IKC9*>IC!P4I[F,*^MC.UN[C
M*++?6/?)UM3>.T03$X6A0!$4$H<+# 4*H"#-/1L4F;NNGXC&FW3,#0:XX?JN
M8;CC&>AXJQXH,K]<?B(:)X.[GJ&]@#EN@VBT8*:VJ\SQA0/P(!V$8;CO&?J(
MB,UT[6^$!*QO(!-3S<TP1QC@B(P<+C ?&."#796P7WLQ*LO6N0K"J&$ -=+!
M5H:[GH&NER:MH,BJ&HD2LV0@BEU%8\@P@(;8@0:.T< 1&LRBD2@V]AW/T),Q
M,FOHR='\').( W[$CH;DF!\<\,,N&HCBR"P:B1S+CF/ < "8V'$(PQV'%  P
M=CU %)LK%XH<;SZ.T<(!6A+7F0M&"P=H,>M9(Y'5/\'-$6.NRGUWHEQY&WTN
MZO9,Z^;I]=3Z@;9'E,;S%9D]$?#\F<S6_9GTI_O^B/S/M-P?B\I[TW6M\^[X
M<J=UK9K<PR_-&!U4NKW>9&I7MY>RN2[[H^G^IM:GX=@]N)[]+_\'4$L#!!0
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MI,SM0M^+?L/O!XJWPV$&C2>JXB]02P,$%     @ Q7A+3V,C16XS P  H0X
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M+@_66TH9X9;<)VYFS^^+ET9!MDR\1OR];B]-;8/1@[H0.I=;Z>P_4$L#!!0
M   ( ,5X2T^$L@VHZ0(  ,\+   9    >&PO=V]R:W-H965T<R]S:&5E=#0P
M+GAM;(U6ZVZ;,!1^%<0#!-^ 4"61UO2R29M4==KVVTV<!!4P R?IWGZV<6B"
M#VG[HV#R78X/_HQG1]F\MCLA5/!6%E4[#W=*U3=1U*YVHN3M1-:BTK]L9%-R
MI8?--FKK1O"U)95%1!!*HI+G5;B8V6=/S6(F]ZK(*_'4!.V^+'GS[U84\C@/
M<7AZ\)QO=\H\B!:SFF_%3Z%^U4^-'D6]RCHO1=7FL@H:L9F'7_#-([$$B_B=
MBV-[=A^8J;Q(^6H&W];S$)F*1"%6RDAP?3F(I2@*HZ3K^.M$P][3$,_O3^H/
M=O)Z,B^\%4M9_,G7:C</IV&P%AN^+]2S/'X5;D)Q&+C9?Q<'46BXJ41[K&31
MVO_!:M\J63H574K)W[IK7MGKT>F?:#"!. +I"?0Z@3H"[0DDN4I@CL!Z LZN
M$F)'B-\=\%5"X@C)9PFI(Z3O!&9?8-==^[KNN.*+62./0=.MN)J;A8UO4KT@
M5N:A??_V-_W&6OWTL&"8S**#$7*8VPY#+C#T$K.$,.P2<P=AXDO,O8^A9*#S
M\ G,(^25])A(]Z1O# $;0ZP NQ!(!Y/N,(G%5!TFHTDZ9; 1!8TH8#2%!1@H
MP "!;-"R#A.?54HP,G^P40P:Q9X190062$"!Q*^4H,%B2[Q*8\+BT4I3T"@%
MC/# J,-,SXSP!,6PRQ1TF0(N(_W(0($,$!@$ZS'SRD03A&$7C.",(^#%C?03
MCVP3&)# PST >WD8B1R&,X?]T(VN, RG"?MQHLS;K#J0Z<MY5VF<C7C!P<-
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MT32@<)*ZFZD^'Z[C82!9-[XT:'KNBK]02P,$%     @ Q7A+3^:MYG$E @
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M5'N$6KWE&*\R=--!@V;;:Z*))GI4[!R*^%%2."1XE"#%.()&3M#(^/$#*+9
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M'YA,#IR_F\&74Q&N#!!0."H3@>CF!A50:@)IC%]CS'!:TACG_7OT9YN[SN5
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M(JN;D(B0_2Q'=)4C&N2(ACFBFPY1LX<$SBD NNAI-)QT[6D74*<XZXR7V"+
M3@':\:'#.28-'2TP3 .&T:%S!D4TEQVB9C0"Y#2''%^>-8=<R_JLI<H+(8Z.
M",UKJM81H046:L3"0'L9B2*-J%W4C$9@H$8,3#0:($JLY&P7-:,1(*DY) W=
M&)Y6HNU$%#3@3LE5MV30+1EV2VY:)<U>$9"N ?22HC/!@\JY92H(<-0 CDE3
M7QR.WAG9E\!&#>K 9 0; ALU8&-BE-B(E-K.P1NCC.#,"( T &M)P)H1L&9
M[98(:]Y!D5#-&P%J!NPGZ5QZ9\!&,7EYGRAM% &)$CV$@B*A[#<"K@R'C*/U
MX3O#2[;6AQ)@9#B,7*&H+T"LK:6CZ4B8WX;/;U=HP88P;PV:MV18'0.1*Z0Y
M($Q:@PH:0QU%OD_T4<Z ,+D-FMR1^D(B85A986);/K'9L#JV?/=F?)(/'00
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M\MP6@6U@Z3!LP 8$';8]*S8="]7%DY2X^_M1DN-FA5_,BPX/#RFYFJQ[\0-
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MX(K3(GIK R#AY@ZY!GSI2Z"@#]%]0-_E^\Y!L./\E-GR/S7_ %!+ P04
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MK?W(F*3*+WA0MRO4:=]/*GJ4>KA08VZ//#N1K'7'.>K_4^3_ %!+ P04
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M,VS+N6(:*+W3F\U>%TY]HV);96[U.1^)KGKH&HJWKC)*^O)L_@]02P,$%
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M90TZN014EM3[O7+3[4!Q7R3U##!4 88J@J$:-& %&*H(AGK96M @VQB]4"A
M24504J.* 2653TGOW.W&@D8>E2E 2$40TA\8Z0V,G@E4%#I+I&@KW4@^'\F#
MSZ!WXM_\'/9G6KSN#N7D*:^J?-^>\+_D>65JG^&L]K8UZ>9\DYF7JKF,ZNNB
M^QFJNZGRH_V)+3C_SK?X'U!+ P04    " #%>$M/*J7.,^@!  !X!0  &0
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ME-DF>B^F83 %B@_SG,/+L"W_ E!+ P04    " #%>$M/^C3AOX\"  "?"0
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MV?T+M05%KF.K_T9OM%1PK43E.+!2F*MSN K)*LNBI%3DH[T7M;G?+?\C# [
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M8(PIPMB$@]KO:OG,NEJ"0:8(9!,.+9K"0<-9YKK)F'<*>+?HH#;O[Y2$>:>
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M9::IGHNAZPT+Q;NQH9/I7Z7X!U!+ P04    " #%>$M/3WTLM^P!   #!0
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MU,V!+!F3H$PZ#\I?K=ZT:4&@E'KZI.9\N-G#0K)N?+30]'(F_P!02P,$%
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M<'X#NB5  1LLHUA%C=KN0$J"& $H1M8*RQK/](J5-7=\&5TKXHG<G>F_*V:
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M?4K  THD#8;E+(,V7VC>M(28-TR(MZ7]3LU[GC5FD@O+>YM3-F4:1KX)24+
M,4EQ-]%DIAX4#UFM3VC<*34T(:+F^QQ>5$JB*:&OP<)Q@[XIQG1HJI:^_.-@
M=_P4CTDBU8+[S').5^A9L7!G1&Z<+[&5:M.JJME@=_)4@JB8#XW'$*>Y:[5&
MPC<AC.Y>57!T 'FCDD2VGH\&Y!@^^$FYF70F= 1)#;S%1B4E?$.(R&60Y7#/
M+3K%-[.J3(P#E<RY<3*Z!MGL37$0CXR&-@HO\-'0;;E<:E*+7I#M)AWR+J!4
M+O;3, 0*(6BTN,30T+/_/-HKPOZ%T#]W!9#K)0;L[R@SB"Z:@:9O F $;(NO
MPWHE[*&FD+2.X'*20.TG-HAS$"]X [AG0\Z[B'-Y!"9581F>LN,8).#87M35
M;VZ*CK2%MI^:+C9^AB[S5=L:DXYWJNIK(W=)$1J\Q)GX3P7)^&3>CMDPV=]#
MSD#S_,_FPC>T?KBK!K0I(;J9HAT?(TF*#P;*TF?32^Q]N,'E=,<Q1&J8(2BN
M^"Y]NB%?T*1*"4NUX2JS]4UHN7)*"2""Z'%>/,8?LH-2M;L+CI MSB?%O @
MF+4@2&PL(#=.6LIOY6@UPJSPD5P<:.*)%1 <:]WR-N^.*)_#K<SG)=,D^\'=
ME+#/P)"_]^Z3LL8T+77+$'2F=:"3U(ITIE#]+VPL45X!;41IBXDJ."!#[2*Q
M@C#:^U9_'+RFA(1QC+#ZI6*7%?GB:Z*';DHQNY@,TA'AD+.-0OQ35S^4\,=&
MSW6H3&X4<6K21*?D,LR=R60=%NB,&$EG)W%G7_&0:X\\BOM,!N1,Z41TS"X6
M- /9GF+&7WV)T1"R?]1+Y83(2PQY%U/O:+03$3RUPR&0*C)/B3@A?Z<.Z: [
M_^8%6=)U/:HX5W7F'/5,T@-_7,[9R4ZP# ?GE"R3-4W*@G47X2->L9Q(>]6
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MA)H8IX<Q$-1;9C'ZJ0O##HZ@P<L5G,ET1A+Q3OF%4AX'._#_WEY=43%/_?2
MR[(BE[#[U6O/=^Y_R0CLVV3_!Z\IK:.'C'GP%/[?FH%3OP)&;4</G:BJHEQ"
MFX_B4^6M/2,-M7/*Y]O.(?D+R'EPV&7W'V5]GO-??UV[X$2+9^M;U,D9_T]G
M:2?P_Q++.SD<0'/)1<8WUB[TT<G@:+QAN7</#Y_"_XPW+?KX /]G/[WT#^.P
MYP4>[_N5/4VL;*_Z.!=OT6M_EL?/GBO(_YT!^2?>>U XYG"4:F)PGL@=^#XR
M!)W'&BM!^J=RRZ$0G>"23 ['K@L^H0"5_5Q! 8/QV<G@<.*?2]<=&1P?'3H(
M(0C#54&04LSD* K+>4X^KL$!".;9D0A@(H$"Q64X/CJ%_YX>G21G] A6DZMQ
M:DC^ X7DS2$9O_?!!0W@J^%;STWJX\;%/!IM^C)"L\F*-@/G,)$:E-_M!- O
M]=2#(96;=#2:Y2K$62B%Y-Q?>)2W\G?7I.J-]4.D+W^3@&\<^GH9W]DHVQMD
M>GMY7B?(.TD9.@;Q?0!R.VZ#*)>^V80Y'CVD#P/_;'@'/*3U.%K+4DNS3Y$[
MS+$C1'DG7H5-=^-T;*6^_7)%\*F>&C8Q2VL082@K+C*(5/QT <C]L+-S"2YL
M^_PS$UT-.YSM(N&L1X+Z$*2?.!\9_[/A8',1G/%X>#KIC<O=<8(/1=;@+9Z2
MOGB!6=A=21R@9<S.Q!70ET,CN3#F_4LD176N%70'(Z(H5[IY@OXL.$KHPI88
M6ST9[1\_X=0,<@\2')%\WHWQ2"C;S<$^W,#NF8+[.3+W-MGK5\_>OM?P8YC%
M]V>\KW]8-JAX_Z->4?Q:T4R8P^7<_;/<A=_)?F1_6AA&!*F9"1*0GW%4/ R_
MDI&3$YLW.?I.,,JX/QJ?/>&<""M2ZIE23WQ)?DVF3PLSY:QKQLHLW;*9:RP,
M#^&%/N2?'1^.V0121[X5UJ_KB=D-PX=TA0)T+#^I%Z@V7R&Q!ZE;@XC3V&OG
M*'EMK1HCD(8+UH&+7"/*MM^;_P.C.PA\B#9*S)N[HQ[&HZ.M7WE&6,3@J!IB
M"X</_^C^ SX:)5&'A'/> 8 LFS8_8KV/\T<X!,>G!S\1;EN@PSP@JW:QMZ*-
M3"&Q12'R&*K)4?=19%Y6=.F56\D]<FXXD#0/C2,*!6$L_"MHBB@7.-46TMJL
M\*Q#%XN32X@DBB]P$#D>?H9S$M0Z*H.9&7(*"?"58=!:3HHHJ=;NIGV_D!&I
M),8-D6="8'@T&QQ0A;?XDD/\GVTAWYM)G15A)M,J)(;P*<\NT0PHI()D/3<G
M+25L?:X)B,*K(/G&*RG531+AOZ6?86>D,,62^]0$PB):RCA2FZL["-:"4^ .
MW$HTZ3>J[BIT7NY6."$5A^VYJ2/=%R;/E(S2"SE$\VB[*MNX)#Q;QZ#10HZ\
M9E4)>BS*'4%;46(<O+([1_M>0?K'2 HZ'#]=FKT16:3[L!O]IB0?_98;LC+?
M1#D3=G><_L)S^VK<FC"<^C?%7BF"-,2511/#;2]1'KD3SIM.V"C+UU_#;\@D
MCW7$QQO?L5PVOGHS=ZOZ+K.8OJ<BFPC<4U"$@4)P;CN,R2HS24+Y+329GM.;
M!.R.*@8I-M"W#-\)TC@F'8GJ"-[D^PB>_ ?MVO'9V4\^S.>]+QD7@; 45,%1
MQ- *6X3-FBB2B4\)&8FSG4Q!FA;'RS,+V0\Z-HWOADX[QG+;PM87PZAO9(*D
M,GFCI=DYV#_S;JB#@^.@)..6#LNX)B-;+9'QL(R.C%)JIY8^JIL3._%G+,(7
M;+!(8A$ (1@K<[ V\?!FJZ+_FI-WN\C\#"LQGPD/I\ANG^"L6K]CIK:\$XI.
MHAL(]F#]C121"^2DX^1A!U+D&$X73H:_U]QCND<).$]G]Z$N"-N["F]7KASY
MC$EE).E;HJCDE7!Y^)O>-;GA)_+^UN_Z)/+QUW1ULK_]IR0&??S0]WQXV;S%
MM#$4OS#6KE]M7KR@"%=T> ?79,[S]8@"=A6)Z.MQE%MD' G2CP.XE0ZZ5/M6
M5*0B%/LTL$26V"SBX"@UAZK?0/2,(SM'_KK%H,]+XIOL'A-#C@G3V6DF(2WK
MI0,H"YF[VSZT(+F0IJ\J=N3%2$J^[ZZ6-9IF4XJ22W-\0:Z)W0FC\YV1RU8C
MDE/.\FJI?JG,:&S=D4_!+!-1?H48:-+6_'OJK8>(&:O=]$#+&/AR]C!<9T#!
MW7U0!J!\;X52XI[ QL@%PU8TDUMZ!<+FGUV%4%$S#S<)&P?$)49/F$RV1,DB
MH^5R0P73U:&\-B^P],6=SXCWD>VHFM8;B/G5%65V\_(\KZG[[_)F64&WAE@Z
M>4@EWGPPV6 +HA2&H2GWZV+J.O+ F4:'X[ZY/F^!]V4[)?3!D2=&W F"CB#&
M-%Q]8?8U$ ^?)X&HA;KY9-#G2LHLT&+VYU"Y/F-IU%OL,9+:1FRWTR?&%^;X
MDA(*TJ^*Z+Y.66:'5F:U%UCY/:6N4"GLU;'&',;GH*&KDDWO!WQ%)J92JL(\
M83,[!Z9..I.1IO2!S7^(0>8?"BJO_6Q=70D!C*5 O@JAXJR/K=-/8D#F\"&9
M'@8=^BT)'DL+,%R+O0\T7819S<[MGH%F%;X>)110:P8[I"D8"4/64J%?"5Q&
M%,GV\,=M$8^()WS$,/Y^,8R><>:U(^FSKA5?V8(*0<4Z1CC*0AHE=1,X7AM7
M;Z4-J( ZEMFL$(HUQ]Y=:YD$Y8!O3;4TLMP<SXY2L5:%PW(;'N[PHILJ,"*T
MZ!Y!N$X?M2BE^=QO(#!SJ&HN7&^Q #.>!;>WB#+Y4WV'SRJ(S0W15WSB#(>.
MQ>&-TORR_DPT*7G5(3AW/D#K0[RT-,1;4CR;$B8W*0JO-"]48O7QX0TDR%("
M3SYP:7"#KC>N2%I.A5AQNBY-47*R(^.IX.#"$C3T=4&5YF-B[43S#Q@L3RSU
M)@58PLP62O#'!)*@?QWB:];0+GDFOL*03QBG*(^ZAM_NP2T=_:,%<P796)#I
MZ=[S'D.ICMD)^':<;G-US[GJU;?D]!KOVS 6&8^NP!EFS2+8<7K#.B8(OMGT
M41.5\9T*+-STTYZ1A"S@HXTON)I%9AVS\V$0S<.FS!M:E,I$G<E#KX7?L!*1
M$8I1MGFEMXR@Q[$JX[D17\=Q7[MK(^U!%,V%R*T]DPAWQYVQ,[:+Q'D]K)$8
MZOXE;4^'TAL5*,COAQI*;?$.C)C:IF";B'W-X7I[F]VN79B. \9I67QV!WGN
M"@Q (Z"KD-B+_1#)<F <.R>W5U,PEP*<<4' Y#BJ?U!R^;]9D]_AZMF>P=C"
M5YW+3IA= B6<&*IMC"J3T1F$ 'MC/5AO*HJQOR\Y$56/89#.K=Z0YZ"]@ST6
M>$D=48.YT5D?O))\1]\Z'@9QQH-CX\T/[U&N7<^>\U&DB/1CJSEOOP9VXI\&
M-!%3R$O6,T60R',"/6:Z'!16GWI OY8>2GA'*W.VKBZ",4<"N0 =&124IN_(
M!UWXQ*\&S/[!!I^,AA/E(5-TR&^%\LI^0NI=AKCYJ[)!(:DJ#%ZWACC"-*BU
MCY,Q(S_T879CS<YH<#H-7'^4)F'\)(L<8FAN3L6D%+(5<YEP3AD_0IO_2=E%
M)+F3O\_<M4A=./NVR>,N0Y_'3]9V1Z&/1MU2UFK 1V#U5**4Y&41&.Q<1#;$
M)V(?#D>3(]<9[+Z3\Z%C(>_&X7=%8P2=<"L2"40\#^'.1*(!M<V['CFCQ/$H
MG#-Q2>1PTU(!V'TZ-=5?Y_2-92$*YLJY2V3#<D)X;V2J*=@D9>V=4Z5"3@OB
MK25%.N[!II?*JKY<@.9UL\O#542^G1>S:YICSGU%Q4;VULI@YT<1/N:D-ZK\
M4BG"MH@NGY-DA:;'S/KSW&EF S[VS [9_J!725" CY0;EK>M<#B3 _.\8+H,
M*^&:@/1X_QLCTJ^J3HF@O^=T1SR*PQAF="IN7NRA_B8Q^0PB/GK8K(^/OG;6
M)W[6R_9KISVN O<54\_Q^#4XBK'8%/T3PCX3.7'R$*&W+NC%$4%!JI=$\H()
MZX%4;UX.^CK=BB4/O_8XIV"IQDF4VD, 1NT#\$63HV_>5%$]OW^*Q86%2/B^
M@G7:?^@ZS;]RB0Z^<8DZS;<.?$$VB-@$"73>CVFS8.B- JS:-"\: \2[3YI'
M70,BM\]I?JQ ?27@Y$"]OLJY<(N&5F3"!6XH>?[1@48?;[X!*?[M$/&OAH;_
MSC'A6T'"&>H:6-AEVY7/] ?48=#IV%9?/N^ZBT_(C7CZ<%#XV8.0Z+\="KX+
MJG/2]C4YGT?C(X^V.SY,)?1N%^?X1@3=RQ7YJ1)FX=<!Z1*]Y4"[&B5MLB8&
MEL1 S$FG*,:9R\^+.SC8&1P,3P\._LZ8.HSS=8[D!R6S/A!E-PP<;J>C_2?9
M[2@/:X8-C_;WOP:!U].VMKQENQUTWE;-*C;.U&PSGZ-((B/:: T3960>#(W3
MB&H>R".CXQ!"A76N Y2<T(V$A80,SBN^8KG[/3.ZHP@X#BGK]:4_.V_O343;
M%7OYI$P#D4]@^,AY+Q 3--N2V5:(*&E/YTMEK C>%(C!YY(7=WG#3H54.E[_
MG"QO D &0]P8/,8^2$IVN4=?!K'M[Y[N/W'<K>M1<=&'/3A.=JC?CK*(O;W\
M:; [>QH["/^!$7/$)C;8+2+Q[1U=E;UZ]_9[0C-MT>"OQF 2@B*D\-P$H_0"
M4B,9O);1<R0X0NU.A1!MTS)-, MLP_[<K6K%'H^>PE9&_P3@W;XC$-MB3-%&
M[*[52O%R;L+L>K 66K^Q^,N<^&VR20 H5ZMW$_V#8'<M4M=#;;8&ZY[Z[?A0
MS&Z?6DKT@B"\_WP**3Y/'Q72-@H)SZ97E6,-[YK\KMP>_C(D[@S55U)K,;%N
MY"JW&,I;XWQ=\P3TO+P5'AT.J*X3W\C6Z"QU&-L)XD]Y]O^Y'?/2[=M=Y=T2
MW"R55&60@4PF#]==4)[^&@(TE%VU03>AX03?I):T5*&6<.?-^"?&I9/0A9C;
MKT$@;Q+5G?W1P?C@P(AK+Q-YQ*P:P5D':P4U9=7&G*/;BBV*HJ)+DE+)0&;R
M%';$C1R2:GT;IL2@-ZX2 KD"YBI*BLX]VM>2E4A7\J/8!IJ23MQ:03E#1T%!
M#C0A1Z:3,)@"SN],5T)T^:1>%BVZMLIVQN0)8\<@A3')*16U)EG"O>Q\#P3-
M]@-E_S$!LA_=9L=O<A)TC,4,F*-[@*FA]3:&^^0$_N_@Z2"@XG:N;%N,,]H$
M)MW!(SNWJT*[;5E97E'\EZ_T113__'P$3ST &X G(&E#,9\ (=_%$1V]/SYR
M[_MBJ\Z.\6^O28-?,Q%M;_W:H$P8NGT/SSBOE7UD2C:_] 3B 0DZ;2:MPZWB
MQJ]H\8* ?=SZS8V/6%L@_ZQS"SL/+3[CM'LGG(!8.70LFJA!+#DI??E5TK-]
M5>*'B<_A0\6G Y'^70C/P?'I[U)XU@G-]H;D-H<PPE#X'.XU']<<PQ%F4ZHD
M=$Y$K7&P_7%M#+_O>EJ7RX<>SVJ11Q61E<\MA</G64E_88LU&4I"  \?0X!+
MB1->.?. (U)../&/9()**::@(C/&-HR]MZJ\T(7RB.T?<R3.Q BY^)[)X]LN
M&T&R;'>.CR3 ]BOF>/QJ5<U?+7^=Y!$MO=.O%S=IU=*L!U8VJ1)^8U-LA*]M
MLV]3QK]&LLK.?CI59?!RFQ#<T,7@NME^9G-$83XT'R/)5U)N2=^_HGX1[][D
M8%O^5J1,A XLRJ6G4;EPR7L))M>U#W\7]L2U7QB\=25 J>IM&]P0I"IHS52^
M5_E4-S6'"W,J&SQ%HX5+J4;U1$W&#2'L2Z[F&:^@4!EQ!6\$O[;.QN<PIO\*
M?R:L"&MBEQU 9MR?M/J)0D>=N!]'4SFB*45)31L#,\$#(="8')RY2!C^^[W,
M@428YXKJWJ+3PN,RF9C(\N1@$O"X;!>BC@/1K^#Y105*1 _0#MK=PZ%*>?9>
M"FNZ&BK$.H_BT7!LV655?F848F-29]&?4[;B4H]+$;E6<&.Z]E&6&;W&;J%I
M#F+NCM>@K_XM>^AKL_H[KWL<E6QV6\_+J2A K$V*&!.J_7#+6P_;*2H4O3;0
M,%+[]S-M!<QB,) D$5TM#41N)AXP#L>S!<B\1N5:W&30?5S'U4U'0-4.Q_V*
M?$2NV">#5J!W8$$AX&V>W[6KDE<#3=LY)8*6BS82Q;;;'[>#>R#/IEK-93''
M[*!V"].\_RN$FR\K>'<NX16?(<TFN%E!$7^K:-J^/=Z3D'@"^IH57_SGUU2<
M>9C%"O(K%?')Z#=7L,[PP,1-K3!M^"C"7MS;TH&K)?SJ;PR;T"BT@HWPRM37
MK6$&TY2+%?M?>3.;%UCJH*BJ]G[^.:_*7%Q,E(!%08O)_N1@Y(NQ=Z@1AWRW
M<(SP*"%$&@DW"F'] VG&\;XKJRJ?PJS]J<CG8!+^$?I[*Q%S[;P2D1#+Q4$G
M14LR EO'&145(U>@#8GL:A&?2<F#2T6T2TZUY@AZ1R4L4J>/]" ^A+)=#ASA
MXYH@]I1.H\F R(PF$P2N3,;Z&_B?@V/\Q\'@5& <JL1T=.'@!WA)."'V_1^S
M4E@5U,X:[(Z/3YZZ,_#T4)N,146YL+^NB,+8XJW&QT==,\TC/8/R*YK=07^<
MX0#;9</6J>O1EIP&;>QXW4B/)E<#D0:?:ZW%S0NIU>>M?GI4KT]K6M:,22[_
M[&_R?M;S:A:W*UV0JH9+L":6%,;"(WLV&CS?EH>UDTRK+NV=PXD6Q=1-JI?4
MFIW8#^.-4+=+V0:N&5]E,L>K,AC[6ZSRFG/A \9<))SZ+[#GD#>C4\ E?$A(
M[*F)AY1>.,E&P>?46I&/9N\+]*N0#@EQ<1H?HI=[KM<G:RY(1\?#XY/)\/CH
MU,2G)!9UOC86E:Z>:XNA'PR/H >GIXXKW+&]!,9?$-&"GRN-9_H0N^4$<C<Y
M>&*[CN*9,NYU/JR='5!QQV?#R?&D.SOK(W6;9^=X> A-'QP=_]JSLZ&CE4F\
M-B6ZXN=(.WP&^QTI=A370O%<?(ZM>S\X<@%H[OB/V7]R*<CW_)JFN)]GGK:+
MB(\<V9%;5W:/;3$,CM=2)\ECI?1'Z#+]C#N,P!S!1Z)(O:-NH'M&W/Y4:[XY
MKJ71=M*G4RK5,&EU-9XEK'/8']!Q)=CE7$=N3OQ1=[6Y!_7<%1.(1*Q^5O.7
M'KBCNTB3T7:3_]5CQ-71,7[=$!T[(5?;H6/F@5LU->P+(QO?9P77;# F!S/"
M*%]:UM=<\)L_B9%&_6#-H)YVK[S:\^Q?EWE;]G6&04)J$9IN:7U(OR__Y#NY
MS00.F2%#U8"NXTVGE?,U8QYVNJW$96!#FTK:,]=;<<,B-P&<\,IPA^7^)D?C
MH%KD38'Y/BU;@N65+W I((VNA(T2<[!^[WR_WH]/)]_<^S>U^51=I94YE]K;
MV)KEX=_.SP0W7;@@H@F'9]8[+QDJ8*]B-#;>A/TK0_3)@A&XXA\P5[N4_(W;
M"#YC#U3-;1PR(P"7U:77VWS.M&V4/3TTL:5ACZAN@.'T++;'V?%:1F <Q#;E
ML[^N6H4OP'N<?"ZIL= U/6U<*6SW.[>@^HOV%F[IK:^H,2\_%<A%A/%<CL3I
MTJZ6"G3R4N%Q6-6LNX'Y+B$E/25ZMWE31_ WS5:V#76J/.#'\.1^Z!)8.EQB
M'E/J,E5QDBH?RHN2P\PE ! -,=#W;%)TR[RFN[M6/724_S?IE%C,X"9__$\K
M9J% ??P[+#&65+U$J-&B%K5GNL,. 8L>=3:P7[@UI_,H,XDPD3W\XAMMX!"-
M/=0SIKZU,6L>RS"&) 9CHB _VF8X@?A?-BQV;0$/$C!.[^UX_9\J-V[8/T;E
MHO/1VM$1R')=OW;'3].(1F1?D:10@>(ZG"ZC.KJ54&K+;'T84@&S(\'B?/GB
M9<L*CT=@:=Y&K*:4?3QYZM%@E(Q-5;3)JX/UCIMRN2PJ5S<"6C;B%5:<[V):
MW83*!*F@=:3L(P&(4A(4^PP2GB>L$5XWN=3BI% )6RM3J4"/G0FJDZA/$Y]:
M=\'VEQ*B0?'R9$"#/9RKJRH*+>&"")^+,/^DK@\2Q-[V]O^ .>.PA/IEW)V!
MGTC%2G+8F-.Y9')4ZG<G(R5OM7K)$/?##8C WT*T -[XT4&0C0]/NS<=1]L*
M!B26N\XUY!*=QP_V@(S/AD?PP;-C7_!MTSTI/K;\88"V[/9F+&]%(2ZZ]XMA
M5J;W_.2N&G.[82;<>PK$V>.XZWP(_0)M,!9U)R23I4\IF]]_%.<O,++A.LT=
M>\^A(3Z>Q8'_2N%_(=Q-'NS1B/B^..D][_B:,,+:#-9MC)+!-B?1P)$78O^V
M:O8B.']NI2QYTHG&@82D&_4TV]O25=JMPQWN\(T>V],^$9@,]P\.<=-D8\QC
M'AZ<GHAW7#FQ!<$F>!&'_UQ++![Q$B8\.UN;":SP.2HELUL(FS<+Y/I$A5"C
MO P((K6[[PCJ4RA'>;MJ/A.O)CDR,'=B?K_'3%4( RSA/&<F-"2ZL#63Q'$/
M\E H#P8> APX+CIZE ][V(-CU9#)I3L#*5$)C1]PDOL0[_V9H0&-AHXZ0'.9
M73%-%_ Q$=8X]F.1;3BW]_Q&\:5HIF7KS-N.SC.-0]<(7SF_#\ZICTEXEO3.
M?)>I-_868"(161F&:5%1AF7)R,)!+EL)J#JK)Y!@0^O.\#(T%RQ8T:(8*=+4
M%UU#>EBL-'#@<]*3N<Q1@HM*9H=@W]'H\_ E$B9YV7YY2(_+Y--:=ECW<]U>
MVI(IF;K]CE*C/>37QWTPM)&!83"&NX"#-NK77:J&:Q[1]7=JNF[3S]S/B#>3
M=XY'!X?^-DHV!WG473\8U7AOTRM5^%.D_4UAM@8!+QT7HR>K/SAD/!3":KJ2
MS+EQ&@N5DA)QI0W7OSS:9CDG>"W+A2"!"*L@4(4CL9TFQS!2]XT@(R0IB5I;
MZ" 5.E5D:""G@KK8:CD/P&([/.HS&@AO8=<-]CG(FL,E[<!@X$9$7%VGH\F^
M7<UOF:M)&C)YZK5GJK*#/<HX^&7 /O2$2<45;H]B>8?[->"_V^=2,_^QFBN4
M9#^<]8Z:MAL8)3A5/N,AH5)1;16>)J L"9S6+3-D4G2?^("?4F;%:8UJY#H[
M6C*93<)J,J#%QT#_.I+9;227]&8_/P39H>B;8@^Q67HL05#)KSLU<NBD($.J
M\]MV>W1QO'"YAY 9#+R[/_J[]5:+YP89@JC6=2BIFT6QZ]D8:86'=84FF"H+
MT=5IGD\_[7V88DYJ*YD[[AST#-ZD5=BR_M'GELP)WA1D.WL'FV;KX1^)<8IR
M$1I-63\8G4WPI1->WV'6E.VGO2NDK0](RMKHO?'H\/@)B?CH^/C)T'=&[T[9
M?5G,:7L@2GT(5RX,H,R-*\*U=7(PXK9.QZ.C)\J8%J['5I.;\J7VWIB''=^,
M6V=WZW/60K)@#;XOI(,1XQ(6MV)MX6GP.Q3X>C5*FAOCLY/AR?AHPW&>2B[N
MG.B!8"1<_ORJGO[&#8$3&2@9NDKWJABO,=#]M$EA;+L1K6&+%5_,Q[[7[KDJ
MMMX\*/G[&[8*/C09[9\\<%? [XY/1R??)O]V]>)#/YV US_;MF+\@=8YSJ.,
M"TD)^Q9*O?.8U?BX]T;PJ^TV!#F-]Q]WVS_L;CO[JMUV_/UVV\'WVVV3R:^X
MVYYQ!H)/$>OM4FN,WDVE4)ZELK\,LZ(?W>[.F(8G]6K..'$WA/O2'=C/6RU^
M!AWA+CL<GF[(173#< 74 T8HVC]N=PGA+=6_2@FXD6;NGLDGM.P"-#$R5@T*
M8LN4_]L4E%%029IQ6O(M6ZT.831XGY;^Q)?Z]DG9AL2R5,OC8T.NH7O9*1B9
M(=2^FKIT"X3.7).,XA6!<@Y!&O%J'#;!MQP2#Z$'PCT4LK3*S@\&GQ[P"]W,
M9M,F1ELD'BN%C**0FJ$W)5XM,3CIGY*T5JVNMJHTC8:#CY@F4%+T_;;@ "'L
M97I',H48RY\<7*S64N-+9I-B&@3E+M&>@\E61S(O6*B]EHGH+.CJ*35)L01E
MPYSCTF 1*I)[GHQ[N+#?$'[CDP.&$\C,UK:,S[^RFJW:97,?SPEK)3H?RDY7
M8=:GA)V*G4+H*P<MW8AF;#%:1F$"=10*Z!OK;=2+<HJE4['H&:]=#]+0E/O0
MF@\6UO^BYX18)UC1H_$VBGL@\ZOA9KCT,UA/(DJL9X)+^V:W<7RUMP%VQW[R
MK;[B<FM7\7=S! _2?=OJ]'53&-7HWD3O*WD,G&URN)\X?10E QH^+^=M9^M&
MK+D_#MZH4VG L<&!BP,B918*72G!#?E9#,9W: 0.POC>0$U8+IH6_#@Y&K"9
M.!B?G0[$8.8J'/:GR;%[[& BZ3L'!_O?9;*3+"3]=M_Z8&7/F3:8C":G@R?P
MGZ/C)QQI [L!?CJ#7[[OMQ9Q(LE6?#HX0:^&OGDZVC\='-O?G.!OG@?[VI'=
MZG\3Y\_@!!$CT DPU$\/!T^2KE P6"7M)'O+L]!)-T$AV6,E\DY8)L\;\H;0
MOS?&JC 1(OC"]PZHQ+$_$]$E-"MM=G38,F!P5?&_A^MB*J;BUJ\84DG<^#02
MO<[9?GP&BB#(G]FF1^L]\./1>,R5&$;[H3\JB#%$/D6[+AHO0'>479YB<3NO
M[XMBJZ$=G0Q/)Y-H9+:D\[>-<D(@*ASF\1&%'+S;&BLQ@0T#/^M 1 849>+C
MG(Y' [WDC<LG5W(:+.FG;>C@10\KI4OZFN)G\R=?IXQ\Z3IU!&5U%7*E3[#_
MM,A(X94W+=%E<5_KG[0GFNEEZ67$*YX1',#7"(LG.]@;R#OXF4@UMTW7(^JA
M'J@(WH>GQ6UG 9_: ^O/1/I<S-P_LG,TB'&'J:)%>GWH3EM.!V]M&E3GUC78
M&80+W;IUA7[Q,@R.3MWYU]6Y%XIHZ/PE^'(P!?#5'6V2Z;&[?W[0,J1S>[]N
MHIU^-M 7_9WI\^"]NL(CVZ"S*M'?3;N96U0]%3:^W;_FV6L\4%]5&?)EM'9Z
M$Y]A3:>V,_QT@*)P<L#_ S^>N3^"*CRBWPP.3MQ_23_J$Y/]T=D9_0I$99__
M<7 \&;">T:=8UPPFIV>CTS'*E/_73C8Y')T=#4X.L1='8O?$R;5\GR7NW6#I
M,=?&*9BMMZ$<QW*FX\6HJ%K6 YV2%" YZ ,@-B-F:@2KL[[E0@WP\S99S9PW
M?;1O+-F#XX!-9,L,[(A.))V<C'=CEP?<;AZHHZ/P,TF\,$5\7]XY.)-L;Y<+
M[/G2:JY<Z#[,%^_@?2P30@;? ^=?H5*,E$)V$CK7?,<QY[]SR-*DRW1'W"V_
MB]E6*RSH?:S:B&XUJMES_, U@(.7]<9>+GI#O"&D7-&<Y[E(0P7.0MLU>S?'
M^B510; HK*_P,?P=_E5SM%]56*D MP:V$A1RP%^80M<W\HB4+?54!:0(Q"9>
MHPHXUZU"(S.O.OD*(V>(4W-X,7)\1O19+&X)4UF4>DV6;H=?U-+DKSZ\;5T-
MBIHI*#R/6/J=-^:=488MZ$>U2U3Y# ;EP@!N<+L^ 2M-6H-X/V:W0.2_>Q$^
M]";QH>0WH@GL<O^ [$_0\7TPZ<.\-!9QZ^(;T4SW4L?H"J571OM.>#R29FJ'
M"[QK#()U\E(-8:)_T&2"L2%C7\?M29^?WX< T#ASPUX(Y*0*KMW]>.MD65ZY
M8G2!7LCN_N$M#0L6TBY@#@-ZPCT4C#7GV>#9>5G8<8^W&[?/=N@,SFQ/8? 5
M,UQE_-+WG4DW<J[N0M.N2^,JODB;\8X,MK,<LK A/HO7@=*%*&E&:6(X8894
MWE6]:O2D^1@X.[B $5N7H"+[#/I^>C,)!Y+H$O'R/(_=OUL9F_0V>S]^#,S"
MV!C<,_\2N\_]U]O\XLA2@Q%+_ZBS97"NUTMX3]*TU*@=L&&)UJ.Y-B %X!]Q
M&6S'D Z'L?0#X[CY3Y(9+/OS3/R."9<>F(9@VNV/QON#L]'ANB=/X$E6+$A@
M \_N#(Z'QV!VKGGGE%H_D8?/CHX'_\GGJD1<W=E(HM.C;Z(67H3XNO['#X=C
MN+.0._K@)RI_1&$I=Z$O=5)E=Z&77QSL?'VFW55>:8*>PNC8#6M$,U(&ZO-<
MMX77.@H8>G/(Y8#Q7P9 VL_9QX;1R2B3$6?K;?5I*L.@SV3?-M'Y-S#=#_;'
MA@CP[.#;B0#[(Z&_GO6.S##?8+UCG4=KO3N-_4>OL=^ Y?/"]>/O;.2/CW^7
MZ_*U=K[DG'T?.Q\.B?5F/KG!7W$\Z&/^I<O-Y__VH#P-]'W;9H/;O5O_JM98
MU!+:OX1]>54NT92VU+$/41)OZJ"EH*2IIDUT]9L$>8?9=?E9E+ )#QH:M;IM
M8[2LHV(L"0BTP'(LF+<]OV?+!S6C,^UF&J[!3E)*-6?JBKG6%#E1_SFPRPK^
MYHGB<[1FZ#AT1'QJ1V()"FG:3RCMHROF1[DIB-<:O\O( ;X;N>Q3?Q:UP6$4
M4:QSYBSG@F,?+?LT Y,)-IM3E21$OV J[:K!.GN>WEN;HD@TUY9P,J /IPTX
M!\M *!DE,51+6RJCYP3L3OL#T_7>%,M(#'ABL/=W8-R3 3$^(OM@N'\T'KSO
M.W^FT(V2"/TFIX?PO\?[8ZQNT8#!IN5)Z/;4#L[.!N/#R>!E^84L!NRTK_\H
M#'_=@<'WCP['@]/AR=D166F1Z QVZ8&G@UUZY"D-+=&,K2JI_XJO@B%Y."Q;
MN63.!-C8: ;1@4K!.[)P\H9Y16JMW$PL";XZ +'==E=JE#W;,HZ_?J/><,P+
M;]"%UEO:8LLZI=3;P>06AA/%UBR).Z+[=MTF9]KL[N?25IK5@KA0J19GQ;1A
MVL[HS#D[/G2&#FQ&>6AG/)JX9/T'6VPQ!?);ZSJ:6&PWP9.N\3"KF%^URNF\
MPXT-]UJDT__,VF%>7)<M@U3$R"00A<Y1K98UGE87*]%1_U%?MK :R\#OA$_
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M0USAK, AX@)![R]<'.B#[.N#TPE/$Z-ALPN,"]4-TK W*\2KW\YS=.CQR1@
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ML<'0QS"DZ2RQPN_2L!"RTTK<17H!-+1SG[4I3U=./&SI_E)(#EF-\<G6NZ7
MR*$,\*M59=Q-4D"<A$LFUX3<P42_7<:.$@IP+'OXVL>>K[VKI\C!*14_J(PK
MX_VI9^QW2"ON@X3BSD)RH7Y9>4D3621EAFA8<K_^'?&:;%YB]I+P#)Z:QS'N
MJB4G<49G!1*Z06_AN;ARIJ"VBR\P$^0*0"N34_,MNL:.CL^FM-[K6/?B-/#'
M&[[6%/65X,BYCKB4-BNK%"M_>)'@T,3^R*UV:-\03@WE4/Q<[(,A#S:\Q0<?
M$<^UA7P(Z?&K3QJT% =K:WGH\^P2SW:^FI'7V9=8);Z;SS7GK]$:B@>+9%WY
M"ORW]#.<:UH'&\&)/QQ+\Y).]:'LTY %6JO:X(+R=>W +6>3?(-:C5@EU[ *
MN:DB6!J6P6"<0][>J(LGI'& .0L[PHT+;<M]D(T\ISN,X]!95<(SS:]X=7)5
M:(2!5W&'\]/BQVC%IZXZ>-T8GJ-%/7,,LB.X:UR7%64CEFMW,)/N=VQKHJUO
M68^N^/IFK>A?RWS&@TD*THH!@IGY_:8'/$N9J7X'.ITB!THP6K($=B:C_3CP
MY6_B>O[63#OCKO<HX\DN6(\?VW35KWA;#ZTZG:QC8J[8]Q-VQK^@"4W.X ;5
MS:RE\5FN4ZJE.P(/$(Z>"[#0WU2P]*"-\ TW0NJ$^T.:7J(&XBZYR94ZBSX#
M!!3N-5EQ_NT\-"Q<!^2\<-6:2?]4N63*AY@!D.,&GFYB=NT((J%A+]0)0@!
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MZ*UT@O$MRZC %R9<-WZ:X\+<PX6Z7)I@3LVJNL@%N7I]!4[7B<G$S10B,?!
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M9Y"8^$6;-_?"+$/;'S!GT4Y?PQK*IR 8O:[66+;8L]:MK10YJS N2E=6R*T
MH5-M:SO,(.X,)$<5R$ES*+[%+>F-!=%!5)PYYM99GRS1Q2G^R?)S\:!MKTZN
MGI$"L2@W_)GZ R&'C3LY.!Z.4FGL%N#<POJ?N>HH*->FGE9C&2O,E!T%A*84
M2CBT1%F=S,HURL;W3H6'D/%$CR!VX[:U0>P'+1=/N6P#+ !H3VVGX+9BT;>*
M36/V**8)&8/>I[CVKE>!HQ1L&PE##U>E] .3S696ABB1C1)QTI8X"F^$B)NT
M6MA&"7>'A6=7Z+';^5#,=S)U<12/F;JTL3ST&[<\M&/8M IE17C#P4YOWQ2X
ML>OPBE^$ !6=KUBXW.\?*/'@C(R1&IA,#;'E""6+U+OE>_OV+0]7AWV(-+*4
M?UO-[>4IK>K96O]!H@')0-_2E2;,ZSAON_2A2U@655?)BZNO1PB)55:PXT9N
M"EW>2VZ7C;2.'V3IKFKN.0#' *!QZ6K/UB,4>D:U':M*H_2L]#O=,0<2V!YV
MT*-+<'"SZ7HQ3?7Y$UL.59CG2D"L_AF&WA^PWI>:^$@GT!)V2R/IK+B:$!J:
MR'9JT-+M$$JIR^;JX=T$ZMRX Y,AZ8%@))J:E1I0R&"'DI:.11$ =[T08'1%
MZU^*!5C!WD4Q9>Z 4\%[M@S^<TN;EF':N?E'*%5F]U0/E/HKDSO07]BN]F@O
M/)@AR=Y+Q(X&7F-[T5$W-\"'!1L$4 )M(U'%]B0MN68<[A#(CX)3U-Q72S9^
M+D'X1=\BEU.RF^2[D\%0]5$$<U;RD($R55HVW08Q(V5S(?C9[^6FF%NF!M?Z
M6*<0L[5?C/RV"Z&UVR"MO[/!+(\*=S<YB8O,^C09?\-/J2J_V%+^LVTIGH\9
M?-&#9">YQ @)M*]>6E;P:@G=''VT&#F['6JK3.C+ZG>7D\_9=$7Q]8:.TN3(
MF,/?6=[3]Q(^J^9RH<-EWZ 0^E?L86W,REBDCH[PEDAQ":ZC$-%@/&KB!9PF
MK]0:TO_]W1[_K DR#3Y?7;27T-[O'-H;3Z%)VY)GZD;E8[H!/&-KLXT4_#__
MCMFO+QE9_P%AF2]Q=#\TC@ZO\UUUK2CU5[W%L=TG2K*Z)WG]0[:,WM_R3II\
MG(TY[%J_VH)I^1S?B6_KG*X6<RP3206/\J^(NX8'YOSF!DWHTEN'G"&J+?/1
M.ZK)#6&FYD-B]O?V;*TW,#EL,EG=K0382I'YA+BP.L[;G8_!%U, ^(9Q-5_(
M-EW'IC<XI!_>) ?JO\!$![L=P.L(31?>J)WR:+\SZC=,?&M7'>FMW7[3]/M#
M^.%=BIK&CC@EQ;X98[1ERW^A]YY.71_'CXMB)G8/FK;4_T0:DVY-3@O("#,Q
M.NCO=<W7)0G5U(8^>VK-;C*,9 8I(V- +T9U!R\5;U @86=MDFJ8TV ?=FBP
MVV^<6_]P7_'H?M,<]]3ETGZ>0T6GAZ/:Z?;3_NA _7LPV@^2T4B1$?I@M3GC
M$LT99W,LALSFU&:2^@@PS?G4^'238]*F1,%X!OKB+L)+1R1V0C@K^AJB=3(K
M2BWD<R4\PO?Z&QKR/7^OFY23;N;&R\]SHUBB$%410H!:W#7"]ELM]+MB?KN#
M5(8E1JQ<\A9+#,(!R 806>I)!X=ZN@BP:H@7)CA,#X;#N@I'.)JG;_)Q!6%9
M4O!2O-4+#7-ZR,_;\FWCNU82QCZ_W_I=DZW1WV2H@U[[KH[4#B@];&_=]]Z/
M'_W>2(E;E^^MN0TIF60@[%4)30?=WB_)?7?LJGCIJ-?;9(LB;4O++=OUMJ]5
ML[)XEHH-GT</NY(E[O*EP:4^QKR'VVQ>:[9YAP;J5'(FE"R.KA&C\2J!\+UD
M96YJ?/FHT5^A VO;DU.J(&F/G<+_3##:'EO\MY-7R6 XH!B&P6 ??NG+)^K'
M< ]^&28'VO1";6/R^.JN&NP'Y5SV$YC^:_ ZK<CUR+NRU=_;3[:YG5?)0< \
M0R-'E2<PL8XUHPXSB\'P4&^J^CVXD?MJ(W4R1-S0AL^A\Q%J+V:+\D^J<R5?
MYG'YWN;C]IL)7UO-[+/VT%ZJ+5:#/JJK%"</O:E]2/(MT4[;JEE8:W7,2'45
MV'8V>>.]:6"%:0."2WJ@EE3WO>XJ_DF6$9I*33L0^$LY(,WK>R:"PULEZG5.
M3/4V_ILKNWT$J(K.AQ5N @R#X.K<G+:.1, @PQDY?PY&'7:_XI=[]E^#O? *
MZ0F=VIM25V7PK^^QPSKD6=N/P,@<L%V_ZU*I5SI[^JGD>9&7?]\!5'YSQB$N
MMS/H#@XZOZA_1GN_:-N)^NM0?7BA69!$:JW0H'B3X6*C[V"[L]\]'.@W%2L_
MZ.S9G^S#)V]S+!(\31[S;#;5'-V8V[B(Z9<",AC1SKG?[ZH[X)?._E[W8+?S
M2Y!B^SWA HI]$]5'Z=;R]^M@ Q.=EG(#J5+/&/>C><$U"7;^R(#&LZG^)3E2
M= 'I%'H-.V=J"97LFT\ZY^8XI@%#L=+59E"(<*R/,F;%4V0(VQ^56G&B#5S5
MY3R&0S2;!;YQ>G9E/Q3@#29DX.OJ]*W&9/GU_'>LWW@I]+]F2>CDZIETC@V9
M=8YN;P$>:0GOL1N[([T0!WBG"-%:53B8O\(9M6?943<O,8B.1;)T^K;&VQW1
MNP(X9'N=D9IUK]OO=0Z[NW5/[JLGE4PS&( 9\* +%LJ]=$]==C7O'&#K^_SP
MX6BO\WM6"DJ^7=3W2T90^$&?@MN"M7WA+N7QW;3/TG=O^.<.K /&6LF*8U0&
M+JJI%:I4O@E;4]C9;0JC.[FA]B5DJG$BO) .<C'5S)LQ.";.W7:3O.IU=_>P
M)?AM%ZR#7!$ILD@"G+;O>?]:\P3WZDDNT)#:S!^$)]GT*)]9>]6Y$%=#Y8KS
MF$GE>_L FNNP>A1C;\=950(G"\!=T9SMD)7?S:M^MV]0L-1?0Z2S(?U0?Q[J
M+X?=W@@_Z0SW];_JPSW]Q*#7/3S$CQ2'Z]$OP[U!9P"7@7YJ;[37W>UU!@>'
MW8,^L$+SFY*0=[N'H\[^+HQB- QK"WAOG%$TQQ742V\E[KR5^UV]$O/</O&6
M!ONT%;!2E(SY J+@PW@QQ:-.-J7]M#?J0^AOALH@@9A@3#C2\40--%>B=S\=
MJ.NSG^[UV/PUGNEH5E!.RHY:\/[NH'.:?\6SC385K8BQ5<(O#*_Z'^WV.P?I
MOEIM([#HVNZ=+7Q@N[.%CVSCU +-M+#J6[YYLV<5[:Z=]27FFCFHY^ZO.D-0
M:#A4Q(+1H"Q+N%1,:7;U;$_=2I#A7+I/B]VJ\KQ:^]I[0FUUSS/^$!F#^=!*
MUL9]I2@!,@J6.H%@ZVVV5+=HB2ND:, C=#!?<)>'GR[?)ENO@H_TAO2(1]7W
MBZX6%B+O*X&B\1DU_:Z>>HMG]B//'$O<+?YRXN!++=6'C*/$SFTRRHD1UK,0
MH/WPH]@T@NK!1<;E=TZDW-'6D>6 8-UTNZFK]^._%6AH.)O#O5\HBHVI$14#
M)&;^D%Q_@<6_,:)_"I8'B U5_+W:@!+5>YY873. Y)_):;Y0[2/M*7H^7?%U
MSE?VGTH;>"(V[H^+8I)E4TZ@(]-K_=K6C^D2@@NF3QQ4?1>Z@,YFC?N&VLB#
M;1;C_*NZ"J8<EP-6JG?'T?8NN-@P:4B7]^J.2DYAU:VYB:KQ)E>,=0J6?: D
M=<!BC=8H_58_*:O&"'ES 0OD<8QU.WXCF 9'$]4I<4\0S3A2(]C)1O%=55:I
M7H]PF;X3T>%M%43@"2_SF.%8,<->/\Q-G5O]K76KGY!O)$(;9XHH\X7XVM%7
M\0XQ7EE8^4WIWCN*?"!TVCN65@ZP:.MEI)]?R1)R@1"R0*O!!]3W^=WU2A$@
M-AS(;_*R["7:"5'[B;2\IB%N<NN=DHRVP;)\XH48O,7*[>&S4V/B#;[0QC8L
M"Z<T^57TT%;?OY @=DBOQ-WQCD<HW/X392\*O$CLI$2'_9:3N/&*J+Z%Z=D>
M8_1QM9 HWT>@M8B%Q086*&'I "^#"N0_$EZ@#=O2.[?NF:MA[[/96"/8GB$2
M _[*E.$OZ3Q[A/4$Q$"X4>+K54F^BU(I!*]CXAX*_4HNC-YS[ JHN9SC,3!I
MHJCU9C5#];#ZYI!L*_[%^K6VPU'XM6/Q,E\N5U,8S2*[R]4<]29Q?C)#^L E
MB,+>Q:EB<N/9\G/#7>*U?W&D7ZPVTJ9W]>3Q^8?D. /[E?I$@E=R@;T\FMV-
M)XGIEC)@XSM_)""H+ U8>PHRSPK3819PR4ZP3R0XL/':C_VN>+C23^+DX+^>
MU@B,@[V0Q#@:!#\-/ON<LXJSOT%P1,/^MQ[1,#JB_GZH[_[HFXWHZJ$0>]H5
MPIS3$$M\G[' W#,@=N^\ABAW=T,#W@M.[EFF<3[79D&846 2[\?SU0U8C#$$
MN<4<-I$(=R*Y'Z47G"^RHR4S)J_ ;'\ECJFZ&&O36FST-<'=ZS4,RISU #F?
M4IT,T.R[6KO1^'E]0J/Q(R>B9*29YJ5>NX$-E_1Y^XFO\O/V$U_XS0Z8"4YV
M1;BJ4U5FH<6X#8[<L%9KLV3%6H*-AW![MZP;>!T59-<,[O9XP[>-U(XO@A>J
MW41ZOM09B>7?,5'\WJHU9&@$R7*H6A2C"..6MC*,2J05T]>KY+^Y1EZ=B90?
MCC\HYM;P$V@ME7BI>(]>& 0H^9#3RY:9WSC(Y9^1][75L$G-\>R-EEDK3=YD
M<S1QJCO),OR<4DUIKZD&^P*'L^")3VUKA';FIF37_0B!H?],XJLC*+9Q =CN
MB5A,N+\W1?%W9DMU'1KX)3:Z<,[!F4Z?% "F[9BUD^CRZ%:);;301B)/SA_F
M:FD_Y_? 3=3@K]'FS-;(E"QC"Y_X#X+2^#/TY&UM/R@B-MKZU)I:9",<CNQ
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M'^43G;T#Y*".WQM(0S 16"PF@;>@KOG=[F#DS:-Z7K6A&!=*BQPF"A"&L/'
M)6\ ; OTVS9<>O'YK-U3N ],K:"I[)Q#G7293[7]O5XR'3]Z'_='X<\W'T[U
M0;]+RJ,XC R(OAT.PU_;4:0X1KJ_)T$#L:\[/P/K=F3:MP7(7>N$^O.:A18J
M^72/D LS.%*/G%8VP?1^[!UMA-X9W@TO5#5:?SXA^0O!^&5AO+<V6H0ZP0V
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M\QLY/#83\J2DM?F+!H!L><Q#8DYSN%>CD.+,*B(<QUZ*BR>Q-]:0,G!]#AV
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M/;$ >EW'WQTOKQ5J66OTO/\NR^7__']02P,$%     @ Q7A+3Q:B:!UH @
M2@T   T   !X;"]S='EL97,N>&ULU9=M;YLP$,>_BN5.4RM-!9*5MBM$VBI5
MFK1-E9H7>U<Y8,"2'Y@Q6=)//Q_F(6%JNV;=E+P)YSO?_W[&)AQ19=:<WA64
M&K027%8Q+HPI/WA>E114D.I4E53:2*:T(,8.=>Y5I:8DK2!)<&_B^Z$G")-X
M%LE:W A3H435TL0X[%W(Y5^KE,;X_OCMCUJ9JS?(78_>'1WY]R=78_]Q$SC!
MR&E\3F,<A.^Q]^>BI[[_N# $1^)G+Q1_2GLD'3XBW:. V  V3C]_Z;*?7O=8
M_N(YNBVX4?(E)'OMWL^B3,GA"$RQ<UAU(BA:$A[C:\+90C/(RHA@?.W<$W D
MBBN-C#U[MGH GNK!A0,W@F/9Z@@FE6YJNPKN=]%.'P6Z$0 RSGO "7:.6502
M8ZB6-W;03&Z<OX50:\_7I27,-5D'DS,\)#076V2A=$IU7R; G6L6<9H!CF9Y
M 5>C2@^"QBAAC9217$G2,'09K6%E$\KY'3RSW[,M[56&W!S8$A\CH.A,N^K6
M'';-;Y WU9SVINQT)UU4LJ4RGVJ['-F,X>C16TTSMFK&JZP'L.JD+/GZ(V>Y
M%-0MYMF"P8X%9Q'IZJ!":?9@]>"H)-9!-49+J@U+-CT_-2GG=&6ZX[3*=F6>
M'"#S:]_GG$JJ"=^$MF=_G^_R?R:&M]M?,S=_*V/B5X2<GN\_([S)#P RW'_(
MZ>7^,T)W= "0%X< ^:^WVVN;C(U.9JN/Z;UH43-NF&QQ"Y:FU/% (QGC;]"E
M\JUN8FAGK+PA"_MALZ5O<U.:D9J;6UAB$XSQ8'\!\"#L9\U[B1@/]E>:LEJX
MGG?X>IK] E!+ P04    " #%>$M/R6!N<U$%   ]+@  #P   'AL+W=O<FMB
M;V]K+GAM;,6:6T_C.!2 _XK5EYU]8-M<N0B0&&!VD9@!#6CV<602M[5([([M
M</OU>YQ.P8;F:%]Z^M0F<9(OOGW'E\-';>[OM+YG3VVC[-%H[MSB8#RVU5RT
MW/ZE%T+!E:DV+7=P:&9CNS""UW8NA&N;<3J9E..62S4Z/EP]Z]J,PP/M1.6D
M5G#2G_@AQ:-]N^X/&8<$#^*6WQV-)B/&.Z>_R,8)<\:=^-OH;B'5[&B4C-A4
M&NMN_+O[E*U4LI4OHNZ/[%P__J.-?-'*\>:F,KII^KO\A?XF>(-]/?-#&">K
M**'C=]\YL!Z-R@D\\$%:>2<;Z9Z/1OW_1HS@*\;!9_3YL/I=9N*!^3_9J*=3
M68DS776M4&Z9CT8T_NW*SN7"CICBK3@:K9*P$U6S<^6 AEVHY:,@K?\6>/5%
MO?PN!SGV!LO,@80+YJ).//CF($^UJH6RHF;PS^I&UL!1L\^\X:H2+(!,$<AT
MBY _TP R0R"SK4#>>!RX-8#,$<A\BY!13A8(9+%-R"R +!'(<K.0WZ!W9 G;
M85=FQI5\Z5,PKGRUM-(&D+L(Y"X!9 J0-UW;<O/,])3=R)F2<#]7+H#<0R#W
M"" S@/PN'H2Q@GT59B9, +>/P.T3P.4 !SI<@'>>^R(^_]7)A;\S[,0G6"\^
M(<(\J2K306.YE+P7H!1A54Q0TVQ8-3UCX5N,FPOSJIC>[R#&$!-S3;)AV?28
M)6#>"M.R2\V5[<L<^B*HGE&)8[9)-JR;5\Q3W;;2^=2OG$Y&N8GY)MFP<'K,
M7<"\%-S&=1$S3+)AQ;QBW3A=W<]U4T//\P<[$W"_C,H84TQ"X9B]OF>L!3P-
MWKZJADN2-TQ,,@F%9?8!\U]N#&@E*F5,+ F%69+)JIC9U:)/$N)A:DDHW-+C
M7:A*MX+=\J>HB:284E(*I21)7_L:'X#M++CWWRT4L>55B(E9):6P2N)CG/-V
MT>AG(=AGH: =.W8-@@DQT1$,A56292AV9\6OS@\,SQ]$W%I2S"CIAHT2!(8^
MC-"=]\B,74, 7L5A1(H9):4PRE!,&PUA4LPP*85AA@+'&!-33$JAF(' D7VZ
M#3$QQ:04BAF*'>/<Q(234@AG*':,,3'QI!3B&8H=X_D4S$ 9A8'>8D>HCCX"
MLG^&?)AZ,@KU# :1X=Q9AJDGHU#/7A">K<U(=.:,8BSS,4Y;<8:8F'DR"O-\
MB-?6YB9FGHS"/$,S4W'KQLR349AGT./A+%^&F2?;YA3:SSS$Q,R349AG$+,(
M,3'S9!3F^3C7QSZ="<=E$TZ28^;)J:;3U@9O8=W,,0'E% (:Q SK9HX)**<0
MT%",N1-Z,L<LE%-8:##&C H=7<&AL- @9E3HF(5R"@L-AL)1;F(6RBDL-(@9
MY29FH9S"0H.88?>>8Q;*MSK^*4-,S$+Y5L<_8=TL, L5%!8:Q SK9H%9J* :
M!JV&:4N76Z@$3Z[C(29FH8+"0@'F#OO2N<Y ".+WHG0A)F:A@L)"0X/*>(4>
MLU!!M:ZS%C-J0NA. @H+#:V@Q+F)6:B@L-!^-$0/&U&(B5FHH%[H@;\K3AAO
MA)B8A0H*"[W#?/U[$DXG%)B%"K+EGW>S'A_&0B5FH9)D'>@]9K^X\BYZ+S$+
ME23K0!]S\_=QB(E9J"19!UJ+Z0?N(29FH9)L1BZ>ZOK=VD-,S$+E=F;D^HAI
M$6VQ+#$+E20S<FLP3_SV61EBHCO:2+:T#:SX1K(L,0N5%!8:6O&-,3$+E22;
M#[)U*[Z^'868F(7*WD+C/K$]/JSA.Y6HO\$K+)RO>%-=&^9_EANG\L)O:9AV
M37,*YZX4C,'\^?X9JYW;Q_\!4$L#!!0    ( ,5X2T]1_3"31 (  (0I   :
M    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%VL%NVD 0QO%707Z +#N[
M,R15R*F77-.^@ 4+1@';\FZ5Y.WK<JDK)?YZ0)\O( 2:^9]^6&L_OJ1S74Y=
MFYM3GU?OEW.;MU532O_-N;QKTJ7.=UV?VO&;0S=<ZC)^'(ZNKW>O]3$Y6:_-
M#=,9U=/C=.;J>;^MAN>]KU8_Z^&8RK9R[V?WU@VON4FI9'=]\W?C@O$G'WWZ
MG_7=X7#:I>_=[M<EM>63BK\+*O=YD,P'"3THS <%>E"<#XKT()T/4GJ0S0<9
M/6@S'[2A!]W/!]W3@Q[F@Q[H07X-9%SSDQ#6?*T]X-KSO?8 ;,\7VP.R/=]L
M#]#V?+4]8-OSW?8 ;L^7VP.Z/=]N#_#V?+T%Z"U\O07H+0M<:Z.+;;[> O06
MOMX"]!:^W@+T%K[> O06OMX"]!:^W@+T%K[> O06OMX!Z!WX>@>@=^#K'8#>
M88&S$G18PM<[ +T#7^\ ] Y\O0/0._#U#D#OP-<[ +T#7^\ ] Y\O2/0._+U
MCD#OR-<[ KTC7^\(](X+G'6CPVZ^WA'H'?EZ1Z!WY.L=@=Z1KW<$>D>^WA'H
M'?EZ*]!;^7HKT%OY>BO06_EZ*]!;^7HKT%L7N%>);E;R]5:@M_+U5J"W\O56
MH+?R]5:@M_+U-J"W\?4VH+?Q]3:@M_'U-J"W\?4VH+?Q]3:@MRWPK EZV(2O
MMP&]C:^W ;V-K[<!O8VO]V:B=V[J(>U_E.'4'O.M2_X9_F7-!.Y</L[I]AG7
MJ5_NGRA=QBW)75]O_G=QG?HGPDTK\M-O4$L#!!0    ( ,5X2T\%#51C 0(
M +,H   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:RT[C,!0&X%>ILD6-ZRL7
M43; =@9I> &3G#91D]BR#92W'R=<)%"1BFBE?],T.<XY?U+K6_7R_L53G&W[
M;HC+HDG)7S 6JX9Z&TOG:<B5E0N]3?DTK)FWU<:NB8G%PK#*#8F&-$]CC^+J
M\H96]K%+L^O7ZV/K96&][]K*IM8-[&FHOS2=OS4L W73FMBT/I[D!<7L=IN[
MQ'QM6>1J+-@>$[[>.)[G^_X^40AM33^*YE:KMJ+:58]]OJ6,/I"M8T.4^JZ,
MC0U4_TNA'=9O>>]L2']LGQNS;<<^+2B/ER.]=+0[P%0YY.24MP7M&C457C_Y
MKP:^[X;*!9K[D*LAM3L>+T>ZR]7(QH6'?$0:MTY-]5[#<^OC_;#/+FRF[[M>
M^$<QLNGPN[=^N!P")(<$R:% <FB0' 8DQRE(CC.0'.<@.?@")0B*J!R%5(YB
M*D=!E:.HRE%8Y2BN<A18.8JL D56@2*K0)%5H,@J4&05*+(*%%D%BJP"15:!
M(JM$D56BR"I19)4HLDH4626*K!)%5HDBJT215:+(JE!D52BR*A19%8JL"D56
MA2*K0I%5H<BJ4&15*+)J%%DUBJP:15:-(JM&D56CR*I19-4HLFH4636*K 9%
M5H,BJT&1U:#(:E!D-2BR&A19#8JL!D56<T19IV/9VW;X+LF#<YOW^6SZK^+5
M?U!+ 0(4 Q0    ( ,5X2T\?(\\#P    !,"   +              "  0
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,5X2T\GZ(<.@@   +$    0
M          "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ Q7A+
M3T0-E<OO    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ Q7A+3YE<G",0!@  G"<  !,              ( !
MMP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #%>$M/2H0:-"T"
M  !.!P  &               @ 'X"   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ Q7A+3TA#U*=1!   ?!8  !@              ( !
M6PL  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,5X2T_&
M(.M05@,  +(/   8              "  >(/  !X;"]W;W)K<VAE971S+W-H
M965T,RYX;6Q02P$"% ,4    " #%>$M/4&W&_)<#  !-#P  &
M    @ %N$P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MQ7A+3Q @I)L8"   MS<  !@              ( !.Q<  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ,5X2T_!WJI@+P4  -L;   8
M          "  8D?  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " #%>$M/W+33",P!  !M!   &               @ 'N)   >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ Q7A+3X_&"R[. 0  ;00
M !@              ( !\"8  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( ,5X2T^S@JTBM@$  -(#   8              "  ?0H  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #%>$M/&!&5G=(!
M  !M!   &0              @ '@*@  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( ,5X2T\)9U4TN $  -0#   9              "
M >DL  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ Q7A+
M3\_T:(RV 0  T@,  !D              ( !V"X  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " #%>$M/)_??--(!  !M!   &0
M        @ '%,   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( ,5X2T^BF]D.N0$  -0#   9              "  <XR  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ Q7A+3T7C\B:V 0  T@,
M !D              ( !OC0  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " #%>$M/*[UZ8[D!  #4 P  &0              @ &K-@
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,5X2T\>O)80
MM@$  -(#   9              "  9LX  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ Q7A+3P#8N3G0 0  ;00  !D
M ( !B#H  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #%
M>$M/?E1-'=(!  !M!   &0              @ &//   >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,5X2T^D_?[QN $  -0#   9
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M970R-"YX;6Q02P$"% ,4    " #%>$M/2(O"*MT!  #V!   &0
M    @ &O20  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M ,5X2T_.L_*QT $  &T$   9              "  <-+  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ Q7A+3W3<P4#0 0  ;00  !D
M             ( !RDT  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " #%>$M/3;&KI]\!  #2!   &0              @ '13P  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,5X2T]$QV#XW@$
M -($   9              "  >=1  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ Q7A+3[P7;+_4 0  ;00  !D              ( !
M_%,  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #%>$M/
M8O5 B-0!  !M!   &0              @ $'5@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ,5X2T]'PC)SMP$  -0#   9
M      "  1)8  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ Q7A+3X&U*$#8 0  NP0  !D              ( ! %H  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #%>$M/BKQH8=H!  #2!
M&0              @ $/7   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( ,5X2T\,+"(#Q@$  #D$   9              "  2!>  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ Q7A+3^>W.!+]
M @  90P  !D              ( !'6   'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " #%>$M/SP#KOX($   '&   &0
M@ %18P  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ,5X
M2T\-2FH/60(  %T)   9              "  0IH  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ Q7A+3V,C16XS P  H0X  !D
M         ( !FFH  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    " #%>$M/A+(-J.D"  #/"P  &0              @ $$;@  >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ,5X2T\V_;?"  (  %$%
M   9              "  21Q  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L! A0#%     @ Q7A+3TQ\@P1= @  # D  !D              ( !6W,
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #%>$M/!9>L
MQ"T"  #Z!@  &0              @ 'O=0  >&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;%!+ 0(4 Q0    ( ,5X2T_FK>9Q)0(  +D&   9
M  "  5-X  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
MQ7A+3^(6^I\* @  ) 8  !D              ( !KWH  'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " #%>$M/*8Z=G&@)  !I/@  &0
M            @ 'P?   >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( ,5X2T_3.:L5F@$  %L#   9              "  8^&  !X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ Q7A+3Y3J U\V @
MG <  !D              ( !8(@  'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " #%>$M/BX@,&T@"  !?"   &0              @ '-
MB@  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ,5X2T]"
M- ,N)P(  #8&   9              "  4R-  !X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ Q7A+3VPY/YS! 0  6 0  !D
M     ( !JH\  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,5X2T]"7HM!H (  *H)   9              "
M 1B=  !X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ Q7A+
M3T,&@M0F!0  \QL  !D              ( ![Y\  'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    " #%>$M/*J7.,^@!  !X!0  &0
M        @ %,I0  >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   ( ,5X2T_Z-.&_CP(  )\)   9              "  6NG  !X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ Q7A+3[X'Q/("!   +10
M !D              ( !,:H  'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"% ,4    " #%>$M/0\9<*EP#  !P#@  &0              @ %JK@
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ,5X2T]0.3^0
MD0,  *$1   9              "  ?VQ  !X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L! A0#%     @ Q7A+3TP 8*'2 P  4Q(  !D
M ( !Q;4  'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #%
M>$M/=2L=8M,"  !&"P  &0              @ '.N0  >&PO=V]R:W-H965T
M<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( ,5X2T]'23'U%P(  &$&   9
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M970V.2YX;6Q02P$"% ,4    " #%>$M/\LQ[>,*I  #_1P, %
M    @ '+R@  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " #%>$M/
M%J)H'6@"  !*#0  #0              @ &_= $ >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( ,5X2T_)8&YS404  #TN   /              "  5)W 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #%>$M/4?TPDT0"  "$*0  &@
M            @ '0? $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " #%>$M/!0U48P$"  "S*   $P              @ %,?P$ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     3@!. %05  !^@0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6673071024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Term Loans and Convertible Promissory Notes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Note 6.&nbsp;&nbsp;&nbsp;Term Loans and Convertible Promissory Notes </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Term Loans </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">On November&nbsp;24, 2015, the Company entered into a loan and security agreement (&#x201C;Loan Agreement&#x201D;) with Oxford, pursuant to which the Company received $3.0&nbsp;million in proceeds from a Term Loan A and $2.0&nbsp;million in proceeds from a Term Loan B under the Loan Agreement (collectively the &#x201C;Term Loans&#x201D;). Warrants to purchase 11,829 shares of common stock were issued to Oxford in connection with the Term Loans (&#x2018;</font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Note 9&#x2009;&#x2014; Warrants&#x2019;</font><font style="display:inline;color:#000000;font-size:10pt;">). The Term Loans bear interest at a floating per annum rate equal to (a)&nbsp;7.06% plus (ii) the greater of&#x2009; (a)&nbsp;the 30 day U.S. Dollar LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (b)&nbsp;0.19%. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Term Loan A was recorded at its initial carrying value of&#x2009; $3.0&nbsp;million less debt issuance costs of approximately $141,000, and the Term Loan B was recorded at its initial carrying value of&#x2009; $2.0&nbsp;million, less debt issuance costs of approximately $3,000. The debt issuance costs are being amortized to interest expense over the life of the Term Loans using the effective interest method. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">As of December&nbsp;31, 2018, $2.3&nbsp;million was outstanding under Term Loan A and $1.5&nbsp;million was outstanding under Term Loan B. At June&nbsp;30, 2019, $1.4&nbsp;million was outstanding under Term Loan A and $1.0&nbsp;million was outstanding under Term Loan B. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The following modifications have been made during the six&nbsp;months ended June&nbsp;30, 2019: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 10pt;font-family:Symbol;color:#000000;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In January&nbsp;2019, the Company and Oxford agreed to amend the Loan Agreement. Oxford agreed to two&nbsp;months of interest-only payments followed by eight&nbsp;months of repayments upon delivery by February&nbsp;1, 2019 of an executed term sheet for equity financing that would result in aggregate proceeds to the Company of&#x2009; $20.0&nbsp;million. The Company was also required to place $200,000 in a segregated bank account that is subject to a blocked control agreement in favor of Oxford. The funds in the segregated account were to be released upon the earlier of the consummation of a merger by March&nbsp;31, 2019 or the consummation of an equity financing by March&nbsp;31, 2019. The Company recorded the $200,000 as restricted cash in its balance sheet at June&nbsp;30, 2019. The maturity date of the Term Loans remained unchanged. The amendment fee amounted to $50,000. The amendment was accounted for as a debt modification. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
			<font style="display:inline;color:#000000;font-size:1pt;">&#x200B;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 10pt;font-family:Symbol;color:#000000;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In May&nbsp;2019, the Company and Oxford agreed to an amendment to provide consent to the Merger. This consent amended certain provisions of the Term Loans to protect Oxford&#x2019;s rights under the original Loan Agreement. The consent allowed Alliqua (now Adynxx, Inc.) to be named as an additional borrower. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 10pt;font-family:Symbol;color:#000000;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In June&nbsp;2019, the Company and Oxford agreed to amend the Loan Agreement. Oxford agreed to two&nbsp;months of interest-only payments and the maturity date of the Term Loans was extended two&nbsp;months to January&nbsp;1, 2020. The amendment fee amounted to $20,000. The amendment was accounted for as a debt modification. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:1pt;">&#x200B;&#x200B;</font><font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">&#x2007;</font><font style="display:inline;color:#000000;font-size:10pt;">Upon the respective dates of the debt modifications, no gain or loss was recorded, and a new effective interest rate was established based on the carrying value of the debt and the revised cash flows. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Interest expense associated with the Term Loans was $309,000 and $336,000 for the six&nbsp;months ended June&nbsp;30, 2018 and 2019, respectively. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">As of June&nbsp;30, 2019, the Company was in compliance with all covenants under the Loan Agreement. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Principal payments for the Term Loans due under the Loan Agreement as of June&nbsp;30, 2019 are due monthly beginning September&nbsp;1, 2019 and the Term Loans mature on January&nbsp;1, 2020. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Convertible Promissory Notes </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The table below reflects the principal amount of the Notes issued by the Company (in thousands): </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">June&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Convertible note payable, due on March&nbsp;29, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,500
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Convertible note payable, due on September&nbsp;27, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,500
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Convertible note payable, due on December&nbsp;21, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,500
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,500
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Convertible note payable, due on March&nbsp;29, 2020</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,500
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Convertible note payable, due on April&nbsp;26, 2020</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,000
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Convertible note payable, due on May&nbsp;29, 2020</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>500
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,500
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,500
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Outstanding Notes </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Notes outstanding at June&nbsp;30, 2019 were issued with conversion and repayment rights as described below: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size:10pt;;"> (a)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">in the event that the Company issues and sells equity securities with proceeds to the Company of at least $5&nbsp;million, on or before the maturity date, then the outstanding principal amount of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities of the same class sold in the equity financing at a conversion price equal to the cash price paid per share for equity securities in the financing, and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 10pt 54pt;text-indent: -18pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
			<font style="display:inline;color:#000000;font-size:1pt;">&#x200B;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size:10pt;;"> (b)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">if the Company consummates a change of control while the Notes remain outstanding, the Company shall repay the holders in cash in an amount equal to 200% of the outstanding principal amount of the Notes. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:1pt;">&#x200B;</font><font style="display:inline;color:#000000;font-size:10pt;">In April&nbsp;2019 and May&nbsp;2019, affiliates of Domain Partners, LLC, a significant shareholder of the Company, purchased from the Company $2.0&nbsp;million and $0.5&nbsp;million aggregate principal amount of Notes. The proceeds from the issuances were used for general corporate purposes and working capital. These Notes accrue simple interest on the outstanding principal amount at a rate of 8% per annum and mature on April&nbsp;26, 2020 and May&nbsp;29, 2020, respectively. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Converted Notes </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In May&nbsp;2019, under the terms of the then-outstanding Notes, the principal and accrued unpaid interest of two Notes totaling $3.2&nbsp;million were automatically converted into the Company&#x2019;s Series&nbsp;B convertible preferred stock. Upon consummation of the Merger, and subject to the terms and conditions of the Merger Agreement, each outstanding share of capital stock of Adynxx was converted into the right to receive the number of shares of the combined Company&#x2019;s common stock equal to the Exchange Ratio. An aggregate of 367,041 post-Merger common shares were issued associated with the conversion of these Notes. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In connection with a previous modification, the Company had computed a contingent BCF that was contingent upon the occurrence of a reverse merger. In accordance with ASC 470-20-25-6, the contingent BCF is not recognized in earnings until the contingency is resolved. Upon the date of the Merger, the full amount of beneficial conversion feature of&#x2009; $2.1&nbsp;million was recognized as interest expense in the condensed consolidated statement of operations for the six&nbsp;months ended June&nbsp;30, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Derivative Liability </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Company evaluated its outstanding Notes and determined that certain embedded components relating to conversion and redemption features of those contracts qualified as derivatives, which need to be separately accounted for in accordance with ASC 815. With the consummation of the Merger, several of these clauses no longer apply. However, the redemption provision upon change of control described above is an embedded feature that is required to be bifurcated. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">As of December 31, 2018, the Company evaluated the fair value of the derivative liability and determined that the bifurcated derivative liability had no value because the Company estimated a zero probability of the embedded feature being triggered. As a result, the Company estimated the fair value of the derivative liability to be zero at December 31, 2018. Similarly, the embedded derivatives that were in place at June&nbsp;30, 2019 also had a fair value of zero. </font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#231F20;">Note&nbsp;</font><font style="display:inline;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term Loans and Convertible Promissory Notes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Term Loans</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">On November&nbsp;&nbsp;24, 2015, the Company&nbsp;&nbsp;entered into a loan and security agreement (&#x201C;Loan&nbsp;&nbsp;Agreement&#x201D;) with Oxford Finance, LLC (&#x201C;Oxford&#x201D;), pursuant to which Oxford agreed to lend the Company&nbsp;&nbsp;up to $10.0 million, issuable in three tranches of $3.0 million (the &#x201C;Term Loan A&#x201D;), $2.0 million (the &#x201C;Term Loan B&#x201D;) and $5.0 million (the &#x201C;Term Loan C&#x201D;). Term Loan A, Term Loan B and Term Loan C will collectively be referred to as Term Loans. On November&nbsp;&nbsp;24, 2015, the Company&nbsp;&nbsp;received $3.0 million in proceeds from Term Loan A and on January&nbsp;&nbsp;29, 2016, the Company&nbsp;&nbsp;received $2.0 million in proceeds from Term Loan B. Warrants were issued in connection&nbsp;&nbsp;with Term Loan A and Term Loan B (See </font><font style="display:inline;font-style:italic;">Note 8 &#x2014; Warrants</font><font style="display:inline;">). Under the terms of the Loan Agreement, the Company&nbsp;&nbsp;may, at its sole discretion, borrow $5.0 million under the Term Loan C following the achievement of a defined milestone event until the earlier of 30 days thereafter&nbsp;&nbsp;or March 31, 2016. The Company&nbsp;&nbsp;did not draw on Term Loan C at March 31, 2016 and the availability of the $5.0 million under Term Loan C expired.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">All outstanding Term Loans will mature on November&nbsp;&nbsp;1, 2019 (the &#x201C;Maturity Date&#x201D;) and the Company will have interest only payments through&nbsp;&nbsp;November&nbsp;&nbsp;1, 2016, followed by 36 months of principal and interest payments. The term loans will bear interest at a floating per annum rate equal to (a) 7.06% plus (ii) the greater of (a) the 30 day U.S. Dollar LIBOR rate reported&nbsp;&nbsp;in the Wall Street Journal&nbsp;&nbsp;on the last business day of the month that immediately precedes the month in which the interest will accrue or (b) 0.19%.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;has the option to prepay all, but not less than all, of the borrowed&nbsp;&nbsp;amounts,&nbsp;&nbsp;provided that the Company&nbsp;&nbsp;will be obligated to pay a prepayment fee equal to (i) 3% of the outstanding principal balance of the applicable Term Loan if prepayment is made prior to the first anniversary&nbsp;&nbsp;of the applicable funding date of the Term Loan, provided, however, the prepayment fee will be reduced to 1% if the Company is acquired within six months from the Term Loan closing date, or (ii) 2% of the outstanding principal balance of the applicable Term Loan if prepayment is made prior to the second anniversary&nbsp;&nbsp;of the applicable funding date of the Term Loan, or (iii) 1% of the applicable Term Loan prepaid thereafter&nbsp;&nbsp;and prior to the Maturity Date. The Company&nbsp;&nbsp;will be required to make a final payment of 4.25% of the funded amount, payable on the earlier of (i) the Maturity Date or (ii) the prepayment of the Term Loan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;may use the proceeds from the Term Loans solely for working capital and to fund its general business requirements. The Company&#x2019;s obligations&nbsp;&nbsp;under the Loan Agreement are secured by a perfected first priority lien in all of its assets with a negative pledge on owned intellectual property.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In January&nbsp;&nbsp;2017, the Company&nbsp;&nbsp;and Oxford Finance agreed to amend the Loan Agreement. After the Company&nbsp;&nbsp;made principal payments on December 1, 2016 and January&nbsp;&nbsp;1, 2017, Oxford agreed to an additional 12 months of interest-only payments followed by 23 months of amortization. The amendment fee amounted to $100,000. The amendment was accounted&nbsp;&nbsp;for as a debt modification.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In March 2018, the Company&nbsp;&nbsp;and Oxford Finance agreed to amend the Loan Agreement. After the Company&nbsp;&nbsp;made principal payments on January&nbsp;&nbsp;1, 2018, February 1, 2018 and March 1, 2018 Oxford agreed to another&nbsp; 5 months of interest-only payments followed by 15 months of amortization. The amendment fee amounted to $200,000. This amendment was accounted&nbsp;&nbsp;for as a debt modification.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In September 2018, the Company&nbsp;&nbsp;and Oxford Finance agreed to amend the debt agreement. Oxford agreed to 1 month of interest-only payments upon closing a $1.5 million convertible promissory note with current investors followed by 2 months of interest-only payments upon entering into a merger followed by 11 months of repayments.&nbsp;&nbsp;The maturity&nbsp;&nbsp;date of the Term Loans remains unchanged.&nbsp;&nbsp;The amendment fee amounted to $25,000. The amendment was accounted&nbsp;&nbsp;for as a debt modification.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In December 2018, the Company&nbsp;&nbsp;and Oxford Finance agreed to amend the debt agreement. Oxford agreed to 1 month of interest-only payments upon closing a $1.5 million convertible promissory note with current investors by December 31, 2018, followed by 10 months of repayments.&nbsp;&nbsp;The maturity&nbsp;&nbsp;date of the loans remains unchanged.&nbsp;&nbsp;The amendment fee amounted to $35,000. The amendment was accounted&nbsp;&nbsp;for as a debt modification.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The amendment fees are due and payable upon the earlier of: (i) the Maturity Date, (ii) the acceleration of any Term Loan, or (iii) the prepayment of a Term Loan, and are being accrued over the expected term of the Term Loan as interest expense.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Upon the respective dates of the debt modifications, no gain or loss was recorded, and a new effective interest rate was established based on the carrying value of the debt and the revised cash flows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Term Loan A was recorded at its initial carrying value of $3.0 million less debt issuance costs of approximately $141,000, Term Loan B was recorded at its initial carrying value of $2.0 million, less debt issuance costs of approximately $3,000. The debt issuance costs are being amortized&nbsp;&nbsp;to interest expense over the life of the Term Loan using the effective interest method.&nbsp;&nbsp;The final payment is accrued over the life of the Term Loan through&nbsp;&nbsp;interest expense using the effective interest method.&nbsp;&nbsp;At December 31, 2017, $2.8 million was outstanding under Term Loan A and $1.9 million was outstanding under Term Loan B. As of December 31, 2018, $2.3 million was outstanding under Term Loan A and $1.5 million was outstanding under Term Loan B.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Interest expense recorded for the years ended December 31, 2017 and 2018 was $515,000 and $644,000, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2018, the Company&nbsp;&nbsp;was in compliance with all covenants under the Loan Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Future&nbsp;&nbsp;principal payments for the Term Loans due under the Loan Agreement as of December 31, 2018, were as follows (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">Year Ending, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Total principal payments</font></p>
				</td>
				<td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 3,833</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Convertible Promissory Notes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The table below reflects the principal amount&nbsp;&nbsp;of the Notes issued by the Company&nbsp;&nbsp;to current investors (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">As of December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Convertible&nbsp;&nbsp;note payable, due on March 29, 2019, interest at 8.0% p.a</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 1,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Convertible&nbsp;&nbsp;note payable, due on September 27, 2019, interest at 8.0% p.a</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 1,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Convertible&nbsp;&nbsp;note payable, due on December 21, 2019, interest at 8.0% p.a</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 1,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Total&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 4,500</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Conversion rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The December 2018 Notes were issued with conversion and repayment&nbsp;&nbsp;rights, which are as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(a)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"></font>in the event that the Company&nbsp;&nbsp;issues and sells shares of its preferred stock to the investors with proceeds to the Company&nbsp;&nbsp;of at least $5 million, on or before the maturity&nbsp;&nbsp;date, and prior to the closing of a reverse merger, then the outstanding principal amount&nbsp;&nbsp;of these Notes and any unpaid accrued interest will automatically convert in whole into equity securities sold in the preferred stock financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the such preferred stock financing;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(b)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"></font>in the event that the Company&nbsp;&nbsp;issues and sells shares of its common stock to the investors with proceeds to the Company&nbsp;&nbsp;of at least $5 million, on or before the maturity&nbsp;&nbsp;date, and after the closing of a reverse merger, then the outstanding principal amount&nbsp;&nbsp;of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities sold in the common stock financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the common stock financing,</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(c)&nbsp;&nbsp;&nbsp;in the event of a preferred stock financing after the Company&#x2019;s Board of Directors&nbsp;&nbsp;(the &#x201C;Board&#x201D;) has determined&nbsp;&nbsp;that the Company&nbsp;&nbsp;should not pursue the proposed&nbsp;&nbsp;reverse merger with Alliqua BioMedical, Inc. or that such reverse merger is not viable, then in connection&nbsp;&nbsp;with the preferred stock financing the conversion price shall equal eighty percent (80%) of the cash price paid per share for the preferred securities by the investors in the preferred stock financing;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(d)&nbsp;&nbsp;&nbsp;if the Company&nbsp;&nbsp;consummates&nbsp;&nbsp;a change of control while the Notes remain outstanding, the Company&nbsp;&nbsp;shall repay the holders in cash in an amount&nbsp;&nbsp;equal to 200% of the outstanding principal amount&nbsp;&nbsp;of the Notes; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(e)&nbsp;&nbsp;&nbsp;in the event the Company&nbsp;&nbsp;consummates&nbsp;&nbsp;an IPO on or before the maturity&nbsp;&nbsp;date, then the outstanding principal amount&nbsp;&nbsp;of the Notes and any unpaid accrued interest will automatically convert into common stock at a conversion price equal to the per share offering price to the public for common stock in the IPO.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Modified March 2018 and Modified September 2018 Notes were outstanding as of December 31, 2018, and had conversion and repayment&nbsp;&nbsp;rights as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(a)&nbsp;&nbsp;&nbsp;in the event that the Company&nbsp;&nbsp;issues and sells shares of its preferred stock to the investors on or before the maturity&nbsp;&nbsp;date, in a preferred stock financing, then the outstanding principal amount&nbsp;&nbsp;of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities sold in the qualified financing at a conversion price equal to 80% of the cash price paid per share for equity securities by the investors in the qualified financing;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(b)&nbsp;&nbsp;&nbsp;if the Company&nbsp;&nbsp;consummates&nbsp;&nbsp;a change of control while the Notes remain outstanding, the Company&nbsp;&nbsp;shall repay the holders in cash in an amount&nbsp;&nbsp;equal to 200% of the outstanding principal amount&nbsp;&nbsp;of the Notes; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(c)&nbsp;&nbsp;&nbsp;in the event the Company&nbsp;&nbsp;consummates&nbsp;&nbsp;an IPO on or before the maturity&nbsp;&nbsp;date, then the outstanding principal amount&nbsp;&nbsp;of the Notes and any unpaid accrued interest will automatically convert into common stock at a conversion price equal to the per share offering price to the public for common stock in the IPO.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(d)&nbsp;&nbsp;&nbsp;In October 2018, the Company&nbsp;&nbsp;modified the terms of the March 2018 and September 2018 Notes to add an additional conversion option.&nbsp;&nbsp;The additional conversion option stipulated&nbsp;&nbsp;that if the Company&nbsp;&nbsp;consummates&nbsp;&nbsp;a reverse merger on or before the Maturity Date and prior to a Qualified Financing&nbsp;&nbsp;(as such terms are defined in the Notes Agreement), then the outstanding principal amount&nbsp;&nbsp;of the Notes and any unpaid accrued interest, shall automatically convert in whole without any further action by the Holder into shares of the Company&#x2019;s Series B convertible preferred stock at a conversion price equal to $0.3133 per share immediately prior to the closing of the reverse merger.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In October 2018, the Company&nbsp;&nbsp;determined&nbsp;&nbsp;that the modification&nbsp;&nbsp;of the March 2018 and September 2018 Notes adding the additional conversion right upon a reverse merger was a &#x201C;substantial modification&#x201D; as outlined in ASC 470-50 </font><font style="display:inline;font-style:italic;">&#x2018;Debt: Modifications and Extinguishments&#x2019;</font><font style="display:inline;"> and treated this modification&nbsp;&nbsp;as an extinguishment&nbsp;&nbsp;of the original Notes and recognized an $11,000 gain from debt extinguishment&nbsp;&nbsp;in its statement&nbsp;&nbsp;of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Derivative Liability</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;evaluated its Notes and determined&nbsp;&nbsp;that embedded components&nbsp;&nbsp;relating to conversion and redemption features of those contracts&nbsp;&nbsp;qualified as derivatives, which need to be separately accounted for in accordance&nbsp;&nbsp;with ASC 815. The Notes contained&nbsp;&nbsp;embedded features that are required to be bifurcated as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(1)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"></font>On or before the maturity&nbsp;&nbsp;date of the March 2018 and September 2018 notes, the principal and accrued interest of the notes will automatically convert into equity securities issued and sold in the initial closing of the Company&#x2019;s next qualified equity financing with gross proceeds of at least $5.0 million, exclusive of the conversion of the notes. The number of shares to be issued to the note holders will be equal to dividing the outstanding principal and any unpaid accrued interest by 80% of the price paid per share of the next equity security sold to investors. The discount in share price to note holders is not considered clearly and closely related to the debt host and results in an embedded derivative that must be bifurcated&nbsp;&nbsp;and accounted&nbsp;&nbsp;for separately from the debt host.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(2)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"></font>For all Notes, in the event of a change in control prior to repayment,&nbsp;&nbsp;the outstanding principal and unpaid accrued interest will be repaid in cash, plus a repayment&nbsp;&nbsp;premium equal to 100% of the outstanding principal at the time of the change in control. Change in control means (i) a merger, consolidation, or other capital reorganization or business combination transaction of the Company,&nbsp;&nbsp;with or into, another&nbsp;&nbsp;corporation after which the shares of the capital stock represent a minority after the close of the transaction, or (ii) any transaction or series of related transactions to which the Company&nbsp;&nbsp;is a party in which in excess of 50% of the Company&#x2019;s voting power is transferred, or (iii) the sale of all or substantially&nbsp;&nbsp;all of the Company&#x2019;s assets or the exclusive license of all or substantially&nbsp;&nbsp;all of the Company&#x2019;s material intellectual property.&nbsp;&nbsp;The premium to note holders is not considered clearly and closely related to the debt host and results in an embedded derivative that must be bifurcated&nbsp;&nbsp;and accounted&nbsp;&nbsp;for separately from the debt host.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(3)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"></font>For the December 2018 Notes, in the event the Company&#x2019;s Board of Directors&nbsp;&nbsp;has determined&nbsp;&nbsp;the proposed&nbsp;&nbsp;reverse merger should not be pursued or is not viable, then in connection&nbsp;&nbsp;with the closing of a preferred stock financing with gross proceeds of at least $5.0 million exclusive of the conversion of the notes, the conversion price shall equal 80% of the cash price paid per share for the securities in the preferred stock financing. However, if any of the holder&#x2019;s shares of preferred stock of the Company&nbsp;&nbsp;are converted into common stock or any other equity security that is junior to the shares issued in the preferred stock financing, the notes shall not convert into equity securities sold in the preferred stock financing without the holder&#x2019;s prior written consent and instead shall remain outstanding. The discount in share price to note holders is not considered clearly and closely related to the debt host and results in an embedded derivative that must be bifurcated&nbsp;&nbsp;and accounted&nbsp;&nbsp;for separately from the debt host.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Accordingly, upon the issuance of the March 2018 Notes, the estimated fair value of the embedded derivative was determined&nbsp;&nbsp;using a bond plus option valuation&nbsp;&nbsp;model and assuming a probability of 30% that a qualified financing would occur and a probability of 15% that a change in control would occur. The Company&nbsp;&nbsp;recorded the estimated fair value of these embedded derivatives as a liability of $496,000 with an offsetting amount&nbsp;&nbsp;recorded as debt discount,&nbsp;&nbsp;which offsets the carrying amount&nbsp;&nbsp;of the debt. The debt discount is amortized&nbsp;&nbsp;over the debt&#x2019;s expected term of one year.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Upon the issuance of the September 2018 Notes, the estimated fair value of the embedded derivatives was determined&nbsp;&nbsp;using a bond plus option valuation&nbsp;&nbsp;model and assuming a probability of 40% that a qualified financing would occur and a zero probability that a change in control would occur. The Company recorded the estimated fair value of these embedded derivatives as a liability of $368,000 with an offsetting amount&nbsp;&nbsp;recorded as debt discount,&nbsp;&nbsp;which offsets the carrying amount&nbsp;&nbsp;of the debt. The debt discount is amortized&nbsp;&nbsp;over the debt expected term of one year.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In October 2018, the Company&nbsp;&nbsp;modified the March 2018 and September 2018 Notes by adding an additional conversion right upon a reverse merger. The Company&nbsp;&nbsp;deemed this modification&nbsp;&nbsp;to be a </font><font style="display:inline;font-style:italic;">&#x201C;substantial modification&#x201D;</font><font style="display:inline;"> as defined in ASC 470-50 </font><font style="display:inline;font-style:italic;">&#x2018;Debt: Modifications and Extinguishments&#x2019;</font><font style="display:inline;"> and treated it as an extinguishment&nbsp;&nbsp;of the original Notes and the termination of the related derivative liability. The extinguishment&nbsp;&nbsp;of the March 2018 and September 2018 Notes, resulted in a net gain of $11,000 being recorded in other income due to the expensing of the unamortized debt discount of $641,000 and the release of the then fair value of the derivative liabilities of $653,000. As of December 31, 2018, the Company&nbsp;&nbsp;evaluated the fair value of the derivative liability associated with the modified March 2018, modified September 2018 and December 2018 Notes. It determined&nbsp;&nbsp;that the bifurcated&nbsp;&nbsp;derivative liability had no value because the Company&nbsp;&nbsp;assumed a zero probability that a qualified financing would occur if the then planned reverse merger was not consummated and a zero probability that a change in control would occur. As a result, the Company&nbsp;&nbsp;estimated the fair value of the derivative liability to be $0 at December 31, 2018.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">For the years ended December 31, 2017, and 2018, the Company&nbsp;&nbsp;had recorded interest expense for debt discount on these Notes of $0 and $223,000, respectively.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799606720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.</div>&nbsp;Redeemable Convertible Preferred Stock </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>Private Adynxx had<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,034,548</div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div> shares of Series A convertible preferred stock issued and outstanding, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,833,387</div></div> shares of Series B convertible preferred stock issued and outstanding. During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019,</div> prior to the Merger, an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">367,041</div> shares were issued upon conversion of convertible notes described in <div style="display: inline; font-style: italic;">&#x2018;Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div> - Term Loans and Convertible Promissory Notes&#x2019;.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Upon the consummation of the Merger, all outstanding shares of Series A and Series B convertible preferred stock were cancelled and exchanged for shares of the Company&#x2019;s common stock. Following the Merger, Private Adynxx survived as a wholly-owned subsidiary of new Adynxx, Inc. and adopted a new certificate of incorporation with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div></div> shares of preferred stock authorized or outstanding. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000,000</div> shares of preferred stock authorized under its certificate of incorporation, as amended.</div></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6819738480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799473072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;" />
<div style="WIDTH: 100%;">
<table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Number&#160;of<br />
Options</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Weighted<br />
Average<br />
Exercise<br />
Price</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Weighted&#160;Average&#160;Remaining<br />
Life&#160;In&#160;Years</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Intrinsic<br />
Value</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">Outstanding, December&#160;31, 2018</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
690</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
2.76</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">Alliqua options assumed in Merger</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">58</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right;" valign="bottom" colspan="2" nowrap="nowrap">
<div style="FLOAT: left;"></div>
289.76</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">Exercised</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">&#8212;</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">&#8212;</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">Cancelled</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">&#8212;</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">&#8212;</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">Outstanding, June&#160;30, 2019</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
748</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
24.95</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 25%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
6.2</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
188</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">Exercisable, June&#160;30, 2019</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
530</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
33.93</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 25%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
5.7</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.86%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
188</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.86%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>

</table>
</div>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;">&#160;</p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;" />
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%; TEXT-INDENT: 20pt;" />
<div style="WIDTH: 100%;">
<table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" align="center">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 35.76%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="9">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #231f20; DISPLAY: inline;">Outstanding Options</font></p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Weighted-</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Weighted-</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Average</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Average</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Remaining</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Shares</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Exercise</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Contractual</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Aggregate</font></p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Available</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Options</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Price</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Life</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Intrinsic</font></p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">&#160;&#160;&#160;&#160;</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">For&#160;Grant</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">&#160;&#160;&#160;&#160;</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Outstanding</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">&#160;&#160;&#160;&#160;</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Per&#160;Share</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">&#160;&#160;&#160;&#160;</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">(in&#160;years)</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.3%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Value</font><font style="FONT-SIZE: 4pt; POSITION: relative; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline; LINE-HEIGHT: 100%; TOP: -3.2pt;">(a)</font></p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">Balance at December 31, 2016</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">5</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
19,222</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">$</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">0.10</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">9.4</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">&#160;&#160;</font></p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">Balance at December 31, 2017</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">5</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap">19,222</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
0.10</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">8.4</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">$</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">6,639</font></p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">Balance at December 31, 2018</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">5</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
19,222</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
0.10</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">7.4</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">$</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">6,956</font></p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">Vested and expected to vest as of December 31, 2018</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #231f20; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
19,222</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
0.10</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">7.4</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">$</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">6,956</font></p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">Exercisable at December 31, 2018</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #231f20; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
11,146</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
0.09</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">7.4</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">$</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">4,119</font></p>
</td>
</tr>

</table>
</div>
<div>
<hr style="BORDER-LEFT-WIDTH: 0px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 25%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000;" align="left" /></div>
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 1pt; COLOR: #000000; DISPLAY: inline;">&#8203;</font></p>
<div style="WIDTH: 100%;">
<table style="text-align:left;WIDTH: 100%; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 0pt;">
<p style="FONT-SIZE: 0pt; WIDTH: 0pt;" />
</td>
<td style="WIDTH: 18pt;" valign="top" align="left">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%;">(a)</font></p>
</td>
<td style="WIDTH: 0pt;">
<p style="FONT-SIZE: 0pt; WIDTH: 0pt;" />
</td>
<td valign="top" align="left">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company&#8217;s common stock of $0.46 and $0.44 per share as of December&#160;31, 2018 and 2017.</font></p>
</td>
</tr>

</table>
</div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;WIDTH: 100%;">
<table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 36.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 22.5%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="3">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Options&#160;Outstanding</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 35%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="5">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Options&#160;Exercisable</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 36.5%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Range&#160;of&#160;Exercise&#160;Price</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Weighted Average Exercise Price</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Outstanding Number of Options</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Weighted Average Exercise Price</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Weighted Average Remaining Life In Years</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Exercisable Number of Options</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">$1.11 &#8212; $1.38</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;">$</div>
1.11</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">73</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;">$</div>
1.11</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
2.5</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">73</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">1.39 &#8212; 3.05</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">1.39</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">37</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">1.39</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
3.2</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">37</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">3.06 &#8212; 20.99</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">3.06</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">580</font>&#160;&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">3.06</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
7.5</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">362</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">21.00 &#8212; 656.40</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">289.81</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">58</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">289.81</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
0.7</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">58</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="top" nowrap="nowrap">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;24.95</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">748</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;">$</div>
24.76</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
5.7</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">530</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>

</table>
</div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6808965296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; "> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%; border-bottom: 1px solid rgb(0, 0, 0); padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Period ending December 31</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); width: 0%; padding: 0px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Future Commitments</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 0%; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019 (remaining 6 months)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">232</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">227</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">232</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">236</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total future minimum lease payments</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,007</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(167</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 0px 2px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div>
<span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Future</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Year ending December 31</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Commitments</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 239</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 239</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6827987664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Commitments and Contingencies - Future Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details', window );"><strong>Note 6 - Commitments and Contingencies - Future Lease Payments (Details)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019 (remaining 6 months)</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_statement-statement-note-6-commitments-and-contingencies-future-lease-payments-details</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6804877456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Deficit - Shares Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock options issued and outstanding (in shares)</a></td>
<td class="nump">19,222<span></span>
</td>
<td class="nump">19,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_EquitySharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">127,294<span></span>
</td>
<td class="nump">127,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsReserveForSeriesAConvertiblePreferredStockMember', window );">Warrants Reserve for Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">330,000<span></span>
</td>
<td class="nump">330,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance', window );">Series A convertible preferred stock (in shares)</a></td>
<td class="nump">56,673,000<span></span>
</td>
<td class="nump">56,673,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion Of Stock Shares Issued1</a></td>
<td class="nump">11,335<span></span>
</td>
<td class="nump">11,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance', window );">Series A convertible preferred stock (in shares)</a></td>
<td class="nump">51,069,000<span></span>
</td>
<td class="nump">51,069,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion Of Stock Shares Issued1</a></td>
<td class="nump">10,214<span></span>
</td>
<td class="nump">10,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_EquitySharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of equity shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_EquitySharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of nonredeemable convertible preferred shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsReserveForSeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsReserveForSeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6803892816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Warrants - Warrants Assumptions (Details) - Warrants for Series A Convertible Preferred Stock [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 01, 2010</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Risk-free interest rate</a></td>
<td class="nump">2.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Risk-free interest rate</a></td>
<td class="nump">2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Risk-free interest rate</a></td>
<td class="nump">6.92<span></span>
</td>
<td class="nump">7.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Risk-free interest rate</a></td>
<td class="nump">7.08<span></span>
</td>
<td class="nump">8.08<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Risk-free interest rate</a></td>
<td class="nump">76.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799757328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableOneMember', window );">Convertible Note Payable, One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Mar. 29,  2019<span></span>
</td>
<td class="text">Mar. 29,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableTwoMember', window );">Convertible Note Payable Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Sep. 27,  2019<span></span>
</td>
<td class="text">Sep. 27,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableThreeMember', window );">Convertible Note Payable, Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Dec. 21,  2019<span></span>
</td>
<td class="text">Dec. 21,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ConvertibleNotePayableThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6701194880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Other Balance Sheet Information - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_AccruedPayrollAndRelatedExpensesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_AccruedTermLoanPaymentsCurrent', window );">Accrued term loan final payment</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expense</a></td>
<td class="nump">8<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees and other costs</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 1,480<span></span>
</td>
<td class="nump">$ 857<span></span>
</td>
<td class="nump">$ 1,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trail expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_AccruedPayrollAndRelatedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for payroll and related expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_AccruedPayrollAndRelatedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_AccruedTermLoanPaymentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued term loan payments. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_AccruedTermLoanPaymentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6820740560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Reverse Merger (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 29, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 03, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 21, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_NumberOfSharesHeldByEquityHolders', window );">Number of Shares Held by Equity Holders | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,936,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt Instrument, Convertible, Beneficial Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=adyx_AlliquaBiomedicalIncMember', window );">Alliqua Biomedical, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends, Total</a></td>
<td class="nump">$ 5,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common Stock, Dividends, Per Share, Cash Paid | $ / shares</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=adyx_AquaMedMember', window );">AquaMed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_CommonStockStockDividendsPerShareBookValue', window );">Common Stock, Stock Dividends, Per Share, Book Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=adyx_ReverseStockSplitFromMember', window );">Reverse Stock Split From [Member] | Alliqua Biomedical, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember', window );">Alliqua Biomedical, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_BusinessAcquisitionExchangeRatio', window );">Business Acquisition, Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible Assets, Net (Including Goodwill), Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer', window );">Merger Agreement, Percentage Ownership in Combined Company, Acquirer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree', window );">Merger Agreement, Percentage Ownership in Combined Company, Acquiree</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember', window );">Alliqua Biomedical, Inc. [Member] | Conversion of Notes into Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtConversionOriginalDebtAmountPrincipal', window );">Debt Conversion, Original Debt, Amount, Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest', window );">Debt Conversion, Original Debt, Amount, Cumulative Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,041<span></span>
</td>
<td class="nump">367,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt Instrument, Convertible, Beneficial Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_BusinessAcquisitionExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares that will be given to existing shareholders of a company that has been acquired or that has merged with another.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_BusinessAcquisitionExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_CommonStockStockDividendsPerShareBookValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The book value amount of stock dividends of common stock, per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_CommonStockStockDividendsPerShareBookValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative accrued interest portion of the amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtConversionOriginalDebtAmountPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The principal portion of the amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtConversionOriginalDebtAmountPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the acquiree's percentage ownership in the combined company immediately following a merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the acquirer's percentage ownership in the combined company immediately following a merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_NumberOfSharesHeldByEquityHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares held by equity holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_NumberOfSharesHeldByEquityHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=adyx_AlliquaBiomedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=adyx_AlliquaBiomedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=adyx_AquaMedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=adyx_AquaMedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=adyx_ReverseStockSplitFromMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=adyx_ReverseStockSplitFromMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6820509248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,138,000)<span></span>
</td>
<td class="num">$ (2,946,000)<span></span>
</td>
<td class="num">$ (5,985,000)<span></span>
</td>
<td class="num">$ (11,561,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">168,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
<td class="nump">301,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrant liability</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Changes in fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(60,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB', window );">Accretion of final charge upon maturity of Oxford Term Loan A and B</a></td>
<td class="nump">148,000<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
<td class="nump">224,000<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of issuance cost and discounts for term loans and convertible notes</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense on convertible promissory notes</a></td>
<td class="nump">2,304,000<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_NoncashPortionOfLeaseExpense', window );">Non-cash operating lease cost</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,611,000)<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,255,000<span></span>
</td>
<td class="num">(607,000)<span></span>
</td>
<td class="num">(212,000)<span></span>
</td>
<td class="nump">601,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">475,000<span></span>
</td>
<td class="num">(312,000)<span></span>
</td>
<td class="num">(650,000)<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_IncreaseDecreaseInLeaseLiability', window );">Lease liability</a></td>
<td class="num">(136,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,223,000)<span></span>
</td>
<td class="num">(3,527,000)<span></span>
</td>
<td class="num">(6,019,000)<span></span>
</td>
<td class="num">(10,183,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromProductiveAssets', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on term loan</a></td>
<td class="num">(1,437,000)<span></span>
</td>
<td class="num">(616,000)<span></span>
</td>
<td class="num">(890,000)<span></span>
</td>
<td class="num">(139,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of convertible promissory notes - related party</a></td>
<td class="nump">3,996,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,559,000<span></span>
</td>
<td class="nump">884,000<span></span>
</td>
<td class="nump">3,610,000<span></span>
</td>
<td class="num">(59,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(1,664,000)<span></span>
</td>
<td class="num">(2,643,000)<span></span>
</td>
<td class="num">(2,414,000)<span></span>
</td>
<td class="num">(10,245,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">1,942,000<span></span>
</td>
<td class="nump">4,356,000<span></span>
</td>
<td class="nump">4,356,000<span></span>
</td>
<td class="nump">14,601,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">278,000<span></span>
</td>
<td class="nump">1,713,000<span></span>
</td>
<td class="nump">1,942,000<span></span>
</td>
<td class="nump">4,356,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Other supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">173,000<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">$ 376,000<span></span>
</td>
<td class="nump">$ 355,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations(1)</a></td>
<td class="nump">227,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ReclassificationOfWarrantLiabilityToPaidInCapital', window );">Reclassification of warrant liability to paid in capital</a></td>
<td class="nump">234,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="nump">$ 34,015,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accretion of final charge upon maturity of Oxford term loan A and B.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_AccretionOfChargeUponMaturityOfOxfordTermLoanAAndB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_NoncashPortionOfLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the noncash portion of the operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_NoncashPortionOfLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ReclassificationOfWarrantLiabilityToPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reclassification of warrant liabilities to paid in capital as a result of a merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ReclassificationOfWarrantLiabilityToPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6807181824">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock Options - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, outstanding (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,222<span></span>
</td>
<td class="nump">19,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, exercised (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercised (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, cancelled (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, cancelled (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">748,000<span></span>
</td>
<td class="nump">19,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, outstanding (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24.95<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life in Years, outstanding (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 73 days<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 6,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Vested and expected to vest (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Life, Vested and expected to vest (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, exercisable (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">530,000<span></span>
</td>
<td class="nump">19,222,032<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercisable (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33.93<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life in Years, exercisable (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years 255 days<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value, exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 4,119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available For Grant, Balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember', window );">Alliqua Biomedical, Inc. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, outstanding (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,449.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company's common stock of $0.46 and $0.44 per share as of December 31, 2018 and 2017.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799467120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Related-party Transactions (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>May 03, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Severance Pay [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="nump">$ 1,091,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes Payable, Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=adyx_SeverancePayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=adyx_SeverancePayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6819081040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 1,887,000<span></span>
</td>
<td class="nump">$ 4,301,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">254,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,622,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">1,952,000<span></span>
</td>
<td class="nump">4,335,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,703,000<span></span>
</td>
<td class="nump">1,980,000<span></span>
</td>
<td class="nump">4,421,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,748,000<span></span>
</td>
<td class="nump">491,000<span></span>
</td>
<td class="nump">703,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">1,480,000<span></span>
</td>
<td class="nump">857,000<span></span>
</td>
<td class="nump">1,158,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible promissory notes - related party</a></td>
<td class="nump">5,497,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of term loan, net of discount</a></td>
<td class="nump">2,390,000<span></span>
</td>
<td class="nump">3,812,000<span></span>
</td>
<td class="nump">1,711,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,461,000<span></span>
</td>
<td class="nump">9,660,000<span></span>
</td>
<td class="nump">3,572,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan, net of current portion and discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,951,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 1,000,000 shares authorized no shares issued or outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 95,000,000 shares authorized, 5,807,877 shares issued and outstanding at June 30, 2019 (unaudited) 148,000,000 shares authorized, 701,808 shares issued and outstanding at December 31, 2018</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">35,160,000<span></span>
</td>
<td class="nump">747,000<span></span>
</td>
<td class="nump">419,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(44,417,000)<span></span>
</td>
<td class="num">(37,279,000)<span></span>
</td>
<td class="num">(31,294,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(9,251,000)<span></span>
</td>
<td class="num">(36,531,000)<span></span>
</td>
<td class="num">(30,855,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock and stockholders' deficit</a></td>
<td class="nump">2,703,000<span></span>
</td>
<td class="nump">1,980,000<span></span>
</td>
<td class="nump">4,421,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmountAbstract', window );"><strong>Redeemable convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,814,000<span></span>
</td>
<td class="nump">12,814,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmountAbstract', window );"><strong>Redeemable convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15,897,000<span></span>
</td>
<td class="nump">$ 15,897,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adyx_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adyx_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799814816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Related-party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Note 11.&nbsp;&nbsp;&nbsp;Related-Party Transactions </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">At June&nbsp;30, 2019, the Company had $5.5&nbsp;million aggregate principal amount of outstanding convertible notes issued to a significant shareholder. &#x2018;</font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Note 6&#x2009;&#x2014;&#x2009;Term Loans and Convertible Promissory Notes&#x2019;</font><font style="display:inline;color:#000000;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In connection with the Merger, Alliqua&#x2019;s existing CEO resigned from the company and received severance pay of&#x2009; $1,091,000. As such amounts were accrued by Alliqua prior to the Merger, this severance payment had no impact to our condensed consolidated statement of operations for six&nbsp;months ended June&nbsp;30, 2019.</font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#231F20;">Note&nbsp;</font><font style="display:inline;">11.&nbsp;&nbsp;&nbsp;Related-Party Transactions</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In March 2018, September 2018, and December 2018, the Company&nbsp;&nbsp;issued Notes to the Company&#x2019;s majority investors totaling&nbsp;$4.5 million as of December 31, 2018. These Notes accrue simple interest on the outstanding principal amount&nbsp;&nbsp;at the rate of&nbsp;8%&nbsp;per annum.&nbsp;&nbsp;As of December 31, 2018, accrued interest on the Notes was&nbsp;$126,000&nbsp;&#x2014; for further details see the section above titled </font><font style="display:inline;font-style:italic;">&#x2018;Note 5 &#x2014; Term Loans and Convertible Promissory Notes&#x2019;</font><font style="display:inline;">.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799423392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; "> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">As of December 31, 2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1 </div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2 </div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3 </div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total </div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Financial liabilities</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Warrant liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total financial liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div>
<span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:49.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">As of December 31, 2017&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Level 1</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Level 2</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Level 3</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Financial liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Warrant liability </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Total financial liabilities </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:49.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">As of December 31, 2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Financial liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Level 1</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Level 2</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Level 3</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Warrant liability </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Total financial liabilities </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Fair value, beginning of period</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Change in fair value of preferred stock warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Exchange of warrants upon Merger</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(234
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Fair value at end of period</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:20.15pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:70.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Fair value, beginning of period</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Embedded derivative liability from the issuance of Notes</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>496
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Change in value of embedded derivatives</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(60
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Fair value at end of period</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>436
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="middle" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Years Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="middle" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Fair value, beginning of period&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 54</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Preferred stock warrants &#x2013; exercised </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (8)</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Change in fair value of preferred stock warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (4)</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 98</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Fair value at end of period&nbsp;&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 42</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="middle" style="width:20.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Years Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="middle" style="width:20.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Fair value, beginning of period </font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$ &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Embedded derivative liability from the issuance of Notes&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 864</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Change in value of embedded derivatives&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (211)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Termination of the embedded derivative liability due to the extinguishment&nbsp;&nbsp;of the related Notes</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> (653)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Fair value at end of period </font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799536096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Term Loans and Convertible Promissory Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">Year Ending, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Total principal payments</font></p>
				</td>
				<td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 3,833</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Debt [Table Text Block]</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">June&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Convertible note payable, due on March&nbsp;29, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,500
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Convertible note payable, due on September&nbsp;27, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,500
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Convertible note payable, due on December&nbsp;21, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,500
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,500
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Convertible note payable, due on March&nbsp;29, 2020</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,500
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Convertible note payable, due on April&nbsp;26, 2020</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,000
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Convertible note payable, due on May&nbsp;29, 2020</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>500
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,500
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,500
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table>
</div>
<span></span>
</td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">As of December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Convertible&nbsp;&nbsp;note payable, due on March 29, 2019, interest at 8.0% p.a</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 1,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Convertible&nbsp;&nbsp;note payable, due on September 27, 2019, interest at 8.0% p.a</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 1,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Convertible&nbsp;&nbsp;note payable, due on December 21, 2019, interest at 8.0% p.a</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 1,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Total&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 4,500</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6819744480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Basis of Presentation (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 03, 2019</div></th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 1,887,000<span></span>
</td>
<td class="nump">$ 4,301,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,417,000)<span></span>
</td>
<td class="num">$ (37,279,000)<span></span>
</td>
<td class="num">$ (31,294,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member] | First Note to Fund the Company's Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member] | Second Note to Fund the Company's Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member] | Notes to Fund the Company's Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adyx_OxfordFinanceLLCMember', window );">Oxford Finance, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=adyx_ReverseStockSplitFromMember', window );">Reverse Stock Split From [Member] | Alliqua Biomedical, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember', window );">Alliqua Biomedical, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_BusinessAcquisitionExchangeRatio', window );">Business Acquisition, Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_BusinessAcquisitionExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares that will be given to existing shareholders of a company that has been acquired or that has merged with another.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_BusinessAcquisitionExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_FirstNoteToFundTheCompanysOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_FirstNoteToFundTheCompanysOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_SecondNoteToFundTheCompanysOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_SecondNoteToFundTheCompanysOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_NotesToFundTheCompanysOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_NotesToFundTheCompanysOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adyx_OxfordFinanceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adyx_OxfordFinanceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=adyx_ReverseStockSplitFromMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=adyx_ReverseStockSplitFromMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=adyx_AlliquaBiomedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=adyx_AlliquaBiomedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6600060640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Stockholders Equity [Table Text Block]</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:70.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56,673
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56,673
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Series&nbsp;B convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51,069
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51,069
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Warrants for Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Common stock options issued and outstanding</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,222
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,222
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,294
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,294
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table>

</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799428672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock Options<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payment Arrangement [Text Block]</a></td>
<td class="text"><div>
<div>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Note 10.&#160;&#160;&#160;Stock Options</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;">On May&#160;3, 2019, in connection with the closing of the Merger, each outstanding Private Adynxx stock option, whether vested or unvested, was converted into a stock option to purchase shares of the Company&#8217;s common stock at the Exchange Ratio and, as a result, the Company issued options to purchase an aggregate of 690,058 shares of the Company&#8217;s common stock at exercise prices ranging from $1.11 to $3.06 per share.</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;">Additionally, at the date of the Merger, Alliqua had outstanding employee options to purchase an aggregate of 57,822 shares of the post-Merger Company&#8217;s common stock at exercise prices ranging from $21.00 to $656.40 per share to former Alliqua option holders that were assumed as part of the merger. All Alliqua employees were terminated in connection with the Merger; however, such options have provisions that extend the expiration date beyond the employees&#8217; termination date.</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;">A summary of the Company&#8217;s stock option activity during the six&#160;months ended June&#160;30, 2019 is as follows (in thousands, except exercise prices):</font></p>
<div style="WIDTH: 100%;">
<table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Number&#160;of<br />
Options</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Weighted<br />
Average<br />
Exercise<br />
Price</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Weighted&#160;Average&#160;Remaining<br />
Life&#160;In&#160;Years</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Intrinsic<br />
Value</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">Outstanding, December&#160;31, 2018</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
690</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
2.76</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">Alliqua options assumed in Merger</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">58</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right;" valign="bottom" colspan="2" nowrap="nowrap">
<div style="FLOAT: left;"></div>
289.76</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">Exercised</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">&#8212;</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">&#8212;</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">Cancelled</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">&#8212;</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">&#8212;</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 25%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">Outstanding, June&#160;30, 2019</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
748</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
24.95</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 25%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
6.2</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
188</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">Exercisable, June&#160;30, 2019</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 12%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
530</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.88%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
33.93</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 25%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
5.7</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1.12%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10.86%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
188</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 28%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 12%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.88%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 25%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.12%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10.86%; BORDER-BOTTOM: #000000 2pt double; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>

</table>
</div>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;">&#160;</p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;">A summary of the Company&#8217;s stock options as of June&#160;30, 2019 is as follows (in thousands, except exercise prices):</font></p>
<div style="WIDTH: 100%;">
<div style="WIDTH: 100%;">
<table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 36.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 2.5%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 22.5%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="3">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Options&#160;Outstanding</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 35%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="5">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Options&#160;Exercisable</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 36.5%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 10.1pt; LINE-HEIGHT: 100%; TEXT-INDENT: -10.1pt;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Range&#160;of&#160;Exercise&#160;Price</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Weighted Average Exercise Price</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Outstanding Number of Options</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Weighted Average Exercise Price</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Weighted Average Remaining Life In Years</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; DISPLAY: inline;">Exercisable Number of Options</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">$1.11 &#8212; $1.38</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;">$</div>
1.11</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">73</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;">$</div>
1.11</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
2.5</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">73</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">1.39 &#8212; 3.05</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">1.39</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">37</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">1.39</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
3.2</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">37</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">3.06 &#8212; 20.99</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">3.06</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">580</font>&#160;&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">3.06</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
7.5</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">362</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">21.00 &#8212; 656.40</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">289.81</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">58</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">289.81</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
0.7</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">58</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="top">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="top" nowrap="nowrap">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;24.95</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">748</font></p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;">$</div>
24.76</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 10%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
5.7</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 10%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; DISPLAY: inline;">530</font></p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;">
<td style="WIDTH: 36.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="top">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 2.5%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="WIDTH: 1%; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>

</table>
</div>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;">&#160;</p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;">The Company did not grant any stock options to employees during the six months ended June 30, 2019. Stock-based compensation expense recorded in research and development and general and administrative expenses was $150,000 and $136,000 for the six months ended June 30, 2018 and 2019, respectively. As of June 30, 2019, unrecognized stock-based compensation expense related to employees totaled approximately $395,000, which is expected to be recognized over approximately 1.5 years.</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;">Stock-based compensation expense recorded in exchange for services related to non-employee options was $0 and $32,000 for the six months ended June 30, 2018 and 2019, respectively. As of June 30, 2019, unrecognized stock-based compensation expense related to unvested non-employees stock options was approximately $16,000, which is expected to be recognized over a weighted-average period of three months.</font></p>
</div>
</div>
</div><span></span>
</td>
<td class="text"><div>
<div>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%;"><font style="FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Note 9.&#160;&#160;&#160;Stock Option Plans</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="COLOR: #000000; DISPLAY: inline;">In December&#160;2010, the Company adopted the 2010 Equity Incentive Plan (the &#8220;Plan&#8221;). The Plan provides for the granting of stock options to employees and consultants of the Company. Options granted under the Plan may be either incentive stock options (&#8220;ISOs&#8221;) or non-qualified stock options (&#8220;NSOs&#8221;). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants. The Company has 19,222,032 shares of common stock reserved for issuance under the Plan as of December&#160;31, 2018.</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="COLOR: #000000; DISPLAY: inline;">Options under the Plan may be granted for periods of up to 10&#160;years and at prices no less than 100% of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the Board of Directors provided, however, that the exercise price of an ISO and NSO granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. The Plan requires that options be exercised no later than 10&#160;years after the grant. Options granted to employees generally vest ratably on a monthly basis over four&#160;years.</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="COLOR: #000000; DISPLAY: inline;">The following table summarizes stock option activity under the Company&#8217;s stock plan and related information (in thousands, except exercise prices and&#160;years):</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%; TEXT-INDENT: 20pt;" />
<div style="WIDTH: 100%;">
<table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" align="center">

<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="OVERFLOW: hidden; FONT-SIZE: 0pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;" />
</td>
</tr>
<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 35.76%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="9">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #231f20; DISPLAY: inline;">Outstanding Options</font></p>
</td>
</tr>
<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Weighted-</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Weighted-</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Average</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Average</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Remaining</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
</tr>
<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Shares</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Exercise</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Contractual</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Aggregate</font></p>
</td>
</tr>
<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Available</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Options</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Price</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Life</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Intrinsic</font></p>
</td>
</tr>
<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">&#160;&#160;&#160;&#160;</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">For&#160;Grant</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">&#160;&#160;&#160;&#160;</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Outstanding</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">&#160;&#160;&#160;&#160;</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.34%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Per&#160;Share</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">&#160;&#160;&#160;&#160;</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">(in&#160;years)</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.3%; BORDER-BOTTOM: #000000 1pt solid; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom" colspan="2">
<p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Value</font><font style="FONT-SIZE: 4pt; POSITION: relative; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline; LINE-HEIGHT: 100%; TOP: -3.2pt;">(a)</font></p>
</td>
</tr>
<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">Balance at December 31, 2016</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">5</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
19,222</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">$</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">0.10</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">9.4</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">&#160;&#160;</font></p>
</td>
</tr>
<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">Balance at December 31, 2017</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">5</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap">19,222</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
0.10</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">8.4</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">$</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">6,639</font></p>
</td>
</tr>
<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">Balance at December 31, 2018</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; TEXT-ALIGN: center; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">5</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #000000 1pt solid; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
19,222</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
0.10</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">7.4</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">$</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">6,956</font></p>
</td>
</tr>
<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">Vested and expected to vest as of December 31, 2018</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #231f20; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
19,222</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
0.10</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">7.4</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">$</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">6,956</font></p>
</td>
</tr>
<tr style="padding:0;">
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 53.66%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">Exercisable at December 31, 2018</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 7.28%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; TEXT-ALIGN: right; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.8%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #231f20; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
11,146</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">$</font></p>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: #d9d9d9 1pt; FONT-FAMILY: Times New Roman,Times,serif; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.3%; BORDER-BOTTOM: #d9d9d9 1pt; COLOR: #000000; TEXT-ALIGN: right; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 3pt; BACKGROUND-COLOR: #cceeff;" valign="bottom" nowrap="nowrap">
<div style="FLOAT: left;"></div>
0.09</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.64%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 8.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">7.4</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 0.52%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;">&#160;</p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 1.04%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; MARGIN: 0pt 0pt 0.05pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">$</font></p>
</td>
<td style="BORDER-TOP: #d9d9d9 1pt; BORDER-RIGHT: #d9d9d9 1pt; WIDTH: 6.26%; BORDER-BOTTOM: #d9d9d9 1pt; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; BORDER-LEFT: #d9d9d9 1pt; PADDING-RIGHT: 0pt; BACKGROUND-COLOR: #cceeff;" valign="bottom">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #231f20; TEXT-ALIGN: right; MARGIN: 0pt 3pt 0.05pt 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #231f20; DISPLAY: inline;">4,119</font></p>
</td>
</tr>

</table>
</div>
<div>
<hr style="BORDER-LEFT-WIDTH: 0px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 25%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000;" align="left" /></div>
<p style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 1pt; COLOR: #000000; DISPLAY: inline;">&#8203;</font></p>
<div style="WIDTH: 100%;">
<table style="text-align:left;WIDTH: 100%;" cellspacing="0" cellpadding="0">

<tr style="padding:0;">
<td style="WIDTH: 0pt;">
<p style="FONT-SIZE: 0pt; WIDTH: 0pt;" />
</td>
<td style="WIDTH: 18pt;" valign="top" align="left">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%;">(a)</font></p>
</td>
<td style="WIDTH: 0pt;">
<p style="FONT-SIZE: 0pt; WIDTH: 0pt;" />
</td>
<td valign="top" align="left">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company&#8217;s common stock of $0.46 and $0.44 per share as of December&#160;31, 2018 and 2017.</font></p>
</td>
</tr>

</table>
</div>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="FONT-SIZE: 1pt; COLOR: #000000; DISPLAY: inline;">&#8203;</font><font style="COLOR: #000000; DISPLAY: inline;">The Company did not grant any common stock options to employees during the&#160;years ended December&#160;31, 2017 and 2018. Stock-based compensation expense recorded in research and development and general and administrative expenses was $301,000 and $293,000 for the&#160;years ended December&#160;31, 2017 and 2018, respectively. As of December&#160;31, 2018, unrecognized stock-based compensation expense related to employees totaled approximately $531,000, which is expected to be recognized over approximately 2.0&#160;years.</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; FONT-STYLE: italic; DISPLAY: inline;">Stock Options Granted to Non-Employees</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 20pt;"><font style="COLOR: #000000; DISPLAY: inline;">Stock-based compensation expense recorded in exchange for services related to non-employee options was $0 and $16,000 for the&#160;years ended December&#160;31, 2017 and 2018, respectively.</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman,Times,serif; MARGIN: 0pt; LINE-HEIGHT: 100%;"><font style="COLOR: #000000; DISPLAY: inline;">As of December&#160;31, 2018, unrecognized stock-based compensation expense related to unvested non-employees stock options was approximately $48,000, which is expected to be recognized over a weighted-average period of nine&#160;months.</font></p>
</div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799474080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#231F20;">Note&nbsp;</font><font style="display:inline;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued Liabilities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Accrued liabilities consist of the following (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">As of December 31,</font><font style="display:inline;font-family:Times New Roman;color:#231F20;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Payroll and related expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 273</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 241</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Accrued term loan final payment&nbsp;&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 197</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 421</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Accrued clinical trial expense&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 654</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Professional fees and other costs </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 34</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 195</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Total accrued liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 1,158</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 857</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799629680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Note 7.&nbsp;&nbsp;&nbsp;Leases </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Company leases office facilities under a non-cancelable operating lease agreement expiring on December&nbsp;31, 2019. The Company also leases a corporate office facility previously utilized by Alliqua through an operating lease agreement, located in Yardley, Pennsylvania that expires in 2023. Effective February&nbsp;1, 2019, this property has been subleased to The Pinnacle Health Group, Inc. through April&nbsp;20, 2023 and the Company receives monthly lease payments. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Future minimum payments under non-cancellable leases as of June&nbsp;30, 2019 are as follows (in thousands): </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Period ending December 31</font></p>
				</td>
				<td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Future Commitments</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;">2019 (remaining 6 months)</font></p>
				</td>
				<td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;"> 232</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;"> 227</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;">2021</font></p>
				</td>
				<td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;"> 232</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;">2022</font></p>
				</td>
				<td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;"> 236</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;">2023</font></p>
				</td>
				<td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;"> 80</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;">Total future minimum lease payments</font></p>
				</td>
				<td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;"> 1,007</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;">Less: imputed interest</font></p>
				</td>
				<td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;"> (167)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;color:#000000;font-size:10pt;"> 840</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Total operating lease expenses for the six&nbsp;months ended June&nbsp;30, 2018 and 2019 was $115,000 and $165,000, respectively, and are reflected in general and administrative expenses in the condensed consolidated statements of operations. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">As of June&nbsp;30, 2019, the Company had no leases that were classified as a financing lease. As of June&nbsp;30, 2019, the Company did not have additional operating and financing leases that have not yet commenced.&nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">During the six&nbsp;months ended June&nbsp;30, 2019, the Company recognized $42,000 of sublease income on its condensed consolidated statement of operations, which is recorded as an offset against general and administrative expenses. </font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799918896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019 (remaining 6 months)</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6829395648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Warrants (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 03, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 01, 2010</div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 24, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="num">$ (12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ExchangeOfWarrantsUponMerger', window );">Exchange of Warrants Upon Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember', window );">Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,810<span></span>
</td>
<td class="nump">197,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2276<span></span>
</td>
<td class="nump">$ 0.2276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants Not Settleable in Cash, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_PercentageOfNotePayablePrincipal', window );">Percentage of Note Payable Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ClassOfWarrantsOrRightExercisableTerm', window );">Class of Warrants or Right, Exercisable, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember', window );">Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember', window );">Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember', window );">Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0209<span></span>
</td>
<td class="nump">0.0207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember', window );">Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.686<span></span>
</td>
<td class="nump">0.687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember', window );">Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member] | Measurement Input, Conversion Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember', window );">Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Warrants For Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ClassOfWarrantsOrRightExercisableTerm', window );">Class of Warrants or Right, Exercisable, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Warrants For Series A Convertible Preferred Stock [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.92<span></span>
</td>
<td class="nump">7.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Warrants For Series A Convertible Preferred Stock [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.08<span></span>
</td>
<td class="nump">8.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Warrants For Series A Convertible Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Warrants For Series A Convertible Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Warrants For Series A Convertible Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Warrants For Series A Convertible Preferred Stock [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Warrants For Series A Convertible Preferred Stock [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Warrants For Series A Convertible Preferred Stock [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Warrants For Series A Convertible Preferred Stock [Member] | Measurement Input, Conversion Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantIssuedInConnectionWithTermLoanAAndBMember', window );">Warrant Issued In Connection With Term Loan A And B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="num">$ (12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_AlliquaWarrantsAssumedInMergerMember', window );">Alliqua Warrants Assumed in Merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding | shares</a></td>
<td class="nump">38,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_AlliquaWarrantsAssumedInMergerMember', window );">Alliqua Warrants Assumed in Merger [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 26.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_AlliquaWarrantsAssumedInMergerMember', window );">Alliqua Warrants Assumed in Merger [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 28.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember', window );">Alliqua Biomedical, Inc. [Member] | Warrant to Purchase Common Stock Converted in Merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="nump">11,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 6.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ExchangeOfWarrantsUponMerger', window );">Exchange of Warrants Upon Merger</a></td>
<td class="nump">$ 234,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ClassOfWarrantsOrRightExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of warrant exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ClassOfWarrantsOrRightExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ExchangeOfWarrantsUponMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of warrants upon their reclassification from liabilities to equity as a result of a merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ExchangeOfWarrantsUponMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_PercentageOfNotePayablePrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of notes payable principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_PercentageOfNotePayablePrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantIssuedInConnectionWithTermLoanAAndBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantIssuedInConnectionWithTermLoanAAndBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_AlliquaWarrantsAssumedInMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adyx_AlliquaWarrantsAssumedInMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchaseCommonStockConvertedInMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchaseCommonStockConvertedInMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6698732544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Note 2.&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Use of Estimates </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Actual results could differ from those estimates and such differences could be material to the Company&#x2019;s financial position and results of operations. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Significant estimates and assumptions include the valuation of equity instruments and equity-linked instruments, including the valuation of the Company&#x2019;s common stock and the valuation of the Company&#x2019;s common stock options for purposes of accounting for stock-based compensation, and accruals for clinical trials and the valuation allowances on deferred tax assets. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Concentration of Credit Risk and Other Risks and Uncertainties </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation insured limits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company&#x2019;s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company&#x2019;s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company&#x2019;s ability to attract and retain employees necessary to support its growth. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Company&#x2019;s postoperative pain reduction product candidate, brivoligide, is an oligonucleotide. The Company currently uses Nitto-Denko Avecia, Inc. (&#x201C;Avecia&#x201D;) as a single supplier for the brivoligide drug substance. There are currently a limited number of oligonucleotide manufacturers with commercial scale capabilities globally. While the Company intends to develop secondary sources for manufacturing of its drug candidates in the future, there can be no assurance that it will be able to do so on commercially reasonable terms, or at all. Any interruption in the supply of this key material could significantly delay the research and development process or increase the expenses for development and commercialization of the Company&#x2019;s product candidates. The quality of materials can be critical to the performance of a drug delivery technology. Therefore, the lack of a reliable source that provides a consistent supply of high quality materials would harm the Company. At June&nbsp;30, 2019, this vendor&#x2019;s activity was not material to total accounts payable. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">At December&nbsp;31, 2018, three vendors represented 52%, 26% and 15% of total accounts payable. Two of these vendors supported general and administrative activities, primarily associated with the Merger and next round of equity financing, which accounted for 67% of the total accounts payable. The remaining vendor supported clinical study activities. At June&nbsp;30, 2019, three vendors represented 26%, 22% and 17% of total accounts payable, respectively. Two of these vendors supported general and administrative activities associated with the Merger and the next round of equity financing, which accounted for 44% of the total accounts payable. The remaining supported clinical study activities. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Clinical Trial Accruals </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Company&#x2019;s clinical trial accruals are based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical trials on the Company&#x2019;s behalf. The Company accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, the Company modifies the estimates of accrued expenses accordingly. To date, the Company has had no significant adjustments to accrued clinical trial expenses. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Cash and Cash Equivalents </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Company considers all highly liquid investments purchased with a maturity of three&nbsp;months or less on the date of acquisition to be cash and cash equivalents. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Property and Equipment, Net </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line method over the estimated useful lives of the assets, generally three to five&nbsp;years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Impairment of Long-Lived Assets </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Company&#x2019;s long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. As of December&nbsp;31, 2018 and June&nbsp;30, 2019, the Company had not experienced any impairment losses on its long-lived assets. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Restricted Cash </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">At December 31, 2018 and June 30, 2019, the Company had $55,000 restricted and held by a bank as collateral for a letter of credit provided to the Company&#x2019;s facility landlord. In addition, as of June 30, 2019, the Company had $200,000 restricted from withdrawal and held by a bank in the form of a secured money market account as collateral for Oxford in conjunction with a debt amendment that occurred in January 2019. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Stock-Based Compensation </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Company uses the Black-Scholes option-pricing model (the &#x201C;Black-Scholes model&#x201D;) as the method for determining the estimated fair value of stock options. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Expected Term</font><font style="display:inline;color:#000000;font-size:10pt;">&#x2009;&#x2014; The expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Expected Volatility&#x2009;&#x2014; </font><font style="display:inline;color:#000000;font-size:10pt;">Expected volatility is estimated using comparable public companies&#x2019; volatility for similar terms. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Expected Dividend&#x2009;&#x2014; </font><font style="display:inline;color:#000000;font-size:10pt;">The Black-Scholes model calls for a single expected dividend yield as an input. Other than the dividend paid in connection with the Merger, the Company has never paid dividends and has no plans to pay dividends. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Risk-Free Interest Rate&#x2009;&#x2014; </font><font style="display:inline;color:#000000;font-size:10pt;">The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Research and Development </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, preclinical studies, clinical studies performed by contract research organizations (&#x201C;CROs&#x201D;), materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development costs, including clinical study costs, to expense when incurred. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Collaboration Agreement </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In June&nbsp;2018, the Company entered into a collaboration agreement with twoXAR, an artificial intelligence-driven drug discovery company, in order to identify potential product candidates for the treatment of endometriosis. In May&nbsp;2019, the Company made a collaboration initiation payment of $75,000, which was charged to research and development expenses for the six&nbsp;months ended June&nbsp;30, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In June&nbsp;2019, Adynxx received an initial set of candidate predictions from twoXAR. The Company has initiated a review of the potential products to determine if any are viable candidates for further research and development. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Grant Reimbursements </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In December&nbsp;2018, the Company received a Notice of Award from the National Institute on Drug Abuse (&#x201C;NIDA&#x201D;), part of the National Institutes of Health (&#x201C;NIH&#x201D;), to support the clinical development of its lead product candidate, brivoligide. NIH grants provide funds for certain types of expenditures in connection with research and development activities over a contractually defined period. The maximum funding expected to be available under this grant for qualified expenditures over the two-year period through December&nbsp;2020 is&#x2009;approximately $5.7&nbsp;million. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">On January&nbsp;1, 2019, the Company adopted Accounting Standards Update (ASU) 2018-08, &#x201C;Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.&#x201D; Based on this guidance, the Company determined that grant payments received met the definition of a &#x2018;conditional contribution&#x2019; (versus an exchange contract) because (i)&nbsp;the Company has limited discretion in the way the funds may be spent, which creates a barrier to entitlement, and (ii) the grant contains provisions that release the awarding agency from the obligation to transfer funds that are not expended at the time the award is terminated. The Company recognizes grant reimbursements as a contra operating expense and reflects this as a component of its loss from operations in the period during which the qualifying expenses are incurred and the related services rendered, provided that the applicable performance obligations have been met. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">For the six&nbsp;months ended June&nbsp;30, 2019, the Company incurred qualified expenses and recognized $1,198,000 of grant reimbursements. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Income Taxes </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company&#x2019;s tax return. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Convertible Preferred Stock Warrants </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">At December&nbsp;31, 2018, freestanding warrants to acquire shares of convertible preferred stock were classified as liabilities on the accompanying balance sheet. These warrants were subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. In connection with the Merger, the warrants were exchanged into warrants that no longer met the definition of a derivative and thus, $234,000 of warrant liabilities was reclassified into equity during the six&nbsp;months ended June&nbsp;30, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Debt Modifications and Extinguishments </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">When the Company modifies debt, it does so in accordance with Accounting Standards Codification (&#x201C;ASC&#x201D;) 470-50, </font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Debt: Modifications and Extinguishments</font><font style="display:inline;color:#000000;font-size:10pt;">, which requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#x201C;substantial modifications&#x201D;. A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, the Company determined that the October&nbsp;2018 modification of the March&nbsp;2018 and September&nbsp;2018 Notes, to add an additional conversion option in the event of a reverse merger, was considered to be a &#x201C;substantial modification&#x201D;. As a result, it treated this modification as an &#x2018;extinguishment&#x2019; of those debts and recognized $11,000 of net gain from this debt extinguishment in other income in October&nbsp;2018. All other changes to debt provisions were not considered substantial and were treated as debt modifications. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Derivative Instruments </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">ASC 815-15, </font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Derivatives and Hedging: Embedded Derivatives</font><font style="display:inline;color:#000000;font-size:10pt;">, generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a)&nbsp;the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b)&nbsp;the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)&nbsp;a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirement of ASC 815. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">At December 31, 2018 and June&nbsp;30, 2019, the Company maintained outstanding Notes which contained various embedded derivative features. In particular, these Notes contained the following features: </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A share settled redemption in a qualified preferred stock financing; and </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The right to an accelerated cash repayment in the event of a change in control. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:1pt;">&#x200B;</font><font style="display:inline;color:#000000;font-size:10pt;">These embedded features were not considered clearly and closely related to the debt host, therefore, they were bifurcated and accounted for separately from the debt host as a derivative liability. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in the statement of operations at each period end while such instruments are outstanding. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">As of December 31, 2018 and June&nbsp;30, 2019, the Company determined that there was no fair value associated with the embedded derivatives that remained with the outstanding convertible notes. See </font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">&#x2018;Note&nbsp;6&#x2009;&#x2014; Term Loans and Convertible Promissory Notes&#x2019; </font><font style="display:inline;color:#000000;font-size:10pt;">for further discussion of the Notes and the bifurcated derivative liability. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Fair Value of Financial Instruments </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">ASC 820-10, </font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Fair Value Measurement</font><font style="display:inline;color:#000000;font-size:10pt;">, provides a framework for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. The standard defines fair value as an exit price, representing the amount that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. The standard also establishes a fair value hierarchy, which prioritizes the inputs used in measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Level&nbsp;1</font><font style="display:inline;color:#000000;font-size:10pt;">&#x2009;&#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Level&nbsp;2</font><font style="display:inline;color:#000000;font-size:10pt;">&#x2009;&#x2014; Inputs other than quoted prices included within Level&nbsp;1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Level&nbsp;3</font><font style="display:inline;color:#000000;font-size:10pt;">&#x2009;&#x2014; Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The following table presents the Company&#x2019;s fair value hierarchy for its warrant liability measured at fair value on a recurring basis at December&nbsp;31, 2018 (in thousands): </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:47.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Level&nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Financial liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Warrant liability</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Total financial liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:20.15pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Level&nbsp;3 derivative at December&nbsp;31, 2018 consisted of a warrant liability of Private Adynxx that, at December&nbsp;31, 2018, was exercisable into preferred shares that were potentially redeemable. In connection with the Merger, the warrants were exchanged into warrants that no longer met the definition of a derivative and thus, the balance was reclassified into equity during the six&nbsp;months ended June&nbsp;30, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The change in fair value of the warrant liability for the six&nbsp;months ended June&nbsp;30, 2018 and 2019 are as follows (in thousands): </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Fair value, beginning of period</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Change in fair value of preferred stock warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Exchange of warrants upon Merger</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(234
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Fair value at end of period</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:20.15pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the Company&#x2019;s term loan is based on the borrowing rate currently available to the Company for borrowings with similar terms and maturity and approximates its carrying value. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Derivative liability instruments are considered Level&nbsp;3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level&nbsp;3 liability instruments consist of the preferred stock warrant liability and derivative liability, for both of which there is no observable market data for the determination of fair value and requires significant management judgment and estimation. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">While the Company&#x2019;s Notes contain embedded derivative liabilities, the Company determined that the fair value of these liabilities were zero at December&nbsp;31, 2018 and June&nbsp;30, 2019. See &#x2018;</font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Note 6&#x2009;&#x2014; Term Loans and Convertible Promissory Notes&#x2019;</font><font style="display:inline;color:#000000;font-size:10pt;"> for further discussion on the derivative liability activity. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The change in fair value of the derivative liability relating to the Notes for the six&nbsp;months ended June&nbsp;30, 2018 and 2019 is summarized below (in thousands): </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Fair value, beginning of period</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Embedded derivative liability from the issuance of Notes</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>496
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Change in value of embedded derivatives</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(60
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Fair value at end of period</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>436
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Discontinued Operations </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Discontinued operations represent the activities of the AquaMed business between the date of the Merger and the date of the spin-off. See &#x2018;</font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Note 3&#x2009;&#x2014; Reverse Merger&#x2019;</font><font style="display:inline;color:#000000;font-size:10pt;">. There are no ongoing activities or obligations associated with discontinued operations at June&nbsp;30, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Recently Adopted Accounting Pronouncements </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Lease Accounting </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In February&nbsp;2016, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued ASU No. 2016-02, Leases (Topic 842) (&#x201C;ASU 2016-02&#x201D;). ASU 2016-02 is intended to improve financial reporting of leasing transactions by requiring organizations that lease assets to recognize assets and liabilities for the rights and obligations created by leases that extend more than twelve&nbsp;months on the balance sheet. This accounting update also requires additional disclosures surrounding the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for financial statements issued for annual and interim periods beginning after December&nbsp;15, 2018 for public business entities. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1)&nbsp;its effective date or (2)&nbsp;the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company adopted the new standard on January&nbsp;1, 2019 and used the effective date as its date of initial application. Consequently, the Company has not adjusted prior period amounts. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Company has elected the package of practical expedients permitted in ASC Topic 842. Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a)&nbsp;whether the contracts contain a lease under ASC Topic 842, (b)&nbsp;whether classification of the operating leases would be different in accordance with ASC Topic 842, or (c)&nbsp;whether the unamortized initial direct costs would have met the definition of initial direct costs in ASC Topic 842 at lease commencement. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The most significant impact from the adoption of this standard was the recognition of right-of-use, or ROU, assets and lease obligations on the balance sheet for operating leases. This standard did not have a material impact on the Company&#x2019;s cash flows from operations and operating results. As a result of the adoption of the new lease accounting guidance, the Company recognized on January&nbsp;1, 2019 (a)&nbsp;a lease liability of approximately $227,000, which represents the present value of the remaining lease payments of approximately $239,000, discounted using the Company&#x2019;s incremental borrowing rate of 9.41%, and (b)&nbsp;a right-of-use asset of approximately $227,000 which represents the lease liability of&#x2009; $227,000. The ROU asset is being amortized over the remaining term of the lease of twelve&nbsp;months from January&nbsp;1, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Recent Accounting Pronouncements Not Yet Effective </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In August&nbsp;2018, the FASB issued No. ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. This ASU is effective for fiscal&nbsp;years beginning after December&nbsp;15, 2019, including interim periods within that fiscal year, with early adoption permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements. </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In August&nbsp;2018, the FASB issued ASU 2018-15, Intangibles&#x2009;&#x2014;&#x2009;Goodwill and Other&#x2009;&#x2014;&#x2009;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, (&#x201C;ASU 2018-15&#x201D;). The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January&nbsp;1, 2020 and early adoption is permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#231F20;">Note&nbsp;</font><font style="display:inline;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Use of Estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">The preparation of financial statements&nbsp;&nbsp;in conformity&nbsp;&nbsp;with GAAP requires management to make estimates and assumptions&nbsp;&nbsp;that affect the reported&nbsp;&nbsp;amounts&nbsp;&nbsp;of assets and liabilities, the disclosure of contingent&nbsp;&nbsp;liabilities at the date of the financial statements,&nbsp;&nbsp;and the reported&nbsp;&nbsp;amounts&nbsp;&nbsp;of expenses incurred during the reporting&nbsp;&nbsp;period. Actual results could differ from those estimates and such differences could be material to the Company&#x2019;s financial position and results of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">Significant estimates and assumptions&nbsp;&nbsp;include the valuation&nbsp;&nbsp;of equity instruments and equity-linked instruments, including the valuation&nbsp;&nbsp;of the Company&#x2019;s common stock and the valuation&nbsp;&nbsp;of the Company&#x2019;s common stock options for purposes of accounting&nbsp;&nbsp;for stock-based&nbsp;&nbsp;compensation, and accruals for clinical trials and the valuation&nbsp;&nbsp;allowances on deferred tax assets.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Concentration of Credit Risk and Other Risks and Uncertainties</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Financial&nbsp;&nbsp;instruments that potentially&nbsp;&nbsp;subject the Company&nbsp;&nbsp;to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance&nbsp;&nbsp;Corporation insured limits. To date, the Company&nbsp;&nbsp;has not experienced any losses on its deposits of cash and cash equivalents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company&#x2019;s future financial position, results of operations, or cash flows: ability to obtain&nbsp;&nbsp;future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory&nbsp;&nbsp;approval&nbsp;&nbsp;and market acceptance of the Company&#x2019;s products;&nbsp;&nbsp;development&nbsp;&nbsp;of sales channels; certain strategic relationships;&nbsp;&nbsp;litigation or claims against the Company&nbsp;&nbsp;based on intellectual property,&nbsp;&nbsp;patent,&nbsp;&nbsp;product,&nbsp;&nbsp;regulatory, or other factors; and the Company&#x2019;s ability to attract&nbsp;&nbsp;and retain employees necessary to support&nbsp;&nbsp;its growth.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s postoperative pain reduction&nbsp;&nbsp;product&nbsp;&nbsp;candidate,&nbsp;&nbsp;brivoligide, is an oligonucleotide.&nbsp;&nbsp;The Company&nbsp;&nbsp;currently uses Avecia as a single supplier for the brivoligide drug substance.&nbsp;&nbsp;There are currently a limited number of oligonucleotide&nbsp;&nbsp;manufacturers with commercial scale capabilities globally. While the Company&nbsp;&nbsp;intends to develop secondary sources for manufacturing of its drug candidates&nbsp;&nbsp;in the future, there can be no assurance that it will be able to do so on commercially reasonable&nbsp;&nbsp;terms, or at all. Any interruption in the supply of this key material could significantly delay the research and development process or increase the expenses for development&nbsp;&nbsp;and commercialization of the Company&#x2019;s product candidates.&nbsp;&nbsp;The quality of materials can be critical to the performance of a drug delivery technology. Therefore, the lack of a reliable source that provides a consistent supply of high quality materials would harm the Company.&nbsp;&nbsp;At December 31, 2018, this vendor&#x2019;s activity was not material to total accounts payable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">At December 31, 2017, two vendors represented&nbsp; 56% and 31%, of total accounts payable. The vendor that represented&nbsp; 56% of the Company&#x2019;s accounts payable, supported manufacturing activities and the other vendor was associated with clinical study activities. At December 31, 2018, three vendors represented&nbsp; 52%, &nbsp;26% and 15% of total accounts payable. Two of these vendors supported general and administrative activities, primarily associated with the Merger and next round of equity financing, which accounted&nbsp;&nbsp;for 67% of the total accounts payable. The remaining vendor supported clinical study activities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Clinical Trial Accruals</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">The Company&#x2019;s clinical trial accruals are based on patient enrollment and related costs at clinical investigator&nbsp;&nbsp;sites as well as for the services received and efforts expended pursuant to contracts&nbsp;&nbsp;with multiple research institutions and contract&nbsp;&nbsp;research organizations that conduct and manage clinical trials on the Company&#x2019;s behalf. The Company&nbsp;&nbsp;accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol.&nbsp;&nbsp;If timelines or contracts&nbsp;&nbsp;are modified based upon changes in the clinical trial protocol&nbsp;&nbsp;or scope of work to be performed, the Company&nbsp;&nbsp;modifies the estimates of accrued expenses accordingly. To date, the Company&nbsp;&nbsp;has had no significant adjustments to accrued clinical trial expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">In March 2018, the Company&nbsp;&nbsp;closed its contracts&nbsp;&nbsp;with Premier Research International LLC and CRF Health,&nbsp;&nbsp;Inc. (&#x201C;Contract Research Organizations or CROs&#x201D;) upon completion&nbsp;&nbsp;of a Phase 2 clinical trial in March 2018. For the years ended December 31, 2017 and 2018, the Company&nbsp;&nbsp;incurred $6.2 million and $95,000, respectively, of expenses in connection&nbsp;&nbsp;with this clinical study.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">In November&nbsp;&nbsp;2018, the Company&nbsp;&nbsp;entered into agreements with PRA Health,&nbsp;&nbsp;Inc. and CRF Health, Inc. (&#x201C;Contract Research Organizations or CROs&#x201D;) pursuant to which the CROs agreed to assist the Company&nbsp;&nbsp;with the conduct of a Phase 2 clinical trial. To support&nbsp;&nbsp;additional clinical trial activities the Company&nbsp;&nbsp;also entered into agreements with Premier Research International LLC for biostatistical services, ICON Central Laboratories for laboratory services and Almac Clinical Services for storage and distribution services. In connection&nbsp;&nbsp;with this clinical study, the Company&nbsp;&nbsp;incurred expenses of $0 and $185,000 for the years ended December 31, 2017 and 2018, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">The Company&nbsp;&nbsp;considers all highly liquid investments purchased&nbsp;&nbsp;with a maturity&nbsp;&nbsp;of three months or less on the date of acquisition&nbsp;&nbsp;to be cash and cash equivalents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Property and Equipment, Net</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Property&nbsp;&nbsp;and equipment&nbsp;&nbsp;are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line&nbsp;&nbsp;method over the estimated useful lives of the assets, generally three to five years. Leasehold improvements&nbsp;&nbsp;are amortized&nbsp;&nbsp;over the shorter of the estimated useful life of the asset or the remaining term of the lease.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Expenditures&nbsp;&nbsp;for repairs and maintenance are charged to expense as incurred. Upon disposition&nbsp;&nbsp;of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements&nbsp;&nbsp;of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Impairment of Long-Lived Assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">The Company&#x2019;s long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount&nbsp;&nbsp;of the asset may not be recoverable. Recoverability&nbsp;&nbsp;of an asset to be held and used is measured by a comparison of the carrying amount&nbsp;&nbsp;of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount&nbsp;&nbsp;by which the carrying amount of the asset exceeds its fair value. As of December 31, 2017 and 2018, the Company&nbsp;&nbsp;had not experienced any impairment losses on its long-lived assets.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Restricted Cash</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2017 and 2018, the Company&nbsp;&nbsp;had $55,000 restricted and held by a bank as collateral for a letter of credit provided to the Company&#x2019;s facility landlord.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line&nbsp;&nbsp;basis over the requisite service period, which is generally the vesting period. The Company&nbsp;&nbsp;recognizes forfeitures as they occur.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;uses the Black-Scholes option-pricing model (the &#x201C;Black-Scholes model&#x201D;) as the method for determining&nbsp;&nbsp;the estimated fair value of stock options.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Term &#x2014;</font><font style="display:inline;"> The expected term represents the period that the Company&#x2019;s stock-based&nbsp;&nbsp;awards are expected to be outstanding and is determined&nbsp;&nbsp;using the simplified method.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Volatility &#x2014;</font><font style="display:inline;"> Expected volatility is estimated using comparable public companies&#x2019; volatility for similar terms.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Dividend &#x2014; </font><font style="display:inline;">The Black-Scholes model calls for a single expected dividend yield as an input. The Company&nbsp;&nbsp;has never paid dividends and has no plans to pay dividends.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Risk-Free Interest Rate &#x2014; </font><font style="display:inline;">The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero-coupon&nbsp;&nbsp;issues in effect at the time of grant for periods corresponding with the expected term of the option.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Research and development&nbsp;&nbsp;expenses consist of personnel costs, including salaries, benefits and stock-based&nbsp;&nbsp;compensation, preclinical studies, clinical studies performed&nbsp;&nbsp;by Contract Research Organizations (or &#x201C;CROs&#x201D;), materials and supplies, licenses and fees, and overhead allocations&nbsp;&nbsp;consisting of various administrative and facilities related costs. The Company&nbsp;&nbsp;charges research and development&nbsp;&nbsp;costs, including clinical study costs, to expense when incurred.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Collaboration Agreement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In June 2018, the Company&nbsp;&nbsp;entered into a collaboration agreement with twoXAR,&nbsp;&nbsp;an artificial intelligence-driven drug discovery company, in order to identify potential&nbsp;&nbsp;product&nbsp;&nbsp;candidates&nbsp;&nbsp;for the treatment of endometriosis.&nbsp;&nbsp;Through&nbsp;&nbsp;December 31, 2018, the Company&nbsp;&nbsp;was not obligated to make any payments under the terms of the collaboration agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Grant Reimbursements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In December 2018, the Company&nbsp;&nbsp;received a Notice of Award from the National Institute&nbsp;&nbsp;on Drug Abuse (&#x201C;NIDA&#x201D;), part of the National Institutes&nbsp;&nbsp;of Health (&#x201C;NIH&#x201D;), to support&nbsp;&nbsp;the clinical development&nbsp;&nbsp;of its lead product&nbsp;&nbsp;candidate,&nbsp;&nbsp;brivoligide. NIH grants provide funds for certain types of expenditures in connection&nbsp;&nbsp;with research and development&nbsp;&nbsp;activities over a contractually defined period. The maximum funding expected to be available under this grant for qualified expenditures over the two year period through December 2020 is approximately $5.7 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2018, the Company&nbsp;&nbsp;had not incurred qualified expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">The Company&nbsp;&nbsp;accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined&nbsp;&nbsp;based on differences between the financial reporting&nbsp;&nbsp;and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company&nbsp;&nbsp;provides a valuation&nbsp;&nbsp;allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">In evaluating the ability to recover its deferred income tax assets, the Company&nbsp;&nbsp;considers all available positive and negative evidence, including its operating&nbsp;&nbsp;results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company&nbsp;&nbsp;determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation&nbsp;&nbsp;allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined&nbsp;&nbsp;not to be realizable in the future, an adjustment to the valuation&nbsp;&nbsp;allowance would be charged to earnings in the period such determination is made.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;font-style:normal;">The Company&nbsp;&nbsp;recognizes the tax benefit from uncertain&nbsp;&nbsp;tax positions in accordance&nbsp;&nbsp;with GAAP, which prescribes a recognition threshold&nbsp;&nbsp;and measurement&nbsp;&nbsp;attribute for the financial statement&nbsp;&nbsp;recognition and measurement&nbsp;&nbsp;of uncertain&nbsp;&nbsp;tax positions taken or expected to be taken in a company&#x2019;s tax return.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Convertible Preferred Stock Warrants</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Freestanding warrants&nbsp;&nbsp;to acquire shares of convertible preferred stock are classified as liabilities on the accompanying balance sheets. These warrants&nbsp;&nbsp;are subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. The Company&nbsp;&nbsp;will continue to adjust the carrying values of freestanding&nbsp;&nbsp;warrants&nbsp;&nbsp;classified as liabilities for changes in fair value until the earlier of the exercise or expiration&nbsp;&nbsp;of the warrants&nbsp;&nbsp;or the completion&nbsp;&nbsp;of a liquidation event, including the completion&nbsp;&nbsp;of an initial public offering.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Debt Modif ications and Extinguishments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">When the Company&nbsp;&nbsp;modifies debt, it does so in accordance with Accounting Standards Codification (&#x201C;ASC&#x201D;) 470-50, </font><font style="display:inline;font-style:italic;">Debt: Modifications and Extinguishments</font><font style="display:inline;">, which requires modification&nbsp;&nbsp;to debt instruments to be evaluated to assess whether the modifications&nbsp;&nbsp;are considered &#x201C;substantial modifications&#x201D;. A substantial modification&nbsp;&nbsp;of terms shall be accounted&nbsp;&nbsp;for like an extinguishment.&nbsp;&nbsp;Based on the guidance relied upon and the analysis performed,&nbsp;&nbsp;the Company&nbsp;&nbsp;determined&nbsp;&nbsp;that the October 2018 modification&nbsp;&nbsp;of the March 2018 and September 2018 Notes, to add an additional conversion option in the event of a reverse merger, was considered to be a &#x201C;substantial modification&#x201D;. As a result, it treated this modification&nbsp;&nbsp;as an &#x2018;extinguishment&#x2019; of those debts and recognized $11,000 of net gain from this debt extinguishment&nbsp;&nbsp;in other income. All other changes to debt provisions were not considered substantial and were treated as debt modifications.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Derivative Instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">ASC 815-15, </font><font style="display:inline;font-style:italic;">Derivatives and Hedging: Embedded Derivatives</font><font style="display:inline;">, generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding&nbsp;&nbsp;derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics&nbsp;&nbsp;and risks of the embedded derivative instrument&nbsp;&nbsp;are not clearly and closely related to the economic characteristics&nbsp;&nbsp;and risks of the host contract,&nbsp;&nbsp;(b) the hybrid instrument&nbsp;&nbsp;that embodies both the embedded derivative instrument&nbsp;&nbsp;and the host contract&nbsp;&nbsp;is not re-measured at fair value under otherwise applicable generally accepted accounting&nbsp;&nbsp;principles with changes in fair value reported&nbsp;&nbsp;in earnings as they occur and (c) a separate instrument&nbsp;&nbsp;with the same terms as the embedded derivative instrument&nbsp;&nbsp;would be considered a derivative instrument&nbsp;&nbsp;subject to the requirement&nbsp;&nbsp;of ASC 815.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;issued certain Notes in March 2018, September 2018, and December 2018, which contained&nbsp;&nbsp;various embedded derivative features. In particular, these Notes contained&nbsp;&nbsp;the following features:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(1)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"></font>A share settled redemption in a qualified preferred stock financing; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(2)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"></font>The right to an accelerated cash repayment&nbsp;&nbsp;in the event of a change in control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">These embedded features were not considered clearly and closely related to the debt host, therefore, they were bifurcated&nbsp;&nbsp;and accounted&nbsp;&nbsp;for separately from the debt host as a derivative liability. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in the statement&nbsp;&nbsp;of operations at each period end while such instruments are outstanding.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In October 2018, the Company&nbsp;&nbsp;modified the March 2018 and September 2018 Notes to add an additional conversion feature. The Company determined this was a </font><font style="display:inline;font-style:italic;">&#x201C;substantial modification&#x201D;</font><font style="display:inline;"> as defined in ASC 470-50 </font><font style="display:inline;font-style:italic;">&#x2018;Debt: Modifications and Extinguishments&#x2019;</font><font style="display:inline;">. As a result, these Notes were accounted&nbsp;&nbsp;for as an &#x2018;extinguishment&#x2019; of the debt and related derivative liability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2018, the Company&nbsp;&nbsp;determined&nbsp;&nbsp;that there was no fair value associated with the embedded derivatives that remained with the modified March 2018, the modified September 2018 and December 2018 Notes. See </font><font style="display:inline;font-style:italic;">&#x2018;Note 5 &#x2014; Term Loans and Convertible Promissory Notes&#x2019;</font><font style="display:inline;"> for further discussion of the Notes and the bifurcated&nbsp;&nbsp;derivative liability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Fair Value of Financial Instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">ASC 820-10, </font><font style="display:inline;font-style:italic;">Fair Value Measurement</font><font style="display:inline;">, provides a framework&nbsp;&nbsp;for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. The standard defines fair value as an exit price, representing the amount&nbsp;&nbsp;that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. The standard also establishes a fair value hierarchy, which prioritizes the inputs used in measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Level 1</font><font style="display:inline;"> &#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the Company&nbsp;&nbsp;has the ability to access as of the measurement&nbsp;&nbsp;date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Level 2</font><font style="display:inline;"> &#x2014; Inputs&nbsp;&nbsp;other than quoted prices included within Level 1 that are directly observable for the asset or liability or indirectly observable through&nbsp;&nbsp;corroboration with observable market data.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Level 3</font><font style="display:inline;"> &#x2014; Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement&nbsp;&nbsp;date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining&nbsp;&nbsp;fair value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The following tables present the Company&#x2019;s fair value hierarchy for all of its financial instruments measured at fair value on a recurring basis as of December 31, 2017 and December 31, 2018 (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:49.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">As of December 31, 2017&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Level 1</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Level 2</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Level 3</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Financial liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Warrant liability </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Total financial liabilities </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:49.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">As of December 31, 2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Financial liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Level 1</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Level 2</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Level 3</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Warrant liability </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Total financial liabilities </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities.&nbsp;&nbsp;The fair value of the Company&#x2019;s term loan is based on the borrowing&nbsp;&nbsp;rate currently available to the Company&nbsp;&nbsp;for borrowings&nbsp;&nbsp;with similar terms and maturity&nbsp;&nbsp;and approximates its carrying value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Derivative liability instruments are considered Level 3 when their fair values are determined&nbsp;&nbsp;using pricing models, discounted&nbsp;&nbsp;cash flow methodologies,&nbsp;&nbsp;or similar techniques, and at least one significant model assumption or input is unobservable. Level 3 liability instruments consist of the preferred stock warrant liability and derivative liability, for both of which there is no observable market data for the determination of fair value and requires significant management judgment and estimation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The fair value of the warrant liability was determined&nbsp;&nbsp;using the Black-Scholes model (see </font><font style="display:inline;font-style:italic;">&#x2018;Note 8 &#x2014; Warrants&#x2019;</font><font style="display:inline;"> for a further discussion of the preferred stock warrants). The change in fair value of the preferred stock warrant liability is summarized below (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="middle" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Years Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="middle" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Fair value, beginning of period&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 54</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 42</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Preferred stock warrants &#x2013; exercised </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (8)</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Change in fair value of preferred stock warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (4)</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 98</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Fair value at end of period&nbsp;&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 42</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 140</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The fair value of the embedded derivative liability related to the Company&#x2019;s Notes was determined using a bond plus option model. As of December 31, 2018, the Company&nbsp;&nbsp;determined&nbsp;&nbsp;that there was no fair value remaining for the embedded derivatives associated with the modified March 2018, modified September 2018 and December 2018 Notes. See </font><font style="display:inline;font-style:italic;">&#x2018;Note 5 &#x2014; Term Loans and Convertible Promissory Notes&#x2019;</font><font style="display:inline;"> for further discussion on the derivative liability activity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The change in fair value of the derivative liability relating to the Notes is summarized below (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="middle" style="width:18.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">Years Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="middle" style="width:18.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Fair value, beginning of period </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$ &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Embedded derivative liability from the issuance of Notes&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 864</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Change in value of embedded derivatives&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (211)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Termination of the embedded derivative liability due to the extinguishment&nbsp;&nbsp;of the related Notes</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> (653)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Fair value at end of period </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Recently Adopted Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Restricted Cash</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In November&nbsp;&nbsp;2016, the FASB issued ASU No. 2016-18, Statement&nbsp;&nbsp;of Cash Flows: Restricted&nbsp;&nbsp;Cash. This ASU requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts&nbsp;&nbsp;shown on the statement&nbsp;&nbsp;of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation&nbsp;&nbsp;of the total in the statement&nbsp;&nbsp;of cash flows to the related captions in the balance sheet. This guidance is effective for fiscal periods beginning after December 15, 2017 and interim periods within that fiscal year, with early adoption permitted.&nbsp;&nbsp;The amendments in this ASU should be applied retrospectively to all periods presented. The Company&nbsp;&nbsp;adopted the guidance on a retrospective basis on January&nbsp;&nbsp;1, 2018 and the beginning and ending of cash and cash equivalents for all periods presented in our statements&nbsp;&nbsp;of cash flows include restricted cash.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Non-employee Share-Based Payment Accounting</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In June 2018, FASB issued ASU No. 2018-07, &#x201C;Compensation &#x2014; Stock Compensation (Topic 718): Improvements to Nonemployee&nbsp;&nbsp;Share-Based Payment Accounting&#x201D; (&#x201C;ASU 2018-07&#x201D;). This new guidance changes the accounting&nbsp;&nbsp;for non-employee share-based&nbsp;&nbsp;payments to align with the accounting&nbsp;&nbsp;for employee stock compensation. The Company&nbsp;&nbsp;early adopted&nbsp;&nbsp;the guidance as of January&nbsp;&nbsp;1, 2018 and the impact to its financial statements&nbsp;&nbsp;was not material.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Recent Accounting Pronouncements Not Yet Effective</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Lease Accounting</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In February 2016, the Financial&nbsp;&nbsp;Accounting&nbsp;&nbsp;Standards Board (&#x201C;FASB&#x201D;) issued ASU No. 2016-02. This standard introduces the new leases standard that applies a right-of-use (&#x201C;ROU&#x201D;) model and requires a lessee to record, for all leases with a lease term of more than 12 months,&nbsp;&nbsp;an asset representing its right to use the underlying asset and a liability to make lease payments. For leases with a term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. At inception, lessees must classify all leases as either finance or operating&nbsp;&nbsp;based on five criteria. Balance sheet recognition of finance and operating&nbsp;&nbsp;leases is similar, but the pattern of expense recognition in the income statement, as well as the effect on the statement&nbsp;&nbsp;of cash flows, differs depending on the lease classification. This ASU is effective for public entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted&nbsp;&nbsp;for all entities. The Company&nbsp;&nbsp;is currently assessing whether these amendments will have a material effect on its financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In August 2018, the FASB issued No. ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements&nbsp;&nbsp;as part of its disclosure framework&nbsp;&nbsp;project. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year, with early adoption permitted.&nbsp;&nbsp;The Company&nbsp;&nbsp;is currently assessing whether these amendments will have a material effect on its financial statements.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6833868512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Subsequent Events (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 02, 2019</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 03, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 20, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 24, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of convertible promissory notes - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,996,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member] | First Note to Fund the Company's Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member] | Second Note to Fund the Company's Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member] | Notes to Fund the Company's Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember', window );">Oxford Finance, LLC [Member] | Term Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid', window );">Debt Instrument, Periodic Payment Terms, Increase (Decrease) in Balloon Payment to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.06%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember', window );">Oxford Finance, LLC [Member] | Term Loans [Member] | Domain [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet', window );">Debt Instrument, Increase of Periodic Payments Upon Delivery of Executed Term Sheet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">240 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid', window );">Debt Instrument, Periodic Payment Terms, Increase (Decrease) in Balloon Payment to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer', window );">Merger Agreement, Percentage Ownership in Combined Company, Acquirer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree', window );">Merger Agreement, Percentage Ownership in Combined Company, Acquiree</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds From Issuance Or Sale Of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Reverse Stock Split [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Reverse Stock Split [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Conversion of Notes into Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtConversionOriginalDebtAmountPrincipal', window );">Debt Conversion, Original Debt, Amount, Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest', window );">Debt Conversion, Original Debt, Amount, Cumulative Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Conversion of Notes into Series B Convertible Preferred Stock [Member] | Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,223,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Domain [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of convertible promissory notes - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Majority Investors [Member] | First Note to Fund the Company's Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 26,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Majority Investors [Member] | Second Note to Fund the Company's Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 29,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Majority Investors [Member] | Notes to Fund the Company's Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Oxford Finance, LLC [Member] | Term Loans [Member] | Domain [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet', window );">Debt Instrument, Increase of Interest-Only Periodic Payments Upon Delivery of Executed Term Sheet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet', window );">Debt Instrument, Increase of Periodic Payments Upon Delivery of Executed Term Sheet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">240 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid', window );">Debt Instrument, Periodic Payment Terms, Increase (Decrease) in Balloon Payment to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative accrued interest portion of the amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtConversionOriginalDebtAmountCumulativeAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtConversionOriginalDebtAmountPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The principal portion of the amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtConversionOriginalDebtAmountPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase of interest-only periodic payments upon the delivery of an executed term sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponDeliveryOfExecutedTermSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase of period repayments of debt upon the delivery of an executed term sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the acquiree's percentage ownership in the combined company immediately following a merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the acquirer's percentage ownership in the combined company immediately following a merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_MergerAgreementPercentageOwnershipInCombinedCompanyAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_FirstNoteToFundTheCompanysOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_FirstNoteToFundTheCompanysOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_SecondNoteToFundTheCompanysOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_SecondNoteToFundTheCompanysOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_NotesToFundTheCompanysOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_NotesToFundTheCompanysOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adyx_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adyx_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adyx_DomainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adyx_DomainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=adyx_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=adyx_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adyx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795429936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 3,226<span></span>
</td>
<td class="nump">$ 1,269<span></span>
</td>
<td class="nump">$ 2,137<span></span>
</td>
<td class="nump">$ 8,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,317<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">2,982<span></span>
</td>
<td class="nump">2,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_GrantReimbursementsExpense', window );">Grant reimbursements</a></td>
<td class="num">(1,198)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses, net</a></td>
<td class="nump">4,345<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
<td class="nump">5,119<span></span>
</td>
<td class="nump">11,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(992)<span></span>
</td>
<td class="num">(515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,345)<span></span>
</td>
<td class="num">(2,561)<span></span>
</td>
<td class="num">(5,119)<span></span>
</td>
<td class="num">(11,063)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(2,641)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
<td class="num">(644)<span></span>
</td>
<td class="num">(515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(94)<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="num">(7,080)<span></span>
</td>
<td class="num">(2,946)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,138)<span></span>
</td>
<td class="num">$ (2,946)<span></span>
</td>
<td class="num">$ (5,985)<span></span>
</td>
<td class="num">$ (11,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per basic and diluted share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Loss from continuing operations (in dollars per share)</a></td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare', window );">Loss from discontinued operations (in dollars per share)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per basic and diluted share (in dollars per share)</a></td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">4,966,491<span></span>
</td>
<td class="nump">4,569,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_GrantReimbursementsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of grant reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_GrantReimbursementsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613673-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6819582352">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock Option Plans - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details', window );"><strong>Note 9 - Stock Option Plans - Summary of Stock Option Activity (Details)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available For Grant, Balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Alliqua options assumed in merger (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">748,000<span></span>
</td>
<td class="nump">19,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Alliqua options assumed in merger (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24.95<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life in Years, outstanding (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 73 days<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 6,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Vested and expected to vest (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Life, Vested and expected to vest (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, exercisable (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">530,000<span></span>
</td>
<td class="nump">19,222,032<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercisable (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33.93<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life in Years, exercisable (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years 255 days<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value, exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 4,119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company's common stock of $0.46 and $0.44 per share as of December 31, 2018 and 2017.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_statement-statement-note-9-stock-option-plans-summary-of-stock-option-activity-details</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6819222928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details', window );"><strong>Note 10 - Income Taxes - Components of Deferred Tax Assets (Details)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 7,051<span></span>
</td>
<td class="nump">$ 6,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">8,795<span></span>
</td>
<td class="nump">7,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (8,795)<span></span>
</td>
<td class="num">$ (7,541)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_statement-statement-note-10-income-taxes-components-of-deferred-tax-assets-details</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6837470288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Term Loans and Convertible Promissory Notes (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">41 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 03, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 27, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 01, 2016</div></th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 29, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 25, 2015</div></th>
<th class="th">
<div>Nov. 24, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 20, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,641,000<span></span>
</td>
<td class="nump">$ 445,000<span></span>
</td>
<td class="nump">644,000<span></span>
</td>
<td class="nump">$ 515,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_BeneficialConversionFeatureConversionOfConvertibleNote', window );">Beneficial Conversion Feature, Conversion of Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember', window );">Conversion of Notes into Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember', window );">Conversion of Notes into Series B Convertible Preferred Stock [Member] | Alliqua Biomedical, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt Instrument, Convertible, Beneficial Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_BeneficialConversionFeatureConversionOfConvertibleNote', window );">Beneficial Conversion Feature, Conversion of Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2019AndModifiedDecember2018NotesMember', window );">Modified March 2019 and Modified December 2018 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentConvertiblePreferredStockProceedsTrigger', window );">Debt Instrument, Convertible, Preferred Stock Proceeds Trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentConvertibleCommonStockProceedsTrigger', window );">Debt Instrument, Convertible, Common Stock Proceeds Trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentConversionToCashInCaseOfChangeInControl', window );">Debt Instrument, Conversion to Cash in Case of Change in Control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_FinancingThresholdProceedsToConvertNotesToEquity', window );">Financing Threshold, Proceeds to Convert Notes to Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember', window );">Modified March 2018 and Modified September 2018 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentConversionToCashInCaseOfChangeInControl', window );">Debt Instrument, Conversion to Cash in Case of Change in Control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_FinancingThresholdProceedsToConvertNotesToEquity', window );">Financing Threshold, Proceeds to Convert Notes to Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium', window );">Debt Instrument, Conversion to Cash in Case of Change in Control, Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_VotingRightsTransferredToBeConsideredAChangeInControl', window );">Voting Rights Transferred to be Considered a Change in Control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded Derivative, Fair Value of Embedded Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ReleaseOfDerivativeLiabilities', window );">Release of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember', window );">Modified March 2018 and Modified September 2018 Notes [Member] | Convert Notes And Accrued Interest To Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ConvertiblePromissoryNoteIssuedOnMarch292019Member', window );">Convertible Promissory Note Issued On March292019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ProbabilityOfQualifiedFinancingOccurring', window );">Probability of Qualified Financing Occurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded Derivative, Fair Value of Embedded Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 496,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Debt Instrument, Convertible, Remaining Discount Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Debt Instrument, Unamortized Discount, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 496,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ProbabilityOfChangeInControlOccurring', window );">Probability of Change in Control Occurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ConvertiblePromissoryNoteIssuedSeptember272018Member', window );">Convertible Promissory Note Issued September272018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ProbabilityOfQualifiedFinancingOccurring', window );">Probability of Qualified Financing Occurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded Derivative, Fair Value of Embedded Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Debt Instrument, Convertible, Remaining Discount Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Debt Instrument, Unamortized Discount, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ProbabilityOfChangeInControlOccurring', window );">Probability of Change in Control Occurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2018September2018December2018AndMarch2019NotesMember', window );">Modified March 2018, September 2018, December 2018, and March 2019 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ProbabilityOfQualifiedFinancingOccurring', window );">Probability of Qualified Financing Occurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded Derivative, Fair Value of Embedded Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ProbabilityOfChangeInControlOccurring', window );">Probability of Change in Control Occurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember', window );">Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,810<span></span>
</td>
<td class="nump">197,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember', window );">Oxford Finance, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember', window );">Oxford Finance, LLC [Member] | Term Loan A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember', window );">Oxford Finance, LLC [Member] | Term Loan B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember', window );">Oxford Finance, LLC [Member] | Term Loan C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Debt Instrument, Unused Borrowing Capacity, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentUnusedBorrowingCapacityExpired', window );">Debt Instrument, Unused Borrowing Capacity, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember', window );">Oxford Finance, LLC [Member] | Term Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage', window );">Debt Instrument, Prepayment Fee Before First Anniversary,Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage', window );">Debt Instrument, Prepayment Fee if Company is Acquired Within Six Months of Closing, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage', window );">Debt Instrument, Prepayment Fee Between First and Second Anniversary, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage', window );">Debt Instrument, Prepayment Fee After Second Anniversary, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage', window );">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_LongtermDebtPrincipalAndInterestPaymentsTerm', window );">Long-term Debt, Principal and Interest Payments, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid', window );">Debt Instrument, Periodic Payment Terms, Increase (Decrease) in Balloon Payment to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments', window );">Debt Instrument, Periodic Payment, Increase (Decrease) of Interest-Only Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments', window );">Debt Instrument, Periodic Payment, Increase (Decrease) of Periodic Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 90 days<span></span>
</td>
<td class="text">1 year 330 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_GainLossDebtModification', window );">Gain (Loss) Debt Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,000<span></span>
</td>
<td class="nump">$ 171,000<span></span>
</td>
<td class="nump">336,000<span></span>
</td>
<td class="nump">$ 309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember', window );">Oxford Finance, LLC [Member] | Term Loans [Member] | Domain [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet', window );">Debt Instrument, Increase of Periodic Payments Upon Delivery of Executed Term Sheet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">240 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid', window );">Debt Instrument, Periodic Payment Terms, Increase (Decrease) in Balloon Payment to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember', window );">Oxford Finance, LLC [Member] | Term Loans [Member] | Convertible Promissory Note of 1.5 Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger', window );">Debt Instrument, Increase of Interest-Only Periodic Payments Upon Entering Into a Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger', window );">Debt Instrument, Increase of Periodic Payments Following Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">330 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote', window );">Debt Instrument, Increase of Periodic Payments Following the Closing of a Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">300 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid', window );">Debt Instrument, Periodic Payment Terms, Increase (Decrease) in Balloon Payment to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote', window );">Debt Instrument, Increase of Interest-Only Periodic Payments Upon Closing of Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember', window );">Oxford Finance, LLC [Member] | Term Loans [Member] | London Interbank Offered Rate (LIBOR) Swap Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.19%<span></span>
</td>
<td class="nump">0.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member] | First Note to Fund the Company's Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member] | Second Note to Fund the Company's Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember', window );">Majority Investors [Member] | Notes to Fund the Company's Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_BeneficialConversionFeatureConversionOfConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of favorable spread between the value of notes being converted and the value of the securities issued upon the conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_BeneficialConversionFeatureConversionOfConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentConversionToCashInCaseOfChangeInControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The conversion rate of the outstanding principal amount to cash owed to the holders of a note in the event that the company consummates a change of control.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentConversionToCashInCaseOfChangeInControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The premium, equal to a percentage of outstanding principal, of cash owed to the holders of a note in the event that the company consummates a change of control.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentConversionToCashInCaseOfChangeInControlPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentConvertibleCommonStockProceedsTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In the event that the Company issues and sells shares of its common stock to the investors with proceeds to the Company of at least this amount, on or before the maturity date, and after the closing of a reverse merger, then the outstanding principal amount of the debt instrument and any unpaid accrued interest will automatically convert in whole into equity securities sold in the common stock financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the common stock financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentConvertibleCommonStockProceedsTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentConvertiblePreferredStockProceedsTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the company issues and sells shares of its preferred stock to the investors with proceeds of this amount or higher, on or before the maturity date, and prior to the closing of a reverse merger, then the outstanding principal amount of the debt instrument and any unpaid accrued interest will automatically convert in whole into equity securities sold in the preferred stock financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the such preferred stock financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentConvertiblePreferredStockProceedsTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase of interest-only periodic payments upon closing of a convertible note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponClosingOfConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase of interest-only periodic payments upon entering into a merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentIncreaseOfInterestonlyPeriodicPaymentsUponEnteringIntoAMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase of periodic repayments of debt following a merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase of periodic repayments of debt following the closing of a convertible note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentIncreaseOfPeriodicPaymentsFollowingTheClosingOfAConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase of period repayments of debt upon the delivery of an executed term sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentIncreaseOfPeriodicPaymentsUponDeliveryOfExecutedTermSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) of interest-only payments to be made over the course of the applicable loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfInterestonlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) of periodic payments to be made over the course of the applicable loan which includes both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentPeriodicPaymentIncreaseDecreaseOfPeriodicPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment which is greater than the preceding installment payments, as a percentage of the funded amount, to be paid at final maturity date of debt or prepayment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentPeriodicPaymentTermsIncreaseDecreaseInBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of outstanding principal balance due as a fee in the case of an early payment of the borrowed amount if the payment is made after the second anniversary and prior to the maturity date of the applicable loan funding date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentPrepaymentFeeAfterSecondAnniversaryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of outstanding principal balance due as a fee in the case of an early payment of the borrowed amount if the payment is made prior to the first anniversary of the applicable loan funding date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentPrepaymentFeeBeforeFirstAnniversarypercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of outstanding principal balance due as a fee in the case of an early payment of the borrowed amount if the payment is made after the first anniversary, but prior to the second anniversary, of the applicable loan funding date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentPrepaymentFeeBetweenFirstAndSecondAnniversaryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of outstanding principal balance due as a fee in the case of an early payment of the borrowed amount if the company is acquired within six months from the loan closing date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentPrepaymentFeeIfCompanyIsAcquiredWithinSixMonthsOfClosingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DebtInstrumentUnusedBorrowingCapacityExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused borrowing capacity under the long-term financing arrangement which is no longer available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DebtInstrumentUnusedBorrowingCapacityExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_FinancingThresholdProceedsToConvertNotesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum gross proceeds required of qualified equity financing to trigger a conversion of earlier notes and accrued interest into equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_FinancingThresholdProceedsToConvertNotesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_GainLossDebtModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unrealized and realized gain (loss) on debt following a modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_GainLossDebtModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_LongtermDebtPrincipalAndInterestPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period between the interest-only payment term, and the maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_LongtermDebtPrincipalAndInterestPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ProbabilityOfChangeInControlOccurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The probability of a change in control occurring.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ProbabilityOfChangeInControlOccurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ProbabilityOfQualifiedFinancingOccurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The probability that a qualified financing would occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ProbabilityOfQualifiedFinancingOccurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ReleaseOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The release of an embedded derivative liability as a result of the associated debt instrument being extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ReleaseOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_VotingRightsTransferredToBeConsideredAChangeInControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of voting rights which must be transferred in order to be considered a change in control.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_VotingRightsTransferredToBeConsideredAChangeInControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2019AndModifiedDecember2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2019AndModifiedDecember2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=adyx_ConvertNotesAndAccruedInterestToSeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ConvertiblePromissoryNoteIssuedOnMarch292019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ConvertiblePromissoryNoteIssuedOnMarch292019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ConvertiblePromissoryNoteIssuedSeptember272018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ConvertiblePromissoryNoteIssuedSeptember272018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2018September2018December2018AndMarch2019NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2018September2018December2018AndMarch2019NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantToPurchasePreferredSeriesAConvertiblePreferredStockUnderOxfordLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=adyx_OxfordFinanceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adyx_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adyx_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adyx_TermLoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adyx_TermLoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adyx_TermLoanCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adyx_TermLoanCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adyx_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adyx_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adyx_DomainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adyx_DomainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ConvertiblePromissoryNoteOf15MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ConvertiblePromissoryNoteOf15MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLiborSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLiborSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=adyx_MajorityInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_FirstNoteToFundTheCompanysOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_FirstNoteToFundTheCompanysOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_SecondNoteToFundTheCompanysOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_SecondNoteToFundTheCompanysOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_NotesToFundTheCompanysOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_NotesToFundTheCompanysOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6820727552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adyx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adyx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adyx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6809042208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Note 12.&nbsp;&nbsp;&nbsp;Subsequent Events </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In July&nbsp;2019, affiliates of Domain Partners, LLC, a significant shareholder of the Company, purchased from the Company $600,000 aggregate principal amount of Notes. The proceeds from the issuance of the Notes will be used for general corporate purposes and working capital. These Notes accrue simple interest on the outstanding principal amount at a rate of 8% per annum and mature one year from the date of issuance. </font>
		</p>
<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">On August&nbsp;1, 2019 and August&nbsp;2, 2019, the Company&#x2019;s board of directors and a majority of the Company&#x2019;s stockholders, respectively, approved a reverse stock split at a range of between 1-for-2 and 1-for-10, with the final exchange ratio to be determined by the board of directors, which as of the date of filing has not yet occurred. The share and per share information contained in the financial statements and footnotes do not reflect the impact of any such reverse stock split.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In August 2019, the Company and Oxford agreed to amend the Loan Agreement pursuant to a ninth amendment to the Loan Agreement. The ninth amendment provides for two additional months of interest-only payments by the Company, contingent upon the completion of certain financing events by specified dates. The ninth amendment also clarifies that the secured funds will be released by Oxford upon the receipt by the Company of net proceeds of at least $10 million from the issuance and sale of its equity securities.</font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; FONT-WEIGHT: bold; MARGIN: 0pt 0pt 12pt;"><font style="font-family: Times New Roman,Times,serif; COLOR: #231f20; DISPLAY: inline;">Note&#160;</font><font style="DISPLAY: inline;">13.&#160;&#160;&#160;Subsequent Events</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">In January&#160;&#160;2019, the Company and Oxford Finance agreed to amend the debt agreement. Oxford agreed to 2 months of interest-only payments followed by 8 months of repayments&#160;&#160;upon delivery by February 1, 2019 of an executed term sheet between the Company&#160;&#160;and Domain,&#160;&#160;the Company&#8217;s majority investor and an affiliate thereof, that would result in aggregate proceeds to the Company&#160;&#160;of $20.0 million. The Company&#160;&#160;was also required to place $200,000 in a segregated bank account that is subject to a blocked control agreement in favor of Oxford. The funds in the segregated account were to be released upon the earlier of, the consummation of a merger by March 31, 2019 or the consummation of the equity financing. The Company&#160;&#160;recorded the $200,000 as restricted cash in its balance sheet at March 31, 2019. The maturity date of the loans remained unchanged.&#160;&#160;The amendment fee amounted to $50,000. The amendment was accounted&#160;&#160;for as a debt modification.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">Beginning in January&#160;&#160;2019, the Company&#160;&#160;amended the 401(k) Plan to discontinue&#160;&#160;the nonelective safe harbor&#160;&#160;contribution on behalf of each employee equal to 3% of their annual salary.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">In April 2019 and May 2019, the Company&#8217;s primary investor agreed to provide the Company&#160;&#160;with $2.0 million and $0.5 million in the form of Notes to fund the Company&#8217;s operations. These notes accrue simple interest on the outstanding principal amount&#160;&#160;at the rate of 8% per annum and mature on April 26, 2020 and May 29, 2020.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">In May 2019, the Company and Oxford Finance agreed to a seventh amendment to provide consent to the Merger. This consent amended certain provisions of the term loan to protect Oxford&#8217;s rights under the original term loan agreement. The consent allowed Alliqua to be named as an additional borrower.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">On May 3, 2019 the Company completed its Merger into Alliqua Biomedical Inc. (&#8220;Alliqua&#8221;). Immediately following the Merger, the combined company&#8217;s name was changed from &#8220;Alliqua BioMedical, Inc.&#8221; to &#8220;Adynxx, Inc.&#8221; The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal&#160;&#160;Revenue Code of 1986, as amended. Under the Exchange Ratio formula in the Merger Agreement, as of immediately following the Merger, but excluding the effect of certain financings (as further described in the Merger Agreement), Adynxx equity holders now own approximately 86% of the aggregate number of shares of the combined company and Alliqua equity holders own approximately 14% of the combined company.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">Subject to the terms and conditions of the Merger Agreement (a) each outstanding share of capital stock of Adynxx, was converted into the right to receive the number of shares of Alliqua&#8217;s common stock equal to the Exchange Ratio formula in the Merger Agreement and (b) each outstanding Adynxx stock option,&#160;&#160;whether vested or unvested, and warrant that has not previously been exercised, was assumed by the post merged company and converted into a stock option or warrant, as the case may be, to purchase shares of the post merged Adynxx Company&#8217;s common stock at the Exchange Ratio formula in the Merger Agreement.</font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: left; text-justify: inter-ideograph; MARGIN: 0pt 0pt 12pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;"><span style="FONT-SIZE: 13px; TEXT-DECORATION: none; font-family: Times New Roman; FONT-VARIANT: normal; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; text-align: left; ORPHANS: 2; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: transparent; TEXT-INDENT: 26px; -webkit-text-stroke-width: 0px;">On May&#160;3, 2019, prior to the closing of the Merger, the $3.0&#160;million of Notes and $203,000 of cumulative accrued interest, was converted into 10,223,996 shares of Series&#160;B convertible preferred stock.</span></font></p>
<p style="FONT-SIZE: 10pt; font-family: Times New Roman,Times,serif; text-align: justify; text-justify: inter-ideograph; MARGIN: 0pt; TEXT-INDENT: 36pt;"><font style="DISPLAY: inline;">The Company has evaluated subsequent events through June 7, 2019, the date the financial statements were issued, for appropriate accounting&#160;&#160;and financial statement&#160;&#160;disclosures.</font></p>
</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6809006032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="font-size:10pt;font-family:Times New Roman;">
<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">June&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Payroll and related expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>241
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>508
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Accrued term loan final payment</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>421
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>569
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Accrued clinical trial expense</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Professional fees and other costs</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>195
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>395
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">Total accrued liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>857
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:times new roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,480
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:60.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:times new roman;line-height:107.92%;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table>
</div>
<span></span>
</td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">As of December 31,</font><font style="display:inline;font-family:Times New Roman;color:#231F20;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Payroll and related expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 273</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 241</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Accrued term loan final payment&nbsp;&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 197</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 421</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Accrued clinical trial expense&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 654</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Professional fees and other costs </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 34</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 195</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Total accrued liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 1,158</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 857</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6819781984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Redeemable Convertible Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series B Redeemable Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="nump">56,321,165<span></span>
</td>
<td class="nump">51,069,262<span></span>
</td>
<td class="nump">140,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 12,734<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="num">$ (19,733)<span></span>
</td>
<td class="num">$ (19,595)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_StockIssuedDuringPeriodSharesWarrantExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">351,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_StockIssuedDuringPeriodValueWarrantExercised', window );">Exercise of warrants</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,561)<span></span>
</td>
<td class="num">(11,561)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 12,814<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="num">(31,294)<span></span>
</td>
<td class="num">(30,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,523)<span></span>
</td>
<td class="num">(1,523)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2018</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2018</a></td>
<td class="nump">$ 12,814<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">513<span></span>
</td>
<td class="num">(32,817)<span></span>
</td>
<td class="num">(32,303)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 12,814<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="num">(31,294)<span></span>
</td>
<td class="num">(30,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,946)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2018</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2018</a></td>
<td class="nump">$ 12,814<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="num">(34,239)<span></span>
</td>
<td class="num">(33,650)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 12,814<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="num">(31,294)<span></span>
</td>
<td class="num">(30,855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,985)<span></span>
</td>
<td class="num">(5,985)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 12,814<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="num">(37,279)<span></span>
</td>
<td class="num">(36,531)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2018</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2018</a></td>
<td class="nump">$ 12,814<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">513<span></span>
</td>
<td class="num">(32,817)<span></span>
</td>
<td class="num">(32,303)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2018</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2018</a></td>
<td class="nump">$ 12,814<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="num">(34,239)<span></span>
</td>
<td class="num">(33,650)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 12,814<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="num">(37,279)<span></span>
</td>
<td class="num">(36,531)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,462)<span></span>
</td>
<td class="num">(2,462)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 12,814<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="num">(39,741)<span></span>
</td>
<td class="num">(38,909)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 12,814<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="num">(37,279)<span></span>
</td>
<td class="num">(36,531)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,138)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,807,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">35,160<span></span>
</td>
<td class="num">(44,417)<span></span>
</td>
<td class="num">(9,251)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">701,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 12,814<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="num">(39,741)<span></span>
</td>
<td class="num">(38,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes into convertible preferred stock (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(367,041)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible notes into convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,203<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_BeneficialConversionFeatureConversionOfConvertibleNote', window );">Recognition of beneficial conversion feature upon conversion of convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,101<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock', window );">Conversion of of convertible preferred stock into common stock (in shares)</a></td>
<td class="num">(2,034,548)<span></span>
</td>
<td class="num">(2,200,428)<span></span>
</td>
<td class="nump">4,234,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock', window );">Conversion of of convertible preferred stock into common stock</a></td>
<td class="num">$ (12,814)<span></span>
</td>
<td class="num">$ (21,201)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">34,011<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">34,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for merger (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">854,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for merger</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_EquityIssuanceCostsPaidInStockShares', window );">Equity issuance costs paid in stock (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_EquityIssuanceCostsPaidInStock', window );">Equity issuance costs paid in stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ExchangeOfWarrantsUponMerger', window );">Impact of change of warrants subject to fair value measure to equity warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_EquityImpactOfSpinoff', window );">Spin-off of AquaMed</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,807,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 35,160<span></span>
</td>
<td class="num">$ (44,417)<span></span>
</td>
<td class="num">$ (9,251)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_BeneficialConversionFeatureConversionOfConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of favorable spread between the value of notes being converted and the value of the securities issued upon the conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_BeneficialConversionFeatureConversionOfConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_EquityImpactOfSpinoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity impact after a spin-off in which a portion of the parent company's assets are used to form a new entity, and shares of the new entity are distributed back to the parent company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_EquityImpactOfSpinoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_EquityIssuanceCostsPaidInStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of stock issued as payment for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_EquityIssuanceCostsPaidInStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_EquityIssuanceCostsPaidInStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of shares issued for the payment of equity issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_EquityIssuanceCostsPaidInStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ExchangeOfWarrantsUponMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of warrants upon their reclassification from liabilities to equity as a result of a merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ExchangeOfWarrantsUponMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common stock shares issued during the period as a result of the conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_StockIssuedDuringPeriodSharesWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period for exercise warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_StockIssuedDuringPeriodSharesWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of common stock issued during the period upon the conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_StockIssuedDuringPeriodValueWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as warrant exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_StockIssuedDuringPeriodValueWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6821053136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock Options (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 03, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">748,000<span></span>
</td>
<td class="nump">748,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,222<span></span>
</td>
<td class="nump">19,222<span></span>
</td>
<td class="nump">19,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount', window );">Non-employee Stock Options, Comensation Expense, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition', window );">Non-employee Stock Options, Comensation Expense, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">270 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,222<span></span>
</td>
<td class="nump">19,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.07<span></span>
</td>
<td class="nump">$ 61.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 293,000<span></span>
</td>
<td class="nump">$ 301,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 395,000<span></span>
</td>
<td class="nump">$ 395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 182 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adyx_NonEmployeeOptionsMember', window );">Non-employee Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount', window );">Non-employee Stock Options, Comensation Expense, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=adyx_AlliquaBiomedicalIncMember', window );">Alliqua Biomedical, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="nump">57,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Alliqua Biomedical, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price</a></td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Alliqua Biomedical, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price</a></td>
<td class="nump">$ 656.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember', window );">Alliqua Biomedical, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">690,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember', window );">Alliqua Biomedical, Inc. [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price</a></td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember', window );">Alliqua Biomedical, Inc. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price</a></td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adyx_ThePlanMember', window );">The Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Minimum Price as Percentage of Estimated Fair Value of Underlying Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Minimum Price as Percentage of Estimated Fair Value of Underlying Shares, 10% Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adyx_ThePlanMember', window );">The Plan [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of unrecognized stock-based compensation expense related to unvested non-employees stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_NonEmployeeStockOptionsComensationExpenseCostNotYetRecognizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period over which unrecognized stock-based compensation expense related to unvested non-employee stock options is expected to be recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_NonemployeeStockOptionsComensationExpenseCostNotYetRecognizedPeriodForRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum price of options as a percentage of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the board of directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum price, for ten percent shareholders, of options as a percentage of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the board of directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumPriceAsPercentageOfEstimatedFairValueOfUnderlyingShares10PercentShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adyx_NonEmployeeOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adyx_NonEmployeeOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=adyx_AlliquaBiomedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=adyx_AlliquaBiomedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=adyx_AlliquaBiomedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adyx_ThePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adyx_ThePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6819583168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred Income Tax Assets, Net, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="num">(964,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_NumberOfForeignSubsidiaries', window );">Number of Foreign Subsidiaries</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">$ 33,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_OperatingLeaseCarryforwardsWithExpirationDates', window );">Operating Lease Carryforwards with Expiration Dates</a></td>
<td class="nump">28,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_OperatingLossCarryforwardsExpiringIndefinitely', window );">Operating Loss Carryforwards Expiring Indefinitely</a></td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2014 2015 2016 2017 2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating Loss Carryforwards, Expiration Date</a></td>
<td class="text">Dec. 31,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year [Member] | Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Tax Credit Carryforward, Expiration Date</a></td>
<td class="text">Dec. 31,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_NumberOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of foreign subsidiaries of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_NumberOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_OperatingLeaseCarryforwardsWithExpirationDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of operating lease carryforwards that have specific expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_OperatingLeaseCarryforwardsWithExpirationDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_OperatingLossCarryforwardsExpiringIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of operating loss carryforwards that expire indefinitely.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_OperatingLossCarryforwardsExpiringIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6803931632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adynxx, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001054274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">AMENDMENT NO. 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6603534992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Reverse Merger<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ReverseMergerDisclosureTextBlock', window );">Reverse Merger Disclosure [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Note 3.&nbsp;&nbsp;&nbsp;Reverse Merger </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Merger </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">On May&nbsp;3, 2019 the Company completed its reverse merger with Alliqua BioMedical Inc. (&#x201C;Alliqua&#x201D;). Immediately following the Merger, the combined company&#x2019;s name was changed from &#x201C;Alliqua BioMedical, Inc.&#x201D; to &#x201C;Adynxx, Inc.&#x201D; Private Adynxx changed its name to &#x201C;Adynxx Sub, Inc.&#x201D; and is currently a wholly owned subsidiary of the Company. The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section&nbsp;368(a) of the Internal Revenue Code of 1986, as amended. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Subject to the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of October&nbsp;11, 2018, as amended and supplemented from time to time (the &#x201C;Merger Agreement&#x201D;), (a)&nbsp;each outstanding share of capital stock of Private Adynxx, was converted into the right to receive the number of shares of Alliqua&#x2019;s common stock equal to the exchange ratio formula in the Merger Agreement (&#x201C;Exchange Ratio&#x201D;) of 0.0359 shares of common stock (which exchange rate reflects a 1-for-6 reverse stock split of the issued and outstanding capital stock of Alliqua BioMedical, Inc. effected on May&nbsp;3, 2019 immediately prior to the Merger) and (b)&nbsp;each outstanding Private Adynxx stock option, whether vested or unvested, and warrant that has not previously been exercised, was assumed by the post-Merger company and converted into a stock option or warrant, as the case may be, to purchase shares of the post-Merger Adynxx Company&#x2019;s common stock at the Exchange Ratio formula in the Merger Agreement. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">On May&nbsp;3, 2019, prior to the closing of the Merger, $3.0&nbsp;million aggregate principal amount of Notes and $203,000 of cumulative accrued interest on such Notes were converted into 367,041 shares of common stock.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Upon the completion of the Merger, Private Adynxx equity holders held 4,936,784 shares of common stock. Equity issuance costs in connection with the Merger were recorded as an offset to additional paid in capital. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">As described in &#x201C;Spin-off&#x201D; below, at the time of the Merger, Alliqua had in place a plan to spin-off all existing operations. Since Alliqua was deemed to have no operations upon consummation of the Spin-off, Alliqua was not considered to be a business for accounting purposes. Accordingly, no goodwill or intangible assets were recorded as a result of the Merger. Because Private Adynxx is treated as the acquiring company, Private Adynxx&#x2019;s assets and liabilities are recorded at their pre-combination carrying amounts and the historical operations that are reflected in periods prior to the closing date of the Merger will be those of Private Adynxx. All share and per share amounts have been retroactively restated to give effect to the Exchange Ratio. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Private Adynxx was determined to be the accounting acquirer based upon the terms of the Merger Agreement and other factors including: (i)&nbsp;Private Adynxx equity holders owned approximately 86% of the voting interests of the combined company immediately following the closing of the transaction and Alliqua equity holders owned approximately 14%; (ii) directors appointed by Private Adynxx hold a majority of board seats in the combined company; and (iii) Private Adynxx management hold all key positions in the management of the combined company. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In connection with a previous modification of its Notes, the Company had computed a contingent beneficial conversion feature (&#x201C;BCF&#x201D;) that was contingent upon the occurrence of a reverse merger. In accordance with ASC 470-20-25-6, the contingent BCF is not recognized in earnings until the contingency is resolved. Upon the date of the Merger, the full amount of beneficial conversion feature of&#x2009; $2.1&nbsp;million was recognized as interest expense in the condensed consolidated statement of operations for the six&nbsp;months ended June&nbsp;30, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Dividend </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In contemplation of the Merger, Alliqua declared a special cash dividend to the pre-Merger shareholders of Alliqua as of April&nbsp;22, 2019. The aggregate dividend of&#x2009; $5,245,000, or $1.05 per share, was paid on May&nbsp;29, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Spin-off </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">On November&nbsp;27, 2018, Alliqua had entered into an agreement whereby its existing operations would be distributed to existing shareholders as of a record date. With the exception of a corporate lease, substantially all of Alliqua&#x2019;s assets and liabilities were contributed to a subsidiary, AquaMed Technologies Inc. (&#x201C;AquaMed&#x201D;), whose shares were then distributed to the pre-Merger shareholders of Alliqua by way of a pro&nbsp;rata stock dividend on June&nbsp;21, 2019. The book value of the dividend was less than $0.01 per share. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Because the historical periods presented prior to the merger are those of Private Adynxx, the results of AquaMed are only reflected in these financial statements from the merger date to the date of the pro&nbsp;rata dividend of AquaMed and are presented as discontinued operations in the condensed consolidated statement of operations. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Pro Forma Financial Information </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">As the only significant operations of Alliqua have been discontinued with the spin-off transaction, pro&nbsp;forma financial information for periods prior to the merger is not presented herein as such results are not meaningful.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ReverseMergerDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure for the reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ReverseMergerDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6805517696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Employee Benefit Plan (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_NoteToFinancialStatementDetailsTextual', window );"><strong>Note To Financial Statement Details Textual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary', window );">Defined Contribution Plan, Non-elective Safe Harbor Contribution, Percentage of Annual Salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_DefinedContributionPlanNonelectiveSafeHarborContributionAmount', window );">Defined Contribution Plan, Non-elective Safe Harbor Contribution, Amount</a></td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the company's nonelective safe harbor contribution made by the company on behalf of each employee, expressed as a percentage of each employee's annual salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DefinedContributionPlanNonElectiveSafeHarborContributionPercentageOfAnnualSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_DefinedContributionPlanNonelectiveSafeHarborContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount paid during the period for non-elective safe harbor contributions under a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_DefinedContributionPlanNonelectiveSafeHarborContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_NoteToFinancialStatementDetailsTextual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_NoteToFinancialStatementDetailsTextual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6669506304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Term Loans and Convertible Promissory Notes - Future Principal Payments of Term Loans (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adyx_TermLoansMember', window );">Term Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Total principal payments</a></td>
<td class="nump">$ 3,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adyx_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adyx_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6805608672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details', window );"><strong>Note 4 - Accrued Liabilities - Accrued Liabilities (Details)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_AccruedPayrollAndRelatedExpensesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_AccruedTermLoanPaymentsCurrent', window );">Accrued term loan final payment</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expense</a></td>
<td class="nump">8<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees and other costs</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 1,480<span></span>
</td>
<td class="nump">$ 857<span></span>
</td>
<td class="nump">$ 1,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trail expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_AccruedPayrollAndRelatedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for payroll and related expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_AccruedPayrollAndRelatedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_AccruedTermLoanPaymentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued term loan payments. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_AccruedTermLoanPaymentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_statement-statement-note-4-accrued-liabilities-accrued-liabilities-details</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799575264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefits Disclosure [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;">Note 12.</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman;">Employee Benefit Plan</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;font-weight:normal;">The Company&nbsp;&nbsp;has established a 401(k) Plan (the &#x201C;401(k) Plan&#x201D;) that permits participants to make contributions by salary deduction&nbsp;&nbsp;pursuant to Section 401(k) of the IRC. The Company&nbsp;&nbsp;may, at its discretion, make matching contributions to the 401(k) Plan. The Company&nbsp;&nbsp;has made no contributions to the 401(k) Plan since its inception. The Company&nbsp;&nbsp;makes a nonelective 401(k) safe harbor&nbsp;&nbsp;contribution on behalf of each employee equal to 3% of their annual salary. The Company&#x2019;s non-elective safe harbor contributions totaled $54,000 and $49,000 for the years ended December 31, 2017 and 2018, respectively.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6607950016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:59.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.28%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">June&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Furniture and fixtures</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Office equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Computer equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Total property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Less accumulated depreciation</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(41
				</td>
				<td valign="bottom" style="width:02.88%;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(45
				</td>
				<td valign="bottom" style="width:00.96%;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">As of December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Furniture and fixtures&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 29</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 29</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Office equipment&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Computer equipment </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 24</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 18</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Total property and equipment&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 57</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 51</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Less accumulated depreciation </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (44)</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (41)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 13</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 10</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6821058496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,226,000<span></span>
</td>
<td class="nump">$ 1,269,000<span></span>
</td>
<td class="nump">$ 2,137,000<span></span>
</td>
<td class="nump">$ 8,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of Long-Lived Assets Held-for-use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payments of Dividends, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_GrantReimbursements', window );">Grant Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_ReclassificationOfWarrantIntoEquity', window );">Reclassification of Warrant into Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt, Total</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, Payments, Due, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,007,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, Payments, Due, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.41%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember', window );">Modified March 2018 and Modified September 2018 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt, Total</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset', window );">Embedded Derivative, Fair Value of Embedded Derivative Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded Derivative, Fair Value of Embedded Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_CollaborationInitiationPayment', window );">Collaboration Initiation Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=adyx_LetterOfCredit1Member', window );">Letter of Credit 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=adyx_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember', window );">Clinical Study, Premier Research International LLC and CRF Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=adyx_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember', window );">Clinical Study, PRA Health, CRF Health, Inc., Premier Research International LLC, ICON Central Laboratories, and Almac Clinical Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=adyx_AccountsPayable1Member', window );">Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | Vendor 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=adyx_AccountsPayable1Member', window );">Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | Vendor 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=adyx_AccountsPayable1Member', window );">Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | Vendor 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=adyx_AccountsPayable1Member', window );">Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | Two of the Three Vendors Supporting Clinical Study Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=adyx_AccountsPayable1Member', window );">Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | One of the Two Vendors Supporting Manufacturing Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_CollaborationInitiationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment to start a collaborative project.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_CollaborationInitiationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_GrantReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of expense in the current period that reflects the allocation of grants receivable over the life of the project for which the grants were provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_GrantReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_ReclassificationOfWarrantIntoEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of reclassification of warrant into equity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_ReclassificationOfWarrantIntoEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 220<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873921&amp;loc=SL114875236-224282<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adyx_ModifiedMarch2018AndModifiedSeptember2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=adyx_LetterOfCredit1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=adyx_LetterOfCredit1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=adyx_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=adyx_ClinicalStudyPremierResearchInternationalLLCAndCRFHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=adyx_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=adyx_ClinicalStudyPRAHealthCRFHealthIncPremierResearchInternationalLLCICONCentralLaboratoriesAndAlmacClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=adyx_AccountsPayable1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=adyx_AccountsPayable1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=adyx_Vendor1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=adyx_Vendor1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=adyx_Vendor2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=adyx_Vendor2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=adyx_Vendor3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=adyx_Vendor3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=adyx_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=adyx_TwoOfTheThreeVendorsSupportingClinicalStudyActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=adyx_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=adyx_OneOfTheTwoVendorsSupportingManufacturingActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6802210688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text"><div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0.5pt;">
			<tr>
				<td valign="bottom" style="width:52.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:8pt;">Issuance&nbsp;Date</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:8pt;">Expiration&nbsp;Date</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:8pt;">Exercise&nbsp;Price</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;font-size:8pt;">Number&nbsp;of&nbsp;Shares&nbsp;(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">November, 2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">November, 2025</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.2276
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>198
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:52.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">January, 2016</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">January, 2026</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.2276
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:52.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:100%;text-indent: -10.1pt;font-family:times new roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:times new roman;font-size: 1pt;">
						<font style="display:inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember', window );">Warrants For Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">As&nbsp;of&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 2.28</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">2.56% &#x2013; 2.59</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Remaining contractual life (in years) </font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">7.92 &#x2013; 8.08</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">6.92 &#x2013; 7.08</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 71.00</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 76.84</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adyx_WarrantsForSeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6673037408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Note 4.&nbsp;&nbsp;&nbsp;Property and Equipment, Net </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Property and equipment, net, consist of the following (in thousands): </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:59.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.28%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">June&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Furniture and fixtures</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Office equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Computer equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Total property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Less accumulated depreciation</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(41
				</td>
				<td valign="bottom" style="width:02.88%;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(45
				</td>
				<td valign="bottom" style="width:00.96%;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;text-indent: -10.1pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Depreciation expense at December 31, 2018 and for the six&nbsp;months ended June&nbsp;30, 2018 and 2019 was $8,000, $4,000 and $4,000, respectively. </font>
		</p><div /></div> </div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#231F20;">Note&nbsp;</font><font style="display:inline;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and Equipment, Net</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Property&nbsp;&nbsp;and equipment,&nbsp;&nbsp;net, consist of the following (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">As of December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#231F20;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#231F20;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Furniture and fixtures&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 29</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 29</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Office equipment&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Computer equipment </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 24</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 18</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> &nbsp;2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Total property and equipment&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 57</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 51</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Less accumulated depreciation </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (44)</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> (41)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 13</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#231F20;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#231F20;"> 10</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Depreciation expense for the years ended December 31, 2017 and 2018 was $10,000 and $8,000, respectively.</font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6808966896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman;color:#231F20;">Note&nbsp;</font><font style="display:inline;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Operating Leases</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;leases office facilities under a non-cancelable&nbsp;&nbsp;operating&nbsp;&nbsp;lease agreement expiring on December 31, 2019. The total undiscounted future non-cancellable&nbsp;&nbsp;lease payments under the Company&#x2019;s operating&nbsp;&nbsp;lease as of December 31, 2018 are as follows (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Future</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Year ending December 31</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Commitments</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 239</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman;color:#000000;"> 239</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Rent expense related to the Company&#x2019;s operating&nbsp;&nbsp;leases was $225,000 and $232,000 for the years ended December 31, 2017 and 2018, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size: 10pt;">
			<font style="display:inline;">Indemnif ications</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;has agreed to indemnify its directors and officers for certain events or occurrences arising as a result of the officers or directors serving in such capacity. The Company&nbsp;&nbsp;has a directors&#x2019; and officers&#x2019; liability insurance policy that limits its exposure and enables the Company&nbsp;&nbsp;to recover a portion&nbsp;&nbsp;of any future amounts&nbsp;&nbsp;paid resulting from the indemnification of its officers and directors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company&nbsp;&nbsp;has not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. The Company&#x2019;s management believes the estimated fair value of these indemnification agreements is minimal and has not recorded a liability for these agreements as of December 31, 2018. </font>
		</p><div /></div> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799814816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_WarrantsDisclosureTextBlock', window );">Warrants Disclosure [Text Block]</a></td>
<td class="text"><div>
<div>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%;"><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; COLOR: #000000; DISPLAY: inline;">Note 9.&#160;&#160;&#160;Warrants</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;">Private Adynxx had issued warrants that were previously classified as a liability as they were exercisable for preferred shares that were potentially redeemable. The fair value of the warrant liability was re-measured at each balance sheet date up through the date of the Merger with the change as other income recorded in the statements of operations.</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;">On May&#160;3, 2019, in connection with the closing of the Merger, each outstanding Adynxx warrant that had not previously been exercised was converted into a stock warrant to purchase shares of the Company&#8217;s common stock at the Exchange Ratio and, as a result, outstanding warrants were converted into warrants to purchase an aggregate of 11,829 shares of the Company&#8217;s common stock at an exercise price of $6.34 per share. As such warrants qualify for equity classification, the Company reclassified the balance of&#8201; $234,000 from warrant liability to additional paid in capital. These warrants are exercisable at any time and expire in 2025 and 2026.</font></p>
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; COLOR: #000000; MARGIN: 0pt 0pt 10pt; LINE-HEIGHT: 100%; TEXT-INDENT: 36pt;"><font style="FONT-SIZE: 10pt; COLOR: #000000; DISPLAY: inline;">Additionally, upon the closing of the Merger on May&#160;3, 2019, the Company assumed outstanding Alliqua warrants to purchase an aggregate of 38,945 shares of common stock at exercise prices ranging from $26.40 to $28.20 per share. These warrants are exercisable at any time and expire in 2022.</font></p>
</div>
</div><span></span>
</td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 10pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">Note 8.&nbsp;&nbsp;&nbsp;Warrants </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">In connection with convertible notes agreements with investors issued between January&nbsp;1, 2009 and July&nbsp;1, 2010, the Company issued warrants to purchase such number of shares of Series&nbsp;A convertible preferred stock issued in the next round of equity financing equal to 20% of notes payable principal amounts divided by the price per share of such preferred stock. The warrants are exercisable after closing of each preferred stock financing for five&nbsp;years and expire seven&nbsp;years from the issuance date. At the issuance dates, the Company estimated the fair value of issued warrants as minimal due to the uncertainty of the Series&nbsp;A convertible preferred stock financing. The Company estimated the fair value of outstanding warrants at the date of closing of the Series&nbsp;A convertible preferred stock financing and used the Black-Scholes model with the following assumptions: expected lives equal to the remaining contractual life in a range of 3.92 to 7&nbsp;years, risk-free interest rates in a range of 1.46% to 2.66%, expected dividend yield of zero, volatility in the range of 73.6% to 81.5%, and a fair value of Series&nbsp;A convertible preferred stock of $0.2276 per share. As of December&nbsp;31, 2017, the outstanding warrants had been exercised.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">In connection with the Oxford Loan Agreement signed in November&nbsp;2015, the Company issued a warrant to purchase 197,715 shares of the Company&#x2019;s preferred stock at an exercise price equal to the Series&nbsp;A preferred stock price of&#x2009; $0.2276. The warrant is exercisable after closing and expires ten&nbsp;years from the issuance date. The Company estimated the fair value of the warrant at closing and used the Black-Scholes model with the following assumptions: expected life equal to the remaining contractual life of 10&nbsp;years, risk-free interest rate of 2.07%, expected dividend yield of zero, volatility of 68.7%, and a fair value of Series&nbsp;A convertible preferred stock of&#x2009; $0.20 per share. The Company recorded the fair value of the warrant of&#x2009; $33,000 as a debt discount to be amortized to interest expense over the life of the Term Loan&nbsp;A. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">In January&nbsp;2016, in connection with the Oxford Loan Agreement signed in November&nbsp;2015, the Company issued a warrant to purchase 131,810 shares of the Company&#x2019;s preferred stock at an exercise price equal to the Series&nbsp;A preferred stock price of&#x2009; $0.2276. The warrant is exercisable after closing and expires ten&nbsp;years from the issuance date. The Company estimated the fair value of the warrant at closing and used the Black-Scholes model with the following assumptions: expected life equal to the remaining contractual life of 10&nbsp;years, risk-free interest rate of 2.09%, expected dividend yield of zero, volatility of 68.6%, and a fair value of Series&nbsp;A convertible preferred stock of&#x2009; $0.23 per share. The Company recorded the fair value of the warrant of&#x2009; $22,000 as a debt discount to be amortized to interest expense over the life of the Term Loan B. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The change in fair value of the warrants issued in connection with Term Loan A and B at December&nbsp;31, 2017 and 2018 of&#x2009; ($12,000) and $98,000 respectively, were recorded to other expense (income). As of December&nbsp;31, 2018, the warrants remained outstanding and exercisable.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The above Black-Scholes model assumptions were determined as follows: </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;">Term</font><font style="display:inline;color:#000000;">&#x2009;&#x2014; The term represents the remaining contractual term of the warrants. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;">Risk-free interest rate&#x2009;&#x2014; </font><font style="display:inline;color:#000000;">The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal the remaining term of the warrants. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;">Expected</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;font-style:italic;color:#000000;">volatility</font><font style="display:inline;color:#000000;">&#x2009;&#x2014; The expected volatility is derived from historical volatilities of several unrelated publicly listed peer companies over a period approximately equal to the remaining term of the warrants because the Company has limited information on the volatility of the preferred stock since there is currently no trading history. When making the selections of the Company&#x2019;s industry peer companies to be used in the volatility calculation, the Company considered the size and operational and economic similarities to the Company&#x2019;s principal business operations. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;">Expected dividend yield</font><font style="display:inline;color:#000000;">&#x2009;&#x2014; The expected dividend yield is based on the Company&#x2019;s history of not paying dividends. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The warrants are classified as a liability as they are exercisable into shares that are potentially redeemable. The fair value of the warrant liability is re-measured at each balance sheet date with the change as other income recorded in the statements of operations. </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The fair value of the Series&nbsp;A convertible preferred stock warrants outstanding at December&nbsp;31, 2017 and 2018 was $42,000 and $140,000 respectively, and the details of the warrants were as follows: </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:54.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Shares</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Issuance Date</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Expiration&nbsp;Date</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Exercise&nbsp;Price</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">November, 2015</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">November, 2025</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> 0.2276</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> 198</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">January, 2016</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">January, 2026</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> 0.2276</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> 132</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> 330</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:20pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The fair value of the Series&nbsp;A convertible preferred stock warrants was determined using the following assumptions: </font>
		</p>
		<p style="margin:0pt;text-indent:20pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">As&nbsp;of&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> 2.28</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">2.56% &#x2013; 2.59</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Remaining contractual life (in years) </font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">7.92 &#x2013; 8.08</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">6.92 &#x2013; 7.08</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> 71.00</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> 76.84</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799958848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Leases (Details Textual)<br> xbrli-pure in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="nump">$ 232,000<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance Lease, Liability, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_LesseeOperatingLeaseNotYetCommenced', window );">Lessee, Operating Lease, Not yet Commenced</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adyx_LesseeFinanceLeaseNotYetCommenced', window );">Lessee, Finance Lease, Not yet Commenced</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_LesseeFinanceLeaseNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of finance leases the company has that have not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_LesseeFinanceLeaseNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adyx_LesseeOperatingLeaseNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of operating leases the company has that have not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adyx_LesseeOperatingLeaseNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6804070240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Redeemable Convertible Preferred Stock (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember', window );">Conversion of Notes into Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">367,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">56,672,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,034,548<span></span>
</td>
<td class="nump">56,672,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">51,069,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,833,387<span></span>
</td>
<td class="nump">51,069,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=adyx_ConversionOfNotesIntoSeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adyx_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adyx_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adyx_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
